{
  "evaluation_metadata": {
    "evaluator_name": "LLM-as-Judge Evaluator (Model: qwen3-235b-reasoning)",
    "evaluator_model": "qwen3-235b-reasoning",
    "model_evaluated": "gpt-oss-120b",
    "experiment": "e4_page_window_relevance_desc",
    "pattern": "qualitative_2hop_cross_year",
    "sample_size": null,
    "random_seed": null,
    "total_questions_in_experiment": 1000,
    "successful_questions_in_experiment": 1000,
    "failed_questions_in_experiment": 0,
    "questions_evaluated": 1000,
    "completed": true,
    "input_file": "/Users/reeturajharsh/domyn/multihopQA-benchmarking/src/experiments/outputs/experiments/gpt-oss-120b/e4_page_window_relevance_desc/qualitative_2hop_cross_year.json",
    "timestamp": "2026-02-05T01:46:12.108759"
  },
  "evaluation_results": [
    {
      "question_id": 77,
      "question": "How did the gross benefit obligation and the actuarial losses for LMT's nonqualified defined benefit pension plans evolve between 2023 and 2024?",
      "original_answer": "In 2023, the gross benefit obligation for LMT's nonqualified defined benefit pension plans was $1.0 billion with actuarial losses totaling $347 million. By 2024, the gross benefit obligation decreased to $905 million, and the actuarial losses declined to $303 million. This indicates a reduction in both the liability and the associated actuarial losses over the period.",
      "llm_answer": "Lockheed Martin’s non‑qualified defined‑benefit pension plans saw the gross benefit obligation fall from **about $1.0 billion at year‑end 2023 to roughly $905 million at year‑end 2024**.  Correspondingly, the actuarial losses recorded in accumulated other‑comprehensive loss dropped from **approximately $347 million in 2023 to about $303 million in 2024**.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the gross benefit obligation decreased from $1.0 billion in 2023 to $905 million in 2024, and actuarial losses declined from $347 million to $303 million. The use of 'about' and 'approximately' is acceptable as it reflects rounding and does not distort the actual figures. (2) Quantitative accuracy is perfect—both dollar amounts and years match the original answer exactly in value, with only minor, acceptable wording variations (e.g., 'about' vs exact). No calculations were required, but the directional changes (decreases) are correctly interpreted. (3) The multi-hop reasoning is sound: the model correctly synthesized data across two years and two financial metrics (gross benefit obligation and actuarial losses) for LMT's nonqualified defined benefit pension plans. (4) The answer is contextually relevant, directly addressing the evolution of both metrics between 2023 and 2024. All entities—Lockheed Martin (LMT), nonqualified defined benefit pension plans, and the correct years—are accurately identified and discussed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1181,
        "completion_tokens": 325,
        "total_tokens": 1507
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did General Motors' long-term rate of return assumptions on U.S. pension plan assets evolve between 2022 and 2024, and what does this indicate about the company's strategic asset mix adjustments?",
      "original_answer": "In 2022, General Motors reported that the weighted-average long-term rate of return on U.S. pension plan assets decreased from 5.6% at December 31, 2020, to 5.4% at December 31, 2021. By contrast, in 2024, the company indicated that the weighted-average long-term rate of return on U.S. pension plan assets increased from 6.3% at December 31, 2023, to 6.5% at December 31, 2024. This indicates a notable shift in the company's strategic asset mix, moving from a more conservative assumption in 2022 to a more optimistic projection in 2024, likely reflecting changes in capital market assumptions and investment strategies aimed at improving funded status.",
      "llm_answer": "- In the 2022 filing GM assumed a **5.63 % long‑term rate of return on U.S. pension‑plan assets** (see “Expected rate of return on plan assets” in the 2022 table)【page_84】.  \n- By the 2024 filing that assumption had risen to **6.27 %** (the same row in the 2024 table)【page_87】, an increase of roughly 0.6 percentage point.\n\nThe higher return assumption reflects GM’s deliberate shift in the pension‑plan strategic asset mix toward higher‑return, higher‑risk assets (e.g., private‑equity, real‑estate and other “Other” strategies) to improve funded status and tolerate more volatility, as described in the 2024 discussion of asset‑mix adjustments【page_88】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, in 2022, GM reported a decrease to 5.4% (from 5.6%), but the LLM claims a 5.63% assumption in 2022, which does not align with the stated trend. Similarly, for 2024, the ground truth states an increase to 6.5% (from 6.3%), but the LLM reports 6.27%, which is inconsistent. These discrepancies in key percentages undermine factual correctness. (2) The calculations and comparisons are partially correct in direction (an increase is correctly identified), but the magnitude (~0.6 percentage points) is only approximately accurate and based on incorrect base values. The actual change from 5.4% to 6.5% would be 1.1 points, not 0.6. (3) The multi-hop reasoning is sound in structure—comparing assumptions across years and linking them to strategic asset mix changes—and the qualitative interpretation about shifting toward higher-risk, higher-return assets (e.g., private equity, real estate) aligns with the ground truth’s implication of a more optimistic projection reflecting strategic shifts. (4) Contextually, the answer is highly relevant and addresses both parts of the question: evolution of return assumptions and strategic implications. While the reasoning and intent are correct, the incorrect numerical values significantly reduce overall accuracy, warranting a mid-range score. Semantic equivalence fails on numbers but holds on directional trend and strategic interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 412,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Chevron's relationship with PDC Energy evolved between 2023 and 2024, and what specific operational and financial impacts were attributed to this change?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, and as a result, PDC was excluded from Chevron’s internal control assessment due to the business combination. By 2024, the integration had progressed to the point where Chevron reported a $2.2 billion increase in U.S. upstream earnings attributed to legacy PDC assets, and a 19% increase in net oil-equivalent production driven by the full-year contribution from PDC. This reflects a shift from acquisition to operational integration and performance contribution.",
      "llm_answer": "In 2023 Chevron reported that it had just completed a business‑combination with PDC Energy, treating PDC as a newly‑acquired wholly‑owned subsidiary and even excluding it from its internal‑control assessment (Item 9 B, 2023 10‑K). By 2024 the PDC assets were fully integrated and described as “legacy PDC production,” which lifted U.S. upstream earnings by $3.5 billion (about $2.2 billion of that from higher sales volumes) and added roughly 250 k barrels of oil‑equivalent per day – a 19 % rise in net oil‑equivalent production – to Chevron’s upstream results.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 acquisition of PDC Energy by Chevron and the exclusion of PDC from internal control assessment, as well as the 19% increase in net oil-equivalent production in 2024, which matches the ground truth. However, it incorrectly states the U.S. upstream earnings increase as $3.5 billion (with $2.2 billion attributed to higher sales volumes), whereas the ground truth specifies a total increase of $2.2 billion — not $3.5 billion — with no breakdown provided. This is a significant quantitative error. (2) The production increase of 250k barrels per day is plausible contextually but not mentioned in the original answer, introducing unverified detail. The 19% production growth is correctly reported. (3) The multi-hop reasoning is sound: the model connects the 2023 acquisition to 2024 operational integration and financial impact, correctly attributing performance to legacy PDC assets. It synthesizes across time and entities appropriately. (4) While the core narrative and qualitative progression (acquisition → integration → contribution) are accurate and relevant, the inflated earnings figure reduces quantitative accuracy. The answer remains contextually relevant and mostly complete, but the financial figure discrepancy prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 366,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did Southern Company's treatment and valuation of energy-related derivatives change between 2022 and 2024, particularly in terms of unrealized gains (losses) and their presentation in financial statements?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred, specifically as of December 31, 2021, and 2020. By 2024, the company shifted its disclosure focus to the fair value of energy-related derivatives, interest rate derivatives, and foreign currency derivatives, which were presented as either assets or liabilities in the balance sheets, typically under 'Other' or separately as 'Risk Management Activities'. This indicates a change in both the valuation approach and the presentation of these instruments in financial disclosures.",
      "llm_answer": "In the 2022 Form 10‑K the company still reported its energy‑related derivatives primarily as **regulatory hedges**.  Unrealized gains and losses were shown as “Other regulatory assets” or “Other regulatory liabilities” and then recovered through fuel expense.  For Southern Company the net regulatory‑hedge position was a **$155 million unrealized gain** (assets of $(17) million offset by $107 million of current liabilities and $65 million of deferred liabilities).  \n\nBy the 2024 filing the presentation had changed.  Energy‑related derivatives are now shown on the balance sheet as **separate derivative assets and liabilities** (net‑ted under “Risk Management Activities/Other”), with the net amounts recognized of **$28 million of assets and $84 million of liabilities** for Southern Company.  Gains and losses on cash‑flow hedges are deferred in AOCI and re‑classified to earnings when realized, while regulatory‑hedge gains are still recorded as regulatory assets/liabilities but are much smaller than in 2022.  \n\nThus, between 2022 and 2024 Southern Company moved from a large, regulatory‑asset‑focused unrealized‑gain presentation to a net‑ted derivative‑asset/liability presentation with a modest net liability position and the usual AOCI treatment for cash‑flow hedges.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core shift in Southern Company's treatment and presentation of energy-related derivatives between 2022 and 2024, correctly identifying the move from regulatory-hedge-focused reporting (with unrealized gains recorded in regulatory assets/liabilities) to a more standardized presentation under 'Risk Management Activities' with netted derivative assets and liabilities. The qualitative reasoning is sound: it correctly notes the use of AOCI for cash-flow hedges and the diminished role of regulatory hedges by 2024. Contextual relevance is high, as the response directly addresses changes in valuation and presentation.\n\nHowever, the quantitative accuracy is problematic. The LLM cites a '$155 million unrealized gain' in 2022, broken down into specific asset and liability components, but the original answer does not provide these numbers—it only states that unrealized gains (losses) were deferred and reported as of Dec 31, 2021, and 2020. These specific dollar figures ($17M, $107M, $65M, $155M) are not present in the ground truth and cannot be verified, suggesting potential hallucination. Similarly, the 2024 figures of '$28M assets and $84M liabilities' are not in the original answer, which only mentions a change in disclosure format, not specific amounts. While such details might exist in actual filings, they are not part of the provided ground truth, so including them as factual reduces accuracy.\n\nThe multi-hop reasoning is partially correct: the model infers a trend from regulatory deferral to fair value presentation, which aligns with the original answer. But the addition of unsupported numerical precision undermines factual correctness. The conclusion about the shift in presentation is semantically equivalent and valid, but the inclusion of unverified figures lowers the overall correctness and quantitative accuracy scores.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1504,
        "completion_tokens": 506,
        "total_tokens": 2010
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Chevron's financial relationship with Tengizchevroil evolve between 2022 and 2024, particularly in terms of its investment carrying value and equity earnings?",
      "original_answer": "In 2022, Chevron disclosed that its carrying value of its investment in Tengizchevroil (TCO) was about $100 higher than its underlying equity in TCO's net assets, with a significant portion of the investment tied to a $4,500 loan to fund the FGP/WPMP development. By 2024, Chevron's financial stake in Tengizchevroil had grown substantially, with its investment and advances reaching $27,368 million in 2024, compared to $26,954 million in 2023. Additionally, Chevron's equity in earnings from TCO declined from $4,386 million in 2022 to $3,033 million in 2024, indicating a reduction in profitability from the venture over this period.",
      "llm_answer": "- **Carrying value of the TCO investment** – In the 2024 Form 10‑K Chevron recorded its 50 % equity interest in Tengizchevroil (TCO) at **$27.4 billion** (the “Investments and Advances” line). The 2022 filing showed a lower carrying amount (the 2024 note indicates the premium over TCO’s net‑asset book value had fallen to about **$73 million** in 2024, down from the roughly **$100 million** premium reported in the 2021‑2022 period), meaning the balance had risen modestly but the excess over underlying equity had narrowed.\n\n- **Equity earnings from TCO** – Chevron’s share of TCO’s earnings fell from **$4.386 billion in 2022** (as shown in the 2024 note’s “Equity in Earnings – 2022” column) to **$3.033 billion in 2024**.  \n\nThus, between 2022 and 2024 Chevron’s recorded investment in Tengizchevroil grew to about $27.4 billion, while the earnings it recognized from that affiliate declined by roughly $1.35 billion, and the premium of the carrying value over TCO’s underlying net‑asset equity narrowed to about $73 million.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures all key financial figures and trends from the ground truth. The carrying value of Chevron's investment in Tengizchevroil is accurately reported as $27.4 billion in 2024 (matching $27,368 million in the original answer, rounded appropriately). The $100 million premium in 2022 and its reduction to $73 million in 2024 are correctly stated, with proper context about the narrowing of the carrying value over net assets. Equity earnings are exactly correct: $4.386 billion in 2022 and $3.033 billion in 2024, reflecting the decline in profitability. The LLM also correctly notes the 2023 investment value ($26,954 million) is implied through comparison, though not explicitly restated. (2) All numbers match or are validly rounded versions of the ground truth: $27,368 million ≈ $27.4 billion, $4.386 billion = $4,386 million, $3.033 billion = $3,033 million. The $73 million premium is correctly presented as a 2024 figure, consistent with the trend from $100 million in 2022. No calculation errors. (3) Multi-hop reasoning is sound: the LLM synthesizes data across years (2022 to 2024), distinguishes between carrying value, underlying net assets, and equity earnings, and correctly interprets the significance of the narrowing premium. It references the 2024 10-K note that retrospectively reports 2022 figures, showing proper cross-temporal document use. (4) The answer is fully contextually relevant, directly addressing the evolution of Chevron’s financial relationship with TCO in terms of investment carrying value and equity earnings. The only minor shortcoming is that the original answer mentions the $4,500 million loan for FGP/WPMP development as a key reason for the initial premium, which the LLM omits. While not critical to the core quantitative comparison, this contextual detail slightly reduces completeness in explaining the 'why' behind the carrying value structure. Hence, a 9 instead of 10 on qualitative accuracy and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 541,
        "total_tokens": 1963
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Walmart's ownership stake in Alert Innovation evolve between fiscal 2023 and fiscal 2024, and what specific transaction occurred to change its relationship with the entity?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, which was previously consolidated as a variable interest entity, resulting in Walmart becoming a 100% owner. However, by fiscal 2024, Walmart had subsequently sold and deconsolidated Alert Innovation, indicating a complete exit from the entity. This marks a full transformation from full ownership to no ownership within a single fiscal year.",
      "llm_answer": "Walmart’s stake in Alert Innovation did not change between fiscal 2023 and fiscal 2024 – it was already a 100 % owned subsidiary in fiscal 2023 and remained so through fiscal 2024.  The change in relationship came from the **$0.4 billion acquisition of Alert Innovation in fiscal 2023**, which bought out the non‑controlling interest and converted the company from a variable‑interest entity into a wholly‑owned subsidiary (the sale of the entity was not completed until fiscal 2025).【page_66】",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims Walmart's ownership stake did not change between fiscal 2023 and 2024 and that it remained 100% owned, which is false. The original answer states Walmart fully exited Alert Innovation by fiscal 2024 through a sale and deconsolidation. (2) The $0.4 billion acquisition figure is correctly cited, but the timing and consequence are misrepresented: the LLM claims the sale occurred in fiscal 2025, which is not supported by the ground truth—deconsolidation occurred in fiscal 2024. (3) The multi-hop reasoning fails: the model does not recognize the full transformation from pre-acquisition VIE to 100% ownership to complete divestiture within one year. Instead, it incorrectly asserts continuity of ownership. (4) The mention of converting from a VIE to a wholly-owned subsidiary is partially accurate for the 2023 acquisition, but the overall narrative misrepresents the ownership trajectory. The answer is contextually relevant in discussing the acquisition and entity status but fundamentally wrong on the key point: Walmart exited the investment, it did not retain it.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 324,
        "total_tokens": 1562
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions change from fiscal year 2022 to 2023, and what does this indicate about the company's exposure management strategy?",
      "original_answer": "In fiscal year 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in Accumulated Other Comprehensive Income (AOCI) with $32.5 million expected to be reclassified into earnings within 12 months. By fiscal year 2023, Starbucks had shifted its position significantly, reporting foreign currency - other derivative assets of $1.9 million in current assets and $1.7 million in long-term assets, while carrying derivative liabilities of $4.7 million in current liabilities and $4.1 million in long-term liabilities. This indicates a substantial reduction in overall foreign currency - other derivative exposure and a shift from unrealized gains in equity to more balanced short- and long-term asset and liability positions.",
      "llm_answer": "In FY 2022 Starbucks reported foreign‑currency‑other derivative assets of $39.9 million (current‑asset line) plus $33.5 million (long‑term assets) – a total of about $73.4 million – and only $0.3 million of related liabilities【page_68】. By FY 2023 those asset balances had fallen to $32.0 million (current) and $22.9 million (long‑term), or $54.9 million, while liabilities rose to $2.0 million (accrued) and no long‑term liability was recorded【page_72】. The roughly $18‑$20 million net reduction in the foreign‑currency‑other hedge position indicates Starbucks is actively scaling back the notional of this hedge, likely because anticipated foreign‑currency cash‑flow exposures have decreased and the company is tightening its exposure‑management strategy.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both asset and liability figures for both fiscal years. For FY 2022, the original answer states that Starbucks reported a foreign currency - other derivative asset of $55.3 million in AOCI (Accumulated Other Comprehensive Income), with $32.5 million expected to be reclassified into earnings within 12 months. However, the LLM incorrectly reports $39.9 million in current assets and $33.5 million in long-term assets (totaling $73.4 million), which misrepresents both the amount and the accounting classification (AOCI vs. balance sheet asset lines). This is a critical error because AOCI reflects unrealized gains/losses in equity, not direct balance sheet assets. (2) For FY 2023, the original answer specifies foreign currency - other derivative assets of $1.9 million (current) and $1.7 million (long-term), with liabilities of $4.7 million (current) and $4.1 million (long-term). The LLM reports $32.0 million and $22.9 million in assets (total $54.9 million) and only $2.0 million in accrued liabilities, which is vastly different from the correct values. The LLM’s numbers are off by tens of millions and fail to reflect the actual scale of reduction. (3) The multi-hop reasoning is flawed because the LLM misidentifies the nature of the derivative positions (confusing AOCI unrealized gains with balance sheet assets) and fails to recognize the shift from an equity-based unrealized gain to a more balanced asset/liability structure across current and long-term categories. The conclusion that Starbucks is 'tightening its exposure-management strategy' may be directionally plausible, but it is based on incorrect data and thus unsupported. (4) The contextual relevance is moderate because the answer attempts to address changes in derivative positions and infer strategy, but due to severe quantitative and qualitative errors, the overall correctness score is low. The model fails to capture the true extent of the reduction—from $55.3 million in AOCI gains to minimal asset/liability positions—and mischaracterizes the financial structure, leading to an incorrect interpretation of the company's risk management shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 589,
        "total_tokens": 1980
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Medtronic's treatment of A Preferred Shares evolve between fiscal years 2022 and 2024, and what specific action was taken regarding these shares in 2022?",
      "original_answer": "In fiscal year 2022, Medtronic redeemed 1,872 A Preferred Shares for $0.075 million during the third quarter, and no A Preferred Shares were outstanding by April 29, 2022. By fiscal year 2024, no A Preferred Shares remained outstanding, indicating that the company did not reissue or reintroduce this class of shares after the redemption in 2022. This shows a discontinuation of the A Preferred Shares following their redemption.",
      "llm_answer": "In fiscal 2022 Medtronic still had a small number of A Preferred Shares outstanding, but in the third quarter of that year it **redeemed the 1,872 A Preferred Shares for $0.075 million**, leaving the class with no shares outstanding at the April 29, 2022 balance‑sheet date. By fiscal 2024 the authorized 500 thousand A Preferred Shares remained authorized but **no A Preferred Shares were outstanding**, indicating that after the 2022 redemption the company did not issue or otherwise change the status of this share class.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the redemption of 1,872 A Preferred Shares for $0.075 million in the third quarter of fiscal year 2022 and notes that no shares were outstanding by April 29, 2022. It also accurately states that by fiscal year 2024, no A Preferred Shares were outstanding. These facts align with the ground truth. The only minor discrepancy is that the LLM adds information not present in the original answer — specifically, that the 500 thousand A Preferred Shares remained authorized — which, while potentially true, was not confirmed or mentioned in the ground truth. This does not make the answer factually incorrect but adds a detail beyond the provided knowledge. (2) All numeric values — 1,872 shares, $0.075 million, April 29, 2022 — are correct and match the ground truth exactly. Format variations are acceptable and handled appropriately. (3) The multi-hop reasoning is sound: the model correctly synthesizes the 2022 redemption event with the continued absence of shares in 2024 to infer that the shares were not reissued, demonstrating proper logical continuity. (4) The answer is contextually fully relevant, addressing both parts of the question: the evolution between 2022 and 2024 and the specific 2022 action. The qualitative accuracy is slightly reduced due to the addition of unverified detail about authorization status, but core reasoning and facts remain strong. Correctness score is 9 due to this minor over-specification, but all critical facts and calculations are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 422,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did Comcast's financial relationship with Atairos evolve between 2022 and 2023, particularly in terms of equity income (losses) driven by fair value adjustments on underlying investments?",
      "original_answer": "In 2022, Comcast's equity in net income (losses) from investees, particularly Atairos, showed a loss of $(434) million due to fair value adjustments on its underlying investments. In contrast, by 2023, Atairos generated income of $1.1 billion for Comcast, reflecting a significant turnaround. This change indicates a substantial improvement in the performance of Atairos's underlying investments over the period.",
      "llm_answer": "In 2022 Comcast’s equity‑method investment in Atairos generated a **$537 million loss** (equity in net income ‑ $537 m), which stemmed from a **$434 million fair‑value loss** on Atairos’s underlying holdings. In 2023 the result flipped to a **$789 million gain** on the investment, driven by a **$1.1 billion fair‑value gain** on those same underlying assets【page_39】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. According to the ground truth, Comcast's equity loss from Atairos in 2022 was $(434) million, which matches the LLM's mention of a $434 million fair-value loss. However, the LLM incorrectly states the total equity loss as $537 million, which does not align with the original answer and introduces a number not present in the ground truth. For 2023, the ground truth reports a $1.1 billion income for Comcast from Atairos, but the LLM reports only a $789 million gain on the investment, despite correctly citing a $1.1 billion fair-value gain on underlying assets. This discrepancy between the stated fair-value gain and the resulting equity income is not explained and contradicts the expected direct relationship. (2) Number verification: 2022 fair-value loss of $434 million is correct; total equity loss should be $(434) million, not $537 million. 2023 income should be $1.1 billion, not $789 million. The $1.1 billion fair-value gain in 2023 is correctly cited, but the resulting equity income is understated. (3) Multi-hop reasoning is partially sound—the model recognizes that fair-value adjustments drive equity income and attempts to link them across years. However, it fails to correctly synthesize the final equity income figures, suggesting a breakdown in mapping fair-value changes to reported equity earnings. (4) Scores reflect major quantitative errors (especially the $537M and $789M figures), partial qualitative accuracy in understanding the mechanism of fair-value adjustments, and high contextual relevance as the answer addresses the evolution of Comcast's financial relationship with Atairos and the role of fair-value changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1206,
        "completion_tokens": 475,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure slightly declined to 296 billion cubic feet. This minor decrease suggests limited growth or a strategic reallocation of resources in the region during that period.",
      "llm_answer": "In the 2024 10‑K the consolidated‑operations table shows the Asia Pacific/Middle East natural‑gas reserve balance falling from 312 billion cubic feet (BCF) at year‑end 2023 to 296 BCF at year‑end 2024 (undeveloped volumes were unchanged at 7 BCF), a modest decline of roughly 5 percent. At the same time, the “Equity affiliates” column – which represents reserves that are all located in the Asia Pacific/Middle East – grew from 5,275 BCF in 2023 to 5,870 BCF in 2024, reflecting new purchases and extensions in that region. Together, the data indicate that while the company’s own consolidated reserves in the area slipped slightly, ConocoPhillips is deliberately bolstering its strategic position there through equity‑affiliate growth and acquisitions.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the decline in COP's consolidated natural gas reserves from 312 BCF in 2023 to 296 BCF in 2024, matching the ground truth. The 5% decline is approximately accurate (actual drop is ~5.1%, so rounding is acceptable). However, the LLM introduces new information not present in the original answer — specifically, the 'Equity affiliates' reserves increasing from 5,275 BCF to 5,870 BCF — which, while potentially factual from the 10-K, goes beyond the scope of the provided ground truth and introduces a multi-hop inference not supported by the original answer. (2) Quantitatively, the core numbers (312, 296, and implied 5% drop) are correct. The equity affiliate figures are plausible but not verified by the ground truth, making their inclusion a risk to factual alignment. (3) The reasoning extends beyond the original answer’s conclusion — while the ground truth suggests 'limited growth or strategic reallocation,' the LLM infers a deliberate strategic bolstering via equity affiliates. This is a reasonable interpretation but represents an additional analytical layer not confirmed by the ground truth, thus weakening qualitative accuracy. (4) The answer is contextually relevant and addresses both the evolution of reserves and strategic positioning. However, the strategic interpretation is partially unsupported by the original answer, which only notes a minor decrease without referencing equity investments. Hence, correctness is reduced due to introduction of unverified synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 421,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the revenue performance of ENBREL in Canada evolve between 2022 and 2024, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ENBREL in Canada generated $113 million in revenue, which declined to $47 million in 2023, and further dropped to $28 million in 2024. This indicates a consistent downward trend in revenue, suggesting a shrinking market presence or reduced demand for ENBREL in Canada over this period.",
      "llm_answer": "In Canada, ENBREL sales fell from $73 million in 2022 to $47 million in 2023 (a 36 % drop) and then to $28 million in 2024 (a further 40 % drop) 【page 71】【page 72】. This steep, roughly 62 % decline over two years signals a rapidly contracting Canadian market for ENBREL, reflecting weakening demand and/or increasing pricing and competitive pressures.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $47 million revenue in 2023 and $28 million in 2024, which matches the ground truth. However, it incorrectly states the 2022 revenue as $73 million instead of the correct $113 million, a significant factual error. This affects the accuracy of the percentage decline calculations. (2) The claimed 36% drop from $73M to $47M is mathematically correct based on those numbers, and the 40% drop from $47M to $28M is approximately correct (actual: ~40.4%). However, using the correct 2022 figure ($113M), the actual drop to $47M is about 58.4%, and the overall decline from 2022 to 2024 is closer to 75%, not 62%. Thus, the quantitative inaccuracies stem from an incorrect starting value. (3) The reasoning about a declining market trajectory is sound and aligns with the ground truth—revenue is clearly falling over time. The LLM correctly synthesizes multi-hop data across years and draws a reasonable conclusion about market contraction, demand, and competition. (4) Despite correct directional interpretation and use of later-year data, the incorrect 2022 figure undermines the quantitative accuracy. The answer is contextually relevant and qualitatively logical, but the core financial data for 2022 is wrong, leading to a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1159,
        "completion_tokens": 364,
        "total_tokens": 1523
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Qualcomm's approach to linking human capital advancements with executive compensation evolved from fiscal 2023 to fiscal 2024, and what specific performance modifier range was applied in fiscal 2024?",
      "original_answer": "In fiscal 2023, Qualcomm indicated that human capital advancements would be considered in determining executives' fiscal 2024 bonus. By fiscal 2024, this approach evolved into a more defined structure where progress toward human capital advancements served as a non-financial performance modifier that could adjust executives' bonus payouts by a multiplier ranging from 0.9 to 1.1. This represents a shift from a general consideration to a quantified performance modifier in executive compensation.",
      "llm_answer": "In fiscal 2023 Qualcomm said that the Board would **consider** progress on its human‑capital goals when setting executive bonuses, but it did not attach a specific numeric multiplier to that consideration. By fiscal 2024 the company formalized the link – the HR and Compensation Committee now uses progress on human‑capital advancements as a **non‑financial performance modifier** that can adjust an executive’s bonus by **0.9 × to 1.1 ×** the target amount.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately captures the evolution from fiscal 2023 to 2024: in 2023, human capital advancements were a general consideration for executive bonuses, while in 2024 they became a formal non-financial performance modifier. (2) The quantitative range of 0.9× to 1.1× is correctly reported, matching the ground truth's 'multiplier ranging from 0.9 to 1.1'. (3) The reasoning correctly synthesizes the multi-hop progression—showing a shift from qualitative consideration to a quantified adjustment mechanism. (4) All entities (Qualcomm, fiscal years 2023 and 2024, executive compensation, HR and Compensation Committee) are accurately referenced. Wording differs slightly but maintains semantic equivalence. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 246,
        "total_tokens": 1500
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has the therapeutic scope of Breyanzi evolved between 2022 and 2024, based on the specific indications and approvals documented in those years?",
      "original_answer": "In 2022, Breyanzi was associated with trials for 3L+ Chronic Lymphocytic Leukemia (TRANSCEND-CLL-004) and 3L+ Follicular Lymphoma (TRANSCEND-FL), both with expected timing in 2023/24. By 2024, Breyanzi received FDA accelerated approvals for two distinct indications: relapsed or refractory Follicular Lymphoma (FL) after at least two prior lines of therapy (approved in May 2024), and relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) after at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor (approved in March 2024). This reflects a shift from being in late-stage trials to having concrete accelerated approvals in specific patient populations.",
      "llm_answer": "In the 2022 filing the company only listed Breyanzi in its late‑stage pipeline, with registrational trials planned for **relapsed‑or‑refractory chronic lymphocytic leukemia/small‑lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL)** (see the “Breyanzi – 3L+ CLL” and “Breyanzi – 3L+ FL” entries in the 2022 table of anticipated readouts【page_20】).  \n\nBy the 2024 filing Breyanzi had secured **accelerated‑approval FDA clearances for relapsed‑or‑refractory CLL/SLL (March 2024), FL (May 2024) and mantle‑cell lymphoma (MCL) (May 2024)**, plus a **Japanese approval for relapsed‑or‑refractory FL after only one prior line of therapy (August 2024)**, and the company’s narrative notes that Breyanzi now treats the “broadest array of B‑cell malignancies”【page_45】【page_44】【page_46】.  \n\nThus, between 2022 and 2024 Breyanzi’s therapeutic scope expanded from being a pipeline candidate for CLL/SLL and FL to an approved CAR‑T therapy covering CLL/SLL, FL and MCL, with broader indication breadth and earlier‑line use in Japan.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies Breyanzi's status in 2022 as being in late-stage trials for CLL/SLL and FL, aligning with the ground truth. It also accurately notes FDA accelerated approvals in 2024 for CLL/SLL (March 2024) and FL (May 2024), which matches the original answer. However, the LLM introduces a significant factual error by claiming an FDA approval for mantle cell lymphoma (MCL) in May 2024 and a Japanese approval for FL after only one prior line of therapy in August 2024—neither of which are present in the ground truth. The original answer makes no mention of MCL or any Japanese approval, so these are unsupported additions. Additionally, the claim about treating the 'broadest array of B-cell malignancies' is interpretive and not directly substantiated by the provided ground truth. While the core progression from trials to approvals in CLL/SLL and FL is correct, the inclusion of unverified indications (MCL) and foreign regulatory approvals (Japan) constitutes major factual overreach. Quantitative accuracy is partially maintained for the correct dates and indications but undermined by the false MCL and Japan claims. Reasoning is sound in structure—comparing 2022 pipeline status to 2024 approvals—but flawed due to hallucinated data. Contextual relevance is high as the response directly addresses the evolution of therapeutic scope. Overall, the answer is partially correct but contains critical inaccuracies that distort the actual scope expansion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 406,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the financial performance of Disney's Resorts and Vacations segment evolved from 2023 to 2024, and how does this compare to the overall revenue growth of the Parks & Experiences segment?",
      "original_answer": "The Resorts and Vacations segment saw an increase in revenue from $7,949 million in 2023 to $8,375 million in 2024, representing a 5% growth. This growth was slightly below the overall Parks & Experiences revenue growth of 5%, which increased from $32,549 million in 2023 to $34,151 million in 2024. The Resorts and Vacations segment remained a significant contributor to the overall Parks & Experiences division, maintaining a consistent proportion of total revenue despite the modest growth difference.",
      "llm_answer": "Disney’s Resorts & Vacations revenue rose from **$7.949 billion in 2023 to $8.375 billion in 2024**, a **≈5 % increase**【page_47】.  The broader Parks & Experiences segment also grew about **5 %**, with total revenues climbing from **$32.549 billion to $34.151 billion**【page_49】.  Thus, the Resorts & Vacations line‑item grew at roughly the same rate as the overall Parks & Experiences segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all financial figures: Resorts & Vacations revenue increased from $7,949 million (=$7.949 billion) in 2023 to $8,375 million (=$8.375 billion) in 2024, representing approximately 5% growth. Similarly, Parks & Experiences revenue grew from $32,549 million to $34,151 million, also about 5%, which matches the ground truth. All numbers are accurate with acceptable format variation (billion vs. million). (2) Calculations are correct: (8,375 - 7,949)/7,949 ≈ 5.36%, and (34,151 - 32,549)/32,549 ≈ 4.92%, both reasonably rounded to '≈5%' as stated. (3) The multi-hop reasoning is sound—comparing segment growth to overall division growth is correctly executed. However, the LLM states the segments 'grew at roughly the same rate', which is factually accurate, but omits the nuance in the original answer that Resorts & Vacations growth was 'slightly below' overall Parks & Experiences growth (5.36% vs 4.92%—though this is counter to the original claim, suggesting a possible error in the original answer’s comparison logic; thus, the LLM’s equivalence statement is defensible). (4) The answer is contextually complete and relevant, addressing both the evolution of Resorts & Vacations and its comparison to overall segment growth. The only minor shortcoming is the lack of mention that Resorts & Vacations maintained a consistent proportion of total revenue, a qualitative point in the original. Given the numerical accuracy and logical reasoning, the correctness score is 9/10, deducting one point for partial omission of a contextual insight.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 436,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has the structure and value of CVS's forward contracts associated with accelerated share repurchase (ASR) transactions evolved between 2023 and 2024?",
      "original_answer": "In 2023, CVS executed a $2.0 billion ASR with Citibank, N.A., which was accounted for as an initial treasury stock transaction of $1.6 billion and a forward contract of $0.4 billion. The forward contract was classified as an equity instrument and recorded within capital surplus, with the final 20% of shares received in February 2023. In 2024, CVS entered into a larger $3.0 billion ASR with Morgan Stanley, accounted for as an initial treasury stock transaction of $2.6 billion and a forward contract of $0.4 billion. The forward contract was similarly classified and recorded, but the remaining 15% of shares were received later, in March 2024. Despite the increase in the ASR size, the forward contract value remained constant at $0.4 billion, indicating a shift in the proportion of the ASR allocated to the forward contract component.",
      "llm_answer": "In 2023 CVS completed a $2.0 billion fixed‑dollar ASR with Citibank that was accounted for as an initial treasury‑stock purchase of $1.6 billion (80 % of the notional) and a forward‑contract liability of $0.4 billion (the remaining 20 %). The forward contract was recorded as an equity instrument in capital surplus and was re‑classified to treasury stock when the final 5.4 million shares were delivered in February 2023. In 2024 the company entered a larger $3.0 billion ASR with Morgan Stanley, again splitting the transaction into an initial treasury‑stock purchase of $2.6 billion (85 %) and a $0.4 billion forward contract (the remaining 15 %); the forward contract was likewise recorded in capital surplus and moved to treasury stock after the additional 8.3 million shares were received in March 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key numbers are correct: $2.0 billion ASR in 2023 with $1.6 billion initial treasury purchase and $0.4 billion forward contract; $3.0 billion ASR in 2024 with $2.6 billion initial and $0.4 billion forward. Dates (February 2023, March 2024) and percentages (80%/20%, 85%/15%) match or are consistent with the original. The mention of 5.4 million and 8.3 million shares is additional detail not in the ground truth but does not contradict it. (2) Quantitative accuracy is perfect: $1.6B + $0.4B = $2.0B and $2.6B + $0.4B = $3.0B; 20% and 15% allocations are correctly implied. (3) Multi-hop reasoning is sound: the model correctly synthesizes the structure, value, accounting treatment, and evolution of the ASR forward contracts across two years and two counterparties. (4) One minor discrepancy: the original states the forward contract was 'classified as an equity instrument', while the LLM calls it a 'forward-contract liability' initially—this is a technical inconsistency since equity-classified forward contracts are not liabilities. However, the LLM correctly notes it is recorded in capital surplus and reclassified to treasury stock, which aligns with equity treatment. This does not undermine the overall correctness but slightly affects qualitative precision. Otherwise, entity names (Citibank, Morgan Stanley), years, and financial terms are accurate. The answer fully addresses the evolution in structure and value, noting the constant $0.4B forward value despite larger ASR size.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 435,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Duke Energy's disclosure regarding the Master Retirement Trust's pension asset valuation methodology evolve from 2023 to 2024, particularly in terms of transparency around fair value categorization?",
      "original_answer": "In 2023, Duke Energy disclosed the allocation percentages of the Master Retirement Trust among its subsidiaries and noted that certain investments measured at fair value using the net asset value per share practical expedient were not categorized in the fair value hierarchy. In 2024, the company maintained the same allocation percentages but added a new disclosure element — a reconciliation of beginning and ending balances of the Master Retirement Trust's qualified pension and other post-retirement assets, specifically those valued using significant unobservable inputs (Level 3). This represents a significant increase in transparency regarding the fair value categorization of pension assets.",
      "llm_answer": "In the 2023 Form 10‑K Duke Energy explained that the Master Retirement Trust’s assets are measured at fair value using the ASC 820 hierarchy (Level 1, 2 and 3) and that “certain investments that are measured at fair value using the net‑asset‑value‑per‑share practical expedient have not been categorized in the fair‑value hierarchy” (see 2023 Note 17, pages 218‑219).  \n\nThe 2024 filing repeats the same hierarchy‑based approach and the same footnote about “not‑categorized” investments, but it now presents a separate “Not Categorized (b)” column in the fair‑value tables and quantifies those amounts (e.g., $14 million of equity securities and $178 million total, down from $15 million and $179 million in 2023).  \n\nThus, the valuation methodology itself did not change, but the 2024 disclosure became slightly more transparent by explicitly tabulating the uncategorized fair‑value amounts and showing a modest reduction in those items.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but misses the key evolution in disclosure highlighted in the ground truth. It correctly notes that Duke Energy continued to exclude certain investments measured at net asset value (NAV) from the fair value hierarchy in both years and mentions a 'Not Categorized (b)' column with dollar amounts in 2024, which aligns with increased transparency. However, the LLM incorrectly emphasizes the quantification of uncategorized amounts as the primary enhancement, while the ground truth identifies the addition of a Level 3 reconciliation (beginning and ending balances for assets valued with significant unobservable inputs) as the major new disclosure. This is a critical omission, as reconciliations of Level 3 balances are a significant regulatory and transparency requirement under ASC 820 and represent a more material improvement than merely tabulating uncategorized amounts. The dollar figures cited ($14M, $178M, etc.) are plausible but not confirmed in the ground truth, which does not provide specific numbers for the uncategorized amounts—thus introducing unverified quantitative detail. While the entity (Duke Energy), years (2023–2024), and general topic (fair value categorization) are accurate, the reasoning fails to capture the correct multi-hop evolution: from no Level 3 reconciliation in 2023 to its inclusion in 2024. The answer is contextually relevant and correctly identifies that the methodology did not change, but the core transparency improvement is mischaracterized, leading to a partially correct assessment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 430,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did Pfizer's financial obligations and revenue recognition related to Paxlovid change between 2023 and 2024, particularly concerning the U.S. government's inventory return and the creation of the U.S. Strategic National Stockpile?",
      "original_answer": "In 2023, Pfizer recorded a non-cash revenue reversal of $3.5 billion related to the expected return of 6.5 million EUA-labeled Paxlovid treatment courses previously purchased by the U.S. government. In 2024, this estimate was adjusted based on the actual return of 5.1 million treatment courses, resulting in a favorable final adjustment of $771 million. Additionally, in 2024, Pfizer recognized $442 million of revenue in connection with the creation of the U.S. Strategic National Stockpile (SNS) of 1.0 million Paxlovid treatment courses for future pandemic preparedness. These developments reflect a shift from revenue reversal and inventory transition in 2023 to revenue recognition and strategic stockpile establishment in 2024.",
      "llm_answer": "In 2023 Pfizer booked a $3.5 billion non‑cash revenue reversal for Paxlovid because the U.S. government was expected to return about 6.5 million EUA‑labeled treatment courses, and the company carried roughly $3.4 billion of deferred Paxlovid revenue (about $1.5 billion current and $1.9 billion non‑current) and a $3.4 billion performance‑obligation liability for future deliveries.  \n\nIn 2024 the actual return of 5.1 million courses was recorded as a $771 million favorable adjustment in Q1, and in Q3 Pfizer supplied a 1‑million‑course U.S. Strategic National Stockpile at no cost, recognizing $442 million of revenue for that stockpile; these actions cut deferred Paxlovid revenue to $2.2 billion and reduced the remaining performance‑obligation liability to about $1 billion.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures all key financial events and figures from the ground truth. The $3.5 billion non-cash revenue reversal in 2023 due to expected return of 6.5 million Paxlovid courses is accurately stated. The 2024 favorable adjustment of $771 million based on the actual return of 5.1 million courses is correct. The $442 million revenue recognized in 2024 for the 1-million-course U.S. Strategic National Stockpile (SNS) is also accurately reported. (2) All numeric values match the ground truth: $3.5B reversal, $771M adjustment, $442M SNS revenue, 6.5M and 5.1M course quantities. The additional details about deferred revenue ($3.4B) and performance-obligation liability are not in the original answer but are factually consistent and add context without contradicting the ground truth. The reduction to $2.2B deferred revenue and $1B liability are plausible derived figures and do not introduce errors. (3) The multi-hop reasoning is sound: the answer connects 2023 revenue reversal to 2024 adjustment and links the SNS delivery to revenue recognition, correctly showing the shift in financial obligations and revenue recognition over time. The mention of Q1 and Q3 timing adds precision not in the original but aligns with typical reporting and does not conflict. (4) The only minor shortcoming is that the original answer emphasizes the conceptual shift from reversal to recognition and stockpile creation, which the LLM captures implicitly but not explicitly in summary form. However, all factual components are present and correctly synthesized. Thus, the answer is highly accurate, complete, and contextually appropriate, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 485,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the financial performance of ERLEADA evolved between 2022 and 2023, and what does this indicate about its role in J&J's oncology portfolio?",
      "original_answer": "ERLEADA's sales increased from $1,881 million in 2022 to $2,387 million in 2023, representing a 26.9% growth. This indicates that ERLEADA has become a more prominent contributor to J&J's oncology segment, which saw overall growth of 10.5% in 2023. The strong performance of ERLEADA contrasts with the decline in other key oncology products like IMBRUVICA and ZYTIGA, suggesting that ERLEADA is playing an increasingly important role in sustaining J&J's oncology revenue.",
      "llm_answer": "ERLEADA’s worldwide sales rose from $1.9 billion in 2022 to $2.4 billion in 2023 – a 26.9% increase (27.5% operational growth).  The 2023 MD&A notes that this growth was driven by continued share‑gain and market expansion in metastatic‑castration‑resistant prostate cancer, helping lift total oncology sales 10.5% year‑over‑year.  The strong sales acceleration signals that ERLEADA is becoming an increasingly important, growth‑driving pillar of Johnson & Johnson’s oncology portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports ERLEADA's sales growth from $1.9 billion in 2022 to $2.4 billion in 2023, which aligns with the ground truth values of $1,881 million and $2,387 million (rounded appropriately). The calculated growth rate of 26.9% is accurate and matches the ground truth. The mention of 27.5% operational growth is an additional detail not in the original answer but does not contradict it, as operational growth adjusts for currency effects and may come from the MD&A. (2) All numeric values are factually correct when accounting for rounding: $1.9B ≈ $1,881M and $2.4B ≈ $2,387M; the 26.9% growth is precisely calculated [(2387 - 1881) / 1881 ≈ 0.269]. (3) The reasoning is sound: the LLM correctly identifies ERLEADA’s role in driving oncology segment growth (10.5% YoY), which matches the ground truth. It also infers ERLEADA’s increasing strategic importance, supported by market expansion and share gains. However, the LLM omits the contrast with declining products like IMBRUVICA and ZYTIGA, which is a key part of the original answer’s multi-hop reasoning that underscores ERLEADA’s rising prominence. This omission slightly weakens the qualitative depth but does not invalidate the conclusion. (4) The answer is highly contextually relevant, directly addressing both parts of the question—financial performance evolution and strategic role. Scores reflect near-perfect quantitative accuracy and strong qualitative reasoning, with a minor deduction in qualitative accuracy due to missing comparative product performance context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 431,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the global sales performance of ERLEADA evolve from 2022 to 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA reported worldwide sales of $1,291 million, with a significant growth rate of 70.0% compared to the previous year. By 2023, the product's global sales increased further to $2,387 million, reflecting a 26.9% growth from 2022. This indicates that ERLEADA continued to experience strong market adoption and revenue expansion, albeit at a slower growth rate compared to the prior year, suggesting a maturing growth phase in its lifecycle.",
      "llm_answer": "In 2023 Johnson & Johnson reported worldwide ERLEADA sales of **$2.387 billion**, up from **$1.881 billion** in 2022 – a **26.9 % increase** year‑over‑year【page_31】. The company attributes this rise to “continued share gains and market growth in metastatic castration‑resistant prostate cancer”【page_32】, signalling that ERLEADA is gaining traction and expanding its market presence rather than plateauing.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical error in the 2022 sales figure. The ground truth states ERLEADA's 2022 global sales were $1,291 million, but the LLM incorrectly reports $1.881 billion ($1,881 million), which is factually wrong. The 2023 sales figure is correct at $2.387 billion ($2,387 million), and the reported year-over-year growth rate of 26.9% is accurate. However, this growth rate is only correct if comparing $2,387M to $1,881M — which itself is incorrect. In reality, the 26.9% growth from $1,291M to $2,387M is accurate, but the LLM’s input numbers do not support this — suggesting either a data error or miscalculation. (2) The quantitative accuracy is low because the 2022 sales number is significantly off by $590 million, which undermines the validity of the growth narrative. While the 26.9% growth and 2023 sales are correct, the foundational data is flawed. (3) The reasoning is partially sound: the LLM correctly interprets the 26.9% growth as indicative of continued market traction and references clinical context (metastatic castration-resistant prostate cancer) from the document, showing appropriate multi-hop synthesis between financial performance and therapeutic area dynamics. However, it fails to note the deceleration from 70.0% growth in 2022 (vs 2021), which is a key part of the market trajectory analysis in the ground truth. (4) Contextual relevance is high because the answer addresses the evolution of sales and infers market trajectory, using appropriate context from the filing. However, due to the incorrect 2022 baseline, the overall correctness score is reduced to 5 — partially correct but with significant factual inaccuracies affecting interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 467,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did NVDA's debt management strategy evolve regarding the 0.584% Notes Due 2024 between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a balance of $1,250 million for the 0.584% Notes Due 2024, with an effective interest rate of 0.66%. By fiscal year 2024, NVDA disclosed in its 10-K filing that it repaid these notes in fiscal year 2025, resulting in no remaining balance for this instrument as of January 26, 2025. This indicates a shift in NVDA's debt management strategy, where it chose to retire the obligation before or shortly after the due date rather than rolling it over or extending it.",
      "llm_answer": "In FY 2023 NVIDIA reported $1.25 billion of 0.584 % notes due 2024, with a remaining term of about 0.4 year and an effective interest rate of 0.66 %. The same amount and terms appear in the FY 2024 balance sheet, indicating the company kept the low‑cost, short‑term debt on its books through the year and did not refinance or retire it until after FY 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $1.25 billion (i.e., $1,250 million) balance and 0.66% effective interest rate for the 0.584% Notes Due 2024 in FY 2023, which matches the ground truth. However, it incorrectly states that the same amount 'appears in the FY 2024 balance sheet,' implying the debt remained outstanding at the end of FY 2024. The ground truth clarifies that NVDA repaid the notes in fiscal year 2025, with no remaining balance as of January 26, 2025—meaning the debt was retired, not carried forward. This misrepresents NVDA's debt management strategy. (2) Quantitatively, the dollar amount and interest rate are accurate, and formatting variations ($1.25 billion vs $1,250 million) are acceptable. However, the claim about the 'remaining term of about 0.4 year' is not in the original answer and appears speculative. More critically, the failure to reflect the repayment in FY 2025 introduces a major factual error. (3) The multi-hop reasoning is flawed: the model should have inferred from the original answer that the debt was repaid in FY 2025, indicating a strategy of retiring rather than rolling over the debt. Instead, the LLM concludes the debt was 'kept on books through the year,' which contradicts the ground truth. (4) Contextual relevance is fair—the response addresses NVDA's debt strategy and the specific notes—but due to the core error in interpreting the repayment timeline and strategic implication, the qualitative and overall correctness scores are low. The answer mischaracterizes the evolution of the strategy, which is the central focus of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1206,
        "completion_tokens": 442,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Honeywell's investment in Mortgage/Asset-backed securities evolve between 2022 and 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, Honeywell reported $982 million invested in Mortgage/Asset-backed securities under U.S. Plans. By 2023, this amount had significantly decreased to $10 million under Non-U.S. Plans. This represents a reduction of $972 million, or over 98%, indicating a major shift in Honeywell's investment strategy concerning Mortgage/Asset-backed securities.",
      "llm_answer": "Honeywell’s pension‑plan holding of mortgage‑ and asset‑backed securities fell sharply. The U.S. plans reported $1,119 million at 12/31/2022 and only $676 million at 12/31/2023 – a reduction of about $443 million (≈ 39 %). (2023 table shows $676 M; 2022 table shows $1,119 M)【page_109】",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Honeywell's investment in Mortgage/Asset-backed securities was $982 million in 2022 under U.S. Plans and dropped to $10 million in 2023 under Non-U.S. Plans, a reduction of $972 million (over 98%). However, the LLM claims $1,119 million in 2022 and $676 million in 2023 under U.S. Plans, citing a $443 million (39%) decrease. These numbers do not match the ground truth and misrepresent both the magnitude and direction of the change. (2) The quantitative accuracy is very low: the reported values are off by hundreds of millions of dollars, and the calculated reduction ($443M vs $972M) and percentage (39% vs >98%) are severely incorrect. The LLM also references 'page_109' as a source, but this does not align with the verified knowledge graph data. (3) The reasoning is flawed in terms of multi-hop synthesis: the model fails to correctly identify the shift from U.S. to Non-U.S. Plans and does not reflect the near-elimination of this asset class. Instead, it suggests a moderate decline within U.S. Plans, which contradicts the ground truth. (4) While the answer is contextually relevant—addressing Honeywell's investment trend in mortgage/asset-backed securities over 2022–2023—and attempts a quantitative comparison, the severe factual and numerical errors undermine correctness. The qualitative score is slightly higher because the model attempts correct reasoning structure (comparing two years, calculating change), but with wrong inputs. Hence, correctness is rated 2/10 due to major factual divergence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1157,
        "completion_tokens": 443,
        "total_tokens": 1601
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role in the company's funding mix and their fair value classification?",
      "original_answer": "In 2022, securitized debt obligations were described as a key component of Capital One's diversified funding strategy, used alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances to maintain access to wholesale funding sources. By 2023, the company disclosed that the carrying value of securitized debt obligations was $18,043 million, with an estimated fair value of $18,067 million, all classified under Level 2 of the fair value hierarchy. This indicates that while the company continued to rely on securitized debt obligations as a funding source, the 2023 data provides more specific transparency into their valuation and classification, showing a shift toward more detailed disclosure and potentially more structured risk management.",
      "llm_answer": "In 2022 Capital One reported $16.9 billion of securitized debt obligations, which it described as a core component of its long‑term funding mix alongside senior and subordinated notes. By year‑end 2023 the balance had risen to about $18.1 billion, reflecting a modest increase in the share of wholesale funding coming from securitizations, while the instruments remained measured at fair value on a Level 2 basis (no Level 1 or Level 3 classification).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Capital One's use of securitized debt obligations between 2022 and 2023, noting their role in the funding mix and fair value classification. The 2022 description aligns with the ground truth, identifying securitized debt as a core component of long-term funding. In 2023, the reported balance of $18.1 billion closely matches the ground truth carrying value of $18,043 million ($18.043 billion), with acceptable rounding. The estimated fair value of $18,067 million is not explicitly mentioned in the LLM answer, but the emphasis on the carrying value and Level 2 classification is accurate. (2) The quantitative values are largely correct: $16.9 billion in 2022 is a reasonable approximation (though the original answer does not provide the 2022 carrying value, so this may be from external data; however, it does not contradict the ground truth). The 2023 figure of $18.1 billion is a rounded version of $18,043 million, which is acceptable. The Level 2 classification is correctly stated. (3) The multi-hop reasoning is sound: the model synthesizes information about the role of securitized debt in the funding mix over two years and integrates fair value hierarchy classification. It correctly infers continuity in usage and increased reliance, supported by the increase in balance. (4) The answer is contextually excellent, directly addressing the evolution in funding mix role and fair value treatment. The only minor shortcoming is the lack of explicit mention of the 2023 fair value estimate ($18,067 million), which slightly reduces completeness. However, the core facts, trends, and classifications are accurately conveyed, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 470,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did JPMorgan's treatment of CECL capital transition provisions under U.S. capital rules evolve from 2023 to 2024, and what was the quantitative change in the CECL-related capital benefit during this period?",
      "original_answer": "In 2023, JPMorgan reported a $1.4 billion benefit from the CECL capital transition provisions included in its CET1 capital. By 2024, this benefit had decreased to $720 million, reflecting a phased reduction in the CECL-related capital benefit as the provisions were being phased in under U.S. capital rules. The capital metrics indicated that the CECL benefit was fully phased in by January 1, 2025.",
      "llm_answer": "JPMorgan continued to apply the U.S. CECL capital‑transition adjustments, but the benefit was being phased out. In 2023 its CET1 capital still included the full CECL transition credit of about **$1.4 billion**; by year‑end 2024 that credit had been reduced to the **remaining $720 million** that will be fully eliminated on 1 January 2025 (see 2024 tables – “CET1 capital reflected the remaining $720 million CECL benefit…as of Dec 31 2023…a $1.4 billion benefit”【page_104】 and the capital‑components note – $720 m vs. $1.4 bn 【page_105】).  \n\nThe CECL‑related capital benefit therefore fell by roughly **$680 million** from 2023 to 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the key facts: JPMorgan's CECL-related capital benefit decreased from $1.4 billion in 2023 to $720 million by the end of 2024, with full elimination scheduled for January 1, 2025. All numeric values match the ground truth exactly, including the correct dollar amounts and the phase-out timeline. The calculation of the reduction ($1.4B - $720M = $680M) is accurate and properly reported. 2) Quantitative accuracy is perfect: $1.4 billion and $720 million are correctly cited, and the $680 million decrease is a correct arithmetic derivation. Dates (year-end 2023, year-end 2024, January 1, 2025) align with the original answer. 3) The reasoning is sound and reflects proper multi-hop synthesis: the model connects the declining benefit to the regulatory phase-in process and correctly interprets the trajectory toward full elimination. The only minor issue is a slight misstatement in the parenthetical citation where it says the $720 million benefit was 'as of Dec 31, 2023' — this appears to be a citation error mixing two data points, but the main narrative correctly places $720M as the 2024 figure. This does not affect the overall correctness but slightly impacts qualitative precision. 4) The answer is contextually fully relevant, directly addressing both the evolution of the rule treatment and the quantitative change. Semantic equivalence with the original answer is strong, with only minor wording differences and one inconsequential citation confusion. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, but full marks for quantitative and contextual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 444,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did the terms and capacity of Salesforce's Revolving Loan Credit Agreement evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Salesforce had a $3.0 billion unsecured revolving credit facility under the Revolving Loan Credit Agreement, which was scheduled to mature in December 2025. By fiscal 2024, this agreement was replaced with a new $5.0 billion unsecured revolving credit facility that matures in October 2029. The increase in capacity and the extension of the maturity date reflect a strategic enhancement of the company’s credit resources.",
      "llm_answer": "In the 2023 filing Salesforce’s revolving‑loan facility was the “Prior Credit Agreement” dated December 23, 2020, which gave the company an **$3.0 billion unsecured revolving credit facility that was scheduled to mature in December 2025** and had no borrowings outstanding at the end of fiscal 2023【page_53】.  \n\nBy fiscal 2024 the company had replaced that agreement with a new **Revolving Loan Credit Agreement signed in October 2024**, expanding the facility to **$5.0 billion of unsecured borrowing capacity and extending the maturity to October 2029** (the new agreement superseded the 2020 $3 billion facility)【page_51】.  \n\nThus, between fiscal 2023 and fiscal 2024 the credit agreement’s borrowing limit increased by $2 billion and its maturity was pushed out by roughly four years.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitative accuracy: The dollar amounts ($3.0 billion in fiscal 2023 and $5.0 billion in fiscal 2024) are correct, as are the maturity dates (December 2025 and October 2029). The increase of $2 billion in capacity and extension of maturity by approximately four years is accurately calculated. (2) Completeness: The answer addresses both the capacity and terms (maturity date) of the Revolving Loan Credit Agreement across both fiscal years, as required by the question. (3) Entity accuracy: Salesforce is correctly identified, and the fiscal years 2023 and 2024 are properly referenced. The mention of the 'Prior Credit Agreement' dated December 23, 2020, and its replacement in October 2024 aligns with the timeline in the filings. (4) Reasoning: The multi-hop synthesis—comparing the old and new agreements across two fiscal years—is sound. The conclusion about increased capacity and extended maturity correctly reflects the strategic evolution. (5) Semantic equivalence: Though the LLM adds minor contextual details (e.g., no borrowings outstanding, agreement superseding prior one), all added information is consistent with the ground truth, and the core facts are conveyed accurately. Minor wording differences do not affect factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 370,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did UPS's relationship with Coyote evolve between 2022 and 2024, and what financial impact did this change have on UPS in 2024?",
      "original_answer": "In 2022, UPS had an active business relationship with Coyote, operating it as a branded subsidiary that provided truckload brokerage services in the U.S. and Europe. Coyote was integrated into UPS’s broader supply chain offerings, leveraging the UPS fleet and third-party carrier networks to provide customized transportation solutions. However, by 2024, UPS had completed the divestiture of Coyote, recording a pre-tax gain of $156 million ($152 million after tax) as a result of the transaction. This change marks a full transition from a strategic business unit to a divested asset, reflecting a shift in UPS's supply chain strategy.",
      "llm_answer": "In the 2022 filing UPS still owned Coyote – it was described as the “Coyote‑branded subsidiaries” that provide truck‑load brokerage services within the Supply Chain Solutions segment. By 2024 UPS had sold the business; the 2024 filing notes that the divestiture of Coyote was completed in the third quarter and produced a pre‑tax gain of roughly $156 million (about $152 million after tax) that was recorded in other expenses for the year.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) All key facts are correct: UPS owned Coyote in 2022 as a branded subsidiary providing truckload brokerage services, and by 2024 had completed its divestiture. The financial impact—a pre-tax gain of $156 million ($152 million after tax)—is accurately reported. (2) Quantitative accuracy is perfect: the dollar amounts and tax implications match exactly, with acceptable phrasing like 'roughly $156 million' reflecting the original figure without distortion. (3) Multi-hop reasoning is sound: the answer synthesizes information across time (2022 to 2024), entities (UPS and Coyote), and financial outcomes (gain on divestiture), correctly identifying the strategic shift and its accounting treatment. (4) The answer addresses both parts of the question: the evolution of the relationship and the financial impact in 2024. Wording differs slightly from the original but maintains full semantic equivalence. No errors in entities, years, or metrics. All aspects meet the highest standard.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 303,
        "total_tokens": 1568
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Union Pacific's relationship with chassis evolved between 2023 and 2024, particularly in terms of total units and ownership structure?",
      "original_answer": "In 2023, Union Pacific had a total of 48,340 chassis units, with 30,635 owned and 17,705 leased. By 2024, the total number of chassis dropped significantly to 5,553 units, with only 4,356 owned and 1,197 leased. This represents a transformation in Union Pacific's relationship with chassis, shifting from a heavy reliance on both owned and leased chassis to a much smaller, still mixed but significantly reduced footprint. The drastic reduction in total chassis units indicates a strategic shift in how the company manages this asset class.",
      "llm_answer": "Union Pacific’s chassis inventory contracted sharply from 2023 to 2024. In 2023 the company reported 48,340 chassis (30,635 owned + 17,705 leased), whereas in 2024 the total fell to 5,553 chassis, of which 4,356 were owned and 1,197 were leased. Thus, the overall number of chassis dropped dramatically and the ownership mix shifted toward a higher proportion of owned units.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All numeric values are correct: 2023 totals (30,635 owned + 17,705 leased = 48,340) and 2024 totals (4,356 owned + 1,197 leased = 5,553) match the original answer exactly. There are no calculation errors. (2) The answer addresses both parts of the question—total units and ownership structure—across 2023 and 2024, confirming completeness. (3) Entities (Union Pacific, chassis units, ownership types, years) are correctly identified. (4) The reasoning is sound: the LLM correctly infers a dramatic reduction in chassis inventory and notes a shift toward a higher proportion of owned units, which is valid (in 2023, 63.4% owned; in 2024, 78.4% owned). The only minor shortcoming is that it does not explicitly characterize the change as a 'strategic shift' or comment on the broader transformation in asset management as the original answer does, slightly reducing qualitative depth. However, the core facts, numbers, and synthesis are correct, and the answer is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 304,
        "total_tokens": 1531
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Boeing's treatment and disclosure of aluminum agreements evolved between 2022 and 2024, particularly in terms of their classification as derivatives and the time horizon for these agreements?",
      "original_answer": "In 2022, Boeing disclosed that its aluminum agreements were classified as derivatives but were not designated for hedge accounting treatment, with changes in fair value recorded in earnings immediately. The agreements were described in the context of long-term strategic sourcing objectives and non-U.S. business requirements. By 2024, the disclosure evolved to indicate that these aluminum agreements were now part of a broader set of commodity contracts hedging forecasted transactions through 2028. This represents a shift from purely strategic sourcing to a more structured hedging strategy with a defined time horizon extending to 2028.",
      "llm_answer": "- 2022 10‑K – Boeing disclosed that its long‑term purchase‑ and sale‑agreements for aluminum are **treated as derivative instruments** for accounting purposes, but **they are not designated for hedge accounting** and the filing gave no specific forward‑looking time frame for those contracts.  \n\n- 2024 10‑K – The company repeats that the aluminum agreements are **derivatives not eligible for hedge accounting**, but now explicitly states that the commodity contracts (including the aluminum agreements) are used to **hedge forecasted transactions through 2028**, indicating a disclosed multi‑year horizon that was not mentioned in the 2022 filing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, Boeing classified aluminum agreements as derivatives not designated for hedge accounting, with no specified time horizon; by 2024, these were included in commodity contracts hedging forecasted transactions through 2028. (2) Quantitative accuracy is perfect: the time horizon 'through 2028' matches the ground truth, and no incorrect numbers are presented. (3) The multi-hop reasoning is sound—correctly identifying the evolution between years and the shift in disclosure from strategic sourcing to structured hedging. (4) The only minor shortcoming is that the LLM does not explicitly mention the 'long-term strategic sourcing objectives and non-U.S. business requirements' context from 2022, nor the broader conceptual shift toward a 'structured hedging strategy.' While the functional evolution is captured (no time frame → 2028 horizon), the deeper strategic repositioning is slightly under-articulated. However, the core factual and quantitative content is fully correct, with excellent semantic equivalence. Hence, a score of 9 is warranted for correctness, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 348,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Procter & Gamble's exposure to currency rate risk evolved between the fiscal years ended June 30, 2023 and June 30, 2024, particularly in terms of its hedging instruments and confidence in mitigating near-term exchange rate fluctuations?",
      "original_answer": "Procter & Gamble's exposure to currency rate risk remained materially unchanged between the fiscal years ended June 30, 2023 and June 30, 2024. The company continued to use forward contracts and currency swaps with maturities of less than 18 months to manage exchange rate risk. Additionally, P&G maintained its assessment that, at a 95% confidence level based on historical currency rate movements, the impact of a near-term change in currency rates would not materially affect its financial statements in either reporting period.",
      "llm_answer": "Procter & Gam­ble’s currency‑rate risk profile was essentially unchanged from FY 2023 to FY 2024.  The company continues to rely on its natural‑hedge balance sheet and to manage financing‑related exposure with short‑term forward contracts and currency swaps (generally under 18 months), and it reports that “our market‑risk exposures … have not changed materially versus the previous reporting period.”  Accordingly, management still says that, based on a 95 %‑confidence VaR analysis, a near‑term move in exchange rates would not be expected to have a material effect on its financial statements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Procter & Gamble's currency risk exposure remained materially unchanged between FY2023 and FY2024; the company used forward contracts and currency swaps with maturities under 18 months; and it maintained a 95% confidence level (via VaR analysis) that near-term exchange rate fluctuations would not materially affect financial statements. (2) Quantitative elements—'95%', 'under 18 months', and 'near-term'—are correctly reported with no calculation errors. Format variations (e.g., '95 %' vs '95%') are acceptable. (3) The multi-hop reasoning is sound: the answer synthesizes information about risk exposure, hedging instruments, and confidence level across two fiscal years, correctly concluding no material change. The inclusion of 'natural-hedge balance sheet' and a direct quote adds contextual richness not in the original but does not contradict it. (4) The only minor deviation is the use of 'VaR analysis' (Value at Risk), which is implied by '95% confidence level based on historical movements' in the original, but not explicitly named—this is a reasonable inference and commonly understood in financial contexts. Thus, the answer is highly accurate, complete, and relevant, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 392,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How has Adobe's positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its functional scope and integration with other Adobe products?",
      "original_answer": "In 2022, Frame.io was listed among Adobe's trademarks, indicating it was an established product within Adobe's portfolio but with no detailed description of its functionality or integration. By 2024, Frame.io was actively described as a 'cloud-native creative collaboration platform' with expanded capabilities such as real-time upload, review and approval, frame-accurate commenting, and Camera to Cloud functionality. It was also integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and positioned as part of Adobe GenStudio for large-scale content production. This reflects a significant evolution from a trademarked asset to a core collaborative tool deeply embedded in Adobe's creative workflow.",
      "llm_answer": "In the 2022 Form 10‑K Adobe did not highlight Frame.io at all, treating it as a peripheral acquisition rather than a distinct product in its portfolio. By the 2024 filing, Adobe positions Frame.io as a “cloud‑native creative collaboration platform” that now supports real‑time upload, frame‑accurate commenting, camera‑to‑cloud ingest, and workflow management for video, still images, design files and PDFs, and it is **directly integrated** into Premiere Pro, After Effects, Photoshop, Lightroom, Workfront and the GenStudio suite alongside Express and Firefly Services. This reflects a shift from a modest, post‑production‑focused tool to a broadly scoped, tightly‑woven collaboration hub across Adobe’s Creative Cloud, Document Cloud and GenStudio offerings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that Frame.io was not highlighted in the 2022 10-K beyond being a trademark, and by 2024 is described as a 'cloud-native creative collaboration platform' with expanded functionality—this matches the original answer's timeline and evolution narrative. (2) All functional capabilities mentioned—real-time upload, frame-accurate commenting, camera-to-cloud, integration with Premiere Pro, After Effects, Photoshop, Lightroom, Workfront, and GenStudio—are factually correct and consistent with the ground truth; no numeric inaccuracies exist (dates: 2022 vs 2024 are correct). (3) The multi-hop reasoning is sound: the model infers a strategic shift from peripheral asset to core integrated tool, correctly synthesizing changes in positioning and integration across years. (4) Minor deduction in qualitative accuracy due to the claim that Adobe 'did not highlight Frame.io at all' in 2022—while it wasn't described in detail, it was listed as a trademark, so 'not highlighted' is slightly overstated but not factually incorrect. Otherwise, the answer is semantically equivalent, comprehensive, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 341,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between the 2022 and 2023 fiscal years, particularly in terms of the carrying value of its investment and the nature of its financial disclosures?",
      "original_answer": "In the 2022 filing, AMD disclosed that the carrying value of its investment in the ATMP JV was $69 million as of December 25, 2021, and $63 million as of December 26, 2020. Additionally, AMD provided detailed figures regarding purchases from and resales to the ATMP JV, including purchases of $1.1 billion in 2021 and $831 million in 2020. In contrast, the 2023 filing omits any mention of the carrying value of the investment and specific transaction figures, only reiterating the structural details of the relationship, such as AMD's 15% equity interest and the accounting method used. This indicates a reduction in the level of financial disclosure regarding the ATMP JV, even though the nature of the relationship and AMD's equity stake remained unchanged.",
      "llm_answer": "In the 2022 Form 10‑K AMD reported that its 15 % equity interest in the ATMP joint venture was carried at about **$83 million** at year‑end, and it disclosed a $14 million equity‑income gain for that year. The 2023 Form 10‑K shows the carrying amount had risen to roughly **$99 million** at year‑end, with a $16 million equity‑income gain, and the filing now includes a more detailed note (expanded “Related Parties‑Equity Joint Ventures” section) that spells out the JV’s purchase and resale volumes, payables and receivables, and reiterates that AMD has no funding obligation while continuing to use the equity method. Thus, the investment’s book value increased and the company’s disclosures became more granular and comprehensive.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth in both quantitative and qualitative aspects. (1) Quantitatively, the LLM reports a carrying value of $83 million in 2022 and $99 million in 2023, but the ground truth states the carrying values were $69 million as of December 25, 2021 (reported in the 2022 filing) and $63 million as of December 26, 2020 — there is no data provided for the 2023 filing year-end value, and the LLM fabricates an increase when no such data exists. Additionally, the LLM invents equity income figures of $14 million and $16 million, which are not present in the original answer and cannot be verified from the provided truth. (2) The LLM falsely claims that the 2023 filing includes more detailed disclosures, including expanded notes on purchase/resale volumes, payables, and receivables. In reality, the ground truth states the opposite: the 2023 filing omits transaction figures and carrying values entirely, providing only structural details. This is a complete reversal of the actual disclosure trend. (3) The multi-hop reasoning is flawed: the question asks about the evolution of AMD's financial relationship and disclosure practices, and the correct inference is a reduction in transparency. The LLM incorrectly infers increased disclosure and financial growth in the investment, which is unsupported and factually wrong. (4) While the LLM correctly identifies AMD’s 15% equity interest and use of the equity method, this minor accuracy does not compensate for the pervasive factual errors. The contextual relevance is moderate because it addresses the right topic (ATMP JV, carrying value, disclosures), but the substance is fundamentally incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 465,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did Honeywell's revenue from Commercial Aviation Original Equipment evolve between 2023 and 2024, and what does this indicate about its position in the aerospace sector?",
      "original_answer": "Honeywell's revenue from Commercial Aviation Original Equipment decreased from $2,397 million in 2023 to $2,223 million in 2024. This decline suggests a contraction in this segment despite overall growth in the Aerospace Technologies division, indicating a potential weakening in original equipment demand or supply constraints in this specific product line.",
      "llm_answer": "Honeywell’s Commercial Aviation Original Equipment revenue fell from **$2,397 million in 2023 to $2,223 million in 2024**, a drop of about $174 million (≈7 %). The decline signals a modest contraction in OEM sales, yet the still‑large $2.2 billion figure underscores Honeywell’s continued relevance and strong foothold in the aerospace market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reported the revenue figures for Honeywell's Commercial Aviation Original Equipment: $2,397 million in 2023 and $2,223 million in 2024, matching the ground truth exactly. The calculated drop of $174 million (≈7%) is accurate: (2,397 - 2,223) = 174; (174 / 2,397) ≈ 7.26%, which rounds to ≈7%, so the percentage is reasonably approximated. (2) The question had two parts: evolution of revenue and what it indicates about Honeywell’s position. The LLM addressed both: it correctly described the decline and offered interpretation—contraction in OEM sales but maintained relevance due to the large revenue base. While the ground truth emphasizes 'potential weakening in original equipment demand or supply constraints,' the LLM focuses on 'continued relevance and strong foothold,' which is a slightly more positive spin but not factually incorrect given the still-significant revenue. (3) Multi-hop reasoning is sound: the model synthesized year-over-year revenue data and inferred a trend in market position. The entity identification (Honeywell, Commercial Aviation Original Equipment, correct years) is accurate. (4) The answer is semantically equivalent in quantitative terms and mostly aligned in qualitative interpretation. The only minor shortcoming is that it omits the nuance about supply constraints or demand weakness explicitly mentioned in the ground truth, instead emphasizing resilience. This does not make it incorrect but slightly less precise in diagnostic reasoning. Hence, full marks for quantitative accuracy and contextual relevance, near-perfect for qualitative accuracy, and a 9 overall for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1182,
        "completion_tokens": 453,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How did the global revenue contribution from Heart Failure Devices evolve between 2023 and 2024, and what was the percentage change in this segment's total revenue?",
      "original_answer": "In 2023, the global revenue from Heart Failure Devices was $1,161 million, while in 2024, this figure increased to $1,279 million. This represents a 10.2% increase in total revenue for the Heart Failure Devices segment. The growth was consistent across both U.S. and international markets, with minimal impact from exchange rate fluctuations, indicating strong underlying demand and market expansion.",
      "llm_answer": "In 2023 Abbott reported **$1.161 billion** of worldwide sales from its Heart‑Failure medical‑device portfolio; in 2024 that figure rose to **$1.279 billion**.  The segment’s total revenue therefore grew by **approximately 10 % (10.2 % increase)** year‑over‑year.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: 2023 revenue is correctly stated as $1.161 billion ($1,161 million), 2024 revenue as $1.279 billion ($1,279 million), and the percentage change as 10.2% (noted as 'approximately 10%' with exact value in parentheses). (2) Quantitative accuracy is perfect: the dollar amounts match exactly (allowing for format variation: billion vs million), and the 10.2% increase is correctly calculated — (1,279 - 1,161) / 1,161 ≈ 0.1016 ≈ 10.2%. (3) The reasoning is sound: the LLM correctly identifies year-over-year growth in the Heart Failure Devices segment and synthesizes the two data points to compute the percentage change, fulfilling the multi-hop requirement. (4) While the LLM omits the detail about U.S. and international market consistency and exchange rate impact, this contextual information was not explicitly required by the question, which only asked for revenue evolution and percentage change. Thus, the answer is complete for the scope of the question. All entities (Heart Failure Devices, years 2023 and 2024, revenue metric) are correct. The answer is highly relevant, precise, and factually aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1170,
        "completion_tokens": 350,
        "total_tokens": 1520
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How has IBM's treatment of the 0.300% Notes due 2028 evolved between the 2022 and 2023 filings?",
      "original_answer": "In the 2022 filing, the 0.300% Notes due 2028 were referenced as part of a list of debt instruments, with their rights defined in Exhibit 4.1 to Form 8-K filed February 10, 2020, and incorporated by reference. By 2023, the 0.300% Notes due 2028 were formally listed in the table of registered securities with a specific trading symbol (IBM 28B) and explicitly called out as a distinct class of notes registered on the New York Stock Exchange. This reflects a shift from general incorporation by reference to explicit disclosure and formal registration.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K filings continue to list the 0.300 % Notes due 2028 (IBM 28B) among IBM’s registered debt securities, with no new redemption, amendment or retirement provisions disclosed. In other words, IBM’s accounting and reporting treatment of the 0.300 % Notes due 2028 remained unchanged between the two filings.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains some correct entities and formatting (e.g., '0.300% Notes due 2028', 'IBM 28B'), which supports a moderate quantitative accuracy score. However, the core claim—that IBM’s treatment of the notes 'remained unchanged'—is factually incorrect per the ground truth. The original answer shows a clear evolution: in 2022, the notes were only incorporated by reference via an Exhibit 4.1 to a Form 8-K from 2020, while in 2023, they were explicitly listed in the registered securities table with a trading symbol and formal NYSE registration. This shift from indirect reference to explicit disclosure and registration represents a meaningful change in reporting and regulatory treatment, which the LLM answer completely misses. The LLM incorrectly asserts no change in 'accounting and reporting treatment', failing the multi-hop reasoning requirement to compare the two filings’ disclosures. This fundamental error in qualitative analysis and contextual understanding severely undermines the answer’s correctness. While the mention of IBM 28B aligns with the 2023 filing, the absence of any recognition of the enhanced disclosure and formal registration leads to a low correctness and qualitative accuracy score. Contextual relevance is moderate because the answer addresses the right instrument and timeframe but mischaracterizes the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1209,
        "completion_tokens": 376,
        "total_tokens": 1585
      },
      "error": null
    },
    {
      "question_id": 158,
      "question": "How has Apple's financial performance in the Rest of Asia Pacific region evolved from 2022 to 2023, based on changes in net sales and operating income?",
      "original_answer": "In 2022, Apple's Rest of Asia Pacific segment reported net sales of $29,375 million and operating income of $11,569 million. In 2023, these figures increased to $29,615 million in net sales and $12,066 million in operating income. This represents a moderate growth in both metrics, with net sales rising by $240 million (0.8%) and operating income increasing by $497 million (4.3%).",
      "llm_answer": "Apple’s Rest of Asia Pacific segment saw modest growth from 2022 to 2023. Net sales rose from $29,375 million in 2022 to $29,615 million in 2023 (≈ + $240 million), while operating income increased from $11,569 million to $12,066 million (≈ + $497 million)【page_50】. This reflects a slight uptick in sales and a stronger gain in profitability for the region.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) All numeric values are accurate: net sales of $29,375 million in 2022 and $29,615 million in 2023, and operating income of $11,569 million in 2022 and $12,066 million in 2023. The differences of +$240 million in net sales and +$497 million in operating income are correctly calculated. (2) The percentage increases (0.8% and 4.3%) are not explicitly stated but the absolute changes are accurately reported, and the qualitative description of 'modest growth' and 'stronger gain in profitability' aligns with the data. (3) The entities—Apple, Rest of Asia Pacific, 2022–2023 time frame, net sales, and operating income—are correctly identified and synthesized. (4) The reasoning is sound: the model correctly infers growth trends from multi-year financial data, accurately compares the two years, and draws a reasonable conclusion about sales and profitability trends. The answer is semantically equivalent to the original, with only minor wording differences (e.g., 'modest growth' vs 'moderate growth'). All evaluation criteria are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1186,
        "completion_tokens": 319,
        "total_tokens": 1505
      },
      "error": null
    },
    {
      "question_id": 169,
      "question": "How has the vesting period for stock options issued under the 2007 Omnibus Incentive Plan evolved between grants made prior to 2022 and those made after December 31, 2021, based on disclosures in the 2022 and 2024 10-K filings?",
      "original_answer": "In the 2022 10-K filing, stock options granted prior to 2022 under the 2007 Omnibus Incentive Plan generally vested pro rata over a five-year period, while those granted after December 31, 2021, under the amended and restated plan, generally vested pro rata over a four-year period. The 2024 10-K confirms that stock options granted prior to 2022 continued to vest pro rata over a five-year period, and those granted after December 31, 2021, also continued to vest pro rata over a four-year period. This indicates a consistent reduction in the vesting period from five to four years for post-2021 grants, showing a structural change in the incentive plan's vesting terms over time.",
      "llm_answer": "The 2007 Omnibus Incentive Plan originally provided that stock‑option awards granted **before 2022 vest pro‑rata over five years** (with a ten‑year expiration). In the amendments reflected in the 2024 filing, any options **granted after December 31, 2021 vest pro‑rata over four years** (still terminating ten years from the grant date). Thus, the standard vesting schedule was shortened from five to four years for post‑2021 grants.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential information from the ground truth. (1) Quantitatively, all key facts are correct: stock options granted before 2022 (i.e., prior to January 1, 2022) vest pro-rata over five years; those granted after December 31, 2021 (i.e., on or after January 1, 2022) vest over four years. The dates and time periods match exactly with the original answer. (2) The LLM correctly identifies the structural change in vesting periods due to amendments to the 2007 Omnibus Incentive Plan, as reflected in the 2024 10-K. (3) The multi-hop reasoning is sound—synthesizing data from both the 2022 and 2024 10-K filings to show consistency in treatment over time. However, the LLM does not explicitly mention that the 2024 10-K *confirms* the continued application of both vesting schedules (for pre-2022 and post-2021 grants), which is a minor omission in completeness. The ground truth emphasizes this continuity, while the LLM implies it but doesn't state it directly. (4) Despite this slight gap, the answer is semantically equivalent in substance, uses correct terminology, and addresses the evolution of vesting terms accurately. Hence, a score of 9 is appropriate—excellent accuracy with only a minor reduction for lack of explicit confirmation from the 2024 filing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 364,
        "total_tokens": 1663
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How has CVS's approach to validating the fair value estimates for its Level 2 debt securities evolved from 2022 to 2023, particularly in terms of price adjustments and secondary source comparisons?",
      "original_answer": "In 2022, CVS obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December 31, 2021 or 2020. The company compared selected sample prices quarterly to secondary sources and reviewed variances over a specified threshold. In 2023, the company maintained the same validation methodology, obtaining one price per Level 2 debt security without any adjustments at December 31, 2023 or 2022, and continued to compare prices quarterly to secondary sources. Despite maintaining the same process, the emphasis on consistent internal validation by the investment team appears to have remained stable, indicating a sustained but unchanging approach to fair value estimation.",
      "llm_answer": "In the 2022 filing CVS explained that it reviews Level 2 debt‑security prices each quarter, compares a sample to a secondary‑source price, investigates any variance that exceeds a set threshold, and also checks the prices against its own investment‑team fair‑value estimates. It noted that the company “obtained one price for each of its Level 2 debt securities and did **not adjust any of those prices at December 31, 2021 or 2020**.”  \n\nThe 2023 filing repeats the same validation process—quarterly sampling, secondary‑source comparison and internal‑team cross‑checks—but updates the statement to say the company “did **not adjust any of those prices at December 31, 2023 or 2022**.”  \n\nThus, the approach has remained consistent; the only evolution is that the same no‑adjustment policy now extends to the most recent year‑end (2022‑2023) rather than the earlier years.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all dates and statements about price adjustments are accurate: the LLM correctly notes that CVS did not adjust prices at year-end 2021/2020 in the 2022 filing and extends this to 2022/2023 in the 2023 filing. The time periods are correctly referenced and aligned with the reporting years. (2) The answer is complete, addressing both years, the validation process (quarterly sampling, secondary-source comparison, threshold review), and the lack of price adjustments. It correctly identifies that the methodology did not change, which is the key insight. (3) Entity accuracy is perfect: 'CVS', 'Level 2 debt securities', and the correct years (2020–2023) are all properly referenced. (4) The reasoning is sound and reflects multi-hop synthesis: the model compares the 2022 and 2023 disclosures, infers consistency in methodology, and correctly interprets the updated date range as evidence of continuity rather than change. The conclusion that the only 'evolution' is the extension of the same policy to more recent years is semantically equivalent to the ground truth’s emphasis on a 'sustained but unchanging approach'. Wording differs slightly but meaning is preserved. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 367,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How did CVS's classification and valuation methodology for privately-placed equity securities evolve between 2022 and 2023, particularly in terms of fair value determination and unobservable inputs?",
      "original_answer": "CVS maintained a consistent classification of privately-placed equity securities as Level 3 in both 2022 and 2023, indicating no active market for these securities. However, the company emphasized in both years that it uses an internal analysis of financial statements and cash flow projections to determine fair value. In 2022, the significant unobservable inputs included earnings and revenue multiples, discount for lack of marketability, and comparability adjustments. In 2023, the same unobservable inputs were referenced, but with an added emphasis on the potential impact of changes in these inputs on fair value measurements, suggesting a more detailed sensitivity analysis or increased scrutiny of these inputs in the valuation process.",
      "llm_answer": "In both the 2022 and 2023 10‑K filings CVS continued to place privately‑placed equity securities in **Level 3** of the fair‑value hierarchy because no active market exists. The fair value of these securities is still determined **internally** using a financial‑statement and cash‑flow analysis, with the key **unobservable inputs** being earnings and revenue multiples, a discount for lack of marketability and other comparability adjustments. Thus, the classification (Level 3) and the valuation approach—including the reliance on those unobservable inputs—remained unchanged from 2022 to 2023【page 148】【page 152】.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies that CVS classified privately-placed equity securities as Level 3 in both 2022 and 2023 and used an internal valuation approach based on financial statements and cash flow projections, with the same unobservable inputs (earnings and revenue multiples, discount for lack of marketability, comparability adjustments). This aligns with the ground truth and satisfies quantitative and entity accuracy—no numbers, dates, or financial terms are incorrect. However, the LLM answer states that the classification and valuation approach 'remained unchanged,' which omits a key qualitative evolution noted in the original answer: in 2023, CVS placed added emphasis on the sensitivity of fair value to changes in unobservable inputs, indicating enhanced scrutiny or more detailed sensitivity analysis. This nuance represents a meaningful development in valuation methodology that the LLM fails to capture, resulting in a partial miss on multi-hop reasoning and completeness. While the core facts are correct, the answer does not fully address how the methodology evolved in terms of fair value determination and unobservable inputs. Hence, correctness and qualitative accuracy are reduced, but not severely, as the main framework is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 353,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 184,
      "question": "How did the total net revenue from Alphagan/Combigan change between 2023 and 2024, and what was the trend in its international revenue during this period?",
      "original_answer": "The total net revenue from Alphagan/Combigan decreased from $272 million in 2023 to $248 million in 2024, reflecting an 8.8% decline. During the same period, its international revenue slightly increased from $151 million in 2023 to $153 million in 2024, representing a 1.5% growth.",
      "llm_answer": "The product’s total net revenue fell from **$272 million in 2023 to $248 million in 2024**, a drop of roughly $24 million (about an 8‑9% decline)【page_43】.  By contrast, the **international portion grew modestly**, rising from **$151 million in 2023 to $153 million in 2024** (about a 1‑2% increase)【page_43】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All numeric values match: total net revenue decreased from $272 million in 2023 to $248 million in 2024, a decline of $24 million. The percentage decline is correctly approximated as 8–9% (exact: 8.8%), and international revenue increased from $151 million to $153 million, a $2 million rise, with a growth rate of about 1–2% (exact: 1.5%). Minor rounding in percentages is acceptable and common. (2) Calculations are accurate: (272 - 248)/272 ≈ 8.8%, and (153 - 151)/151 ≈ 1.5%. The LLM correctly reports these as 'roughly' or 'about,' indicating appropriate approximation. (3) Multi-hop reasoning is sound: the model correctly synthesizes two distinct revenue trends (total vs. international) for the same product across two years, addressing both parts of the question. (4) Entities (Alphagan/Combigan, revenue types, years) are correctly identified and contextualized. The answer is complete, factually precise, and directly relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1149,
        "completion_tokens": 296,
        "total_tokens": 1446
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Chevron's relationship with PDC Energy evolved from 2023 to 2024, and what specific operational impact did this change have on Chevron's overall production performance?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, Inc. (PDC), and as a result, PDC was excluded from Chevron's internal control assessment over financial reporting due to the timing of the acquisition. By 2024, Chevron's relationship with PDC had evolved from a newly acquired entity to an integral operational component, as evidenced by the 7% increase in Chevron's worldwide oil-equivalent production, which was attributed in part to the full-year contribution from legacy PDC operations. This indicates that PDC Energy transitioned from being a recent acquisition in 2023 to a key contributor to Chevron's production growth in 2024.",
      "llm_answer": "In 2023 Chevron completed a business‑combination with PDC Energy, which was then reported as a wholly‑owned subsidiary (its revenues made up about 5 % of consolidated results). By the 2024 filing the company treated PDC Energy as an integrated part of Chevron’s operations, and the “full‑year of legacy PDC Energy production” lifted total oil‑equivalent output to 3.3 million bbl per day – roughly a 7 % rise (about 225,000 bbl per day) over 2023. This incorporation of PDC’s assets was the primary driver of the production increase shown in the 2024 results.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 acquisition of PDC Energy by Chevron and its integration into operations by 2024, aligning with the ground truth. It accurately notes the 7% increase in oil-equivalent production attributed to the full-year contribution from legacy PDC operations. The statement that PDC revenues made up about 5% of consolidated results is plausible and consistent with integration at that scale, though this specific percentage is not in the original answer; however, it does not contradict it and may be inferred. (2) Quantitatively, the 7% production increase is correctly stated, matching the original answer. The derived figure of ~225,000 bbl/day increase leading to 3.3 million bbl/day is logically consistent: a 7% rise on ~3.075 million bbl/day (2023 base) yields approximately 3.3 million, and the incremental 225k bbl/day is accurate. These numbers are not explicitly in the original answer but are reasonable inferences supported by the 7% growth claim. (3) The multi-hop reasoning is sound: the model connects the 2023 acquisition to 2024 operational integration and correctly infers the production impact as a result of full-year inclusion. It synthesizes timing, ownership change, and operational outcome across years. (4) Minor deduction in quantitative accuracy due to introduction of specific bbl/day figures (3.3 million, 225k) not present in the ground truth, though they are mathematically plausible. No error in core facts or logic. Qualitative accuracy is high due to correct entity identification (Chevron, PDC Energy), timeline (2023 acquisition, 2024 integration), and causal reasoning. Contextual relevance is perfect—directly addresses both parts of the question: evolution of relationship and operational impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 485,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has UPS's investment in cold-chain logistics capabilities evolved from 2023 to 2024, and what specific acquisitions contributed to this change?",
      "original_answer": "In 2023, UPS expanded its cold-chain logistics capabilities through the acquisition of Bomi Group and MNX Global Logistics, aiming to enhance its healthcare logistics services. By 2024, this strategic focus intensified with the acquisition of Frigo-Trans and Biotech & Pharma Logistics in Germany for approximately $440 million, signaling a significant increase in international investment in complex cold-chain logistics. This represents a shift from general expansion to targeted, high-value international acquisitions in the cold-chain sector.",
      "llm_answer": "UPS’s cold‑chain logistics investment expanded in 2023 when it bought two temperature‑sensitive providers – MNX Global Logistics and Bomi Group – to boost “complex cold‑chain logistics capabilities both in the U.S. and internationally”【page_6】.  By the end of 2024 the related goodwill in the Supply‑Chain‑Solutions segment fell from $3.522 billion to $2.966 billion, reflecting the divestiture of the Coyote truck‑load brokerage business and the fact that 2024’s only acquisition was a small franchise‑development purchase (≈$71 million) that did not add cold‑chain capacity【page_101】【page_103】.  Thus, UPS grew its cold‑chain footprint with the 2023 MNX and Bomi acquisitions, but the investment contracted in 2024 as no new cold‑chain assets were added and goodwill was reduced.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims that UPS did not make any cold-chain acquisitions in 2024 and that investment contracted, directly conflicting with the original answer, which states that UPS acquired Frigo-Trans and Biotech & Pharma Logistics in Germany in 2024 for approximately $440 million. These acquisitions represent a significant expansion, not contraction, of cold-chain capabilities. (2) The quantitative details are partially accurate but misapplied: the goodwill decrease from $3.522 billion to $2.966 billion and the $71 million franchise acquisition are factually consistent with the cited pages, but they are used to incorrectly infer that no cold-chain investments occurred in 2024. The $440 million acquisition in Germany is entirely omitted. (3) The multi-hop reasoning fails: instead of connecting the 2023 and 2024 acquisitions to show an evolution toward targeted international expansion, the model incorrectly infers a contraction due to goodwill reduction and divestitures unrelated to cold-chain logistics. (4) Entity accuracy is mixed: MNX Global Logistics and Bomi Group in 2023 are correctly identified, but Frigo-Trans and Biotech & Pharma Logistics are missing. The year 2024 is incorrectly characterized. (5) The answer is contextually relevant in discussing UPS’s cold-chain evolution but fundamentally wrong in conclusion, making it misleading despite some accurate data points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 401,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Linde plc's non-employee director restricted stock unit award program evolved between 2022 and 2024, particularly in terms of governance structure and long-term shareholder alignment mechanisms?",
      "original_answer": "In 2022, Linde plc introduced the Non-Employee Director Restricted Stock Unit Award under the 2021 Linde plc Long Term Incentive Plan, establishing a framework for equity-based compensation tied to long-term performance metrics. This initiative was part of a broader suite of incentive programs aimed at aligning director interests with those of shareholders. By 2024, the company expanded this framework by introducing the Linde plc Non-employee Director Deferral Program, adopted by the Board of Directors on July 30, 2024. This deferral program enhances governance by allowing directors to defer receipt of stock units, thereby reinforcing long-term alignment with shareholder value creation. The evolution from a basic restricted stock unit award to a more sophisticated deferral mechanism indicates Linde’s strategic emphasis on strengthening board accountability and promoting sustained corporate governance standards.",
      "llm_answer": "- In the 2022 filing the company disclosed two parallel vehicles for non‑employee directors – a “Form of Non‑Employee Director Restricted Stock Unit Award” that was part of the legacy 2009 Praxair Long‑Term Incentive Plan (see Exhibit 10.11h) and a separate RSU form that was tied to the newer 2021 Linde plc Long‑Term Incentive Plan (see Exhibit 10.0e) 【page_107】【page_105】.  \n\n- By the 2024 filing the program had been streamlined under the 2021 Linde plc LTIP (the same Exhibit 10 form is listed again) and was supplemented by a Board‑approved Non‑Employee Director Deferral Program (adopted July 30 2024) 【page_94】【page_96】.  The 2024 LTIP was also amended (First Amendment effective Jan 29 2024) to tighten long‑term shareholder‑alignment provisions such as performance metrics tied to total shareholder return 【page_94】.  \n\nThus, between 2022 and 2024 Linde moved from a dual‑plan structure to a single, 2021‑based RSU framework, added a formal deferral program, and amended the LTIP to link award vesting more directly to long‑term shareholder value, reflecting a stronger governance oversight and alignment with shareholders.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2022 introduction of the Non-Employee Director RSU under the 2021 Linde plc LTIP, the existence of legacy Praxair plan documents in 2022, the July 30, 2024 adoption of the Non-Employee Director Deferral Program, and the January 29, 2024 First Amendment to the LTIP. These dates and program names match the ground truth exactly. (2) Quantitative accuracy is perfect: all dates (July 30, 2024; January 29, 2024), plan names, and structural changes are correctly reported. The mention of Exhibit references and page numbers adds precision, though not required for correctness. (3) The reasoning is sound and reflects proper multi-hop synthesis: the LLM correctly infers evolution from a dual-plan structure (legacy Praxair and new Linde plans) to a unified framework under the 2021 LTIP, identifies the addition of the deferral program as a governance enhancement, and notes strengthened shareholder alignment via performance metrics tied to total shareholder return. This goes slightly beyond the ground truth by specifying the nature of the performance metric (TSR), which is a valid inference from 'long-term shareholder alignment' and consistent with typical LTIP designs. (4) The only minor gap is that the ground truth emphasizes the 'strategic emphasis on strengthening board accountability' and 'sustained corporate governance standards'—a broader interpretive point slightly underdeveloped in the LLM answer, though the core evolution in governance and alignment is clearly captured. Overall, the answer is factually superior, contextually precise, and semantically equivalent to the original with excellent reasoning and no factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1528,
        "completion_tokens": 475,
        "total_tokens": 2004
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did General Motors' financial and legal relationship with Stellantis evolve between 2022 and 2024, particularly regarding indemnification obligations and investment gains?",
      "original_answer": "In 2022, General Motors reported a gain of $0.2 billion related to Stellantis N.V. (Stellantis) warrants, indicating a positive financial relationship. However, by 2024, the relationship had evolved into a more complex and potentially costly one. GM had agreed to indemnify Stellantis for certain liabilities tied to pre-sale emissions claims, product liabilities, and recalls related to the 2017 sale of the Opel/Vauxhall business. Additionally, GM faced potential future liabilities from ongoing investigations into Opel’s historical conduct in Europe. Unlike the earlier gains, GM's 2024 disclosures highlighted contingent liabilities and legal risks rather than financial benefits from its relationship with Stellantis.",
      "llm_answer": "In the 2022 Form 10‑K GM disclosed that its non‑operating income included a **$0.2 billion gain on Stellantis N.V. warrants** (see page 36) but did not yet detail any post‑sale indemnification exposure to Stellantis. By the 2024 filing the company’s relationship had shifted to a **purely legal‑indemnity role**: GM Holdings LLC agreed to indemnify Stellantis for certain representations, warranties, emissions, product‑liability and recall costs arising from the 2017 Opel/Vauxhall sale, with the obligations subject to time limits, thresholds and caps (see page 93‑94). The 2024 note no longer highlights the Stellantis‑warrant gain, indicating that the investment‑related benefit reported in 2022 had faded, while the indemnification commitments remain on the books but are considered immaterial.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: the $0.2 billion gain in 2022 is accurately reported, and the absence of such gains in 2024 is correctly noted. The 2017 Opel/Vauxhall sale date is correct. (2) The answer correctly identifies the evolution from a financial gain (warrant-related) in 2022 to indemnification obligations in 2024, including specific liabilities: emissions, product liability, and recalls. It adds granular detail (e.g., time limits, thresholds, caps) not in the original but consistent with typical indemnification structures and SEC disclosures, which enhances accuracy without contradicting the ground truth. (3) Multi-hop reasoning is sound: it synthesizes information across two years (2022 and 2024), two companies (GM and Stellantis), and two types of relationships (financial investment and legal indemnity). (4) The only minor shortcoming is the claim that the indemnification role is 'purely legal-indemnity' and that obligations are 'immaterial'—the latter is an interpretation not present in the original answer, which emphasizes 'contingent liabilities and legal risks' without assessing materiality. This slight overreach prevents a perfect 10 on qualitative accuracy. Otherwise, the answer is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 379,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolved from 2022 to 2024, particularly in terms of their financial presentation and categorization?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of energy-related derivatives not designated as hedging instruments on the statements of income for prior years (2021, 2020, and 2019), indicating a focus on income statement impacts. By 2024, the company shifted its disclosure to emphasize the fair value of energy-related derivatives as either assets or liabilities on the balance sheets, specifically categorized under 'Other' or 'Risk Management Activities'. This represents a shift from income-focused reporting to balance sheet-oriented transparency.",
      "llm_answer": "In the 2022 Form 10‑K Southern Company disclosed its energy‑related derivatives only in a consolidated “derivatives” table that grouped them by hedge type (regulatory, cash‑flow/fair‑value and non‑designated) and showed only gross, offset and net amounts, with a brief discussion of the income‑ and OCI‑effects of those hedges. By the 2024 filing the company had broken the disclosure out by entity (Southern Company, Alabama Power, Georgia Power, Mississippi Power, Southern Power and Southern Company Gas), separated current‑ and non‑current assets and liabilities, and presented the three hedge categories side‑by‑side with interest‑rate and foreign‑currency derivatives, while also adding a narrative that spells out the three accounting methods (regulatory hedge, cash‑flow hedge and non‑designated) and provides volume and maturity information. Thus, the treatment of the derivatives remained the same, but the presentation evolved from a single consolidated summary to a much more granular, entity‑level, balance‑sheet‑location format that distinguishes assets versus liabilities and adds supplemental explanatory detail.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Southern Company's derivative disclosures from 2022 to 2024. It accurately captures the shift in presentation from a consolidated income-focused format in 2022 to a more detailed, balance-sheet-oriented, entity-level breakdown in 2024. The dates (2022 and 2024) and entities (Southern Company and its subsidiaries) are correctly identified, and there are no numerical inaccuracies—since the original answer does not include specific dollar amounts or percentages, the absence of such figures in the LLM response is not a deficiency. The LLM adds granular detail not present in the ground truth (e.g., breakdown by subsidiary, separation of current/non-current, inclusion of interest-rate and foreign-currency derivatives), which is consistent with enhanced disclosure practices and plausibly reflects the actual evolution in reporting. However, the ground truth emphasizes a conceptual shift from 'income statement impacts' to 'balance sheet-oriented transparency,' particularly highlighting the categorization under 'Other' or 'Risk Management Activities.' While the LLM describes balance sheet location and categorization implicitly, it does not explicitly mention these specific categories, which slightly weakens the qualitative match. The reasoning is sound and multi-hop: it synthesizes changes in disclosure format, structure, and narrative detail across years. The answer is highly relevant and provides a richer descriptive account than the ground truth, though minor omission of the exact categorization labels ('Other' or 'Risk Management Activities') prevents a perfect score. Overall, the semantic meaning and factual core are preserved with high accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 479,
        "total_tokens": 1910
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did GILD's strategic relationship with Arcus evolve between 2023 and 2024, particularly in terms of equity ownership and governance influence?",
      "original_answer": "In 2023, GILD owned approximately 19.9% of Arcus' issued and outstanding voting stock and had two designees on Arcus' board of directors. In January 2024, GILD made an additional $320 million equity investment in Arcus, increasing its ownership to 33%, and expanded its board representation to three designees. This represents a significant increase in both financial commitment and governance influence over Arcus within a year.",
      "llm_answer": "In 2023 Gilead’s Arcus partnership gave it roughly 19.9 % of Arcus’s voting shares (the maximum it could own under the stock‑purchase agreement) and two seats on Arcus’s board. In January 2024 Gilead amended the agreement, invested $320 million, lifted its stake to about 33 % (near the 35 % ceiling) and increased its board representation to three designees, thereby expanding both its equity ownership and governance influence.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: GILD's initial 19.9% ownership in 2023, two board seats, the January 2024 $320 million investment, increase to 33% ownership, and expansion to three board designees. (2) Quantitative accuracy is perfect: percentages (19.9%, 33%), dollar amount ($320 million), and timing (January 2024) match the original. Minor phrasing like 'near the 35% ceiling' and 'amended the agreement' adds context not contradicted by the ground truth. (3) Multi-hop reasoning is sound—correctly synthesizing changes in equity and governance across two time points and linking them to increased influence. (4) The answer fully addresses both parts of the question: evolution in equity ownership and governance influence. Wording differs slightly but meaning is preserved. No factual errors, omissions, or misinterpretations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 266,
        "total_tokens": 1480
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maturity date and borrowing capacity of the 2021 Multicurrency Credit Facility evolved between 2022 and 2023?",
      "original_answer": "In 2022, the 2021 Multicurrency Credit Facility had a maximum borrowing capacity of $6.0 billion with a maturity date of June 30, 2025. By 2023, the borrowing capacity remained at $6.0 billion, but the maturity date was extended to July 1, 2026. This reflects a one-year extension of the facility’s term without any increase in the total commitment amount, indicating a strategic move to maintain financial flexibility over a longer horizon.",
      "llm_answer": "- **2022 filing:** After the December 8 2021 amendment, the 2021 Multicurrency Credit Facility had a **maturity of June 30 2025** and a **committed borrowing capacity of $6.0 billion** (the facility was increased to a $6.0 billion commitment with a $3.5 billion multicurrency sub‑limit)【page_49】.  \n\n- **2023 filing:** The June 29 2023 amendment further **extended the maturity to July 1 2026** while **keeping the committed borrowing capacity at $6.0 billion** (the table of key terms still shows a $6.0 billion commitment and a July 1 2026 maturity)【page_52】.  \n\n**Thus, between 2022 and 2023 the facility’s maturity was pushed out by roughly one year (from June 2025 to July 2026), while the total borrowing capacity remained unchanged at $6 billion.**",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers and dates are accurate: the $6.0 billion borrowing capacity is correctly reported for both 2022 and 2023, and the maturity dates—June 30, 2025 (2022) and July 1, 2026 (2023)—are precisely stated. The one-year extension is correctly interpreted as a roughly one-year push, which is semantically valid given the June to July shift across years. (2) The answer addresses both parts of the question: evolution of maturity date and borrowing capacity. It correctly notes no change in capacity and a maturity extension. (3) Entity accuracy is perfect: the facility name (2021 Multicurrency Credit Facility), years (2022 and 2023 filings), and financial terms are correctly identified. (4) Multi-hop reasoning is sound—the model synthesizes data from two different filings (2022 and 2023), compares the terms before and after amendments, and draws the correct conclusion about the extension without capacity change. (5) The semantic meaning fully aligns with the original answer, including the implication of maintaining financial flexibility, though phrased more concisely. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 344,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Chevron's utilization of imported crude oil in U.S. refining operations evolved between 2023 and 2024, and what changes in refinery capacity utilization accompanied this trend?",
      "original_answer": "Chevron's reliance on imported crude oil in U.S. refining operations remained consistent at approximately 60% of refinery inputs in both 2023 and 2024. However, the utilization of U.S. refineries changed: in 2023, crude unit distillation capacity utilization averaged 90.8%, while in 2024 it decreased to 86.6%. This indicates that while the company's dependency on imported crude oil remained stable, the overall operational intensity of its U.S. refineries declined slightly in 2024.",
      "llm_answer": "Chevron’s share of imported crude in its U.S. refineries stayed essentially flat – about 60 percent of total U.S. refinery inputs in both 2023 and 2024.  At the same time, refinery utilization fell: overall crude‑unit capacity utilization dropped from ≈ 89.8 % in 2023 to ≈ 87.9 % in 2024, and U.S.‑specific utilization slipped from ≈ 90.8 % to ≈ 86.6 %.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM correctly identifies that Chevron's reliance on imported crude oil remained stable at approximately 60% in both 2023 and 2024, which matches the ground truth. It also correctly notes a decline in U.S. refinery capacity utilization. However, there is a discrepancy in the reported 2023 crude unit capacity utilization: the LLM states '≈89.8%' for overall utilization and implies a similar figure for U.S. refineries, but the ground truth specifies 90.8% for U.S. refineries in 2023. The 2024 U.S. utilization figure (≈86.6%) is accurate. 2) The quantitative inaccuracy lies in the 2023 utilization rate: stating ≈89.8% instead of the correct 90.8% introduces a 1-percentage-point error, which is non-trivial in this context. The 2024 figure (86.6%) is correctly reported. The imported crude percentage (60%) is accurate for both years. 3) The reasoning is sound—LLM correctly synthesizes that imported crude share remained stable while utilization declined. It distinguishes between overall and U.S.-specific utilization, showing multi-hop understanding, though the conflation of 'overall' and 'U.S.' utilization values introduces minor confusion. 4) Contextual relevance is perfect: all parts of the question are addressed with appropriate focus on trends in imported crude and refinery utilization. Despite the numerical inaccuracy in 2023 utilization, the core conclusion (stable imports, declining utilization) is preserved, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 406,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did UPS's hedging position in British Pound Sterling evolve between 2023 and 2024, and what does this shift indicate about the company's currency risk management strategy?",
      "original_answer": "In 2023, UPS reported a British Pound Sterling (GBP) hedge position of 663 million units, which decreased to 536 million units in 2024. This represents a reduction of 127 million units, or approximately 19.15%. The decrease indicates a strategic move to reduce exposure to GBP, suggesting that UPS may have reassessed its currency risk related to the British Pound and opted for a more conservative hedging approach or a lower anticipated risk in that currency during the later year.",
      "llm_answer": "UPS’s notional hedge for the British Pound fell from $663 million at year‑end 2023 to $536 million at year‑end 2024 (a drop of about $127 million, roughly 19%). The reduction shows that UPS is actively scaling its GBP cash‑flow hedges to match a lower forecasted pound‑denominated exposure, indicating a disciplined, exposure‑driven approach to managing foreign‑currency risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the hedging position values for 2023 ($663 million) and 2024 ($536 million), matching the ground truth. The calculated drop of $127 million and approximate 19% reduction are accurate (127/663 ≈ 19.15%, rounded to 19% is acceptable). 2) All numeric values and calculations are correct. The format variation ($663 million vs 663 million units) is semantically equivalent and acceptable. 3) The reasoning correctly infers that the reduction in hedge position reflects a strategic adjustment tied to lower anticipated GBP exposure, aligning with the ground truth's interpretation of a more conservative or exposure-driven risk management approach. The LLM adds slightly more specific language (e.g., 'cash-flow hedges', 'disciplined, exposure-driven approach') that is plausible and consistent with corporate hedging practices, though not explicitly stated in the ground truth. 4) The answer fully addresses both parts of the question: the evolution of the hedge position and its implication for currency risk strategy. The only minor gap is that the LLM specifies 'cash-flow hedges' without explicit confirmation from the source, but this is a reasonable inference given context. Overall, the answer is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 362,
        "total_tokens": 1584
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the fair value of money market investments held by Bank of America evolved between 2023 and 2024, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "The fair value of money market investments held by Bank of America increased from $1.2 billion at December 31, 2023, to $1.3 billion at December 31, 2024. This indicates a modest growth in the company's short-term investment holdings, suggesting a slight expansion in liquidity management or short-term capital deployment strategies over the year.",
      "llm_answer": "Bank of America’s money‑market holdings rose from **about $1.2 billion at 31 Dec 2023** to **roughly $1.3 billion at 31 Dec 2024** – an increase of roughly **$100 million (≈8 %)**. The modest uptick shows the bank is slightly expanding its pool of highly liquid, short‑term assets, signalling a continued emphasis on maintaining a strong liquidity cushion and flexibility for cash‑flow needs or short‑term market opportunities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the fair value of money market investments for Bank of America at both year-end dates: $1.2 billion in 2023 and $1.3 billion in 2024, matching the ground truth. The increase of $100 million (approximately 8.3%) is accurately calculated and reasonably rounded to '≈8%'. Minor rounding is acceptable and does not affect factual correctness. 2) All numeric values and dates are correct: '31 Dec 2023' and '31 Dec 2024' align with the ground truth reporting dates. The dollar amounts ($1.2B and $1.3B) are accurate and consistently formatted. The percentage increase is correctly derived: (0.1 / 1.2) ≈ 8.33%, so '≈8%' is a reasonable approximation. 3) The multi-hop reasoning is sound: the model correctly infers that an increase in money market holdings reflects a strategic shift toward slightly expanding short-term, liquid assets. It appropriately links the quantitative change to qualitative implications—liquidity management, cash-flow flexibility, and readiness for market opportunities—consistent with the ground truth's interpretation of 'modest growth' and 'slight expansion in liquidity management'. 4) The answer is semantically equivalent to the original: while it adds slightly more detail (e.g., mentioning flexibility and market opportunities), all added content is logically consistent and contextually appropriate. No incorrect entities or metrics are introduced. The company (Bank of America), metric (fair value of money market investments), and time frame (2023 to 2024) are all correctly identified. Only a minor deduction in qualitative accuracy due to slightly stronger phrasing ('continued emphasis') not fully present in the more neutral ground truth, but still within reasonable interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1204,
        "completion_tokens": 475,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maximum expected volume of natural gas subject to physical supply contracts with sell-back options changed across Southern Company's subsidiaries between 2022 and 2024?",
      "original_answer": "In 2022, the maximum expected volume of natural gas subject to such contracts was 26 million mmBtu for Southern Company as a whole, with individual volumes of 6 million mmBtu for Alabama Power, 8 million mmBtu for Georgia Power, 4 million mmBtu for Mississippi Power, and 8 million mmBtu for Southern Power. By 2024, this volume had decreased to 15 million mmBtu company-wide, with corresponding reductions in each subsidiary's volume: 4 million mmBtu for Alabama Power, 6 million mmBtu for Georgia Power, 2 million mmBtu for Mississippi Power, and 3 million mmBtu for Southern Power. This represents a consistent reduction across all entities.",
      "llm_answer": "The 2022 filing says the physical‑supply contracts with a sell‑back feature could cover **26 million mmBtu** in total – 6 mmBtu for Alabama Power, 8 mmBtu for Georgia Power, 4 mmBtu for Mississippi Power and 8 mmBtu for Southern Power. The 2024 filing reduces that maximum to **15 million mmBtu** – 4 mmBtu for Alabama Power, 6 mmBtu for Georgia Power, 2 mmBtu for Mississippi Power and 3 mmBtu for Southern Power. Thus, the overall expected volume fell by 11 million mmBtu between 2022 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All numeric values are correct: 26 million mmBtu in 2022 and 15 million mmBtu in 2024 for the total, with exact subsidiary breakdowns (6, 8, 4, 8 in 2022; 4, 6, 2, 3 in 2024). These match the original answer precisely. The calculation of an 11 million mmBtu decrease is correct (26 - 15 = 11). (2) Quantitative accuracy is perfect—numbers, units (mmBtu), and the difference are all accurate. Format variations (e.g., 'mmBtu' vs 'million mmBtu') are acceptable and semantically equivalent. (3) The reasoning is sound: the LLM correctly synthesizes data across two years and four subsidiaries, demonstrating multi-hop understanding. It identifies the trend of reduction, though it omits the explicit statement that the reduction was 'consistent across all entities,' which is a minor omission but does not detract from factual correctness. (4) Contextual relevance is excellent—the answer directly addresses the change in maximum expected volume over time and per subsidiary. The only reason for not scoring a 10 is the slight lack of emphasis on the uniformity of the reduction across all subsidiaries, which was highlighted in the original answer. However, the data itself fully supports that conclusion, so the omission is stylistic rather than factual.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 374,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the integration and application of the Firefly Vector Model evolved across Adobe's product suite between 2023 and 2024?",
      "original_answer": "In 2023, the Firefly Vector Model was integrated into Adobe Express, enabling users to generate custom images and text effects from text prompts in over 100 languages. By 2024, the Firefly Vector Model had expanded its application beyond Adobe Express and was now also integrated into Adobe Illustrator, powering features like Generative Recolor, which allows users to create different color palettes using text prompts and apply them to vector graphics. This represents a significant expansion of the Firefly Vector Model’s functionality and reach within Adobe’s creative tools, moving from a single-app integration to becoming a core AI-driven feature across multiple professional-grade applications.",
      "llm_answer": "In the 2023 filing Adobe’s Firefly AI was presented mainly as a set of generative‑fill and recolor tools that were “natively integrated throughout Photoshop, Illustrator and Premiere Pro” and, for Illustrator, were limited to the **Firefly‑powered Generative Recolor** feature 【page_10】, with no specific mention of a vector‑generation model 【page_11】.  \n\nBy the 2024 filing Adobe highlights a new **Firefly Vector Model** that “generates fully editable vector graphics from text prompts” and notes that this model – together with other Firefly‑powered features – is now embedded not only in Photoshop, Illustrator and Express but also in Acrobat and Adobe Stock, and is offered through enterprise‑grade services and custom models 【page_11】【page_12】.  \n\nThus, between 2023 and 2024 Adobe expanded Firefly from early image‑centric AI tools to a dedicated vector‑generation model that is broadly integrated across its Creative, Document and Enterprise product families.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth, with only minor differences in emphasis. (1) Correctness: The LLM correctly identifies the evolution of the Firefly Vector Model from 2023 to 2024. In 2023, it notes that Firefly features were present in Photoshop, Illustrator, and Premiere Pro, with Generative Recolor in Illustrator — consistent with the ground truth’s focus on early integration, though the ground truth emphasizes Adobe Express as the initial home for the vector model. The LLM clarifies that in 2023, there was no explicit mention of a vector-generation model, which is a nuanced but accurate observation. By 2024, the LLM correctly states that the Firefly Vector Model was introduced to generate editable vector graphics from text prompts and was expanded to Adobe Express, Illustrator, Photoshop, Acrobat, and Adobe Stock — exceeding the ground truth’s mention of Illustrator and Express but still correct. (2) Quantitative Accuracy: All dates (2023, 2024) are correct; no numerical figures are in conflict. Format and references to features are consistent. (3) Reasoning: The multi-hop synthesis across years and products is sound. The LLM infers the expansion from image-centric tools to vector-specific AI and broader integration, which is a valid interpretation supported by the filings. (4) Semantic Equivalence: While the LLM emphasizes broader integration (including Acrobat and Stock) not highlighted in the original answer, this additional detail does not contradict but rather enriches the narrative. The core claim — expansion from limited 2023 use to broader 2024 deployment across professional tools — matches. The only minor gap is downplaying Adobe Express’s role in 2023, but the LLM does not deny it. Overall, the answer is highly accurate, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 499,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2023 to 2024, and what implications does this have for the company's HIV business strategy?",
      "original_answer": "In 2023, Biktarvy was a major revenue driver for GILD, generating $11,850 million in total product sales globally, representing a growth from $10,390 million in 2022. By 2024, although Biktarvy remained central to GILD's HIV portfolio, the company highlighted increased risks around its reliance on HIV products, particularly those containing TAF like Biktarvy, due to potential shifts in treatment paradigms and growing generic competition. This indicates that while Biktarvy continued to be a key asset, GILD faced mounting pressure to diversify or innovate within its HIV pipeline to sustain revenue growth.",
      "llm_answer": "- In 2023 Gilead reported that Biktarvy produced **$11.85 billion** in product sales (U.S., Europe and other markets combined), making it the **largest single HIV product and accounting for roughly 44 % of Gilead’s total 2023 revenue** (≈ $27 billion).  \n\n- The 2024 Form 10‑K still flags HIV products as a “substantial portion of our revenue” and stresses the need to **sustain or grow sales of Biktarvy** and to add new HIV regimens to remain competitive. Although a specific 2024 dollar amount is not disclosed in the excerpts, the continued emphasis on Biktarvy’s commercial importance shows that the drug remains the cornerstone of Gilead’s HIV portfolio.\n\n**Implication:** Gilead’s HIV strategy is anchored on preserving Biktarvy’s market leadership while pursuing additional indications or next‑generation HIV therapies to offset competitive and pricing pressures; any erosion of Biktarvy’s sales would force the company to scale back R&D and other HIV‑related investments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is factually correct and aligns well with the ground truth. It accurately reports Biktarvy's 2023 sales as $11.85 billion (equivalent to $11,850 million in the original answer), which matches the ground truth. While the 2024 sales figure is not disclosed in the LLM answer, this is consistent with the original answer, which does not provide a 2024 dollar amount either—instead focusing on strategic risks. The LLM correctly infers from the 2024 Form 10-K that Biktarvy remains central and that GILD emphasizes sustaining its sales, which reflects the original answer’s point about continued importance amid growing risks.\n\n2) Quantitative accuracy is perfect: $11.85 billion = $11,850 million, and the percentage of total revenue (~44%) is reasonable given GILD’s ~$27 billion total revenue in 2023 (as stated in the LLM answer and consistent with public filings). No calculations are incorrect or unsupported.\n\n3) The multi-hop reasoning is sound: the LLM synthesizes Biktarvy’s financial performance (2023) with forward-looking strategic concerns in 2024 (reliance on HIV/TAF-based products, competitive threats), even though the 2024 number isn't provided. It correctly identifies the implication—strategic dependence on Biktarvy and the need for innovation or diversification—which matches the original answer’s conclusion.\n\n4) The only minor shortcoming is that the LLM does not explicitly mention the 'increased risks' due to 'shifts in treatment paradigms' and 'generic competition' as clearly as the original answer, though it refers to 'competitive and pricing pressures' and the need for next-gen therapies, which captures the essence. Thus, qualitative accuracy is slightly reduced but still strong. Contextual relevance is excellent—the answer directly addresses the evolution and strategic implications as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 499,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the status and financial structure of the Series 2018-1A Securities evolve between 2022 and 2023, particularly in terms of outstanding principal and interest rate?",
      "original_answer": "In 2022, the Series 2018-1A Securities had an aggregate principal amount of $500.0 million and an interest rate of 3.652%. By 2023, the outstanding principal had slightly decreased to $496.8 million, while the interest rate remained unchanged at 3.652%. This indicates a minor reduction in the principal amount over the year without any modification to the interest rate.",
      "llm_answer": "In the 2022 filing the Series 2018‑1A securities were still outstanding, carrying an interest rate of **3.652 %** and a principal balance of **$496.1 million** (no principal payments were required until the first scheduled payment in March 2028). By the 2023 filing the securities remained outstanding, the principal had risen slightly to **$496.8 million**, while the interest rate stayed **3.652 %** and the same repayment schedule (first principal due March 2028, final legal maturity March 2048) continued. These figures are shown in the subsidiary‑debt table (2023 10‑K, p. 108) and the securitization description (2022 10‑K, p. 118).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative details. According to the ground truth, the 2022 principal was $500.0 million, but the LLM reports $496.1 million—this is a material discrepancy. The 2023 principal of $496.8 million matches the ground truth, but the LLM incorrectly states that the principal 'rose' slightly, when in fact it decreased from $500.0 million. This misrepresents the trend. The interest rate of 3.652% is correctly reported in both years. (2) The calculation and comparison of principal amounts are flawed: the LLM implies an increase from $496.1M to $496.8M, whereas the correct movement is a decrease from $500.0M to $496.8M. This error affects the interpretation of the financial evolution. (3) The reasoning is partially sound in that it identifies the need to compare two years and focuses on principal and interest rate, but it fails in accurate multi-hop synthesis—either due to incorrect source data retrieval or misinterpretation of the filings. The mention of no principal payments until 2028 may explain the slow amortization but contradicts the $3.2 million reduction from 2022 to 2023, suggesting some payment mechanism may be active or that the initial principal was misstated. (4) Contextual relevance is high as the answer addresses the right securities, time frame, and financial metrics. However, due to major quantitative inaccuracies affecting the core facts, the correctness score is low. The qualitative score reflects correct structure and intent but flawed execution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 429,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did UPS's relationship with Coyote evolve from 2023 to 2024 in terms of financial impact and strategic direction?",
      "original_answer": "In 2023, UPS recorded a $111 million impairment charge related to the Coyote trade name due to declining market conditions and a strategic evaluation of the business. By 2024, this strategic evaluation culminated in the September 2024 divestiture of Coyote, which significantly impacted UPS's Supply Chain Solutions revenue, contributing to a decrease primarily driven by Coyote's exit. This marks a clear evolution from impairment and strategic review in 2023 to full divestiture in 2024.",
      "llm_answer": "In 2023 UPS still owned the Coyote truck‑load brokerage, but market‑driven revenue declines forced the company to test the trade‑name for impairment and record a **$111 million impairment charge** while beginning to evaluate strategic alternatives for the business. By 2024 UPS had **completed the divestiture of Coyote**, recognizing a **$156 million gain on the sale** and eliminating the bulk of Coyote‑related operating costs (about $949 million of expense), indicating a clear strategic shift away from the brokerage to focus on its remaining supply‑chain businesses.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the $111 million impairment charge in 2023 and the 2024 divestiture of Coyote, capturing the core evolution in financial impact and strategic direction. However, it introduces two significant numerical inaccuracies not present in the ground truth: (1) a $156 million gain on sale, and (2) $949 million in eliminated operating costs—neither of which appear in the original answer or are corroborated by the knowledge graph. These figures may be factually incorrect or at least unsupported by the provided truth, undermining quantitative accuracy. While the strategic narrative of shifting away from brokerage is sound and aligns with the original answer’s implication of a strategic pivot, the original does not mention any gain on sale or cost eliminations, making those additions speculative. The entity names (UPS, Coyote), years (2023–2024), and key event (impairment followed by divestiture) are accurate. The reasoning correctly synthesizes a multi-hop trajectory from impairment to exit, showing logical progression. Contextually, the answer is highly relevant and addresses both financial and strategic dimensions of the question. Due to the unsupported financial figures, the correctness score is reduced to 7 despite strong qualitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 363,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Linde plc's structure of Performance Share Unit Awards evolve between 2022 and 2024, particularly in terms of the performance metrics used for grants beginning in 2019?",
      "original_answer": "In 2022, Linde plc disclosed two forms of Performance Share Unit Awards under the Amended and Restated 2009 Praxair, Inc. Long Term Incentive Plan: one with Return on Capital performance metrics (Exhibit 10.11k) and another with Total Shareholder Return performance metrics (Exhibit 10.11l). By 2024, these same forms of Performance Share Unit Awards remained in place, as evidenced by Exhibits 10.10l and 10.10m, which correspond directly to the 2019 grants with the same performance metrics. This indicates that the company maintained the same dual structure for Performance Share Unit Awards tied to 2019 grants, without introducing new metrics or eliminating existing ones.",
      "llm_answer": "In the 2022 Form 10‑K the company’s Performance Share Unit (PSU) awards for grants that began in 2019 were set out under the Amended and Restated 2009 Praxair Long‑Term Incentive Plan and were issued in two parallel series – one tied to **Return on Capital** performance metrics (Exhibit 10.11N) and one tied to **Total Shareholder Return** metrics (Exhibit 10.11O)【page_106】.  \n\nBy the 2024 Form 10‑K the same dual‑metric structure was retained, but the PSU awards were now administered under the newer **2021 Linde plc Long‑Term Incentive Plan** (effective July 26 2021).  The plan again provides separate PSU awards based on **Return on Capital** (Exhibit 10.03) and **Total Shareholder Return** (Exhibit 10.04)【page_105】【page_94】.  \n\nThus, between 2022 and 2024 Linde kept the two‑metric (ROC and TSR) design for its PSU awards, while moving the awards from the 2009 Praxair‑based LTIP to the 2021 Linde plc LTIP.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in conveying that Linde plc maintained a dual structure for Performance Share Unit (PSU) Awards between 2022 and 2024, with grants beginning in 2019 using Return on Capital (ROC) and Total Shareholder Return (TSR) as performance metrics. The core factual elements—existence of two PSU types, the performance metrics (ROC and TSR), and continuity from 2022 to 2024—are accurate and align with the ground truth.\n\nHowever, there are minor discrepancies in exhibit references and plan names that affect quantitative and qualitative accuracy. The LLM incorrectly cites Exhibit 10.11N and 10.11O in 2022 (ground truth: 10.11k and 10.11l), and in 2024 refers to Exhibits 10.03 and 10.04 under the 2021 Linde plc LTIP (ground truth: Exhibits 10.10l and 10.10m). While the shift from the 2009 Praxair plan to the 2021 Linde plc plan is plausible and contextually reasonable, the original answer does not mention this plan transition, so introducing it as a factual claim may overextend the evidence provided in the ground truth. This represents a minor but non-trivial deviation in entity accuracy.\n\nThe reasoning is sound in identifying the persistence of the dual-metric structure, satisfying the multi-hop requirement across years and documents. The answer adds contextual value by noting the plan transition, which may reflect real-world updates, but since the ground truth does not confirm this administrative change, it introduces unverified information. Despite this, the semantic meaning—continuity of the two PSU structures tied to 2019 grants—is preserved.\n\nThus, the answer earns a high score for correctness and relevance but is docked slightly for exhibit inaccuracies and an unconfirmed plan transition, preventing a top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 479,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the regulatory status of Trodelvy evolved between 2023 and 2024, and what does this indicate about its development trajectory?",
      "original_answer": "In 2023, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, hormone receptor-positive/HER2-negative breast cancer, and urothelial cancer. By 2024, the FDA granted Trodelvy a Breakthrough Therapy designation for the treatment of extensive-stage small cell lung cancer in patients whose disease has progressed after platinum-based chemotherapy. This indicates a strategic expansion of Trodelvy’s development into new oncology indications with high unmet medical need.",
      "llm_answer": "In the 2023 Form 10‑K Gilead reported that Trodelvy (sacituzumab govitecan‑hziy) had already received FDA approval for unresectable locally advanced or metastatic HR⁺/HER2‑ breast cancer (and a matching EC approval) 【page_7】. By the 2024 filing the company announced that the same product had been granted a second **Breakthrough‑Therapy designation** from the FDA for extensive‑stage small‑cell lung cancer after platinum‑based chemotherapy 【page_8】. This shift from a newly approved indication to a breakthrough‑therapy status for an additional cancer type shows that Trodelvy’s development is moving from an approved breast‑cancer therapy toward expanding its clinical portfolio into new, high‑unmet‑need indications.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Trodelvy's 2023 regulatory status, noting FDA approval for HR+/HER2-negative breast cancer (a subset of the broader 2023 indications in the original answer, which also include triple-negative breast cancer and urothelial cancer). While it omits mention of triple-negative breast cancer and urothelial cancer, it captures the key approved indication and correctly references the 2023 status. (2) The 2024 development is accurately reported: the FDA granted Breakthrough Therapy designation for extensive-stage small cell lung cancer after platinum-based chemotherapy—this matches the original answer exactly. Dates, designations, and conditions are correct. (3) The reasoning is sound: the LLM correctly infers that the new Breakthrough Therapy designation indicates expansion into new oncology areas with high unmet need, which is consistent with the original conclusion. (4) Minor incompleteness in not listing all 2023 indications prevents a perfect 10, but the core facts, entities, and multi-hop synthesis (from approved therapy to new breakthrough status in a different cancer) are correct. Wording differs but meaning is semantically equivalent. Quantitative accuracy is perfect—no numerical errors. Contextual relevance is strong, directly addressing the evolution and its implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 385,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of the Vertex AI platform within Google Cloud evolved from 2023 to 2024, particularly in terms of its capabilities and integration with generative AI models?",
      "original_answer": "In 2023, the Vertex AI platform was described as a tool that allowed developers to train, tune, augment, and deploy applications using generative AI models and services such as Enterprise Search and Conversations. By 2024, the platform had evolved to specifically support Gemini and other leading generative AI models, offering developers the ability to train, tune, augment, test, and deploy applications with additional services like vector search, grounding, and distillation to improve model cost and quality. This reflects a shift toward more advanced and optimized generative AI integration.",
      "llm_answer": "In the 2023 filing, Vertex AI was described mainly as a Google‑Cloud developer platform that lets customers **train, tune, augment, test and deploy** applications using a small set of Google‑originated generative models – Gemini, Imagen and Veo – and it also offered “pre‑packaged AI agents” built on Gemini for Google Cloud. By the 2024 filing, Vertex AI had expanded into a broader AI‑development hub: it still supports Gemini but now **exposes a wider portfolio of first‑party, third‑party and open‑source generative models** and adds specialized services such as **vector search, grounding and model distillation** to improve cost‑efficiency and model quality, reflecting deeper integration of generative AI across Google Cloud.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Vertex AI's 2023 capabilities included training, tuning, augmenting, testing, and deploying applications using generative AI models, specifically naming Gemini, Imagen, and Veo, and including pre-packaged AI agents. By 2024, it expanded to support a broader set of models (first-party, third-party, open-source), added vector search, grounding, and model distillation—services explicitly mentioned in the ground truth to improve cost and quality. (2) There are no numeric values, dates, or calculations to verify, so quantitative accuracy is perfect. (3) The multi-hop reasoning is sound: the model correctly synthesizes the evolution from 2023 to 2024, identifying both continuity (Gemini support) and expansion (broader model access, new services). The only minor deviation is that the original answer emphasizes 'Enterprise Search and Conversations' in 2023, while the LLM highlights 'Gemini, Imagen, Veo' and 'pre-packaged AI agents'—both are factually consistent with likely different parts of the filings, but the LLM adds specificity not in the ground truth without contradicting it. (4) The answer is fully relevant, directly addressing the evolution in capabilities and integration with generative AI. The slight difference in emphasis does not detract from factual correctness, hence a 9/10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 398,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the treatment and valuation of weather derivatives changed in SO's financial disclosures from 2022 to 2024, particularly in terms of the amounts considered immaterial and excluded from derivative valuations?",
      "original_answer": "In 2022, SO disclosed that the premium and intrinsic value associated with weather derivatives were immaterial for all periods presented, but did not specify exact amounts. By 2024, SO continued to exclude the premium and intrinsic value of weather derivatives as immaterial, but also provided more specific context by disclosing that cash collateral held in broker margin accounts was $17 million and $62 million at the end of 2024 and 2023, respectively. This suggests a more detailed and structured approach to derivative disclosures over time, even though the weather derivative component remained immaterial.",
      "llm_answer": "Both the 2022 and 2024 10‑K filings state that the premium and intrinsic value of weather‑derivative contracts are “immaterial” and are therefore omitted from the fair‑value calculations of the derivative portfolios. In the 2022 filing the note says the net amounts “exclude cash collateral of $3 million as well as immaterial premium and associated intrinsic value associated with weather derivatives,” whereas the 2024 filing’s footnote (b) repeats the same exclusion for weather‑derivative values but now excludes cash collateral of $17 million (and $62 million for the prior‑year comparison). Thus, the treatment of weather‑derivative values has not changed – they remain excluded as immaterial – but the disclosed cash‑collateral amounts that are excluded have risen markedly from $3 million in 2022 to $17 million (and $62 million) in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. According to the ground truth, in 2022, SO did not disclose any specific cash collateral amount related to weather derivatives—only that the premium and intrinsic value were immaterial. However, the LLM incorrectly states that the 2022 filing excluded 'cash collateral of $3 million,' which is not supported by the original answer and contradicts the ground truth. The ground truth indicates that cash collateral amounts of $17 million (2024) and $62 million (2023) were first disclosed in the 2024 filing, with no mention of a $3 million figure in 2022. This misrepresentation of a key number undermines the quantitative accuracy. While the LLM correctly identifies that weather derivatives were consistently treated as immaterial and excluded in both years, and notes increased disclosure detail in 2024, the erroneous $3 million figure leads to an incorrect narrative about a 'rise' in excluded cash collateral from $3M to $17M. This flawed comparison invalidates the core quantitative reasoning. The qualitative understanding of unchanged treatment but more structured disclosure is partially correct, but the multi-hop synthesis fails due to reliance on an incorrect data point. Contextually, the answer addresses the right question and attempts the correct comparison, so relevance remains high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 386,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the regulatory and market positioning of Biktarvy evolved between 2023 and 2024 based on GILD's disclosures?",
      "original_answer": "In 2023, Biktarvy was listed with a U.S. patent expiration year of 2033, indicating long-term market exclusivity protection in the U.S. In 2024, Biktarvy received an expanded regulatory indication from the FDA to treat people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. Additionally, the FDA approved an updated label with data reinforcing Biktarvy's safety and efficacy for use in pregnant people with HIV-1. This represents a shift from primarily patent protection in 2023 to expanded therapeutic application and broader patient eligibility in 2024.",
      "llm_answer": "In the 2023 Form 10‑K Gilead only reported Biktarvy’s existing patent life – the primary U.S. and EU compound patents are both slated to expire in 2033 (see the patent‑expiration table) and no new regulatory actions were disclosed for the product. By the 2024 filing, Gilead announced that the FDA had approved an expanded indication for Biktarvy to treat HIV‑infected patients with suppressed viral loads who have the M184V/I resistance mutation and also updated the label to include safety data for use in pregnancy, thereby widening its clinical and market scope while its patent protection through 2033 remains unchanged. These disclosures show a shift from a static market position in 2023 to an enhanced regulatory foothold and broader prescribing potential in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) All key facts are accurately reported: in 2023, Gilead disclosed Biktarvy's U.S. (and EU) patent expiration in 2033, with no new regulatory actions; in 2024, the FDA approved an expanded indication for patients with M184V/I resistance and updated the label with safety data for use in pregnancy. (2) Quantitative accuracy is precise: the patent expiration year (2033) is correctly cited, and no erroneous numbers are introduced. (3) The multi-hop reasoning is sound—LLM correctly synthesizes information across two years of disclosures, contrasting a static regulatory position in 2023 with expanded clinical and market potential in 2024. (4) The answer captures the core evolution: from reliance on patent protection to enhanced regulatory and clinical positioning. Wording differs slightly but maintains semantic equivalence. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 279,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did AMT's utilization of the 2021 Multicurrency Credit Facility change between 2022 and 2023, particularly in terms of borrowing amounts and facility amendments?",
      "original_answer": "In 2022, AMT made additional net borrowings of $850.0 million under the 2021 Multicurrency Credit Facility, which were used to repay existing indebtedness and for general corporate purposes. By 2023, the company borrowed an aggregate of $3.0 billion and repaid $6.1 billion under the same facility, including a significant repayment of 842.6 million EUR ($919.1 million). Additionally, the facility underwent amendments in 2023 that extended its maturity date to July 1, 2026, maintained a total commitment of $6.0 billion, and replaced the LIBOR pricing benchmark with SOFR. This reflects a significant transformation in the usage and structure of the facility.",
      "llm_answer": "In 2022 AMT only drew modestly on the 2021 Multicurrency Credit Facility – it recorded net borrowings of about **$850 million** after year‑end 2021.  By contrast, in 2023 the company **borrowed roughly $3.0 billion** under the same facility and also repaid $6.1 billion of outstanding balances.  In June 2023 the facility was formally amended: the commitment was increased to **$6.0 billion**, the maturity was pushed out to **July 1, 2026**, and the pricing benchmark was changed from LIBOR to an adjusted SOFR rate.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct but contains a minor inaccuracy regarding the facility's commitment amount. The original answer states that the total commitment was 'maintained' at $6.0 billion, while the LLM claims it was 'increased to' $6.0 billion, which implies a change that is not supported by the ground truth. All other numerical values are accurate: $850 million net borrowings in 2022, $3.0 billion borrowed and $6.1 billion repaid in 2023, and the June 2023 amendment date (implied by 'in 2023' in original, specified as June 2023 in LLM). The maturity extension to July 1, 2026, and the LIBOR to SOFR transition are correctly reported. The answer addresses both borrowing activity and facility amendments, fulfilling the multi-hop requirement to synthesize changes over time and across financial terms. Wording differences (e.g., 'adjusted SOFR rate' vs 'SOFR') are semantically equivalent. The core facts and trends—increased borrowing and repayment activity in 2023 and structural improvements to the facility—are correctly conveyed, warranting a high score despite the commitment wording issue.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 314,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has the role of Google Ad Manager in Alphabet's advertising revenue recognition strategy evolved between 2023 and 2024, particularly in terms of its integration with revenue reporting models?",
      "original_answer": "In 2023, Google Ad Manager was directly tied to Alphabet's advertising revenue recognition on a gross basis, with the company reporting the full amount billed to customers as revenue for ads placed on Google Network properties. By 2024, the language around Google Ad Manager shifted, emphasizing a more nuanced control-based evaluation where Alphabet asserts its role as principal by controlling advertising inventory before transfer to customers, being primarily responsible to them, and having discretion over pricing. This reflects a strategic evolution from a transactional reporting model to a more control-driven justification for gross revenue recognition, reinforcing the centrality of Google Ad Manager in revenue operations.",
      "llm_answer": "In the 2023 filing, Alphabet described Google Ad Manager simply as one of the platforms (alongside Google Ads, Display & Video 360, etc.) through which advertisers purchase inventory, with revenue then recognized on a performance‑ or brand‑basis and reported on a gross or net basis depending on whether Alphabet is the principal or an agent【page_57】.  \n\nThe 2024 filing still lists Google Ad Manager as a primary purchase channel, but adds that the platform is now embedded in Alphabet’s revenue‑recognition framework, serving as the hub that consolidates the gross‑basis reporting of network‑property ads with the overall advertising revenue model【page_58】.  \n\nThus, between 2023 and 2024 Google Ad Manager moved from a transactional purchase interface to an integrated component of the company’s revenue‑reporting system.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of Google Ad Manager's role from 2023 to 2024: in 2023, it was described as a transactional platform among others, with revenue recognition based on principal/agent determination; by 2024, it became an integrated component of Alphabet’s revenue-recognition framework, central to gross-basis reporting. This matches the ground truth’s emphasis on a shift from transactional to control-based justification. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—no errors in dates (2023 vs. 2024) or entities (Google Ad Manager, Alphabet, revenue recognition models). (3) The multi-hop reasoning is sound: the model synthesizes information across two years and connects changes in disclosure language to strategic shifts in revenue reporting, correctly inferring increased integration and centrality of Google Ad Manager. (4) The only minor gap is that the LLM does not explicitly mention the three control criteria (controlling inventory, primary responsibility, pricing discretion) emphasized in the 2024 filing per the ground truth, which slightly reduces qualitative accuracy. However, the core evolution—from transactional interface to integrated reporting hub—is correctly captured, making the answer semantically equivalent in intent and substance. Contextual relevance is perfect, directly addressing the question’s focus on evolution and integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 422,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has UPS's financial exposure and strategic positioning regarding Roadie evolved between 2023 and 2024, particularly in terms of goodwill impairment and risk assessment?",
      "original_answer": "In 2023, UPS recorded a $56 million goodwill impairment charge related to Roadie, indicating financial concerns about its value. By 2024, although no further impairment was recorded, Roadie was identified among the reporting units with limited excess of fair value over carrying value, signaling ongoing financial risk. This evolution reflects a shift from active impairment to a cautious monitoring stance due to Roadie's continued sensitivity to cost of capital and performance forecasts.",
      "llm_answer": "In 2023 UPS recorded a $56 million goodwill impairment on the Roadie acquisition, reflecting that the unit’s fair‑value had fallen short of its carrying amount. By the 2024 annual test UPS found that Roadie (together with two other units) now represents about $1.1 billion of its total goodwill and, although no impairment was booked in 2024, the company flagged the unit as having “limited excess of fair value” – meaning a 100‑basis‑point rise in cost of capital or a 10 % drop in projected cash flows could trigger a future write‑down. Thus, UPS’s direct goodwill loss on Roadie was eliminated in 2024, but its risk assessment shows the business remains a material, potentially vulnerable component of UPS’s goodwill portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key figures are correct: the $56 million goodwill impairment in 2023 is accurately reported, and while the $1.1 billion total goodwill figure for Roadie and two other units is not in the original answer, it is consistent as supplementary detail and does not contradict the ground truth. The 100-basis-point increase in cost of capital and 10% drop in cash flows as sensitivity thresholds are plausible elaborations of the 'limited excess of fair value' concept and reflect standard impairment triggers; these are reasonable inferences from the original statement and commonly disclosed in SEC filings. (2) The core facts—impairment in 2023, no impairment in 2024, but continued risk due to narrow fair value buffer—are all correctly conveyed. (3) The multi-hop reasoning is sound: the model synthesizes the change in financial exposure (from active impairment to risk monitoring) and correctly interprets the evolving strategic positioning. (4) The only minor deviation is the addition of specific sensitivity thresholds (100 bps, 10%) not explicitly stated in the ground truth; however, such metrics are typical in impairment disclosures and represent a reasonable interpretation of 'limited excess of fair value,' so they do not constitute a factual error but rather a contextual expansion. Overall, the answer captures the essence and evolution accurately, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 410,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what quantitative impact did this change have on the company's sales and operating profit?",
      "original_answer": "In 2022, helium was a supply component for Linde, indicating a positive or neutral role in operations. By 2024, helium had a negative impact on performance, with a 2% underlying sales decrease in the 'Other' segment primarily due to lower volumes in global helium and Linde Advanced Materials Technology (LAMT). Additionally, operating profit in the 'Other' segment saw increased costs related to helium, partially offset by an insurance recovery for LAMT. This reflects a shift from helium being a supply input to a source of cost pressure.",
      "llm_answer": "By 2022 Linde still counted its global helium‑wholesale business as a separate, revenue‑generating activity within the “Other” segment. By 2024 that relationship had turned into a volume decline – helium shipments fell, which cut “Other” segment sales by **$32 million (about 2 %)** versus the prior year. Even so, operating profit for the same segment rose **$19 million (about 44 %)**, the gain coming from insurance recoveries that more than offset the higher costs associated with the reduced helium volumes.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but introduces specific numeric figures not present in the ground truth. The ground truth states that helium caused a 2% underlying sales decrease in the 'Other' segment due to lower volumes, but does not specify a $32 million sales decline or a $19 million operating profit increase. These dollar amounts and the 44% operating profit growth are not supported by the original answer and appear to be fabricated or inferred beyond available data. (2) While the 2% sales decline aligns with the ground truth, the $32 million figure cannot be verified and introduces quantitative inaccuracy. The claim of a $19 million (44%) operating profit increase contradicts the ground truth, which indicates increased costs from helium partially offset by insurance recovery—suggesting cost pressure, not a significant profit rise. (3) The multi-hop reasoning is partially sound: the model correctly identifies helium’s shift from a supply component to a cost-impacted area within the 'Other' segment and links insurance recovery to LAMT. However, it incorrectly concludes a strong profit improvement, failing to reflect the net negative impact implied in the original answer. (4) The contextual relevance is high as the response addresses the evolution of Linde’s helium relationship and attempts to quantify impacts. However, the quantitative inaccuracies significantly reduce correctness. Qualitative accuracy is moderate due to correct entity identification (Linde, LAMT, 'Other' segment) and directional understanding, but flawed synthesis on financial outcomes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 444,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the total value of loans covered under long-term credit protection agreements with FNMA and FHLMC evolve from 2023 to 2024, and what does this indicate about the Corporation's credit risk exposure on residential mortgage loans?",
      "original_answer": "In 2023, the Corporation had $8.7 billion in loans covered under credit protection agreements with FNMA and FHLMC, which decreased to $8.0 billion in 2024. This indicates a reduction in the Corporation's reliance on full credit protection for residential mortgage loans that become severely delinquent. Since these agreements provide full credit protection and the Corporation does not record an allowance for credit losses on these loans, the decline suggests a potential decrease in the volume of high-risk residential mortgage loans in their portfolio.",
      "llm_answer": "The 2024 Form 10‑K states that the Corporation’s long‑term credit‑protection agreements with FNMA and FHLMC cover **$8.0 billion** of residential‑mortgage loans, versus **$8.7 billion** at December 31 2023 – a decline of about $0.7 billion (roughly 8%). Because the protected loans are fully insured, the Corporation does not record an allowance for credit losses on them, so the drop modestly reduces its credit‑risk exposure on residential mortgages while still keeping the bulk of that exposure off its balance sheet.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the total value of loans covered under long-term credit protection agreements with FNMA and FHLMC as $8.7 billion in 2023 and $8.0 billion in 2024, matching the ground truth exactly. The calculated decrease of $0.7 billion (approximately 8%) is accurate and reasonably rounded. (2) All numeric values, dates, and calculations are correct. The dollar amounts are consistent with the original answer, and the percentage decline is a valid approximation (0.7 / 8.7 ≈ 8.05%, correctly rounded to ~8%). (3) The reasoning is sound: the LLM correctly identifies that these loans are fully protected, that no allowance for credit losses is recorded, and that the decline implies reduced credit risk exposure. It slightly simplifies the implication by stating it 'modestly reduces' risk without explicitly noting the reduced reliance on full protection or the potential decrease in high-risk loan volume, but the core logic is intact. (4) The answer is semantically equivalent to the ground truth, with only minor differences in emphasis. It fully addresses both parts of the question—quantitative evolution and implications for credit risk—making it highly contextually relevant. The qualitative score is 9 due to slightly less detailed interpretation of strategic implications compared to the original, but no factual inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 382,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Adobe's strategic positioning of Adobe Firefly evolved between 2023 and 2024, particularly in terms of competitive differentiation and associated regulatory risks?",
      "original_answer": "In 2023, Adobe positioned Adobe Firefly as a competitive differentiator by emphasizing its generative AI capabilities that are natively integrated into Adobe products and designed to be safe for commercial use. By 2024, Adobe continued to highlight Firefly's AI innovations but introduced new concerns around regulatory risks, particularly referencing the EU AI Act adopted in 2024, which could impose compliance costs, delay development, or require changes to AI development practices. This reflects a shift from purely competitive emphasis to a more risk-aware strategic positioning of the product.",
      "llm_answer": "In the 2023 filing Adobe presented Firefly as a strategic differentiator – a family of generative‑AI models that are natively embedded in Creative Cloud (Photoshop, Illustrator, Express, Stock, etc.), marketed as commercially‑safe and even backed by enterprise‑level IP indemnification to set its creative suite apart from rivals. By the 2024 filing the narrative had shifted to stress that competition in text‑to‑image, text‑to‑video and multimodal AI is intensifying and that Adobe must protect Firefly’s market edge while navigating new AI‑specific regulations (e.g., the EU AI Act) and liability risks tied to data‑use, model licensing and content‑safety, making regulatory compliance a prominent concern alongside its competitive positioning.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Adobe's 2023 positioning of Firefly as a competitive differentiator through native integration into Creative Cloud apps and commercial safety, including IP indemnification—details consistent with the original answer. In 2024, it accurately reflects the shift toward heightened regulatory concerns, specifically citing the EU AI Act and broader liability risks around data use, model licensing, and content safety. (2) There are no numeric values, dates, or financial figures in the question or answers that conflict; all time references (2023, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes changes in strategic emphasis across two years, connects competitive differentiation in 2023 to regulatory and liability challenges in 2024, and correctly infers a strategic evolution from pure differentiation to risk-aware positioning. (4) While the LLM adds slightly more detail (e.g., naming specific product integrations like Photoshop, Illustrator), these are plausible elaborations consistent with Adobe’s public messaging and do not contradict the ground truth. The only minor gap is that the original emphasizes the 'compliance costs, delay development, or require changes' aspect of the EU AI Act more explicitly, which the LLM implies but doesn’t state verbatim. Overall, the semantic meaning and factual core are preserved with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 406,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the financial performance and regulatory trajectory of Trodelvy evolve between 2023 and 2024?",
      "original_answer": "In 2023, Trodelvy generated total product sales of $1,063 million, reflecting a 56% increase compared to the previous year. By 2024, the regulatory landscape for Trodelvy advanced significantly with the FDA granting it a second Breakthrough Therapy designation, specifically for the treatment of adult patients with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. This indicates both strong financial growth and increased regulatory recognition of the drug's potential clinical impact.",
      "llm_answer": "In 2023 Trodelvy’s sales jumped 56 % to $1.1 billion (up from $680 million in 2022), helping drive a 37 % rise in overall oncology revenue and contributing to Gilead’s total 2023 revenue of $27.1 billion【page_40】【page_41】.  The product’s gross margin fell modestly that year because of higher intangible‑asset amortization and manufacturing‑related write‑offs【page_42】.  In 2024 the drug’s regulatory profile expanded – after its U.S. and EU approvals for HR⁺/HER2‑ metastatic breast cancer in early‑2023, the FDA granted a second Breakthrough‑Therapy designation for Trodelvy in extensive‑stage small‑cell lung cancer, signaling continued clinical development and potential future sales growth【page_39】【page_8】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 56% sales growth for Trodelvy in 2023 and reports sales of $1.1 billion, which is a rounded version of the ground truth $1,063 million—this is acceptable under semantic equivalence and common financial reporting practices. The mention of $680 million in 2022 is consistent with a 56% increase leading to ~$1.06 billion. The ground truth does not include 2022 sales, but the calculation is approximately correct (56% of $680M ≈ $381M increase → $1,061M total), so this is a reasonable inference. (2) The 2024 regulatory update—the FDA granting a second Breakthrough Therapy designation for extensive-stage small cell lung cancer—is accurately reported and matches the original answer verbatim in substance. (3) The LLM adds contextual details not in the ground truth (e.g., impact on Gilead’s overall revenue, gross margin changes, EU approvals), which are factually consistent and enhance completeness without introducing errors. These do not contradict the ground truth but provide broader context. (4) Multi-hop reasoning is sound: the model synthesizes financial performance (2023 sales growth) and regulatory developments (2024 FDA designation), correctly attributing both to Trodelvy across time. The only minor deviation is the rounding of $1,063M to $1.1B, which is acceptable. No incorrect entities, years, or metrics are used. The answer fully addresses both financial performance and regulatory trajectory as required by the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 413,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Chevron's financial involvement and strategic positioning in Angola LNG evolved from 2022 to 2024, based on specific disclosures regarding its equity investments and affiliate transactions?",
      "original_answer": "In 2022, Chevron reported improved income from equity affiliates, including upstream-related earnings from Angola LNG, which contributed to an overall increase in income from equity affiliates to $5,657 million. By 2024, Chevron's specific interest in Angola LNG Limited was disclosed as a 36.4% ownership stake, with Angola LNG Limited described as a key entity that processes and liquefies natural gas produced in Angola for delivery to international markets. This evolution reflects a continued strategic emphasis on LNG as part of Chevron’s broader upstream portfolio, with a clear quantification of its stake in 2024, suggesting a more defined and stable long-term positioning compared to the more general mention of earnings contribution in 2022.",
      "llm_answer": "In the 2022 Form 10‑K Chevron only referenced Angola LNG as a source of “higher upstream‑related earnings” (MD&A, page 42) and did not disclose the size of its ownership stake or the dollar amount of its investment. By the 2024 filing Chevron spells out the partnership: it holds a **36.4 % equity interest** in Angola LNG Limited, carries an **investment balance of $1.665 billion** (down from $1.762 billion in 2023) and recorded **equity earnings of $405 million** for the year (down from $513 million in 2023) (Note 15, Investments and Advances, page 84). Thus, Chevron moved from a vague earnings‑contributor description in 2022 to a clearly quantified, sizable equity stake and associated earnings in 2024, reflecting a more explicit strategic positioning in the Angola LNG project.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a detailed, well-supported evolution of Chevron's involvement in Angola LNG from 2022 to 2024. (1) It correctly states that in 2022, Chevron only referenced Angola LNG as a source of higher upstream-related earnings without disclosing ownership stake or investment amount, which aligns with the ground truth. In 2024, it accurately reports Chevron’s 36.4% equity interest, $1.665 billion investment balance (down from $1.762 billion in 2023), and $405 million in equity earnings (down from $513 million in 2023), all of which are consistent with disclosures in Note 15 of the 2024 10-K. (2) Quantitative accuracy is strong: all percentages, dollar figures, and year-over-year comparisons are correct and precisely cited. The only minor limitation is that the original answer does not include the $5,657 million total income from equity affiliates in 2022, which the ground truth highlights as context—though this omission does not invalidate the LLM’s correct focus on Angola LNG specifics. (3) The multi-hop reasoning is sound: the model synthesizes information across years, distinguishes between general mentions in 2022 and specific disclosures in 2024, and draws a valid conclusion about Chevron’s increasingly defined strategic positioning. (4) The answer is contextually excellent, directly addressing the question about financial involvement and strategic positioning evolution with precise, relevant data. The slight deduction in quantitative and qualitative scores reflects the absence of the broader 2022 equity affiliate income figure, but the LLM’s inclusion of Angola LNG-specific earnings and investment balances adds value beyond the ground truth. Overall, the answer exceeds the original in specificity and remains factually aligned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 485,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the value and issuance activity of META's Fixed-Rate Senior Unsecured Notes evolve from 2023 to 2024?",
      "original_answer": "In 2023, META issued $8.46 billion of net proceeds from Fixed-Rate Senior Unsecured Notes in May. By the end of 2024, the total value of these Notes had increased to $29.0 billion, up from $18.50 billion at the end of 2023, with an additional $10.50 billion issued in August 2024. This reflects both continued reliance on this form of debt financing and a significant increase in the total outstanding amount over the two-year period.",
      "llm_answer": "By the end of 2023 Meta reported $18.5 billion of fixed‑rate senior unsecured notes outstanding (the “Notes”) and had raised about $8.5 billion of net cash from a May 2023 issuance of those notes 【page_80†L31-L38】. At year‑end 2024 the outstanding principal had grown to $29.0 billion, reflecting a new $10.5 billion series issued in August 2024, and the fair‑value of the Notes rose to roughly $27.8 billion from $18.5 billion a year earlier 【page_110†L1-L9】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key facts from the ground truth: $8.46 billion (rounded to $8.5 billion) in net proceeds from the May 2023 issuance, $18.5 billion outstanding at end of 2023, $29.0 billion outstanding at end of 2024, and a $10.5 billion issuance in August 2024. These values match or are acceptably rounded versions of the original figures. (2) Quantitative accuracy is perfect—minor rounding of $8.46B to $8.5B is acceptable and common in financial reporting; all other numbers ($18.5B, $29.0B, $10.5B) are exact. The fair value increase to $27.8B is an additional detail not in the original answer but is factually consistent and does not contradict it. (3) The multi-hop reasoning is sound: the model correctly synthesizes data across two years and two issuances, linking the increase in outstanding principal to the new August 2024 issuance. It accurately infers the evolution of issuance activity and value over time. (4) The only reason for not scoring a 10 in qualitative accuracy is that the original answer emphasizes the 'continued reliance' and 'significant increase' as an interpretive conclusion, which the LLM omits—though the factual basis for that interpretation is fully present. Otherwise, the answer is semantically equivalent, contextually precise, and highly relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 370,
        "total_tokens": 1584
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did LIN's financial exposure to helium as a raw material change from 2023, when it was categorized as a supply, to 2024, when it became a dependency, based on specific cost or sourcing disclosures?",
      "original_answer": "In 2023, LIN categorized helium as a supply, indicating it was a standard input with manageable sourcing dynamics, and reported helium costs at 4.2% of total raw material expenses. By 2024, the relationship shifted to 'depends_on,' signaling increased strategic importance, and helium costs rose to 6.8% of raw material expenses, reflecting a more critical role in operations and a corresponding increase in cost exposure.",
      "llm_answer": "In the 2023 filing LIN grouped helium with its other “raw‑materials and supplies” inventory – $614 million at year‑end – and did not call out any separate cost, treating it as a routine supply item. By the 2024 filing the company explicitly described helium as a **dependency**, and the same inventory line fell to $529 million, signalling that a larger share of the raw‑material budget now hinged on helium and that the company was tracking its cost impact more closely.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. While it correctly identifies the shift in categorization from a routine supply to a 'dependency' from 2023 to 2024, it does not report the key quantitative metrics from the ground truth—specifically, that helium costs were 4.2% of total raw material expenses in 2023 and rose to 6.8% in 2024. Instead, the LLM introduces dollar values for total raw materials and supplies inventory ($614M in 2023 and $529M in 2024) that are not mentioned in the original answer and are not directly tied to helium costs. These figures may be factually present in the filings but are used misleadingly here to infer increased exposure without linking them to helium specifically. (2) The quantitative accuracy is low because the critical percentages (4.2% and 6.8%) are omitted, and the introduced dollar amounts, while possibly accurate in context, are not relevant to the specific question about helium’s cost exposure as a proportion of raw material expenses. There is no calculation or comparison of helium-specific cost changes. (3) The reasoning partially captures the multi-hop element—recognizing a shift in language from general supply to dependency—but fails to synthesize the actual cost proportion data that demonstrates increased financial exposure. The inference that a 'larger share of the raw-material budget now hinged on helium' based solely on a decline in total inventory value is logically flawed and unsupported. (4) Despite missing key data and introducing potentially misleading figures, the answer correctly identifies the conceptual shift in categorization and the increased strategic focus on helium, which maintains moderate qualitative and contextual relevance. However, the absence of the core quantitative evidence from the ground truth significantly undermines factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 503,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what was the percentage change in the amount approved for such activities?",
      "original_answer": "In 2022, PayPal had $3.8 billion approved to fund credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, the approved amount decreased to $3.0 billion, representing approximately 39% of European customer balances. This indicates a reduction in the absolute amount approved for credit activities, even though the percentage slightly increased, signaling a more conservative approach to utilizing customer balances for credit funding.",
      "llm_answer": "In 2022 PayPal had **$3.8 billion** of European customer balances approved for credit use, representing **about 37 %** of the balances it could deploy. By year‑end 2023 that approval fell to **$3.0 billion**, but the share of balances earmarked rose to **roughly 39 %**. The approved amount therefore **declined by about 21 %** (‑$0.8 billion ÷ $3.8 billion).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) All numeric values are accurate: $3.8 billion in 2022 (37%), $3.0 billion in 2023 (39%) — matching the original answer exactly. (2) The percentage change calculation is correct: ($3.8B - $3.0B) / $3.8B = 0.8 / 3.8 ≈ 21.05%, which the model correctly rounds to 'about 21%'. The negative direction ('declined') is also properly conveyed. (3) Multi-hop reasoning is sound: the model correctly synthesizes both absolute amounts and their relative percentages over two years, noting the divergence between declining absolute approval and slightly increasing percentage share — a nuanced point that reflects understanding of PayPal's more conservative utilization strategy. (4) Entity accuracy is perfect: 'PayPal', 'European customer balances', 'credit activities', and years 2022–2023 are all correctly identified and contextualized. (5) The answer addresses both parts of the question: evolution of utilization (declining amount, rising percentage) and the percentage change in approved amount (~21% decrease). Wording differs slightly but maintains full semantic equivalence. No factual, quantitative, or reasoning errors present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 339,
        "total_tokens": 1563
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Starbucks' exposure to foreign currency - other instruments evolve between 2023 and 2024, particularly in terms of their fair value and the expected reclassification impact on earnings?",
      "original_answer": "In 2023, Starbucks reported a fair value of $1,164 million for foreign currency - other instruments, with a net gain of $39.6 million included in AOCI. By 2024, the fair value decreased to $920 million, and the net gain included in AOCI dropped to $11.5 million. Additionally, the amount expected to be reclassified from AOCI into earnings within 12 months declined from $55.3 million in 2023 to $9.5 million in 2024, indicating a reduced short-term earnings impact from these instruments.",
      "llm_answer": "Starbucks’ “foreign‑currency – other” hedge portfolio shrank sharply from fiscal 2023 to fiscal 2024.  At September 29 2024 the fair‑value of the designated assets fell to $1.9 million (prepaid) and $1.7 million (long‑term) versus $32.0 million and $22.9 million at October 1 2023, while the related liabilities rose modestly to $4.7 million (accrued) and $4.1 million (long‑term) versus $2.0 million and $0 million a year earlier.  Consequently, the amount expected to be re‑classified from AOCI into earnings within 12 months dropped to about $9.5 million in 2024 (down from essentially none reported in 2023), and the earnings impact switched from a $3.6 million loss in 2023 to a $0.1 million gain in 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Starbucks reported a fair value of $1,164 million in 2023 and $920 million in 2024 for foreign currency - other instruments. The LLM instead reports asset and liability values in the millions but with completely different magnitudes (e.g., $1.9 million prepaid assets in 2024 vs. correct total fair value of $920 million), indicating a fundamental misunderstanding or misrepresentation of the data. The LLM also states that the amount expected to be reclassified dropped to $9.5 million in 2024 from 'essentially none' in 2023, which contradicts the ground truth stating $55.3 million in 2023. While the $9.5 million expected reclassification in 2024 is correct, the baseline is wrong. Additionally, the LLM mentions a $3.6 million loss in 2023 switching to a $0.1 million gain in 2024, which is not supported by the ground truth—instead, the net gain in AOCI was $39.6 million in 2023 and $11.5 million in 2024. (2) Number verification: Correct values are $1,164M (2023 fair value), $920M (2024), $39.6M and $11.5M net gains in AOCI, and $55.3M vs $9.5M reclassification expectations. LLM reports none of these correctly except the $9.5M 2024 reclassification. All other figures (e.g., $32M, $22.9M, $4.7M) are unrelated to the actual total fair value of the instruments. (3) Multi-hop reasoning is flawed: The model fails to synthesize the correct total fair value and misinterprets component-level hedge accounting entries as the total exposure. It also fails to correctly compare AOCI impacts across years and misstates the earnings reclassification baseline. (4) Scores justified: Correctness is low (2/10) due to almost all key facts being incorrect. Quantitative accuracy is poor (2/10) as only one number ($9.5M) is correct. Qualitative accuracy is slightly higher (3/10) because the direction of change (decrease in reclassification impact) is correct, but reasoning is unsound. Contextual relevance is moderate (6/10) as the answer addresses the right topic and structure but with wrong data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 565,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the fair value of energy-related derivatives held by Alabama Power and Georgia Power evolve from 2022 to 2023, and what was the directional change in their asset versus liability positions?",
      "original_answer": "In 2022, Alabama Power reported energy-related derivatives with a fair value of $55 million in assets and $11 million in liabilities, while Georgia Power reported $75 million in assets and $8 million in liabilities. By 2023, Alabama Power's energy-related derivatives decreased to $15 million in assets but increased significantly to $110 million in liabilities. Similarly, Georgia Power's derivatives were valued at $13 million in assets and $124 million in liabilities in 2023. This indicates a substantial shift toward liability exposure for both entities over the period.",
      "llm_answer": "In the 2023 filing the two utilities reported only modest asset‑side fair values for their energy‑related derivatives – Alabama Power held **$15 million** and Georgia Power held **$13 million** – but much larger liability‑side fair values – Alabama Power had **$110 million** of liabilities and Georgia Power **$124 million** (see page 281).  \n\nThe 2022 filing did not break out separate subsidiary amounts; the company only disclosed a consolidated $199 million of derivative assets versus $210 million of liabilities (page 283). Thus, from 2022 to 2023 each subsidiary moved from having no reported derivative position to a **net‑liability position**, with liabilities now far exceeding the modest asset amounts.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partially correct quantitative information for 2023, correctly stating Alabama Power's $15 million in assets and $110 million in liabilities, and Georgia Power's $13 million in assets and $124 million in liabilities. However, it incorrectly claims that the 2022 filing 'did not break out separate subsidiary amounts' and that 'the company only disclosed a consolidated' figure. This contradicts the ground truth, which explicitly provides 2022 subsidiary-level data: Alabama Power had $55M in assets and $11M in liabilities, and Georgia Power had $75M in assets and $8M in liabilities. These figures are critical for assessing the evolution from 2022 to 2023 and the directional change in asset versus liability positions. By omitting and misrepresenting the 2022 breakdown, the LLM fails the multi-hop requirement to compare changes over time at the subsidiary level. The conclusion that each subsidiary 'moved from having no reported derivative position to a net-liability position' is factually wrong, as both had significant asset positions in 2022. While the 2023 numbers are accurate and the direction of change (increasing liabilities) is qualitatively correct, the absence of correct 2022 subsidiary data undermines the reasoning and leads to an incorrect narrative. Quantitative accuracy is moderate due to correct 2023 values but missing/incorrect 2022 values. Qualitative accuracy is low due to flawed reasoning and incorrect synthesis across years. Contextual relevance is high as the answer addresses the right entities and topic, just with incorrect data for one year.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 437,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the asset allocation strategy for the U.S. Retiree Health Care Plan evolve from 2022 to 2023, particularly in terms of the percentage distribution between fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan allocated 65% to fixed income securities and cash equivalents and 35% to equity securities. By 2023, the allocation to fixed income securities increased to 80%, while equity securities decreased to 20%. This represents a shift toward a more conservative investment strategy in 2023 compared to 2022.",
      "llm_answer": "By the end of 2022 the U.S. Retiree Health Care plan was invested roughly two‑thirds in fixed‑income securities (about 65 %) and one‑third in equities (about 35 %). A year later, at 31 December 2023, the plan’s weighted‑average allocation had moved to about 80 % fixed‑income and only 20 % equity 【page_49†L31-L38】. This reflects a shift toward a higher proportion of bonds and cash equivalents and a lower proportion of stock holdings.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages for both years are accurate: 65% fixed income and 35% equity in 2022, shifting to 80% fixed income and 20% equity in 2023. The use of 'about' is acceptable as it reflects rounding and matches the precision of the original data. (2) The answer is complete, addressing the evolution of asset allocation between the two years and specifically covering both fixed income and equity securities as asked. (3) Entities are correct: 'U.S. Retiree Health Care Plan', years 2022 and 2023, and asset classes are accurately identified. (4) The reasoning is sound—correctly identifying a shift toward a more conservative strategy by increasing fixed income and decreasing equity exposure. The citation to page 49 supports the data. (5) Semantic equivalence is maintained: 'two-thirds' ≈ 65%, 'one-third' ≈ 35%, and the conclusion about increased bond/cash and reduced stock holdings aligns with the ground truth's 'more conservative investment strategy'. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 314,
        "total_tokens": 1524
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has the regulatory approval status of Trodelvy evolved between 2022 and 2023, and what new indications were granted in 2023?",
      "original_answer": "In 2022, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies and for metastatic urothelial cancer after platinum-based chemotherapy and a PD-1/PD-L1 inhibitor. By 2023, Trodelvy received additional approvals: it was granted EC approval and FDA approval for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. This represents a significant expansion of the drug’s therapeutic applications.",
      "llm_answer": "In the 2022 Form 10‑K, Trodelvy (sacituzumab govitecan‑hziy) was listed as having **U.S. FDA accelerated‑approval** for two indications – triple‑negative breast cancer and urothelial cancer. By the 2023 filing, Gilead reported that **a new indication was added**: the drug received **U.S. FDA approval (and full European Commission marketing authorization) for the treatment of adult patients with unresectable locally advanced or metastatic hormone‑receptor‑positive, HER2‑negative (HR⁺/HER2‑) breast cancer** who have progressed after endocrine‑based therapy and at least two other systemic therapies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the 2022 indications for Trodelvy—triple-negative breast cancer and urothelial cancer—with appropriate context about prior therapies. It accurately states that in 2023, a new indication was approved: for HR+/HER2- breast cancer, specifying the required prior treatments (endocrine-based therapy and at least two other systemic therapies). (2) All dates (2022, 2023) and regulatory bodies (U.S. FDA, European Commission) are correct. The LLM correctly distinguishes between FDA accelerated approval in 2022 and full EC authorization in 2023. There are no numerical inaccuracies, and all factual elements match the original answer. (3) The multi-hop reasoning is sound—comparing the 2022 and 2023 Form 10-K filings to identify changes in approval status and indications. The synthesis across years and regulatory jurisdictions is accurate. (4) The only minor shortcoming is that the original answer explicitly mentions 'EC approval and FDA approval' in 2023, while the LLM implies FDA approval was new in 2023—though contextually it's clear the new indication received both. However, the original does not clarify whether the FDA approval for this indication was accelerated or full, so the LLM’s wording is reasonable. Overall, the answer is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 386,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Meta's disclosure regarding user perception as a risk factor evolve between 2023 and 2024, particularly in terms of the nature of risks highlighted and their potential impact on business operations?",
      "original_answer": "In 2023, Meta emphasized user perception risks related to privacy, safety, content quality, and regulatory changes, specifically noting concerns around decreased user sentiment and engagement due to data practices and content policies. In 2024, while user perception was still acknowledged, the focus shifted toward broader operational and financial risks, such as integration challenges from acquisitions, tax liabilities, and investor sentiment. The explicit mention of user perception as a direct risk factor was notably reduced in 2024, indicating a strategic shift in how Meta communicated its risk profile.",
      "llm_answer": "In the 2023 Form 10‑K (Item 1A, p. 16) Meta warned that **if users do not view its products as useful, reliable or trustworthy, the company could lose or fail to grow its user base, which would cut ad‑impression volume and therefore damage its revenue, financial condition and results of operations**【page_16】.  \n\nBy the 2024 filing (Item 1A, p. 35) the company had broadened the perception risk: **it now notes that acquisitions or other strategic moves could be perceived negatively by users (as well as marketers, developers or investors), and that such negative perception could hurt the business and depress the price of its Class A stock**【page_35】.  \n\nThus, the risk narrative shifted from a focus on **product‑level user trust and engagement** affecting advertising revenue in 2023, to a **broader reputational risk tied to corporate actions** that could impact overall business performance and share‑price in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in Meta's risk disclosures between 2023 and 2024: in 2023, the focus was on user perception related to product trustworthiness affecting user engagement and ad revenue; in 2024, the emphasis broadened to include reputational risks from corporate actions (e.g., acquisitions) affecting multiple stakeholders and stock price. This matches the original answer’s claim of a shift from user perception as a direct product-level risk to a broader reputational and financial risk. (2) There are no numeric values, dates, or calculations in the question or answers that require verification—both years (2023, 2024) and document references (Form 10-K, Item 1A, page numbers) are correctly cited and consistent with typical SEC filing structures. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, compares the nature of the disclosed risks, and infers a strategic shift in narrative—exactly what the question demands. (4) The LLM slightly reframes the shift using terms like 'reputational risk' and 'corporate actions,' which are not verbatim in the original but are semantically valid interpretations. The only minor gap is that the LLM does not explicitly mention the reduced emphasis on privacy, safety, and content quality in 2024, which the original answer notes. However, this is implied by the shift in focus. Overall, the answer is factually correct, contextually precise, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 425,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has the notional amount of Lockheed Martin's variable interest rate swaps evolved from 2021 to 2024, and what does this indicate about the company's interest rate risk management strategy?",
      "original_answer": "In 2021, the notional amount of Lockheed Martin's variable interest rate swaps was $500 million, while by 2024, it had increased to $1.3 billion. This indicates a significant shift in the company's interest rate risk management strategy, with a growing emphasis on converting fixed-rate borrowings to variable-rate borrowings, likely in response to changes in the interest rate environment and the company's borrowing profile over the period.",
      "llm_answer": "Lockheed Martin’s disclosed notional amount for its outstanding interest‑rate swaps rose from **about $500 million at December 31 2021** (down from $572 million in 2020) to **approximately $1.3 billion at December 31 2024 (and 2023)**【page_66】【page_52】.  \n\nThe more than doubling of the swap notional suggests the company has broadened its use of interest‑rate derivatives—likely converting a larger share of its debt exposure between fixed and floating rates—to more actively hedge interest‑rate risk and stabilize earnings and cash‑flow sensitivity to rate movements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the notional amounts for Lockheed Martin's variable interest rate swaps in 2021 ($500 million) and 2024 ($1.3 billion), matching the ground truth exactly. It also accurately notes that the amount was $572 million in 2020, which is an additional detail not in the original answer but factually correct and contextually helpful. The statement that the notional amount was approximately $1.3 billion in both 2023 and 2024 aligns with typical disclosure patterns and does not contradict the ground truth, which only specifies 2024.\n\n2) Quantitatively, all numbers and dates are accurate. The increase from $500 million to $1.3 billion is correctly described as 'more than doubling,' which is mathematically sound (a 160% increase). No calculation errors are present.\n\n3) The reasoning is sound and reflects appropriate multi-hop synthesis: the LLM infers that the increase in notional amount indicates a strategic shift toward more active interest rate risk management, specifically converting debt exposure between fixed and floating rates. This aligns with the ground truth's interpretation of a shift toward converting fixed-rate borrowings to variable-rate, likely in response to interest rate environment changes. The LLM slightly rephrases the strategy but maintains semantic equivalence, emphasizing hedging and stabilization of earnings and cash flow.\n\n4) The answer is contextually relevant and fully addresses both parts of the question: the evolution of the notional amount (2021 to 2024) and the implication for risk management strategy. The only minor limitation is that it does not explicitly state the direction of conversion (fixed to variable) as clearly as the original answer, instead saying 'between fixed and floating rates,' which is slightly less precise. However, the overall inference remains correct and well-supported.\n\nThus, the answer is highly accurate, with only a slight deduction in qualitative accuracy due to slightly less precise characterization of the conversion direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 550,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did PayPal's approach to its Seller Protection Programs evolve between 2022 and 2023, particularly in terms of financial provisions for transaction losses?",
      "original_answer": "In 2022, PayPal acknowledged the risk of losses from its Seller Protection Programs and noted that historical loss rates ranged between 0.09% and 0.15% of TPV, with the potential for increased losses due to macroeconomic conditions such as the ongoing impacts of the COVID-19 pandemic. By 2023, PayPal provided more structured financial disclosures, showing that the allowance for transaction losses was $64 million (down from $66 million in 2022), indicating a slight decrease in expected losses. This shift reflects a more defined and quantified approach to managing seller protection risk in 2023 compared to the more qualitative risk assessment in 2022.",
      "llm_answer": "In 2022 PayPal’s Seller‑Protection allowance for transaction losses stood at **$66 million**.  The company recorded a **$1.17 billion provision**, incurred **$1.417 billion of realized losses**, received **$170 million of recoveries**, and ended the year with a **$278 million allowance**.\n\nIn 2023 the allowance was trimmed to **$64 million**.  PayPal raised the **provision to $1.192 billion**, but realized **smaller losses of $1.313 billion**, and recoveries fell to **$125 million**, leaving an **ending allowance of $282 million**.\n\nThus, between 2022 and 2023 PayPal increased its provision for Seller‑Protection losses while actual loss experience improved, resulting in a slightly lower year‑end allowance for transaction losses.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, PayPal's allowance for transaction losses was $66 million in 2022 and $64 million in 2023 — these two numbers are correctly stated. However, the LLM introduces additional figures not present in the original answer — such as a $1.17 billion provision, $1.417 billion realized losses, $170 million recoveries, and ending allowances of $278M and $282M — which are not mentioned in the ground truth and appear to be fabricated or misattributed. There is no support in the original answer for these detailed P&L or allowance roll-forward figures. (2) The ground truth does not provide any data on provisions, realized losses, or recoveries; it only states the allowance amounts and references historical loss rates as a percentage of TPV (0.09%–0.15%). The LLM invents a level of financial detail that contradicts the scope of the original answer. Additionally, the claim that the allowance 'ended the year at $278 million' in 2022 directly contradicts the stated $66 million figure. This indicates a fundamental misunderstanding or misrepresentation of what the 'allowance' represents. (3) The multi-hop reasoning is flawed. The original answer contrasts a qualitative risk-focused discussion in 2022 with a more structured, quantified disclosure in 2023 centered on the $66M → $64M decrease. The LLM incorrectly frames the evolution as involving increased provisions and complex roll-forwards, which is not supported. The conclusion that 'provision increased while actual loss experience improved' is not inferable from the ground truth and reflects incorrect synthesis. (4) Due to major quantitative errors and incorrect financial modeling, the correctness and quantitative accuracy scores are low. Qualitative accuracy is slightly higher because the model attempts to analyze evolution over time and uses appropriate financial terminology. Contextual relevance is moderate since the topic and direction (evolution of seller protection provisions) are on track, but the substance is wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 561,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Starbucks' derivative asset and liability positions in foreign currency - other change from fiscal year 2023 to fiscal year 2024, and what was the magnitude of this change on the balance sheet?",
      "original_answer": "In fiscal year 2023, Starbucks reported a derivative asset of $1,164 million under 'Foreign currency - other.' By fiscal year 2024, this amount significantly decreased to $1.9 million in derivative assets under the same category. Additionally, the derivative liability for 'Foreign currency - other' increased from $2.0 million in 2023 to $4.7 million in 2024. This indicates a major reduction in the company's foreign currency derivative assets and a moderate increase in liabilities tied to foreign currency over this period.",
      "llm_answer": "Starbucks’ “foreign‑currency – other” derivative positions fell sharply. The fair‑value of those derivative assets dropped from $54.9 million in FY 2023 (‑ $32.0 m in current assets + $22.9 m in long‑term assets) to only $3.6 million in FY 2024 (‑ $1.9 m + $1.7 m), a decline of roughly **$51 million**. At the same time, the related derivative liabilities rose from **$2 million** to **$8.8 million** (‑ $4.7 m accrued + $4.1 m long‑term), an increase of about **$7 million**, leaving a net reduction of roughly **$58 million** on the balance sheet.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, Starbucks' derivative asset for 'Foreign currency - other' was $1,164 million in FY2023, not $54.9 million as stated by the LLM. The FY2024 asset value is reported as $1.9 million in the truth, while the LLM states $3.6 million—both figures are incorrect. The liability increase is also wrong: truth shows an increase from $2.0 million to $4.7 million, but the LLM claims an increase from $2 million to $8.8 million, which is more than double the correct amount. (2) Calculations are therefore also flawed: the claimed $51 million decline in assets is off by over $1.1 billion; the actual decline is approximately $1,162.1 million. The reported $7 million increase in liabilities is incorrect—the actual increase is $2.7 million. The net reduction of $58 million on the balance sheet is entirely unsupported by correct data. (3) While the LLM attempts multi-hop reasoning by breaking down current vs. long-term components and calculating net changes, it fails to use the correct source data. The structure suggests an understanding of how to analyze derivative positions, but the synthesis is based on incorrect inputs, undermining the reasoning. (4) Despite these major quantitative errors, the answer is contextually relevant—it addresses the right category ('foreign currency - other'), the correct company (Starbucks), and the correct time frame (FY2023 to FY2024). It also correctly identifies the directional trend (assets decreased, liabilities increased), which prevents a score of 0. However, the magnitude errors are so severe that the answer cannot be considered factually reliable. Hence, correctness is scored low at 3, with similarly low quantitative accuracy (2), modest qualitative accuracy (4) for structure and directionality, and decent contextual relevance (7).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 513,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial impact of energy-related derivatives on natural gas cost and revenue hedging positions evolve from 2022 to 2023?",
      "original_answer": "In 2022, energy-related derivatives had a negative impact of $117 million on natural gas revenues and a $27 million negative impact on the cost of natural gas. In 2023, the impact shifted positively with a $59 million gain on the cost of natural gas, while the revenue impact remained neutral at $0. This indicates a transformation in the role and effectiveness of these derivatives in managing natural gas exposure.",
      "llm_answer": "In 2022 Southern Company’s energy‑related derivative contracts produced a **$37 million pre‑tax gain** on the cash‑flow hedge of its natural‑gas cost (and a modest gain on the natural‑gas revenue hedge), but by 2023 the same hedge **generated a $44 million pre‑tax loss** on natural‑gas cost and the revenue hedge moved into a loss (the 2023 natural‑gas revenue hedge recorded a loss versus the 2022 gain). In short, the derivative position that had helped offset natural‑gas costs and revenues in 2022 turned into a net loss on both the cost and revenue sides in 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both direction and magnitude of financial impacts. According to the ground truth, in 2022, derivatives had a negative impact of $117M on natural gas revenues and $27M on costs, whereas the LLM claims a $37M gain on cost and a 'modest gain' on revenue—directly contradicting the negative impacts. In 2023, the ground truth states a $59M gain on cost and $0 on revenue, but the LLM reports a $44M loss on cost and a loss on revenue, again reversing the actual outcome. (2) All key numbers are wrong: $37M gain vs. actual $27M loss (cost, 2022); $44M loss vs. actual $59M gain (cost, 2023); revenue impact described as gain then loss vs. actual $117M loss then $0. No accurate calculations or figures are presented. (3) The multi-hop reasoning fails—instead of showing a shift from negative to positive impacts on cost and neutralization of revenue impact, the LLM incorrectly infers a deterioration from gain to loss on both fronts. It also introduces 'Southern Company' not mentioned in the original answer, raising entity accuracy issues. (4) Despite incorrect facts, the answer attempts to address the evolution of derivative impacts on cost and revenue hedging, so it retains partial contextual relevance. However, due to severe quantitative and qualitative errors, the overall correctness score is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 379,
        "total_tokens": 1623
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Walmart's treatment of its Deferred Compensation Matching Plan evolve between the 2023 and 2024 10-K filings, particularly in terms of its documentation status and effective date?",
      "original_answer": "In the 2023 10-K filing, the Deferred Compensation Matching Plan was newly introduced as 'Walmart Inc. Deferred Compensation Matching Plan, as amended and restated effective November 8, 2023.' By the 2024 10-K filing, the plan was no longer labeled as newly introduced but was instead referenced as being 'incorporated by reference' to the 2024 Annual Report on Form 10-K, indicating that it had become an established, ongoing plan. The effective date remained unchanged at November 8, 2023, suggesting no substantive changes to the plan’s implementation timeline, but its treatment shifted from being newly introduced to being formally integrated into the company's long-term compensation framework.",
      "llm_answer": "In the 2023 Form 10‑K the Deferred Compensation Matching Plan was listed simply as “Walmart Inc. Deferred Compensation Matching Plan, as amended and restated effective November 8, 2022, incorporated by reference to Exhibit 10.1” (no asterisk, i.e., a publicly filed exhibit). In the 2024 Form 10‑K the same plan is still incorporated by reference, but it now appears with an asterisk (10.1*), indicating that the exhibit is being filed under confidential‑treatment rules, and its effective date has been updated to November 8, 2023 【page 84 (2023)】 vs. 【page 84 (2024)】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its correctness. (1) The effective date in the 2023 10-K is stated as November 8, 2023 in the ground truth, but the LLM incorrectly reports it as November 8, 2022, which is a critical error in quantitative accuracy. (2) The LLM claims that in the 2024 10-K the effective date was 'updated' to November 8, 2023, implying a change from 2022 to 2023, but the ground truth states the effective date remained unchanged at November 8, 2023, meaning no update occurred. This misrepresents the evolution of the plan. (3) The LLM introduces the idea of an asterisk (*) indicating confidential treatment in the 2024 filing, which is not mentioned or supported by the original answer; this is an unsupported detail that distorts the actual documentation status change (from newly introduced to incorporated by reference). (4) The original answer emphasizes a shift in treatment—from being newly introduced in 2023 to being formally integrated and referenced in 2024—reflecting maturity of the plan. The LLM fails to capture this conceptual evolution and instead invents a narrative around confidentiality and date changes that contradicts the ground truth. While the LLM does correctly identify that the plan is incorporated by reference in both years and attempts to analyze exhibit labeling, its core facts about dates and changes are incorrect. The reasoning is therefore flawed, and the multi-hop synthesis fails. Contextual relevance is moderate because it addresses the right document types and general idea of documentation status, but factual inaccuracies dominate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 443,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the disclosure and treatment of LTIP Units evolved between 2023 and 2024, particularly in terms of their dilutive effect and accrual policy?",
      "original_answer": "In 2023, LTIP Units were described as potentially dilutive securities that are convertible into units and exchangeable for common stock, with no material dilutive effect reported for the years 2023, 2022, and 2021. The company stated it does not adjust net income attributable to common stockholders or weighted average shares outstanding due to no dilutive impact. In 2024, the disclosure simplified, stating that LTIP Units are potentially dilutive but again noting no material dilutive effect for the years 2024, 2023, and 2022. Additionally, the accrual policy remained consistent, stating that distributions are accrued when declared. The treatment of LTIP Units remained stable with no significant change in dilutive impact or accrual policy.",
      "llm_answer": "In the 2023 filing the company noted that LTIP units (and other securities exchangeable for common stock) were “potentially dilutive” but that **no securities had a material dilutive effect** and that **dividends were accrued when declared** (for the corporation) or **distributions were accrued when declared** (for the operating partnership). The 2024 filing repeats the same conclusion – LTIP units remain potentially dilutive but **still have no material dilutive impact**, and the company continues to **accrue dividends or partnership distributions at the time they are declared**, adding only slightly more description of the LTIP units’ convertibility.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: LTIP Units are described as potentially dilutive with no material dilutive effect in both 2023 and 2024, and the accrual policy is consistently stated as distributions (or dividends) being accrued when declared. The LLM correctly identifies that the treatment remained stable across years. (2) There are no numeric values requiring calculation, but the years referenced (2023, 2022, 2021 in 2023 filing; 2024, 2023, 2022 in 2024 filing) are accurately reflected in the context of disclosure scope. (3) The multi-hop reasoning is sound—comparing disclosures across two years, synthesizing changes (or lack thereof) in dilutive effect and accrual policy. The LLM correctly infers stability in treatment despite slight elaboration in 2024. (4) The only minor shortcoming is the addition of detail about 'dividends for the corporation' vs 'distributions for the operating partnership' and 'slightly more description of convertibility'—details not present in the ground truth—which slightly extends beyond the provided information but does not introduce inaccuracy. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high score with only a small deduction for slight over-elaboration not grounded in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 378,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Meta's compliance approach to the EU-U.S. Data Privacy Framework (EU-U.S. DPF) evolved between 2023 and 2024, particularly in response to regulatory actions and decisions?",
      "original_answer": "In 2023, Meta was in the process of implementing steps to comply with corrective orders from the Irish Data Protection Commission (IDPC) following a EUR €1.2 billion fine and a directive to suspend unlawful data transfers to the U.S. under Standard Contractual Clauses (SCCs). At that time, the EU-U.S. DPF had just been finalized, and Meta viewed its implementation as a key milestone to address data transfer compliance. By 2024, Meta had implemented compliance measures with the corrective orders and was actively engaging with regulators on new compliance models, such as the 'subscription for no ads' alternative introduced in November 2023. In 2024, the European Commission opened formal proceedings into the compliance of this model with the Digital Markets Act (DMA), issuing preliminary findings in July 2024 that suggested non-compliance. This reflects a shift from foundational compliance with the EU-U.S. DPF framework to navigating more complex regulatory scrutiny around specific business models under evolving EU laws.",
      "llm_answer": "In the 2023 filing Meta noted that the July 2023 EU adequacy decision for the new EU‑U.S. Data‑Privacy Framework was “an important and welcome milestone” and that the company was **implementing steps to comply with the Irish Data Protection Commission’s corrective orders** while it appealed the Commission’s 2023 SCC fine (Meta 10‑K 2023, p. 10).  \n\nBy the 2024 filing Meta still relies on the EU‑U.S. DPF but its compliance posture has broadened: it **continues to engage with regulators on the framework, monitors the risk of a CJEU invalidation, and has added product‑level changes (e.g., less‑personalised‑ads options and a “no‑ads” subscription) to meet emerging EU rules such as the Digital Markets Act**, indicating a more proactive, multi‑layered response to the evolving regulatory landscape (Meta 10‑K 2024, p. 11).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: Meta's characterization of the July 2023 EU adequacy decision as a 'milestone,' its implementation of corrective orders from the Irish Data Protection Commission (IDPC), and the €1.2 billion fine (implied in context though not explicitly restated in the LLM answer) are consistent with the original. The mention of appealing the SCC fine adds contextual precision supported by the 10-K. (2) Quantitative accuracy is perfect: no incorrect numbers, dates (July 2023 adequacy decision), or financial figures are presented. The LLM correctly avoids misstating the fine amount or timeline. (3) Multi-hop reasoning is sound—linking Meta’s use of EU-U.S. DPF, ongoing regulatory engagement, product changes (e.g., 'no-ads' subscription), and alignment with the Digital Markets Act (DMA) reflects proper synthesis across 2023 and 2024 filings. The evolution from foundational compliance to proactive adaptation is accurately captured. (4) The only minor shortcoming is that the LLM does not explicitly mention the European Commission’s formal proceedings in July 2024 or its preliminary finding of non-compliance with the DMA, which is a notable detail in the ground truth. However, it does correctly note engagement on new models and monitoring regulatory risks, capturing the essence. Wording differs slightly but maintains semantic equivalence. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 416,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Linde's approach to green hydrogen production evolved between 2023 and 2024, particularly in terms of production methods and emphasis on renewable energy sources?",
      "original_answer": "In 2023, Linde described green hydrogen as being produced primarily through electrolysis using renewable energy or from steam methane reforming of biomethane, and it was presented as one of the company's clean energy offerings alongside blue hydrogen. By 2024, the company had expanded its description to emphasize green hydrogen as 'renewable hydrogen' produced by electrolysis using renewable energy and water as feedstock, and it was clearly differentiated from low-carbon (blue) hydrogen. Additionally, in 2024, Linde placed more emphasis on the carbon intensity metric to differentiate production methods, indicating a more refined and strategic framing of green hydrogen within the broader context of clean energy solutions.",
      "llm_answer": "In the 2023 filing Linde defined “green hydrogen” as hydrogen made either by water‑electrolysis powered with renewable electricity **or** by steam‑methane reforming of biomethane 【page_4】. By the 2024 filing the company’s description had shifted to stress that renewable (green) hydrogen is produced **solely** by electrolysis using renewable‑energy electricity and water as feedstock, positioning renewable power as the core source for its low‑carbon hydrogen portfolio 【page_4】. This reflects a move from a broader set of feed‑stock options in 2023 to a tighter focus on pure renewable‑energy‑driven electrolysis in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution in Linde's definition of green hydrogen: in 2023, it included both electrolysis using renewable energy and steam methane reforming (SMR) of biomethane, while in 2024 the definition narrowed to only electrolysis using renewable energy and water. The key shift from 'or' to 'solely' is accurately emphasized. (2) There are no numerical values requiring verification (e.g., dates are correct—2023 to 2024—and no calculations are needed), so quantitative accuracy is perfect. (3) The multi-hop reasoning is sound: the model synthesizes changes in terminology, production methods, and strategic emphasis across two years. The only minor omission is that the 2024 filing also introduced a greater emphasis on carbon intensity as a differentiator between production methods, which the LLM answer does not mention. This is a small but relevant detail present in the original answer. (4) Despite this omission, the LLM answer conveys the core evolution accurately and uses semantically equivalent language (e.g., 'renewable hydrogen' for 'green hydrogen', 'tighter focus' reflecting strategic refinement). Contextual relevance is excellent as it directly addresses both production methods and emphasis on renewable energy sources as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 373,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Southern Company's relationship with Sequent evolve between 2022 and 2023, and what were the financial implications of this change?",
      "original_answer": "Southern Company's relationship with Sequent evolved from a business ownership relationship in 2022 to a completed divestiture in 2023. In 2022, Southern Company Gas completed the sale of Sequent to Williams Field Services Group for $159 million, recognizing a pre-tax gain of $121 million. Additionally, the sale resulted in $85 million of additional tax expense due to changes in state apportionment rates. By 2023, Sequent was no longer part of Southern Company's portfolio, and the financial impact of the sale was fully reflected in the company's financial statements, with the gain from the sale reported as a $121 million pre-tax benefit. This marked a complete transformation in the relationship, shifting from operational integration to full separation.",
      "llm_answer": "By 2022 Southern Company Gas no longer reported a “Wholesale Gas Services” segment because it had sold its Sequent business (the July 1 2021 sale). The same situation persisted in 2023 – Sequent was fully removed from the segment lineup and appears only in the “All Other” column. The divestiture produced a pre‑tax gain of roughly $121 million (about $92 million after tax) but also triggered an additional $85 million of tax expense, which together altered Southern Company’s consolidated earnings in both years.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. The pre-tax gain of $121 million and the additional $85 million tax expense are correctly reported, aligning with the ground truth. However, the LLM incorrectly states that the sale occurred on July 1, 2021, which contradicts the ground truth stating the sale was completed in 2022. This is a critical factual error affecting the timeline of the relationship evolution. Additionally, the after-tax gain of $92 million is mentioned but not present in the original answer, and its derivation is unclear—$121M - $85M = $36M, not $92M, suggesting a flawed calculation or misattribution. (2) Quantitative accuracy is partially correct: $121M pre-tax gain and $85M tax expense are accurate, but the implied after-tax figure is inconsistent and unsupported by the ground truth. The date of the sale (2021 vs 2022) is a major discrepancy. (3) The reasoning correctly identifies the divestiture and its financial reporting impact, such as the removal of Sequent from segment reporting and inclusion in 'All Other'. However, the multi-hop synthesis fails on timing—claiming the sale happened in 2021 undermines the core of the question about the 2022–2023 evolution. The relationship did not evolve between 2022 and 2023 if the sale occurred in 2021. (4) Contextual relevance is high—the answer addresses the financial implications and structural changes. However, due to the incorrect sale date and miscalculated after-tax gain, the overall correctness is significantly reduced. The core narrative of divestiture and financial impact is sound, but key facts are wrong, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 456,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Walmart's relationship with the Allswell brand evolved between 2023 and 2024, and what does this indicate about its strategic positioning within the company's private brand portfolio?",
      "original_answer": "In 2023, Walmart introduced the Allswell brand as part of its private brand offerings, indicating its initial entry into the market. By 2024, the brand was not only retained but explicitly listed among other mature private brands like 'bettergoods,' 'Equate,' and 'Great Value,' suggesting that Allswell has transitioned from a newly introduced brand to a more established part of Walmart's private label strategy. This evolution indicates that Allswell has likely gained traction and is being positioned as a core component of Walmart’s private brand portfolio.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K filings list Allswell among Walmart’s private‑brand labels in the Walmart U.S. segment (“We also market lines of merchandise under our private brands, including … ‘Allswell’ …”). The brand’s continued presence in the private‑brand roster shows that Walmart has maintained, rather than discontinued or de‑emphasized, its partnership with Allswell, using it to deepen the breadth of low‑price, high‑quality private‑label offerings and reinforce the strategic focus on expanding its private‑brand portfolio.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Allswell was listed in both the 2023 and 2024 Form 10-K filings as part of Walmart’s private-brand labels, which aligns with the ground truth that the brand was introduced in 2023 and retained in 2024. The entity accuracy (Walmart, Allswell, 2023, 2024) and dates are correct, and there are no numeric inaccuracies—this supports a high quantitative accuracy score. (2) However, the LLM answer misses a key nuance present in the original answer: the evolution from a newly introduced brand in 2023 to being grouped with mature brands like 'bettergoods,' 'Equate,' and 'Great Value' in 2024. This omission weakens the qualitative accuracy, as it fails to fully capture the strategic progression from new to established brand. (3) The reasoning is sound in noting continued presence implies no de-emphasis, but it does not fully synthesize the multi-hop insight that inclusion among mature brands signals strategic elevation within the portfolio. The LLM interprets retention as maintenance, but the ground truth indicates advancement. (4) Despite this, the answer remains contextually relevant and factually consistent with the filings, just less precise in conveying the strategic implication of Allswell’s repositioning. Hence, correctness and qualitative accuracy are slightly reduced, but not severely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 379,
        "total_tokens": 1665
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the strategic importance of Embedded Processing products evolved from 2022 to 2023 based on TXN's revenue composition and strategic emphasis?",
      "original_answer": "In 2022, Embedded Processing products were described as one of two core segments, positioned alongside Analog as a key part of the business, though no specific revenue figures were disclosed. By 2023, Embedded Processing remained a strategic focus area, and notably, it partially offset a decline in Analog revenue, contributing to a $17.52 billion total revenue. This indicates that while Embedded Processing maintained its strategic importance, it also played a more pronounced compensatory role in the revenue mix during a year of overall revenue decline.",
      "llm_answer": "In 2023 Texas Instruments reported $3.37 billion of Embedded‑Processing revenue, up 3 % from the $3.26 billion earned in 2022 (see 2023 segment table, page 20) and representing roughly 19 % of total 2023 revenue versus about 17 % in 2022 (≈$3.05 billion of $18.34 billion in 2022, page 33).  The MD&A repeatedly stresses that the company’s “strategic focus is on analog and embedded‑processing products” (page 19) and that its business model is built around a “broad portfolio of analog and embedded‑processing products” (page 18).  Together, the modest revenue growth and the continued strategic emphasis indicate that Embedded‑Processing has become an even larger, more central growth pillar for TI from 2022 to 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that no specific revenue figures for Embedded Processing were disclosed in 2022, but the LLM claims $3.26 billion (and imputes $3.05 billion from a total of $18.34 billion), which contradicts the original answer. The 2023 revenue figure of $3.37 billion and 19% of total revenue is not corroborated in the ground truth, which does not provide segment-level revenue numbers. These specific numeric claims are unsupported and incorrect. (2) Calculations such as 3% growth, 17% to 19% share, and implied totals ($18.34 billion in 2022) are fabricated or misattributed; the ground truth reports $17.52 billion total revenue in 2023, not $3.37 billion for Embedded Processing alone. The LLM’s numbers do not align with the disclosed total, making the quantitative foundation invalid. (3) The reasoning is partially sound in identifying that Embedded Processing remained strategically important and may have offset Analog declines, but it overreaches by asserting increased centrality due to growth, which is not supported by the ground truth—no revenue growth or exact figures were provided. The multi-hop synthesis fails because it relies on incorrect data extraction. (4) Despite the incorrect numbers, the LLM correctly identifies the continued strategic emphasis on Embedded Processing alongside Analog and cites the right qualitative language (e.g., 'strategic focus'). It addresses the evolution question and remains contextually relevant. However, the core factual errors—especially the invented revenue figures—severely undermine correctness, warranting a low score. Quantitative accuracy is poor (3), qualitative reasoning is moderate (5) due to correct use of strategic language, and contextual relevance is high (8) as it directly engages the question’s intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 504,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has Chevron's involvement in Angola LNG evolved from 2022 to 2024, and what does this indicate about its strategic positioning in the LNG market?",
      "original_answer": "In 2022, Chevron's involvement in Angola LNG was referenced in the context of its production volumes, indicating operational participation. By 2024, Chevron's stake in Angola LNG Limited was explicitly stated as a 36.4% interest, highlighting a more defined and structured investment approach. This evolution suggests a strategic shift toward securing a stable position in the LNG market through formalized equity stakes.",
      "llm_answer": "In the 2022 filing Chevron reported that its 36.4 % stake in Angola LNG generated **$1.86 billion of equity earnings**. By the 2024 filing the investment balance had slipped only modestly (from about $1.76 billion in 2023 to **$1.67 billion in 2024**) and the equity earnings from the project fell sharply to **$405 million** (down from $1.86 billion in 2022).  \n\nThis shows that Chevron has kept its ownership position in Angola LNG but the project’s contribution to earnings has waned, indicating that while the company maintains a strategic foothold in the LNG market through the Angola asset, it is likely relying on a broader, more diversified LNG portfolio rather than counting on Angola LNG as a major growth driver.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Chevron's 36.4% stake was explicitly mentioned in 2024, but the LLM claims this stake was already reported in 2022 with specific financial figures ($1.86 billion equity earnings), which are not present in the original answer. There is no mention in the ground truth of equity earnings, investment balances, or any financial performance metrics for Angola LNG in either 2022 or 2024. These numbers appear to be fabricated or hallucinated. (2) The quantitative claims—$1.86 billion equity earnings in 2022, a drop to $405 million in 2024, and investment balances of $1.76B and $1.67B—are entirely unsupported by the original answer and cannot be verified from the provided context. No calculations can be validated because the source data does not exist in the ground truth. (3) The multi-hop reasoning is flawed: while the LLM attempts to infer strategic positioning from financial trends, it builds this analysis on false data. The original answer focuses on the evolution from operational participation (2022) to a clearly defined 36.4% equity stake (2024), indicating formalization of involvement. The LLM misrepresents the timeline and nature of this evolution. (4) Despite the incorrect facts, the LLM does address the question’s intent—analyzing Chevron’s evolving role in Angola LNG and its strategic implications—giving it moderate contextual relevance. However, due to severe quantitative and qualitative inaccuracies, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 430,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the financial contribution and production status of the CH-53K program evolved between 2021 and 2024, and what does this indicate about its role within Lockheed Martin's RMS division?",
      "original_answer": "In 2021, the CH-53K program contributed to a $540 million increase in RMS net sales, driven by higher production volume alongside the Black Hawk and CRH programs. Additionally, it contributed to a $140 million increase in operating profit due to higher risk retirements and production volume. By 2024, the CH-53K program was described as being in a 'production ramp-up' phase, contributing $1.1 billion to higher product sales within RMS, indicating a shift from early-stage production and risk retirement to a more mature, high-volume production phase. This evolution shows that the CH-53K has transitioned from a developing program with growing financial impact to a key growth driver within RMS.",
      "llm_answer": "In 2021 the CH‑53K helped lift RMS’s results, with Sikorsky‑helicopter sales (Black Hawk, CH‑53K and CRH) adding about **$540 million of net sales** and generating roughly **$140 million of additional operating profit** for the segment【page_50】. By 2024 the program was still expanding – the RMS product‑sales increase was “partly due to higher production volume on the CH‑53K program” (alongside radar and laser‑system growth) and drove higher product‑costs as the helicopter ramped up production【page_34】. This trajectory shows the CH‑53K has moved from a strong profit‑boosting contributor in 2021 to an even larger, ongoing production driver in 2024, underscoring its status as a core, growth‑critical asset within Lockheed Martin’s Rotary and Mission Systems division.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $540 million increase in net sales and $140 million in operating profit for 2021, matching the ground truth exactly. For 2024, while the original answer specifies a $1.1 billion contribution to higher product sales, the LLM answer does not include this exact figure but accurately describes the program as being in a 'production ramp-up' phase and contributing significantly to increased product sales and costs. This omission of the precise $1.1 billion number is a minor gap but does not distort the overall financial trajectory. (2) All provided numbers are accurate and correctly attributed to the right years and financial metrics. Format variations are acceptable and consistent with the ground truth. (3) The multi-hop reasoning is sound: the LLM synthesizes information across 2021 and 2024 to show an evolution from a profit-boosting program to a major production driver, correctly inferring the program’s growing strategic importance within RMS. The conclusion that CH-53K has become a 'core, growth-critical asset' aligns semantically with the ground truth’s characterization as a 'key growth driver'. (4) The answer is highly contextually relevant, addressing both the financial contribution and production status across the specified time frame and drawing a valid inference about the program’s role in RMS. The only reason for not scoring a 10 is the missing $1.1 billion figure in 2024, which is a factual omission but not an error in reasoning or interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 422,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did PayPal's use of macroeconomic factors in its loss curves for revolving consumer credit products evolve between 2022 and 2023?",
      "original_answer": "In 2022, PayPal applied macroeconomic factors such as forecasted trends in unemployment and benchmark credit card charge-off rates to its revolving consumer credit loss curves, using a single scenario deemed most appropriate for the economic conditions. By 2023, the company updated its expected credit loss models for revolving consumer receivables to include forecasted trends in household disposable income and retail e-commerce sales, replacing unemployment rates after the first quarter of 2023. This reflects a shift in the macroeconomic indicators used to inform loss curves for this segment.",
      "llm_answer": "In the 2022 filing, PayPal’s revolving‑consumer‑credit loss curves were built on historical loss data plus a single‑scenario macro‑economic outlook (unemployment and benchmark credit‑card charge‑off rates) using a **≈ 2‑year forecast horizon**. By the 2023 filing, the company had **extended that horizon to roughly 5 years (about 5 years + 7 months)** and refreshed the revolving‑credit loss model in Q2 2023—still relying on the same external macro‑economic factors, but with a longer‑term view; the update did not materially change the provision recorded for the year.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents key aspects of PayPal's evolution in using macroeconomic factors in its loss curves between 2022 and 2023. (1) Quantitatively, the claim of extending the forecast horizon from '≈2-year' to 'roughly 5 years + 7 months' is not supported by the ground truth, which does not mention any change in forecast horizon length—this is a fabrication. There are no numbers in the original answer about time horizons, so these specific durations are incorrect. (2) The LLM states that PayPal continued using the same macroeconomic factors (unemployment and charge-off rates), but the ground truth explicitly states that by 2023, the company replaced unemployment rates with forecasted trends in household disposable income and retail e-commerce sales. This is a major qualitative error: the model did not keep the same factors. (3) The LLM claims the model was refreshed in Q2 2023, but the original answer specifies that the change occurred after the first quarter of 2023, which may align loosely, but the lack of mention of the actual new variables undermines accuracy. (4) The LLM incorrectly asserts that the update 'did not materially change the provision recorded for the year,' which is not mentioned in the original answer and introduces unsupported conclusions. (5) The core multi-hop reasoning fails: the question asks how the *use of macroeconomic factors* evolved, and the LLM misses the key shift in indicators (from unemployment to income/e-commerce), which is the central point of the ground truth. Instead, it invents a change in forecast horizon that isn't in the source. While the answer is framed around the right topic (model updates for revolving credit loss curves), it conveys a different narrative than the truth. Thus, despite some contextual relevance, the factual and qualitative accuracy is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 507,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Starbucks' foreign currency debt-related gains or losses included in AOCI change from 2023 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2023, Starbucks reported a foreign currency debt-related loss of $6.3 million included in OCI before reclassifications, while in 2024, the company reported a gain of $135.2 million in AOCI related to foreign currency debt. This indicates a significant shift from a loss to a substantial gain, suggesting a reversal in the company's exposure to foreign currency fluctuations over this period.",
      "llm_answer": "Starbucks reported foreign‑currency‑debt gains of **$140.2 million** in AOCI for fiscal 2023, which fell to **$135.2 million** in fiscal 2024 – a decline of roughly **$5 million**. The modest reduction shows that the company’s net exposure to foreign‑currency movements on its debt has eased slightly, likely reflecting a smaller amount of foreign‑denominated debt or more effective hedging, though the exposure remains material.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in both direction and magnitude of the foreign currency debt-related gains/losses. According to the ground truth, Starbucks had a loss of $6.3 million in 2023 and a gain of $135.2 million in 2024, representing a dramatic shift from loss to gain. However, the LLM claims gains of $140.2 million in 2023 and $135.2 million in 2024, implying a small decrease in gains—this is the opposite of the actual trend. The numbers are therefore factually wrong, with the 2023 figure being especially inaccurate (reporting a large gain instead of a loss). (2) The quantitative inaccuracies are severe: the 2023 value is off by over $146 million when accounting for the sign change (from -$6.3M to +$140.2M), and the calculation of a $5 million decline is based on false premises. The 2024 number ($135.2M) is correct, but the comparison is invalid due to the incorrect 2023 figure. (3) The multi-hop reasoning fails because the model did not correctly retrieve or synthesize the data across years. Instead of identifying a reversal in foreign currency exposure (loss to large gain), it suggests only a slight easing of exposure, which contradicts the evidence. The conclusion about reduced exposure or better hedging is unsupported by the actual data, which shows a significant improvement likely due to favorable currency movements, not risk reduction. (4) Scores reflect major factual errors in numbers and direction of change (correctness: 2), very poor quantitative accuracy (2), weak reasoning and entity synthesis (3), and moderate contextual relevance since the answer addresses the right topic and metric (AOCI, foreign currency debt) but with wrong data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 465,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the fair value of energy-related derivatives for Alabama Power and Georgia Power change between 2022 and 2023, and what was the overall trend in their combined liabilities related to these derivatives?",
      "original_answer": "In 2022, Alabama Power reported a net liability of $144 million related to derivatives in non-designated hedging relationships, including energy-related derivatives. In 2023, Alabama Power had $15 million in assets and $110 million in liabilities related to energy-related derivatives, resulting in a net liability of $95 million. Georgia Power had $13 million in assets and $124 million in liabilities related to energy-related derivatives in 2023, yielding a net liability of $111 million. Therefore, the combined net liability for energy-related derivatives across both entities decreased from $255 million in 2022 to $206 million in 2023, indicating a reduction in exposure.",
      "llm_answer": "- **Fair‑value of the derivative assets:** In 2022 the combined fair‑value of energy‑related derivative assets for Alabama Power and Georgia Power was **$199 million** (the amount reported for the company’s energy‑related derivatives). By 2023 the two utilities together held only **$28 million** of such assets ($15 million for Alabama Power and $13 million for Georgia Power).  \n\n- **Combined liability trend:** The liability side rose from **$210 million** in 2022 to **$234 million** in 2023 (Alabama Power $110 million + Georgia Power $124 million).  \n\n**Overall, the assets tied to energy‑related derivatives fell sharply, while the related liabilities increased, resulting in a higher net liability exposure in 2023 versus 2022.**",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual and calculation errors, despite addressing the right entities and time periods. (1) Quantitative inaccuracy: The LLM incorrectly states that in 2022, the combined derivative assets were $199 million and liabilities were $210 million. The ground truth does not provide asset or liability breakdowns for Georgia Power in 2022, only Alabama Power's net liability of $144 million. The LLM fabricates a combined $199M in assets and $210M in liabilities for 2022 with no support from the original answer. (2) The 2023 numbers for assets ($15M for Alabama Power, $13M for Georgia Power) are correct, and the 2023 liabilities ($110M and $124M) are also correct. However, the conclusion that liabilities increased from $210M to $234M is invalid because the $210M figure is invented. (3) The original answer computes a combined net liability of $255M in 2022 (Alabama Power’s $144M net liability + assumption that Georgia Power had no data, but inference from context suggests prior net liability was part of that total). The LLM fails to compute net liabilities correctly and instead separates assets and liabilities incorrectly across years. (4) The LLM concludes that net liability exposure increased in 2023, which contradicts the ground truth: combined net liability decreased from $255M to $206M. This reversal of the actual trend is a major error in reasoning and conclusion. (5) While the LLM identifies the correct companies and years and attempts multi-hop synthesis, the reasoning is flawed due to unsupported data and incorrect calculations. The answer is contextually relevant but factually incorrect in key aspects, especially the overall trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 459,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Walmart's financial relationship with Alert Innovation evolve between fiscal 2023 and fiscal 2024, particularly in terms of acquisition and subsequent disposition activities?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, bringing its ownership to approximately 100%. However, in fiscal 2024, Walmart sold and deconsolidated the Alert Innovation entity, signaling a complete exit from the investment. This represents a full evolution from acquisition to divestiture within a one-year span.",
      "llm_answer": "In fiscal 2023 Walmart bought Alert Innovation for about $0.4 billion, taking its ownership to roughly 100 percent 【page_44】. During fiscal 2024 the company reported no further purchase or sale of Alert Innovation, indicating the business was simply held through that year; the subsequent divestiture was not disclosed until it occurred in fiscal 2025 【page_44】.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $0.4 billion acquisition in fiscal 2023 and Walmart's ~100% ownership, which matches the ground truth. However, it incorrectly states that no sale occurred in fiscal 2024 and claims the divestiture was disclosed in fiscal 2025, which directly contradicts the ground truth stating that Walmart sold and deconsolidated Alert Innovation in fiscal 2024. This is a major factual error regarding timing and event sequence. (2) Quantitatively, the $0.4 billion figure is accurate, and the 100% ownership is correctly reported. However, the misattribution of the divestiture to fiscal 2025 (instead of 2024) introduces a critical date error, reducing quantitative accuracy. (3) The multi-hop reasoning fails because the model does not correctly synthesize the evolution from acquisition to disposition within fiscal 2023–2024. Instead, it introduces a false timeline involving fiscal 2025, which breaks the logical chain and misrepresents the financial relationship. (4) Contextually, the answer addresses the question's focus on acquisition and disposition, so relevance is moderate. However, due to the core error in timing and failure to reflect the full cycle (acquisition and divestiture) within the specified period, the overall correctness is severely compromised, warranting a low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1186,
        "completion_tokens": 374,
        "total_tokens": 1561
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the regulatory approval status of Trodelvy evolve between 2022 and 2023, and what does this indicate about Gilead's oncology strategy?",
      "original_answer": "In 2022, Trodelvy was part of Gilead's marketed product portfolio and contributed to growth in the oncology franchise, though no specific regulatory updates were mentioned. By 2023, Trodelvy received both FDA and EC approvals for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who had received prior endocrine-based therapy and at least two additional systemic therapies. This regulatory progress indicates a strategic focus by Gilead on expanding the therapeutic applications of Trodelvy and strengthening its position in the oncology market, particularly in breast cancer treatment.",
      "llm_answer": "In the 2022 Form 10‑K Gilead reported that Trodelvy was already FDA‑approved (accelerated) for locally advanced/metastatic urothelial cancer and had full FDA and EU approval for metastatic triple‑negative breast cancer, with additional Health‑Canada and EU authorizations. By the 2023 filing the company added new approvals – both FDA and European Commission – for Trodelvy as a monotherapy in HR⁺/HER2‑ metastatic breast cancer, expanding the label beyond its original indications. This progression shows Gilead’s oncology strategy of leveraging an existing asset to capture new tumor‑type markets, using regulatory wins to broaden the product’s reach and drive growth in its cancer franchise.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Trodelvy was already approved for certain indications (metastatic triple-negative breast cancer and urothelial cancer), which is consistent with being part of Gilead's marketed portfolio, though the original answer does not specify these indications. The 2023 update accurately reflects the new FDA and European Commission approvals for HR+/HER2- metastatic breast cancer. (2) There are no numerical values requiring calculation, but all dates (2022 and 2023 filings) and regulatory bodies (FDA, EC) are correctly cited. Format variations (e.g., 'EU' vs 'EC') are semantically acceptable. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings to show label expansion, correctly inferring Gilead's strategy of broadening Trodelvy’s use to grow its oncology franchise. (4) While the original answer does not mention urothelial cancer or Health Canada approvals, the LLM provides additional context not contradicted by the ground truth—this enhances completeness without introducing error. The strategic interpretation about leveraging existing assets is logically supported and semantically equivalent. Minor deduction in qualitative accuracy due to inclusion of slightly more detailed prior indications than in the ground truth, but this does not undermine correctness. Overall, the answer is factually correct, fully addresses both parts of the question, and demonstrates strong contextual and logical alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 429,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Simon Property Group's financial relationship with ABG evolved between 2023 and 2024, particularly in terms of capital transactions and strategic positioning?",
      "original_answer": "In 2023, Simon Property Group (SPG) engaged in multiple capital transactions with ABG, including recognizing a non-cash pre-tax gain of $36.4 million from a dilution of ownership in ABG during the second quarter and an additional $145.8 million gain in the third quarter due to further dilution from SPARC Group issuing equity. Additionally, SPG had a long-standing strategic partnership with ABG dating back to 2021, involving licensing ventures such as Forever 21, Brooks Brothers, and Eddie Bauer, which resulted in significant gains. In 2024, SPG no longer reported active capital transactions with ABG, such as gains from dilution or new equity investments. Instead, the 2024 filing only referenced historical transactions, such as the 2021 sale of a portion of SPG’s ABG interest for a pre-tax gain of $18.8 million and the 2022 acquisition of Reebok assets alongside a strategic partnership. This indicates a shift from active financial engagement and restructuring with ABG in 2023 to a more stable, historically referenced relationship in 2024.",
      "llm_answer": "In 2023 Simon still held a minority stake in Authentic Brands Group (ABG) and was repeatedly “diluted” by ABG‑initiated capital transactions – for example, a Q4‑2023 sale of a portion of its ABG interest generated a pre‑tax gain of **$157.1 million** (tax expense $39.3 million) and, concurrently, ABG’s transaction reduced Simon’s ownership to about **9.6 %**, giving Simon a non‑cash pre‑tax gain of **$10.3 million** (deferred taxes $2.6 million)【page_71】【page_73】.  \n\nBy the first quarter of 2024 Simon had **exited the partnership entirely**, selling its remaining ABG interest for **$1.2 billion**, which produced a pretax gain of **$414.8 million** (tax expense $103.7 million)【page_73】. The move shifts Simon from a strategic, albeit minority, equity relationship with ABG in 2023 to a full cash divestiture and re‑positioning of capital toward its core REIT operations in 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) Quantitative Accuracy: The numbers reported are incorrect. The LLM claims a Q4-2023 sale generated a $157.1 million pre-tax gain and a separate $10.3 million non-cash gain, but the ground truth states a $36.4 million gain in Q2 and $145.8 million in Q3 2023—no such Q4 transaction is mentioned. Additionally, the LLM reports a 2024 divestiture of remaining ABG interest for $1.2 billion with a $414.8 million gain, which contradicts the ground truth: in 2024, SPG did not report any active capital transactions with ABG, let alone a full exit or sale. The ground truth only references historical transactions (2021 and 2022) in 2024, indicating no new gains or sales. (2) Completeness: While the question asks about the evolution of financial relationship in terms of capital transactions and strategic positioning, the LLM fabricates a full exit in Q1 2024 that is not supported by the original answer. It omits the actual strategic licensing ventures (Forever 21, Brooks Brothers, Eddie Bauer) central to the 2021 partnership. (3) Entity Accuracy: The companies (SPG, ABG) and general timeline (2023 vs 2024) are correct, but the financial events and their timing are not. (4) Reasoning: The multi-hop synthesis is flawed—the LLM incorrectly infers an active divestiture in 2024 when the truth is a lack of new activity, misrepresenting the nature of the relationship shift. (5) Semantic Equivalence: The conclusion that SPG shifted from active engagement to divestiture is plausible but factually wrong per the ground truth, which describes a transition from active transactions in 2023 to passive, historical references in 2024—not a full exit. Overall, the answer is largely incorrect due to fabricated financial figures and events, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1489,
        "completion_tokens": 503,
        "total_tokens": 1993
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Chevron's relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2024, particularly in terms of financial reporting and investment value?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was included in Chevron’s consolidated financial disclosures, specifically in Note 8 on page 70 of the 10-K filing, indicating it was a consolidated subsidiary. By 2024, the company was reported as an equity method investee under 'Downstream' in the Investments and Advances section, with a disclosed investment value of $8,571 million as of December 31, 2024, up from $7,765 million in 2023. This reflects a shift from full consolidation to an equity method investment, suggesting a structural or ownership change in Chevron’s relationship with the entity.",
      "llm_answer": "In the 2022 Form 10‑K Chevron disclosed that it owned 50 % of Chevron Phillips Chemical Company LLC and reported an equity‑method investment of roughly **$867 million** (the amount shown in the 2022 “Equity in earnings” column).  \n\nBy the 2024 filing the same 50 % ownership is still stated, but the carrying value of the investment had risen to **about $8.6 billion** and equity earnings were **$903 million** for the year (up from $867 million in 2022).  The 2024 notes also detail a **$669 million loan** to Chevron Phillips for the Golden Triangle Polymers project, showing a more granular financial‑reporting treatment and a substantially larger investment stake.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and quantitative errors that undermine its correctness. (1) Quantitative Accuracy: The reported 2022 investment value of '$867 million' is incorrect — this appears to be a misinterpretation of 'equity in earnings' as the carrying value. The ground truth shows Chevron Phillips was a consolidated subsidiary in 2022, not an equity method investee, so no standalone investment value was reported that year. The 2024 investment value is stated as $8.6 billion in the LLM answer, but the correct figure is $8,571 million (i.e., $8.571 billion), which is close but still inaccurate. The LLM also fabricates a '$669 million loan' not mentioned in the ground truth. (2) Completeness & Entity Accuracy: The answer incorrectly states that Chevron reported an equity-method investment in 2022, contradicting the ground truth that the entity was consolidated that year. This misrepresents the core evolution — the shift from consolidation to equity method — which the LLM fails to identify. Instead, it assumes consistent 50% ownership and equity reporting across both years, which is factually wrong. (3) Reasoning: The multi-hop reasoning is flawed. The key insight — a change in accounting treatment from consolidation to equity method — is entirely missed. The LLM incorrectly assumes continuity in reporting method while focusing on fabricated or misinterpreted numbers. (4) Semantic Equivalence: Despite some correct elements (e.g., 50% ownership likely correct, and investment value increasing), the overall narrative contradicts the ground truth. The mention of a loan and incorrect valuation metrics reduce accuracy. While the answer addresses financial reporting and investment value, it does so with incorrect data and reasoning, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 488,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did the status and financial impact of Meta's Facilities Consolidation Strategy evolve between the end of 2023 and the end of 2024?",
      "original_answer": "At the end of 2023, Meta had 'substantially completed' its facilities consolidation initiatives as part of the 2022 Restructuring, indicating the process was still ongoing. By the end of 2024, the company reported that it had 'completed the 2022 restructuring initiatives,' which included the facilities consolidation strategy, showing the process had reached full completion. Additionally, the 2024 disclosure included a financial summary of the 2022 Restructuring pre-tax charges across three years (2022–2024), indicating a retrospective quantification of the financial impact that was not explicitly detailed in 2023.",
      "llm_answer": "- **Status** – At 31 Dec 2023 Meta said the facilities‑consolidation initiatives were “substantially completed” (2023 10‑K)【page_102】. By 31 Dec 2024 the company reported that the 2022 restructuring, including the facilities‑consolidation work, was “completed” (2024 10‑K)【page_102】.  \n\n- **Financial impact** – In 2023 the portion of restructuring attributed to facilities consolidation was $2.506 billion of pre‑tax charges (cost‑of‑revenue $177 m, R&D $1.581 b, marketing $396 m, G&A $352 m)【page_102】. In 2024 all restructuring charges were related to facilities consolidation and amounted to $389 million of pre‑tax charges (cost‑of‑revenue $31 m, R&D $254 m, marketing $54 m, G&A $50 m)【page_102】.  \n\nThus, the program moved from “substantially completed” with a $2.5 billion cost in 2023 to fully completed with a remaining $389 million cost in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the financial data. The original answer (ground truth) states that in 2024, Meta provided a retrospective summary of total pre-tax charges across 2022–2024 for the 2022 Restructuring, but does not specify that $389 million was incurred in 2024 or that all 2024 charges were related to facilities consolidation. The LLM incorrectly presents 2024 financials as if they were newly incurred charges in that year, while the ground truth implies a cumulative or final accounting, not a year-specific breakdown. Similarly, the $2.506 billion figure attributed to 2023 is not confirmed in the original answer — the ground truth does not provide annual cost breakdowns by year or category (R&D, G&A, etc.), making these detailed allocations unsupported. (2) The quantitative accuracy is low because the LLM fabricates granular financial figures (e.g., $1.581b R&D, $389m total in 2024) that are not present in the ground truth. There is no verification that these numbers match actual filings; the original answer only notes that a financial summary was disclosed in 2024, not the amounts per year. (3) The qualitative accuracy is moderate: the LLM correctly identifies the progression from 'substantially completed' in 2023 to 'completed' in 2024, showing proper multi-hop reasoning across years and correct entity identification (Meta, 2022 Restructuring, facilities consolidation). However, it overreaches by introducing unverified financial details, undermining the reasoning. (4) Contextual relevance is high because the structure and intent align well with the question — it attempts to compare status and financial impact across years using appropriate sourcing cues (10-K page references). However, the inclusion of unsupported numbers reduces overall correctness. The core status evolution is accurate, but the financial impact is misrepresented with false precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 524,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2024, particularly in terms of strategic focus and program status?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a key growth area that was dependent on U.S. Government authorization and funding, indicating that the programs were still in a development phase with uncertain future funding. By 2024, the company was actively producing hypersonic strike weapons under multiple programs with the U.S. Air Force and Army, showing a shift from a funding-dependent future initiative to an active production program. This evolution reflects a significant advancement in the maturity and strategic importance of hypersonics within Lockheed Martin's portfolio.",
      "llm_answer": "In the 2022 Form 10‑K Lockheed Martin first flagged hypersonics as a key growth pillar, noting that it was “advancing hypersonic capabilities” and that its Missiles & Fire Control and Space segments were running “several programs with the U.S. Army and U.S. Navy to design, develop and build hypersonic strike weapons.” By the 2024 filing the company’s strategy still places hypersonics at the center of its 21st Century Security vision, now emphasizing the work of its Skunk Works/Advanced Development Programs and the continued pursuit of new Army‑ and Navy‑funded contracts, indicating that the effort has moved from early‑stage development toward a broader, more mature portfolio of ongoing and award‑seeking hypersonic programs.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in terms of dates (2022 and 2024) and correctly identifies Lockheed Martin as the company involved, with accurate reference to its segments (Missiles & Fire Control, Space, Skunk Works). There are no numeric values requiring verification, so quantitative accuracy is not compromised. The answer captures the strategic focus on hypersonics as a key growth area and notes ongoing programs with the U.S. Army and Navy, which aligns with the ground truth. However, it omits a critical evolution highlighted in the original answer: the shift from a funding-dependent, development-phase status in 2022 to active production in 2024. Instead, the LLM answer describes a progression to 'a broader, more mature portfolio of ongoing and award-seeking programs,' which understates the advancement to actual production under Air Force and Army contracts. This missing detail weakens the qualitative accuracy, as the core transformation—from uncertain development to active manufacturing—is not fully conveyed. The reasoning is sound but incomplete in synthesizing the full multi-hop progression. The answer remains contextually relevant and well-structured, but the lack of emphasis on production status in 2024 results in a partial mismatch with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 358,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolve from 2022 to 2023, particularly in terms of their designation and financial impact?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred. By 2023, the company expanded its disclosure to include the pre-tax effects of energy-related derivatives not designated as hedging instruments on its statements of income, covering the years 2023, 2022, and 2021. This indicates a shift from focusing only on regulatory hedging instruments to providing a broader view of its energy-related derivative activities.",
      "llm_answer": "In the 2022 filing Southern Company reported that its energy‑related contracts were classified as **regulatory cash‑flow hedges**; they produced a modest **$3 million gain in OCI**, a **$37 million gain in earnings** (Southern Company) and a **$9 million net unrealized gain** on the balance sheet. By the 2023 filing the same contracts were still disclosed as regulatory hedges, but the results had reversed – the company recorded an **$81 million loss in OCI**, a **$44 million loss in earnings**, and a **$257 million net unrealized loss** on the balance sheet, while non‑designated energy derivatives remained immaterial. This shows a shift from a small positive financial impact in 2022 to a sizable negative impact in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The original answer states that Southern Company evolved its *disclosure practices* from 2022 to 2023—specifically, in 2022 it reported only the pre-tax effects of derivatives designated as regulatory hedging instruments, while in 2023 it expanded disclosure to include non-designated derivatives across 2023, 2022, and 2021. The LLM answer, however, fabricates specific financial figures (e.g., $3M gain in OCI, $37M gain in earnings, $81M loss in OCI, etc.) that are not present in the ground truth and misrepresents the nature of the change as a shift in financial performance rather than a change in disclosure scope. (2) There are no verifiable calculations or accurate numbers in the LLM response because all numeric values are invented. The ground truth does not provide any specific dollar amounts related to OCI, earnings, or balance sheet impacts for any year. (3) The multi-hop reasoning is flawed: instead of identifying the evolution in *accounting disclosure and designation practices*, the model incorrectly interprets the change as a deterioration in financial results due to derivative positions, missing the core point about transparency and reporting breadth. It also fails to mention the retrospective inclusion of 2021 data in the 2023 disclosures, a key element of the expanded disclosure. (4) While the answer is contextually relevant—focusing on Southern Company and energy-related derivatives—and attempts to compare 2022 and 2023, the factual inaccuracies and invented data severely undermine correctness. The conclusion about a 'shift' exists but is based on false premises, leading to a low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 469,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Gilead's intellectual property strategy regarding Truvada evolve between 2022 and 2023, particularly in terms of patent disclosures?",
      "original_answer": "In 2022, Gilead highlighted the October 2020 loss of exclusivity of Truvada in the United States as a transitory headwind, indicating that the product was no longer protected under patent, which likely affected revenue. In 2023, Gilead provided structured disclosures regarding the patent expiration dates of its principal products, including Truvada, focusing on the actual or estimated expiration dates in the U.S. and the EU. This represents a shift from acknowledging a past loss of exclusivity to proactively disclosing future intellectual property timelines for key products.",
      "llm_answer": "In the 2022 Form 10‑K Gilead’s IP discussion simply noted that **Truvada’s U.S. exclusivity had ended in October 2020** and the company did not list any remaining Truvada‑related patents or expiration dates in its patent‑expiration tables.  \n\nBy the 2023 Form 10‑K the company still listed Truvada (and Truvada for PrEP) as a marketed product, but again provided no specific patent‑expiration or new‑patent‑filing information for it—its patent‑expiration tables cover other HIV products but omit Truvada. Thus, between 2022 and 2023 Gilead’s strategy shifted from merely acknowledging the loss of exclusivity to continuing to market the drug without disclosing any new or surviving Truvada patents, indicating that it is not pursuing additional patent protection for Truvada.",
      "correctness_score": 4,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct in stating that Truvada's U.S. exclusivity ended in October 2020, which aligns with the ground truth. This date is accurately cited, satisfying quantitative accuracy. However, the qualitative analysis and reasoning are flawed. The ground truth states that in 2023, Gilead shifted to proactively disclosing patent expiration timelines for key products including Truvada, implying structured transparency. In contrast, the LLM claims that Truvada was omitted from patent-expiration tables in the 2023 10-K and that no new disclosures were made, which contradicts the original answer’s assertion of increased structured disclosure. This misrepresents Gilead’s 2023 strategy as passive (no new patents disclosed) rather than proactive (systematic disclosure of expiration dates). The LLM fails to capture the evolution from reactive acknowledgment of past loss to forward-looking IP transparency, which is the core of the multi-hop reasoning required. While the entity (Gilead), drug (Truvada), and time period (2022–2023) are correct, the interpretation of the strategic shift is incorrect, leading to a low qualitative accuracy score. Contextual relevance is moderate because the answer addresses the topic and timeframe but draws an incorrect conclusion about the nature of the strategy change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 368,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did SPG's use of the Supplemental Facility evolve between 2022 and 2024, particularly in terms of borrowing and repayment activities?",
      "original_answer": "In 2022, SPG borrowed $1.05 billion under the Supplemental Facility in January 2022, which was used to fund the early extinguishment of nine mortgages with a principal balance of $1.16 billion. This borrowing was repaid shortly after issuance. By 2024, SPG again utilized the Supplemental Facility, borrowing €750.0 million ($815.4 million U.S. dollar equivalent) in November 2023, which was repaid on November 17, 2023. Additionally, in 2024, SPG issued new senior unsecured notes to redeem other outstanding notes at maturity, indicating a shift in financing strategy. The evolution shows a continued reliance on the Supplemental Facility for short-term financing needs but with a more structured approach to repayment and refinancing.",
      "llm_answer": "In the 2022 filing SPG reported that it had drawn **$1.05 billion** from the Supplemental Facility on December 14 2021 and then **repaid the entire amount** with proceeds from a $1.25 billion senior‑note issuance on January 12 2022 【page_73】.  \n\nBy the 2024 filing the company’s Supplemental Facility had been **re‑extended (October 2021) to a $3.5‑$4.5 billion borrowing capacity with a new maturity of January 31 2029, later extendable to 2030** 【page_69】, and the only remaining balance – a **€750 million** draw – was **retired in November 2023** when the proceeds of a €750 million senior‑bond issuance were used to repay that amount 【page_70】.  \n\nThus, the facility went from having a $1.05 billion outstanding in early 2022 (which was fully paid off) to carrying a smaller euro‑denominated loan that was also extinguished by the end of 2023, leaving the facility available for future borrowing but with **no outstanding balance as of 2024**.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution of SPG's use of the Supplemental Facility between 2022 and 2024, with only minor discrepancies in dates and details. (1) Quantitatively, the $1.05 billion borrowing in 2022 and €750 million (≈$815.4M) draw in 2023 are accurately reported. However, the LLM states the $1.05B was drawn on December 14, 2021, and repaid January 12, 2022, while the ground truth says it was borrowed in January 2022 (no specific date given), used to repay $1.16B in mortgages, and repaid shortly after issuance. The LLM’s date discrepancy (Dec 2021 draw) is slightly off but within plausible range given filing timelines. (2) The €750M repayment in November 2023 is correctly reported, though the LLM attributes it to proceeds from a euro bond issuance, while the ground truth notes it was repaid on November 17, 2023, without specifying funding source—this is a minor inference but reasonable. (3) The LLM adds contextual detail about the facility being extended to 2029/2030 with increased capacity, which is accurate and enhances completeness, though not in the original answer. (4) The conclusion that the facility was used for short-term needs and had no balance in 2024 aligns with the ground truth’s emphasis on short-term use and repayment. (5) The ground truth mentions a shift to issuing senior unsecured notes for redemptions in 2024, which the LLM partially reflects by referencing senior note and bond issuances, but does not explicitly frame as a strategic shift. This is a minor omission. Overall, core facts, numbers, and reasoning are correct with only small timing and emphasis differences. Hence, high scores across the board with a slight deduction in correctness and quantitative accuracy due to date precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 480,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the role of cash buffer needs in MetLife's capital management strategy evolved from 2022 to 2024, particularly in terms of liquidity levels and their impact on capital allocation decisions?",
      "original_answer": "In 2022, MetLife maintained a short-term liquidity position of $12.4 billion and a total liquid asset base of $223.0 billion, reflecting a strong buffer to meet business requirements under both normal and stress scenarios. The company emphasized its belief in having ample liquidity and highlighted active monitoring and adjustment of liquidity and capital plans. By 2024, the narrative shifted to a more cautious tone, noting that maintaining or increasing cash buffers could limit capital available for innovation, acquisitions, and shareholder returns. This indicates that while liquidity remained a strategic priority, the implications of holding larger cash buffers became more pronounced, potentially constraining other capital deployment opportunities.",
      "llm_answer": "In the 2022 filing MetLife described its cash‑buffer as a core element of liquidity management, reporting a $12.4 billion short‑term liquidity position and $223 billion of overall liquid assets, and warned that “if we increase the buffer… we may have less capital to devote to innovation, acquisitions, development and return of capital to shareholders.” By the 2024 filing the same buffer is still maintained, but the discussion is framed more directly around capital‑allocation trade‑offs: the company now emphasizes that any rise in cash‑buffer needs will explicitly constrain the amount of capital it can allocate to growth initiatives and shareholder‑return programs, even though the specific liquidity figures are no longer disclosed.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $12.4 billion short-term liquidity position and $223 billion total liquid assets from MetLife's 2022 filing, matching the ground truth exactly. While the 2024 liquidity figures are not disclosed in the LLM answer, this is consistent with the ground truth, which also does not provide updated quantitative figures for 2024—only a qualitative shift in tone. Thus, the absence of 2024 numbers is not an error. (2) All numeric values are accurate and properly attributed to 2022. No calculations are required, and the figures align with the original answer. Format variations (e.g., $223 billion vs $223.0 billion) are acceptable and semantically equivalent. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes information across 2022 and 2024 filings, identifying the evolution from strong liquidity assurance to a more cautious discussion of capital allocation trade-offs. It accurately captures the forward-looking warning in 2022 about increasing buffers limiting capital deployment, and notes that by 2024 this concern became a central framing in capital allocation decisions. The progression in narrative tone and strategic emphasis is correctly interpreted. (4) The answer is contextually fully relevant, addressing both liquidity levels and their impact on capital allocation across the specified time frame. The only minor limitation is that the LLM attributes the exact quote about increasing the buffer reducing capital for innovation to the 2022 filing, while the ground truth does not quote directly but paraphrases the same idea—this is a slight overattribution but does not distort the meaning. Overall, the answer is factually correct, well-reasoned, and comprehensive.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 477,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did Starbucks' exposure to 'Foreign currency - other' derivatives evolve between 2022 and 2023, particularly in terms of asset and liability classifications?",
      "original_answer": "In 2022, Starbucks reported 'Foreign currency - other' derivative liabilities of $0.3 million under accrued liabilities and no corresponding asset value. By 2023, the company had a derivative asset of $1.9 million under prepaid expenses and other current assets and a derivative liability of $4.7 million under accrued liabilities for the same category. This indicates a significant increase in exposure and a shift toward a more balanced treatment across asset and liability classifications.",
      "llm_answer": "In fiscal 2022 Starbucks held “foreign‑currency‑other” derivative contracts almost entirely as assets – $39.9 million in prepaid‑expenses/current‑asset and $33.5 million in other long‑term assets (≈$73 million total) – with only $0.3 million recorded as an accrued‑liability and no long‑term liability. By fiscal 2023 the asset balances had fallen to $32.0 million (current) and $22.9 million (long‑term) (≈$55 million total), while liability balances rose to $2.0 million accrued plus $4.1 million in other long‑term liabilities (≈$6 million total), indicating a reduction in asset exposure and a modest increase in liability exposure.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content. According to the ground truth, in 2022, Starbucks reported only a $0.3 million liability for 'Foreign currency - other' derivatives with no asset value. However, the LLM claims there were significant asset values ($39.9 million current and $33.5 million long-term), which contradicts the original answer. Similarly, in 2023, the ground truth states there was a $1.9 million asset and $4.7 million liability, but the LLM reports $32.0 million and $22.9 million in assets and $2.0 million and $4.1 million in liabilities—values that are completely inconsistent with the correct data. (2) All key numbers are wrong: the LLM fabricates large asset positions in both years that do not exist in the ground truth. The only correct number is the $0.3 million liability in 2022. Calculations based on these incorrect figures (e.g., ~$73 million total assets in 2022) are therefore also invalid. (3) The reasoning is flawed because it assumes a large asset position exists when it does not, leading to an incorrect conclusion about a 'reduction in asset exposure.' The actual evolution—from no asset/liability in 2022 to both asset and liability positions in 2023—reflects a new and growing exposure, not a reduction. The LLM fails this multi-hop synthesis entirely. (4) Despite the severe factual inaccuracies, the answer is contextually relevant—it addresses the right topic (derivative classifications over time) and attempts to compare assets and liabilities across years. Hence, moderate relevance score. However, due to major quantitative and qualitative errors, the correctness score is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 457,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has The Coca-Cola Company's relationship with Coca-Cola FEMSA evolved from 2023 to 2024, particularly in terms of its strategic engagement and financial stake?",
      "original_answer": "In 2023, Coca-Cola FEMSA was one of The Coca-Cola Company's five largest independent bottling partners, operating in multiple countries including Mexico, Brazil, and Argentina, and collectively these top five bottlers accounted for 42% of Coca-Cola's worldwide unit case volume. By 2024, the relationship had evolved significantly, as Coca-Cola FEMSA transitioned from being a key bottler to becoming an equity method investee in which The Coca-Cola Company held a 28% ownership stake. This shift indicates a deeper financial commitment and alignment beyond the traditional bottler-concentrate supplier model.",
      "llm_answer": "In 2024 The Coca‑Cola Company still owned **28 % of Coca‑Cola FEMSA** and reported a **$1.8 billion equity‑method investment** that generated **$1.77 billion of equity income** (page 87).  While the ownership percentage did not change from 2023, the 2024 filing stresses a more‑integrated strategic partnership – the company highlights FEMSA as a “key bottling partner” and notes continued shared‑value initiatives such as incidence‑based concentrate pricing, marketing‑support programs and joint‑growth objectives (pages 7‑8), indicating a deeper collaborative engagement than was described in the 2023 filing.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies The Coca-Cola Company's 28% ownership stake in Coca-Cola FEMSA in 2024, which aligns with the ground truth. However, it introduces financial figures—$1.8 billion equity-method investment and $1.77 billion equity income—not present in the original answer and not verifiable from the provided ground truth, raising concerns about hallucination or unsupported specificity. The original answer does not mention any dollar amounts or income figures, only the shift in relationship and ownership percentage. (2) The quantitative accuracy is partially compromised because while the 28% ownership is correct, the additional financial data lacks corroboration from the ground truth and may be inaccurate or taken from a source outside the scope. There are no calculations in the ground truth to validate the $1.77B or $1.8B figures. (3) The qualitative reasoning is strong: the LLM correctly interprets the evolution as a deepening of strategic engagement, noting integrated initiatives like pricing models and joint growth objectives, which supports the ground truth’s claim of a shift beyond traditional bottler relationships. It also correctly frames Coca-Cola FEMSA as a key bottling partner in 2024, consistent with the transition to a more aligned, equity-based relationship. (4) Contextual relevance is perfect—the response directly addresses both strategic engagement and financial stake across 2023–2024. The core evolution (from top bottler to equity investee with 28% stake) is accurately captured, though the added financial details reduce quantitative precision. The answer reflects multi-hop synthesis between ownership structure and strategic collaboration, but the inclusion of unsupported numbers prevents a higher correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 487,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Intel's strategic positioning of FPGAs evolved between 2022 and 2024, particularly in terms of their role within adjacent products and their broader production focus?",
      "original_answer": "In 2022, Intel positioned FPGAs as part of its 'adjacent products' within the Client Computing Group (CCG), Data Center Group (DCG), and Internet of Things Group (IOTG), indicating a supporting role within comprehensive platform solutions. By 2024, FPGAs were explicitly listed under direct product definitions, signaling a shift toward a more central production focus. This reflects a transformation in the strategic importance of FPGAs, moving from a supplementary role to a core product offering.",
      "llm_answer": "In the 2022 filing Intel grouped FPGAs under **“adjacent products”** – non‑platform items (modems, Ethernet, silicon‑photonic, Mobileye, etc.) that were sold alongside its core CPU/SoC platforms to complete a customer solution. By the 2024 filing the company had moved the FPGA out of that ancillary bucket and positioned it as one of the four primary **xPU** architectures (CPU, GPU, AI‑accelerator and FPGA) within the Programmable Solutions Group, emphasizing a dedicated, larger‑scale production effort and integration of FPGAs across data‑center, edge and AI workloads.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth, with only minor differences in framing. (1) All key facts are correct: in 2022, FPGAs were categorized as 'adjacent products' alongside modems, Ethernet, etc., indicating a supplementary role; by 2024, they were elevated to a primary xPU architecture (CPU, GPU, AI-accelerator, FPGA) within the Programmable Solutions Group, signaling a strategic shift to a core product. This aligns with the ground truth's claim of moving from a supporting to a central production focus. (2) There are no numeric values, dates, or financial figures in dispute—years (2022, 2024) are correct and consistently used. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes in product categorization across filings and infers strategic significance from structural repositioning. The mention of 'xPU' architectures and integration into data center, edge, and AI workloads adds contextual depth not in the original but is consistent with the strategic evolution. (4) The only reason for not scoring a 10 is that the original answer emphasizes the shift from 'adjacent products' in CCG/DCG/IOTG to direct product status, while the LLM frames it as a move into the xPU category under PSG—both are accurate, but the LLM slightly reinterprets the organizational context without contradicting facts. Overall, the answer is semantically equivalent, factually correct, and contextually rich.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 406,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did ConocoPhillips' financial activity related to the Lower 48 region evolve from 2022 to 2023, particularly in terms of asset acquisition and depreciation, depletion, and amortization expenses?",
      "original_answer": "In 2022, ConocoPhillips noted that purchases in the Lower 48 were driven by the Concho acquisition, indicating a strategic expansion in that region. The depreciation, depletion, amortization, and impairments expense for the Lower 48 was $4,854 million. In 2023, the company's expense for the same category in the Lower 48 increased to $5,729 million, showing a significant rise of $875 million. This increase suggests continued investment and asset utilization in the Lower 48 following the acquisition.",
      "llm_answer": "In 2023 ConocoPhillips stepped up spending on its Lower 48 assets – capital‑expenditure outlays rose to **$6.5 billion**, up from **$5.6 billion** in 2022, although “investments in and advances to affiliates” for the region fell to **$118 million** from **$235 million** a year earlier【page 135】.  At the same time, the cost of using those assets grew, with **depreciation, depletion and amortization (DD&A) rising to $5.73 billion** in 2023 versus **$4.85 billion** in 2022【page 133】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the depreciation, depletion, and amortization (DD&A) expenses for the Lower 48 region as $4.85 billion in 2022 and $5.73 billion in 2023, which aligns with the ground truth values of $4,854 million and $5,729 million (rounded appropriately). The increase of $875 million is accurately reflected as a rise from $4.85B to $5.73B (~$880M difference), showing strong quantitative accuracy. (2) While the original answer emphasizes the Concho acquisition as the driver of 2022 activity, the LLM answer does not mention this specific acquisition but instead introduces capital expenditures ($5.6B in 2022, $6.5B in 2023) and investments in affiliates, which are relevant financial activities but not explicitly tied to the acquisition. This is a minor omission in qualitative completeness, though the core focus on financial activity evolution is maintained. (3) The multi-hop reasoning is sound—comparing DD&A across years and noting increased spending shows synthesis across time periods and financial metrics. The LLM correctly identifies ConocoPhillips, the Lower 48 region, and the relevant financial metrics for 2022 and 2023. (4) The answer is contextually relevant, directly addressing how financial activity evolved, particularly in asset utilization (via DD&A) and capital spending. The only slight gap is the lack of explicit mention of the Concho acquisition as a 2022 driver, but the financial trends are accurately presented. Overall, the answer is factually correct, well-synthesized, and highly accurate, warranting a 9/10 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 438,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial impact on gross margins?",
      "original_answer": "In 2022, Emerson completed the acquisition of AspenTech, contributing approximately $6.0 billion in cash, paying $87.69 per share to Heritage AspenTech stockholders, and retaining $168 million in AspenTech's balance sheet. The acquisition positively impacted gross margins by 0.6 percentage points in 2023. By 2024, Emerson owned 55% of AspenTech on a fully diluted basis, and AspenTech continued to operate under its former name and ticker symbol 'AZPN.' The acquisition's financial impact persisted, contributing to a gross margin increase of 1.8 percentage points to 50.8% in 2024, despite a negative impact from acquisition-related inventory step-up amortization of $231 million, which reduced margins by 1.3 percentage points.",
      "llm_answer": "In 2022 Emerson completed the Heritage AspenTech transaction, contributing two of its own software businesses and about $6 billion in cash and emerging as the accounting acquirer with a **55 % owned‑share** of the newly‑formed “New AspenTech.”  By fiscal 2024 Emerson’s stake had risen to **≈57 %** and the company announced a cash offer to purchase the remaining shares, effectively moving toward full ownership.  The AspenTech deal lifted Emerson’s gross‑margin profile – it added roughly **0.6 percentage‑point** to gross margin in 2023 (raising the margin to 49.0 %) and helped sustain the continued improvement to **50.8 % in 2024**, although the 2024 gain was driven mainly by other acquisitions and pricing effects.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also significant inaccuracies. It correctly identifies the 2022 acquisition, the $6 billion cash contribution, and the positive impact on gross margins in 2023 (0.6 percentage points). It also correctly notes the 50.8% gross margin in 2024. However, it incorrectly states Emerson's ownership as 55% at the time of acquisition and rising to ≈57% by 2024; the ground truth specifies that Emerson owned 55% by 2024 (not at acquisition), with no mention of an increase to 57% or a cash offer for remaining shares. This misrepresents the ownership timeline and strategic evolution. Additionally, the LLM claims the 2024 margin improvement was 'driven mainly by other acquisitions and pricing effects,' which contradicts the original answer stating the acquisition itself contributed 1.8 percentage points to gross margin in 2024 despite a $231 million amortization drag (1.3 percentage points). This omits a key financial dynamic and misattributes the margin driver. (2) Number verification: $6 billion cash is correct. The 0.6 percentage point boost in 2023 is accurate. The 50.8% gross margin in 2024 is correct. However, the ≈57% ownership in 2024 is unsupported; the ground truth says 55%. The absence of the $231 million amortization impact and the 1.8 percentage point contribution in 2024 is a major quantitative omission. (3) Multi-hop reasoning is partially sound—linking acquisition to margin impact across years—but fails in synthesizing the full financial impact in 2024, especially the offsetting effect of amortization. The claim about a cash offer for remaining shares introduces unverified strategic developments. (4) Correctness score is 5 due to partial factual accuracy but major omissions and one directional error in ownership progression and margin attribution. Quantitative accuracy is 5 due to correct numbers in some places but missing critical figures and incorrect ownership percentages. Qualitative accuracy is 6 because reasoning is logical but based on incomplete or slightly distorted data. Contextual relevance is 9—answer stays focused and addresses the core question areas.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 581,
        "total_tokens": 1953
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has the treatment and availability of shares under the 2015 Director Stock Plan evolved between 2022 and 2024, particularly in terms of share recovery and issuance mechanics?",
      "original_answer": "In 2022, the 2015 Director Stock Plan specified that each share issued under the plan reduced the number of shares remaining for issuance by one, and shares recovered from expired, forfeited, or cash-settled awards were again available for issuance. By 2024, the plan had a total of 35,395,894 shares authorized for issuance as of January 1, 2015, with 37,608,213 shares recovered for issuance between 2015 and 2024. However, 42,343,146 shares were covered by new awards and reinvested dividends since 2015, leaving 30,660,961 shares available for future issuance. This reflects a net reduction in available shares over time despite ongoing share recovery, indicating a shift in the balance between new issuances and recovered shares.",
      "llm_answer": "By 2024 MetLife still applied the same recovery rules that were set out in 2022 – any shares freed by award termination, cash settlement, exchange, tax‑withholding tender‑in, or the net‑share result of a share‑settled Stock Appreciation Right are added back to the 2015 Director Stock Plan pool on a one‑for‑one basis (with the same award‑ratio adjustments described in 2022 Note 16 and reiterated in 2024 Note 19) 【page_335】【page_312】.  \n\nHowever, the size of the pool changed markedly: the cumulative “additional shares recovered for issuance” rose from 31.5 million in the 2022 filing to 37.6 million by the end of 2024, while the shares still available for future grants fell from 34.07 million to 30.66 million 【page_334】【page_311】.  \n\nThus, the mechanics of recovery and issuance remained unchanged, but the amount of shares reclaimed grew and the remaining authorized share pool contracted between 2022 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the key numbers are correct: '37.6 million' shares recovered by 2024 matches the ground truth of 37,608,213. The available shares in 2024 are correctly stated as 30.66 million (vs. 30,660,961 in ground truth). The 2022 recovery figure of '31.5 million' is not explicitly in the ground truth, but since the ground truth only provides cumulative recovery from 2015–2024 (37.6M), this earlier number likely comes from the 2022 filing and is contextually valid. The available shares dropping from 34.07M to 30.66M is consistent with the net reduction described. (2) The mechanics of share recovery—expired, forfeited, or cash-settled awards being added back on a one-for-one basis—are correctly preserved across years, matching the ground truth’s description. (3) The reasoning is sound: the LLM correctly infers that while the recovery mechanics remained unchanged, the net effect is a shrinking available pool despite growing recoveries, indicating higher issuance volume. (4) The answer fully addresses the evolution in treatment and availability, covering both mechanics (unchanged) and quantitative trends (growing recovery, declining availability). The only minor limitation is that the ground truth includes total authorized shares (35,395,894) and total issued/reinvested (42,343,146), which the LLM omits—this contextual detail would strengthen completeness, but the core multi-hop synthesis (comparing recovery and availability over time) is accurate. Wording differences are semantically equivalent. No factual errors in entities, years, or metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 449,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Starbucks' relationship with the Global Coffee Alliance evolved from fiscal year 2022 to fiscal year 2023 in terms of strategic emphasis and revenue contribution?",
      "original_answer": "In fiscal year 2022, the Global Coffee Alliance contributed to the growth of the Channel Development segment, which saw a $250 million increase in revenue driven by product sales and royalty income from the alliance. By fiscal year 2023, the strategic emphasis on the Global Coffee Alliance had evolved, with Starbucks explicitly highlighting its licensing relationship with Nestlé under the alliance as a core channel for product distribution, indicating a deeper integration and ongoing importance to Starbucks' global licensing and product expansion strategy. This evolution reflects a shift from viewing the alliance primarily as a revenue driver to positioning it as a strategic enabler of global product reach and brand extension.",
      "llm_answer": "In fiscal 2022 Starbucks highlighted the Global Coffee Alliance as a distinct growth engine – “Other revenues increased $249 million, primarily due to higher product sales and royalty revenue in the Global Coffee Alliance ($216 million)” and the Channel Development segment’s $250 million increase was “driven by higher product sales to and royalty revenue from the Global Coffee Alliance” (2022 10‑K, pages 32‑31). By fiscal 2023 the filing only refers to the Alliance in the business description as a licensing and distribution partnership with Nestlé (“...through our Global Coffee Alliance with Nestlé S.A.”) and does not break out a separate revenue amount, indicating the relationship has shifted from a highlighted, quantified revenue contributor to a broader strategic licensing channel within the company’s overall operations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $250 million revenue increase in fiscal year 2022 attributed to the Global Coffee Alliance, aligning with the ground truth. It accurately cites the $249 million increase in 'Other revenues' and specifies that $216 million of that came from the Alliance, which is consistent with the 2022 10-K (though the exact breakdown is not in the ground truth, it does not contradict it and appears to be a more granular extraction). The absence of a specific revenue figure for fiscal year 2023 is correctly noted, and the shift in language from quantified contributor to strategic channel is accurately observed. (2) All numbers are factually correct or appropriately approximated; $249M and $250M are consistent with the ground truth's $250M increase. No calculation errors. (3) The multi-hop reasoning is sound: the model synthesizes information from two fiscal years, compares the treatment of the Alliance in disclosures, and infers a strategic evolution based on the presence (2022) and absence (2023) of specific revenue attribution. The conclusion that the Alliance shifted from a highlighted revenue driver to a broader strategic channel is logically supported and semantically equivalent to the ground truth’s 'shift from viewing the alliance primarily as a revenue driver to positioning it as a strategic enabler.' (4) The only reason for not scoring a 10 is that the LLM slightly overemphasizes the lack of 2023 revenue disclosure as evidence of de-emphasis, whereas the ground truth interprets the continued mention in business description with Nestlé as evidence of deeper integration. However, this is a nuanced difference in interpretation, not a factual error. Overall, the answer is factually accurate, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 490,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has NEE's financial stake and involvement in the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's equity method investments totaled $6,159 million, and the Mountain Valley Pipeline was listed among key equity method investees alongside NEP OpCo, Sabal Trail, and Silver State South Solar, with NEE's interest ranging from approximately 32% to 55%. By 2023, NEE's total equity method investments were $6,156 million, with its interest in the principal entities, including the Mountain Valley Pipeline, ranging from approximately 32.8% to 52.6%. The shift from a broader range (32%–55%) in 2022 to a narrower range (32.8%–52.6%) in 2023 suggests a slight adjustment in ownership stakes, potentially reflecting a more refined or strategic investment posture. Additionally, in 2023, the Mountain Valley Pipeline was specifically noted in the context of Nonrecurring Fair Value Measurements, indicating a possible revaluation or change in financial treatment.",
      "llm_answer": "By the end of 2022 NEE still reported a Mountain Valley Pipeline (MVP) equity‑method investment of roughly $5 billion on its balance sheet, but it already carried a large impairment charge. At 31 December 2023 the carrying amount of the MVP‑related investment had fallen to about $4 billion and the net difference between the carrying amount and the underlying equity was a $2.4 billion negative balance, reflecting a full‑write‑off‑type impairment of the pipeline’s value. This swing shows NEE is actively removing the financially‑stranded MVP asset from its portfolio, signaling a shift away from fossil‑fuel pipeline exposure toward its core renewable‑energy and clean‑energy strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to align with the ground truth. (1) Quantitative Accuracy: The claimed $5 billion and $4 billion carrying amounts for MVP in 2022 and 2023 are not supported by the original answer, which reports total equity method investments of $6,159M and $6,156M in 2022 and 2023 respectively, without isolating MVP's specific value. The $2.4 billion negative balance and 'full-write-off-type impairment' are entirely absent from the ground truth. No such impairment or write-off is mentioned; instead, MVP was noted under Nonrecurring Fair Value Measurements in 2023, suggesting revaluation, not write-off. (2) Completeness: The answer fails to mention NEE's ownership stake range (32%–55% in 2022, 32.8%–52.6% in 2023), a key part of the evolution. It also omits the context of MVP being listed among other equity method investees like Sabal Trail and NEP OpCo. (3) Entity Accuracy: While NEE and MVP are correctly identified, the financial treatment (impairment, write-off) is incorrect. The term 'financially-stranded asset' and 'removing from portfolio' are speculative and unsupported. (4) Reasoning: The conclusion that NEE is shifting away from fossil fuel pipelines toward renewables is not directly supported by the provided ground truth, which only notes a slight narrowing of ownership ranges and a change in financial disclosure category. The multi-hop synthesis is flawed—no data in the original answer supports a strategic divestment narrative. (5) Semantic Equivalence: The LLM answer conveys a completely different narrative (active divestment due to impairment) versus the ground truth (minor stake adjustments and revaluation). Despite addressing the general topic of MVP's financial treatment, the core facts and implications are incorrect, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 498,
        "total_tokens": 1893
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Medtronic's InterStim Therapy product line evolved between 2022 and 2024 in terms of neurostimulator offerings and therapeutic indications?",
      "original_answer": "In 2022, InterStim therapy was described with a range of neurostimulators including InterStim II, InterStim Micro, and InterStim X, targeting symptoms of overactive bladder, urinary retention, and bowel incontinence. By 2024, the product line continued to include InterStim II and InterStim X, now specifically labeled as 'recharge-free' neurostimulators, and retained its focus on overactive bladder and urinary retention, but expanded its therapeutic scope to include 'chronic fecal incontinence.' This reflects a refinement in product positioning and a broadening of clinical applications over the two-year period.",
      "llm_answer": "By fiscal 2022 Medtronic’s InterStim pelvic‑health portfolio already comprised three neurostimulators – the InterStim II recharge‑free system, the InterStim Micro rechargeable system and the newly launched InterStim X (also recharge‑free) – together with SureScan MRI‑compatible leads, and they were marketed for over‑active bladder, urinary retention and chronic fecal (bowel) incontinence. In the 2024 filing the line is described as the same three devices (InterStim II, InterStim X and InterStim Micro) with the same three therapeutic indications, indicating that the portfolio has been consolidated around these three neurostimulators while continuing to grow sales of the InterStim X addition introduced after 2022.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several correct elements but has a critical factual error in the therapeutic indications, which significantly undermines its correctness. (1) The LLM correctly identifies the neurostimulator offerings in 2022: InterStim II, InterStim Micro, and InterStim X, and notes their recharge-free/rechargeable status. It also correctly references MRI-compatible leads and the three indications. However, the ORIGINAL ANSWER states that in 2022, the indications were overactive bladder, urinary retention, and bowel incontinence — while the LLM claims 'chronic fecal (bowel) incontinence' was already included in 2022. The ground truth indicates that the expansion to include 'chronic fecal incontinence' occurred by 2024, implying it was not previously labeled as such or was not emphasized. More critically, the LLM claims that in 2024, the same three indications are present, directly contradicting the ground truth that shows an *expansion* to include chronic fecal incontinence as a new or more explicitly recognized indication. This misrepresents the evolution of the product line. (2) Quantitatively, the years (2022, 2024) and device names are accurate. There are no numerical calculations, so this dimension is not heavily tested, but entity names and timeframes are correctly used. (3) The multi-hop reasoning is partially sound — the model attempts to compare 2022 and 2024 product lines — but fails in synthesis because it does not detect the change in therapeutic scope. Instead, it incorrectly asserts continuity. (4) Contextually, the answer is relevant and well-structured, addressing both neurostimulator offerings and indications. However, the core claim about indication evolution is wrong, which is central to the question. Hence, while the answer appears detailed and plausible, it is factually incorrect on a key point, warranting a low correctness score despite good structure and partial accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 519,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Simon Property Group's financial stake and strategic relationship with Authentic Brands Group (ABG) evolve from 2022 to 2024?",
      "original_answer": "In 2022, Simon Property Group held a 1.37% interest in ABG and had merged Forever 21 operations into SPARC Group after increasing its stake to 50% alongside ABG. By 2024, Simon sold a portion of its ABG stake, realizing a pre-tax gain of $18.8 million, and later acquired additional interests in ABG for $100 million in cash, indicating a dynamic evolution in their financial relationship.",
      "llm_answer": "In 2022 Simon still held a material equity position in Authentic Brands Group – about a 10 % non‑controlling stake that it had increased in late‑2021 (selling a small portion for $65.5 million and buying $100 million of additional ABG shares) and it deepened the relationship by entering a long‑term Reebok licensing partnership with ABG and swapping its Eddie Bauer licensing venture for more ABG equity. During 2023 a series of ABG capital‑transaction dilutions and partial sales cut Simon’s ownership to roughly 9.6 % and generated pre‑tax gains on the disposals. By the first quarter of 2024 Simon sold its remaining ABG interest for $1.2 billion, realizing a $414.8 million pretax gain and ending the partnership with no remaining equity stake.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Simon Property Group held a 1.37% interest in ABG in 2022, not a 10% stake as claimed. The LLM incorrectly states that Simon sold its 'remaining' ABG interest in Q1 2024 for $1.2 billion, realizing a $414.8 million gain, whereas the truth is that Simon only sold a portion of its stake, realizing a $18.8 million pre-tax gain, and then later acquired additional interests in ABG for $100 million in cash—indicating an ongoing, not terminated, relationship. The claim of ending the partnership with 'no remaining equity stake' is false. (2) Quantitatively, nearly all numbers are incorrect: the 10% initial stake, $65.5 million sale, 9.6% post-2023 ownership, $1.2 billion final sale, and $414.8 million gain do not appear in the ground truth and contradict it. The only correct figure mentioned—$100 million in additional ABG shares—aligns with the truth but is embedded in an incorrect narrative. (3) The multi-hop reasoning is flawed: the model fails to correctly trace the evolution of the financial stake, incorrectly infers dilution and multiple transactions not in the source, and concludes the relationship ended when it actually continued. It fabricates a Reebok licensing deal and Eddie Bauer swap not mentioned in the original. (4) Scores reflect major factual and quantitative errors, poor qualitative reasoning, though the answer is contextually relevant in attempting to describe the evolving relationship between Simon and ABG, hence moderate relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 433,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has ConocoPhillips' investment activity in the Lower 48 region evolved from 2021 to 2023, particularly in terms of depreciation, depletion, and amortization expenses?",
      "original_answer": "ConocoPhillips' depreciation, depletion, and amortization (DD&A) expenses in the Lower 48 region increased from $4,067 million in 2021 to $5,729 million in 2023, indicating a significant rise in asset utilization or investment activity. This reflects a growing emphasis on the Lower 48 as a core operational area for the company.",
      "llm_answer": "ConocoPhillips’ Lower 48 segment saw its depreciation, depletion and amortization (DD&A) rise steadily after a dip in 2021: $4.07 billion in 2021, $4.85 billion in 2022 and $5.73 billion in 2023【page_133】.  This upward trend mirrors higher investment outlays in the same region, with capital expenditures climbing from $3.13 billion in 2021 to $5.63 billion in 2022 and $6.49 billion in 2023【page_135】.  Together, the figures indicate that ConocoPhillips has been increasing its investment activity in the Lower 48, reflected in both higher spending and growing DD&A charges.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the DD&A expenses for ConocoPhillips' Lower 48 region: $4.07 billion in 2021 (matches ground truth $4,067 million), $4.85 billion in 2022 (not in ground truth but consistent with upward trend), and $5.73 billion in 2023 (matches $5,729 million, within rounding). These values are accurately presented with acceptable format variations (e.g., $4.07 billion = $4,067 million). (2) The LLM adds capital expenditure figures not present in the original answer but relevant to investment activity; while these are not required for correctness, they enhance context and are correctly cited from the source (page references provided). (3) The multi-hop reasoning is sound: the LLM correctly infers that rising DD&A and capex reflect increased investment activity and asset utilization in the Lower 48, aligning with the ground truth's conclusion about growing emphasis on the region. (4) The only minor deviation is the characterization of 2021 as a 'dip'—the ground truth does not suggest a decline prior to 2021, so this implies extra context not confirmed in the original. However, this does not affect the core factual accuracy. All entities (ConocoPhillips, Lower 48, DD&A, years) are correct. The answer is semantically equivalent and contextually complete, earning a high score with only slight deduction in qualitative accuracy due to the unsupported 'dip' characterization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 394,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Verizon's (VZ) treatment and valuation approach for international bonds evolved from 2023 to 2024 based on their 10-K disclosures?",
      "original_answer": "In 2023, Verizon described that international bonds were valued using matrix prices with input from independent third-party valuation sources as part of the broader fixed income securities category. By 2024, international bonds were specifically itemized in a detailed table with a total value of $12 million, broken down into $10 million in Level 1 and $2 million in Level 2 inputs. This represents a shift from a general description in 2023 to a more transparent and segmented valuation approach in 2024, indicating a more refined disclosure strategy and possibly a more structured approach to valuing international bonds.",
      "llm_answer": "In the 2023 Form 10‑K Verizon said that its international‑bond holdings were valued “using matrix prices with input from independent third‑party valuation sources,” and the bonds were largely classified as Level 2 (e.g., $341 million in the pension plan – $3 million Level 1 and $338 million Level 2, and $12 million in the health‑care plan – $10 million Level 1 and $2 million Level 2).  \n\nThe 2024 Form 10‑K repeats the same matrix‑price/third‑party methodology, but the composition has shifted: the pension‑plan international bonds fall to $113 million and are now 100 % Level 2 (no Level 1), while the health‑care plan’s international bonds rise to $15 million, with a modest increase in Level 2 exposure (11 million Level 1, 4 million Level 2).  \n\nThus, Verizon’s valuation approach for international bonds remained the same, but the classification moved toward more observable (Level 2) pricing and the overall amount of international‑bond assets was reduced in the pension plan and modestly increased in the health‑care plan.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that in 2023, Verizon described international bonds generally as valued using matrix pricing without specific dollar amounts, and that in 2024 they were specifically itemized at $12 million total ($10M Level 1, $2M Level 2). However, the LLM answer fabricates detailed breakdowns for 2023 (e.g., $341M in pension plan, $12M in healthcare plan) and 2024 ($113M pension, $15M healthcare) that are not present in the ground truth. These numbers are entirely incorrect and unsupported by the original answer. (2) The quantitative inaccuracies are severe: the LLM invents figures like $341 million, $113 million, and $15 million that do not appear in the ground truth. The only correct number is the $12 million total in 2024 with $10M Level 1 and $2M Level 2, but this is misrepresented as part of a healthcare plan rather than the total value. The LLM also incorrectly claims a shift in composition between pension and healthcare plans, which is not mentioned in the original answer. (3) The multi-hop reasoning is flawed. The original answer highlights a shift in disclosure approach—from general description in 2023 to specific itemization in 2024—as the key evolution. The LLM instead focuses on fabricated changes in asset allocation between pension and healthcare plans, missing the core point about transparency and disclosure refinement. It incorrectly concludes the valuation approach 'remained the same' when the original emphasizes a more segmented and transparent method in 2024, indicating a qualitative shift in reporting even if the underlying methodology was similar. (4) The contextual relevance is moderate because the answer discusses valuation levels and third-party sources, which are relevant concepts, but it fails to capture the actual evolution described in the ground truth. Due to major factual and quantitative errors, the correctness score is low at 2, with similarly low scores for quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 550,
        "total_tokens": 1962
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Emerson's relationship with AspenTech evolve between 2022 and 2024, particularly in terms of financial stake and operational integration?",
      "original_answer": "In 2022, Emerson had a financial stake in AspenTech valued at $8,326 million, as shown in the balance sheet following acquisitions and currency adjustments. By 2024, Emerson's relationship had transformed significantly: it contributed the AspenTech Industrial Software Business along with $6.0 billion in cash to form 'New AspenTech,' retaining a 55% ownership stake in the newly structured company. This indicates a strategic restructuring rather than a simple financial investment, with increased operational integration and a formalized majority ownership.",
      "llm_answer": "In 2022 Emerson completed the “Heritage AspenTech” transaction, contributing two of its own software businesses and $6 billion in cash in exchange for a **55 % equity stake** in the newly‑formed AspenTech (recorded as goodwill of $8.3 billion). By 2024 Emerson’s holding had risen to **about 57 %** and the company announced a cash offer to purchase the remaining shares, moving the relationship toward full ownership. During this period AspenTech was treated as a distinct operating segment whose software and control businesses were integrated into Emerson’s Software & Control results, driving sales growth and appearing in the goodwill and segment disclosures.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Emerson had a financial stake in AspenTech valued at $8,326 million on its balance sheet, not a 55% equity stake resulting from a transaction that year. The LLM incorrectly states that Emerson acquired its 55% stake in 2022 via contribution — but the ground truth indicates that the 55% ownership arose in 2024 through the formation of 'New AspenTech'. The LLM reverses the timeline and misattributes the nature of the 2022 position. Additionally, the claim that Emerson’s stake rose to 'about 57%' by 2024 and that it made a cash offer for the remaining shares is unsupported by the original answer, which makes no mention of an increased stake or buyout offer. (2) Quantitative inaccuracies include: misstating the $8.326 billion as 'goodwill' rather than a financial stake on the balance sheet; incorrectly placing the $6.0 billion cash contribution in 2022 instead of 2024; and fabricating a 57% ownership and acquisition attempt. While $6 billion and $8.3 billion are close in magnitude to the true $6.0B and $8,326M, their context and timing are wrong, undermining accuracy. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution from passive financial stake (2022) to active operational integration and majority control (2024). Instead, it assumes majority ownership began in 2022 and progressed further, which contradicts the ground truth. The integration into Software & Control is contextually plausible but not explicitly confirmed in the original answer. (4) Despite these errors, the answer is contextually relevant — it addresses financial stake evolution and operational integration — and uses appropriate financial terminology. However, core facts are incorrect, leading to a low correctness and quantitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 511,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Starbucks' position in interest rate swaps evolve between 2022 and 2023, particularly in terms of their classification and associated liabilities?",
      "original_answer": "In 2022, Starbucks had an interest rate swap classified as a long-term liability with a value of $34.0 million. By 2023, the company's interest rate swaps were categorized under both current and long-term liabilities, with $0.4 million listed under accrued liabilities (current) and $19.2 million under other long-term liabilities. This reflects a shift in the classification and a net decrease in the overall liability associated with interest rate swaps from $34.0 million in 2022 to $19.6 million in 2023.",
      "llm_answer": "In the 2022 filing Starbucks reported its fixed‑to‑floating interest‑rate swaps as **designated derivatives** with **no asset balance** and a **$34 million liability recorded in other long‑term liabilities** (plus a $12 million accrued‑liability component for “interest rates”).  \n\nIn the 2023 filing the swaps remained classified as **designated derivatives**, still with **no asset balance**, but the **liability on other long‑term liabilities fell to $19.2 million**.  \n\nThus, between 2022 and 2023 the company’s interest‑rate‑swap position stayed in the same classification (designated fair‑value hedge) while the associated long‑term liability decreased from roughly $34 million to about $19 million.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the classification of Starbucks' interest rate swaps as designated derivatives (fair-value hedges) in both years and accurately reports the $19.2 million long-term liability in 2023 and $34 million in 2022. However, it incorrectly states that in 2022 there was a $12 million accrued-liability component for interest rates, which is not present in the ground truth; the 2022 liability was solely $34.0 million as a long-term liability. The ground truth specifies that in 2023, the total liability is split into $0.4 million current (accrued liabilities) and $19.2 million long-term, totaling $19.6 million. The LLM omits the $0.4 million current portion and thus underrepresents the full classification shift. (2) Quantitative accuracy is partially compromised: while the $34 million (2022) and $19.2 million (2023 long-term) figures are correct, the erroneous $12 million accrued component in 2022 is unsupported and misleading. The net decrease from $34.0 million to $19.6 million is accurate in the ground truth, but the LLM implies a drop to about $19 million without acknowledging the full $19.6 million total in 2023. (3) The multi-hop reasoning is sound in recognizing consistent classification as designated derivatives and a reduction in liability, but it fails to fully capture the evolution in classification structure—i.e., the shift from entirely long-term in 2022 to bifurcated current/long-term in 2023. (4) Scores reflect high qualitative accuracy and full contextual relevance, with a moderate deduction in quantitative accuracy due to the incorrect $12 million figure and omission of the $0.4 million current liability, leading to a correctness score of 8 for mostly accurate but partially incomplete and slightly erroneous quantitative reporting.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 491,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did NextEra Energy Resources' financial commitment and involvement in the Mountain Valley Pipeline evolve from 2022 to 2023?",
      "original_answer": "In 2022, NextEra Energy Resources recorded an impairment charge of approximately $0.8 billion related to its equity method investment in the Mountain Valley Pipeline, which was fully written off due to the very low probability of pipeline completion. By 2023, despite the ongoing challenges, NEE's subsidiary NEER maintained a 32.8% equity investment in the joint venture and committed to a 20-year natural gas transportation agreement with an annual obligation of approximately $70 million, subject to the completion of construction.",
      "llm_answer": "In the 2022 filing, NextEra Energy Resources (NEER) recorded a major loss on the Mountain Valley Pipeline: it wrote off its $0.6 billion equity‑method investment, booked an impairment charge of about $0.8 billion (≈$0.6 billion after tax) and recognized a $0.2 billion liability for estimated future ARO costs. By the 2023 filing, the company’s exposure had shifted to a forward‑looking commitment – NEER is planning an equity contribution in 2024 and has entered a 20‑year natural‑gas transportation agreement with the joint‑venture that entails roughly $70 million of annual payments, reflecting continued involvement but without a new impairment charge.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $0.8 billion impairment charge in 2022 and the $70 million annual obligation in 2023, which aligns with the ground truth. However, it incorrectly states that the equity-method investment written off was $0.6 billion, while the original answer does not specify the exact book value of the investment prior to impairment—only that the total impairment charge was $0.8 billion. Additionally, the LLM introduces a $0.2 billion liability for ARO (Asset Retirement Obligation) costs, which is not mentioned in the ground truth and cannot be verified from the provided information. The mention of a 'planned equity contribution in 2024' is also absent from the original answer and may represent an overinterpretation or external knowledge. (2) Quantitative accuracy is partially compromised: while $0.8 billion impairment and $70 million annual obligation are correct, the breakdown into $0.6B investment + $0.2B ARO is speculative and unsupported by the original answer. The 32.8% equity stake mentioned in the ground truth is missing in the LLM response, reducing completeness. (3) The multi-hop reasoning is generally sound—linking 2022 impairment to 2023 forward commitments shows understanding of evolution over time. The shift from write-off to ongoing contractual obligation is correctly framed. However, the addition of unverified details (ARO, future equity contribution) weakens the factual synthesis. (4) Despite some inaccuracies, the core narrative of reduced financial exposure in 2022 followed by continued strategic involvement via long-term contract in 2023 is preserved, earning high marks for qualitative accuracy and full relevance to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 468,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has The Coca-Cola Company's investment in equity and debt securities related to its captive insurance company reinsuring group annuity insurance contracts evolved between 2023 and 2024?",
      "original_answer": "In 2023, The Coca-Cola Company reported that its captive insurance company reinsuring group annuity insurance contracts held $1,643 million in equity and debt securities as part of its solvency capital funds. By 2024, this amount increased to $1,883 million, indicating a growth in the company's investment in these securities over the year.",
      "llm_answer": "The captive that reinsures the company’s group‑annuity contracts held **$1.643 billion of equity‑plus‑debt securities at 12/31/2023**, and this amount rose to **$1.883 billion at 12/31/2024** – an increase of roughly **$240 million** in the captive’s investment portfolio.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the captive insurance company's holdings in equity and debt securities were $1,643 million (i.e., $1.643 billion) at the end of 2023 and increased to $1,883 million ($1.883 billion) by the end of 2024. The format variation (billion vs. million) is acceptable and numerically consistent. (2) The calculation of the increase—$1,883M - $1,643M = $240M—is accurate and correctly stated. (3) The multi-hop reasoning is sound: the answer correctly identifies the entity (captive insurance company reinsuring group annuity contracts), the financial instruments (equity and debt securities), and the year-over-year evolution of the investment. (4) The response is contextually precise, directly addressing how the investment evolved between 2023 and 2024 with all necessary details. No factual, quantitative, or qualitative errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1164,
        "completion_tokens": 276,
        "total_tokens": 1440
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of production status and strategic positioning within Intel's product roadmap?",
      "original_answer": "In 2022, Intel was incurring higher period charges related to the ramp-up of Intel 4, indicating early-stage production challenges and investment. By 2024, Intel 4 had transitioned to high-volume manufacturing in Ireland and became the process node for the high-volume Intel Core Ultra processor, marking its strategic importance in Intel's product roadmap. This evolution shows a shift from initial investment and production ramp-up in 2022 to full-scale production and product integration by 2024.",
      "llm_answer": "In the 2022 filing Intel said it was still “ramping up” the Intel 4 node, noting higher‑period charges tied to the node’s early‑stage production and that it was not yet in high‑volume manufacturing. By the 2024 filing Intel 4 had become its first EUV‑lithography, high‑volume node – moved to full‑scale production in Ireland in 2024 and already shipping the Core Ultra client CPUs – and was positioned as the cornerstone EUV platform that precedes Intel 3 and the upcoming Intel 18A node in the company’s product roadmap.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Intel was in the ramp-up phase of Intel 4 with higher-period charges and not yet in high-volume manufacturing, matching the original answer. By 2024, it accurately states that Intel 4 transitioned to high-volume manufacturing in Ireland and is shipping in Core Ultra processors—consistent with the ground truth. The strategic positioning as a cornerstone EUV platform preceding Intel 3 and Intel 18A is an added detail that enhances, but does not contradict, the original. (2) There are no numeric values (e.g., dollar amounts, percentages) in the question or answers, so quantitative accuracy is based on correct time periods (2022, 2024), which are accurately cited. (3) The multi-hop reasoning—linking 2022 production challenges to 2024 high-volume status and strategic role—is sound and correctly synthesizes information across years and contexts. (4) The only minor gap is that the original emphasizes the 'shift from investment/ramp-up to full-scale production' as an evolution, while the LLM focuses more on technical attributes (EUV, roadmap positioning); however, the core evolution is still clearly conveyed. Wording differs slightly but maintains semantic equivalence. No factual errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 368,
        "total_tokens": 1632
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Emerson's strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial integration?",
      "original_answer": "In 2022, AspenTech was described as a strategic partner of Emerson, with no mention of ownership stakes or integration into Emerson's financials. By 2024, Emerson had merged its industrial software business with AspenTech, creating 'New AspenTech,' and retained a 55% ownership stake in the newly formed entity. This marked a significant shift from a partnership to a partially owned subsidiary structure. Additionally, AspenTech's financials were now integrated into Emerson's results, with the acquisition positively impacting gross margins by 0.6 percentage points in 2023 and influencing SG&A expenses in 2024 due to the deeper integration.",
      "llm_answer": "In 2022 Emerson spun out its two stand‑alone industrial‑software businesses and contributed roughly $6 billion in cash to create “New AspenTech,” emerging with a **55 % equity stake** in the newly‑public software company and beginning to consolidate its results into Emerson’s financial statements【page_26】. By 2024 Emerson’s holding had risen to **about 57 %** and the company announced a **cash‑offer to acquire all remaining AspenTech shares** at $240 per share, moving the relationship toward full ownership; AspenTech’s performance is now reflected in Emerson’s segment reporting, adjusted EBITA and related‑party interest income, and other integration‑related line items such as the Micromine purchase‑price hedge【page_25】【page_28】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, AspenTech was a strategic partner with no ownership stake or financial integration by Emerson. However, the LLM incorrectly states that in 2022, Emerson contributed $6 billion in cash and already held a 55% stake, which contradicts the original timeline. The 55% ownership and financial consolidation occurred only in 2024, not 2022. Additionally, the LLM claims ownership increased to 57% by 2024 and that Emerson made a cash offer to acquire all remaining shares at $240 per share—information not present in the ground truth and unsupported by the provided context. (2) Quantitative inaccuracies include the $6 billion cash contribution (not mentioned in ground truth), the 57% ownership (ground truth states 55%), and the $240 per share offer (not in original answer). The only correct number is the 55% stake, but it is misattributed to 2022 instead of 2024. (3) The multi-hop reasoning is flawed: the model fails to correctly trace the evolution from partnership (2022) to partial ownership (2024), instead portraying an accelerated and factually incorrect integration timeline. It introduces new details (e.g., spin-out of two businesses, cash offer, Micromine hedge) that may be plausible but are not supported by the ground truth. (4) Despite these errors, the answer is contextually relevant—addressing ownership evolution and financial integration—and captures the direction of change (from partner to owner), though with incorrect specifics. Hence, partial credit is given for structure and intent, but major deductions apply for factual and quantitative inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 461,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of its manufacturing readiness and performance improvements?",
      "original_answer": "In 2022, Intel 4 was newly introduced as part of a restructured naming convention for manufacturing process nodes, signaling its position as a next-generation node following Intel 7. By 2024, Intel 4 had transitioned from a conceptual roadmap item to a fully realized product, with high-volume manufacturing ramped up in Ireland. Intel 4, as the company's first EUV lithography node, delivered a 20% performance-per-watt improvement over Intel 7 and was used in the production of the Intel Core Ultra processor, which began shipping in 2023. This represents a significant evolution from its initial naming in 2022 to full-scale production and performance quantification by 2024.",
      "llm_answer": "In the 2022 Form 10‑K Intel’s “Intel 4” was presented only as a new name for its 10 nm Enhanced SuperFin node – a future‑technology label with no indication that it was in production. By the 2024 filing Intel described Intel 4 as its first EUV‑lithography node, already in high‑volume manufacturing (initially in Ireland) and delivering roughly a 20 % performance‑per‑watt gain versus Intel 7, with the first client products (e.g., the Core Ultra Series 1) shipping on the node.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Intel 4 was rebranded from 10nm Enhanced SuperFin in 2022 and not yet in production; by 2024, it was in high-volume manufacturing in Ireland using EUV lithography. The 20% performance-per-watt improvement over Intel 7 is accurately stated. The mention of Core Ultra Series 1 shipping on the node aligns with the original answer's reference to Intel Core Ultra processors shipping in 2023. (2) Quantitative elements—'20%' improvement, '2022' and '2024' time points—are correct and match the ground truth. No calculations are required, but comparative metrics are properly used. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across two years of 10-K filings, tracking the evolution from naming/positioning in 2022 to manufacturing and performance validation in 2024. (4) The answer is fully contextually relevant, directly addressing both manufacturing readiness (from roadmap to HVM) and performance improvements (EUV adoption, 20% gain). Minor wording differences (e.g., 'Core Ultra Series 1' vs 'Core Ultra processor') do not affect factual accuracy and may reflect more specific product naming. All criteria for a perfect score are met.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 358,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has the role and positioning of InterStim Micro evolved within MDT's Pelvic Health therapies between 2022 and 2024?",
      "original_answer": "In 2022, InterStim Micro was listed as one of several neurostimulators within MDT's Pelvic Health product portfolio, which also included InterStim X and InterStim II, used to treat overactive bladder, urinary retention, and fecal incontinence. By 2024, InterStim Micro was specifically highlighted as the rechargeable neurostimulator option, differentiated from the recharge-free InterStim X and InterStim II. This indicates a more defined strategic positioning of InterStim Micro as the rechargeable variant within the broader InterStim therapy lineup, with an emphasis on its continued global growth and adoption.",
      "llm_answer": "In the 2022 filing, InterStim Micro was introduced simply as one of the three neurostimulators (InterStim X, Micro and II) that Medtronic’s Specialty‑Therapies unit offers for over‑active bladder, non‑obstructive urinary retention and chronic fecal incontinence. By the 2024 filing, InterStim Micro is singled out as the rechargeable member of the “InterStim therapy” suite and is highlighted as a product experiencing continued acceptance and growth within the Pelvic‑Health portfolio, indicating a shift from a listed component to a growth‑focused, rechargeable solution.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: InterStim Micro was one of several neurostimulators in 2022 (alongside InterStim X and II), used for overactive bladder, urinary retention, and fecal incontinence. By 2024, it was specifically positioned as the rechargeable option, differentiated from recharge-free models, and highlighted for growth. (2) There are no numeric values to verify, so quantitative accuracy is not applicable beyond correct use of years (2022, 2024), which are accurate. (3) The multi-hop reasoning is sound—correctly synthesizing changes in product positioning over time across filings. The answer captures the evolution from being a listed product to a strategically differentiated, growth-focused rechargeable solution. (4) Minor deduction in qualitative accuracy due to slight rephrasing: 'Specialty-Therapies unit' is not in the original answer, and 'growth-focused' is an interpretive phrase, though semantically consistent. Otherwise, the answer is contextually complete, relevant, and factually aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 320,
        "total_tokens": 1610
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the disclosure around the dilutive effect of LTIP Units evolved from 2022 to 2024, particularly in terms of material impact across reporting periods?",
      "original_answer": "In 2022, the disclosure stated that LTIP units were exchangeable for common stock and that no securities had a material dilutive effect for the years ended December 31, 2021, 2020, and 2019. By 2024, the disclosure simplified to state that no securities had a material dilutive effect for the years ended December 31, 2024, 2023, and 2022, without explicitly referencing the exchangeability of LTIP units into common stock. This indicates a reduction in the level of detail provided about LTIP units' conversion features, while maintaining the same conclusion regarding dilution impact.",
      "llm_answer": "In the 2022 filing the footnote simply said that “potentially dilutive securities include LTIP units” and that “no securities had a material dilutive effect for the years ended 2021, 2020 and 2019.” By the 2024 filing the language was broadened to note both “units that are exchangeable for common stock and LTIP units,” and it now states that “no securities had a material dilutive effect for the years ended 2024, 2023 and 2022.” Thus the disclosure has been updated to cover the most recent three years—including 2022—and continues to confirm that the LTIP units have not produced a material dilutive impact.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the evolution of disclosure. The original answer states that in 2022, the disclosure explicitly mentioned that LTIP units were exchangeable for common stock, but by 2024 this detail was removed. However, the LLM answer incorrectly claims that in 2024 the language was 'broadened' to include both 'units that are exchangeable for common stock and LTIP units,' which contradicts the ground truth showing a reduction in detail, not an expansion. This misrepresents the direction of change in disclosure. (2) Quantitatively, the years referenced are mostly accurate: the 2022 filing covers 2021–2019, and the 2024 filing covers 2024–2022. These time periods align with the ground truth, so the temporal scope is correctly identified. However, the LLM incorrectly implies that the 2024 disclosure added new categories of securities, which is not supported. (3) The multi-hop reasoning is flawed because the model fails to correctly synthesize the change in disclosure tone and content—it interprets increased breadth where there was actually simplification. The core conclusion about lack of material dilution is correct, but the characterization of how the disclosure evolved is backwards. (4) Contextually, the answer addresses the question about changes in disclosure over time and maintains focus on dilutive impact, so relevance is high. However, due to the critical error in describing the nature of the disclosure change—saying it became more detailed when it became less—the overall correctness is significantly compromised. Minor wording differences would be acceptable, but this is a substantive misrepresentation of the trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 467,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has MetLife's approach to managing cash buffer needs in relation to stock repurchases evolved from 2022 to 2024, particularly in terms of remaining repurchase authorization and liquidity considerations?",
      "original_answer": "In 2022, MetLife had $1.5 billion remaining under its $3.0 billion common stock repurchase authorization as of December 31, 2021, indicating a significant but partially utilized capacity for returning capital to shareholders. By 2024, the company emphasized increased caution around cash buffer needs, noting that maintaining or increasing liquidity buffers could limit capital available for repurchases, acquisitions, and innovation. This reflects a shift from a more active repurchase posture in 2022 to a more conservative liquidity strategy in 2024, influenced by regulatory, market, and internal capital considerations.",
      "llm_answer": "In the 2022 Form 10‑K MetLife disclosed that its board had authorized a **$3 billion share‑repurchase program** and that, as of 31 December 2021, **about $1.5 billion of that authority remained**.  At the same time the filing warned that the company “maintains a buffer of cash and other liquid assets, and may increase it,” which could reduce the amount of capital available for repurchases.\n\nThe 2024 filing still stresses the same discipline – the need to keep a cash‑and‑liquidity buffer and that “liquidity … may limit our ability to … repurchase our common stock” – but it no longer cites a specific dollar amount of remaining repurchase authority.  The language has shifted from reporting a concrete $‑balance to a broader, liquidity‑first stance, indicating that MetLife now manages repurchases more flexibly and is willing to preserve cash resources even if it means leaving less (or no) explicit repurchase capacity on the books.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: the $3.0 billion repurchase authorization and $1.5 billion remaining as of December 31, 2021 (reported in the 2022 10-K) are accurately cited. The absence of a specific remaining authorization in the 2024 filing is correctly noted, consistent with the shift toward qualitative liquidity emphasis. (2) The reasoning is sound: the answer correctly identifies a strategic evolution from a more concrete, capacity-driven repurchase posture in 2022 to a more cautious, liquidity-first approach in 2024. This multi-hop synthesis across two years’ filings captures the core of the question. (3) The only minor shortcoming is that the LLM slightly overreaches by stating MetLife may leave 'no explicit repurchase capacity on the books'—a speculative interpretation not directly supported in the ground truth. The original answer notes increased caution and potential limitations on repurchases due to buffer needs but does not claim that explicit authorization might be eliminated. This small interpretive leap prevents a perfect 10 on qualitative accuracy. (4) Contextual relevance is excellent: the response directly addresses the evolution in cash buffer management and stock repurchase strategy, with appropriate focus on remaining authorization and liquidity considerations. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the ground truth with only minor interpretive overstatement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 424,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions evolve from fiscal year 2022 to 2023, and what specific changes occurred in their balance sheet classifications?",
      "original_answer": "In fiscal year 2022, Starbucks reported foreign currency - other derivative assets of $103.9 million recognized in OCI before reclassifications and $22.0 million reclassified from AOCI to earnings. By fiscal year 2023, the foreign currency - other derivative assets on the balance sheet were reported as $1.9 million in prepaid expenses and other current assets and $1.7 million in other long-term assets as of October 1, 2023, while derivative liabilities were $4.7 million in accrued liabilities and $4.1 million in other long-term liabilities. This represents a significant reduction in asset positions compared to the prior year, with a shift in balance sheet classification.",
      "llm_answer": "In fiscal 2022 Starbucks reported foreign‑currency‑other derivative assets of **$39.9 million** in prepaid expenses (current) and **$33.5 million** in other long‑term assets (total ≈ $73 million), with only a **$0.3 million** accrued‑liability and no long‑term liability. By fiscal 2023 the same line had shrunk to **$1.9 million** of current assets and **$1.7 million** of long‑term assets (total ≈ $3.6 million), while liabilities grew to **$4.7 million** accrued and **$4.1 million** other long‑term (total ≈ $8.8 million). Thus, the foreign‑currency‑other position moved from a large net‑asset position in 2022 to a modest net‑liability position in 2023, with the liability now split between current (accrued) and long‑term balance‑sheet classifications.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. According to the ground truth, in fiscal year 2022, Starbucks reported foreign currency - other derivative assets of $103.9 million recognized in OCI before reclassifications and $22.0 million reclassified from AOCI to earnings — none of which is reflected in the LLM answer. Instead, the LLM incorrectly states that in 2022, these assets were $39.9 million (current) and $33.5 million (long-term), totaling ~$73 million, which contradicts the ground truth. Additionally, the LLM claims only $0.3 million in accrued liability in 2022, but the original answer does not provide 2022 liability data, so this figure is unsupported. (2) For 2023, the LLM correctly reports the asset and liability classifications: $1.9 million in prepaid expenses, $1.7 million in other long-term assets, $4.7 million in accrued liabilities, and $4.1 million in other long-term liabilities — these numbers match the ground truth. However, it fails to mention that the 2022 data was reported in OCI and reclassified from AOCI, which is a critical part of the balance sheet classification evolution. (3) The multi-hop reasoning is partially sound in that it compares 2022 and 2023 positions and infers a shift from net asset to net liability, but this conclusion is based on incorrect 2022 figures. The actual evolution involves a change in reporting location and derecognition of most of the asset position, not just a reduction. (4) The contextual relevance is high because the answer addresses the evolution of derivative positions and balance sheet classification changes. However, due to major quantitative errors and omission of key accounting treatment (OCI and reclassifications), the correctness and qualitative accuracy scores are low. The answer fabricates 2022 balance sheet line items not present in the ground truth, severely undermining factual reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 525,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Procter & Gamble's global cash management strategy evolved in relation to its restructuring activities and corporate-level financial performance between fiscal 2022 and fiscal 2024?",
      "original_answer": "In fiscal 2022, Procter & Gamble incurred restructuring costs within its historical range of $250 to $500 million before tax, with $147 million in restructuring accruals as of June 30, 2022. Corporate net earnings improved by $872 million to $485 million, partly due to tax benefits and lower restructuring charges. By fiscal 2024, restructuring costs increased significantly to $659 million before tax, including $216 million in non-cash foreign currency translation losses. Corporate net earnings decreased by $1.0 billion, largely due to the $1.4 billion impairment charge of the Gillette intangible asset and incremental restructuring charges. This indicates a shift toward more aggressive restructuring actions, particularly in Enterprise Markets like Nigeria, which impacted both cash flow and earnings. The global cash management strategy remained focused on liquidity and tax considerations, but faced increased pressure from these restructuring activities and impairment charges.",
      "llm_answer": "Between fiscal 2022 and fiscal 2024 Procter & Gamble’s cash‑management approach remained centered on generating operating cash to fund dividends, share repurchases and strategic acquisitions while preserving liquidity and tax‑efficient foreign cash balances. In 2022 the company produced $16.7 billion of operating cash (a 9 % decline) and incurred restructuring costs of $250‑$500 million, with about 65 % settled in cash; adjusted free‑cash‑flow productivity was 93 %. By 2024 operating cash had risen to $19.8 billion (an 18 % increase), restructuring outlays jumped to $659 million (≈64 % cash‑settled) and adjusted free‑cash‑flow productivity improved to 105 %, even as corporate‑level earnings swung from a $485 million profit to a $1.4 billion loss driven by a Gillette impairment and higher restructuring charges.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several correct elements but contains significant quantitative inaccuracies that undermine its factual correctness. While the general trend of increasing restructuring costs and declining corporate earnings is correctly identified, specific numbers do not align with the ground truth. For example, the LLM states that restructuring costs in fiscal 2022 were in the range of $250–$500 million — which matches the original answer — but fails to mention the actual accrual of $147 million as of June 30, 2022, a key data point. More critically, the LLM introduces operating cash flow figures ($16.7B in 2022, $19.8B in 2024) and free cash flow productivity metrics (93%, 105%) that are not present in the ground truth and cannot be verified from the provided knowledge graph. These additions appear to be hallucinated or inferred beyond available data. The $1.4 billion loss in corporate earnings is partially correct in magnitude but misattributed — the original answer states a $1.0 billion decrease in corporate net earnings, not a $1.4 billion loss; the $1.4 billion figure refers specifically to the Gillette impairment charge, not total earnings. (2) Calculations such as percentage changes in operating cash (9% decline, 18% increase) are based on unsupported figures and thus incorrect. The claim that ~65% of restructuring costs were cash-settled in 2022 and ~64% in 2024 introduces precision not present in the source and lacks corroboration. (3) The multi-hop reasoning is partially sound: the model correctly links increased restructuring charges and the Gillette impairment to downward pressure on earnings and cash management. It also correctly infers that cash management remained focused on liquidity and tax efficiency. However, it fails to mention the specific impact on Enterprise Markets like Nigeria, which is a key part of the original answer’s causal chain. (4) Despite these issues, the answer remains contextually relevant and captures the strategic evolution — increased restructuring impacting earnings and cash flows — even if the numerical foundation is flawed. Hence, correctness is scored at 6 due to partial factual accuracy with major quantitative errors, qualitative reasoning at 7 for logical synthesis despite gaps, quantitative accuracy at 5 due to unsupported metrics, and contextual relevance at 9 for staying focused on the core question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1463,
        "completion_tokens": 642,
        "total_tokens": 2105
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has NVIDIA's positioning and application of Omniverse evolved between 2022 and 2023, particularly in terms of its integration with enterprise solutions and simulation technologies?",
      "original_answer": "In 2022, NVIDIA Omniverse was positioned primarily as a virtual world simulation and collaboration platform for 3D workflows, emphasizing its availability as a software subscription for enterprise use and free for individuals. It was highlighted in use cases such as virtual car showrooms, surgical training, and architectural walkthroughs, and was integrated with DRIVE Sim software for automotive simulation and validation. By 2023, Omniverse had evolved into a more robust development platform and operating system for building virtual world simulation applications. It was increasingly tied to industrial enterprises for digitalizing complex physical assets and processes, including digital twins of factories and real-time 3D product configurators. Additionally, it was more explicitly linked to NVIDIA's accelerated computing infrastructure both on-premises and in the cloud, indicating a broader integration with enterprise-grade simulation and AI workflows.",
      "llm_answer": "In the 2022 Form 10‑K, NVIDIA presented Omniverse chiefly as a real‑time 3‑D design‑collaboration and virtual‑world simulation tool – a subscription‑based platform that mainly served creative designers and was used in a few automotive‑simulation cases such as DRIVE Sim for digital‑cockpit development. By the 2023 filing, the company had repositioned it as **Omniverse Enterprise**, an operating‑system‑style platform that powers digital‑twin, real‑time 3‑D product configurators and the testing/validation of autonomous robots and vehicles, and is tightly integrated with NVIDIA’s AI‑Enterprise, on‑premise and cloud‑based accelerated‑computing infrastructure for broader enterprise‑level simulation workloads.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies NVIDIA's positioning of Omniverse in 2022 as a real-time 3D collaboration and simulation platform, particularly for design and limited automotive use via DRIVE Sim—matching the original answer's emphasis on virtual car showrooms, architectural walkthroughs, and simulation. In 2023, the repositioning as 'Omniverse Enterprise' as an OS-style platform for digital twins, product configurators, and autonomous system validation is factually correct and reflects the evolution described in the ground truth. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification—so quantitative accuracy is not compromised; all references to years (2022, 2023) are correct. (3) The multi-hop reasoning is sound: the model synthesizes changes in positioning, target users (from creative designers to industrial enterprises), and integration with broader infrastructure (AI Enterprise, accelerated computing on-prem and cloud). The mention of integration with NVIDIA’s AI-Enterprise and cloud/on-prem infrastructure matches the ground truth’s emphasis on deeper enterprise and simulation workflow integration. (4) The only minor shortcoming is that the LLM answer does not explicitly mention surgical training or free availability for individuals in 2022, which were part of the original answer’s completeness. However, these omissions are minor in the context of the question, which focuses on enterprise solutions and simulation technologies. Overall, the answer captures the core evolution accurately and with strong semantic equivalence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 457,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did AMT's financial commitments related to communications sites evolve from 2023 to 2024, particularly in terms of anticipated spending and future obligations?",
      "original_answer": "In 2023, AMT anticipated spending approximately $450 million related to data center assets as part of its construction plans for 2,500 to 3,500 communications sites globally. By 2024, the company disclosed a much larger financial commitment, with an estimated undiscounted future cash outlay of $4.5 billion for asset retirement obligations tied to leased sites hosting communications infrastructure. This indicates a significant increase in long-term financial exposure related to communications sites, shifting from near-term capital allocation planning in 2023 to a more mature and substantial obligation structure in 2024.",
      "llm_answer": "In 2023 American Tower actually spent about **$1.83 billion** on capital projects, of which **$849 million** was discretionary spending that built **≈3,200 communications sites** worldwide and funded **≈$395 million** of data‑center work.  \n\nFor 2024 the company now **expects to spend $790‑$820 million** on discretionary projects, covering the construction of **≈2,500‑3,500 communications sites** (a slightly lower‑bound range than 2023) and **≈$450 million** of data‑center spend – a modest reduction in site‑related outlays.  \n\nBeyond the 2024 build‑out, AMT’s ongoing **operating‑lease obligations** tied to retaining those sites are disclosed as future cash requirements of **$986.9 million in 2025**, falling to about **$802 million by 2029**, reflecting the continuing long‑term financial commitments for its communications‑site portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the evolution of AMT's financial commitments from 2023 to 2024 as described in the ground truth. (1) In the ORIGINAL ANSWER, AMT anticipated spending $450 million on data center assets in 2023 as part of construction plans for 2,500–3,500 communications sites; however, the LLM claims AMT 'actually spent' $1.83 billion in capital projects in 2023 with $395 million on data centers — these figures are not supported by the ground truth and introduce unverified details (e.g., actual spend, discretionary vs. non-discretionary breakdown). (2) For 2024, the ground truth states AMT disclosed a $4.5 billion estimated undiscounted future cash outlay for asset retirement obligations (AROs) on leased sites — a major increase in long-term liability — but the LLM instead reports only $790–$820 million in expected discretionary spending and $450 million for data centers, completely missing the $4.5 billion ARO figure. Instead, it introduces unrelated operating lease obligations ($986.9 million in 2025, etc.), which are not the same as asset retirement obligations and were not mentioned in the original answer. (3) The multi-hop reasoning is flawed: the question asks about evolution in financial commitments, particularly anticipated spending and future obligations. The correct interpretation requires recognizing a shift from near-term capital planning (2023) to a large-scale long-term liability (2024 AROs). The LLM misidentifies the nature of the 2024 obligation, confusing operating leases with asset retirement obligations, and omits the key $4.5 billion figure entirely. (4) While the LLM attempts to address spending on communications sites and future commitments, its numerical inaccuracies, incorrect financial concepts, and failure to capture the core shift in obligation type and scale severely undermine correctness. Minor contextual relevance is retained by discussing site construction and future cash outflows, but the substance is incorrect. Thus, the answer is mostly wrong with major factual and conceptual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 567,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has ExxonMobil's characterization of asset divestitures in relation to strategic objectives evolved between 2023 and 2024, particularly in terms of the language used to describe the proceeds from these transactions?",
      "original_answer": "In 2023, ExxonMobil described proceeds from asset sales as part of 'sales of subsidiaries, property, plant and equipment, and sales and returns of investments,' emphasizing a disciplined review process to ensure assets align with strategic goals. By 2024, the company refined its language, referring more broadly to 'proceeds from asset sales and returns of investments,' maintaining the same strategic alignment rationale but streamlining the description. This evolution indicates a more consolidated framing of divestiture proceeds without specific mention of subsidiaries or equipment sales, suggesting a possible shift toward a more generalized narrative around asset management.",
      "llm_answer": "In the 2023 Form 10‑K the company said that it uses a “long‑standing and regular disciplined review process to ensure that assets are contributing to the Corporation’s strategic objectives” and that assets are divested when they no longer meet those objectives or can be sold for a higher value.  It instructed investors to look at the “proceeds associated with asset sales” together with operating cash.  \n\nIn the 2024 filing the same core language is retained, but the description is broadened: the cash‑flow metric now includes “proceeds from asset sales **and returns of investments**,” and the narrative adds that these proceeds are considered “when evaluating cash available for investment in the business and financing activities, **including shareholder distributions**.”  This reflects a more expansive framing of the proceeds from divestitures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in ExxonMobil's language between 2023 and 2024: in 2023, the company emphasized a disciplined review process tied to strategic objectives and referenced proceeds from asset sales; in 2024, the language broadened to include 'proceeds from asset sales and returns of investments,' which matches the original answer's claim of a more consolidated framing. (2) There are no numerical values to verify, so quantitative accuracy is not applicable in a traditional sense, but all referenced terms, years (2023, 2024), and entities (ExxonMobil, Form 10-K) are correct. (3) The multi-hop reasoning is sound—comparing disclosures across two years and identifying shifts in narrative tone and scope. The LLM correctly infers a more 'expansive framing' in 2024, which is semantically equivalent to the ground truth's 'more consolidated framing' and 'generalized narrative.' (4) The only minor shortcoming is that the LLM does not explicitly note the removal of specific mentions of 'subsidiaries, property, plant and equipment' from the 2023 description, which the original answer highlights as part of the streamlining. However, the core evolution in language and strategic context is accurately captured. Thus, the answer is factually correct and contextually relevant, warranting a high score with only a slight deduction for incomplete detail on the narrowed terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 406,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2023, based on the changes in consolidated asset and liability amounts?",
      "original_answer": "In 2022, Comcast's consolidated balance sheet included $9.7 billion in assets and $8.1 billion in liabilities related to Universal Beijing Resort. By 2023, these figures had decreased to $7.8 billion in assets and $7.2 billion in liabilities. This indicates a reduction in both the scale of assets and liabilities associated with the Universal Beijing Resort, suggesting either asset depreciation, debt repayment, or a strategic reduction in the resort's financial footprint within Comcast's consolidated statements.",
      "llm_answer": "In the 2022 filing Comcast reported that the Universal Beijing Resort entity was carried on the balance sheet with about **$9.7 billion of assets and $8.1 billion of liabilities**.  By the 2023 filing those amounts had fallen to **$7.8 billion of assets and $7.2 billion of liabilities**.  Thus, from 2022 to 2023 Comcast’s consolidated exposure to the resort shrank – assets dropped roughly $1.9 billion and liabilities about $0.9 billion, lowering the net amount of the VIE that could affect the company.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $9.7 billion in assets and $8.1 billion in liabilities for 2022, decreasing to $7.8 billion in assets and $7.2 billion in liabilities in 2023. The calculated differences—$1.9 billion decrease in assets ($9.7B - $7.8B) and $0.9 billion decrease in liabilities ($8.1B - $7.2B)—are correct. (2) The answer is complete, addressing both years, both financial statement items (assets and liabilities), and the evolution of exposure. (3) Entities—Comcast, Universal Beijing Resort, and the relevant financial metrics—are correctly identified and contextualized within the consolidated balance sheet. (4) The reasoning is sound: the LLM correctly infers a reduction in financial exposure and notes the implications (lower VIE impact), which aligns with the qualitative interpretation in the ground truth. Minor wording differences (e.g., 'carried on the balance sheet' vs. 'included') do not affect semantic equivalence. The answer demonstrates accurate multi-hop synthesis across two years of financial data and correct interpretation of financial trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 329,
        "total_tokens": 1588
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the nature of Customer Demand Volatility as a risk factor for Caterpillar evolved between 2023 and 2024, particularly in relation to its impact on financial performance and supply chain stability?",
      "original_answer": "In 2023, Customer Demand Volatility was described as being primarily driven by economic uncertainties, including the lingering effects of a global pandemic, which led to inflationary pressures, supply chain disruptions, and labor inefficiencies, all of which limited Caterpillar's ability to meet customer demand. By 2024, while the risk remained, the focus shifted slightly to include broader commodity price changes, material price increases, and significant disruptions to supply chains or shortages of labor and material as key contributors to financial performance risks. This evolution indicates a broadening of the risk profile to include more systemic supply-side challenges alongside demand volatility.",
      "llm_answer": "In the 2023 Form 10‑K Caterpillar described “fluctuations in demand for our products and services” mainly as a trigger for excess inventories, higher operating costs and reduced profitability, and warned that an inability to realign production or purchases with that demand could hurt its financial results and strain the supply chain. By the 2024 filing the company broadened the risk, tying demand volatility to macro‑economic headwinds (higher real‑interest rates, tighter credit, and commodity‑price swings) and to “catastrophic events” such as pandemics, and emphasized that this volatility can now generate not only profit‑margin pressure but also larger inventory imbalances, supply‑chain inefficiencies and potential allowance‑for‑doubtful‑account or impairment charges. Thus, the risk factor has evolved from a focus on inventory‑cost impacts to a more comprehensive view that connects demand swings directly to both financial performance and supply‑chain stability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of Customer Demand Volatility as a risk factor from 2023 to 2024 for Caterpillar. In 2023, the focus was on demand fluctuations leading to excess inventories, higher costs, and supply chain strain—consistent with the original answer’s mention of inflationary pressures and supply chain disruptions due to pandemic aftereffects. By 2024, the LLM correctly notes a broadening of the risk to include macroeconomic factors such as higher real interest rates, tighter credit, commodity-price swings, and catastrophic events like pandemics, which matches the ground truth’s emphasis on commodity price changes, material cost increases, and systemic supply-side challenges. (2) There are no numeric values in the question or answers that require verification; all references to years (2023, 2024) are correct, satisfying quantitative accuracy. (3) The multi-hop reasoning is sound: the model synthesizes changes across two years, connects shifts in risk language to financial performance (profit margins, impairment charges) and supply chain stability (inefficiencies, inventory imbalances), and correctly infers an expansion in the scope of the risk factor. (4) While the wording differs, the semantic meaning matches the original answer. One minor point preventing a perfect 10 is that the LLM emphasizes 'catastrophic events' and 'allowance for doubtful accounts'—which are valid inclusions but not explicitly highlighted in the ground truth—while the ground truth specifically mentions labor and material shortages more prominently. Still, these additions do not contradict but rather complement the core evolution described. Overall, the answer is factually correct, comprehensive, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 491,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value and valuation methodology of Net derivative assets (liabilities) evolve from 2022 to 2024?",
      "original_answer": "In 2022, the fair value of Net derivative assets (liabilities) was $19 million as of December 31, 2021, with changes in value primarily tied to derivative activity such as issuances ($68 million), settlements ($-37 million), and transfers ($6 million). By 2024, the fair value had increased significantly to $58 million as of December 31, 2023. Additionally, the valuation methodology shifted from being primarily based on realized and unrealized gains/losses reported in net income to being assessed using discounted cash flows with a focus on observable inputs like swap rates (3-5%, weighted average of 4%). This indicates both a material increase in value and a methodological shift toward more transparent and observable valuation techniques.",
      "llm_answer": "In the 2022 filing the net derivative liabilities were recorded at a fair‑value of **$19 million** and were valued using a **discounted‑cash‑flow model** that relied on **swap‑rate inputs of 1 %–2 % (weighted‑average 2 %)** (Level 3). By the 2024 filing the fair‑value had risen to **$69 million**; the same discounted‑cash‑flow methodology was retained, but the swap‑rate inputs had moved higher – a **3 %–5 % range with a 4 % weighted‑average in 2023 and a 4 % rate shown for 2024**. Thus, the valuation approach stayed unchanged (discounted cash flows with unobservable swap‑rate assumptions), while both the assumed swap rates and the reported fair‑value of the net derivative liabilities increased markedly from 2022 to 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers and methodology. The fair value in 2022 is correctly stated as $19 million, but this refers to the value as of December 31, 2021 (reported in the 2022 filing), which the LLM does not clarify. However, the 2024 filing reports the fair value as $58 million as of December 31, 2023, but the LLM incorrectly states it as $69 million — a material error. Additionally, the LLM claims the 2022 valuation used a discounted cash flow model with swap rates of 1%–2% (weighted average 2%), Level 3, but the ground truth states that in 2022 the valuation was based on realized and unrealized gains/losses in net income, not discounted cash flows. The shift to discounted cash flows with observable inputs (3%–5%, 4% average) is a key methodological evolution, but the LLM incorrectly asserts that the methodology 'stayed unchanged', directly contradicting the ground truth. (2) Quantitative accuracy is poor: $69M vs $58M is off by $11M (~19% error); swap rate ranges are misattributed to the wrong years and incorrectly assigned to a model that wasn't used in 2022. The original answer notes a methodological shift toward more transparent, observable inputs, while the LLM claims unobservable assumptions persisted, which is incorrect. (3) Multi-hop reasoning is partially sound — the model attempts to compare two years and identify changes in inputs and values — but fails at synthesizing the correct methodology evolution. It incorrectly assumes the same model was used both years, undermining the core of the multi-hop analysis. (4) Contextual relevance is high — the answer addresses fair value changes and valuation methodology as asked — but factual and qualitative errors severely limit correctness. The conclusion that 'the valuation approach stayed unchanged' is factually wrong, leading to a low correctness score despite relevant structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 520,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has NVIDIA's GeForce NOW cloud gaming offering evolved from 2022 to 2023 in terms of its positioning within the company's broader GPU and cloud platform ecosystem?",
      "original_answer": "In 2022, GeForce NOW was positioned as a cloud platform enabling gamers to access interactive graphics applications from nearly any device, emphasizing its role in extending NVIDIA’s graphics leadership and ecosystem reach. It was mentioned alongside other cloud platforms like vGPU for enterprise use. By 2023, GeForce NOW was more specifically integrated into the broader NVIDIA accelerated computing platform narrative, and its positioning shifted to emphasize cloud gaming as part of a suite of GPU-driven services, including AI training platforms like NVIDIA DGX Cloud. This evolution reflects a more strategic alignment of GeForce NOW with NVIDIA’s expanding cloud infrastructure and software offerings, particularly in the context of gaming as a service.",
      "llm_answer": "In the 2022 filing, GeForce NOW was presented mainly as a consumer‑focused game‑streaming service that sits in the Graphics segment alongside GeForce RTX/GTX GPUs and “related infrastructure.” By the 2023 filing, NVIDIA describes GeForce NOW as one of its cloud platforms—grouped with vGPU, AI‑Enterprise and Omniverse—that uses the same accelerated‑computing stack to deliver interactive graphics “to almost any device, almost anywhere,” signaling its evolution from a standalone gaming service to an integrated component of the company’s broader GPU‑and‑cloud ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of GeForce NOW from a consumer-focused game-streaming service in 2022 to a more integrated component of NVIDIA’s broader GPU and cloud ecosystem in 2023. The key shift—from standalone gaming service to part of a unified accelerated-computing platform—is accurately captured. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification; all temporal references (2022, 2023) are correct and consistent with the original answer. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years and connects GeForce NOW’s positioning to other platforms (vGPU, AI Enterprise, Omniverse), correctly inferring its strategic repositioning within NVIDIA’s ecosystem. It accurately reflects the integration with NVIDIA’s accelerated computing narrative, though it does not explicitly mention DGX Cloud or 'gaming as a service'—minor omissions that prevent a perfect 10 on qualitative accuracy. (4) The answer is contextually excellent, directly addressing how GeForce NOW evolved in positioning within NVIDIA’s broader strategy. Wording differs slightly but maintains semantic equivalence. Minor deduction from correctness score due to omission of AI training platforms like DGX Cloud as a specific anchor point in the 2023 narrative, but overall factual integrity remains strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 402,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors influenced this change?",
      "original_answer": "In 2022, Inlyta had total global revenue of $1,003 million, while in 2023, its revenue increased to $1,036 million, representing a 3% growth. This growth was primarily driven by continued adoption of Inlyta in combination with immune checkpoint inhibitors for the first-line treatment of advanced renal cell carcinoma (RCC) in the U.S., and growth in emerging markets. However, this increase was partially offset by lower volumes and lower net prices in certain European markets.",
      "llm_answer": "In 2023 Pfizer’s Inlyta revenue rose modestly versus 2022 – U.S. sales grew from $618 million to $642 million (≈ 4 % increase) and worldwide revenue climbed from $1.003 billion to $1.036 billion (≈ 3 % increase). The uptick was driven mainly by expanded use of Inlyta in combination with immune‑checkpoint inhibitors for first‑line advanced renal‑cell carcinoma in the United States, while growth was partially offset by lower volumes and reduced net price in some European markets and modest gains in emerging‑market sales.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the global revenue for Inlyta in 2022 ($1.003 billion) and 2023 ($1.036 billion), matching the ground truth exactly, and accurately calculates the ≈3% growth. It also correctly identifies U.S. sales figures rising from $618 million to $642 million (≈4% increase), which, while not part of the original answer, are factually consistent and add useful context without contradicting the ground truth. (2) All numeric values and percentages are accurate. The $1,003 million = $1.003 billion and $1,036 million = $1.036 billion formatting is acceptable and standard. The 3% growth is correctly derived: (1,036 - 1,003) / 1,003 ≈ 3.3%, which rounds to ≈3%, as stated. (3) The reasoning is sound and reflects multi-hop synthesis: the driver of growth—increased use in combination with immune checkpoint inhibitors for first-line advanced RCC in the U.S.—is correctly identified. The offsetting factors—lower volumes and net prices in certain European markets—are also accurately included. The mention of 'modest gains in emerging-market sales' is slightly less precise than the original's 'growth in emerging markets' but does not distort the meaning. (4) The answer is highly factually accurate, complete, and contextually relevant. The only minor shortcoming is the addition of U.S.-specific figures not present in the ground truth, which, while plausible and consistent, could introduce slight overprecision if unverified. However, since they do not conflict with the original and support the overall narrative, the impact is minimal. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 468,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the treatment and valuation of network location intangibles evolved from 2023 to 2024, particularly in terms of amortization assumptions and impairment review processes?",
      "original_answer": "In 2023, the company amortized network location intangibles on a straight-line basis over their estimated useful lives, with a weighted average amortization period of 15 years as of December 31, 2023. The focus was on the relationship between these intangibles and tower assets, particularly in terms of potential revenue growth from leasing excess capacity. By 2024, the company expanded its disclosures to include a more detailed impairment review process for network location intangibles, assessing impairment on an individual tower basis and identifying specific triggers such as lack of tenant leases or expenses exceeding revenues. Additionally, while amortization remained a key treatment, the company's broader discussion of asset retirement obligations in 2024, including a $470 million increase in liability due to revised settlement dates, indirectly impacts the valuation and useful life assumptions for these intangible assets.",
      "llm_answer": "In the 2023 filing the company said that acquired network‑location intangibles were amortized on a straight‑line basis over the shorter of the related ground‑lease term (including renewal options) or a maximum of 20 years, with a weighted‑average remaining amortization period of about 15 years, and that each tower’s intangibles were examined at least annually for impairment by testing undiscounted future cash‑flows and, if needed, measuring loss using discounted cash‑flows or market‑based fair value ( page 103 & page 96 ).\n\nIn the 2024 filing the company extended the assumed useful life of those intangibles to 30 years (matching the revised tower‑asset life) and now amortizes them over the remaining estimated life on a straight‑line basis, cutting depreciation‑and‑amortization expense, while retaining the same tower‑by‑tower annual impairment review that compares the carrying amount to projected undiscounted cash‑flows and, when a loss is indicated, measures it against discounted cash‑flows or market fair value ( page 95 & page 96 ).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding the amortization period change from 15 to 30 years in 2024, which contradicts the ground truth. The original answer states that amortization remained a key treatment with no indication of a change in useful life from 15 to 30 years. Instead, the evolution was in the impairment review process, not in extending amortization periods. Additionally, the LLM incorrectly claims the useful life was extended to 30 years 'matching the revised tower-asset life,' which is not supported by the ground truth. The $470 million increase in asset retirement obligations is mentioned in the ground truth as indirectly affecting valuation and useful life assumptions, but this is absent in the LLM response. (2) Quantitatively, the 15-year weighted average amortization period in 2023 is correctly reported, but the assertion of a 30-year life in 2024 is false. There is no mention of a 30-year period or any extension in the ground truth. The impairment testing methodology described (undiscounted cash flows, then discounted or market-based) is consistent with standard practices but not explicitly confirmed in the original answer, making this an over-specific addition not grounded in the provided truth. (3) The multi-hop reasoning is partially sound in structure—comparing 2023 and 2024 treatments—but flawed in content. The model synthesizes changes where none were stated, inventing a major policy shift in amortization life rather than identifying the actual evolution: enhanced disclosure of impairment triggers (e.g., lack of leases, expenses exceeding revenue) and the indirect impact of increased asset retirement obligations. The LLM fails to mention the key 2024 development: impairment now assessed on an individual tower basis with specific triggers, which is a central point in the ground truth. (4) Contextual relevance is high because the answer addresses amortization and impairment as requested, and references appropriate concepts. However, correctness is low due to fabricated quantitative details and missed qualitative developments. The inclusion of page numbers suggests confidence but does not align with the verified facts provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1505,
        "completion_tokens": 599,
        "total_tokens": 2104
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, particularly in terms of its upstream growth portfolio and production capacity?",
      "original_answer": "In 2023, ExxonMobil highlighted Guyana as a key component of its upstream growth portfolio, noting four additional discoveries on the Stabroek Block and the startup of the Prosperity FPSO vessel, which brought production to nearly 440 kbd in the fourth quarter. By 2024, Guyana was formally categorized under 'Advantaged Assets' within the updated earnings drivers, reflecting its strategic elevation alongside the Permian and LNG projects as a core contributor to earnings through volume/mix growth. This shift indicates a transition from a discovery and early production phase in 2023 to a more mature, financially impactful asset in 2024.",
      "llm_answer": "In the 2023 filing Guyana was highlighted mainly as an “advantaged‑volume” contributor – the earnings factor analysis notes that the upstream earnings boost from volume/mix was driven by growth in Guyana (and the Permian) 【page_53】. By the 2024 filing the company positions Guyana as a centerpiece of its upstream growth portfolio, describing four new discoveries, the start‑up of the Prosperity FPSO (reaching name‑plate capacity in early 2024) and a combined ≈ 390 kb/d production in 2023 that rose to ≈ 440 kb/d in Q4, with a plan for six FPSOs operating by 2027 and a sixth project (Whiptail) under regulatory review 【page_52】.  Thus, ExxonMobil’s emphasis shifted from treating Guyana as a volume‑mix boost in 2023 to a core, capacity‑expanding growth platform in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the evolution of ExxonMobil's strategic emphasis on Guyana between 2023 and 2024, with accurate qualitative and quantitative details. However, there are minor discrepancies in the numerical data and terminology compared to the ground truth. (1) Quantitatively, the LLM states 'combined ≈390 kb/d production in 2023' rising to '≈440 kb/d in Q4'—this is mostly accurate, but the ground truth specifies that nearly 440 kbd was reached in Q4 2023, not 2024, and does not mention a full-year 2023 average of 390 kb/d. This introduces a slight timing misalignment. (2) The LLM correctly identifies four new discoveries and the Prosperity FPSO startup, but notes it reached nameplate capacity in early 2024, while the original answer emphasizes the Q4 2023 production level, implying earlier ramp-up. This creates a small discrepancy in timeline precision. (3) The mention of six FPSOs by 2027 and Whiptail under review adds detail beyond the ground truth, which is not incorrect but not confirmed in the provided answer. (4) Qualitatively, the shift from 'volume/mix' contributor in 2023 to a core growth platform in 2024 is well-reasoned and aligns with the ground truth’s 'Advantaged Assets' reclassification. However, the LLM uses 'advantaged-volume' and 'centerpiece' rather than the exact term 'Advantaged Assets' used in the original, slightly reducing terminological accuracy. (5) Contextually, the answer fully addresses the question about strategic evolution, upstream portfolio role, and production capacity, making it highly relevant. Overall, the core facts and reasoning are sound, but minor inaccuracies in timing and phrasing prevent a top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 461,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the X1 platform's integration with third-party streaming services evolved between 2022 and 2023, and what does this evolution indicate about Comcast's strategy in reducing cord-cutting and increasing average revenue per user (ARPU)?",
      "original_answer": "In 2022, the X1 platform integrated third-party streaming services such as Disney+ and Netflix, and provided access to Peacock's premium tier, with Comcast earning commission revenue from the sale of these services. By 2023, the X1 platform continued to support third-party integrations but now included Xumo Play, NBC, and Sky as part of the NOW TV service, which was specifically marketed to residential broadband customers. This expansion indicates a strategic pivot toward enhancing the value of broadband subscriptions and bundling streaming access to retain customers and potentially increase ARPU through deeper content integration and commission-generating partnerships.",
      "llm_answer": "In the 2022 filing Comcast described the X1 platform as a “cloud‑based” system that **aggregates linear TV and internet‑based streaming content** through its Xumo Stream Box, giving customers access to third‑party DTC services such as Disney+, Netflix and the ad‑supported tier of Peacock (see 2022 p. 6‑5). By the 2023 filing the same X1 platform (and the newly‑named Flex device) was said to **integrate those services directly into the X1 interface**, now also delivering Peacock’s premium tier and offering a unified voice‑activated search experience across linear and streaming apps (see 2023 p. 7‑4). This deeper, more seamless integration shows Comcast’s strategy of keeping cord‑cutters inside its ecosystem—bundling premium streaming with traditional cable to curb churn and lift average revenue per user through higher‑value, bundled subscriptions.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of factual content and strategic interpretation. (1) It accurately identifies the 2022 integration of third-party streaming services like Disney+, Netflix, and the ad-supported tier of Peacock via the X1 platform, citing the correct context of aggregation through the Xumo Stream Box. It also correctly notes the evolution in 2023: deeper integration into the X1 interface, inclusion of Peacock’s premium tier, and enhanced features like unified voice search. These details are semantically consistent with the original answer, though the LLM emphasizes user experience improvements (e.g., voice search) not explicitly mentioned in the ground truth. (2) There are no numerical values, dates, or financial figures in dispute—both answers reference 2022 and 2023 correctly, and no calculations are required. Thus, quantitative accuracy is perfect. (3) The multi-hop reasoning is sound: the LLM connects platform evolution to Comcast’s broader strategy of reducing cord-cutting and increasing ARPU through bundling and ecosystem retention. However, the LLM omits mention of Xumo Play, NBC, Sky, and NOW TV’s targeting of broadband customers—a key component of the 2023 expansion in the ground truth. This missing element slightly weakens completeness and entity accuracy. Conversely, the LLM adds specific detail about the Flex device and interface enhancements, which may be accurate but are not in the ground truth, introducing minor extraneous information. (4) Despite these omissions and additions, the core strategic interpretation—deepening integration to retain users and boost ARPU via bundled, commission-generating services—is correctly inferred and matches the original answer’s conclusion. Hence, the answer is contextually highly relevant and qualitatively strong, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 510,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Caterpillar's relationship with FG Wilson evolved between 2023 and 2024 in terms of its distribution network coverage for electric power generation systems?",
      "original_answer": "In 2023, FG Wilson's electric power generation systems were distributed through a network of 110 distributors covering 109 countries. By 2024, this distribution network had slightly contracted to 108 distributors, now covering 158 countries. This indicates a minor reduction in the number of distributors but an expansion in the geographic reach of the network. The change suggests a strategic shift toward optimizing distributor efficiency while broadening market access.",
      "llm_answer": "In 2023 Caterpillar reported that the FG Wilson‑branded electric power‑generation systems were sold through a worldwide network of **110 distributors in 109 countries**. By the 2024 filing the network had been trimmed to **108 distributors, but those distributors now covered **158 countries** — so the dealer base became slightly smaller while its geographic reach expanded markedly. 【page_65】【page_66】",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the numbers are accurate: 110 distributors in 109 countries in 2023, and 108 distributors in 158 countries in 2024. These match the original answer exactly. (2) The answer is complete, addressing both years, the change in distributor count, and the expansion in geographic coverage. (3) Entities are correctly identified: Caterpillar, FG Wilson, electric power generation systems, and the correct time frame (2023 to 2024). (4) The reasoning is sound: the LLM correctly infers a strategic shift—slight reduction in distributors but a marked increase in country coverage—demonstrating proper multi-hop synthesis across the two time points. The semantic meaning is equivalent to the ground truth, with only minor wording differences (e.g., 'trimmed' vs 'contracted', 'markedly expanded' vs 'expansion'). All citations are appropriately referenced. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 286,
        "total_tokens": 1509
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Capital One's exposure to securitized debt obligations change between 2022 and 2024, particularly in terms of the carrying value and fair value of these obligations?",
      "original_answer": "In 2022, Capital One reported that the assets and liabilities of consolidated VIEs, including securitized debt obligations, were primarily composed of loan receivables and debt securities issued by the VIEs, with the liabilities reported under 'securitized debt obligations' on the consolidated balance sheets. By 2024, the carrying value of 'Securitized debt obligations' was $18,043 million, with a fair value of $18,067 million, all categorized under Level 2 of the fair value hierarchy. This indicates that Capital One maintained a significant exposure to securitized debt obligations, with a slight increase in fair value relative to carrying value, suggesting stable valuation and continued involvement in securitization activities.",
      "llm_answer": "In the 2022 Form 10‑K Capital One reported securitized‑debt obligations with a **carrying amount of about $18.0 billion** and an **estimated fair value of roughly $18.1 billion**.  By the 2024 Form 10‑K the same liability had fallen to a **carrying amount of $14.3 billion** and an **estimated fair value of $14.3 billion**.  Thus, between 2022 and 2024 Capital One reduced both the book‑value and the fair‑value of its securitized‑debt obligations by roughly $3.7 billion.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its quantitative claims, which invalidates the core of the response. According to the ground truth, in 2024, Capital One's securitized debt obligations had a carrying value of $18,043 million ($18.043 billion) and a fair value of $18,067 million ($18.067 billion), both of which are close to the $18.0–18.1 billion range mentioned by the LLM for 2022. However, the LLM incorrectly states that by 2024, these values had dropped to $14.3 billion, which directly contradicts the ground truth showing an increase (or at minimum, stability) in exposure. The LLM claims a reduction of ~$3.7 billion in both carrying and fair value, but the actual data shows the values remained nearly flat or slightly increased. This represents a severe factual error in financial figures and trend direction. While the LLM correctly identifies the relevant metric ('securitized debt obligations') and attempts a year-over-year comparison (2022 to 2024), the reasoning is based on false data. The contextual relevance is moderate because it addresses the right concept (change in carrying and fair value of securitized debt obligations), but the incorrect numbers lead to a false conclusion about Capital One reducing exposure, when in fact the ground truth indicates continued significant involvement with stable valuation. No source in the ground truth supports a decline to $14.3 billion in 2024. The qualitative reasoning structure is sound—comparing two years’ carrying and fair values—but the data inputs are wrong, making the synthesis invalid. Number formatting is acceptable ($18.0 billion = $18,043 million), but the actual values do not align.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 455,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has McDonald's use of line of credit agreements evolved between 2023 and 2024 in relation to its financing activities and cash flow management?",
      "original_answer": "In 2023, McDonald's cash used for financing activities totaled $4.4 billion, a decrease of $2.2 billion compared to 2022, primarily due to increased bond issuances. The company's cash and equivalents balance was $4.6 billion at the end of 2023, reflecting sufficient liquidity supported by cash from operations and access to commercial paper borrowings and line of credit agreements. In 2024, cash used for financing activities increased to $7.5 billion, a rise of $3.1 billion compared to 2023, driven by decreased bond issuances. The company's cash and equivalents balance dropped to $1.1 billion at year-end 2024, with the prior year's higher balance attributed to the timing of debt issuances that funded 2024's required cash outflows. The company continued to rely on its line of credit agreements and commercial paper to meet short-term funding needs. This indicates a shift from surplus liquidity and bond financing in 2023 to a more cash-constrained environment in 2024, with greater reliance on existing credit facilities.",
      "llm_answer": "In 2023 McDonald’s noted that, beyond its cash on hand and operating cash flow, it could meet short‑term funding needs through its existing commercial‑paper program and “line of credit agreements.” By 2024 the company still retained a committed $4 billion line of credit, but cash and equivalents fell to $1.1 billion (from $4.6 billion in 2023) as financing outflows rose and bond issuances declined, so the line of credit remained a key source of short‑term liquidity while the firm’s overall borrowing capacity was reshaped (‑$7.4 billion of the $15 billion authorized remained available and a new $15 billion program was put in place for 2025).",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of McDonald's use of line of credit agreements between 2023 and 2024, noting continued reliance on credit facilities amid declining cash balances and reduced bond issuances. It accurately states that cash and equivalents dropped from $4.6 billion in 2023 to $1.1 billion in 2024, which matches the ground truth. However, the LLM introduces a specific figure of a '$4 billion line of credit' and mentions that '-$7.4 billion of the $15 billion authorized remained available,' along with a 'new $15 billion program was put in place for 2025'—details not present in the original answer and not verifiable from the provided ground truth. These additions, while plausible, are unsupported by the source and reduce quantitative accuracy. (2) The core financial figures—cash used for financing activities—($4.4B in 2023, $7.5B in 2024) are not mentioned in the LLM answer, which is a significant omission given their importance in explaining the shift in financing behavior. The drop in cash from $4.6B to $1.1B is correctly reported. The claim about a new $15B program for 2025 and remaining availability under an authorization cannot be verified and likely stems from external knowledge or inference, lowering quantitative accuracy. (3) The multi-hop reasoning is strong: the model correctly infers that reduced bond issuance and higher financing outflows led to greater reliance on credit lines, and it connects declining cash balances to increased dependence on short-term funding—this aligns with the ground truth’s conclusion of a shift to a more cash-constrained environment. (4) Despite missing key quantitative inputs (financing outflows), the LLM conveys the essential qualitative shift in McDonald’s liquidity and financing strategy. The answer remains contextually relevant and semantically aligned with the core message of increased reliance on credit facilities in 2024. The correctness score is 8 due to accurate synthesis and context, but docked for unverified numerical claims and omission of key financing activity figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 563,
        "total_tokens": 1983
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the role of the Worldwide Business Conduct Manual in reinforcing internal controls evolved between 2022 and 2024, and what does this indicate about Procter & Gamble's approach to governance?",
      "original_answer": "In 2022, the Worldwide Business Conduct Manual was described as reinforcing the company's commitment to conducting business with integrity and within the letter and spirit of the law, emphasizing its role in supporting internal controls through policies, segregation of duties, and employee development. In 2024, while the core description remained similar, the manual was more specifically tied to governance frameworks such as the oversight activities of the Global Leadership Council and the responsibilities of the Disclosure Committee in evaluating significant business activities. This indicates a shift toward emphasizing structured governance mechanisms alongside ethical conduct, suggesting a more integrated approach to internal control over time.",
      "llm_answer": "In both the 2022 and 2024 Form 10‑K filings Procter & Gamble states that “strong internal controls is an objective that is reinforced through our Worldwide Business Conduct Manual,” using the manual to embed the company’s commitment to integrity and compliance into its control framework. The 2024 filing adds that management’s annual COSO‑based assessment and the independent auditor’s unqualified opinion on internal‑control effectiveness are expressly linked to the manual’s guidance, showing that the manual’s role has been deepened and formalized as a cornerstone of the company’s governance architecture. This continuity and the tighter integration of the manual with formal control assessments signal that P&G treats its conduct manual as a living, governance‑driving instrument rather than a static policy.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually consistent in its portrayal of the Worldwide Business Conduct Manual’s role in reinforcing internal controls at Procter & Gamble in 2022 and 2024. It correctly identifies that the manual reinforces integrity, compliance, and internal controls in both years. However, it introduces specific details not present in the ground truth—namely, the mention of management’s COSO-based assessment and the independent auditor’s unqualified opinion being 'expressly linked' to the manual in the 2024 filing. The ground truth does not reference COSO, auditor opinions, or formal control assessments in connection with the manual; instead, it highlights the manual’s integration with governance bodies like the Global Leadership Council and the Disclosure Committee. These are distinct governance mechanisms not mentioned in the LLM answer. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is partially sound: the LLM correctly infers continuity in the manual’s role from 2022 to 2024 and identifies an evolution toward greater formalization. However, it synthesizes incorrect supporting details (COSO, auditor linkage) that are not in the ground truth, indicating a failure to accurately represent the specific governance evolution described. The correct multi-hop synthesis should connect the manual’s increasing alignment with internal governance structures (Global Leadership Council, Disclosure Committee), not external audit processes. (4) The answer is contextually relevant and well-articulated, capturing the spirit of an evolving governance role. However, due to the substitution of key entities and mechanisms, the qualitative accuracy is reduced. The correctness score reflects that the core idea of increased formalization is present, but key factual components of the evolution are incorrect or misplaced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 534,
        "total_tokens": 1939
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Exxon's strategic positioning in Guyana evolved between 2023 and 2024, as reflected in its long-lived asset disclosures and earnings driver definitions?",
      "original_answer": "In 2023, Exxon disclosed $9,689 million in long-lived assets in Guyana, indicating it was already a significant contributor among non-U.S. assets. By 2024, Guyana was explicitly named as part of Exxon's 'Advantaged Assets' under the new 'Advantaged Volume Growth' earnings driver, which includes key growth projects like Guyana and LNG. This evolution shows that Guyana transitioned from being a quantitatively notable asset in 2023 to a strategically emphasized growth engine in 2024.",
      "llm_answer": "In the 2023 filing Exxon reported that its Guyana operations had become a sizable long‑lived asset – $9.7 billion of property, plant and equipment were recorded for Guyana (up from $6.8 billion in 2022) 【page_115】.  By the 2024 filing the company had moved Guyana from a line‑item asset balance into its strategic growth narrative, listing it as one of the “Advantaged Assets” (along with Permian and LNG) that drive Advantaged Volume Growth in the new earnings‑driver framework 【page_37】.  Together, these disclosures show that Exxon’s Guyana portfolio not only grew in size but was also elevated to a core, high‑value growth project in its 2024 strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the $9.7 billion figure for Guyana's long-lived assets in 2023 is correctly reported (ground truth: $9,689 million, which rounds to $9.7 billion); the increase from $6.8 billion in 2022 is an accurate contextual addition not in the original answer but factually consistent. (2) The qualitative evolution—Guyana's elevation to 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver in 2024—is correctly identified and matches the ground truth. (3) Multi-hop reasoning is sound: the model synthesizes asset value data from 2023 with strategic framing in 2024, correctly inferring a strategic upgrade in positioning. (4) Semantic equivalence is strong: while the LLM adds minor contextual detail (2022 comparison), it does not introduce errors and enhances clarity. The only minor deviation is the use of 'property, plant and equipment' instead of the broader 'long-lived assets,' which may be a simplification but is contextually acceptable in financial reporting. All entities (Exxon, Guyana, Advantaged Assets, Permian, LNG, earnings driver) are correct. The answer fully addresses both parts of the question: asset disclosures and earnings driver definitions across 2023–2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 359,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Capital One's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, based on the disclosed figures and descriptions?",
      "original_answer": "In 2022, Capital One identified securitized debt obligations as part of its diversified funding mix, which also included deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. While no specific dollar value was disclosed in 2022, the company emphasized the strategic importance of securitized debt obligations in maintaining access to wholesale funding. By 2024, Capital One disclosed that its securitized debt obligations had a carrying value of $14,264 million and an estimated fair value of $14,335 million. This represents a concrete quantification of the instrument's role in the company's capital structure, showing an increased transparency and continued use of this funding source.",
      "llm_answer": "In the 2022 filing Capital One highlighted that its long‑term funding – which is dominated by securitized debt – had risen to about $42 billion, driven by a net issuance of $6.25 billion of securitized‑debt obligations in 2021 and a shelf‑registration capacity of up to $25 billion for credit‑card and $20 billion for auto‑loan securitizations. By the 2024 filing, the balance sheet shows the actual outstanding securitized‑debt obligations had fallen to roughly $14.3 billion (down from about $18 billion a year earlier), indicating that the company’s reliance on securitized debt as a funding source has decreased since 2022.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that no specific dollar value for securitized debt obligations was disclosed in 2022, but the LLM claims a figure of $42 billion and attributes it to the 2022 filing, which is incorrect. Additionally, the LLM asserts that securitized debt decreased to $14.3 billion in 2024 from $18 billion in 2023, implying a downward trend and reduced reliance. However, the ground truth only provides 2024 figures ($14,264 million carrying value) with no 2023 data, so the claimed decrease is unsupported. The ground truth emphasizes increased transparency and continued use, not reduced reliance. (2) Quantitatively, the $14.3 billion figure in 2024 is approximately correct (matches $14,264 million), but the $42 billion in 2022 and $18 billion in 2023 are not supported by the original answer or implied data. The $6.25 billion issuance in 2021 and shelf capacities are not mentioned in the ground truth, making them fabricated details. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers a decline in reliance based on unsupported year-over-year comparisons and misrepresents the 2022 disclosure. It fails to recognize that the key evolution is increased disclosure (from no specific number in 2022 to a precise value in 2024), not a change in funding strategy. (4) The contextual relevance is moderate because the answer addresses the topic of securitized debt evolution and cites relevant funding instruments, but the core factual claims about amounts and trends are incorrect, leading to a misleading conclusion. The qualitative reasoning is poor due to incorrect entity mapping and synthesis across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 466,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has NVIDIA's Omniverse platform evolved in terms of its positioning and enterprise adoption between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Omniverse was described as 'real-time 3D design collaboration and virtual world simulation software' aimed at empowering creators to collaborate across leading design applications. By fiscal year 2023, Omniverse had evolved into a more robust enterprise-focused development platform and operating system for building virtual world simulation applications. It was made available as a software subscription for enterprise use and offered free for individual users, with industrial enterprises adopting its 3D and simulation technologies to digitalize complex physical assets and environments, including digital twins of factories and real-time 3D product configurators. This indicates a strategic shift from a creative collaboration tool to a broader enterprise simulation and digital twin platform.",
      "llm_answer": "In FY 2022 NVIDIA described Omniverse primarily as a real‑time 3‑D design‑collaboration and virtual‑world simulation platform that is offered as a free‑for‑individual tool and a paid‑subscription for enterprise use, with early enterprise pilots such as virtual car showrooms, surgical‑training and architectural walkthroughs. By FY 2023 the company had repositioned Omniverse as “Omniverse Enterprise,” a core part of its industrial‑digitalization strategy, stressing broad adoption by industrial enterprises for digital twins of factories, real‑time product configurators and testing of autonomous robots and vehicles, and highlighting its integration with on‑premises and cloud‑based accelerated‑computing infrastructure. Thus, Omniverse moved from an emerging collaboration platform to a widely‑adopted enterprise‑grade solution for industrial simulation and digital‑twin workloads.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Omniverse's positioning in FY 2022 as a real-time 3D collaboration and simulation platform for creators, offered free to individuals and via enterprise subscription, is accurately described. The evolution in FY 2023 to a more robust enterprise-focused platform—rebranded as 'Omniverse Enterprise'—is correctly captured, including its role in industrial digitalization, digital twins of factories, real-time 3D product configurators, and simulation of autonomous systems. (2) There are no numeric values, dates, or financial figures in dispute; all time references (FY 2022, FY 2023) are correct. (3) Multi-hop reasoning is sound: the model synthesizes changes in positioning (from creative tool to enterprise OS/platform) and adoption (from early pilots to broad industrial use), correctly inferring a strategic shift. (4) Semantic equivalence is strong—while the LLM uses slightly different phrasing (e.g., 'industrial-digitalization strategy', 'enterprise-grade solution'), the core meaning matches the original answer. The only minor gap is that the original emphasizes Omniverse as an 'operating system' and 'development platform', which the LLM implies but does not explicitly state. This slight omission in technical framing prevents a perfect 10, but overall the response is factually complete, contextually appropriate, and logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 402,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Pfizer's financial relationship with Viatris evolved between 2022 and 2023, particularly in terms of net amounts due under their various agreements?",
      "original_answer": "In 2022, the net amounts due to Viatris under the agreements were $94 million as of December 31, 2022. By 2023, this amount had decreased to $33 million as of December 31, 2023. This indicates a significant reduction in the net financial obligations between the two companies over the period, suggesting a winding down or stabilization of transitional financial arrangements established post-separation.",
      "llm_answer": "Pfizer’s post‑separation balances with Viatris have fallen sharply. At year‑end 2022 the company recorded **$94 million** of net amounts owed to Viatris under the separation‑related MSAs, TSAs, agency and other agreements, but by year‑end 2023 that liability had dropped to **$33 million** (see 2023 Form 10‑K, Note B – “Upjohn Separation and Combination with Viatris”). Thus, the net amount due to Viatris fell by roughly two‑thirds between 2022 and 2023, reflecting a winding‑down of the transitional services and agency arrangements.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the dollar amounts are accurate: $94 million as of December 31, 2022, and $33 million as of December 31, 2023. The statement that the liability 'fell by roughly two-thirds' is a reasonable approximation (actual reduction is ~65%, which is close to two-thirds). (2) The answer is complete, addressing the evolution of Pfizer's financial relationship with Viatris over the specified period and focusing on net amounts due under their agreements. (3) Entity accuracy is correct: Pfizer, Viatris, and the relevant agreements (MSAs, TSAs, agency agreements) are properly identified, and the time periods (2022 to 2023) are accurate. (4) The reasoning is sound: the answer correctly infers a winding-down of transitional arrangements based on the decreasing liability, which aligns with the ground truth's interpretation. The citation of the 2023 Form 10-K, Note B, adds contextual support. (5) Semantic equivalence is achieved — while the LLM provides additional detail (e.g., naming specific agreement types), the core information and conclusion match the original answer precisely. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 344,
        "total_tokens": 1581
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, and what specific changes in project activity or classification reflect this evolution?",
      "original_answer": "In 2023, ExxonMobil's operations in Guyana were characterized by active exploration and development, with 12.6 net exploratory and development wells completed, and key projects such as Payara, Yellowtail, and Uaru underway. By 2024, Guyana was formally classified as part of ExxonMobil's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, signaling a strategic elevation of its importance alongside the Permian Basin and LNG. This reclassification reflects a shift from operational reporting to strategic prioritization, indicating increased emphasis on Guyana as a core growth asset.",
      "llm_answer": "In the 2023 filing ExxonMobil treated Guyana as one of many regional operations – reporting 4.6 million offshore acres, 12.6 net exploratory‑development wells completed, the start‑up of the Payara development (with the Prosperity FPSO), ongoing work on Yellowtail and the funding of the Uaru project. By the 2024 filing the company had elevated Guyana to an “Advantaged asset” – it is now listed under the Advantaged Volume‑Growth driver (alongside Permian and LNG), signalling that Guyana is being classified as a high‑value, growth‑oriented project rather than just another operating region. This re‑classification marks a clear shift toward a more strategic, priority‑driven emphasis on Guyana’s development.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively, the LLM correctly reports 12.6 net exploratory and development wells completed in 2023 and accurately references the Payara, Yellowtail, and Uaru projects. However, it incorrectly states '4.6 million offshore acres' — the ground truth does not mention this number, and no such figure appears in the original answer, making this a minor factual addition not supported by the source. (2) The strategic reclassification in 2024 is correctly identified: Guyana is now part of the 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, grouped with Permian and LNG — this is accurately reflected. (3) The reasoning is sound: the LLM correctly infers a shift from operational reporting to strategic prioritization, capturing the multi-hop evolution from project activity (2023) to strategic classification (2024). (4) The answer fully addresses both parts of the question — the evolution of strategic emphasis and the specific changes in project activity or classification. The only deviation is the unsupported acreage figure, which does not undermine the overall correctness but slightly affects quantitative accuracy. Wording differs but semantic equivalence is maintained. Contextual relevance is perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 370,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the weighted-average interest rate and face value of senior notes with maturities greater than 10 years evolve from 2022 to 2023?",
      "original_answer": "In 2022, the weighted-average interest rate for senior notes with maturities greater than 10 years was 3.67%, with a face value of $54.536 billion. In 2023, the interest rate remained unchanged at 3.8%, but the face value slightly decreased to $53.4 billion. This indicates a slight reduction in long-term debt in this category, while the interest rate stayed stable.",
      "llm_answer": "In the 2023 filing, Comcast reported that its senior notes with maturities > 10 years carried a weighted‑average interest rate of **3.8 %**, the same rate shown for the same class of notes in 2022.  The face‑value of those notes grew slightly, from **$52.8 billion at year‑end 2022** to **$53.4 billion at year‑end 2023**.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM answer correctly identifies the 2023 weighted-average interest rate (3.8%) and matches it to 2022 as unchanged, which aligns with the ground truth. However, the 2022 face value is incorrect: the LLM states $52.8 billion, while the ground truth is $54.536 billion. The 2023 face value ($53.4 billion) is accurate. The direction of change (slight decrease) is correct, but the LLM incorrectly states the face value 'grew' when it actually decreased from a higher starting point.\n\n2) Quantitative accuracy is partially correct: the 3.8% interest rate is accurate for both years (though ground truth reports 3.67% in 2022, rounded or updated to 3.8%), but the 2022 face value is significantly off by over $1.7 billion. This error affects the validity of the comparison.\n\n3) The reasoning is logically structured and attempts the correct multi-hop synthesis across years and metrics. However, the incorrect 2022 face value undermines the conclusion that the value 'grew'—in fact, it decreased slightly from a higher base. The model fails to note the actual reduction from $54.536B to $53.4B.\n\n4) Contextual relevance is high—the answer addresses both parts of the question (interest rate and face value evolution), uses correct entities (Comcast, senior notes, maturities >10 years, correct years), and maintains appropriate focus. The core issue is factual inaccuracy in one key number, not relevance or understanding of the task.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1170,
        "completion_tokens": 396,
        "total_tokens": 1566
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the nuclear decommissioning trusts managed by Alabama Power and Georgia Power shift their domestic equity investment allocations and valuation methodologies between 2023 and 2024, particularly in terms of Level 1 and Level 2 input classifications?",
      "original_answer": "In 2023, Alabama Power reported $396 million in domestic equity investments under Level 1 inputs and $169 million under Level 2 inputs, totaling $565 million. Georgia Power reported $255 million in Level 1 and $1 million in Level 2, totaling $256 million. By 2024, Alabama Power’s domestic equity investments increased to $443 million in Level 1 and $208 million in Level 2, totaling $651 million. Georgia Power saw its Level 1 domestic equity investments rise to $321 million while Level 2 remained at $1 million, totaling $322 million. This indicates a strategic shift toward higher allocations in domestic equities, particularly through more actively traded (Level 1) instruments, which may reflect a more transparent or liquid investment approach in line with evolving trust management strategies.",
      "llm_answer": "In the 2023 filing the nuclear‑decommissioning trusts of both utilities held their domestic‑equity positions almost entirely under **Level 2** observable‑input pricing (Alabama Power $443 million, Georgia Power $321 million) with only a modest amount measured at **Level 3** ($208 million for Alabama, $1 million for Georgia).  By the 2024 filing the trusts had moved those same domestic‑equity holdings into the **Level 1** quoted‑price hierarchy, eliminating the Level 2 (and Level 3) classifications that were used in 2023.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect in both quantitative and qualitative aspects. (1) Quantitative Accuracy: The numbers are completely wrong and misattributed. For 2023, the LLM claims Alabama Power had $443M in Level 2 domestic equity, but the truth is $396M in Level 1 and $169M in Level 2. Similarly, it claims Georgia Power had $321M in Level 2 in 2023, but the truth is $255M in Level 1 and $1M in Level 2. The LLM reverses the years and misclassifies the levels. It also invents Level 3 inputs ($208M for Alabama), which were not mentioned in the original answer for domestic equities. The $443M and $321M figures actually belong to 2024 Level 1 values, not 2023 Level 2 as claimed. (2) Completeness: The answer fails to report the correct allocations for 2023 and 2024, omits total amounts, and introduces non-existent shifts from Level 2/3 to Level 1, when in reality both companies already held significant Level 1 investments in 2023. (3) Entity Accuracy: While the company names (Alabama Power, Georgia Power) and topic (nuclear decommissioning trusts) are correct, the years, input levels, and financial figures are all mismatched. (4) Reasoning: The multi-hop synthesis is fundamentally flawed. The LLM incorrectly infers a shift from Level 2/3 to Level 1, but the ground truth shows both companies consistently used Level 1 and Level 2, with increases in Level 1 over time—not a reclassification. There is no evidence of moving from Level 2 to Level 1; rather, there was growth in Level 1 holdings. (5) Semantic Equivalence: The meaning is not preserved—this answer suggests a methodological reclassification occurred, while the truth reflects increased investment in more liquid (Level 1) assets, not a re-categorization of existing holdings. The conclusion about eliminating Level 2/3 is false. Only contextual relevance receives a moderate score because the answer addresses the general topic of input classification shifts in nuclear decommissioning trusts, albeit incorrectly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 537,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has NVIDIA's strategic positioning of CUDA evolved from 2022 to 2023 in terms of its role within the company's full-stack computing platform and its integration across different end markets?",
      "original_answer": "In 2022, CUDA was positioned as a fundamental building block of NVIDIA's accelerated computing platform, supporting a variety of end markets such as Gaming, Data Center, Professional Visualization, and Automotive through a unified underlying architecture. It was described as essential for leveraging GPU capabilities across these markets. By 2023, CUDA's role had evolved into being the foundational programming model within NVIDIA's full-stack computing infrastructure, extending its integration beyond traditional markets into domain-specific verticals such as healthcare, telecom, automotive, and manufacturing. Additionally, in 2023, CUDA was positioned as the base layer supporting hundreds of domain-specific software libraries, SDKs, and APIs, which were not explicitly emphasized in 2022. This indicates a strategic shift from CUDA being a foundational component to becoming the core enabler of a broader, more vertically integrated software stack aimed at accelerating deployment across computationally intensive workloads.",
      "llm_answer": "In the 2022 filing NVIDIA portrayed CUDA mainly as the “fundamental building block” that powers its GPU‑based solutions and fuels a ~3 million‑developer ecosystem across all of its end markets (data‑center, gaming, professional visualization and automotive). By the 2023 filing the company had elevated CUDA to the centerpiece of a **full‑stack computing platform**—the foundation on which it layers the CUDA‑X libraries, APIs, SDKs and AI‑Enterprise services—and explicitly ties it to both the Compute & Networking and Graphics segments, showing its deeper integration into every hardware‑software layer and across every market vertical.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of CUDA's strategic positioning from 2022 to 2023 as described in the ground truth. (1) It correctly identifies CUDA as a 'fundamental building block' in 2022 across end markets (Gaming, Data Center, Professional Visualization, Automotive), matching the original answer. In 2023, it accurately reflects the elevated role of CUDA as the foundation of a full-stack computing platform, integrated with CUDA-X libraries, APIs, SDKs, and AI-Enterprise services—consistent with the ground truth's emphasis on domain-specific software libraries and vertical integration. (2) The only quantitative element is the mention of a '~3 million-developer ecosystem', which is not present in the original answer; however, since this detail does not contradict the ground truth and may be derived from external but plausible context, it does not detract significantly from accuracy. All other factual elements (dates, entities, markets) are correct. (3) The multi-hop reasoning is sound: the model synthesizes the shift in CUDA’s role across two years, connects it to deeper integration across hardware-software layers and market verticals, and correctly infers strategic elevation. (4) The LLM omits explicit mention of new verticals like healthcare and manufacturing, which are cited in the original answer as expanded domains in 2023. This is a minor omission but doesn't undermine the overall correctness. Wording differs but maintains semantic equivalence. Thus, the answer is factually strong, contextually relevant, and well-reasoned, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 466,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did Pfizer's financial obligations and contractual relationships with Viatris evolve from 2022 to 2023, particularly in terms of transitional service agreements and net amounts owed?",
      "original_answer": "In 2022, Pfizer disclosed that amounts recorded under transitional service agreements (TSAs) and master services agreements (MSAs) with Viatris were not material to operations, and the TSA services were largely completed by the end of 2022. By 2023, services under the TSAs were fully completed as of December 31, 2023, and the net amounts due to Viatris under the agreements decreased from $94 million in 2022 to $33 million in 2023. This reflects a reduction in intercompany financial obligations and the winding down of transitional support following the 2020 spin-off of the Upjohn Business into Viatris.",
      "llm_answer": "By the end of 2022 Pfizer still owed Viatris $94 million under the suite of post‑spin‑off contracts (MSAs, agency arrangements and transitional‑service agreements) that were put in place after the Upjohn‑Mylan separation. By December 31 2023 that balance had fallen to $33 million, and the company notes that “services under the TSAs were largely completed as of December 31 2023.” Thus, the Viatris‑related obligations shrank dramatically and the transitional‑service agreements were essentially wound down between 2022 and 2023.【page_73】",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the net amounts owed to Viatris were $94 million in 2022 and decreased to $33 million in 2023, and TSA services were largely completed by December 31, 2023. These numbers match the original answer exactly, satisfying quantitative accuracy. (2) The dates (end of 2022 and December 31, 2023) are correctly cited. (3) The reasoning correctly infers that the decline in net amounts owed and completion of TSAs reflect the winding down of transitional support post-spin-off, which is consistent with the multi-hop synthesis required. (4) Minor difference: the original answer notes that TSA services were 'largely completed' by end of 2022 and 'fully completed' by end of 2023, while the LLM says 'largely completed as of December 31, 2023'—this slightly understates the finality ('fully completed') but does not materially misrepresent the situation. The LLM also groups MSAs and agency arrangements together accurately. Overall, the answer is factually sound, contextually relevant, and semantically equivalent to the ground truth, warranting a high correctness score with only a minor deduction in qualitative accuracy for the slight imprecision in describing the completion status.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 358,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the relationship between retail deregulation pressures and Duke Energy's environmental regulation compliance costs evolved from 2022 to 2023?",
      "original_answer": "In 2022, Duke Energy highlighted that retail deregulation could result in unrecovered costs, including those related to above-market purchased power commitments from qualifying facilities (QFs) under PURPA, which could hinder the recovery of environmental compliance costs through regulatory rate structures. By 2023, the company noted increased regulatory emphasis on environmental compliance, including EPA regulations on CO2 emissions and cooling water intake structures, as well as new state-level carbon reduction goals more aggressive than the company’s own plans. These developments suggest that deregulation pressures have compounded the challenge of recovering rising environmental compliance costs, as competitive market conditions limit the ability to pass on these expenses to customers.",
      "llm_answer": "In the 2022 Form 10‑K Duke Energy warned that retail‑deregulation legislation could leave it with stranded generation assets, lower margins and unrecovered costs, while noting that new environmental rules (e.g., CCR and EPA requirements) would raise operating and capital expenses but were not expected to have a material near‑term impact. In the 2023 filing the same deregulation risk is reiterated, but the discussion now ties it more closely to environmental‑compliance costs – emphasizing that the need to recover both stranded‑asset losses and higher CCR‑related expenses through rate cases could materially affect earnings and cash flow, showing a stronger, more‑interconnected concern about how deregulation pressure and environmental‑regulation costs together could hurt the company’s financial results.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the original ground truth. (1) All factual elements are correct: Duke Energy's 2022 concerns about retail deregulation leading to unrecovered costs (including environmental compliance and PURPA-related commitments) and rising environmental expenses (CCR, EPA rules) are accurately reflected. In 2023, the increased linkage between deregulation and environmental cost recovery is correctly emphasized. (2) There are no numeric values in the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) Multi-hop reasoning is sound: the LLM synthesizes information across two years and two regulatory domains (retail market structure and environmental compliance), correctly identifying the evolving interconnection between deregulation risks and cost recovery challenges. (4) The LLM slightly omits mention of specific 2023 EPA regulations on CO2 emissions and cooling water intake structures, and does not reference state-level carbon goals exceeding Duke’s plans—minor contextual omissions that reduce completeness slightly but do not undermine the core accurate synthesis. Wording differs but semantic meaning is equivalent. Contextual relevance is perfect—directly addresses the evolution of the relationship as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 362,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did the retail share of Skoal oral tobacco products change between 2023 and 2024, and how does this contrast with the pricing strategy applied to Skoal during 2023?",
      "original_answer": "The retail share of Skoal oral tobacco products decreased from 9.3% in 2023 to 7.6% in 2024, reflecting a decline in market presence. This contrasts with the pricing strategy in 2023, where multiple price increases were applied to Skoal products, including a $0.11 per can increase effective January 23, 2024 (announced in 2023), following earlier increases of $0.09, $0.09, and $0.08 per can in May, February, and January 2022, respectively. The cumulative effect of these increases may have impacted consumer demand, contributing to the drop in retail share.",
      "llm_answer": "The oral‑tobacco segment’s retail‑share data show Skoal fell from roughly 9.3 % of the market in 2023 to 7.6 % in 2024 – a decline of about 1.7 percentage points. In contrast, the 2023 pricing actions for Skoal were modestly upward: USSTC raised the list price on Skoal (along with Copenhagen and Red Seal) by $0.09 per can in August 2023 (and again by $0.09 per can on January 24 2023). Thus, while Skoal’s market share slipped, the company was still pursuing a small price increase during 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM correctly identifies the decline in Skoal's retail share from 9.3% in 2023 to 7.6% in 2024, which matches the ground truth. However, it misrepresents the 2023 pricing strategy. The LLM states that there was a $0.09 increase in August 2023 and another $0.09 increase on January 24, 2023 — but the latter date is in 2023, not 2024, and contradicts the timeline. More critically, the ground truth specifies that the $0.11 price increase (effective January 23, 2024) was announced in 2023 and was part of a series of prior increases in 2022, not 2023. The LLM omits the $0.11 increase and incorrectly places two $0.09 increases in 2023, one of which is backdated (January 24, 2023), while the actual 2022 increases were $0.09, $0.09, and $0.08. 2) Quantitative accuracy is compromised: while the market share numbers (9.3% to 7.6%) are correct, the price increase amounts and timing are wrong. The LLM invents two $0.09 increases in 2023, whereas the only 2023-relevant action was the announcement of the $0.11 increase effective in January 2024. The prior increases occurred in 2022, not 2023. 3) The multi-hop reasoning is partially sound — the model connects pricing and market share trends — but fails to accurately synthesize the correct timeline and magnitude of price changes. It incorrectly implies that only minor price increases occurred in 2023, missing the significance of the announced $0.11 hike and the cumulative effect of earlier increases. 4) Contextual relevance is high — the answer addresses both parts of the question (market share change and pricing strategy) and attempts to contrast them. However, due to factual inaccuracies in the pricing details, the conclusion that the company pursued only 'small price increases' during 2023 is misleading, as the announced $0.11 increase (though effective in 2024) was a major action taken in 2023. Thus, the correctness score is reduced to 6 due to significant quantitative and qualitative errors in the pricing strategy description, despite correct market share data and reasonable structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 552,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did Amgen's investment in 'Other short-term interest-bearing securities' evolve between 2023 and 2024, and what does this indicate about the company's short-term investment strategy?",
      "original_answer": "Amgen's investment in 'Other short-term interest-bearing securities' remained unchanged at $138 million in both 2023 and 2024. This stability suggests that the company maintained a consistent approach to this segment of its short-term investment portfolio over the two-year period.",
      "llm_answer": "Amgen’s “other short‑term interest‑bearing securities” fell slightly, from **$138 million at year‑end 2023 to $135 million at year‑end 2024** (a $3 million decrease). The near‑flat level shows the company is keeping a modest, stable pool of short‑term, high‑liquidity assets, consistent with its stated policy of preserving principal safety and maintaining ample cash resources rather than actively expanding or contracting this segment of its investment portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that Amgen's investment in 'Other short-term interest-bearing securities' decreased from $138 million in 2023 to $135 million in 2024. The ground truth confirms the amount remained unchanged at $138 million in both years. This is a critical factual error affecting the core of the response. (2) The quantitative inaccuracy is significant: the $3 million decrease is entirely fabricated, and the calculation (implied or explicit) is incorrect. While the initial value ($138 million) is correct for 2023, the 2024 figure is wrong. (3) The reasoning about Amgen maintaining a stable, modest pool of short-term assets aligns conceptually with the ground truth's interpretation of consistency in strategy, so the qualitative logic is partially sound. However, it is based on false numerical premises, undermining the validity of the conclusion. The multi-hop synthesis is minimal here (only two time points for one company), but the model fails at accurately retrieving and comparing the two values. (4) The correctness score is low (3) due to the major factual error in financial figures. Quantitative accuracy is severely lacking (2). Qualitative accuracy is slightly higher (4) because the general interpretation of a stable strategy is directionally reasonable, though not fully supported by the incorrect data. Contextual relevance is acceptable (7) as the answer addresses the right metric, company, and time frame, and attempts to interpret strategic implications appropriately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1196,
        "completion_tokens": 421,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the nature of General Dynamics' involvement in Abrams Main Battle Tank Upgrades evolved from 2022 to 2024, particularly in terms of contract scope and value?",
      "original_answer": "In 2022, General Dynamics received a $360 million contract from the Army for Abrams main battle tank upgrades, mission control units, and systems technical support. By 2024, the company's involvement had evolved to include both production and support services, as evidenced by a $350 million contract for Abrams upgrades, engineering and logistics support, and system and sustainment technical support services. Additionally, a separate $285 million contract was awarded for producing Abrams tanks in the SEPv3 configuration for Romania. This indicates a shift from primarily upgrade-focused contracts to a broader scope that includes both upgrades and production of new configurations, with an increase in total contract value.",
      "llm_answer": "In the 2022 filing GD reported a **$360 million Army award** that was limited to “Abrams main‑battle‑tank upgrades, mission‑control units and systems technical support,” and a separate **$350 million award** for “Abrams upgrades, engineering and logistics support services and system‑sustainment technical support.” By the 2024 filing the only Abrams‑related award listed is a **$350 million contract** that emphasizes **engineering, logistics and sustain‑ment services** rather than the earlier focus on hardware upgrades and mission‑control units. Thus, the scope has broadened from primarily upgrade‑and‑hardware work to a more comprehensive life‑cycle support role, while the contract value has stayed roughly the same (around $350‑$360 million).",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. It incorrectly states that in 2022, General Dynamics received two contracts: one for $360 million and another for $350 million. However, the ground truth only confirms a single $360 million contract in 2022; the $350 million contract is from 2024, not 2022. This misattribution of timing and duplication of contracts is a significant factual error. Additionally, the LLM answer fails to mention the separate $285 million contract awarded in 2024 for producing Abrams tanks in the SEPv3 configuration for Romania, which is a key part of the evolution in contract scope and value. (2) Quantitatively, the $360 million and $350 million figures are accurate but misassigned to the wrong years. The $285 million contract is entirely omitted, leading to an incomplete and misleading picture of total contract value evolution. The conclusion that 'contract value has stayed roughly the same' is incorrect, as the total value of contracts in 2024 ($350M + $285M = $635M) represents a significant increase over the 2022 $360M contract. (3) The reasoning is partially sound in identifying a shift toward broader support services, but it fails the multi-hop synthesis by not connecting the 2024 production contract with Romania, which indicates expansion into new production, not just sustainment. The omission of this key contract undermines the conclusion about scope evolution. (4) Despite these errors, the answer is contextually relevant and correctly interprets the qualitative shift toward life-cycle support. However, due to major factual and quantitative errors—especially the misattribution of contracts and omission of a major award—the correctness score is limited to 5, reflecting partial accuracy with significant gaps.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 484,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did AIG's financial relationship with Corebridge evolve from 2023 to 2024, particularly in terms of borrowing arrangements and income recognition?",
      "original_answer": "In 2023, AIG disclosed that Corebridge had the ability to continue borrowing through February 25, 2025, indicating an ongoing financial arrangement. By 2024, AIG's relationship with Corebridge had transformed, as AIG began recognizing equity method income tied to Corebridge’s stock price changes and dividends received since June 9, 2024. This shift reflects a change from a borrowing-based relationship to one focused on equity-based returns.",
      "llm_answer": "- **Borrowing arrangements:** In 2023 Corebridge’s debt was shown on AIG’s balance sheet, including a $1.5 billion “DDTL facility” that was not guaranteed by AIG and was reduced by $1.25 billion of repayments, leaving a $250 million balance (page 112). The 2024 debt‑maturity table shows that the remaining $250 million of the DDTL facility is scheduled to mature in the first quarter of 2024, and a note says Corebridge can continue borrowing under the facility through Feb 25 2025 (page 113).\n\n- **Income recognition:** In 2023 Corebridge’s results were reported as discontinued operations, giving AIG a net income of $902 million attributable to AIG for that year (page 110). After the June 9 2024 de‑consolidation, Corebridge is treated as an equity‑method investment; AIG now records dividends and changes in Corebridge’s stock price as equity‑method income (about $601 million for the June‑Dec 2024 period) and reflects Corebridge’s pre‑tax earnings in net investment income, while also recognizing a $4.8 billion loss from the de‑consolidation (pages 108‑109).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution of AIG's financial relationship with Corebridge from 2023 to 2024, focusing on borrowing arrangements and income recognition. (2) Quantitatively, all key numbers are correct: the $1.5 billion DDTL facility, $1.25 billion repayment, $250 million remaining balance, maturity in Q1 2024, borrowing availability through February 25, 2025, de-consolidation date of June 9, 2024, $601 million equity-method income for June–Dec 2024, and the $4.8 billion de-consolidation loss. These figures match or are consistent with the disclosed data. The only minor omission is that the original answer does not mention the $4.8 billion loss or the $902 million discontinued operations figure—so while the LLM adds detail beyond the ground truth, it does not contradict it. (3) The reasoning is sound: it correctly identifies the shift from a borrowing-based relationship (with on-balance-sheet debt) to an equity-method investment post-deconsolidation, which marks a fundamental change in accounting and financial relationship. The multi-hop synthesis—linking the 2023 borrowing structure to the 2024 equity income treatment—is well executed. (4) The LLM provides more granular detail than the original answer, enhancing completeness without introducing errors. The only reason for not scoring a 10 is that the original answer emphasizes the forward-looking borrowing ability through 2025 as a key point, while the LLM notes the $250M matures in Q1 2024 but can still be borrowed against through 2025—this nuance is handled correctly, but slightly more complexity than necessary may distract from the core evolution. Overall, the answer is factually excellent, contextually relevant, and semantically equivalent with added precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 494,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2022, Tesla was actively selling the Solar Roof and improving installation efficiency through collaboration with real estate developers and builders. The company emphasized its engineering efforts to combine aesthetics, durability, and power generation. By 2024, however, Tesla's 10-K highlights that the future of the Solar Roof (alongside other products) 'depends in large part' on overcoming production ramp challenges, including bottlenecks, supplier risks, and cost control. This reflects a shift from product development and sales emphasis to a more complex production and dependency landscape.",
      "llm_answer": "In the 2022 Form 10‑K Tesla described the Solar Roof as a product it designs and manufactures in‑house and said it was “continuing to improve our installation capability and efficiency, including through collaboration with real‑estate developers and builders” (2022 p. 6). By the 2024 filing the company was flagging that the Solar Roof’s “ramp[ing] production” has been subject to “delays” and that its rollout now depends on the same supply‑chain, component‑supplier and manufacturing‑capacity constraints that affect its other energy‑generation products (2024 p. 17). Thus, Tesla’s approach shifted from emphasizing design and installation improvements to acknowledging production‑ramp challenges and a strategic reliance on external suppliers and scalable manufacturing infrastructure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Tesla's evolving approach to the Solar Roof between 2022 and 2024: in 2022, the focus was on in-house design, manufacturing, and improving installation efficiency through collaboration with developers and builders—directly citing the 2022 10-K (p. 6). By 2024, the emphasis shifted to production ramp challenges, including delays, supply-chain constraints, supplier risks, and manufacturing capacity—accurately reflecting the 2024 10-K (p. 17). (2) There are no numerical values (e.g., dollar amounts, percentages, units) in either the original or LLM answer, so quantitative accuracy is not applicable in that sense, but all referenced years (2022, 2024) and document locations (page numbers) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two different years of Tesla’s 10-K filings, correctly identifying a strategic shift from installation and design focus to production and supply-chain dependencies. The use of direct quotes strengthens accuracy. (4) The LLM captures the core evolution described in the ground truth—shifting from product development and sales emphasis to grappling with production bottlenecks and external dependencies. The only minor shortcoming is that it does not explicitly mention 'cost control' as a challenge noted in the original answer, which slightly reduces qualitative accuracy. However, 'manufacturing-capacity constraints' and 'component-supplier' issues imply cost-related pressures. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 457,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the retail share of Skoal in the U.S. oral tobacco market changed between 2023 and 2024, and what does this indicate about its competitive positioning?",
      "original_answer": "In 2023, Skoal held a 9.3% retail share in the U.S. oral tobacco market, which decreased to 7.6% in 2024. This decline indicates a weakening in Skoal's competitive positioning within the oral tobacco segment over this period. The drop in market share for Skoal contrasts with the growth seen in other products like on!, which increased from 6.8% to 8.3% during the same timeframe.",
      "llm_answer": "Skoal’s retail share fell from 9.3 % of the U.S. oral‑tobacco market in 2023 to 7.6 % in 2024 – a decline of about 1.7 percentage points (≈18 % relative drop)【page_48】. This drop signals that Skoal is losing ground to competing brands (e.g., Copenhagen and the fast‑growing on! nicotine‑pouch line), indicating a weakening competitive position within the oral‑tobacco category.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports Skoal's retail share in 2023 (9.3%) and 2024 (7.6%), matching the ground truth exactly. The absolute decline of 1.7 percentage points is accurately calculated, and the relative drop of approximately 18% is a correct derivation ((1.7 / 9.3) ≈ 18.3%), so all quantitative elements are precise. 2) The answer addresses both parts of the question: the change in market share and its implication for competitive positioning. It correctly infers that the decline indicates weakening competitiveness, aligning with the ground truth. 3) The entities mentioned—Skoal, on! (as a growing competitor), and Copenhagen—are consistent with known competitive dynamics in the oral tobacco market. While the ground truth specifically highlights on!'s growth (6.8% to 8.3%), the LLM answer references on! as a fast-growing brand, which is contextually accurate and supports the reasoning. However, the ground truth does not mention Copenhagen’s market share trend, so including it as a direct cause introduces a minor unsupported inference, slightly reducing qualitative accuracy. 4) The multi-hop reasoning is sound: the model synthesizes year-over-year share data, computes the change, and draws a valid conclusion about competitive positioning. The contrast with on! is implied rather than explicitly quantified, but the overall logic and semantic meaning match the original answer closely. Minor deduction from qualitative accuracy due to the addition of Copenhagen without explicit support in the ground truth, but not enough to affect overall correctness significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1192,
        "completion_tokens": 434,
        "total_tokens": 1627
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the risk associated with the concentration of device share among premium tier companies evolved between 2023 and 2024, particularly in terms of its potential impact on Qualcomm's pricing power and revenue stability?",
      "original_answer": "In 2023, Qualcomm highlighted that the concentration of device share among a few premium tier companies was contributing to a trend of deriving a significant portion of revenues from a small number of customers, particularly Chinese OEMs. This concentration was noted to potentially result in lower prices for Qualcomm's products due to the purchasing power of these companies. In 2024, the risk factor remained present, but the emphasis shifted slightly to underscore the broader implications of this concentration, including the potential for even greater pricing pressure and revenue fluctuation due to the timing and success of customer product introductions. The continued reliance on a small group of customers, especially those developing their own integrated circuits or using competitors, suggests that the risk has not only persisted but potentially intensified, increasing its impact on Qualcomm's pricing power and revenue stability.",
      "llm_answer": "Qualcomm’s 2023 filing warned that a “small number of customers and licensees…particularly at the premium‑tier” accounted for a large share of its revenue, but it stopped short of linking that concentration directly to pricing pressure. In the 2024 filing the risk language is sharpened – the company now says the “concentration of device share among a few premium‑tier companies…gives those customers greater purchasing power and may force Qualcomm to lower product prices, creating more volatile and potentially lower revenue and margin streams.” Thus, between 2023 and 2024 the risk has been portrayed as more acute, with a clearer threat to Qualcomm’s pricing power and revenue stability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original (ground truth) answer. (1) It correctly identifies that in 2023, Qualcomm noted revenue concentration among a small number of premium-tier customers, particularly Chinese OEMs, though the original answer emphasizes the link to pricing power more implicitly than the LLM suggests ('stopped short of linking' is slightly off—ground truth confirms the link was present). In 2024, the LLM accurately captures the sharpened risk language regarding greater purchasing power, pricing pressure, and revenue volatility. (2) There are no numeric values to verify (dates 2023 and 2024 are correct), so quantitative accuracy is perfect. (3) The multi-hop reasoning—comparing risk disclosures across two years and inferring increased severity—is sound and well-executed. The LLM correctly synthesizes the evolution in tone and implication. (4) The only minor shortcoming is that the LLM slightly understates the 2023 pricing power concern; the original answer confirms that pricing pressure was already noted in 2023, not just implied. Thus, the LLM's claim that 2023 'stopped short' is a small mischaracterization, but the overall trajectory and conclusion are correct. Hence, high scores across the board with a 9 on correctness and qualitative accuracy due to this nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 369,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "Given Amgen's approach to managing short-term liquidity, how did its allocation to money market mutual funds evolve between 2023 and 2024?",
      "original_answer": "Amgen's allocation to money market mutual funds remained unchanged at $10,266 million in both 2023 and 2024. The disclosed investment values for money market mutual funds under available-for-sale investments were identical in both years, indicating no shift in this portion of the company's short-term investment strategy.",
      "llm_answer": "Amgen’s short‑term liquidity strategy kept the bulk of its cash in money‑market mutual funds. The fair‑value balance of those funds grew from $10,266 million at year‑end 2023 to $10,354 million at year‑end 2024—an increase of roughly $88 million.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that Amgen's allocation to money market mutual funds increased from $10,266 million in 2023 to $10,354 million in 2024. The ground truth confirms that the allocation remained unchanged at $10,266 million in both years. This is a critical error in quantitative accuracy. (2) The reported increase of $88 million ($10,354M - $10,266M) is therefore also incorrect, as there was no change. The numbers cited in the LLM answer do not match the disclosed values in the source data. (3) While the LLM correctly identifies the relevance of money market mutual funds to Amgen's short-term liquidity strategy, it fails in the multi-hop reasoning required to compare the two years' investment values accurately. The model incorrectly infers a change where none exists, undermining the core of the answer. (4) Despite the incorrect numbers, the response is contextually relevant—addressing Amgen, short-term liquidity, money market funds, and the 2023–2024 timeframe—and uses appropriate financial terminology. Hence, contextual relevance is high, but correctness and quantitative accuracy are severely compromised due to the false claim of growth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1140,
        "completion_tokens": 338,
        "total_tokens": 1478
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has General Dynamics' participation in the Capital Construction Fund evolved between 2022 and 2024, particularly in terms of the amount of U.S. government accounts receivable pledged to the fund?",
      "original_answer": "In 2022, General Dynamics had U.S. government accounts receivable pledged to the Capital Construction Fund (CCF) of $295 million as of December 31, 2021. By 2024, the amounts pledged to the CCF had increased to $315 million on December 31, 2023, and $333 million on December 31, 2024. This indicates a steady increase in GD's participation in the CCF over the period, reflecting a growing utilization of the tax deferral benefits offered by the program.",
      "llm_answer": "General Dynamics’ participation in the U.S. government‑run Capital Construction Fund has been growing. The company reported that the amount of U.S. government accounts receivable pledged (and therefore deposited) to the fund was about **$295 million** in the most recent year covered by the 2022 filing, rose to **$315 million** in 2023, and increased further to **$333 million** at year‑end 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key figures: $295 million (as of end of 2021, reported in 2022 filing), $315 million (as of end of 2023), and $333 million (as of end of 2024). These match the ground truth exactly in amount and timing. (2) All numeric values are accurate and properly attributed to the correct years. The phrasing 'most recent year covered by the 2022 filing' correctly refers to data from December 31, 2021, which is standard in annual reporting and aligns with the original answer. (3) The reasoning is sound: the LLM correctly infers a growing trend in General Dynamics' participation in the CCF based on increasing pledged receivables over time. It synthesizes data across multiple years and filings, demonstrating effective multi-hop understanding. (4) The only minor shortcoming is that the LLM does not explicitly mention the tax deferral benefit context, which is included in the original answer and adds qualitative insight into why the increase matters. However, the core facts, numbers, and trend interpretation are fully correct. Wording differs slightly but maintains semantic equivalence. Thus, high scores across all categories with a 9 on correctness due to the omission of the tax benefit rationale.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 352,
        "total_tokens": 1578
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of its tax implications and investment income following the IPO and subsequent deconsolidation?",
      "original_answer": "In 2023, AIG's ownership in Corebridge dropped below 80% after Corebridge's IPO on September 19, 2022, resulting in the tax deconsolidation of Corebridge from AIG’s U.S. federal income tax group. This deconsolidation had significant tax implications, including restrictions on future consolidated tax filings for five years and the retention of Corebridge's net operating losses and tax credit carryforwards by Corebridge entities. By 2024, AIG no longer consolidated Corebridge's financials, and instead, AIG reported its investment in Corebridge under the equity method, recognizing $X in equity method income for the period from June 10, 2024, to December 31, 2024, based on dividends received and changes in Corebridge's stock price. This marks a shift from a consolidated tax and financial reporting relationship to a more arms-length investment relationship.",
      "llm_answer": "In 2023, after Corebridge’s 2022 IPO AIG’s ownership fell below the 80 % threshold, triggering a tax‑deconsolidation that left Corebridge’s net‑operating‑loss and tax‑credit carryforwards in a separate U.S. tax group (unavailable to AIG) and the company continued to report Corebridge‑related earnings as part of its consolidated net investment income (about $3.4 bn for 2023). In 2024, when AIG formally de‑consolidated Corebridge on June 9 2024, it recorded an after‑tax loss of $4.75 bn (including a $545 m tax expense on the gain portion), and re‑classified its remaining 48.4 % stake as an equity‑method investment that generated $601 m of equity‑method income (and $1.574 bn of Corebridge pre‑tax earnings) which now flow into AIG’s net investment income.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution of AIG's financial relationship with Corebridge, including tax deconsolidation due to ownership falling below 80% post-IPO and the shift to equity method accounting in 2024. However, there are key quantitative inaccuracies. The original answer states that equity method income was reported for the period June 10, 2024, to December 31, 2024, but does not specify the amount as $601M or link it to $1.574B in pre-tax earnings—these figures are absent from the ground truth and appear to be fabricated or misattributed. Similarly, the $4.75B after-tax loss and $545M tax expense are not mentioned in the original answer, making them unsupported. The $3.4B consolidated net investment income for 2023 is also not in the ground truth and cannot be verified. (2) Dates are mostly correct: Corebridge IPO was September 19, 2022 (implied correctly), and deconsolidation is cited as June 9, 2024, close to the June 10, 2024 start date in the original. However, the exact numbers like 48.4% stake and specific dollar figures lack support in the ground truth. (3) The multi-hop reasoning is sound—LLM correctly infers that falling below 80% triggers tax deconsolidation, that NOLs remain with Corebridge, and that AIG shifts from consolidation to equity method. It also correctly identifies the change in financial reporting treatment. (4) Despite strong qualitative reasoning and contextual relevance, the inclusion of unsupported numerical values significantly reduces quantitative accuracy. The answer goes beyond the original by adding precise figures not present in the ground truth, which harms factual correctness. Hence, correctness score is 7—core facts are right, but key numbers are unverified or incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 480,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Tesla's approach to Solar Roof production and its dependencies evolved from 2022 to 2024, particularly in terms of operational strategy and supply chain challenges?",
      "original_answer": "In 2022, Tesla emphasized improving Solar Roof installation capabilities by onboarding and training new installers and collaborating with real estate developers to reduce installation time and costs. The company also highlighted the need to maintain adequate battery cell supply and hire additional skilled electricians to support the ramp. By 2024, Tesla's focus had shifted to broader manufacturing and supply chain risks, with Solar Roof production now described as being dependent on the company's ability to manage global component procurement, avoid bottlenecks, and maintain cost-effective production amid potential supplier failures and inflationary pressures. The evolution reflects a shift from localized installer development to systemic supply chain and production scalability concerns.",
      "llm_answer": "In the 2022 filing Tesla described Solar Roof as still in an early‑ramp phase, emphasizing a “low‑cost and simplified online ordering experience,” the onboarding and training of new installers, collaboration with builders to cut installation time and cost, and the need to secure enough battery‑cell supply and skilled electricians to support the rollout (see 2022 Energy Generation and Storage Demand, Production and Deployment). By the 2024 filing the company acknowledges that those early‑ramp challenges have materialized – it notes “delays … in ramping the production of … Solar Roof” and now stresses scaling installer training, tighter coordination with real‑estate partners, and the broader supply‑chain risks (supplier reliability, component shortages, raw‑material volatility) that could limit cell and component availability for Solar Roof (see 2024 Risk Factors and the 2024 Energy Generation and Storage Demand section).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Tesla's 2022 focus on installer training, collaboration with builders, battery cell supply, and skilled electricians is accurately reported. The 2024 shift toward systemic supply chain risks—such as supplier reliability, component shortages, and raw material volatility—is also correctly described. (2) There are no numeric values (e.g., dollar amounts, percentages, quantities) in either the question or the original answer, so quantitative accuracy is not compromised; dates (2022 and 2024) are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years and different sections of Tesla’s filings (e.g., Energy Generation and Storage Demand, Risk Factors), correctly identifying the evolution from early-ramp operational challenges to broader supply chain dependencies. The mention of 'delays in ramping production' in 2024 adds contextual detail consistent with the original answer’s implication of ongoing challenges. (4) The only minor gap is that the LLM answer does not explicitly frame the evolution as a shift from 'localized installer development' to 'systemic supply chain and production scalability concerns'—a synthesis emphasized in the original answer—but this conceptual framing is implied through the contrast presented. Wording differs slightly but maintains semantic equivalence. Overall, the answer is factually complete, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 426,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Duke Energy's estimated total cost to permanently close all coal ash basins in North Carolina and South Carolina evolved from 2022 to 2023, and what does this indicate about the company's progress under the Coal Ash Act?",
      "original_answer": "In 2022, Duke Energy estimated the total cost to permanently close all coal ash basins in North Carolina and South Carolina to be approximately $8 billion to $9 billion. By 2023, this estimate had decreased to approximately $7 billion to $8 billion, indicating a downward adjustment in projected costs. Additionally, the amount already spent on these closures increased from approximately $3.1 billion through 2021 (as reported in 2022) to approximately $4 billion through 2023. This evolution suggests that Duke Energy has made measurable progress in implementing closure plans under the Coal Ash Act, with more basins excavated and cost estimates refined over time.",
      "llm_answer": "- **2022 filing:** Duke Energy said the total undiscounted cost to permanently close all coal‑ash basins in North Carolina and South Carolina was **about $8 billion to $9 billion**, and that **≈ $3.1 billion** had been spent to date (through 2021) 【page_71】.  \n\n- **2023 filing:** The company’s later estimate fell to **about $7 billion to $8 billion**, with **≈ $4 billion** already incurred through 2023 【page_69】.  \n\n**What this shows:** The overall cost outlook has been trimmed slightly while the amount already invested has risen, indicating that Duke Energy is making measurable progress in excavating and closing the ash basins required under the Coal Ash Act.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the 2022 cost estimate of $8 billion to $9 billion and $3.1 billion spent through 2021 are correctly reported, as is the 2023 revised estimate of $7 billion to $8 billion and $4 billion spent through 2023. Minor formatting variations (≈, 'about') are acceptable and do not affect meaning. (2) The answer is complete, addressing both the evolution of cost estimates and the implications for progress under the Coal Ash Act. (3) Entities—Duke Energy, coal ash basins, North Carolina and South Carolina, and the relevant years—are correctly identified. (4) The reasoning is sound: the downward revision in total projected costs combined with increased spending indicates progress in basin closures, reflecting refined estimates and execution under the Coal Ash Act. The multi-hop synthesis across 2022 and 2023 filings is accurate and logically interpreted. Semantic equivalence is maintained throughout.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 293,
        "total_tokens": 1647
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did the retail share of the 'on!' oral tobacco product evolved between 2023 and 2024, and what does this indicate about its market position relative to the overall oral tobacco product segment during this period?",
      "original_answer": "The retail share of the 'on!' oral tobacco product increased from 6.8% in 2023 to 8.3% in 2024. This indicates that 'on!' gained market share during this period. In contrast, the total oral tobacco product segment saw a decline in retail share, dropping from 42.5% in 2023 to 37.5% in 2024. This divergence suggests that 'on!' strengthened its position within the broader oral tobacco market between these years.",
      "llm_answer": "The retail‑share table for the oral‑tobacco segment shows that **on! grew from 6.8 % in 2023 to 8.3 % in 2024** (a 1.5‑percentage‑point increase). During the same period the segment’s total retail share fell from 42.5 % to 37.5 %, so on!’s rise indicates it is gaining market traction and improving its position relative to the overall oral‑tobacco product category, which was losing share overall.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: 'on!' retail share increased from 6.8% in 2023 to 8.3% in 2024, and the total oral tobacco segment's retail share declined from 42.5% to 37.5%, as confirmed in both answers. The 1.5-percentage-point increase is correctly calculated (8.3 - 6.8 = 1.5). (2) The answer is complete, addressing both parts of the question: the evolution of 'on!'s retail share and its market position relative to the overall segment. (3) Entity accuracy is perfect: the product name 'on!' is correctly identified, and the time frame (2023 to 2024) and metric (retail share) are accurate. (4) The reasoning is sound and reflects proper multi-hop synthesis: the model correctly infers that 'on!' is gaining market traction even as the broader segment declines, indicating relative strength. The conclusion that 'on!' improved its position is logically supported and semantically equivalent to the original answer. Minor wording differences (e.g., 'gaining market traction' vs. 'gained market share') do not affect factual equivalence. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 331,
        "total_tokens": 1551
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Qualcomm's reliance on Chinese OEMs for revenue evolved from 2023 to 2024, and what implications does this have for its business stability?",
      "original_answer": "In 2023, Qualcomm derived a significant portion of its revenues from a small number of Chinese OEMs, highlighting its dependency on their device share growth in China and other regions. By 2024, this dependency persisted, with the company continuing to emphasize that it derives a significant portion of its revenues from these same OEMs. This ongoing reliance indicates that any political, economic, or market shifts affecting Chinese OEMs could continue to pose a risk to Qualcomm's revenue stability, particularly given the persistent U.S./China trade and national security tensions mentioned in both filings.",
      "llm_answer": "Qualcomm’s 2024 filing still stresses that a “significant portion of our revenues … comes from Chinese OEMs,” noting that many of those OEMs have been gaining device share and that the company now expects no further product revenue from Huawei after the May 2024 export‑license revocation (about $560 million of FY‑2024 revenue was lost). The 2023 filing made the same concentration point but did not yet reflect the Huawei loss, indicating that the company’s overall reliance on Chinese OEMs has persisted while the composition of that exposure has shifted. Because a large share of sales is tied to a few Chinese manufacturers, any further vertical integration, government restrictions or loss of a major OEM (as with Huawei) could materially destabilize Qualcomm’s revenue and cash‑flow outlook.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that Qualcomm continued to derive a significant portion of its revenue from Chinese OEMs in both 2023 and 2024, which matches the original answer's core claim. (2) The LLM introduces specific new information—the May 2024 export license revocation affecting Huawei and the loss of $560 million in FY-2024 revenue—which is consistent with external knowledge and adds precision not present in the original answer but does not contradict it. This detail enhances the response by explaining a key shift in the composition of Qualcomm’s exposure. The dollar amount ($560 million) and timing (May 2024) are plausibly accurate based on public filings and news, and while not explicitly in the ground truth, they do not violate it. (3) The reasoning is sound: the LLM correctly infers that while overall reliance persists, the composition has changed due to Huawei’s exclusion, demonstrating strong multi-hop synthesis across time and entities (Qualcomm, Chinese OEMs, Huawei, U.S. export policy). (4) The implications for business stability—risk from government restrictions, loss of major OEMs, or vertical integration—are logically derived and match the original answer’s concern about political, economic, and market risks. The only reason for not scoring a 10 is that the original answer does not mention Huawei or the $560M loss, so including it introduces a detail beyond the provided ground truth, which could be seen as an unsupported addition if strictly confined to the knowledge graph. However, since it is factually correct and improves contextual understanding, it does not warrant a major deduction. All entities (Qualcomm, Chinese OEMs, Huawei), years (2023, 2024), and financial impacts are accurately represented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 492,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did Amgen's composition of total available-for-sale investments evolve between 2022 and 2023, particularly in terms of specific security types held?",
      "original_answer": "In 2022, Amgen reported total available-for-sale investments of $4,335 million, which included $1,676 million in marketable securities alongside $2,659 million in cash and cash equivalents. By 2023, Amgen no longer held any marketable securities or U.S. Treasury bills, and instead, the entire $10,404 million in total available-for-sale investments was composed of $10,266 million in money market mutual funds and $138 million in other short-term interest-bearing securities. This reflects a strategic shift toward more liquid and short-term interest-bearing instruments.",
      "llm_answer": "In 2022 Amgen’s available‑for‑sale portfolio was $4.3 billion and was split between U.S. Treasury bills ($1.7 billion) and money‑market mutual funds ($2.7 billion), with no “other short‑term” securities. By 2023 the composition had shifted dramatically: Treasury bills were eliminated, money‑market mutual funds rose to $10.3 billion, and a modest $138 million of other short‑term interest‑bearing securities was added, lifting total available‑for‑sale investments to $10.4 billion.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the composition of Amgen's 2022 available-for-sale investments. According to the ground truth, in 2022, Amgen held $1,676 million in marketable securities and $2,659 million in cash and cash equivalents (totaling $4,335 million), not U.S. Treasury bills and money market mutual funds as stated. The LLM incorrectly assigns $1.7 billion to Treasury bills and $2.7 billion to money-market mutual funds in 2022, which contradicts the original data—Amgen did not report holding money market mutual funds in 2022, and the $2.659 billion was in cash and cash equivalents, not money-market funds. In 2023, the LLM correctly reports $10.3 billion in money-market mutual funds (close to the exact $10,266 million) and $138 million in other short-term interest-bearing securities, with a total of $10.4 billion (vs. $10,404 million), which is acceptably accurate. (2) Calculations: The 2023 total is approximately correct ($10,266M + $138M = $10,404M), but the 2022 breakdown is wrong—$1.7B + $2.7B = $4.4B, which is close in total but misrepresents the components. More critically, the components themselves are factually incorrect. (3) Multi-hop reasoning: The model attempts to show evolution between years and identifies the elimination of Treasury bills and growth in money-market funds, but it fabricates the 2022 composition. The strategic shift toward more liquid instruments is implied, but the reasoning is based on incorrect premises. (4) Scores justified: Correctness is low (4) due to core factual errors in 2022 composition; quantitative accuracy is poor because the security types and amounts for 2022 are wrong; qualitative accuracy is moderate as the direction of change and 2023 data are partially correct; contextual relevance is high because the answer addresses the evolution and composition as asked, despite factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 516,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the presence of Shake Shack as a tenant evolved across SPG's premium outlet properties between 2022 and 2023?",
      "original_answer": "In 2022, Shake Shack was listed as a tenant at Woodbury Common Premium Outlets in New York. By 2023, Shake Shack not only remained at Woodbury Common but also expanded its presence to Las Vegas Outlets North Premium in Nevada. This indicates a strategic expansion of Shake Shack’s footprint within SPG's portfolio of properties over the two years.",
      "llm_answer": "In the 2022 Form 10‑K, Shake Shack is listed as a tenant at Woodbury Common Premium Outlets (the only premium‑outlet location where it appears). In the 2023 Form 10‑K, Shake Shack does not appear in any of the premium‑outlet tenant tables, indicating that the brand is no longer present in SPG’s premium‑outlet portfolio.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is completely incorrect and contradicts the ground truth. (1) According to the original answer, Shake Shack was present at Woodbury Common Premium Outlets in 2022 and expanded to Las Vegas Outlets North Premium in 2023, indicating growth in SPG's portfolio. However, the LLM claims that Shake Shack disappeared from all premium outlet tenant tables in 2023 and is no longer present, which is factually wrong. (2) There are no numeric values in this question, but the temporal and presence/absence assertions (2022 vs 2023) are critical and incorrectly reported. The LLM misidentifies the tenant presence data across years, failing basic factual accuracy. (3) The multi-hop reasoning required—comparing Shake Shack's presence across SPG's premium outlets between two years—is fundamentally flawed. The model fails to recognize the expansion and instead infers disappearance, showing incorrect synthesis of information across the two 10-K filings. (4) Contextual relevance is slightly maintained because the answer discusses the correct companies (Shake Shack, SPG), property types (premium outlets), and time frame (2022–2023), but the conclusion is diametrically opposed to the truth. Thus, while the context is relevant, the factual and qualitative accuracy is extremely low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1159,
        "completion_tokens": 358,
        "total_tokens": 1518
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the classification of retirement annuity contracts within the fair value hierarchy evolve between 2022 and 2024, and what does this indicate about GD's valuation methodology for these assets?",
      "original_answer": "In 2022, retirement annuity contracts were part of Level 3 assets, indicating that their fair value was determined using unobservable inputs. By 2024, these contracts remained in Level 3, but the disclosure noted that investments valued using net asset value (NAV) as a practical expedient were now included in the tables for reconciliation to total plan assets, which was not explicitly stated in 2022. This suggests a refinement in disclosure practices rather than a change in hierarchy classification, indicating that while the valuation methodology remained complex and less observable, GD improved transparency in how these assets are reported.",
      "llm_answer": "In the 2022 filing, retirement‑annuity contracts were reported as Level 3 assets (significant unobservable inputs) with a fair‑value balance of $35 million. The 2024 filing still places these contracts in Level 3 (fair‑value balance $22 million), showing no change in classification. This consistency indicates that General Dynamics continues to value retirement‑annuity contracts using internal, unobservable assumptions rather than observable market inputs.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that retirement annuity contracts remained in Level 3 of the fair value hierarchy from 2022 to 2024, which aligns with the ground truth. It also accurately infers that this indicates continued use of unobservable inputs in valuation, reflecting sound qualitative reasoning. However, the LLM introduces specific dollar amounts ($35 million in 2022 and $22 million in 2024) that are not present in the original answer and cannot be verified against the provided ground truth, reducing quantitative accuracy. The original answer emphasizes a refinement in disclosure practices—specifically, the inclusion of investments valued using NAV as a practical expedient in reconciliation tables in 2024, which was not explicitly stated in 2022. This nuance about improved transparency and disclosure evolution is missing in the LLM response, representing a gap in completeness and contextual depth. While the core classification and reasoning are correct, the addition of unverified figures and omission of the disclosure practice change prevent a higher score. The entities (General Dynamics, Level 3 assets, retirement annuity contracts, years 2022 and 2024) are correctly identified, and the response stays focused on the question. Thus, the answer is factually sound in its main claim but lacks full completeness and introduces unsupported specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 380,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of potential equity dilution and income recognition?",
      "original_answer": "In 2023, AIG had a stake in Corebridge that included a potential equity dilution mechanism tied to Blackstone's right to exchange its ownership interest in Corebridge for AIG common shares, which would have introduced up to 24.1 million additional shares in 2022 (and 4.4 million in 2023) had the IPO not occurred before 2024. However, since the IPO occurred on September 19, 2022, this exchange right was terminated. By 2024, AIG's relationship with Corebridge had shifted from a stakeholding to an equity method investment, where AIG reported income based on dividends received and changes in Corebridge's stock price from June 9, 2024 onwards. This reflects a transformation from a potential equity dilution scenario to a post-divestiture equity income model.",
      "llm_answer": "In 2023 AIG still owned about 52 percent of Corebridge and reported the business as a discontinued operation; the only possible dilution came from ordinary share‑based‑compensation awards (≈ 4.4 million potential shares) because Blackstone’s exchange right was terminated after Corebridge’s 2022 IPO. In 2024 AIG cut its stake to 48.4 percent, de‑consolidated Corebridge and re‑classified the remaining interest to an equity‑method investment, so dividends and the change in Corebridge’s stock price are now recognized in net‑investment income (e.g., $601 million equity‑method income in the June‑Dec 2024 period) and the de‑consolidation generated a $4.8 billion loss (including a $7.2 billion accumulated comprehensive loss) while a June‑2024 secondary offering added $261 million to AIG equity.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution of AIG's financial relationship with Corebridge between 2023 and 2024, correctly noting the shift from ownership stake to equity-method investment and the termination of Blackstone’s exchange right post-IPO. However, there are key quantitative inaccuracies. The original answer states that the potential dilution from Blackstone’s exchange right was up to 24.1 million shares in 2022 and 4.4 million in 2023, but only if the IPO had not occurred—since the IPO occurred on September 19, 2022, the right was terminated. The LLM incorrectly frames the 4.4 million shares as still being a potential source of dilution in 2023 via share-based compensation, conflating two distinct mechanisms. The 4.4 million figure in the ground truth refers to the *reduction* in potential dilution due to the IPO, not ongoing compensation awards. (2) The LLM introduces specific dollar amounts not in the original answer: $601 million equity-method income (June–Dec 2024), $4.8 billion de-consolidation loss, $7.2 billion accumulated comprehensive loss, and $261 million from a secondary offering. These figures, while plausible, are not present in the ground truth and cannot be verified against it, representing over-specificity or hallucination. (3) The qualitative reasoning is strong: the model correctly identifies the shift from consolidation to equity-method accounting, de-consolidation, and income recognition via dividends and stock price changes starting June 9, 2024. It also correctly notes the stake reduction from 52% to 48.4%, indicating ongoing divestment. (4) Contextual relevance is excellent—the answer directly addresses both parts of the question: equity dilution (though with flawed interpretation) and income recognition. The core transformation from dilution risk to equity income is accurately conveyed, warranting a 7 for correctness. Quantitative accuracy is penalized due to unverified figures and misinterpretation of the 4.4 million share number. Qualitative and contextual scores remain high due to sound structure and multi-hop synthesis across ownership, accounting treatment, and financial impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 582,
        "total_tokens": 1974
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2024, based on its debt disclosures and consolidation treatment?",
      "original_answer": "In 2022, Comcast disclosed that Universal Beijing Resort had $3.6 billion in debt as of December 31, 2021, and $2.5 billion as of December 31, 2020. By 2024, Comcast clarified that Universal Beijing Resort had $3.4 billion in debt outstanding as of December 31, 2024, and $3.5 billion as of December 31, 2023. This indicates that the debt levels stabilized after earlier reductions, and Comcast now consolidates Universal Beijing Resort as a variable interest entity (VIE), with its assets and liabilities fully included in Comcast’s consolidated balance sheets at $7.3 billion in assets and $7.0 billion in liabilities as of 2024.",
      "llm_answer": "Comcast’s disclosed “un‑guaranteed” debt for Universal Beijing Resort rose from about **$2.5 billion in 2022** (see the “Debt Not Guaranteed” line in the 2022 filing) to **$3.4 billion of debt outstanding as of 31 Dec 2024** (the term‑loan component of the resort’s financing) 【page_71】【page_86】.  Although the resort is treated as a variable‑interest entity that Comcast **consolidates** (so its $7.3 billion of assets and $7.0 billion of liabilities appear on Comcast’s balance sheet), the company notes that there are **no liquidity guarantees** and its maximum loss is limited to its **30 % equity stake**.  Thus, while the absolute debt exposure has increased modestly, the underlying risk to Comcast remains capped at its 30 % ownership interest.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in numbers and dates. The ground truth states that Universal Beijing Resort had $3.6 billion in debt as of December 31, 2021, and $2.5 billion as of December 31, 2020 — not $2.5 billion in 2022 as the LLM claims. The LLM incorrectly labels the $2.5 billion figure as being from 2022, when it actually refers to 2020. Additionally, the 2024 debt is stated as $3.4 billion as of December 31, 2024 in the LLM answer, but the ground truth reports $3.4 billion as of December 31, 2024 and $3.5 billion as of December 31, 2023 — the LLM omits the 2023 figure entirely. The LLM also introduces the term 'un-guaranteed' debt and 'term-loan component', which are not in the original answer and may reflect misinterpretation. (2) The consolidation details are mostly correct: the LLM correctly notes that Universal Beijing Resort is consolidated as a VIE with $7.3 billion in assets and $7.0 billion in liabilities on Comcast’s balance sheet as of 2024, matching the ground truth. However, the original answer does not mention Comcast’s 30% equity stake or lack of liquidity guarantees — this is additional information not present in the ground truth, potentially from external knowledge, which may be accurate but is not supported by the provided context. (3) The multi-hop reasoning is partially sound: the LLM connects debt disclosures over time and links them to consolidation treatment, but misaligns the timeline and sources of data. It fails to show the full evolution from 2020 to 2024 as presented in the original answer, particularly missing the reduction and subsequent stabilization of debt. (4) The contextual relevance is high — the answer addresses debt evolution and consolidation — but quantitative inaccuracies and timeline confusion reduce correctness. The qualitative reasoning is logical but based on incorrect data points, leading to a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 521,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the structure of aircraft trade-in commitments changed between 2022 and 2023, particularly in terms of customer eligibility and risk exposure?",
      "original_answer": "In 2022, the Aerospace segment had outstanding options with 'some customers' to trade in aircraft as partial consideration for new aircraft purchases, indicating a broader or less-specific customer eligibility. By 2023, the eligibility was narrowed to 'some Gulfstream customers,' suggesting a more specific subset of customers was offered trade-in options. Additionally, while both years acknowledged the risk associated with adverse market changes affecting trade-in values, 2023 introduced a more specific framing by highlighting Gulfstream, a key business jet brand, which may indicate a strategic focus or increased risk concentration in that segment. Despite these structural changes, both years reported that the estimated change in fair market values from the commitment date was 'not material.'",
      "llm_answer": "In the 2022 filing the company said that “some customers” could exercise an option to trade‑in an aircraft as partial consideration for a new Gulfstream, with the trade‑in value normally set at the fair‑market price determined ≈ 45 days before delivery; a separate set of commitments fixed a pre‑determined trade‑in price, which exposed the company to greater risk if market values fell.  \n\nThe 2023 filing repeats the same mechanics but narrows the eligible parties to “some Gulfstream customers,” and again distinguishes between fair‑market‑value‑based trade‑ins and fixed‑price trade‑ins. The risk profile is unchanged – the fixed‑price commitments still carry the higher market‑risk exposure, and the company notes that the estimated change in fair‑market values from the commitment dates remained immaterial.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the change in customer eligibility from 'some customers' in 2022 to 'some Gulfstream customers' in 2023, capturing the narrowing of eligibility. It also accurately notes that both years distinguish between fair-market-value-based and fixed-price trade-ins, with the latter posing higher risk due to market fluctuations. The statement that the estimated change in fair market values remained immaterial matches the original answer exactly in meaning. (2) There are no numeric values (e.g., dollar amounts, percentages, dates) in the ground truth that are contradicted; the mention of '≈45 days before delivery' is a detail not present in the original answer but does not conflict with it and may reflect additional accurate context from the filing. Since the ground truth does not include or contradict this timing detail, it does not reduce accuracy. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes in eligibility, risk exposure structure, and the immateriality of fair value changes across two years. The focus on Gulfstream in 2023 is correctly interpreted as a refinement of customer scope. (4) The only minor shortcoming is that the original answer emphasizes the 2023 framing as potentially indicating 'strategic focus or increased risk concentration'—a subtle interpretive point the LLM omits. However, this does not affect factual correctness. Overall, the answer is factually complete, contextually relevant, and semantically equivalent to the ground truth with excellent qualitative and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 448,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2022 and 2024, particularly in terms of its production status and strategic positioning within Tesla's product lineup?",
      "original_answer": "In 2022, Tesla had only announced the Tesla Semi as part of its planned electric vehicles, indicating it was in the conceptual and development phase. By 2024, Tesla had moved the Tesla Semi into 'pilot production' at its Nevada facility, signaling a significant advancement in its development and a step closer to commercialization. This evolution reflects Tesla's strategic shift from merely planning the vehicle to actively preparing it for market entry.",
      "llm_answer": "In the 2022 filing Tesla described the Semi only as a “planned commercial electric vehicle” — a future addition to its lineup of upcoming models such as the Cybertruck and Roadster (see Item 1, Future Consumer and Commercial Electric Vehicles). By the 2024 filing the Semi had progressed to “pilot production” at the Nevada plant (see the production‑status table) and was being highlighted as one of the newer vehicle models that Tesla is expanding capacity for, tying it to its next‑generation platform and overall manufacturing growth strategy.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly states that in 2022, the Tesla Semi was described as a 'planned commercial electric vehicle,' aligning with the original answer's characterization of it being in the conceptual and development phase. By 2024, it accurately notes the progression to 'pilot production' at the Nevada facility, matching the ground truth. (2) There are no numerical values requiring calculation, but the years (2022 and 2024) and production status terms ('planned,' 'pilot production') are correct and consistent. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two time points (2022 and 2024 filings), identifies the evolution in production status, and contextualizes the Semi’s strategic positioning within Tesla’s product lineup and manufacturing growth strategy, including its link to the next-generation platform. (4) The answer is fully relevant, directly addressing both parts of the question—production status and strategic positioning—and provides additional context (e.g., connection to Cybertruck, Roadster, and capacity expansion) that enriches the response without introducing inaccuracies. Minor wording differences (e.g., 'planned commercial electric vehicle' vs. 'planned electric vehicles') do not affect factual equivalence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 378,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the valuation allowance related to Altria's investment in Cronos evolve between 2022 and 2024, and what does this indicate about the company's expectations regarding the realizability of associated deferred tax assets?",
      "original_answer": "Between 2022 and 2024, the valuation allowance related to Altria's investment in Cronos increased from $379 million in 2022 to $402 million in 2024. This indicates that Altria continued to maintain significant uncertainty regarding the realizability of deferred tax assets associated with the Cronos investment, as the company still did not expect the temporary difference to reverse in the foreseeable future. The steady increase in the allowance suggests a cautious stance by Altria in recognizing the full value of these assets.",
      "llm_answer": "Altria’s valuation allowance for the deferred‑tax asset tied to its Cronos investment rose modestly over the three‑year period – $379 million at the end of 2022, $397 million at the end of 2023 and $402 million at the end of 2024. The fact that a valuation allowance is still required (and has even increased slightly) signals that the company continues to view a significant portion of the Cronos‑related deferred tax asset as unlikely to be realized in the near term.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is factually correct in all key aspects: it accurately reports the valuation allowance amounts for 2022 ($379 million), 2023 ($397 million), and 2024 ($402 million). While the original answer only explicitly states 2022 and 2024 values, the LLM correctly includes the intermediate 2023 figure ($397 million), which is consistent with ground truth data and adds useful detail without contradicting the original. The trend of increasing allowance is correctly identified.\n\n2) Quantitative accuracy is perfect: all dollar amounts and years are correct. The progression from $379M to $402M over the period is accurately portrayed, and the incremental increase in 2023 aligns with actual filings. No calculation errors.\n\n3) The reasoning is sound: the LLM correctly infers that the continued and increasing valuation allowance indicates Altria's ongoing skepticism about the realizability of the deferred tax assets related to Cronos. It correctly links the accounting treatment (maintaining/increasing allowance) with management’s expectation of non-realization in the near term, which reflects proper multi-hop synthesis between financial data and accounting principles.\n\n4) The answer is semantically equivalent to the ground truth and adds slight value by including the 2023 data point. The only reason it doesn’t score a 10 is that the original answer emphasizes Altria’s expectation that the temporary difference won’t reverse 'in the foreseeable future'—a nuance slightly more precise than 'near term'—but this is a minor wording difference with minimal impact on meaning. All entities (Altria, Cronos, deferred tax assets, valuation allowance) are correctly identified and contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 465,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the financial treatment and valuation impact of Amgen's investment in BeiGene evolve between 2023 and 2024?",
      "original_answer": "In 2023, Amgen changed the accounting method for its investment in BeiGene from the equity method to fair value, resulting in gains recognized in connection with this revaluation. By 2024, the investment contributed net unrealized losses within Amgen's Other income (expense), net, reflecting a shift from gains in 2023 to losses in 2024 due to market or valuation changes. This evolution shows a reversal in the financial benefit derived from the BeiGene investment over the two years.",
      "llm_answer": "In 2023 Amgen switched its BeiGene holding from the equity‑method to a fair‑value measurement, so the change was recorded as a **gain** on the investment and was reflected as a positive boost to “other income (expense), net.” By 2024 the same fair‑value accounting remained, but the fair‑value movement was **negative**, producing a net unrealized loss on the strategic equity investment that turned “other income (expense), net” from a gain in 2023 to a loss in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies the change in accounting method in 2023 from equity method to fair value, resulting in a gain recognized in 'other income (expense), net'—this matches the original answer. (2) For 2024, it accurately states that the investment generated net unrealized losses under the same fair-value accounting due to negative valuation movements, reflecting the reversal from gain to loss. (3) The multi-hop reasoning is sound: it synthesizes the continuity of fair-value accounting with the change in direction of financial impact (gain to loss), which is central to the question about evolution between years. (4) All entities—Amgen, BeiGene, the relevant financial statement line ('other income (expense), net'), and the years 2023 and 2024—are correctly identified and contextualized. There are no numerical inaccuracies; while exact dollar amounts are not provided in either answer, the directional financial impacts (gain in 2023, loss in 2024) are correctly described. Wording differs slightly but meaning is preserved. All scoring categories warrant full marks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 329,
        "total_tokens": 1560
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the positioning and market strategy for Disney+ Hotstar evolved between 2023 and 2024, particularly in terms of its regional branding and service structure?",
      "original_answer": "In 2023, Disney+ Hotstar was described as a DTC service primarily in India that offered general entertainment, family, and sports programming. It was positioned as a distinct regional brand within Disney’s broader Direct-to-Consumer portfolio. By 2024, while still branded as Disney+ Hotstar in India and Southeast Asia, the company had merged its previously separate Star+ and Disney+ services in Latin America into a single Disney+ product offering by the end of June 2024. This indicates a strategic shift toward consolidating regional streaming services under the Disney+ brand umbrella, streamlining offerings, and possibly enhancing content integration across markets.",
      "llm_answer": "In the 2023 filing Disney+ Hotstar was described simply as the company’s direct‑to‑consumer service “primarily in India that offers general‑entertainment, family and sports programming” 【page_4】. By the 2024 filing the same regional brand is still used – “In India and certain other Southeast Asian countries, the service is branded Disney+ Hotstar” 【page_57】 – but the company now stresses that it is a **stand‑alone** product that is **not bundled in any multi‑product offerings** 【page_58】. This reflects a shift toward keeping the Hotstar brand distinct in its key markets and positioning it as a separate subscription tier rather than part of bundled bundles.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct in that it accurately identifies Disney+ Hotstar's regional branding in India and Southeast Asia in both 2023 and 2024, and correctly cites that it remains a distinct brand. It also correctly notes from the 2024 filing that Disney+ Hotstar is a stand-alone product not included in multi-product bundles. However, the LLM answer misses the key strategic evolution highlighted in the ground truth: the merger of Star+ and Disney+ into a single Disney+ service in Latin America by June 2024. This is a critical component of Disney’s broader market strategy shift toward consolidation under the Disney+ brand, which the LLM answer fails to mention entirely. Instead, the LLM emphasizes the 'stand-alone' nature of Hotstar as a strategic distinction, which, while factually noted in the filing, does not reflect the overarching trend of brand consolidation that the question asks about. The answer is factually accurate in the details it provides (hence full marks for quantitative accuracy and decent contextual relevance), but it misinterprets the strategic direction by focusing on separation rather than the larger pattern of integration and streamlining. The multi-hop reasoning is weak because it fails to synthesize the Latin America consolidation with the continued use of Hotstar in Asia to form a complete picture of Disney’s evolving regional strategy. As such, the qualitative accuracy and overall correctness are significantly reduced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 406,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did PayPal's approach to its Protection Programs evolve between 2023 and 2024, particularly in terms of risk exposure and loss recovery mechanisms?",
      "original_answer": "In 2023, PayPal disclosed that the costs associated with its protection programs were recorded in 'transaction and credit losses' during the period the payment transaction was completed, and it did not provide a separate service to customers under these programs. By 2024, PayPal introduced more detailed disclosures around its protection programs, highlighting that it incurs substantial losses from these programs due to customer disputes and faces challenges in recovering losses from merchants, especially in cases involving fraud or merchant insolvency. Additionally, PayPal noted that it may face increased exposure due to evolving fraud schemes and potential regulatory changes affecting chargeback requirements. This indicates a shift toward more explicit risk acknowledgment and a broader understanding of potential financial impact.",
      "llm_answer": "In the 2023 filing PayPal simply noted that its merchant‑ and consumer‑protection programs are “intended to protect … from fraud and counter‑party performance” and that the estimated costs of those programs are recorded as transaction‑ and credit‑loss expenses in the period the payment is completed. By the 2024 filing the discussion had expanded to stress that the programs now represent a material source of loss exposure – the company often cannot fully recoup losses from merchants, must absorb reimbursement claims from card‑issuers, and faces the risk that regulators or card‑network rule changes could broaden charge‑back requirements – while still relying on limited merchant recoveries and external reimbursements to offset those losses. Thus, PayPal’s approach evolved from a basic internal‑cost accounting of protection‑program losses to a more explicit acknowledgment of heightened risk exposure and the constrained, external‑focused mechanisms it uses to recover those losses.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original ground truth. (1) All factual elements are correct: in 2023, PayPal recorded protection program costs in 'transaction and credit losses' without offering a separate service, which is accurately reflected. By 2024, the company expanded disclosures to emphasize material loss exposure, challenges in recovering losses from merchants (especially in fraud or insolvency cases), and risks from regulatory or network-driven changes to chargeback rules—this evolution is correctly captured. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; dates (2023 and 2024) are correct. (3) The multi-hop reasoning—comparing disclosures across two years to infer a shift in risk acknowledgment and recovery mechanisms—is sound and well-synthesized. The LLM correctly infers a qualitative shift from internal cost accounting to explicit risk exposure management. (4) Minor deduction in qualitative accuracy due to slightly stronger phrasing in the LLM answer (e.g., 'material source of loss exposure' and 'heightened risk') that, while reasonable, are slightly more emphatic than the original's neutral tone, but still within semantic equivalence. Overall, the answer is contextually complete, factually correct, and appropriately focused on risk exposure and loss recovery evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1459,
        "completion_tokens": 395,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has NextEra Energy's relationship with solar generation facilities evolved from 2022 to 2024, particularly in terms of ownership structure and financial exposure?",
      "original_answer": "In 2022, NextEra Energy Resources was actively divesting ownership stakes in solar generation facilities, including the sale of a 100% ownership interest in a 100 MW solar facility in Arizona and the sale of a 90% ownership interest in a portfolio that included four solar facilities. These transactions resulted in significant cash proceeds and the recognition of gains. By 2024, the company's relationship had transformed into a more complex structure involving equity stakes and consolidated variable interest entities (VIEs). For example, NextEra consolidated eight VIEs owning solar generation facilities with approximately 765 MW of capacity and held a 10% direct ownership interest in additional solar facilities. This shift indicates a strategic move from outright ownership and divestiture to a more diversified and financially leveraged stake through VIEs, with increased financial exposure through guarantees and credit support.",
      "llm_answer": "By 2022 NextEra Energy had been divesting solar plants – it sold a 90 % non‑controlling interest in a portfolio that included four solar facilities (and later sold other solar assets outright), creating sizable non‑controlling‑interest balances on its balance sheet and recording the sales as disposals 【page_81】.  \n\nIn the 2024 filing the company’s approach had shifted to retaining majority control: eight indirect subsidiaries now own ≈ 50 %‑67 % of separate entities that operate about 765 MW of solar generation, and these entities are treated as variable‑interest entities that NextEra consolidates, exposing it to roughly $1.7 billion of solar‑related assets and $520 million of debt (non‑recourse to the parent) 【page_97】.  \n\nThus, the relationship moved from selling down to minority stakes to holding majority ownership through VIEs, increasing NextEra’s consolidated financial exposure to its solar portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the shift in NextEra Energy's strategy from 2022 divestitures to 2024 consolidation of VIEs. The 2022 divestiture of a 90% interest in a portfolio including four solar facilities is accurately reported, though it omits the additional 100% sale of a 100 MW Arizona facility mentioned in the original answer. This is a minor omission but does not undermine the core accuracy. (2) Quantitatively, the LLM correctly reports the ≈765 MW of solar capacity in 2024 and references consolidation of VIEs with approximately $1.7 billion in assets and $520 million in non-recourse debt, which are consistent with the knowledge graph's implication of increased financial exposure. While exact dollar figures for 2022 proceeds or gains are not included, the focus is on structural evolution, so this is acceptable. (3) The reasoning is sound: the LLM correctly infers a strategic shift from minority stake sales to majority control via VIE consolidation, demonstrating proper multi-hop synthesis across years and ownership structures. (4) The terminology (e.g., 'non-controlling interest', 'VIEs', 'non-recourse debt') is used accurately, and the conclusion about increased consolidated financial exposure is logically supported. The only minor shortcoming is the omission of the 100% Arizona facility sale in 2022, which slightly reduces completeness. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 425,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did ACN's investment in Mutual Fund Debt Securities evolve from 2022 to 2023, and what was the change in valuation methodology as reflected in the fair value hierarchy levels?",
      "original_answer": "In 2022, ACN reported Mutual Fund Debt Securities valued at $379,989 with the entire amount categorized under Level 2 of the fair value hierarchy. In 2023, this investment decreased to $253,025, and the valuation remained entirely under Level 2. The decrease in value indicates a reduction in exposure to Mutual Fund Debt Securities over the year, while the valuation methodology remained consistent, relying on observable market data.",
      "llm_answer": "In the 2022 filing Accenture reported a **$379.9 million** holding of mutual‑fund debt securities in its non‑U.S. defined‑benefit pension plans, and those securities were **valued using Level 2 inputs** (quoted prices for similar instruments)【page_89】.  \n\nThe 2023 filing no longer shows any mutual‑fund debt‑security balance in the fair‑value tables, indicating that the investment was eliminated (or re‑classified) and therefore is no longer measured under the Level 2 hierarchy. This reflects a shift away from the Level 2 valuation methodology that was used in 2022.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies the 2022 value of $379.9 million (matching the ground truth $379,989 thousand), it incorrectly states that the 2023 value is zero or no longer reported. The ground truth confirms that in 2023, the investment was $253,025 (i.e., $253.025 million), not eliminated. The LLM falsely claims the investment was 'eliminated (or re-classified)', which is unsupported by the data. (2) Quantitative accuracy is partially correct: the 2022 figure is accurate in magnitude (allowing for unit conversion), but the 2023 figure is entirely wrong. The decrease from ~$380M to ~$253M is a material change that the model fails to report. (3) The multi-hop reasoning is flawed: the model incorrectly infers a change in valuation methodology because the item is absent in 2023 tables, but the ground truth states the 2023 value remains fully in Level 2—no methodology shift occurred. The model fails to synthesize that the investment still exists and is still Level 2. (4) Contextual relevance is moderate—the response addresses the right metric and hierarchy level, but draws incorrect conclusions about elimination and methodology change, undermining the core answer. The mention of 'non-U.S. defined-benefit pension plans' adds context not in the original but does not compensate for factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 385,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Chevron's financial stake and involvement in Tengizchevroil evolved between 2022 and 2023?",
      "original_answer": "In 2022, Chevron's carrying value of its investment in Tengizchevroil was $23,727 million with a reported equity in earnings of $1,238 million. By 2023, Chevron disclosed that its carrying value was approximately $80 million higher than its underlying equity in Tengizchevroil's net assets, indicating a more complex valuation approach. Additionally, Chevron highlighted that it provided a loan of $4,500 million to Tengizchevroil to fund the Future Growth Project and Wellhead Pressure Management Project (FGP/WPMP). This shows a significant deepening of Chevron's financial involvement and strategic commitment to the partnership in 2023 compared to 2022.",
      "llm_answer": "Chevron’s 50 percent ownership of Tengizchevroil (TCO) remained unchanged, but the carrying amount of the investment rose modestly from **$26.5 billion at 31 Dec 2022 to $26.95 billion at 31 Dec 2023** (an increase of about $0.42 billion)【page_82】.  At the same time, Chevron’s share of TCO’s earnings fell, with **equity‑in‑earnings declining from $4.386 billion in 2022 to $3.375 billion in 2023**【page_82】.  The change reflects a slightly higher recorded stake value while the profitability contribution from the joint‑venture decreased over the year.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. According to the ground truth, Chevron's carrying value in Tengizchevroil was $23,727 million ($23.727 billion) in 2022, not $26.5 billion as stated by the LLM. The LLM claims a 2023 carrying value of $26.95 billion, which is also incorrect — the ground truth does not provide an exact updated carrying value but notes a qualitative point about an $80 million excess over equity in net assets. Additionally, the LLM reports equity in earnings of $4.386 billion in 2022 and $3.375 billion in 2023, which are drastically different from the ground truth values of $1,238 million ($1.238 billion) in 2022 and no 2023 earnings figure provided. These numerical discrepancies are severe and undermine the answer’s validity. (2) The calculations based on incorrect numbers (e.g., $26.5B to $26.95B increase) are therefore also wrong. The ground truth emphasizes a new $4.5 billion loan to fund FGP/WPMP in 2023, a critical piece of financial involvement completely omitted in the LLM response. (3) While the LLM correctly identifies that Chevron maintains a 50% ownership and attempts to compare year-over-year changes, it fails to capture the multi-hop evolution described in the original answer — particularly the strategic deepening of involvement via a major loan and complex valuation changes. The reasoning is partially sound in structure (comparing carrying value and earnings), but based on incorrect data. (4) The contextual relevance is moderate because the answer addresses the general theme of financial stake evolution, but due to major factual and quantitative errors and omission of key strategic developments, the correctness score is low. The answer does not reflect the actual evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 495,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Disney's relationship with ABC Network evolved between 2023 and 2024, particularly in terms of its strategic positioning within Disney's broader entertainment ecosystem?",
      "original_answer": "In 2023, ABC Network was positioned as a core component of Disney's 'Linear Networks' within the Entertainment segment, specifically highlighting its domestic footprint through eight owned ABC television stations and its role in content distribution. By 2024, ABC Network's role had evolved, with its programming becoming more integrated into Disney's direct-to-consumer platforms, such as Hulu and Disney+. Specifically, content from ABC Network was made available on Hulu's SVOD service one day after its linear airing. This shift indicates a strategic move toward digital integration and away from traditional linear distribution. Additionally, while ABC Network was still referenced in the context of affiliate fees in 2023, 2024 emphasized its contribution to streaming services rather than standalone linear revenue.",
      "llm_answer": "In the 2023 filing Disney described ABC simply as one of its “Domestic” linear‑network assets – a broadcast outlet that, together with its owned stations, carried the company’s news, daytime and primetime programming. By the 2024 filing the company had elevated ABC’s strategic role, emphasizing that it now reaches “almost 100 % of U.S. television households” through 245 affiliates and eight owned stations and that it serves as the primary carriage platform for ESPN‑branded sports (“ESPN on ABC”) and for cross‑promoting Disney’s Direct‑to‑Consumer services. Thus, between 2023 and 2024 ABC moved from a basic linear property to a central hub that links Disney’s broadcast, sports and streaming businesses within the broader entertainment ecosystem.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general strategic evolution of ABC Network within Disney's ecosystem between 2023 and 2024, correctly identifying a shift from a basic linear network to a more integrated, strategically central role. However, there are significant factual inaccuracies that reduce correctness. First, the claim that ABC reaches 'almost 100% of U.S. television households' through 245 affiliates is not present in the ground truth and cannot be verified from the provided data—this specific quantitative assertion (245 affiliates, 100%) is unsupported and likely incorrect. The ground truth emphasizes ABC's integration with streaming platforms (e.g., next-day availability on Hulu), which the LLM answer omits entirely. Instead, the LLM focuses on ABC as a platform for 'ESPN on ABC' and cross-promotion of DTC services, which, while plausible, is not mentioned in the original answer and represents a divergence in key strategic emphasis. The ground truth highlights a shift from linear revenue (affiliate fees) to contribution to streaming—this critical financial and strategic pivot is missing. While the LLM correctly notes ABC's role in content distribution and owned stations, it fails to mention the eight owned stations in both years (only mentions them in 2024), and misrepresents the nature of the evolution by emphasizing broadcast reach and sports carriage over digital integration. The reasoning is logically structured and contextually relevant, showing an understanding of multi-hop synthesis (comparing 2023 to 2024 positioning), but the substitution of unverified quantitative claims and omission of core digital transition details (Hulu SVOD delay) undermines factual accuracy. Thus, while the answer is semantically in the right direction, it introduces unsupported specifics and misses key elements of the actual strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 501,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has General Dynamics' positioning of the ASCOD vehicle within its Land Systems portfolio evolved between 2022 and 2023, and what does this indicate about potential shifts in production focus or investment allocation?",
      "original_answer": "In 2022, General Dynamics explicitly stated it was 'producing and upgrading' the ASCOD vehicle, indicating active development and enhancement of the platform. By 2023, the company's disclosure shifted to simply 'offering' the ASCOD, without specific mention of production or upgrades. This change in language suggests a potential shift in focus away from active investment or development of the ASCOD platform, possibly reallocating resources to other vehicle programs like the Piranha 5 and AJAX, which are explicitly called out in both years with continued production and international deployments.",
      "llm_answer": "In the 2022 filing the ASCOD was mentioned only as one of the “highly versatile tracked combat vehicles” that European Land Systems (ELS) offers, without any detail on current production. By the 2023 filing GD explicitly states that ELS is **producing** ASCOD‑derived vehicles (the Spanish Pizarro and Austrian Ulan) for Luxembourg, Switzerland and Germany and is providing full‑range support for the German armed forces. This change signals that General Dynamics is moving the ASCOD from a catalog‑item description to an active production program, indicating a modest re‑allocation of resources and investment toward expanding its European‑market vehicle output.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. According to the ground truth, in 2022 General Dynamics stated it was 'producing and upgrading' the ASCOD vehicle, indicating active development. By 2023, the language changed to simply 'offering' the ASCOD, suggesting a reduction in active investment. However, the LLM answer reverses this trajectory, falsely claiming that in 2022 the ASCOD was only mentioned as an offered vehicle with no production detail, and that in 2023 GD began explicitly stating it was producing ASCOD-derived vehicles for multiple countries. This is factually wrong and contradicts the ground truth. The LLM introduces specific details not in the original answer—such as production for Luxembourg, Switzerland, and Germany, and support for the German armed forces—which are not supported by the provided truth data. There is no mention of Pizarro or Ulan vehicles in the ground truth. The reasoning is therefore flawed: instead of identifying a potential drawdown in focus on ASCOD, the LLM incorrectly infers an expansion. While the answer addresses the question's structure and attempts multi-hop reasoning (comparing 2022 and 2023 disclosures), the underlying facts are inverted or fabricated, leading to an incorrect conclusion about resource allocation. Quantitative accuracy is low because the answer fabricates deployment and production details with no numerical or factual basis. Qualitative accuracy fails due to incorrect entity relationships and misrepresentation of company disclosures. Contextual relevance is moderate because the response attempts to address the evolution of ASCOD's role and implications for investment, but the incorrect facts undermine the analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 471,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has PayPal's utilization of European customer balances for credit activities evolved between 2023 and 2024, and what does this shift indicate about the company's credit funding strategy?",
      "original_answer": "In 2023, PayPal had approved $3.0 billion of European customer balances for credit activities, representing approximately 39% of balances made available for corporate use. By 2024, the approved amount had decreased to $2.0 billion, or 26% of European customer balances. This indicates a strategic shift toward reducing reliance on customer balances for credit funding, potentially in favor of external financing sources, as evidenced by PayPal's multi-year agreement to sell consumer installment receivables, which saw $20.8 billion in loans sold in 2024 compared to $5.5 billion in 2023.",
      "llm_answer": "In 2023 PayPal was allowed to earmark $3.0 billion of European customer balances – about 39 % of the cash it could use for corporate purposes – to fund credit activities in Europe, the U.K. and the U.S. By the end of 2024 that approved amount had fallen to $2.0 billion, or roughly 26 % of the available European balances. The reduction shows the company is pulling back on using internal European deposits as a source of credit funding and is likely turning to external financing or a more conservative liquidity stance for its credit‑product growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the key figures: $3.0 billion approved in 2023 (39%) and $2.0 billion in 2024 (26%), matching the ground truth exactly. These numbers are presented with accurate percentages and timeframes. (2) All numeric values, including dollar amounts and percentages, are factually correct and consistent with the original answer. There are no calculation errors. (3) The reasoning is sound: the LLM correctly infers a strategic pullback from using European customer balances for credit funding. It accurately identifies the shift as a move away from internal deposits, suggesting a pivot to external financing or a more conservative liquidity approach. However, it omits the specific supporting evidence of PayPal’s multi-year receivables sale agreement and the significant increase in loans sold—from $5.5 billion in 2023 to $20.8 billion in 2024—which is a key part of the original answer and strengthens the conclusion about external financing. This omission slightly weakens the qualitative depth and completeness of the multi-hop synthesis. (4) Despite this, the LLM answer remains semantically equivalent in its core message and correctly addresses both parts of the question: the evolution between 2023 and 2024 and the strategic implication. The contextual relevance is high, and the wording differences do not affect factual accuracy. The score is reduced by one point due to the missing detail about receivables sales, which is important for full completeness in a multi-hop financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 424,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the valuation and categorization of equity securities within NEE's Special Use Funds evolve between 2022 and 2024, and what does this indicate about changes in transparency or investment composition?",
      "original_answer": "In 2022, NEE's Special Use Funds reported equity securities at a carrying amount of $906 million (with an estimated fair value of $907 million) for NEE and $672 million (with an estimated fair value of $672 million) for FPL, without detailed categorization by valuation levels. By 2024, the equity securities in the Special Use Funds had grown significantly, with NEE holding $2,614 million in Level 1 equity securities and FPL holding $1,028 million in Level 1 equity securities, alongside more granular disclosures that included Level 2 and Level 3 valuations. This indicates a substantial increase in equity investments and a shift toward more transparent and detailed reporting of asset valuation methodologies.",
      "llm_answer": "In the 2022 filing the equity portion of NEE’s special‑use funds was reported almost entirely at the higher‑observable levels – roughly **$2.5 billion at Level 1 and $3.0 billion at Level 2**, with **no Level 3 amount** (total ≈ $5.5 billion).  \nBy the 2024 filing the same line shows **$2.6 billion at Level 1, $3.3 billion at Level 2 and a new $0.23 billion at Level 3**, raising the total equity‑security balance to **about $6.2 billion**.\n\nThe appearance of a Level 3 component and the rise in the overall equity‑security balance indicate that NEE’s special‑use funds have taken on a larger share of securities that are valued using unobservable inputs (e.g., commingled‑fund holdings), reducing the transparency of the valuation while expanding the size and complexity of the investment mix.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and quantitative errors. (1) In 2022, the ground truth reports NEE's equity securities at a carrying amount of $906 million (fair value $907 million) and FPL at $672 million, with no Level 1/2/3 breakdown provided. The LLM incorrectly states $2.5 billion at Level 1 and $3.0 billion at Level 2 in 2022, which is more than double the actual total and misrepresents both the magnitude and categorization. (2) For 2024, the ground truth states NEE holds $2,614 million in Level 1 equity securities and FPL holds $1,028 million in Level 1, with additional disclosures including Level 2 and Level 3, but the LLM aggregates these into a single $6.2 billion total with $2.6B Level 1, $3.3B Level 2, and $0.23B Level 3 — figures not supported by the original data. There is no evidence in the ground truth that the total equity securities reached $6.2 billion or that Level 3 was $230 million. (3) The LLM misattributes the increase to 'NEE’s special-use funds' collectively without distinguishing between NEE and FPL, failing to correctly synthesize entity-specific data. (4) While the LLM correctly infers that the introduction of Level 3 implies less transparency and more complex investments, this reasoning is based on fabricated numbers, undermining the validity of the conclusion. The contextual relevance is moderate because it addresses valuation levels and transparency, but the answer is built on incorrect foundations. Minor formatting variations are acceptable, but here the discrepancies are severe in both magnitude and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 431,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the scope and utilization of Accenture's share purchase program evolve from fiscal 2022 to fiscal 2023, particularly in terms of shares acquired under the public program versus those acquired through employee-related transactions?",
      "original_answer": "In fiscal 2022, Accenture purchased 1,964,612 Class A ordinary shares under the publicly announced open-market share purchase program for an aggregate price of $576 million. Additionally, 97,251 shares were acquired through employee-related transactions, such as share withholding for payroll tax obligations, which do not affect the aggregate available authorization. In fiscal 2023, there is no mention of shares purchased under the public program, but the company continued acquiring shares through employee-related transactions under equity share plans. This indicates a shift where the public share purchase program saw reduced or no activity, while employee-related share acquisitions remained consistent.",
      "llm_answer": "In fiscal 2022 Accenture bought ≈ 1.96 million Class A shares through its publicly announced open‑market repurchase program and ≈ 0.10 million shares in separate employee‑related transactions (share withholding for payroll‑tax obligations). For fiscal 2023 the Board expanded the overall repurchase authority to $6.1 billion (adding $3 billion to the prior $3.1 billion) and continued to use the same open‑market program, increasing the amount of shares purchased under that public program while the employee‑related purchases remained a small, distinct tranche that does not draw on the public‑program authorization.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly reports the approximate number of shares purchased under the public program in fiscal 2022 (~1.96 million) and employee-related transactions (~0.10 million), it fabricates key information for fiscal 2023. The ground truth states there is no mention of shares purchased under the public program in fiscal 2023, but the LLM claims the board expanded the repurchase authority to $6.1 billion and that the company increased shares purchased under the public program—information not supported by the original answer. These details are entirely incorrect and contradict the ground truth, which indicates reduced or no activity in the public program. (2) Quantitative accuracy is partially correct for fiscal 2022: 1,964,612 shares ≈ 1.96 million and 97,251 ≈ 0.10 million are acceptable approximations. However, the $6.1 billion authorization and $3 billion addition are completely fabricated and not present in the original answer, making fiscal 2023 figures wholly inaccurate. (3) The multi-hop reasoning is flawed. The question asks how the scope and utilization evolved, requiring accurate comparison across years. The LLM incorrectly infers continued and expanded use of the public program in 2023, when the ground truth explicitly notes no mention of such purchases, indicating a shift away from the public program. This misrepresents the evolution and fails to identify the key trend: public program inactivity versus consistent employee-related acquisitions. (4) Contextual relevance is moderate—the answer addresses share purchases and distinguishes between public and employee-related transactions, which is relevant. However, due to major factual and reasoning errors, especially in the 2023 analysis, the overall correctness score is very low. The answer conveys the opposite of the true trend, warranting a score of 2 out of 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 520,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did Chevron's financial reporting relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of its consolidation status and investment accounting approach?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was consolidated into Chevron’s financial statements, as indicated by the inclusion of 'Note 8: Summarized Financial Data - Chevron Phillips Chemical Company LLC' among other consolidated subsidiaries. However, in 2023, Chevron explicitly stated that its investment in Chevron Phillips Chemical Company LLC was accounted for using the equity method, and it was no longer consolidated under Chevron U.S.A. Inc.'s financial data. This reflects a significant structural change where Chevron transitioned from consolidating the entity to reporting its investment under the equity method, altering how its financial performance is reflected in Chevron’s consolidated results.",
      "llm_answer": "In both the 2022 and the 2023 Form 10‑K Chevron reported that its 50 % stake in Chevron Phillips Chemical Company LLC was **not consolidated** into the Chevron consolidated statements.  In 2022 the joint‑venture interest was disclosed as an **equity‑method investment**, and the 2023 filing repeats that treatment – the investment is still shown under “Investments and advances” and the 100 % financial results of CPChem are presented only in a supplemental note, not as a consolidated subsidiary.  Thus, the reporting relationship did not change; CPChem remained a non‑consolidated equity‑method investment throughout the two years.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect. (1) According to the ground truth, Chevron consolidated Chevron Phillips Chemical Company LLC (CPChem) in 2022 but switched to the equity method in 2023, meaning the accounting treatment changed significantly. The LLM incorrectly claims that CPChem was not consolidated in either year and that the treatment remained unchanged. (2) The LLM states Chevron has a '50%' stake, which may be factually accurate, but this detail is not in the original answer and does not compensate for the core error in consolidation status. The key financial reporting change — from consolidation to equity method — is entirely misrepresented. (3) The multi-hop reasoning fails: the model should have identified the presence of CPChem in the consolidated subsidiary notes in 2022 (e.g., 'Note 8: Summarized Financial Data') as evidence of consolidation, and then recognized the explicit 2023 disclosure shifting to equity-method accounting. Instead, it falsely asserts consistent equity-method treatment. (4) The answer contradicts the ground truth on the central point of consolidation evolution, making it highly inaccurate despite some contextual relevance to CPChem and reporting methods. Minor elements like mentioning 'Investments and advances' or supplemental notes do not salvage correctness. The conclusion that 'the reporting relationship did not change' is directly false per the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 393,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Hydra-70 rockets in General Dynamics' Combat Systems segment evolved from 2022 to 2023, particularly in terms of contract involvement and production capacity expansion?",
      "original_answer": "In 2022, General Dynamics received a $175 million contract for the production of Hydra-70 rockets as part of its Combat Systems segment. By 2023, the company's role had evolved significantly, with OTS (Orbital Technologies Corporation, part of Combat Systems) maintaining a market-leading position in the supply of Hydra-70 rockets and expanding its production capacity. Specifically, OTS received awards to increase metal parts production capacity for munitions from 18,000 to 86,000 rounds per month by 2025, which includes Hydra-70 rockets as part of its broader munitions portfolio.",
      "llm_answer": "In the 2022 filing the Combat Systems segment’s involvement with Hydra‑70 rockets was limited to a single Army award – a $175 million contract to produce the rockets (see page 42). By the 2023 filing the focus had shifted to scaling that capability: OTS was awarded contracts to grow its metal‑parts line for Hydra‑70 rockets from 18,000 to 86,000 rounds per month by 2025 (and to boost propellant capacity as well) – a clear expansion of production capacity to meet higher demand (see page 12).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $175 million 2022 contract for Hydra-70 rockets is accurately cited, and the expansion of production capacity from 18,000 to 86,000 rounds per month by 2025 is correctly reported. The entity OTS (Orbital Technologies Corporation) is properly identified as part of Combat Systems, though its full name is not spelled out. (2) Quantitative accuracy is perfect: dollar amount ($175M), production figures (18,000 to 86,000 rounds/month), and timeline (by 2025) match the original answer exactly. Format variations are acceptable and do not affect correctness. (3) Multi-hop reasoning is sound: the LLM correctly synthesizes information across 2022 and 2023 filings to show evolution from initial contract to capacity expansion. It captures the shift from production under a single contract to broader capacity scaling. (4) The only minor omission is that the original answer specifies the capacity expansion is for 'metal parts production for munitions' and that Hydra-70 rockets are part of a broader portfolio, while the LLM implies the expansion is exclusively for Hydra-70 rockets. This slightly over-narrows the scope but does not invalidate the core accuracy. Wording differences are semantically equivalent and acceptable. Overall, the answer is factually correct, well-reasoned, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 393,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has PayPal's treatment of the Global Restricted Stock Unit Award Grant Notice evolved between the 2023 and 2024 filings, particularly in terms of its documentation status and associated agreements?",
      "original_answer": "In the 2023 filing, the Global Restricted Stock Unit Award Grant Notice was listed as Exhibit 10.07+ and was associated with the PayPal Holdings, Inc. 2015 Equity Incentive Award Plan, with its form incorporated by reference from 10-12B/A filed on May 14, 2015. By 2024, the same form of the Global Restricted Stock Unit Award Grant Notice (Exhibit 10.07+) remained in place, still referencing the 2015 plan and incorporated by reference from the same 10-12B/A filing on May 14, 2015. However, in the 2024 filing, there was an updated form of the Global Performance Based Restricted Stock Unit Award Grant Notice (Exhibit 10.08+), which was now filed under the amended and restated plan and was linked to a more recent 10-Q filing on April 30, 2024. This indicates that while the base RSU grant notice remained unchanged, the performance-based variant saw active revision and documentation updates in 2024.",
      "llm_answer": "In the 2023 Form 10‑K the “Form of Global Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement” (Exhibit 10.07+) was listed only as an exhibit reference – it was not attached to the filing (no “X” indicating it was filed). In the 2024 Form 10‑K the same Global RSU Grant Notice remains listed as Exhibit 10.07+ and is still not filed with the report, but the company now also includes a related “Form of Global Performance‑Based Restricted Stock Unit Award Grant Notice and Agreement” (Exhibit 10.08+) that is filed as a 10‑Q on April 30 2024, showing an added, filed agreement alongside the unchanged reference to the original Global RSU notice.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution between the 2023 and 2024 filings. Quantitatively, all key details are correct: Exhibit 10.07+ in both years is referenced but not filed (no 'X'), and the new Exhibit 10.08+ in 2024 is correctly tied to the April 30, 2024 10-Q filing. The dates (May 14, 2015 and April 30, 2024) and exhibit numbers (10.07+, 10.08+) match the ground truth. The LLM correctly identifies that the base Global RSU notice remains unchanged in documentation status (still incorporated by reference, not filed), while a new performance-based variant (Exhibit 10.08+) was introduced and filed in 2024. The only minor omission is that the LLM does not explicitly mention that the 2023 exhibit was incorporated by reference from the May 14, 2015 10-12B/A, which adds context to its documentation status. However, stating it was 'listed only as an exhibit reference' and 'not filed' captures the essential point. The reasoning is sound: it correctly synthesizes across years and exhibit types, distinguishing between the static base RSU notice and the updated performance-based version. The answer is semantically equivalent to the ground truth, with slightly less detail on the incorporation source but no factual errors. Contextual relevance is perfect—it directly addresses the evolution in documentation status and associated agreements as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 383,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Opdivo within Bristol-Myers Squibb's portfolio evolved from 2022 to 2024, based on its revenue performance and new regulatory approvals?",
      "original_answer": "In 2022, Opdivo generated $7,523 million in revenue, indicating it was a major contributor to Bristol-Myers Squibb's oncology portfolio. By 2024, Opdivo received a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. This regulatory expansion demonstrates a strategic evolution in Opdivo’s therapeutic application and reinforces its continued importance in the company's oncology pipeline, despite not showing a significant revenue increase from earlier years.",
      "llm_answer": "In the 2022 filing Opdivo was already a core revenue driver, generating $7.5 billion of net product sales in the most recent year reported (2021) 【page_110】. By 2024 the drug’s role has broadened from a single‑indication blockbuster to a multi‑indication platform: BMS secured FDA, EC and Japanese approvals for new uses (first‑line urothelial carcinoma, neoadjuvant NSCLC, combination with Yervoy for MSI‑H colorectal cancer, and the sub‑cutaneous Opdivo Qvantig formulation) 【page_45】【page_44】, and the company’s strategy notes that Opdivo remains the foundation of its IO portfolio 【page_46】. This evolution shows Opdivo moving from a high‑revenue product to an expanding, multi‑formulation cornerstone of BMS’s oncology strategy.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Opdivo as a major revenue driver for Bristol-Myers Squibb and notes its strategic evolution, aligning with the ground truth. However, there are key quantitative inaccuracies: it states that the $7.5 billion figure is from 2021, while the ground truth specifies $7,523 million in 2022. This misattribution of the year reduces quantitative accuracy. Additionally, the LLM mentions multiple 2024 approvals including FDA, EC, and Japanese approvals for several indications (neoadjuvant NSCLC, MSI-H colorectal cancer, subcutaneous formulation), but the ground truth only confirms the March 2024 FDA approval for first-line urothelial carcinoma in combination with cisplatin and gemcitabine. The other approvals are not mentioned in the ground truth and thus constitute unverified or incorrect additions. (2) The revenue number is approximately correct ($7.5B vs $7,523M), but the year is wrong, and the additional approvals lack support. The format variation ($7.5B vs $7,523 million) is acceptable, but the temporal misalignment and unsupported expansions affect precision. (3) The reasoning is sound in interpreting Opdivo’s strategic evolution from a high-revenue product to a broader platform, and the synthesis of regulatory and strategic context reflects multi-hop understanding. However, the inclusion of unconfirmed approvals weakens the factual basis of the conclusion. (4) Despite the overstatement of approvals, the core message about Opdivo’s expanding role and continued importance is consistent with the ground truth, making the answer contextually relevant and qualitatively strong, though not fully factually accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 459,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Chevron's financial involvement and strategic support for Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of project funding and investment structure?",
      "original_answer": "In 2022, Chevron highlighted its 50% ownership in Chevron Phillips Chemical Company LLC (CPChem), emphasizing ongoing investments in global manufacturing facilities and expansion projects, such as the planned 1-hexene unit in Old Ocean, Texas, and a C3 splitter at Cedar Bayou, with targeted start-ups in 2023. By 2023, Chevron's involvement had evolved to include a direct loan of $387 million to fund a portion of the Golden Triangle Polymers Project in Orange, Texas, in which CPChem owns 51%. This indicates a shift from general equity ownership and project announcements in 2022 to more direct financial support and structured investment in specific projects in 2023.",
      "llm_answer": "In 2022 Chevron’s 50‑percent joint‑venture stake in Chevron Phillips Chemical Company LLC was carried at $6.84 billion, with $867 million of additional investments/advances (including a loan to the affiliate). By year‑end 2023 the carrying amount had risen to $7.77 billion, but new advances fell to $608 million, reflecting a smaller net outlay of fresh funding while the overall equity value grew. The investment structure remained unchanged—a 50 percent ownership plus a direct loan (now $387 million) that Chevron used to finance the Golden Triangle Polymers Project in Orange, Texas, underscoring continued strategic support of CPChem’s expansion.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the evolution of Chevron's financial involvement and strategic support for Chevron Phillips Chemical Company LLC (CPChem) between 2022 and 2023, with strong qualitative reasoning and contextual relevance. It correctly identifies the 50% ownership, the direct loan of $387 million in 2023 for the Golden Triangle Polymers Project, and the continued strategic support through funding and investment. However, there are minor quantitative inaccuracies: the ground truth does not mention the $6.84 billion or $7.77 billion carrying amounts, nor the $867 million and $608 million investment figures—these specific numbers are not present in the original answer and appear to be fabricated or sourced from outside the provided knowledge graph. While the $387 million loan is correctly cited, the additional financial details (carrying amounts, year-over-year investment advances) go beyond the ground truth and introduce unsupported data, reducing quantitative accuracy. The reasoning is otherwise sound: it correctly infers a shift toward more direct financial support in 2023 and maintains correct entity and project names (CPChem, Golden Triangle Polymers Project, Orange, Texas). The answer addresses both project funding and investment structure as required by the question, demonstrating multi-hop synthesis across years and financial mechanisms. Despite the extraneous numbers, the core factual evolution—equity ownership in 2022 to direct loan funding in 2023—is accurately conveyed, warranting a high correctness score with a deduction for unsupported figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 438,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did PayPal's protection programs evolve between 2023 and 2024 in terms of financial commitments and disclosures regarding transaction loss reserves?",
      "original_answer": "In 2023, PayPal disclosed that it estimated and recorded costs associated with protection programs in transaction and credit losses, but did not specify the exact amounts for the allowance for transaction losses or negative customer balances. In 2024, PayPal provided more detailed disclosures, including specific figures: the allowance for transaction losses increased from $64 million in 2023 to $86 million in 2024, and the allowance for negative customer balances rose from $218 million to $256 million. This indicates a significant increase in PayPal's financial commitments and potential risk exposure under its protection programs in 2024 compared to the prior year.",
      "llm_answer": "- 2023 10‑K – PayPal described its consumer‑ and merchant‑protection programs as “assurance‑type warranties” whose costs are estimated and recorded in **transaction and credit‑loss expenses** (see page 77).  At year‑end 2023 the company held an allowance of **$64 million for transaction losses** and **$218 million for negative customer balances** (the allowance figures are disclosed in the 2024 filing as the prior‑year amounts).\n\n- 2024 10‑K – The same note now provides a detailed breakdown of the reserve activity.  For the year ended 2024 the allowance for transaction losses rose to **$86 million** and the allowance for negative customer balances to **$256 million**.  The company recorded a **$1.114 billion provision**, **$1.218 billion realized losses**, and **$164 million recoveries**, leaving an **ending balance of $342 million** (up from $282 million in 2023) (see page 110).  \n\nThus, between 2023 and 2024 PayPal increased its financial commitment to protection programs, raising both the transaction‑loss reserve and the negative‑balance reserve and providing a more granular disclosure of the provision, realized losses and recoveries.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key financial figures are correct: the allowance for transaction losses increased from $64 million in 2023 to $86 million in 2024, and the allowance for negative customer balances rose from $218 million to $256 million—these match the ground truth exactly. The additional disclosure of a $1.114 billion provision, $1.218 billion in realized losses, and $164 million in recoveries, leading to an ending balance of $342 million (up from $282 million), is factually consistent with enhanced 2024 disclosures and adds valuable detail not contradicted by the original answer. (2) Quantitative accuracy is perfect—no calculation or number errors. The LLM correctly notes that the 2023 allowance figures are reported in the 2024 filing as prior-year amounts, which is consistent with SEC filing practices. (3) Reasoning is sound: the model correctly infers that increased reserves and more granular disclosures indicate greater financial commitment and transparency in 2024 versus 2023. The multi-hop synthesis across two years’ filings is accurate and well-supported. (4) The only minor shortcoming is that the original answer emphasizes the *lack* of specific 2023 disclosures in the 2023 10-K, while the LLM implies they were disclosed (though clarifies they appear in the 2024 filing as prior-year data). This nuance is important but does not invalidate the overall correctness. The LLM answer enhances the original with additional reserve activity details, improving completeness without introducing error. Thus, the answer is factually excellent and contextually appropriate, warranting a 9/10 due to slight overstatement of 2023 disclosure transparency.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1458,
        "completion_tokens": 470,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has McDonald's strategic framing of its relationship with franchisees changed between 2022 and 2024, particularly in terms of franchising as a core business model and the role of franchisee co-investment?",
      "original_answer": "In 2022, McDonald's described its relationship with franchisees in neutral, structural terms, emphasizing the division of responsibilities such as franchised arrangements and license agreements, and presenting franchisees as co-participants in operating restaurants. By 2024, the framing evolved significantly, with franchising being described as 'paramount' to delivering food quality, customer experience, and profitability. The 2024 filing also emphasized the importance of franchisee co-investment, noting that it enables McDonald's to achieve high restaurant performance. This represents a shift from a descriptive to a more strategic and value-laden framing of the franchisee relationship.",
      "llm_answer": "In the 2022 filing McDonald’s described its franchise system chiefly as a “heavily franchised business model” that provides stable, predictable revenue, with franchisees viewed mainly as capital‑reinvestors and occasional co‑investors to speed specific improvement projects. By the 2024 filing the company positions franchising as the core strategic engine—“paramount” to delivering the brand experience and growth—and frames co‑investment as a collaborative, brand‑building partnership that modernizes restaurants and lifts local performance, emphasizing franchisees as active partners rather than just sources of capital.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in McDonald's strategic framing between 2022 and 2024. It correctly identifies the shift from a neutral, structural description in 2022—where franchisees are portrayed as capital-reinvestors and occasional co-investors—to a more strategic, value-laden framing in 2024, where franchising is described as 'paramount' and co-investment as a collaborative, brand-building partnership. The use of 'paramount' aligns exactly with the original answer and reflects the heightened strategic importance McDonald's placed on franchising by 2024. The LLM accurately conveys the qualitative shift in tone and intent, including the emphasis on franchisee co-investment enabling restaurant modernization and performance improvement. There are no numeric values to verify, so quantitative accuracy is scored as 10. The only minor gap is that the LLM does not explicitly mention 'food quality' and 'customer experience' as elements tied to franchising in 2024, which were included in the ground truth; instead, it uses the broader term 'brand experience.' This is semantically close but slightly less specific. Otherwise, the reasoning is sound, entities (McDonald's, franchisees, years 2022 and 2024) are correct, and the multi-hop synthesis across years is well executed. The answer is fully contextually relevant and directly addresses the question about strategic framing changes regarding franchising and co-investment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 404,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the FDA's authorization of Marlboro HeatSticks evolved between 2022 and 2023, and what does this indicate about Altria's regulatory progress with heated tobacco products?",
      "original_answer": "In 2022, the FDA had not yet authorized Marlboro HeatSticks and was considering them on a case-by-case basis regarding graphic health warnings. By 2023, the FDA had authorized PMTAs for three new tobacco-flavored varieties of Marlboro HeatSticks in January 2023, marking a significant regulatory milestone. This indicates that Altria made notable progress in securing FDA approval for its heated tobacco product line, which is a key part of its innovation strategy.",
      "llm_answer": "In the 2022 Form 10‑K Altria reported that the FDA had **authorized, in January 2023, PMTAs for three new tobacco‑flavored Marlboro HeatSticks** (the heated‑tobacco sticks used with the IQOS system). By the time of the 2023 Form 10‑K the company noted that, although the FDA had considered a marketing order for the HeatSticks, **the agency had not yet exempted them from the graphic‑warning rule and no final marketing order had been issued**. Together, these disclosures show that Altria has moved from obtaining limited flavor authorizations to still awaiting a full FDA marketing order, indicating modest but incomplete regulatory progress for its heated‑tobacco products.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly states that the FDA authorized PMTAs for three new tobacco-flavored Marlboro HeatSticks in January 2023, which aligns with the ground truth. However, it incorrectly claims that 'no final marketing order had been issued' and that the FDA had 'not yet exempted them from the graphic-warning rule' as of the 2023 10-K, which contradicts the ground truth indicating that the 2023 authorization was a significant milestone implying regulatory progress. The original answer presents the 2023 authorization positively as progress, while the LLM interprets it as incomplete, which misrepresents the implication. (2) The date 'January 2023' is correct and matches the ground truth. There are no numerical values requiring calculation, so quantitative accuracy is acceptable but limited by the qualitative misinterpretation. (3) The multi-hop reasoning is flawed: the LLM incorrectly synthesizes the regulatory status by emphasizing ongoing limitations (graphic warning rule, no final order) not mentioned in the ground truth, and fails to conclude that this represents 'notable progress' as stated in the original. Instead, it downplays the achievement as 'modest but incomplete,' which is not supported by the source. (4) While the LLM identifies the correct entities (Altria, FDA, Marlboro HeatSticks, PMTA, 2022–2023 timeline) and is contextually relevant in addressing the evolution and implications, the incorrect interpretation of the regulatory outcome significantly undermines factual accuracy and reasoning quality, warranting a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 451,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did the valuation of mutual fund equity securities held by ACN evolve between 2022 and 2023, and what does this shift indicate about the company's investment positioning in this category?",
      "original_answer": "In 2022, ACN reported $239,293 (in millions) in mutual fund equity securities. By 2023, this figure decreased to $196,226 (in millions), indicating a reduction of $43,067 (in millions). This decline suggests a strategic shift or reallocation away from mutual fund equity securities during the period.",
      "llm_answer": "In the 2022 filing Accenture reported that its defined‑benefit and post‑retirement plans held mutual‑fund equity securities with a fair‑value of **$239 million** (approximately $4.9 million at Level 1 and $234 million at Level 2). The 2023 filing no longer shows any balance for “mutual‑fund equity securities” in the pension‑plan asset tables, indicating that the amount has been reduced to **essentially zero**.  \n\nThis drop signals that the company’s pension and post‑retirement investments have moved out of the mutual‑fund equity category, shifting the portfolio toward a more conservative, debt‑focused positioning.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and misrepresents the data. The original answer states that ACN held $239,293 million (i.e., $239.3 billion) in mutual fund equity securities in 2022, not $239 million — this is a critical error of three orders of magnitude. Similarly, the 2023 value is $196,226 million (~$196.2 billion), not 'essentially zero' as claimed. The LLM incorrectly asserts that mutual-fund equity securities were completely removed from the portfolio, which contradicts the ground truth showing a reduction, not elimination. (2) The calculation of the decline is also wrong: the actual decrease is $43,067 million (~$43 billion), whereas the LLM implies a drop from $239 million to zero, which is both numerically and proportionally incorrect. Additionally, the mention of 'Level 1' and 'Level 2' fair value hierarchies and $4.9 million at Level 1 introduces granular detail not present in the original and potentially misleading in this context. (3) The multi-hop reasoning is partially sound in that it attempts to interpret a trend between two years and infer strategic positioning; however, because the underlying data is grossly inaccurate, the conclusion about a shift to 'debt-focused positioning' is unsupported by the provided truth. The original answer only notes a reduction without specifying where the capital was reallocated. (4) The contextual relevance is moderate — the answer addresses the right topic (evolution of mutual fund equity holdings and strategic implication) and the correct company (ACN/Accenture), but the severe quantitative errors undermine the validity of the response. Wording flexibility is acceptable, but factual precision — especially on financial magnitudes — is critical and here it fails. Hence, correctness is scored low at 4 due to major factual and numerical discrepancies, despite some structural alignment with the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 522,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Chevron's involvement in Angola LNG Limited evolved from 2022 to 2023, particularly in terms of its operational focus and investment emphasis?",
      "original_answer": "In 2022, Chevron operated and held a 36.4% interest in Angola LNG Limited, emphasizing its role in processing and liquefying associated natural gas from multiple fields and operators in Angola. The company was also involved in developing non-associated gas resources to supply the Angola LNG plant. By 2023, Chevron continued to hold the same 36.4% interest, but the disclosure shifted focus to its broader portfolio of equity affiliates and non-equity investments, with Angola LNG Limited being listed alongside other major investments like Tengizchevroil and Chevron Phillips Chemical Company LLC. This indicates a shift in disclosure emphasis from operational development to financial stake and integration within Chevron’s global portfolio.",
      "llm_answer": "In both years Chevron continued to own a 36.4 % equity interest in Angola LNG Limited, the on‑shore plant that liquefies associated natural‑gas feedstock from Angola’s oil fields.  However, the carrying value of that investment fell from about **$1.96 billion in 2022** to **$1.76 billion in 2023** (Note 15, “Investments and Advances”), indicating a modest reduction in the amount of capital Chevron is allocating to the venture while its operational focus – processing and exporting LNG – remained unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies Chevron's consistent 36.4% equity interest in Angola LNG Limited in both 2022 and 2023, which aligns with the ground truth. It also accurately notes the operational focus on processing associated natural gas for liquefaction and export. However, the LLM introduces specific dollar amounts—$1.96 billion in 2022 and $1.76 billion in 2023—for the carrying value of the investment, which are not present in the original answer and cannot be verified against the provided ground truth. These figures may be factually accurate in external sources, but since they are absent from the knowledge graph and not inferable from the original answer, their inclusion constitutes a quantitative overreach, undermining quantitative accuracy. Furthermore, the original answer emphasizes a shift in disclosure focus—from operational development in 2022 to financial stake and portfolio integration in 2023—highlighting a change in reporting emphasis rather than a reduction in capital allocation. The LLM interprets the decreased carrying value as indicating reduced capital allocation, which is a speculative inference not supported directly by the ground truth and misrepresents the nature of the evolution. While the LLM captures part of the qualitative shift, it misattributes the reason, focusing on financial devaluation rather than strategic disclosure. The reasoning is partially sound but flawed in its conclusion. Contextually, the answer remains highly relevant, addressing both operational focus and investment emphasis as asked. Overall, the answer is partially correct with significant factual additions not in the ground truth and a misinterpretation of the evolution, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 471,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did MMM's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, MMM held $14 million in Certificates of Deposit/Time Deposits, as disclosed in the fair value measurements. By 2023, this amount increased to $49 million, indicating a significant growth in this category of investment. This represents an increase of $35 million, or approximately 250%, from the prior year.",
      "llm_answer": "MMM’s marketable‑securities schedule shows that certificates of deposit/time deposits rose from **$21 million at year‑end 2022 to $49 million at year‑end 2023**. That represents an **increase of $28 million** (about a 133 % jump) in the company’s investment in these instruments.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the 2023 value of $49 million and the general trend of growth in Certificates of Deposit/Time Deposits for MMM, which aligns with the ground truth. However, it reports the 2022 amount as $21 million instead of the correct $14 million from the original answer, leading to an incorrect increase of $28 million rather than $35 million. This error propagates into the percentage change, calculating a 133% increase instead of the correct ~250%. These quantitative inaccuracies are significant because they misrepresent the magnitude of the change, despite correct reasoning structure. The entity (MMM), metric (Certificates of Deposit/Time Deposits), and years (2022 to 2023) are correctly identified, and the answer addresses both parts of the question—evolution and magnitude—demonstrating sound multi-hop reasoning framework. The contextual relevance is high as the response stays focused on the required financial evolution. However, due to the critical errors in core financial figures and calculations, the correctness and quantitative accuracy scores are low. Semantic equivalence fails on the numbers, which are central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1145,
        "completion_tokens": 330,
        "total_tokens": 1475
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of the percentage of franchised restaurants between 2021 and 2024?",
      "original_answer": "In 2021, 93% of McDonald's restaurants were franchised, while by 2024, this percentage increased to approximately 95%. This indicates a slight but deliberate shift toward further reliance on franchisees to operate McDonald's restaurants, reinforcing the company's strategic emphasis on franchising as a core business model.",
      "llm_answer": "In 2021, McDonald’s reported that 37,295 of its 40,031 restaurants – about **93 %** – were franchised. By year‑end 2024, the company said it had 43,477 restaurants, of which **approximately 95 %** were franchised. Thus, the share of franchised locations has risen modestly, moving from roughly 93 % to about 95 % over the three‑year period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages (93% in 2021 and approximately 95% in 2024) are accurately reported, and the supporting restaurant counts (37,295 of 40,031 in 2021; 95% of 43,477 in 2024) align with the expected figures, with minor rounding acceptable. The calculation of ~93% in 2021 from the provided numbers is accurate (37,295 / 40,031 ≈ 93.16%, correctly rounded to 93%). (2) The answer is complete, addressing the evolution of McDonald's franchisee relationship over the specified time period (2021 to 2024) with correct time-bound data points. (3) Entities—McDonald's, franchised restaurants, years 2021 and 2024—are correctly identified and contextualized. (4) The reasoning is sound: the LLM correctly infers a modest increase in the franchised share, reflecting the strategic shift, which matches the original answer’s conclusion. The synthesis across two time points from multi-hop data is accurate and clearly communicated. (5) Semantic equivalence is maintained: while the LLM includes additional detail (total restaurant counts), the core message—that the franchised percentage increased from 93% to 95%—is identical to the ground truth. No factual, numerical, or interpretive errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1163,
        "completion_tokens": 359,
        "total_tokens": 1523
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the effective date and structure of the 2015 Stock Compensation Plan for Non-Employee Directors evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was described as 'amended and restated effective March 31, 2021.' By 2023, the plan was further amended and restated, with a new effective date of 'October 26, 2022.' This indicates that the plan underwent at least one additional amendment during the 2022–2023 period, reflecting a structural or procedural update to the plan’s terms.",
      "llm_answer": "- 2022 Form 10‑K – the “2015 Stock Compensation Plan for Non‑Employee Directors” was described as **amended and restated effective October 26, 2022** and was shown to provide **about 589,927 shares** available for future issuance.  \n\n- 2023 Form 10‑K – the same plan is now referenced as **amended and restated effective March 31, 2021** (the most recent amendment incorporated in the 2023 filing) and the share pool listed under the plan had grown to **about 703,256 shares**.  \n\nThus, between the two years the filing moved from a 2022‑effective amendment to relying on the earlier 2021 amendment, while the plan’s basic structure remained a stock‑compensation vehicle for non‑employee directors, with the authorized share amount increasing.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors in dates and reasoning, directly contradicting the ground truth. (1) The 2022 Form 10-K should state the plan was amended and restated effective March 31, 2021, not October 26, 2022 — the LLM reverses the correct timeline. Conversely, the 2023 filing correctly reflects the October 26, 2022 effective date, but the LLM incorrectly claims the 2023 filing uses the March 31, 2021 date as the most recent. This inversion of facts undermines the entire response. (2) While the share numbers (~589,927 in 2022 and ~703,256 in 2023) may be factually accurate, they are irrelevant to the question, which asks about the evolution of the effective date and structure, not share availability. Including them distracts from the core issue. (3) The multi-hop reasoning fails: instead of identifying that the plan was updated from a March 31, 2021 effective date to a new October 26, 2022 effective date between 2022 and 2023 filings, the LLM incorrectly asserts the opposite direction of change. (4) Contextually, the answer addresses the plan’s existence and general purpose, but the critical timeline is reversed, leading to an incorrect conclusion about the evolution. The structure discussion is superficial and misaligned with the actual amendments. Thus, despite some correct peripheral data, the core facts are wrong, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 385,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did Accenture's financial relationship with Duck Creek Technologies evolve between fiscal years 2022 and 2023, particularly in terms of investment valuation and reported financial impact?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with a carrying amount of $138,902, and was accounted for using the equity method. By fiscal 2023, the investment resulted in a $253 million gain, which was specifically called out in the financial statements as impacting the adjusted earnings per share and effective tax rate calculations. This indicates a shift from a long-term equity stake to a more active financial realization event.",
      "llm_answer": "In fiscal 2022 Accenture reported that its equity‑method investment in Duck Creek Technologies – roughly a 16 % ownership – was carried on the balance sheet at $138.9 million, with an estimated fair‑value of $223.2 million. By fiscal 2023 the company said the Duck Creek stake had appreciated enough to generate a $253 million investment gain, which was disclosed as a distinct financial‑impact line item in its 2023 MD&A.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: 16% ownership, $138.9 million carrying amount (vs. $138,902 in original, interpreted correctly as $138.9 million), $223.2 million fair value (vs. $223,166, rounded appropriately), and the $253 million gain in fiscal 2023. The format variations are acceptable and semantically equivalent. (2) Quantitative accuracy is excellent—minor rounding differences ($138,902 to $138.9M and $223,166 to $223.2M) are standard and do not affect correctness. The $253 million gain is reported exactly as in the original. (3) The reasoning correctly synthesizes the evolution from an equity-method investment in 2022 to a significant gain realization in 2023, indicating a financial shift. The mention of the gain being a 'distinct financial-impact line item' aligns with the original's emphasis on its impact on adjusted EPS and tax rate, though the LLM omits those specific metrics. (4) The answer is fully contextually relevant, directly addressing the evolution in valuation and financial impact. The only minor shortcoming is the omission of the specific effects on adjusted earnings per share and effective tax rate, which slightly reduces qualitative completeness. Hence, a 9/10 on correctness and qualitative accuracy, but full marks on quantitative and contextual dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 384,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has the therapeutic application of Breyanzi evolved between 2022 and 2024, and what specific new indications were approved in 2024 that expand its market potential?",
      "original_answer": "In 2022, Breyanzi was indicated for the treatment of adult patients with certain types of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. By 2024, Breyanzi received two new approvals: in March 2024 for the treatment of adult patients with relapsed or refractory CLL or SLL who have received at least two prior lines of therapy, and in May 2024 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. These new indications significantly expand the patient populations eligible for Breyanzi treatment.",
      "llm_answer": "In the 2022 Form 10‑K the company described Breyanzi (lisocabtagene maraleucel) as a CD‑19‑directed CAR‑T therapy **approved only for adult patients with relapsed or refractory large B‑cell lymphoma after two or more lines of systemic therapy**【page_72】.  \n\nBy 2024 the label had been broadened to cover several additional B‑cell cancers.  In 2024 the FDA granted accelerated approvals for Breyanzi in **relapsed or refractory chronic lymphocytic leukemia/small‑lymphocytic lymphoma (CLL/SLL)** (March 2024)【page_45】, **relapsed or refractory follicular lymphoma (FL)** (May 2024)【page_45】, and **relapsed or refractory mantle‑cell lymphoma (MCL)** (May 2024)【page_44】.  Japan also approved Breyanzi in August 2024 for **relapsed or refractory FL** after one prior line of therapy in high‑risk patients (and after two or more lines)【page_44】.  \n\nThese new approvals expand Breyanzi’s market potential from a single large‑B‑cell‑lymphoma indication in 2022 to a portfolio of four distinct B‑cell malignancies (CLL/SLL, FL, MCL and expanded FL) by 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the 2022 indication and two of the three 2024 approvals mentioned in the ground truth: relapsed or refractory CLL/SLL (March 2024) and follicular lymphoma (FL) (May 2024). However, it introduces a fact not present in the ground truth — an approval for mantle cell lymphoma (MCL) in May 2024 — which is incorrect based on the provided original answer. This is a significant factual error that undermines the correctness. Additionally, the mention of a Japanese approval for FL in August 2024 is not referenced in the ground truth, making it extraneous and unsupported. While the core evolution from a single indication in 2022 to expanded use in 2024 is accurately conveyed, the inclusion of unverified indications (MCL and Japan) distorts the factual landscape. The dates for the correct approvals (March and May 2024) are accurate, and the description of the patient populations for CLL/SLL and FL aligns with the original answer. However, the erroneous expansion to four indications (including MCL) overstates the market potential. The reasoning is partially sound but flawed due to the inclusion of unsupported approvals. Contextually, the answer is well-structured and relevant, citing specific pages and aligning with the question’s focus on therapeutic evolution and market expansion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 367,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has 3M's approach to estimating and recording insurance receivables related to legal proceedings under ASC 450 evolved between 2022 and 2023, particularly in relation to respirator mask/asbestos litigation?",
      "original_answer": "In 2022, 3M referenced its compliance with ASC 450 for recording liabilities related to legal proceedings but did not specifically mention the methodology for estimating insurance receivables. By 2023, the company explicitly described applying the loss recovery and/or gain contingency models under ASC 450 and ASC 610-30 to estimate insurance receivables, including analysis of policy terms, case law, and claim nature. Additionally, the number of individual claimants in respirator mask/asbestos litigation increased from approximately 4,028 in 2022 to 4,042 in 2023, indicating a growing exposure that likely influenced the more detailed approach to insurance receivables in 2023.",
      "llm_answer": "In the 2022 filing (see Note 16 on “Legal Proceedings” – page 36), 3M said it accrued liabilities for legal claims that were probable and reasonably estimable under ASC 450, but it gave only a brief statement that insurance recoveries are recorded when a liability is accrued. By the 2023 filing (the “Process for Disclosure and Recording of Insurance Receivables” on page 80) the company expanded that discussion, describing a detailed analysis of policy terms, exclusions, case law and prior experience to estimate the amount of insurance receivable that is recognizable under ASC 450 (and ASC 610‑30). For the respirator‑mask/asbestos litigation, 3M increased its accruals by $57 million in 2023, recorded an immaterial insurance‑receivable balance for that litigation (page 82), and disclosed that the Aearo bankruptcy stay had been lifted—showing a more granular, litigation‑specific approach than the generic 2022 description.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in its qualitative assessment of 3M's evolving approach to estimating insurance receivables under ASC 450 between 2022 and 2023. It accurately notes that in 2022, 3M provided only a brief statement on insurance recoveries being recorded when a liability is accrued, while in 2023, the company expanded its disclosure to include a detailed methodology involving policy terms, case law, exclusions, and prior experience under ASC 450 and ASC 610-30—this aligns with the ground truth. The mention of the Aearo bankruptcy stay being lifted adds relevant context indicating increased litigation activity. However, the LLM introduces a $57 million increase in accruals for respirator-mask/asbestos litigation in 2023, which is not present in the original answer and cannot be verified against the provided ground truth; this is a quantitative inaccuracy. Additionally, the original answer highlights the increase in individual claimants from 4,028 to 4,042 as evidence of growing exposure influencing the change in approach, a key factual point missing in the LLM response, reducing completeness. While the LLM correctly identifies the shift toward a more granular, litigation-specific approach, it omits this critical supporting data point. The reasoning is otherwise sound, with proper multi-hop synthesis between years and accounting standards. Contextual relevance is high as all information pertains directly to the question. Wording differences are acceptable, but the missing claimant numbers and unverified $57M figure prevent a top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 430,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did PepsiCo's relationship with Naked evolve between 2022 and 2023, particularly in terms of its operational involvement and financial stake?",
      "original_answer": "In 2022, PepsiCo sold its Tropicana, Naked, and other select juice brands to PAI Partners while retaining a 39% noncontrolling interest in a newly formed joint venture, The Beachbody Company (TBG), which operates across North America and Europe. Additionally, PepsiCo acted as the exclusive distributor for TBG's portfolio of brands, including Naked, for small-format and foodservice customers via chilled direct-store-delivery. By 2023, PepsiCo no longer directly distributed Naked products and instead primarily disclosed its relationship through its retained 39% noncontrolling interest in TBG, with no further operational involvement in the distribution of Naked products. This represents a shift from active distribution to a purely financial stake.",
      "llm_answer": "In the 2022 Form 10‑K PepsiCo disclosed that it had sold the Naked juice brand (along with Tropicana and other juice brands) to PAI Partners, but it kept a **39 % non‑controlling interest in the new joint‑venture, Tropicana Brands Group (TBG)** and agreed to act as the **exclusive U.S. distributor for TBG’s portfolio of brands for small‑format and food‑service customers**.  \n\nThe 2023 Form 10‑K repeats that same arrangement – PepsiCo still holds the **39 % non‑controlling equity stake** in TBG and continues to **serve as the exclusive distributor** of the Naked (and other TBG) brands, indicating that its operational role and financial ownership of Naked did not change between 2022 and 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct in terms of quantitative accuracy: it correctly identifies the 39% noncontrolling interest in TBG and the sale to PAI Partners in 2022, which aligns with the ground truth. The entity names (PepsiCo, Naked, PAI Partners, TBG) and years (2022, 2023) are accurate, and the financial stake is correctly reported. However, the critical error lies in the qualitative and reasoning aspects—the LLM claims that PepsiCo continued its role as exclusive distributor in 2023, which directly contradicts the ground truth stating that by 2023, PepsiCo no longer directly distributed Naked products and had ceased operational involvement. This misrepresents the evolution of the relationship, failing the multi-hop synthesis between the 2022 and 2023 disclosures. The answer incorrectly asserts continuity in distribution, when the actual shift was from operational involvement to a purely financial stake. While the wording and structure are relevant and mostly well-articulated, the core conclusion about the relationship’s stability is factually wrong, significantly undermining the correctness. Thus, despite strong quantitative accuracy, the failure to capture a key change in operational role results in a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 356,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the accounting treatment or disclosure around the ExtraBucks Rewards program evolved between 2023 and 2024, particularly regarding the recognition of revenue and the determination of performance obligations?",
      "original_answer": "In 2023, the ExtraBucks Rewards program was described as creating an additional performance obligation at the time of the initial transaction, with revenue allocated based on relative standalone selling prices that consider historical redemption patterns. Revenue was recognized as the rewards were redeemed, and unredeemed rewards were reflected as a contract liability. In 2024, the disclosure remained consistent in terms of revenue recognition timing and contract liability treatment, but the language around performance obligations became more refined, emphasizing that the determination of an additional performance obligation was specifically tied to customers who accumulate ExtraBucks based on historical spending levels. The 2024 filing also included more structured language around how the Company allocates transaction prices and evaluates standalone selling prices, suggesting a more mature and formalized approach to the program’s accounting treatment.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K the company treats ExtraBucks Rewards as a distinct performance‑obligation that is identified at the time of the original sale. The transaction price is allocated between the retail purchase and the reward based on each element’s relative standalone selling price (using historical redemption patterns), and revenue for the reward is recognized only when the points are actually redeemed, with any unredeemed balance recorded as a contract liability. The 2024 filing adds detail that the liability also reflects expected “breakage” (redemption that will never occur) and the impact of contract‑liability acquisitions, but the underlying revenue‑recognition approach and performance‑obligation determination remain unchanged.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in its description of the accounting treatment for the ExtraBucks Rewards program in both 2023 and 2024, correctly identifying the recognition of a distinct performance obligation, allocation of transaction price based on relative standalone selling prices using historical redemption patterns, and revenue recognition upon redemption with unredeemed amounts recorded as contract liabilities. All entities (ExtraBucks Rewards, Form 10-K, performance obligations, contract liability) and years (2023, 2024) are correct, and there are no numerical inaccuracies—this supports a high quantitative accuracy score of 10 and contextual relevance of 10. However, the qualitative accuracy is slightly lower because the LLM mischaracterizes the evolution between years. The original answer notes that the 2024 filing refined the language around performance obligations, specifically tying them to customers who accumulate ExtraBucks based on historical spending levels, and included more structured language on price allocation and standalone selling price evaluation—indicating a more mature approach. The LLM instead claims the 'underlying revenue-recognition approach and performance-obligation determination remain unchanged,' which contradicts the ground truth that there was a qualitative refinement in how performance obligations are described and assessed. Additionally, the LLM introduces 'breakage' and 'contract-liability acquisitions' as new disclosures in 2024, but these specific terms and concepts are not mentioned in the original answer, suggesting potential hallucination or overinterpretation. While the core accounting model is accurately summarized, the evaluation of the evolution in disclosure and treatment lacks precision, resulting in a correctness score of 7—reflecting accurate fundamentals but incomplete or slightly misleading characterization of the changes between years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1448,
        "completion_tokens": 519,
        "total_tokens": 1967
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Netflix's reliance on integrated payment partners evolved between 2023 and 2024, based on the specific details provided in the cost of revenues section for each year?",
      "original_answer": "In 2023, Netflix specifically mentioned that payment processing fees paid to integrated payment partners were part of other operating costs within the cost of revenues. In 2024, the company continued to reference payment processing fees paid to integrated payment partners as part of other operating costs, but the overall structure of the cost of revenues section was streamlined, removing some of the granular details about these fees. This indicates that while the relationship persisted, the level of explicit detail about the financial impact of integrated payment partners decreased, suggesting a shift in disclosure strategy rather than a substantive discontinuation of the relationship.",
      "llm_answer": "In the 2023 filing, Netflix’s cost‑of‑revenues was $19.7 billion and the footnote explained that “other operating costs include customer‑service and payment‑processing fees, **including those we pay to our integrated payment partners**.” In the 2024 filing the cost‑of‑revenues rose to $21.0 billion and the same description appears, again noting payments to integrated payment partners as part of those other operating costs. The increase in total cost‑of‑revenues (about $1.3 billion) – even as the cost‑of‑revenues share of total revenue fell from 58 % in 2023 to 54 % in 2024 – shows that Netflix’s reliance on integrated payment‑partner fees grew in absolute terms between 2023 and 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that payment processing fees to integrated payment partners were included in 'other operating costs' within cost of revenues in both 2023 and 2024, which aligns with the ground truth. However, it introduces specific financial figures—$19.7 billion for 2023 and $21.0 billion for 2024 cost of revenues, and a $1.3 billion increase—that are not present in the original answer or implied by the provided context. These numbers may be factually accurate in reality but were not part of the knowledge graph ground truth provided, making their inclusion unsupported in this evaluation context. Additionally, the claim that Netflix’s 'reliance... grew in absolute terms' due to rising total costs is an inference not confirmed by the original answer, which instead emphasizes a reduction in disclosure detail, not an increase in reliance. (2) The quantitative accuracy is partially correct in structure—cost of revenues increasing while representing a smaller share of revenue could indicate efficiency improvements—but since the specific dollar amounts and percentages (58%, 54%) are not in the original answer, they cannot be verified as part of the knowledge graph and thus constitute unsupported additions. (3) The multi-hop reasoning is flawed: the original answer focuses on a change in disclosure granularity (streamlining in 2024), indicating a shift in reporting, not necessarily in economic reliance. The LLM instead infers increased reliance based on total cost growth, which does not logically follow without direct data on payment partner fees themselves. It fails to capture the key qualitative point that explicit details about these fees were reduced in 2024, suggesting a disclosure strategy shift. (4) Correctness is scored at 5 because core elements (continued inclusion of payment partner fees in other operating costs) are accurate, but significant unsupported numerical claims and incorrect reasoning about 'increased reliance' undermine factual fidelity. Quantitative accuracy is 6 due to plausible but unverified numbers. Qualitative accuracy is 5 because the reasoning misinterprets the nature of the change (disclosure vs. economic). Contextual relevance is high (8) as the response stays on topic and addresses the evolution of payment partner treatment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 620,
        "total_tokens": 1973
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has 3M's approach to managing PFAS contamination in Minnesota evolved from 2022 to 2023, particularly in response to regulatory changes and new health-based standards?",
      "original_answer": "In 2022, 3M had substantially completed remediation work at the Cottage Grove site and was continuing operational and maintenance activities at Oakdale and Woodbury sites in Minnesota under the May 2007 Settlement Agreement and Consent Order. The company was also addressing PFAS discharges at its Decatur, Alabama facility under a 2020 interim Consent Order with ADEM, which included obligations for on-site and off-site investigations and future capital improvements. By 2023, the Minnesota Department of Health issued updated, more stringent Health Based Values (HBVs) for PFOA and PFOS in January 2024, prompting 3M to evaluate the potential impact on its obligations under the SACO. Additionally, MPCA issued a Notice of Violation in March 2023 alleging PFAS in stormwater discharge at 3M’s Hutchinson facility, and in December 2022, MPCA issued an order addressing stormwater from the Cottage Grove facility. In January 2024, MPCA proposed a new Clean Water Act permit for Cottage Grove with significantly revised, often below-quantification-level limits on PFAS, indicating a tightening regulatory environment that 3M is actively engaging with.",
      "llm_answer": "In the 2022 filing, 3M said it was carrying out the May 2007 Settlement Agreement with the Minnesota Pollution Control Agency – completing most of the soil‑ and groundwater‑remediation work at Oakdale, Woodbury and the Cottage Grove plant, providing alternative drinking water whenever a Health‑Based Value (HBV) or Health‑Risk Limit (HRL) was exceeded, and continuing routine operation‑and‑maintenance activities. By the 2023 filing, the company’s strategy had broadened in response to new regulatory actions: MPCA issued a storm‑water Notice of Violation and a draft Clean‑Water Act permit with much tighter PFAS limits, and the Minnesota Department of Health adopted more stringent HBVs for PFOA and PFOS, prompting 3M to develop a storm‑water mitigation plan, assess the impact of the stricter health‑based standards, and negotiate the new permit while still honoring its SACO remediation obligations.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of 3M's approach to PFAS contamination in Minnesota from 2022 to 2023, aligning closely with the ground truth. (1) Correct elements include: reference to the May 2007 Settlement Agreement with MPCA, substantial completion of remediation at Oakdale, Woodbury, and Cottage Grove by 2022, ongoing operation and maintenance, provision of alternative drinking water when HBVs/HRLs are exceeded, and continued SACO obligations. In 2023, the LLM correctly notes MPCA’s stormwater Notice of Violation (March 2023), the draft Clean Water Act permit with tighter PFAS limits, and the Minnesota Department of Health’s updated HBVs for PFOA and PFOS—though it incorrectly states they were adopted in the 2023 filing year, when they were issued in January 2024 (post-2023 filing). This is a minor timing misstatement but does not distort the causal relationship. (2) Quantitatively, all dates and regulatory actions are correctly cited except the HBV issuance: ground truth specifies January 2024, while LLM implies it occurred by 2023 filing—this is a small but notable error in temporal accuracy, hence quantitative accuracy docked slightly. (3) Multi-hop reasoning is strong: the LLM synthesizes information across time, regulatory bodies (MPCA, MDH), facilities (Cottage Grove, Hutchinson), and compliance frameworks (SACO, Clean Water Act), correctly inferring that tighter standards prompted new mitigation planning and permit negotiations. (4) The answer is contextually excellent—directly responsive to the question about evolving strategy in response to regulation and health standards. Only the slight misplacement of the HBV release date prevents a perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1520,
        "completion_tokens": 466,
        "total_tokens": 1987
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did PepsiCo's use of foreign currency derivatives evolve between 2022 and 2023, and what does this indicate about its foreign exchange risk management strategy?",
      "original_answer": "In 2022, PepsiCo reported a total notional value of $3.0 billion for its foreign currency derivatives, while in 2023, this value increased to $3.8 billion. This indicates a strategic expansion in the use of foreign currency derivatives to manage foreign exchange risk, likely in response to increased exposure or volatility in international markets. Additionally, the company emphasized the use of these derivatives to offset changes in the underlying hedged items, resulting in no material net impact on earnings in 2023.",
      "llm_answer": "PepsiCo’s foreign‑exchange derivative program grew markedly from 2022 to 2023.  The notional amount of its foreign‑currency contracts rose from about **$3.0 billion** at year‑end 2022 to roughly **$3.8 billion** at year‑end 2023, and the portion used as net‑investment hedges increased from **$2.9 billion** to **$3.0 billion**.  At the same time, the fair‑value balances of those derivatives expanded (cash‑flow‑hedge liabilities grew from $22 million to $31 million and non‑hedge liabilities from $21 million to $38 million), indicating that PepsiCo is intensifying its use of forward‑type contracts to offset currency risk and is relying more heavily on hedge accounting to manage its growing foreign‑exchange exposure.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in notional value of foreign currency derivatives from $3.0 billion in 2022 to $3.8 billion in 2023, matching the ground truth. It adds additional detail not present in the original answer—specifically, the breakdown of net-investment hedges increasing from $2.9B to $3.0B and fair-value balances (cash-flow-hedge and non-hedge liabilities). While these figures are plausible and consistent with intensifying derivative use, they were not included in the ground truth and cannot be verified as correct from the provided knowledge graph. This introduces unverified specifics but does not contradict known facts. (2) All stated numbers align with acceptable formats and no calculation errors are present. The core financial figures (total notional amounts) are accurate and properly compared across years. (3) The reasoning is sound: the LLM correctly infers that increased notional and fair-value exposures indicate a more active FX risk management strategy. It appropriately links growing derivative usage with hedge accounting and risk mitigation, which is logically consistent with the original answer’s conclusion about strategic expansion. However, it omits the key qualitative point from the original answer that there was 'no material net impact on earnings in 2023'—a critical indicator of hedging effectiveness that directly addresses the risk management outcome. (4) Despite this omission, the answer remains highly relevant and contextually appropriate, adding granular detail about hedge types and fair values. The core multi-hop synthesis—comparing derivative usage across years and interpreting strategic implications—is well-executed. The score is reduced slightly due to the omission of the earnings impact statement, which is central to evaluating the success of the risk management strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 507,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has ExxonMobil's approach to capitalizing on improving living standards evolved between 2022 and 2023, particularly in terms of chemical production capacity additions and geographic focus?",
      "original_answer": "In 2022, ExxonMobil highlighted the completion of a joint venture ethane cracker near Corpus Christi, Texas, and plans for up to 500,000 metric tons annually of advanced recycling capacity in Baytown, Texas, by 2026, as part of its strategy to meet growing demand driven by improving living standards. By 2023, the company shifted focus toward expanding performance polymers and linear alpha olefins capacity in Baytown, Texas, and advancing a 100% foreign-owned petrochemical complex in Dayawan, China, with over 2.5 million metric tons per year of polyethylene and polypropylene capacity. This reflects a strategic evolution from domestic advanced recycling and integrated U.S. projects to high-performance product expansions and significant foreign investment in China to meet local demand.",
      "llm_answer": "In the 2022 filing ExxonMobil said it was positioning to meet “improving living standards” by **re‑starting Gulf‑Coast growth projects (Baytown, Texas and Baton Rouge, Louisiana) and by taking a final investment decision on a new, fully‑foreign‑owned petrochemical complex in Huizhou, Guangdong, China** – a plan that would add ethane‑cracking and other derivative capacity ( page 67 ).  \n\nBy 2023 the company had moved from planning to **bringing new capacity on‑line**, launching a 400 k mt/yr performance‑polymers line and a 350 k mt/yr linear‑alpha‑olefins unit at Baytown, Texas, while still investing in the Dayawan complex in China that will eventually host three polyethylene and two polypropylene lines for **more than 2.5 million mt/yr** of capacity ( page 59 ).  \n\nThus, between 2022 and 2023 ExxonMobil shifted from announcing and restarting projects to actually operating new U.S. Gulf‑Coast units and expanding its Chinese footprint with a much larger, fully‑foreign‑owned complex.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution in ExxonMobil's strategy between 2022 and 2023—shifting from project announcements and restarts to operational execution and foreign expansion—but contains key factual inaccuracies. In 2022, the ground truth specifies the completion of a joint venture ethane cracker near Corpus Christi (not Baytown or Baton Rouge restarts) and plans for advanced recycling in Baytown. The LLM incorrectly attributes Gulf Coast project restarts and a final investment decision in Huizhou, China, to 2022, while the ground truth notes the Dayawan, China complex in 2023 without mentioning Huizhou or final investment timing. (2) Quantitative accuracy issues: the LLM states a 400 kmt/yr performance polymers line and 350 kmt/yr linear alpha olefins unit in Baytown, but the ground truth does not specify exact capacities for these 2023 projects—only that capacity was expanded. The 2.5 million mt/yr figure for China is correctly cited. However, the specific 400k and 350k figures appear to be fabricated or misattributed. (3) Reasoning is sound in identifying a strategic shift from planning to execution and increased focus on China, which aligns with the multi-hop requirement to compare 2022 and 2023 strategies. The synthesis of geographic focus (U.S. to China) and product focus (commodities to performance polymers) is qualitatively accurate. (4) Contextual relevance is high—the answer directly addresses chemical production capacity and geographic focus in both years. However, due to incorrect project details and fabricated capacity numbers, the correctness score is reduced to 7, with quantitative accuracy at 6 due to unsupported figures, qualitative accuracy at 8 for strong reasoning despite factual errors, and contextual relevance at 9 for staying tightly aligned with the question's intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1458,
        "completion_tokens": 501,
        "total_tokens": 1959
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did 3M's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "In 2022, 3M held $21 million in Certificates of Deposit/Time Deposits, which increased to $49 million in 2023 — more than doubling. This indicates a strategic shift toward increasing liquidity or reallocating short-term cash holdings into more stable or higher-yielding instruments within this category.",
      "llm_answer": "3M’s balance‑sheet shows that its holdings of certificates of deposit / time deposits rose from **$21 million at year‑end 2022 to $49 million at year‑end 2023**【page_64】.  \n\nThe jump more than doubles the amount of these short‑term, highly liquid assets, indicating that the company is shifting a larger portion of its cash into low‑risk, readily‑available investments to bolster liquidity and take advantage of short‑term interest‑rate opportunities.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values of $21 million in 2022 and $49 million in 2023 are accurately reported, and the statement that the amount more than doubled is correct (49/21 ≈ 2.33x). (2) The answer addresses both parts of the question: the evolution of 3M's investment in Certificates of Deposit/Time Deposits from 2022 to 2023, and the implication for the company's short-term investment strategy. (3) Entity accuracy is correct—3M is the right company, and the years 2022 and 2023 are properly referenced. (4) The reasoning is sound: increasing holdings in low-risk, liquid instruments like CDs/time deposits aligns with a strategy to enhance liquidity and capitalize on higher short-term interest rates, which is consistent with the ground truth interpretation. Minor wording differences (e.g., 'bolster liquidity' vs. 'increasing liquidity') do not affect semantic equivalence. The citation [page_64] adds contextual support. All criteria for correctness, completeness, and reasoning are met.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1196,
        "completion_tokens": 305,
        "total_tokens": 1501
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Mastercard's approach to proprietary insights evolved from 2022 to 2023, particularly in terms of data responsibility and trust-building language?",
      "original_answer": "In 2022, Mastercard described its proprietary insights as being based on the 'principled use of consumer and merchant data.' By 2023, the language evolved to emphasize 'principled and responsible use of secure consumer and merchant data.' This shift indicates a stronger emphasis on data security and trust as a core component of their proprietary insights strategy. The change in phrasing reflects a broader narrative around cybersecurity and stakeholder confidence in how Mastercard manages sensitive data.",
      "llm_answer": "In the 2022 filing Mastercard described its value‑added services as providing “proprietary insights, drawing on Mastercard’s **principled use** of consumer and merchant data” and said the solutions let parties “transact easily and with confidence.” By the 2023 filing the language had been expanded to stress **responsibility and security**, noting that the insights come from “our **principled and responsible** use of **secure** consumer and merchant data” and that the solutions enable parties to “transact **securely**, easily and with confidence.” Thus, Mastercard’s messaging shifted from a general principled‑use stance to a more explicit commitment to responsible, secure data handling to build trust.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately captures the evolution in Mastercard's language from 2022 to 2023: from 'principled use' to 'principled and responsible use' of 'secure' consumer and merchant data. The inclusion of 'securely' in the 2023 description of transaction capabilities is also correctly noted. (2) There are no numerical values to verify, but the years (2022 and 2023) are correctly attributed to the respective filings and phrasing changes. (3) The multi-hop reasoning is sound—comparing language across two years and interpreting the shift as a stronger emphasis on responsibility, security, and trust. The LLM correctly synthesizes the change in wording and infers the strategic intent behind it. (4) The answer is semantically equivalent to the original, with added contextual precision (e.g., quoting 'transact securely, easily and with confidence') that enriches rather than distorts the meaning. All parts of the question—evolution of approach, data responsibility, and trust-building language—are thoroughly addressed. Hence, all scores are 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 317,
        "total_tokens": 1624
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did the factors influencing the accounting estimates for pension and retiree medical plans evolve between 2022 and 2023, and what does this indicate about the changing external environment affecting these plans?",
      "original_answer": "In 2022, the accounting estimates for pension and retiree medical plans were influenced by uncertainties related to the ongoing impacts of the COVID-19 pandemic. By 2023, this had evolved, and the estimates were instead influenced by business and economic uncertainty stemming from the ongoing conflicts in Ukraine and the Middle East, as well as a high interest rate and inflationary cost environment. This indicates a shift in the external risk factors affecting the company's pension and retiree medical plans from health-related disruptions to broader macroeconomic and geopolitical concerns.",
      "llm_answer": "In the 2022 filing the company disclosed that “other liabilities” were “primarily related to pension and retiree medical plans” and the ROIC‑impact table shows a + 0.3 point pension/retiree‑medical‑related charge, reflecting the need to adjust assumptions for discount rates, inflation and demographic trends. By 2023 that line disappears – the impact is shown as “‑” (no material charge) and the liability note no longer calls out pension/medical plans, indicating the estimates no longer required a material adjustment. This shift suggests the external environment that drove those estimates – such as volatile interest‑rate and inflation assumptions and related demographic uncertainties – has eased or become more predictable, reducing the need for significant pension‑plan accounting adjustments.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its factual claims and misrepresents the evolution of accounting estimates for pension and retiree medical plans between 2022 and 2023. According to the ground truth, in 2022 the key factor was uncertainty from the ongoing impacts of the COVID-19 pandemic, while in 2023 it shifted to macroeconomic and geopolitical risks (conflicts in Ukraine and the Middle East, high interest rates, and inflation). The LLM instead claims that in 2022 there was a +0.3 point charge related to pension/retiree medical plans due to discount rates, inflation, and demographics, and that by 2023 this charge disappeared (marked as ‘-’), implying reduced volatility or stabilization. However, this specific quantitative data (+0.3 point, disappearance of charge) is not present in the ground truth and appears to be fabricated or misattributed. There is no mention of ROIC-impact tables or ‘other liabilities’ in the original answer, nor any indication that adjustments ceased to be material in 2023. The LLM incorrectly infers that the external environment has “eased” or become more predictable, when the ground truth indicates a shift in the nature of risks—from health-related (pandemic) to geopolitical and macroeconomic—not a reduction in uncertainty. This reflects a fundamental misunderstanding of the direction of change. While the LLM correctly identifies that external factors like inflation and interest rates are relevant, it fails to capture the actual evolution described in the ground truth. The reasoning is internally consistent but based on incorrect or hallucinated data, undermining both quantitative and qualitative accuracy. The answer is contextually relevant in discussing pension plan estimates and external factors, but the synthesis is flawed, failing the multi-hop requirement to accurately reflect changing risk drivers across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 514,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has ExxonMobil's undeveloped acreage position in the Other Americas region evolved between 2022 and 2023, and what does this indicate about the company's exploration potential in that region?",
      "original_answer": "ExxonMobil's undeveloped acreage in the Other Americas region decreased from 25,096 gross and 11,977 net thousands of acres in 2022 to 24,221 gross and 11,548 net thousands of acres in 2023. This indicates a reduction in the total acreage under evaluation, suggesting that some properties may have been relinquished or transitioned to developed status, while the company continues to focus on properties with higher exploration potential.",
      "llm_answer": "ExxonMobil’s undeveloped acreage in the “Other Americas” fell modestly from 2022 to 2023 – gross acreage dropped from 25,096 thousand acres to 24,221 thousand acres and net acreage fell from 11,977 thousand acres to 11,548 thousand acres【page_24】. The reduction shows the company is trimming a small portion of its undeveloped land base, yet it still retains more than 24 million gross (≈11.5 million net) acres, indicating a sizable pool of exploration opportunities that remain available in the region.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all numeric values from the ground truth: gross undeveloped acreage decreased from 25,096 thousand acres in 2022 to 24,221 thousand acres in 2023, and net acreage decreased from 11,977 to 11,548 thousand acres. These figures match the original answer exactly, satisfying quantitative accuracy. (2) The answer addresses both parts of the question—evolution of acreage (quantitative change) and its implication for exploration potential. The interpretation that the reduction reflects a trimming of the land base while still maintaining a large exploration pool is consistent with the ground truth’s suggestion that some properties may have been relinquished or reclassified, while focus remains on higher-potential areas. (3) The multi-hop reasoning is sound: the model correctly infers that a decrease in acreage does not necessarily indicate reduced exploration interest, but rather a strategic refinement, which aligns with the original answer’s logic. (4) The only minor shortcoming is that the LLM does not explicitly mention the possibility of acreage transitioning to developed status, which is included in the ground truth and adds nuance to the interpretation. However, the overall reasoning and factual content are highly accurate and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 374,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How did the treatment and financial impact of non-functional currency denominated items evolve from 2022 to 2023, particularly in terms of the use of foreign currency contracts not designated in hedging relationships?",
      "original_answer": "In 2022, MMM used foreign exchange forward and option contracts not designated in hedging relationships to offset the impacts of changes in value of various non-functional currency denominated items, including certain intercompany financing balances, with a gross notional amount of $3.7 billion. By 2023, the company continued to use such contracts for the same purpose but shifted focus to derivatives not designated as hedging instruments, with fair value gains and losses directly impacting earnings. This indicates a shift from primarily designated hedging strategies to a more direct financial exposure management approach.",
      "llm_answer": "In both years 3M continued to use foreign‑currency forward and option contracts that are **not** designated in hedging relationships to offset the value changes of non‑functional‑currency items (such as inter‑company financing balances). The exposure was sharply reduced in 2023 – the gross notional amount fell from $2.8 billion in 2022 to $1.0 billion in 2023 – and the earnings impact turned smaller and less favorable, with a $45 million gain recorded in income in 2022 versus a $21 million gain in 2023 (the fair‑value loss on those contracts was $‑76 million in 2022 and $‑9 million in 2023). Consequently, the overall translation effect moved from a pretax gain in 2022 to a pretax loss in 2023, reflecting the reduced use and diminished benefit of the non‑designated foreign‑currency contracts.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative details. (1) The gross notional amount in 2022 is stated as $2.8 billion in the LLM answer, but the ground truth reports $3.7 billion—this is a major discrepancy. (2) The LLM claims a $45 million gain in 2022 and $21 million gain in 2023 from these contracts, with fair value losses of -$76 million and -$9 million respectively; however, these figures are not present in the original answer and appear fabricated. The ground truth does not provide any specific gains or losses related to these contracts. (3) The LLM asserts that the notional amount dropped to $1.0 billion in 2023, but the original answer does not mention any specific notional amount for 2023 at all, so this number is unsupported. (4) The conclusion about a shift to 'diminished benefit' and a pretax loss in 2023 due to reduced use is speculative and not supported by the original answer, which instead emphasizes a strategic shift in the *type* of hedging instruments used (to non-designated derivatives impacting earnings directly), not a reduction in exposure or notional value. While the LLM correctly identifies that 3M used non-designated foreign exchange contracts in both years to manage non-functional currency items like intercompany balances, and that gains/losses impact earnings directly, it invents numerical data and trends (e.g., sharp reduction, specific gains/losses) that are not in the ground truth. The qualitative reasoning about earnings impact is partially aligned, but the multi-hop synthesis is flawed due to reliance on incorrect data. Contextually, the answer addresses the right topic and timeframe, hence moderate relevance, but the core financial evolution narrative is distorted by incorrect numbers and unsupported conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 490,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the role and emphasis of Cyber and Intelligence Solutions evolved within Mastercard's value proposition between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were mentioned as part of a broader list of value-added services, grouped alongside consulting fees, loyalty programs, gateway services, and other payment-related offerings. This suggests a supporting role within the company's portfolio. By 2023, the Cyber and Intelligence Solutions were more prominently positioned as a core component of Mastercard’s value proposition, explicitly described as enabling secure, easy, and confident transactions across the global payments ecosystem. This indicates a strategic shift toward elevating the importance of cybersecurity within Mastercard’s overall service offering.",
      "llm_answer": "In the 2022 filing, cyber and intelligence solutions were listed only as one component of a broad “other value‑added services” group that also included batch‑and‑real‑time payments, consulting, loyalty and gateway services. By the 2023 filing, Mastercard treats cyber and intelligence solutions as a distinct line‑item within “Other revenues,” explicitly describing them as fees for fraud‑prevention, detection and response services, and cites growth in these solutions as a key driver of the overall increase in value‑added services revenue—signaling a more prominent and clearly articulated role in its value proposition.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Cyber and Intelligence Solutions were part of a broader category of value-added services, listing relevant examples like consulting, loyalty, and gateway services. In 2023, it accurately notes the elevated status of the service line as a distinct 'Other revenues' component, with explicit mention of fraud-prevention, detection, and response services—consistent with the strategic emphasis described in the original answer. (2) There are no numeric values, percentages, or financial figures in either the question or answers, so quantitative accuracy is not applicable beyond correct referencing of years (2022 and 2023), which are accurate. (3) The multi-hop reasoning is sound: the model synthesizes changes in categorization and language between two years’ filings to infer a strategic shift, correctly identifying the evolution from a grouped service to a highlighted, growth-driving offering. (4) The LLM adds slightly more operational detail (e.g., 'fraud-prevention, detection and response services') not in the original answer but plausibly derived from the 10-K and consistent with the core idea of increased prominence. The only minor gap is that it does not explicitly state the broader strategic framing—'enabling secure, easy, and confident transactions'—from the 2023 filing mentioned in the ground truth. However, the emphasis on fraud services and revenue growth supports a similar conclusion. Thus, the answer is semantically equivalent with slightly different emphasis, warranting a high but not perfect qualitative score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 451,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the treatment or disclosure of Income Tax Expense and Accruals evolved in the list of critical accounting policies between 2022 and 2023?",
      "original_answer": "In 2022, 'income tax expense and accruals' was explicitly listed as one of the critical accounting policies and estimates, indicating its significance in financial reporting. By 2023, while still listed as a critical accounting policy, it was moved to a subsection under 'Our Critical Accounting Policies and Estimates' with a more structured presentation of related notes, such as Note 5 - Income Taxes, which provided deeper transparency into tax-related disclosures. This evolution reflects a shift toward more detailed and organized reporting of tax-related matters in 2023.",
      "llm_answer": "In the 2022 Form 10‑K the “Income Tax Expense and Accruals” policy was described in detail – PepsiCo explained that it determines an annual effective tax rate, establishes reserves for positions it believes could be challenged, adjusts those reserves (and related interest) as audits, new laws or settlements evolve, and applies the estimated rate to each quarter’s results. The 2023 filing still lists “Income Tax Expense and Accruals” as one of its critical accounting policies (it appears in the Table of Contents on page 58), but the excerpt provided does not include any revised language, indicating that the company has retained the same overall treatment and disclosure approach as in 2022.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that 'Income Tax Expense and Accruals' was a critical accounting policy in both 2022 and 2023, and accurately references its inclusion in the Table of Contents on page 58 in 2023. However, it contradicts the ground truth by stating that the 'excerpts provided do not include any revised language' and that the 'treatment and disclosure approach' remained the same. The original answer indicates a meaningful evolution in 2023 — specifically, a reorganization into a more structured presentation with deeper transparency via Note 5 - Income Taxes. The LLM answer fails to recognize or report this enhanced disclosure and structural change, which is central to the question about 'evolution' in treatment or disclosure. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable — no errors here. (3) The multi-hop reasoning is partially sound: the model correctly identifies the presence of the policy in both years and attempts to compare disclosures. However, it misses the key qualitative shift in presentation and transparency noted in the ground truth, indicating a failure to fully synthesize the evolution in reporting structure. (4) The correctness score is 5 due to partial factual accuracy — core entity and policy identification is correct, but the conclusion about no change is incorrect. Qualitative accuracy is 5 because reasoning is logical but incomplete. Contextual relevance is high (8) as the response stays on topic and addresses the policy’s presence and general description in both years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 446,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Intel's development and positioning of the Universal Chiplet Interconnect Express standard evolved between 2023 and 2024 in the context of its broader systems of chips strategy?",
      "original_answer": "In 2023, Intel introduced the Universal Chiplet Interconnect Express (UCIe) standard and demonstrated it in silicon, marking the initial phase of its strategic push to enable optimized systems of chips. By 2024, Intel had progressed beyond the demonstration phase and was actively producing based on this standard, integrating it into its broader advanced semiconductor assembly and test offerings. This evolution reflects Intel's deepening commitment to the UCIe standard as a core component of its systems of chips strategy, aimed at enhancing system performance and accelerating customer designs through advanced packaging technologies and system-level standards.",
      "llm_answer": "In the 2023 filing Intel said the Universal Chiplet Interconnect Express (UCIX) standard had just been **demonstrated in silicon** and was presented as a key piece of its “systems‑of‑chips” vision for linking chiplets together. By the 2024 filing Intel was no longer just announcing the demo; it was **re‑emphasizing UCIX as a core standard it continues to develop and promote** to accelerate customers’ designs through its advanced packaging, process‑technology and software ecosystem. Thus, between 2023 and 2024 the standard moved from an initial silicon proof‑of‑concept to a highlighted, ongoing pillar of Intel’s broader systems‑of‑chips strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Intel's UCIe standard from 2023 to 2024, noting the 2023 silicon demonstration and the 2024 shift toward ongoing development and promotion as a core strategic pillar. However, there is a critical error in the acronym: the LLM repeatedly refers to 'UCIX' instead of 'UCIe' (Universal Chiplet Interconnect Express), which is a factual inaccuracy in entity naming. Despite this, the overall trajectory—moving from proof-of-concept to a central element in Intel’s systems-of-chips strategy—is consistent with the ground truth. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable; however, the years 2023 and 2024 are used correctly in context, supporting a score of 10. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points (2023 and 2024 filings) and correctly infers strategic progression. The logic connecting silicon demonstration to broader strategic integration is valid, though the incorrect acronym slightly undermines entity accuracy. (4) The answer is contextually highly relevant and conveys the intended strategic evolution. The correctness score is 8 because the core facts and reasoning are accurate, but the repeated use of 'UCIX' instead of 'UCIe' is a notable factual error that could mislead, though it does not completely invalidate the answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 399,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the accounting treatment and completion timeline of CVS's Accelerated Share Repurchase (ASR) transactions evolved between the 2023 and 2024 10-K filings?",
      "original_answer": "In 2023, CVS completed a $2.0 billion ASR with Citibank, receiving 17.4 million shares initially (80% of the notional amount) and an additional 5.4 million shares in February 2023, concluding the transaction. The forward contract portion was reclassified from capital surplus to treasury stock upon completion. In 2024, CVS completed a $3.0 billion ASR with Morgan Stanley, initially receiving 31.4 million shares (85% of the notional amount) and an additional 8.3 million shares in March 2024. Similar to 2023, the forward contract was reclassified from capital surplus to treasury stock after the final shares were received. The accounting treatment remained consistent, but the scale and timeline of completion evolved, with the 2024 ASR taking two months to conclude compared to one month in 2023.",
      "llm_answer": "In both the 2023 and 2024 10‑K filings CVS continues to record each ASR as an **initial treasury‑stock purchase** for the portion of the notional amount received up‑front and a **forward contract** for the balance, which is first placed in capital surplus as an equity instrument and then **re‑classified to treasury stock** when the final tranche of shares is delivered. The only change is the **completion timing**: the 2022 (Barclays) and 2023 (Citibank) ASRs were settled one month after the January payment (February), whereas the 2024 ASR with Morgan Stanley required a longer settlement – the initial shares were received in January 2024 and the remaining 15 % were delivered in March 2024 before the forward contract was re‑classified.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the consistent accounting treatment—initial treasury stock for upfront shares and forward contract in capital surplus, later reclassified to treasury stock upon completion—which matches the ground truth. However, there are key quantitative inaccuracies: the LLM states the remaining 15% of shares were delivered in March 2024, but the ground truth specifies 8.3 million additional shares (not a percentage), and while 8.3M is approximately 21% of the total 39.7M shares (31.4M + 8.3M), the LLM incorrectly implies the final tranche was 15%, which does not align. Additionally, the LLM references a '2022 (Barclays)' ASR, which is not part of the question or ground truth and introduces an irrelevant transaction, reducing accuracy. (2) The dollar amounts ($2.0B in 2023, $3.0B in 2024) are not mentioned in the LLM answer, which omits a key quantitative dimension. The years and banks (Citibank 2023, Morgan Stanley 2024) are correct. The timeline is partially correct—2023 settlement in February (one month) and 2024 concluding in March (two months)—but the LLM incorrectly frames the 2024 ASR as starting in January 2024 with final delivery in March 2024 (two months), while the ground truth confirms the initial delivery was in January and final in March, which is consistent, but the LLM fails to quantify the share numbers (31.4M + 8.3M), weakening completeness. (3) The multi-hop reasoning is sound in comparing accounting treatment across years and identifying a shift in timeline, but the inclusion of a non-relevant 2022 ASR and mischaracterization of the final share percentage undermines the synthesis. (4) Despite missing specific numbers and introducing an extraneous example, the LLM captures the core evolution: consistent accounting, longer settlement in 2024. Hence, correctness is reduced due to quantitative omissions and errors, but qualitative reasoning and relevance remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 527,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did UPS's financial exposure and reporting approach related to the Central States Pension Fund evolve from 2022 to 2023, particularly in terms of actuarial estimates and sensitivity analysis?",
      "original_answer": "In 2022, UPS disclosed a $2.3 billion pre-tax actuarial loss related to potential coordinating benefits for the Central States Pension Fund, as part of broader pension obligation disclosures. By 2023, the company's reporting shifted focus to sensitivity analysis, referencing a 25 basis point change in expected and actual returns on assets as a key assumption affecting pension liabilities, with an explicit cross-reference to Note 5 for details on the Central States Pension Fund liability. This indicates a shift from quantifying a specific obligation to emphasizing the sensitivity of returns on the overall liability.",
      "llm_answer": "In the 2022 filing UPS reported its exposure to the Central States Pension Fund primarily through the actuarial gain/loss line item – a $5.1 billion pre‑tax gain that reflected a reduction in the estimated “coordinating‑benefits” liability after applying the year‑end discount‑rate assumptions (see the 2022 note on coordinating benefits). By the 2023 filing the company still used the same actuarial framework, but it added a quantitative sensitivity analysis (note 5) that shows how a 25‑basis‑point swing in the discount rate or in the expected return on plan assets would change the projected benefit obligation (e.g., a 25‑bp increase would cut the obligation by $1.55 billion and lower net periodic cost by $15 million), thereby making the potential impact of the CSPF liability more explicit.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that UPS reported a $2.3 billion pre-tax actuarial *loss* in 2022 related to potential coordinating benefits for the Central States Pension Fund. However, the LLM incorrectly claims a $5.1 billion pre-tax *gain*, which is both the wrong magnitude and the wrong direction (gain vs. loss). This is a critical error in financial reporting context. Additionally, the LLM introduces a sensitivity analysis involving a 25-basis-point change in the discount rate affecting the obligation by $1.55 billion and net periodic cost by $15 million — figures that are not present in the original answer and not supported by the ground truth. The ground truth specifies that the 2023 sensitivity analysis focused on a 25 basis point change in *expected and actual returns on assets*, not the discount rate, and does not quantify the dollar impact of that sensitivity. (2) Quantitative accuracy is very low: both the $5.1B gain (vs. $2.3B loss) and the $1.55B/$15M sensitivity impacts are incorrect. The years (2022 vs. 2023) and the nature of the disclosures are misaligned with the source. (3) Qualitatively, the LLM recognizes the shift in reporting approach from a specific actuarial estimate to sensitivity analysis, which aligns with the ground truth’s description of evolving disclosure focus. It also correctly identifies Note 5 as the source of pension details in 2023, showing some correct entity linkage. However, the reasoning is undermined by incorrect financial characterization (gain vs. loss) and misattribution of sensitivity assumptions (discount rate vs. return on assets). (4) Contextual relevance is moderate: the answer addresses the evolution of UPS’s reporting on the Central States Pension Fund and attempts to describe actuarial and sensitivity methods, but the core financial facts and assumptions are wrong, leading to a misleading conclusion. The multi-hop synthesis fails due to incorrect data inputs.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 541,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Mastercard's positioning and emphasis on its Cyber and Intelligence Solutions evolved between 2022 and 2023, particularly in terms of the value proposition communicated to stakeholders?",
      "original_answer": "In 2022, Mastercard described its Cyber and Intelligence Solutions as part of its value-added services that 'allow all parties to transact easily and with confidence' and emphasized principled use of consumer and merchant data. By 2023, the company expanded this messaging, positioning the solutions as central to enabling secure transactions and confidence in the payments ecosystem, while also linking them to strategic investments in new networks like open banking and digital identity. This reflects a broader integration of cyber solutions into the company's overall infrastructure narrative.",
      "llm_answer": "In the 2022 filing, Mastercard presented its Cyber & Intelligence solutions chiefly as a **growth engine**, noting that “the remaining increase … was primarily due to our Cyber & Intelligence and Data & Services solutions” and describing them as value‑added services that let parties “transact easily and with confidence.” By the 2023 filing, the language had shifted to a **broader, security‑focused value proposition**, positioning Cyber and Intelligence solutions alongside other value‑added services as tools that “make payments safer, simpler, smarter and accessible” and that “allow all parties to transact securely, easily and with confidence” while emphasizing responsible use of data. Thus, the emphasis moved from highlighting Cyber & Intelligence as a direct revenue driver to framing it as an integral part of a secure, confidence‑building ecosystem for all stakeholders.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in Mastercard's messaging between 2022 and 2023: in 2022, Cyber & Intelligence Solutions were highlighted as a growth engine and value-added service enabling confident transactions; by 2023, the emphasis shifted to a broader security-focused value proposition integrated into the payments ecosystem. The key phrases like 'transact easily and with confidence' and responsible data use are accurately reflected. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the original answer, so quantitative accuracy is not applicable—no errors here. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, compares the shift in language and strategic framing, and infers the evolution from revenue driver to ecosystem enabler. The only minor shortcoming is that the LLM does not explicitly mention the linkage to strategic investments in new networks like open banking and digital identity, which is part of the 2023 expansion per the ground truth. This omission slightly reduces completeness but does not distort the overall accurate narrative. (4) The answer is contextually relevant, directly addressing how the value proposition communicated to stakeholders evolved. Wording differs but semantic meaning matches. Thus, high scores across all dimensions with a 9/10 on correctness due to the missing reference to open banking and digital identity integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 428,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did PepsiCo's presentation of the 4.450% Senior Note due 2046 evolve between its 2022 and 2023 SEC filings, particularly in terms of exhibit referencing and associated documentation dates?",
      "original_answer": "In the 2022 filing, the 4.450% Senior Note due 2046 was listed as Exhibit 4.12, incorporated by reference from PepsiCo's Form 8-K filed on October 14, 2015. In the 2023 filing, the same note was reclassified as Exhibit 4.13 and referenced the Form 8-K filed on February 24, 2016. This indicates a shift in how PepsiCo organized or updated its capital structure disclosures, potentially reflecting revised documentation or administrative reclassification over time.",
      "llm_answer": "In the 2022 Form 10‑K the 4.450 % Senior Note due 2046 was listed as **Exhibit 4.4** and was tied to PepsiCo’s prior Current Report on Form 8‑K dated **October 14, 2015** (and a second entry pointed to the same Exhibit 4.4 in a later 8‑K dated **February 24, 2016**).  \n\nIn the 2023 Form 10‑K the same 4.450 % Senior Note appears again as **Exhibit 4.4**, but the reference now points to a much more recent Current Report on Form 8‑K filed **February 15, 2023** (the note is shown with a new maturity of 2033).  \n\nThus, between the two filings PepsiCo changed the supporting documentation for the 4.450 % Senior Note due 2046 from the 2015/2016 8‑K exhibits to a 2023 8‑K exhibit, updating the filing date (and, in the 2023 filing, the note’s maturity designation).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in the 2022 filing, the 4.450% Senior Note due 2046 was listed as Exhibit 4.12 (not 4.4 as claimed), referencing the Form 8-K filed on October 14, 2015. In the 2023 filing, it was reclassified as Exhibit 4.13 (again, not 4.4), referencing the Form 8-K filed on February 24, 2016 — not February 15, 2023 as the LLM claims. The LLM incorrectly states that the note’s maturity was changed to 2033 in the 2023 filing, which contradicts both the original answer and the premise of the question (the note remains due 2046). (2) Quantitative accuracy is very low: all exhibit numbers (4.4 vs 4.12/4.13), dates (February 15, 2023 vs February 24, 2016), and even the maturity year are incorrect. These are not formatting differences but fundamental factual errors. (3) The multi-hop reasoning is flawed — the LLM fails to correctly identify the exhibit renumbering and misattributes the documentation shift to a 2023 filing, suggesting a non-existent update. It invents a new maturity date, indicating a failure to synthesize or retrieve the correct information across filings. (4) Contextual relevance is moderate because the answer attempts to address exhibit referencing and documentation dates, but the incorrect data renders the response misleading. The core evolution — administrative reclassification between 2022 and 2023 with updated exhibit numbers and consistent underlying note — is misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 415,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Intel's relationship with Positive Technologies evolved between 2023 and 2024, particularly in terms of their engagement under OFAC licensing following the U.S. sanctions?",
      "original_answer": "In 2023, Intel disclosed that it had communicated with Positive Technologies regarding IT security research and coordinated disclosure of vulnerabilities, and that it resumed such communications under an OFAC license following the sanctions. By 2024, Intel's relationship had evolved from mere disclosure of past communication to an explicit statement of intent to continue these interactions in accordance with the OFAC license. While both years clarify that there were no gross revenues or net profits associated with these activities, the 2024 filing reflects a more forward-looking and sustained partnership posture with Positive Technologies under the sanctioned conditions.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K disclosures state that after Positive Technologies was designated on April 15 2021, Intel resumed its pre‑designation security‑research communications with the firm under a specific OFAC General License. In each filing Intel emphasizes that the interactions generate no gross revenue or profit and that it “plans to continue these communications in accordance with the terms and conditions of the OFAC license.” Thus, between 2023 and 2024 Intel’s relationship with Positive Technologies remained unchanged – limited, license‑authorized information‑sharing with no commercial component.",
      "correctness_score": 5,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a critical misinterpretation of the evolution in Intel's relationship with Positive Technologies between 2023 and 2024. (1) Quantitatively, the answer correctly references the April 15, 2021 designation date and accurately notes the absence of gross revenue or profit, which aligns with the ground truth. The mention of OFAC licensing is factually consistent. (2) However, the core reasoning error lies in claiming the relationship 'remained unchanged' between 2023 and 2024. This contradicts the ground truth, which states that while 2023 merely disclosed past communication, 2024 included a forward-looking commitment to continue interactions—indicating a shift toward a more sustained and intentional partnership posture under the license. The LLM incorrectly concludes no change occurred, missing this qualitative evolution. (3) The multi-hop synthesis fails to capture the nuanced progression from retrospective disclosure to prospective engagement. While entities (Intel, Positive Technologies, OFAC), years (2023, 2024), and context (sanctions, licensing) are correctly identified, the reasoning does not reflect the evolving nature of the relationship as required by the question. (4) Therefore, despite strong quantitative and contextual accuracy, the qualitative inaccuracy in interpreting the relationship's development significantly undermines the correctness, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 398,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has the balance of CVS's 4.78% Senior Notes due March 2038 evolved between 2023 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "The balance of CVS's 4.78% Senior Notes due March 2038 remained stable at $5,000 million in both 2023 and 2024, indicating that the company did not retire or issue additional amounts of this particular debt instrument during the period. This stability contrasts with other senior notes, such as the 2.7% senior notes due August 2040, which decreased from $1,250 million in 2023 to $367 million in 2024, suggesting selective debt management and refinancing activity in other long-term obligations.",
      "llm_answer": "The tables of long‑term borrowings show that CVS carried $5.0 billion of the 4.78 % senior notes due March 2038 at both December 31 2023 and December 31 2024 (the amount is listed as 5,000 million in each year’s “borrowings” schedule). Because the balance did not change, the company has left this tranche untouched while issuing and retiring other notes, indicating that the 4.78 % March 2038 issue remains a stable component of CVS’s long‑term debt structure rather than a target for early repayment or refinancing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that the balance of CVS's 4.78% Senior Notes due March 2038 remained at $5,000 million (or $5.0 billion) in both 2023 and 2024, matching the ground truth exactly. All numeric values, dates, and percentages are accurate. (2) Quantitative accuracy is perfect: the dollar amount, interest rate (4.78%), maturity date (March 2038), and time points (2023 and 2024) are all correctly reported. Format variation ($5.0 billion vs. 5,000 million) is acceptable and clearly equivalent. (3) The reasoning is sound: the LLM correctly infers that the stability of this debt tranche indicates it was not targeted for retirement or refinancing, which aligns with the ground truth’s implication of selective debt management. However, the LLM does not explicitly contrast this stability with changes in other notes (e.g., the 2.7% senior notes due August 2040 decreasing from $1,250M to $367M), which is a key part of the multi-hop synthesis in the original answer. This omission slightly weakens the qualitative depth, though the core logic remains valid. (4) The answer is highly contextually relevant, directly addressing both parts of the question—evolution of the note balance and its implication for long-term debt structure. The conclusion about stability is well-supported. Scored 9/10 for correctness due to missing comparative context with other senior notes, which limits full multi-hop synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 398,
        "total_tokens": 1657
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has the status of the 0.835% Notes due 2032 evolved between the 2022 and 2024 SEC filings for Exxon Mobil Corporation?",
      "original_answer": "In the 2022 filing, the 0.835% Notes due 2032 were listed among other notes with distinct trading symbols, including the 0.142% Notes due 2024 (XOM24B), indicating a broader set of publicly traded debt instruments. By 2024, the 0.835% Notes due 2032 remained listed with the trading symbol XOM32, but the 0.142% Notes due 2024 no longer appeared in the 2024 filing, suggesting that the 2024 notes were either redeemed or no longer publicly traded. Therefore, while the 0.835% Notes due 2032 remained a consistent part of Exxon Mobil's publicly disclosed debt structure, the removal of the 2024 notes indicates a change in the company's short-to-intermediate term debt composition.",
      "llm_answer": "Both the 2022 and the 2024 Form 10‑K filings list the 0.835 % Notes due 2032 among Exxon Mobil’s registered debt securities. The notes appear in the 2022 filing’s securities table and are again shown in the 2024 filing’s table, indicating that they remain outstanding and have not been retired, amended or otherwise removed between the two reports.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually correct in stating that the 0.835% Notes due 2032 were listed in both the 2022 and 2024 Form 10-K filings, confirming their continued outstanding status. All quantitative elements—interest rate (0.835%), maturity year (2032), and the comparison across 2022 and 2024—are accurate. However, the LLM answer is incomplete compared to the ground truth, which includes additional multi-hop reasoning: the 2022 filing included the 0.142% Notes due 2024 (XOM24B) alongside the 2032 notes, but these 2024 notes were absent in the 2024 filing, suggesting redemption or delisting. This contextual change highlights a shift in Exxon Mobil’s debt composition, which the LLM answer omits. While the core fact about the 2032 notes is correct and relevant, the lack of comparative analysis with other notes (especially the disappeared 2024 notes) limits the depth of reasoning. The answer is semantically aligned on the status of the 2032 notes but fails to synthesize the broader evolution in the debt structure, which is central to the question about 'evolution' between filings. Thus, quantitative accuracy is perfect, qualitative accuracy is reduced due to incomplete reasoning, and overall correctness is good but not comprehensive.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 348,
        "total_tokens": 1599
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has American Express's investment strategy toward U.S. Government treasury obligations evolved between 2022 and 2024, particularly in terms of fair value allocation and maturity distribution?",
      "original_answer": "In 2022, American Express held U.S. Government treasury obligations exclusively in short-term instruments with a fair value of $477 million and no long-term exposure. By 2024, the company shifted its strategy to include both short-term ($189 million) and intermediate-term ($98 million) treasury obligations, indicating a more diversified maturity profile. This reflects a transformation in the company's investment approach, expanding beyond less than 12-month instruments to include holdings maturing within 1 to 5 years.",
      "llm_answer": "American Express sharply trimmed its exposure to U.S. Treasury securities. In the 2022 filing the company held $1.68 billion of Treasury debt at cost (fair‑value $1.704 billion), but by 2024 the portfolio was only $289 million at cost (fair‑value $287 million) 【page_120†L13-L19】【page_124†L13-L19】. At the same time the maturity profile moved from a mix of short‑ and medium‑term holdings (≈$832 m due ≤ 1 yr, $862 m due 1‑5 yr, $10 m due 5‑10 yr) to a much tighter, short‑dated slate (≈$189 m due ≤ 1 yr and $98 m due 1‑5 yr, with no longer‑dated Treasuries) 【page_121†L31-L38】【page_126†L9-L13】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative Accuracy: The reported 2022 fair value of $1.704 billion and cost of $1.68 billion contradict the ground truth, which states a 2022 fair value of $477 million in short-term instruments only. Similarly, the 2024 fair value is reported as $287 million, whereas the ground truth specifies $189 million (short-term) + $98 million (intermediate-term) = $287 million total — this total is correct, but the breakdown is misrepresented as a reduction rather than a strategic shift. The LLM incorrectly frames the change as a 'sharp trim' in exposure, which is not supported by the ground truth: $477M (2022) vs $287M (2024) may indicate a decrease, but the key evolution is diversification in maturity, not just size. (2) More critically, the 2022 maturity distribution described in the LLM answer — with $832M ≤1 yr, $862M 1-5 yr, and $10M 5-10 yr — directly contradicts the ground truth that American Express held *exclusively* short-term instruments in 2022 with *no long-term exposure*. This is a major factual error. (3) Qualitative Accuracy: The reasoning is flawed because it mischaracterizes the investment strategy evolution. The ground truth emphasizes a shift from *only short-term* to *including intermediate-term*, indicating diversification. The LLM instead portrays it as a portfolio contraction with a 'tighter, short-dated slate', which misrepresents the strategic expansion in maturity range. (4) Contextual Relevance: The answer addresses fair value and maturity distribution, so it is relevant to the question, but the incorrect data and misinterpretation of the strategy shift severely limit its usefulness. While the 2024 figures align approximately ($189M + $98M = $287M), the synthesis across years is invalid due to incorrect 2022 data. The citations reference specific pages but conflict with the verified ground truth, suggesting possible misreading of source data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 533,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Amazon's introduction and subsequent treatment of the 2.500% Note due 2050 evolve between 2022 and 2024?",
      "original_answer": "In 2022, the 2.500% Note due 2050 was introduced as part of an Officers' Certificate dated June 3, 2020, and was listed alongside other notes in Exhibit 4.5. By 2024, the 2.500% Note due 2050 was reintroduced in Exhibit 4.6, which was an exact replication of Exhibit 4.5 from 2020, indicating that Amazon continued to maintain this long-term debt instrument without modification. The reintroduction in 2024 reaffirmed the note's role in Amazon's capital structure.",
      "llm_answer": "Amazon first disclosed the 2.500 % Note due 2050 in its 2022 Form 10‑K as part of Exhibit 4.5 – an Officers’ Certificate dated June 3 2020 that listed that note together with several other senior‑rate notes. In the 2024 Form 10‑K the same note is still shown, now appearing in Exhibit 4.6 (the same June 3 2020 Officers’ Certificate) and is again listed among the company’s outstanding debt instruments, indicating that the note remains outstanding and has not been retired, amended or otherwise removed between the two filings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2.500% Note due 2050 was first disclosed in the 2022 Form 10-K as part of Exhibit 4.5, which references the Officers’ Certificate dated June 3, 2020; in the 2024 Form 10-K, it appears in Exhibit 4.6, which is the same document. These details match the original answer exactly. (2) Quantitative accuracy is perfect: dates (June 3, 2020), percentages (2.500%), maturity year (2050), exhibit numbers (4.5 and 4.6), and filing years (2022 and 2024) are all correct. Format variations (e.g., spacing in '2.500 %') do not affect meaning. (3) The multi-hop reasoning is sound—linking the 2022 and 2024 disclosures to show continuity of the note in Amazon’s capital structure without amendment or retirement. The answer correctly infers that the note remains outstanding based on its reappearance in a later filing. (4) The only minor shortcoming is that the LLM does not explicitly state that Exhibit 4.6 in 2024 is an 'exact replication' of Exhibit 4.5 from 2020, though this is implied by saying it's the 'same' certificate. This slight omission prevents a perfect 10 on qualitative accuracy, but the core reasoning and synthesis remain strong. Overall, the answer is contextually complete, precise, and directly responsive to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 373,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the number of amendments to the Citibank, N.A. Co-Branded Credit Card Agreement evolve between 2022 and 2023?",
      "original_answer": "In 2022, the most recent amendment to the Citibank, N.A. Co-Branded Credit Card Agreement was the Eighth Amendment, filed on March 10, 2022. By 2023, the agreement had undergone further modifications, with the Twelfth Amendment being filed on October 11, 2023, indicating a total of four additional amendments during this period. This demonstrates a continued evolution and refinement of the agreement terms over the 12-month period.",
      "llm_answer": "The 2022 Form 10‑K exhibit list shows the Citibank, N.A. Co‑Branded Credit Card Agreement through its **tenth amendment** (10.8.9 – Ninth Amendment and 10.8.10 – Tenth Amendment, both filed 12/29/2022)【page_68†L9-L14】.  \n\nThe 2023 Form 10‑K exhibit list extends the same agreement to an **eleventh and twelfth amendment** (10.8.11 – Eleventh Amendment filed 3/9/2023 and 10.8.12 – Twelfth Amendment filed 10/11/2023)【page_68†L9-L14】.  \n\nThus, the number of listed amendments grew from **10 amendments in 2022** to **12 amendments in 2023**, adding two new amendments during 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is partially correct but contains a critical factual discrepancy in the number of amendments in 2022. The ground truth states that the most recent amendment in 2022 was the Eighth Amendment, filed on March 10, 2022. However, the LLM claims that by the end of 2022, the agreement had reached the Tenth Amendment, citing two amendments filed on December 29, 2022. This contradicts the original answer and introduces conflicting data not present in the ground truth. The 2023 information aligns with the ground truth: the Twelfth Amendment was indeed filed on October 11, 2023. However, the LLM reports an Eleventh Amendment on March 9, 2023, which is not mentioned in the original answer. While the net increase of two amendments (from 10 to 12) is consistent with the LLM’s internal logic, the ground truth indicates four additional amendments occurred between 2022 and 2023 (from Eighth to Twelfth), implying the LLM undercounts the number of new amendments. Thus, the quantitative accuracy is compromised due to incorrect starting and intermediate amendment counts. The reasoning is logically structured and contextually relevant, correctly interpreting the evolution as an increase in amendment numbers year-over-year. Entity identification (Citibank, N.A. Co-Branded Credit Card Agreement) and time periods (2022–2023) are accurate. The multi-hop synthesis across 2022 and 2023 filings is appropriate, but based on incorrect source data. Therefore, while the conclusion that two new amendments were added in 2023 is internally consistent, it conflicts with the ground truth assertion of four additional amendments over the period. This results in a moderate correctness score due to significant factual divergence on key numbers despite sound structure and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 482,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration with new computing architectures and software ecosystems?",
      "original_answer": "In 2022, NVIDIA emphasized CUDA as a foundational building block across its target markets, including Gaming, Data Center, Professional Visualization, and Automotive, highlighting its role in enabling accelerated computing and deep learning. CUDA was positioned as a core component of the company's unified architecture, supporting a wide range of applications through internal and third-party software stacks. By 2024, NVIDIA had significantly expanded the scope of CUDA's integration, describing it as part of a broader full-stack computing platform that includes the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific application frameworks. Additionally, CUDA was now explicitly tied to NVIDIA's expanded data center platform, which now includes CPUs (introduced in fiscal 2024) alongside GPUs and DPUs, showing a strategic evolution toward deeper integration with heterogeneous computing architectures and enterprise-grade AI ecosystems.",
      "llm_answer": "In the 2022 filing NVIDIA described CUDA primarily as the core parallel‑programming model that runs on its GPUs and underpinned a developer ecosystem of roughly three million users. By the 2024 filing CUDA is portrayed as a cornerstone of a full‑stack platform that now spans heterogeneous compute units—including the new Blackwell GPU architecture, the Grace data‑center CPU and the DPUs introduced in FY‑2022—and is packaged with the CUDA‑X libraries, SDKs and APIs to support AI, HPC, graphics and edge workloads across an expanded software ecosystem. This reflects a shift from a GPU‑only programming model to an integrated, cross‑architecture foundation for NVIDIA’s broader computing stack.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution of CUDA from a GPU-centric programming model in 2022 to a full-stack, cross-architecture platform by 2024. Key elements such as the expansion into heterogeneous computing (GPUs, CPUs, DPUs), integration with CUDA-X libraries, SDKs, and APIs, and the role in AI, HPC, and enterprise ecosystems are all present and factually correct. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; all references to years (FY-2022, 2024) are consistent with the source. (3) The multi-hop reasoning is sound: the LLM synthesizes CUDA’s role across time, architectures (Blackwell GPU, Grace CPU), and software ecosystems, correctly inferring a strategic shift from GPU-only to heterogeneous integration. The mention of 'developer ecosystem of roughly three million users' is not in the original answer, but this detail does not contradict the ground truth and may reflect additional context from the filing; however, its inclusion slightly deviates from the provided ground truth, preventing a perfect 10. (4) The answer is contextually relevant, directly addressing the evolution of CUDA in integration with new architectures and software ecosystems between 2022 and 2024. Overall, the LLM conveys semantic equivalence with high fidelity, demonstrating strong qualitative and contextual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 410,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Pfizer's financial relationship with Paxlovid evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual obligations?",
      "original_answer": "In 2023, Paxlovid generated $1.279 billion in revenue, but this figure was significantly impacted by a non-cash revenue reversal of $3.5 billion due to the expected return of 6.5 million treatment courses of EUA-labeled U.S. government inventory. By 2024, this reversal was adjusted favorably by $771 million as only 5.1 million treatment courses were actually returned, and an additional $442 million in revenue was recorded in connection with the creation of the U.S. Strategic National Stockpile (SNS). Furthermore, as of December 31, 2024, Pfizer reported approximately $1 billion in remaining performance obligations related to Paxlovid supply contracts, indicating ongoing but reduced commercial activity compared to the prior year. This evolution reflects a shift from a high-volume, government-driven revenue model in 2023 to a more stable, contracted future delivery model in 2024.",
      "llm_answer": "In 2023 Pfizer’s Paxlovid sales collapsed – revenue fell to $1.3 billion (down 92 % from 2022) and a $3.5 billion non‑cash reversal was recorded for the expected return of 6.5 million EUA‑labeled courses, leaving $5.1 billion of Paxlovid‑related deferred revenue on the balance sheet. By 2024 the company had amended its government contracts, shifted the product to the commercial market and recognized the previously‑deferred amounts (including a $771 million favorable adjustment and $442 million SNS revenue), boosting Paxlovid revenue to $5.7 billion, cutting deferred revenue to $2.2 billion and leaving roughly $1 billion of remaining performance‑obligation contracts for future deliveries.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. While it correctly identifies the $3.5 billion non-cash reversal in 2023 due to expected returns of 6.5 million treatment courses, it incorrectly states that Paxlovid revenue in 2023 was $1.3 billion — the ground truth is $1.279 billion, which is acceptable as a rounded figure. However, the LLM claims that 2024 Paxlovid revenue increased to $5.7 billion, which is not supported by the original answer. The original does not state total 2024 Paxlovid revenue; instead, it mentions a $771 million favorable adjustment and $442 million in SNS-related revenue — these are incremental adjustments, not total revenue. The LLM incorrectly aggregates these into a total revenue figure of $5.7 billion, which is a major quantitative error. Additionally, the claim that deferred revenue was cut to $2.2 billion is unsupported — the original answer does not mention deferred revenue balances in 2024. The $1 billion in remaining performance obligations is correctly cited. (2) The calculation of a 92% drop from 2022 is not in the ground truth and cannot be verified from the provided information; thus, introducing this comparison is speculative. The favorable adjustment of $771 million and $442 million SNS revenue are correctly identified as occurring in 2024. (3) The reasoning partially captures the shift from government-driven to contracted delivery, and the multi-hop synthesis of revenue reversal, adjustment, and future obligations is partially sound, but the incorrect aggregation of incremental adjustments into total revenue undermines the logic. (4) The contextual relevance is high — the answer addresses revenue recognition and contractual obligations as asked. However, due to significant numerical inaccuracies and unsupported calculations, the correctness score is limited to 5, with lower quantitative accuracy dragging down the overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 530,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the availability and structure of shares under the 2003 Incentive Program evolved between 2022 and 2024?",
      "original_answer": "In 2022, the 2003 Incentive Program had 65,754,069 shares available for award. By 2024, the total maximum number of shares that could be issued under the program was increased to 220 million, with 47 million remaining available for awards by the end of 2024. This indicates a significant expansion in the program's capacity, although actual usage had grown moderately over time, with restricted stock units granted increasing from 9,392 thousand in 2022 to 10,393 thousand in 2024.",
      "llm_answer": "The 2003 Incentive Program continued to be a “no‑term” equity‑based plan that can issue stock options, stock‑appreciation rights, restricted stock and other awards (options and SARs must be granted at ≥ 100 % of market price and may have up to a 10‑year term, with a total ceiling of 220 million shares). In the 2022 filing the company reported that about **65.8 million shares** were still available for grant, whereas the 2024 filing shows that the pool had fallen to **approximately 47 million shares** remaining. Thus, between 2022 and 2024 the program’s share availability declined by roughly 18 million shares, while its overall structure and maximum limit remained unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the evolution of share availability. While it correctly states that 65.8 million shares were available in 2022 (matching the ground truth of 65,754,069), it incorrectly claims that the 220 million share ceiling was already in place in 2022 and remained unchanged. The ground truth indicates that the maximum number of shares was *increased* to 220 million by 2024, implying a structural change, not a static cap. The LLM fails to mention this key expansion, misrepresenting the program's evolution. Additionally, the LLM states that the share pool 'declined' to 47 million by 2024 due to usage, but omits that the total authorized shares had actually increased significantly, making the remaining 47 million consistent with a larger overall program. (2) Quantitatively, the 65.8 million (2022 available) and 47 million (2024 remaining) figures are approximately correct, though the LLM rounds 65,754,069 to 65.8 million, which is acceptable. However, it misses the critical detail that the total maximum shares rose to 220 million by 2024, and incorrectly implies the cap was always 220 million. The claim of an 18 million share decline is misleading because it ignores the increase in total authorization. (3) The multi-hop reasoning is flawed: the model fails to synthesize the increase in the program's total capacity between 2022 and 2024, which is central to the question about 'evolution'. It also omits the increase in restricted stock units granted (from 9,392 thousand to 10,393 thousand), a key indicator of usage trends. (4) Contextual relevance is high—the answer addresses share availability and program structure—but correctness is undermined by missing the expansion of the share ceiling, a core aspect of the program's evolution. Thus, while some numbers are accurate, the overall narrative is factually incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 516,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has AdSense's role within Google's advertising revenue streams evolved between 2022 and 2024, particularly in relation to the company's broader advertising technology portfolio?",
      "original_answer": "In 2022, AdSense was explicitly cited as a key growth driver within the Google Network, contributing to an $8.6 billion year-over-year revenue increase alongside AdMob and Google Ad Manager. By 2024, while AdSense remained part of the Google Network, it was no longer specifically quantified as a growth lever. Instead, newer AI-powered advertising products like Demand Gen and Performance Max were highlighted as central to advertiser success, suggesting a strategic shift where AdSense became a more foundational, mature offering within Google's broader advertising technology stack.",
      "llm_answer": "In the 2022 filing, Google Network revenue – the segment that houses the company’s publisher‑facing products – was still described as being “driven by strength in AdMob, Google Ad Manager, and AdSense,” even though impressions from AdSense had slipped that year (see 2022 page 35). By the 2024 filing, AdSense is no longer called out as a separate growth engine; the discussion of advertising now centers on AI‑powered, integrated solutions such as Demand Gen, Performance Max, Product Studio and other Google‑wide ad‑tech platforms (see 2024 pages 8‑9). This reflects a shift from treating AdSense as a distinct revenue pillar in 2022 to embedding its functionality within a broader, AI‑driven advertising technology portfolio by 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: AdSense was explicitly named as a growth driver in 2022 alongside AdMob and Google Ad Manager, and by 2024 it was no longer highlighted as a standalone growth lever. The shift toward AI-powered products like Demand Gen and Performance Max is accurately described, with appropriate context about integration into broader ad-tech platforms. (2) Quantitative accuracy is perfect—while the $8.6 billion year-over-year increase in Google Network revenue is not explicitly mentioned in the LLM answer, this figure is contextually implied through the reference to AdSense being part of a growing segment in 2022. The omission is minor and does not detract from the core correctness, especially since the LLM correctly identifies the trend without misrepresenting any numbers. (3) Multi-hop reasoning is sound: the model synthesizes information across 2022 and 2024 filings, correctly infers a strategic evolution from AdSense as a named growth driver to its integration within AI-driven platforms, and supports this with specific product names and filing references. (4) Semantic equivalence is strong—the LLM conveys the same conclusion as the original answer using different but equally valid phrasing (e.g., 'embedding its functionality' vs 'became a more foundational, mature offering'). The only reason for not scoring a 10 is the slight incompleteness in omitting the specific $8.6B revenue growth figure, which was part of the original answer’s quantitative grounding. However, this does not undermine the overall correctness or interpretation of the trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 454,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did the UPS Retirement Plan's benefit accrual structure evolve between 2022 and 2023, and what specific changes were made to future benefit accruals for non-union participants?",
      "original_answer": "In 2022, the UPS Retirement Plan was described as noncontributory and covering substantially all eligible employees hired before July 1, 2016, who were not part of a collective bargaining unit or certain employees covered by a collective bargaining agreement. The plan provided retirement benefits based on average compensation and was subject to IRS limits. It was also disclosed that the plan would cease accruals of additional benefits for future service and compensation for non-union participants effective January 1, 2023. In 2023, this cessation of accruals was confirmed as effective, and the plan was described with the same eligibility and benefit structure but explicitly stated that no further accruals would occur for non-union participants. This marks a transformational change in the plan's structure, as the accrual freeze was implemented as planned, shifting the plan from an active benefit-accruing structure to a closed one for non-union employees. The change represents a significant strategic shift in UPS's retirement benefit policy.",
      "llm_answer": "In the 2022 filing the UPS Retirement Plan was still a non‑contributory, defined‑benefit plan that accrued benefits based on average compensation, but the company disclosed that it would **stop accruing any additional benefits for future service or compensation for non‑union participants beginning January 1 2023**. By the 2023 filing that change had taken effect, so the plan no longer adds benefit credits for non‑union employees after that date, effectively freezing their future accruals.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the essential evolution of the UPS Retirement Plan between 2022 and 2023. (1) It correctly identifies that in 2022, the plan was still accruing benefits but with a disclosed intention to cease future accruals for non-union participants effective January 1, 2023. It accurately states that by 2023, this change had taken effect, freezing future benefit accruals for non-union employees. (2) All dates (January 1, 2023) and plan characteristics (non-contributory, defined-benefit, based on average compensation) are factually correct and match the ground truth. There are no numerical inaccuracies, and while no calculations are involved, the timeline and implementation status are precise. (3) The multi-hop reasoning—synthesizing disclosures from two consecutive years to show a policy transition—is sound. The LLM correctly infers the transformation from an active to a frozen state based on the implementation of the previously announced change. (4) The answer is contextually excellent, directly addressing both parts of the question: the evolution over time and the specific change to future accruals. The only minor shortcoming is that it omits some contextual details present in the original answer—such as the eligibility cutoff date (hired before July 1, 2016) and the mention of IRS limits—but these omissions do not detract from the core factual accuracy or the main thrust of the change. Thus, the answer is semantically equivalent in substance, meriting a high score but not perfect completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 425,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Amazon's utilization and structure of its short-term credit facilities evolved between 2022 and 2024, particularly in terms of credit capacity, interest rate terms, and outstanding borrowings?",
      "original_answer": "In 2022, Amazon had a $7.0 billion unsecured revolving credit facility with an interest rate of benchmark rate plus 0.50% and a commitment fee of 0.04%, and no borrowings were outstanding under this facility. Additionally, Amazon had $7.2 billion in unused letters of credit as of December 31, 2021. By 2024, Amazon had significantly expanded its credit capacity by entering into a new $15.0 billion unsecured revolving credit facility with a lower interest rate of benchmark rate plus 0.45% and a reduced commitment fee of 0.03%. In addition, Amazon introduced a new $5.0 billion unsecured 364-day revolving credit facility in October 2024, which also carried a rate of SOFR plus 0.45% and a 0.03% commitment fee. Notably, there were still no borrowings outstanding under the main Credit Agreement or the Short-Term Credit Agreement as of December 31, 2024. However, Amazon had $147 million and $151 million in borrowings under other short-term credit facilities as of December 31, 2023 and 2024, respectively, which were included in 'Accrued expenses and other.' The company also increased its unused letters of credit to $8.3 billion by the end of 2024.",
      "llm_answer": "By 2022 Amazon’s short‑term financing consisted of a single $7 billion unsecured revolving credit facility (benchmark + 0.50%, 0.04% commitment fee) and a commercial‑paper program of up to $10 billion; neither the revolving facility nor the commercial‑paper program had any borrowings outstanding at year‑end (the only short‑term debt was a modest amount recorded in “accrued expenses”).  \n\nIn the 2024 filing the revolving facility was expanded to $15 billion (benchmark + 0.45%, 0.03% fee) and a new $5 billion 364‑day revolving “short‑term credit agreement” was added (SOFR + 0.45%, 0.03% fee); the commercial‑paper capacity was also raised to $20 billion.  While the revolving facilities still had zero balances, Amazon reported $147‑$151 million of borrowings under other short‑term facilities in 2023‑24, and the earlier $725 million of commercial‑paper borrowings had been eliminated.  \n\nThus, between 2022 and 2024 Amazon more than doubled its revolving‑credit capacity, trimmed the spread on its benchmark rate, and moved from essentially no short‑term debt to a modest $150 million of other short‑term borrowings.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies that significantly affect correctness. While it correctly identifies the expansion of Amazon's credit capacity from $7.0 billion in 2022 to $15.0 billion in 2024, and the improved interest rate (benchmark +0.45%) and fee (0.03%), it incorrectly introduces a $10 billion commercial paper program in 2022 and claims it was increased to $20 billion in 2024—this is not supported by the ground truth and is a major fabrication. The ground truth makes no mention of a commercial paper program or any such borrowings. Additionally, the LLM claims there were 'earlier $725 million of commercial-paper borrowings' that were eliminated, which is entirely false—the ground truth states there were no borrowings under the main credit facilities and only $147M and $151M under other short-term facilities in 2023 and 2024, respectively. The LLM also misstates the 2022 letters of credit: it says nothing about the $7.2 billion in unused letters of credit as of end-2021 (referenced in 2022 context), and fails to report the increase to $8.3 billion by end-2024. (2) Quantitative accuracy is partially correct: the $7B → $15B expansion, $5B 364-day facility, and $147M/$151M other borrowings are accurate. However, the invented $10B/$20B commercial paper limits and $725M prior borrowings are serious numerical errors. (3) Reasoning is sound in structure—comparing 2022 to 2024, identifying capacity growth, rate reductions, and emergence of small borrowings—but flawed due to reliance on non-existent commercial paper data. The multi-hop synthesis is partially correct but undermined by hallucinated data. (4) Contextual relevance is high: the answer addresses credit capacity, interest terms, and outstanding borrowings as asked. However, the inclusion of fabricated commercial paper details distorts the overall picture. The conclusion that Amazon moved to 'modest $150M of other short-term borrowings' is directionally correct but misleading due to incorrect framing around eliminated commercial paper. Overall, the answer gets core elements right but fails on key facts, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1583,
        "completion_tokens": 578,
        "total_tokens": 2162
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Costco's use of variable-priced contracts for energy purchases evolved between 2022 and 2023, and what does this indicate about its commodity price risk management strategy?",
      "original_answer": "In 2022, Costco entered into variable-priced contracts for some purchases of electricity and natural gas, as well as fuel for its gas stations, on an index basis. These contracts met the definition of derivatives but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. By 2023, Costco continued this approach but specifically called out natural gas and fuel for gas stations as key components of its variable-priced contract usage. This indicates a continued reliance on variable-priced contracts as part of its commodity price risk management, with no significant shift away from index-based pricing mechanisms. The strategy remains consistent, showing stability in how Costco manages exposure to energy price fluctuations.",
      "llm_answer": "In the 2022 filing Costco said it “enters into variable‑priced contracts for some purchases of **electricity and natural gas**, in addition to fuel for its gas stations” (Item 7A – Commodity Price Risk, p. 31). The 2023 filing narrows that language to “variable‑priced contracts for some purchases of **natural gas**, in addition to fuel for its gas stations” (Item 7A – Derivatives, p. 47), dropping the reference to electricity. This shift suggests Costco is moving more of its electricity needs into fixed‑price agreements while keeping only limited natural‑gas exposure, indicating a tighter, more proactive approach to managing commodity‑price risk.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct in that it accurately cites the use of variable-priced contracts for natural gas and fuel for gas stations in both 2022 and 2023, and correctly references the relevant sections of the filings (Item 7A). However, it introduces a significant misinterpretation: it claims that the removal of 'electricity' from the 2023 description indicates a shift toward fixed-price agreements for electricity. This conclusion is not supported by the ground truth, which states that Costco's strategy remained consistent between 2022 and 2023, with no significant shift away from index-based pricing. The original answer emphasizes continuity in risk management strategy, whereas the LLM infers a strategic tightening or proactive shift that is not present in the source data. This flawed reasoning undermines the qualitative accuracy. There are no numerical errors (quantitative accuracy is high), and the response is contextually relevant, addressing the evolution and implications of contract usage. However, the incorrect inference about electricity contracts leads to a misleading conclusion about risk management strategy, warranting a moderate correctness score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 334,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the strategic positioning and commercial role of NVIDIA AI Enterprise evolved within NVIDIA's data center offerings between 2022 and 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, indicating its foundational role in NVIDIA's AI and accelerated computing strategy. By 2024, the product had evolved into a more prominent commercial offering, described as a 'comprehensive suite of enterprise-grade AI software' that is actively licensed and integrated into broader data center solutions. This shift reflects NVIDIA's move from positioning it as a strategic initiative to a key monetization vehicle within its full-stack data center platform, alongside offerings like NVIDIA DGX Cloud and the expansion into CPUs and DPUs.",
      "llm_answer": "In the 2022 filing, NVIDIA’s AI Enterprise was mentioned only as one element of its broader data‑center software stack – an internal, bundled component that helped enable AI workloads on its GPUs and networking solutions. By the 2024 filing, AI Enterprise is portrayed as a standalone, commercial software suite that is sold under paid licenses, described as the “operating system” for enterprise‑grade AI and tightly integrated with DGX Cloud, NIM, Nemo and AI Blueprints, signaling its evolution from a background‑stack feature to a revenue‑generating, strategic product within NVIDIA’s data‑center portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of NVIDIA AI Enterprise from a bundled software component in 2022 to a standalone, commercial, revenue-generating product by 2024. The description of it becoming a 'paid license' offering and being integrated with DGX Cloud, NIM, Nemo, and AI Blueprints matches the strategic shift described in the original answer. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification—only years (2022, 2024), which are correctly used. (3) The multi-hop reasoning is sound: the model synthesizes information across time (2022 to 2024) and product positioning (from internal tool to monetized suite), correctly inferring a strategic shift in commercial role within the data center segment. (4) The only minor gap is that the LLM answer does not explicitly mention the 'Compute & Networking segment' label from 2022 or the full-stack platform context including CPUs and DPUs in 2024, which slightly reduces completeness in entity context. However, the core evolution in strategic and commercial positioning is accurately captured with strong semantic equivalence. Hence, a 9/10 on correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 373,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Pfizer's contractual obligations related to Paxlovid evolve between 2023 and 2024, and what does this indicate about the company's future revenue expectations for the product?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of Paxlovid labeled under Emergency Use Authorization (EUA) from the U.S. government. This indicated uncertainty and potential decline in demand for Paxlovid. By 2024, however, remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, signaling a stabilization and expectation of future revenue from existing contracts. This shift from a large revenue reversal to a defined forward-looking contractual obligation suggests improved demand forecasting and a more stable outlook for Paxlovid in 2024 compared to the uncertainty in 2023.",
      "llm_answer": "By the end of 2024 Pfizer’s remaining performance‑obligation balance for Paxlovid had fallen to about **$1 billion** (see 2024 Form 10‑K p. 109), whereas at the end of 2023 the company carried **$5.1 billion** of combined deferred‑revenue obligations for Paxlovid (and Comirnaty) – $2.6 billion in current liabilities and $2.5 billion in non‑current liabilities (see 2024 Form 10‑K p. 110). The reduction reflects the 2023‑24 shift from large government‑stockpile contracts to commercial sales, the termination of the EUA‑labeled U.S. government supply agreement and the return of unused courses (see 2024 Form 10‑K p. 108). Consequently, Pfizer now expects Paxlovid revenue to be lower overall and to be recognized gradually over 2025‑2028 rather than through a sizable upfront government‑supply stream.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that in 2023, Pfizer recorded a $3.5 billion non-cash revenue reversal due to expected returns of 6.5 million treatment courses under EUA. However, the LLM claims a $5.1 billion combined deferred revenue obligation for Paxlovid and Comirnaty at the end of 2023, which conflates two different products and misrepresents the nature of the obligation (deferred revenue vs. revenue reversal). This is a major error. The $1 billion remaining performance obligation in 2024 matches the ground truth and is correctly cited. (2) The calculation and characterization of the 2023 figure are incorrect: the $5.1 billion cited is not specific to Paxlovid alone and includes Comirnaty (Pfizer's COVID-19 vaccine), which is not mentioned in the original question or answer. Additionally, the LLM frames this as a deferred revenue liability split into current and non-current portions, whereas the ground truth emphasizes a revenue reversal due to product returns — a fundamentally different accounting event. The LLM also introduces a timeline (2025–2028) for revenue recognition not present in the original answer and unsupported by the provided truth. (3) The reasoning partially captures the shift from government to commercial sales and references the termination of the EUA agreement, which aligns with the broader context. However, it fails to correctly synthesize the key multi-hop insight: the 2023 revenue reversal signaled demand uncertainty, while the 2024 $1B obligation indicates stabilization. Instead, the LLM concludes that revenue will be 'lower overall' and recognized over several years, implying a long-term decline, which contradicts the original answer’s interpretation of stabilization and improved forecasting. (4) Despite correct citation of the 2024 $1B figure and relevant 10-K pages, the quantitative inaccuracy severely undermines the answer. The qualitative reasoning is partially sound but based on incorrect premises. The answer is contextually relevant and addresses the evolution of contractual obligations, but the factual foundation is flawed, leading to an incorrect overall conclusion about future revenue expectations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 603,
        "total_tokens": 2002
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "Compare and contrast how Google's exposure to new regulatory costs in international markets evolved between 2022 and 2024, particularly in terms of the scope and nature of regulatory challenges described?",
      "original_answer": "In 2022, Google highlighted that an evolving foreign policy landscape could subject the company to 'new regulatory costs and challenges,' specifically mentioning data transfers between the EU and the UK, as well as new customer requirements. By 2024, the scope of regulatory challenges expanded significantly. The 2024 filing not only reiterated the exposure to 'new regulatory costs and challenges' but also introduced elements like 'uncertainty regarding regulatory outcomes' and the risk of 'other liabilities under local laws that may not offer due process or clear legal precedent.' This indicates a shift from primarily data-related regulatory concerns in 2022 to broader, more unpredictable regulatory risks in 2024, reflecting an increased complexity in Google's international regulatory environment.",
      "llm_answer": "In the 2022 Form 10‑K, Google’s international‑regulatory exposure was described mainly as an “evolving foreign‑policy landscape” that could create **new regulatory costs and challenges such as EU‑UK data‑transfer rules and a few new customer‑requirement obligations**. By the 2024 filing, the scope had broadened dramatically: the company now lists **sanctions, import‑export controls, market‑access barriers, political unrest, geopolitical tensions, anti‑corruption and labor‑law compliance, and heightened litigation risk** as additional sources of regulatory cost, showing that Google expects far more varied and complex regulatory challenges in foreign markets than it did two years earlier.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates (2022 and 2024) and correctly identifies Google as the subject, satisfying entity and temporal accuracy. However, there is a significant discrepancy in the qualitative content: the LLM introduces specific regulatory risks such as 'sanctions, import-export controls, market-access barriers, political unrest, geopolitical tensions, anti-corruption and labor-law compliance, and heightened litigation risk' that are not present in the original ground truth. The original answer states that in 2024, Google expanded its risk disclosure to include 'uncertainty regarding regulatory outcomes' and 'other liabilities under local laws that may not offer due process or clear legal precedent'—a more legally procedural and systemic concern, not the broad geopolitical and compliance categories listed by the LLM. While both answers agree on an expansion in scope and increased complexity, the nature of the regulatory challenges described in the LLM answer is factually inconsistent with the ground truth. The LLM appears to have hallucinated specific regulatory domains not cited in the original. This undermines the qualitative accuracy despite correct framing and timing. Quantitative accuracy is perfect—no numbers, but years and references are correct. Contextual relevance is high as the answer addresses the evolution of regulatory exposure, but the incorrect specifics reduce overall correctness. Multi-hop reasoning is partially sound (comparing 2022 to 2024 disclosures), but synthesis is based on inaccurate content for 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 432,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has UPS's approach to funding postretirement medical benefits evolved between 2022 and 2023, particularly in terms of the sources used for expected benefit payments?",
      "original_answer": "In 2022, UPS indicated that expected benefit payments for postretirement medical benefits would be paid from both plan trusts and corporate assets. In 2023, the language remained unchanged, indicating continuity in the funding approach. Therefore, there was no change in the sources used for expected benefit payments for postretirement medical benefits between the two years.",
      "llm_answer": "UPS still expects to pay post‑retirement medical benefits from a combination of plan‑trust assets and corporate (non‑trust) assets in both years. However, the mix of **employer‑funded contributions** changed: the 2022 filing projected $177 million of contributions to the plan trusts and only $49 million to participants, while the 2023 filing projects a much lower $74 million to the trusts and a higher $92 million to participants. Thus, UPS shifted toward relying more on participant‑direct contributions while continuing to use both trust assets and corporate assets for the expected benefit payments.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces information not present in the ground truth. (1) The original answer states that UPS's funding approach remained unchanged between 2022 and 2023, with expected benefit payments coming from both plan trusts and corporate assets—no shift in mix or source is indicated. (2) The LLM claims a change in 'employer-funded contributions' with specific dollar amounts: $177M to trusts in 2022 vs $74M in 2023, and $49M/$92M to participants. However, these figures are either misinterpreted or fabricated; the ground truth contains no such data about contributions to participants or changes in trust funding levels. There is no mention of participant-directed contributions or a shift in funding mix. (3) The multi-hop reasoning is flawed: instead of recognizing the consistency in language and approach across years, the model invents a narrative of strategic shift unsupported by the source. (4) While the answer correctly notes that both plan-trust and corporate assets are used, it incorrectly infers a change in mix, contradicting the ground truth assertion of 'no change.' Thus, despite some contextual relevance and partial entity accuracy (UPS, years, postretirement benefits), the quantitative and qualitative inaccuracies severely undermine the response, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 371,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the role and scope of NVIDIA AI Enterprise evolved from its introduction in 2022 to its broader supply and integration in 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, described as a software suite aimed at simplifying the deployment of AI applications across data centers and enterprise environments. By 2024, the platform had evolved into a more comprehensive and integrated solution, including components such as NVIDIA NIM, NVIDIA NeMo, and AI Blueprints, with specific performance improvements like a 2.5x increase in token throughput. This reflects a shift from a foundational offering to a full-stack, production-grade generative AI platform with enhanced capabilities and broader deployment options.",
      "llm_answer": "In the 2022 Form 10‑K NVIDIA first disclosed AI Enterprise as a **paid‑license, enterprise‑grade AI software suite** that was offered alongside its data‑center hardware and other software (see 2022 p. 6). By the 2024 filing the suite had become a **core component of the Data‑Center platform**, listed together with DGX Cloud and the company’s GPUs, and was described in detail as a comprehensive, end‑to‑end generative‑AI solution that includes NVIDIA NIM, NEMO and AI Blueprints, enabling customers to develop, fine‑tune and securely run AI applications anywhere (see 2024 p. 5‑7). Thus, AI Enterprise has moved from a standalone licensed product in 2022 to a broadly supplied, integrated part of NVIDIA’s full‑stack data‑center offering by 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: NVIDIA AI Enterprise was introduced in 2022 as an enterprise AI software suite and evolved by 2024 into a full-stack generative AI platform. The inclusion of NVIDIA NIM, NeMo (spelled as NEMO in the answer, minor variation), and AI Blueprints is accurately reported. (2) There are no numeric inaccuracies—while the ground truth mentions a 2.5x increase in token throughput, the LLM answer does not include this specific metric, which is a minor omission but not incorrect. All dates (2022, 2024) and entity names (NVIDIA, DGX Cloud, GPUs) are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of 10-K filings to show evolution from a standalone software suite to an integrated part of the data-center platform. (4) The answer captures the semantic shift from a foundational offering to a comprehensive solution, even using similar language (e.g., 'end-to-end generative-AI solution' vs 'full-stack, production-grade generative AI platform'). The only reason for not scoring a 10 is the omission of the specific performance improvement (2.5x token throughput), which is a factual detail present in the ground truth but missing in the LLM response. However, this does not undermine the overall correctness. Contextual relevance is perfect—the answer directly addresses the evolution in role and scope as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 405,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has ExxonMobil's proved reserves through equity companies evolved from 2022 to 2024, and what does this indicate about its strategic positioning in different regions?",
      "original_answer": "In 2022, ExxonMobil's total proved reserves from equity companies amounted to 14 million barrels gross (1 million net) across the United States, Europe, Africa, and Asia. By 2024, these reserves had significantly increased to 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas, with the majority of this growth concentrated in Asia. This indicates a major strategic shift toward strengthening its upstream presence in the Asia region through equity companies.",
      "llm_answer": "ExxonMobil’s equity‑company share of proved reserves has risen modestly since 2022.  In the 2024 filing the equity‑company portfolio totals about **3 billion oil‑equivalent barrels** (≈1.48 billion bbl OE developed + ≈1.51 billion bbl OE undeveloped) – up from roughly **2.5 billion bbl OE in 2022** (the 2022 10‑K shows a smaller equity‑company total).  The growth is concentrated in **Asia**, where equity‑company proved reserves climbed from about **0.8 billion bbl OE in 2022 to 1.28 billion bbl OE in 2024**, while Europe and Africa remain flat or slightly lower (Europe ≈2 million bbl OE, Africa ≈7 million bbl OE in 2024).  \n\n**Implication:** ExxonMobil is increasingly leveraging its equity‑company interests in high‑growth Asian basins, signaling a strategic shift toward expanding its presence in Asia’s oil‑and‑gas markets, while maintaining only a modest, largely defensive footprint in Europe and Africa.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in numbers and units. The ground truth states that in 2022, ExxonMobil's total proved reserves from equity companies were 14 million barrels gross (1 million net), but the LLM claims 2.5 billion oil-equivalent barrels, which is over 178 times higher. In 2024, the ground truth reports 467 million barrels of crude oil, 120 million barrels of NGLs, and 5,367 Bcf of natural gas — the LLM converts this into approximately 3 billion bbl oil-equivalent, which is a massive overstatement. Even converting natural gas using standard oil-equivalent (6 Mcf = 1 bbl), 5,367 Bcf equals ~894 million bbl OE, plus 467M + 120M = ~1.48 billion bbl OE total — far below the 3 billion claimed. The LLM also incorrectly states Asia grew from 0.8 to 1.28 billion bbl OE, which has no support in the original data. (2) The original answer does not provide oil-equivalent conversions or regional breakdowns beyond stating 'majority of growth in Asia' — so the LLM fabricated granular regional data. There is no mention in the ground truth of Europe having ~2 million bbl OE or Africa ~7 million in 2024. These numbers are invented. (3) While the LLM correctly infers a strategic shift toward Asia as a qualitative conclusion, this reasoning is based on fabricated quantitative data rather than correct multi-hop synthesis. The original answer supports a strategic shift due to large reserve increases in Asia, but the LLM invents precise regional oil-equivalent figures not present in the source. (4) Correctness score is low (2/10) because nearly all numerical claims are factually wrong. Quantitative accuracy is 1/10 due to severe errors in scale and made-up figures. Qualitative accuracy is 3/10 because while the general direction of strategy (Asia focus) aligns, it's unsupported by correct data. Contextual relevance is 6/10 because the answer addresses the right question and regions, but with incorrect evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 530,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of their role in revenue generation and cost structure?",
      "original_answer": "In 2022, Google Network Partners played a central role in the revenue generation process as Google acted as the principal for ads placed on Google Network properties, reporting advertising revenues on a gross basis, with payments to partners recorded as cost of revenues. By 2024, Google continued to pay Google Network partners, but the focus of the financial reporting shifted to emphasize the net cash flow impact, noting that payments to these partners were a primary use of cash from operating activities. This reflects a more cost-centric framing of the relationship in the later year.",
      "llm_answer": "In both the 2022 and 2024 filings Google Network Partners are described as the distribution partners that display ads on their properties (AdMob, AdSense, Ad Manager). The company records the full ad‑sale amount as revenue (gross reporting) and treats the payments it makes to those partners as part of “Traffic Acquisition Costs” (TAC) within cost of revenues 【page 55‑56 (2022)】, and the 2024 filing still lists cash generated from “advertising revenues … Google Network properties” and cash outflows to “distribution and Google Network partners” as a primary use of operating cash 【page 42 (2024)】. Thus, from 2022 to 2024 the financial relationship has remained the same—Google Network Partners continue to drive a significant share of ad revenue while also representing a material cost line (TAC); the absolute amounts have grown in line with overall advertising growth, but their functional role has not changed.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the original answer in terms of entities, years, and financial structure: Google Network Partners are correctly identified as distribution partners for ads (e.g., AdSense, AdMob), revenue is reported on a gross basis, and payments to partners are classified as Traffic Acquisition Costs (TAC) within cost of revenues in both 2022 and 2024. The citations to specific pages (55–56 for 2022, 42 for 2024) support the claims and indicate accurate sourcing. However, the key nuance in the original answer—that there was a *shift in framing* from a revenue-centric view in 2022 to a cost- and cash flow-centric view in 2024—is missed. The LLM concludes that 'the financial relationship has remained the same' and 'their functional role has not changed,' which contradicts the ground truth that emphasizes an evolution in financial reporting emphasis: from gross revenue recognition (2022) to highlighting payments to partners as a primary use of operating cash (2024), indicating a more cost-centric narrative. While the underlying mechanics (gross reporting, TAC) may persist, the qualitative shift in disclosure focus is significant and was not acknowledged. This constitutes a failure in multi-hop reasoning: the model did not synthesize the change in emphasis across years, treating continuity of accounting treatment as equivalent to no evolution in financial relationship. Quantitative accuracy is perfect—no numbers, dates, or terms are incorrect. Contextual relevance is high as the answer directly addresses the question’s focus on revenue and cost roles. Thus, correctness is partially compromised due to missing the conceptual evolution, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 465,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has UPS's foreign currency exchange risk management strategy evolved between 2022 and 2023, particularly in terms of the financial impact of undesignated foreign currency forward contracts on earnings volatility?",
      "original_answer": "In 2022, UPS disclosed that foreign currency exchange forward contracts were used to economically offset foreign currency remeasurement and settlement risk for certain balance sheet assets and liabilities, and that changes in their fair value affected earnings directly. For 2023, UPS expanded the disclosure to emphasize that undesignated derivative settlements are now explicitly linked to earnings volatility, with a specific focus on how these contracts impact income statement recognition. The 2023 filing also introduced a more structured presentation of fair value changes and settlements for these contracts, with amounts for both 2023 and 2022 now reported side-by-side in millions, indicating a more transparent and systematic approach to disclosing the financial effects of these instruments.",
      "llm_answer": "In 2022 UPS reported a **$69 million loss** in earnings from foreign‑currency forward contracts that were **not designated as hedges** (recorded in investment income and other). By 2023 that loss had fallen to **about $7 million**, reflecting a sharp reduction in the earnings impact of undesignated forwards and a move that dampens earnings volatility. The change shows UPS shifted more of its currency exposure into designated hedge relationships, limiting the volatility from non‑hedged forward contracts.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer introduces specific numerical values—$69 million loss in 2022 and $7 million loss in 2023—that are not present in the original ground truth answer. The ground truth does not provide any actual financial figures related to the gains or losses from undesignated foreign currency forward contracts; instead, it focuses on the evolution of disclosure practices and transparency in reporting. Therefore, the quantitative claims in the LLM answer are factually unsupported and incorrect, leading to a low quantitative accuracy score. While the LLM attempts to address earnings volatility and the role of undesignated forwards, it fabricates data to support its point, which undermines the factual basis of the response. The qualitative reasoning—suggesting a shift toward designated hedges to reduce volatility—is plausible but not stated in the original answer, which emphasizes improved disclosure and structured presentation rather than operational changes in hedging strategy. Thus, the reasoning is partially sound but based on invented numbers. The answer is contextually relevant as it addresses foreign currency risk management and earnings volatility, but it fails on factual correctness due to hallucinated figures. The multi-hop synthesis is flawed because it invents financial impacts rather than reporting documented changes in disclosure practices. Overall, the answer misrepresents the nature of the evolution (from qualitative disclosure improvements to a quantitative narrative), warranting a correctness score of 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 421,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the role of the membership format in Costco's profitability strategy evolved between 2022 and 2023, particularly in terms of its impact on member loyalty and fee revenue?",
      "original_answer": "In 2022, the membership format was described as 'an integral part of our business and has a significant effect on our profitability,' with an emphasis on growth in the membership base, increasing Executive member penetration, and sustaining high renewal rates as key drivers of profitability. By 2023, the language evolved to underscore that the membership format 'is an integral part of our business and profitability,' indicating a more consolidated role in the company's financial model. Additionally, in 2023, Costco introduced a new concern about the potential adverse impact of lower renewal rates in newer markets on the worldwide renewal rate, which was not explicitly mentioned in 2022. This suggests that while the membership model remained central to profitability, the company faced emerging challenges in sustaining renewal rates as it expanded into newer markets.",
      "llm_answer": "The membership format continued to be described as a “core part of our business and profitability” that “reinforces member loyalty and provides continuing fee revenue,” and the 2023 filing repeats the same emphasis on growing the membership base, expanding Executive‑member penetration and sustaining high renewal rates. Between the two years the format’s financial impact grew in absolute terms—membership‑fee revenue rose from $4.224 billion in 2022 (a 9 % increase) to $4.828 billion in 2023 (a 5 % increase)—showing higher fee income but a slower growth rate as the base matures, while the company’s focus on loyalty and renewal remained unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the continued importance of the membership format to Costco's profitability and mentions key elements like member loyalty, fee revenue, Executive member penetration, and renewal rates. However, it introduces specific numerical figures—$4.224 billion in 2022 and $4.828 billion in 2023—that are not present in the original ground truth answer, nor are they referenced in the question or provided context. There is no way to verify these numbers from the given information, making their inclusion factually unsupported. Additionally, the claim of a 9% increase in 2022 and 5% in 2023 involves calculations not corroborated by the ground truth, which does not mention growth rates or absolute revenue figures. (2) Since the original answer contains no financial data, the introduction of precise dollar amounts and percentage changes constitutes a significant quantitative inaccuracy, even if the numbers happen to be correct in reality—within the scope of the provided knowledge graph, they are unverified and thus incorrect. (3) On qualitative grounds, the LLM captures the continuity in strategy between 2022 and 2023 and correctly notes the persistent focus on membership growth and renewals. However, it misses a critical evolution highlighted in the ground truth: the emergence in 2023 of concern about lower renewal rates in newer markets affecting the worldwide renewal rate—a key shift in risk awareness that reflects changing strategic dynamics. This omission weakens the multi-hop synthesis required to show how the role of the membership model evolved beyond just revenue growth. (4) The answer remains contextually relevant and well-structured, addressing the core themes of loyalty and fee revenue. While the reasoning is logical, the unsupported numbers reduce factual reliability. The correctness score is 6 due to partially accurate qualitative insights offset by significant unverified quantitative claims and a missing key strategic nuance from 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 543,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration within the broader data center platform and software ecosystem?",
      "original_answer": "In 2022, CUDA was primarily positioned as a key component of NVIDIA's AI ecosystem, with nearly 3 million developers using CUDA and other software tools to deploy AI and accelerated computing technologies. It was described as central to NVIDIA's partnerships and developer programs, including the Deep Learning Institute and Inception program. By 2024, CUDA had evolved into a more deeply integrated part of a full-stack computing platform, specifically within the data center. It was described as the foundation of the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific frameworks, emphasizing its role in enabling end-to-end optimized computing across GPUs, CPUs, and DPUs. This reflects a strategic shift from promoting CUDA as a developer-focused tool to positioning it as a core infrastructure layer for enterprise-scale computing solutions.",
      "llm_answer": "In the 2022 filing NVIDIA described CUDA mainly as the “foundational CUDA programming model” that unlocks the parallel power of its GPUs and underpins a software stack of libraries, SDKs and APIs for AI, analytics and scientific workloads. By the 2024 filing CUDA is presented as a central pillar of a **full‑stack data‑center platform** that now spans GPUs, the new Grace CPUs and DPUs, high‑performance networking, and services such as NVIDIA AI Enterprise and DGX Cloud, with the CUDA‑X library collection and a developer ecosystem that has grown from roughly 3 million users to about 5.9 million. This evolution shows CUDA moving from a GPU‑focused programming model to an integrated software layer that ties together heterogeneous compute, networking and storage resources across NVIDIA’s data‑center offerings.",
      "correctness_score": 9,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of CUDA from 2022 to 2024 as described in the ground truth. It correctly identifies CUDA's shift from a GPU-focused programming model to a full-stack data center platform integrating GPUs, CPUs (specifically naming Grace CPUs), DPUs, and networking, which aligns with the 'heterogeneous compute' integration emphasized in the original answer. The mention of CUDA-X, APIs, SDKs, and developer ecosystem growth supports the qualitative shift toward enterprise-scale infrastructure. However, there is a discrepancy in the quantitative claim: the LLM states the developer ecosystem grew from ~3 million to ~5.9 million by 2024, while the ground truth only confirms ~3 million in 2022 and does not provide a 2024 figure. This introduces a plausible but unverified number, slightly reducing quantitative accuracy. Otherwise, all entities (CUDA-X, AI Enterprise, DGX Cloud) and strategic themes (full-stack integration, end-to-end optimization) are correctly identified and synthesized across the two time points. The reasoning is sound, demonstrating multi-hop understanding of how CUDA’s role expanded within NVIDIA’s broader platform. Wording differs but semantic meaning matches closely, and the answer fully addresses the question about CUDA’s evolving integration in the data center and software ecosystem.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 379,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2023 to 2024, particularly in terms of expected future revenue and product delivery timelines?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled Paxlovid from U.S. government inventory. By the end of 2024, Pfizer reported remaining performance obligations for Paxlovid at approximately $1 billion, with expected product delivery and revenue realization scheduled from 2025 through 2028, indicating a shift from uncertain returns and revenue reversals to a more defined forward-looking revenue outlook based on firm contracts.",
      "llm_answer": "By the end of 2023 Pfizer was carrying roughly $5.1 billion of deferred revenue tied to Paxlovid (government‑ and other pre‑specified‑course contracts) and had recorded a $3.5 billion non‑cash revenue reversal for expected returns of EUA‑labeled inventory. At 31 December 2024 the remaining performance‑obligation balance for Paxlovid had fallen to about $1 billion of contracted revenue (with $2.2 billion of total deferred revenue now split between current‑ and non‑current liabilities) and the contracts now call for product deliveries spanning 2025 through 2028, rather than the primarily 2022‑2023 government‑supply horizon. Thus, Pfizer’s financial commitment to Paxlovid has been reduced and shifted from near‑term government deliveries to longer‑term commercial shipments with a lower expected future revenue stream. (See 2024 Form 10‑K pp. 109‑110 and 2023 Form 10‑K pp. 108‑110).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the $3.5 billion non-cash revenue reversal in 2023 related to expected returns of EUA-labeled Paxlovid from U.S. government inventory, matching the original answer. It also accurately states that by the end of 2024, remaining performance obligations for Paxlovid were approximately $1 billion, with delivery timelines extending from 2025 through 2028. (2) The LLM adds additional context not in the ground truth—$5.1 billion deferred revenue in 2023 and $2.2 billion total deferred revenue split across liabilities in 2024—which are plausible and consistent with Pfizer’s 10-K disclosures (pp. 109–110 in cited filings), but not contradicted by the ground truth. These extras do not introduce errors but enhance detail. (3) The multi-hop reasoning is sound: the model correctly infers a shift from uncertain government returns (2023) to firm, long-term commercial contracts (2025–2028), reflecting a maturation of revenue expectations. (4) Semantic equivalence is maintained: the core evolution—reduced financial commitment, shift from reversals to firm obligations, and extended delivery timeline—is accurately conveyed. The only minor point preventing a 10 is that the ground truth does not mention the $5.1B or $2.2B figures, so while not incorrect, their inclusion without qualification slightly exceeds the verified scope. Overall, the answer is factually correct, well-supported, and fully addresses the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 417,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2022 and 2024, based on its disclosures around reserves development and advantaged asset reporting?",
      "original_answer": "In 2022, ExxonMobil reported that Guyana was a key contributor to extensions and discoveries, adding approximately 1.3 billion oil-equivalent barrels (GOEB) of proved undeveloped reserves. By 2024, Guyana was explicitly listed as one of the core 'Advantaged Assets' in the company's updated earnings drivers, signaling a strategic shift to highlight Guyana's role in driving earnings through volume growth. This evolution reflects a transition from Guyana being primarily a reserves growth region to being a recognized source of advantaged production and earnings visibility.",
      "llm_answer": "In the 2022 filing, ExxonMobil noted that “extensions and discoveries, primarily in the United States, Brazil, **and Guyana**, resulted in an addition of about 1.3 GOEB of proved undeveloped reserves,” indicating that Guyana was being highlighted as a source of new reserve upside and early‑stage development. By the 2024 filing, Guyana is listed explicitly among the company’s **“Advantaged Assets (Advantaged growth projects)”**—alongside Permian and LNG—showing that the project has moved from a reserve‑addition focus to a core, high‑return asset that drives the corporation’s advantaged‑volume growth strategy.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies that in 2022, Guyana contributed to extensions and discoveries with approximately 1.3 billion oil-equivalent barrels (GOEB) of proved undeveloped reserves, matching the original answer. (2) The 2024 disclosure correctly notes Guyana's inclusion in 'Advantaged Assets' (specifically labeled as 'Advantaged growth projects'), aligning with the strategic shift described in the ground truth. (3) The multi-hop reasoning is sound: the model synthesizes information across 2022 and 2024 filings to show an evolution from reserves growth to advantaged production and earnings visibility. (4) All entities—ExxonMobil, Guyana, Permian, LNG—are accurately referenced, and the qualitative interpretation (transition from reserve-addition to core earnings driver) is consistent with the original. Minor wording differences (e.g., 'high-return asset' not in original) are interpretive but reasonable and do not distort meaning. No calculation errors; all dates and metrics are correct. Full credit across all dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 317,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the planned utilization of the ATR 72-600F aircraft evolve from 2022 to 2024, and what does this indicate about its role in the company's fleet strategy?",
      "original_answer": "In 2022, the ATR 72-600F was projected to have a decreasing role in the company's fleet, with planned units dropping from 11 in 2023 to just 1 by 2026. By 2024, however, the company's projections showed a shift, with ATR 72-600F units remaining steady at 7 for 2025 and declining only slightly to 3 by 2026. This indicates that while the aircraft was initially expected to phase out more rapidly, it continued to play a more sustained, albeit reduced, role in the fleet strategy.",
      "llm_answer": "In the 2022 filing FedEx committed to receive 11 ATR 72‑600F aircraft in 2023, 6 in 2024, 6 in 2025 and 1 in 2026 (24 total). By the 2024 filing the schedule had been trimmed to only 7 ATR 72‑600F deliveries in 2025 and 3 in 2026 (10 total), with no further deliveries slated for 2023‑2024. This shift shows the ATR 72‑600F is being positioned as a modest, later‑stage feeder‑plane addition rather than a primary growth engine in FedEx’s fleet strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, in 2022 the projection was for ATR 72-600F units to drop from 11 in 2023 to 1 by 2026. However, the LLM claims 11 units in 2023, 6 in 2024, 6 in 2025, and 1 in 2026, which misrepresents the original plan. The 2024 update in the ground truth shows 7 units in 2025 and 3 in 2026, which the LLM correctly reports as 7 in 2025 and 3 in 2026. However, the LLM incorrectly frames these as 'deliveries' rather than 'planned units', and introduces a total of 24 and 10, which are not in the original answer and imply a different interpretation (e.g., cumulative deliveries vs. fleet size). (2) The numbers do not align with the ground truth: the original answer does not mention 6 units in 2024 or any deliveries in 2023–2024 being canceled, only that the 2022 plan had 11 units in 2023 declining to 1 by 2026. The 2024 revision shows 7 units in 2025 and 3 in 2026, with no mention of 2023–2024 deliveries. The LLM invents a delivery schedule not present in the ground truth. (3) The multi-hop reasoning is partially sound—comparing 2022 and 2024 projections to infer strategic shift is valid, and the conclusion that the aircraft plays a reduced but sustained role is semantically similar to the LLM’s 'modest, later-stage feeder-plane addition'. However, the reasoning is based on incorrect numerical premises. (4) Contextual relevance is high—the answer addresses the evolution and strategic implication. Qualitative accuracy is moderate due to correct direction of change and strategic interpretation. Quantitative accuracy is low due to fabricated delivery numbers and totals. Correctness score is 6 due to correct directional trend and strategic insight but major factual errors in numbers and timeline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 491,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has NVIDIA's approach to offering Omniverse evolved between 2022 and 2024, particularly in terms of its integration with other AI and simulation platforms?",
      "original_answer": "In 2022, NVIDIA Omniverse was primarily described as a virtual world simulation and collaboration platform for 3D workflows, available as a software subscription for enterprise use and free for individual use. It was highlighted as being integrated with VR and AR in enterprise applications such as virtual car showrooms and surgical training. By 2024, NVIDIA's offering of Omniverse had evolved into a more comprehensive development platform and operating system for building and running virtual world simulation applications. It was now emphasized as being used by industrial enterprises to digitalize complex physical assets and processes—such as building digital twins of factories and testing autonomous robots and vehicles—powered by NVIDIA's accelerated computing infrastructure both on-premises and in the cloud. This represents a shift from general 3D collaboration to a more specialized, enterprise-focused simulation and digital twin platform.",
      "llm_answer": "In the 2022 filing, NVIDIA described Omniverse chiefly as a real‑time 3D‑design and digital‑twin platform – a standalone collaboration and simulation tool offered as an enterprise subscription (with a free tier) for professional‑visualization customers. By the 2024 filing, Omniverse had become a core piece of NVIDIA’s broader AI‑and‑simulation stack, being bundled with AI Enterprise, DGX Cloud and the DRIVE Constellation/Avatar solutions, so that it now serves as the simulation engine for automotive, industrial and other AI‑driven workloads across the company’s data‑center‑scale platforms.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of NVIDIA's Omniverse offering between 2022 and 2024. It correctly identifies that in 2022, Omniverse was positioned as a 3D design and digital twin collaboration tool with enterprise and free tiers. By 2024, it accurately reflects the shift toward integration within NVIDIA’s broader AI and simulation stack, specifically naming key components like AI Enterprise, DGX Cloud, and DRIVE Constellation/Avatar—demonstrating correct multi-hop synthesis across platforms. The answer conveys the transformation from a standalone tool to a core simulation engine for AI-driven industrial applications, aligning well with the ground truth’s emphasis on digital twins, factory modeling, and autonomous systems. The only minor shortcoming is that it does not explicitly mention the expansion into cloud and on-premises accelerated computing infrastructure or specific use cases like surgical training or virtual car showrooms from 2022, which slightly reduces completeness. However, these omissions do not detract from the central factual accuracy. There are no numerical or date inaccuracies (quantitative accuracy is perfect), and the reasoning is sound and contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 346,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has the role of Google Play in generating non-advertising revenue evolved between 2022 and 2023?",
      "original_answer": "In 2022, Google Play was introduced as part of the company's broader strategy to expand non-advertising revenues, specifically through the sales of apps, in-app purchases, and digital content. By 2023, Google Play had transitioned into a more defined revenue stream under 'platforms,' where it was explicitly tied to revenues from app sales and in-app purchases. This evolution indicates a strategic shift toward solidifying Google Play’s role as a key monetization platform rather than just a component of diversification. The change reflects a more structured categorization and likely a stronger contribution to revenue stability within the ecosystem.",
      "llm_answer": "In the 2022 filing Alphabet described Google Play as a “platform” that contributes to its non‑advertising revenues – the sales of apps, in‑app purchases and digital content that are part of the growing non‑advertising portion of the business【page_30】.  \nThe 2023 filing continues to list Google Play under the same “platforms” category and notes that non‑advertising revenues – which now include a larger share from Google Play – have risen, showing that Google Play’s role in the non‑advertising mix has become more significant as the overall non‑advertising segment expands【page_33】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies that in 2022, Google Play was described as a platform contributing to non-advertising revenue through app sales, in-app purchases, and digital content, citing the appropriate context from the filing. It also accurately reflects the 2023 development: Google Play remained under the 'platforms' category and its contribution to non-advertising revenue became more significant as that segment expanded. While the LLM does not explicitly mention the 'strategic shift toward solidifying Google Play’s role as a key monetization platform' or the 'structured categorization' noted in the original answer, it captures the core evolution — increased significance within a growing non-advertising segment — which is supported by the filings. There are no numerical inaccuracies (quantitative accuracy is perfect, even though no specific dollar amounts or percentages are involved), and the entities (Google Play, Alphabet, non-advertising revenue, platforms, years 2022 and 2023) are correctly identified. The reasoning is sound and reflects multi-hop synthesis across two years of filings. The answer is semantically equivalent in substance, though slightly less detailed in strategic interpretation. Hence, a high correctness score of 9 is warranted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 372,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has AIG's use of expected loss ratio methods in workers' compensation reserving evolved between 2022 and 2023, particularly in relation to guaranteed cost and excess of deductible business?",
      "original_answer": "In 2022, AIG generally gave significant weight to expected loss ratio methods for guaranteed cost business only in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that changes in claims strategy and loss mitigation efforts were accelerating settlements, increasing paid losses along the latest diagonals. In 2023, the reserving methodology remained broadly consistent, with AIG continuing to use a combination of loss development, frequency/severity, and expected loss ratio methods. However, the 2023 filing emphasized that incurred and paid losses were now presented net of reinsurance and undiscounted, which may reflect a refinement in reporting transparency rather than a change in reserving philosophy. Additionally, the increased proportion of large deductible business continued to slow the reporting pattern of claims in 2023, consistent with the trend noted in 2022.",
      "llm_answer": "In the 2022 filing AIG explained that **expected‑loss‑ratio (ELR) techniques were applied only to the most recent accident year for its guaranteed‑cost workers‑comp business**, while **for excess‑of‑deductible (high‑deductible) business the ELR was given “significant weight” for the most recent five accident years**.  \n\nThe 2023 filing repeats the same overall approach – AIG still uses a mix of loss‑development, frequency‑severity and ELR methods for workers’ compensation and still **places significant weight on ELR for excess‑of‑deductible business over the last five accident years** – but it no longer calls out a restriction that ELR be limited to just the most recent year for guaranteed‑cost business, indicating that the weighting for guaranteed‑cost work remains broadly the same (still recent‑year focused) while the emphasis on ELR for excess‑of‑deductible work continues unchanged.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in its factual content and accurately captures the core evolution (or lack thereof) in AIG's use of expected loss ratio (ELR) methods between 2022 and 2023. It correctly states that in 2022, ELR methods were given significant weight only for the most recent accident year in guaranteed cost business, and for the most recent five accident years in excess of deductible business — matching the ground truth exactly. It also correctly notes that in 2023, the methodology remained consistent, with continued significant weighting of ELR for excess of deductible business over five years. The inference that the 2023 filing no longer explicitly restricts ELR to the most recent year for guaranteed cost business is a reasonable interpretation, though the original answer does not make this specific point. However, the LLM omits two important contextual details present in the ground truth: (1) the change in reporting incurred and paid losses net of reinsurance and undiscounted in 2023, which reflects a transparency refinement, and (2) the continued impact of large deductible business slowing claims reporting patterns in 2023, a trend noted in both years. These omissions reduce completeness and qualitative accuracy slightly, but do not undermine the core correctness of the reserving methodology description. All entities (AIG, guaranteed cost, excess of deductible, accident years) and time periods (2022, 2023) are accurate. There are no numerical or calculation errors, and the reasoning is sound, though not fully comprehensive. The answer is highly relevant to the question and synthesizes key multi-hop elements correctly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1488,
        "completion_tokens": 452,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Cisco's product category segmentation evolved between fiscal 2022 and fiscal 2024, particularly in relation to the Collaboration category?",
      "original_answer": "In fiscal 2022, Cisco introduced a product revenue segmentation that included 'Collaboration' as one of six distinct categories, which also included Secure, Agile Networks; Internet for the Future; End-to-End Security; Optimized Application Experiences; and Other Products. By fiscal 2024, Cisco restructured its product categories into four main areas, retaining 'Collaboration' but now grouping it alongside Networking, Security, and a new category called Observability. This indicates a consolidation and realignment of product offerings, with the introduction of Observability as a distinct area and the removal or reclassification of Optimized Application Experiences and Internet for the Future.",
      "llm_answer": "- **2022 segmentation:** Cisco reported product revenue in six categories – Secure Agile Networks, Internet for the Future, Collaboration, End‑to‑End Security, Optimized Application Experiences and Other Products (see 2022 “Product Revenue by Category” table)【page_44】.  \n\n- **2024 segmentation:** Beginning in fiscal 2024 the company consolidated those groups into four categories – Networking, Security, Collaboration and Observability, and restated prior‑year numbers to the new format (see 2024 “Product Revenue by Category” table)【page_41】. The former Secure Agile Networks, Internet for the Future and parts of End‑to‑End Security were folded into **Networking**; End‑to‑End Security and parts of Optimized Application Experiences became **Security**; Optimized Application Experiences and other smaller lines were placed in **Observability**.\n\n- **Collaboration category:** Collaboration remained a distinct line in both frameworks. In FY 2022 it generated $4.47 billion (a 5 % decline year‑over‑year)【page_44】【page_45】; after the re‑segmentation it reported $4.11 billion in FY 2024 (a 2 % increase versus FY 2023)【page_41】. Thus, while the overall category persisted, its share shifted from one of six groups to one of four, and its revenue moved from a modest decline in 2022 to modest growth in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Cisco's 2022 product segmentation into six categories, including Collaboration, and accurately lists the categories (Secure Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products). It also correctly states that in 2024, Cisco consolidated into four categories: Networking, Security, Collaboration, and Observability. (2) The quantitative details are mostly correct: Collaboration revenue was $4.47 billion in FY2022 (per 2022 10-K, page 44) and $4.11 billion in FY2024 (per 2024 10-K, page 41). The year-over-year decline of 5% in 2022 and 2% growth in 2024 vs 2023 are consistent with the filings. (3) The reasoning is sound: the model correctly infers that Collaboration remained a standalone category, while other segments were merged or reclassified. It accurately explains that Secure Agile Networks and Internet for the Future were folded into Networking, and parts of other segments contributed to Security and Observability. (4) The only minor shortcoming is that the ground truth emphasizes the removal or reclassification of Optimized Application Experiences and Internet for the Future, while the LLM answer could more explicitly state that these categories were eliminated as standalone segments. However, this is implied in the consolidation narrative. The inclusion of specific page references and restatement of prior years adds credibility. All entities, years, and metrics are correct. Semantic equivalence is strong, with no factual errors—only slight room for improved clarity on category discontinuation. Hence, a score of 9 is appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1503,
        "completion_tokens": 470,
        "total_tokens": 1973
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Amgen's disclosure regarding the 3.125% 2025 Notes evolved from 2022 to 2023 in terms of financial presentation and associated interest rate framework?",
      "original_answer": "In 2022, Amgen reported a carrying value of $1,000 million for the 3.125% 2025 Notes within its debt table, but no specific interest rate framework was disclosed. By 2023, Amgen included the 3.125% 2025 Notes in a new table that explicitly outlined the interest rate mechanism, identifying it as SOFR + 2.1%. This evolution reflects a shift from a purely quantitative disclosure in 2022 to a more detailed qualitative and quantitative presentation in 2023, including the interest rate benchmark and spread.",
      "llm_answer": "In the 2022 Form 10‑K Amgen listed the 3.125 % 2025 Notes as a $1 billion series in its long‑term‑debt schedule and disclosed that the interest‑rate‑swap tied to those notes gave them an **effective rate of LIBOR + 1.8 %** (see the “Effective interest rates on notes …” table – LIBOR + 1.8 % for the 3.125 % 2025 Notes)【page_132】.  \n\nIn the 2023 Form 10‑K the same $1 billion series is still shown, but the swap disclosure now uses the new benchmark and states an **effective rate of SOFR + 2.1 %** for the 3.125 % 2025 Notes (see the 2023 “Effective interest rates …” table)【page_144】.  \n\nThus, Amgen’s presentation moved from a LIBOR‑based effective‑interest‑rate framework in 2022 to a SOFR‑based framework in 2023, while the principal amount of the notes remained unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The Original Answer (ground truth) states that in 2022, Amgen did *not* disclose any specific interest rate framework for the 3.125% 2025 Notes—only the $1,000 million carrying value was reported. However, the LLM claims that in 2022, the notes had an 'effective rate of LIBOR + 1.8%' tied to an interest rate swap, which contradicts the ground truth. This misrepresents the 2022 disclosure and introduces a detail (LIBOR + 1.8%) that was not present. (2) While the 2023 disclosure correctly identifies the shift to SOFR + 2.1%, the LLM incorrectly frames this as a change in the 'effective rate' due to a benchmark transition (LIBOR to SOFR), implying continuity in rate disclosure between years, when in fact the 2022 rate framework was *not disclosed at all*. (3) The LLM invents a comparative evolution (LIBOR → SOFR) that is not supported by the ground truth: the 2022 report had *no* interest rate mechanism disclosed, so there is no basis for claiming a shift from LIBOR to SOFR. (4) The principal amount ($1 billion) is correctly stated and consistent with the ground truth (allowing for format variation: $1 billion = $1,000 million). (5) The multi-hop reasoning is flawed because it assumes the presence of rate framework data in 2022 that does not exist in the ground truth, leading to an incorrect synthesis. While the answer is relevant to the question and attempts to address the evolution in disclosure, the core factual error—fabricating a 2022 interest rate framework—results in a mostly incorrect response. Hence, the correctness score is low despite some structural relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 458,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure had decreased to 296 billion cubic feet. This indicates a reduction in the company's natural gas holdings in the region over the two-year period, suggesting a potential strategic shift or divestment in that geographic area.",
      "llm_answer": "- The developed natural‑gas reserve base that ConocoPhillips reports for its own (consolidated) Asia Pacific/Middle East operations fell from **326 BCF at the end of 2022** to **296 BCF at the end of 2024** (undeveloped reserves stayed flat at 4‑7 BCF, giving a total regional reserve decline from about 330 BCF to 303 BCF)【page_145】.  \n- At the same time, the company’s **equity‑affiliate gas reserves – all located in the Asia Pacific/Middle East – rose to **5.87 TCF** by year‑end 2024 (up from 5.75 TCF in 2022)【page_145】, and the 2024 filing notes that extensions and discoveries in equity affiliates were in the Middle East and Australia and that purchases added affiliate interest in Asia Pacific【page_146】.  \n\n**Interpretation:** While direct, developed gas reserves in the region have modestly contracted, ConocoPhillips is bolstering its exposure there through equity‑affiliate growth and acquisitions, indicating a strategic shift toward partnership‑driven expansion rather than organic development of its own gas assets in Asia Pacific/Middle East.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the 2022 and 2024 natural gas reserves for COP in the Asia Pacific/Middle East region as 326 BCF and 296 BCF, respectively, matching the ground truth. However, it introduces additional data not present in the original answer—specifically, undeveloped reserves (4–7 BCF), total regional reserves (330 BCF to 303 BCF), and equity-affiliate reserves increasing from 5.75 TCF to 5.87 TCF. These figures, while possibly accurate in context, are not part of the ground truth and were not requested in the question, leading to a partial mismatch in focus. (2) The core numbers (326 BCF to 296 BCF decline) are correct and consistent with the original answer. However, the LLM performs extra calculations (e.g., summing developed and undeveloped reserves) that are not supported by the ground truth, which only references the 326 → 296 BCF drop. The equity-affiliate data, though cited with page references, is not mentioned in the original answer and represents a divergence in scope. (3) The multi-hop reasoning is sound in that the LLM synthesizes data across years and distinguishes between consolidated and equity-affiliate reserves. It draws a plausible strategic conclusion about a shift toward partnership-driven expansion. However, the original answer draws a simpler, more conservative conclusion—suggesting divestment or strategic shift due to the decline—without referencing affiliate growth. Thus, while the LLM’s reasoning is internally logical, it goes beyond the evidence provided in the ground truth. (4) The correctness score is 6 because the key factual trend (decline in reserves) is accurate, but the answer adds unverified layers of detail and interpretation not present in the ground truth, reducing factual fidelity. Quantitative accuracy is 6 due to correct core numbers but unsupported derived values. Qualitative accuracy is 7 because reasoning is strong but overreaches in synthesis. Contextual relevance is 9 as the response directly addresses the question’s focus on evolution and strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 557,
        "total_tokens": 1922
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did the repurchase activity of Class C Capital Stock by Alphabet change between 2022 and 2023, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023, the repurchase amount increased to $62.2 billion. Additionally, in April 2023, the Board authorized an additional $70.0 billion for share repurchases, with $36.3 billion remaining available as of December 31, 2023. This indicates a continued and expanding emphasis on returning capital to shareholders through share repurchases, with a notable increase in the scale of buybacks year-over-year.",
      "llm_answer": "In 2022 Alphabet repurchased 469 million Class C shares for about $52.6 billion, while in 2023 it bought slightly fewer shares — 450 million — but spent a bit more, about $52.9 billion (page 81). The drop in share count combined with a higher dollar outlay reflects a higher per‑share price, showing that the company kept a strong buy‑back focus but adjusted the program to prevailing market prices, underscoring a capital‑allocation strategy that prioritizes returning cash to shareholders through ongoing stock repurchases.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Alphabet repurchased $59.3 billion in 2022 and $62.2 billion in 2023, but the LLM claims $52.6 billion in 2022 and $52.9 billion in 2023—both figures are incorrect. Additionally, the LLM cites specific share counts (469 million in 2022, 450 million in 2023), which are not present in the ground truth and appear to be fabricated or misattributed. The ground truth does not break down repurchases by share count or separate Class C from Class A, whereas the LLM incorrectly isolates Class C repurchases. (2) The dollar amounts are quantitatively wrong: $52.6B and $52.9B vs. the correct $59.3B and $62.2B. The year-over-year increase is also misrepresented—LLM shows a negligible rise from $52.6B to $52.9B, while the actual increase was from $59.3B to $62.2B (~4.9% increase). Furthermore, the LLM omits the critical fact that in April 2023, an additional $70.0 billion was authorized for buybacks, with $36.3 billion still available at year-end—key evidence of strategic capital allocation expansion. (3) The reasoning is partially sound in interpreting that buybacks reflect a shareholder return strategy, but it fails the multi-hop synthesis: it does not connect the increased total repurchase amount with the new authorization and remaining capacity, which are essential to answering the strategic implication. The focus on per-share price changes due to fewer shares bought at higher cost is speculative and not supported by the ground truth, which only provides total dollar amounts. (4) Correctness is low due to major numerical and factual errors. Quantitative accuracy is poor because the core financial figures are wrong. Qualitative accuracy is modest because the general idea of shareholder returns via buybacks is correct, but entity and metric attribution is flawed. Contextual relevance is moderate since the answer addresses repurchases and capital allocation, but misses key strategic developments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 543,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has AIG's use of frequency/severity methods evolved between 2022 and 2023, particularly in terms of the lines of business where they are applied and the reasoning behind their usage?",
      "original_answer": "In 2022, AIG primarily used frequency/severity methods for short-tail classes such as U.S. Property, and explicitly avoided using them for aviation exposures due to the high severity and varying mix of claims year to year. By 2023, AIG expanded the application of frequency/severity methods to include U.S. Workers' Compensation, a long-tail line of business, as part of a combination of methods that also included loss development and expected loss ratio methods. This reflects a strategic shift toward using frequency/severity methods in more complex, long-tail environments, especially where risk-sharing features and large deductible business have increased.",
      "llm_answer": "- **2022 filing (pages 271‑273):** AIG said it uses “frequency/severity methods” — multiplying an estimated ultimate claim count by an average severity — to set reserves for short‑tail classes such as **U.S. Property** (and similar short‑tail lines), because claim frequencies are stable and the approach yields reliable results. The company explicitly notes that these methods are **not used for high‑severity, long‑tail lines** (e.g., aviation) where severity dominates the loss pattern.  \n\n- **2023 filing (page 200):** The term “frequency/severity” disappears; instead AIG describes an **Average Loss method**, which likewise projects ultimate loss by multiplying projected claim numbers by an estimated ultimate severity average. It is applied to “reserve categories where loss‑development patterns are inconsistent or too variable to be relied on exclusively,” effectively covering the same short‑tail lines (e.g., property) but with a more generic, data‑driven wording.  \n\n**Evolution:** AIG moved from explicitly naming a “frequency/severity” technique for short‑tail property lines in 2022 to embedding the same concept within an “Average Loss” method in 2023, reflecting a shift in terminology and a broader justification that the method is used when development patterns are erratic rather than simply because the line is short‑tail.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct elements but fails on key aspects of the multi-hop reasoning and factual evolution described in the ground truth. (1) Correctly identifies that in 2022, AIG used frequency/severity methods for short-tail lines like U.S. Property and avoided them for high-severity lines such as aviation — this aligns with the original answer. However, the claim that the term 'frequency/severity' 'disappears' in 2023 is incorrect; the 2023 filing does still reference frequency/severity methods, particularly in the context of expanding their use. (2) The LLM incorrectly states that the method was rebranded as the 'Average Loss method' in 2023 and implies a narrowing or rewording of the approach, whereas the ground truth indicates a meaningful expansion — specifically to U.S. Workers' Compensation, a long-tail line, which represents a strategic shift. This is a major omission. (3) The multi-hop reasoning is flawed: the question asks about evolution in usage (lines of business and reasoning), but the LLM misses the critical point that AIG extended frequency/severity methods to long-tail business in 2023, contrary to prior practice. Instead, it suggests only a terminological shift, which contradicts the original answer. (4) While the entities (AIG, years, property lines) and general method descriptions are accurate, the core evolution — expansion into long-tail lines due to risk-sharing and large deductible trends — is entirely missing. The reasoning for usage in 2023 is misrepresented. Thus, despite correct formatting and some accurate details, the answer fails on the central factual development, warranting a low correctness score. Quantitative accuracy is higher because there are no numerical errors per se (no numbers were misstated), and contextual relevance is moderate because the response addresses the general topic and timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1511,
        "completion_tokens": 506,
        "total_tokens": 2017
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Amgen's financial relationship with BeiGene evolved from 2022 to 2023, particularly in terms of cost recovery, product sales, and profit and loss sharing?",
      "original_answer": "In 2022, Amgen recovered $199 million in R&D costs from BeiGene, recorded product sales of $64 million, and recognized $53 million in profit and loss sharing expenses. In 2023, these figures changed to $109 million in cost recovery, $125 million in product sales, and $40 million in profit and loss sharing expenses. This indicates a decrease in cost recovery and profit-sharing expenses, but a significant increase in product sales to BeiGene. The shift suggests a maturation of the collaboration, with more product sales occurring in 2023, while the level of R&D cost sharing declined.",
      "llm_answer": "In 2023 Amgen’s collaboration with BeiGene showed a shift from the prior year: net cost recoveries fell to **$109 million** (down from **$199 million** in 2022), product sales that Amgen shipped to BeiGene rose to **$125 million** (up from **$64 million** in 2022), and the profit‑and‑loss‑share expense for the initial product‑specific commercialization period declined to **$40 million** (versus **$53 million** in 2022).  These figures are disclosed in the “Collaborations” section of Amgen’s 2023 and 2022 Form 10‑K filings.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) All numeric values are accurate: $199 million and $109 million for cost recovery in 2022 and 2023 respectively; $64 million and $125 million for product sales; $53 million and $40 million for profit and loss sharing expenses. These figures are correctly attributed to the respective years and entities. (2) The answer addresses all components of the multi-part question—cost recovery, product sales, and profit and loss sharing—across both years. (3) Entities (Amgen, BeiGene, Form 10-K filings) and financial metrics are correctly identified and contextualized. (4) The reasoning is sound: the LLM correctly infers a shift in the collaboration dynamics, noting decreased cost recovery and profit-sharing expenses alongside increased product sales, which aligns with the ground truth interpretation of maturation in the partnership. Minor wording differences (e.g., 'profit-and-loss-share expense for the initial product-specific commercialization period') add precision without altering meaning. Semantic equivalence is maintained, and all information is contextually relevant and factually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 332,
        "total_tokens": 1615
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what specific changes occurred in terms of revisions, production, and purchases during this period?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. During this period, revisions in 2023 added 9 billion cubic feet, but production subtracted 25 billion cubic feet in 2024. Additionally, there were no purchases reported directly affecting this region in 2024, indicating a reduction in active reserve growth strategies compared to earlier years.",
      "llm_answer": "- **Reserve size** – The total (developed + undeveloped) natural‑gas reserve base in the Asia Pacific/Middle East fell from **326 BCF at the end of 2022** to **312 BCF at the end of 2023** and to **296 BCF at the end of 2024** (a 30‑BCF decline over the three‑year span)【page_145】.  \n\n- **Revisions** – 2022 showed a modest upward revision of **+6 BCF**; 2023 had an upward revision of **+9 BCF**; 2024 recorded a net **downward revision of about ‑26 BCF** (price‑driven cuts of 81 BCF partially offset by technical gains of 55 BCF)【page_145】【page_146】.  \n\n- **Production** – Gas produced from this region was **24 BCF in 2022**, **25 BCF in 2023**, and rose sharply to **51 BCF in 2024**【page_145】.  \n\n- **Purchases** – No purchases were reported for the Asia Pacific/Middle East in any of the three years; the “Purchases” line for this region is blank (‑) in the 2022‑2024 tables【page_145】.  ",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies compared to the ground truth, particularly in reserve evolution, revisions, and production figures. While the starting (326 BCF in 2022) and ending (296 BCF in 2024) reserve levels match the original answer, the LLM incorrectly reports an intermediate value of 312 BCF in 2023, which is not mentioned in the ground truth and introduces a false data point. (2) Revisions: The ground truth states only that 9 BCF were added in 2023; the LLM adds unsupported details about +6 BCF in 2022 and a large -26 BCF downward revision in 2024 with technical breakdowns (price-driven cuts, technical gains), which are not present in the original answer and contradict its narrative of a simple 25 BCF subtraction due to production in 2024. (3) Production: The original answer specifies only 25 BCF subtracted in 2024, implying production for that year, but does not provide 2022 or 2023 production data. The LLM reports 24 BCF (2022), 25 BCF (2023), and 51 BCF (2024), introducing a sharp increase not supported by the ground truth. The 51 BCF figure is especially problematic as it implies a major operational shift absent from the original. (4) Purchases: Both answers agree no purchases occurred in 2024, so this part is accurate. However, the LLM extends this to all three years, which goes beyond the scope of the original answer that only comments on 2024. (5) Multi-hop reasoning: The LLM attempts deeper synthesis using what appears to be table data (e.g., page references), but this leads to overreach and inclusion of unsupported details. The original answer presents a simplified, high-level summary, while the LLM provides granular annual data that may be from the source but contradicts the synthesized truth in the original answer. (6) Semantic equivalence fails on key metrics: although the net change (30 BCF decrease) is close to the actual 30 BCF drop (326 → 296), the path is misrepresented. The LLM’s detailed breakdown conflicts with the original’s explanation, undermining correctness. (7) Contextual relevance is high—the answer addresses all aspects of the question (reserves, revisions, production, purchases) and cites specific pages, showing good structure. However, quantitative accuracy is low due to incorrect numbers and unsupported calculations. Qualitative accuracy is moderate because the reasoning framework is sound but based on potentially misinterpreted or overly detailed data extraction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 660,
        "total_tokens": 2016
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did FedEx's planned usage of the B767F aircraft evolve from 2022 to 2024, and what does this indicate about its strategic fleet planning?",
      "original_answer": "In 2022, FedEx projected using 14 B767F aircraft in both 2023 and 2024, with a planned reduction to 10 by 2025. By 2024, the projections had changed, showing a decrease to 11 B767F aircraft for 2025 and only 3 by 2026. This indicates a strategic shift toward a more accelerated reduction in the planned use of B767F aircraft, reducing reliance on this model over time.",
      "llm_answer": "In the 2022 Form 10‑K FedEx reported that it had committed to buy **14 Boeing 767‑300 Freighters (B767F) in 2023 and another 14 in 2024**, with a further 10 slated for 2025 and no B767F purchases after 2026【page_40】.  \nBy the 2024 filing the remaining commitments had shifted to **11 B767F for delivery in 2025 and only 3 in 2026**, with the earlier‑year purchases already fulfilled or cancelled【page_117】.  \n\nThis downward‑trend shows FedEx is scaling back the total number of B767F aircraft it will add to its fleet, concentrating the remaining deliveries in later years as part of its broader modernization program that emphasizes newer, more fuel‑efficient types such as the Boeing 777F【page_116】, indicating a strategic move to streamline the fleet toward higher‑efficiency aircraft.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative details. The original answer states that FedEx *projected using* 14 B767F aircraft in 2023 and 2024 (not purchasing 14 each year), with a reduction to 10 by 2025. However, the LLM incorrectly claims FedEx 'committed to buy 14 B767F in 2023 and another 14 in 2024', which misrepresents the nature and timing of the commitments. This is a critical error because the original data reflects projected fleet *usage*, not purchase commitments. The 2024 update correctly notes a reduction to 11 for 2025 and 3 for 2026, aligning with the ground truth, but the earlier misstatement undermines overall accuracy. (2) The numbers for 2025 and 2026 in the 2024 filing (11 and 3) are correct and match the ground truth, but the 2022 projection is completely misrepresented—original says 14 aircraft *in use* in 2023/2024, not 14 *purchased* each year. There is no mention in the ground truth of 'no purchases after 2026', which the LLM adds without support. (3) The reasoning about strategic fleet planning—shifting to more fuel-efficient aircraft like the 777F—is contextually sound and reflects valid synthesis from the 2024 filing, showing good qualitative understanding of the strategic intent behind the numbers. However, the multi-hop reasoning fails because it conflates fleet usage projections with purchase commitments, leading to incorrect inferences. (4) The contextual relevance is high because the answer addresses both the evolution and strategic implications. Qualitative accuracy is moderate due to correct interpretation of directionality (reduction, modernization) but flawed data sourcing. Quantitative accuracy is low due to major errors in numbers and their meanings. Correctness score is 6 because while the later-year numbers and strategic interpretation are partially correct, the foundational data is misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 518,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did AIG's use of Expected Loss Ratio Methods evolve between 2022 and 2023, particularly in terms of the lines of business and the reasoning behind their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to the high severity nature of claims and varying mix across years. By 2023, AIG applied Expected Loss Ratio Methods more broadly, particularly in U.S. Workers' Compensation, a long-tail line of business, where they used a combination of methods including Expected Loss Ratio, to account for extended loss emergence periods and complex risk-sharing features in policies. This reflects a shift from a focus on short-term forecasting in high-severity contexts to a broader application in long-tail, structurally complex lines.",
      "llm_answer": "In the 2022 filing AIG said it applied the Expected‑Loss‑Ratio (ELR) method mainly where loss‑development patterns were inconsistent, losses emerged very slowly or there was little loss history – most notably for business written in excess of a deductible, which could receive “significant weight” for the five most recent accident years【page_271】.  \n\nIn the 2023 filing the same basic rationale is retained, but AIG expands the use of ELR to additional lines – for example, it now relies on ELR (combined with loss‑development techniques) to set reserves for the latest accident year of its aviation exposures and other program business, and it explicitly adjusts the ratios for rate changes, inflation and evolving market conditions【page_200】【page_273】.  \n\nThus, between 2022 and 2023 AIG broadened the ELR application from primarily excess‑of‑deductible lines to also include aviation (and similar program) lines, while continuing to use it where loss history is thin or development is slow and refining the ratios with current pricing and trend adjustments.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its description of AIG's use of the Expected Loss Ratio (ELR) method in 2022 and 2023, with correct citations and no numerical errors (quantitative accuracy is perfect, as there are no miscalculations or incorrect figures). The answer correctly identifies that in 2022, ELR was used primarily in contexts with thin loss history or slow development, such as excess-of-deductible business, and that in 2023, it was expanded to include aviation and program business, with adjustments for rate changes and inflation. However, the original answer emphasizes a key evolution: a strategic shift from short-term forecasting in high-severity lines (like aviation in 2022) to broader use in long-tail, structurally complex lines like U.S. Workers' Compensation in 2023. The LLM answer misses this specific shift to Workers' Compensation and instead focuses on aviation and program business, which were already partially covered in 2022. This omission of a major new line of business (Workers' Compensation) and the deeper reasoning around long-tail risk and extended emergence periods reduces qualitative accuracy. While the LLM captures expansion and refinement of ELR use, it does not fully reflect the multi-hop synthesis between years or the significance of applying ELR to a fundamentally different class of long-tail business. Contextual relevance remains high because the response directly addresses the evolution, lines of business, and reasoning, albeit with incomplete coverage of the key new application in Workers' Compensation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 428,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has Cisco's positioning around Enterprise Data Center Transformation evolved between 2022 and 2024, particularly in relation to its strategic alliances and competitive landscape?",
      "original_answer": "In 2022, Cisco highlighted that the enterprise data center was undergoing a fundamental transformation due to the convergence of technologies like computing, networking, storage, and software, with strategic alliance partners sometimes acquiring or aligning with competitors, reducing business with Cisco. By 2024, Cisco continued to emphasize this transformation but expanded its focus on strategic alliances aimed at industry advancement and new market creation, while also updating its competitive landscape to include new entrants like Nvidia Corporation, signaling a shift in market dynamics and alliance strategies.",
      "llm_answer": "In the 2022 filing Cisco framed the enterprise‑data‑center market as “undergoing a fundamental transformation” driven by the convergence of compute, networking, storage and software, and warned that many of its strategic‑alliance partners (e.g., cloud and hardware vendors) could also become direct competitors in that space【page_11】. By the 2024 filing the company’s narrative had shifted to a broader “build‑buy‑partner‑invest‑co‑develop” model that stresses collaborative product development and advisory services, and it highlights newly‑added alliances with firms such as Apple, Equinix and Google rather than focusing on the data‑center transformation itself【page_10】. The competitive set remains extensive, but Cisco now positions its alliances as a way to co‑create end‑to‑end solutions rather than a source of heightened rivalry in a transforming data‑center market.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of core facts and evolution of Cisco's positioning between 2022 and 2024. It accurately captures the 2022 context where Cisco noted the enterprise data center transformation due to technology convergence and the risk of alliance partners becoming competitors. The 2024 update correctly reflects a strategic pivot toward broader collaboration models (build-buy-partner-invest-co-develop) and highlights new alliances with Apple, Equinix, and Google, which is consistent with the ground truth’s emphasis on expanded strategic alliances for industry advancement. However, the LLM answer does not explicitly mention the addition of Nvidia Corporation to the competitive landscape, a key detail in the original answer that signals a shift in market dynamics. While the LLM conveys a shift in alliance strategy and reduced emphasis on rivalry, it omits this specific new entrant, which is a meaningful entity-level gap. There are no numerical inaccuracies (quantitative accuracy is perfect as no numbers are misstated), and the reasoning is sound in synthesizing changes in strategic posture across years. The answer remains contextually relevant and semantically close to the original, but the missing reference to Nvidia slightly weakens completeness and entity accuracy in the multi-hop synthesis. Hence, a score of 8 is justified for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 416,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the effective interest rate and notional amount associated with the 3.125% 2025 Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 3.125% 2025 Notes were part of a $5.2 billion principal amount on which new interest rate swaps were entered into after the termination of previous swaps, indicating a dynamic hedging strategy due to low interest rates. By 2023, the notional amount of the 3.125% 2025 Notes under interest rate swaps had decreased to $1.0 billion, with an effective interest rate of SOFR + 2.1%. This reflects a reduction in the hedged notional exposure and a shift in the interest rate environment.",
      "llm_answer": "- **2022:** The 3.125 % 2025 Notes were hedged with an interest‑rate‑swap having a notional amount of **$1 billion** and an effective rate of **LIBOR + 1.8 %** (see the 2022 filing’s swap table, which lists the 3.125 % 2025 Notes at a $1 bn notional and LIBOR + 1.8 % effective rate).  \n\n- **2023:** The same 3.125 % 2025 Notes continued to have a **$1 billion** notional, but the swap benchmark shifted to **SOFR + 2.1 %** (the 2023 filing shows the 3.125 % 2025 Notes with a $1 bn notional and an effective rate of SOFR + 2.1 %).  \n\nThus, between 2022 and 2023 the notional amount stayed unchanged at $1 billion, while the effective interest rate moved from LIBOR + 1.8 % to SOFR + 2.1 %.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in its quantitative claims. According to the ground truth, in 2022 the 3.125% 2025 Notes were part of a $5.2 billion principal amount on which new swaps were entered, not $1 billion as claimed. The LLM incorrectly states that the 2022 notional amount was $1 billion with an effective rate of LIBOR + 1.8%, but the ground truth does not mention LIBOR or that specific rate, nor does it confirm the $1 billion figure for 2022. By 2023, the ground truth confirms the notional amount under swaps decreased to $1.0 billion with an effective rate of SOFR + 2.1%, which matches the LLM's 2023 claim. However, the LLM falsely asserts the notional remained unchanged, when in fact it decreased from $5.2 billion (hedged portion) in 2022 to $1.0 billion in 2023. (2) The key numbers — $5.2 billion in 2022 and the shift from LIBOR to SOFR — are either wrong or unsupported. The LLM introduces LIBOR + 1.8% without grounding in the original answer, which does not specify the 2022 effective rate. (3) The multi-hop reasoning is flawed: the LLM fails to recognize the evolution from a larger hedged position in 2022 to a reduced one in 2023, misrepresenting the dynamics of the hedging strategy. It also misses the broader context of a changing interest rate environment and strategic reduction in exposure. (4) While the 2023 data partially aligns and the shift to SOFR is correctly noted, the core facts about notional evolution are wrong, leading to a low correctness score. Contextual relevance is moderate because the answer addresses the right instrument and time frame, but with significant factual inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 453,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Cisco's strategic positioning of AppDynamics within its product portfolio evolved from 2022 to 2024, particularly in terms of its emphasis within observability offerings?",
      "original_answer": "In 2022, Cisco explicitly introduced AppDynamics as a key component of its full-stack observability strategy, positioning it alongside Intersight and ThousandEyes to provide application performance monitoring capabilities. However, by 2024, Cisco restructured its product revenue reporting to include a new category called 'Observability,' which subsumed offerings like AppDynamics. This shift indicates a more formalized and integrated strategic emphasis on observability as a standalone pillar within Cisco's broader portfolio.",
      "llm_answer": "In the 2022 filing Cisco described AppDynamics only as one of several “key elements” added to its **full‑stack observability** portfolio – together with Intersight, ThousandEyes and security innovations – but it was not singled out as a separate revenue line (see 2022 page 5). By the 2024 filing Cisco had reorganized its product reporting to create a distinct **Observability** category, grouping AppDynamics (now part of the “Observability Suite”) with network‑assurance, monitoring and analytics offerings, and highlighting its contribution to a 27 % revenue increase in that category (see 2024 pages 41‑42). Thus, AppDynamics moved from a supporting role in a broad observability narrative to a core component of a dedicated observability segment within Cisco’s portfolio.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies Cisco's 2022 positioning of AppDynamics as part of its full-stack observability strategy alongside Intersight and ThousandEyes, without being a standalone revenue line. By 2024, it accurately notes the creation of a formal 'Observability' category in revenue reporting, which includes AppDynamics as a core component. (2) The 27% revenue increase mentioned in the LLM answer aligns with the 2024 filing details (pages 41–42), and while the original answer does not include this percentage, it is consistent with the knowledge graph data and adds precision without introducing error. No incorrect numbers, dates, or calculations are present. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, infers the strategic evolution from narrative mention to formal revenue categorization, and draws a valid conclusion about AppDynamics’ elevated strategic role. (4) All entities—Cisco, AppDynamics, Intersight, ThousandEyes—are correctly identified and contextualized. The answer fully addresses the question about strategic positioning evolution and emphasis within observability offerings, making it complete, accurate, and contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 365,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the effective interest rate and notional amount associated with the 4.663% 2051 Notes evolve from 2022 to 2023?",
      "original_answer": "In 2022, the 4.663% 2051 Notes were part of a $5.2 billion principal amount of notes that were hedged using interest rate swaps, with the swaps terminated and replaced at then-current interest rates. In 2023, the notional amount of the 4.663% 2051 Notes was $1.5 billion, and the effective interest rate was SOFR + 4.3%. This indicates a continuation of the hedging strategy but with updated interest rate terms and a more specific disclosure of the notional amount and rate for the 2051 Notes.",
      "llm_answer": "- **Effective interest rate:** The 4.663 % 2051 Notes were reported to have an effective interest rate of **5.6 %** in the 2022 filing (page 130) and the same rate is still disclosed in the 2023 filing (page 142), where it is expressed as **SOFR + 4.3 %** (page 144) – a level that is equivalent to the 5.6 % figure.  \n\n- **Notional amount of the related interest‑rate swap:** Both the 2022 and 2023 filings show a **$1.5 billion** notional amount for the swap covering the 4.663 % 2051 Notes (page 132 for 2022; page 144 for 2023).  \n\nThus, from 2022 to 2023 the effective interest rate remained essentially unchanged (about 5.6 %/SOFR + 4.3 %) and the swap notional stayed at $1.5 billion.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies compared to the ground truth. It claims the effective interest rate was 5.6% in both 2022 and 2023, with the 2023 rate expressed as SOFR + 4.3%, which it equates to 5.6%. However, the original answer states that in 2022, the 4.663% 2051 Notes were part of a $5.2 billion hedged portfolio, with swaps terminated and replaced at then-current rates — but does not specify an effective rate of 5.6% or mention SOFR + 4.3% for that year. The $1.5 billion notional amount is only mentioned in the 2023 context in the ground truth, not in 2022, contradicting the LLM's claim that the swap notional was $1.5 billion in both years. (2) Quantitatively, the $1.5 billion notional amount is correctly cited for 2023, and the SOFR + 4.3% rate aligns with the original answer. However, the attribution of a 5.6% effective rate and $1.5 billion swap notional to 2022 is unsupported by the ground truth, which describes a broader $5.2 billion hedged amount without specifying how much applied to the 2051 Notes specifically. (3) The multi-hop reasoning is flawed: the LLM incorrectly assumes continuity between years by asserting unchanged terms, while the original answer emphasizes a change — swaps were terminated and replaced, indicating evolution in the hedging structure. The LLM fails to capture the key development that the 2023 data reflects a more specific disclosure of terms for the 2051 Notes, not a continuation of identical terms. (4) Despite these errors, the answer is contextually relevant, addressing the right financial instrument and timeframe, and correctly interpreting SOFR + 4.3% as the 2023 effective rate. However, major factual and synthetic inaccuracies reduce correctness and qualitative accuracy significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 488,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of the lines of business and segmentation criteria applied?",
      "original_answer": "In 2022, AIG referenced the use of expected loss ratio methods in a general sensitivity analysis related to loss reserve assumptions, without specifying detailed segmentation or particular lines of business. By 2023, AIG explicitly applied expected loss ratio methods to U.S. Workers' Compensation, a long-tail line of business, and introduced more granular segmentation criteria such as risk-sharing features, state and industry subsets, deductible size, and claim handling entities. This indicates a more structured and detailed application of the method in 2023 compared to 2022.",
      "llm_answer": "In the 2022 filing AIG said that **expected‑loss‑ratio (ELR) techniques were used only on a few long‑tail lines** – chiefly U.S. Workers’ Compensation, U.S. Excess Casualty, U.S. Other Casualty and other run‑off businesses – and that the ELR inputs were segmented by **deductible size, state/industry subsets and the “excess‑of‑deductible” versus guaranteed‑cost portion of the business** (AIG 2022 p.66; p.68).  \n\nBy the 2023 filing the company’s reserving discussion shows the ELR approach has been **expanded to all business written in excess of a deductible and is now applied to the most recent five accident years**, with the ratios adjusted for **rate changes, loss‑trend (including inflation) and prevailing market conditions**, while still being broken out by **line of business and accident year** in the loss‑development tables (AIG 2023 p.200‑201).  \n\nThus, between 2022 and 2023 AIG moved from a relatively narrow, segment‑by‑deductible application of ELR to a broader, more systematic use across excess‑of‑deductible lines, emphasizing recent accident‑year trends and market‑adjusted loss ratios.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies compared to the ground truth, particularly regarding the timeline and scope of AIG's use of expected loss ratio (ELR) methods. According to the original answer, in 2022 AIG only referenced ELR methods in a general sensitivity analysis without specifying lines of business or segmentation—however, the LLM claims that in 2022, ELR was already applied to specific lines like U.S. Workers’ Compensation, U.S. Excess Casualty, and others, with detailed segmentation. This contradicts the ground truth and misrepresents the evolution. The LLM also asserts that in 2022, segmentation included deductible size, state/industry subsets, and excess-of-deductible vs. guaranteed-cost—details that the ground truth attributes to 2023, not 2022. While the LLM correctly identifies U.S. Workers’ Compensation as a key line in 2023, it incorrectly expands the 2023 segmentation and methodology to a broader set of lines and accident years (e.g., 'all business written in excess of a deductible' and 'most recent five accident years') not mentioned in the ground truth. The claim about adjustments for rate changes, loss-trend, and market conditions in 2023 is not supported by the original answer. The reasoning is logically structured but based on incorrect premises, leading to flawed multi-hop synthesis. Quantitative accuracy is moderate because there are no explicit numerical errors (e.g., dates like 2022/2023 are correct), but the financial or methodological details are misrepresented. Contextual relevance is high as the answer addresses the evolution of ELR methods, lines of business, and segmentation as asked. However, the core factual misalignment between years severely undermines correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 473,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did PepsiCo's engagement with the 2.850% Senior Notes due 2026 evolve between 2023 and 2024, particularly in terms of its broader debt issuance strategy as reflected in the additional notes introduced in 2024?",
      "original_answer": "In 2023, PepsiCo referenced the 2.850% Senior Notes due 2026 as part of a broader set of debt instruments, including other senior notes with varying interest rates and maturity dates. By 2024, the company introduced a significantly expanded range of senior notes, including higher-yielding instruments such as the 7.00% Senior Notes due 2029 and the 5.50% Senior Notes due 2035, indicating a more diversified and long-term debt issuance strategy. This evolution suggests that PepsiCo not only maintained its commitment to the 2.850% Senior Notes due 2026 but also broadened its capital structure by incorporating a wider spectrum of debt instruments with different risk-return profiles.",
      "llm_answer": "In the 2023 Form 10‑K, PepsiCo’s board authorized a package of new debt that included the **2.850 % Senior Notes due 2026** (see the list of notes in the 2023 resolutions 【page_130†L1-L4】). When the company filed its 2024 Form 10‑K, the same 2.850 % Senior Notes due 2026 were again listed, but the board also added several other issuances – notably a **5.125 % Senior Note due 2026**, a **5.250 % Senior Note due 2025**, a **4.500 % Senior Note due 2029**, a **4.800 % Senior Note due 2034**, and a **5.250 % Senior Note due 2054** (see the 2024 resolutions 【page_129†L1-L4】). Thus, PepsiCo maintained its original 2.850 % issuance while expanding its debt program in 2024 with a broader set of new senior notes across a range of maturities and coupon rates.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the specific debt instruments introduced in 2024. The ground truth states that PepsiCo introduced higher-yielding notes such as the 7.00% Senior Notes due 2029 and 5.50% Senior Notes due 2035. However, the LLM claims new notes including a 5.125% due 2026, 5.250% due 2025, 4.500% due 2029, 4.800% due 2034, and 5.250% due 2054 — none of which match the ground truth. These are entirely different coupon rates, maturities, and instruments. (2) Quantitative accuracy is low because all percentages and maturity dates cited in the LLM answer are incorrect. While the 2.850% Senior Notes due 2026 are correctly referenced as existing in both years, the additional notes in 2024 are fabricated or misreported. There is no overlap between the LLM’s listed new notes and the ground truth’s 7.00% due 2029 and 5.50% due 2035. (3) The multi-hop reasoning is partially sound — the model correctly infers that PepsiCo maintained the 2.850% notes and expanded its debt program — but the synthesis is based on incorrect data. The conclusion about broadening the debt program is directionally correct, but the specific evidence used is wrong. (4) Contextual relevance is high because the answer addresses the evolution of the 2.850% notes and attempts to describe a broader debt strategy. However, due to the incorrect identification of the new notes, the qualitative accuracy is limited. The core factual error in the 2024 debt instruments severely undermines the correctness score despite a reasonable structure and logical flow.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 436,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Cisco's exposure to channel partner financing guarantees evolved between fiscal years 2022 and 2024, and what does this indicate about the company's financial risk management strategy?",
      "original_answer": "In fiscal year 2022, Cisco disclosed that the volume of channel partner financing was $27.9 billion, with a balance of financing subject to guarantees amounting to $1.4 billion as of July 30, 2022. By fiscal year 2024, while the company continued to provide financing guarantees, the specific volume of channel partner financing and the balance subject to guarantees were no longer explicitly quantified in the disclosures. This shift indicates a potential strategic move toward reducing transparency around these financial commitments, which may reflect a broader risk management approach to limit visibility into contingent liabilities. However, the absence of updated figures prevents definitive conclusions about the actual change in exposure.",
      "llm_answer": "In FY 2022 Cisco reported that the aggregate amount of channel‑partner financing guarantees outstanding was $188 million of maximum potential future payments (net of $9 million of deferred‑revenue offset). By FY 2024 that exposure had fallen to about $127 million of maximum potential future payments (with $13 million recorded as deferred revenue). The decline in the guaranteed amount shows Cisco is actively curbing the size of its contingent financing obligations, reflecting a tighter risk‑management stance that seeks to limit potential out‑flows from partner‑guarantee programs.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in FY 2022, Cisco reported a volume of channel partner financing of $27.9 billion, with $1.4 billion subject to guarantees. The LLM incorrectly states that the guaranteed amount was $188 million (net of $9 million), which does not match the disclosed $1.4 billion. Similarly, for FY 2024, the LLM claims exposure fell to $127 million (with $13 million deferred revenue), but the original answer states that Cisco no longer disclosed specific figures in FY 2024, making any precise quantification unsupported. Thus, all key numbers are incorrect. (2) The quantitative accuracy is very low: the LLM invents precise figures for both years that are not present in the ground truth, especially for FY 2024 where no such data was disclosed. There is no evidence of $188M or $127M figures in the source. (3) The reasoning is flawed: the LLM assumes a downward trend and concludes Cisco is actively reducing exposure, but the original answer emphasizes that post-2022 disclosures lack quantification, preventing definitive conclusions. The model fails the multi-hop synthesis by not recognizing the absence of data in 2024 as a key point, instead fabricating numbers and drawing unsupported conclusions about risk management. (4) Contextual relevance is moderate because the answer addresses the right topic (Cisco's channel financing guarantees and risk management), but the incorrect data and false trend analysis undermine the validity. The conclusion about tighter risk management is speculative and contradicts the cautious interpretation in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 453,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has the status and interest rate structure of the 2.45% 2030 Notes evolved between 2022 and 2023?",
      "original_answer": "In 2022, Amgen disclosed that it had entered into interest rate swap contracts with an aggregate notional amount of $1.0 billion with respect to the 2.45% 2030 Notes, effectively converting the fixed-rate interest to a floating LIBOR-based coupon. By 2023, the 2.45% 2030 Notes remained outstanding with a notional amount of $1.0 billion, but the interest rate structure had transitioned from LIBOR to SOFR, now stated as SOFR + 1.3%. This reflects a continuation of the note's existence but with a modified floating-rate benchmark.",
      "llm_answer": "In the 2022 filing the 2.45 % 2030 senior notes were still on the balance sheet with a $1.250 billion principal amount and were hedged by a $1 billion interest‑rate‑swap whose effective rate was LIBOR + 1.0 % (the coupon remained 2.45 %). By the 2023 filing the notes were no longer listed in the debt‑balance table, but the swap schedule still shows a $1 billion notional for the 2.45 % 2030 notes, now priced at an effective rate of SOFR + 1.3 %—indicating the hedge was moved from a LIBOR‑based to a SOFR‑based structure while the fixed‑rate coupon stayed at 2.45 %.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it states the principal amount of the 2.45% 2030 Notes was $1.250 billion in 2022, but the ground truth specifies a $1.0 billion notional amount for both the notes and the swap—this is a significant numerical error. Second, the LLM claims the effective rate under the swap in 2022 was LIBOR + 1.0%, but the original answer does not specify this rate, only that the fixed rate was converted to a floating LIBOR-based coupon. The LLM invents a specific spread not present in the ground truth. Third, the LLM incorrectly states that the notes were 'no longer listed in the debt-balance table' in 2023, contradicting the ground truth that the notes 'remained outstanding'—this misrepresents the status of the debt. (2) Quantitative accuracy is partially correct regarding the $1 billion notional swap amount and the SOFR + 1.3% rate in 2023, which aligns with the ground truth. However, the $1.250 billion principal and LIBOR + 1.0% rate are unsupported and incorrect. (3) The multi-hop reasoning is flawed: the model incorrectly infers the notes were deconsolidated or paid off due to absence from a table, when the ground truth confirms they remained outstanding. It also fails to accurately synthesize the evolution of the interest rate benchmark from LIBOR to SOFR while maintaining the fixed coupon, instead suggesting the hedge was restructured independently of the note’s continued existence. (4) Despite these errors, the answer is contextually relevant—it addresses the evolution of the interest rate structure and attempts to track changes across years. However, major factual and reasoning errors reduce correctness significantly, warranting a score of 4. Quantitative accuracy is moderate (5) due to partial number correctness. Qualitative accuracy is low (4) due to incorrect inferences and entity status. Contextual relevance is high (8) as the structure and intent align with the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 532,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has FedEx's relationship with Pass-Through Certificates evolved between 2022 and 2023, particularly regarding its financial guarantees and obligations?",
      "original_answer": "In 2022, FedEx Express had issued $970 million of Pass-Through Certificates, Series 2020-1AA, which were fully and unconditionally guaranteed by FedEx. These certificates were secured by 19 Boeing aircraft with a net book value of $1.8 billion. However, in 2023, FedEx clarified that pass-through certificates associated with leveraged operating leases were not direct obligations of, nor guaranteed by, FedEx or FedEx Express. This indicates a shift from direct financial guarantees in 2022 to a position of no direct financial obligation in 2023.",
      "llm_answer": "In the 2022 filing FedEx disclosed that it had issued $970 million of Pass‑Through Certificates (Series 2020‑1AA) secured by 19 Boeing aircraft and that **the payment obligations on those certificates were “fully and unconditionally guaranteed” by FedEx**. The 2023 filing repeats the same guarantee language and adds that **FedEx Express services the certificates through leveraged operating‑lease payments, and the certificates are still described as not being direct obligations of, or guaranteed by, FedEx or FedEx Express**. Thus, from 2022 to 2023 the relationship remained essentially unchanged: FedEx continues to guarantee the certificates while the actual cash‑flow obligation is met via FedEx Express lease payments.",
      "correctness_score": 3,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $970 million Pass-Through Certificates, Series 2020-1AA, the 19 Boeing aircraft, and the $1.8 billion net book value (implied from context), so quantitative accuracy is high. However, the core factual claim about FedEx's guarantee is incorrect and directly contradicts the ground truth. The LLM states that the 2023 filing 'repeats the same guarantee language,' but the ground truth states that in 2023, FedEx clarified that the certificates were *not* guaranteed by FedEx or FedEx Express—marking a clear shift from 2022. The LLM incorrectly concludes that the relationship 'remained essentially unchanged' and that FedEx 'continues to guarantee,' which is false. (2) All numeric values (e.g., $970 million, 19 aircraft) are accurate and match the original answer. (3) The multi-hop reasoning fails: the model should have contrasted the 2022 guarantee with the 2023 disavowal of obligation, but instead conflates the two years and asserts consistency. This undermines the qualitative accuracy. (4) While the answer is relevant and includes correct entities and numbers, the central conclusion about the evolution of the relationship is factually wrong, warranting a low correctness score despite strong quantitative performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 359,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Mastercard's use of risk mitigation arrangements to manage gross settlement exposure evolve from 2023 to 2024, and what does this indicate about the company's risk management strategy?",
      "original_answer": "In 2023, Mastercard had $75,023 million in gross settlement exposure, with $12,167 million covered by risk mitigation arrangements. By 2024, gross settlement exposure increased to $78,385 million, and the company applied $13,466 million in risk mitigation arrangements, reflecting an increase in both total exposure and the amount mitigated. This indicates that Mastercard's risk management strategy became more robust over time, as it increased its use of mitigation tools in response to growing settlement exposure.",
      "llm_answer": "In 2023 Mastercard estimated $75 billion of gross settlement exposure and applied $12.2 billion of risk‑mitigation arrangements (cash collateral, letters of credit, guarantees), leaving a net exposure of $62.9 billion. By year‑end 2024 the gross exposure had risen to $78.4 billion and the company increased its mitigation instruments to $13.5 billion, resulting in a net exposure of $64.9 billion. The parallel rise in both exposure and mitigation shows that Mastercard actively scales its collateral and credit‑enhancement requirements as transaction volumes grow, underscoring a disciplined, forward‑looking risk‑management strategy that seeks to keep net settlement risk proportionate to the underlying gross exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually correct in all key aspects. It accurately reports the increase in gross settlement exposure from $75,023 million in 2023 to $78,385 million in 2024, rounding to $75 billion and $78.4 billion respectively, which is acceptable. Similarly, risk mitigation arrangements are correctly reported as $12.2 billion (vs. $12,167 million) and $13.5 billion (vs. $13,466 million), with minor rounding that does not affect accuracy. Net exposures of $62.9 billion and $64.9 billion are correctly derived (75 - 12.2 = 62.8 ≈ 62.9; 78.4 - 13.5 = 64.9), with slight rounding in the first case likely due to precise underlying values. (2) All calculations and comparisons are logically sound and numerically accurate within reasonable rounding. The trend of increasing gross exposure and corresponding increase in mitigation is correctly identified. (3) The multi-hop reasoning—comparing two years of data across gross exposure, mitigated amounts, and net exposure—is fully and correctly synthesized. The conclusion about Mastercard’s risk management strategy being disciplined and forward-looking aligns with and even enriches the ground truth’s assertion of a 'more robust' strategy. (4) The answer is contextually excellent, addressing both the evolution and strategic implication. The only reason for not scoring a 10 in quantitative accuracy is the slight rounding in the 2023 net exposure, but this is within acceptable limits given the use of rounded inputs. Overall, the answer is semantically equivalent and factually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 429,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Nike's liabilities related to foreign exchange forwards and options designated as hedging instruments change between 2022 and 2024, and what does this indicate about the company's exposure or strategy?",
      "original_answer": "In 2022, Nike reported $37 million in liabilities for foreign exchange forwards and options designated as hedging instruments under accrued liabilities, and $11 million under deferred income taxes and other liabilities, totaling $48 million. By 2024, the liability under accrued liabilities for the same category increased to $110 million, while the amount under deferred income taxes and other liabilities decreased to $5 million, resulting in a total of $115 million. This represents a significant increase in total liabilities for designated hedging instruments related to foreign exchange forwards and options, indicating a potential increase in Nike's foreign exchange risk exposure or a strategic shift in hedging activity.",
      "llm_answer": "Nike’s balance‑sheet liabilities for foreign‑exchange forwards and options that were designated as hedging instruments rose from **about $48 million in fiscal 2022** (the 2022 10‑K shows $37 million in accrued liabilities and no deferred‑tax liability, total $48 million) to **about $115 million in fiscal 2024** (the 2024 10‑K shows $110 million in accrued liabilities plus $5 million in deferred‑tax liabilities, total $115 million of the $146 million “designated‑hedge” liabilities). This near‑three‑fold increase signals that Nike has expanded the amount of foreign‑currency cash‑flow risk it is actively hedging, reflecting either greater exposure to currency fluctuations or a more aggressive hedging strategy to protect its earnings and cash flows.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: $37M in accrued liabilities and $11M in deferred income taxes/other liabilities in 2022 (totaling $48M), and $110M in accrued liabilities and $5M in deferred income taxes/other liabilities in 2024 (totaling $115M). The total liabilities are accurately calculated and match the original answer. The only minor discrepancy is that the LLM states 'no deferred-tax liability' in 2022, while the ground truth specifies $11M under 'deferred income taxes and other liabilities.' This category may include non-tax items, so labeling it solely as a 'deferred-tax liability' is slightly imprecise, but the total sum is correct. (2) All calculations are accurate: $37M + $11M = $48M (2022), $110M + $5M = $115M (2024), and the increase is correctly characterized as nearly threefold. (3) The multi-hop reasoning is sound—information is synthesized across two fiscal years and two balance sheet categories (accrued liabilities and deferred income taxes/other liabilities), and the conclusion about increased hedging activity or exposure is logically supported by the data. (4) The answer fully addresses both parts of the question: the change in liabilities and its implication for exposure or strategy. Wording differs slightly but maintains semantic equivalence. The interpretation—that the increase reflects greater hedging due to higher exposure or a more aggressive strategy—is consistent with the original. The slight deduction in qualitative accuracy is due to the minor mischaracterization of the 2022 deferred liability component, but overall, the answer is factually strong, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 466,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the representation of Bounty within P&G's Baby, Feminine & Family Care segment evolve between the 2022 and 2023 10-K filings, and what does this suggest about its brand visibility?",
      "original_answer": "In the 2022 10-K filing, Bounty was mentioned as part of P&G's Family Care business within the Baby, Feminine & Family Care segment, but it was not explicitly listed among the key brands. In contrast, the 2023 10-K filing explicitly included Bounty among the major brands under the Family Care category. This change suggests an increase in Bounty's brand visibility within P&G's portfolio, though the filings do not provide specific market share or sales figures to quantify this shift. The explicit mention in 2023 indicates a possible strategic move to highlight Bounty's role, though no direct strategic intent is stated in the evidence provided.",
      "llm_answer": "In the 2022 Form 10‑K, Bounty was called out as a stand‑alone “major brand” in the Baby, Feminine & Family Care segment (listed alongside Charmin, Luvs, Pampers, etc.). In the 2023 filing the brand is no longer listed separately; it appears only as part of the combined “Tampax Bounty” entry, although the narrative still notes that the family‑care business is “predominantly … comprised primarily of the Bounty paper‑towel …” brand. This shift from a distinct line‑item to a grouped mention suggests that Bounty’s visibility remains strong within the segment but is being presented with slightly less standalone emphasis.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both direction and facts. According to the ground truth, Bounty was *not* listed as a major brand in the 2022 10-K but *was* explicitly included as a major brand in the 2023 10-K, indicating increased visibility. The LLM incorrectly states the opposite: that Bounty was a standalone 'major brand' in 2022 and then demoted to a 'Tampax Bounty' grouped mention in 2023, which contradicts the evidence. There is no mention of a 'Tampax Bounty' entry in the filings, and Tampax is a feminine care product, unrelated to Bounty’s paper towel category. The narrative description in the LLM answer about being 'predominantly comprised primarily' misquotes and misrepresents the actual filing language. Quantitatively, while no numerical data is involved, the years (2022 vs 2023) are referenced but applied to completely reversed scenarios, making them factually wrong. The reasoning is flawed as it draws an incorrect conclusion from non-existent evidence, failing the multi-hop requirement to accurately compare brand representation across filings. Contextually, the answer addresses brand visibility but does so based on fabricated details, resulting in low relevance despite topical alignment. All core claims are inverted or false, warranting a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 364,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has Oracle's approach to its hardware business, particularly Oracle Engineered Systems, evolved between fiscal 2022 and fiscal 2023 in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle's hardware business, which includes Oracle Engineered Systems, was described in terms of its contractual activities and revenue recognition, with an emphasis on the timing of revenue recognition for cloud and license contracts. By fiscal 2023, Oracle introduced a more detailed explanation of how hardware and related software are treated as a combined performance obligation, with revenue recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve and develop new hardware products and services, which was not explicitly mentioned in 2022. This indicates a shift toward a more strategic focus on innovation and integration of hardware and software components within the hardware business.",
      "llm_answer": "In the 2022 filing Oracle described its hardware business – which includes Oracle Engineered Systems – as selling “infrastructure technologies” and noted that **hardware‑product revenue is recognized when the product (and its bundled software) is delivered and ownership transfers, while hardware‑support revenue is recognized ratably over the contract term**【page_105】.  \n\nThe 2023 filing repeats the same recognition policy – “revenues for this combined performance obligation are generally recognized at the point in time that the hardware product and its related software are delivered… hardware‑support contracts are recognized ratably”【page_43】 – but adds that **hardware now accounts for only about 6 % of total revenue (down from roughly 7‑8 % in 2022) and the company emphasizes continued R&D investment to improve existing hardware and develop new products, treating hardware as a lower‑margin, strategically smaller segment**【page_43】【page_105】.  \n\nThus, while the accounting treatment for hardware sales and support remained consistent, Oracle’s strategic emphasis shifted toward a reduced revenue contribution and a focus on product development rather than growth of the hardware line.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and percentages are correct: the decrease in hardware's revenue contribution from roughly 7–8% in 2022 to about 6% in 2023 is consistent with the knowledge graph data. The revenue recognition policies are correctly cited for both years, with point-in-time recognition for hardware (including bundled software) upon delivery and ratable recognition for support. (2) The LLM correctly identifies that the accounting treatment remained unchanged between fiscal 2022 and 2023, which matches the ground truth. (3) Qualitatively, the model captures the key strategic shift: Oracle’s increased emphasis on R&D investment in hardware innovation in 2023, which was not explicitly mentioned in 2022. It also correctly infers that hardware is now treated as a smaller, lower-margin segment, reflecting a strategic repositioning. (4) The answer addresses both parts of the question—revenue recognition (stable) and strategic emphasis (shift toward R&D and integration despite declining revenue share)—demonstrating sound multi-hop reasoning across fiscal years and disclosures. The only minor shortcoming is that the original answer highlights the 'combined performance obligation' concept as a new emphasis in 2023, which the LLM mentions but does not explicitly frame as a change in disclosure emphasis. However, the substance is conveyed. Wording differences are within acceptable semantic equivalence. No factual or calculation errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1510,
        "completion_tokens": 420,
        "total_tokens": 1930
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the sales performance of the product ERLEADA evolve between 2022 and 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA generated $1,881 million in sales, and by 2023, its sales increased to $2,387 million, representing a 26.9% growth. This indicates a strong upward trajectory for ERLEADA in the market, suggesting increased adoption or improved commercial performance over the period.",
      "llm_answer": "In 2023 Johnson & Johnson reported ERLEADA sales of **$2.387 billion**, up from **$1.881 billion** in 2022 – a **≈27 % increase** year‑over‑year (operations growth of 27.5 %)【page_31】. This sizable rise shows that ERLEADA’s market traction is accelerating, reflecting continued share gains and expanding demand for the apalutamide therapy in metastatic castration‑resistant prostate cancer.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurate: ERLEADA sales were $1.881 billion in 2022 and $2.387 billion in 2023, matching the ground truth values (with acceptable format variation: $1,881 million = $1.881 billion). The calculated growth is approximately 27%, which aligns with the exact 26.9% in the original answer; the LLM's ≈27% and mention of 27.5% operational growth are reasonable refinements based on source data and do not contradict the ground truth. (2) Quantitative accuracy is perfect—numbers, years, and percentage change are correct and properly derived. (3) The reasoning is sound: the answer correctly synthesizes year-over-year performance and infers positive market trajectory, including context about market traction, share gains, and demand in the target therapy area, which enriches the ground truth without introducing error. (4) The response addresses both parts of the question: sales evolution (with exact figures and growth rate) and market trajectory (interpreting growth as strong momentum). All entities—ERLEADA, the correct years, and implied parent company (Johnson & Johnson)—are accurate. The citation of 'page_31' suggests grounding in the source document. Thus, all dimensions score perfectly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1166,
        "completion_tokens": 361,
        "total_tokens": 1528
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the nature of CMCSA's relationship with local broadcast television stations evolved from 2023 to 2024, particularly in terms of competitive positioning and dependency for content distribution?",
      "original_answer": "In 2023, CMCSA's Media segment directly competed with local broadcast television stations for viewers' attention and advertising revenue. By 2024, the relationship shifted to a more interdependent one, where CMCSA's linear television networks became reliant on local broadcast television stations for retransmission consent, which is necessary for distributing broadcast network programming to video service customers. This marks a shift from competition to dependency, reflecting a strategic and operational evolution in how CMCSA interacts with local broadcast stations.",
      "llm_answer": "In the 2023 filing Comcast described its local‑broadcast stations mainly as **affiliation partners** – the company competes with other networks and streaming services to win and keep the “affiliations” that let its owned national networks reach viewers through independently‑owned stations. By 2024 the discussion had shifted to **retransmission‑consent negotiations**, noting that Comcast now pays the stations for the right to carry their broadcast‑network programming and is exposed to growing payment demands and consolidation‑driven cost pressure; the company’s ability to distribute its linear networks therefore depends increasingly on the terms it can negotiate with those stations, reflecting a more dependent and less favorable competitive position.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core evolution described in the ground truth: a shift from competition in 2023 to dependency in 2024 due to retransmission consent dynamics. (1) All entities are correct—CMCSA (Comcast), local broadcast television stations, proper timeframes (2023 to 2024), and key terms like 'retransmission-consent negotiations' and 'affiliation partners' are used appropriately. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised—score is 10 by default. (3) The multi-hop reasoning is sound: the model correctly synthesizes a strategic shift by connecting changes in language and business model between two years—moving from competing for affiliations to being financially and operationally dependent on stations for content distribution. (4) The LLM adds contextual detail not in the original (e.g., payment demands, consolidation pressure, competitive disadvantage), which is consistent with typical 10-K disclosures and enhances the explanation without introducing inaccuracies. The only minor gap is that the original emphasizes the Media segment’s prior *direct competition* for viewers and ad revenue, while the LLM frames 2023 more around affiliation competition. This is a subtle but relevant nuance—the original highlights a broader competitive stance, while the LLM focuses on partnership mechanics. Still, the overall semantic meaning and strategic trajectory align closely, warranting a 9 on correctness and qualitative accuracy. Contextual relevance is perfect—directly addresses competitive positioning and dependency evolution as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 454,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did the value of Held-to-Maturity (HTM) securities held by MA evolve between 2023 and 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2023, MA held $306 million in HTM securities, but by 2024, this amount dropped significantly to $38 million. This indicates a major shift in MA's investment strategy, with a sharp reduction in long-term held securities, likely reflecting a move toward more liquid or short-term investment positions.",
      "llm_answer": "The company’s held‑to‑maturity portfolio fell sharply, from **$306 million at year‑end 2023** to only **$38 million at year‑end 2024** – a decline of about $268 million (roughly 88 %).【page_86】【page_83】\n\nThis large reduction shows Mastercard is moving out of the relatively inflexible, short‑term “time‑deposit” HTM position and reallocating capital toward more liquid or market‑priced securities (e.g., available‑for‑sale assets), indicating a shift to a more flexible, market‑responsive investment strategy.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values of $306 million in 2023 and $38 million in 2024 are accurately reported, and the calculated decline of $268 million (approximately 88%) is correct. (2) The answer addresses both parts of the question: the change in HTM value between 2023 and 2024, and the implication for MA's investment strategy. (3) Entities are correct—'MA' is properly identified as Mastercard, and the years 2023 and 2024 are accurately referenced. (4) The reasoning is sound: the sharp reduction in HTM securities is correctly interpreted as a strategic move toward more liquid or market-responsive investments, such as available-for-sale securities, which aligns with the ground truth's interpretation of increased flexibility. The use of source citations (e.g., page_86, page_83) further supports the factual grounding. Minor wording differences (e.g., 'short-term time-deposit HTM position') do not affect semantic accuracy and are reasonable interpretations. Overall, the answer demonstrates accurate multi-hop synthesis, correct calculations, and appropriate qualitative inference.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1208,
        "completion_tokens": 328,
        "total_tokens": 1537
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the positioning of the Always brand within Procter & Gamble's Baby, Feminine & Family Care segment evolved between 2022 and 2023, particularly in terms of its product categorization and associated sub-categories?",
      "original_answer": "In 2022, Always was categorized under Feminine Care within the Baby, Feminine & Family Care segment, which included sub-categories like Adult Incontinence and Feminine Care. By 2023, the brand remained part of the same reportable segment but was more specifically aligned with 'Menstrual Care' under the updated Feminine Care sub-category, reflecting a more targeted positioning. This evolution indicates a strategic shift in how Always is being categorized to emphasize its core focus area.",
      "llm_answer": "In the 2022 filing the “Baby, Feminine & Family Care” segment was described with three broad sub‑categories—Baby Care, Feminine Care and Family Care—and the brand list simply grouped **Always** with the other segment brands (Luvs, Pampers, Always Discreet, Tampax, etc.). By the 2023 filing the segment’s product‑category table had been refined: Baby Care was dropped, and **Feminine Care** was split into the sub‑categories **Adult Incontinence** and **Menstrual Care**, with **Always** now explicitly placed in the Menstrual‑Care sub‑category (while Always Discreet is listed under Adult Incontinence). Thus, Always moved from a generic “Feminine Care” label in a mixed baby‑family segment to a clearly defined menstrual‑care brand within the Feminine‑Care sub‑categories.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies that in 2022, Always was grouped under the broader 'Feminine Care' category within the Baby, Feminine & Family Care segment, alongside other brands, without further sub-categorization. In 2023, it accurately notes the structural change: Feminine Care was split into 'Adult Incontinence' and 'Menstrual Care', with Always explicitly placed in Menstrual Care while Always Discreet moved to Adult Incontinence. (2) There are no numeric values requiring calculation, but the dates (2022 vs 2023) and categorizations are correct. (3) The multi-hop reasoning is sound—LLM synthesizes changes in segment structure, sub-category reorganization, and brand repositioning across two years. (4) The answer adds contextual clarity not in the original (e.g., noting Baby Care was dropped), which enhances accuracy without introducing error. Wording differs but meaning fully aligns with the ground truth. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 303,
        "total_tokens": 1638
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has Oracle's positioning and financial contribution of Oracle Engineered Systems evolved between 2022 and 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In 2022, Oracle Engineered Systems were disclosed as part of hardware revenues, but no specific percentage of total revenue was provided. Revenue recognition for hardware products, including Engineered Systems, was described as occurring at the point in time when the product and related software were delivered. By 2023, Oracle explicitly stated that the hardware business, which includes Engineered Systems, represented 6% of total revenues in both fiscal 2023 and fiscal 2024, indicating a clearer and more consistent measurement of the product line's contribution. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve hardware offerings and introduced more detailed factors affecting hardware revenue predictability, such as manufacturing partner performance and competitive positioning against cloud infrastructure offerings. This reflects both quantitative and strategic evolution in how Oracle presents and manages the Engineered Systems product line.",
      "llm_answer": "- **Positioning:** In both fiscal 2022 and fiscal 2023 Oracle Engineered Systems were grouped with the company’s **hardware business**. The 2023 filing (p. 43) notes that the hardware segment – which includes Oracle Engineered Systems, servers, storage and related software – **accounted for about 6 % of total revenue in fiscal 2023 (the same share it held in fiscal 2024)**, indicating that the engineered‑systems line has remained a small, steady component of Oracle’s overall mix.\n\n- **Revenue‑recognition treatment:** The 2022 notes (p. 76) explain that **hardware products and their associated software are treated as a combined performance obligation and revenue is recognized at the point in time the hardware is delivered and ownership transferred**. This point‑in‑time recognition continues to apply to Engineered Systems in 2023.\n\n- **Strategic emphasis:** The 2023 MD&A (p. 43) stresses that, despite its modest revenue share, Oracle will **continue to invest in research and development to improve existing hardware products and to create new hardware offerings**, but it also notes that the hardware business “generally has lower operating margins” than the cloud and license businesses. Thus, Oracle’s strategy keeps Engineered Systems as a niche, lower‑margin platform while maintaining a focus on incremental R&D rather than aggressive growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Oracle Engineered Systems are part of the hardware business; hardware accounted for 6% of total revenue in fiscal 2023 and 2024 (as stated in the 2023 filing); revenue recognition remains point-in-time upon delivery, consistent between 2022 and 2023. These match the original answer exactly. (2) Quantitative accuracy is perfect: the 6% figure is correctly cited, and no incorrect numbers are introduced. The LLM correctly notes that the 6% share applied to both fiscal 2023 and 2024, which is consistent with the ground truth. (3) Reasoning is sound: the LLM synthesizes information across two years and correctly infers that while Engineered Systems remain a small, stable portion of revenue, strategic emphasis persists through R&D investment despite lower margins. It accurately reflects the shift toward more transparent disclosure in 2023. (4) The only minor shortcoming is that the original answer highlights a broader strategic evolution—such as new factors affecting predictability (e.g., manufacturing partners, competition with cloud infrastructure)—which the LLM mentions only implicitly via R&D and margin context. This slight omission in depth prevents a perfect 10 on qualitative accuracy, but overall the response is factually complete, well-structured, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1594,
        "completion_tokens": 392,
        "total_tokens": 1987
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Comcast's relationship with representation firms evolved in terms of advertising sales strategy between 2023 and 2024?",
      "original_answer": "In 2023, Comcast worked with representation firms as an extension of its sales force to sell a portion of the advertising units allocated to them, recording revenue net of agency commissions. By 2024, Comcast had evolved this relationship into formal representation agreements under which they sell advertising on behalf of third parties, indicating a deeper strategic alignment and expanded role for these firms. This reflects a shift from a co-selling model to a more formalized representation structure.",
      "llm_answer": "In 2023 Comcast said it “represent[s] the advertising sales efforts of certain third parties” and, when it works with representation firms, treats them as an “extension of our sales force” and records the advertising net of agency commissions【page_75】.  \nBy 2024 the language had shifted to a more formal arrangement: Comcast “enter[s] into representation agreements” to sell advertising on behalf of third parties, but it still uses those firms as an extension of its sales force and records the revenue net of commissions in the same way【page_74】.  \n\nThus, the strategy has remained the same—using external representation firms to sell a portion of its allocated ad inventory and recognizing revenue net of commissions—but the company has moved from a general “representation” description to explicitly stating that it now operates under formal representation agreements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies the evolution in Comcast's relationship with representation firms between 2023 and 2024: in 2023, representation firms were treated as an extension of the sales force with revenue recorded net of commissions; by 2024, the relationship evolved into formal representation agreements. The LLM accurately captures the shift in language and structure from a co-selling model to a more formalized arrangement, while correctly noting that certain aspects (use of firms as sales extensions, net revenue recognition) remained consistent. All entities (Comcast, representation firms), time periods (2023 to 2024), and financial treatment (revenue net of commissions) are correct. There are no numerical inaccuracies—dates and financial treatments match the original answer. The reasoning is sound and reflects proper multi-hop synthesis across the two years. The only minor shortcoming is that the LLM slightly underemphasizes the strategic depth of the shift (e.g., 'deeper strategic alignment' in the original), but the core factual and conceptual content is preserved. Thus, the answer is semantically equivalent with high completeness and precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 348,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Oracle's approach to its industry-specific hardware offerings evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle described its hardware business as including industry-specific hardware and recognized hardware revenues at the point in time when products and related software were delivered to customers. By fiscal 2023, Oracle introduced a more detailed explanation of revenue recognition for hardware, stating that revenues for combined performance obligations (hardware plus related software) are generally recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing investments in R&D to improve existing hardware offerings and develop new products, signaling a more strategic focus on innovation in this area compared to 2022, where the description was more general and focused on the breadth of offerings.",
      "llm_answer": "In its FY 2022 filing Oracle explained that industry‑specific hardware (and the embedded operating‑system or firmware) is accounted for as a **single performance obligation** – the product‑plus‑software revenue is recorded **at the point in time the hardware is delivered and title passes**, while the associated hardware‑support contract is **recognized ratably over the support period**.  \n\nThe FY 2023 filing repeats the same treatment – hardware and its related software are still recognized when shipped, and support revenue continues to be spread over the contract term – but adds that the hardware line now **accounts for about 6 % of total revenue** and is **primarily sold through indirect channels**. Oracle also stresses that it will keep investing in R&D to improve existing and develop new industry‑specific hardware, positioning the business as a modest, steady‑growth complement to its expanding cloud and license operations rather than a growth engine.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution in Oracle's hardware approach between fiscal 2022 and 2023. (1) It accurately describes revenue recognition in both years: hardware and related software are treated as a single performance obligation recognized at delivery, with support revenue recognized ratably—this aligns with the ground truth. The addition in FY2023 of hardware accounting for about 6% of total revenue and being primarily sold through indirect channels is factually consistent with typical disclosures, though this specific 6% figure and indirect channel detail are not present in the original ground truth provided. Since the ground truth does not include this data, the LLM may be introducing plausible but unverified details, which slightly affects factual accuracy. (2) Quantitatively, the 6% figure is plausible but not confirmed by the original answer, so while not demonstrably wrong, it introduces unverified specificity. No calculation errors are present. (3) The multi-hop reasoning is sound: the model correctly identifies changes in strategic emphasis, noting increased R&D investment in industry-specific hardware in FY2023 compared to a more general description in FY2022. It correctly synthesizes revenue recognition continuity and enhanced strategic framing. (4) Contextual relevance is excellent—the response directly addresses both revenue recognition and strategic emphasis across the two fiscal years. The slight deduction in correctness is due to the introduction of unverified quantitative details (6%, indirect channels) not present in the ground truth, though the core evolution in accounting and strategy is accurately portrayed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 459,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the sales performance of IMBRUVICA (ibrutinib) evolve between 2022 and 2023, and what factors contributed to this change?",
      "original_answer": "IMBRUVICA sales decreased from $3.784 billion in 2022 to $3.264 billion in 2023, a decline of 13.7%. In 2022, the growth of IMBRUVICA was already being offset by competitive pressures from novel oral agents and market dynamics related to the pandemic, such as delays in new patient starts. By 2023, this downward trend continued, with the product experiencing a significant drop in sales, reflecting sustained competitive pressures and likely increased market saturation or treatment shifts in the oncology space.",
      "llm_answer": "IMBRUVICA’s worldwide sales dropped from $3.78 billion in 2022 to $3.26 billion in 2023 – a decline of roughly 13.7 % (operations down 13.2 % and a modest 0.5 % currency impact). The 2023 filing attributes the fall to “global competitive pressures” on the drug, reflecting increasing competition from newer oral oncology agents that eroded its market share.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the sales figures for IMBRUVICA in 2022 ($3.78 billion) and 2023 ($3.26 billion), which are accurate to within rounding differences compared to the ground truth ($3.784B and $3.264B). The calculated decline of 13.7% is correct and matches the ground truth. The breakdown into operational decline (13.2%) and currency impact (0.5%) is an additional detail not in the original answer but does not contradict it and may reflect a more granular source; this enhances rather than detracts from accuracy. (2) All numeric values are factually consistent with the ground truth when accounting for rounding: (3.784 - 3.264) / 3.784 ≈ 13.74%, correctly rounded to 13.7%. The dollar amounts are presented with appropriate precision. (3) The reasoning is sound: the LLM identifies competitive pressures from newer oral oncology agents as the primary driver of declining sales, which aligns with the original answer’s mention of 'competitive pressures from novel oral agents' in 2022 and continued decline in 2023. It correctly synthesizes the cause-effect relationship across time periods. (4) The only minor shortcoming is that the LLM omits mention of pandemic-related delays in new patient starts in 2022 and does not reference market saturation or treatment shifts explicitly, which were part of the original explanation for the sustained trend. However, the core contributing factor—competitive pressures—is accurately highlighted, and the omission of secondary context does not invalidate the main conclusion. Thus, the answer is highly accurate, complete in key aspects, and contextually appropriate, warranting a 9/10 for overall correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 467,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Comcast's involvement with Universal Beijing Resort evolved from 2023 to 2024 in terms of debt levels, ownership structure, and financial risk exposure?",
      "original_answer": "In 2023, Universal Beijing Resort had $3.5 billion of debt outstanding, including a $3.1 billion term loan, and was consolidated by Comcast, which owns a 30% interest. By 2024, the debt level slightly decreased to $3.4 billion, with the term loan principal reducing to $3.0 billion. Comcast continues to consolidate Universal Beijing Resort as a VIE, maintaining its 30% ownership stake. The maximum financial risk exposure for Comcast remains limited to its 30% equity interest, indicating a stable risk profile despite the slight reduction in debt. This evolution reflects a minor decrease in leverage but no change in ownership or governance structure.",
      "llm_answer": "- **Debt levels:** The resort’s debt fell modestly – the outstanding debt was $3.5 billion (including a $3.1 billion term loan) at 12/31/2023, and declined to $3.4 billion (with a $3.0 billion term loan) at 12/31/2024【page_86†L9-L13】【page_56†L31-L38】.  \n\n- **Ownership structure:** Comcast’s equity stake stayed the same; it continues to own 30 percent of Universal Beijing Resort in both years【page_86†L9-L12】.  \n\n- **Financial‑risk exposure:** Both filings state that there are no liquidity arrangements, guarantees or other financial commitments between Comcast and the resort, so Comcast’s maximum loss risk is limited to its 30 percent equity interest【page_86†L13-L16】. This risk profile is unchanged from 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitative accuracy: All numbers are correct — $3.5 billion debt in 2023 (including $3.1 billion term loan), decreasing to $3.4 billion in 2024 (with $3.0 billion term loan); Comcast’s 30% ownership stake is accurately reported for both years. These figures align exactly with the original answer, with acceptable formatting (e.g., $3.5 billion vs $3.5 billion). (2) Completeness: The answer addresses all three components of the question — debt levels, ownership structure, and financial risk exposure — with precise data and context for both 2023 and 2024. (3) Entity accuracy: 'Comcast', 'Universal Beijing Resort', 'VIE consolidation', and '30% equity interest' are correctly identified and consistently referenced. The time periods (12/31/2023 and 12/31/2024) match the required scope. (4) Reasoning: The multi-hop synthesis is sound — the model correctly infers that despite a slight reduction in debt, ownership and risk exposure remain unchanged, and it correctly cites the absence of guarantees or liquidity arrangements as the reason Comcast’s risk is limited to its equity stake. (5) Semantic equivalence: The LLM conveys the same meaning as the ground truth, using slightly different phrasing (e.g., 'maximum loss risk is limited to its 30 percent equity interest' vs 'maximum financial risk exposure remains limited to its 30% equity interest') but preserving factual and conceptual accuracy. All citations reference appropriate document locations, further supporting validity. No errors or omissions are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 439,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the financial commitment related to future lease payments for build-to-suit facilities and equipment evolve from 2022 to 2023, and what does this indicate about FedEx's leasing strategy?",
      "original_answer": "In 2022, FedEx disclosed future undiscounted payments of approximately $3.4 billion for build-to-suit facilities that had not yet commenced, with expected commencement dates from 2023 to 2024. By 2023, the company reported a significant reduction in these future commitments, with undiscounted payments dropping to approximately $0.9 billion for build-to-suit facilities and equipment, with commencement dates expected from 2025 to 2027. This indicates a strategic shift toward fewer long-term build-to-suit lease commitments and a more extended timeline for asset utilization.",
      "llm_answer": "In the 2022 Form 10‑K FedEx disclosed that, as of May 31 2022, it had entered into “build‑to‑suit” lease agreements for facilities and equipment with undiscounted future payments of roughly **$3.4 billion**, scheduled to begin in 2023‑2024.  \nThe 2023 Form 10‑K shows that the same category of non‑commencing leases now carries undiscounted future payments of only **about $0.9 billion**, with start‑up dates pushed out to 2025‑2027.  \n\nThe sharp reduction in the amount and the later commencement dates indicate that FedEx is scaling back its reliance on build‑to‑suit leasing, moving toward a more modest, longer‑term leasing approach rather than aggressively expanding its lease‑backed facility footprint.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $3.4 billion commitment in 2022 (undiscounted payments for build-to-suit facilities not yet commenced, starting 2023–2024) and the drop to $0.9 billion in 2023 with commencement dates shifted to 2025–2027. These figures match the original answer exactly in value and context, with acceptable formatting (e.g., $3.4 billion vs $3.4B). (2) Quantitative accuracy is perfect—both amounts and date ranges are correctly reported. (3) The reasoning is sound: the reduction in financial commitment and the extension of commencement dates are correctly interpreted as a strategic shift away from aggressive build-to-suit leasing toward a more conservative, longer-term approach. The phrase 'scaling back its reliance on build-to-suit leasing' and 'more modest, longer-term leasing approach' semantically matches the original conclusion about a strategic shift. (4) The only minor difference is that the LLM includes 'equipment' in the 2022 figure, while the original specifies 'facilities' in 2022 and adds 'equipment' in 2023. However, the 2023 LLM answer correctly includes both, matching the original. This slight over-inclusion in 2022 does not materially misrepresent the data. Overall, the multi-hop synthesis across two years of 10-K disclosures is accurate and well-reasoned, with excellent contextual relevance to the question about evolution and strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 403,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Mastercard's relationship with Dynamic Yield LTD evolved between 2023 and 2024, and what does this indicate about the company's strategic focus during this period?",
      "original_answer": "In 2023, Mastercard disclosed that it had acquired Dynamic Yield LTD in April 2022 for $325 million, with $200 million of goodwill attributed to synergies expected after the acquisition. By 2024, the relationship is described as stable, with no new investments or acquisitions involving Dynamic Yield reported during the year. This indicates that the integration of Dynamic Yield was largely completed by 2023, and Mastercard shifted focus to newer acquisitions like Recorded Future in 2024, signaling a strategic pivot toward cybersecurity and threat intelligence.",
      "llm_answer": "In the 2023 Form 10‑K Mastercard reported that it had **finalized the purchase‑accounting for its 2022 acquisition of Dynamic Yield LTD** (a $325 million cash deal that generated $200 million of goodwill) and that no further activity with that business occurred in 2023【page_79】. The 2024 Form 10‑K references the same 2022 acquisition as a historical item while the company’s focus shifted to new, larger purchases (e.g., Recorded Future) and to growing its **value‑added services**, which rose to $10.8 billion in 2024 from $9.3 billion in 2023【page_81】. Together, these disclosures show that Dynamic Yield has moved from a newly‑integrated acquisition in 2023 to a settled, intangible‑asset component of Mastercard’s portfolio by 2024, reflecting a strategic emphasis on building a broader suite of data‑driven, digital‑experience services rather than pursuing additional small‑scale deals.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Mastercard acquired Dynamic Yield LTD in 2022 for $325 million, with $200 million attributed to goodwill, which matches the ground truth. It accurately notes that by 2023, the purchase accounting was finalized and no further activity occurred, and that in 2024 the relationship remained stable with no new developments. The shift in strategic focus toward new acquisitions like Recorded Future and growth in value-added services ($10.8B in 2024 vs $9.3B in 2023) is consistent with the ground truth’s indication of a pivot toward cybersecurity and digital services. (2) All numeric values—$325 million acquisition cost, $200 million goodwill, $9.3B to $10.8B growth in value-added services—are factually correct and properly contextualized. Dates (2022 acquisition, 2023 and 2024 reporting) are accurate. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of 10-K filings, connects the lack of new activity with Dynamic Yield to integration completion, and infers strategic focus from new acquisitions and service growth. The only minor gap is that it does not explicitly name the 'strategic pivot toward cybersecurity and threat intelligence' in the same terms as the ground truth, though it references Recorded Future and digital services, which implies the same direction. (4) The answer is highly relevant, directly addressing both the evolution of the relationship and what it indicates about strategy. The slight deduction in qualitative accuracy is due to slightly less precise framing of the strategic shift, but the core inference is valid and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 456,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the Severance Plan for Senior Officers at Lowe's evolved between 2022 and 2024, particularly in terms of the most recent amendment dates and associated filings?",
      "original_answer": "In 2022, the Severance Plan for Senior Officers was described as 'amended and restated May 29, 2020' and was filed on August 26, 2020 (Exhibit 10.29). By 2024, the plan had been further amended and restated on May 26, 2022, with the updated version filed on November 27, 2024 (Exhibit 10.28). This indicates that Lowe's updated its Severance Plan for Senior Officers at least once between 2022 and 2024, with the most recent amendment occurring in mid-2022 and formally disclosed in late 2024.",
      "llm_answer": "The Severance Plan for Senior Officers was last amended on **May 26, 2022**. In the 2022 Form 10‑K the plan was disclosed as Exhibit 10.28 (the “Severance Plan for Senior Officers as amended and restated May 26, 2022”) and was attached to that filing at the time. In the 2024 Form 10‑K the same amendment remains the most recent, but the plan is now filed as Exhibit 10.28 on **November 27, 2024**【page_79†L28-L30】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the most recent amendment date of the Severance Plan for Senior Officers as May 26, 2022, and the filing date of the updated plan as November 27, 2024, which matches the ground truth. It also correctly references Exhibit 10.28 in both the 2022 and 2024 Form 10-K filings. The only minor discrepancy is that the original answer notes the 2020 version was filed on August 26, 2020 (Exhibit 10.29), which the LLM omits. However, since the question focuses on the evolution between 2022 and 2024, this earlier detail is contextually secondary. (2) All dates and exhibit numbers are accurate: May 26, 2022 (amendment), November 27, 2024 (filing), and Exhibit 10.28 are all factually correct and match the ground truth. (3) The reasoning is sound: the LLM correctly infers that the plan was amended in 2022 and remained the latest version through 2024, with the updated filing appearing in the 2024 10-K. It synthesizes information across two filings appropriately. (4) The answer is highly relevant, directly addressing the evolution of the plan, amendment dates, and associated filings. The omission of the 2020 filing detail slightly reduces completeness but does not affect the core accuracy of the 2022–2024 evolution. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 391,
        "total_tokens": 1623
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the fair value of Netflix's 6.375% Senior Notes change between December 31, 2021, and December 31, 2023, and what does this evolution indicate about market perceptions of the company's debt over this period?",
      "original_answer": "The fair value of Netflix's 6.375% Senior Notes increased from $999 million as of December 31, 2021, to $872 million as of December 31, 2023. This indicates a decrease in the fair value of the notes over the two-year period, suggesting a potential decline in market confidence or an increase in required yields for this debt instrument.",
      "llm_answer": "The Level 2 fair‑value of Netflix’s 6.375 % senior notes fell from **about $999 million at 12/31/2021** to **about $872 million at 12/31/2023** – a drop of roughly **$127 million (≈13 %)**【page_56】.  \n\nThis decline in fair value signals that market participants were willing to pay less for the same‑coupon debt, reflecting higher required yields (or a higher perceived credit risk) for Netflix’s bonds over the two‑year period. In other words, investors’ view of the company’s debt became less favorable between 2021 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the fair value of Netflix's 6.375% Senior Notes as $999 million on December 31, 2021, and $872 million on December 31, 2023, matching the ground truth exactly. The calculated drop of $127 million and approximate 13% decline are accurate and correctly derived. (2) All numeric values, dates, and calculations are correct. The percentage decrease is approximately (127/999) ≈ 12.7%, which rounds to 13%, so the LLM's '≈13%' is appropriate. Format variations like 'about $999 million' are acceptable and do not affect factual accuracy. (3) The reasoning is sound: the decrease in fair value implies higher required yields or increased perceived credit risk, which aligns with the ground truth interpretation that market confidence declined or risk perception increased. The LLM correctly synthesizes the implication of falling bond prices (inverse relationship with yield) and links it to market sentiment. (4) The only minor shortcoming is that the LLM refers to 'Level 2 fair-value' which, while likely accurate contextually, adds specificity not present in the ground truth without clarification; however, this does not detract from correctness. All parts of the question are addressed: the change in fair value and its implication for market perceptions. Thus, the answer is factually complete, quantitatively precise, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 388,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the sales performance of IMBRUVICA evolve between 2022 and 2023, and what does this indicate about its market position in the oncology segment?",
      "original_answer": "IMBRUVICA's sales decreased from $4,369 million in 2022 to $3,264 million in 2023, representing a decline of 25.2%. This indicates a weakening market position for IMBRUVICA within the oncology segment, especially as other products like DARZALEX and ERLEADA experienced significant growth during the same period.",
      "llm_answer": "IMBRUVICA’s sales fell from $3.8 billion in 2022 to $3.3 billion in 2023 – a 13.7 % decline (operations‑only ‑13.2 %)【page_31†L31-L38】. During the same period the overall oncology portfolio grew 10.5 % to $17.7 billion【page_31†L23-L27】, indicating that while the oncology segment is expanding, IMBRUVICA is losing momentum and market share, likely due to heightened competitive pressures and loss of exclusivity.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative data. The ground truth states IMBRUVICA sales were $4,369 million in 2022 and $3,264 million in 2023, representing a 25.2% decline. However, the LLM reports $3.8 billion (i.e., $3,800 million) in 2022 and $3.3 billion ($3,300 million) in 2023, implying a decline of only about 13.2%, which is less than half the actual drop. These numbers are materially incorrect, even allowing for rounding or format differences. (2) The calculation based on LLM's own numbers ($3.8B to $3.3B) is approximately 13.2%, which aligns with its stated 13.7% decline (minor discrepancy likely due to rounding), so internal calculation logic is sound, but the inputs are wrong. (3) The qualitative reasoning is partially correct: the LLM correctly infers that IMBRUVICA is losing momentum within a growing oncology segment, citing competitive pressures and loss of exclusivity, which is consistent with the ground truth's implication of weakening market position amid growth in other products like DARZALEX and ERLEADA. It correctly performs multi-hop reasoning by contrasting IMBRUVICA’s performance with the overall oncology portfolio growth. (4) Despite correct reasoning and contextual relevance, the severe quantitative inaccuracies—especially the understated decline—undermine the factual correctness. The answer suggests a moderate decline rather than a steep 25.2% drop, leading to an incorrect perception of the severity of IMBRUVICA’s market erosion. Hence, correctness and quantitative accuracy scores are low, while qualitative and contextual scores are moderate to high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1182,
        "completion_tokens": 452,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did LOW's inventory shrink reserve and LCNRV reserve evolve between 2022 and 2024, and what were the implications for net earnings?",
      "original_answer": "Between 2022 and 2024, LOW's inventory shrink reserve increased from $414 million to $427 million, while the LCNRV reserve increased from $168 million to $222 million. In 2024, a 10% change in either the amount of inventory subject to markdown or the weighted average estimated loss rate used in the LCNRV reserve calculation would have affected net earnings by approximately $17 million, and a 10% change in the estimated shrinkage rate would have impacted net earnings by approximately $32 million. These changes indicate a growing need for reserves, particularly for shrinkage, and highlight the increasing sensitivity of net earnings to inventory valuation assumptions.",
      "llm_answer": "In fiscal 2022 the company reported an LCNRV (lower‑of‑cost‑or‑net‑realizable‑value) inventory reserve of **$168 million** and an inventory‑shrink reserve of **$414 million** (as of January 28, 2022). By fiscal 2024 the LCNRV reserve had risen to **$222 million** (down $23 million from the prior year but up $54 million versus 2022) and the shrink reserve had climbed to **$427 million** (up $13 million versus 2022). Both reserves are material to earnings – a 10 % change in the LCNRV reserve would alter net earnings by roughly **$17 million**, and a 10 % change in the shrink reserve would affect net earnings by about **$32 million** in fiscal 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key figures from the ground truth: LCNRV reserve increased from $168M in 2022 to $222M in 2024, and shrink reserve rose from $414M to $427M. The sensitivity impacts on net earnings—a 10% change affecting $17M for LCNRV and $32M for shrink—are accurately stated. (2) Quantitative accuracy is perfect: all dollar amounts, comparisons (e.g., $54M increase in LCNRV, $13M in shrink), and fiscal years (2022 to 2024) match the original. The mention of a $23M decrease from prior year is consistent with a multi-year trend not fully detailed in the ground truth but does not contradict it. (3) Reasoning is sound: the model correctly synthesizes the evolution of both reserves and their earnings implications. However, the phrase 'down $23 million from the prior year' introduces a detail (2023 value) not in the ground truth, which could imply unsupported inference, slightly weakening qualitative accuracy. (4) The answer is contextually complete and relevant, addressing both the evolution of reserves and their impact on net earnings with precise, semantically equivalent information. The minor addition about the prior-year decline does not distort meaning but adds context that, while plausible, isn't verified by the provided truth. Overall, the response is factually correct, well-reasoned, and fully aligned with the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 384,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did Qulipta's status and financial contribution evolve from 2022 to 2023, particularly in terms of its development and commercialization progress?",
      "original_answer": "In 2022, Qulipta was among the products that contributed to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights upon receiving regulatory approvals. By 2023, Qulipta had transitioned from development to commercialization, generating $405 million in revenue in the United States and $3 million internationally, indicating a significant shift from a developmental asset to a revenue-generating product.",
      "llm_answer": "In the 2022 filing Qulipta was still a pipeline asset – it had received regulatory approval only in the prior year’s R&D re‑classifications and generated no meaningful sales. By the 2023 filing AbbVie reported that Qulipta obtained FDA approval (April 2023) and EU approval (August 2023) and began commercial sales, with U.S. net revenues rising from about $158 million in 2022 to $405 million in 2023 (a > 100 % increase) and overall net‑revenue contribution growing sharply.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it incorrectly states that Qulipta received FDA approval in April 2023, but the ground truth indicates it was approved earlier, as it contributed to the $1.0 billion reclassification of R&D assets in 2022—implying approval occurred prior to 2022 or early 2022. The claim of FDA and EU approvals in 2023 is therefore incorrect. Second, the LLM claims Qulipta had $158 million in U.S. revenue in 2022, but the original answer states it generated no meaningful sales in 2022 and only $405 million in the U.S. in 2023 (plus $3 million internationally). There is no mention of $158 million in the ground truth, making this figure fabricated or misattributed. (2) Quantitative accuracy is low: the $158 million figure is unsupported, the 100%+ revenue increase is based on incorrect prior-year data, and international revenue ($3 million) is omitted. Only the $405 million U.S. revenue in 2023 is correct. (3) The reasoning partially captures the transition from development to commercialization, which aligns with the multi-hop intent—using regulatory and financial data across years. However, the flawed timeline and invented revenue for 2022 undermine the synthesis. (4) Contextual relevance is high as the answer addresses both development and commercialization progress. Overall, the answer gets the general direction of progress correct (from developmental asset to revenue generator) but fails on key facts and numbers, warranting a mid-low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 422,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities evolved between 2022 and 2023, and what does this indicate about the company's risk exposure?",
      "original_answer": "Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities remained consistent between 2022 and 2023, with Resideo's subsidiary still obligated to pay 90% of Honeywell's annual net spending on environmental matters at specified sites, up to a maximum of $140 million per year. This ongoing arrangement indicates that Honeywell continues to rely on Resideo's payments to offset a significant portion of its environmental costs, suggesting that the risk mitigation strategy through this indemnification agreement has not changed over the two years.",
      "llm_answer": "In 2022 Honeywell recorded a $157 million receivable from Resideo (the Resideo subsidiary) for 90 % of its estimated environmental‑related costs and received $140 million of cash reimbursements that year. In 2023 the receivable grew to $187 million (still $140 million in short‑term assets and $521 million in long‑term assets) while the cash reimbursement remained $140 million. The larger receivable shows Honeywell’s reliance on Resideo to fund a greater share of its environmental liabilities, but because the indemnification agreement caps payments at $140 million annually, the company’s overall risk exposure is limited to that cap and the credit risk of the subsidiary.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While the ground truth states that Resideo's subsidiary is obligated to pay 90% of Honeywell's annual net spending on environmental matters up to a $140 million annual cap, the LLM introduces specific receivable amounts ($157M in 2022, $187M in 2023) and breaks down long-term/short-term assets ($521M long-term in 2023) that are not present in the original answer and cannot be verified from the provided truth. These numbers contradict the consistency emphasized in the ground truth. (2) The quantitative inaccuracies are critical: the original answer does not mention receivables of $157M or $187M, nor a $521M long-term asset, making these hallucinations. While the $140M annual cap is correctly noted, the LLM implies increasing dependency due to growing receivables, which is unsupported by the ground truth that explicitly states the arrangement 'remained consistent' between 2022 and 2023. (3) The multi-hop reasoning is partially sound in linking Resideo's payments to Honeywell's risk exposure, but it draws an incorrect conclusion about increasing reliance, failing to recognize that the cap and obligation structure did not change. The model misinterprets receivable growth as increased dependency, whereas the ground truth emphasizes stability in the indemnification agreement. (4) Despite the incorrect numbers and reasoning, the answer is contextually relevant, addressing the right entities (Honeywell, Resideo), time frame (2022–2023), and topic (environmental liabilities and risk exposure). However, the core factual inaccuracies severely undermine correctness, warranting a low score of 4. Quantitative accuracy is particularly poor (3), qualitative reasoning is partially valid (5), and relevance is high (8).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 489,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Target's definition or treatment of 'original maturity' for cash equivalents evolved between 2022 and 2024, and what does this indicate about potential changes in their cash management strategy?",
      "original_answer": "In 2022, Target defined cash equivalents as highly liquid investments with an original maturity of three months or less, with no additional context or clarification. By 2024, the company maintained the same three-month threshold for original maturity but added a broader discussion around fair value measurements for other short-term assets and liabilities, suggesting a more comprehensive approach to short-term financial instruments. This evolution indicates a potential refinement in how Target evaluates and manages its cash and near-cash assets within a broader financial framework.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K notes define cash equivalents as “highly liquid investments with an **original maturity of three months or less** from the time of purchase,” and both also include the short‑term receivables from credit‑ and debit‑card transactions. The 2024 note adds a clarification that those receivables “typically settle in five days or less” and reiterates that the carrying value approximates fair value because the maturities are under three months. The unchanged maturity threshold shows the policy has stayed the same, while the added detail signals a tighter emphasis on ultra‑short‑term liquidity, suggesting Target is continuing (and perhaps sharpening) a cash‑management strategy that relies on very brief‑term, highly liquid holdings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that Target maintained the three-month original maturity threshold for cash equivalents in both 2022 and 2024, which matches the original answer. The inclusion of short-term receivables and their settlement timing (five days or less) is factually consistent with Target's 2024 10-K and adds contextual detail not contradicted by the ground truth. (2) There are no numerical or date inaccuracies—'three months or less' is correctly cited, and no calculations are required. (3) The reasoning is sound: the LLM correctly infers that while the core definition hasn't changed, the added detail in 2024 reflects a more refined emphasis on ultra-short-term liquidity, which is semantically equivalent to the ground truth's interpretation of a 'more comprehensive approach.' (4) The only minor difference is that the LLM emphasizes 'tighter emphasis on ultra-short-term liquidity' rather than the broader 'fair value measurements' context mentioned in the ground truth. However, this is a valid interpretation given the added disclosure about settlement timing and fair value. The answer fully addresses both parts of the question—evolution in definition/treatment and implications for cash management strategy—making it contextually complete and factually correct. A score of 9 is appropriate due to slight variation in emphasis but no factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 397,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the valuation and classification of NVDA's 3.50% Notes Due 2040 evolve between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, the 3.50% Notes Due 2040 were listed under liabilities with a carrying value of $851 million as of January 28, 2024, and were categorized as Level 2 in the pricing hierarchy. By 2024, the valuation of the same notes increased to $1,000 million as of January 26, 2025, with a more detailed breakdown including an effective interest rate of 3.54% and a remaining term of 15.2 years. This indicates a strategic emphasis on long-term financing with stable interest rate structures.",
      "llm_answer": "In the 2023 filing the 3.50 % Notes Due 2040 were reported as Level 2‑measured liabilities with a fair‑value of **$870 million**; the 2024 filing shows the same notes still classified as Level 2 but with a slightly lower fair‑value of **$851 million**. Both years the notes are carried on the balance sheet at their original issuance amount (net of unamortized discount and issuance costs) and are listed as long‑term senior unsecured debt, indicating that NVIDIA continues to rely on low‑coupon, long‑dated notes as a stable source of financing rather than trading or refinancing them. This modest decline in fair value, coupled with unchanged classification, reflects a deliberate strategy to lock in inexpensive long‑term funding while keeping the debt on the books for strategic flexibility.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key numerical values. According to the ground truth, in 2023 the carrying value was $851 million as of January 28, 2024, but the LLM incorrectly states the 2023 fair value as $870 million and then claims a decrease to $851 million in 2024 — reversing the correct trend. The ground truth shows an increase in valuation from $851 million to $1,000 million by 2024, which the LLM completely misses. Additionally, the LLM fails to mention the updated effective interest rate (3.54%) and remaining term (15.2 years), which are critical details in the evolution of the note's classification and valuation. (2) The quantitative inaccuracies are severe: the direction of change (decrease vs actual increase), the starting value ($870M vs $851M), and the ending value ($851M vs $1,000M) are all incorrect. These are not minor rounding differences but fundamental errors in financial data. (3) The reasoning is partially sound in interpreting the strategic use of long-term debt, but it is based on incorrect data. The conclusion about 'modest decline in fair value' contradicts the actual increase, undermining the validity of the inference. The model correctly identifies the consistent Level 2 classification and long-term senior unsecured categorization, showing some accurate entity and classification tracking. (4) While the general theme of long-term financing strategy is relevant, the incorrect numbers and reversed trend severely limit factual correctness. The answer fails the multi-hop requirement to accurately track changes over time between filings. Thus, correctness and quantitative accuracy are low; qualitative accuracy is moderate due to correct classification details; contextual relevance is acceptable as the topic and strategy discussion are on point.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 497,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the financial performance of Venclexta evolve between 2022 and 2023, particularly in terms of total global revenue and the growth rate?",
      "original_answer": "In 2022, Venclexta generated a total global revenue of $2,009 million, with a growth rate of 10.4%. In 2023, the total global revenue from Venclexta increased to $2,288 million, representing a growth rate of 13.9%. This indicates an upward trend in both absolute revenue and growth rate year-over-year.",
      "llm_answer": "Venclexta’s worldwide net revenues grew from **$2.009 billion in 2022 to $2.288 billion in 2023**.  That represents an increase of roughly **14‑15 % year‑over‑year** – 13.9 % at actual currency rates (15 % at constant‑currency rates)【page_42】.  The 2023 filing also notes that “Net revenues for Venclexta increased 15 % in 2023”【page_43】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports Venclexta's global revenues as $2.009 billion in 2022 and $2.288 billion in 2023, matching the ground truth ($2,009 million and $2,288 million). The growth rate is accurately stated as 13.9% at actual currency rates, with an additional mention of 15% at constant-currency rates and a direct quote from the filing. While the ground truth only specifies 13.9% growth, the LLM provides more granular context (actual vs. constant currency), which is factually consistent and adds value without contradicting the original. (2) All numeric values are correct and properly formatted; $2.009 billion = $2,009 million, $2.288 billion = $2,288 million. The year-over-year growth calculation is accurate: (2,288 - 2,009) / 2,009 ≈ 13.9%. (3) The reasoning is sound and synthesizes information correctly across time periods and reporting metrics. The LLM references specific pages and quotes the filing, demonstrating proper multi-hop support. (4) The answer is semantically equivalent and slightly more detailed than the ground truth, without introducing errors. The only minor deviation is emphasizing 15% growth (constant currency) alongside the reported 13.9%, but this is transparently qualified and supported by the source. Thus, the answer is highly accurate, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1159,
        "completion_tokens": 373,
        "total_tokens": 1532
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has Netflix's approach to executive severance and retention incentives evolved between the 2022 and 2023 SEC filings, particularly in terms of plan amendments and their effective dates?",
      "original_answer": "In 2022, the filing referenced the 'Amended and Restated Executive Severance and Retention Incentive Plan' with a filing date of September 10, 2021, indicating that the plan had undergone revisions by that date. By 2023, the filing showed further evolution, introducing the 'Executive Severance and Retention Incentive Plan as Amended and Restated effective January 1, 2024,' with a filing date of December 8, 2023. This demonstrates Netflix’s ongoing adjustments to executive compensation frameworks, with a forward-looking amendment effective in 2024.",
      "llm_answer": "In the 2022 Form 10‑K the only Executive Severance and Retention Incentive Plan amendment disclosed was the **Amended and Restated Executive Severance and Retention Incentive Plan** filed on **September 10, 2021** (see Exhibit 10.6†)【page_65】.  \nThe 2023 Form 10‑K shows that Netflix has adopted a new amendment – the **Executive Severance and Retention Incentive Plan as Amended and Restated** – which is slated to become **effective January 1, 2024** (see Exhibit 10.16†)【page_68】.  \n\nThus, between the two filings Netflix moved from a 2021‑dated amendment to a fresh amendment that pushes the plan’s effective date forward to the start of 2024, indicating an ongoing update of its executive severance and retention framework.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the dates and effective periods are accurate: the 2022 filing references the 'Amended and Restated Executive Severance and Retention Incentive Plan' filed on September 10, 2021, and the 2023 filing discloses a new amendment effective January 1, 2024, filed on December 8, 2023 (implied by exhibit date in context). The LLM correctly identifies the forward-looking nature of the 2024 effective date. (2) The answer is complete, addressing both the 2022 and 2023 filing disclosures, the plan amendments, and their respective dates. (3) Entity accuracy is perfect: 'Netflix', 'Executive Severance and Retention Incentive Plan', correct exhibit numbers (10.6† and 10.16†), and correct years are used. (4) The reasoning is sound and demonstrates proper multi-hop synthesis: it compares the two filings across years, identifies the evolution in plan amendments, and correctly infers that Netflix is continuously updating its executive compensation framework. (5) The semantic meaning is equivalent to the original answer, with slightly different phrasing but identical factual content and conclusion. No errors in logic, facts, or interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 346,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Lowe's documentation and structure of its Benefit Restoration Plan evolve from 2022 to 2024, and what does this indicate about the company's approach to employee retirement benefits?",
      "original_answer": "In 2022, Lowe's maintained the Benefit Restoration Plan as part of its defined contribution retirement offerings, supplementing benefits under the 401(k) Plan for employees affected by IRS limitations. The plan included both employee salary deferrals and employer contributions in the form of a Company Match. By 2024, the company formally introduced an updated and restated version of the Benefit Restoration Plan, effective January 1, 2025, as evidenced by the new exhibit filing (10.3) in the 2024 10-K. This indicates a deliberate effort to formalize and likely enhance the structure of the plan, signaling a more strategic and forward-looking approach to managing executive and high-earner compensation through improved documentation and alignment with long-term benefit policies.",
      "llm_answer": "In the 2022 Form 10‑K the Benefit Restoration Plan was described only in narrative terms – a supplemental 401(k)‑style arrangement that lets affected employees make salary deferrals and receive a company match to offset restrictions imposed by the Internal Revenue Code. By the 2024 filing the plan appears as a formal exhibit (Exhibit 10.3) and is disclosed as “amended and restated as of January 1 2025,” showing that Lowe’s has revised and codified the plan’s terms. This progression signals that Lowe’s is actively refining and formalizing its retirement‑benefit safety‑net, underscoring a proactive, long‑term commitment to protecting employees’ retirement savings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, the Benefit Restoration Plan was described narratively as a supplemental defined contribution plan allowing salary deferrals and company match; by 2024, it was formally filed as Exhibit 10.3, 'amended and restated as of January 1, 2025.' These details match the original answer exactly. (2) Quantitative elements—specifically the effective date (January 1, 2025) and exhibit number (10.3)—are correctly cited, with no calculation errors. Format variations are not applicable here, but precision on dates and document identifiers is perfect. (3) The multi-hop reasoning is sound: the model correctly infers that moving from narrative disclosure to a formal exhibit indicates increased formalization and strategic intent, which reflects accurate synthesis across the 2022 and 2024 filings. (4) The LLM conveys the same core implication as the ground truth—that Lowe’s is taking a more structured, forward-looking approach to retirement benefits—though it uses slightly different phrasing (e.g., 'retirement-benefit safety-net' vs. 'strategic and forward-looking approach'). One minor point preventing a perfect 10 is that the LLM does not explicitly mention IRS limitations by name, though it references 'restrictions imposed by the Internal Revenue Code,' which is semantically equivalent. Overall, the answer is factually complete, contextually appropriate, and logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 410,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did NVDA's financial obligations related to the 0.584% Notes Due 2024 evolve between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a liability of $1,185 million for the 0.584% Notes Due 2024. By fiscal year 2024, this obligation was fully repaid, as stated in the 2024 10-K filing. This indicates a complete resolution of this specific debt obligation over the two-year period.",
      "llm_answer": "In the 2023 filing, NVIDIA reported $1.185 billion of 0.584 % Notes Due 2024 on its balance sheet (Jan 29 2023). The 2024 filing shows this liability at $1.228 billion (Jan 28 2024), indicating a modest increase of roughly $43 million year‑over‑year.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both magnitude and direction of change. The ground truth states that the $1,185 million liability was fully repaid by fiscal year 2024, resulting in $0 outstanding. Instead, the LLM claims the liability increased to $1.228 billion, which contradicts the actual repayment. (2) Quantitative inaccuracies include the erroneous $1.228 billion figure for 2024 (should be $0), and the claimed $43 million increase (should be a $1,185 million decrease). The 2023 amount ($1.185 billion) is correctly stated. Dates (Jan 29, 2023 and Jan 28, 2024) are plausible fiscal year-ends but not directly relevant given the incorrect liability values. (3) The multi-hop reasoning failed: the model did not recognize that 'Notes Due 2024' should be extinguished by the 2024 filing, indicating a failure to synthesize the maturity and repayment logic inherent in debt instruments. Instead, it incorrectly treated the liability as increasing. (4) Correctness and quantitative accuracy are severely penalized due to the core error in financial obligation direction and magnitude. Qualitative accuracy is low due to flawed reasoning. Contextual relevance is moderate because the answer addresses the right company, debt instrument, and time frame, but with incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1125,
        "completion_tokens": 365,
        "total_tokens": 1490
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the global revenue performance of Mavyret evolve between 2022 and 2023, and what were the trends in its United States and international markets during this period?",
      "original_answer": "In 2022, Mavyret generated total global revenue of $1,541 million, with $755 million from the United States and $786 million from international markets. By 2023, total revenue from Mavyret decreased to $1,430 million, driven by a decline in both U.S. and international markets. Specifically, U.S. revenue dropped to $659 million, a decrease of 12.7%, while international revenue slightly declined to $771 million, a marginal decrease of 1.9%. This indicates a contraction in Mavyret's market performance across both regions, with a more pronounced decline in the U.S. market.",
      "llm_answer": "Mavyret’s worldwide net revenue slipped from **$1.541 billion in 2022 to $1.430 billion in 2023**, a decline of roughly **7 %** (‑7.2 % at actual‑currency rates)【page_43】.  \n\n- **United States:** sales fell from **$755 million to $659 million**, a drop of about **13 %** (‑12.7 % at actual rates)【page_43】.  \n- **International markets:** revenue was essentially flat, moving from **$786 million to $771 million**, a modest **2 % decline** (‑1.9 % at actual rates, with a slight 1 % gain on a constant‑currency basis)【page_43】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitative accuracy: All dollar amounts are correct—$1.541 billion (2022) and $1.430 billion (2023) global revenue; U.S. revenue correctly stated as $755M (2022) and $659M (2023); international revenue as $786M (2022) and $771M (2023). Percentages are accurately calculated: 12.7% U.S. decline and 1.9% international decline, with the LLM rounding to 13% and 2% respectively, which is acceptable and common in reporting. The overall global decline of 7.2% is correctly noted. (2) Completeness: The answer addresses all parts of the question—global revenue evolution, U.S. trend, and international trend—across both years. (3) Entity accuracy: 'Mavyret' is correctly identified, and all financial metrics (revenue, regional breakdown) and years (2022, 2023) are accurate. (4) Reasoning: The multi-hop synthesis across regions and years is sound. The LLM correctly infers that both regions contributed to the global decline, with a steeper drop in the U.S., and even adds context about constant currency (not required but enhances accuracy). (5) Semantic equivalence: Despite slightly different phrasing and formatting (e.g., using 'slipped' or 'essentially flat'), the meaning fully aligns with the ground truth. No factual or interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 369,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Netflix's compliance with covenant limitations related to its Senior Notes evolve between 2022 and 2024, particularly in terms of repayment obligations and the scope of restrictions?",
      "original_answer": "In 2022, Netflix was in compliance with all covenant limitations tied to its Senior Notes, which included restrictions on creating liens, entering into sale and lease-back transactions, incurring additional indebtedness by certain subsidiaries, and merging or transferring substantial assets. These notes included various euro-denominated tranches with principal amounts totaling €5,170 million. By 2024, Netflix remained in compliance with these covenants, but the scope of limitations had slightly evolved—specifically, certain Senior Notes no longer referenced restrictions on sale and lease-back transactions, suggesting a narrowing of covenant scope for some notes. Additionally, in 2024, Netflix repaid $400 million of its 5.750% Senior Notes upon maturity, indicating active debt management and a shift in its debt composition.",
      "llm_answer": "In the 2022 Form 10‑K Netflix reported that, as of December 31 2021 (and 2020), it was in full compliance with all covenants attached to its senior unsecured notes – covenants that limit the company and its subsidiaries from incurring additional debt, granting liens, undertaking sale‑and‑lease‑back transactions, or merging‑/selling‑off substantially all assets. By the 2024 filing the same compliance statement still applied (as of December 31 2024 and 2023), but Netflix also disclosed that it had repaid the $400 million principal of its 5.750 % senior notes when they matured in 2024, showing an active repayment of a tranche while the scope of the covenant restrictions remained unchanged.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in terms of quantitative details and compliance status. It accurately reports Netflix's continued compliance with covenants in both 2022 and 2024, correctly identifies the $400 million repayment of the 5.750% Senior Notes in 2024, and accurately describes the core covenants (indebtedness, liens, sale-and-lease-back, mergers/asset sales). The quantitative accuracy is high: the dollar amount, interest rate, and repayment event are all factually correct. Contextual relevance is strong, as the response directly addresses Netflix's covenant compliance and repayment activity. However, there is a key qualitative inaccuracy: the LLM states that 'the scope of the covenant restrictions remained unchanged,' which contradicts the ground truth. The original answer specifies that by 2024, certain Senior Notes no longer included restrictions on sale-and-lease-back transactions, indicating a narrowing of covenant scope. This evolution is a critical part of the question about how compliance and restrictions 'evolved' between 2022 and 2024. By missing this change, the LLM fails to fully capture the multi-hop nuance of covenant scope evolution, even though it correctly reports compliance and repayment. Thus, while the core facts and numbers are right, the reasoning and synthesis are partially flawed, leading to a correctness score of 7 rather than 9 or 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 384,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Honeywell's approach to the Safety and Retail product line evolve between 2022 and 2023, and what structural change was introduced in 2023 that reflects this evolution?",
      "original_answer": "In 2022, Honeywell reported the Safety and Retail business unit as a standalone component under the Safety and Productivity Solutions segment, generating $2,387 million in revenue. By 2023, the company had realigned its organizational structure, merging the Safety and Retail unit with the Advanced Sensing Technologies unit to form a new business unit called Sensing and Safety Technologies. This structural change, introduced in July 2022 but reported in the 2023 filing, reflects a strategic shift toward integrating sensing capabilities with safety solutions to enhance technological offerings and streamline operations.",
      "llm_answer": "In the 2022 filing Honeywell still reported a separate **Safety and Retail** line within the Safety and Productivity Solutions segment, but it disclosed that in July 2022 it had **realigned the unit – merging the Safety and Retail business with the Advanced Sensing Technologies unit to create a new “Sensing and Safety Technologies” business unit** and retro‑cast prior periods to reflect that change【page_68】.  \n\nThe 2023 filing no longer shows a Safety and Retail line; instead the segment’s revenue is presented under the **new “Sensing and Safety Technologies”** category, confirming that the Safety and Retail product line had been folded into this newly created business unit【page_68 (2023)】.  \n\nThus, Honeywell moved from treating Safety and Retail as a distinct product line in 2022 to integrating it into the consolidated Sensing and Safety Technologies unit in 2023, a structural re‑organization that was formally reflected in the 2023 segment reporting.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) All key facts are correct: in 2022, Safety and Retail was a standalone unit under Safety and Productivity Solutions; in July 2022, Honeywell announced a realignment merging it with Advanced Sensing Technologies to form Sensing and Safety Technologies; this change was reflected in the 2023 filing. (2) Quantitative accuracy: while the exact revenue figure ($2,387 million) is not mentioned in the LLM answer, the omission does not detract from correctness as the question focuses on structural evolution rather than financial performance, and no incorrect numbers are presented. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across 2022 and 2023 filings, identifies the timing of the change (July 2022), and explains its reporting impact in 2023, including retroactive restatement. (4) Semantic equivalence is maintained: the LLM captures the strategic evolution and structural change accurately, using different but equivalent phrasing (e.g., 'folded into', 'consolidated unit'). The answer addresses both parts of the question—evolution of approach and the structural change—demonstrating strong contextual relevance and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 351,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the status and role of Class B-2 Common Stock evolved between 2023 and 2024, particularly in terms of its convertibility and impact on corporate governance?",
      "original_answer": "In 2023, Class B-2 Common Stock was described as part of a structure that would become convertible into Class A Common Stock, with potential dilutive effects on voting power and market price. It also played a role in approving significant corporate actions, indicating a governance influence. By 2024, no shares of Class B-2 Common Stock were outstanding prior to the Class B-1 Common Stock exchange offer, suggesting a strategic shift in equity structure. This indicates a transformation in the role of Class B-2 Common Stock, moving from an active governance and conversion position to a non-outstanding status, reducing its influence on corporate decisions.",
      "llm_answer": "In the 2023 filing Visa explained that its Class B‑2 common stock, together with Class B‑1, “will become convertible into Class A common stock…no later than 2028” and that, although its voting rights are limited, holders may vote on “a proposed consolidation or merger, a decision to exit our core payments business and any other vote required under Delaware law” (2023 p. 34). By the 2024 filing the total number of Class B shares (B‑1 + B‑2) had fallen from 245 shares in 2023 to 125 shares in 2024, reflecting an exchange‑offer‑driven conversion of many B‑2 shares (2024 p. 58) and the fact that no B‑2 shares were outstanding before the exchange offer (2024 p. 59). Thus, between 2023 and 2024 the B‑2 stock remained a convertible, limited‑voting security, but a substantial portion was converted/exchanged, reducing its outstanding count while preserving its role in approving only certain major corporate actions.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and addresses the evolution of Class B-2 Common Stock between 2023 and 2024, particularly regarding convertibility and governance. It correctly notes that in 2023, Class B-2 shares were convertible into Class A shares by 2028 and had limited voting rights focused on major corporate actions (e.g., merger, exit from core business), which aligns with the ground truth. It also correctly states that by 2024, no Class B-2 shares were outstanding prior to the exchange offer, citing page 59 of the 2024 filing—this matches the ground truth. However, the LLM introduces a quantitative claim not present in the original answer: that total Class B shares (B-1 + B-2) dropped from 245 in 2023 to 125 in 2024 due to an exchange offer. While this may be factually accurate in the actual filing, the ground truth does not include these specific numbers, and thus this detail introduces precision beyond the verified knowledge graph, risking overclaim. Additionally, the ground truth emphasizes that Class B-2 went from an active governance role to non-outstanding status, implying a structural shift, while the LLM concludes that the 'role' was preserved in approving major actions—this understates the transformation, as non-outstanding shares have no ongoing role. The reasoning is mostly sound and synthesizes across years and documents, but the emphasis on preserved function slightly misaligns with the ground truth's conclusion of reduced influence. Wording differences are acceptable, but the inclusion of unverified numeric details and slight misinterpretation of the post-2023 role justify a score of 8 for correctness. Quantitative accuracy is scored 7 due to unsupported specific share counts. Qualitative accuracy is 8 due to correct entity identification (Visa, Class B-2, conversion terms) and multi-hop synthesis across 2023 and 2024 filings. Contextual relevance is perfect—directly addresses the question's focus on convertibility and governance evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 535,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has The Home Depot's approach to enhancing the ease of shopping experience evolved between 2023 and 2024, particularly in terms of digital and in-store capabilities?",
      "original_answer": "In 2023, The Home Depot focused on improving the ease of shopping experience by investing in mobile app-enabled store navigation, electronic shelf labels, reconfigured service desks, and enhanced self-checkout options. These efforts were aimed at improving store navigation, convenience, and checkout speed. By 2024, the company expanded its focus to include more personalized digital experiences, such as customer product review summaries and enhanced product content, while continuing to invest in digital platforms to improve navigation and 'shopability.' The 2024 strategy placed greater emphasis on leveraging customer data to meet personalized expectations, indicating a shift toward deeper integration of data-driven insights into the shopping journey.",
      "llm_answer": "In fiscal 2023 Home Depot’s “ease‑of‑shopping” plan was centered on adding physical‑store aids – way‑finding signage, store‑refresh packages, self‑service lockers, curb‑side pickup, electronic shelf‑labels, redesigned front‑ends and expanded self‑checkout – and on launching a mobile‑app map that let shoppers locate items in‑store, while its digital platform was upgraded to improve navigation, product “shopability,” search, checkout speed and fulfillment options. By fiscal 2024 the company said it was **building on those investments** by further expanding and enhancing self‑checkout, adding new self‑help tools in the app, and deepening the integration of its mobile‑app navigation with the in‑store experience, all supported by a $3.5 billion cap‑ex program that continues to improve website and mobile‑app functionality, personalized messaging and omnichannel fulfillment. Thus, the focus shifted from establishing the basic digital‑and‑store infrastructure in 2023 to scaling and tightening that infrastructure in 2024, delivering more seamless, mobile‑driven navigation and checkout options across both channels.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of The Home Depot's ease-of-shopping strategy from 2023 to 2024. (1) It accurately captures the 2023 focus on physical and digital infrastructure: electronic shelf labels, self-checkout, mobile app navigation, and store reconfigurations (referred to as 'redesigned front-ends' and 'store-refresh packages'), which matches the original answer's emphasis on navigation, convenience, and checkout speed. In 2024, the LLM correctly identifies a shift toward scaling and integrating these capabilities, mentioning enhanced self-checkout, deeper app integration, and personalized messaging—consistent with the ground truth's emphasis on personalized digital experiences and data-driven insights. (2) Quantitatively, the LLM introduces a $3.5 billion cap-ex program, which is not present in the original answer. However, since this figure does not contradict any provided data and may reflect additional context from the filings, it does not count as an error but rather as supplementary detail; thus, quantitative accuracy remains high. (3) The reasoning is sound: the LLM correctly synthesizes a multi-hop narrative showing progression from infrastructure development (2023) to refinement and integration (2024), capturing the strategic evolution. (4) Minor gap: the original answer specifically mentions 'customer product review summaries' and 'enhanced product content' as 2024 digital enhancements, which the LLM omits. Instead, it generalizes to 'personalized messaging' and 'shopability,' which are related but not exact substitutes. This omission prevents a top score, but the overall semantic meaning and strategic direction are preserved. Contextual relevance is perfect—directly addresses both digital and in-store evolution across the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1476,
        "completion_tokens": 498,
        "total_tokens": 1974
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the structure of the Target Corporation Long-Term Incentive Plan evolved from 2022 to 2024, particularly in terms of the specific forms of equity awards included under the plan?",
      "original_answer": "In 2022, the Long-Term Incentive Plan included forms such as Non-Qualified Stock Options, Restricted Stock Units, Performance-Based Restricted Stock Units, Performance Share Units, Price-Vested Stock Options, Non-Employee Director Non-Qualified Stock Options, and Non-Employee Director Restricted Stock Units. By 2024, the plan introduced new forms of equity awards, including the Cliff-Vested Restricted Stock Unit Agreement and the Performance Award Performance Share Unit Agreement, indicating an expansion in the types of equity compensation vehicles available under the plan.",
      "llm_answer": "In the 2022 Form 10‑K the Long‑Term Incentive Plan was described as containing a mix of equity awards – restricted‑stock units, performance‑based RSUs, performance‑share units, price‑vested stock options and both non‑employee director stock‑option and restricted‑stock agreements (see exhibits U, V, W, X, Y and Z)【page_68】.  \n\nThe 2024 filing still includes RSUs, performance‑RSUs and performance‑share units, but the plan now adds a cliff‑vested RSU and a performance‑award performance‑share unit, while the price‑vested stock‑option form is no longer listed (exhibits 10.4.1‑10.4.6)【page_73】.  \n\nThus, between 2022 and 2024 the LTIP shifted away from stock‑option awards and expanded its equity‑award menu to include cliff‑vested RSUs and a new performance‑share award.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the equity award types under Target Corporation's Long-Term Incentive Plan (LTIP) in 2022, including restricted stock units (RSUs), performance-based RSUs, performance-share units, price-vested stock options, and non-employee director awards. In 2024, it accurately notes the addition of cliff-vested RSUs and performance-award performance-share units, which matches the original answer's claim of expanded award types. (2) There are no numeric values (e.g., dollar amounts, percentages) in the question or ground truth, so quantitative accuracy is not applicable in that sense, but all factual assertions about award forms and their presence in specific years are correct. (3) The multi-hop reasoning is sound: the model synthesizes information from two different years (2022 and 2024) and compares the plan structures, correctly identifying both continuity (retention of RSUs, performance awards) and change (addition of new forms, removal of price-vested options). The observation that the plan 'shifted away from stock-option awards' is a reasonable inference given the removal of price-vested options and introduction of RSU-centric awards. (4) The only minor shortcoming is that the original answer explicitly lists Non-Qualified Stock Options (beyond price-vested) and Non-Employee Director Non-Qualified Stock Options as part of the 2022 plan, which the LLM answer condenses into 'non-employee director stock-option agreements'—slightly less granular but not factually incorrect. Overall, the answer is semantically equivalent, contextually precise, and demonstrates strong qualitative and factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 466,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Qulipta's commercial performance evolve from its FDA approval in 2021 through 2023, based on AbbVie's financial disclosures?",
      "original_answer": "Qulipta was approved by the FDA in September 2021 for the preventive treatment of episodic migraine in adults, marking its entry into the market. By 2023, Qulipta had generated $405 million in U.S. revenue and $3 million internationally, totaling $408 million. This indicates a significant commercial trajectory following its approval, especially considering it had no revenue in 2021 and only $158 million in U.S. revenue in 2022. The product demonstrated strong growth, suggesting robust market adoption and positioning within AbbVie's portfolio.",
      "llm_answer": "AbbVie’s disclosures show that Qulipta generated no net revenue in 2021 (the year it received its first FDA approval for episodic migraine).  After launch, it earned about $158 million in U.S. sales (and negligible international sales) in 2022, and then more than doubled that amount in 2023—totaling roughly $500 million‑plus—with “greater than 100%” growth driven by strong market‑share uptake and the April 2023 FDA approval (and August 2023 EU approval) for preventive treatment of chronic migraine.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Qulipta's FDA approval in 2021 with no revenue that year, and reports $158 million in U.S. sales in 2022, which aligns with the ground truth. However, it significantly overstates 2023 revenue: the LLM claims 'roughly $500 million-plus' and 'greater than 100%' growth, while the ground truth reports $408 million total revenue ($405M U.S., $3M international). This is a major quantitative error, as $500M+ is ~22% higher than the actual figure. Additionally, the claim of 'greater than 100%' growth from 2022 to 2023 is incorrect: revenue grew from $158M to $408M, which is about 158% growth—while this does exceed 100%, the phrasing may mislead given the inflated base. (2) The LLM correctly notes the April 2023 FDA approval for chronic migraine and August 2023 EU approval, which are relevant to commercial expansion and growth drivers, adding valuable context not in the original answer but plausibly from AbbVie disclosures. (3) The multi-hop reasoning is sound—linking approval timelines to revenue progression and market adoption—but the synthesis is undermined by inaccurate revenue figures. (4) Despite strong contextual relevance and correct qualitative trajectory (rapid growth post-launch), the significant overstatement of 2023 revenue reduces factual reliability. The answer captures the trend but fails on key metrics, warranting a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 391,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has Netflix's treatment and disclosure of the 2020 Stock Plan evolved between the 2022 and 2024 SEC filings, particularly in terms of its structural description and associated equity compensation activities?",
      "original_answer": "In 2022, the 2020 Stock Plan was referenced primarily through its inclusion in the exhibit list as a filed document (Def 14A, filed April 22, 2020), with no detailed description of its provisions or activities. In contrast, by 2024, the 2020 Stock Plan was not only explicitly described in detail but also linked to specific equity compensation activities, including the granting of incentive stock options, nonstatutory stock options, and restricted stock units (RSUs) with defined vesting schedules and performance-based criteria. This represents a significant shift from mere documentation to a more comprehensive disclosure of the plan's operational role in equity compensation.",
      "llm_answer": "In the 2022 Form 10‑K the 2020 Stock Plan is mentioned only in the exhibit index (Def 14A) – a brief reference that identifies the plan but gives no description of its mechanics or the equity awards it generates. By the 2024 filing Netflix expands the disclosure: the “Stock Option Plan” section characterizes the 2020 Stock Plan as a stock‑holder‑approved vehicle that authorizes incentive and non‑statutory stock options, stock‑appreciation rights, restricted stock and RSUs for employees, directors and consultants, and it provides detailed tables of option balances, grants, exercises, RSU activity and the related stock‑based compensation expense. This reflects a shift from a simple structural listing to a full narrative and quantitative description of the plan’s operation and its impact on equity compensation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, the 2020 Stock Plan was only referenced in the exhibit list (Def 14A, filed April 22, 2020), with no detailed description—consistent with the original answer. In 2024, it accurately notes the expanded disclosure, including detailed descriptions of plan provisions and equity compensation activities. (2) There are no numeric values (e.g., dollar amounts, percentages, share counts) in either the question or ground truth, so quantitative accuracy is not applicable in that sense, but all dates and document references (e.g., Def 14A) are correct—thus scored as 10. (3) The reasoning is sound: the LLM correctly synthesizes the evolution from minimal to comprehensive disclosure, capturing the multi-hop aspect by contrasting two filings across time. It accurately describes the types of equity awards (incentive/nonstatutory options, RSUs) and mentions vesting and performance criteria indirectly via 'detailed tables of option balances, grants, exercises, RSU activity.' Only minor phrasing differences exist—e.g., 'performance-based criteria' in ground truth is implied but not explicitly stated in the LLM answer, which prevents a perfect 10. (4) The answer is fully contextually relevant, directly addressing the evolution in structural description and equity compensation activities between 2022 and 2024. Overall, the LLM conveys semantic equivalence with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 410,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the company's approach to aluminum purchase agreements evolve between 2022 and 2023, particularly in terms of their classification and strategic use of derivative instruments?",
      "original_answer": "In 2022, the company described its aluminum purchase agreements as derivative instruments entered into for long-term strategic sourcing objectives and non-U.S. business requirements. By 2023, the company continued to use these agreements but provided additional clarity that the quantities of aluminum in these contracts offset each other and are priced at prevailing market prices. This evolution indicates a more refined strategy around market pricing alignment and potentially reduced exposure through offsetting positions.",
      "llm_answer": "In the 2022 filing the company only noted that its aluminum purchase‑sale agreements were “derivative instruments” whose quantities offset and were priced at market rates, and it grouped them with other commodity swaps that did not qualify for hedge accounting. By the 2023 filing the same agreements are described as “long‑term strategic sourcing” tools and are explicitly listed in the derivative tables – the aluminum contracts appear as commodity contracts (both designated as hedging instruments and as non‑hedged derivatives), showing a clearer classification and a more intentional use of derivatives to manage sourcing risk.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies in the qualitative description of the company's approach to aluminum purchase agreements between 2022 and 2023, despite correct dates and proper contextual framing around derivatives and strategic sourcing. In the 2022 ground truth, the company described the aluminum agreements as derivative instruments used for 'long-term strategic sourcing objectives and non-U.S. business requirements'—a key strategic rationale that the LLM omits. Instead, the LLM incorrectly states that in 2022 the company only noted the offsetting quantities and market pricing, which reverses the timeline of disclosure emphasis. The evolution described in the ground truth is that by 2023, the company added clarity about offsetting quantities and market pricing—whereas the LLM claims this was already stated in 2022 and implies a shift in 2023 toward strategic sourcing, which contradicts the original sequence. This misrepresents the direction of the evolution. Additionally, the LLM introduces new details not in the original, such as grouping with other commodity swaps that don’t qualify for hedge accounting and explicit inclusion in derivative tables, which were not mentioned in the ground truth. While the answer correctly identifies the use of derivatives and strategic sourcing as themes, the reversal of the timeline and addition of unsupported details undermine the multi-hop reasoning. Quantitatively, there are no numbers to assess, so no errors there. Contextually, the response is relevant and addresses the question's intent, but with flawed logic in the year-over-year comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 444,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the disclosure or treatment of the Directors' Code of Conduct evolved between 2023 and 2024, particularly in terms of its accessibility and scope?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly referenced and posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors-code-of-conduct.pdf. In 2024, the URL for the Directors' Code of Conduct changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf, indicating a shift in how the document is categorized or accessed. Additionally, in 2024, the company introduced a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES,' which was not present in 2023, suggesting an expanded focus on compliance mechanisms beyond the Code itself. These changes reflect a transformation in the presentation and accessibility of the Directors' Code of Conduct, as well as an increased emphasis on insider trading compliance.",
      "llm_answer": "In the 2023 Form 10‑K the Directors’ Code of Conduct was said to “apply to all directors of BNY Mellon” and was made available on the company’s website at a bnymellon.com PDF link, with any amendments or waivers to be posted there. In the 2024 filing the same statement of applicability is retained, but the code is now referenced on a bny.com URL ( …/investor‑relations/directors‑code‑of‑conduct.pdf ), reflecting a shift to the newer corporate web domain while preserving the same universal‑director scope and the commitment to post any changes online.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the key changes in the Directors' Code of Conduct between 2023 and 2024, particularly the shift in URL from bnymellon.com to bny.com, which reflects the domain update. It accurately notes that the code applied to all directors in both years and that amendments would be posted online, preserving the scope and accessibility commitment. The quantitative and entity accuracy is perfect: correct years (2023 vs 2024), correct companies (BNY Mellon), and correct URLs (with only minor formatting differences like hyphens vs spaces, which do not affect accuracy). However, the LLM answer omits a key qualitative addition mentioned in the ground truth: the introduction of a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES' in 2024, which was not present in 2023. This reflects an expansion in the document’s scope beyond just accessibility and presentation, which the question specifically asks about. While the answer captures the accessibility evolution (URL change), it fails to mention the substantive content expansion, making the response incomplete on the 'scope' aspect of the question. The reasoning is sound regarding the domain shift and consistent applicability, but the multi-hop synthesis is partial—only addressing accessibility and not the full scope evolution. Hence, the correctness and qualitative accuracy scores are reduced accordingly, though the answer remains factually sound where it does respond.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 402,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the structure and value of HD's 4.95% Senior Notes evolved between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, HD issued $750 million of 4.95% senior notes due September 30, 2026, at a discount of $1.6 million. By 2024, the carrying amount of these 4.95% senior notes due September 2026 was $747 million as of February 2, 2025, and the company also reported $980 million in 4.95% senior notes due September 2052. This indicates that while the original 2026 notes remained outstanding with only a slight reduction in carrying value, HD expanded its 4.95% senior note structure to a much longer maturity in 2052, suggesting a strategy of extending debt maturities and potentially locking in fixed interest rates over a longer horizon.",
      "llm_answer": "- **2023 filing:** Home Depot’s 4.95 % senior‑note portfolio consisted of three tranches – $750 million due September 2026 (carrying amount $744 million), $750 million due April 2029 (carrying amount $743 million) and $1.0 billion due September 2052 (carrying amount $980 million)【page_59】.  \n\n- **2024 filing:** The September 2026 tranche’s carrying amount rose slightly to $745 million, the April 2029 and 2052 tranches remained unchanged, and the company added a new $1.75 billion 4.95 % tranche due June 2034 (issued at a $16.7 million discount)【page_62】【page_63】.  \n\n**Implication:** By retaining the existing 4.95 % notes and introducing a much larger 4.95 % issuance, HD is using a consistent mid‑rate coupon to broaden its maturity schedule and lock in fixed‑rate financing, signaling a deliberate strategy to diversify long‑term debt maturities while maintaining a stable, moderate cost of capital.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 HD issued only $750 million of 4.95% senior notes due September 30, 2026, at a $1.6 million discount (carrying amount ~$748.4 million, amortized to $747 million by 2024). However, the LLM claims three tranches existed in 2023, including a $750 million April 2029 tranche and a $1.0 billion 2052 tranche — none of which are supported by the ground truth. The ground truth confirms only $980 million in 4.95% notes due 2052 in 2024, with no mention of issuance timing or prior existence in 2023. The LLM incorrectly states that the 2026 carrying amount rose to $745 million in 2024, while the truth reports $747 million as of February 2, 2025. Most critically, the LLM fabricates a new $1.75 billion 4.95% tranche due June 2034 issued in 2024, which is not present in the ground truth. (2) Quantitative accuracy is severely compromised: multiple dollar amounts, maturities, carrying values, and issuance details are incorrect or invented. The only partially correct figure is the $980 million 4.95% note due 2052 in 2024, though even its context is misrepresented. (3) Multi-hop reasoning is flawed — the LLM incorrectly synthesizes non-existent tranches across years and draws conclusions based on fabricated data. The reasoning about extending maturities and locking in rates has some alignment with the ground truth’s interpretation, but it is based on false premises. (4) Contextual relevance is moderate because the answer addresses the general theme of debt strategy and maturity extension, but the factual foundation is unsound, leading to an incorrect overall conclusion. The model fails to accurately represent the evolution of the 4.95% notes, misrepresenting both structure and value changes between 2023 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 497,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did Intel's financial treatment and valuation of its investment in Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of observable price adjustments and net book value?",
      "original_answer": "In 2021, Intel recognized $471 million in observable price adjustments in its investment in Beijing Unisoc Technology Ltd. By the end of 2023, Intel was accounting for its interest in Unisoc as a non-marketable equity security, with a net book value of $1.1 billion as of December 30, 2023 (the same as December 31, 2022). This indicates that while Intel continued to hold the investment without marketability, the valuation remained stable over the two-year period despite the earlier price adjustment.",
      "llm_answer": "In 2021 Intel treated its stake in Beijing Unisoc Technology Ltd. as a non‑marketable equity security and recorded a **$471 million observable‑price adjustment** (part of a $750 million total adjustment on non‑marketable equity securities) to reflect an upward fair‑value change. By 2023 the same investment was still carried as a non‑marketable equity security, but the **observable‑price adjustment had fallen to only $17 million**, while the **net book value of the Unisoc investment was $1.1 billion** (the same amount reported for the end of 2022).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the claim that the observable-price adjustment in 2023 was $17 million. The original answer (ground truth) states that Intel recognized $471 million in observable price adjustments in 2021 and does not mention any such adjustment in 2023. Furthermore, the LLM incorrectly implies that the $471 million was part of a $750 million total adjustment on non-marketable securities — this detail is not present in the ground truth and cannot be verified from the provided information. The net book value of $1.1 billion in 2023 is correct and matches the ground truth. (2) Quantitative accuracy is low: while the $471 million (2021) and $1.1 billion (2023) figures are accurate, the introduction of a $17 million observable-price adjustment in 2023 is unsupported and incorrect. There is no indication in the ground truth that such an adjustment occurred or decreased over time. The $750 million total adjustment is extraneous and unverified. (3) The multi-hop reasoning is partially sound in that the model correctly identifies the treatment of the investment as a non-marketable equity security in both years and correctly reports the 2023 net book value. However, it fabricates a trend in observable-price adjustments between 2021 and 2023 that is not supported by the original answer, undermining the reasoning. (4) Contextual relevance is high because the answer addresses the evolution of financial treatment and valuation, including both observable price adjustments and net book value. However, due to the inclusion of incorrect quantitative details and unsupported claims about changes in adjustments, the overall correctness score is low despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 479,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did AbbVie's engagement with Qulipta evolve from 2022 to 2023, particularly in terms of its regulatory and commercial development status?",
      "original_answer": "In 2022, Qulipta was part of a group of products that received regulatory approvals, leading to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights. By 2023, AbbVie had introduced Qulipta with specific regulatory milestones: it received FDA approval in April 2023 for the preventive treatment of chronic migraine in adults and EC approval in August 2023 for the preventive treatment of migraine in adults with four or more migraine days per month. This evolution reflects a shift from asset reclassification to active regulatory and commercial advancement.",
      "llm_answer": "In the 2022 filing AbbVie listed Qulipta only as an investigational neuroscience product – it had not yet received any regulatory clearance and generated no sales. By the 2023 filing the drug had moved into the commercial phase: the U.S. FDA approved Qulipta in April 2023 and the European Commission approved it (as Aquipta) in August 2023, and AbbVie reported Qulipta‑related revenue for 2023.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution of Qulipta from 2022 to 2023. In 2022, it correctly states that Qulipta was still investigational with no regulatory approval or sales, aligning with the ground truth that it was part of R&D assets reclassified upon approval. The 2023 milestones are accurately reported: FDA approval in April 2023 and EC approval in August 2023. The mention of Qulipta-related revenue in 2023 correctly reflects its commercial launch. However, the LLM omits the specific $1.0 billion reclassification of intangible assets to developed product rights in 2022, which is a key financial and regulatory accounting event detailed in the original answer. This omission slightly weakens completeness and qualitative accuracy. Additionally, the LLM incorrectly refers to the European brand name as 'Aquipta' instead of 'Qulipta' (no indication in ground truth of a different trade name in Europe), which is a minor entity error. Quantitative accuracy is high: all dates and the implication of commercialization (revenue generation) are correct. The reasoning correctly traces the drug’s progression from investigational to approved and commercial, demonstrating sound multi-hop logic across years and regulatory domains. Contextual relevance is excellent, directly addressing the regulatory and commercial evolution asked in the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 381,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has Boeing's framing and strategic emphasis on 'upgrades and conversions' within the Global Services segment evolved between 2022 and 2023, based on the language used in the 10-K filings?",
      "original_answer": "In 2022, 'upgrades and conversions' were listed as part of a broader set of services under the Global Services segment, grouped alongside supply chain logistics, engineering, maintenance, spare parts, training systems, technical documents, and digital services. The description was general and lacked strategic framing. In 2023, while the service was still included, the context shifted subtly: it was now positioned within a more structured narrative that emphasized the full spectrum of sustaining aerospace platforms and systems, indicating a more integrated and strategic role within the segment. This evolution suggests a more deliberate positioning of 'upgrades and conversions' as a core capability rather than a general service offering.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K describe “upgrades and conversions” as one element of the Global Services (BGS) portfolio’s “full spectrum of products and services.” In 2022 the filing says the segment “provides services … including … engineering, maintenance and modifications, **upgrades and conversions**, spare parts, … and data‑analytics and digital services,” and the 2023 filing repeats the same phrasing in both the Item 1 Business description and the dedicated Global Services section. Thus, Boeing’s framing of upgrades and conversions has remained consistent—positioned as a core, but routine, component of a broad service suite—without a noticeable shift in strategic emphasis between the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core conclusion, directly contradicting the ground truth. While it correctly identifies that 'upgrades and conversions' were mentioned in both years as part of the Global Services portfolio, it claims the phrasing was identical and that there was 'no noticeable shift' in strategic emphasis. However, the ground truth confirms a subtle but meaningful evolution in framing: from a general listing among other services in 2022 to a more integrated role within a 'structured narrative' emphasizing the full spectrum of sustaining aerospace platforms in 2023. The LLM incorrectly asserts that the exact same phrasing was used in both years, failing to detect or acknowledge the contextual shift in presentation and strategic positioning. This represents a failure in qualitative analysis and multi-hop reasoning, as the model did not interpret the change in narrative structure as a strategic evolution. There are no numerical errors (hence high quantitative accuracy), and the response is contextually relevant to the question, but the central claim is wrong, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 320,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Intel's financial relationship with Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of the valuation and recognition of this investment?",
      "original_answer": "Intel's financial relationship with Beijing Unisoc Technology Ltd. remained consistent in terms of total net book value, which stayed at $1.1 billion as of both December 25, 2021 (from the 2022 filing) and December 30, 2023 (from the 2023 filing). However, in 2021, Intel recognized $471 million in observable price adjustments related to its investment in Unisoc, indicating a revaluation event during that year. This type of valuation adjustment was not explicitly mentioned in the 2023 filing, suggesting a stabilization of the investment's value over time or a lack of significant observable price changes in 2023 compared to 2021.",
      "llm_answer": "In 2021 Intel reported that its non‑marketable equity stake in Beijing Unisoc Technology Ltd. was carried at **about $1.1 billion** (up from $658 million a year earlier) and that it **recorded a $471 million observable‑price adjustment** on that investment during 2021. By the end of 2023 the same investment was still shown as a non‑marketable equity security with a **net book value of roughly $1.1 billion** (the same amount reported at the end of 2022), indicating that after the 2021 price adjustment the valuation has essentially remained unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key facts: Intel's investment in Beijing Unisoc had a net book value of $1.1 billion as of the end of 2021 and remained at $1.1 billion through 2023. It accurately reports the $471 million observable-price adjustment in 2021. These figures match the ground truth exactly in amount and context. (2) Quantitative accuracy is perfect: $1.1 billion book value in both years, $471 million adjustment in 2021. The mention of the prior year's $658 million (end of 2020) is an additional but accurate detail not in the original answer, which is acceptable and adds context without error. (3) The reasoning is sound: the LLM correctly infers that the valuation stabilized after the 2021 adjustment, which aligns with the ground truth’s implication of stabilization or lack of significant changes in 2023. The synthesis across years and filings is accurate. (4) The only minor shortcoming is that the original answer notes the absence of observable price adjustments in 2023 as a contrast to 2021, which the LLM implies but does not explicitly state. However, saying the value 'essentially remained unchanged' captures the same idea. Thus, the answer is semantically equivalent and highly accurate, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 380,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role of Self-Service Lockers evolved within Home Depot's interconnected shopping experience between 2023 and 2024?",
      "original_answer": "In 2023, Self-Service Lockers were described as part of Home Depot's investments to improve the customer shopping experience, specifically to enable convenient online order pickup options alongside other features like wayfinding signage and electronic shelf labels. By 2024, Self-Service Lockers were positioned more strategically as part of the company's broader fulfillment network, specifically referenced in the context of leveraging stores as 'convenient customer pickup, return, and delivery fulfillment locations' under interconnected retail programs such as BOSS, BOPIS, BODFS, and BORIS. Additionally, in 2024, approximately 50% of U.S. online orders were fulfilled through a store, highlighting a more integrated and operationally significant role for Self-Service Lockers in the fulfillment process. This reflects a shift from a convenience-focused feature to a core component of the omnichannel delivery strategy.",
      "llm_answer": "In fiscal 2023, Home Depot added self‑service lockers as a store‑refresh investment that let customers conveniently retrieve online orders, positioning them as one of several new pickup options within the emerging “interconnected shopping experience.” By fiscal 2024, the lockers had been elevated to a core omnichannel fulfillment tool—located at store entrances and tied into the BOPIS, BOSS and other pickup programs—so they now serve as a key link that ties online ordering, in‑store pickup and curbside services together for a truly seamless customer journey.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of Self-Service Lockers in Home Depot's interconnected shopping experience between 2023 and 2024. (1) It correctly identifies that in 2023, lockers were introduced as part of store-refresh investments to improve online order pickup convenience, aligning with the ground truth's description of them being part of customer experience improvements. In 2024, it accurately reflects their elevated role as a core omnichannel fulfillment tool integrated with BOPIS, BOSS, and other programs. (2) There are no numeric values in the LLM answer, so no quantitative inaccuracies; it does not mention the specific 'approximately 50% of U.S. online orders fulfilled through a store' statistic from the ground truth, but this omission does not distort the overall meaning. (3) The multi-hop reasoning is sound: the model synthesizes the shift from a convenience feature to a strategically integrated component of fulfillment, correctly linking lockers to broader retail programs and operational strategy. (4) While the LLM answer conveys the core transformation and strategic integration accurately (semantic equivalence achieved), it omits the specific data point about 50% of U.S. online orders being store-fulfilled, which slightly reduces completeness. However, this does not undermine the essential correctness of the narrative. Hence, a score of 9 is justified—very close to full accuracy with only minor contextual detail missing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 407,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the level of detail and specificity in Costco's disclosure regarding the estimation methods for Insurance/Self-insurance Liabilities evolved from 2023 to 2024?",
      "original_answer": "In 2023, Costco provided a general description of its self-insurance practices and risk management mechanisms, including the use of a captive insurance subsidiary and a reinsurance program, but did not specify the factors used in estimating liabilities. In 2024, the company significantly expanded its disclosure, detailing that liabilities are estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions. Additionally, 2024's disclosure included a discussion of the unpredictability of claim costs and the potential for significant differences between actual and recorded liabilities, which was not present in 2023. This represents a meaningful increase in transparency and specificity.",
      "llm_answer": "In the 2023 filing Costco’s note on Insurance/Self‑insurance Liabilities not only described the estimation approach – using historical claims experience, demographic and severity factors and other actuarial assumptions – but also disclosed the actual liability balances ($1.513 billion in 2023 and $1.612 billion in 2024). The 2024 filing repeats the same methodological language but omits the specific dollar amounts, offering only a brief comment that adjustments have historically been immaterial, so the disclosure is less quantitative while the description of the estimation method remains essentially unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It falsely claims that in 2023, Costco disclosed the use of 'historical claims experience, demographic and severity factors and other actuarial assumptions'—but the original answer states this level of methodological detail was absent in 2023 and only introduced in 2024. This misrepresents the core evolution of disclosure. (2) The LLM cites specific liability balances ($1.513 billion in 2023, $1.612 billion in 2024), but the ground truth does not confirm whether these numbers were disclosed in the respective filings, nor does it mention them—making their inclusion unsupported and potentially hallucinated. (3) The claim that the 2024 filing 'omits the specific dollar amounts' and is 'less quantitative' directly contradicts the original answer, which emphasizes that 2024 included *more* detailed qualitative and risk-related disclosures, representing an increase in transparency. (4) The reasoning fails on multi-hop synthesis: the question asks about evolution in *detail and specificity of estimation methods*, but the LLM incorrectly asserts the method description was present in 2023 and unchanged in 2024, when in fact the detailed methodology was only added in 2024. The answer also introduces immateriality comments not present in the ground truth. While the response is framed around the right topic (disclosure evolution), its factual inaccuracies severely undermine correctness. Quantitative accuracy is low due to unverified dollar figures; qualitative accuracy is poor due to incorrect characterization of disclosure content across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 444,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How did the financial impact of the Aldevron acquisition on inventory-related costs evolve from 2022 to 2023?",
      "original_answer": "In 2022, the Aldevron acquisition contributed to a $59 million increase in cost of sales due to fair value adjustments to inventory. By 2023, this specific acquisition-related cost associated with Aldevron was no longer present; instead, a new $87 million charge emerged in the second quarter, primarily related to excess inventory in the Biotechnology segment due to reduced demand. This indicates a shift from acquisition-driven inventory adjustments to operational inventory challenges.",
      "llm_answer": "The 2022 filing notes that the year‑over‑year rise in cost of sales was “partially offset by lower incremental acquisition‑related charges associated with fair‑value adjustments to inventory in connection with the 2021 acquisition of Aldevron,” indicating that the Aldevron‑related inventory adjustment was smaller (the $59 million charge that had hit cost of sales in 2021 was no longer present). By 2023 the Aldevron‑related inventory effect had essentially disappeared; instead the company recorded a $87 million inventory charge in Q2 2023 tied to excess biotechnology inventory, not to the Aldevron purchase. Thus, the Aldevron acquisition’s inventory impact went from a reduced, still‑present charge in 2022 to no discernible impact in 2023.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the timing and presence of the Aldevron-related inventory charge. The ground truth states that in 2022, the Aldevron acquisition caused a $59 million increase in cost of sales due to fair value adjustments. However, the LLM incorrectly claims that this $59 million charge occurred in 2021 and was no longer present in 2022, stating instead that only a 'lower incremental charge' remained in 2022. This misrepresents the financial timeline and the nature of the expense. The $59 million charge was present in 2022, not 2021. (2) The LLM correctly identifies the $87 million inventory charge in Q2 2023 and correctly attributes it to excess biotechnology inventory unrelated to Aldevron, which aligns with the ground truth. However, it incorrectly frames the 2022 situation by asserting the Aldevron effect was 'reduced' and 'still present' rather than correctly stating it was a major $59M contributor in 2022. (3) The multi-hop reasoning is partially sound—linking the absence of Aldevron charges in 2023 and the emergence of a new operational charge—but fails on the critical first hop: misplacing the $59M charge to 2021 and downplaying its role in 2022. This undermines the synthesis across years. (4) Despite correct mention of the $87M 2023 charge and the shift away from acquisition-related costs, the incorrect dating and mischaracterization of the 2022 charge significantly reduce factual accuracy. The contextual relevance is high as the answer addresses the evolution of inventory costs and attempts the correct comparison. Quantitative accuracy is low due to the wrong year attribution of the $59M charge. Qualitative accuracy is moderate because the reasoning structure is logical but based on incorrect premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 490,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the treatment and recognition of shop card liabilities evolved between 2023 and 2024, and what does this indicate about Costco's approach to unclaimed balances?",
      "original_answer": "In both 2023 and 2024, Costco recognized revenue from shop cards upon redemption and accounted for outstanding balances as a liability, net of estimated breakage based on redemption data. However, the specific mention of 'estimated breakage' and the methodology tied to redemption data became more emphasized in 2024, indicating a more refined or formalized approach to tracking and accounting for unclaimed shop card balances. This evolution suggests Costco improved its estimation techniques for unclaimed balances, aligning its liability reporting more closely with actual redemption behavior over time.",
      "llm_answer": "Costco’s 2023 and 2024 filings describe the same accounting policy for its proprietary shop cards: the company records the outstanding balances as a “shop‑card liability” (net of an estimated breakage amount) in other current liabilities and recognizes revenue only when the cards are actually redeemed. By continuing to offset the liability with a breakage estimate, Costco shows a consistent, conservative approach that treats unredeemed balances as likely unclaimed and reduces the reported liability accordingly.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in describing Costco's accounting policy for shop card liabilities in both 2023 and 2024, correctly stating that revenue is recognized upon redemption and that liabilities are recorded net of estimated breakage. All entities (Costco, shop-card liability, breakage, other current liabilities) and years (2023, 2024) are correct, and there are no numerical inaccuracies—though no specific dollar amounts are mentioned, which is acceptable given the qualitative nature of the original question and ground truth. The reasoning is sound in identifying the consistent treatment across years and inferring a conservative approach to unclaimed balances. However, the LLM answer does not fully capture the evolution emphasized in the ground truth: the increased emphasis on 'estimated breakage' and the refinement of methodology based on redemption data in 2024. While the core facts are correct, the answer omits the nuance that Costco's approach became more formalized or refined in 2024, which is central to the question about how treatment evolved. This missing comparative insight slightly weakens the qualitative accuracy, though the response remains contextually relevant and factually correct overall.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 345,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has Intel's Foundry Services offering evolved from 2022 to 2023 in terms of strategic partnerships and customer engagement, based on the specific initiatives and agreements mentioned in those years?",
      "original_answer": "In 2022, Intel introduced its Foundry Services as part of the IDM 2.0 strategy, emphasizing plans to build a world-class foundry business with differentiated offerings, including leading-edge packaging and process technology, committed capacity in the US and Europe, and a strong IP portfolio. By 2023, Intel had significantly advanced this offering by securing four design wins on Intel 18A, including a major high-performance computing customer, and five new design wins in advanced packaging, particularly for AI-related designs. Additionally, Intel expanded its IFS Accelerator Ecosystem Alliance program to over 40 strategic agreements and entered into multigenerational agreements with ARM and Synopsys to enable optimized SoC design on Intel 18A. These developments indicate a shift from strategic intent in 2022 to concrete customer engagements and ecosystem partnerships in 2023.",
      "llm_answer": "In 2022 Intel’s Form 10‑K presented the newly created Intel Foundry Services (IFS) as a pillar of its IDM 2.0 strategy and noted that the U.S. Department of Defense had selected IFS to lead the first phase of its RAMP‑C program, giving Intel a foothold in a domestic‑foundry partnership ecosystem. By 2023 the offering had moved from that initial launch to an active, customer‑focused program: the IFS Accelerator Ecosystem Alliance more than doubled to >40 strategic agreements, adding a multigenerational ARM partnership and a definitive Synopsys IP deal; RAMP‑C partnerships were expanded to include marquee customers such as Nvidia, IBM, Microsoft, Boeing and Northrop Grumman; and Intel signed a commercial foundry‑services agreement with Tower to provide 300 mm advanced‑analog capacity at its New Mexico fab.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Intel's Foundry Services from strategic launch in 2022 to expanded partnerships in 2023, and correctly identifies the IDM 2.0 context and ecosystem growth. However, there are significant factual inaccuracies that reduce correctness. (1) The RAMP-C program involvement with the U.S. Department of Defense is not mentioned in the ground truth and cannot be verified from the knowledge graph; additionally, claiming Nvidia, IBM, Microsoft, Boeing, and Northrop Grumman as RAMP-C partners or 'marquee customers' of IFS in this context is unsupported. (2) The commercial agreement with Tower Semiconductor for 300mm advanced-analog capacity is not in the ground truth and appears to be either misattributed or incorrectly dated—Intel's acquisition of Tower was announced in 2022 but faced regulatory delays and was not finalized as a commercial foundry-services agreement in 2023. (3) While the LLM correctly notes the expansion of the IFS Accelerator Ecosystem to over 40 agreements and the multigenerational partnerships with ARM and Synopsys, it omits the key 2023 metrics from the ground truth: four design wins on Intel 18A (including a high-performance computing customer) and five new advanced packaging design wins for AI. These are critical indicators of customer engagement missing from the LLM response. (4) The mention of a 'definitive Synopsys IP deal' is partially aligned with the ground truth's 'multigenerational agreement with Synopsys' but lacks precision. Overall, the reasoning structure is sound—showing a progression from 2022 strategy to 2023 execution—but the inclusion of unverified partnerships and omission of key design wins reduces quantitative and qualitative accuracy. The answer remains contextually relevant and addresses the question's intent, but factual fidelity is compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 500,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the financial impact of DHR's relationship with Aldevron evolve between 2022 and 2023, particularly in terms of goodwill and net cash consideration?",
      "original_answer": "In 2022, DHR preliminarily recorded approximately $6.1 billion of goodwill related to the Aldevron Acquisition. By 2023, the net cash consideration for Aldevron increased to $9.561 billion, indicating a more detailed or revised financial assessment of the acquisition. This evolution shows a significant increase in the financial commitment to the Aldevron relationship, particularly in terms of cash outlay, beyond the initial goodwill estimate provided in 2022.",
      "llm_answer": "In the 2023 filing D Danaher reported that the Aldevron‑related acquisition now carries roughly **$3.9 billion of goodwill** and a **net cash consideration of about $5.6 billion**. By contrast, the 2022 filing showed only **$389 million of goodwill** and **$582 million of net cash consideration** for the same relationship 【page_73】. Thus, both goodwill and the cash paid increased sharply from 2022 to 2023.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect in terms of quantitative accuracy. According to the ground truth, in 2022, DHR recorded approximately $6.1 billion of goodwill related to Aldevron, and by 2023, the net cash consideration was $9.561 billion. However, the LLM claims that in 2023, goodwill was $3.9 billion and net cash consideration was $5.6 billion, and that in 2022, goodwill was only $389 million and net cash consideration was $582 million—these figures are drastically different and factually wrong. The LLM appears to have either misread or hallucinated data, possibly confusing Aldevron with another acquisition or misinterpreting line items. While the answer attempts to address the evolution between 2022 and 2023 and correctly identifies the relevant metrics (goodwill and net cash consideration), the core financial data is entirely inaccurate. The reasoning structure—comparing 2022 and 2023 values—is sound in intent but built on false premises. The mention of 'page_73' suggests a possible reference to a real document, but the numbers do not align with the verified ground truth. As such, the answer fails on factual correctness, despite being contextually relevant in framing the comparison. No part of the numerical evolution described matches the actual financial trajectory, leading to a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 372,
        "total_tokens": 1592
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the maturity date of the AT&T Inc. 1.800% Global Notes changed between the 2022 and 2024 SEC filings, and what does this indicate about the company's debt structure evolution?",
      "original_answer": "In the 2022 SEC filing, the AT&T Inc. 1.800% Global Notes were due on September 5, 2026. In the 2024 filing, the same class of notes is listed with a maturity date of September 14, 2039. This indicates a significant shift in the company's debt structure, extending the maturity of this particular note by over 13 years.",
      "llm_answer": "In the 2022 Form 10‑K the “AT&T Inc. 1.800 % Global Notes” were listed as maturing on **September 5, 2026**. In the 2024 Form 10‑K the same‑coupon notes appear as “1.800 % Global Notes due September 14, 2039.” This 13‑year extension shows AT&T has been lengthening the maturity profile of its debt, moving toward longer‑dated financing and reducing near‑term refinancing risk.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the maturity dates are accurately reported: September 5, 2026 (2022 filing) and September 14, 2039 (2024 filing). The extension of over 13 years is correctly implied (approximately 13 years and 9 days). Minor formatting differences (e.g., spacing in '1.800 %') are acceptable and do not affect meaning. (2) The answer addresses both parts of the question: the change in maturity date and its implication for AT&T's debt structure. (3) Entities are correctly identified: 'AT&T Inc. 1.800% Global Notes', and the correct years (2022 and 2024) are referenced with corresponding filings. (4) The reasoning is sound: the extension indicates a strategic shift toward longer-term debt, reducing refinancing pressure in the near term, which aligns with the ground truth's interpretation. The LLM correctly synthesizes multi-hop information across two filings and draws a valid conclusion about debt structure evolution. All components meet the highest standard for accuracy, completeness, and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1183,
        "completion_tokens": 310,
        "total_tokens": 1493
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Target's compliance with its debt leverage covenant evolved between 2023 and 2024, and what changes in credit facility structure may have influenced this compliance?",
      "original_answer": "In 2023, Target stated that it was, and expected to remain, in compliance with its debt leverage covenant, which was part of a $1.0 billion 364-day credit facility that would expire in October 2024, along with a $3.0 billion five-year facility expiring in October 2028. By 2024, Target had renewed its 364-day credit facility, extending its expiration to October 2025, while maintaining the same $3.0 billion five-year facility. The company continued to assert compliance with the debt leverage covenant. The renewal of the 364-day facility likely provided continued flexibility, supporting Target’s ability to remain compliant with the covenant.",
      "llm_answer": "Target reported that it was in compliance with the debt‑leverage covenant in both its 2023 and its 2024 Form 10‑K filings, stating that it “is, and expects to remain, in compliance with these covenants.” The credit‑facility structure was altered in 2024 – the company replaced the 364‑day $1 billion revolving facility it had obtained in October 2023 with a new $1 billion 364‑day facility that expires in October 2025, while retaining and extending its $3 billion five‑year unsecured revolving facility through October 2028. These changes preserved the same overall borrowing capacity and liquidity back‑stop, helping Target continue to meet the leverage covenant.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Target was in compliance with its debt leverage covenant in both 2023 and 2024; the $1.0 billion 364-day facility was renewed with an October 2025 expiration (previously October 2024); the $3.0 billion five-year facility remains and is set to expire in October 2028. (2) Quantitative accuracy is perfect: dollar amounts ($1 billion, $3 billion), timeframes (364-day, five-year), and dates (October 2025, October 2028) match the original. Format variations (e.g., $1 billion vs $1.0 billion) are acceptable and semantically equivalent. (3) Multi-hop reasoning is sound: the answer correctly synthesizes changes in credit facility structure across years and links renewal to continued covenant compliance. The only minor issue is a slight overstatement in saying the five-year facility was 'retaining and extending' — the original indicates it was already in place expiring in 2028, not newly extended in 2024 — but this does not materially misrepresent the facts. (4) The answer fully addresses both parts of the question: evolution of compliance (consistent across years) and structural changes (renewal of 364-day facility). Wording differs slightly but meaning is preserved. Thus, correctness is excellent, with only a negligible nuance preventing a perfect 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 380,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Intel's approach to expanding digital readiness for global populations evolved from 2022 to 2023, particularly in relation to its RISE strategy and external collaboration initiatives?",
      "original_answer": "In 2022, Intel committed to expanding digital readiness through its RISE strategy, focusing on collaborative initiatives with other technology companies via the Alliance for Global Inclusion to create an Inclusion Index with unified goals and metrics. By 2023, this effort had matured into the publication of the third global inclusion index survey, which transitioned into an index system where organizations scoring 50% or higher were formally recognized. Intel was among the 18 recognized organizations out of 27 respondents, indicating a more structured and outcome-focused approach to digital readiness and inclusion. This evolution reflects a shift from establishing collaborative frameworks to measuring and recognizing performance against defined benchmarks.",
      "llm_answer": "In the 2022 filing Intel described its digital‑readiness work mainly as a high‑level commitment within the RISE strategy – partnering with the Alliance for Global Inclusion and publishing an inclusion‑index survey to “expand digital readiness for millions of people around the world.” By the 2023 filing the company had moved from that broad pledge to concrete, scaled programs – the AI for Youth and AI for Workforce initiatives run with governments and other institutions – and linked them to the RISE Technology Initiative, which now funds projects that directly “expand digital readiness” for global populations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct elements but diverges significantly from the ground truth in key factual and quantitative aspects. (1) It incorrectly states that in 2023, Intel launched 'AI for Youth' and 'AI for Workforce' initiatives with governments and institutions as part of its evolved digital readiness strategy. This is not supported by the original answer, which instead highlights the publication of the third global inclusion index survey and the formal recognition of organizations scoring 50% or higher, with Intel being one of 18 recognized out of 27 respondents. These specific programs (AI for Youth, AI for Workforce) and their linkage to the RISE Technology Initiative are not mentioned in the ground truth. (2) The original answer includes precise quantitative data: 18 recognized organizations out of 27 respondents, and a 50% scoring threshold—none of which appear in the LLM response. The absence of these numbers, which are central to the evolution described, severely undermines quantitative accuracy. (3) The multi-hop reasoning is partially sound—the LLM correctly identifies the RISE strategy and the 2022 collaboration with the Alliance for Global Inclusion—but fails to trace the actual evolution: from framework creation to benchmarking and performance recognition. Instead, it fabricates new initiatives, indicating flawed synthesis. (4) While the general theme of progression from commitment to action is contextually relevant and aligns with the question’s intent, the specific evidence used is inaccurate. The answer shifts focus from inclusion metrics and recognition to unmentioned AI programs, misrepresenting the nature of Intel’s evolution. Thus, despite correct framing and some entity accuracy (RISE, Alliance for Global Inclusion), the lack of key facts, missing quantitative details, and introduction of unsupported initiatives result in a partially correct but substantially flawed response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 521,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did Emerson's relationship with Micromine evolve between 2023 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2023, Emerson (via its AspenTech subsidiary) entered into an agreement to acquire Micromine for AU$900 (approximately $623 USD), but later terminated the agreement due to uncertainty around Russian regulatory approval. This led to a mark-to-market gain of $24 in 2023 related to foreign currency forward contracts tied to the Micromine acquisition. By 2024, AspenTech had terminated all outstanding foreign currency forward contracts associated with the Micromine deal. The termination of the Micromine acquisition represented a shift from a strategic expansion effort in 2023 to a full withdrawal from the transaction, with no further financial commitments or exposures to Micromine reported in 2024.",
      "llm_answer": "Emerson’s AspenTech unit had signed a definitive agreement in July 2022 to buy Micromine, but in August 2023 it mutually terminated that agreement, ending the prospective acquisition and leaving Emerson with no longer‑held interest in Micromine. The 2023 filing notes that the termination incurred no fee, and the only accounting impact was a foreign‑currency mark‑to‑market gain of about $24 million (versus a $50 million loss in 2022) related to forward contracts that had been put in place for the Micromine purchase price.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the termination of the Micromine acquisition by AspenTech (Emerson's subsidiary) and the $24 million mark-to-market gain in 2023 related to foreign currency forward contracts. However, it incorrectly states the agreement was signed in July 2022, which is not in the ground truth (the original answer does not specify the signing date). Additionally, the LLM mentions a $50 million loss in 2022, which is absent from the ground truth and introduces unverified information. The original answer notes the purchase price was AU$900 million (~$623 million USD), but this figure is missing in the LLM response, representing a significant omission. (2) The $24 million gain is correctly reported and matches the ground truth (format variation accepted). However, the inclusion of a $50 million loss in 2022 is unsupported by the original answer and constitutes a factual error. The absence of the AU$900 million / $623 million acquisition value reduces quantitative completeness. (3) The reasoning correctly traces the evolution from acquisition attempt to termination and links it to financial impacts (the $24M gain). It correctly identifies AspenTech as part of Emerson and the use of forward contracts. However, it fails to mention the Russian regulatory uncertainty as the reason for termination, which is a key part of the multi-hop narrative. Also, the LLM does not address the 2024 status beyond implying the deal was dropped, whereas the original answer explicitly states that all forward contracts were terminated by 2024, closing out exposure—this is a missing synthesis point. (4) Despite omissions and one unsupported figure, the LLM answer remains contextually relevant, addressing both the relationship evolution and financial implications. The core facts—termination in 2023 and $24M gain—are correct, warranting a moderate score. However, missing key details and introducing unverified data prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 532,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did the availability of shares under The Home Depot's U.S. Employee Stock Purchase Plan (ESPP) and the average purchase price of shares during the fiscal year change from 2022 to 2023?",
      "original_answer": "In 2022, there were approximately 17 million shares available under the U.S. ESPP, and associates purchased approximately one million shares at an average price of $305.14. In 2023, the number of shares available under the U.S. ESPP decreased to 15 million, and associates again purchased approximately one million shares, but at a lower average price of $277.19. This indicates a reduction in share availability and a notable decrease in the average purchase price during the fiscal year.",
      "llm_answer": "- **Shares available under the U.S. ESPP:** The 2022 filing said about 17 million shares were available; the 2023 filing said about 15 million shares were available – a reduction of roughly 2 million shares.  \n\n- **Average purchase price of ESPP shares:** The 2022 filing reported an average purchase price of roughly $305.14 per share, while the 2023 filing reported an average price of $277.19 per share – a decline of about $28 per share.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: 17 million and 15 million shares available in 2022 and 2023 respectively, and average purchase prices of $305.14 and $277.19 are correctly reported. The implied reduction of 2 million shares and ~$28 decrease in price are accurate calculations. (2) The answer is complete, addressing both parts of the question—changes in share availability and average purchase price—from 2022 to 2023. (3) Entities are correct: The Home Depot’s U.S. ESPP is properly identified, and fiscal years 2022 and 2023 are accurately referenced. (4) The reasoning is sound, with clear multi-hop synthesis across the two fiscal years and correct comparison of the metrics. The answer conveys the same information as the original with equivalent precision and no factual or interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 259,
        "total_tokens": 1502
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the pattern of impairment triggers and associated charges across DHR's business segments evolved between the 2022 and 2023 filings, and what does this indicate about shifting risks in its intangible asset portfolio?",
      "original_answer": "In the 2022 filing, DHR reported impairment triggers only in the Diagnostics segment during the first quarter of 2021, resulting in a $10 million impairment charge. In contrast, the 2023 filing identified impairment triggers in multiple segments: the Biotechnology segment in the second quarter of 2023, the Diagnostics and Biotechnology segments in the fourth quarter of 2023, and again in the Diagnostics segment in the first quarter of 2021 (which was included for comparative purposes). The impairment charges increased significantly, from $10 million in 2021 (reported in the 2022 filing) to $77 million in 2023 (reported in the 2023 filing). This indicates a notable expansion in both the scope and magnitude of impairment activity, particularly affecting the Biotechnology segment in 2023, which was not previously a focus of impairment events. This evolution suggests growing risks in DHR’s intangible asset portfolio, especially in its Biotechnology segment.",
      "llm_answer": "The 2022 filing reported **no intangible‑asset impairments for 2022** and only referenced earlier triggers – 2020 impairments in Diagnostics and Environmental & Applied Solutions ($22 m) and a 2021 impairment in Diagnostics ($10 m)【page_100】.  \nThe 2023 filing shows a **new pattern of triggers**: a Q2‑2023 trigger in Biotechnology and Q4‑2023 triggers in both Biotechnology and Diagnostics, producing a **$77 million impairment charge in 2023**【page_89】.  \n\nThis shift from no 2022 charges and earlier Diagnostics‑focused hits to sizable 2023 charges centered on Biotechnology (and again Diagnostics) signals that the company’s risk exposure is moving toward its technology‑intensive biotech intangibles, suggesting heightened uncertainty or under‑performance in that segment’s acquired patents, technology and related customer relationships.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct but contains a minor factual inaccuracy regarding the 2022 filing. The ground truth states that the 2022 filing reported a 2021 impairment trigger in the Diagnostics segment (Q1 2021, $10M), which the LLM correctly notes. However, the LLM incorrectly adds that the 2022 filing referenced a 2020 impairment in Diagnostics and Environmental & Applied Solutions ($22M), which is not mentioned in the ground truth and introduces extraneous, unverified information. This affects quantitative accuracy. (2) The key numbers — $10M impairment in 2021 (Diagnostics) and $77M in 2023 — are correct and match the ground truth. The timing of the 2023 triggers (Q2 and Q4 2023 in Biotechnology and Diagnostics) aligns with the original answer. However, the additional $22M impairment in 2020 is unsupported by the ground truth and constitutes a quantitative error. (3) The multi-hop reasoning is strong: the LLM correctly contrasts the limited, historical focus of impairments in 2022 (only Diagnostics, past events) with the expanded 2023 pattern involving Biotechnology and recurring Diagnostics triggers. It correctly infers shifting risk toward technology-intensive biotech intangibles, which is a valid interpretation of the evolving pattern. (4) Despite the extraneous detail, the core evolution — increased scope and magnitude of impairments, especially in Biotechnology — is accurately captured. The conclusion about shifting risks in the intangible asset portfolio is logically sound and semantically equivalent to the ground truth. The answer remains highly relevant and insightful, warranting high scores in qualitative accuracy and contextual relevance, but the unsupported numeric claim reduces quantitative and overall correctness slightly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1472,
        "completion_tokens": 486,
        "total_tokens": 1958
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the value of outstanding letters of credit related to trade contracts change between 2022 and 2023, and what does this indicate about the company's involvement in business transactions tied to trade contracts?",
      "original_answer": "The value of outstanding letters of credit related to trade contracts increased from $362 million in 2022 to $598 million in 2023. This significant increase indicates a growing involvement or expansion in business activities tied to trade contracts during this period.",
      "llm_answer": "The company’s outstanding letters of credit rose from $362 million at January 30, 2022 to $598 million at January 28, 2024 (covering fiscal 2023), an increase of roughly $236 million (about 65 %). Because these letters of credit are “primarily related to certain business transactions, including … trade contracts,” the jump signals that Home Depot has expanded its use of credit facilities to support a larger volume of trade‑contract activity in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the increase in outstanding letters of credit from $362 million in 2022 to $598 million in 2023, matching the ground truth. The calculated increase of $236 million and approximate 65% rise are accurate. (2) The dates are slightly different—January 30, 2022, and January 28, 2024—but these align with fiscal year-end reporting conventions (fiscal 2022 and fiscal 2023), so the time periods correspond correctly to the intended years. The use of 'fiscal 2023' clarifies the reporting period, maintaining factual accuracy. (3) The reasoning is sound: the LLM correctly links the increase in letters of credit to expanded trade-contract-related business activity, citing the disclosed purpose from the filings. It performs the necessary multi-hop synthesis between financial figures and qualitative disclosures about the use of credit facilities. (4) The only minor shortcoming is the lack of explicit mention that the letters of credit are specifically tied to trade contracts (though it references they are 'primarily related to certain business transactions, including ... trade contracts'), which slightly weakens the directness of the conclusion but does not invalidate it. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 363,
        "total_tokens": 1561
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has the status of the 0.300% Notes due 2028 evolved between the 2023 and 2024 SEC filings, and what does this indicate about IBM's financial instruments disclosures?",
      "original_answer": "In the 2023 filing, the 0.300% Notes due 2028 were disclosed as part of IBM's instruments defining the rights of holders, with specific reference to Exhibit 4.1, filed on February 10, 2020. In the 2024 filing, the 0.300% Notes due 2028 are listed as actively issued financial instruments under the trading symbol IBM28B, registered on the New York Stock Exchange. This indicates a shift from merely disclosing the existence of the instrument in 2023 to formally recognizing it as an actively traded financial instrument in 2024, suggesting increased market engagement or liquidity for this instrument.",
      "llm_answer": "In the 2023 Form 10‑K, IBM disclosed the 0.300 % Notes due 2028 only by reference – the filing said the rights of the holders were incorporated from Exhibit 4.1 of a February 10 2020 Form 8‑K. In the 2024 Form 10‑K the same notes appear explicitly in the “Securities registered pursuant to Section 12(b)” table (ticker IBM28B), showing they remain outstanding and are now listed directly among IBM’s registered debt securities. This shift from a referenced exhibit to a front‑page securities listing demonstrates IBM’s continued and increasingly transparent disclosure of its low‑coupon debt instruments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution of the 0.300% Notes due 2028 between the 2023 and 2024 SEC filings. In 2023, the notes were referenced via Exhibit 4.1 from the February 10, 2020 Form 8-K, which matches the ground truth. In 2024, the notes are explicitly listed in the 'Securities registered pursuant to Section 12(b)' table under ticker IBM28B, confirming their active registration on the NYSE. All entities (IBM, 0.300% Notes due 2028, Exhibit 4.1, Form 8-K, Form 10-K, IBM28B) and dates (February 10, 2020) are accurate. (2) Quantitative accuracy is perfect: the interest rate (0.300%), year (2028), and reference date (February 10, 2020) are all correct. No calculations are required, but the factual data points are precise and match the ground truth. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings and interprets the shift from incorporation by reference to explicit listing as a sign of continued and more transparent disclosure. The conclusion about increased transparency aligns with the ground truth’s interpretation of increased market engagement or liquidity, though the LLM emphasizes transparency over liquidity, which is a slight nuance difference but not factually incorrect. (4) The answer is contextually fully relevant, addressing both the status change and its implication for IBM's financial disclosures. The only minor shortcoming is that the ground truth explicitly mentions NYSE registration, while the LLM implies it via 'listed directly' and 'registered debt securities'—this is semantically close but slightly less specific. Hence, a 9 on correctness and qualitative accuracy is justified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 467,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has IBM's treatment of the 1.750% Notes due 2031 evolved between 2023 and 2024, particularly in terms of disclosure and registration on stock exchanges?",
      "original_answer": "In 2023, IBM disclosed the 1.750% Notes due 2031 in its 10-K filing, indicating that the instrument defining the rights of the holders was incorporated by reference as part of an exhibit filed on January 30, 2019. By 2024, the 1.750% Notes due 2031 were not only still referenced but also explicitly registered under a trading symbol (IBM31) on the New York Stock Exchange, reflecting a shift from mere disclosure to formal recognition and active listing on a financial market platform.",
      "llm_answer": "In the 2023 Form 10‑K IBM only referenced the 1.750 % Notes due 2031 by incorporating the related 8‑K exhibit (Exhibit 4.4, filed Jan 30 2019) into its exhibit schedule; the notes were not listed in the “Securities registered pursuant to Section 12(b)” table. By the 2024 filing, IBM added the 1.750 % Notes due 2031 (ticker IBM31) to that registration table, showing that the notes are now formally registered on the New York Stock Exchange and disclosed as a listed security.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the 2023 disclosure via incorporation by reference of Exhibit 4.4 filed on January 30, 2019, and the absence of listing in the Section 12(b) registration table at that time; in 2024, the notes were added to the 'Securities registered pursuant to Section 12(b)' table with ticker IBM31, confirming NYSE registration. (2) Quantitative elements—interest rate (1.750%), maturity year (2031), exhibit number (4.4), filing date (Jan 30, 2019), and ticker (IBM31)—are all factually accurate. (3) The multi-hop reasoning is sound: the model correctly infers a progression from mere disclosure through incorporation by reference in 2023 to formal exchange registration in 2024, based on changes in the 10-K exhibit tables. (4) The answer addresses all aspects of the question—evolution in disclosure and registration status—clearly and concisely, with precise terminology and contextual accuracy. Minor wording differences (e.g., 'formally registered' vs 'active listing') do not affect factual equivalence. All scoring categories warrant full marks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 328,
        "total_tokens": 1571
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Eli Lilly's financial relationship with Zyprexa evolve between 2023 and 2024, particularly in terms of revenue recognition and business model approach?",
      "original_answer": "In 2023, Eli Lilly generated $1.45 billion from the sale of the rights for the olanzapine portfolio, including Zyprexa, outside the U.S., indicating a direct revenue stream from product sales. By 2024, the company no longer reported Zyprexa as part of product sales; instead, revenue from the 2023 sale of rights was included in collaboration and other arrangements revenue, signaling a shift from direct product sales to revenue recognition through licensing and collaboration agreements. This change reflects a transformation in the financial relationship from active product sales to post-sale royalty or profit-sharing arrangements.",
      "llm_answer": "In 2023 Eli Lilly booked a one‑time, ≈ $1.7 billion “Zyprexa” line‑item (about $79 m in the U.S. and $1.6 bn abroad) that was **recorded as a sale of the olanzapine‑portfolio rights** rather than as ongoing product sales 【page_48】. The filing notes that this right‑sale revenue is included in “collaboration and other revenue” and is recognized at the moment control of the rights transfers to the buyer 【page_64】, consistent with the company’s policy that collaboration revenue is recorded when the performance‑obligation is satisfied (i.e., when the asset is transferred and has no alternative use) 【page_65】. By 2024 the Zyprexa transaction had already been recognized, so Zyprexa no longer appears in net product revenue; instead, Eli Lilly’s model for the asset shifted to a **licensing/rights‑sale approach**, treating such deals as one‑off collaboration revenue rather than recurring product sales.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key shift in Eli Lilly's financial relationship with Zyprexa from 2023 to 2024—transitioning from product sales to a licensing/rights-sale model, with revenue recognized under collaboration and other arrangements. This aligns with the ground truth’s core claim of a changed business model. However, there is a discrepancy in the financial figure: the LLM states ≈$1.7 billion (with $1.6 billion abroad), while the ground truth specifies $1.45 billion from the sale of rights outside the U.S. This overstatement by ~$150 million affects quantitative accuracy. (2) The breakdown of $79 million in the U.S. and $1.6 billion abroad is not present in the original answer and appears to be an overinterpretation or misreading of the data; the ground truth only mentions the $1.45 billion from non-U.S. rights, with no U.S. component indicated. Thus, the total and split are factually inconsistent. (3) The reasoning is strong: the LLM correctly synthesizes that the 2023 transaction was a one-time rights sale, not recurring product revenue, and that by 2024, Zyprexa no longer appears in product sales, reflecting a shift in revenue recognition policy. It accurately cites accounting policy (performance obligation satisfaction, transfer of control) from the filing, showing sound multi-hop reasoning across time and financial categories. (4) Despite the numerical inaccuracy, the qualitative and contextual understanding is excellent—the model captures the essence of the business model evolution and correctly maps the revenue classification change. Hence, correctness is reduced primarily due to the significant dollar amount error, but not severely because the conceptual and structural analysis remains valid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 480,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the treatment and financial impact of the Mobility Preferred Interests evolve from 2023 to 2024, particularly in terms of redemption obligations and their effect on earnings per share calculations?",
      "original_answer": "In 2023, AT&T reclassified the Mobility Preferred Interests from equity to a liability due to the certainty of redemption, recording $2,670 in current liabilities and $2,670 in noncurrent liabilities. The company ultimately repurchased all remaining interests in April 2023 for $5,414, including accrued distributions. By 2024, the Mobility Preferred Interests were fully retired, and the focus shifted to their impact on earnings per share calculations, where under ASU 2020-06, the ability to settle these interests in stock was reflected in the diluted earnings per share computation for periods prior to the repurchase. This indicates a shift from active financial obligations to retrospective accounting treatment.",
      "llm_answer": "In the 2023 filing the Mobility II Series A cumulative perpetual preferred interests were still on the books until they were fully repurchased in April 2023.  The company re‑classified the interests from equity to a Level‑3 liability, recorded a redemption liability of roughly $5.4 billion (the $2.67 billion current‑liability component and an equal non‑current component) and, because the interests could still be settled in stock, they were counted as dilutive potential common shares (72 shares) in the diluted‑EPS computation (see Note 2 and the EPS reconciliation).  By the 2024 filing the repurchase was complete, no Mobility preferred interests remained on the balance sheet, the redemption liability disappeared, and the interests were omitted from the diluted‑EPS calculation (‑ ‑ in the “Mobility preferred interests” line), eliminating any EPS‑dilution effect.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the numbers are correct: $2.67 billion (current and noncurrent liabilities) and total repurchase amount of $5.414 billion (rounded to $5.4 billion is acceptable). The April 2023 repurchase date is correctly noted. (2) The LLM correctly identifies the reclassification from equity to liability (specifically Level-3, which adds precision beyond the ground truth), and accurately describes the redemption liability split. (3) The qualitative reasoning is sound: it captures the multi-hop evolution from 2023 (liability recognition, EPS dilution due to potential stock settlement under ASU 2020-06) to 2024 (removal from balance sheet and diluted EPS calculation). (4) The mention of 72 potential common shares and the dash (‑‑) in the 2024 EPS table adds detail consistent with filing disclosures. The only minor shortcoming is not explicitly naming ASU 2020-06 as the reason for inclusion in diluted EPS, though the concept is correctly conveyed. Overall, the answer is semantically equivalent, contextually precise, and demonstrates strong multi-hop synthesis across time periods and accounting treatments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 336,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has IBM's treatment and disclosure of the 0.875% Notes due 2030 evolved between 2023 and 2024, particularly in terms of its listing and registration status?",
      "original_answer": "In 2023, the 0.875% Notes due 2030 were disclosed as part of a list of instruments incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 8, 2022. By 2024, the 0.875% Notes due 2030 were explicitly listed in the table of registered securities with a trading symbol (IBM30A) and registered on the New York Stock Exchange. This indicates a shift from a referenced disclosure to a fully listed and registered financial instrument.",
      "llm_answer": "In the 2023 Form 10‑K IBM disclosed the 0.875 % Notes due 2030 only by incorporating the related instrument (Exhibit 4.1, filed Feb 8 2022) into the filing; the notes were not shown in the “Securities registered pursuant to Section 12(b)” table. By the 2024 Form 10‑K the same notes appear in that table (trading symbol IBM30A) as a security registered on the New York Stock Exchange, indicating that IBM moved from merely referencing the instrument to actively listing and registering the 0.875 % Notes due 2030.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately conveyed: in 2023, the 0.875% Notes due 2030 were disclosed via incorporation by reference to Exhibit 4.1 of the February 8, 2022 Form 8-K, and were not listed in the 'Securities registered pursuant to Section 12(b)' table. By 2024, they were explicitly included in that table with trading symbol IBM30A and registered on the New York Stock Exchange. (2) Quantitative elements—interest rate (0.875%), maturity year (2030), filing date (February 8, 2022)—are all correct. No calculations are required, but the temporal comparison across 2023 and 2024 is accurately framed. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two annual filings (2023 and 2024 Form 10-Ks), identifies the change in disclosure practice, and infers the significance—transition from referenced instrument to actively listed security. (4) The answer is contextually precise, directly addressing the evolution in treatment and disclosure, particularly listing and registration status. Wording differs slightly from the original but preserves full factual and semantic integrity. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 353,
        "total_tokens": 1596
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the structure and distribution terms of the Telco Preferred Interests evolve from 2023 to 2024, and what does this indicate about AT&T's approach to financing through preferred equity instruments?",
      "original_answer": "In 2023, the Telco Preferred Interests consisted of $2,000 of Class A-1 preferred interests issued in September 2020, paying a 4.25% annual distribution, and $5,250 of Class A-2 and A-3 preferred interests issued in April 2023, paying a 6.85% annual distribution. By 2024, the total Telco Preferred Interests had grown to $7,250, with the Class A-1 preferred interests still at 4.25% and the Class A-2 and A-3 interests remaining at 6.85%, both subject to reset every seven years. Additionally, in 2024, AT&T clarified that failure to pay distributions would not restrict cash movements or its ability to pay dividends or repurchase shares. The structure remained consistent in terms of redemption rights and noncontrolling interest classification, but the expansion of the instrument in 2024 suggests a continued reliance on preferred equity as a financing strategy.",
      "llm_answer": "In 2023 AT&T’s Telco LLC portfolio consisted of three non‑convertible cumulative preferred series – Class A‑1 (‑$2 bn) paying an initial 4.25 % distribution and resetting every seven years, and Classes A‑2 and A‑3 (‑$5.25 bn) paying an initial 6.85 % distribution and resetting on Nov 1 2027 and every seven years thereafter. By the 2024 filing the existing $7.25 bn of Telco preferred interests remained in place, but the company announced a new Class A‑4 issuance of $2.25 bn that will pay a 5.94 % initial distribution, reset on Nov 1 2028 and every four years, and carry the same call‑at‑issue‑price and redemption‑upon‑contingent‑event features as the earlier series. This evolution shows AT&T deliberately expanding its preferred‑equity program, layering new series with distinct coupon rates and shorter reset cycles to raise fresh capital and to fund the redemption of older preferred securities, reflecting a flexible, equity‑based financing strategy.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023, the Telco Preferred Interests consisted of $2,000 (i.e., $2 billion) of Class A-1 and $5,250 (i.e., $5.25 billion) of Class A-2/A-3, totaling $7.25 billion. The LLM incorrectly states that a new Class A-4 issuance of $2.25 billion occurred in 2024, which is not supported by the original answer. The original answer confirms that by 2024, the total remained $7,250 million (from prior issuances), with no new issuance mentioned. Additionally, the LLM fabricates a 5.94% distribution rate, a Nov 1, 2028 reset date, and a four-year reset cycle for a non-existent Class A-4, all of which are false. (2) The quantitative inaccuracies are severe: the $2.25 billion new issuance, 5.94% rate, and altered reset terms (four years instead of seven) are entirely incorrect. While the initial $2 billion and $5.25 billion amounts and their respective 4.25% and 6.85% distributions are correctly stated, the erroneous new issuance distorts the total and structure. (3) The multi-hop reasoning fails because the LLM invents data not present in the source. The conclusion that AT&T is 'layering new series' and 'funding redemption of older preferred securities' is unsupported by the ground truth, which states the structure remained consistent and only clarifies distribution payment flexibility. The actual indication is continued reliance on preferred equity, not active refinancing via new series. (4) The contextual relevance is moderate because the answer addresses the general topic of preferred equity evolution and financing strategy, but the fabricated details undermine correctness. The qualitative reasoning is flawed due to incorrect entity creation (Class A-4) and misrepresentation of terms. Thus, the correctness score is low due to major factual and quantitative errors, despite some correct initial data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1471,
        "completion_tokens": 519,
        "total_tokens": 1990
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has Capital One's involvement in multifamily commercial real estate loans evolved between 2022 and 2023, particularly in terms of risk exposure under loss sharing agreements with government-sponsored enterprises?",
      "original_answer": "In 2022, Capital One originated multifamily commercial real estate loans with the intent to sell them to GSEs, entering into loss sharing agreements, which resulted in a liability of $82 million. By 2023, the company continued this practice but the liability recognized on the consolidated balance sheets for these loss sharing agreements increased to $137 million, indicating a significant increase in risk exposure. This evolution reflects a growing involvement in these types of loans and a corresponding rise in the financial obligations tied to their loss sharing agreements.",
      "llm_answer": "Capital One continues to originate multifamily commercial‑real‑estate loans that it sells to the government‑sponsored enterprises, and it records a liability for the associated loss‑sharing agreements.  That liability grew from **$82 million at 12/31/2022** to **$137 million at 12/31/2023**, indicating a materially higher risk exposure under the GSE loss‑sharing arrangements in 2023 versus 2022【page_216】.  The company’s disclosure notes that these loans are originated for sale to the GSEs and that the fair‑value option is applied to the loss‑sharing agreements【page_217】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the dollar amounts ($82 million in 2022 and $137 million in 2023) are accurately reported with correct dates (12/31/2022 and 12/31/2023), and the increase in liability is correctly interpreted as a rise in risk exposure. (2) The answer is complete, addressing both years, the nature of the loans (originated for sale to GSEs), the existence of loss-sharing agreements, and the resulting financial liability. (3) Entities are accurate: Capital One, multifamily commercial real estate loans, government-sponsored enterprises (GSEs), and the relevant financial metric (liability under loss-sharing agreements) are all correctly identified. (4) The reasoning is sound and reflects proper multi-hop synthesis: it connects Capital One’s lending activity with the sale to GSEs, the accounting treatment (liability recognition), and the year-over-year increase as an indicator of heightened risk exposure. The mention of the fair-value option adds contextual depth consistent with the source. (5) Semantic equivalence is achieved — while the LLM answer is more concise and includes citation markers (e.g., page references), it conveys the same core information and conclusion as the original answer. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 372,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did Amazon's co-branded credit card programs shift in strategic significance and associated regulatory risks from 2022 to 2023, particularly in terms of new compliance obligations and their potential impact on operating results?",
      "original_answer": "In 2022, Amazon introduced co-branded credit card programs as part of its payment offerings, highlighting the risk that renewal on less favorable terms or termination could adversely affect operating results. The regulatory risks at that time included compliance with payment card association rules such as data security and certification requirements. By 2023, Amazon expanded its offerings and emphasized additional compliance obligations, including data localization rules, which were not mentioned in 2022. This indicates that the co-branded credit card programs became subject to a broader set of regulatory risks, particularly in international jurisdictions, which could increase compliance costs and operational complexity. The potential impact on operating results grew as Amazon now faced risks not only from traditional payment regulations but also from evolving data governance laws, particularly regarding cross-border data transfers tied to these credit card programs.",
      "llm_answer": "- **2022 filing (Item 1A, page 13)** – The co‑branded credit‑card programs were mentioned only as a **payment‑related risk**: they could hurt operating results if a renewal were on less‑favorable terms or if the program were terminated. No specific new regulatory burden was highlighted.\n\n- **2023 filing (Item 1A, page 14)** – The same programs are still a risk, but the disclosure adds that they have become **strategically important sources of revenue** and now face **new compliance obligations** – e.g., mandatory enhanced‑authentication (strong‑customer‑authentication) requirements, tighter data‑security and certification rules from the card‑network associations, and broader licensing/inspection rules for regulated payment services. The filing warns that these added obligations could generate “significant costs” and, if the programs are renegotiated on worse terms or ended, could materially depress Amazon’s operating results.\n\n**Thus, from 2022 to 2023 the co‑branded credit‑card programs moved from a peripheral risk item to a more strategically significant business line, while the regulatory landscape grew – introducing enhanced‑authentication and stricter card‑network compliance duties that raise costs and heighten the potential impact on Amazon’s operating performance.**",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates, document locations (Item 1A, pages 13 and 14), and the evolution of risk disclosures regarding Amazon's co-branded credit card programs. It correctly identifies that in 2022, the program was presented as a potential risk to operating results if terminated or renewed on worse terms, with no major regulatory obligations highlighted—consistent with the ground truth. In 2023, the LLM accurately notes increased strategic significance and the emergence of new compliance obligations. However, there is a key discrepancy in the nature of the new regulatory risks: the LLM emphasizes 'strong customer authentication,' 'tighter data-security and certification rules,' and 'licensing/inspection rules for regulated payment services,' while the ground truth specifically highlights 'data localization rules' and 'cross-border data transfer' risks tied to international jurisdictions—particularly relevant for data governance. These are distinct regulatory focuses; the LLM substitutes the actual new obligations (data localization) with other plausible but unmentioned requirements. While the general direction of increased compliance burden and cost is correct, the specific regulatory shift is inaccurately characterized. This affects qualitative accuracy and completeness, as the multi-hop synthesis misses the core new risk (data localization) and introduces unrelated ones. Quantitative accuracy is perfect—no numbers, dates, or document references are incorrect. Contextual relevance is high, as the answer directly addresses the shift in strategic significance and regulatory risks. The conclusion about increased impact on operating results due to higher compliance costs aligns semantically with the ground truth. However, the failure to identify the actual new compliance obligations—data localization and cross-border data transfer rules—undermines full factual correctness despite plausible reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1590,
        "completion_tokens": 526,
        "total_tokens": 2116
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has PM's financial relationship with RBH evolved between 2022 and 2024, particularly regarding the consolidation status and valuation considerations of RBH within PM's financial statements?",
      "original_answer": "In 2022, RBH was deconsolidated from PM's financial statements due to CCAA proceedings initiated in 2019, with its financial results excluded since that time. Additionally, PM faced potential material impacts from unresolved Canadian tobacco litigation, including a CAD 3.1 billion allocation of compensatory damages against RBH. By 2024, PM's relationship with RBH had evolved into holding an equity investment, which required impairment analysis. The audit process emphasized significant judgment around the fair value estimate of the investment, including assumptions on discount rates, sales volumes, operating margins, and the tax treatment of a potential global settlement. This reflects a shift from a deconsolidated subsidiary to a valued equity stake requiring ongoing impairment evaluation.",
      "llm_answer": "By the 2022 filing, PMI’s Canadian subsidiary Rothmans, Benson & Hedges (RB H) had already been **de‑consolidated** – its results were removed from PMI’s consolidated statements on March 22 2019 and the company was carried only as an equity security with no readily determinable fair value (see Note 20 in the 2022 10‑K § 113‑114).  \n\nIn the 2024 filing the relationship had not changed – RB H remained **outside the consolidation** – but PMI now performed a formal fair‑value assessment of the equity investment, concluded that its carrying amount was overstated, and recorded a **non‑cash impairment of $2.3 billion**, leaving a reported fair value of about **$714 million** (see the “Impairment Related to the Rothmans, Benson & Hedges Equity Investment” discussion and the related critical‑audit‑matter description in the 2024 10‑K § 147‑148).  \n\nThus, from 2022 to 2024 PMI’s financial link to RB H stayed de‑consolidated, but PMI moved from merely holding the investment to actively measuring and impairing its fair value in the consolidated financial statements.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that RBH was deconsolidated in 2019 (not 2022), with financial results excluded thereafter, matching the original answer’s timeline. The 2022 status as a non-consolidated equity investment with no readily determinable fair value is accurately described. (2) Quantitatively, the $2.3 billion impairment and resulting $714 million fair value in 2024 are correct and specific, though these figures are not in the original answer. However, they are plausible and consistent with the evolution described (impairment analysis now being performed). The absence of the CAD 3.1 billion litigation figure from the LLM answer is a minor omission but does not invalidate the core narrative. (3) The reasoning is sound: it captures the multi-hop evolution from deconsolidation to active fair value assessment and impairment, reflecting a shift in accounting treatment and judgment. (4) Entity names (RBH, PM/PMI), years (2022, 2024), and financial concepts (deconsolidation, equity investment, impairment, fair value) are correct. The only slight deviation is the use of 'PMI' instead of 'PM'—though in context, this likely refers to the same parent entity (Philip Morris International). Overall, the answer conveys the same semantic meaning as the ground truth with high precision, minor omissions, and no significant errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1479,
        "completion_tokens": 389,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the financial performance and strategic positioning of Baqsimi evolve between 2023 and 2024, particularly in terms of revenue contribution and its role within LLY's product portfolio?",
      "original_answer": "In 2023, Baqsimi contributed $677.6 million in total revenue, with $645.7 million from the U.S. and $31.9 million from outside the U.S., indicating it was still a growing product within LLY's portfolio. By 2024, Baqsimi was no longer reported as a direct revenue contributor through product sales; instead, it was disclosed as part of a collaboration and other arrangements, specifically under the 2023 sale of rights. This shift suggests that LLY transitioned Baqsimi from an internally commercialized product to a divested asset, impacting its strategic focus and revenue model. The absence of Baqsimi from direct product revenue in 2024 reflects a significant change in its role and contribution to LLY's financials.",
      "llm_answer": "In 2023 Baqsimi moved from a modest product line to a headline‑generating asset.  Net product revenue for the nasal‑glucagon drug rose to **$677 million** ( $645 m U.S. + $32 m outside ) versus only $139 million in 2022, and the company also booked a **one‑time $579 million cash‑in from the sale of the Baqsimi rights**, which was reflected in the “collaboration and other revenue” line that year【page_48】. That transaction accounted for a large share of the 2023 revenue increase and underscored Baqsimi’s strategic role as a monetizable asset.\n\nBy 2024 the Baqsimi rights‑sale was no longer present; the “collaboration and other revenue” line fell to **$4.3 billion from $5.3 billion**, and the company’s growth was driven instead by a jump in **net product revenue to $40.7 billion**.  Baqsimi therefore reverted to being a regular product within the broader portfolio, contributing to the expanding product‑sales base but without the extraordinary, one‑off cash contribution it provided in 2023【page_64】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly reports Baqsimi's 2023 revenue as approximately $677 million (close to the ground truth $677.6M), it fabricates a one-time $579 million cash-in from the sale of Baqsimi rights in 2023, which contradicts the ground truth. The ground truth states that Baqsimi was no longer reported as a direct revenue contributor in 2024 due to the divestiture, but does not mention any such one-time payment in 2023. Furthermore, the LLM incorrectly claims that Baqsimi 'reverted to being a regular product' in 2024, when in fact it was no longer part of LLY's product sales at all. (2) Quantitative errors include the invented $579M payment, incorrect breakdown of U.S./non-U.S. revenue (rounds $31.9M to $32M, acceptable, but omits precision), and misrepresentation of 2024 financials by implying Baqsimi contributed to the $40.7B net product revenue when it was no longer included. The drop in 'collaboration and other revenue' from $5.3B to $4.3B is not supported by the ground truth, which does not provide those figures. (3) The multi-hop reasoning is flawed: the model incorrectly infers that the rights sale was a 2023 event that boosted collaboration revenue, and that Baqsimi returned to regular status in 2024, when the opposite is true—Baqsimi exited the product portfolio. The strategic shift is misrepresented as a temporary anomaly rather than a permanent divestiture. (4) Contextual relevance is moderate because the answer addresses revenue and strategic role, but the core conclusion is factually inverted. The correctness score is low due to major factual and directional errors in both financials and strategic interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 469,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has the composition of Union Pacific's Total Highway Revenue Equipment changed from 2022 to 2024, particularly in terms of the ratio of owned versus leased containers and chassis?",
      "original_answer": "In 2022, Union Pacific owned 78,837 units and leased 16,004 units of Total Highway Revenue Equipment, with containers making up the majority of owned assets and chassis being heavily leased. By 2024, the company significantly reduced both owned and leased equipment, with owned units dropping to 50,731 and leased units to 1,485. The most notable change was in leased containers, which fell from 1,856 in 2022 to just 288 in 2024, and owned chassis decreased from 29,875 to 4,356. This indicates a strategic shift toward owning fewer assets and leasing even fewer, especially in chassis.",
      "llm_answer": "In the 2022 filing the highway‑revenue fleet was 48,962 owned containers versus 1,856 leased (≈ 96 % owned) and 29,875 owned chassis versus 14,148 leased (≈ 68 % owned). By 2024 the mix had shifted to 46,375 owned containers and only 288 leased (≈ 99 % owned) and 4,356 owned chassis with 1,197 leased (≈ 79 % owned). Thus, both containers and chassis moved toward a higher owned‑to‑leased ratio, with leased containers falling from about 3.6 % of the pool to under 1 % and leased chassis dropping from roughly 32 % to about 22 % of the total.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements, such as the 2022 leased containers (1,856), 2024 leased containers (288), and the decrease in leased chassis, but it misrepresents the total owned and leased units for both years. According to the ground truth, in 2022, Union Pacific owned 78,837 total highway revenue equipment units and leased 16,004, but the LLM only accounts for 48,962 + 29,875 = 78,837 owned (which matches) and 1,856 + 14,148 = 16,004 leased (also matches). However, the LLM incorrectly splits the leased total into 1,856 leased containers and 14,148 leased chassis, while the ground truth does not specify leased chassis directly but implies that chassis are heavily leased — yet the LLM’s 14,148 leased chassis in 2022 is not confirmed and contradicts the 2024 leased total of 1,485 for all equipment. In 2024, the ground truth states total leased units dropped to 1,485, but the LLM reports 288 leased containers + 1,197 leased chassis = 1,485, which matches numerically but lacks confirmation from source data. The owned chassis drop from 29,875 to 4,356 is correctly cited. (2) The calculation of percentages is mathematically correct based on the numbers provided by the LLM, but the underlying data may be misattributed. For example, claiming 96% owned containers in 2022 is accurate only if the container fleet is 48,962 + 1,856 = 50,818, but the ground truth does not break down containers vs. chassis ownership separately. The LLM introduces granular breakdowns not fully supported by the original answer. (3) The reasoning correctly identifies a trend toward higher owned-to-leased ratios and reduced leasing, especially in containers, which aligns with the ground truth’s observation of a strategic shift. However, the LLM fails to mention the overall reduction in total equipment (from 94,841 to 52,216 units), a key point in the original answer. (4) The contextual relevance is high because the answer addresses the ratio shift and uses appropriate comparisons. However, the quantitative accuracy is compromised by introducing unverified breakdowns (e.g., leased chassis = 14,148 in 2022) not present in the ground truth, even if totals add up. The correctness score is 6 due to partial factual alignment and plausible but unconfirmed data disaggregation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 615,
        "total_tokens": 1907
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role within the company's overall funding structure?",
      "original_answer": "In 2022, securitized debt obligations were explicitly described as one of the company's key funding sources alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. By 2023, while still present in the funding structure at $18.043 billion in carrying value, securitized debt obligations were categorized under Level 2 in the fair value hierarchy, indicating a shift toward more standardized valuation methods. This evolution suggests a more structured and possibly less volatile role for securitized debt obligations in Capital One's funding strategy.",
      "llm_answer": "In 2022 Capital One reported $16.9 billion of securitized‑debt obligations on its balance sheet (carrying value $16,973 million; fair‑value $16,918 million) 【page_65】, which accounted for roughly 4 percent of its total funding sources (about $15 billion of a $354 billion funding mix) 【page_66】. By the end of 2023 the balance‑sheet amount had risen to $18.0 billion (carrying $18,043 million; fair‑value $18,067 million) 【page_210】, keeping securitizations as a modest but growing component of Capital One’s overall funding structure, slightly increasing its share of total liabilities relative to deposits and senior notes.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several correct quantitative details: the 2022 carrying value of $16,973 million (~$16.9B) and 2023 carrying value of $18,043 million (~$18.0B) match the ground truth. These figures are accurately cited and reflect an increase in securitized debt obligations. However, the claim that securitized debt accounted for 'roughly 4 percent of total funding sources (about $15 billion of a $354 billion funding mix)' is problematic—the original answer does not mention this percentage or breakdown, and the $15B figure does not align with the $16.973B carrying value reported, suggesting a possible misstatement or miscalculation. (2) The fair value numbers cited ($16,918M in 2022 and $18,067M in 2023) are specific and may be factually correct per the source pages, but the ground truth does not include fair value data, so their relevance to the evolution in funding structure is unclear. The increase from $16.9B to $18.0B is correctly noted. (3) The qualitative reasoning is partially flawed: while the LLM correctly observes that securitized debt obligations remained a component of funding and grew slightly, it misses the key qualitative shift emphasized in the original answer—namely, the reclassification of securitized debt obligations under Level 2 of the fair value hierarchy in 2023, indicating a move toward standardized valuation methods. This omission represents a failure in multi-hop reasoning, as the evolution in role (not just size) is central to the question. Instead, the LLM focuses on relative share in liabilities without supporting data. (4) Contextually, the answer is relevant and addresses the time frame and topic. However, the emphasis on quantitative growth overshadows the more important structural and methodological evolution in how these obligations were accounted for. The answer is factually partially correct but misses a critical conceptual shift, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 529,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did the nature of LLY's revenue from Zyprexa evolve between 2023 and 2024, particularly in terms of the source and recognition method of that revenue?",
      "original_answer": "In 2023, Zyprexa revenue was primarily derived from the sale of the rights for the olanzapine portfolio. By 2024, the revenue associated with Zyprexa was recognized as part of collaboration and other arrangements, specifically stemming from the 2023 sale of rights for the olanzapine portfolio, and was included in collaboration revenue rather than product sales. This reflects a shift in how Zyprexa-related revenue was categorized and recognized in 2024 compared to 2023.",
      "llm_answer": "In the 2023 filing LLY reported Zyprexa as neuroscience product revenue (U.S. $79.4 m + outside‑U.S. $1,615.4 m), noting that the amount “includes the sale of the rights for the olanzapine portfolio.” The revenue was therefore recorded in net product revenue and recognized when control of the product (or rights) transferred to the buyer.  \n\nIn the 2024 filing the same transaction is no longer shown in product revenue; it is now disclosed as part of collaboration and other revenue, described as “the 2023 sales of rights for the olanzapine portfolio, including Zyprexa.” Thus the revenue is treated as a one‑time sale of intellectual‑property rights and is recognized at the point the rights are transferred, consistent with the company’s royalty/rights‑sale accounting policy.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2023, Zyprexa revenue included the sale of rights for the olanzapine portfolio and was recorded in net product revenue, while in 2024 it shifted to collaboration and other revenue. This captures the core evolution in source and recognition method. (2) The quantitative details—U.S. $79.4 million and outside-U.S. $1,615.4 million—are specific and correctly attributed to 2023; though the original answer doesn't include these figures, their presence adds precision without contradiction. The description of revenue recognition upon transfer of control and alignment with IP sale accounting policy is consistent with proper GAAP treatment. (3) The multi-hop reasoning is sound: the model connects the 2023 sale of rights to its subsequent classification in 2024 as collaboration revenue, showing understanding of how a past transaction affects future reporting categories. (4) Minor deduction in score due to slightly more granular financial data than confirmed in the ground truth (though plausible and consistent), but no factual errors. Semantic equivalence is strong, and all parts of the question—source, recognition method, and evolution across years—are fully addressed. Contextual relevance is perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 366,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the valuation methodology and classification of Federal Government Securities in the pension plan evolved from 2022 to 2024?",
      "original_answer": "In 2022, Federal Government Securities were valued under the 'Significant Other Observable Inputs (Level 2)' category and totaled $742 million. By 2024, the company clarified that these securities are valued using a bid evaluation process with bid data from independent pricing sources and are explicitly classified as Level 2 investments. This reflects a continuation in classification but adds specificity in methodology explanation.",
      "llm_answer": "- **2022 filing (UNP 10‑K 2022, page 70)** – Federal Government Securities were described as “bills, notes, bonds, and other fixed‑income securities issued directly by the U.S. Treasury or by government‑sponsored enterprises. These assets are valued using a **bid‑evaluation process with bid data provided by independent pricing sources** and are **classified as Level 2 investments** in the fair‑value hierarchy.  \n\n- **2024 filing (UNP 10‑K 2024, page 56)** – The same language is used: the securities are “valued using a **bid‑evaluation process with bid data provided by independent pricing sources**” and are **still classified as Level 2 investments**.  \n\n**Evolution:** The valuation methodology (bid‑evaluation using independent pricing) and the classification (Level 2) for Federal Government Securities have remained unchanged from 2022 to 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that Federal Government Securities were classified as Level 2 in both 2022 and 2024 and that the valuation methodology involves a bid-evaluation process using independent pricing sources. However, it omits the specific $742 million value for 2022 mentioned in the ground truth, which is a key quantitative detail required for full accuracy. (2) The absence of the $742 million figure results in a partial failure in quantitative completeness, though no incorrect numbers are presented. The years (2022, 2024) and entity (Federal Government Securities) are correct. (3) The reasoning is logically sound—correctly identifying consistency in classification and methodology across years—but fails to acknowledge that while the classification remained the same, the 2024 filing added specificity in explanation (as noted in the ground truth), which represents an evolution in disclosure clarity, not just repetition. The LLM interprets 'same language' as no evolution, but the ground truth emphasizes added specificity in 2024, which the model overlooks. (4) Scores reflect high contextual relevance and mostly accurate qualitative and quantitative information, but deductions are made for missing the dollar amount and underrepresenting the nuance in methodological clarification in 2024, which is central to the question about 'evolution.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 384,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did Capital One's credit score data utilization for product segmentation decisions evolve from 2022 to 2023, and what does this indicate about their credit risk modeling strategy?",
      "original_answer": "In 2022, Capital One used credit score data for product segmentation decisions based on historical credit score distributions from 2020 to 2021, as shown in Table 21. In 2023, the company updated its data to reflect credit score distributions from 2022 to 2023 in the same table. This shift indicates a more current and dynamic credit risk modeling strategy, with product segmentation decisions being informed by the most recent borrower behavior and risk profiles, suggesting a proactive approach to managing credit risk in evolving economic conditions.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K disclosures state that Capital One “uses borrower credit scores … for sub‑prime classification, competitive benchmarking and, in some cases, to drive product‑segmentation decisions,” showing that the firm’s reliance on score data for shaping product lines remained unchanged.  However, the 2023 credit‑score distribution shows a small dip in the share of high‑score (>660) credit‑card accounts (68 % versus 69 % a year earlier) while the proportion of high‑score auto loans stayed flat at 53 %, indicating that Capital One’s risk models are now applying segmentation across a slightly broader credit‑quality spectrum while still using scores as a core driver of product strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Capital One uses credit scores for product segmentation in both 2022 and 2023, which aligns with the original answer. However, it fails to mention the key evolution highlighted in the ground truth: the shift from using historical credit score data (2020–2021) in 2022 to more recent data (2022–2023) in 2023. This omission undermines the core of the question about how utilization evolved. Instead, the LLM claims the reliance 'remained unchanged,' which contradicts the ground truth indicating a strategic shift toward more current data. (2) The quantitative data cited—68% vs. 69% for high-score credit card accounts and 53% for auto loans—is plausible but not present in the ground truth, and no source (e.g., Table 21) is referenced. These percentages may be factually accurate in the actual filings, but their inclusion distracts from the main point about data recency in modeling. There are no calculation errors, but the numbers do not support the specific evolution asked about. (3) The multi-hop reasoning is partially sound—linking credit score usage across years and inferring risk strategy—but it misses the critical synthesis: updating data sources to reflect more recent borrower behavior indicates a dynamic risk modeling strategy. The LLM focuses on distributional shifts rather than data freshness, misrepresenting the strategic evolution. (4) While contextually relevant and using appropriate terminology, the answer is factually incomplete on the central point of data timeliness and thus earns a moderate correctness score. Quantitative accuracy is acceptable but not fully verifiable or aligned with the ground truth focus. Qualitative reasoning is weakened by incorrect conclusion about no change. Contextual relevance remains high as it addresses product segmentation and risk strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 505,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Amazon's strategic positioning of AWS evolved from 2022 to 2023 in terms of its role within the company's broader business segments and investment priorities?",
      "original_answer": "In 2022, AWS was positioned primarily as a key area of investment within Amazon's broader technology and content spending, with an emphasis on supporting geographic expansion, new product categories, and internal operational efficiencies. The document highlighted that Amazon was investing in AWS alongside initiatives to build and deploy innovative software and electronic devices, indicating a strategic alignment with internal growth and infrastructure enhancement. By 2023, AWS had evolved into one of Amazon's three core business segments—alongside North America and International—reflecting its elevated strategic importance. The 2023 filing explicitly states that AWS serves developers and enterprises by offering a broad set of on-demand technology services, including compute, storage, database, analytics, and machine learning, and is now a distinct and central pillar of Amazon’s business model. This shift demonstrates a transformation in AWS's role from a strategic investment area to a standalone, mission-critical business segment.",
      "llm_answer": "In the 2022 filing, AWS was described mainly as a **technology‑infrastructure cost driver** – a large share of capital‑expenditure and fixed‑cost spending was “to support AWS” and the “costs necessary to run AWS” were listed among the company’s variable and fixed expenses【page_18】. By the 2023 filing, AWS had been elevated to a **stand‑alone operating segment** alongside North America and International, and the narrative stresses that Amazon is “investing in AWS” as a core growth engine that provides a broad set of on‑demand services to developers and enterprises【page_3】【page_19】. This shift shows AWS moving from a supporting technology platform in 2022 to a strategic, revenue‑generating segment and top‑priority investment area in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of AWS from a cost/investment focus in 2022 to a standalone operating segment in 2023, matching the core narrative of strategic elevation. The characterization of AWS in 2022 as a 'technology-infrastructure cost driver' is consistent with the original answer's emphasis on AWS being part of technology and content spending and supporting internal infrastructure. In 2023, the LLM correctly notes AWS's elevation to a core business segment alongside North America and International, and accurately describes its role in serving developers and enterprises with on-demand services. (2) There are no numeric values, dates, or financial figures in dispute; both answers reference 2022 and 2023 appropriately, and no calculations are required. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years and correctly infers the strategic shift based on changes in segment reporting and narrative emphasis. The only minor shortcoming is that the LLM does not explicitly mention 'geographic expansion' or 'internal operational efficiencies' from the 2022 context, nor does it highlight machine learning as a specific service offered in 2023 (though it mentions 'on-demand services' broadly). These omissions slightly reduce completeness but do not undermine the central correctness. (4) The answer is contextually fully relevant, directly addressing the question about AWS’s evolving strategic positioning. Overall, the LLM captures the essential transformation accurately and concisely, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1453,
        "completion_tokens": 449,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Philip Morris International's financial relationship with Rothmans, Benson & Hedges Inc. (RBH) evolved between 2022 and 2024, particularly in terms of its accounting treatment and potential financial exposure?",
      "original_answer": "In 2022, RBH was deconsolidated from Philip Morris International’s financial statements due to its CCAA restructuring, and its financial results were no longer included in PMI’s consolidated financials. At that time, there was a comprehensive stay of Canadian tobacco litigation until March 31, 2022, and no loss accruals were made due to the inability to estimate potential losses. By 2024, PMI’s relationship with RBH had shifted from deconsolidation to an equity investment model. A proposed settlement of CAD 32.5 billion in the Canadian tobacco litigation emerged, prompting PMI to assess its investment in RBH for impairment. As a result, PMI recorded a non-cash impairment charge of $2,316 million in 2024, reflecting a decline in the estimated fair value of its investment. This marks a significant evolution from a deconsolidated entity with uncertain liabilities to a recognized equity investment with a quantified impairment.",
      "llm_answer": "By 2022 PMI’s relationship with RBH was already “off‑balance‑sheet” – RBH had been de‑consolidated in 2019 and PMI’s only recorded impact was a one‑time pre‑tax charge of about $194 million (net of tax $142 million) for the trust‑account deposit required by the Létourneau and Blais judgments, with no ongoing provision because a loss was not deemed probable or estimable. By the 2024 filing the picture had changed: the equity stake that PMI still held in RBH was re‑measured as impaired, triggering a non‑cash impairment charge of $2.3 billion (≈$1.49 diluted‑EPS) and a fair‑value adjustment, reflecting the unresolved CAD 32.5 billion settlement plan in the CCAA proceedings and a much larger potential financial exposure than the earlier $194 million charge.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution in PMI's financial relationship with RBH—shifting from deconsolidation to an equity investment with impairment—and correctly identifies the $2.3 billion impairment charge in 2024 and the CAD 32.5 billion settlement context, which aligns with the ground truth. However, there are significant factual inaccuracies in the quantitative details and timeline: (1) The deconsolidation is incorrectly stated to have occurred in 2019, while the ground truth specifies it happened in 2022 due to CCAA restructuring; this misrepresents a key event timing and undermines the chronological accuracy. (2) The $194 million pre-tax charge (net $142 million) is mentioned but not present in the original answer, which makes no reference to such a charge or trust-account deposit related to Létourneau and Blais judgments—this appears to be extraneous or incorrectly sourced information. (3) The 2024 impairment is reported as $2.3 billion, which is close to the correct $2,316 million and acceptable within rounding, but the original specifies it as a non-cash charge directly tied to the equity investment’s fair value decline, which the LLM captures conceptually. (4) The original emphasizes that no loss accruals were made in 2022 due to inability to estimate, whereas the LLM implies only a one-time charge with no ongoing provision, which partially conflates accounting treatments. The reasoning is logically structured and addresses the shift in accounting treatment and increased financial exposure, showing sound multi-hop synthesis between deconsolidation, equity method, and impairment. Contextually, the answer is highly relevant and focused on the question. However, the incorrect deconsolidation date and introduction of unverified financial figures reduce quantitative accuracy significantly. While the qualitative narrative is mostly coherent, the factual errors in key events and numbers prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 524,
        "total_tokens": 1966
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2022 to 2024, considering both its revenue contribution and associated product risks?",
      "original_answer": "In 2022, Biktarvy was a major revenue driver for GILD, generating $8,624 million in total product sales globally, indicating its strong market position in the HIV treatment segment. By 2024, while specific revenue figures are not provided, the company's risk disclosures highlight Biktarvy's ongoing importance but also emphasize heightened risks related to the HIV product class, particularly concerning the reliance on TAF-based therapies and potential shifts in treatment paradigms. This evolution suggests that although Biktarvy remains central to GILD's revenue, its commercial outlook has become more vulnerable to competitive and regulatory pressures.",
      "llm_answer": "In the 2022 Form 10‑K, Gilead disclosed that Biktarvy generated **about $8.6 billion in product sales** for the year ended 2021 (U.S. $7.0 bn + Europe $0.97 bn + Other $0.61 bn), making it the single largest contributor to the company’s HIV franchise and a core driver of total revenue. The 2024 filing still treats Biktarvy as a cornerstone of its HIV portfolio, but the risk‑factor discussion now emphasizes **heightened commercial risks** – intense competition (including generics), reliance on the tenofovir alafenamide (TAF) platform, and possible shifts in HIV treatment paradigms – that could curb future sales. Thus, while Biktarvy’s revenue importance remains strong, Gilead’s 2024 disclosures highlight growing product‑specific risks that could affect its continued commercial performance.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the quantitative section: it states that the $8.6 billion in Biktarvy sales was for the year ended 2021, based on the 2022 Form 10-K. However, the ground truth specifies that the $8,624 million (i.e., $8.624 billion) was for 2022, not 2021. This misalignment in fiscal year reporting is a critical error, especially since the question explicitly asks about the evolution from 2022 to 2024. While the dollar amount is approximately correct ($8.6B vs $8.624B), the incorrect attribution to 2021 undermines temporal accuracy. (2) The breakdown of regional sales (U.S. $7.0 bn, Europe $0.97 bn, Other $0.61 bn) summing to ~$8.58 bn is not present in the original answer and appears to be an external inference or hallucination; the ground truth does not provide regional splits, so this detail introduces unverified data. (3) Qualitatively, the answer correctly identifies the shift in risk disclosures by 2024, noting increased emphasis on competition, reliance on TAF, and potential treatment paradigm shifts—this aligns well with the original answer’s point about heightened risks. The reasoning correctly synthesizes information across time (2022 vs 2024 filings) and captures the evolving risk profile despite revenue importance. (4) Contextually, the response is highly relevant, addressing both revenue contribution and product risks as required. It correctly interprets the multi-hop nature of the question—tracking change over time in both performance and risk. However, due to the incorrect year attribution of the revenue figure and inclusion of unsupported regional breakdowns, the quantitative accuracy is reduced. Overall, core facts about Biktarvy’s importance and growing risks are correct, but key numerical and temporal inaccuracies prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 498,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has Union Pacific Railroad's financial stake and operational relationship with TTX evolved from 2022 to 2024, particularly in terms of investment value and car hire expenses?",
      "original_answer": "Union Pacific Railroad's financial stake in TTX increased from $1.6 billion in 2021 (referenced in the 2022 filing) to $1.9 billion in 2024. Additionally, UPRR's car hire expenses rose from $375 million in 2021 to $432 million in 2024. These increases indicate a growing financial and operational involvement with TTX over the period.",
      "llm_answer": "Union Pacific’s equity‑method stake in TTX has risen modestly. In the 2022 filing the company reported a TTX investment of roughly $1.6 billion (the most recent figure shown), and by the 2024 filing that balance had grown to about $1.9 billion – an increase of roughly $300 million. At the same time, the cost of renting TTX rail cars has climbed: the 2022 report listed car‑hire expense of $375 million (2021) and $402 million for 2022, while the 2024 report shows the expense at $432 million for 2024 (up from $399 million in 2023), indicating a rise of about $30‑$60 million over the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in Union Pacific's investment in TTX from $1.6 billion (as reported in the 2022 filing, referencing 2021 value) to $1.9 billion in 2024, matching the ground truth. Car hire expenses are accurately reported as $375 million in 2021 and $432 million in 2024, aligning with the original answer. The LLM adds additional granularity not in the ground truth—specific values for 2022 ($402M) and 2023 ($399M)—which are consistent with a rising trend and do not contradict the overall pattern. (2) All key numbers match: $1.6B → $1.9B investment increase; $375M → $432M expense increase. The LLM correctly interprets that the 2022 filing reports 2021 data, which is critical for accurate year-over-year comparison. The calculation of a $300M increase in investment is correct. The car hire increase from $375M to $432M is a $57M rise, and the LLM’s phrasing of 'rise of about $30–$60 million over the period' is approximate but reasonable given the multi-year span and intermediate data points. (3) Multi-hop reasoning is sound: the model synthesizes data across 2022 and 2024 filings, correctly attributes values to the appropriate years (noting that 2022 filing contains 2021 data), and draws a logical conclusion about growing involvement. The added detail enhances clarity without introducing error. (4) The answer is fully contextually relevant, directly addressing both financial stake and operational (car hire) aspects. The only minor shortcoming is the slightly imprecise characterization of the total car hire increase as '$30–$60 million' when the actual increase is $57 million—this is close but not exact. Otherwise, all facts, entities, and trends are correct. Hence, a high score of 9 is warranted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 481,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Tesla's approach to scaling Solar Roof production change from 2022 to 2023, particularly regarding installer training initiatives and supply chain risk management?",
      "original_answer": "In 2022, Tesla emphasized expanding Solar Roof production by on-boarding and training new installers, collaborating with real estate developers, and reducing installation time and costs. The company also highlighted its need to hire additional personnel, particularly skilled electricians, to support the ramp. By 2023, Tesla's focus had shifted toward addressing broader supply chain risks and production ramp challenges, with language indicating that Solar Roof production now depended more on managing supplier reliability, global component constraints, and cost-effective manufacturing processes. The 2023 filing also noted that delays in production ramps could harm the business, signaling a shift from installer-focused growth to a more risk-averse strategy centered on supply chain resilience.",
      "llm_answer": "- 2022 10‑K – Tesla said that Solar Roof production was still constrained by a “limited installer base” and by “exposure to component‑supply shortages,” so the company’s focus was mainly on monitoring and diversifying suppliers rather than on a formal installer‑training program【TSLA_10k_2022.pdf page 33】.  \n\n- 2023 10‑K – Tesla added a specific scaling plan that “improves installation capabilities and price efficiencies for Solar Roof by on‑boarding and training new installers, and by collaborating with real‑estate developers and builders to reduce installation time and cost”【TSLA_10k_2023.pdf page 34】, while again emphasizing broader supply‑chain risk management –‑ “our suppliers may fail to deliver…global component shortages…we will need to secure additional or alternate sources”【TSLA_10k_2023.pdf page 16】.  \n\nThus, the approach shifted from merely acknowledging supply‑chain exposure in 2022 to actively expanding installer training and partnership programs in 2023, alongside continued emphasis on diversifying and monitoring the supply chain.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains a critical factual reversal: it incorrectly states that in 2022, Tesla focused on monitoring and diversifying suppliers rather than on formal installer training, and that in 2023, Tesla began actively on-boarding and training new installers. However, the ground truth shows the opposite trajectory — in 2022, Tesla emphasized expanding production by training new installers and collaborating with real estate developers, while in 2023, the focus shifted toward managing supply chain risks, supplier reliability, and global component constraints. The LLM flips the timeline of strategic emphasis. While the cited risks (component shortages, supplier reliability) are factually present in the filings and the quotes appear plausible (though citation page numbers are not verifiable here), the core reasoning is flawed. The multi-hop synthesis fails because it misattributes the evolution of Tesla’s strategy — the shift is not from passive supply chain monitoring to active installer training, but from installer expansion in 2022 to supply chain risk mitigation in 2023. This reverses the actual strategic pivot. Quantitative accuracy is not applicable (no numbers involved), so score is high by default. Contextual relevance is moderate because the answer discusses relevant themes (installers, supply chain, training) but misrepresents their temporal progression. The conclusion is therefore fundamentally incorrect, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1471,
        "completion_tokens": 405,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has The Coca-Cola Company's relationship with fountain retailers evolved between 2022 and 2023, particularly regarding the manufacturing and distribution of fountain syrups in the United States?",
      "original_answer": "In 2022, The Coca-Cola Company stated that U.S. bottlers were generally not authorized to manufacture fountain syrups, and instead, the Company itself manufactured and sold fountain syrups directly to authorized fountain wholesalers (including some bottlers) and certain fountain retailers. By 2023, the Company clarified that it continues to manufacture fountain syrups in the U.S., but now explicitly states that it sells these syrups to both fountain retailers and authorized fountain wholesalers or bottling partners who then distribute them to fountain retailers. This indicates a more explicit acknowledgment of a tiered distribution model involving bottling partners in 2023, suggesting a potential expansion of their distribution network or clarification of roles.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K describe the same U.S. arrangement: Coca‑Cola Company manufactures the fountain syrups itself and then sells them either directly to fountain retailers or to authorized fountain wholesalers (including some bottling partners) that distribute the syrups to those retailers. Outside the United States the company’s bottling partners are generally authorized to produce and distribute fountain syrups, but in the United States that manufacturing role has not changed between 2022 and 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that the arrangement was the same in 2022 and 2023, which contradicts the ground truth. The original answer correctly identifies a shift in language and emphasis between the two years: in 2022, the Company stated that U.S. bottlers were generally not authorized to manufacture fountain syrups and that it sold directly to wholesalers and certain retailers. By 2023, the Company updated its disclosure to explicitly include 'bottling partners' as recipients of fountain syrups for distribution to retailers, indicating a more formalized or clarified tiered distribution model. The LLM incorrectly asserts there was no change, missing this nuance entirely. While the LLM accurately describes the general structure of syrup manufacturing and distribution (Coca-Cola manufactures, sells to wholesalers/retailers), it fails to capture the evolution in the role of bottling partners in the distribution chain as emphasized in 2023. There are no numerical figures to verify, so quantitative accuracy is scored as 10 by default. Contextual relevance is high because the answer addresses the right topic and entities, but qualitative accuracy is low due to the failure in multi-hop reasoning—comparing the two years’ disclosures to detect a shift in wording and implication. Thus, the correctness score is moderate (4) due to a partially accurate description but major omission of the key evolution in the distribution relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 406,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has IBM's treatment and disclosure of the 0.950% Notes due 2025 evolved from 2022 to 2024, particularly in terms of its financial instrument classification and registration details?",
      "original_answer": "In 2022, the 0.950% Notes due 2025 were disclosed as part of IBM's exhibits in Form 8-K filings, specifically referenced under Exhibit 4.1 filed on May 22, 2017. By 2024, the 0.950% Notes due 2025 were not only still present but were actively listed as a financial instrument with a trading symbol 'IBM25B' on the New York Stock Exchange. This evolution indicates a shift from merely disclosing the instrument to formally registering and listing it for trading.",
      "llm_answer": "In IBM’s 2022 Form 10‑K the 0.950 % notes due 2025 were disclosed only in the notes to the consolidated financial statements, where they were classified as a long‑term debt instrument and were not shown in the Form 10‑K “Securities registered pursuant to Section 12(b)” table (the 2022 exhibit list on pages 28‑32 makes no separate entry for these notes). By the 2024 filing, the same 0.950 % notes are explicitly listed in the registration table, identified with the ticker IBM25B and noted as being registered on the New York Stock Exchange under Section 12(b) (see the securities‑registration table on page 1 of the 2024 10‑K).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key details are correct: the 0.950% interest rate, the 2025 maturity, the IBM25B ticker symbol, and the New York Stock Exchange listing are all accurately reported. The years 2022 and 2024 are correctly used as comparison points. (2) The LLM correctly identifies the evolution: in 2022, the notes were disclosed in the financial statements but not registered under Section 12(b), while by 2024 they appear in the 'Securities registered pursuant to Section 12(b)' table with ticker IBM25B. This matches the ground truth's claim of a shift from disclosure to formal registration and listing. (3) The reasoning is sound and represents valid multi-hop synthesis across two years of 10-K filings, correctly interpreting the significance of registration status changes. (4) The only minor discrepancy is that the original answer references a 2017 Form 8-K (Exhibit 4.1) as the initial disclosure source, which the LLM does not mention. However, the question focuses on the evolution from 2022 to 2024, so this omission does not materially affect correctness. The LLM’s focus on the 10-K disclosures in those years is appropriate and sufficient. Wording differs slightly but maintains semantic equivalence. Overall, the answer is factually correct, complete for the time frame asked, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 385,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has GILD's strategic positioning of Biktarvy evolved from 2022 to 2024, particularly in terms of its financial risk exposure and competitive differentiation within the HIV treatment market?",
      "original_answer": "In 2022, Biktarvy was listed among GILD’s key marketed products, indicating its central role in the company's HIV portfolio and suggesting strong commercial positioning. By 2024, the company highlighted increasing financial risk tied to its reliance on nucleoside-based therapies like Biktarvy, particularly due to the potential shift in HIV treatment paradigms away from TAF-based regimens. This evolution reflects a growing concern over Biktarvy’s long-term competitive differentiation and its ability to sustain revenue, especially in the face of rising generic competition and changing therapeutic preferences.",
      "llm_answer": "In the 2022 Form 10‑K Gilead identified Biktarvy as a core HIV product and warned that its HIV franchise – which relies heavily on tenofovir‑alafenamide‑based regimens – was exposed to “market‑share gains by competitive products, including generics” and to “pricing pressures…rebates and discounts,” creating revenue volatility and financial‑risk exposure (2022 p. 63; 2022 p. 18‑20).  \n\nBy the 2024 filing the company still counts Biktarvy among its flagship HIV medicines but frames it as a differentiated, single‑tablet regimen with a high barrier to resistance, while explicitly noting that new reimbursement reforms (the Inflation Reduction Act, potential Medicare price negotiations, and increased rebate obligations) heighten the financial risk tied to the product’s gross‑to‑net deductions (2024 p. 18‑20).  \n\nThus, Gilead’s positioning has evolved from emphasizing the product’s vulnerability to competition and pricing risk to stressing its clinical differentiation, even as it acknowledges growing financial‑risk pressures from evolving payer policies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Biktarvy as a core product in 2022 and notes GILD's concerns about competition and pricing pressures, including generics and rebates, which matches the original answer's emphasis on financial risk exposure due to market dynamics. By 2024, it accurately reflects the shift in tone to highlight clinical differentiation (e.g., high barrier to resistance, single-tablet regimen) while acknowledging increased financial risks from policy changes like the Inflation Reduction Act—this captures the evolution in strategic positioning. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; references to page numbers (e.g., 2022 p. 18–20) are consistent with typical 10-K citation practices and do not affect factual correctness. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly identifying both continuity (Biktarvy as flagship) and change (from competitive risk to policy-driven financial risk and emphasis on differentiation). (4) The only minor shortcoming is that the original answer emphasizes the 'shift away from TAF-based regimens' as a specific scientific/therapeutic concern, which the LLM answer does not explicitly mention—though it references payer policy changes more broadly. This omission slightly affects completeness but not core accuracy. Overall, the LLM conveys semantically equivalent, well-reasoned, and contextually appropriate information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 441,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Lockheed Martin's approach to defined contribution retirement savings plans evolve between 2022 and 2023, particularly in terms of pension obligation transfers and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin transferred $4.3 billion of gross defined benefit pension obligations through group annuity contracts, recognizing a noncash pension settlement charge of $1.5 billion. In 2023, instead of another annuity purchase, the company made $414 million in settlement payments to approximately 6,500 former employees who had not yet started receiving benefits. This shift indicates a strategic evolution from transferring large blocks of pension obligations to insurers (as in 2022) to directly settling smaller portions of obligations with individual participants in 2023.",
      "llm_answer": "In 2022 Lockheed Martin completed a major transfer of pension risk – it bought group‑annuity contracts that moved roughly $4.3 billion of gross defined‑benefit obligations (covering about 13,600 retirees) to an insurer and recorded a non‑cash pension‑settlement charge of about $1.5 billion (shown as a $1.47 billion settlement charge in the 2022 FAS income). By 2023 the company was dealing only with smaller, voluntary lump‑sum settlements – a $414 million payment for about 6,500 former employees – and no comparable settlement charge appeared in the 2023 statements, indicating that the large pension‑obligation transfers had been largely completed in the prior year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, Lockheed Martin transferred $4.3 billion in gross defined-benefit pension obligations via group annuity contracts and recognized a $1.5 billion noncash pension settlement charge (noted as $1.47 billion in financial statements, which is consistent with rounding in reporting). In 2023, the company made $414 million in settlement payments to about 6,500 former employees, with no large-scale annuity purchase or major settlement charge. These numbers match the original answer exactly in substance, with acceptable formatting variations. (2) Quantitative accuracy is perfect: all dollar amounts ($4.3B, $1.5B, $414M), participant counts (13,600 retirees in 2022, ~6,500 in 2023), and the absence of a settlement charge in 2023 are correctly reported. The minor clarification of $1.47 billion vs $1.5 billion is a rounding detail and does not constitute an error. (3) The reasoning is sound and captures the strategic evolution: shifting from large insurer-mediated annuity transfers in 2022 to smaller, individual lump-sum settlements in 2023. The conclusion that the major obligation transfers were 'largely completed' in 2022 is a reasonable inference. (4) The only minor shortcoming is that the original answer explicitly frames this as a 'strategic evolution,' while the LLM implies it through contrast but doesn't use similar interpretive language—this slight reduction in qualitative depth prevents a perfect 10, but the factual and logical synthesis remains excellent. Contextual relevance is full: every part of the question (evolution, pension obligation transfers, financial impacts) is addressed directly and accurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 473,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 2.875% Notes due 2025?",
      "original_answer": "In 2022, IBM listed the 2.875% Notes due 2025 (IBM 25A) among other Notes due in 2025, including the 0.950% Notes due 2025 (IBM 25B) and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 2.875% Notes due 2025 (IBM25A) remained, but the 0.875% Notes due 2025 (IBM 25C) were no longer listed, indicating a shift in the debt composition for that year. The 2.875% Notes due 2025 continued to be a key part of IBM's debt structure in 2024, suggesting a strategic decision to maintain this specific financial instrument while retiring or restructuring others.",
      "llm_answer": "In the 2022 Form 10‑K IBM reported three separate 2025‑maturing notes – the 2.875 % Notes (IBM 25A), the 0.950 % Notes (IBM 25B) and the 0.875 % Notes (IBM 25C) – together with a 7 % debenture due 2025. By the 2024 filing the 0.875 % Notes are no longer listed; the 2025 bucket now consists of the 2.875 % Notes, the 0.950 % Notes and the 7 % debenture, indicating that the 0.875 % issue has been retired or otherwise removed while the 2.875 % Notes remain unchanged.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the presence of the 2.875% Notes (IBM 25A), 0.950% Notes (IBM 25B), and 0.875% Notes (IBM 25C) in 2022 and the absence of the 0.875% Notes in 2024, which aligns with the ground truth. It also correctly states that the 2.875% Notes remain unchanged, capturing the core evolution in debt composition. However, the LLM introduces a '7% debenture due 2025' that is not mentioned in the original answer or implied by the ground truth, which adds potentially inaccurate information. This affects quantitative and qualitative accuracy despite not undermining the main conclusion. (2) All percentages and years related to the notes are accurate: 2.875%, 0.950%, 0.875%, and 2025 are correctly cited. The erroneous addition of a 7% debenture is a factual overstatement not supported by the ground truth, though it does not contradict the focus on the 2.875% Notes. (3) The multi-hop reasoning is sound—comparing IBM’s debt instruments from 2022 to 2024 and inferring a shift due to the disappearance of the 0.875% Notes. The logic that the 2.875% Notes remained a key component is valid and consistent with the original answer. The mention of the 7% debenture suggests possible conflation with another filing or instrument, weakening the purity of the synthesis. (4) The correctness score is 8 because the core facts about the 2.875% Notes and the removal of the 0.875% Notes are correct, and the answer addresses the evolution in composition. The extra detail about the 7% debenture prevents a higher score. Quantitative accuracy is 9 due to one unverified number. Qualitative accuracy is 8 due to strong reasoning but a minor factual overreach. Contextual relevance is 10 as the response directly addresses the question’s focus on debt composition changes and the role of the 2.875% Notes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 495,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the strategic importance and risk profile of Biktarvy within Gilead's HIV portfolio evolved from 2022 to 2024, particularly in light of competitive pressures and changes in the treatment paradigm?",
      "original_answer": "In 2022, Biktarvy was positioned as a key growth driver for Gilead, with the company noting its 'continued growth in all geographies' and attributing part of the 11% revenue increase to its performance. By 2024, however, the strategic importance of Biktarvy appears more precarious. The 2024 10-K highlights increased risks around Gilead's HIV franchise, noting that 'many of our HIV products contain TAF' and that any shift away from nucleoside-based therapies could materially impact sales. This suggests that while Biktarvy was a growth asset in 2022, by 2024 it was increasingly seen as vulnerable to paradigm shifts in HIV treatment, representing a change in both strategic positioning and risk exposure.",
      "llm_answer": "In the 2022 Form 10‑K, Gilead presented Biktarvy as the cornerstone of its HIV franchise – sales were rising, a pediatric low‑dose tablet was approved (Oct 2021) and the drug’s higher demand and pricing were explicitly credited with offsetting the loss of Truvada/Atripla and driving a “continued growth of our Biktarvy franchise” (2022 MD&A, p. 38‑41). By the 2024 filing, while Biktarvy still represents a large share of Gilead’s HIV revenue, the company flags a markedly higher risk profile: the product is grouped with other TAF‑containing regimens that could be hurt if the treatment paradigm moves away from nucleoside‑based therapies, and it is exposed to “market‑share gains by competitive products, including generics” and other new HIV agents (2024 Risk Factors, p. 18‑20). Thus, from 2022 to 2024 Biktarvy’s strategic importance remains high as a primary growth driver, but its risk exposure has grown because of intensified generic/brand competition and the possibility that clinicians shift to non‑nucleoside‑based regimens.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Biktarvy was a growth driver in 2022, with rising sales and new approvals contributing to franchise growth; by 2024, it faced increased risk due to reliance on TAF, potential paradigm shifts away from nucleoside-based therapies, and competitive pressures including generics. These points are consistent with the original answer. (2) Quantitative accuracy is perfect: no incorrect numbers, percentages, or dates are cited. The mention of the pediatric low-dose tablet approval in October 2021 is factually accurate and contextually relevant, even if not in the ground truth—this is a permissible detail enhancement. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across the 2022 and 2024 10-Ks, identifying both the strategic importance and the evolving risk profile over time. It correctly links Biktarvy’s TAF component to broader franchise risk, demonstrating understanding of the interconnectedness of Gilead’s HIV portfolio. (4) The only minor deviation is in emphasis: the LLM states that strategic importance 'remains high as a primary growth driver,' while the ground truth suggests a more precarious positioning by 2024, implying a relative decline in strategic confidence. This nuance is not incorrect but slightly overstates continuity in strategic importance. Overall, the answer is factually correct, well-reasoned, and fully responsive to the multi-part question about evolution in strategic importance and risk.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 429,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the balance of the U.S. litigation escrow account evolve between the end of fiscal year 2022 and the end of fiscal year 2023, and what were the specific deposit contributions during each period?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1,449 million at the end of fiscal year 2022 to $3,089 million at the end of fiscal year 2023. During this time, deposits into the account rose from $1,000 million in fiscal year 2022 to $1,500 million in fiscal year 2023.",
      "llm_answer": "- At the close of fiscal 2022 the U.S. litigation escrow account held **$1,449 million**; during fiscal 2022 the company **deposited $850 million** into the escrow account (see Note 20‑Legal Matters, page 102).  \n- At the close of fiscal 2023 the balance had risen to **$1,764 million**; during fiscal 2023 the company **deposited $1,000 million** (see the escrow‑account table for 2023, page 73).  \n\nThus, the escrow balance increased by $315 million from FY 2022 to FY 2023, driven by larger deposits in FY 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the U.S. litigation escrow account balance was $1,449 million at the end of FY 2022 and increased to $3,089 million at the end of FY 2023. However, the LLM incorrectly reports the FY 2023 balance as $1,764 million. Additionally, the deposit contributions are wrong: the LLM states $850 million was deposited in FY 2022 and $1,000 million in FY 2023, whereas the correct figures are $1,000 million in FY 2022 and $1,500 million in FY 2023. These errors affect both the starting and ending balances and the year-over-year change. (2) The quantitative inaccuracies are severe: the reported increase in balance is $315 million ($1,764M - $1,449M), but the actual increase was $1,640 million ($3,089M - $1,449M). The deposit amounts are also off by $150 million in FY 2022 and $500 million in FY 2023. These are not minor rounding or formatting differences but substantial errors in financial data. (3) The reasoning is partially sound in structure—comparing end-of-year balances and citing deposits as a driver—but fails on multi-hop synthesis because it uses incorrect source data. The model appears to reference specific document sections (e.g., Note 20, page 102), suggesting an attempt at evidence-based reasoning, but the numbers do not align with the ground truth. (4) The contextual relevance is high because the answer addresses the right account, time periods, and concept (deposit contributions affecting balance), but the factual foundation is flawed. Due to major quantitative and qualitative errors, the correctness score is low despite appropriate framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 456,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the role of fountain syrups in Coca-Cola's North America operating segment evolved between 2022 and 2023, particularly regarding the company's manufacturing and distribution responsibilities?",
      "original_answer": "In 2022, Coca-Cola explicitly stated that it manufactured fountain syrups in the United States and sold them directly to fountain retailers or to authorized fountain wholesalers or bottling partners for further distribution. By 2023, the company's description shifted: while it still referenced selling fountain syrups in the North America segment, it also indicated that outside the U.S., bottling partners were authorized to manufacture fountain syrups using company concentrates. This suggests a nuanced evolution where Coca-Cola may be emphasizing a more decentralized, authorization-based model, particularly outside the U.S., while maintaining direct control within the U.S. There is no explicit mention of a change in manufacturing responsibilities within North America itself, indicating operational continuity there.",
      "llm_answer": "In both the 2022 and 2023 Form 10‑K filings Coca‑Cola states that its U.S. fountain‑syrup business is classified in the North America operating segment. The company continues to **manufacture the fountain syrups itself** and then **sell them to fountain‑retailers, to authorized fountain wholesalers, or to its bottling partners**, which in turn distribute the syrups to the retailers. Thus, between 2022 and 2023 the role of fountain syrups did not change – Coca‑Cola still manufactures the syrups and relies on its bottling‑partner/wholesale network for distribution.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate regarding Coca-Cola's continued manufacturing and distribution model for fountain syrups in the U.S. within the North America operating segment in both 2022 and 2023, and correctly identifies that the company manufactures syrups and sells them to retailers, wholesalers, or bottling partners. There are no numeric inaccuracies (quantitative accuracy is perfect), and the entities (Coca-Cola, North America segment, bottling partners) and years (2022, 2023) are correct. However, the LLM misses a key nuance present in the original answer: the 2023 filing introduced a new detail about bottling partners outside the U.S. being authorized to *manufacture* fountain syrups using company concentrates, indicating a shift toward a more decentralized, authorization-based model internationally. While the LLM correctly notes no change in the U.S., it fails to acknowledge this evolution in the broader North America context (which may include cross-border implications or strategic shifts) and incorrectly concludes there was no change at all between years. This omission affects qualitative accuracy and completeness, as the question asks about the evolution of the role, not just continuity. The reasoning is sound but incomplete, missing the multi-hop synthesis of comparing the expanded authorization model in 2023 to the more centralized 2022 description. Despite this, the answer remains contextually relevant and correctly captures the core operational model in the U.S.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 413,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 0.950% Notes due 2025?",
      "original_answer": "In 2022, IBM had three sets of notes maturing in 2025: the 2.875% Notes due 2025 (IBM 25A), the 0.950% Notes due 2025 (IBM 25B), and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 0.875% Notes due 2025 were no longer listed, leaving only the 2.875% Notes due 2025 (IBM 25A) and the 0.950% Notes due 2025 (IBM 25B). This indicates a reduction in the diversity of interest rate profiles for debt maturing in 2025, with the removal of the 0.875% instrument.",
      "llm_answer": "In the 2022 Form 10‑K IBM listed three separate 2025‑maturing notes – a 2.875 % note, a 0.950 % note and a 0.875 % note (plus a 7.00 % debenture). By the 2024 filing the 0.875 % note no longer appears; only the 2.875 % and the 0.950 % notes (and the 7.00 % debenture) remain. Thus, the 0.950 % Notes due 2025 have persisted, while the overall 2025‑maturing debt mix has been simplified with the 0.875 % issue being retired.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the three notes maturing in 2025 in 2022: 2.875%, 0.950%, and 0.875%, matching the ground truth. It accurately notes that by 2024, the 0.875% note is no longer present, leaving only the 2.875% and 0.950% notes. The persistence of the 0.950% Notes due 2025 is correctly highlighted. However, the LLM introduces a '7.00% debenture' not mentioned in the original answer or ground truth, which may be factually accurate in the actual filing but was not part of the knowledge graph's verified data. Since the question focuses on the composition change specifically regarding the 0.950% Notes and the evolution among the 2025 maturities, adding unverified instruments risks overcomplication and slight deviation from the provided truth. (2) All percentages and years are correct: 2.875%, 0.950%, 0.875%, and 2022 to 2024 timeline are accurately reported. No calculations were required, but the comparison across years is sound. (3) The multi-hop reasoning—comparing IBM’s debt instruments from 2022 to 2024 filings—is correctly executed. The model synthesizes changes over time and draws a valid conclusion about simplification of the debt mix. The only gap is the introduction of an entity (7.00% debenture) not in the ground truth, which slightly affects qualitative accuracy. (4) The answer is highly relevant, directly addressing how the composition evolved and the status of the 0.950% Notes. The core facts are correct, and the conclusion about simplification aligns with the original answer. The extra detail about the debenture does not contradict but adds unverified information, hence a minor deduction from qualitative accuracy. Correctness score is 9 due to high factual accuracy with a small overreach in entity inclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 482,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Disney's strategic approach to cruise ships evolved between 2022 and 2024 based on disclosures in their 10-K filings?",
      "original_answer": "In 2022, Disney mentioned cruise ships as part of its broader travel and resort experiences, indicating that their success depended on consumer demand for out-of-home entertainment and travel. By 2024, Disney had elevated its approach, explicitly stating plans to 'expand investment in our Experiences segment' and 'additional expansion of our fleet of cruise ships.' This evolution reflects a shift from general dependence on consumer demand to an active investment and growth strategy in cruise ship operations. The 2024 filing also notes that new offerings, such as additional cruise ships, come with increased costs and uncertain returns, signaling a more capital-intensive and strategic focus compared to the more passive mention in 2022.",
      "llm_answer": "In the 2022 Form 10‑K Disney’s cruise‑ship strategy was still largely recovery‑focused – the filing notes that COVID‑19 had forced a suspension of Disney Cruise Line sailings and that the company was preparing a single new destination, the 550‑acre Lighthouse Point site in the Bahamas, slated to open in 2024【page_23】. By the 2024 filing the emphasis had shifted to growth: Disney disclosed that it “announced plans for additional expansion of our fleet of cruise ships” and is investing further in its Experiences segment, signalling a move from merely resuming service to actively enlarging the cruise‑ship portfolio【page_22】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution in Disney's cruise strategy from recovery in 2022 to growth in 2024. It accurately notes the suspension of sailings due to COVID-19 in 2022 and the planned opening of Lighthouse Point in 2024, which aligns with the broader context of recovery and expansion. The 2024 shift to active fleet expansion is correctly identified with a direct quote about 'additional expansion of our fleet of cruise ships.' However, the original answer emphasizes a strategic shift from passive dependence on consumer demand to active investment, including acknowledgment of increased costs and uncertain returns in 2024—this risk disclosure is missing in the LLM answer, representing a minor omission. (2) Quantitatively, all dates (2022, 2024), the 550-acre size of Lighthouse Point, and the single new destination are factually correct and consistent with known disclosures. No calculations are required, and all numbers are accurate. (3) The multi-hop reasoning is sound: the LLM synthesizes information across 2022 and 2024 filings, correctly identifying a shift in tone and strategy. It connects the resumption of operations with future growth plans, demonstrating valid cross-year analysis. (4) The contextual relevance is excellent—the answer directly addresses the question about strategic evolution. The scores reflect high accuracy with a slight deduction in correctness and qualitative accuracy due to the missing nuance about cost and return risks in the 2024 strategy, which is part of the original answer’s key insight into Disney’s more capital-intensive approach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 444,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did Lockheed Martin's approach to pension risk transfer transactions evolve from 2022 to 2023, particularly in terms of financial impact and strategic intent?",
      "original_answer": "In 2022, Lockheed Martin detailed a specific pension risk transfer transaction from August 3, 2021, where $4.9 billion of gross defined benefit pension obligations were transferred via group annuity contracts (GACs), resulting in a noncash pension settlement charge of $1.7 billion. The company also noted that since December 2018, it had transferred approximately $11.6 billion in pension obligations, eliminating volatility for around 95,000 retirees. By 2023, the company reiterated its strategic intent to continue evaluating such transactions but shifted focus toward the broader financial and risk implications, including potential future contributions to the pension trust and the possibility of additional noncash settlement charges. The 2023 filing also introduced a nuanced risk: while most GACs relieve Lockheed of pension obligations, some could leave the company liable if the insurer defaults. This reflects a more cautious framing of pension risk transfer, acknowledging residual liability exposure not emphasized in 2022.",
      "llm_answer": "In the 2022 filing Lockheed Martin reported that it had already used its master retirement trust to buy group‑annuity contracts covering $4.9 billion of pension obligations (part of a total $11.6 billion of contracts purchased since 2018) and that the August 2021 transaction generated a one‑time, pretax, non‑cash pension‑settlement charge of $1.7 billion while eliminating the need for further cash contributions in 2022. The 2023 filing shows the company still viewing pension‑risk‑transfer deals as a key tool to “mitigate the risk … and reduce volatility,” but it reports no new settlement charge or additional GAC purchase for the year, instead emphasizing that it will continue to evaluate future transfers and that any future deal could require extra contributions or a non‑cash charge. Thus, the strategy moved from having just completed a large transfer that produced a material accounting charge to a more cautious, evaluation‑focused stance that keeps the option open but has not yet produced another financial impact.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) All key facts are correct: the $4.9 billion pension obligation transfer in August 2021, the $1.7 billion noncash settlement charge, and the $11.6 billion total transferred since 2018 are all accurately reported. The dates and financial figures match the original answer exactly, with acceptable formatting (e.g., $4.9 billion). (2) Quantitative accuracy is perfect—no errors in numbers, dates, or financial metrics. (3) The reasoning correctly captures the evolution: from a completed major transaction in 2022 with clear financial impact to a more cautious, forward-looking evaluation stance in 2023. The LLM notes the absence of new charges or purchases in 2023 and correctly identifies the strategic shift toward assessing future contributions and potential noncash charges. (4) The only minor omission is that the LLM does not explicitly mention the new risk highlighted in 2023 about potential residual liability if insurers default on GACs—a nuance present in the original answer. While the 'cautious' framing is noted, this specific risk is not articulated, slightly reducing qualitative completeness. However, the core strategic evolution and financial impacts are accurately synthesized across years and filings, making the answer semantically equivalent in intent and substance. Contextual relevance is excellent, directly addressing both financial impact and strategic intent as required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1520,
        "completion_tokens": 406,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Tesla's relationship with its financing partners evolved between 2022 and 2023, particularly in terms of accounts receivable management and leasing program risks?",
      "original_answer": "In 2022, Tesla disclosed that accounts receivable from financing partners could take up to approximately two weeks to settle based on contractual payment terms, directly impacting the company's short-term liquidity and balance sheet fluctuations. By 2023, Tesla highlighted increased complexity and risk in managing its financing programs, noting that its leasing business depends on securing adequate financing or partners, and that residual value risks from leased vehicles could negatively affect profitability. This indicates a shift from a focus on operational cash flow timing in 2022 to a broader concern over credit, compliance, and residual value risks in 2023 as the leasing program scaled.",
      "llm_answer": "In the 2022 filing Tesla said that most of its accounts‑receivable came from banks and leasing companies, that collections can take up to two weeks, and that no single partner represented ≥ 10 % of the balance – a structure it used to manage credit risk on its vehicle‑leasing and MyPower loan programs. By the 2023 filing the company stressed that its leasing business now depends even more on securing adequate financing from those partners, warning that a loss of partner funding or a drop in the resale‑value guarantees could impair the program’s profitability and limit vehicle deliveries, although the basic AR‑management approach (receivables from financing institutions with a diversified partner base) remains unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: in 2022, Tesla noted accounts receivable from financing partners (banks and leasing companies) could take up to two weeks to settle, and no single partner accounted for ≥10% of receivables—this matches the ground truth’s emphasis on credit risk management and operational timing. The 2023 update correctly reflects increased reliance on financing partners and new risks around resale-value guarantees (i.e., residual value risk), which could impact profitability and delivery capacity. (2) Quantitatively, all numbers and percentages (e.g., 'up to two weeks', '≥10%') are accurate and consistent with the original. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years and two aspects (accounts receivable management and leasing risks), identifying both continuity (diversified partner base, AR from institutions) and evolution (increased risk focus in 2023). (4) The only minor gap is that the LLM does not explicitly mention 'compliance' or 'credit risk' as broadened concerns in 2023, which the ground truth includes as part of the 'increased complexity.' However, it captures the core shift in risk profile. Wording differs but semantic meaning is equivalent. Contextual relevance is perfect—directly addresses both sub-questions about AR management and leasing risks over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 396,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "What changes occurred in Coca-Cola's fountain syrup distribution strategy between 2022 and 2023, and how did the roles of bottlers and fountain wholesalers evolve during this period?",
      "original_answer": "In 2022, Coca-Cola manufactured and sold fountain syrups directly to authorized fountain wholesalers (including certain authorized bottlers), who then sold or delivered the syrups to retailers. Bottlers in the U.S. were generally not authorized to manufacture fountain syrups. By 2023, the strategy evolved such that outside the United States, bottlers were typically authorized to manufacture fountain syrups using Coca-Cola concentrates, which they could sell to fountain retailers or authorized fountain wholesalers. This represents a shift from a more centralized syrup distribution model to a more integrated one, where bottlers play a more active role in the fountain syrup supply chain, particularly in international markets.",
      "llm_answer": "- 2022 10‑K – The Company said that in the United States it **manufactured all fountain syrups itself** and **sold them only to fountain retailers or to authorized fountain wholesalers (and, only in a limited way, to bottling partners as distributors).** Bottlers were expressly **not authorized to manufacture fountain syrups** in the U.S.; outside the U.S. bottlers could produce syrups and sell them either directly to retailers or to fountain wholesalers.  \n\n- 2023 10‑K – The Company’s description no longer contains the “bottlers are not authorized to manufacture fountain syrups” language. It now states that in the United States it **manufactures fountain syrups and sells them to fountain retailers, to authorized fountain wholesalers, or to bottling partners, which then distribute the syrups to retailers.** Thus, the role of bottlers expanded from a purely downstream distributor to a direct recipient (and potential distributor) of fountain syrups, while fountain wholesalers continue to operate alongside bottlers in the U.S. distribution channel.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the shift in Coca-Cola's fountain syrup distribution strategy between 2022 and 2023, particularly within the U.S., and accurately notes the removal of the restriction on bottlers manufacturing fountain syrups in the 2023 10-K. It correctly states that in 2022, Coca-Cola manufactured all fountain syrups in the U.S. and sold them directly to retailers or authorized fountain wholesalers, with limited involvement of bottlers as distributors, and that bottlers were not authorized to manufacture syrups in the U.S. This aligns with the ground truth. However, the LLM answer misrepresents the international aspect: it claims in 2022 that 'outside the U.S. bottlers could produce syrups,' but the ground truth states that this broader authorization for bottlers to manufacture syrups using concentrates occurred as a change in 2023, not as a pre-existing condition in 2022. Thus, the LLM incorrectly implies that international bottlers already had this role before 2023, when in fact the evolution was toward authorizing them to do so. This is a significant qualitative error in multi-hop reasoning and entity-time linkage. While the U.S.-focused evolution is well-explained, the answer fails to capture the core international shift described in the original answer, which is central to the question about how bottler and wholesaler roles evolved globally. There are no numerical inaccuracies (hence full quantitative score), and the response is contextually relevant, but the incomplete and partially incorrect synthesis of the international strategy limits its correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1457,
        "completion_tokens": 438,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of receivables and new investment activities?",
      "original_answer": "In 2023, AMD had receivables from the ATMP JV of $9 million, and there was no mention of any direct investment or loan made by AMD to the JV. By 2024, AMD's receivables from the ATMP JV increased to $12 million, and the company entered into a new $100 million one-year term loan agreement with one of the ATMP JVs to support its general corporate purposes. This marks a significant shift from a purely transactional relationship in 2023 to a more financially integrated one in 2024, where AMD is not only a customer but also a creditor and strategic supporter of the JV.",
      "llm_answer": "In 2024 AMD’s exposure to the ATMP joint venture grew modestly.  The receivable balance from the JV rose from $9 million at year‑end 2023 to $12 million at year‑end 2024, and AMD made a new equity contribution of $17 million, which lifted the carrying amount of its 15 % equity stake from roughly $99 million in 2023 to about $149 million in 2024.  In addition, AMD entered a one‑year, $100 million term‑loan with the JV in October 2024, further deepening the financial relationship.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly states that AMD's receivables from the ATMP JV increased from $9 million in 2023 to $12 million in 2024, and correctly identifies the new $100 million one-year term loan in October 2024, it introduces a major error by claiming AMD made a 'new equity contribution of $17 million' and that AMD holds a '15% equity stake'—information not present in the ground truth. The original answer explicitly states there was no mention of direct investment or loan by AMD in 2023, and no equity stake is referenced. The carrying amount increase from $99M to $149M is entirely fabricated. (2) Quantitative accuracy is partially correct for receivables and the term loan amount/date, but the $17M equity contribution and $99M/$149M carrying amounts are unsupported and incorrect. Calculations based on these numbers are therefore invalid. (3) The multi-hop reasoning is partially sound in connecting receivables and new loan activity to indicate a deepening financial relationship, but the reasoning is undermined by the inclusion of false investment details. The conclusion about deepening ties is directionally correct but based on incorrect premises. (4) Contextual relevance is high—the answer addresses the evolution of the financial relationship and focuses on receivables and investment-like activities as asked. However, the introduction of non-existent equity investments significantly reduces factual correctness, warranting a low overall correctness score despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 431,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Lockheed Martin's approach to managing its nonqualified defined benefit pension plans evolve between 2022 and 2023, particularly in terms of pension obligation settlements and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin purchased group annuity contracts to transfer $4.3 billion of gross defined benefit pension obligations and recognized a noncash pension settlement charge of $1.5 billion. In 2023, the company continued its strategy of reducing pension liabilities by making voluntary settlement payments of $414 million to approximately 6,500 former employees, significantly smaller in scale compared to the 2022 transaction. This indicates a shift from large-scale pension obligation transfers to a more targeted approach involving smaller settlements with former employees who had not yet started receiving benefits.",
      "llm_answer": "In 2022 Lockheed Martin continued to off‑load its non‑qualified pension risk by buying a group‑annuity contract that transferred about $4.3 billion of gross pension obligations (and related assets) to an insurer; the transaction was recorded as a non‑cash pension‑settlement charge of roughly $1.5 billion in the 2022 quarter. By 2023 the company shifted to a much smaller, voluntary approach – it paid $414 million in lump‑sum settlements to roughly 6,500 former employees, which reduced the benefit obligation but “had no impact on year‑2023 FAS pension income.” Thus the strategy moved from large, accounting‑impacting annuity purchases in 2022 to modest, cash‑settlement payments with negligible earnings effect in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key facts from the ground truth: in 2022, Lockheed Martin transferred $4.3 billion in pension obligations via group annuity contracts and recognized a $1.5 billion noncash settlement charge. In 2023, it made $414 million in voluntary lump-sum payments to about 6,500 former employees. These numbers, dates, and entities are accurate. (2) Quantitative accuracy is perfect—$4.3 billion, $1.5 billion, $414 million, and 6,500 employees all match the original answer. Format variations (e.g., 'about $4.3 billion' vs. '$4.3 billion') are acceptable and do not affect meaning. (3) The reasoning correctly synthesizes the shift in strategy from large-scale annuity transfers in 2022 to smaller, targeted settlements in 2023. The addition that the 2023 payments 'had no impact on year-2023 FAS pension income' is consistent with the original answer’s implication of reduced financial impact and adds context without contradicting the ground truth. (4) The only minor shortcoming is that the original answer explicitly frames this as a 'shift from large-scale... to a more targeted approach,' while the LLM implies it. However, the semantic meaning and factual content are equivalent. The LLM slightly enhances the answer with relevant accounting context. Thus, correctness is excellent, with only negligible difference in emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 384,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did AMD's financial relationship with the ATMP JV evolve between 2023 and 2024, particularly in terms of its investment and equity income?",
      "original_answer": "In 2023, AMD recorded $16 million in equity income from the ATMP JV and had a carrying value of $99 million as of the end of the year. In 2024, AMD contributed an additional $17 million to the JV, increasing its investment's carrying value to $149 million by the end of the year. Equity income also rose to $33 million. This indicates a significant increase in both AMD's investment stake and the returns it received from the ATMP JV.",
      "llm_answer": "In 2023 AMD reported **$16 million of equity‑income from its 15 % stake in the ATMP joint venture** and the investment was carried on the balance sheet at **about $99 million** (up from $83 million a year earlier). In 2024 that equity‑income more than doubled to **$33 million**, and AMD **added a $17 million cash contribution** to the JV, raising the carrying amount of the investment to **roughly $149 million** as of year‑end 2024【page_78】【page_75】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: $16 million equity income in 2023, $33 million in 2024, a $17 million contribution in 2024, and carrying values of $99 million (2023) and $149 million (2024). These numbers match the original answer exactly, with acceptable formatting variations (e.g., 'about' and 'roughly' used for rounding, which does not affect factual accuracy). (2) Quantitative accuracy is perfect: all dollar amounts, time periods, and implied changes (e.g., increase in carrying value from $99M to $149M after $17M contribution) are consistent with the data. The mention of a prior year carrying value of $83 million is an additional detail not in the ground truth but is factually consistent and does not contradict it. (3) The multi-hop reasoning is sound—LLM synthesizes investment changes and equity income across two years and correctly infers increased returns and investment. The addition of AMD's 15% stake is extra context not in the original answer but is factually accurate and enhances understanding without distorting the core response. (4) The answer is semantically equivalent to the ground truth, with slightly more detail and clear contextualization. The only minor deduction is for adding 'about' and 'roughly' where the original data appears precise, but this does not undermine correctness. All parts of the question—evolution of investment and equity income—are fully addressed with accurate, relevant information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 416,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Johnson & Johnson's financial stake and ownership relationship with Kenvue evolve between 2023 and 2024, particularly in terms of retained equity and associated gains or losses?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% ownership stake in Kenvue valued at $4.3 billion following the exchange offer, which resulted in a non-cash gain of $21.0 billion, including a $2.8 billion gain on the retained shares. By the end of 2024, the company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock, thereby eliminating its ownership stake and incurring a loss of approximately $0.4 billion in the process. This marks a full exit from Kenvue after initially reducing its stake significantly in 2023.",
      "llm_answer": "In 2023, after the Kenvue IPO Johnson & Johnson held about 89.6 % of Kenvue’s shares; the August 23, 2023 exchange offer sold 80.1 % of that stake, leaving J&J with a 9.5 % residual interest that was recorded in “other assets” at a fair‑value of roughly $4.3 billion (later $3.9 billion).  The de‑consolidation generated a one‑time, tax‑free gain of $21 billion (including a $2.8 billion gain on the retained Kenvue stock) in 2023.  In 2024 J&J completed a debt‑for‑equity swap of its remaining 182 million Kenvue shares, eliminating its ownership entirely and recognizing an approximately $0.4 billion loss in other (income) expense.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth with only minor discrepancies. (1) Quantitatively: The key numbers are correct — the 9.5% retained stake, $4.3 billion valuation (later adjusted to $3.9 billion, which is additional but not contradictory), $21.0 billion total gain (rounded to $21 billion), $2.8 billion gain on retained shares, and the 2024 debt-for-equity exchange of 182 million shares (precisely 182,329,550 in truth) resulting in a ~$0.4 billion loss. The only minor inaccuracy is the claim that J&J held 89.6% pre-exchange and sold 80.1% of that — while consistent with a reduction to 9.5%, this level of detail is not in the ground truth and introduces unverified intermediate percentages; however, it does not contradict the final retained stake. (2) The timeline is correct: 2023 exchange offer leading to 9.5% stake and $21B gain, followed by full exit in 2024 via debt-for-equity swap. (3) Multi-hop reasoning is sound — the answer correctly synthesizes the deconsolidation gain, retained equity accounting, and subsequent disposal. (4) The answer addresses all parts of the question: evolution of ownership, retained equity, and gains/losses in both years. The slight over-specification of initial ownership and sale percentage is not factually incorrect but goes beyond the ground truth; this does not undermine correctness. Wording differences (e.g., 'recorded in other assets', 'tax-free', 'later $3.9 billion') add context without distorting facts. Overall, the answer is semantically equivalent and factually robust.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 434,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. evolve between 2022 and 2023, particularly in terms of its inclusion in guarantee agreements?",
      "original_answer": "AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained consistent between 2022 and 2023, with the company continuing to guarantee certain obligations of Southwestern Bell Telephone Co. in both years. In 2022, the guarantee was listed in Exhibit 4-c, which included multiple entities such as Southwestern Bell Telephone Company. In 2023, the guarantee was again referenced in Exhibit 4-c, maintaining the same inclusion of Southwestern Bell Telephone Co. within the list of guaranteed entities. This indicates no change in the nature or scope of the guarantee.",
      "llm_answer": "In the 2022 Form 10‑K the filing does not list a guarantee for Southwestern Bell Telephone Co. among the company’s disclosed guaranty agreements. By the 2023 Form 10‑K, AT&T has added a specific “Guaranty of certain obligations of Pacific Bell Telephone Co. and **Southwestern Bell Telephone Co.**” (listed as Exhibit 4‑c under item 4‑b), showing that the company’s financial guarantee relationship with Southwestern Bell Telephone Co. was formally included in the guarantee agreements in 2023.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. According to the ground truth, AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained consistent between 2022 and 2023, with the guarantee included in Exhibit 4-c in both years. However, the LLM claims that the guarantee was *not* listed in 2022 and was *added* in 2023, which contradicts the original answer. This misrepresents the evolution of the relationship, asserting a change (addition) where none occurred. The mention of Pacific Bell Telephone Co. is not present in the ground truth and introduces an unsupported detail. The LLM also mislabels Exhibit 4-c as being under 'item 4-b', which is not corroborated by the original answer and adds procedural inaccuracy. While the question involves multi-hop reasoning across years and filings, the LLM fails to correctly synthesize the information, instead inferring a change that did not happen. There are no correct quantitative elements (dates are misapplied in context), and the qualitative reasoning is flawed. The response is somewhat contextually relevant as it discusses the right entities and document type (Form 10-K, Exhibit 4-c), but the core conclusion is false.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 346,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2023, particularly in terms of strategic positioning and program development responsibilities?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a growth area that was dependent on U.S. Government authorization and funding, and was listed among other key development areas like classified programs and next-generation franchise programs. By 2023, the company's role had evolved significantly, with hypersonics programs now explicitly listed among major programs under the Space segment, indicating a more concrete and active role in designing, developing, and building hypersonic strike weapons for the U.S. Army and Navy. This reflects a shift from a potential growth area to a clearly defined and active program portfolio.",
      "llm_answer": "In the 2022 Form 10‑K, hypersonics was cited only in the risk‑factor discussion as one of the “key areas such as hypersonics programs” that could affect the company’s growth, indicating that it was viewed mainly as a strategic growth priority. By the 2023 Form 10‑K, Lockheed Martin is describing hypersonics as an active portfolio‑segment: the Space section lists “hypersonics programs … to design, develop and build hypersonic strike weapons,” and the Aeronautics section notes that its Advanced Development (Skunk Works) organization is focused on next‑generation capabilities including hypersonics. Thus, between 2022 and 2023 the company moved from positioning hypersonics as a future growth focus to taking concrete development and production responsibility for multiple Army‑ and Navy‑focused hypersonic strike‑weapon programs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, hypersonics was mentioned as a strategic growth area, specifically in the risk factors section, indicating dependency on government funding and authorization. In 2023, it accurately notes the shift to active program status, with explicit mention in the Space segment and involvement in designing, developing, and building hypersonic strike weapons. The inclusion of Skunk Works in Aeronautics adds contextual depth, though not in the original answer, it does not contradict and is consistent with Lockheed's structure. (2) There are no numerical values to verify, so quantitative accuracy is not applicable beyond correct use of years (2022, 2023), which are accurate. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of 10-K filings, identifying a shift in strategic positioning and program responsibility. It infers evolution from potential growth area to active development role, which is the core of the ground truth. (4) The answer is contextually excellent, directly addressing both strategic positioning and program development responsibilities. The only minor deviation is the mention of Skunk Works in Aeronautics, which adds detail beyond the ground truth but is not incorrect. Overall, the answer captures the essential evolution accurately and completely, warranting a 9/10 due to slight over-attribution of detail not in the original, but without factual error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 422,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did the balance of the U.S. litigation escrow account evolve from fiscal year 2022 to fiscal year 2023, and what were the respective amounts deposited into the account during those years?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1.4 billion as of September 30, 2022, to $3.089 billion as of September 30, 2023. During fiscal year 2022, $850 million was deposited into the account, while in fiscal year 2023, $1.0 billion was deposited.",
      "llm_answer": "- At the end of fiscal 2022 the U.S. litigation escrow account held **about $1.4 billion**; by the end of fiscal 2023 the balance had risen to **about $1.76 billion**.  \n- The company **deposited $850 million** into the escrow account during fiscal 2022, and **deposited $1.0 billion** during fiscal 2023.  \n\nThese figures come from the 2022 filing (page 46) and the 2023 filing (pages 73‑74 and the restricted‑cash reconciliation on page 72).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $850 million deposit in fiscal year 2022 and $1.0 billion deposit in fiscal year 2023, which matches the ground truth. However, the ending balance for fiscal year 2023 is incorrect: the LLM states 'about $1.76 billion' instead of the correct $3.089 billion. The starting balance of $1.4 billion for fiscal 2022 is accurate. (2) Quantitative accuracy is severely impacted by the incorrect 2023 balance. The actual increase from $1.4B to $3.089B reflects a net addition of $1.689B, consistent with the $850M and $1.0B deposits (plus potential interest or adjustments). The LLM's $1.76B figure does not align with these inputs, suggesting a failure in synthesis or data extraction. (3) The reasoning is partially sound—multi-hop information about deposits across two years is correctly retrieved, and sources are cited. However, the balance evolution is misrepresented, indicating a failure to correctly extract or reconcile the ending balance from the 2023 filing. This undermines the multi-hop synthesis required to describe how the account evolved. (4) Contextual relevance is high because the answer addresses both parts of the question (balance evolution and deposits) and cites specific pages. However, the major numerical error in the 2023 balance significantly reduces correctness and quantitative accuracy, warranting a mid-low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1193,
        "completion_tokens": 387,
        "total_tokens": 1581
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the role and positioning of Outdoor Garden within HD's product strategy evolved from 2022 to 2024, based on its classification and performance metrics?",
      "original_answer": "In 2022, Outdoor Garden was disclosed as a distinct product line with $10,317 million in net sales, accounting for 6.8% of total net sales, indicating its importance as a standalone category. By 2024, Outdoor Garden was grouped under the broader 'Hardlines' merchandising department, suggesting a strategic integration into a larger product segment. This shift reflects a change in how HD positions Outdoor Garden within its overall product portfolio, moving from a separate focus area to a component of a consolidated category.",
      "llm_answer": "In the 2022 filing Outdoor Garden was listed as a separate merchandising department within the **Hardlines** product line and generated $10.0 billion of net sales, representing **about 6.4 % of total net sales**. By the 2024 filing the company had re‑aligned its merchandising structure, but Outdoor Garden remained in the Hardlines group (now grouped with Hardware, Indoor Garden, Power and Storage & Organization) and its sales rose to **$10.3 billion, or roughly 6.5 % of net sales**. Thus, from 2022 to 2024 Outdoor Garden’s classification stayed the same—still a core Hardlines category—but its contribution grew modestly in both dollar amount and share of overall sales, underscoring a steady, slightly expanding role in Home Depot’s product strategy.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both quantitative and qualitative aspects. According to the ground truth, in 2022, Outdoor Garden was a *distinct product line* with $10,317 million ($10.317 billion) in net sales, representing 6.8% of total net sales. The LLM incorrectly states $10.0 billion and 6.4%, which are not aligned with the original data. In 2024, the ground truth indicates that Outdoor Garden was *grouped under the broader 'Hardlines' department*, implying a structural reclassification from a standalone line to a subcomponent. However, the LLM claims Outdoor Garden was *already part of Hardlines* in 2022, which contradicts the original answer and misrepresents the evolution. Additionally, the LLM states sales rose to $10.3 billion (6.5%) in 2024, but the ground truth does not provide 2024 performance metrics—only the reclassification—so introducing new sales figures is unsupported. (2) Quantitative accuracy is partially correct: $10.3 billion is close to $10,317 million, but the 2022 percentage (6.4% vs 6.8%) and the 2024 sales/share claims are inaccurate or unverifiable. (3) The multi-hop reasoning is flawed: the key insight in the ground truth is the *strategic shift from standalone to integrated category*, but the LLM incorrectly assumes continuity within Hardlines, reversing the narrative of change. It fails to recognize the significance of the reclassification as a downgrading of strategic prominence. (4) Despite these errors, the answer is contextually relevant—addressing classification and performance trends—and uses appropriate terminology. Hence, partial credit is given for structure and relevance, but major deductions apply for factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 475,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has AMD maintained its emphasis on an engaging and open environment as its global workforce expanded from 2023 to 2024, and what does this suggest about its talent retention strategy in a competitive semiconductor industry landscape?",
      "original_answer": "In 2023, AMD reported having approximately 26,000 employees and emphasized being at its best when 'our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' By 2024, AMD’s global workforce grew to approximately 28,000 employees, and the company reiterated the same language, stating it is 'at our best when our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' Despite a 7.7% increase in workforce size, AMD maintained identical messaging around its cultural values. This suggests that AMD is intentionally preserving its inclusive and innovative culture as a strategic element to retain top talent in the highly competitive semiconductor industry, where attracting skilled professionals is critical.",
      "llm_answer": "AMD’s 2023 filing noted a workforce of roughly 26,000 employees and stressed that “we are at our best when our culture … works together in an engaging and open environment.” By the 2024 filing the headcount had grown to about 28,000 and AMD reiterated the same mantra, adding that its annual AMDer Survey again placed the company in the top‑10 % of technology peers for culture, manager quality and employee engagement, that more than 85 % of new hires join an Employee Resource Group, and that it continues to back the open culture with competitive pay, flexible hybrid/remote options, robust mentorship and leadership‑development programs. Together, these actions show AMD is using a deliberately inclusive, high‑visibility engagement model and generous total‑rewards package to lock in talent as the semiconductor market becomes ever more competitive.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the workforce numbers for 2023 (~26,000) and 2024 (~28,000), which aligns with the ground truth, and accurately notes the repetition of AMD's cultural statement. However, it introduces several specific details not present in the original answer or implied by the knowledge graph: the claim that the AMDer Survey placed AMD in the top-10% of tech peers for culture, manager quality, and engagement; that over 85% of new hires join an Employee Resource Group; and specific programs like competitive pay, hybrid/remote options, mentorship, and leadership development. These additions, while plausible, are not supported by the provided ground truth and represent unverified elaborations. (2) The quantitative accuracy is partially correct: the headcount figures (26,000 and 28,000) are accurate, and the implied ~7.7% growth is correct (2,000 / 26,000 ≈ 7.7%), but the 85% figure and top-10% survey ranking are unsupported and thus factually unverifiable from the source. (3) The multi-hop reasoning is sound in linking consistent cultural messaging with talent retention strategy, and the conclusion about strategic culture preservation in a competitive landscape is logically consistent with the original. However, the LLM overreaches by introducing new data points that were not in the source, weakening the fidelity of the synthesis. (4) The contextual relevance is high—the answer directly addresses how AMD maintained its culture during workforce expansion and infers a strategic talent retention approach. While the core insight is valid, the inclusion of unsupported specifics reduces factual correctness, warranting a mid-range score of 6 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1450,
        "completion_tokens": 467,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did AT&T's relationship with The Ohio Bell Telephone Company evolve between 2022 and 2023, particularly in terms of its guarantee obligations?",
      "original_answer": "In 2022, AT&T had a guarantee obligation covering The Ohio Bell Telephone Company as part of a broader list of subsidiaries under Exhibit 4-c, which was originally filed in 2011. In 2023, although the structure of the guarantee remained similar, the exhibit reference was updated to reflect current documentation practices, indicating a continuation of the guarantee without any explicit discontinuation or expansion. This suggests that the nature of the relationship remained stable, but documentation was maintained in line with current reporting standards.",
      "llm_answer": "In the 2022 Form 10‑K, AT&T disclosed that it had provided a guaranty of certain obligations of The Ohio Bell Telephone Company (listed in Exhibit 4‑d). The 2023 Form 10‑K repeats the same disclosure—The Ohio Bell Telephone Company is again included in the guaranty of certain obligations (Exhibit 4‑d). Thus, between 2022 and 2023 AT&T’s relationship with The Ohio Bell Telephone Company did not change; the guarantee obligation remained in place.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the core facts: AT&T maintained its guarantee obligation for The Ohio Bell Telephone Company in both 2022 and 2023, with no change in the relationship. The answer correctly identifies that the guarantee was disclosed in both years' Form 10-Ks and included in Exhibit 4-d (though the original answer cites Exhibit 4-c in 2011 and notes an update in exhibit reference in 2023). There is a minor discrepancy in the exhibit number: the LLM states Exhibit 4-d for both years, while the ground truth indicates Exhibit 4-c was originally filed in 2011 and updated in 2023—suggesting possible exhibit renumbering. However, the LLM’s assertion that the disclosure 'repeats the same' may reflect consistency in content despite potential exhibit renumbering, which is plausible. The answer lacks the nuance about documentation updates reflecting current reporting standards, slightly reducing completeness and qualitative accuracy. No quantitative errors exist—dates (2022, 2023) and entities (AT&T, The Ohio Bell Telephone Company) are accurate. The reasoning is sound: the model correctly infers stability in the relationship based on consistent disclosure. Contextual relevance is perfect—it directly addresses the evolution of the relationship and guarantee obligations. Minor omission of documentation practice updates prevents a top score, but overall factual correctness remains high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 402,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of gains on retained and sold ownership interests?",
      "original_answer": "In 2023, GE reported a $5.7 billion increase in corporate operating profit due to higher gains on retained and sold ownership interests, primarily driven by its AerCap and GE HealthCare investments. However, in 2024, the gains on retained and sold ownership interests decreased by $5.2 billion compared to 2023, again primarily related to AerCap and GE HealthCare. This indicates a significant reduction in the value or realization of these investments year-over-year.",
      "llm_answer": "In 2023 GE booked a **$5.8 billion gain** on retained and sold ownership interests – the bulk of it coming from its AerCap (and GE HealthCare) investment. By 2024 that windfall had essentially disappeared; the gain fell to roughly **$0.5‑$0.6 billion**, a **decline of about $5.2 billion** versus the prior year, reflecting the reversal of the AerCap‑related upside.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely correct in both factual content and reasoning. The ground truth states a $5.7 billion gain in 2023, while the LLM reports $5.8 billion — a minor $0.1 billion discrepancy, likely due to rounding or source variation, but within acceptable tolerance. The 2024 decline of $5.2 billion is accurately reflected in the LLM answer, which calculates a drop to $0.5–0.6 billion (i.e., $5.8B - $5.2B = $0.6B), aligning closely with the ground truth's implied post-decline value. (2) Quantitatively, the $5.2 billion year-over-year decrease is correctly reported, and the directional change (sharp decline) is accurate. The slight variance in the 2023 base figure ($5.8B vs $5.7B) prevents a perfect score, but all derived values and comparisons remain logically consistent. (3) The multi-hop reasoning is sound: the LLM correctly identifies AerCap (and GE HealthCare) as the primary drivers in both years, synthesizes the change in gains between 2023 and 2024, and infers the diminished financial impact in 2024. It correctly attributes the decline to the reversal of AerCap-related gains. (4) The answer is contextually fully relevant, directly addressing the evolution of GE's financial relationship with AerCap in terms of gains on ownership interests. Semantic equivalence is strong — despite slightly different phrasing and a negligible numerical variance, the core message (large gain in 2023, ~$5.2B drop in 2024 due to AerCap/HealthCare) matches the ground truth. Minor deduction only for the $0.1B overstatement in the 2023 gain.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 431,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Home Depot's strategic use of HD Supply evolved between 2022 and 2024, particularly in relation to its focus on professional customers and MRO services?",
      "original_answer": "In 2022, Home Depot highlighted the integration risks and challenges associated with its acquisition of HD Supply in 2020, noting that achieving synergies and benefits was subject to significant uncertainty and complexity. By 2024, HD Supply had become a core component of Home Depot’s strategy to serve professional customers, specifically through its MRO offerings to multifamily, hospitality, healthcare, and government housing facilities. The 2024 filing explicitly references HD Supply as a key contributor to Pro-focused growth initiatives, indicating a shift from post-acquisition integration concerns to a more mature and strategic role in supporting Home Depot's professional customer segment.",
      "llm_answer": "In the 2022 filing, Home Depot described HD Supply as a subsidiary it had acquired in 2020 that “provides MRO products and related value‑added services … primarily through our subsidiary HD Supply” to multifamily, hospitality, health‑care and government facilities, positioning it as a way to serve its professional‑customer segment. By the 2024 filing, HD Supply is still the core platform for those MRO offerings, but the company now frames it explicitly as part of a broader “Pros” growth strategy—highlighting a dedicated online site (hdsupply.com) and its role in delivering customized, credit‑enabled, high‑volume solutions for professional renovators, contractors and facility managers. Thus, between 2022 and 2024 Home Depot moved from treating HD Supply as a standalone MRO subsidiary to integrating it more tightly into its overall professional‑customer ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: HD Supply was acquired in 2020, serves MRO needs for multifamily, hospitality, healthcare, and government sectors, and supports professional customers. The evolution from a standalone subsidiary in 2022 to a strategically integrated component of the 'Pros' growth strategy by 2024 is correctly captured. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across 2022 and 2024 filings to show a strategic shift—from integration challenges (implied in 2022 tone) to active strategic role in 2024. The mention of hdsupply.com and credit-enabled, high-volume solutions adds contextual detail consistent with deeper integration, even if not in the original answer; this does not contradict but enriches the narrative. (4) The only minor gap is that the LLM answer does not explicitly mention the 'integration risks and uncertainties' emphasized in the 2022 filing per the ground truth, which slightly weakens the contrast between early challenges and later maturity. However, the implication is present in describing HD Supply as initially 'standalone' and later 'integrated.' Overall, the answer is factually correct, contextually rich, and semantically equivalent to the original answer with only slight omission of the risk language. Hence, a 9/10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 433,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has AMD's reliance on cross-licensing agreements evolved between 2023 and 2024, particularly in terms of patent portfolio size and its implications for technology exchange?",
      "original_answer": "In 2023, AMD reported having approximately 18,500 patent matters worldwide, including 12,800 issued patents and 5,600 pending applications. In 2024, this portfolio grew slightly to approximately 18,800 patent matters, with 13,200 issued patents and 5,600 pending applications. This increase in issued patents indicates a strengthening of AMD's intellectual property position, which likely enhances its leverage in cross-licensing agreements. AMD continues to emphasize that these agreements are critical for transferring and receiving technology and intellectual property rights, suggesting that the company's reliance on such agreements remains strong and possibly more strategically advantageous in 2024 due to the expanded patent portfolio.",
      "llm_answer": "In its 2023 filing AMD reported roughly 7,500 U.S. patents, 2,000 U.S. pending applications and about 12,800 issued patents worldwide (≈18,500 total patent matters). By the 2024 filing the U.S. patent count was unchanged, pending applications fell to ≈1,900, while worldwide issued patents rose to ≈13,200 (≈18,800 total matters). The company’s disclosure still emphasizes “numerous cross‑licensing and technology‑exchange agreements,” indicating that as the portfolio has modestly expanded (about 400 additional issued patents), AMD’s reliance on these agreements has remained strong and is likely supporting broader technology sharing with partners.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct in its portrayal of AMD's patent portfolio evolution and reliance on cross-licensing agreements. It correctly identifies the total worldwide patent matters (≈18,500 in 2023 and ≈18,800 in 2024) and the increase in worldwide issued patents from ≈12,800 to ≈13,200. However, it introduces U.S.-specific data (7,500 U.S. patents, 2,000 pending) that are not present in the original answer and may not be supported by the ground truth used here, which focuses on global totals. The drop in U.S. pending applications to ≈1,900 is also not in the original and introduces unverified detail. (2) The core global numbers (12,800 → 13,200 issued, 5,600 pending both years, total 18,500 → 18,800) are accurately reflected in the LLM answer, though the breakdown into U.S. vs. worldwide is an addition not in the source. The calculation of a ~400 increase in issued patents is correct (13,200 - 12,800 = 400) and supports the conclusion. (3) The multi-hop reasoning is sound: the LLM correctly infers that a growing patent portfolio strengthens AMD’s position in cross-licensing and that continued emphasis on such agreements indicates sustained reliance. It synthesizes patent growth with strategic implications appropriately. (4) The answer is contextually excellent—directly addressing patent portfolio changes and their impact on technology exchange via cross-licensing. The qualitative reasoning and conclusion align with the original. However, the quantitative accuracy is slightly reduced due to the introduction of unverified U.S.-specific figures not in the ground truth, even if they might exist in actual filings. Overall, the core facts and synthesis are correct, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 477,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did Johnson & Johnson's financial stake and strategic relationship with Kenvue evolve from 2023 to 2024, particularly regarding the retention and subsequent disposal of Kenvue shares?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% stake in Kenvue valued at $4.3 billion after completing the exchange offer in August. This stake was recorded in other assets and experienced a $0.4 billion expense by year-end due to subsequent changes. By 2024, the company completed a debt-for-equity exchange in May, using its remaining 182,329,550 shares of Kenvue Common Stock to satisfy $3.6 billion of commercial paper. This resulted in a $0.4 billion loss and marked the complete exit from Kenvue, ending any financial stake in the company.",
      "llm_answer": "In the 2023 filing Johnson & Johnson disclosed that after the August 23, 2023 exchange offer it retained about 9.5 % of Kenvue’s common stock (≈182 million shares) – recorded as a $4.3 billion equity‑investment in “other assets” and supported by transition‑service, manufacturing‑service and trademark agreements that were expected to run for up to 24 months. By the 2024 filing the company had eliminated that holding: on May 17 2024 it completed a debt‑for‑equity exchange, swapping its remaining Kenvue shares for outstanding commercial‑paper debt, which removed the equity investment from the balance sheet (carrying value fell to $0) and generated a roughly $0.4 billion loss in other (income) expense, ending J&J’s direct ownership of Kenvue.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Johnson & Johnson retained a 9.5% stake in Kenvue valued at $4.3 billion after the August 2023 exchange offer, recorded in other assets, and disposed of the remaining ~182 million shares (specifically 182,329,550 in ground truth; '≈182 million' is an acceptable approximation) in a May 17, 2024 debt-for-equity exchange. The $0.4 billion expense/loss is correctly reported, with the 2024 transaction resulting in a $0.4 billion loss and removal of the investment from the balance sheet. (2) Quantitative accuracy is excellent: percentages (9.5%), dollar amounts ($4.3B, $0.4B), share count approximation, and date (May 17, 2024) align with or closely approximate the ground truth. The use of '≈182 million' is reasonable given the exact figure is 182,329,550. (3) Multi-hop reasoning is sound—information is synthesized correctly across 2023 and 2024 filings, showing the evolution from partial retention to complete exit via a specific financial mechanism. (4) Contextual details such as transition-service agreements and the impact on the balance sheet (carrying value to $0) add appropriate qualitative depth without introducing error. The answer fully addresses the evolution of the financial stake and strategic relationship, concluding with complete disposal and exit. All scores are 10 due to full factual correctness, precise numbers, logical reasoning, and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 410,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AT&T's relationship with Indiana Bell Telephone Co. Inc. evolved between 2022 and 2023 in terms of its inclusion in guarantee disclosures?",
      "original_answer": "In 2022, Indiana Bell Telephone Co. Inc. was listed among the entities whose obligations were guaranteed by AT&T under Exhibit 4-d. In 2023, the company continued to reference the same guarantee for Indiana Bell Telephone Co. Inc. under Exhibit 4-d, indicating that the guarantee remained in place without any modification or removal. Therefore, there was no change in the nature or status of the guarantee relationship between the two entities from 2022 to 2023.",
      "llm_answer": "In the 2022 Form 10‑K, AT&T’s guarantee schedule does not list Indiana Bell Telephone Co. Inc. at all. By the 2023 Form 10‑K, Indiana Bell Telephone Co. Inc. appears in Exhibit 4‑c (“Guaranty of certain obligations of … Indiana Bell Telephone Co. Inc.”), indicating that AT&T added a specific guarantee for that subsidiary between the two years.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both facts and reasoning. (1) According to the ground truth, Indiana Bell Telephone Co. Inc. was listed in AT&T’s guarantee disclosures in 2022 under Exhibit 4-d, but the LLM claims it was not listed at all in 2022—this is false. (2) The LLM states that in 2023, the company appeared in Exhibit 4-c with a new guarantee, implying a change in the relationship; however, the original answer confirms the guarantee was unchanged and still referenced under Exhibit 4-d, not 4-c. (3) The multi-hop reasoning fails: instead of recognizing continuity between years, the model incorrectly infers an addition or change in the guarantee status. (4) Entity accuracy is poor—wrong exhibit (4-c vs 4-d), wrong characterization of inclusion (‘not listed’ vs ‘listed’), and incorrect conclusion about evolution. The only relevant aspect is that the answer addresses the right entities and time frame, hence minimal contextual relevance. All key facts—presence in 2022, exhibit number, and status change—are wrong, leading to a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1202,
        "completion_tokens": 307,
        "total_tokens": 1509
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How did GE's financial relationship with AerCap evolve from 2023 to 2024, particularly in terms of cash involvement and investment gains?",
      "original_answer": "In 2023, GE had a continuing financial involvement with AerCap through a note receivable, product leases, and transition services, which included a net cash payment of $203 million to AerCap. By 2024, GE no longer had continuing operational involvement but instead held an investment stake in AerCap. This shift resulted in a significant financial impact, as GE reported a decrease in gains on retained and sold ownership interests by $5.2 billion, largely attributed to its AerCap and GE HealthCare investments. This indicates a strategic and financial transition from operational collaboration to investment-based returns.",
      "llm_answer": "In 2023 GE still owned an AerCap equity stake and a senior note, so it recorded a $203 million net cash outflow to AerCap for product‑leasing and transition‑service activities (see page 51) and reported a large gain on retained and sold ownership interests that included the AerCap investment (the $5.7 billion boost noted in the 2023 earnings discussion, page 9). By 2024 GE had sold its remaining AerCap shares (the note in page 52) and the AerCap note was the only residual exposure; consequently there was no cash payment to AerCap and the gains on AerCap disappeared, contributing to a $5.2 billion decline in gains on retained and sold ownership interests in 2024 (page 9).",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution in GE's financial relationship with AerCap from operational involvement in 2023 to investment exit in 2024, and correctly identifies the $5.2 billion decline in gains in 2024. However, it incorrectly states that GE recorded a 'large gain' in 2023 including AerCap, citing a $5.7 billion boost, which contradicts the ground truth that the $5.2 billion decrease in 2024 was due to lower gains from AerCap and GE HealthCare—implying 2023 had higher gains. While the direction of change is correct, the specific $5.7 billion figure is not in the original answer and introduces unsupported detail. The $203 million net cash outflow to AerCap in 2023 is correctly reported. (2) Quantitative accuracy issues: the $5.7 billion gain in 2023 is not mentioned in the ground truth and appears fabricated or misattributed; the original answer does not quantify the 2023 gain, only the $5.2 billion decrease in 2024. The LLM incorrectly implies the $5.2 billion decline is due solely to AerCap, while the ground truth attributes it to both AerCap and GE HealthCare. (3) Multi-hop reasoning is mostly sound: the model correctly infers that selling the AerCap shares and winding down the note led to no further cash payments and disappearance of gains. It synthesizes the shift from operational to investment-based relationship, though it overstates specificity on gains. (4) Scores justified: correctness 7 due to accurate structural narrative but flawed quantitative claims; quantitative accuracy 6 due to incorrect or unsupported figures; qualitative accuracy 8 for correct entity identification and logical flow; contextual relevance 10 as all parts of the question are addressed with relevant financial and temporal context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 481,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has The Home Depot's approach to store appearance and its role in competition evolved from 2022 to 2024, particularly in relation to customer experience and digital integration?",
      "original_answer": "In 2022, The Home Depot emphasized store appearance as a competitive factor alongside customer experience, price, and product availability. The company highlighted the importance of store location, appearance, and ease of shopping experience in both brick-and-mortar and online contexts. By 2024, the company expanded its focus, integrating store appearance into a broader 'interconnected shopping experience' that linked physical stores, digital platforms, and on-site services. The 2024 report specifically noted investments in digital platforms to enhance the presentation and ease of navigation for users, reflecting a shift toward digital integration as a core component of store and shopping experience competitiveness. This evolution shows a strategic shift from physical store aesthetics alone to a more holistic, digitally-enhanced customer experience.",
      "llm_answer": "In its 2022 filing, Home Depot noted that “store and branch location and appearance, presentation of merchandise, and ease of the shopping experience” were key competitive levers, but the discussion was limited to describing appearance as one of many factors that affect customer experience. By the 2024 filing the company had moved from simply recognizing appearance to actively reshaping it—investing in “store refresh packages, way‑finding signage, redesigned front‑end areas, electronic‑shelf‑labels, self‑service lockers, curb‑side pickup and mobile‑app‑enabled store navigation” and equipping associates with digital “hdPhone” devices and computer‑vision tools—to make the store a seamless, digitally‑integrated hub that drives higher satisfaction and strengthens its competitive position.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution from 2022 to 2024 in The Home Depot's approach: in 2022, store appearance was one of several competitive factors, and by 2024, it became part of a more integrated, digitally enhanced shopping experience. The specific initiatives mentioned—store refresh packages, way-finding signage, electronic shelf labels, self-service lockers, curbside pickup, mobile-app navigation, and digital tools for associates—are consistent with the strategic shift toward digital integration described in the original answer. (2) There are no numeric values, dates, or financial figures in either answer, so quantitative accuracy is not applicable beyond correct use of years (2022 and 2024), which are accurate. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points and connects changes in language and strategy regarding store appearance and digital integration. The LLM adds specific examples (e.g., hdPhone, computer vision) that enrich the answer without contradicting the ground truth. (4) The only reason for not scoring a perfect 10 is that the LLM answer, while more detailed, slightly omits the explicit framing of 'interconnected shopping experience' as used in the original 2024 description, though the concept is clearly conveyed through examples. Overall, the answer is factually correct, contextually rich, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 412,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of resales and new financial arrangements?",
      "original_answer": "In 2023, AMD's resales to the ATMP JV amounted to $14 million, with no mention of direct financial arrangements such as loans. By 2024, AMD's resales to the ATMP JV increased significantly to $121 million. Additionally, in October 2024, AMD entered into a one-year $100 million term loan agreement with one of the ATMP JVs to support the joint venture's general corporate purposes. This indicates a notable deepening of the financial relationship, moving beyond operational services to include direct financial support.",
      "llm_answer": "In 2023 AMD’s only cash‑flow with the ATMP joint venture was modest – it bought about $1.7 billion of inventory from the JV, resold roughly $14 million to the JV and carried $363 million of payables and $9 million of receivables. In 2024 the resale volume jumped to $121 million (still on a $1.7 billion purchase base), payables rose to $476 million and receivables to $12 million, and AMD added a new $100 million one‑year term loan to the JV (interest at SOFR + 50 bps, secured by the JV’s receivable), a financing arrangement that did not exist in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that AMD's resales to the ATMP JV were $14 million in 2023 and increased to $121 million in 2024, it introduces incorrect data not present in the ground truth: specifically, the claim that AMD 'bought about $1.7 billion of inventory from the JV' in both years is unsupported by the original answer and contradicts typical JV dynamics where AMD would be the supplier, not the buyer. Additionally, the figures of $363M payables (2023), $476M payables (2024), $9M/$12M receivables, and the interest rate term (SOFR + 50 bps) and collateral (JV’s receivable) for the loan are all absent from the ground truth and thus unverified or incorrect. (2) Quantitative accuracy is low because while the resale figures ($14M and $121M) and the $100M loan amount are correct, the other financial figures (inventory purchases, payables, receivables, interest rate) are either fabricated or misrepresented. The $1.7B inventory purchase is particularly problematic as it distorts the nature of the relationship. (3) The reasoning partially captures the evolution—increased resales and new loan arrangement—but misrepresents the direction of financial flows by suggesting AMD is a major buyer from the JV, which undermines the multi-hop synthesis. The core insight about deepening financial ties due to the new loan is valid, but it's overshadowed by incorrect premises. (4) Contextual relevance is high because the answer addresses the evolution of the financial relationship, resales, and new arrangements as asked. However, the inclusion of unsupported metrics reduces reliability. The answer gives the impression of precision but introduces noise and inaccuracies that compromise correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 482,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has Johnson & Johnson's approach to privacy compliance programs evolved between 2023 and 2024, particularly in response to new privacy laws and international data flow regulations?",
      "original_answer": "In 2023, Johnson & Johnson had established privacy compliance programs and controls that its global businesses were required to follow, with an emphasis on addressing new privacy laws expected in 'other territories' and increasing enforcement by governmental authorities, especially concerning data localization and international data flows. By 2024, the company maintained these privacy compliance programs but expanded its focus to include evolving technology and data-driven initiatives across the company, involving multiple vendors and third parties. The 2024 disclosure also specifically notes the expectation of new privacy laws 'globally' (not just in other territories) and highlights legislative actions imposing limitations on the use, sharing, and cross-border flows of personal data. This indicates a broadening of the company's compliance focus and a more anticipatory posture toward global regulatory changes.",
      "llm_answer": "In the 2023 filing J&J noted that it had **established privacy‑compliance programs and controls** to meet existing global data‑protection statutes and anticipated new privacy laws, emphasizing mandatory employee training and basic oversight of cross‑border data flows. By the 2024 filing the company said it had **strengthened those programs**, adding more detailed controls for data‑localization and international transfers, expanding third‑party risk management, and placing privacy oversight under the Board’s Regulatory Compliance & Sustainability Committee with regular CISO updates—reflecting a proactive response to the wave of new privacy regulations and tighter international data‑flow rules.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Johnson & Johnson's privacy compliance programs from 2023 to 2024. It accurately captures the established nature of the programs in 2023 and the strengthening and expansion in 2024 in response to new privacy laws and international data flow regulations. The mention of 'strengthened programs' with 'more detailed controls for data-localization and international transfers' and 'expanding third-party risk management' reflects the broader focus on global legislative changes and third-party involvement noted in the original answer. The addition of Board-level oversight via the Regulatory Compliance & Sustainability Committee and CISO reporting is contextually plausible and consistent with a maturing compliance program, though this specific governance detail is not present in the ground truth. While the core evolution—broader scope, global anticipation of laws, increased third-party and cross-border focus—is correctly conveyed, the LLM introduces specific structural details (e.g., Board committee oversight, CISO updates) not found in the original knowledge base, which slightly affects qualitative accuracy. There are no numerical values, so quantitative accuracy is scored based on absence of incorrect numbers (scored as 10). The answer is fully contextually relevant and addresses both years and the multi-hop aspect of regulatory evolution. Semantic equivalence is high on the key points, but minor over-specification prevents a top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 424,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has GE's financial exposure to Bank BPH evolved between 2023 and 2024, particularly in terms of estimated borrower litigation losses and related valuation allowances?",
      "original_answer": "In 2023, GE reported $2,669 million in total estimated losses related to borrower litigation for Bank BPH's foreign currency-denominated mortgage portfolio, with $1,712 million in valuation allowances against financing receivables held for sale and $957 million in other liabilities. By 2024, this total estimated loss decreased to $2,461 million, with $1,517 million in valuation allowances and $944 million in other liabilities. Additionally, the valuation allowance fully offset the financing receivables balance by the end of 2024, indicating a strategic shift in how GE managed its exposure to Bank BPH through a settlement program. This represents a reduction in GE's financial exposure to Bank BPH litigation risks over the period.",
      "llm_answer": "GE’s exposure to Bank BPH narrowed in 2024.  The company now estimates total borrower‑litigation losses of **$2.46 billion**, down from **$2.67 billion** at the end of 2023, and the related valuation allowance on the financing‑receivable portfolio fell to **$1.59 billion** (including $1.52 billion for the litigation component) from **$1.96 billion** a year earlier, fully offsetting the receivable balance by year‑end 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the overall trend of decreasing financial exposure from 2023 to 2024 and correctly identifies that the valuation allowance fully offset the receivable balance by year-end 2024, which aligns with the ground truth. However, several key numbers are inaccurate. The 2023 total estimated losses are reported as $2.67 billion (correct: $2,669 million), which is approximately accurate, but the 2024 total estimated losses are stated as $2.46 billion (correct: $2,461 million), which is acceptable within rounding. The major discrepancy lies in the valuation allowances: LLM reports $1.59 billion total with $1.52 billion for litigation, while the ground truth specifies $1,517 million in valuation allowances—close but not exact. More critically, the LLM inflates the 2023 valuation allowance to $1.96 billion, whereas the correct figure is $1,712 million, a significant overstatement of $248 million. (2) Calculations: The LLM implies a larger reduction in valuation allowances than actually occurred. Ground truth shows a decrease from $1,712M to $1,517M ($195M drop), but LLM suggests a drop from $1,960M to $1,520M ($440M drop), misrepresenting the scale. Additionally, the split between valuation allowance and other liabilities is missing—the ground truth notes $957M and $944M in other liabilities for 2023 and 2024 respectively, which the LLM omits entirely. (3) Multi-hop reasoning: The model correctly infers a strategic shift due to the valuation allowance fully offsetting receivables by 2024, demonstrating sound qualitative synthesis across time points and accounting treatments. It connects litigation losses, valuation allowances, and balance sheet impact appropriately. (4) Justification: The correctness score is 6 due to partial factual accuracy—core trends are right, but key financial figures are incorrect or imprecise, especially the 2023 valuation allowance. Quantitative accuracy is penalized heavily (5/10) due to material deviations in dollar amounts. Qualitative accuracy is higher (7/10) because the reasoning and interpretation of the strategic shift are valid. Contextual relevance is strong (9/10) as the response directly addresses the evolution of GE’s exposure to Bank BPH litigation risks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 603,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has HD's treatment and positioning of the Indoor Garden product line evolved from 2022 to 2024, given its financial performance in 2022 and its merchandising department categorization in 2024?",
      "original_answer": "In 2022, HD's Indoor Garden product line generated $15,546 million in net sales, accounting for 10.3% of total revenue, indicating its significance as a standalone category. By 2024, the Indoor Garden product line was grouped under the 'Hardlines' merchandising department, suggesting a strategic shift to integrate it with related product lines rather than treating it as a distinct category. This reclassification implies a change in how HD is organizing and potentially promoting the product line within its broader offerings.",
      "llm_answer": "In fiscal 2022 the Indoor Garden department was a top‑line driver, posting about $15.5 billion of net sales (≈10 % of total company sales) and ranking among the highest‑percentage merchandising groups. By fiscal 2024 its sales had slipped to roughly $10.5 billion (≈6.5‑6.6 % of net sales) and the line was no longer a stand‑alone category; it was placed under the Hardlines merchandising department (along with hardware, outdoor garden, power and storage & organization). This reflects both a material decline in the Indoor Garden’s contribution and a repositioning of the product line within the broader Hardlines segment.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the financial data for 2024. The ground truth states that in 2022, the Indoor Garden product line generated $15,546 million (≈$15.5 billion) in net sales, which the LLM correctly approximates. However, the LLM claims that by 2024, sales 'slipped to roughly $10.5 billion', which is not supported by the original answer — no 2024 sales figure is provided in the ground truth. This introduces a fabricated data point, making the quantitative claim false. Additionally, the 2022 percentage is stated as ≈10% by the LLM, while the original specifies 10.3%, which is acceptable as a rounding approximation. (2) The LLM incorrectly implies a decline in performance as a rationale for reclassification, but the original answer does not mention any 2024 financial performance — only a reorganization into the Hardlines department. Thus, the calculation of 6.5–6.6% of net sales in 2024 is speculative and unsupported. (3) The multi-hop reasoning is partially sound: the model correctly identifies the shift from standalone category to inclusion under 'Hardlines' in 2024, which addresses the positioning change. However, it overreaches by inferring a sales decline without evidence, conflating structural reorganization with performance trends not present in the source. (4) While the contextual relevance is high — the answer addresses both financial performance and merchandising evolution — the introduction of false quantitative data severely undermines correctness. The qualitative reasoning is plausible but not justified by the provided facts, leading to a moderate score on qualitative accuracy. The answer synthesizes across time and categories but fails on factual fidelity, especially in unsupported numerical claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 491,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Colgate-Palmolive's use of sourcing strategies to manage cost volatility evolved from 2022 to 2024, particularly in relation to commodity price fluctuations?",
      "original_answer": "In 2022, Colgate-Palmolive utilized sourcing strategies as part of a broader risk management framework to manage volatility in foreign exchange, interest rates, and commodity prices, specifically mentioning the use of derivative instruments and local currency borrowings. By 2024, the company continued to rely on sourcing strategies but placed greater emphasis on managing raw material cost volatility, including commodities like resins, essential oils, and soybeans, while also incorporating more proactive cost containment and productivity initiatives. The 2024 disclosure highlights increased exposure to geopolitical and climatic disruptions, indicating a shift toward more defensive sourcing and cost management tactics in response to external pressures.",
      "llm_answer": "In its 2022 filing, Colgate‑Palmolive said it managed raw‑material price swings chiefly through “cost‑containment measures, sourcing strategies, ongoing productivity initiatives and the limited use of commodity‑hedging contracts,” using futures only sparingly (mainly in the Hill’s Pet Nutrition segment). By the 2024 filing the same approach is still emphasized, but the company adds that it now couples those sourcing actions with broader cost‑efficiency programs, selective price increases and a heightened focus on climate‑ and sustainability‑related supply‑chain risks, while continuing to rely only modestly on commodity hedges. Thus, the firm’s sourcing strategy has remained the primary tool for volatility mitigation, evolving to incorporate sustainability considerations and more proactive pricing and efficiency measures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Colgate-Palmolive's use of sourcing strategies in both 2022 and 2024, noting continuity in approach while highlighting evolution. The mention of 'limited use of commodity-hedging contracts' and their sparing use, especially in Hill’s Pet Nutrition, is consistent with the original answer’s reference to derivative instruments being part of the strategy but not dominant. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10 by default. (3) The multi-hop reasoning is sound: the model synthesizes information across years (2022 to 2024), identifies the persistent role of sourcing strategies, and correctly infers an evolution toward broader cost-efficiency programs, sustainability risks, and proactive pricing—elements that map to the original answer’s emphasis on increased focus on geopolitical/climatic disruptions and defensive tactics. The only minor gap is that the LLM answer emphasizes 'sustainability considerations' slightly more than the original, which focuses on 'geopolitical and climatic disruptions' as risk drivers rather than sustainability per se. However, this is a reasonable interpretive link, not a factual error. (4) Contextual relevance is perfect—the response directly addresses how sourcing strategies evolved in response to commodity price fluctuations over the specified period. Overall, the LLM captures the core factual and conceptual content with high fidelity, warranting a 9/10 correctness score due to slight rephrasing emphasis but no material inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 462,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did the sales performance of TREMFYA evolve between 2023 and 2024, and what factors contributed to this change?",
      "original_answer": "In 2023, TREMFYA (guselkumab) experienced growth driven by market expansion, continued strength in PsO/PsA (Psoriasis and Psoriatic Arthritis), and favorable patient mix. By 2024, TREMFYA achieved sales of $3,670 million, an increase of 16.6% compared to $3,147 million in 2023. The growth in 2024 was attributed to an 18.1% change from operations, despite a negative currency impact of 1.5%. This indicates that TREMFYA not only maintained its market position but also expanded further in its therapeutic areas during this period.",
      "llm_answer": "TREMFYA’s worldwide sales rose from $3.147 billion in 2023 to $3.670 billion in 2024 – a 16‑17 % increase (operations up ≈ 18 % with a modest ‑1.5 % currency headwind). The boost was attributed to overall market growth and share‑gain momentum, especially the drug’s continued strength in psoriasis/psoriatic‑arthritis and favorable patient‑mix dynamics, while currency effects slightly dampened the rise.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: TREMFYA sales increased from $3.147 billion in 2023 to $3.670 billion in 2024, representing a 16.6% increase (the LLM rounds to 16–17%, which is acceptable). The breakdown of growth—18.1% from operations and a 1.5% negative currency impact—is correctly reflected (LLM reports ≈18% and -1.5%, respectively). (2) Quantitative accuracy is perfect: dollar amounts match exactly ($3.147B and $3.670B), percentage changes are accurate within reasonable rounding, and the directional impact of currency is correctly noted. (3) Qualitative reasoning is sound: the LLM correctly identifies market growth, strength in psoriasis/psoriatic arthritis, favorable patient mix, and currency headwinds as contributing factors, aligning with the original answer. (4) The answer addresses both parts of the multi-hop question: the sales performance evolution (quantitative change over time) and the contributing factors (qualitative drivers). All entities (TREMFYA, 2023, 2024, sales, operations, currency) are correctly identified and synthesized. No factual errors, omissions, or misinterpretations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 338,
        "total_tokens": 1564
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the structural change in Disney's relationship with A&E from 2022 to 2023 affect its reporting of subscriber numbers and financial stake in the partnership?",
      "original_answer": "In 2022, Disney reported A&E as a partner with 69 million domestic subscribers, indicating a collaborative but arms-length relationship. By 2023, Disney's relationship with A&E had evolved into a 50% equity stake, with A+E now classified as a significant equity investment. The 2023 report noted that A+E's channels, including A&E, had 58 million domestic subscribers. This shift from a partnership to a joint ownership model altered how Disney reported both subscriber data and financial performance, moving from simple subscriber counts in 2022 to including A+E’s financial results under 'Equity in the income of investees' in 2023.",
      "llm_answer": "In the 2022 filing Disney described its A & E relationship as a **50 % equity investment** and gave subscriber estimates for every A & E network – A &E (69 m), HISTORY (70 m), Lifetime (69 m), LMN (52 m) and FYI (42 m).  \n\nBy the 2023 filing the partnership had been re‑characterized as a **joint‑venture reported under the equity‑method** (still 50 % owned), but Disney now disclosed subscriber numbers only for the three flagship A & E channels – A &E, HISTORY and Lifetime – each at **about 58 million** subscribers, omitting the LMN and FYI figures. The ownership percentage stayed at 50 %, but the reporting of subscriber data was narrowed and presented through the equity‑method line rather than a full channel‑by‑channel breakdown.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies. Crucially, it incorrectly states that in 2022 Disney already had a 50% equity investment in A&E, which contradicts the ground truth: in 2022, Disney reported A&E as a partner with 69 million subscribers, not as an equity investee. The shift to a 50% equity stake occurred in 2023, not 2022. This misrepresents the core structural change. Additionally, the LLM claims Disney reported subscriber numbers for multiple A&E networks (HISTORY, Lifetime, etc.) in 2022, but the ground truth only confirms A&E's 69 million subscribers—no breakdown by network is provided in the original answer. In 2023, the LLM correctly notes the shift to equity-method reporting and reduced disclosure (only three flagship channels), but fabricates that all three had 'about 58 million' subscribers, while the ground truth only confirms 58 million for A+E collectively, not per channel. (2) Quantitative accuracy is low: the 50% stake is correctly mentioned, but misattributed to 2022; the 69 million subscriber figure for A&E in 2022 is correct; the 58 million in 2023 is directionally correct but over-specified (applied to each channel rather than the group). The omission of LMN and FYI is speculative and not supported in the ground truth. (3) The multi-hop reasoning is partially sound—recognizing a shift in reporting method and narrowing of disclosures—but flawed due to incorrect temporal assignment of the equity stake. The synthesis fails because it assumes the 50% ownership existed before the structural change. (4) Contextual relevance is high: the answer addresses subscriber reporting changes and financial stake evolution, aligning with the question’s focus. However, due to major factual errors in ownership timeline and subscriber data granularity, the correctness score is low despite relevant structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 502,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of realized and unrealized gains or losses?",
      "original_answer": "In 2023, GE reported an unrealized gain of $129 million from its investment in and note with AerCap. However, in 2024, the relationship had evolved such that GE recognized a significant decrease in gains on retained and sold ownership interests, which dropped by $5.2 billion compared to 2023, with AerCap being one of the primary contributors to this decline. This indicates a negative shift in the financial performance of the AerCap investment from a gain in 2023 to a loss or significantly reduced gain in 2024.",
      "llm_answer": "In 2023 GE’s AerCap holding still produced a modest positive result – the “investment in and note with AerCap” line in the 2023 10‑K shows a net realized‑and‑unrealized gain of **about $129 million**.  \n\nBy the 2024 filing the picture had reversed: the company says that the **gain on retained and sold ownership interests fell by $5.2 billion** in 2024, “primarily related to our GE HealthCare and AerCap investments,” turning the AerCap relationship from a small gain in 2023 into a material loss (or unrealized loss) that drove the multi‑billion‑dollar decline in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the $129 million unrealized gain in 2023 and the $5.2 billion decrease in gains in 2024 are accurately reported, with acceptable phrasing such as 'about $129 million' matching the original $129 million. The comparison between years is correctly framed as a decline of $5.2 billion in gains, primarily due to AerCap and GE Healthcare. (2) The calculation and temporal comparison are sound—no mathematical or logical errors. (3) Entity accuracy is strong: GE, AerCap, 2023, and 2024 are correctly identified, and the financial metrics ('gain on retained and sold ownership interests') are properly referenced. (4) The reasoning correctly synthesizes the shift from a positive gain in 2023 to a significant decline in 2024, attributing the drop to AerCap as a key contributor. The only minor shortcoming is that the LLM slightly generalizes the 2024 impact as a 'material loss (or unrealized loss)'—while logically inferred, the original answer specifies a drop in gains rather than explicitly confirming a loss. However, this is a reasonable interpretation of a $5.2B decline from a prior gain, so the qualitative leap is justified. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 369,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Mastercard's multi-layered security approach evolved between 2022 and 2024, particularly in terms of addressing risks associated with third-party service providers, and what does this evolution indicate about the company's strategic response to emerging cybersecurity threats?",
      "original_answer": "In 2022, Mastercard's multi-layered security approach included a robust program to protect its network from cyber and information security threats, with multiple layers of protection and third-party assessments. However, there was no explicit mention of addressing risks related to third-party service providers. By 2024, Mastercard explicitly integrated third-party provider risk management into its security framework, noting that it works with experts across the organization and through public-private partnerships to monitor and respond to threats associated with the use of services provided by third-party providers. This indicates a strategic shift toward strengthening the ecosystem-wide resilience of its security architecture, particularly in response to the growing complexity and interconnectedness of the payments landscape.",
      "llm_answer": "Mastercard’s 2022 filing described a “multi‑layered approach” that relied on internal security programs, resilience planning and periodic third‑party assessments, but it did not single out the cyber‑risk exposure from the services that third‑party providers deliver. By the 2024 filing the company had broadened that framework to explicitly monitor, test and mitigate “threats and incidents associated with services provided by third‑party providers,” adding dedicated Security Operations, Fusion and Intelligence Centers and deeper public‑private partnership engagement. This evolution shows Mastercard is moving from a primarily internal‑focused defense to a supply‑chain‑aware strategy, signaling a proactive response to the growing complexity of cyber‑threats that originate outside its own network.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, Mastercard had a multi-layered security approach with third-party assessments but did not explicitly address risks from third-party service providers; by 2024, it explicitly included monitoring and mitigating threats related to third-party provider services. The LLM correctly identifies the evolution and strategic implication. (2) There are no numeric values (e.g., dollar amounts, percentages) in the question or ground truth, so quantitative accuracy is not applicable—however, the years (2022 and 2024) are correctly used, satisfying temporal accuracy. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points and infers the strategic shift from internal defense to ecosystem-wide, supply-chain-aware security, which matches the ground truth’s conclusion about 'ecosystem-wide resilience.' The mention of 'Security Operations, Fusion and Intelligence Centers' and 'public-private partnerships' adds detail consistent with the 2024 enhancement. (4) Semantic equivalence is strong—while the LLM uses slightly different phrasing (e.g., 'supply-chain-aware strategy' vs. 'ecosystem-wide resilience'), the meaning is equivalent and well-justified. The only minor gap is that the LLM does not explicitly mention 'experts across the organization' as in the original, but this does not detract from the core accuracy. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 440,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Target Corporation's compliance with its debt leverage covenant evolved between 2022 and 2023, particularly in light of changes to its credit facilities?",
      "original_answer": "In 2022, Target Corporation stated that it was in compliance with its debt leverage covenant and expected to remain so, with a $3.0 billion unsecured revolving credit facility set to expire in October 2026. By 2023, Target had obtained a new $1.0 billion 364-day unsecured revolving credit facility (expiring in October 2024) and extended the expiration of its five-year $3.0 billion facility to October 2028. Despite these structural changes to its credit facilities, Target continued to assert compliance with the debt leverage covenant in 2023, indicating consistent adherence to regulatory requirements even as its financing arrangements evolved.",
      "llm_answer": "Both in the 2022 filing and in the 2023 filing Target states that its credit‑facility agreements contain a debt‑leverage covenant and that the company “is, and expects to remain, in compliance” with that covenant. In 2023 Target added a new $1 billion 364‑day unsecured revolving facility (replacing the prior one) and extended its five‑year $3 billion revolving facility to 2028, but no balances were drawn on any facility, and the company reaffirmed that it continues to meet the leverage covenant despite these changes. Thus, compliance with the debt‑leverage covenant was maintained from 2022 through 2023 even as the credit facilities were restructured.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: Target maintained compliance with its debt leverage covenant in both 2022 and 2023; it had a $3.0 billion unsecured revolving credit facility extended to October 2028 (originally expiring in 2026); and in 2023, it added a new $1.0 billion 364-day unsecured revolving facility expiring in October 2024. The statement that no balances were drawn is consistent with typical disclosures, though not explicitly required for the question. (2) Quantitative accuracy is perfect: dollar amounts ($1 billion, $3 billion), timeframes (364-day, five-year), and expiration years (2024, 2028) all match the ground truth. (3) The multi-hop reasoning is sound—correctly linking covenant compliance across years while accounting for changes in credit facilities. (4) Minor deduction in qualitative accuracy because the LLM implies the $1 billion facility replaced a prior one, while the ground truth does not confirm replacement—only that a new facility was added. This could suggest consolidation rather than replacement, but the overall synthesis remains strong. Contextual relevance is full, as all parts of the question are addressed: evolution of compliance and changes to credit facilities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 362,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the nature of the risks associated with Salesforce's AI offerings, including generative AI such as Agentforce, evolved from 2023 to 2024?",
      "original_answer": "In 2023, Salesforce's primary risk related to third-party integrations and applications centered on potential claims or liabilities stemming from customer expectations for warranties, despite the company not developing or selling these third-party offerings. By 2024, the risk profile expanded significantly with the increased integration of AI into Salesforce's offerings, particularly generative and agentic AI like Agentforce. The 2024 disclosures highlight new risks such as ethical concerns, regulatory scrutiny, and potential legal liabilities from AI-generated content that may be inaccurate, biased, or infringe on copyright. Additionally, the company now anticipates increased costs related to AI governance, compliance, and testing, which were not specifically tied to AI in 2023.",
      "llm_answer": "In the 2023 filing Salesforce framed AI risk mainly as “emerging ethical and technical uncertainties” around its new generative‑AI and agentic products (e.g., Agentforce), warning that inaccurate, biased, toxic or copyrighted output, privacy‑security issues and the need for governance could hurt adoption and expose the company to reputational or legal harm. By the 2024 filing the language had broadened: the company still cites the same accuracy‑bias‑toxicity‑privacy risks, but now stresses the added complexity of scaling a larger generative‑AI portfolio (including Einstein GPT), the higher‑cost compliance and licensing requirements, the uncertainty of consumption‑based pricing for AI services such as Agentforce and Data Cloud, and intensified competitive and regulatory scrutiny. Thus, the risk picture has evolved from a focus on early‑stage ethical/technical concerns to a more comprehensive set of financial, regulatory, governance and market‑competition risks tied to a mature, revenue‑focused generative‑AI suite.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. It correctly identifies the evolution of Salesforce's AI-related risks from 2023 to 2024, capturing the shift from early-stage ethical and technical concerns (e.g., bias, inaccuracy, copyright, privacy) to broader financial, regulatory, compliance, and competitive risks in 2024. The mention of Agentforce, Einstein GPT, and Data Cloud is consistent with the expanded AI portfolio. The LLM accurately reflects new 2024 risks such as higher compliance costs, licensing, consumption-based pricing uncertainty, and intensified regulatory scrutiny—elements that map to the ground truth's emphasis on increased governance costs and legal exposure. All entities (Salesforce, Agentforce, generative AI) and years (2023, 2024) are correct. There are no numerical inaccuracies (quantitative accuracy is perfect as no specific numbers are involved). The reasoning is sound and demonstrates proper multi-hop synthesis across time periods and risk categories. The only minor shortcoming is that the LLM does not explicitly mention that third-party integration risks (warranty expectations) were central in 2023 before AI risks expanded in 2024—a nuance present in the original answer. While the LLM implies a shift in focus, it omits this baseline context, slightly weakening the completeness of the evolution narrative. However, the core factual progression and qualitative assessment remain robust and semantically equivalent in substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1454,
        "completion_tokens": 412,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Lowe's delivery capability for parcel-eligible items evolved between fiscal years 2023 and 2024, and what specific improvements were made?",
      "original_answer": "In fiscal year 2023, most parcel-eligible items could be delivered within two business days at standard shipping rates. By fiscal year 2024, Lowe's improved this capability, enabling delivery of most parcel-eligible items within two business days or less. Additionally, in 2024, Lowe's expanded its delivery capabilities to include next-day delivery for major appliances in nearly every zip code in the United States. This represents a refinement and expansion of their delivery speed and geographic coverage.",
      "llm_answer": "By fiscal 2023 Lowe’s said that “most parcel‑eligible items can be ordered by a customer and delivered within two business days at standard shipping rates,” and that the nationwide expansion of its gig network was already providing same‑day delivery for certain products. In fiscal 2024 the company kept the two‑day delivery promise but added “the ability to deliver major appliances next‑day in almost every zip code in the United States” and completed the rollout of its market‑based delivery model, further expanding the gig‑provider network for same‑day service. These steps sharpened speed and geographic coverage for parcel‑eligible orders.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that in fiscal 2023, most parcel-eligible items were delivered within two business days at standard rates, and that same-day delivery was available via gig network for certain products—this contextual detail is consistent with the knowledge graph, even if not explicitly in the original answer. (2) For fiscal 2024, it accurately notes the continuation of the two-day delivery standard and adds the key improvement: next-day delivery for major appliances in nearly every U.S. zip code. It also mentions the completion of the market-based delivery model rollout and expansion of the gig network, which represents a valid synthesis of enhanced speed and coverage. (3) Multi-hop reasoning is sound—LLM correctly compares delivery capabilities across years and synthesizes improvements in speed, product category (major appliances), and geographic scope. (4) Minor deduction in qualitative accuracy due to the addition of 'same-day delivery for certain products' in 2023 and 'completion of market-based delivery model'—details not present in the original answer—though these are plausible and do not contradict the ground truth. No quantitative inaccuracies; all dates, timeframes, and service levels are correctly represented. The answer fully addresses both parts of the question: evolution between years and specific improvements. Semantic equivalence is strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 401,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial impact of the Dermstore LLC sale evolved from 2022 to 2023 in terms of Target's consolidated revenues and operating income?",
      "original_answer": "The financial impact of the Dermstore LLC sale remained minimal in both years, as Dermstore represented less than 1 percent of Target's consolidated revenues, operating income, and net assets in both 2022 and 2023. The sale, which occurred in February 2021, resulted in a $335 million pretax gain included in Net Other (Income)/Expense, and no significant post-sale financial contribution or change was observed in either year.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K filings note that the February 2021 sale of Dermstore LLC generated a $356 million cash proceeds and a $335 million pretax gain, but that Dermstore “represented less than 1 percent of our consolidated revenues, operating income and net assets.” Thus, the transaction’s impact on Target’s consolidated revenue and operating‑income remained immaterial – under 1 % – in both 2022 and 2023, showing no material change year‑over‑year【page_21】【page_24】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that Dermstore represented less than 1 percent of Target's consolidated revenues, operating income, and net assets in both 2022 and 2023, and that the financial impact remained immaterial year-over-year. The $335 million pretax gain from the February 2021 sale is accurately reported. (2) The only minor discrepancy is the mention of '$356 million cash proceeds', which is not present in the ground truth and was not asked for in the question; however, this does not contradict any provided facts and may be an additional detail from the filing. All other numbers (335M gain, <1%) are correct. (3) The reasoning is sound: the model correctly synthesizes information across the 2022 and 2023 10-Ks, recognizes that the sale occurred in 2021, and concludes no material change post-sale in 2022–2023, which reflects proper multi-hop logic. (4) The answer is contextually complete and directly addresses the evolution of financial impact on revenues and operating income. The extra detail about cash proceeds slightly distracts but doesn't reduce factual correctness. Thus, near-perfect accuracy with only a minor non-critical addition prevents a full 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 349,
        "total_tokens": 1575
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the strategic positioning of Data Cloud evolved between 2023 and 2024, particularly in terms of its role within Salesforce's broader service offerings and competitive landscape?",
      "original_answer": "In 2023, Data Cloud was described as a 'hyperscale, trusted data engine native to Salesforce' that unified enterprise data to deliver a 360-degree view of customers, emphasizing its integration across Salesforce's offerings like Marketing and Analytics. By 2024, Data Cloud was positioned within a broader context of competitive risk, with the filing noting that markets for offerings like Data Cloud are 'relatively new and uncertain,' and that Salesforce faces increasing competition as AI and data platforms evolve. Additionally, in 2024, Salesforce acknowledged limited experience in pricing consumption-based models like that of Data Cloud, signaling a shift from product-centric messaging to one that includes strategic risk and monetization challenges.",
      "llm_answer": "In the 2023 filing Data Cloud was presented as a foundational “hyperscale, trusted data engine” native to the Customer 360 platform – the glue that unifies structured and unstructured data, powers analytics (Tableau) and AI (Einstein 1) across Salesforce’s Sales, Service, Marketing, Commerce, Slack and Integration offerings. By the 2024 filing the company treats Data Cloud as a newer, consumption‑based product whose monetization model is still being refined; it is now highlighted as part of Salesforce’s broader push to expand its service portfolio and is explicitly called out as competing with traditional business‑intelligence, data‑preparation, integration and AI‑software vendors. Thus, Data Cloud has shifted from a core, integrated data layer to a growth‑focused, stand‑alone offering that must prove its pricing and market traction amid a more crowded competitive landscape.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of Data Cloud's strategic positioning between 2023 and 2024 with strong fidelity to the original answer. In 2023, it correctly identifies Data Cloud as a 'hyperscale, trusted data engine' integrated across Salesforce’s offerings (Sales, Service, Marketing, etc.), aligning with the ground truth. It accurately reflects the 2024 shift by noting Data Cloud’s consumption-based model, monetization challenges, and increased competitive pressures—key points from the original answer. The LLM adds contextual detail (e.g., Tableau, Einstein 1, Slack, integration offerings) not in the original but consistent with Salesforce’s ecosystem, enhancing completeness without introducing inaccuracies. It correctly infers the strategic shift from integration-focused to growth- and competition-focused positioning. There are no numeric values to verify, so quantitative accuracy is scored as 10 (no errors, all dates correct). Qualitative accuracy is 9 because while the core reasoning and entity identification (Data Cloud, Salesforce, competitive landscape, pricing model) are correct, the original does not explicitly call Data Cloud a 'stand-alone offering' or 'growth-focused'—slight interpretive expansion, but semantically reasonable. Contextual relevance is perfect: the answer directly addresses the question about strategic positioning evolution, service offerings integration, and competitive landscape. Minor phrasing differences do not affect factual correctness, and multi-hop synthesis across years and strategic themes is sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 434,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has LOW's treatment and accounting of forward interest rate swap contracts evolved between 2023 and 2024, particularly in terms of hedge designation and financial impact?",
      "original_answer": "In 2023, LOW disclosed forward interest rate swap contracts related to its March 2023 Notes with a notional amount of $2.0 billion, from which it received $247 million upon settlement. These contracts were designated as cash flow hedges and their (loss)/gain was recorded in other comprehensive (loss)/income and earnings. By 2024, the company clarified that its fixed-to-floating interest rate swap agreements are accounted for as fair value hedges using the shortcut method, under which the hedges are assumed perfectly effective. This resulted in no net impact on the consolidated statements of earnings from the fair value of the derivatives, indicating a shift in both hedge designation and accounting treatment compared to the prior year.",
      "llm_answer": "In the 2023 Form 10‑K Lowe’s reported a **$1.29 billion notional amount of forward interest‑rate swap contracts that were designated as cash‑flow hedges** (Note 8, “Cash flow hedges – Forward interest‑rate swap agreements $ 1,290 m”) and the gains or losses on those swaps flowed through other‑comprehensive income and earnings. By the 2024 filing, the company no longer held any forward‑rate swaps in the cash‑flow‑hedge bucket – the same note shows **“Forward interest‑rate swap agreements $ ‑”**, leaving only the $850 million of fixed‑to‑floating swaps classified as fair‑value hedges. Thus, between 2023 and 2024 Lowe eliminated its cash‑flow‑hedge forward swaps, removing the OCI impact that previously existed.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in key quantitative details, undermining its correctness. (1) The notional amount of forward interest rate swaps in 2023 is reported as $1.29 billion, but the ground truth states $2.0 billion—this is a major discrepancy. (2) The LLM claims Lowe’s received no proceeds upon settlement or fails to mention the $247 million receipt, which is a critical financial impact highlighted in the original answer. (3) The LLM incorrectly implies that the $850 million fixed-to-floating swaps were present in 2024 as the only remaining swaps, but the original answer does not specify this amount, nor does it confirm elimination of all cash flow hedges—only a shift in accounting treatment. (4) While the LLM correctly identifies a shift from cash flow hedges (recorded in OCI) to fair value hedges (with shortcut method implying no earnings impact), this reasoning is based on incorrect underlying data. (5) The conclusion that Lowe’s 'eliminated' its cash flow hedges oversimplifies and potentially misrepresents the evolution—the original answer emphasizes a change in designation and accounting method, not necessarily elimination of instruments. The qualitative reasoning about hedge designation shift and OCI impact is directionally correct and contextually relevant, but the faulty numbers and incomplete financial impact (missing $247M receipt) severely limit accuracy. Multi-hop synthesis is attempted but flawed due to incorrect data grounding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 410,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has Target's strategy around its owned brands evolved from 2022 to 2023, particularly in terms of portfolio emphasis and strategic objectives?",
      "original_answer": "In 2022, Target highlighted a significant portion of sales coming from its owned brands, listing over 40 such brands across multiple categories, indicating a strong but descriptive presence in the market. By 2023, the company elevated its focus by strategically positioning owned brands as a core element of its overall strategy to 'delight with newness, style, and value,' explicitly aiming to strengthen the portfolio as part of broader efforts to drive traffic, sales, and market share growth. This shift reflects a move from simply showcasing owned brands to actively leveraging them as a strategic differentiator.",
      "llm_answer": "- **2022:** Target’s 2022 filing made the owned‑brand portfolio a central growth lever, explicitly stating that it would “strengthen our owned brands portfolio” and listing more than 70 owned and exclusive brands (e.g., A New Day™, Goodfellow & Co., Archer Farms™, up & up™, etc.) as a way to differentiate from competitors【page_5】. The strategy was framed around **expanding** the breadth and depth of that portfolio to drive newness, style and value【page_3】.  \n\n- **2023:** In the 2023 filing the language shifted to using the owned‑brand portfolio as a **differentiation and guest‑engagement tool**, emphasizing that owned brands help “differentiate from our competition” and deliver “newness, style, and value” rather than merely expanding the list of brands【page_3】. The strategic objective therefore moved from pure portfolio growth to leveraging the existing owned‑brand set to deepen relevance, increase traffic and support overall growth.  ",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the strategic evolution from 2022 to 2023 in Target's approach to owned brands, noting a shift from portfolio expansion to leveraging existing brands for differentiation and guest engagement. This aligns well with the ground truth’s emphasis on moving from descriptive presence to strategic differentiation. However, there is a significant quantitative discrepancy: the LLM claims 'more than 70 owned and exclusive brands' in 2022, while the original answer states 'over 40 such brands.' This overstatement affects factual accuracy. (2) The years (2022 vs 2023) and strategic objectives (e.g., 'newness, style, and value') are correctly cited and contextually accurate. No dollar amounts or percentages are involved, so numerical precision is limited to brand count, which is incorrect. (3) The multi-hop reasoning is sound—the model synthesizes a strategic shift across two years and correctly infers that the objective evolved from expansion to leveraging for traffic and differentiation. The logic mirrors the ground truth’s narrative of increased strategic emphasis. (4) Despite the incorrect number of brands, the qualitative interpretation and contextual relevance are strong. The answer addresses both parts of the question—portfolio emphasis and strategic objectives—and does so with appropriate framing. The error in brand count prevents a higher score on quantitative and overall correctness, but the core strategic insight remains valid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 413,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has GM's approach to software-enabled services evolved from 2022 to 2023, particularly in terms of service offerings and platform deployment, and what does this indicate about the company's investment in scalable digital solutions?",
      "original_answer": "In 2022, GM described its software-enabled services in general terms as part of its broader operations, noting that it 'provides software-enabled services worldwide' and integrates them into its automotive business alongside investments in AV technology and automotive financing. By 2023, GM's approach had evolved significantly, with specific details on its end-to-end software platform that enables over-the-air updates for features like Super Cruise, active safety, infotainment, and EV ownership experience. The 2023 filing highlights that select 2024 models, such as the Cadillac LYRIQ and Chevrolet Silverado EV, were already using this platform, indicating a strategic shift toward scalable, software-defined vehicles. This evolution shows a transition from general involvement in digital services to concrete platform deployment across product lines, reflecting increased investment and operational maturity in software-enabled offerings.",
      "llm_answer": "In the 2022 filing GM described its software‑enabled services mainly as “after‑sale services such as maintenance, OnStar, vehicle‑connectivity and extended service warranties,” with revenue recognized over the life of bundled service contracts. By the 2023 filing the company is positioning an “end‑to‑end software platform” that delivers OTA updates, expands the OnStar ecosystem, adds Super Cruise and other digital features, and is already being rolled out on new models (e.g., the 2024 Cadillac Lyriq and Chevrolet Silverado EV) and will be deployed across most future products. This shift from isolated service items to a unified, over‑the‑air software platform shows GM is investing heavily in a scalable digital infrastructure that can be leveraged across its entire vehicle portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution from 2022 to 2023: in 2022, GM described software-enabled services in more general, service-oriented terms (e.g., OnStar, connectivity, warranties), while in 2023 it emphasized a strategic shift to an 'end-to-end software platform' enabling OTA updates. The specific examples of the 2024 Cadillac LYRIQ and Chevrolet Silverado EV are accurately cited as early adopters. (2) There are no numeric values requiring calculation, but all dates (2022, 2023, 2024 models) and product names are correct. (3) The multi-hop reasoning is sound—comparing disclosures across two years to infer a strategic shift toward scalable digital infrastructure. The LLM correctly infers investment in scalable solutions based on platform deployment across future products. (4) The only minor shortcoming is that the original answer notes GM’s integration of software services with AV tech and financing in 2022, which the LLM omits, but this is a secondary contextual detail. The LLM adds useful specificity (e.g., revenue recognition for bundled contracts) not in the ground truth, enhancing clarity. Overall, the answer is factually correct, contextually relevant, and semantically equivalent, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1456,
        "completion_tokens": 365,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has the revenue contribution from ThousandEyes within the Optimized Application Experiences/Observability product category evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Optimized Application Experiences category, which included ThousandEyes, saw revenue growth of $75 million (11%), driven by ThousandEyes and Intersight. By fiscal year 2023, the Observability category (which includes ThousandEyes) experienced a revenue increase of $80 million (14%), specifically attributed to growth in ThousandEyes and monitoring and analytics offerings. This shows a continued upward trend in ThousandEyes' revenue contribution, with both absolute and percentage growth increasing from 2022 to 2023.",
      "llm_answer": "In fiscal 2022 the Optimized Application Experiences category (which includes ThousandEyes) grew 11% – about a **$75 million** increase – and Cisco said that growth was “driven by … our **ThousandEyes** and Intersight offerings”【page_45】.  \n\nIn fiscal 2023 the category was renamed Observability and grew 14% – roughly a **$80 million** increase – with the filing noting the rise was “driven by growth in our **ThousandEyes** and monitoring and analytics offerings”【page_42】.  \n\nThus, ThousandEyes’ contribution rose from a $75 million boost in FY‑2022 to a $80 million boost in FY‑2023, indicating a modest increase in its revenue impact.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: in FY2022, the Optimized Application Experiences category grew by $75 million (11%), driven by ThousandEyes and Intersight; in FY2023, the renamed Observability category grew by $80 million (14%), driven by ThousandEyes and monitoring/analytics offerings. These numbers and attributions match the original answer exactly. (2) Quantitative accuracy is perfect: $75M and $80M increases, 11% and 14% growth rates are correctly reported. The conclusion that ThousandEyes' contribution increased from FY2022 to FY2023 is supported by the data. (3) Multi-hop reasoning is sound: the model correctly tracks the rebranding of the product category (from Optimized Application Experiences to Observability), maintains continuity of ThousandEyes as a contributing factor, and synthesizes information across two fiscal years and filings (as indicated by page references). (4) The only minor shortcoming is that the LLM slightly simplifies the nuance in the original answer by not explicitly stating that the *percentage growth contribution* also increased (from 11% to 14%), which the original emphasizes as part of the 'upward trend'. However, the $75M to $80M increase is clearly noted, capturing the core evolution. Wording differences are acceptable under semantic equivalence. Overall, the answer is factually correct, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 400,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did the treatment of Amendment No. 4 to the Lockheed Martin Executive Severance Plan evolve between the 2023 and 2024 10-K filings, and what does this indicate about its inclusion in the company's disclosure strategy?",
      "original_answer": "In the 2023 10-K filing, Amendment No. 4 to the Executive Severance Plan was disclosed as part of the exhibit list (Exhibit 10.34) and referenced as being incorporated from the September 2022 10-Q filing. However, in the 2024 10-K filing, Amendment No. 4 is no longer listed as a standalone exhibit but appears instead as part of a sequence that includes earlier amendments (Nos. 2, 3, 4, and 5), with Amendment No. 4 specifically incorporated from the same September 2022 10-Q filing. This indicates that while the amendment itself remained relevant, its treatment shifted from a highlighted disclosure in 2023 to a more integrated part of the broader severance plan history in 2024, suggesting a more consolidated and retrospective approach to disclosure.",
      "llm_answer": "In the 2023 Form 10‑K, Amendment No. 4 to the Executive Severance Plan was listed as Exhibit 10.34 and incorporated by reference to the September 25 2022 10‑Q. In the 2024 Form 10‑K the same amendment is still disclosed, but it now appears as Exhibit 10.36—its number shifted because Amendments 2 and 3 were inserted ahead of it. This shows that Lockheed Martin continues to include Amendment 4 in its filings, but its placement is adjusted as newer amendments are added, reflecting an evolving but consistent disclosure approach.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that Amendment No. 4 was disclosed in both the 2023 and 2024 10-K filings and was incorporated by reference from the September 25, 2022 10-Q, which matches the ground truth. The date (September 25, 2022) and exhibit references (Exhibit 10.34 in 2023) are factually accurate, supporting a high quantitative accuracy score. However, the LLM introduces a significant factual error by claiming that in the 2024 10-K, Amendment No. 4 appears as Exhibit 10.36 due to Amendments 2 and 3 being 'inserted ahead'—this is incorrect. The ground truth states that Amendment No. 4 is no longer a standalone exhibit but is instead included within a sequence that incorporates Amendments 2 through 5 collectively, not that its exhibit number changed due to reordering. There is no evidence of renumbering or insertion of earlier amendments; rather, the disclosure strategy shifted toward consolidation. This misrepresents the nature of the evolution in disclosure treatment. The reasoning is therefore flawed in a way that affects the qualitative accuracy: the conclusion that the change reflects 'an evolving but consistent disclosure approach' misses the key point that the shift indicates a move from highlighted to integrated/consolidated disclosure, which is a meaningful change in strategy. While the answer addresses the evolution in exhibit treatment and attempts to interpret its significance, it fails to capture the correct mechanism (consolidation vs. renumbering) and thus provides an incorrect explanation of the company's disclosure strategy. The answer is contextually relevant and addresses both parts of the question (treatment evolution and strategic implication), but the reasoning and factual basis for the conclusion are partially incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 481,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did JPMorgan's compliance with capital ratio requirements evolve from 2023 to 2024, particularly in terms of its Tier 1 leverage ratio and Standardized CET1 capital ratio?",
      "original_answer": "In 2023, JPMorgan's Standardized CET1 capital ratio was 15.0%, exceeding the requirement of 11.4%. In 2024, the Tier 1 leverage ratio was 7.2%, which was above the requirement of 4.0%. This indicates that JPMorgan maintained compliance with capital ratio requirements across both years, with consistent capital strength relative to evolving regulatory expectations.",
      "llm_answer": "JPMorgan stayed comfortably above the leverage‑ratio floor and improved its risk‑based capital buffer. The Tier 1 leverage ratio was 7.2 % at the end of both 2023 and 2024 – well above the 4.0 % regulatory minimum (see 2024 table “Tier 1 leverage ratio 7.2 %” and the same 2023 figure)【page_104】. At the same time, the Standardized CET1 capital ratio rose from 15.0 % in 2023 to 15.7 % in 2024, both comfortably exceeding the applicable Basel III minimums (11.4 % in 2024 and 11.4 % in 2023)【page_104】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies compared to the ground truth. While it correctly states that JPMorgan's 2023 Standardized CET1 ratio was 15.0% and that the 2024 Tier 1 leverage ratio was 7.2%, it incorrectly claims the Tier 1 leverage ratio was also 7.2% in 2023—this information is not in the ground truth, which only provides the 2024 Tier 1 leverage ratio (7.2%) and does not mention the 2023 value. Additionally, the LLM states that the Standardized CET1 ratio increased to 15.7% in 2024, but the ground truth does not provide the 2024 CET1 ratio at all—only the 2023 value (15.0%) and the requirement (11.4%). Thus, the LLM introduces unsupported data. (2) Quantitative accuracy is compromised because two key numbers (2023 Tier 1 leverage ratio and 2024 CET1 ratio) are fabricated or incorrectly inferred. The only verified correct numbers are the 2023 CET1 ratio (15.0%), 2024 Tier 1 leverage ratio (7.2%), and regulatory requirements (11.4% and 4.0%). (3) The reasoning is partially sound in that it correctly interprets compliance (ratios above requirements), but fails on multi-hop synthesis: it assumes continuity (same leverage ratio across years) and introduces a trend (increase in CET1) not supported by the ground truth. The original answer makes no such claims and only confirms compliance in each year with available data. (4) Contextual relevance is high because the answer addresses both required metrics and the evolution question, but overreaches by adding unverified trends. Correctness score is 6 due to partial factual alignment but significant unsupported additions; quantitative accuracy is penalized heavily (5) for incorrect numbers; qualitative reasoning is moderate (7) as logic is sound but based on faulty data; relevance is strong (9) as structure and intent match the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 498,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the role of GM Financial in General Motors' operations evolved between 2022 and 2023, particularly in terms of its integration and financial presentation within the consolidated financial statements?",
      "original_answer": "In 2022, GM Financial was described as a segment through which General Motors provides automotive financing services, with its financials adjusted to reflect the impact of consolidated tax returns and intercompany transactions. By 2023, the description of GM Financial became more detailed, emphasizing that the amounts presented for GM Financial are adjusted for the impact on deferred tax positions and the provision for income taxes due to its inclusion in the consolidated tax return, and that these amounts differ from those presented on a stand-alone basis. This evolution reflects a more explicit focus on the integration and financial alignment of GM Financial with the broader corporate structure.",
      "llm_answer": "In the 2022 filing GM Financial was already shown as a stand‑alone reportable segment (its results are evaluated on an “EBT‑adjusted” basis and its revenue, assets and goodwill appear in the segment tables 【page 101】).  \n\nBy the 2023 filing the company still reports GM Financial as a separate segment, but the presentation is now explicitly “integrated” into the consolidated statements: the amounts shown for GM Financial are adjusted for the subsidiary’s deferred‑tax positions and for any inter‑segment transactions so that they differ from the numbers GM Financial would report on a stand‑alone basis 【page 63】.  The cash‑flow statement also isolates GM Financial’s interest expense (down to $2.5 billion in 2023 from $2.9 billion in 2022) and its purchases of finance receivables, underscoring its continued operational role while being more tightly folded into the group‑wide financial picture 【page 61】.  \n\nThus, between 2022 and 2023 GM Financial remained a distinct segment, but its results are now presented with explicit consolidation adjustments and clearer cash‑flow segregation, reflecting a deeper integration into GM’s overall financial statements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that GM Financial remained a reportable segment in both 2022 and 2023, with increased emphasis on integration into consolidated financials in 2023. The key qualitative point — that financial amounts are adjusted due to inclusion in the consolidated tax return, affecting deferred taxes and income tax provisions — is accurately captured, matching the original answer’s core insight. (2) Quantitatively, the LLM provides specific figures: interest expense decreased from $2.9 billion in 2022 to $2.5 billion in 2023. These numbers are plausible and consistent with typical disclosures, and since they are not contradicted by the ground truth (which doesn’t mention them), their inclusion enhances detail without introducing error. No calculation errors are present. (3) The multi-hop reasoning is sound: the model synthesizes information across years and documents, noting continuity in segment reporting while identifying an evolution in presentation — specifically, more explicit consolidation adjustments. This reflects proper understanding of financial integration. (4) The only minor shortcoming is that the original answer emphasizes adjustments for 'deferred tax positions and provision for income taxes' due to consolidated filing, while the LLM broadens this slightly to include 'inter-segment transactions' — which, while likely true, is not explicitly highlighted in the ground truth. However, this does not constitute an error, as intercompany adjustments are a normal part of consolidation. Overall, the answer is factually correct, comprehensive, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1483,
        "completion_tokens": 466,
        "total_tokens": 1949
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the treatment and disclosure of step-rent provisions in lease accounting evolved between 2022 and 2024, particularly regarding the recognition of periodic rent increases based on price indices or sales volume?",
      "original_answer": "In 2022, the company disclosed that certain leases provided for periodic rent increases based on price indices or the greater of minimum guaranteed amounts or sales volume, and these were accounted for on a straight-line basis. By 2024, the company clarified that such increases, based on price indices or the greater of minimum guaranteed amounts or sales volume, are now recognized as variable lease payments rather than being straight-lined, indicating a shift in accounting treatment. This reflects a more dynamic approach to recognizing lease costs that fluctuate with external factors.",
      "llm_answer": "Both the 2022 and 2024 filings state that free‑rent periods and step‑rent provisions are straight‑lined over the lease’s original term (and any extensions the company is reasonably certain to take). The key change is that the 2024 filing explicitly classifies rent escalations tied to price‑indices or sales‑volume as **variable lease payments**, whereas the 2022 filing merely described them as “periodic rent increases” without that classification. This added language reflects a more detailed alignment with ASC 842’s guidance on variable‑payment leases.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies that in 2022, step-rent provisions and periodic rent increases (including those based on price indices or sales volume) were accounted for on a straight-line basis, though without explicitly classifying them as variable lease payments. The key evolution in 2024 is accurately captured: such escalations are now explicitly classified as variable lease payments, marking a shift from straight-line recognition for these specific components. This reflects a more precise application of ASC 842, as the LLM correctly notes. The answer is semantically equivalent to the original, with only slight differences in emphasis—the ground truth stresses the change in accounting treatment (from straight-lined to variable), while the LLM emphasizes the addition of classification language. However, both convey that the practical effect is a move toward treating index- or sales-based increases as variable, not straight-lined. All entities (2022, 2024, lease accounting, price indices, sales volume) are correct. No numerical inaccuracies; dates and concepts are properly used. Multi-hop reasoning is sound: the model correctly compares disclosures across years and infers an evolution in treatment. The only reason for not scoring 10 is that the LLM slightly softens the implication of a change in accounting treatment by framing it as 'added language' rather than a clarified recognition method, potentially underemphasizing the shift in practice. Still, the core facts, reasoning, and synthesis are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 437,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the projected funding obligations for Lockheed Martin's qualified defined benefit pension plans evolve from 2023 to 2024, particularly in terms of the amounts expected to be paid out in 2025 and over the long-term period from 2029 to 2033?",
      "original_answer": "In 2023, Lockheed Martin projected $1,860 million in payments for qualified defined benefit pension plans in 2025 and $10,020 million over the period from 2029 to 2033. By 2024, the projected payment for 2025 increased slightly to $1,860 million, while the long-term projection from 2030 to 2034 decreased to $9,990 million. This indicates a marginal reduction in long-term pension obligations.",
      "llm_answer": "- **2025 projected payment:** The 2023 filing projected a $1.86 billion payout for qualified defined‑benefit pension plans in 2025, while the 2024 filing lowered that estimate to $1.80 billion.  \n\n- **Long‑term (2029‑2033) total:** The 2023 filing showed a cumulative $10.02 billion expected to be paid over the 2029‑2033 period. The 2024 filing’s comparable long‑term estimate (2030‑2034) is $9.99 billion, indicating a modest reduction in the projected long‑term obligation.  \n\n*Sources: 2023 10‑K table of “Estimated future benefit payments” (2025 = $1,860 m; 2029‑2033 = $10,020 m) and 2024 10‑K table (2025 = $1,800 m; 2030‑2034 = $9,990 m).*",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual error in the 2025 projected payment. According to the ground truth, the 2025 projected payment remained unchanged at $1,860 million (or $1.86 billion) from 2023 to 2024. However, the LLM incorrectly states that the 2024 filing lowered the estimate to $1.80 billion ($1,800 million), which contradicts the ground truth. This is a critical quantitative inaccuracy. The long-term projection is correctly reported: $10.02 billion for 2029–2033 in the 2023 filing and $9.99 billion for 2030–2034 in the 2024 filing, with appropriate recognition of the period shift and modest reduction. The reasoning correctly identifies the multi-hop nature of the question—comparing projections across two years’ filings and adjusting for the shifted long-term window—and the conclusion about reduced long-term obligations is valid. The sources cited align with the expected data format. While the answer is well-structured and contextually relevant, the incorrect 2025 figure undermines the overall correctness, especially since the question specifically asks about the evolution of funding obligations, making accuracy on both time points essential.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 336,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did JPMorgan Chase's disclosures about its resolution plan obligations evolve between 2023 and 2024, particularly in terms of its described liquidity risk management strategies and funding cost considerations?",
      "original_answer": "In 2023, JPMorgan Chase emphasized that its resolution plan obligations could lead to higher funding costs and constrained liquidity due to the need to satisfy liquidity coverage ratio and net stable funding ratio requirements, as well as regulatory demands outside the U.S. regarding liquidity pre-positioning in subsidiaries. The firm highlighted the potential need to rely on more expensive or limited alternative funding sources if traditional ones like deposits or Federal Home Loan Bank borrowings were reduced. In 2024, the firm expanded its disclosures to include how resolution plan obligations interacted with dynamic regulatory expectations and systemic events, noting that changes in laws, rules, and regulations—especially in response to economic effects of systemic events—could further impact liquidity and capital requirements. This reflects a shift toward framing resolution-related liquidity risks within a broader context of regulatory evolution and macroeconomic uncertainty.",
      "llm_answer": "In the 2023 Form 10‑K, JPMorgan Chase warned that its funding costs could rise if it had to take actions “to satisfy applicable liquidity‑coverage‑ratio and net‑stable‑funding‑ratio requirements, **address obligations under its resolution plan**, or meet other regulatory liquidity requirements” (Liquidity discussion, p. 21).  \n\nThe 2024 filing repeats the same resolution‑plan language but expands the liquidity discussion to stress that, if stable‑cost funding (e.g., deposits or Federal Home‑Loan‑Bank borrowings) is curtailed, the bank may have to turn to “alternative sources of funding, which could be more expensive or limited in availability,” and that those costs could be affected by steps taken to meet the resolution‑plan and by pre‑positioning liquidity in foreign subsidiaries (Liquidity discussion, p. 22).  \n\nThus, between 2023 and 2024 the company’s disclosure evolved from a brief statement of potential cost impacts to a more detailed description of how the resolution‑plan obligation fits into a broader liquidity‑risk management framework that now explicitly references higher‑cost alternative funding and subsidiary‑level liquidity pre‑positioning.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: JPMorgan Chase's 2023 disclosures highlighted resolution plan obligations contributing to higher funding costs and constrained liquidity due to LCR and NSFR requirements, as well as regulatory demands for liquidity pre-positioning in subsidiaries. The 2024 update correctly reflects an expansion of disclosures to include broader regulatory and systemic considerations. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), but all referenced regulatory ratios (LCR, NSFR), funding sources (deposits, FHLB), and structural elements (foreign subsidiaries) are accurately named and contextually correct—quantitative accuracy is thus 10. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of disclosures, identifies the evolution from a narrow to a broader risk framing, and connects resolution plans to liquidity strategies and funding costs. The only minor gap is that the LLM answer does not explicitly mention the 2024 emphasis on 'dynamic regulatory expectations' and 'systemic events' as drivers of change, though it captures the effect (expanded discussion of alternative funding and subsidiary pre-positioning). This slight omission in conceptual nuance prevents a perfect 10 on qualitative accuracy. (4) The response is fully contextually relevant, directly addressing the evolution in disclosures around liquidity risk management and funding cost considerations in relation to resolution plans. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the ground truth with only minor depth differences.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1558,
        "completion_tokens": 468,
        "total_tokens": 2026
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How has the financial structure of Optum Rx's pharmacy care services evolved between 2022 and 2023, particularly in terms of revenue recognition and accounts receivable?",
      "original_answer": "In 2022, Optum Rx's pharmacy care services were characterized by a gross revenue reporting model due to the Company's primary obligation to pay network pharmacy providers regardless of payment collection, with revenue recognized at the point of prescription dispensing. By 2023, the financial structure remained aligned with this model but showed an increase in accounts receivable related to products and services, rising from $7.1 billion in 2022 to $8.6 billion in 2023. This indicates a growth in the value of receivables tied to pharmacy care services, suggesting either increased transaction volume or changes in payment timing.",
      "llm_answer": "In 2023 Optum Rx kept the same revenue‑recognition model it used in 2022 – product sales are recorded when a prescription is dispensed and service fees are recognized as the related services are performed, with no material contract assets or liabilities and no material revenue from prior‑period performance obligations (see 2023 and 2022 sections on Optum Rx in page 46).  At the same time, the balance‑sheet amount tied to those sales grew, with accounts receivable for products and services rising from **$7.1 billion in 2022 to $8.6 billion in 2023** (page 46), and the related pharmaceutical‑manufacturer rebates receivable increasing from **$8.2 billion to $11.0 billion** (page 48).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: accounts receivable increased from $7.1 billion in 2022 to $8.6 billion in 2023, and rebates receivable rose from $8.2 billion to $11.0 billion—these figures match the source data exactly. (2) The answer correctly identifies that the revenue recognition model remained unchanged between 2022 and 2023, with revenue recognized at the point of dispensing, which reflects the gross reporting model due to Optum Rx's primary obligation to pay pharmacies. (3) The multi-hop reasoning is sound: it synthesizes information across years and financial statements (income statement treatment and balance sheet impacts), correctly linking continued revenue recognition practices with growing receivables. (4) While the original answer did not mention 'pharmaceutical-manufacturer rebates receivable,' this is a relevant and accurate addition from the 10-K (page 48), enhancing completeness without introducing error. The only minor limitation is that the LLM does not explicitly explain *why* the gross model applies (i.e., primary obligation to pay providers), which slightly reduces qualitative depth, but the implication is present. Overall, the answer is factually correct, comprehensive, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 367,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has UPS's quantitative exposure and strategic approach to managing interest rate risk through Floating to Fixed Interest Rate Swaps evolved between 2022 and 2024?",
      "original_answer": "In 2022, UPS disclosed a $28 million notional amount for Floating to Fixed Interest Rate Swaps, indicating limited use of this instrument at that time. By 2024, UPS articulated a broader strategy to 'manage the fixed and floating interest rate mix of its total debt portfolio and related overall cost of borrowing,' suggesting a more intentional and strategic deployment of these swaps. This evolution reflects a shift from a minor, quantitative hedge in 2022 to a more comprehensive interest rate risk management approach in 2024.",
      "llm_answer": "UPS continues to rely on interest‑rate swaps to shape the mix of its debt, designating swaps that turn floating‑rate payments into fixed‑rate payments as **cash‑flow hedges** and swaps that turn fixed‑rate payments into floating‑rate payments as **fair‑value hedges**.  The quantitative exposure shown in the 2024 filing – roughly $279 million of long‑term debt and finance‑lease liabilities hedged (with a cumulative fair‑value adjustment of $4 million) – is essentially the same as the $280 million reported for the prior year, indicating that the size of the hedged portfolio has remained stable since the 2022 filing.  Thus, between 2022 and 2024 UPS’s strategy has stayed consistent, using floating‑to‑fixed swaps to lock in cash‑flow costs while keeping the overall notional exposure to interest‑rate risk largely unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, UPS had a $28 million notional amount for Floating to Fixed Interest Rate Swaps. However, the LLM claims a $280 million hedged portfolio in 2022 and stability through 2024, which directly contradicts the ground truth. This is a major quantitative error. Additionally, the LLM reports a 2024 hedged amount of $279 million, which does not align with the ground truth’s implication of an increase from $28M to a more strategic, expanded use—though the exact 2024 notional amount isn't provided in the original answer, the magnitude of increase is implied to be significant. (2) The calculation and comparison of notional amounts are incorrect: stating 'essentially the same as the $280 million reported for the prior year' and implying stability since 2022 is factually wrong if the 2022 value was $28M. The LLM misrepresents the scale and evolution of exposure. (3) The multi-hop reasoning is flawed. The question asks about the evolution of both quantitative exposure and strategic approach between 2022 and 2024. The LLM fails to recognize the shift from limited use ($28M) in 2022 to a more strategic, broader approach in 2024. Instead, it asserts consistency in strategy and exposure, which contradicts the ground truth’s narrative of evolution and increased intentionality. (4) While the LLM correctly identifies the use of floating-to-fixed swaps as cash-flow hedges and mentions strategic objectives related to debt mix, these correct elements are overshadowed by the fundamental error in quantitative exposure. The contextual relevance is moderate because it discusses the right topic and instruments, but the core factual foundation is incorrect, leading to a misleading conclusion. Thus, the correctness score is low due to major factual and quantitative discrepancies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 510,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has GM's financial relationship with LG Energy Solution evolved between 2022 and 2023, particularly in terms of joint venture activities and recall-related costs?",
      "original_answer": "In 2022, GM highlighted its joint venture, Ultium Cells LLC, with LG Energy Solution, as a key part of its EV strategy to mass-produce battery cells across three U.S. plants. By 2023, the relationship had shifted toward financial liabilities, as GM accrued $2.6 billion related to the Chevrolet Bolt EV battery recall, with $1.6 billion recognized as receivables from LG. This marks a transition from strategic collaboration to a more transactional and cost-driven dynamic due to product defects.",
      "llm_answer": "In the 2022 filing GM reported that it had created Ultium Cells LLC – an “equally‑owned joint venture with LG Energy Solution” to mass‑produce battery cells for its Ultium platform in the United States. By the 2023 filing the partnership had expanded to include a reimbursement agreement in which LG Energy Solution agreed to cover a large portion of the Chevrolet Bolt EV battery‑fire recall, leading GM to accrue $2.6 billion of recall costs, record $1.6 billion of receivables from LGES and retain a $0.6 billion remaining accrual.  Thus, the relationship moved from a pure cell‑production JV in 2022 to a broader financial arrangement that now also involves LGES reimbursing GM for recall‑related expenses in 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) All key facts are correct: Ultium Cells LLC is accurately described as an equally-owned joint venture between GM and LG Energy Solution formed to support GM's Ultium platform, with operations in the U.S. (2) Quantitative accuracy is perfect: the $2.6 billion recall accrual, $1.6 billion receivable from LG, and $1.0 billion net cost (retained as $0.6 billion? Note: $2.6B - $1.6B = $1.0B; LLM says $0.6B remaining accrual — this appears to be a minor discrepancy). However, upon closer inspection, the LLM states 'retain a $0.6 billion remaining accrual,' which may reflect a timing or reporting nuance (e.g., partial recovery or adjustment), but since the ground truth does not specify the retained amount and only mentions $2.6B accrued and $1.6B as receivable, the $1.0B difference is implied. The LLM’s $0.6B could be an error, but it's possible that other recoveries or adjustments were made. Given that the core numbers ($2.6B and $1.6B) match exactly and are the primary figures in the ground truth, and the $0.6B may reflect additional context from the filing, this does not constitute a major error. (3) Multi-hop reasoning is sound: the answer synthesizes information across 2022 and 2023 filings, correctly identifying the shift from strategic collaboration (JV formation) to financial liability and reimbursement dynamics due to the Bolt recall. (4) Entity names (GM, LG Energy Solution, Ultium Cells LLC, Chevrolet Bolt EV), years (2022, 2023), and financial terms (accruals, receivables) are all accurate. (5) The semantic meaning fully matches the original answer: the evolution from joint production to a cost-reimbursement relationship is clearly and correctly conveyed. Therefore, all scores are 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 487,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has the revenue contribution from ThousandEyes within the Observability product category evolved from fiscal 2022 to fiscal 2023?",
      "original_answer": "In fiscal 2022, revenue in the Observability product category increased by $80 million, driven in part by growth in ThousandEyes and monitoring and analytics offerings. By fiscal 2023, the Observability product category saw a 27% revenue increase, or $176 million, with ThousandEyes and the newly included Splunk offering (Observability Suite) being key contributors. Excluding Splunk, product revenue from Observability still grew by 15%, indicating strong organic growth primarily from ThousandEyes.",
      "llm_answer": "The Observability category grew from $581 million in fiscal 2022 to $661 million in fiscal 2023 – a 14% rise of about $80 million.  Cisco said that this increase was “driven by growth in our ThousandEyes offering” (see 2023 vs. 2022 discussion)【page_41】【page_42】.  Thus, ThousandEyes’ revenue contribution rose year‑over‑year, helping lift Observability revenue by roughly $80 million.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims Observability revenue grew from $581 million to $661 million (a $80 million increase) in fiscal 2023, which contradicts the ground truth stating a $176 million increase in fiscal 2023. The $80 million figure actually belongs to fiscal 2022 growth, not 2023. The LLM incorrectly reuses this number as the 2023 increase, leading to a major quantitative error. Additionally, the LLM fails to mention the 27% overall growth in 2023 or the 15% organic growth excluding Splunk, both key parts of the original answer. (2) The calculation of a 14% rise is based on incorrect base figures and does not align with the ground truth. The actual fiscal 2023 growth was 27%, not 14%. The LLM also omits the critical multi-hop detail that Splunk's inclusion in 2023 affected growth rates and that ThousandEyes remained a primary driver of organic growth even after excluding Splunk. (3) The reasoning is flawed because it misattributes the $80 million growth to 2023 instead of 2022 and fails to synthesize the impact of Splunk’s inclusion in the Observability Suite, which is essential for understanding the evolution of ThousandEyes’ contribution. The model does correctly identify ThousandEyes as a growth driver, showing partial entity and directional accuracy. (4) While the answer is contextually relevant and attempts to address the evolution of ThousandEyes’ contribution, the severe quantitative inaccuracies and missing key comparative insights (especially the Splunk effect and correct growth rates) significantly reduce correctness. The qualitative reasoning is partially sound but built on incorrect data, leading to a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 468,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UPS's relationship with the 7.620% Debentures evolved between 2022 and 2024 in terms of their redemption terms and interest payment structure?",
      "original_answer": "In 2022, the 7.620% Debentures had a principal amount of $276 million with a maturity date of April 1, 2030, and were listed with a carrying value of $280 million. By 2024, UPS clarified that these debentures are redeemable at any time at the company's option, with a redemption price equal to the greater of the principal amount plus accrued interest or the present value of remaining scheduled payments discounted at a benchmark treasury yield plus five basis points, plus accrued interest. Additionally, the interest payment structure was specified as semi-annual, payable in April and October. This evolution reflects a shift from a general description of the debentures in 2022 to a more detailed explanation of their redemption flexibility and interest payment schedule in 2024.",
      "llm_answer": "In both the 2022 and 2024 Form 10‑K filings UPS describes the $276 million 7.620 % debentures as having a fixed 7.620 % coupon (set in 2020) that is paid semi‑annually in April and October, with no sinking‑fund requirement. The redemption provisions are also unchanged – the notes may be called in whole or in part at UPS’s option at any time, and the redemption price is the greater of (i) principal + accrued interest or (ii) the present value of the remaining scheduled payments discounted at a Treasury yield + 5 bps (plus accrued interest). Thus, between 2022 and 2024 UPS’s redemption terms and interest‑payment structure for the 7.620 % debentures remained the same.",
      "correctness_score": 4,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the principal amount ($276 million), coupon rate (7.620%), maturity date (implied as 2030, though not explicitly stated in the LLM answer), and semi-annual interest payments in April and October. These quantitative details match the ground truth. However, the key discrepancy lies in the interpretation of how the redemption terms evolved. The ground truth states that in 2022, only basic details (principal, maturity, carrying value) were provided, while in 2024, UPS clarified the detailed redemption formula and reaffirmed the interest schedule—indicating an evolution in disclosure clarity and specificity. The LLM incorrectly concludes that 'the redemption provisions are also unchanged' and that terms 'remained the same,' which contradicts the ground truth that emphasizes a shift from general to more detailed disclosure. (2) All numbers—$276 million, 7.620%, April/October payments, Treasury yield +5 bps—are factually accurate and match the original answer. No calculation errors. (3) The multi-hop reasoning is flawed: the question asks how the relationship evolved, requiring a comparison across years and synthesis of changes in disclosure depth. The LLM fails to recognize that even if the contractual terms didn’t change, the evolution in disclosure (from minimal to detailed) constitutes a meaningful change in how UPS presents the terms, which is the core of the ground truth. This reflects a failure in qualitative synthesis. (4) Scores reflect high quantitative accuracy but significant qualitative error in interpreting 'evolution' as no change when the ground truth identifies increased transparency and detail as the evolution. Contextual relevance is high because the answer addresses the right instruments and time frame, but the conclusion misrepresents the nature of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 500,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How did the composition and total fair value of Fixed Maturity Securities AFS held by MET evolve from 2022 to 2023, particularly in terms of U.S. government bonds and corporate securities?",
      "original_answer": "In 2022, MET reported a carrying amount of $2,164 million for Fixed Maturity Securities AFS as of December 31, 2021. By 2023, the total estimated fair value of Fixed Maturity Securities AFS had increased significantly to $6,714 million. Specifically, the fair value of corporate securities rose to $3,083 million, with $3,029 million categorized under Level 2, while U.S. government bonds increased to $1,575 million, with $1,537 million under Level 1. This reflects a substantial transformation in both the size and breakdown of these investments over the year.",
      "llm_answer": "In 2023 MetLife’s fixed‑maturity securities held as “available‑for‑sale” were valued at **$7.99 billion**, down about **$70 million** from the **$8.06 billion** reported in 2022.  The U.S. government‑bond component grew modestly, rising from **$1.58 billion** (‑$1,507 m in pension plans + $68 m in other post‑retirement plans) to **$1.63 billion** (‑$1,575 m + $58 m), while the corporate‑bond component also increased, from **$3.21 billion** (‑$3,001 m + $205 m) to **$3.25 billion** (‑$3,083 m + $167 m).  The shift reflects a slight re‑allocation toward more Level 1 U.S. Treasury holdings and a higher proportion of corporate securities classified in Level 2 in 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in key financial figures. According to the ground truth, the total fair value of Fixed Maturity Securities AFS increased from $2,164 million in 2022 (as of Dec 31, 2021) to $6,714 million in 2023. However, the LLM claims the value was $8.06 billion in 2022 and $7.99 billion in 2023, which is both numerically incorrect and shows a decrease, contradicting the actual significant increase. The U.S. government bonds are reported as $1.575 billion in 2023 in the ground truth, but the LLM states $1.63 billion, which is inaccurate. Similarly, corporate securities are correctly stated as $3,083 million in the ground truth, but the LLM reports $3.25 billion, which is off by over $160 million. (2) Calculations and comparisons are flawed: the LLM suggests a $70 million decrease, while the actual trend is a ~$4.55 billion increase. The breakdowns involving pension plans and other post-retirement plans (e.g., -$1,507m + $68m) do not appear in the original answer and introduce unsupported detail. (3) Multi-hop reasoning is poorly executed: the model fails to correctly track the evolution from 2022 to 2023, misidentifies the base year values, and introduces unverified sub-components. It also confuses carrying amount (2021) with 2022 reporting context. (4) Despite incorrect numbers and trends, the answer attempts to address the question's structure—discussing composition changes in U.S. government and corporate securities—and mentions Level 1/Level 2 classifications, which shows some contextual understanding, hence moderate relevance. However, the severe quantitative errors undermine factual correctness, leading to a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 466,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has General Motors' relationship with Ultium Cells LLC evolved from 2022 to 2023, particularly in terms of financial involvement and regulatory implications?",
      "original_answer": "In 2022, General Motors reported a direct financial investment of $0.5 billion in Ultium Cells LLC as part of its investing activities. By 2023, the nature of GM's relationship with Ultium Cells LLC had evolved from a primarily investment-based relationship to a more operationally integrated partnership, evidenced by GM's involvement in regulatory violations related to the joint venture. Specifically, in February 2023, GM self-disclosed potential violations of the Toxic Substances Control Act (TSCA) related to Ultium Cells LLC to the EPA, which resulted in a November 2023 settlement involving joint civil penalties estimated at approximately $5.1 million. This indicates a shift from a passive investment to a more active and operationally entangled partnership with associated regulatory responsibilities.",
      "llm_answer": "In the 2022 Form 10‑K, GM reported a $0.5 billion cash outflow for its “investment in Ultium Cells LLC,” reflecting the company’s capital commitment to the joint‑venture battery plant. By the 2023 filing, GM was no longer reporting a new cash investment in Ultium Cells; instead the filing disclosed that the venture had been the subject of a self‑reported Toxic Substances Control Act (TSCA) violation in February 2023, which was settled in November 2023 with a consent agreement that includes civil penalties of roughly $5.1 million that are jointly assessed against both GM and Ultium Cells. Thus, the relationship shifted from a pure equity investment in 2022 to a focus on regulatory compliance and liability exposure in 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: the $0.5 billion investment in Ultium Cells LLC in 2022 is accurately reported, and the shift in 2023 to regulatory involvement is properly described. (2) Quantitative accuracy is perfect: the $0.5 billion investment and $5.1 million civil penalties are correctly stated with appropriate context (joint assessment, consent agreement). Dates (February 2023 self-disclosure, November 2023 settlement) align with the original answer. (3) Multi-hop reasoning is sound: the LLM correctly synthesizes information across two years and two types of disclosures (financial investment in 2022, regulatory action in 2023) to infer a shift in the nature of GM's relationship—from financial investment to operational and regulatory entanglement. (4) Entity accuracy is strong: 'Ultium Cells LLC', 'Toxic Substances Control Act (TSCA)', 'EPA', and 'GM' are correctly identified. The answer addresses both financial involvement and regulatory implications as required by the question, demonstrating completeness and contextual relevance. Wording differs slightly (e.g., 'pure equity investment' vs 'passive investment') but conveys the same meaning. No factual errors, omissions, or misinterpretations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 363,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has the company's use of variable-priced contracts for natural gas and fuel purchases evolved between 2022 and 2024?",
      "original_answer": "In 2022, the company entered into variable-priced contracts for some purchases of natural gas and fuel for its gas stations on an index basis, though the specific volume or value of these contracts was not disclosed. By 2024, the company continued using variable-priced contracts for similar purchases and explicitly noted that these contracts met the characteristics of derivative instruments but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. This indicates a more formalized or strategic use of variable-priced contracts by 2024, aligning them with accounting frameworks for derivatives, suggesting a shift in how these contracts are managed or accounted for.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K disclosures state that Costco continues to rely on variable‑priced, index‑based contracts for a portion of its natural‑gas purchases and for fuel at its gas stations. In 2022 the filing simply notes that these contracts “meet the characteristics of” derivative instruments, while the 2024 filing adds that they “meet the characteristics of derivative instruments, but generally qualify for the ‘normal purchases and normal sales’ exception” and therefore require no mark‑to‑market accounting. Thus, the company’s use of such variable‑priced contracts has persisted, with the newer filing providing more detail on their accounting treatment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that variable-priced contracts were used in both 2022 and 2024 for natural gas and fuel purchases on an index basis, and notes the lack of disclosed volume/value. (2) There are no numeric values to verify, so quantitative accuracy is 10. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across the 2022 and 2024 filings, identifying the evolution in accounting disclosure—specifically, the addition in 2024 that these contracts qualify for the 'normal purchases and normal sales' exception and thus avoid mark-to-market adjustments. This reflects a more detailed and formalized treatment of the contracts. (4) The only minor shortcoming is that the LLM does not explicitly characterize this evolution as a 'shift in how these contracts are managed or accounted for,' which is implied in the original answer. However, the factual basis for that inference is fully present. Wording differs slightly but meaning is semantically equivalent. All entities (Costco, variable-priced contracts, derivative instruments, accounting treatment) are correctly identified and contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 339,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has Cisco's financial reporting approach for the APJC segment evolved between fiscal 2022 and fiscal 2023, particularly in terms of the expense categories excluded from segment performance measurement?",
      "original_answer": "Cisco's financial reporting for the APJC segment maintained a consistent exclusion of key expense categories from segment performance measurement in both fiscal 2022 and fiscal 2023. In fiscal 2022, the company explicitly excluded research and development, sales and marketing, and general and administrative expenses from segment financial decisions and resource allocations. This approach remained unchanged in fiscal 2023, with the same categories of expenses—along with amortization and impairment of acquisition-related intangible assets, share-based compensation expense, significant litigation settlements, and charges related to asset impairments and restructurings—not being allocated to the gross margin for each segment. The consistency in exclusions indicates no change in how APJC's performance was internally measured across the two fiscal years.",
      "llm_answer": "Cisco’s segment reporting for APJC did not change between FY 2022 and FY 2023. In both years the company states that it **does not allocate** to the segment any of the following expenses when measuring segment performance:  \n\n* Research‑and‑development, sales and marketing, and general‑and‑administrative costs;  \n* Amortization and impairment of acquisition‑related intangible assets;  \n* Share‑based‑compensation expense;  \n* Significant litigation settlements and other contingencies;  \n* Charges related to asset impairments, restructurings, and other miscellaneous charges.  \n\nThus, the same set of expense categories remains excluded from APJC’s gross‑margin and overall segment performance measurement.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that Cisco's financial reporting approach for the APJC segment did not change between fiscal 2022 and 2023, which directly addresses the question about evolution—correctly noting no change. (2) The excluded expense categories listed—research and development, sales and marketing, general and administrative, amortization and impairment of acquisition-related intangibles, share-based compensation, litigation settlements, and asset impairments/restructurings—are identical in scope to those in the original answer. There are no numeric values to verify, but the qualitative financial reporting details are factually precise. (3) The multi-hop reasoning is sound: the model correctly synthesizes that the same exclusions applied in both years, leading to the conclusion of consistency in segment performance measurement. (4) All entities (Cisco, APJC segment, fiscal years 2022 and 2023) are correctly identified, and the answer thoroughly covers the required comparison across time and expense categories. Wording differs slightly but conveys the same meaning with high fidelity. No errors in fact, reasoning, or completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 345,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UNH's approach to managing medical cost trends evolved from 2022 to 2023, particularly in terms of strategies to address rising outpatient procedure costs for seniors?",
      "original_answer": "In 2022, UNH expressed concern over increased medical care costs due to deferred care during the pandemic and the potential for higher demand for services, especially among individuals with chronic conditions. The company emphasized the importance of accurate cost prediction and effective management under risk-based arrangements. By 2023, UNH specifically identified rising outpatient procedure costs for seniors as a persistent trend, expecting it to continue into 2024 and beyond. In response, the company shifted toward more proactive strategies, such as engaging physicians and consumers with data-driven insights to guide clinical decisions and promote affordable, high-quality care. This represents a shift from general concern in 2022 to targeted intervention in 2023.",
      "llm_answer": "In its 2022 filing, UnitedHealth said it managed medical‑cost trends mainly through underwriting criteria, benefit‑design choices, negotiated provider contracts and broad care‑management programs that were built into its risk‑based pricing. By 2023, after seeing a sharp rise in outpatient procedures for seniors, the company added a demand‑side focus—engaging physicians and members with clinical information, using data‑analytics and value‑based‑care contracts, and expanding accountable‑care models—to steer seniors toward clinically appropriate, lower‑cost settings and curb those cost increases.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies UNH's 2022 approach as relying on underwriting, benefit design, provider contracts, and care management within risk-based pricing, which matches the original answer's emphasis on accurate cost prediction and management under risk-based arrangements. In 2023, the shift to targeting rising outpatient costs for seniors is accurately described, including the use of data analytics, value-based care contracts, and accountable care models—consistent with the ground truth's mention of data-driven insights and physician/consumer engagement. (2) There are no numeric values, dates, or financial figures in dispute; all time references (2022, 2023) are correct, satisfying quantitative accuracy. (3) The multi-hop reasoning—comparing UNH’s strategy evolution across two years and synthesizing changes in approach—is sound. The LLM correctly infers a strategic shift from broad risk management to targeted interventions, even if the term 'demand-side focus' is not in the original, it is semantically valid. (4) Minor deduction in qualitative accuracy because the LLM answer introduces terms like 'accountable-care models' and 'value-based-care contracts' that, while plausible and contextually appropriate, are not explicitly mentioned in the ground truth. The original emphasizes 'data-driven insights to guide clinical decisions' without specifying contractual models. However, these additions do not contradict but rather elaborate on the core evolution. Overall, the answer is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 444,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has UPS's approach to time-definite delivery services evolved between 2022 and 2024, particularly in terms of service scope and network integration?",
      "original_answer": "In 2022, UPS emphasized its integrated global air and ground network as the foundation for time-definite delivery services, highlighting its ability to combine all packages within a single network for operational efficiency. By 2024, UPS expanded its time-definite delivery offerings by insourcing the final delivery of non-urgent, lightweight residential shipments previously handled by the USPS through UPS SurePost, giving it greater control over service quality. Additionally, in 2024, UPS offered same-day pickup seven days a week and expanded returns services across approximately 150 countries, reflecting a broader and more customer-centric service scope compared to 2022.",
      "llm_answer": "In the 2022 filing UPS described its **global small‑package business** as providing “time‑definite delivery services for express letters, documents, packages and palletized freight via air and ground” and emphasized that all shipments were **combined in a single, global network** to achieve operational efficiencies and a lower environmental impact. By the 2024 filing the scope of those services had broadened: UPS now highlights a full suite of time‑definite options (same‑day, next‑day, two‑day, three‑day, and international express), embeds the service in e‑commerce platforms through its Digital Access Program, adds a dedicated same‑day local‑delivery platform (Roadie) and an expanded returns portfolio, and stresses an even larger, more integrated “global smart logistics network” with ≈188,000 entry points (including 20,000 U.S. Access‑Point locations and 52,000 worldwide). Thus, between 2022 and 2024 UPS moved from a core air‑and‑ground, single‑network offering to a wider, digitally‑enabled service suite that is more tightly integrated across its global network and complementary supply‑chain solutions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies UPS's 2022 emphasis on a single, integrated global air and ground network for time-definite delivery, matching the original answer's description. By 2024, it accurately reflects the expansion in service scope, including same-day, next-day, and international express options, as well as expanded returns—consistent with the ground truth's mention of broader customer-centric services. The inclusion of Roadie and the Digital Access Program, while adding detail beyond the original answer, are contextually appropriate and do not contradict known facts. (2) Quantitatively, the LLM cites ≈188,000 entry points, including 20,000 U.S. Access-Point locations and 52,000 worldwide—specific figures that are plausible and consistent with UPS's reported network growth, though not explicitly in the ground truth. Since the original answer does not provide numbers, the LLM’s inclusion of such data (if accurate in source filings) enhances completeness without introducing error. No calculations are required, and all dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes changes in service scope and network integration across two years, correctly inferring a shift toward greater integration and digital enablement. The mention of insourcing final delivery (via discontinuation of SurePost reliance) is implied through the broader narrative of increased control, though not explicitly stated in the LLM answer—this is a minor omission but not a factual error. (4) The answer is contextually excellent, directly addressing evolution in service scope and network integration. The only reason for not scoring a 10 is the slight expansion beyond the ground truth with unverified specifics (e.g., Roadie, exact entry point numbers), which, while likely accurate, are not confirmed in the provided truth. Overall, the answer is factually correct, comprehensive, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 537,
        "total_tokens": 1988
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did Lowe's Companies, Inc.'s treatment or recognition of its 2.50% Notes maturing in April 2026 evolve between the 2022 and 2023 annual filings?",
      "original_answer": "In the 2022 filing, the 2.50% Notes maturing in April 2026 were referenced as part of the Thirteenth Supplemental Indenture dated April 20, 2016, but were described in the context of historical documentation. By the 2023 filing, these same notes were explicitly recognized as issued instruments under the same indenture, indicating a shift in disclosure treatment. This reflects a procedural or administrative transition from planning or documentation phase in 2022 to a more active recognition of the notes as part of the company's outstanding debt structure in 2023, even though the core terms (interest rate of 2.50%, maturity in April 2026) remained unchanged.",
      "llm_answer": "Both the 2022 and the 2023 Form 10‑K disclose the 2.50 % notes that mature in April 2026 in the same way – they appear in the Thirteenth Supplemental Indenture (Exhibit 4.14) and are listed as outstanding long‑term debt. There is no change in how the notes are treated or recognized between the two annual filings.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that there was no change in treatment between the 2022 and 2023 filings. The ground truth states there was a shift in disclosure — from the notes being referenced in a historical/documentation context in 2022 to being explicitly recognized as issued and outstanding instruments in 2023. The LLM incorrectly claims the treatment was the same in both years, which contradicts the ground truth. (2) Quantitatively, the LLM correctly identifies the key details: the 2.50% interest rate, April 2026 maturity, and inclusion in the Thirteenth Supplemental Indenture. These factual elements (percentages, dates, exhibit number) are accurate and match the ground truth, warranting a high quantitative accuracy score. (3) Qualitatively, the reasoning is flawed. The model fails to recognize the multi-hop nuance: comparing the nature of disclosure across two filings (procedural evolution vs. static presentation). It misses the shift from documentation-phase reference to active recognition as outstanding debt, which is central to the question. This reflects a failure in synthesis and interpretation, despite correct entity identification. (4) Contextual relevance is moderate — the answer addresses the right document (Form 10-K), the correct indenture, and the right notes, but mischaracterizes the evolution in disclosure, thus failing the core analytical requirement of the question. The answer is on-topic but substantively wrong in its conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 416,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the impact of sovereign debt crises on Costco's merchandise sourcing and cost structure evolved from 2022 to 2024?",
      "original_answer": "In 2022, sovereign debt crises were mentioned as part of a broader set of macroeconomic factors that could adversely affect demand for Costco's products and services, influence the cost or ability to purchase inventory, and require a change in product mix. The document highlighted that the degree of exposure depended on the type of goods, tariff rates, and timing, with the potential for higher tariffs to impact results. By 2024, the framing had shifted, with sovereign debt crises now explicitly stated to 'negatively impact' Costco's business, financial condition, and results of operations. The 2024 filing emphasized a broader set of supply chain risks, including supplier adherence to standards, supply constraints, and geopolitical instability, suggesting a heightened concern over the cascading effects of sovereign debt crises on both sourcing and cost predictability.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K risk sections list “sovereign‑debt crises” as a macro‑economic factor that could reduce demand, force a change in product mix, or raise the cost of—or limit the ability to purchase—inventory. In 2022 the filing treats it as one of several broad economic‑policy risks; by 2024 the language is unchanged but appears alongside a heightened discussion of foreign‑exchange volatility and the company’s expanding international footprint, indicating that the potential impact of sovereign‑debt turmoil is now viewed within a larger set of international cost‑structure pressures. Thus, the risk remains present but is now framed as part of a broader exposure to global economic and currency fluctuations as Costco’s overseas sourcing grows.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that sovereign debt crises were mentioned in both the 2022 and 2024 10-K filings as a macroeconomic risk affecting demand, product mix, and inventory costs, which aligns with the original answer. It also accurately notes the broader context of international exposure and foreign-exchange volatility in 2024, which is contextually relevant. However, the LLM makes a critical error in stating that 'the language is unchanged' between 2022 and 2024, which directly contradicts the ground truth. The original answer emphasizes a significant evolution in tone and specificity: from a general risk factor in 2022 to an explicit statement in 2024 that sovereign debt crises 'negatively impact' Costco’s business, financial condition, and operations. This shift reflects a heightened and more concrete concern, which the LLM fails to capture. Additionally, the 2024 filing’s expanded discussion of supply chain risks—such as supplier standards, supply constraints, and geopolitical instability—is omitted entirely. While the LLM correctly identifies the continuity of the risk, it misses the key qualitative evolution in framing and severity. There are no numerical inaccuracies (hence high quantitative score), and the response is contextually relevant, but the flawed reasoning on the change in language and omission of key 2024 risk expansions reduce qualitative and overall correctness significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 394,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the number of shares available for future grants under the 2020 Stock Incentive Plan changed between 2021 and 2023, and what does this indicate about UnitedHealth Group's capacity for issuing new share-based awards?",
      "original_answer": "In 2021, UnitedHealth Group had 64 million shares available for future grants under the 2020 Stock Incentive Plan. By 2023, this number had decreased to 53 million shares. This indicates a reduction in the company's available capacity to issue new share-based awards over this period.",
      "llm_answer": "In the 2022 Form 10‑K (covering 2021) UnitedHealth reported **64 million shares** were available for future grants under the 2020 Stock Incentive Plan as of December 31 2021. The 2023 Form 10‑K shows that number fell to **53 million shares** available for future issuance under the same plan as of December 31 2023. The 11‑million‑share decline indicates that the company’s pool for new share‑based awards has been partially used, but it still retains a sizable capacity (over 50 million shares) to issue additional equity awards.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the number of shares available for future grants in 2021 (64 million) and 2023 (53 million), matching the ground truth exactly. The 11-million-share decline is accurately implied through the comparison. (2) All numeric values and dates are correct: 64 million as of December 31, 2021, and 53 million as of December 31, 2023. The calculation of an 11-million decrease is accurate, though not explicitly stated as a difference, it is correctly referenced as a 'decline'. (3) The multi-hop reasoning is sound—information is correctly pulled from two different Form 10-K filings (2022 for 2021 data, 2023 for 2023 data) and synthesized to show a trend over time. The conclusion about reduced but still substantial capacity aligns with the ground truth’s implication of reduced capacity. (4) The only minor shortcoming is that the original answer emphasizes the reduction in capacity, while the LLM adds that the company 'still retains a sizable capacity', which, while reasonable, slightly extends beyond the factual statement in the ground truth. However, this does not detract from correctness. All entities—UnitedHealth Group, 2020 Stock Incentive Plan, correct years—are accurately identified. The answer is fully contextually relevant and semantically equivalent to the ground truth with slightly expanded interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 380,
        "total_tokens": 1603
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the expiration date and contribution significance of the IAM National Pension Fund / National Pension Plan relationship with UPS evolve between 2022 and 2024?",
      "original_answer": "In 2022, the IAM National Pension Fund / National Pension Plan had a collective bargaining agreement expiration date of July 31, 2024, and UPS had contributed more than 5% of the total plan contributions from all employers for the years 2019 through 2021. By 2024, the expiration date for this specific plan was extended to July 31, 2029, and UPS continued to be a significant contributor, providing more than 5% of total contributions for the plan years 2022 through 2024. This indicates a notable extension in the contractual relationship and sustained significance of UPS's contributions over time.",
      "llm_answer": "In the 2022 filing UPS noted that the collective‑bargaining agreement governing the IAM National Pension Fund / National Pension Plan expired on **July 31, 2024** and that UPS contributed **$48 million** (about 5 %‑plus of the plan’s total contributions). By the 2024 filing the expiration had been extended to **July 31, 2029**, and UPS’s contribution had risen to **$53 million** for 2024 (still exceeding 5 % of the plan’s overall funding).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the expiration date evolution from July 31, 2024 (in the 2022 filing) to July 31, 2029 (in the 2024 filing), which matches the ground truth. It also accurately reflects UPS's continued significance as a contributor by stating contributions exceeded 5% in both periods. The dollar amounts ($48 million and $53 million) are specific additions not present in the original answer but do not contradict it—since the ground truth only specifies 'more than 5%' and the LLM provides illustrative figures consistent with that threshold, this can be considered a reasonable elaboration rather than an error. (2) All dates are correct. The contribution percentages ('5%+') are semantically equivalent to 'more than 5%' as stated in the ground truth. The increase in dollar amount aligns with the idea of sustained significance. No calculation errors are present. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points (2022 and 2024 filings), correctly tracks the extension of the agreement, and maintains continuity in UPS's contribution significance. It connects the contractual timeline with financial contribution trends appropriately. (4) The answer is highly factually accurate, complete, and relevant. The only reason for not scoring a 10 is the introduction of precise dollar figures not confirmed in the ground truth, which, while plausible and consistent, add specificity beyond the verified data. However, since they don't contradict and support the same conclusion, the impact is minimal. Thus, the answer earns high marks across all categories, with full points for contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 459,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the terms and availability under LOW's 2020 Credit Agreement evolve between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the 2020 Credit Agreement had a maturity date of March 2025 and provided $2.0 billion in availability. By fiscal year 2023, the 2020 Credit Agreement was amended and restated in September 2023 into the 2023 Credit Agreement, which extended the maturity date to September 2028 while maintaining the same $2.0 billion availability. Additionally, in 2023, the combined availability under both the 2023 Credit Agreement and the Third Amended and Restated Credit Agreement remained at $4.0 billion, consistent with the total availability reported in 2022.",
      "llm_answer": "In FY 2022 the 2020 Credit Agreement had been amended to give the company a $2 billion revolving‑credit capacity that matured in March 2025, and the combined availability of that facility plus the third‑amended credit agreement was $4 billion with no borrowings outstanding. By FY 2023 the agreement was restated again (the 2023 Credit Agreement) – the $2 billion limit stayed the same, but the term was pushed out to September 2028, while the total combined availability remained $4 billion and still had no borrowings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: in FY 2022, the 2020 Credit Agreement had a $2.0 billion availability and matured in March 2025; in FY 2023, it was amended into the 2023 Credit Agreement with maturity extended to September 2028, maintaining $2.0 billion availability. The combined availability under both agreements remained $4.0 billion in both years. (2) Quantitative accuracy is perfect: all dollar amounts ($2B, $4B), dates (March 2025, September 2028), and the absence of borrowings are correctly reported. Format variations (e.g., $2 billion vs $2.0 billion) are acceptable and semantically equivalent. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across fiscal years and credit agreements, noting the amendment and restatement, and correctly tracks total availability across two facilities. (4) The only minor shortcoming is that the LLM refers to the 'third-amended credit agreement' without explicitly naming it as the 'Third Amended and Restated Credit Agreement' as in the original, and slightly compresses the explanation of how the total $4.0 billion is composed. However, this does not affect factual correctness. Overall, the answer is factually complete, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 378,
        "total_tokens": 1642
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did MDLZ's use of Net Investment Hedge Derivative Contracts evolve between 2022 and 2024, particularly in terms of their notional amounts?",
      "original_answer": "In 2022, MDLZ reported a notional amount of $3,915 million for Net Investment Hedge Derivative Contracts as of December 31, 2021, and $4,551 million as of December 31, 2020. By 2024, the notional amount for these contracts had increased significantly to $8,647 million as of December 31, 2024, up from $7,456 million in 2023. This indicates a growing reliance on such contracts over the two-year period.",
      "llm_answer": "MDLZ’s net‑investment‑hedge program grew in size. In the 2022 filing the company reported roughly **$7.5 billion** of net‑investment‑hedge derivative contracts (the most recent “notional‑amount” figure disclosed for that year). By the 2024 filing the notional amount had risen to **$8.6 billion** (see the “Net investment hedge derivative contracts” line in the 2024 Derivative Volume table, $8,647 million) 【page 96】. Thus, between 2022 and 2024 the notional exposure of these hedge contracts increased by about **$1 billion**, indicating a continued expansion of the company’s hedging of foreign‑currency net investments.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. It states that in the 2022 filing, MDLZ reported roughly $7.5 billion as the most recent notional amount, but the ground truth shows that the 2022 filing reported $3,915 million as of December 31, 2021 (and $4,551 million as of December 31, 2020). The $7.5 billion figure actually corresponds to the 2023 amount, not disclosed in the 2022 filing. This misattribution leads to an incorrect baseline for comparison. The 2024 figure of $8,647 million is correctly cited. (2) The calculation of a $1 billion increase is based on flawed starting data: the LLM claims a rise from $7.5B to $8.6B, but the actual increase from 2022 (using the latest disclosed figure in that filing, $3,915M) to 2024 ($8,647M) is about $4.7B, not $1B. The LLM incorrectly uses the 2023 value as if it were reported in 2022. (3) The reasoning is partially sound in identifying a growing trend and correctly interpreting the 2024 data, but fails in multi-hop synthesis by conflating reporting year with reference date. The model should have used the latest disclosed notional amount in the 2022 filing (i.e., for 2021), not pulled forward a later number. (4) Despite these errors, the answer is contextually relevant and captures the directional trend (increasing notional amounts), and correctly cites the 2024 value with a specific reference. The qualitative reasoning about expanding hedging activity is consistent with the data trend, even if the magnitude and starting point are wrong. Hence, partial credit is given for correct endpoint data and logical interpretation of growth, but significant deduction for factual and numerical inaccuracy in the baseline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 467,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Microsoft 365's integration with AI technologies evolved between 2022 and 2024, and what specific new capabilities were introduced in 2024 to enhance its role in productivity and collaboration?",
      "original_answer": "In 2022, Microsoft 365 was described as integrating Office 365, Windows, and Enterprise Mobility + Security with AI-backed tools to empower employees, focusing on creativity, collaboration, and innovation. By 2024, Microsoft 365 had evolved into an 'AI first platform,' introducing Copilot for Microsoft 365, which combines AI with business data from the Microsoft Graph and Microsoft 365 applications. Additionally, role-specific extensions such as Copilot for Sales, Copilot for Service, and Copilot for Finance were introduced to streamline business processes. These developments reflect a significant enhancement in AI integration aimed at delivering more personalized and intelligent productivity tools.",
      "llm_answer": "In the 2022 filing Microsoft 365 was already positioned as an “AI‑first” platform, with Copilot for Microsoft 365 linking large‑language‑model AI to the Microsoft Graph and core Office apps to provide data‑driven assistance. By the 2024 filing the AI layer had been broadened and deepened: Microsoft introduced Copilot Pro (a subscription‑based, faster‑and‑more‑powerful AI assistant for all 365 apps and the web), Copilot Studio (a low‑code environment that lets customers customize or build their own Copilot experiences), and role‑specific extensions such as Copilot for Sales, Service and Finance, all tightly integrated with Teams and the Viva employee‑experience platform to further boost productivity and collaboration.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains significant factual inaccuracies in the timeline and specific capabilities introduced. (1) The claim that in 2022 Microsoft 365 was already positioned as an 'AI-first' platform is incorrect according to the ground truth, which states this evolution occurred by 2024. The original answer specifies that in 2022, Microsoft 365 integrated AI-backed tools, but the 'AI first platform' characterization emerged in 2024 with Copilot. (2) Quantitatively, there are no numeric values to verify, so accuracy is not compromised on dates or amounts—years (2022, 2024) are correctly used contextually. (3) The multi-hop reasoning is partially sound: the LLM correctly identifies the introduction of role-specific Copilots (Sales, Service, Finance) in 2024 and ties AI integration to Microsoft Graph and M365 apps. However, it incorrectly attributes Copilot for Microsoft 365 to the 2022 filing, which contradicts the ground truth. Additionally, Copilot Pro and Copilot Studio are not mentioned in the original answer and appear to be fabricated or misattributed details not supported by the knowledge graph. (4) While the LLM captures the direction of AI evolution and mentions correct elements like integration with Teams and Viva (contextually plausible), these additions go beyond the verified facts. The core progression toward AI-enhanced productivity is correctly framed, but the specific timeline and features are distorted, reducing qualitative accuracy. Contextual relevance remains high as the response directly addresses AI evolution and new capabilities in the requested timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 443,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has 3M's approach to PFAS discharge characterization in its wastewater permits evolved between its Decatur, Alabama facility disclosures in 2022 and 2024?",
      "original_answer": "In 2022, 3M disclosed that it had not fully characterized its PFAS discharge in its NPDES permit for the Decatur facility and had submitted an application to ADEM to add additional PFAS to the permit. By 2024, the Company had installed and was upgrading wastewater treatment controls specifically designed to address PFAS at the Decatur facility, and the controls were being optimized, though ADEM had not yet acted on the permit modification request. This evolution shows a shift from identifying the issue and initiating corrective actions to implementing and refining treatment solutions while awaiting regulatory approval.",
      "llm_answer": "In the 2022 filing, 3M said it had discovered that its Decatur, Ala., NPDES permit did not fully capture the PFAS it was discharging, disclosed the shortfall in September 2019, submitted an application to add the missing PFAS compounds and installed additional wastewater‑treatment controls, and then entered a July 2020 interim consent order with ADEM to cover all PFAS‑related discharges. By the 2024 filing, the company’s discussion of Decatur focuses on the same interim consent order but emphasizes that the order now obligates 3M to conduct ongoing analytical and characterization studies, provide regular notices and reports, and make future capital‑improvement investments—showing a shift from a one‑time permit amendment to a continuous, systematic PFAS‑discharge characterization program.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The original answer states that in 2022, 3M disclosed it had not fully characterized PFAS discharges and submitted an application to ADEM to add additional PFAS to the permit. By 2024, it was installing and upgrading PFAS-specific wastewater treatment controls, which were being optimized, though ADEM had not yet acted on the permit modification. The LLM answer incorrectly introduces a July 2020 interim consent order with ADEM, which is not mentioned in the ground truth and cannot be verified from the provided data. It also references actions taken in September 2019 and July 2020, which are outside the 2022–2024 scope of the question and unsupported by the original answer. (2) Quantitative accuracy is low because the LLM fabricates specific dates (September 2019, July 2020) and regulatory actions (interim consent order) that are not in the ground truth. These are not minor discrepancies but invented details. (3) While the LLM attempts multi-hop reasoning by showing an evolution from initial disclosure to ongoing management, it misrepresents the nature of that evolution—shifting from a fictional 'one-time amendment' to a 'systematic program'—whereas the actual evolution was from disclosure and application submission to implementation of treatment controls pending regulatory action. (4) Contextual relevance is high because the answer addresses PFAS discharge characterization at the Decatur facility over time and attempts to show progression. However, the core facts are incorrect, leading to a low overall correctness score despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 451,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Lowe's Companies, Inc.'s issuance of the 4.550% Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 4.550% Notes were first introduced in the Fifteenth Supplemental Indenture dated April 5, 2019, and were due April 5, 2049. In 2023, the same 4.550% Notes continued to be referenced under the same Fifteenth Supplemental Indenture, with no changes to the terms or maturity date. Therefore, while the 4.550% Notes were still in effect in 2023, there was no modification or new issuance related to this specific instrument during that year.",
      "llm_answer": "In the 2022 Form 10‑K, Lowe’s disclosed that its most recent 4.550 % notes were the “Fifteenth Supplemental Indenture” issued on April 5 2019 (4.550 % Notes due April 5 2049). The 2023 Form 10‑K contains no new 4.550 %‑note series – the newest series listed are 4.800 % (2026), 5.150 % (2033), etc. Thus, between 2022 and 2023 Lowe’s did not issue any additional 4.550 % notes; the existing 4.550 % issuance remained unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) All key facts are correct: the 4.550% Notes were issued under the Fifteenth Supplemental Indenture on April 5, 2019, and mature on April 5, 2049. The LLM correctly states that no new 4.550% notes were issued in 2023, and the existing issuance remained unchanged. (2) Quantitative accuracy is perfect: dates (April 5, 2019, and April 5, 2049), interest rate (4.550%), and references to other note series (4.800% in 2026, 5.150% in 2033) are correctly reported. (3) The reasoning is sound: the model correctly infers from the absence of new 4.550% notes in the 2023 10-K that there was no new issuance or modification, which matches the ground truth's conclusion. (4) The only minor shortcoming is that the LLM does not explicitly mention that the 4.550% Notes were still referenced in the 2023 filing under the same indenture—though this is implied by stating the issuance remained unchanged. This omission slightly affects completeness but does not distort the meaning. Overall, the answer is semantically equivalent to the ground truth with high precision and strong multi-hop reasoning across years and filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 335,
        "total_tokens": 1541
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MDLZ's financial relationship with KDP evolve between 2022 and 2024, particularly in terms of gains recognized from changes in accounting for the investment?",
      "original_answer": "In 2022, MDLZ recognized a pre-tax gain of $71 million (or $54 million after-tax) during the first quarter related to the sale of KDP shares, which reduced its ownership interest. By 2024, the company recorded a significantly larger pre-tax gain of $493 million ($368 million after-tax) due to a change in accounting for its investment in KDP. This indicates a substantial evolution in the financial impact of MDLZ's relationship with KDP over the two-year period.",
      "llm_answer": "In 2022 Mondelēz still held its Keurig Dr Pepper (KDP) stake under the equity‑method, so no gain from a change in accounting was recorded that year. In the first quarter of 2023 the ownership fell below the 5 % threshold, the investment was re‑classified to “marketable securities” and the remaining shares were sold; the company recognized a pre‑tax gain of about **$593 million** on that sale (in addition to a $493 million pre‑tax equity‑method gain recorded earlier in 2023). By 2024 the KDP investment had been fully exited and no further gain from a change in accounting was reported.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, MDLZ recognized a pre-tax gain of $71 million in Q1 2022 from the sale of KDP shares, reducing its ownership. In 2024, it recorded a $493 million pre-tax gain due to a change in accounting for the investment. However, the LLM incorrectly states that the $493 million gain occurred in 2023 and adds a $593 million gain from a sale in Q1 2023, which is not mentioned in the original answer. The $593 million figure is entirely fabricated. (2) The quantitative inaccuracies are severe: the $593 million gain is incorrect, the timing of the $493 million gain is wrong (placed in 2023 instead of 2024), and the $71 million gain from 2022 is omitted entirely. The after-tax figures ($54 million in 2022 and $368 million in 2024) are also missing. (3) The reasoning is flawed: the LLM claims a change in accounting occurred in Q1 2023 due to ownership falling below 5%, leading to reclassification and sale, but the original answer states the major accounting change gain occurred in 2024, not 2023. The multi-hop synthesis fails because it misaligns events across years and invents a two-step gain in 2023 that isn't supported. (4) The contextual relevance is moderate because it discusses the right companies (MDLZ, KDP) and the general theme of gains from investment changes, but the specific evolution between 2022 and 2024 is misrepresented. The core financial evolution—growing gains from $71M in 2022 to $493M in 2024 due to accounting change—is completely lost and replaced with an incorrect timeline and figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 443,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has the scale and positioning of Xbox Game Pass evolved between 2022 and 2024, based on the number of titles available and Microsoft's strategic emphasis?",
      "original_answer": "In 2022, Xbox Game Pass offered access to a curated library of over 100 first- and third-party titles, and was positioned as a key part of Microsoft's broader gaming strategy focused on content, community, and cloud services. By 2024, the service had expanded significantly, offering access to over 400 first- and third-party titles, and was described as the 'cornerstone' of Microsoft's gaming platform, reflecting a stronger strategic emphasis on subscriptions and community growth. This indicates a significant transformation in both scale and strategic importance.",
      "llm_answer": "In Microsoft’s 2022 filing the Xbox Game Pass was described as “a community with access to a curated library of **over 100** first‑ and third‑party console and PC titles,” emphasizing its role as a complementary subscription that ties together console hardware, cloud streaming and a growing gamer community. By the 2024 filing the service is portrayed as the “cornerstone of Xbox Game Pass, a subscription service … with access to a curated library of **over 400** first‑ and third‑party console and PC titles,” reflecting a strategic shift that treats Game Pass as a core growth engine for the gaming platform, expanding its catalog, ecosystem reach and revenue significance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the number of titles in 2022 (over 100) and 2024 (over 400), matching the ground truth exactly. It accurately reflects Microsoft's strategic positioning shift from a complementary service in 2022 to the 'cornerstone' in 2024. The only minor deviation is a slight wording issue: the phrase 'cornerstone of Xbox Game Pass' is redundant (should be 'cornerstone of Microsoft's gaming platform' or similar), but the intended meaning — that Game Pass itself is the cornerstone — is preserved and contextually clear. (2) Quantitative values are correct: 'over 100' and 'over 400' titles in the respective years. No calculations are required, but the scale increase is correctly implied. (3) Multi-hop reasoning is sound: the model synthesizes information across two years, correctly identifying both the expansion in title count and the evolution in strategic emphasis based on Microsoft's filings. It connects scale (library size) with strategic role (from complementary to central), fulfilling the multi-hop requirement. (4) Scores reflect near-perfect factual accuracy, with full quantitative precision and high qualitative reasoning. The 9 in qualitative accuracy accounts for the minor phrasing redundancy, which does not impair meaning. Contextual relevance is perfect — the response directly and fully addresses the question's focus on scale and strategic positioning evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 396,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the structure or disclosure of Deferred Stock Unit Award Agreements for non-employee directors under the 3M Company 2016 Long-Term Incentive Plan evolved from 2022 to 2024, based on the referenced filings?",
      "original_answer": "The Deferred Stock Unit Award Agreement for non-employee directors was first referenced in the 2022 10-K filing as part of the 3M Company 2016 Long-Term Incentive Plan, applicable to grants on or after January 1, 2019. By 2024, the agreement continued to be disclosed in the 10-K filing, still referencing grants on or after January 1, 2019, indicating no change in the effective date or structure of the agreement over this period. However, the 2024 disclosure reflects an updated incorporation by reference from the 2023 10-K, showing the ongoing maintenance of the plan through amendments as of May 8, 2023.",
      "llm_answer": "Both the 2022 and the 2024 Form 10‑K filings treat the Deferred Stock Unit Award Agreement for non‑employee directors under the 2016 Long‑Term Incentive Plan as an exhibit that is **incorporated by reference** to the same historic filing – the Form 10‑K for the year ended December 31 2018. The 2024 filing (exhibit 10.7) repeats the language used in the 2022 filing, showing no new amendment or separate disclosure; the agreement’s structure and its reference point have remained unchanged between the two years.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that the Deferred Stock Unit Award Agreement for non-employee directors under the 3M Company 2016 Long-Term Incentive Plan is incorporated by reference in both the 2022 and 2024 10-K filings and that the structure appears unchanged. However, it contains a critical factual error: it claims the agreement is incorporated by reference to the 2018 10-K filing, whereas the ground truth states that the 2024 disclosure reflects an updated incorporation by reference from the 2023 10-K, with amendments as of May 8, 2023. This misrepresents the evolution of the disclosure, as the LLM implies static referencing since 2018, while the original answer notes ongoing maintenance and updates through 2023. The LLM also omits the key detail that the agreement applies to grants on or after January 1, 2019, which is central to understanding its scope and continuity. While the reasoning is logically structured and contextually relevant, the incorrect reference year and omission of the 2023 amendment undermine quantitative and qualitative accuracy. The conclusion that 'no new amendment' occurred is contradicted by the ground truth’s mention of the May 8, 2023 amendment, indicating a failure in multi-hop synthesis across the 2022–2024 filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 354,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the composition of Charles Schwab Bank's First Mortgages and HELOCs portfolio evolved between 2023 and 2024, particularly in terms of origination costs and geographic concentration in California?",
      "original_answer": "In 2023, the First Mortgages and HELOCs portfolio included $100 million in unamortized premiums, discounts, and direct origination costs, with 43% of the portfolio concentrated in California. By 2024, these costs increased to $112 million, while the California concentration slightly decreased to 42%. This indicates a slight shift in geographic risk exposure and an increase in loan origination activity or associated costs over the year.",
      "llm_answer": "In 2024 the First‑Mortgage and HELOC portfolio carried slightly higher direct origination costs – $112 million versus $100 million at the end of 2023 – while the share of those loans located in California edged down marginally, from about 43 % of the portfolio in 2023 to roughly 42 % in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: origination costs increased from $100 million in 2023 to $112 million in 2024, and California concentration decreased from 43% to 42%. These numbers match the original answer exactly, satisfying quantitative accuracy. (2) The answer addresses both parts of the question—evolution of origination costs and geographic concentration—confirming completeness. (3) Entities (Charles Schwab Bank's First Mortgages and HELOCs portfolio, years 2023 and 2024, California) are correctly identified and referenced. (4) The reasoning is sound: the slight increase in costs and marginal decrease in California exposure are logically presented, though the LLM omits the interpretive conclusion about 'geographic risk exposure' and 'increase in loan origination activity,' which slightly reduces qualitative depth. However, since the question asks for how the composition evolved—not for interpretation—this omission does not undermine correctness. Wording differences (e.g., 'edged down marginally' vs 'slightly decreased') are semantically equivalent. Overall, the answer is factually complete, precise, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1197,
        "completion_tokens": 347,
        "total_tokens": 1544
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Nike's strategic emphasis on the Dri-FIT technology evolved between fiscal 2023 and fiscal 2024, based on the language in Nike's product research and development sections?",
      "original_answer": "Nike's strategic emphasis on the Dri-FIT technology remained stable between fiscal 2023 and fiscal 2024. In both years, Dri-FIT was listed among key technologies such as Nike Air, Zoom, Free, Flyknit, FlyEase, ZoomX, Air Max, and React, indicating consistent strategic importance. The exact same language was used in both the 2023 and 2024 10-K filings, showing no change in the description or emphasis of Dri-FIT's role in Nike’s innovation strategy.",
      "llm_answer": "In the FY 2023 filing the product‑research‑and‑development narrative lists Nike’s key innovations (Air, Zoom, Free, Flyknit, FlyEase, Zoom X, Air Max, React, etc.) but **does not call out Dri‑FIT** as a distinct technology. In the FY 2024 filing the same section explicitly includes Dri‑FIT in the rollout of “the proliferation of Nike Air, Zoom, Free, **Dri‑FIT**, Flyknit, FlyEase, Zoom X, Air Max, and React technologies” (page 6, 2024 10‑K). This change shows that Nike moved Dri‑FIT from being omitted to being highlighted alongside its flagship performance platforms, indicating a stronger strategic emphasis on the Dri‑FIT fabric in FY 2024.",
      "correctness_score": 1,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim. According to the ground truth, Dri-FIT was mentioned in both the fiscal 2023 and fiscal 2024 10-K filings using the exact same language, indicating no change in strategic emphasis. The LLM incorrectly states that Dri-FIT was 'not called out' in FY2023 but was explicitly added in FY2024, which contradicts the ground truth. This misrepresents the primary fact of the comparison. While the fiscal years (2023 and 2024) and the list of associated technologies (Air, Zoom, etc.) are correctly identified entities, the reasoning based on omission and inclusion is fundamentally flawed. There are no numerical values in question, so quantitative accuracy is not applicable beyond correct year references, which are accurate. The contextual relevance is low because the answer describes a change that did not occur. The qualitative accuracy is very low due to the incorrect interpretation of the source language across the two years, leading to an invalid conclusion about strategic emphasis. The model failed the multi-hop reasoning by not recognizing the consistency in language across filings, instead inferring a shift that is not supported by the data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 338,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Mondelez International's investment in backup and disaster recovery evolved from 2022 to 2024, particularly in response to increasing cybersecurity threats?",
      "original_answer": "In 2022, Mondelez was on heightened alert regarding cybersecurity risks, dedicating focused resources to backup and disaster recovery as part of its response to increased global cybersecurity threats, especially during the pandemic. By 2024, the company significantly expanded its efforts, explicitly stating that it continues to invest and augment its cybersecurity program with enhanced backup and disaster recovery solutions, among other measures, to address increasingly sophisticated threats including those from state-sponsored actors and emerging technologies like artificial intelligence.",
      "llm_answer": "In its 2022 Form 10‑K, Mondelez said it was “on heightened alert and dedicating focused resources to network security, **backup and disaster recovery**” as cyber‑threats grew (MDLZ 2022 p. 45). By the 2024 filing the company notes that it is **continuing to invest and augment** its cybersecurity program, specifically adding “network security, **backup and disaster recovery**” among a broader set of enhanced controls such as identity‑management, multi‑factor authentication and 24/7 monitoring (MDLZ 2024 p. 21). Thus, the firm has moved from allocating dedicated resources in 2022 to a more expansive, ongoing investment that further strengthens backup and disaster‑recovery capabilities in response to the rising frequency and sophistication of cyber‑attacks.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies Mondelez International's evolving investment in backup and disaster recovery from 2022 to 2024, citing appropriate context from both the 2022 and 2024 Form 10-K filings. (2) There are no numerical values requiring calculation in this question, but the years (2022, 2024) and page references (p. 45, p. 21) are accurately reported and contextually valid. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, showing progression from 'heightened alert and focused resources' in 2022 to 'continuing to invest and augment' in 2024, with expanded cybersecurity measures. (4) The answer addresses all parts of the question—evolution over time and response to increasing cybersecurity threats—and includes relevant details such as state-sponsored actors and AI-driven threats (implied through 'increasing sophistication'). Wording differs slightly but meaning is preserved, and citations enhance credibility. All evaluation dimensions are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 317,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Microsoft's financial commitment and engagement with Black and African American-owned suppliers evolved from fiscal year 2022 to fiscal year 2024?",
      "original_answer": "In fiscal year 2022, Microsoft reported that it had enriched its supplier pipeline, reaching more than 90% of its goal to spend $500 million with double the number of Black and African American-owned suppliers. By fiscal year 2024, Microsoft had not only achieved its $500 million spending goal but also expanded its financial commitments by allocating $150 million to Minority Depository Institutions and funds supporting Black and African American-owned small businesses. This evolution indicates a deepening of Microsoft's strategic focus on supplier diversity and community economic development over time.",
      "llm_answer": "In fiscal 2022 Microsoft’s filing first disclosed a new multi‑year pledge to grow its spend with Black‑ and African‑American‑owned businesses, setting a target of roughly $250 million (and a goal to double the number of such suppliers). By fiscal 2024 the pledge had been expanded and the company reported that it had met a $500 million spend target and had actually doubled the count of Black‑ and African‑American‑owned suppliers in its pipeline, indicating a significant increase in both the financial commitment and supplier engagement.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Microsoft's $500 million spend target achievement by fiscal year 2024 and the doubling of Black and African American-owned suppliers, which aligns with the ground truth. However, it inaccurately states the initial 2022 target as 'roughly $250 million', while the original answer specifies that in 2022, Microsoft had already reached more than 90% of its $500 million goal — implying the $500 million target was set earlier, not a $250 million target. This misrepresents the timeline and magnitude of the financial commitment. (2) The dollar amounts are partially correct: $500 million in 2024 is accurate, but the $250 million figure for 2022 is not supported by the ground truth. Additionally, the LLM omits the $150 million allocation to Minority Depository Institutions and funds supporting Black-owned small businesses in 2024, a key expansion of financial commitment. (3) The reasoning correctly tracks evolution from 2022 to 2024 and infers increased engagement through supplier count doubling, which is consistent with the original answer. However, it fails to capture the full scope of Microsoft's expanded strategy beyond supplier spend, missing a critical multi-hop element involving community investment. (4) Scores reflect mostly correct core facts (hence 7/10 correctness), but quantitative inaccuracies and omission of key financial details reduce quantitative accuracy. Qualitative reasoning is sound but incomplete; contextual relevance is strong as the answer directly addresses the question's focus on evolution over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 436,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the availability of common shares for future issuance under the Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees evolved from 2022 to 2023, and what does this indicate about Abbott's stock-based incentive strategy?",
      "original_answer": "In 2022, as of December 31, 2021, an aggregate of 10,638,639 common shares were available for future issuance under the Employee Stock Purchase Plan. In 2023, as of December 31, 2023, this number had decreased to 8,565,087 common shares. This indicates a reduction in the number of shares available for future issuance, suggesting a potential tightening or adjustment in Abbott's stock-based incentive strategy for non-U.S. employees.",
      "llm_answer": "- At year‑end 2022 Abbott reported that roughly **9.4 million** common shares were available for future issuance under the Employee Stock Purchase Plan for Non‑U.S. Employees. By year‑end 2023 that pool had fallen to **8,565,087** shares (see page 84 of the 2023 10‑K).  \n\n- The decline in the available share pool shows Abbott is modestly tightening the amount of equity it can issue through this plan, while still keeping a substantial reserve. This suggests a disciplined approach to managing dilution, yet a continued commitment to using stock‑based incentives to engage its non‑U.S. workforce.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant quantitative inaccuracy: it states that 9.4 million shares were available at year-end 2022 (i.e., as of December 31, 2022), but the ground truth reports 10,638,639 shares available as of December 31, 2021 (which corresponds to the 2022 filing). The LLM incorrectly characterizes this as the 'year-end 2022' figure, when it should refer to the availability reported in the 2022 10-K (for the prior year). The 2023 figure (8,565,087 shares as of December 31, 2023) is correctly cited. This misalignment in time periods undermines the quantitative accuracy. (2) The calculation of the decline is implied but not explicitly stated; however, the direction (decrease) is correct. The number 9.4 million does not match the ground truth 10,638,639, introducing a material error (~1.2 million share discrepancy). (3) The reasoning and synthesis are otherwise sound: the LLM correctly infers that a reduction in available shares suggests a tightening of the stock-based incentive strategy, while still acknowledging continued commitment—this aligns with the qualitative interpretation in the original answer. (4) The entities (Abbott Laboratories, Employee Stock Purchase Plan for Non-U.S. Employees, correct year references in context of 10-K filings) are mostly accurate, though the temporal reference is misaligned. The answer is fully relevant to the question and addresses both the evolution and strategic implication. Due to the incorrect attribution of the 2022 figure, the correctness score is reduced to 7—core facts are partially right, but with a notable error in a key number and its associated time point.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 454,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Nike's treatment of Nike Air technology evolved in its product development strategy between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal 2023, Nike Air was described as part of a list of technologies that 'typifies our dedication to designing innovative products,' indicating it was still being actively proliferated across product lines. By fiscal 2024, Nike Air was again listed among key technologies, but now embedded alongside mature technologies like Zoom, Free, and React, suggesting that Nike Air had become a standard component of Nike’s broader innovation platform rather than a distinct growth driver. This reflects a strategic shift from emphasizing Nike Air as an emerging innovation to treating it as an integrated, foundational offering within Nike’s product development framework.",
      "llm_answer": "In fiscal 2023 Nike’s 10‑K listed Nike Air only as one of a suite of “proliferating” technologies (Air, Zoom, Free, Dri‑FIT, Flyknit, FlyEase, Zoom X, Air Max, React) that the company was integrating into new products. By fiscal 2024 the filing moved from a generic innovation‑technology list to a concrete operational focus: it describes Air Manufacturing Innovation – a wholly‑owned subsidiary – as the primary supplier of Nike Air‑Sole cushioning components for its footwear, indicating that Air technology has become a dedicated, vertically‑integrated element of Nike’s product‑development and supply‑chain strategy.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct in that it identifies Nike Air as a continuing element in Nike's product development strategy across fiscal years 2023 and 2024, and correctly references the 10-K filings. However, it introduces a significant factual inaccuracy by claiming that in fiscal 2024, Nike described 'Air Manufacturing Innovation' as the primary supplier of Nike Air-Sole components. This detail does not appear in the ground truth and is not supported by the original answer or the knowledge graph. The original answer emphasizes a strategic repositioning of Nike Air from a proliferating innovation (2023) to a mature, integrated technology alongside Zoom, Free, and React (2024), indicating a shift in how the technology is framed strategically—not a shift toward vertical integration via a subsidiary. The LLM answer misrepresents the nature of the evolution by focusing on operational/supply chain integration rather than the conceptual shift in innovation strategy. While the fiscal years are correct and the mention of 'proliferating' technologies in 2023 aligns with the original, the core reasoning and conclusion are misaligned. There are no numerical values to assess, so quantitative accuracy is scored as 10 by default. The contextual relevance is moderate because the answer addresses the right topic and timeframe but misinterprets the key development. The multi-hop synthesis fails because the model draws an unsupported conclusion about structural supply chain changes instead of correctly identifying the shift in strategic positioning of Nike Air within the innovation framework.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 438,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Abbott's positioning of Osmolite within its Nutritional Products segment evolved between 2022 and 2023, particularly in terms of its enteral feeding portfolio and associated product line strategy?",
      "original_answer": "In 2022, Osmolite was listed among Abbott's enteral feeding products used in healthcare institutions, alongside Jevity®, Glucerna® 1.2 Cal, Glucerna® 1.5 Cal, Oxepa®, Freego™, Nepro®, and Vital®. By 2023, Osmolite continued to be included in the enteral feeding portfolio, but Abbott's product listing in this category remained largely consistent, indicating a stable strategic positioning of Osmolite within the institutional enteral nutrition segment. There is no indication of Osmolite being newly introduced, discontinued, or significantly repositioned relative to other products in this category during this period.",
      "llm_answer": "- **2022 filing:** Osmolite was listed simply as one of the “nutritional products used in enteral feeding in health‑care institutions” together with Jevity, Glucerna, Oxepa, Freego, Nepro and Vital 【page_4】.  \n\n- **2023 filing:** Abbott continued to include Osmolite in the same group, but the language was shifted to describe it as a core element of an **enteral‑feeding portfolio** that the company is positioning as a coordinated product line for institutional nutrition (grouped with Jevity, Glucerna, Oxepa, Freego, Nepro and Vital) 【page_4】.  \n\nThus, between 2022 and 2023 Abbott moved from merely listing Osmolite among enteral‑feeding products to presenting it as a strategic pillar of a consolidated enteral‑feeding portfolio, signaling a more integrated product‑line approach for hospital and institutional nutrition.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct in identifying that Osmolite remained in Abbott's enteral feeding portfolio in both 2022 and 2023 and correctly lists the associated products (Jevity, Glucerna, Oxepa, Freego, Nepro, Vital), which aligns with the ground truth. There are no numeric inaccuracies, so quantitative accuracy is high. However, the key qualitative claim—that Abbott evolved its positioning of Osmolite from a listed product in 2022 to a 'strategic pillar' or 'core element' of a consolidated portfolio in 2023—is not supported by the original answer or the underlying knowledge graph. The ground truth explicitly states that Abbott's product listing 'remained largely consistent' and that there was 'no indication of Osmolite being newly introduced, discontinued, or significantly repositioned.' Thus, the LLM infers a strategic shift (more integrated product-line approach) that is not present in the evidence, representing a significant reasoning error. This mischaracterization of subtle language differences as strategic evolution undermines the qualitative accuracy. While the answer addresses the question's focus on evolution and product strategy, it introduces unsupported interpretation, reducing correctness. Contextual relevance is strong as it directly engages with the portfolio and time-based comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 369,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has 3M's regulatory engagement and remediation obligations related to PFAS discharge evolved between 2022 and 2024, particularly in Minnesota and Alabama?",
      "original_answer": "In 2022, 3M was actively working under a 2007 Settlement Agreement and Consent Order with the MPCA to address PFAS contamination in Minnesota, with remediation substantially completed at the Cottage Grove site and ongoing operational and maintenance activities at multiple locations. In Alabama, the Company had entered into a July 2020 Interim Consent Order with ADEM, which included obligations for PFAS-related wastewater discharges and air emissions, and had completed installation of a multilayer cap at the Decatur facility. By 2024, regulatory scrutiny had intensified. In Minnesota, MPCA issued a draft Clean Water Act permit for the Cottage Grove facility with significantly revised effluent limits for certain PFAS compounds, some below current quantification levels, and the Company submitted public comments in August 2024. Additionally, in 2024, MPCA published a revised draft permit in December after considering stakeholder input, which could have a significant adverse impact on the Cottage Grove facility's operations. In Alabama, while the 2020 Interim Consent Order remained in effect, the Company's obligations under ongoing investigations and potential future remediation were still expected to involve additional operating costs and capital expenditures over multiple years. The regulatory landscape evolved to include more stringent standards, such as updated HBVs from MDH in January 2024 and proposed HRLs in October 2024, further complicating 3M's compliance path.",
      "llm_answer": "By the 2022 Form 10‑K, 3M was still in the “disclosure and early‑remediation” phase – it had told the EPA and the Minnesota Pollution Control Agency (MPCA) that its Cottage Grove NPDES permit did not fully characterize PFAS, was working under a 2007 Minnesota Settlement Agreement to evaluate releases, provide alternate drinking‑water treatment if health‑based values were exceeded and complete remedial actions at Cottage Grove, Oakdale and Woodbury, and was operating under a 2020 voluntary remedial‑action agreement and interim consent order with the Alabama Department of Environmental Management (ADEM) that capped historic sludge and required on‑site/off‑site investigations.  \n\nBy the 2024 filing the engagement had progressed to active compliance and remediation: in Minnesota the company filed an application to add PFAS to its NPDES permit, installed a new PFAS‑treatment system, responded to a 2021 MPCA Notice of Violation, complied with a 2022 MPCA storm‑water order, and is commenting on a 2024 draft Clean‑Water Act permit that imposes substantially tighter PFAS effluent limits while also evaluating new, stricter Minnesota Department of Health health‑based values; in Alabama the same voluntary remedial‑action agreement and 2009 TSCA consent order remain in place, but 3M has upgraded and is further optimizing wastewater‑treatment controls at Decatur and continues negotiations with ADEM on a permit amendment and ongoing investigations.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the evolution of 3M's regulatory engagement and remediation obligations related to PFAS in Minnesota and Alabama between 2022 and 2024, with accurate entity identification and sound reasoning. Quantitatively, all dates and regulatory milestones are correctly cited: the 2007 Settlement Agreement in Minnesota, the 2020 Interim Consent Order with ADEM in Alabama, and key 2024 developments such as the draft Clean Water Act permit and public comment submission in August 2024 are accurately reflected. The LLM correctly notes ongoing remediation at Cottage Grove, Oakdale, and Woodbury under the 2007 agreement and the installation of caps and treatment systems in Alabama. It also accurately describes the progression from disclosure/early remediation in 2022 to active compliance and enhanced treatment efforts by 2024. However, the LLM omits specific details from the ground truth about the December 2024 revised draft permit in Minnesota and the updated HBVs from MDH in January 2024 and proposed HRLs in October 2024, which are important for completeness. Additionally, while the LLM mentions a 2009 TSCA consent order, the original answer does not reference this, and the focus should remain on the 2020 Interim Consent Order as the primary regulatory instrument in Alabama. Despite these minor omissions and a slight overreach on the TSCA order, the core facts, timeline, and regulatory evolution are accurately conveyed with strong multi-hop synthesis across years and jurisdictions. Wording differs but meaning is semantically equivalent on key points, and all calculations (none required) and dates are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1739,
        "completion_tokens": 453,
        "total_tokens": 2193
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola HBC AG evolved between 2022 and 2024, particularly in terms of investment classification and stake percentage?",
      "original_answer": "In 2022, Coca-Cola HBC AG was among the listed equity method investees, though the specific ownership percentage was not disclosed in the provided evidence. By 2024, Coca-Cola HBC AG remained an equity method investee, and the company explicitly stated a 22% ownership stake as of December 31, 2024. This indicates a formalization and quantification of the relationship, with Coca-Cola now specifying the exact percentage of ownership, which was absent in the 2022 disclosures.",
      "llm_answer": "By 2024 the Company still accounts for its interest in Coca‑Cola HBC AG under the equity‑method (see Note 6, which lists Coca‑Cola HBC AG among the equity‑method investees).  The ownership share has risen – the 2022 filing reported a 20 % stake in HBC, while the 2024 filing shows a 22 % stake.  Thus, the relationship has remained an equity‑method investment, but the Company’s equity ownership has increased from roughly 20 % in 2022 to about 22 % in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error regarding the ownership percentage in 2022. The original answer (ground truth) states that the ownership percentage was not disclosed in 2022, whereas the LLM claims it was 20%, which is incorrect. The 22% stake is correctly reported for 2024, but the claim of an increase from 20% to 22% is unsupported by the evidence. (2) Quantitative accuracy is low because the 20% figure for 2022 is fabricated or misattributed—no such number appears in the provided evidence. The 22% figure for 2024 is accurate. (3) The multi-hop reasoning is partially sound in that the model correctly identifies Coca-Cola HBC AG as an equity method investee in both years and attempts to compare stake changes. However, it fails in synthesis by asserting a specific percentage for 2022 that was not disclosed, undermining the conclusion of an increase. (4) Contextual relevance is high because the answer addresses the core aspects of investment classification and stake percentage over time. Qualitative accuracy is moderate due to correct identification of the equity method treatment but flawed reasoning on stake change. Correctness score is low due to the critical error in numerical data that alters the interpretation of the relationship’s evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 364,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Oracle's strategic emphasis on hybrid deployments evolved between fiscal 2022 and fiscal 2024, particularly in terms of product development investment and deployment model integration?",
      "original_answer": "In fiscal 2022, Oracle emphasized hybrid deployments as part of its broader deployment model strategy, investing $7.2 billion in research and development to enhance existing offerings and develop new technologies, including hybrid solutions like Oracle Cloud@Customer. By fiscal 2024, Oracle further integrated hybrid deployments into its core offerings, positioning them as a standard deployment choice alongside on-premise and cloud-based models, and reinforcing its commitment to interoperability and customer choice. This reflects a strategic evolution from a development-focused approach to a more mature, integrated deployment model.",
      "llm_answer": "In the 2022 filing Oracle made clear that hybrid‑deployment — including its Oracle Cloud@Customer offering that runs Oracle Cloud inside a customer’s data centre — was a cornerstone of its growth strategy, backing it with a record $7.2 billion of fiscal‑2022 research‑and‑development spending to improve performance, security, integration and cost‑effectiveness across on‑premise, cloud and hybrid environments. By the 2024 filing the company still stresses hybrid as a “flexible and interoperable” delivery model, describing it alongside on‑premise and pure‑cloud options as a fundamental way its SaaS and OCI services are integrated, but the filing no longer cites a specific R&D spend figure, indicating that the emphasis has shifted from highlighting a distinct investment amount to positioning hybrid as an embedded part of its broader cloud‑services portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual information is correct: Oracle emphasized hybrid deployments in fiscal 2022, specifically citing Oracle Cloud@Customer, and invested $7.2 billion in R&D — a figure accurately reported and contextually explained. By fiscal 2024, hybrid deployments were integrated into core offerings as a standard option, though no specific R&D figure was cited, which the LLM correctly notes. (2) Quantitative accuracy is perfect: the $7.2 billion R&D spend in fiscal 2022 matches the original answer exactly, and the absence of a 2024 figure is correctly acknowledged. (3) Multi-hop reasoning is sound: the LLM synthesizes information across two fiscal years, correctly inferring a strategic shift from development-focused investment to integration and embedding of hybrid models, even without explicit 2024 spending data. (4) The answer is contextually complete and relevant, addressing both product development investment and deployment model integration. The only minor limitation is a slightly less explicit articulation of the 'evolution' in strategy compared to the original’s clear 'from development-focused to mature, integrated model' framing — but the implication is clearly conveyed through the observation about shifting emphasis from investment figures to embedded integration. Thus, the answer is semantically equivalent and factually robust.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 394,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has the filing status of the Mandatory Clawback Policy evolved between the 2023 and 2024 SEC 10-K disclosures for Wells Fargo & Company?",
      "original_answer": "In 2023, the Mandatory Clawback Policy was filed directly as part of the 10-K filing under Exhibit 97. In 2024, instead of being filed directly, it was incorporated by reference to Exhibit 97 from the previous year's 10-K filing. This indicates a procedural change in how the policy is disclosed rather than a substantive change to the policy itself.",
      "llm_answer": "In the 2023 Form 10‑K, Wells Fargo listed the Mandatory Clawback Policy as Exhibit 97 and noted it was **“Filed herewith.”** 【page_18】.  \n\nIn the 2024 Form 10‑K, the same Exhibit 97 is no longer attached; the filing states the policy is **“Incorporated by reference to Exhibit 97 to the Company’s Annual Report on Form 10‑K for the year ended December 31, 2023.”** 【page_21】.  \n\nThus, the policy’s status changed from being directly filed with the 2023 report to being incorporated by reference in the 2024 report.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately describes the evolution of the filing status: in 2023, the Mandatory Clawback Policy was directly filed as Exhibit 97 ('Filed herewith'), while in 2024, it was incorporated by reference to the 2023 filing. (2) There are no numeric values requiring calculation, but the years (2023, 2024) and exhibit number (97) are correct and consistent with the original answer. (3) The multi-hop reasoning is sound—LLM correctly synthesized information across two years of 10-K filings and identified the procedural change in disclosure method. (4) The answer addresses all parts of the question, uses precise language from the filings (with citations to page numbers), and correctly concludes that the change is procedural, not substantive, aligning with the original answer's implication. Minor wording differences do not affect factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 270,
        "total_tokens": 1485
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did Thermo Fisher's relationship with CorEvitas, LLC evolve between 2023 and 2024, and what specific financial implications were associated with this change?",
      "original_answer": "In 2023, Thermo Fisher invested $0.91 billion to acquire CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for medical treatments. By 2024, this relationship had evolved from an investment into a full acquisition, as CorEvitas was integrated into the Laboratory Products and Biopharma Services segment. The acquisition in 2023 was part of a broader strategy that included significant capital expenditures and financing activities, such as issuing $5.94 billion in senior notes and repurchasing $3.00 billion of company stock. In 2024, the company began amortizing the definite-lived intangible assets from CorEvitas over a weighted average period of 18 years, reflecting the long-term strategic value of the acquisition.",
      "llm_answer": "In 2023 Thermo Fisher moved from being a non‑owner to an owner of CorEvitas, LLC – it completed the purchase on August 14 2023, paying $730 million in cash, assuming $184 million of CorEvitas debt and recording a total purchase price of $910 million (which generated $627 million of goodwill and related intangible assets)【page_66】. By the 2024 filing the company no longer reports a new acquisition; CorEvitas is simply part of the Laboratory Products and Biopharma Services segment, so the only financial impact of the relationship is the 2023‑year cash outflow, debt assumption and the resulting higher interest expense noted in the 2023 non‑operating items discussion【page_22】.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 acquisition of CorEvitas, LLC by Thermo Fisher and its integration into the Laboratory Products and Biopharma Services segment by 2024, which aligns with the ground truth. The total purchase price of $910 million is accurate and matches the ground truth's $0.91 billion. The breakdown into $730 million cash and $184 million debt assumption is more detailed than the original answer and appears factually consistent. However, the LLM introduces specific details not present in the ground truth—such as the exact date (August 14, 2023), $627 million of goodwill, and sourcing to page numbers (e.g., page 66, page 22)—which cannot be verified against the provided ground truth and may reflect overfitting to a specific document not in scope. (2) Quantitatively, the $910 million total purchase price is correct ($730M + $184M = $914M—minor arithmetic discrepancy of $4M, likely due to rounding; still acceptable). The ground truth does not mention goodwill or amortization period in the context of CorEvitas, but the LLM omits the key 2024 amortization of definite-lived intangibles over 18 years, a specific financial implication highlighted in the original answer. This omission reduces completeness. (3) The multi-hop reasoning is partially sound: the LLM correctly infers that integration into a segment implies full acquisition and no longer being a separate entity. However, it fails to mention the ongoing 2024 financial impact—amortization of intangibles—which is a critical post-acquisition accounting treatment and a direct financial implication. Instead, it incorrectly implies the only financial impact was in 2023. (4) Despite missing the amortization point, the answer is contextually relevant, well-structured, and mostly accurate in describing the evolution of the relationship. The scores reflect high accuracy with a moderate deduction for missing a key financial implication in 2024 and introducing unverifiable specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 538,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How did RTX's flight hour payment obligations under its 2012 agreement with Rolls-Royce evolve between 2022 and 2023, particularly in terms of the timing and capitalization treatment of these payments?",
      "original_answer": "In 2022, RTX disclosed that flight hour payments to Rolls-Royce were contingent upon each hour flown through June 2027 by V2500-powered aircraft in service as of the acquisition date, and these payments were considered in 'Other commercial aerospace commitments' and capitalized as collaboration intangible assets as payments were made. In 2023, RTX reiterated the same contingent payment structure tied to flight hours through June 2027 and maintained that these payments would continue to be capitalized as collaboration intangible assets. There was no indication of a change in the magnitude or timing of these obligations between the two years, suggesting a stable commitment structure.",
      "llm_answer": "In the 2022 Form 10‑K the company said that under the 2012 Rolls‑Royce agreement it must make “flight‑hour” payments for each V2500 engine hour flown through June 2027 and that those payments would be **capitalized as collaboration intangible assets when paid**. At that time the schedule showed most of the obligation occurring in 2022 and 2023 (≈ $735 million in 2022 and $1,053 million in 2023) 【page_112】.  \n\nThe 2023 Form 10‑K repeats the same capitalization treatment, but the payment timetable has been pushed out, now spreading the remaining obligation over 2024‑2027 and beyond (e.g., $836 million in 2024, $862 million in 2025, $705 million in 2026, $687 million in 2027, with $731 million thereafter) 【page_101】.  \n\nThus, between 2022 and 2023 the flight‑hour payments were rescheduled from the near‑term years to later years, while the accounting approach—capitalizing each payment as a collaboration intangible asset—remained unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The original answer (ground truth) states that there was no change in the magnitude or timing of RTX's payment obligations between 2022 and 2023, indicating a stable commitment structure. However, the LLM claims that the payment schedule was 'pushed out' from 2022–2023 to 2024–2027 with specific dollar amounts (e.g., $735M in 2022, $1,053M in 2023, etc.), which directly contradicts the ground truth. These figures and the rescheduling narrative are not supported by the original answer and represent a major factual error. (2) The numbers cited ($735M, $1,053M, $836M, etc.) do not appear in the ground truth and are therefore incorrect. There is no mention of a re-timing of payments or specific annual breakdowns in the original answer, so these values are fabricated or misattributed. (3) The multi-hop reasoning is flawed: while the LLM correctly identifies that payments are tied to flight hours through June 2027 and that they are capitalized as collaboration intangible assets, it incorrectly infers a shift in timing based on what appears to be a misreading of the data. The original answer explicitly states there was 'no indication of a change in the magnitude or timing,' so the conclusion that payments were rescheduled is invalid. (4) Despite the serious factual errors, the LLM captures the correct accounting treatment (capitalization as intangible assets) and the general nature of the obligation (flight-hour payments through June 2027), which maintains some contextual relevance. However, the core claim about evolving timing is false, warranting a low correctness and quantitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 472,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has The Coca-Cola Company's financial relationship with fairlife evolved from 2022 to 2024, particularly regarding contingent payments tied to performance milestones?",
      "original_answer": "In 2022, Coca-Cola's acquisition-related disclosures referenced the 2020 acquisition of the remaining ownership interest in fairlife, with no mention of ongoing contingent payments. By 2024, the company disclosed that there was a remaining milestone payment related to the 2020 acquisition of fairlife, contingent on fairlife achieving certain financial targets through 2024, with the payment scheduled for 2025. This indicates that Coca-Cola's relationship with fairlife has evolved from a completed acquisition in 2020 to one where a performance-linked financial obligation remains active through 2024.",
      "llm_answer": "In the 2022 filing Coca‑Cola’s disclosure about fairlife was limited to the 2020 purchase of the remaining equity stake, with no mention of any ongoing earn‑out or performance‑based payment. By the 2024 filing the company reports a contingent‑consideration liability of roughly $6.1 billion that represents the remaining milestone payment for the fairlife acquisition, which is tied to fairlife meeting specified financial targets through 2024 and will be paid in 2025; a $275 million milestone was already paid in 2023 and the liability is re‑measured each quarter. Thus, the relationship has shifted from a simple equity purchase to a large, performance‑linked earn‑out arrangement.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative details. While it correctly identifies that the 2022 filing did not mention ongoing contingent payments and that a milestone payment was expected in 2025 tied to 2024 performance, it fabricates key financial figures. The claim of a $6.1 billion contingent-consideration liability is grossly inaccurate and orders of magnitude too high—no such figure appears in Coca-Cola's disclosures related to fairlife. Additionally, the statement that a $275 million milestone was paid in 2023 is not supported by the ground truth and appears invented. The ground truth confirms only that a *remaining* milestone payment exists, with no dollar amount specified. The qualitative reasoning about the evolution of the relationship—from a completed acquisition to one with an active performance-linked obligation—is partially sound and aligns with the multi-hop requirement (2022 vs 2024 disclosures). However, the inclusion of false numerical data severely undermines the answer's reliability. The context and structure are relevant and address the question's intent, but the answer misrepresents the financial reality due to fabricated metrics. Thus, while the directional insight is correct, the answer fails on quantitative accuracy, which is critical in financial reporting contexts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 375,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has Oracle's strategic positioning of Oracle Cloud Services evolved between 2022 and 2024, particularly in terms of integration with enterprise applications and infrastructure technologies?",
      "original_answer": "In 2022, Oracle emphasized the transformational potential of Oracle Cloud Services, particularly highlighting the Oracle Autonomous Database as a key OCI offering that utilized machine learning to enable leaner business processes and automation. The focus was on flexibility, interoperability, and customer choice across deployment models, including cloud-based, hybrid, and on-premise environments. By 2024, Oracle expanded this positioning by describing Oracle Cloud Services (including SaaS and OCI) as comprehensive and integrated offerings that provide customers with a full suite of applications and infrastructure services. The 2024 filing explicitly frames Oracle Cloud Services as enabling customers to 'choose the best option that meets their specific business needs,' indicating a more mature and customer-centric strategic approach. This evolution reflects a shift from promoting individual innovations (e.g., Autonomous Database) to positioning Oracle Cloud Services as a holistic, integrated platform for enterprise IT transformation.",
      "llm_answer": "By 2022 Oracle framed its Cloud Services as the “building blocks” that combine its enterprise‑applications portfolio with its infrastructure stack, stressing programs that help customers shift on‑premise licenses to the cloud and marketing SaaS and OCI together so that existing workloads could be migrated and run on a unified, interoperable platform. In the 2024 filing the language shifts to a more mature positioning: Oracle Cloud Services are described as a single, comprehensive suite of SaaS + OCI that delivers fully integrated applications and infrastructure, giving customers the flexibility to choose on‑premise, cloud or hybrid models while “improving utilization of their investments” in Oracle’s applications and infrastructure technologies. Thus the strategy evolved from emphasizing migration and joint‑selling of separate SaaS and infrastructure components to presenting a consolidated, choice‑driven cloud offering that tightly integrates enterprise applications with the underlying cloud infrastructure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth in both factual content and reasoning. (1) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable in a traditional sense; however, the years 2022 and 2024 are correctly referenced, and no incorrect dates or figures are present, earning a perfect score. (2) The LLM correctly identifies Oracle's strategic evolution: in 2022, the focus was on cloud migration, interoperability, and positioning cloud services as 'building blocks' integrating applications and infrastructure, which matches the ground truth emphasis on Autonomous Database and deployment flexibility. By 2024, the LLM accurately captures the shift toward a 'comprehensive suite' and 'fully integrated' SaaS + OCI platform, echoing the ground truth's description of a holistic, customer-centric model that improves investment utilization—semantically equivalent to 'choose the best option that meets their specific business needs.' (3) The multi-hop reasoning is sound: the LLM synthesizes information across time (2022 vs 2024), identifies shifts in strategic language, and correctly infers a maturation from component-based selling to an integrated platform approach. (4) Minor deduction in qualitative accuracy due to slightly different emphasis—ground truth highlights the Autonomous Database as a key 2022 innovation, while the LLM focuses more on migration programs and joint selling. However, this does not contradict but rather complements the original; thus, the answer remains factually consistent and contextually relevant. No irrelevant or incorrect entities are introduced. Overall, the response is concise, accurate, and captures the core evolution in Oracle’s strategic positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1529,
        "completion_tokens": 486,
        "total_tokens": 2015
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has the treatment or status of the Key/Specified Employee Policy evolved between the 2023 and 2024 SEC filings, particularly in terms of its documentation and incorporation by reference?",
      "original_answer": "In the 2023 filing, the Key/Specified Employee Policy was introduced as part of the company's disclosures, specifically incorporated by reference to Exhibit 10(v) from the Annual Report on Form 10-K for the year ended December 31, 2018. By 2024, the policy was no longer newly introduced but was instead announced as a continuing policy, still relying on the same Exhibit 10(v) from the 2018 filing. This indicates that while the policy remained in place, there were no new amendments or updates to its documentation during this period.",
      "llm_answer": "In the 2023 Form 10‑K the “Key/Specified Employee Policy” appears as Exhibit 10(r) and is incorporated by reference to Exhibit 10(v) of Wells Fargo’s 2018 Annual Report on Form 10‑K. The 2024 Form 10‑K lists the same Exhibit 10(r) with the identical reference to Exhibit 10(v) of the 2018 10‑K, showing that the policy has not been re‑documented or filed separately—it remains incorporated by reference to the same 2018 filing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) It correctly identifies that the Key/Specified Employee Policy in both the 2023 and 2024 filings references Exhibit 10(v) from the 2018 Form 10-K, confirming the policy's continued incorporation by reference without updates. (2) All dates (2018, 2023, 2024) and exhibit numbers (10(v), 10(r)) are factually correct; the reference to Exhibit 10(r) in the 2023 and 2024 filings aligns with the actual document structure, and the cross-reference to the 2018 Exhibit 10(v) is accurately maintained—no numeric or date inaccuracies. (3) The multi-hop reasoning is sound: the model correctly synthesizes that the policy was first introduced in 2023 (via reference to 2018) and continues in 2024 without change, indicating no new documentation or amendments. (4) The only minor discrepancy is that the LLM refers to the 2023/2024 exhibit as '10(r)' while the ground truth does not specify the exhibit number in the current filings—this detail is likely correct based on actual Wells Fargo filings but not confirmed in the ground truth statement. However, this does not contradict the truth and adds precision. The answer correctly captures that the policy remains unchanged in documentation and incorporation, satisfying the question’s focus on evolution, documentation, and incorporation by reference. Thus, the answer is semantically equivalent and highly accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 400,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the aggregate principal balance of the 6.700% notes due 2028 evolve between 2022 and 2023, and what does this indicate about RTX's debt management strategy?",
      "original_answer": "In 2022, the aggregate principal balance of the 6.700% notes due 2028 was $115 million. By 2023, this amount increased significantly to $285 million. This indicates that RTX increased its outstanding debt related to this particular note, suggesting a strategic decision to retain or expand exposure to this fixed-rate debt instrument.",
      "llm_answer": "The table of long‑term debt shows the 6.700 % notes due 2028 at an aggregate principal balance of **$285 million in both 2022 and 2023** (2023 column = $285 m; 2022 column = $285 m)【page_84】. The prior‑year schedule confirms the 2022 balance was $285 million (down from $400 million in 2021)【page_94】. Holding the balance steady indicates RTX is not actively retiring or issuing additional 6.700 % 2028 notes, using them as a stable component of its debt portfolio while focusing refinancing and repayment efforts on other series—reflecting a deliberate, steady‑state debt‑management approach.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the aggregate principal balance of the 6.700% notes due 2028 was $285 million in both 2022 and 2023. According to the ground truth, the balance was $115 million in 2022 and increased to $285 million in 2023. This major quantitative error undermines the entire response. The LLM incorrectly claims the balance was unchanged, which contradicts the actual significant increase. (2) The cited numbers are wrong: the 2022 figure is off by $170 million. Even though the 2023 value ($285M) is correct, the 2022 value is not. The LLM references 'page_84' and 'page_94' as support, but either misreads or misrepresents the data, especially since the ground truth indicates a rise from $115M to $285M, not a stable $285M. There are no calculations required beyond comparison, but the comparison is invalid due to incorrect input data. (3) The multi-hop reasoning fails because the model does not recognize the change in balance over time. Instead of identifying an increase and interpreting it as a strategic expansion of fixed-rate debt, the LLM concludes a 'steady-state' strategy based on false stability. This misdiagnosis stems from incorrect data synthesis across years. (4) Contextual relevance is moderate—the response addresses the right metric (aggregate principal balance), time frame (2022–2023), and company (RTX), and attempts to infer debt management strategy. However, due to the core factual error, the qualitative interpretation is flawed. Correctness and quantitative accuracy are severely penalized because financial analysis hinges on accurate figures, especially in debt tracking and trend analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 458,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the carrying value and effective interest rate of TMO's 1.95% 12-Year Senior Notes evolve between 2023 and 2024?",
      "original_answer": "In 2023, the carrying value of the 1.95% 12-Year Senior Notes was $773 million with an effective interest rate of 2.08%. In 2024, the carrying value decreased to $725 million, and the effective interest rate slightly declined to 2.07%. This indicates a reduction in the financial liability associated with these notes and a marginal improvement in the effective borrowing cost.",
      "llm_answer": "- Carrying value: the 1.95 % 12‑year senior notes were carried at **$773 million** at 12/31/2023 and fell to **$725 million** at 12/31/2024【page_62】【page_47】.  \n- Effective interest rate: the notes’ effective interest rate was **2.08 %** at the end of 2023 and slipped marginally to **2.07 %** at the end of 2024【page_62】【page_47】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all factual information from the ground truth. The carrying value in 2023 is accurately stated as $773 million and in 2024 as $725 million. The effective interest rate is correctly given as 2.08% in 2023 and 2.07% in 2024. (2) All numeric values match the original answer exactly, with no calculation errors. The format variations (e.g., $773 million vs $773M) are acceptable and semantically equivalent. (3) The question requires a multi-hop synthesis of data across two years for the same financial instrument; the LLM correctly identifies and compares the carrying value and effective interest rate across 2023 and 2024, demonstrating sound reasoning. (4) The answer is fully complete, addressing both parts of the question (carrying value and effective interest rate) over the specified time period. The inclusion of citation markers 【page_62】【page_47】 adds contextual support without detracting from clarity. All entities (TMO's 1.95% 12-Year Senior Notes, years, metrics) are correctly identified and accurately reported. Therefore, all scores are maximized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1170,
        "completion_tokens": 317,
        "total_tokens": 1488
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "What are the corporate governance implications of the change in how BNY Mellon presents its Directors' Code of Conduct between its 2022 and 2024 SEC filings?",
      "original_answer": "In 2022, BNY Mellon explicitly detailed the availability of the Directors' Code of Conduct on its website with a direct URL link, and it was referenced within the broader context of corporate governance disclosures and ethics policies. By 2024, the Code was listed among other governance materials—such as committee charters and by-laws—without a direct link or specific mention of updates or amendments. This shift in presentation may signal a more streamlined or consolidated approach to governance disclosures, potentially reducing the visibility of the Code as a standalone document. While the Code remains accessible, the change could affect transparency and stakeholder engagement with the specific ethical expectations for directors, which may influence perceptions of governance accountability.",
      "llm_answer": "In the 2022 Form 10‑K, BNY Mellon treated the Directors’ Code of Conduct as a stand‑alone ethics policy that was merely posted on its website and noted that any amendments or waivers would be disclosed there (see 2022 p. 11). By the 2024 filing, the company lists the Directors’ Code of Conduct together with its Corporate‑Governance Guidelines, bylaws and committee charters as documents “incorporated by reference” in the 10‑K (see 2024 p. 3). This shift elevates the code from a supplemental web posting to a formally‑adopted governance instrument, signalling tighter board oversight, greater transparency and a stronger commitment to holding directors to the same documented standards that govern the rest of the board’s governance framework.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable; however, since there are no numbers to misstate, it is scored as accurate by default (10). The core issue lies in qualitative accuracy and reasoning. The LLM incorrectly interprets the change in presentation between 2022 and 2024 as an elevation of the Directors' Code of Conduct from a 'supplemental web posting' to a 'formally-adopted governance instrument' due to being 'incorporated by reference.' This is a fundamental misreading of the corporate governance implications. The ground truth states that in 2022, the Code was explicitly detailed with a direct URL and clear disclosure practices, enhancing transparency. By 2024, it was grouped with other documents without a direct link or mention of updates, which reduces visibility and may weaken perceived accountability. The LLM inverts this trend, interpreting consolidation as increased formality and transparency, when the original answer suggests the opposite: a potential decline in prominence and stakeholder accessibility. This reflects a critical failure in multi-hop reasoning and semantic understanding of disclosure practices. While the answer addresses the question's topic and references the correct company and years (contextual relevance is moderate), the conclusion is factually and logically inverted, warranting a very low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 392,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has Amazon's Short-Term Credit Agreement evolved between 2023 and 2024, particularly in terms of facility size, maturity date, and the timing of its establishment?",
      "original_answer": "In 2023, Amazon entered into a $5.0 billion unsecured 364-day revolving credit facility (Short-Term Credit Agreement) in November, replacing the prior agreement from November 2022, with a maturity date in October 2024. In 2024, Amazon again entered into a new $5.0 billion unsecured 364-day revolving credit facility in October, replacing the 2023 agreement, with a maturity date in October 2025. The facility size remained the same at $5.0 billion, but the establishment date shifted from November to October, and the maturity date moved forward by one year, indicating a procedural renewal rather than a substantive change in the credit structure.",
      "llm_answer": "- 2023 filing – Amazon disclosed that in **November 2023 it entered into a $5.0 billion unsecured 364‑day revolving credit facility** (the “Short‑Term Credit Agreement”) that **replaced the prior 364‑day facility from November 2022** and **matures in October 2024**, with one‑year extension rights 【page_59】.  \n\n- 2024 filing – In the next year Amazon **re‑entered into a new $5.0 billion unsecured 364‑day revolving credit facility in October 2024** (the “Short‑Term Credit Agreement”), which **now matures in October 2025** and also may be extended for an additional 364‑day period 【page_58】.  \n\n**Thus, between 2023 and 2024 the short‑term facility kept the same $5 billion size, but its maturity was pushed out by one year (from Oct 2024 to Oct 2025) and the agreement was refreshed a year later, moving from a November 2023 execution to an October 2024 execution.**",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $5.0 billion facility size is consistent across both years, the 2023 agreement was entered in November 2023 and matures in October 2024, and the 2024 agreement was entered in October 2024 and matures in October 2025. These match the original answer exactly. (2) Quantitative accuracy is perfect: all dollar amounts ($5.0 billion), time durations (364-day), and dates (November 2023, October 2024, October 2025) are correct. The maturity shift from Oct 2024 to Oct 2025 is accurately noted as a one-year extension. (3) The reasoning is sound: the model correctly identifies this as a renewal with procedural timing changes rather than a structural change. It captures the replacement pattern and extension rights, showing proper multi-hop synthesis between the two years’ filings. (4) The only minor issue is a slight misstatement in the summary: it says the agreement was 'refreshed a year later, moving from a November 2023 execution to an October 2024 execution' — while technically correct, this could imply a delay rather than an earlier renewal (October 2024 vs November 2023), but the factual dates are right. The original answer notes the shift from November to October as a procedural change, which the LLM captures in effect but not explicitly in framing. This small nuance prevents a perfect 10. Overall, the answer is factually complete, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 419,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has AMD's APU strategy evolved from 2022 to 2024 in terms of product integration and target markets, and what implications does this shift have for its revenue potential in the AI PC segment?",
      "original_answer": "In 2022, AMD emphasized external GPU-based solutions for AI and HPC workloads, particularly through the Instinct MI200 series and Radeon PRO V620 GPUs, focusing on data center and cloud applications. By 2024, AMD had shifted toward integrating dedicated AI acceleration directly into client devices, becoming the first company to include a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs. This strategic pivot toward integrated APUs with NPU cores indicates a move to capture revenue growth in the emerging AI PC market, where on-device AI processing is becoming critical. This evolution likely enhances AMD's revenue potential by positioning it as a differentiated player in the AI PC segment, moving beyond traditional CPU-GPU combinations.",
      "llm_answer": "In the 2022 filing AMD’s APU roadmap was described mainly as a “CPU‑and‑GPU”‑on‑a‑single‑chip solution that “delivers visual‑processing functionality for value and mainstream PCs” 【page_7】. By the 2024 filing the strategy had shifted to a “CPU‑GPU‑NPU” architecture: AMD highlights the Ryzen AI 300 Series APUs that embed a dedicated neural‑processing unit for “next‑generation AI PCs” and notes that it was the first company to place an NPU on the same SoC as an x86 CPU 【page_7】【page_5】. This move expands AMD’s target market from traditional consumer notebooks and desktops into the fast‑growing AI‑PC segment, giving it a new, higher‑margin revenue stream and the potential to capture a larger share of AI‑enabled PC sales.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies AMD's 2022 APU strategy as centered on CPU-GPU integration for value and mainstream PCs, and the 2024 shift to a CPU-GPU-NPU architecture with the Ryzen AI 300 Series APUs. The claim that AMD was the first to integrate an NPU on the same SoC as an x86 CPU is consistent with the original answer. (2) There are no numeric values requiring calculation (e.g., revenue figures, percentages), so quantitative accuracy pertains to correct use of years (2022, 2024) and product names (MI200 series implied via context, Ryzen AI 300), which are accurate. (3) The multi-hop reasoning is sound: the answer synthesizes AMD’s strategic evolution across time, connects product integration changes (adding NPU), identifies the shift in target markets (from traditional PCs to AI PCs), and correctly infers the implication—new revenue potential in a high-growth, higher-margin segment. (4) The answer fully addresses all parts of the question: product integration evolution, target market shifts, and revenue implications. Wording differs slightly but meaning and factual content align perfectly with the ground truth. No errors in entities, dates, or logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 351,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has the treatment of Irish income tax liability for U.S. shareholders receiving dividends from Medtronic evolved between 2023 and 2024, particularly in relation to the Irish dividend withholding tax?",
      "original_answer": "In both 2023 and 2024, dividends paid by Medtronic were generally subject to Irish dividend withholding tax at a rate of 25 percent unless an exemption applied. For U.S. residents, exemptions were available based on residency documentation, such as a valid U.S. Certification of Residence (Form 6166) or Irish Non-Resident Form V2. In both years, a U.S. resident who met the exemption criteria and did not hold shares through an Irish branch generally had no Irish income tax liability. Additionally, if a U.S. shareholder was subject to the 25% withholding tax, the payment discharged any Irish income tax liability, provided the shareholder submitted the required statement to the Irish Revenue authorities. There was no change in the tax rate or in the conditions for exemption between the years, indicating a stable regulatory framework.",
      "llm_answer": "Both the 2023 and the 2024 Form 10‑K contain the same statement: U.S. shareholders who qualify for an exemption from the Irish 25 % dividend withholding tax (by providing a U.S. address through DTC or a valid Form 6166/Irish Form V2) will not incur any Irish income‑tax liability on Medtronic dividends, and if the withholding tax is applied it fully discharges any Irish income‑tax due, provided the shareholder supplies the required statement to the Irish Revenue. Thus, the treatment of Irish income‑tax liability for U.S. dividend‑receivers has not changed between 2023 and 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately conveyed: the 25% Irish dividend withholding tax rate, the availability of exemptions for U.S. residents via Form 6166 or Irish Form V2, the absence of Irish income tax liability for qualifying U.S. shareholders, and the fact that withholding tax payment discharges any tax liability upon submission of the required statement. (2) Quantitative accuracy is perfect: the 25% rate is correctly stated, and no incorrect numbers or calculations are present. (3) The multi-hop reasoning is sound—by comparing the 2023 and 2024 10-Ks and concluding no change occurred, the model correctly synthesizes information across years and documents. (4) The answer directly addresses the evolution (or lack thereof) in tax treatment, which is the core of the question, making it contextually precise. Minor wording differences (e.g., mentioning DTC address as a method) do not affect factual correctness and are consistent with typical exemption procedures. No errors or omissions impact the accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 311,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the risk disclosure around new products and services evolved between 2022 and 2024, particularly regarding the company's platforms operating model initiative?",
      "original_answer": "In 2022, BNY Mellon highlighted that new lines of business, new products and services, or transformational or strategic project initiatives subject the company to new or additional risks. By 2024, this risk disclosure evolved to specifically include the 'transition to a platforms operating model' as a new source of uncertainty. The 2024 filing explicitly states that the company 'may not realize some or all of the expected benefits of our transition to a platforms operating model,' indicating a more focused risk related to this specific strategic initiative. This evolution shows a shift from general strategic risk language to a more concrete acknowledgment of platform-specific implementation risks.",
      "llm_answer": "- 2022 10‑K – the risk‑factors section warned that “new lines of business, new products and services or transformational or strategic project initiatives” could expose the company to “new or additional risks” and that failure to implement those initiatives could hurt results of operations. 【page_4】\n\n- 2024 10‑K – the same language remains, but the company adds a distinct risk statement that “we may not realize some or all of the expected benefits of our transition to a platforms operating model,” linking the platforms‑operating‑model initiative directly to a potential shortfall in expected benefits. 【page_5】\n\nThus, the disclosure has evolved from a generic warning about new products/services to a more specific risk that the platforms operating model transition may not deliver its anticipated benefits.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately reflects the evolution of risk disclosure between 2022 and 2024: in 2022, BNY Mellon used general language about new products, services, and strategic initiatives introducing new risks, and by 2024, it added a specific risk statement about the platforms operating model transition potentially failing to deliver expected benefits. (2) There are no numerical values requiring calculation, but the years (2022 and 2024) are correctly cited, and the referenced disclosures align with the source documents. (3) The multi-hop reasoning is sound—comparing risk factor language across two filings and identifying the addition of a new, specific risk related to the platforms operating model initiative. (4) The answer is semantically equivalent to the original: it captures the shift from generic to specific risk disclosure, highlights the exact new language, and correctly attributes it to the correct years and filings. All entities (BNY Mellon, platforms operating model, 10-K filings) are accurate. No factual, quantitative, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 324,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Amazon's relationship with the 3.600% Note due 2032 evolved between 2023 and 2024, particularly in terms of its debt instrument disclosures?",
      "original_answer": "In 2023, the 3.600% Note due 2032 was disclosed as part of a Supplemental Indenture dated April 13, 2022, among Amazon.com, Inc., Wells Fargo Bank, National Association (as prior trustee), and Computershare Trust Company, National Association (as successor trustee). In 2024, the same note was referenced under the same Supplemental Indenture, but the trustee structure now only referenced Computershare Trust Company, National Association, as successor trustee, indicating a formal transition away from Wells Fargo Bank. This reflects a procedural evolution in the administration of the note, with no changes to the note’s terms or interest rate, but a shift in the trustee relationship.",
      "llm_answer": "Amazon’s 2023 Form 10‑K lists the 3.600 % Note due 2032 only as part of the “Supplemental Indenture, dated April 13 2022” (Exhibit 4.2) and notes that the company does not file the underlying debt‑instrument agreements because the securities represent less than 10 % of its assets (Item 101). The 2024 Form 10‑K repeats the same disclosure – the 3.600 % Note due 2032 is still included in Exhibit 4.2 (and no new amendment or separate filing is reported) and the same exemption from filing the detailed instrument remains in effect. Thus, between 2023 and 2024 Amazon’s relationship with the 3.600 % Note due 2032 remained unchanged, with the debt still held and disclosed via the supplemental indenture and the same regulatory filing exemption.",
      "correctness_score": 5,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses a key factual evolution in the trustee relationship for the 3.600% Note due 2032 between 2023 and 2024. Quantitatively, all dates and percentages are accurate: the Supplemental Indenture is correctly dated April 13, 2022, and the note's interest rate (3.600%) and maturity (2032) are correctly stated. The mention of Exhibit 4.2 and the <10% asset exemption under Item 101 is factually consistent with SEC filing practices. However, the qualitative analysis fails on a critical multi-hop point: while the LLM claims 'no change' in Amazon's relationship with the note, the ground truth reveals a procedural shift in the trustee structure—from Wells Fargo Bank, National Association (prior trustee) and Computershare (successor trustee) in 2023, to only Computershare being referenced in 2024—indicating a formal transition. The LLM overlooks this administrative evolution, which is central to the question about how the relationship evolved. This omission represents a failure in reasoning and synthesis across the two years’ disclosures. While the core debt terms (interest, maturity, indenture) remained unchanged, the shift in trustee representation is a material update in the governance of the instrument. The answer is contextually relevant and well-structured, but the absence of this key detail significantly undermines completeness and qualitative accuracy. Thus, the correctness score is reduced to 5—partially correct with significant factual omission despite accurate numbers and general framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 424,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How did MDLZ's treatment and disclosure of net investment hedge derivative contracts evolve from 2023 to 2024, particularly in terms of their financial impact and presentation within the financial statements?",
      "original_answer": "In 2023, MDLZ disclosed the fair value of derivative assets and liabilities associated with net investment hedge contracts, with $1,347 million and $377 million in other current assets and $250 million and $413 million in other assets as of December 31, 2023 and 2022, respectively. By 2024, the focus shifted to the income statement impact, where the company noted that 'Other income, net' included amounts excluded from the assessment of hedge effectiveness related to these contracts, indicating a change in emphasis from balance sheet valuation to income volatility effects.",
      "llm_answer": "In 2023 Mondelēz reported its net‑investment‑hedge (NIH) contracts as a **net liability** – the hedge‑designated assets were $163 million versus $382 million of liabilities, creating a $219 million liability on the fair‑value table and leaving the overall derivative position slightly negative ($38 million)【page_95】. By 2024 the balance had flipped to a **net asset**: NIH assets rose to $305 million and liabilities fell to $50 million, producing a $255 million asset on the fair‑value schedule and contributing to a positive total derivative fair value of $1.174 billion【page_94】【page_95】. The contracts continue to be disclosed in Note 10 (Financial Instruments) with the same level‑2 valuation methodology, but the presentation changed from a liability‑focused line‑item to being included in “other current assets” and “other assets” on the balance sheet, reflecting the shift from a loss‑making hedge to a gain‑making one.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and misrepresents the financial data. The ground truth states that in 2023, MDLZ disclosed $1,347 million in other current assets and $250 million in other assets related to derivative assets, with $377 million and $413 million in liabilities for 2023 and 2022 respectively. The LLM incorrectly reports NIH assets as $163 million and liabilities as $382 million in 2023, and $305 million assets and $50 million liabilities in 2024—none of which match the ground truth. These figures are not only wrong but also imply a net liability in 2023 and net asset in 2024 based on fabricated data. (2) There is no mention in the original answer of a 'net liability' or 'net asset' characterization; instead, the focus is on disclosure practices and a shift in emphasis from balance sheet valuation to income statement impact. The LLM invents a narrative about flipping from liability to asset without supporting data. Additionally, the claim that total derivative fair value was $1.174 billion in 2024 has no basis in the provided truth. (3) The multi-hop reasoning is flawed: while the LLM correctly identifies Note 10 and the use of Level 2 valuations, it fails to capture the actual evolution—i.e., the shift in disclosure focus from balance sheet amounts to income statement effects (specifically, 'Other income, net' including amounts excluded from hedge effectiveness). This key qualitative shift is missed entirely and replaced with a quantitative narrative that contradicts the source. (4) Despite incorrect facts, the answer remains contextually relevant by addressing the right topic (NIH hedge treatment), time frame (2023–2024), and disclosure location (Note 10), and attempts to describe a change in presentation. However, due to severe quantitative errors and failure to report the actual evolution in disclosure emphasis, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 525,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the Abrams Main Battle Tank's modernization strategy evolved from 2023 to 2024, particularly in terms of technological development and international demand?",
      "original_answer": "In 2023, General Dynamics was focused on delivering the System Enhancement Package version 3 (SEPv3) for the Abrams tank, which included upgrades in communications, power generation, fuel efficiency, optics, and armor. Additionally, GD announced the development of the M1E3 Abrams, a more significant engineering change aimed at future threats, featuring the latest systems architecture for quicker upgrades and reduced sustainment footprint. By 2024, the company emphasized continued capability enhancement of the Abrams to counter current and potential threats, with increased international demand reflected in a growing installed base across Europe, the Middle East, North Africa, and the Indo-Pacific. While 2023 focused on the technical roadmap (SEPv3 and M1E3), 2024 highlighted the global strategic relevance and procurement momentum of the Abrams platform.",
      "llm_answer": "In the 2023 filing General Dynamics said it was “maximizing the effectiveness and lethality of the Army’s M1A2 Abrams tank fleet with next‑generation upgrades through continued delivery of the System Enhancement Package Version 3 (SEPv3) … and it also announced the new M1E3 Abrams engineering‑change program to give the tank faster‑upgradable architecture, reduced sustainment and greater mobility.” The company noted that demand from NATO members and other allies for Abrams procurements and upgrades was strong, with a growing installed base in Europe, the Middle East, North Africa and the Indo‑Pacific.  \n\nThe 2024 filing shows the strategy has moved to “continuing delivery of the SEPv3 configuration … and continuing to upgrade Abrams tanks for several non‑U.S. partners,” indicating the focus has shifted from launching a new M1E3 development effort to fielding the SEPv3 upgrades and sustaining international upgrade programs, while still emphasizing robust foreign‑partner demand.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2023, General Dynamics was delivering the SEPv3 upgrades and announced the M1E3 program, which included faster-upgradable architecture, reduced sustainment, and improved mobility—matching the original answer’s description of enhanced systems architecture and reduced footprint. The 2024 emphasis on continuing SEPv3 deliveries and international upgrade programs is correctly noted. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—no errors in dates or figures. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, identifying the shift from announcing a new engineering program (M1E3 in 2023) to focusing on fielding SEPv3 and sustaining international programs in 2024. It accurately captures the evolution in strategy from technical development to global deployment and demand. (4) The answer addresses both parts of the question: technological development (SEPv3 and M1E3) and international demand (growing base in Europe, Middle East, North Africa, Indo-Pacific). The only minor shortcoming is that it slightly downplays the 2024 emphasis on the M1E3’s ongoing relevance; while the focus has shifted, the original answer notes that M1E3 remains part of the capability enhancement strategy. However, this does not constitute a factual error, just a slight omission of emphasis. Overall, the answer is factually correct, contextually appropriate, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1468,
        "completion_tokens": 446,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has AMD's role in the development and positioning of APUs evolved between 2022 and 2024, particularly in terms of their market segmentation and strategic emphasis?",
      "original_answer": "In 2022, APUs were discussed as part of AMD's broader Enterprise, Embedded and Semi-Custom product portfolio, which included CPUs, GPUs, and customized SoC products. They were described in general terms without specific market segmentation or strategic emphasis. By 2024, APUs were explicitly included in two of AMD's four reportable segments: the Data Center segment and the Client segment. In the Data Center segment, APUs were listed alongside AI accelerators, CPUs, GPUs, and DPUs, indicating a strategic shift to position APUs as part of data center solutions. In the Client segment, APUs were specifically tied to desktop and notebook CPUs and chipsets, showing a more defined and segmented approach to their market positioning. This evolution reflects a more structured and strategic integration of APUs into AMD's core business segments.",
      "llm_answer": "In the 2022 filing AMD described its APUs mainly as “mobile APUs … that deliver visual‑processing functionality for value‑ and mainstream PCs” and as embedded‑Ryz en V‑ and R‑Series APUs used in specialized embedded and semi‑custom devices (e.g., consoles) 【page_7】【page_10】. By the 2024 filing the company groups APUs in both the **Client** segment (CPUs, APUs and chipsets for desktops and notebooks) and the **Data Center** segment (CPUs, GPUs, APUs, DPUs, etc.), reflecting a strategic shift to treat APUs as a heterogeneous‑computing building block for a wider range of workloads—including AI and data‑center acceleration—rather than solely a PC‑oriented product 【page_69】. This broader segmentation is underscored by the growth of Client‑segment revenue (from $6.2 bn in 2022 to $7.1 bn in 2024) and the inclusion of APUs in the fast‑growing Data Center segment 【page_70】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of AMD's APU strategy from 2022 to 2024, noting the shift from general inclusion in the Enterprise, Embedded and Semi-Custom segment to explicit inclusion in both Client and Data Center segments by 2024. The description of APUs in 2022 as serving value/mainstream PCs and embedded/semi-custom applications matches the broader portfolio context in the original answer. (2) The quantitative data—Client segment revenue increasing from $6.2B in 2022 to $7.1B in 2024—is factually accurate and supports the narrative of growth, though this specific revenue detail is not in the ground truth; however, it does not contradict it and adds contextual support. No calculation errors are present. (3) The multi-hop reasoning is sound: the model synthesizes information across years and segments, correctly inferring a strategic shift in positioning APUs beyond PCs into data center and AI workloads. (4) Semantic equivalence is strong: while the LLM adds revenue figures not in the original, the core evolution in segmentation and strategic emphasis is accurately conveyed. The only minor limitation is that the original answer emphasizes the structural integration into reportable segments without citing revenue, so the added emphasis on revenue, while plausible, slightly extends beyond the ground truth. However, this does not introduce inaccuracy. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 420,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has Medtronic's disclosure regarding the implications of the Financial Transfers Act 1992 on financial transfers between Ireland and third countries evolved from 2023 to 2024?",
      "original_answer": "In 2023, Medtronic disclosed that the Financial Transfers Act 1992 allowed the Irish Minister for Finance to impose restrictions on financial transfers with certain third countries, and that the list of such countries was subject to ongoing change. By 2024, the company continued to disclose the same regulatory framework but no longer emphasized the dynamic nature of the list of restricted countries, suggesting a potential shift in focus or a stabilization in the regulatory environment affecting these transfers.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K contain the same “Irish Restrictions on Import and Export of Capital” paragraph. In each filing Medtronic notes that, under the Financial Transfers Act 1992, the Irish Minister for Finance may restrict financial transfers between Ireland and third‑country jurisdictions, that such restrictions already exist for a number of countries, and that the list is subject to ongoing change. No new language or additional detail was added in the 2024 filing – the disclosure is essentially unchanged from 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in terms of the content disclosed by Medtronic in both years and correctly identifies the relevant regulation (Financial Transfers Act 1992) and its provisions. All entities (Medtronic, Ireland, third countries, Irish Minister for Finance) and years (2023, 2024) are accurate, and there are no numerical inaccuracies, so quantitative accuracy is high. However, the LLM contradicts the ground truth by stating that the disclosure was 'essentially unchanged' and that the 2024 filing still mentions the list being 'subject to ongoing change.' In contrast, the original answer indicates a subtle but meaningful evolution: while the core regulatory framework was still disclosed in 2024, the emphasis on the dynamic nature of the restricted countries list was removed, suggesting a shift in tone or focus. The LLM fails to detect this nuance, which is central to the question about *evolution* in disclosure. This represents a failure in qualitative accuracy and multi-hop reasoning, as the model should have identified not just the presence of text, but changes in emphasis or wording over time. Despite this, the answer remains contextually relevant and addresses the right documents and regulatory context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 347,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How did the status and production outlook of the G700 aircraft evolve from 2023 to 2024 based on GD's disclosures?",
      "original_answer": "In 2023, the G700 was described as the next model to join the Gulfstream lineup, with expectations for it to enter service following FAA certification in early 2024. By 2024, the G700 had begun deliveries in the second quarter, indicating that it successfully completed certification and transitioned from development to active production and customer delivery. This marks a clear evolution from a future product to a realized and delivered aircraft model.",
      "llm_answer": "In the 2023 filing Gulfstream said the ultra‑long‑range G700 was still awaiting FAA certification and was expected to “enter service following certification … in early 2024”【page_5】. By the 2024 filing the company reported that production of the G700 had already been ramped up and that the model “began deliveries in the second quarter of 2024”【page_70】. Thus, the G700 moved from a pending‑certification, pre‑service status in early 2023 to an actively delivered, production‑ramped aircraft by mid‑2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) All key facts are accurately reported: in 2023, the G700 was awaiting FAA certification with expected entry into service in early 2024; by 2024, it had begun deliveries in Q2. (2) The dates ('early 2024' expectation and 'second quarter of 2024' actual delivery start) are factually consistent with the original answer and reflect accurate timeline progression. No numerical calculations were required, but temporal references are correct. (3) The multi-hop reasoning—synthesizing disclosures from two different years (2023 and 2024 filings) to show evolution from pre-certification to active delivery—is sound and well-articulated. (4) The answer captures the full scope of the question, addressing both status and production outlook evolution. Wording differs slightly but maintains semantic equivalence (e.g., 'ramped up production' and 'began deliveries' match 'transitioned from development to active production'). All entities (G700, Gulfstream, FAA, 2023/2024 timelines) are correctly identified. No errors in fact, logic, or relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 317,
        "total_tokens": 1549
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the nature of PMI's relationship with KT&G evolved from 2023 to 2024, particularly in terms of strategic dependency and product commercialization?",
      "original_answer": "In 2023, PMI announced a long-term collaboration with KT&G to commercialize KT&G's smoke-free devices and consumables on an exclusive, worldwide basis (excluding South Korea), under a 15-year agreement running through January 29, 2038. This partnership granted PMI exclusive access to KT&G's smoke-free brands and product pipeline, including offerings for low- and middle-income markets. By 2024, this relationship had evolved into a more integrated dependency, as KT&G's heat-not-burn products were explicitly referenced as part of PMI's heat-not-burn product portfolio, indicating a shift from exclusive distribution to inclusion within PMI's broader smoke-free product strategy. This evolution reflects a deeper strategic alignment and operational integration of KT&G's offerings into PMI's product ecosystem.",
      "llm_answer": "In the 2023 filing PMI described a newly‑renewed, 15‑year exclusive collaboration with KT&G that gave PMI “continued exclusive access” to KT&G’s smoke‑free brands, product‑innovation pipeline and low‑ and middle‑income‑market offerings – a relationship that made PMI strategically dependent on KT&G for new smoke‑free products. By the 2024 filing the partnership is reflected in the results as “licensed KT&G heat‑not‑burn products” (e.g., Fiit and Miix) that are counted in PMI’s heated‑tobacco‑unit volume, indicating the agreement has moved from a broad strategic pipeline deal to the active commercialization of KT&G‑licensed products within PMI’s portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of PMI's relationship with KT&G from 2023 to 2024. (1) It correctly identifies the 15-year exclusive collaboration announced in 2023, granting PMI exclusive access to KT&G’s smoke-free brands and innovation pipeline, including products for low- and middle-income markets—matching the ground truth. The shift in 2024 is accurately described as active commercialization, with licensed KT&G products (Fiit and Miix) now included in PMI’s heated-tobacco-unit volume, indicating integration into PMI’s product portfolio. (2) Quantitatively, the 15-year agreement duration and reference to 2023 and 2024 filings are consistent with the ground truth; no specific dates (e.g., January 29, 2038) are misstated, and no numerical inaccuracies are present. (3) The multi-hop reasoning is sound: the model correctly infers that the inclusion of KT&G products in PMI’s volume metrics reflects a deeper operational integration beyond mere distribution, aligning with the ground truth’s conclusion of increased strategic dependency. (4) The only minor omission is that the original answer specifies the exclusivity excludes South Korea and names the agreement date (January 29, 2038), which the LLM omits. However, this does not undermine the overall correctness. The LLM uses slightly different phrasing (e.g., 'continued exclusive access') but maintains semantic equivalence. Thus, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 452,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has AMD's approach to semi-custom SoC products evolved from 2022 to 2024, particularly in terms of their strategic positioning and integration with broader product ecosystems?",
      "original_answer": "In 2022, AMD's semi-custom SoC products were described as being dependent on third-party product success, with revenue tied to both non-recurring engineering fees and the incorporation of AMD's SoCs into customer devices. There was a clear emphasis on the risks associated with this dependency, including the lack of control over third-party marketing and the uncertainty of revenue realization. By 2024, AMD's approach had evolved significantly, with semi-custom SoCs being positioned as core components of a broader, more integrated product ecosystem that includes AI accelerators, CPUs, GPUs, and APUs. The 2024 filing highlights strategic integration with AI capabilities, such as the inclusion of a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs, and the use of semi-custom SoCs in gaming, cloud services, and embedded systems across multiple industries. This reflects a shift from a dependency model to a more proactive, integrated product leadership strategy.",
      "llm_answer": "In the 2022 filing AMD described its semi‑custom System‑on‑Chip business chiefly as a “non‑recurring engineering‑fee” service whose revenue depended on winning design contracts and on the downstream success of the customers’ products. By the 2024 filing the company had repositioned semi‑custom SoCs as a strategic, co‑engineered platform that is woven into AMD’s broader ecosystem—leveraging its core graphics, AI and software stacks to power today’s leading gaming consoles, handhelds and cloud‑gaming services—rather than merely a fee‑based custom‑design offering. This reflects a shift from a peripheral, revenue‑driven activity to a core, ecosystem‑integrated growth pillar.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in AMD's semi-custom SoC strategy from 2022 to 204 as described in the ground truth. It correctly identifies the 2022 model as being based on non-recurring engineering (NRE) fees and dependent on customer product success, and contrasts this with the 2024 shift toward a strategically integrated, co-engineered platform within AMD's broader ecosystem. The answer reflects the multi-hop synthesis across years and strategic positioning, noting the integration with AI, graphics, and software stacks, and citing applications in gaming consoles, handhelds, and cloud gaming—consistent with the ground truth's mention of gaming, cloud services, and embedded systems. While the ground truth specifically mentions the inclusion of a neural processing unit (NPU) alongside an x86 CPU for AI PCs, this detail is omitted in the LLM response, representing a minor gap in completeness. However, the omission does not undermine the overall correctness or qualitative accuracy, as the broader strategic shift is accurately conveyed. There are no numerical values in the question or answers, so quantitative accuracy is scored based on correct use of years (2022, 2024), which are accurate. The reasoning is sound, and the answer is fully contextually relevant, directly addressing the evolution in strategic positioning and ecosystem integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 386,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the treatment of Irish income tax on dividends paid to U.S. residents evolved between 2023 and 2024, particularly regarding exemptions and withholding tax obligations?",
      "original_answer": "In 2023, Medtronic noted that U.S. residents who are exempt from Irish dividend withholding tax generally would not be subject to Irish income tax on dividends unless they had a connection to Ireland beyond shareholding. Additionally, non-residents subject to withholding tax typically had no further Irish income tax liability. In 2024, the company clarified that U.S. residents who qualify for a withholding tax exemption and do not hold shares through an Irish branch generally will not have Irish income tax liability, and those subject to withholding can discharge any further liability by furnishing a statement to Irish Revenue. The 25% withholding tax rate remained unchanged, but the 2024 disclosure provided more structured conditions for exemption and clarified post-withholding tax procedures.",
      "llm_answer": "In the 2023 filing Medtronic noted that Irish dividend‑withholding tax (currently 25 %) could apply, but U.S. shareholders are exempt — particularly when their shares are held through the Depository Trust Company (DTC) and the broker’s records show a U.S. address, or when they otherwise qualify for a treaty‑based exemption. The 2024 filing repeats the 25 % rate but spells out the exemption more explicitly: a U.S. beneficial owner in DTC with a U.S. address **or** a record owner who provides a valid U.S. Certificate of Residence (Form 6166) or Irish Non‑Resident Form V2 will not face withholding, and, if withholding does occur, it satisfies any Irish income‑tax liability. Thus the core exemption for U.S. residents remains unchanged, but the 2024 disclosure adds clearer documentation requirements and confirms that withholding, when applicable, discharges the Irish income‑tax obligation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 25% Irish dividend withholding tax rate is accurately reported for both 2023 and 2024, and the exemption conditions for U.S. residents are correctly described. The answer correctly notes that U.S. shareholders exempt from withholding generally avoid Irish income tax unless connected to Ireland, and that withholding satisfies any further tax liability—consistent with the 2024 clarification. (2) Quantitative accuracy is perfect: the 25% rate is correctly cited, and no calculations are required. (3) Multi-hop reasoning is sound: the model synthesizes information across Medtronic’s 2023 and 2024 filings, correctly identifying continuity in the tax rate and evolution in disclosure clarity. It adds specific procedural details (e.g., Form 6166, Form V2, DTC holdings) not in the ground truth but plausibly derived from actual filings, enhancing precision without contradicting the original. (4) The only minor shortcoming is that the ground truth emphasizes the 'connection to Ireland beyond shareholding' as a risk factor for tax liability, which the LLM mentions implicitly but not explicitly. However, the core evolution—unchanged rate, clearer exemption rules, and withholding as full discharge—is accurately captured. Wording differs but semantic meaning matches. Contextual relevance is excellent, directly addressing exemptions, withholding obligations, and year-over-year changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 412,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did General Dynamics' financial performance and strategic focus in ship construction change from 2023 to 2024, particularly regarding cost pressures on the Virginia-class and DDG-51 programs and the revenue outlook for the Columbia-class submarine initiative?",
      "original_answer": "In 2023, General Dynamics' Marine Systems segment experienced a 110 basis point decline in operating margin due to supply chain disruptions affecting the Virginia-class submarine schedule and cost overruns on the DDG-51 guided-missile destroyer program. Despite these challenges, revenue from U.S. Navy ship construction rose, driven by increased activity on the Columbia-class submarine program. By 2024, the company projected revenue for the Marine Systems segment to rise to $12.8–12.9 billion with an expected operating margin of approximately 7.6%, suggesting a strategic effort to stabilize and improve profitability. This indicates a shift from cost-driven margin pressure in 2023 to a more optimistic outlook in 2024, likely supported by improved program execution and growth in the Columbia-class program.",
      "llm_answer": "In 2023 General Dynamics said that its Marine Systems margin was squeezed – the Virginia‑class submarine schedule suffered supply‑chain cost pressure and the Arleigh Burke (DDG‑51) destroyer program experienced cost growth, which together knocked about 110 basis points off the segment’s margin, even as higher‑volume work on the Columbia‑class submarine lifted ship‑construction revenue. For 2024 the company projects ship‑construction revenue to rise to roughly $12.8‑$12.9 billion with an operating margin of about 7.6 percent, indicating that the earlier cost pressures are expected to ease and that the Columbia‑class submarine program will continue to be a key revenue driver.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: the 110 basis point margin decline in 2023 due to supply chain issues on the Virginia-class and cost overruns on the DDG-51 program, the increase in ship-construction revenue driven by the Columbia-class program, and the 2024 revenue projection of $12.8–12.9 billion with a 7.6% operating margin. (2) Quantitative accuracy is perfect: the 110 basis points, $12.8–12.9 billion range, and 7.6% margin match the original exactly, with acceptable formatting (e.g., 'about 7.6 percent' = 'approximately 7.6%'). (3) Multi-hop reasoning is sound: the answer correctly synthesizes performance trends across two years, links cost pressures to specific programs, and identifies the Columbia-class as a key revenue driver in both years. (4) The answer fully addresses all parts of the question—financial performance changes, cost pressures, and revenue outlook—while maintaining precise entity references (General Dynamics, Marine Systems, Virginia-class, DDG-51, Columbia-class). Wording differs slightly but meaning is preserved. No omissions or inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 328,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BKNG's financial dependency on Booking.com evolved between 2022 and 2023 based on the proportion of revenue derived from accommodation reservations?",
      "original_answer": "BKNG's financial dependency on Booking.com has remained high but slightly increased between 2022 and 2023. In 2022, Booking.com's accommodation reservations contributed 89% of BKNG's total revenues. This percentage remained unchanged in 2023, indicating BKNG continues to heavily rely on Booking.com for its revenue base. The consistent 89% contribution in both years shows a sustained and concentrated dependency on Booking.com's core service offering.",
      "llm_answer": "Booking Holdings’ reliance on its core accommodation‑booking business has essentially stayed the same. Both 2022 and 2023 show that roughly 89 percent of total revenue comes from online accommodation reservation services, indicating no material shift in the proportion of revenue derived from Booking.com‑related reservations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that 89% of total revenue came from online accommodation reservation services in both 2022 and 2023, which matches the ground truth. The key quantitative data (89%, 2022, 2023) are accurate and consistent with the original answer. (2) All numbers and years are correct—89% in both years is precisely what the ground truth reports. There are no calculation errors, and the percentage values are correctly interpreted. (3) The reasoning is sound: the model correctly infers that the proportion has not materially changed, indicating stable financial dependency. However, the original answer notes a 'slight increase' in dependency despite the same percentage, possibly due to qualitative factors or context not fully reflected in the LLM response. The LLM instead says 'essentially stayed the same,' which is factually correct based on the percentage but slightly underrepresents the nuance in the original answer’s interpretation of sustained high dependency as a form of continued concentration risk. (4) The answer is contextually fully relevant, directly addressing the evolution of BKNG's financial dependency on Booking.com via accommodation revenue. The minor deduction in qualitative accuracy is due to the absence of explicit mention of 'continued heavy reliance' or 'concentrated dependency' as emphasized in the original, though the core message is preserved. Overall, the answer is factually correct and semantically equivalent with only slight nuance missing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1197,
        "completion_tokens": 418,
        "total_tokens": 1615
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did the company's position with respect to its Swiss Franc note evolve between 2023 and 2024, and what does this indicate about its foreign currency obligations?",
      "original_answer": "In 2023, the company disclosed a Swiss Franc note obligation of $299 million, which was completely removed by the end of 2024. This indicates that the company either repaid or restructured this foreign currency obligation over the year, reflecting a strategic shift in managing its Swiss Franc exposure.",
      "llm_answer": "In 2023 the balance sheet still carried a Swiss‑franc note of ≈ $299 million (1.625% due 2024) 【page_105】. By the end of 2024 that line shows “‑” – the note had been fully repaid and no Swiss‑franc debt remained 【page_102】. This removal of the CHF note indicates that PMI eliminated that specific foreign‑currency liability, reducing its exposure to Swiss‑franc exchange‑rate risk.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurate: the Swiss Franc note obligation of $299 million in 2023 is correctly stated, and its complete removal by 2024 is properly noted with the symbol '‑' indicating zero balance. (2) Quantitative accuracy is perfect: the dollar amount ($299 million), interest rate (1.625%), and maturity year (2024) match the source data. The format variation (≈$299 million) is acceptable and does not distort meaning. (3) The multi-hop reasoning is sound—by comparing the 2023 and 2024 disclosures, the model correctly infers that the obligation was fully repaid, leading to elimination of Swiss Franc debt. (4) The conclusion about reduced foreign exchange risk due to elimination of CHF liability aligns with the ground truth's interpretation of strategic shift in currency exposure management. The answer addresses both parts of the question: evolution of the Swiss Franc note position and its implication for foreign currency obligations. Minor wording differences (e.g., 'repaid or restructured' vs. 'repaid') do not affect factual correctness, as repayment is the most direct explanation supported by the data. All entities—Swiss Franc note, time frame (2023–2024), and financial implications—are accurately identified and synthesized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1175,
        "completion_tokens": 370,
        "total_tokens": 1546
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did Goldman Sachs' treatment of Non-Employee Director RSU Award Agreements evolve between the 2023 and 2024 10-K filings, particularly in terms of introduced or modified agreements?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs referenced the 'Form of Non-Employee Director RSU Award Agreement (pre-2015)' as Exhibit 10.8, indicating that the existing documentation pertained to agreements prior to 2015. In the 2024 filing, the company not only retained the reference to the pre-2015 RSU Award Agreement but also introduced a new exhibit titled 'Amendments to Certain Non-Employee Director Equity Award Agreements' as Exhibit 10.18, which was not present in the 2023 filing. This indicates that Goldman Sachs expanded its disclosures to include amendments to these agreements, suggesting a more comprehensive or updated treatment of non-employee director equity arrangements in 2024.",
      "llm_answer": "In the 2023 Form 10‑K Goldman Sachs listed three non‑employee‑director RSU documents – a pre‑2015 template (Exhibit 10.8), the current RSU award template (Exhibit 10.31) and its cash‑settled version (Exhibit 10.32) – and also disclosed an amendment to those awards (Exhibit 10.17).  \n\nThe 2024 Form 10‑K keeps the current RSU templates (now Exhibit 10.32 and the cash‑settled Exhibit 10.33) but renumbers the pre‑2015 template as Exhibit 10.9 and adds a new amendment exhibit (Exhibit 10.18) that updates certain non‑employee‑director equity award agreements. In short, the 2024 filing introduces a refreshed amendment exhibit and updates the exhibit numbering, while the core RSU award forms remain in place.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) According to the ground truth, the 2023 10-K only referenced the 'Form of Non-Employee Director RSU Award Agreement (pre-2015)' as Exhibit 10.8—there was no mention of a current RSU award template (Exhibit 10.31) or cash-settled version (Exhibit 10.32) in that year’s filing, as the LLM claims. This misrepresents the scope of disclosures in 2023. (2) The LLM incorrectly states that an amendment was disclosed in Exhibit 10.17 in the 2023 filing; the ground truth does not mention this exhibit or any prior amendment disclosure, making this detail fabricated or misattributed. (3) In the 2024 filing, while it is correct that a new amendment exhibit (10.18) was added, the LLM falsely asserts that the pre-2015 template was renumbered to Exhibit 10.9 and that current templates were renumbered to Exhibits 10.32 and 10.33—details absent from the original answer and unverifiable without external data. The core correct point is that Goldman Sachs introduced a new amendment exhibit (10.18) in 2024, aligning with the ground truth’s claim of expanded disclosure. However, the LLM invents multiple exhibits and amendments not present in the ground truth, leading to major errors in both quantitative accuracy (exhibit numbers, presence of documents) and qualitative reasoning (incorrect multi-hop synthesis across years). Despite these issues, the answer is contextually relevant, attempting to address the evolution of RSU agreements with appropriate terminology and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 428,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did PM's financial relationship with Swedish Match AB evolve between 2023 and 2024, particularly in terms of long-term debt obligations tied to the acquisition?",
      "original_answer": "In 2023, the long-term debt obligations related to the Swedish Match AB acquisition totaled $6,121 million, while in 2024, this amount decreased to $2,610 million. This indicates a significant reduction in the debt tied to the acquisition, suggesting that PM made substantial repayments or refinanced during the period. The decrease supports the idea that PM's financial dependency or exposure linked to the Swedish Match acquisition lessened over time.",
      "llm_answer": "In 2023 PMI still carried the full €5.5 billion senior unsecured term‑loan that financed the Swedish Match acquisition – €3.0 billion of it (the 3‑year tranche) and €2.5 billion of the 5‑year tranche – reflected on the balance sheet as €6.1 billion of “Euro credit‑facility borrowings related to the Swedish Match acquisition.” By the end of 2024 PMI had prepaid the entire 3‑year tranche (about €3 billion) and only the €2.5 billion 5‑year tranche remained outstanding, so the related long‑term‑debt balance fell to €2.6 billion, a reduction of roughly €3.5 billion.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the LLM reports a decrease from €6.1 billion in 2023 to €2.6 billion in 2024, which matches the original answer's $6,121 million and $2,610 million (conversion from USD to EUR is reasonable given exchange rates and reporting currency differences; €6.1B ≈ $6.6B in 2023, but the LLM may be referencing book values in EUR). The reduction of ~€3.5B is consistent with the actual drop of ~$3.5B. (2) The breakdown into tranches (€3.0B 3-year prepaid, €2.5B 5-year remaining) is plausible and adds detail not in the original but does not contradict it. (3) The entities (PM/PMI, Swedish Match AB, long-term debt obligations) and years (2023–2024) are correct. (4) The reasoning is sound: the LLM correctly infers that prepayment of a tranche led to a significant drop in debt, mirroring the original conclusion about reduced financial dependency. Minor deduction in quantitative accuracy due to currency mismatch (original uses USD, LLM uses EUR) and slight rounding, but not enough to undermine correctness. Overall, the answer demonstrates strong multi-hop synthesis and conveys the same core insight: substantial reduction in acquisition-related debt.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 347,
        "total_tokens": 1607
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did BMY's strategic positioning around KRAS inhibition evolve from 2023 to 2024, particularly in relation to the acquisition of Mirati and the development trajectory of Krazati?",
      "original_answer": "In 2023, BMY had not yet acquired Mirati, and Krazati was not part of its portfolio. However, by 2024, BMY completed the acquisition of Mirati for $4.8 billion, gaining full rights to Krazati, a KRAS G12C inhibitor. Krazati had already received FDA approval for second-line NSCLC and was in clinical development for first-line NSCLC in combination with a PD-1 inhibitor. Additionally, in 2024, Krazati was also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab, expanding its therapeutic footprint. This acquisition marked a significant evolution in BMY’s oncology strategy, positioning it more strongly in the KRAS inhibition space.",
      "llm_answer": "In the 2023 filing BMS presented the Mirati purchase as a way to “add a best‑in‑class KRAS inhibitor, Krazati, to its portfolio” and to gain “additional KRAS inhibitors and enabling programs” that would move Krazati forward as a second‑line NSCLC therapy and into first‑line combinations and KRAS‑mutated colorectal cancer (see page 87). By the 2024 filing the deal had been consummated and BMS had formally valued Krazati as a distinct, definite‑life marketed‑product right (≈ $640 million) within its intangible‑asset pool, underscoring its status as an approved, revenue‑generating KRAS‑targeted medicine while continuing to develop it in first‑line NSCLC‑PD‑1 combos and other indications (see pages 93‑94). Thus, BMS moved from positioning KRAS inhibition as a strategic acquisition target in 2023 to integrating and capital‑allocating Krazati as a core, commercial KRAS‑inhibition asset in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in BMY's (Bristol-Myers Squibb's) strategic positioning around KRAS inhibition from 2023 to 2024. It correctly identifies that in 2023, BMY viewed the acquisition of Mirati as a strategic move to gain Krazati, a best-in-class KRAS G12C inhibitor, and related pipeline assets. It also accurately reflects that by 2024, the acquisition was completed and Krazati was integrated into BMY’s portfolio as a commercial asset, with specific recognition of its valuation as a definite-lived intangible asset (~$640 million), which aligns with accounting disclosures post-acquisition. The answer correctly notes Krazati’s development trajectory: approved in second-line NSCLC, ongoing trials in first-line NSCLC in combination with PD-1 inhibitors, and expansion into KRAS-mutated colorectal cancer with cetuximab. However, the $640 million valuation, while likely accurate to the filing, is not present in the ground truth and introduces a specific figure that wasn't confirmed in the reference answer. The ground truth emphasizes the $4.8 billion total acquisition cost of Mirati, which the LLM omits. This is a minor quantitative omission—while the $640M detail shows depth, the absence of the total deal value slightly reduces quantitative completeness. All entities (BMY/BMS, Mirati, Krazati, KRAS G12C, NSCLC, colorectal cancer) and timelines (2023 strategy, 2024 integration) are correct. The reasoning is sound, demonstrating multi-hop synthesis: from pre-acquisition strategy (2023) to post-acquisition integration and commercialization (2024). The semantic meaning fully aligns with the ground truth, with slightly more accounting detail than the original. Thus, the answer is excellent, with only a partial deduction in quantitative accuracy for missing the $4.8B figure and introducing a non-validated $640M number.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 507,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Goldman Sachs' disclosure and positioning of the Restricted Partner Compensation Plan evolved between 2023 and 2024, particularly in relation to newer compensation governance policies introduced during this period?",
      "original_answer": "In 2023, the Restricted Partner Compensation Plan was listed as Exhibit 10.3 and appeared early in the exhibit list, indicating a prominent position among compensation-related disclosures. By 2024, while the plan itself (still referenced as Exhibit 10.4) remained substantively unchanged, its relative placement shifted later in the exhibit list. Notably, in 2024, the firm introduced the Clawback Policy (Exhibit 10.1), signaling a new emphasis on compensation accountability and governance reforms. This suggests a strategic repositioning of compensation-related disclosures to prioritize risk mitigation and regulatory alignment alongside traditional partner compensation frameworks.",
      "llm_answer": "In the 2023 Form 10‑K the “Goldman Sachs Amended and Restated Restricted Partner Compensation Plan” was listed as Exhibit 10.3, appearing immediately after the Partner Compensation Plan and before the employment‑agreement exhibits. In the 2024 Form 10‑K the same plan is shown as Exhibit 10.4—its description is unchanged (still referencing the 2006 10‑Q filing)—but it has been moved down the exhibit list to accommodate new governance documents, notably the Amended and Restated Clawback Policy (Exhibit 10.1) and the updated Stock Incentive Plan (Exhibit 10.2). This shift signals that Goldman Sachs is positioning the Restricted Partner Compensation Plan within a broader, more formalized compensation‑governance framework introduced in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All entities are correct: Goldman Sachs, Restricted Partner Compensation Plan, Exhibit numbers (10.3 in 2023, 10.4 in 2024), Clawback Policy (Exhibit 10.1), and Stock Incentive Plan (Exhibit 10.2). The reference to the 2006 10-Q filing is an additional detail not contradicted by the original answer. (2) Quantitative accuracy is perfect: exhibit numbers and their sequencing are correctly reported. No calculations were required, but placement shifts are accurately described. (3) Multi-hop reasoning is sound—LLM correctly infers that the plan’s later placement in 2024 is due to the introduction of new governance documents, particularly the Clawback Policy, reflecting a strategic repositioning. The conclusion about a broader compensation-governance framework matches the original’s implication of enhanced governance focus. (4) The only minor gap is that the LLM mentions the updated Stock Incentive Plan (Exhibit 10.2), which is not referenced in the original answer; however, this does not introduce inaccuracy but adds context. The core insight about strategic repositioning due to new governance policies is preserved and well-reasoned. Wording differs slightly but maintains semantic equivalence. Thus, the answer is factually correct, complete, and contextually appropriate, warranting a 9/10 due to slight over-elaboration without error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 394,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of product categorization and business integration?",
      "original_answer": "In 2022, Philip Morris described its heat-not-burn products as part of its Reduced-Risk Products (RRPs) portfolio, emphasizing their role in a smoke-free future and highlighting the IQOS Platform 1 device and various heated tobacco units (HTUs) such as HEETS and Marlboro HeatSticks. These products were positioned as a key part of the company's long-term strategy to replace traditional cigarettes. By 2023, the categorization had evolved, with heat-not-burn products now explicitly grouped under 'smoke-free products' alongside e-vapor and oral nicotine products, as well as wellness and healthcare offerings. Additionally, in 2023, PMI explicitly stated that its heat-not-burn products include licensed KT&G heat-not-burn products, indicating a broader integration and expansion of the product line beyond internally developed offerings.",
      "llm_answer": "In the 2022 filing PMI grouped all heat‑not‑burn consumables under the umbrella term **“heated‑tobacco units (HTU)”**, listing the core brands HEETS, HEETS Creations/Dimensions, Marlboro HeatSticks, TEREA, Fiit and Miix and noting that the category also covered the zero‑tobacco HTU LEVIA.  \n\nBy the 2023 filing the **HTU label was retained but expanded** to include newer brand families such as **BLENDS and DELIA** (in addition to the earlier brands) and still encompassed LEVIA, and the company now reports HTU revenue as part of its **“smoke‑free products”** segment. The 2023 results also show the **integration of the Swedish Match acquisition**, which added oral‑nicotine products to the smoke‑free portfolio and boosted overall smoke‑free (including HTU) shipments and revenues.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key developments from 2022 to 2023 regarding Philip Morris International's (PMI) heat-not-burn product strategy. It accurately notes that in 2022, PMI categorized heat-not-burn consumables under 'heated-tobacco units (HTUs)' and lists correct brand examples (HEETS, Marlboro HeatSticks, etc.), including LEVIA as a zero-tobacco variant. In 2023, it correctly states that the HTU category was expanded to include BLENDS and DELIA and that HTU revenue is now reported under the broader 'smoke-free products' segment—matching the ground truth's emphasis on re-categorization. The mention of Swedish Match acquisition integration is factually accurate and contextually relevant, as it reflects PMI’s broader business integration of smoke-free offerings. However, the LLM omits a specific point highlighted in the original answer: the explicit inclusion of *licensed KT&G heat-not-burn products* in 2023, which signifies a strategic expansion beyond internally developed products. This is a meaningful detail related to business integration and product line broadening, and its absence constitutes a minor but notable gap in completeness. There are no numerical inaccuracies (quantitative accuracy is perfect, score 10), and all entities (PMI, HTU, brand names, Swedish Match) are correctly identified. The reasoning is sound and reflects multi-hop synthesis across years and product categories. Contextual relevance is excellent, directly addressing evolution in categorization and integration. Due to the omission of the KT&G licensing point, the correctness and qualitative accuracy scores are slightly reduced, but overall the response is strong and factually consistent with minor gaps.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 479,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How did Bristol-Myers Squibb's approach to business risk governance evolve between 2023 and 2024 in relation to SEC Consent Order compliance, particularly regarding the role of the business risk and disclosure group?",
      "original_answer": "In 2023, Bristol-Myers Squibb established the business risk and disclosure group specifically to comply with the SEC Consent Order. This included implementing a formal review and certification process for SEC filings, retaining an outside consultant to re-engineer accounting and financial reporting processes, and introducing a governance mechanism to escalate and resolve compliance-related questions. By 2024, the company had fully integrated this group into its ongoing compliance framework, with no indication of modifications or reductions in scope, suggesting that the group remained a central component of financial governance under the Consent. The continued reference to the group in 2024 filings indicates that the company maintained its enhanced risk governance structure without significant changes.",
      "llm_answer": "In the 2023 Form 10‑K Bristol‑Myers Squibb disclosed that, to satisfy the 2004 SEC Consent Order, it **created a new “business‑risk and disclosure group”** as one of several remedial actions (see 2023 p. 65). By the 2024 filing the company had moved the group from a one‑time set‑up to an **ongoing governance function** that ‑ through a formal review‑and‑certification process, an escalation protocol and regular monitoring – **ensures that the company’s sales‑to‑direct‑customer policy and related disclosures remain compliant with the Consent** (see 2024 p. 63‑66).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that Bristol-Myers Squibb created the 'business-risk and disclosure group' in 2023 as part of compliance with the SEC Consent Order, citing the correct context (2004 Consent Order) and referencing the 2023 10-K (p. 65). This matches the original answer's claim about the group's establishment in 2023 for compliance purposes. (2) The LLM accurately states that by 2024, the group had transitioned into an ongoing governance function with formal processes (review-and-certification, escalation protocols, monitoring), which reflects the original answer’s point about full integration into the compliance framework with no reduction in scope. The mention of continued compliance with the Consent Order in 2024 is consistent with the ground truth. (3) Minor omission: the original answer notes the use of an outside consultant to re-engineer accounting processes, which the LLM omits. This is a small but relevant detail related to the remedial actions taken, slightly reducing completeness. However, the core multi-hop reasoning—linking the group’s creation in 2023 to its institutionalization in 2024 within the context of SEC Consent Order compliance—is sound and correctly synthesized across years. (4) All entities (Bristol-Myers Squibb, SEC Consent Order, business-risk and disclosure group), years (2023, 2024), and financial governance concepts are accurate. Wording differs but semantic meaning is equivalent. Quantitative elements (dates, page references) are correct. Contextual relevance is excellent. The omission prevents a perfect 10, but the answer is factually strong overall.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 460,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has UNP's treatment of the relationship between its pension plan's expected return and its asset allocation mix evolved between 2023 and 2024?",
      "original_answer": "In 2023, UNP explicitly stated that the expected return on plan assets was based on the asset allocation mix, historical returns, and market conditions, and included a specific actual return of 6% for that year. By 2024, the language shifted to indicating that the expected return 'depends on' the asset allocation mix, with no explicit mention of historical returns or market conditions, and no disclosure of the actual return for 2024. This represents a shift from a more comprehensive explanation of factors influencing returns to a narrower focus on the asset allocation mix alone.",
      "llm_answer": "UNP’s 2023 filing already stated that the pension‑plan’s expected long‑term return is “based on our asset‑allocation mix and our historical return, taking into account current and expected market conditions,” and it used a 5.25 % target return with a 20‑30 % equity / 70‑80 % debt mix. The 2024 filing repeats the same language and the same 5.25 % target and allocation ranges, indicating that the company has not altered its treatment of the link between expected return and asset‑allocation mix. In short, the methodology and assumptions remained consistent from 2023 to 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth in several key aspects. (1) Quantitatively, the LLM claims UNP used a 5.25% target return in 2023 and maintained it in 2024, but the ground truth states UNP reported an actual return of 6% for 2023 and did not disclose any actual return for 2024. The 5.25% figure and the specific 20-30% equity / 70-80% debt allocation ranges are not present in the ground truth and appear to be fabricated or misattributed. (2) The ground truth emphasizes a shift in language from a comprehensive explanation in 2023 (citing asset allocation, historical returns, and market conditions) to a narrower 'depends on' phrasing in 2024 with no mention of other factors. The LLM incorrectly asserts that the language and methodology remained unchanged, directly contradicting the documented evolution. (3) The qualitative reasoning fails on multi-hop synthesis: instead of identifying a change in disclosure tone and content between years, the model falsely asserts consistency. It misses the narrowing of explanatory factors and the omission of actual return data in 2024. (4) Contextually, the answer addresses the right topic (pension plan expected return and asset allocation), but the factual inaccuracies and erroneous conclusion about consistency severely undermine its validity. The answer would be more accurate if it had noted a shift toward less transparency and a more limited justification of expected returns in 2024 compared to 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 409,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did BNY Mellon's disclosure approach to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of its accessibility and integration within corporate governance reporting?",
      "original_answer": "In 2022, BNY Mellon explicitly stated that the Directors' Code of Conduct was posted on its website and outlined its applicability to all directors. The document was referenced in the context of broader corporate governance disclosures, including Board Meetings and Committee Information. By 2023, the Directors' Code of Conduct was no longer just referenced but was specifically listed among the governance materials 'available on our website,' alongside key governance documents like the Corporate Governance Guidelines and committee charters. This evolution indicates a more structured and centralized approach to governance disclosures, with the Code being more directly tied to the company's overall governance framework in the 2023 filing.",
      "llm_answer": "In the 2022 Form 10‑K the Directors’ Code of Conduct was only referenced indirectly as one of the corporate‑governance documents incorporated by reference; no specific link or statement about posting updates was provided. By the 2023 filing BNY Mellon gave the code its own disclosure, citing a direct URL ( https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/in relations/directors‑code‑of‑conduct.pdf ) and stating that any amendments or waivers would be posted on the website, thereby making the code more readily accessible and embedding it explicitly within the company’s governance reporting.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its core claims about the evolution of BNY Mellon's disclosure approach between 2022 and 2023, with correct years and entities (BNY Mellon, Directors' Code of Conduct, 2022 and 2023 filings). It correctly identifies a shift from indirect reference in 2022 to more explicit disclosure in 2023, including the provision of a direct URL and a statement about posting amendments or waivers—details that align with improved accessibility and integration into governance reporting. The quantitative accuracy is perfect: no numerical errors, and the years are correct. However, the original answer emphasizes that in 2023 the Code was listed alongside other key governance documents (e.g., Corporate Governance Guidelines, committee charters), highlighting a more structured and centralized disclosure framework. The LLM answer omits this contextual nuance about integration within a broader governance structure, instead focusing on the URL and amendment policy. While the LLM correctly infers enhanced accessibility and explicit embedding, it misses the synthesis point about centralization among peer documents, which is a key element of the 'integration within corporate governance reporting' aspect of the question. This omission reduces completeness and qualitative accuracy, though the overall reasoning remains sound and relevant. The answer is semantically close but not fully equivalent due to this missing contextual integration detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 406,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with engineered systems, and what does this indicate about the company's approach to cloud migration and hybrid IT environments?",
      "original_answer": "In 2023, Oracle emphasized the flexibility of running Oracle Database across multiple deployment models, including on-premise, Oracle Cloud, and multicloud environments, with specific offerings like Oracle Exadata Cloud@Customer and Oracle Roving Edge Infrastructure. These options were framed around enabling customers to securely run Oracle Database behind their firewalls while being managed by Oracle. By 2024, Oracle shifted toward deeper integration of Oracle Database within Oracle Engineered Systems, such as the Oracle Exadata Database Machine, which combines database, storage, operating system, and networking hardware into a single optimized platform. This system was highlighted as being available across on-premise, OCI cloud, and hybrid deployments. The evolution from flexible deployment of standalone database services to tightly integrated engineered systems suggests a strategic shift toward offering more holistic, performance-optimized solutions that align with enterprise needs for scalability, security, and simplified maintenance. This indicates a maturation of Oracle's cloud migration strategy, focusing not only on deployment flexibility but also on delivering comprehensive, high-performance infrastructure packages.",
      "llm_answer": "In the 2023 filing Oracle described the Oracle Database as “flexible and open,” able to run **in the Oracle Cloud, on‑premise, or in a hybrid model such as Exadata Cloud@Customer**, and it noted that Engineered Systems (e.g., Exadata) were offered **on‑premise, as an OCI cloud service, or as a hybrid cloud offering**. The 2024 filing expands that narrative, stressing **even broader deployment options—including OCI Dedicated Region, sovereign‑cloud and multicloud scenarios—while still tightly integrating the database with Exadata and other Engineered Systems**. Together, the evolution shows Oracle positioning the database as a seamless bridge for customers‑to‑cloud migration, giving them the choice to keep workloads on‑premise or move them to the cloud without losing the performance and manageability of its engineered‑system platform.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Oracle's 2023 positioning of Oracle Database with flexible deployment options including on-premise, Oracle Cloud, and hybrid models like Exadata Cloud@Customer, and notes the availability of Engineered Systems across deployment models—matching the original answer. In 2024, it accurately reflects the shift toward broader deployment options such as OCI Dedicated Region and sovereign cloud, while emphasizing continued tight integration with Engineered Systems like Exadata. (2) There are no numeric values, dates, or financial figures in the question or answers that require calculation or verification; all temporal references (2023, 2024) are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years and two strategic dimensions (deployment flexibility and integration with engineered systems) to infer a coherent evolution in Oracle’s strategy. It correctly infers that Oracle is enabling seamless cloud migration through hybrid options while maintaining performance via integrated systems. (4) The only minor shortcoming is that the LLM does not explicitly mention the Roving Edge Infrastructure (noted in the ground truth for 2023) or frame the 2024 shift as a move toward 'more holistic, performance-optimized solutions' with emphasis on scalability and simplified maintenance. However, the core strategic implication—that Oracle is offering a seamless bridge for cloud migration with choice and performance—is semantically equivalent. Wording differs slightly but meaning is preserved. Thus, the answer earns a 9 for correctness and qualitative accuracy due to slight omission of detail, but full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1552,
        "completion_tokens": 487,
        "total_tokens": 2039
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the implementation of the formal review and certification process of annual and quarterly SEC reports evolved between 2023 and 2024, particularly in terms of compliance monitoring and governance procedures?",
      "original_answer": "In 2023, the company established a formal review and certification process of SEC filings as part of the Consent agreement, which included governance procedures to escalate potential compliance concerns to appropriate management levels and regular monitoring of compliance. By 2024, the company continued to emphasize the implementation of these governance procedures, noting that compliance with the policy was consistently monitored and that the process was integrated into company-wide sales policies to ensure adherence to inventory and sales limitations. The evolution reflects a shift from initial implementation in 2023 to sustained enforcement and integration into broader operational frameworks in 2024.",
      "llm_answer": "- In the 2023 filing the company first **established** a formal review‑and‑certification process for its annual and quarterly SEC reports as a condition of the SEC Consent Order, created a “business risk and disclosure” group, and put in place a company‑wide sales‑policy that includes a **governance escalation process** for any compliance questions, with compliance “monitored on a regular basis.”【page_63】\n\n- The 2024 filing repeats the same Consent‑order commitments but shows the process has moved from establishment to operational maturity: the formal review‑and‑certification of SEC filings is now **integrated with the business risk and disclosure group**, and the governance process for escalating and resolving compliance issues is described as **regularly monitored** and actively used to ensure ongoing adherence.【page_65】\n\n**Thus, between 2023 and 2024 the formal review and certification mechanism shifted from being newly created to being a continuously monitored, governance‑driven procedure that is embedded in a dedicated risk‑disclosure group and includes routine escalation and oversight.**",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately captures the evolution of the formal review and certification process from 2023 to 2024: in 2023, the process was established as part of the SEC Consent Order, with governance procedures and regular compliance monitoring; by 2024, it had matured into an operationally embedded process integrated with the business risk and disclosure group. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), but the years (2023, 2024) and procedural timelines are correct. (3) The multi-hop reasoning is sound—LLM correctly synthesizes information across two years of filings, identifying the shift from initial implementation to sustained, integrated governance. It references the creation of the 'business risk and disclosure' group and the integration of the certification process with that group, which aligns with the ground truth's emphasis on integration into broader operational frameworks. (4) The answer is contextually precise, directly addressing the question about evolution in compliance monitoring and governance procedures. Minor wording differences (e.g., 'Consent agreement' vs 'Consent Order') do not affect factual accuracy. All key elements—escalation processes, regular monitoring, integration into sales policies and risk groups—are correctly included. Thus, all scores are maximized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1472,
        "completion_tokens": 394,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of their market positioning and product categorization?",
      "original_answer": "In 2022, Philip Morris International (PMI) positioned heat-not-burn products as part of its broader Reduced-Risk Products (RRPs) portfolio, emphasizing their potential to present less harm to smokers who switch from traditional cigarettes. These products, including the Platform 1 device and its consumables, were described as being in various stages of development, scientific assessment, and commercialization. By 2023, PMI had refined its categorization, explicitly including heat-not-burn products within the smoke-free product segment, alongside e-vapor and oral nicotine products. Additionally, PMI began including licensed KT&amp;G heat-not-burn products in its portfolio, indicating a broader market approach and potential expansion of partnerships or offerings. This evolution shows a strategic shift from internal development focus to a more integrated and commercialized product positioning.",
      "llm_answer": "In the 2022 filing PMI grouped heat‑not‑burn devices together with its other reduced‑risk products, referring only to “heat‑not‑burn, vapor and oral nicotine products” as a broad RRP category (see 2022 page 76). By the 2023 filing the company had created a separate “heated‑tobacco unit (HTU)” metric, defining HTU as all heated‑tobacco consumables—including its branded HEETS, Marlboro HeatSticks, TEREA lines and the zero‑tobacco heat‑not‑burn product LEVIA—and began reporting its shipment growth (‑14.7% increase) and market‑share performance as a distinct, fast‑growing segment of its smoke‑free portfolio (2023 pages 40‑41). This shows a shift from a generic RRP grouping in 2022 to a clearly‑positioned, quantitatively tracked heat‑not‑burn category in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in PMI's approach: in 2022, heat-not-burn products were grouped under the broader Reduced-Risk Products (RRPs) category, and by 2023, they were separated into a distinct 'heated-tobacco unit (HTU)' segment. This matches the ground truth's description of a shift from broad RRP categorization to a more defined, commercialized smoke-free product segment. (2) The quantitative details are correct: the LLM notes a '-14.7% increase' in shipment growth. Although this percentage appears misstated (a negative percentage suggesting decline contradicts 'fast-growing segment'), it likely reflects a typo or misinterpretation—the correct figure should indicate a 14.7% decline, which is consistent with PMI's reported HTU shipment decrease in 2023. Despite this minor confusion in presentation, the number itself is accurate as reported in filings. (3) The reasoning is sound: the model correctly synthesizes information across two years of filings, identifying a strategic shift in product categorization and market positioning. It adds specific product names (HEETS, Marlboro HeatSticks, TEREA, LEVIA) and notes the inclusion of zero-tobacco products, enriching the answer beyond the ground truth without introducing errors. (4) The LLM does not explicitly mention the inclusion of licensed KT&G products, which is a minor omission from the ground truth, slightly reducing completeness. However, the core evolution—strategic repositioning and refined categorization—is accurately captured. Wording differs but semantic meaning is equivalent. Overall, the answer is factually strong, contextually relevant, and demonstrates correct multi-hop reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 476,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with other Oracle technologies?",
      "original_answer": "In 2023, Oracle emphasized the deployment flexibility of Oracle Database across cloud-based, on-premise, or other IT environments, highlighting its perpetual licensing model and the company's strategy to provide customer choice. By 2024, Oracle Database's role had evolved to become a foundational component within broader engineered systems, such as Oracle Exadata Database Machine, which integrates the database with storage, operating system software, and hardware components for optimized performance. This shift indicates a move toward deeper integration with Oracle's infrastructure technologies, positioning Oracle Database not just as a standalone product but as a core element of Oracle Engineered Systems, available in on-premise, cloud (OCI), and hybrid cloud deployments.",
      "llm_answer": "In the 2023 filing Oracle stressed that the Oracle Database could be sold and run “on‑premise, cloud‑based and hybrid” with programs that let customers “pivot … licenses … to the Oracle Cloud” and that the database was offered through flexible licensing and Engineered Systems that could be deployed on‑premise, in OCI or as a hybrid solution (see 2023 p. 41‑42, 13). By the 2024 filing the company had moved the narrative to a cloud‑native, autonomous offering—Oracle Autonomous Database—delivered on OCI, on‑premise with Exadata Cloud@Customer, or in OCI Dedicated Region, and tightly integrated with other Oracle Cloud services (Java, Middleware, APEX, AI, etc.) and consumption‑based pricing (see 2024 p. 11‑12). Thus, Oracle’s positioning evolved from emphasizing broad deployment choice and license‑pivot flexibility to promoting an autonomous, integrated, multi‑cloud/edge‑ready database that is a core component of its unified Oracle Cloud ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution in Oracle's strategic positioning of Oracle Database from 2023 to 2024. In 2023, the emphasis on deployment flexibility (on-premise, cloud, hybrid) and license portability is accurately reflected, including references to Engineered Systems and customer choice. By 2024, the shift toward deeper integration with Oracle’s cloud ecosystem—particularly through Oracle Autonomous Database, Exadata Cloud@Customer, and OCI Dedicated Region—is correctly identified. The mention of integration with Oracle Cloud services (Java, Middleware, APEX, AI) and consumption-based pricing adds valuable detail consistent with the direction in the original answer. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification; all references to years (2023, 2024) and product names are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and two strategic narratives—deployment flexibility in 2023 and integrated cloud-native positioning in 2024—demonstrating a clear evolution. The LLM goes slightly beyond the original answer by naming specific technologies (e.g., Autonomous Database, Cloud@Customer), which are contextually accurate and enhance the response without introducing error. (4) The only minor deviation from the original answer is that the LLM emphasizes 'autonomous' and 'cloud-native' features more than the ground truth, which focuses on integration within Engineered Systems. However, this is a reasonable interpretation given Oracle’s public strategy and does not contradict the core evolution described. Overall, the answer is factually correct, comprehensive, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 487,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has BMY's strategic relationship with Krazati evolved from 2023 to 2024, and what specific financial commitments were made in 2024 that reflect this evolution?",
      "original_answer": "In 2023, Krazati was mentioned as part of BMY's oncology portfolio, demonstrating a strategic fit into their offerings. By 2024, BMY had acquired Mirati for $4.8 billion, obtaining the rights to Krazati, which had received FDA and EMA approvals for second-line NSCLC and was in clinical development for first-line NSCLC. Additionally, BMY committed $1.0 billion in contingent value rights tied to the development of PRMT5 Inhibitor, further signaling long-term investment in the acquired assets.",
      "llm_answer": "In 2023 BMS did not own Krazati – the KRAS‑inhibitor was still a Mirati product outside the company’s portfolio. In January 2024 BMS completed the Mirati acquisition, gaining the worldwide commercial rights to Krazati and committing to a multibillion‑dollar purchase. The deal was accounted for at a total consideration of $4.935 billion (cash $4.596 billion, equity‑award cash $205 million, contingent‑value‑right fair value $248 million, less $114 million unvested awards) 【page_93】, and the purchase‑price allocation assigned $640 million of the consideration to the definite‑lived acquired marketed‑product right for Krazati (plus $3.5 billion of indefinite‑lived IPRD assets) 【page_94】.  This large cash and equity outlay marks the shift from no relationship in 2023 to full ownership and commercial exploitation of Krazati in 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the evolution of BMY's (BMS's) relationship with Krazati from non-ownership in 2023 to full acquisition in 2024 via the Mirati deal, which aligns with the ground truth. It accurately notes the strategic shift and commercial rights acquisition. However, there are key quantitative discrepancies: the ground truth states the acquisition was for $4.8 billion, while the LLM reports total consideration as $4.935 billion, which does not match. Additionally, the LLM breaks down the purchase price into components (e.g., $640M assigned to Krazati's marketed product rights, $3.5B to IPRD), which are not mentioned in the original answer and may reflect over-specificity or misinterpretation of allocation versus commitment. The contingent value rights (CVRs) are misrepresented: the original answer specifies a $1.0 billion CVR tied to the PRMT5 inhibitor, but the LLM reports only $248 million in contingent value right fair value without linking it to PRMT5 or signaling future commitment. (2) Number verification: $4.935B total consideration vs. $4.8B in ground truth — significant difference; $248M CVR vs. $1.0B committed — major discrepancy. The $640M and $3.5B allocations, while possibly accurate from the filing, go beyond the scope of the original answer and do not reflect the 'financial commitments made in 2024' as emphasized in the question. (3) Multi-hop reasoning is sound: the model connects BMS’s lack of ownership in 2023, the 2024 acquisition, and the resulting control of Krazati. It correctly infers that acquisition equals strategic evolution. However, it fails to mention FDA/EMA approvals and first-line clinical development, which are key context points in the original answer. Also, it does not identify that the $1B CVR was a forward-looking commitment specifically for PRMT5, which is central to the 'evolution' narrative. (4) Correctness score is 7 because core facts (acquisition, shift in relationship) are correct, but major financial figures and commitments are inaccurate. Quantitative accuracy is 6 due to material deviations in dollar amounts. Qualitative accuracy is 8 because reasoning and entity identification (BMS, Mirati, Krazati, 2023→2024 shift) are strong. Contextual relevance is 10 — the answer directly addresses the question’s focus on strategic evolution and financial commitments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 631,
        "total_tokens": 1969
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the treatment or status of the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV evolved between 2022 and 2023 based on BK's SEC filings?",
      "original_answer": "In 2022, the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV were introduced as securities registered under Section 12(b) of the Act and were listed on the New York Stock Exchange under the trading symbol BK/P, fully and unconditionally guaranteed by The Bank of New York Mellon Corporation. In 2023, the same securities remained registered under Section 12(b) of the Act, retained the same trading symbol BK/P, and continued to be listed on the New York Stock Exchange with the same guarantee structure. Therefore, there was no change in the treatment or status of these securities between the two years.",
      "llm_answer": "Both the 2022 and the 2023 Form 10‑K filings list the 6.244 % Fixed‑to‑Floating Rate Normal Preferred Capital Securities of Mellon Capital IV (ticker BK/P) as a class of securities registered under Section 12(b) of the Securities Act and note that they are “fully and unconditionally guaranteed by The Bank of New York Mellon Corporation.” The 2023 filing repeats the same description and there is no indication of a redemption, conversion or any other change in status—its treatment remains unchanged from 2022.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV are correctly identified with ticker BK/P, registered under Section 12(b), listed on the NYSE, and fully guaranteed by The Bank of New York Mellon Corporation in both 2022 and 2023. (2) There are no numeric or date inaccuracies—percentages, security names, and years match exactly. The answer correctly notes no changes occurred, aligning with the ground truth. (3) The multi-hop reasoning is sound: the model correctly synthesizes information from both the 2022 and 2023 SEC filings, compares the treatment of the securities across years, and concludes there was no change in status, which is the correct inference. (4) The answer is contextually precise, directly addressing the evolution (or lack thereof) in treatment or status. Wording differs slightly from the original answer but conveys the same factual content with no omissions or distortions. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 319,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the capacity and utilization of PMI's short-term credit arrangements changed from 2022 to 2023, and what does this shift suggest about their near-term liquidity posture?",
      "original_answer": "The capacity of PMI's short-term credit arrangements increased from $1.9 billion at the end of 2022 to $2.7 billion at the end of 2023, while the actual utilization decreased slightly from $295 million to $283 million. This indicates that PMI has expanded its available liquidity buffer without increasing its drawdown, suggesting a more conservative approach to short-term financing and working capital management.",
      "llm_answer": "In 2023 PMI’s short‑term credit facilities grew to about **$2.7 billion**, up from roughly **$1.9 billion** at the end of 2022, while actual borrowings on those facilities fell slightly to **$283 million** from **$295 million** a year earlier. The larger, still‑largely untapped pool of short‑term credit indicates that PMI has expanded its liquidity cushion and is maintaining a very conservative, well‑buffered near‑term liquidity position.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: capacity increased from $1.9 billion in 2022 to $2.7 billion in 2023, and utilization decreased from $295 million to $283 million. These values match the original answer exactly, with acceptable formatting variations (e.g., 'about $2.7 billion' vs. '$2.7 billion'). (2) The answer is complete, addressing both the change in capacity and utilization, and drawing the correct implication about PMI's near-term liquidity posture. (3) Entities are accurate—PMI is correctly identified, and the years 2022 and 2023 are properly referenced. (4) The reasoning is sound: the increase in unused credit capacity supports the conclusion of a more conservative liquidity strategy, which aligns with the original answer’s interpretation. The LLM successfully synthesizes multi-hop information (capacity, utilization, trend, implication) and conveys the same semantic meaning with slightly different but equivalent phrasing (e.g., 'larger, still-largely untapped pool' = 'expanded its available liquidity buffer without increasing its drawdown'). All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 336,
        "total_tokens": 1558
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Oracle's positioning of the Autonomous Database evolved between 2023 and 2024, particularly in terms of integration with other cloud services and automation capabilities?",
      "original_answer": "In 2023, Oracle positioned the Autonomous Database as part of its broader Oracle Cloud Infrastructure (OCI) offerings, emphasizing its automated database operations and the ability to run in cloud, on-premise, or hybrid environments. It was described as a service that Oracle runs, manages, upgrades, and supports on behalf of the customer, with a focus on reducing IT process time and resources. By 2024, Oracle expanded its positioning to highlight deeper integration with other Oracle Cloud services, such as Java Cloud and Oracle APEX low-code service, and emphasized open interfaces and native machine learning capabilities. The 2024 filing also introduced a stronger focus on automation powered by machine learning, including diagnostics, fault prediction, error handling, and automatic threat detection. Additionally, 2024 emphasized the Autonomous Database's role in enabling modern cloud-native application development and analytics, including data lake houses and real-time analysis of transactional data.",
      "llm_answer": "In the 2023 filing Oracle presented the Autonomous Database mainly as a cloud‑native, self‑driving service that “automates routine database administration tasks…maintenance, tuning, patching, scaling, security and backup” and is “integrated with other Oracle Cloud services, such as Java Cloud and the Oracle APEX low‑code service, with open interfaces for developers”【page_12】.  \n\nBy the 2024 filing the company expanded that positioning: the Autonomous Database is still self‑driving and ML‑optimized, but it is now offered not only on shared OCI but also on dedicated OCI, on‑premise via Exadata Cloud@Customer and OCI Dedicated Region, and it is tied more tightly to the broader OCI portfolio (AI, analytics, multicloud connectivity).  The 2024 text adds “automatic threat detection and remediation” and stresses “built‑in developer capabilities and automation” that enable rapid data‑mart creation, migration and data‑lake‑house building【page_12】.  \n\nThus, between 2023 and 2024 Oracle moved the Autonomous Database from a primarily cloud‑only, integrated‑service offering to a flexible, multi‑deployment platform that is deeper‑integrated across OCI services and adds stronger automation (auto‑scaling, threat detection, ML‑driven diagnostics) and developer tooling.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Oracle's 2023 positioning emphasized automation of database tasks and integration with Java Cloud and Oracle APEX, which matches the original answer. In 2024, the expanded positioning includes deeper integration with OCI services (AI, analytics, multicloud), stronger automation via ML (threat detection, diagnostics), and developer capabilities for data lake houses and data marts—this is consistent with the ground truth. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a problematic way; the answer correctly avoids inventing figures. (3) The multi-hop reasoning is sound: the model synthesizes information across years and service integrations, correctly identifying the evolution in deployment models (shared OCI, dedicated, on-premise) and enhanced automation. (4) Minor deduction in qualitative accuracy due to slightly overstating the 2023 integration with Java Cloud and APEX—while mentioned in the LLM answer as part of 2023, the original answer specifies this integration was emphasized more in 2024. However, since the LLM cites a source page and the difference may reflect nuanced phrasing in filings, this is a minor issue. Overall, the answer is semantically equivalent, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1579,
        "completion_tokens": 378,
        "total_tokens": 1958
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How did GM's financial relationship with Ultium Cells Holdings LLC evolve between 2023 and 2024, particularly in terms of its capital involvement and strategic positioning?",
      "original_answer": "In 2023, GM's relationship with Ultium Cells Holdings LLC was characterized by contingent capital commitments, with a committed contribution of $0.8 billion, and the entity was classified as a variable interest entity (VIE) where GM lacked voting control. By 2024, GM's involvement evolved into a more direct investment of $0.7 billion, indicating a shift from a potential future obligation to a realized investment stake. This transformation suggests a strategic realignment, providing GM with potentially greater influence over Ultium Cells' operations while stabilizing its financial exposure.",
      "llm_answer": "In 2023 GM’s non‑consolidated VIE disclosures showed that it had pledged roughly $0.8 billion of committed capital to Ultium Cells Holdings LLC and recorded a cash investment of about $0.7 billion. In the 2024 filing the same $0.7 billion cash outlay appears again, and the committed‑capital figure of $0.8 billion remains part of its maximum loss exposure, but GM still lacks voting or other control rights. Thus, between 2023 and 2024 GM’s monetary stake stayed roughly flat while its relationship remained that of a strategic, non‑controlling partner supplying capital to secure a battery‑supply source for its EV program.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 GM had a contingent commitment of $0.8 billion with no indication of a $0.7 billion cash investment being recorded; the $0.7 billion was not a realized investment until 2024. However, the LLM claims that in 2023 GM 'recorded a cash investment of about $0.7 billion', which contradicts the ground truth where the shift from commitment to actual investment is the key evolution in 2024. Additionally, the LLM states that the $0.7 billion cash outlay 'appears again' in 2024, implying continuity rather than a change, which misrepresents the evolution. (2) Quantitatively, the dollar amounts ($0.8B committed, $0.7B invested) are numerically accurate but misassigned in timing and context. The LLM incorrectly treats the $0.7B as already spent in 2023, when the ground truth positions it as a 2024 realization. There are no calculation errors, but the temporal placement of figures is wrong. (3) The multi-hop reasoning is flawed: the core of the question is the evolution from contingent liability to direct investment, signaling increased strategic control. The LLM fails to identify this shift, instead asserting that the 'monetary stake stayed roughly flat' and that control remained unchanged—directly contradicting the ground truth's assertion of a strategic realignment and greater influence. The model does not recognize the significance of moving from a future obligation to a realized investment. (4) Contextual relevance is moderate—the answer addresses GM's relationship with Ultium Cells and discusses capital contributions and control, which are relevant. However, due to the incorrect characterization of the financial evolution, the qualitative and quantitative accuracy scores are low. The conclusion that GM remained a 'non-controlling partner' with 'flat' stake contradicts the ground truth's emphasis on strategic deepening and increased influence, warranting a correctness score of 3 for major factual and interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 552,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has the financial impact of the Litigation Management Deed evolved between 2022 and 2024, particularly in terms of the amount of as-converted value released and the number of series A preferred shares issued during the anniversary releases?",
      "original_answer": "In 2022, as part of the sixth anniversary release assessment required by the Litigation Management Deed, Visa released $3.5 billion of as-converted value and issued 176,655 shares of series A preferred stock. In 2024, during the eighth anniversary release, the company released $2.7 billion of as-converted value and issued 99,264 shares of series A preferred stock. This indicates a decrease in both the value released and the number of shares issued, suggesting a reduction in the financial burden associated with the VE territory covered litigation over time.",
      "llm_answer": "The Litigation Management Deed’s sixth‑anniversary release in 2022 freed about **$3.5 billion** of as‑converted preferred‑stock value and resulted in the issuance of **176,655 Series A preferred shares**【page_74】. By the eighth‑anniversary release in 2024 the amount freed had fallen to roughly **$2.7 billion**, with **99,264 Series A preferred shares** issued【page_75】. Thus, both the value released and the number of Series A shares issued have declined between the two anniversary releases.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the numbers for both years are accurate: $3.5 billion and 176,655 shares in 2022, and $2.7 billion and 99,264 shares in 2024. These match the original answer exactly, with acceptable formatting variations (e.g., 'about' and 'roughly' are reasonable given the context). (2) The answer addresses all parts of the multi-hop question: it compares the financial impact across 2022 and 2024, specifically covering both the as-converted value released and the number of Series A preferred shares issued. (3) Entity accuracy is correct—Visa is implied as the company (consistent with context), the years 2022 and 2024 are correctly tied to the sixth and eighth anniversaries of the Litigation Management Deed, and the financial terms are used appropriately. (4) The reasoning is sound: the LLM correctly infers a decline in both value and shares issued, which aligns with the original conclusion about reduced financial burden. The synthesis across two time points and metrics is accurate and clearly communicated. All criteria for correctness, completeness, and clarity are met.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 329,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How did the financial and strategic relationship between 3M and the Aearo Entities evolve between 2023 and 2024, particularly in terms of litigation impact and business segment adjustments?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities following the dismissal of their bankruptcy filings, lifting the stay on litigation related to Combat Arms Earplugs and entering into the CAE Settlement to resolve existing and future claims. This reconsolidation had an immaterial income statement impact. By 2024, the Aearo Entities were referenced in the context of divestiture and acquisition impacts in the Transportation and Electronics segment, where their deconsolidation in 2022 and reconsolidation in 2023 were each reflected separately as divestiture and acquisition effects. This indicates a shift from litigation-focused involvement in 2023 to a more strategic financial treatment in 2024.",
      "llm_answer": "In 2023 3M re‑consolidated the former de‑consolidated Aearo Entities (the ear‑plug and respirator‑mask businesses) and, as a result, recorded a $4.2 billion pre‑tax charge for the Combat‑Arms‑Earplugs (CAE) settlement and increased its Aearo‑related litigation accrual to about $5 billion; those litigation costs were still reflected in “corporate special items” and, for the Safety & Industrial segment, the respirator‑mask/asbestos expenses remained a corporate‑level charge. By 2024 the parties amended the CAE settlement to require cash‑only payment of the $1 billion stock component, corporate special‑item costs fell year‑over‑year, and the Aearo‑related litigation burden moved out of corporate items, helping lift operating‑margin performance in Safety & Industrial and allowing the Transportation & Electronics segment to show the acquisition impact of the reconsolidated Aearo sales (offset by modest organic declines).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that the reconsolidation of the Aearo Entities in 2023 had an immaterial income statement impact, but the LLM claims a $4.2 billion pre-tax charge and increased litigation accrual to $5 billion, which contradicts the immateriality assertion. These figures are not supported by the original answer and represent a major deviation. Additionally, there is no mention in the ground truth of a $1 billion stock component being converted to cash in 2024 or any amendment to the CAE settlement—this is fabricated information. (2) Quantitative accuracy is very low: the $4.2B charge, $5B accrual, and $1B stock-to-cash amendment are all unsupported by the original answer. The original answer does not provide any specific dollar amounts related to litigation or charges, so introducing such precise figures constitutes a serious error. (3) Qualitatively, the LLM correctly identifies the reconsolidation of Aearo in 2023 and its mention in 2024 within the Transportation and Electronics segment, showing some correct multi-hop reasoning across years and segments. However, it misrepresents the nature of the relationship by focusing on large litigation costs and settlement amendments that are not in the ground truth, distorting the strategic evolution. (4) Contextual relevance is moderate—the response addresses litigation impact and business segment adjustments as asked, and correctly ties Aearo to both 2023 (litigation) and 2024 (segment reporting), but the factual foundation is flawed. The shift from litigation to strategic financial treatment is partially captured, but misrepresented through invented financials. Overall, the answer fails on correctness due to unsupported quantitative claims despite some structural relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 496,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the financial treatment or structure of Class C Common Stock evolved between 2022 and 2024, particularly in terms of its relationship to other stock classes and its earnings per share performance?",
      "original_answer": "In 2022, Class C Common Stock was described in the context of its voting rights and potential influence on corporate actions, particularly in mergers or strategic decisions, with an emphasis on how its holders—typically financial institution clients—might have divergent interests from Class A Common Stockholders. By 2024, Class C Common Stock had a significantly higher earnings per share ($33.17 basic EPS and $33.13 diluted EPS) compared to Class A ($8.29 basic EPS and $8.28 diluted EPS), indicating a shift in its financial performance relative to other stock classes, even though its governance role appeared unchanged.",
      "llm_answer": "Between 2022 and 2024 Visa’s Class C common stock shifted from a non‑traded, limited‑voting class that could only be converted into Class A stock (and whose holders voted only on a few special matters) to a freely‑transferable class created in the 2024 Class B‑1 exchange‑offer (with no transfer restrictions and voting rights that are exercised only together with Class A on defined actions).  In earnings‑per‑share terms, Class C’s basic EPS rose from roughly $28.0 in fiscal 2022 (10 million weighted‑average shares) to about $39.0 in fiscal 2024 (16 million weighted‑average shares), reflecting a higher earnings allocation to the class.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that Class C Common Stock's financial treatment evolved primarily in terms of earnings per share performance, not structural or transferability changes. However, the LLM claims a structural shift occurred in 2024 due to a 'Class B-1 exchange-offer' and describes Class C as transitioning from non-traded to freely transferable—details not present in the ground truth and factually incorrect based on the provided knowledge. (2) Quantitatively, the LLM reports incorrect EPS figures: it claims Class C EPS was ~$28.0 in 2022 and ~$39.0 in 2024, whereas the ground truth reports no EPS for Class C in 2022 and specifies $33.17 (basic) in 2024. Additionally, the LLM invents weighted-average share counts (10M in 2022, 16M in 2024) with no support in the original answer. These numbers are not only incorrect but used to fabricate a trend that isn't substantiated. (3) The multi-hop reasoning is flawed: the LLM conflates governance evolution with financial performance, incorrectly asserting structural changes in stock transferability and voting rights that are not mentioned in the ground truth. The original answer emphasizes consistent governance role but improved financial performance in 2024; the LLM misses this nuance entirely and invents a narrative around corporate restructuring. (4) Contextual relevance is moderate—the response addresses stock class evolution and EPS, which are relevant—but the information is largely fabricated. Due to major errors in numbers, entities, and reasoning, the correctness score is low despite addressing the general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 455,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Qualcomm's involvement in the development and commercialization of ADAS/AD technology evolved from fiscal 2022 to fiscal 2024, based on the specific changes in their strategic activities and revenue categorization?",
      "original_answer": "In fiscal 2022, Qualcomm was actively investing in and developing ADAS/AD technologies as part of its broader innovation and strategic investment initiatives, particularly through its QSI segment and Qualcomm Ventures, with an emphasis on expanding opportunities for its technologies beyond mobile handsets. By fiscal 2024, Qualcomm's engagement had evolved from development to commercialization, as evidenced by the explicit inclusion of ADAS/AD under revenue streams categorized under 'automotive' products. This indicates that ADAS/AD transitioned from a technology under development and investment in 2022 to a revenue-generating product line by 2024.",
      "llm_answer": "In fiscal 2022 Qualcomm’s discussion of ADAS/AD was limited to R&D and strategic‑investment activities – the QSI segment noted that its engineering resources were being used to “continue…development of…ADAS/AD” and the automotive market was only referenced in broad licensing terms, with automotive QCT revenue of $1.5 billion. By fiscal 2024 the company is reporting ADAS/AD as a defined component of its automotive QCT revenue stream (now $2.9 billion) and highlights the Veoneer Arriver acquisition as a means to “design and fund” ADAS/AD capabilities, showing that the technology has moved from a research‑focused effort to a commercial product line that is reflected in revenue categorization.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of Qualcomm's ADAS/AD involvement from R&D and strategic investment in fiscal 2022 to commercialization in fiscal 2024, including the shift in revenue categorization. (2) Quantitatively, it accurately cites automotive QCT revenue of $1.5 billion in 2022 and $2.9 billion in 2024. While the ground truth does not specify these exact figures, they are consistent with known public data and do not contradict the knowledge graph; the increase supports the narrative of commercialization. The mention of the Veoneer Arriver acquisition is factually correct and relevant, though not explicitly in the original answer—it adds contextual detail without introducing error. (3) The reasoning is sound: the LLM correctly infers from strategic development in 2022 to revenue recognition in 2024, demonstrating proper multi-hop synthesis across time, segments (QSI and QCT), and business activities. (4) The answer is semantically equivalent to the original, with slightly more granular detail (e.g., specific revenue figures, acquisition name), enhancing completeness without sacrificing accuracy. The only reason for not scoring a 10 is that the original answer does not include the Veoneer Arriver acquisition or exact revenue splits, so while plausible, those details go beyond the provided ground truth. However, they do not detract from correctness. All entities (Qualcomm, QSI, QCT, ADAS/AD, fiscal years) are correctly identified and contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 425,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Visa's U.S. Retrospective Responsibility Plan evolved between 2022 and 2024, particularly in terms of its mechanisms for addressing liability in covered litigation, and what does this evolution suggest about the company's approach to managing litigation risk?",
      "original_answer": "In 2022, Visa's U.S. Retrospective Responsibility Plan was described as a mechanism to address monetary liabilities from settlements or final judgments in U.S. covered litigation, utilizing a U.S. litigation escrow account, though the accrual for liabilities could differ from the escrow balance. By 2024, the plan had become significantly more structured and detailed, introducing a suite of interrelated mechanisms including a U.S. litigation escrow agreement, a conversion feature for Class B common stock, makewhole agreements related to the Class B-1 exchange offer, indemnification obligations from Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. These additions indicate a more comprehensive and layered strategy to manage litigation risk, suggesting Visa has moved toward a more proactive and diversified approach to mitigate potential financial exposure from ongoing or future litigation outcomes.",
      "llm_answer": "In the 2022 filing Visa’s U.S. Retrospective Responsibility Plan was built around a U.S. litigation‑escrow account (‑$850 million deposited in 2022, $1.4 billion balance) together with a conversion feature that dilutes class B‑1/B‑2 shares, make‑whole agreements for exchange‑offer participants, indemnification obligations of Visa U.S.A. members, and a set of sharing arrangements (interchange‑judgment‑sharing, loss‑sharing and omnibus agreements) that spread any settlement or judgment among Visa and its members 【page_46】【page_48】.  \n\nBy 2024 the plan had been expanded and deepened: the escrow balance grew to $3.1 billion with larger deposits ($1.5 billion in 2024) and payments to opt‑out merchants; the conversion feature and make‑whole agreements remain, but the loss‑sharing and omnibus agreements were formally amended (2015 amendment) to capture post‑amendment opt‑out actions and to allocate settlement proceeds on a 66.7 % Visa/33.3 % Mastercard split 【page_73】【page_74】.  \n\nThis evolution shows Visa moving from a basic escrow‑and‑share‑conversion structure to a more comprehensive, funded and contract‑rich framework that broadens the scope of covered claims and more explicitly allocates risk among members, indicating a increasingly proactive and financially disciplined approach to managing litigation exposure.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of Visa's U.S. Retrospective Responsibility Plan from 2022 to 2024 and correctly identifies key mechanisms such as the escrow account, conversion feature, make-whole agreements, indemnification, and various sharing agreements. It also accurately conveys the qualitative shift toward a more structured and proactive risk management approach, aligning well with the ground truth.\n\nHowever, there are significant quantitative inaccuracies that reduce confidence in the factual precision. The LLM claims a $850 million deposit in 2022 and a $1.4 billion balance, but the ground truth does not specify these numbers—this is an overprecision not supported by the original answer. Similarly, the $3.1 billion escrow balance in 2024 and $1.5 billion deposit are not mentioned in the ground truth, which only states the plan became more structured without citing specific dollar amounts. These fabricated figures constitute a major issue in quantitative accuracy.\n\nAdditionally, the LLM references a '2015 amendment' to the loss-sharing and omnibus agreements, which is factually inconsistent with the 2022–2024 evolution focus of the question and not present in the ground truth. It also introduces a '66.7% Visa / 33.3% Mastercard' split, which is entirely absent from the original answer and represents a significant hallucination. Mastercard is not mentioned in the ground truth.\n\nDespite these errors, the qualitative reasoning—synthesizing the expansion of contractual mechanisms and the strategic shift toward comprehensive risk allocation—is sound and contextually relevant. The answer addresses both parts of the question: the evolution of mechanisms and the implication for litigation risk management. While the core conceptual evolution is correctly interpreted, the inclusion of unsupported numerical and entity-specific details reduces overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1606,
        "completion_tokens": 513,
        "total_tokens": 2119
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did Merck's financial stake in Lynparza evolve between 2023 and 2024, and what indicators suggest changes in the product's performance or strategic importance during this period?",
      "original_answer": "In 2023, Merck reported a $1.5 billion net intangible asset related to Lynparza as part of its collaboration with AstraZeneca. By 2024, although the financial stake amount was not explicitly stated, there was a 9% growth in alliance revenue linked to Lynparza, driven by increased demand in most international markets. Additionally, in January 2025, Lynparza received approval in China for an adjuvant treatment in early breast cancer, indicating expanded market potential. This suggests that while the initial asset value was substantial in 2023, 2024 marked a period of performance-driven growth and regulatory expansion, enhancing its strategic importance.",
      "llm_answer": "- In the 2023 filing Merck reported a net intangible‑asset value for the Lynparza collaboration of **about $1.5 billion** (see “Licenses and other” on page 101).  \n- The 2024 filing shows that Merck’s **share of Lynparza alliance revenue rose from $1.199 billion in 2023 to $1.311 billion in 2024**, a 9 % increase (11 % on a foreign‑exchange‑adjusted basis) (see the “Alliance Revenue – Lynparza” line on page 53 and the commentary on page 55).\n\n**Indicators of changing performance/strategic importance**\n\n- The rise in alliance revenue signals stronger sales and higher demand for Lynparza in 2024, especially “in most international markets” (page 55).  \n- The 2024 filing also highlights a new regulatory milestone – China’s NMPA approval of Lynparza as an adjuvant breast‑cancer therapy in January 2025 – underscoring the product’s growing strategic relevance (page 55).  \n\nTogether, the stable $1.5 bn intangible‑asset stake and the upward‑trending alliance revenue, coupled with expanding market approvals, indicate that Merck’s financial and strategic position in Lynparza improved between 2023 and 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all key aspects. (1) Quantitatively, the $1.5 billion intangible asset in 2023 is accurately reported. The alliance revenue increase from $1.199 billion in 2023 to $1.311 billion in 2024 is correctly cited, and the 9% growth rate (11% FX-adjusted) aligns with the ground truth's mention of 9% growth. The calculation (1.311 / 1.199 ≈ 1.093, or ~9.3%) supports the reported 9% increase. (2) The answer is complete: it addresses both the evolution of Merck's financial stake (stable $1.5B asset, rising revenue) and indicators of performance/strategic importance (revenue growth, international demand, China approval). (3) Entity accuracy is perfect: Merck, Lynparza, AstraZeneca (implied via alliance), correct years (2023, 2024, and January 2025 approval), and proper financial terms (intangible asset, alliance revenue) are all correctly used. (4) Multi-hop reasoning is sound: the model synthesizes data from two years of filings, connects revenue growth to performance, and links the future China approval to strategic importance, even though the approval occurred in 2025—this is correctly framed as a forward-looking indicator disclosed in the 2024 filing. (5) Semantic equivalence is strong: while the LLM provides more granular revenue figures than the original answer, this enhances rather than distorts accuracy. The conclusion that Merck’s financial and strategic position improved is fully supported. No errors or omissions; answer exceeds expectations in precision and sourcing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 425,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did Skoal's market position and competitive performance within Altria's oral tobacco products segment evolve between 2022 and 2024, particularly in relation to its key competitor brands?",
      "original_answer": "In 2022, Skoal was one of the premium oral tobacco brands under Altria, alongside Copenhagen and on!, with a retail share of 9.3%. By 2024, Skoal's retail share had declined to 7.6%, indicating a weakening market position. This decline occurred alongside a broader contraction in Altria's oral tobacco segment, which saw total retail share fall from 42.5% in 2023 to 37.5% in 2024. Notably, Copenhagen, Altria's leading brand, also experienced a drop from 23.5% to 19.1% over the same period, while on! oral nicotine pouches gained traction, rising from 6.8% to 8.3%. These shifts suggest that Skoal not only lost market share overall but also underperformed relative to both its primary brand (Copenhagen) and the newer product category (on!).",
      "llm_answer": "Skoal’s position in Altria’s oral‑tobacco segment has weakened.  In 2024 the brand shipped 147 million cans/packs, down from 163.1 million the year before (‑10 %) and its retail‑share fell to 7.6 % versus 9.3 % in 2023 (page 48).  Compared with the 2022 filing, where Skoal’s share was roughly the same as 2023 (around 9‑10 %), the brand has lost about 1½‑2 percentage points of market share over the two‑year period.  During the same span Copenhagen remained the dominant premium brand (share fell modestly from 23.5 % in 2023 to 19.1 % in 2024, page 48) and the on! nicotine‑pouch brand grew, increasing its share from 6.8 % in 2023 to 8.3 % in 2024 (page 48), further eroding Skoal’s relative position.  Thus, from 2022 through 2024 Skoal’s shipment volume and retail‑share have declined while its key competitors—especially Copenhagen and the fast‑growing on! line—have either held steady or expanded their market presence.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the LLM correctly reports Skoal's retail share declining from 9.3% in 2023 to 7.6% in 2024, which matches the original answer. However, the original answer states the 9.3% share was in 2022, while the LLM references it as 2023 and estimates 2022 as 'roughly the same' or 'around 9-10%'. This is a minor deviation—while logically sound and likely correct given continuity, it slightly weakens precision for the 2022 data point. The shipment volumes (163.1M to 147M, ~10% drop) are accurate and add detail not in the original answer, enhancing completeness. Copenhagen’s decline from 23.5% to 19.1% and on!’s rise from 6.8% to 8.3% are correctly cited with page references. (2) Calculations: the ~1.7–2 percentage point decline from 2022 to 2024 is a reasonable inference if 2022 ≈ 9.3%, so the math is sound. (3) Multi-hop reasoning is strong: the LLM synthesizes Skoal’s performance relative to Copenhagen and on!, correctly concluding that Skoal underperformed both its sibling brand and the growing on! segment. (4) The answer addresses all aspects of the question—market position evolution, competitive dynamics, and relative performance—making it contextually excellent. The only reason for not scoring 10 is the slight ambiguity in attributing the 9.3% share to 2023 rather than clearly stating it was already at that level in 2022 per the ground truth, though the overall trend remains correctly interpreted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 413,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has the revenue contribution from Dynamics 365 within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Dynamics 365 contributed to the $91.2 billion Microsoft Cloud revenue, with Dynamics products and cloud services revenue growing 25%, driven by a 39% increase in Dynamics 365. By fiscal year 2023, the Microsoft Cloud revenue had increased to $111.6 billion, which includes Dynamics 365 as a component. Although the exact growth percentage for Dynamics 365 in 2023 is not explicitly stated, its continued inclusion in the Microsoft Cloud breakdown indicates sustained growth and integration within the broader cloud portfolio.",
      "llm_answer": "Dynamics 365 (reported as “Dynamics products and cloud services”) generated **$4.7 billion in fiscal 2022 and $5.4 billion in fiscal 2023**【page_93】—an increase of roughly **$0.75 billion, or about 16 %** year‑over‑year.  Within Microsoft Cloud overall, its share fell slightly from **≈5.1 % of the $91.4 billion cloud total in 2022** to **≈4.9 % of the $111.6 billion total in 2023**【page_93】, showing modest absolute growth but a marginally smaller proportion of the expanding cloud business.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth does not provide specific revenue figures for Dynamics 365 in either fiscal year 2022 or 2023—only that Dynamics 365 grew 39% in 2022 and is part of the broader Microsoft Cloud revenue ($91.2B in 2022, $111.6B in 2023). The LLM incorrectly asserts exact figures of $4.7B in 2022 and $5.4B in 2023, which are not present in the original answer or supported by the cited knowledge graph. The 16% growth rate and share percentages (5.1%, 4.9%) are derived from these fabricated numbers and thus also incorrect. (2) Calculations like the $0.75B increase and percentage shares rely on unsupported base figures, making them invalid. The Microsoft Cloud totals are mostly correct ($91.4B vs. $91.2B is a minor discrepancy), but the use of $111.6B aligns with ground truth. (3) The reasoning fails on multi-hop synthesis: while the model attempts to contextualize Dynamics 365 within Microsoft Cloud, it invents granular data rather than acknowledging the lack of explicit 2023 growth metrics as stated in the original. It falsely implies precision where the source expresses uncertainty. (4) Despite incorrect numbers, the answer is contextually relevant—addressing revenue evolution and proportion within Microsoft Cloud—and correctly identifies Dynamics 365 as a growing component. However, the invention of specific dollar amounts and derived metrics severely undermines factual correctness, warranting a low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 414,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Merck's approach to managing foreign exchange exposure through its Balance Sheet Risk Management Program evolved from 2023 to 2024, particularly in terms of the instruments used and the scope of hedging activities?",
      "original_answer": "In 2023, Merck primarily used forward exchange contracts to offset the effects of exchange on exposures when economically beneficial, focusing on the euro, Swiss franc, Japanese yen, and Chinese renminbi. These contracts were not designated as hedges and were marked to market through Other (income) expense, net. By 2024, the company expanded its approach under a more structured balance sheet risk management program, continuing to use forward contracts but also introducing a broader framework that included purchased local currency put options and collar options. Additionally, the 2024 disclosure highlights a more strategic layering of hedges over time, increasing the portion of forecasted sales hedged as the expected dates approach, based on cost-benefit assessments.",
      "llm_answer": "In 2023 Merck’s balance‑sheet risk program relied almost exclusively on short‑term **forward‑exchange contracts** (average maturity < 6 months) to offset spot‑rate changes on monetary assets and liabilities, and it used a modest amount of **euro‑denominated senior unsecured notes** as “economic” hedges of net foreign‑operation investments. By 2024 the company had expanded the program – it still uses forwards, but the notional of forward contracts designated as hedges grew (e.g., foreign‑exchange contracts recorded as assets rose from $106 million to $323 million) and the net‑investment hedge became material (a $30 million pretax loss on forward contracts and a $192 million loss on euro‑note hedges), reflecting a broader scope that now includes larger‑scale net‑investment hedges and a more active use of euro‑denominated debt as an economic hedge.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces information not present in the ground truth, particularly regarding the use of euro-denominated senior unsecured notes and specific dollar amounts ($106M, $323M, $30M, $192M), which are not mentioned in the original answer. These figures appear fabricated or misattributed, severely undermining quantitative accuracy. The original answer does not mention hedge designation changes, net-investment hedges, or pretax losses, nor does it reference euro-denominated debt as a hedge instrument—these are erroneous additions. While the LLM correctly identifies forward contracts as a key instrument in both years, it fails to mention the introduction of purchased local currency put options and collar options in 2024, a critical evolution in the hedging program. The mention of a 'more strategic layering of hedges over time' and cost-benefit assessments based on forecasted sales is entirely absent from the LLM response. The reasoning is partially sound in noting an expansion of scope, but the multi-hop synthesis is flawed due to reliance on incorrect data and entities. The context of balance sheet risk management is addressed, and the general direction of program expansion is acknowledged, supporting moderate contextual relevance. However, the absence of key instruments and insertion of unsupported quantitative claims result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 393,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has PayPal's involvement with merchant receivables evolved between 2022 and 2024, particularly in terms of its credit loss provisions and direct investment in merchant financing products?",
      "original_answer": "In 2022, PayPal disclosed its methodology for estimating credit losses on merchant receivables, applying macroeconomic forecasts and historical loss data to calculate allowances, with a principal and interest coverage ratio of approximately 9% as of December 31, 2021, down from 23% in 2020. By 2024, PayPal had significantly expanded its direct involvement by purchasing approximately $1.8 billion in merchant receivables during the year, with an outstanding balance of $1.5 billion as of December 31, 2024, up from $1.2 billion in 2023. This represents a shift from primarily disclosing credit risk exposure to actively investing in and managing merchant receivables through products like PPWC and PPBL, indicating a more strategic and operational role in merchant finance.",
      "llm_answer": "By 2022 PayPal’s merchant‑financing portfolio carried a relatively large credit‑loss allowance – the allowance for merchant loans, advances and fees was roughly $160‑$185 million (provisions of $162 million on loans and $23 million on interest/fees) and the year’s gross charge‑offs were $228 million. By the end of 2024 that allowance had fallen to $113 million (provisions of $79 million on loans and $2 million on interest/fees) and charge‑offs dropped to just $10 million, reflecting markedly better credit quality. At the same time, PayPal’s direct investment in merchant financing grew: it purchased about $1.7 billion of merchant receivables in 2023 and $1.8 billion in 2024, up from a smaller base in 2022, indicating an expanded but lower‑risk merchant‑receivable business.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its correctness. While it correctly notes PayPal's increased direct investment in merchant receivables—citing $1.8 billion purchased in 2024, which aligns with the ground truth—the $1.7 billion figure for 2023 is not supported by the original answer, which only states the outstanding balances ($1.2B in 2023 and $1.5B in 2024), not annual purchase volumes. More critically, the LLM introduces specific allowance and charge-off figures (e.g., $160–185M allowance in 2022, $113M in 2024, $228M charge-offs) that are not present in the ground truth and appear fabricated. The original answer does not provide dollar amounts for credit loss provisions or charge-offs, only a coverage ratio of 9% as of December 31, 2021 (down from 23% in 2020). The LLM incorrectly attributes these detailed financials to 2022 and 2024, introducing false precision. Additionally, the claim that charge-offs dropped to $10 million by 2024 is unsupported. On qualitative aspects, the LLM correctly identifies the strategic shift toward direct investment in merchant receivables and mentions products like PPWC and PPBL (implied in the original’s reference to such products), showing sound reasoning about PayPal’s evolving role. It captures the essence of increased direct involvement and improved credit quality, though the latter is inferred from incorrect data. Contextually, the answer is highly relevant, addressing both credit loss provisions and direct investment as asked. However, the invented numerical details severely compromise factual accuracy, resulting in a partial score. The model synthesizes a plausible narrative but fails on key factual grounding, particularly in financial figures and their timing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 479,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the financial significance of smokeable products to MO evolved from 2022 to 2024, considering both goodwill allocation and operating income performance?",
      "original_answer": "In 2022, the goodwill allocated to smokeable products was $99 million, indicating a relatively small portion of MO's overall asset valuation, with total goodwill at $5,177 million. By 2024, although no updated goodwill figure is disclosed specifically for smokeable products, their operating income contribution rose to $10,821 million in 2024 from $10,670 million in 2023, showing sustained profitability. This suggests that while the strategic asset valuation (via goodwill) remained stable or undisclosed, the operational significance of smokeable products remained high and slightly increased in terms of earnings. The lack of updated goodwill allocation in 2024 filings for this segment implies a potential shift in reporting focus toward performance metrics rather than asset valuations.",
      "llm_answer": "- **Goodwill allocation:** Altria’s 2022 10‑K shows that the smokeable‑products reporting unit carried only **$99 million of goodwill** (the same amount reported in 2021 and 2020) 【page_64】. The 2024 10‑K reports the same **$99 million of goodwill** for smokeable products, indicating that the intangible‑asset weight of this business has remained flat over the period.  \n\n- **Operating‑income performance:** In the 2022 filing the smokeable segment generated roughly **$10.7 billion of operating income before corporate expenses (OCI)** (the figure shown for 2023 in the 2024 filing and unchanged from the prior year) 【page_31】. By 2024 the segment’s OCI had risen modestly to **$10.8 billion** 【page_31】.  \n\n**Overall evolution:** From 2022 to 2024 the smokeable business’s goodwill allocation stayed unchanged at $99 million, while its contribution to earnings improved slightly, with OCI increasing from about $10.7 billion to $10.8 billion. This suggests that the segment’s financial significance grew marginally on an earnings basis while its intangible‑asset footprint remained constant.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually correct in all key aspects. It accurately reports the $99 million goodwill allocation for smokeable products in both 2022 and 2024, which matches the ground truth that goodwill was $99M in 2022 and was not updated in 2024 filings—though the LLM goes further by asserting it remained $99M in 2024, which is consistent with the absence of change and supported by the cited 2024 10-K. This is a reasonable inference and does not contradict the ground truth. Operating income is reported as $10.7 billion in 2022 (approximating $10,670 million) and $10.8 billion in 2024 (matching $10,821 million when rounded), which is quantitatively accurate. (2) Number verification: $99M goodwill (exact match), operating income correctly rounded—$10,670M ≈ $10.7B and $10,821M ≈ $10.8B. No calculation errors. (3) Multi-hop reasoning is sound: the LLM synthesizes goodwill data from 2022 and 2024 filings and combines it with operating income trends across years to assess financial significance. It correctly infers stability in asset valuation and growth in earnings contribution. (4) The only minor deviation from the original answer is that the LLM asserts the 2024 goodwill is still $99M, while the ground truth notes it is 'undisclosed'—but since the LLM cites the 2024 10-K as confirmation, and no change is indicated, this is a defensible and likely accurate interpretation. The original answer’s caution about 'no updated goodwill figure disclosed' is more conservative, but the LLM’s statement does not constitute an error given the context. Overall, the answer is highly accurate, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1475,
        "completion_tokens": 454,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the revenue contribution from the commercial portion of LinkedIn within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Microsoft Cloud revenue, which includes the commercial portion of LinkedIn, was reported at $91.2 billion. By fiscal year 2023, this figure had increased to $111.6 billion, indicating a significant growth in the commercial cloud segment that includes LinkedIn. This increase suggests a stronger revenue contribution from LinkedIn's commercial services within the broader Microsoft Cloud portfolio.",
      "llm_answer": "Microsoft Cloud revenue – which includes Azure, Office 365 Commercial, **the commercial portion of LinkedIn**, Dynamics 365 and other cloud properties – rose from **$91.4 billion in fiscal 2022 to $111.6 billion in fiscal 2023**【page_93】. That represents an increase of roughly **$20.2 billion (about 22 %)**, indicating that the commercial LinkedIn contribution grew as part of the overall Microsoft Cloud expansion between those two years.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the Microsoft Cloud revenue for fiscal 2023 ($111.6 billion) and conveys growth in the commercial portion of LinkedIn as part of this segment, which aligns with the ground truth. However, it reports $91.4 billion for fiscal 2022 instead of the correct $91.2 billion, introducing a minor but measurable inaccuracy in the base figure. This affects the calculated increase: LLM states a $20.2 billion rise (~22%), while the accurate delta is $20.4 billion, or approximately 22.26% (from $91.2B to $111.6B). Though the percentage is reasonably approximated, the incorrect starting value reduces quantitative precision. (2) The entities are correct—Microsoft Cloud, commercial portion of LinkedIn, fiscal years 2022 and 2023—and the metric (revenue contribution via inclusion in Microsoft Cloud) is appropriately interpreted. (3) The reasoning is sound: the model correctly infers that LinkedIn’s commercial revenue contribution grew as part of the overall Microsoft Cloud growth, even though LinkedIn is not broken out separately. This reflects valid multi-hop logic based on the structure of Microsoft’s reporting segments. (4) The answer is contextually complete and relevant, clearly addressing how LinkedIn's commercial revenue contribution evolved through its inclusion in Microsoft Cloud. The minor numerical discrepancy prevents a top score, but the overall factual and logical integrity remains strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 403,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did the commercialization and market expansion of Lynparza evolve between 2023 and 2024, particularly in terms of geographic approvals and revenue growth?",
      "original_answer": "In 2023, Lynparza received FDA and Japan's MHLW approvals for treating BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone and prednisone or prednisolone, based on the PROpel trial. By 2024, alliance revenue related to Lynparza grew by 9%, largely due to higher demand in most international markets. Additionally, in January 2025, Lynparza received China's NMPA approval for adjuvant treatment of germline BRCA-mutated, HER2-negative high-risk early breast cancer, based on the OlympiA trial, indicating a significant geographic and therapeutic area expansion.",
      "llm_answer": "In 2023 Merck first added Lynparza to its commercial portfolio outside the United States when the FDA approved it (May 2023) for BRCA‑mutated metastatic castration‑resistant prostate cancer and Japan’s Ministry of Health, Labour and Welfare granted a matching indication (August 2023) 【page_7】. By 2024 the drug was already marketed in a number of regions for ovarian, breast, pancreatic and prostate cancers, and the company reported that “alliance revenue related to Lynparza grew 9 % in 2024 largely due to higher demand in most international markets” (alliance revenue rose to $1.311 billion) 【page_55】. Thus, after the initial U.S. and Japan approvals in 2023, Lynparza’s commercial footprint broadened globally in 2024, delivering double‑digit alliance‑revenue growth driven by expanding sales across multiple overseas markets.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 FDA and Japan MHLW approvals for BRCA-mutated mCRPC and the 9% growth in alliance revenue in 2024, citing a rise to $1.311 billion, which aligns with the ground truth's emphasis on international demand driving growth. However, it incorrectly attributes Lynparza to Merck; the drug is co-developed and commercialized by AstraZeneca and Merck & Co. (known as MSD outside the U.S.), but Merck did not 'add Lynparza to its portfolio' in 2023—this phrasing misrepresents the long-standing collaboration. Additionally, the LLM omits the January 2025 China NMPA approval for early breast cancer, a key part of the geographic and therapeutic expansion trajectory. (2) Quantitatively, the 9% revenue growth and $1.311 billion figure are accurate and consistent with the ground truth. Dates for FDA (May 2023) and Japan (August 2023) approvals are plausible and match the general 2023 timeframe, though the original answer does not specify months. The omission of the 2025 China approval—a forward-looking expansion—is a significant completeness gap. (3) The reasoning correctly links 2023 approvals to 2024 revenue growth and infers broader international commercialization, showing sound multi-hop logic across time and geography. However, the misattribution to Merck undermines entity accuracy and suggests flawed sourcing or synthesis. (4) Despite the company error and missing China approval, the answer captures the core trend of geographic expansion and revenue growth, warranting a 7 for correctness. Quantitative accuracy is high (8), qualitative accuracy is reduced by entity and completeness issues (7), and relevance remains strong (9) as it directly addresses commercialization and revenue evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 479,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, particularly in terms of its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was noted as a reduction in sales, indicating a negative financial impact. By 2024, the Powder Metal Matter was specifically listed under future income tax benefits at $455 million, down from $644 million in 2023, showing a shift in its financial treatment from a sales reduction to a recognized tax benefit. This represents a decrease of $189 million, or about 29.3%, in its value contribution to future tax benefits.",
      "llm_answer": "In the 2023 filing RTX disclosed that the “Powder Metal Matter” was treated as a **sales‑reduction item** in the segment tables (see the line “Powder Metal Matter – (5,401)” in the 2023 segment‑sales breakdown) and it generated a **deferred‑tax asset of $644 million** for future income‑tax benefits (Deferred Tax Assets table, “Powder Metal Matter $ 644 m” – 2023).  \n\nIn the 2024 filing the separate sales‑reduction line disappears from the segment tables, and the deferred‑tax asset associated with the matter falls to **$455 million** (Deferred Tax Assets table, “Powder Metal Matter $ 455 m” – 2024), indicating that the company now expects a smaller future tax benefit from the issue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2023, the Powder Metal Matter was treated as a sales reduction and had a deferred tax asset of $644 million; in 2024, the sales-reduction line disappeared and the deferred tax asset decreased to $455 million. These numbers match the ground truth exactly. (2) The quantitative accuracy is perfect: $644M and $455M are correctly reported, and while the LLM does not explicitly calculate the $189M decrease or 29.3% reduction, it correctly states the direction and magnitude of the change ('smaller future tax benefit'), which is semantically sufficient. (3) The reasoning is sound: the model correctly infers a shift in financial treatment from sales reduction to a diminishing tax benefit, based on the removal of the line item from segment tables and the updated deferred tax asset. (4) The only minor omission is the lack of explicit percentage or absolute decrease calculation ($189M, 29.3%), which was present in the original answer. However, this does not detract significantly from the overall correctness, as the core multi-hop synthesis—shift in treatment and decline in tax benefit—is accurately conveyed. Entity names (RTX, Powder Metal Matter), years (2023, 2024), and financial concepts (deferred tax asset, sales reduction) are all correctly identified and used. The answer is fully contextually relevant and directly addresses the evolution in financial treatment and its impact on future income tax benefits.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 419,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did the borrowing capacity and terms of the Paidy Credit Agreement evolve from 2022 to 2024?",
      "original_answer": "In 2022, the Paidy Credit Agreement provided a secured revolving credit facility of approximately $198 million, with $98 million outstanding as of December 31, 2021. By 2024, the Paidy Credit Agreement had been modified to increase the borrowing capacity to ¥90.0 billion (approximately $574 million as of December 31, 2024), and it was restructured as an unsecured facility. The interest rate also changed from unspecified terms in 2022 to a rate based on the Tokyo Interbank Offered Rate plus a margin ranging from 0.40% to 0.60% in 2024. The maturity date was set for February 2027, and the agreement now includes a financial covenant requiring a maximum consolidated leverage ratio.",
      "llm_answer": "In the 2022 filing PayPal reported that the Paidy Credit Agreement was a **secured** revolving facility of roughly **$198 million**, of which about **$98 million was outstanding and $100 million remained available** at year‑end 2021. By the 2024 filing the agreement had been **re‑structured as an unsecured revolving facility of ¥60 billion, later amended in September 2022 to ¥90 billion (≈ $574 million)**; the full amount had been drawn down by year‑end 2024, leaving **no borrowing capacity remaining**. The 2024 terms also specify interest at **TIBOR + 0.40‑0.60 %** and a maturity in February 2027, whereas the 2022 filing did not disclose the interest formula.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution of the Paidy Credit Agreement from 2022 to 2024, with accurate entity identification and strong contextual relevance. (1) Quantitatively, most figures are correct: the 2022 secured $198 million facility and $98 million outstanding as of December 31, 2021, are accurate. The 2024 borrowing capacity of ¥90 billion (≈$574 million) is correct, and the interest rate based on TIBOR + 0.40–0.60% and maturity in February 2027 match the ground truth. However, the LLM incorrectly states that the full amount was drawn down by year-end 2024, leaving no borrowing capacity—this contradicts the original answer, which does not mention drawdown status or remaining capacity. This is a significant but not central error. (2) The mention of a September 2022 amendment increasing the facility from ¥60B to ¥90B is additional detail not present in the ground truth; while plausible, it introduces unverified information and slightly undermines quantitative accuracy. (3) Qualitatively, the reasoning is sound: the shift from secured to unsecured, the change in interest rate disclosure, and the addition of a financial covenant (implied by mention of TIBOR-based pricing and maturity) are correctly inferred or stated. However, the LLM omits explicit mention of the new financial covenant (maximum consolidated leverage ratio), which is a notable omission in completeness. (4) Contextual relevance is excellent—the response directly addresses how terms evolved over time, synthesizing multi-hop information across years and agreement terms. Overall, the answer is factually strong with minor inaccuracies and omissions, warranting a score of 8 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 464,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Altria's reliance on long-term senior unsecured notes as part of its capital resources evolved between 2022 and 2024?",
      "original_answer": "In 2022, Altria's capital resources included access to credit markets through the issuance of long-term senior unsecured notes, along with $4.5 billion in cash and cash equivalents. By 2024, Altria continued to rely on long-term senior unsecured notes as a key source of capital, but its cash and cash equivalents decreased to $3.1 billion. While the company maintained its $3.0 billion Credit Agreement and continued to use similar capital instruments, the reduction in cash reserves suggests a potentially increased reliance on external financing mechanisms, including long-term senior unsecured notes, to support its operations and strategic initiatives such as dividend payments, share repurchases, and debt repayment.",
      "llm_answer": "Altria’s 2022 filing notes that its capital resources “include … access to credit markets through the issuance of long‑term senior unsecured notes” (2022 10‑K, Liquidity and Capital Resources) and that it relied on a $3.0 billion revolving credit facility and commercial‑paper program to complement that debt capacity. By the 2024 filing the company still cites the same three pillars—cash, the $3.0 billion credit agreement and “access to credit markets through the issuance of long‑term senior unsecured notes” (2024 10‑K, Liquidity and Capital Resources) but adds that total long‑term debt fell to $24.9 billion from $26.2 billion a year earlier, reflecting repayments of maturing notes and modest new issuances. Thus, while Altria continues to depend on senior unsecured notes for financing, its overall reliance has slightly decreased as the outstanding note balance has been trimmed.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that Altria continued to rely on long-term senior unsecured notes as a capital resource in both 2022 and 2024, and accurately references the $3.0 billion credit agreement and access to credit markets in both years. It also correctly notes a decrease in total long-term debt from $26.2 billion to $24.9 billion, which is factually consistent with the knowledge graph data (though this specific detail was not in the original answer). However, the LLM introduces a claim about a reduction in reliance on long-term notes due to lower outstanding debt, which contradicts the ground truth's conclusion of potentially increased reliance due to declining cash reserves (from $4.5B to $3.1B). The LLM omits the key quantitative change in cash and cash equivalents, which is central to assessing evolution in reliance on external financing. While the entity names, years, and financial instruments are correct, and the wording is semantically precise with proper citations, the reasoning misinterprets the implication of debt reduction without considering the cash reserve decline. This leads to a flawed qualitative conclusion despite some accurate data points. The answer is contextually relevant and well-structured but fails in multi-hop synthesis by not weighing cash levels against debt trends to assess overall reliance. Quantitative accuracy is moderate—numbers cited are plausible and internally consistent, but the critical $4.5B to $3.1B cash drop is missing, and the debt figures, while reasonable, were not confirmed in the original answer and may not align exactly with the knowledge graph's source data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 447,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, and what does this indicate about its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter contributed $644 million to RTX's future income tax benefits. By 2024, this amount decreased to $455 million, indicating a reduced financial benefit from the Powder Metal Matter over time. This decline suggests a diminishing positive impact on RTX's tax position related to this factor.",
      "llm_answer": "In 2023 RTX recorded the Powder‑Metal Matter as a **$2.9 billion charge to operating profit**, which lowered pretax earnings and produced an “approximately 4 %” reduction in the effective tax rate (see 2023 effective‑tax‑rate discussion and the $2.9 bn charge noted in the segment review). By 2024 the charge had been removed from the income statement and the related **deferred‑tax asset fell to $455 million (down from $644 million in 2023)**, showing that the tax benefit from the matter is now being realized and the remaining future income‑tax benefit is shrinking. This evolution indicates that the Powder‑Metal Matter’s tax advantage is being phased out, leaving a much smaller impact on RTX’s future tax savings.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the decrease in deferred tax asset from $644 million in 2023 to $455 million in 2024, which matches the ground truth. However, it introduces additional information not present in the original answer — specifically, a $2.9 billion charge to operating profit and a 4% reduction in effective tax rate — which are not mentioned in the ground truth and cannot be verified from the provided data. These additions, while potentially accurate, go beyond the scope of the known facts and introduce unverified quantitative claims. (2) The key numbers related to the deferred tax asset ($644M → $455M) are correct and properly cited with directional accuracy (downward trend). The $2.9B charge and 4% tax rate impact are not in the ground truth and thus cannot be confirmed; their inclusion lowers quantitative accuracy despite correct core figures. (3) The reasoning is strong: the model correctly infers that the declining deferred tax asset implies the tax benefit is being realized and the future impact is shrinking — this aligns with the ground truth’s conclusion about diminishing future benefits. The synthesis across years and interpretation of trend implications is sound and demonstrates proper multi-hop understanding. (4) Contextual relevance is perfect — the answer directly addresses both parts of the question: evolution between 2023–2024 and implications for future tax benefits. The core factual trajectory and interpretation match the ground truth, warranting a high correctness score despite the extra, unverified details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 432,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has PayPal's utilization of the Paidy Credit Agreement evolved between 2022 and 2024, particularly in terms of borrowing capacity and actual drawdown?",
      "original_answer": "In 2022, PayPal had approximately $198 million in borrowing capacity under the Paidy Credit Agreement, with $98 million outstanding as of December 31, 2021, leaving about $100 million available. By 2024, the borrowing capacity had increased to approximately $574 million (¥90.0 billion), and the full amount was drawn down, leaving no borrowing capacity available. This reflects a significant increase in both the scale of the facility and PayPal's reliance on it over the period.",
      "llm_answer": "By the end of 2022 the Paidy Credit Agreement gave PayPal a secured revolving facility of roughly ¥60 billion (about $100 million); about ¥10 billion (≈ $98 million) was already drawn, leaving roughly ¥50 billion of unused capacity. In September 2022 the agreement was amended to increase the limit to ¥90 billion (≈ $574 million), and in the year ended December 31 2024 PayPal drew the full ¥90 billion, so no borrowing capacity remained under the Paidy facility.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth with only minor discrepancies in presentation. (1) Quantitatively, the LLM correctly states that in 2022, approximately $100 million (¥60 billion) was the initial borrowing capacity, with about $98 million (¥10 billion) drawn, leaving ~$50 billion yen unused. This aligns with the ground truth's $198 million capacity and $98 million outstanding as of Dec 31, 2021, implying ~$100 million available—minor differences likely due to exchange rate timing or rounding. The LLM correctly notes the September 2022 amendment increasing the facility to ¥90 billion (~$574 million), matching the ground truth’s $574 million (¥90.0 billion) capacity by 2024. It also accurately states the full drawdown by end of 2024, leaving no capacity—consistent with the original answer. (2) The only minor issue is that the LLM refers to 'end of 2022' borrowing capacity as ~$100 million, while the ground truth references $198 million capacity with $98 million drawn as of Dec 31, 2021—implying the $100 million available carried into 2022. The LLM slightly conflates timing by not clarifying that the $100 million available was from the prior year, but correctly contextualizes the September 2022 increase. (3) The multi-hop reasoning is sound: the model synthesizes changes over time (2022 vs 2024), tracks capacity, drawdown, and availability, and correctly infers full utilization by 2024. (4) Entity accuracy (PayPal, Paidy Credit Agreement, years, currency conversions) is correct. Wording differs but semantic meaning matches. The answer is fully relevant and addresses both borrowing capacity evolution and actual drawdown. A score of 9 is justified due to high factual accuracy with only negligible timing/rounding ambiguity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 487,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the ownership structure and equity relationship between Accenture plc and Accenture Canada Holdings Inc. evolved from 2023 to 2024, particularly regarding noncontrolling interests and exchangeable shares?",
      "original_answer": "In 2023, the noncontrolling ownership interests in Accenture Canada Holdings Inc. held by certain current and former members of Accenture Leadership were less than 1% as of August 31, 2024. By 2024, the structure had evolved to include detailed provisions around Accenture Canada Holdings Inc. exchangeable shares, which can be exchanged for Accenture plc Class A ordinary shares on a one-for-one basis or redeemed for cash. Additionally, Accenture plc Class X ordinary shares were tied directly to these exchangeable shares, with a restriction ensuring the number of Class X shares does not fall below the number of exchangeable shares held. This indicates a more formalized and structured equity relationship in 2024 compared to the simpler noncontrolling interest disclosure in 2023.",
      "llm_answer": "In the 2023 filing the consolidated statements disclosed that the only ownership of Accenture Canada Holdings Inc. outside the parent was a non‑controlling interest of **less than 1 %**, held by current and former members of Accenture Leadership, and that those holders possessed “exchangeable shares” that could be swapped one‑for‑one for Accenture plc Class A ordinary shares (with corresponding Class X shares issued to pre‑incorporation partners). The 2024 filing shows the same structure – the non‑controlling interest remains **under 1 %** as of August 31 2024, and the exchangeable‑share program continues, with the company purchasing 47,752 exchangeable shares in fiscal 2024 and retaining the right to redeem or exchange them for Class A shares on a one‑for‑one basis. Thus, from 2023 to 2024 the ownership relationship has essentially stayed unchanged, with only modest activity in buying back exchangeable shares and no increase in the non‑controlling stake.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the quantitative facts: the noncontrolling interest was less than 1% in both 2023 and as of August 31, 2024, and exchangeable shares can be exchanged one-for-one for Accenture plc Class A ordinary shares. It also accurately notes that Accenture plc issued Class X shares in connection with the exchangeable share structure. The mention of 47,752 exchangeable shares purchased in fiscal 2024 is a specific detail not present in the ground truth, but since it does not contradict and may reflect additional data, it is not penalized heavily. However, the core error lies in the qualitative interpretation: the LLM concludes that the ownership structure 'has essentially stayed unchanged,' which contradicts the ground truth that emphasizes a more formalized and structured equity relationship in 2024, including explicit provisions about Class X shares and redemption mechanics. The ground truth frames 2024 as having evolved into a more detailed and structured arrangement, while the LLM interprets continuity. This misrepresents the evolution of the equity relationship, missing the multi-hop insight that procedural and structural formalization constitutes meaningful evolution, even if ownership percentages remained stable. Thus, while numbers and entities are correct (supporting high quantitative and contextual scores), the reasoning and qualitative synthesis are flawed, dragging down the overall correctness score to partially correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1455,
        "completion_tokens": 405,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has Merck's approach to managing balance sheet risk through forward exchange contracts evolved between 2022 and 2024, particularly in terms of the currencies and cost-benefit considerations?",
      "original_answer": "In 2022, Merck explicitly outlined a balance sheet risk management program that involved the use of forward exchange contracts to offset exposures in both developed and developing country currencies, with a specific mention of the Chinese renminbi. The decision to hedge developing country currencies was based on a cost-benefit analysis considering exposure magnitude, exchange rate volatility, and hedging instrument cost. By 2024, while the balance sheet risk management program was still referenced, the detailed discussion around cost-benefit analysis and the specific mention of the Chinese renminbi in the context of developing countries was omitted. This suggests a shift in emphasis or a potential simplification of the decision-making framework for hedging non-developed market exposures.",
      "llm_answer": "By 2022 Merck’s balance‑sheet risk program used short‑term forward contracts mainly for “developed‑country” currencies – the euro, Japanese yen, British pound, Canadian dollar and Swiss franc – and would only hedge a developing‑country currency such as the Chinese renminbi when a cost‑benefit test (exposure size, rate volatility and hedge cost) showed it was economical. In the 2024 filing the company still applies the same cost‑benefit analysis, but the list of primary currencies has shifted to the euro, Swiss franc, Japanese yen and now explicitly includes the Chinese renminbi, while the British pound and Canadian dollar are no longer highlighted, indicating a tighter focus on a smaller set of major currencies and a broader, more systematic use of forwards for the renminbi.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) The ORIGINAL ANSWER states that in 2022, Merck hedged both developed and developing country currencies, specifically mentioning the Chinese renminbi, and applied a cost-benefit analysis for developing countries. The LLM incorrectly claims that in 2022, forwards were used 'mainly for developed-country currencies' and that developing countries like China were only hedged when cost-benefit justified — this reverses the emphasis: the ground truth confirms the cost-benefit analysis was explicitly used to justify hedging developing countries, not to exclude them. (2) The LLM claims that by 2024, the Chinese renminbi was 'explicitly included' in the list of hedged currencies and that the British pound and Canadian dollar were dropped — this is unsupported by the ground truth, which states that the 2024 filing omitted details about cost-benefit analysis and the specific mention of renminbi, suggesting less detail, not more systematic hedging. The LLM incorrectly infers increased focus on renminbi when the evidence points to reduced disclosure. (3) Multi-hop reasoning fails: the model should have detected the reduction in disclosure detail from 2022 to 2024 as a shift in emphasis, not an expansion of hedging practice. Instead, it fabricates a change in currency focus without evidence. (4) While the question is addressed in topic (balance sheet risk, currencies, cost-benefit), the factual core is wrong, leading to a low correctness score. Contextual relevance is moderate because the answer discusses the right themes but with incorrect substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 450,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "What does the change in RTX's disclosure about the Powder Metal Matter between 2023 and 2024 suggest about its ongoing financial impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was disclosed as having a net sales charge of $5.3 billion, which negatively impacted net products sales at Pratt & Whitney and contributed to a decline in overall revenue. By 2024, the Powder Metal Matter was listed under future income tax benefits with a value of $455 million, down from $644 million in 2023. This shift indicates that while the matter continues to carry financial significance, its treatment has evolved from a direct operational loss to a deferred tax asset, suggesting a reduction in its immediate negative impact and a potential long-term recovery or resolution.",
      "llm_answer": "In the 2023 filing RTX listed a $644 million deferred‑tax asset tied to the “Powder Metal Matter,” but the 2024 filing reduced that amount to $455 million. The drop shows that the temporary tax difference created by the Powder Metal Matter is shrinking—its tax benefit is being realized or is expected to be smaller—so the matter will have a diminishing, rather than growing, impact on RTX’s future income‑tax benefits.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the 2023 deferred tax asset of $644 million and the 2024 reduction to $455 million are accurately reported. The format ($644 million vs $644 million) is acceptable. (2) The answer correctly identifies the shift in disclosure—from a deferred tax asset in 2023 to a reduced value in 2024—and infers that the tax benefit is diminishing, which matches the ground truth's implication of a shrinking future impact. (3) The reasoning is sound: the LLM correctly interprets the reduction in the deferred tax asset as evidence that the temporary difference is shrinking and that the future income tax benefit is decreasing, indicating proper multi-hop synthesis between years and accounting treatment. (4) While the original answer adds context about the $5.3 billion net sales charge in 2023 affecting operational performance, the LLM omits this detail. However, since the question specifically asks about the change in disclosure related to *future income tax benefits*, the omission does not undermine the core accuracy. The LLM focuses precisely on the tax asset evolution, which is the key to answering the question. Thus, the answer is semantically equivalent in intent and fact, meriting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 365,
        "total_tokens": 1630
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has PayPal's involvement in the merchant receivables space evolved between 2022 and 2024, particularly in terms of its relationship with partner institutions and the scale of its merchant finance offerings?",
      "original_answer": "In 2022, PayPal described its U.S. merchant finance products (PPWC and PPBL) as being provided under a program agreement with WebBank, where PayPal could purchase the related receivables and also sell back a participation interest in the pool of receivables to WebBank. PayPal accounted for this arrangement as a sale and derecognized the portion of participation interests for which control was surrendered. By 2024, PayPal's relationship with partner institutions had evolved, with PayPal now purchasing approximately $1.8 billion in merchant receivables in 2024 (up from $1.7 billion in 2023), and the total outstanding balance in the pool of merchant loans, advances, and interest and fees receivable reached $1.5 billion as of December 31, 2024 (up from $1.2 billion as of December 31, 2023). Additionally, the participation interest sold to the partner institution increased to $53 million in 2024 from $44 million in 2023, indicating a growing level of investment in and collaboration around merchant receivables.",
      "llm_answer": "In 2022 PayPal’s merchant‑finance business was still run through a partnership model – the PayPal Working Capital (PPWC) and PayPal Business Loan (PPBL) products were funded by WebBank in the United States (with the company buying back a participation interest in the pool) and, outside the U.S., advances were originated through PayPal’s own banking subsidiaries in Europe and Australia【page_72】.  \n\nBy 2024 the same partner‑institution structure remained, but the volume of the program had grown dramatically.  PayPal now purchases the U.S. merchant receivables that a partner institution originates, buying roughly $1.8 billion of merchant receivables in 2024 (up from $1.7 billion in 2023) and holding an outstanding pool of about $1.5 billion at year‑end 2024 (versus $1.2 billion in 2023)【page_101】.  \n\nThus, between 2022 and 2024 PayPal has kept its reliance on a partner‑institution financing arrangement while scaling the merchant‑receivables portfolio to multi‑billion‑dollar levels.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All quantitative figures are correct: $1.8 billion in merchant receivables purchased in 2024 (up from $1.7 billion in 2023), outstanding balance of $1.5 billion as of December 31, 2024 (vs. $1.2 billion in 2023), and the increase in participation interest sold to partner institutions from $44M to $53M is implied through context even though the exact $53M figure is not stated. However, the LLM omits the specific 2024 participation interest amount ($53M), which is a minor gap in completeness. (2) The entity identification is accurate—WebBank is correctly named as the U.S. partner institution, and the products (PPWC and PPBL) are correctly referenced. The distinction between U.S. and non-U.S. operations is appropriately noted. (3) The multi-hop reasoning is sound: the LLM synthesizes information across years (2022 to 2024), compares scale increases, and correctly identifies the continuity of the partner-institution model. (4) The semantic meaning matches the original answer—PayPal maintains its partnership structure while scaling the program, now at multi-billion-dollar levels. The only minor shortcoming is the omission of the exact 2024 participation interest value ($53M), which slightly affects completeness but does not undermine the core accuracy. Hence, a 9/10 correctness score is warranted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1519,
        "completion_tokens": 384,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How did Merck's alliance revenue from Lynparza evolve between 2022 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2022, Merck's alliance revenue from Lynparza was $989 million. By 2024, this revenue grew by 9%, driven by increased demand in most international markets. The growth reflects Lynparza's expanding adoption and new approvals, such as in China in January 2025 for adjuvant treatment in early breast cancer based on the OlympiA trial.",
      "llm_answer": "Merck’s alliance‑revenue share from Lynparza rose from **$1.12 billion in 2022** to **$1.20 billion in 2023** (≈ 7 % increase) and to **$1.31 billion in 2024** (≈ 9 % increase versus 2023, about 18 % above the 2022 level)【page_53】. The company attributes the 2024 growth to **higher demand for Lynparza in most international markets** under its collaboration with AstraZeneca【page_55】, while the earlier gains reflect the continued rollout of the drug’s approved indications and expanding market uptake after its 2022 baseline.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative data. The ground truth states Merck's 2022 alliance revenue from Lynparza was $989 million, but the LLM claims $1.12 billion in 2022 and $1.31 billion in 2024 — both figures are incorrect. The reported 9% growth in 2024 in the LLM answer is aligned with the ground truth, but it misattributes this growth to a comparison between 2023 and 2024, whereas the ground truth directly compares 2022 to 2024. Additionally, the LLM introduces a 2023 figure ($1.20 billion) not present in the original answer, creating a false impression of year-over-year progression. (2) Calculations are internally consistent in the LLM answer (e.g., ~9% increase from $1.20B to $1.31B), but since the base numbers are wrong, the overall financial narrative is misleading. The actual 9% growth from $989M should result in ~$1.078 billion in 2024, not $1.31 billion. (3) The qualitative reasoning about growth drivers — increased international demand and expanding adoption — is consistent with the ground truth and shows correct multi-hop synthesis regarding market uptake and collaboration with AstraZeneca. The mention of 'approved indications' aligns with the real-world context, though the LLM omits the specific future approval in China in January 2025 cited in the original, which is a forward-looking factor. (4) Despite correct contextual understanding of the revenue driver and collaboration framework, the severe numerical inaccuracies — especially inflating the 2022 base by over $130 million and projecting an implausibly high 2024 figure — undermine the factual reliability. The answer is relevant and partially correct in reasoning, but fails on core factual accuracy, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1208,
        "completion_tokens": 485,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has PayPal's involvement in merchant receivables evolved between 2022 and 2024, particularly in terms of its financial exposure and operational role?",
      "original_answer": "In 2022, PayPal's involvement in merchant receivables was primarily framed in terms of credit losses and net charge-offs, indicating a focus on risk management and accounting treatment under CECL standards. By 2024, PayPal had significantly expanded its direct involvement through active purchases of merchant receivables—$1.8 billion in 2024 compared to $1.7 billion in 2023—and reported a growing outstanding balance of $1.5 billion, up from $1.2 billion. Additionally, PayPal took on full servicing responsibilities for these receivables, signaling a deeper operational engagement in merchant finance through products like PPWC and PPBL.",
      "llm_answer": "By 2024 PayPal was buying roughly $1.8 billion of merchant‑finance receivables (up from about $1.7 billion in 2022) and the net balance of its merchant loan, advance and interest‑and‑fees portfolio had risen to $1.5 billion (from $1.2 billion at the end of 2022) 【page_101】.  At the same time, credit‑risk exposure improved – the allowance for merchant loans fell to $113 million (down from $160 million a year earlier) and gross charge‑offs dropped sharply to $10 million in 2024 versus $42 million in 2022 【page_102】【page_103】.  Throughout this period PayPal’s role remained the same: it purchases the receivables from a partner institution, services the portfolio, and collects repayments through its PP WC (percentage‑of‑processed‑volume) and PP BL (fixed‑fee) products, with loan repayment tied to the merchant’s PayPal‑processed payment volume 【page_101】.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and addresses the evolution of PayPal's involvement in merchant receivables between 2022 and 2024 with strong contextual relevance. However, there are minor quantitative inaccuracies that affect precision. The LLM states that PayPal purchased $1.8 billion in 2024 (correct) but incorrectly attributes the $1.7 billion figure to 2022, while the ground truth specifies $1.7 billion for 2023 — a critical misalignment in year labeling. Additionally, the LLM claims the net balance rose to $1.5 billion from $1.2 billion at the end of 2022, which aligns with the ground truth, but fails to mention 2023 data ($1.2 billion to $1.5 billion), weakening the multi-year progression. The drop in allowance and charge-offs (from $160M to $113M and $42M to $10M) is accurate and well-integrated, showing improved credit risk, though the original answer did not emphasize this point — so it's a valid addition, not a contradiction. The operational role is correctly described: PayPal purchases receivables via a partner, services them, and collects repayments using PPWC and PPBL, indicating deepened operational engagement. This reflects proper multi-hop synthesis across financial exposure and operational function. While the core facts about increased financial exposure and expanded role are correct, the misattribution of the $1.7 billion to 2022 instead of 2023 reduces quantitative accuracy. The answer remains semantically close and contextually complete, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 417,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Merck's involvement in the development and commercialization of Lynparza evolved from 2022 to 2024, particularly in terms of regulatory progress and revenue growth?",
      "original_answer": "In 2022, Merck was awaiting FDA decision on a supplemental NDA for Lynparza for the adjuvant treatment of BRCA-mutated, HER2-negative high-risk early-stage breast cancer, based on the OlympiA trial, with a PDUFA date in Q1 2022. By 2024, Lynparza had not only maintained its approvals but also expanded its regulatory footprint, with a new approval in China in January 2025 for the same indication, indicating continued global regulatory momentum. Additionally, alliance revenue related to Lynparza grew by 9% in 2024 due to increased demand in international markets, showing a measurable increase in commercial success.",
      "llm_answer": "In the 2022 filing Merck noted that Lynparza was already approved for several advanced ovarian, breast, pancreatic and prostate cancers and that, as part of its AstraZeneca partnership, the FDA had **accepted a supplemental NDA for the OlympiA adjuvant‑breast‑cancer indication and set a PDUFA date for the first quarter of 2022** (see page 22). By the 2024 filing the product remained on the market, the collaboration was generating **higher alliance revenue – $1.311 billion in 2024, a 9 % increase over 2023** (page 53), and Merck announced **new regulatory milestones, including China’s NMPA approval (January 2025) of Lynparza as adjuvant therapy for germline‑BRCA‑mutated, HER2‑negative high‑risk early‑stage breast cancer** (page 55). Thus, between 2022 and 2024 Merck moved from awaiting additional approvals to securing new market authorizations and achieving double‑digit revenue growth for Lynparza.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures all key facts from the ground truth. It accurately states that in 2022, Merck was awaiting an FDA decision on a supplemental NDA for Lynparza for adjuvant treatment of BRCA-mutated, HER2-negative high-risk early-stage breast cancer, with a PDUFA date in Q1 2022. It also correctly reports the 9% revenue growth in 2024 and cites the exact alliance revenue figure of $1.311 billion, which aligns with the '9% increase' mentioned in the ground truth. The January 2025 China approval by NMPA is accurately reported, matching the ground truth's mention of a January 2025 approval in China. (2) Quantitatively, all numbers are correct: 9% revenue growth, $1.311 billion revenue in 2024, PDUFA date in Q1 2022, and approval in January 2025. The LLM adds a specific dollar amount not in the original answer but consistent with a 9% growth trend, which is a reasonable inference from the ground truth and does not contradict it. (3) The multi-hop reasoning is sound: the LLM synthesizes information across years (2022 to 2024), companies (Merck and AstraZeneca partnership), regulatory events (FDA submission, China approval), and financial performance (revenue growth). The conclusion that Merck moved from awaiting approvals to securing new authorizations and revenue growth is logically supported. (4) The only minor issue is the phrase 'double-digit revenue growth'—this is incorrect, as 9% is single-digit. This small factual error prevents a perfect 10 on correctness and qualitative accuracy. Otherwise, the answer is comprehensive, factually accurate, and contextually fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 447,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Boeing's strategy with commodity purchase contracts evolved between 2022 and 2024, particularly in terms of risk management horizon and financial exposure?",
      "original_answer": "In 2022, Boeing disclosed that a 10% change in commodity prices would impact unrealized losses by $46 million, and the company used commodity swaps and purchase contracts to hedge against price volatility, neutralizing material market risk. By 2024, Boeing extended the scope of its hedging strategy, indicating the use of commodity purchase contracts and derivatives to manage exposure through 2031. This represents a shift toward longer-term risk management aligned with extended production planning cycles. The expansion from a general hedging approach in 2022 to a multi-decade horizon in 2024 suggests Boeing is proactively securing cost predictability for strategic business stability.",
      "llm_answer": "In the 2022 Form 10‑K Boeing described commodity swaps and purchase contracts only as “commodity price‑risk” hedges that offset market‑price changes, without stating a specific forward‑looking horizon, and the contracts generated a $31 million cost impact in that year (see page 60). By the 2024 filing the company says its commodity purchase commitments and swaps now hedge forecasted transactions **through 2028**, extending the risk‑management horizon, and the financial exposure has been reduced – the 2024 table shows a $7 million cost impact and a $22 million net liability on long‑dated contracts, down from the larger $31 million impact reported in 2022 (see pages 111‑112).",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies compared to the ground truth. Most critically, it states that Boeing's hedging extends through 2028, while the original answer specifies 2031—a significant discrepancy in the risk management horizon. Additionally, the LLM claims a $31 million cost impact in 2022 and a $7 million cost impact in 2024, but the ground truth states a $46 million sensitivity to a 10% price change in 2022 (not an actual cost impact), and does not provide a comparable figure for 2024. The $22 million net liability is mentioned in the LLM answer but absent from the original, suggesting possible confusion between different financial metrics. (2) The quantitative inaccuracies are substantial: the $46 million sensitivity in 2022 is misrepresented as a $31 million cost impact, and the 2024 exposure is incorrectly quantified. The 2028 horizon conflicts with the correct 2031 horizon. These errors undermine the financial and temporal accuracy. (3) The reasoning partially captures the evolution in Boeing's strategy—recognizing an extension in hedging horizon and use of derivatives—but fails in multi-hop synthesis by relying on incorrect figures and timeframes. It conflates sensitivity exposure with actual cost impacts and misrepresents the duration of hedging commitments. (4) Despite these issues, the answer is contextually relevant, addressing risk management evolution, financial exposure, and strategic intent. The qualitative reasoning about longer-term planning is directionally correct, but lacks factual grounding. Hence, correctness is scored at 5 due to partial accuracy with major factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 454,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did Schwab's exposure to PALs and the associated credit risk evolve between 2021 and 2024, particularly in terms of collateralization and allowance for credit losses?",
      "original_answer": "In 2021, all PALs were fully collateralized by securities with fair values exceeding borrowings, and therefore no allowance for credit losses was required. In contrast, by 2024, although PALs experienced slight growth overall, Schwab observed a decrease in the allowance for credit losses due to lower projected loss rates and improved credit quality metrics. This reflects a shift from a focus on full collateralization as the primary risk mitigant to a broader assessment of credit quality and loss projections.",
      "llm_answer": "In 2021 Schwab’s “pledged‑asset lines” (the pool that contains its portfolio‑level asset‑backed loans, or PALs) amounted to **$12.7 billion** and, as disclosed, the loans were **fully collateralized by securities whose fair‑value exceeded the borrowings**, so **no allowance for credit losses was required** for the PALs (see 2021 Note 7, “All PALs were fully collateralized… therefore no allowance for credit losses for PALs as of those dates was required.” ‑ page 91).\n\nBy year‑end 2024 the same category had grown to **about $17 billion** of pledged‑asset lines (see the 2024 loan‑maturity table – “Pledged asset lines” $17,024 million ‑ page 141). The filing does not indicate any change in the collateral‑maintenance approach, implying that the PALs remain fully collateralized and **the allowance for credit losses on PALs continues to be zero**.\n\n**Thus, Schwab’s exposure to PALs rose roughly $4 billion (≈30 %) from 2021 to 2024, but because the loans stayed fully collateralized, the company still records no allowance for credit losses on those PALs.**",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "1) The LLM answer correctly reports the dollar amounts for pledged-asset lines in 2021 ($12.7 billion) and 2024 (~$17 billion), with accurate sourcing from the respective filings. The calculation of ~$4.3 billion growth (≈30%) is approximately correct, supporting high quantitative accuracy. However, the core qualitative claim—that the allowance for credit losses remained zero in 2024 due to full collateralization—directly contradicts the ground truth, which states that by 2024, Schwab *did* have an allowance for credit losses, albeit decreased due to lower projected loss rates and improved credit quality. The LLM incorrectly assumes no allowance implies zero risk provision, failing to reflect the shift in risk assessment approach described in the original answer.\n\n2) Numeric values are largely accurate: $12.7B in 2021 and $17.024B in 2024 (rounded to ~$17B) are correct. The ~30% growth estimate is reasonable. However, the conclusion that 'no allowance' persisted into 2024 is factually wrong per the ground truth, which explicitly notes a decrease (implying existence) of the allowance, not its continued absence.\n\n3) The multi-hop reasoning fails at a critical point: while the model correctly identifies the 2021 condition (full collateralization → no allowance), it does not recognize that by 2024, Schwab transitioned to a credit-risk model incorporating projected loss rates and credit quality metrics, even if collateralization remained. The LLM overlooks the evolution in risk management philosophy—from reliance solely on collateral to a broader credit assessment—rendering the qualitative synthesis flawed.\n\n4) Contextually, the answer addresses exposure growth and credit risk, but misrepresents the key development: the emergence and subsequent decrease of an allowance for credit losses. This undermines the correctness score despite strong number reporting. The answer is relevant and structured well, but the central conclusion is factually incorrect, warranting a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 539,
        "total_tokens": 1939
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did Boeing's financial treatment and strategic positioning of the 777X program evolve between 2022 and 2024, given the changes in cost impacts and research & development investments?",
      "original_answer": "In 2022, the 777X program negatively impacted Boeing's financials, contributing to higher charges and a cost of sales increase, partly due to a 'reach-forward loss' on the program. By 2024, the program had transitioned to being a strategic investment priority, as evidenced by a $435 million increase in R&D spending in 2024 compared to 2023, following a $525 million increase in 2023 over 2022, indicating a shift from a cost burden to a focal point for future product development.",
      "llm_answer": "In the 2022 filing Boeing still treated the 777X mainly as a loss‑recognition item.  The 10‑K notes that the 777X generated “higher charges … in 2020” that were reflected in cost of sales, and that R&D spending on the program was cut in 2021 (“lower … spending on the 777X program”). By the 2024 filing the company was recording a new “reach‑forward loss on the 777X” that lifted cost‑of‑sales (the 2024 cost‑of‑sales table attributes the increase to the reach‑forward loss on the 777X and 767 programs) and, at the same time, R&D expense rose sharply because of the 777X (“R&D expense increased … primarily due to the 777X program”). Thus, between 2022 and 2024 Boeing moved from a modest write‑down and reduced R&D on the 777X to a larger loss charge in cost of sales and a significant increase in R&D investment, signalling that the program remained a strategic focus despite its cost impact.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and timeline. The ground truth states that R&D spending increased by $525 million in 2023 over 2022 and by $435 million in 2024 over 2023, but the LLM answer does not mention these specific figures at all. Instead, it vaguely references 'higher charges in 2020' and 'R&D spending cut in 2021', which are outside the 2022–2024 timeframe asked in the question and not supported by the original answer. (2) There is a critical error in the use of data: the LLM cites a 'reach-forward loss' in 2024, which aligns with the ground truth, but incorrectly implies that such a loss was already present in 2022, while the original answer specifies the reach-forward loss emerged as part of the 2022 financial impact — not earlier. The LLM misattributes timing by referencing 2020 charges and 2021 R&D cuts, which are irrelevant to the 2022–2024 evolution. (3) The multi-hop reasoning is partially sound: the LLM correctly identifies a shift from cost burden to strategic investment, noting increased R&D in 2024 and ongoing losses affecting cost of sales. It captures the duality of financial strain and strategic importance. However, it fails to quantify the R&D increases accurately or cite the year-over-year escalation ($525M then $435M), which is central to the original answer’s evidence. (4) The contextual relevance is high because the answer addresses the core theme — evolution of financial treatment and strategic positioning — and correctly interprets the significance of rising R&D alongside loss recognition. However, due to the absence of correct quantitative data and misplacement of events outside the requested timeframe, the correctness score is limited to 6. The qualitative accuracy is moderate due to correct conceptual framing, while quantitative accuracy is low due to missing or incorrect figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 512,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has Schwab's exposure to and risk management of Portfolio Against Loans (PALs) evolved between 2022 and 2024, particularly in terms of credit loss allowance methodology and portfolio growth?",
      "original_answer": "In 2022, Schwab applied the practical expedient for PALs due to their collateralized nature and over-collateralization requirements, which limited inherent credit loss. The company monitored collateral daily and maintained strict maintenance levels based on the type of security pledged. By 2024, PALs had contributed to the growth of the average loan portfolio, although there was a slight decrease in 2023. The overall decrease in the allowance for credit losses as a ratio to year-end loans in 2024 was attributed to improved credit quality metrics and lower projected loss rates, indicating a reduced risk profile for PALs despite portfolio growth.",
      "llm_answer": "Schwab’s PAL portfolio is part of its bank‑loan segment. In 2022 the bank‑loan balance (which includes PALs) was $38.8 billion, and by 2024 it had risen to $42.3 billion – an increase of roughly $3.5 billion, with the pledged‑asset‑line (PAL) segment alone reported at $17.0 billion at year‑end 2024. Both years the company continues to use the “practical‑expedient” approach that ties the allowance for credit losses on PALs to the collateral‑maintenance provisions (daily collateral monitoring and over‑collateralisation), but the 2024 filing adds a more granular, loan‑level simulation and statistical‑model framework for its residential‑real‑estate loans while keeping PALs’ allowance based on current‑expected‑credit‑losses and the collateral coverage, indicating a consistent but increasingly data‑driven risk‑management stance as the portfolio expands.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly impact correctness. (1) QUANTITATIVE INACCURACY: The LLM states that the bank loan balance was $38.8 billion in 2022 and $42.3 billion in 2024, with PALs at $17.0 billion in 2024. However, the ground truth does not provide these specific dollar figures for PALs or total bank loans, nor does it mention a $3.5 billion increase. These numbers are fabricated or hallucinated, failing the quantitative accuracy test. (2) COMPLETENESS: The question asks about evolution in risk management, particularly credit loss allowance methodology and portfolio growth. The LLM correctly notes the continued use of the practical expedient and daily collateral monitoring, which aligns with 2022 practices. However, it incorrectly implies that in 2024, Schwab introduced a 'loan-level simulation and statistical-model framework' for PALs, when the ground truth states this was for residential real estate loans, not PALs. This misattribution undermines the reasoning. (3) REASONING: The model attempts multi-hop synthesis by connecting allowance methodology and portfolio trends, but incorrectly extends enhancements in modeling for other loan types to PALs, leading to flawed conclusions about a 'more granular' approach for PALs. The ground truth emphasizes that reduced allowance ratios in 2024 were due to improved credit quality and lower projected losses — a key point missed by the LLM. (4) SEMANTIC EQUIVALENCE: While the LLM captures the general idea of collateral-based risk management and portfolio growth, the inclusion of false specifics and misassigned methodologies reduces factual equivalence. The contextual relevance is high because the answer addresses the right themes (methodology, growth, risk management), but accuracy is compromised by unsupported numbers and incorrect attribution of modeling changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 506,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did MDLZ's value of British pound sterling notes change from 2022 to 2023, and what does this shift indicate about the company's foreign exchange risk management strategy?",
      "original_answer": "In 2022, MDLZ reported a value of $3 million for British pound sterling notes. By 2023, this value had increased significantly to $45 million. This shift indicates a substantial change in MDLZ's foreign exchange risk management strategy, suggesting an increased exposure to the British pound sterling, which could reflect either a strategic decision to hedge more in this currency or an increase in operational activities tied to the UK market.",
      "llm_answer": "MDLZ’s after‑tax result on the British‑pound‑sterling net‑investment‑hedge dropped from a **$45 million gain in 2022** to **$0 (no gain or loss) in 2023**【page_98】. The disappearance of the gain indicates that the company either reduced the pound‑denominated hedge exposure or achieved more effective hedge alignment, signaling a move to neutralize currency‑related earnings volatility and tighten its foreign‑exchange risk‑management posture.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude. The ground truth states that MDLZ's value of British pound sterling notes increased from $3 million in 2022 to $45 million in 2023, indicating growing exposure. In contrast, the LLM claims a $45 million gain in 2022 dropped to $0 in 2023, which reverses the actual trend and confuses the metric (gain/loss on hedge vs. value of notes). (2) Quantitative accuracy is severely compromised: the $3 million figure for 2022 is entirely missing, and the $45 million is misassigned to the wrong year and context (as a gain, not a note value). The calculation or comparison between years is therefore invalid. (3) The multi-hop reasoning fails because the model draws conclusions about foreign exchange risk management based on an incorrect financial metric. While the question requires synthesis of changes in the value of pound-denominated notes and their strategic implication, the LLM instead uses after-tax hedge gains, a different concept. (4) Contextual relevance is moderate because the answer discusses FX risk management strategy, which is relevant, but the underlying data and logic are flawed, leading to an incorrect interpretation. The conclusion about tightening risk management contradicts the ground truth, which suggests increased exposure and possibly more hedging or operational activity in the UK.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 387,
        "total_tokens": 1616
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "Compare the interest rate disclosures for Amgen's 3.125% 2025 Notes in the 2022 and 2024 filings, and explain what this reveals about the company's approach to debt financing for this instrument.",
      "original_answer": "In the 2022 filing, Amgen disclosed a fixed interest rate of 3.125% for the 2025 Notes with no mention of variable rate terms. However, by the 2024 filing, Amgen disclosed that the interest rate for the same 3.125% 2025 Notes was tied to SOFR (Secured Overnight Financing Rate) plus 2.1%. This indicates a shift from a purely fixed-rate structure to a floating-rate mechanism, suggesting Amgen may have refinanced or repriced the notes to adapt to changing market conditions and interest rate environments.",
      "llm_answer": "In the 2022 filing Amgen disclosed that the 3.125 % 2025 notes – although issued with a fixed 3.125 % coupon – were fully hedged with an interest‑rate swap that converted the cash‑flow to **LIBOR + 1.8 %** (see page 132). In the 2024 filing the same notes are still hedged, but the swap now references **SOFR + 2.1 %** (see page 149). This shift from LIBOR to SOFR and the modest increase in the spread shows that Amgen actively manages the interest‑rate risk of this issue, using swaps to maintain a floating‑rate exposure and to transition to the new benchmark while keeping the financing cost roughly in line with market conditions.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces information not present in the ground truth — specifically, the claim that the 3.125% 2025 Notes were 'fully hedged with an interest-rate swap' converting to LIBOR + 1.8% in 2022 and SOFR + 2.1% in 2024. The original answer states that in 2022, the note was disclosed as a fixed rate of 3.125% with no mention of variable rate terms, and in 2024, the rate was disclosed as SOFR + 2.1%, implying a structural change in the debt instrument itself. The LLM interprets this as a result of hedging activity, which is not supported by the ground truth. This misrepresents the nature of the disclosure — a shift in actual terms vs. a shift in risk management via derivatives. (2) Quantitatively, the LLM correctly identifies the 3.125% fixed rate, the SOFR + 2.1% figure in 2024, and correctly associates these with the respective years. However, the introduction of LIBOR + 1.8% in 2022 is not in the ground truth and appears to be an inference or fabrication. There is no verification that the hedging details exist in the cited pages (132, 149), and the ground truth makes no mention of swaps or hedging. (3) The multi-hop reasoning is partially sound — the model identifies a change in rate reference from LIBOR to SOFR and interprets it as active risk management. However, it fails to recognize that the core change is in the disclosed terms of the note itself, not just the hedging strategy. This undermines the correctness of the conclusion about the company's approach to debt financing — the ground truth suggests a shift in the instrument’s structure (fixed to floating), while the LLM suggests a consistent floating exposure via swaps, which contradicts the original answer. (4) The contextual relevance is high because the answer addresses the comparison across years and attempts to explain Amgen’s financing approach. However, due to the fundamental mischaracterization of the disclosures (hedging vs. actual rate terms), the qualitative and quantitative accuracy scores are reduced. The conclusion is plausible but factually misaligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 565,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has Schwab's reliance on its Commercial Paper Issuance Program evolved between 2022 and 2024 in response to market disruptions and rising interest rates?",
      "original_answer": "In 2022, Schwab introduced its Commercial Paper Issuance Program as one of several potential sources of external financing, alongside unsecured bank credit lines and a universal shelf registration, to address liquidity needs during market disruptions. The company emphasized that while these tools were available, access to financing could still be constrained due to credit market volatility and potential credit rating downgrades. By 2024, Schwab's reliance on the program had increased as a complement to other funding mechanisms like FHLB advances and repurchase agreements, particularly in response to rising short-term interest rates in 2022 and 2023, which led to higher client cash outflows. The company noted that these outflows, outpacing cash generated from maturities and paydowns, required supplemental funding sources, including the commercial paper program, to manage liquidity under more costly and constrained conditions.",
      "llm_answer": "In the 2022 filing Schwab simply noted that its holding‑company, CSC, “maintains … a commercial‑paper issuance program” as one of several optional sources of liquidity, without indicating that it was a primary funding tool. By the 2024 filing, after the credit‑market disruptions and the rapid rise in short‑term rates in 2022‑23, Schwab said that when cash outflows outpace cash on hand it may have to “rely on supplemental funding, such as … issuances of commercial paper” – signaling a much greater dependence on the program to meet its liquidity needs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and captures the core evolution in Schwab's reliance on its Commercial Paper Issuance Program between 2022 and 2024. In 2022, the program was introduced as one of several optional liquidity tools, not a primary source, which aligns with the ground truth. By 2024, the LLM correctly identifies increased reliance due to market disruptions and rising short-term interest rates in 2022–2023, which triggered higher client cash outflows. The statement that Schwab may 'rely on supplemental funding, such as … issuances of commercial paper' accurately reflects the heightened dependence described in the original answer. All dates (2022, 2023, 2024) and entities (Schwab, CSC, commercial paper program) are correct. There are no numerical inaccuracies—while no specific dollar amounts or percentages are cited, the qualitative timeline and causal relationships (rising rates → outflows → need for supplemental funding) are sound and consistent with the knowledge graph. The reasoning correctly synthesizes multi-hop information: (1) introduction of the program in 2022, (2) market conditions (rate hikes, volatility), (3) impact on cash flows, and (4) increased reliance by 2024. The only minor limitation is that the LLM omits mention of other funding mechanisms like FHLB advances and repurchase agreements, which the original answer notes as part of the broader funding mix. However, this does not undermine the central point about increased reliance on commercial paper. Wording differs but semantic meaning is equivalent. Thus, the answer is highly accurate, contextually relevant, and well-reasoned, meriting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 477,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has the status and interest rate structure of the 3.625% Notes evolved from 2022 to 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2022, the 3.625% 2024 Notes had a carrying value of $1,400 million with a fixed interest rate of 3.625%. By 2024, these notes were fully paid off, as indicated by the $0 notional amount, and were replaced with floating interest rates tied to SOFR (Secured Overnight Financing Rate). This shift from fixed to floating rate debt indicates a strategic change in Amgen's debt management, aligning with broader market conditions and potentially reducing interest costs in a declining rate environment.",
      "llm_answer": "In the 2022 filing the company still carried $750 million of 3.625 % notes that were due in 2022 and a larger $1.4 billion tranche of 3.625 % notes due in 2024. The 2022‑2023 reports show that the 2022 tranche was fully redeemed in 2021 (with the related $750 million interest‑rate‑swap hedge terminated) and that the 2024 tranche remained outstanding, being hedged at a floating rate of LIBOR + 3.2 % (later SOFR + 3.4 %). By the 2024 filing the 3.625 % 2024 notes and their $1.4 billion swap hedge had been repaid/terminated, indicating that Amgen is actively retiring its higher‑coupon fixed‑rate debt and unwinding the associated swaps, a strategy aimed at lowering overall borrowing costs and preserving flexibility in its capital structure.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. The original answer states that the 3.625% 2024 Notes had a carrying value of $1,400 million in 2022 and were fully paid off by 2024. The LLM correctly identifies the $1.4 billion (i.e., $1,400 million) 2024 tranche but incorrectly introduces a $750 million tranche of 3.625% notes due in 2022, which is not mentioned in the ground truth. There is no mention in the original answer of a 2022 maturity tranche of these notes or its redemption in 2021, making this a significant fabrication. Additionally, the LLM claims the 2024 tranche was hedged at floating rates (LIBOR + 3.2%, later SOFR + 3.4%), but the ground truth does not mention interest rate swaps or hedging activity—only that the new debt is tied to SOFR. While the conclusion about shifting to floating rates is partially aligned, the mechanism (via hedging) is not supported by the original answer. (2) The $1.4 billion figure is accurate and correctly matches $1,400 million. However, the $750 million figure is unsupported, and the claim that the 2022 tranche was redeemed in 2021 contradicts the timeline (pre-2022 activity for a 2022 filing). The interest rate details (LIBOR+/SOFR+) are specific but not present in the ground truth, making them incorrect additions. (3) The multi-hop reasoning is partially sound—the LLM correctly infers a strategic shift in debt management from fixed to floating rates and links repayment to cost reduction. However, it introduces unsupported complexity (swaps, tranches, early redemption) that distorts the actual evolution. The core idea of retiring fixed-rate debt is correct, but the path is misrepresented. (4) The contextual relevance is high—the answer addresses the evolution of the notes and interprets the strategy appropriately. However, due to significant quantitative errors and unsupported details, the correctness score is reduced to 6, reflecting partial accuracy with major factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 543,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has Schwab's approach to providing financial or other support to variable interest entities (VIEs) evolved between 2022 and 2024, particularly in terms of intent and conditions for funding commitments?",
      "original_answer": "In 2022, Schwab explicitly stated that it did not provide or intend to provide financial or other support to VIEs that it was not contractually required to provide. By 2024, Schwab's disclosures indicate a shift, as the company now acknowledges that while it has no contractual obligation, it may choose to provide credit, liquidity, or other support to its proprietary funds in response to significant declines in valuation or redemption activity. This reflects a more proactive stance in supporting funds under certain market conditions, even though it is not mandated.",
      "llm_answer": "In the 2022 Form 10‑K Schwab stated that it “did not provide or intend to provide financial or other support to the VIEs that it was not contractually required to provide,” and that any funding of the VIEs’ remaining commitments would be “dependent upon the occurrence of certain conditions,” with the company expecting to satisfy those commitments between 2022 and 2025. By the 2024 filing, that disclaimer is no longer present; instead Schwab notes that, although not obligated, it may elect to extend credit, liquidity or other support to its funds (and by implication to VIEs) for competitive or other reasons, indicating a shift from a strictly conditional, non‑support stance to a discretionary, potentially unconditional willingness to fund such entities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution in Schwab's approach: in 2022, Schwab stated it did not provide or intend to provide support beyond contractual obligations, and by 2024, it acknowledged a discretionary willingness to provide support to its funds (and by implication, VIEs) under certain conditions. The key shift—from a non-support stance to a discretionary, potentially unconditional one—is accurately conveyed. (2) There are no numeric values (e.g., dollar amounts, percentages) in the original or LLM answer, so quantitative accuracy is not applicable beyond correct handling of years (2022 and 2024), which are accurate. (3) The multi-hop reasoning is sound: the model correctly synthesizes disclosures across two years, identifies the removal of the disclaimer, and infers the strategic shift. The only minor shortcoming is the slight overreach in saying the disclaimer is 'no longer present'—while the tone shifts, the exact wording may still appear in modified form; however, the overall message of a policy evolution is correct. (4) The answer is contextually relevant, directly addressing the intent and conditions for funding commitments as asked. The use of 'competitive or other reasons' adds slight nuance not in the original but does not contradict it. Overall, the answer is factually correct, well-reasoned, and complete, warranting a 9/10 due to minor phrasing interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 405,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has MDLZ's financial relationship with JDE Peet's evolved between 2022 and 2023, particularly in terms of how the investment impacts MDLZ's liquidity and capital structure?",
      "original_answer": "In 2022, MDLZ's relationship with JDE Peet's was characterized as a 'Has_Stake_In' arrangement, where MDLZ reported its proportionate share of significant operating and non-operating items from JDE Peet's including restructuring and acquisition-related costs. By 2023, the relationship was reclassified to 'Invests_In', and the investment in JDE Peet's was described as providing additional financial flexibility within MDLZ's liquidity and capital resources framework. This shift indicates a more strategic and stable investment posture, aligning JDE Peet's more closely with MDLZ's long-term capital planning and funding sources.",
      "llm_answer": "By 2022 the JDE Peet’s investment was still a financing‑related outflow – MDLZ had issued €300 million of zero‑interest exchangeable notes that could be redeemed for cash or JDE Peet’s shares (see 2022 10‑K p. 45). In 2023 the company sold a portion of its JDE Peet’s stake, generating a $2.8 billion cash inflow from investing activities (2023 cash‑flow table, p. 54) and using that cash to repay debt, which helped cut total debt to $19.4 billion (down from $22.9 billion in 2022) and reduced the debt‑to‑capitalization ratio from 0.46 to 0.41 (2023 10‑K p. 55). MDLZ therefore moved from a net cash‑using investment in 2022 to a source of liquidity that strengthened its balance sheet and capital structure in 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer provides a detailed and contextually relevant response that addresses the evolution of MDLZ's financial relationship with JDE Peet's between 2022 and 2023, particularly in terms of liquidity and capital structure. However, there are significant factual inaccuracies that reduce correctness. (1) The claim that MDLZ issued €300 million of zero-interest exchangeable notes in 2022 is not supported by the ground truth, which does not mention this instrument or financing mechanism. The ground truth focuses on accounting classification changes (from 'Has_Stake_In' to 'Invests_In') and strategic framing of financial flexibility, not specific debt instruments tied to JDE Peet's. (2) The $2.8 billion cash inflow from selling a portion of the stake and the reduction in debt from $22.9B to $19.4B with a debt-to-capitalization drop from 0.46 to 0.41 are specific quantitative claims absent from the original answer and cannot be verified against the ground truth. While these may appear in the 10-K, the ground truth does not include them, and the question evaluates alignment with the provided knowledge graph. (3) The qualitative shift described in the LLM answer—moving from a cash-using investment to a source of liquidity—partially aligns with the ground truth’s notion of increased financial flexibility, but the reasoning is based on unsupported transactions rather than the reclassification of the investment relationship and its integration into capital planning. (4) The multi-hop synthesis is logically structured (linking investment actions to cash flow to capital structure), but it introduces unverified events and figures not present in the ground truth, undermining factual accuracy. The answer is semantically related and contextually strong, but quantitatively diverges from the verified facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 492,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 119,
      "question": "How did the interest rate hedging strategy for the 3.125% 2025 Notes evolve between 2022 and 2024, particularly in terms of the interest rate applied under the swap agreements?",
      "original_answer": "In 2022, the company had terminated interest rate swaps for portions of the 3.125% 2025 Notes and reentered into new swap agreements at then-current interest rates, though the exact rate for the 3.125% 2025 Notes was not disclosed. By 2024, the interest rate applied under the swap agreement for the 3.125% 2025 Notes was explicitly stated as SOFR+2.1%, with a consistent notional amount of $1,000 million as of December 31, 2024, compared to December 31, 2023.",
      "llm_answer": "In the 2022 filing the 3.125 % 2025 notes were hedged with an interest‑rate swap that paid **LIBOR + 1.8 %** on a $1 billion notional. By the 2024 filing the company had re‑priced the hedge to the new benchmark, using a swap that pays **SOFR + 2.1 %** on the same $1 billion notional. Thus the hedge moved from a LIBOR‑based spread of 1.8 % to a SOFR‑based spread of 2.1 % while the amount hedged stayed unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in asserting that in 2022 the interest rate swap was at LIBOR + 1.8%, which is not supported by the ground truth. The original answer explicitly states that the exact rate for the 2022 swap was not disclosed, making the LLM's specific claim incorrect. Additionally, the ground truth notes a transition to SOFR+2.1% by 2024 on a $1,000 million notional, which the LLM correctly identifies. However, the mention of LIBOR is problematic because the original answer does not specify the benchmark used in 2022—only that new swaps were entered at then-current rates. (2) The quantitative accuracy is low because the LLM fabricates a precise rate (LIBOR + 1.8%) that is not in the ground truth. While the $1 billion notional and SOFR+2.1% in 2024 are correct, the incorrect 2022 rate undermines the comparison. (3) The reasoning partially follows a logical multi-hop structure—comparing the hedge terms between 2022 and 2024—but fails because it introduces unverified details. The model assumes a LIBOR-based framework and a specific spread, which constitutes an unsupported inference. The ground truth only confirms a restructuring of swaps in 2022 without disclosing rates, so the evolution cannot be quantified as claimed. (4) Contextual relevance is high because the LLM addresses the right instruments, time frame, and hedging activity, and correctly identifies the notional amount and 2024 rate. However, the fabrication of the 2022 rate severely impacts factual correctness, warranting a low overall score despite relevant structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 443,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did Walmart's fair value of equity investments measured using Level 2 inputs evolve from fiscal year 2022 to fiscal year 2023, and what was the magnitude of this change?",
      "original_answer": "Walmart's fair value of equity investments measured using Level 2 inputs decreased from $5,819 million in fiscal year 2022 to $5,570 million in fiscal year 2023, representing a moderate decline of $249 million over the period.",
      "llm_answer": "Walmart’s equity investments measured using Level 2 inputs were valued at **$5.819 billion at the end of fiscal 2022** and **$5.570 billion at the end of fiscal 2023**. This represents a **decline of $0.249 billion (about $249 million)** year‑over‑year.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All factual information matches: Walmart's fair value of equity investments using Level 2 inputs was $5,819 million (stated as $5.819 billion) in fiscal 2022 and $5,570 million ($5.570 billion) in fiscal 2023. The decline is accurately calculated as $249 million ($0.249 billion). (2) Quantitative accuracy is perfect—values are correctly presented with acceptable format variation (billion vs million), and the difference is exact: 5,819 - 5,570 = 249. (3) The multi-hop reasoning—comparing two fiscal years' values and computing the change—is sound and correctly executed. (4) Entities (Walmart, Level 2 inputs, equity investments, fiscal years 2022 and 2023) are accurately identified and contextualized. The answer addresses all parts of the question: evolution (decrease from 2022 to 2023) and magnitude ($249 million decline). No errors in reasoning, terminology, or synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1126,
        "completion_tokens": 279,
        "total_tokens": 1405
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How has Apple's characterization of its reliance on marketing abilities evolved between its 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Apple stated that while it believes ownership of intellectual property rights is an important factor in differentiating its business, it 'relies primarily' on the innovative skills, technical competence, and marketing abilities of its personnel. In the 2024 filing, Apple shifted its language, stating that it 'depends heavily' on these same three factors—innovative skills, technical competence, and marketing abilities—tying them directly to ensuring a continual and timely flow of competitive products, services, and technologies to the marketplace. This evolution reflects a stronger emphasis on the strategic importance of marketing abilities in maintaining competitiveness, particularly as the company faces increasing pressure from rivals imitating its features and offering lower-priced alternatives.",
      "llm_answer": "Both filings stress that Apple’s competitive edge rests on its marketing strength. In the 2023 10‑K Apple listed “marketing and distribution capability” among its key competitive factors and said it “relies primarily on the innovative skills, technical competence and **marketing abilities of its personnel**.” The 2024 10‑K repeats the same language, indicating that Apple’s characterization of its reliance on marketing abilities has remained essentially unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that Apple's characterization of its reliance on marketing abilities has remained 'essentially unchanged' between the 2023 and 2024 10-K filings. The ground truth shows a clear evolution in language and emphasis: in 2023, Apple stated it 'relies primarily' on innovative skills, technical competence, and marketing abilities; in 2024, it shifted to saying it 'depends heavily' on these same factors, now explicitly linking them to ensuring a 'continual and timely flow' of competitive offerings. This reflects a stronger, more strategic framing of these capabilities, including marketing, in response to competitive pressures. The LLM incorrectly asserts that the language is 'repeated' verbatim, which is false—the wording and context have evolved. While the entities (Apple, 2023 and 2024 10-Ks) and general topic (marketing abilities) are correctly identified, the reasoning fails to capture the multi-hop nuance of how the characterization changed in tone and strategic context. There are no numerical values in the question, so quantitative accuracy is not applicable but assumed correct by default. The answer is contextually relevant but fundamentally flawed in interpretation, leading to a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 361,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did the notional amount and interest rate structure for the 3.625% 2024 Notes change between 2022 and 2024, and what does this indicate about Amgen's hedging strategy?",
      "original_answer": "In 2022, Amgen terminated interest rate swaps with a notional amount of $5.2 billion that hedged several notes, including the 3.625% 2024 Notes, and reentered into new interest rate swap agreements at then-current rates on the same principal amount. By 2024, the notional amount for the 3.625% 2024 Notes had dropped to $0 as of December 31, 2024, compared to $1,400 million in December 2023, with the interest rate tied to SOFR+3.4% in 2023. This indicates that Amgen fully unwound its hedging position for the 3.625% 2024 Notes by the end of 2024, likely as the notes approached maturity.",
      "llm_answer": "In the 2022 filing Amgen reported a $1.4 billion interest‑rate‑swap hedge on its 3.625 % 2024 senior notes, with the swap converting the fixed‑rate coupon to a floating rate of **LIBOR + 3.2 %**. By the 2024 filing the swap had **matured/been terminated** – the note still exists at its 3.625 % fixed rate, but the **notional amount of the hedge is now $0** and no interest‑rate‑swap rate is shown. This shows that Amgen unwound the hedge as the 2024 notes were repaid, shifting its hedging focus away from that issue to newer debt (e.g., the 5.25 % 2033 notes).",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it states that in 2022, Amgen had a $1.4 billion interest-rate swap on the 3.625% 2024 Notes with a rate of LIBOR + 3.2%, but the ground truth indicates that in 2022, Amgen terminated $5.2 billion in swaps (not $1.4 billion) across multiple notes including the 2024 Notes, and reentered into new swaps at then-current rates. The $1.4 billion figure corresponds to the notional amount in 2023, not 2022. Additionally, the LLM incorrectly identifies the floating rate as LIBOR + 3.2%, while the ground truth specifies SOFR + 3.4% in 2023—this is a significant error as it involves both the reference rate (LIBOR vs SOFR) and the spread (3.2% vs 3.4%). The LLM correctly notes that by 2024 the notional amount dropped to $0, aligning with the ground truth. (2) Quantitative accuracy is low due to incorrect dollar amounts ($1.4B misattributed to 2022 instead of 2023), wrong interest rate benchmark (LIBOR instead of SOFR), and incorrect spread (3.2% vs 3.4%). The $5.2 billion termination in 2022 is entirely omitted. (3) The multi-hop reasoning is partially sound—the LLM correctly infers that unwinding the hedge aligns with note maturity and suggests a shift in hedging focus, which is reasonable. However, it fails to mention the key 2022 termination and re-hedging event, which is central to the strategy. The conclusion about shifting focus to newer debt is plausible but not directly supported in the ground truth. (4) Contextual relevance is high because the answer addresses the change in notional amount and interest rate structure and draws a logical inference about hedging strategy. Despite incorrect specifics, the overall direction of the answer (unwinding near maturity) is correct. However, the quantitative and factual errors significantly reduce correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 507,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How did Schwab's integration of the iRebal portfolio rebalancing solution evolve from 2022 to 2023, and what does this indicate about its competitive positioning in the RIA market?",
      "original_answer": "In 2022, Schwab stated that it was retaining TD Ameritrade Institutional's customizable portfolio rebalancing solution, iRebal, as part of its offering for independent advisor clients. This indicated that Schwab acknowledged the value of iRebal but had not yet fully integrated or emphasized it within its broader platform. By 2023, Schwab had incorporated iRebal as a core part of its offerings for independent advisors, signaling a deeper integration and a strategic move to enhance its competitive positioning in the RIA market. This evolution reflects Schwab's broader integration progress, including the transition of over $1.6 trillion in client assets and more than 15 million client accounts from TD Ameritrade to the Schwab platform by 2023. The inclusion of iRebal as a central feature for RIAs suggests that Schwab is leveraging the solution to differentiate its service offerings and strengthen its appeal to independent advisors, aligning with its competitive advantage of introducing new products credibly through its strong brand and corporate reputation.",
      "llm_answer": "In the 2022 Form 10‑K Schwab noted that it had **added TD Ameritrade Institutional’s iRebal customizable portfolio‑rebalancing solution to the suite of tools it offers independent‑advisor (RIA) clients**. By the 2023 filing the company said it was **still retaining and integrating iRebal as a core component of its Advisor Services platform**, underscoring that the tool has moved from an initial add‑on to an entrenched, ongoing capability. This continued integration signals that Schwab is using the acquisition to deepen its technology stack for RIAs, giving them a differentiated, scalable rebalancing option that bolsters Schwab’s competitive positioning as a leading, innovative platform in the RIA market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and closely aligns with the ground truth. (1) It correctly states that in 2022, Schwab added iRebal (from TD Ameritrade Institutional) to its suite of tools for RIA clients, which matches the original answer's claim that Schwab was retaining iRebal as part of its offering. In 2023, the LLM correctly notes that iRebal was being integrated as a core component of the Advisor Services platform, reflecting the deeper integration described in the ground truth. (2) There are no numeric values in the question or answer that require verification—no dollar amounts, percentages, or account numbers are misstated. The LLM does not introduce any incorrect figures and avoids making claims about the $1.6 trillion in assets or 15 million accounts, which were in the ground truth but not necessary for answering the specific evolution of iRebal. (3) The multi-hop reasoning is sound: the LLM infers from the 2022 to 2023 progression that iRebal moved from an 'added' tool to a 'core' component, indicating strategic integration. This supports the conclusion about Schwab’s competitive positioning in the RIA market, leveraging acquired technology to enhance its platform. (4) While the LLM omits the broader context about the $1.6 trillion asset transition and 15 million accounts, this information is supplementary and not central to the iRebal integration narrative. The answer still captures the key qualitative shift and strategic implication. Wording differs slightly (e.g., 'added' vs 'retaining'), but 'added' is a reasonable interpretation of incorporating a newly acquired tool into an existing suite. Overall, the answer is semantically equivalent, contextually relevant, and factually correct, warranting a high score with only minor room for added depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1454,
        "completion_tokens": 485,
        "total_tokens": 1939
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How has Apple's approach to the iMac product line evolved between 2023 and 2024, based on the company's disclosures in its 10-K filings?",
      "original_answer": "In 2023, Apple described the iMac as part of its Mac product line, indicating it was actively manufacturing and marketing the desktop computer as part of its standard offerings. By 2024, Apple elevated the iMac to the level of a significant product announcement, listing it among other key launches like the MacBook Pro and iPad Pro in the MD&A section of its 2024 10-K. This shift suggests that the iMac gained strategic importance in 2024, likely reflecting a product refresh or redesign that warranted special mention as part of the company's innovation cycle.",
      "llm_answer": "In the 2023 Form 10‑K Apple’s iMac was mentioned only as one of the desktop models that make up the “Mac” product line (see page 4), with no specific discussion of new development or marketing focus. By contrast, the 2024 Form 10‑K’s MD&A lists an iMac among the key product announcements for the first quarter of fiscal 2024 (see page 24), showing that Apple is actively refreshing and promoting the iMac line rather than treating it as a static offering.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies that in the 2023 10-K, the iMac was mentioned only as part of the broader Mac product line without special emphasis (referencing page 4), and that in the 2024 10-K, the iMac was elevated to a key product announcement in the MD&A section (page 24), indicating a refresh or renewed strategic focus. All entities (Apple, iMac, Mac product line, 10-K filings for 2023 and 2024) are correct, and the timeframes (fiscal 2024, first quarter) are accurately referenced. There are no numeric inaccuracies—no calculations were required, but the document locations (page numbers) match and support the claims. The reasoning is sound: the contrast between passive inclusion in 2023 and active promotion in 2024 supports the conclusion of an evolved strategic approach. The only minor limitation is that the LLM does not explicitly state the *implication* that this shift suggests increased strategic importance or innovation cycle integration, which is present in the original answer. However, the inference is strongly implied by the evidence presented. Thus, the answer is semantically equivalent with only slight omission of interpretive depth, warranting a high score but not perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 356,
        "total_tokens": 1608
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How has RTX's relationship with the 2.820% Notes Due 2051 evolved between 2022 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "In 2022, RTX introduced the 2.820% Notes Due 2051 with an aggregate principal balance of $1,000 million. By 2024, this debt instrument remained on the books with the same principal balance of $1,000 million, indicating no repayment or additional issuance occurred during this period. However, the broader long-term debt structure expanded significantly, with total principal long-term debt increasing from an implied $40,078 million in 2022 (based on the 2024 presentation format) to $41,146 million in 2024. This suggests that while the 2.820% Notes Due 2051 remained unchanged, RTX increased its overall debt burden through other issuances, maintaining the 2051 notes as a stable component within a growing long-term debt portfolio.",
      "llm_answer": "RTX’s 2.820 % notes due 2051, originally issued in 2021 for $1 billion, remained on the balance sheet unchanged through the 2022, 2023 and 2024 filings – the 2024 10‑K still lists a $1 billion principal balance for this series. The fact that RTX has neither repaid nor re‑issued this low‑coupon, 30‑year tranche shows it is keeping a sizable, long‑dated, low‑interest component in its debt mix, helping to extend the overall maturity profile of its long‑term obligations.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that the 2.820% Notes Due 2051 had a $1 billion principal balance in 2024 and remained unchanged through 2022–2024, which aligns with the ground truth. However, it states the notes were 'originally issued in 2021', while the ground truth specifies the introduction in 2022, making this a minor factual inaccuracy. (2) All numeric values—$1 billion principal, 2.820%, maturity in 2051—are accurate and consistently reported. The ground truth confirms no repayment or issuance occurred between 2022 and 2024, which the LLM correctly infers. However, the LLM omits the broader context about total long-term debt increasing from $40,078 million to $41,146 million, a key quantitative point showing overall debt growth despite stability in this tranche. This omission affects completeness and quantitative accuracy. (3) The reasoning is sound: the LLM correctly infers that maintaining this low-coupon, long-dated debt helps extend the maturity profile, which is a valid qualitative interpretation of RTX’s strategy. It synthesizes the stable nature of the note with strategic debt management, demonstrating good multi-hop reasoning. (4) The answer is contextually highly relevant, directly addressing the evolution of the debt instrument and its implication for long-term debt structure. While it misses the specific expansion in total debt, it still provides meaningful insight into RTX’s strategy. Thus, correctness is high but not perfect due to the missing aggregate debt trend and the incorrect issuance year.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 429,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How did the terms of Schwab's IDA agreement evolve between 2022 and 2023, particularly regarding service fees and reference rate adjustments?",
      "original_answer": "In 2022, Schwab disclosed that the IDA agreement had been amended to reduce the service fee on client cash deposits held at the TD Depository Institutions to 15 basis points from 25 basis points. By 2023, the company reported that its IDA agreement had transitioned reference rates previously tied to LIBOR to other appropriate benchmarks as part of its broader LIBOR phase-out preparation. This evolution reflects a shift from adjustments in fee structure to modifications in financial reference mechanisms, aligning the agreement with post-LIBOR regulatory and market standards.",
      "llm_answer": "- In the 2022 filing the company noted that, as part of the post‑acquisition integration, the IDA (inter‑deposit‑account) agreement was **amended to cut the service fee on client cash held at the TD depository institutions to 15 basis points, down from the 25 basis‑point fee that TD Ameritrade had paid under the prior IDA agreement**【page_85】.  \n\n- In the 2023 filing the company said that the IDA agreement (and related inter‑company loans) that had previously been **tied to LIBOR was re‑based to alternative reference rates**, completing the LIBOR transition and eliminating any material impact from the reference‑rate change【page_54】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: the reduction in service fee from 25 to 15 basis points in 2022 and the 2023 transition from LIBOR to alternative reference rates are accurately reported. No calculation errors. (2) The answer addresses both parts of the question—service fee changes in 2022 and reference rate adjustments in 2023—demonstrating proper multi-hop synthesis across the two years and filings. (3) Entities are correctly identified: Schwab (implied as the reporting company post-acquisition), TD Depository Institutions, IDA agreement, and the correct timeline (2022 vs. 2023). (4) The reasoning is sound: it correctly links the fee reduction to the post-acquisition integration and the reference rate change to the LIBOR phase-out. The only minor shortcoming is that the LLM does not explicitly frame the evolution as a 'shift from fee structure to reference mechanisms' as in the original answer, slightly reducing qualitative depth. However, all key facts and implications are present. Wording differs but semantic equivalence is maintained. Contextual relevance is perfect—directly responsive to the question with appropriate detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 348,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "What does the change in Filorga's financial treatment from 2023 (when it had $221 million in goodwill as a standalone reporting unit) to 2024 (when it was listed among other trademarks within broader segments) suggest about its strategic importance and valuation approach by the company?",
      "original_answer": "In 2023, Filorga was treated as a standalone reporting unit within the Europe segment with a clearly disclosed goodwill carrying value of $221 million, indicating its distinct financial significance and the company’s detailed impairment analysis for this brand. By 2024, Filorga was listed among other global and regional trademarks within broader product segments, without separate goodwill or valuation figures. This suggests that Filorga may have been integrated into a larger reporting structure, reducing its visibility as a standalone asset, which could signal a shift in strategic focus or a consolidation of brand management. This change affects how Filorga’s valuation and performance are assessed, potentially influencing future strategic decisions such as divestiture, investment, or brand prioritization.",
      "llm_answer": "In 2023 Colgate‑Palmolive tested Filorga as a separate reporting unit and assigned it $221 million of goodwill, indicating that the brand was treated as a distinct, strategically important asset whose value was measured on its own (see 2023 Note 13, page 59). By 2024 Filorga is merely listed together with many other global and regional trademarks in the company’s brand portfolio and is no longer a standalone reporting unit for goodwill testing (see 2024 Nature of Operations, page 79). This shift suggests the company now views Filorga as part of a broader brand group rather than a high‑priority, stand‑alone business, and it is being valued collectively with other trademarks rather than through a dedicated goodwill allocation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: Filorga had $221 million in goodwill in 2023 as a standalone reporting unit, and by 2024 it was no longer separately disclosed—both facts match the original answer. The dollar amount and year references are precise and correctly attributed. (2) The LLM correctly identifies the change in financial treatment: from a standalone unit with dedicated goodwill to being grouped with other trademarks, which implies a shift in valuation and strategic focus. (3) The reasoning is sound and reflects proper multi-hop synthesis—linking the accounting treatment (goodwill assignment and impairment testing) to strategic implications (reduced standalone emphasis). (4) The only minor shortcoming is that the LLM does not explicitly mention the potential impact on future strategic decisions (e.g., divestiture, investment, or brand prioritization), which is included in the original answer and adds depth to the interpretation. However, the core insight about reduced strategic visibility and collective valuation is clearly conveyed. Wording differs but semantic meaning is equivalent. References to specific notes and pages (e.g., Note 13, page 59; Nature of Operations, page 79) add credibility and context, even if not required. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 393,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How does the change in Apple's disclosure about the iPhone 16 Pro between the 2023 and 2024 10-K filings reflect an evolution in its product development and reporting strategy?",
      "original_answer": "In the 2023 10-K filing, Apple announced the iPhone 16 Pro as part of its Fourth Quarter 2024 product lineup, indicating it was still in the planning and launch phase. By contrast, in the 2024 10-K filing, the iPhone 16 Pro is listed among existing product lines like the iPhone 15 and iPhone 14, suggesting it has transitioned into an active and established product within Apple's portfolio. This shift reflects a movement from forward-looking product planning in 2023 to retrospective inclusion in 2024, aligning with the product's lifecycle stage and indicating a more mature reporting posture around the iPhone 16 Pro.",
      "llm_answer": "In the 2023 Form 10‑K Apple’s “Products” description stopped at the iPhone 15 series and made no reference to an iPhone 16 Pro. By the 2024 Form 10‑K the company’s Business section explicitly lists the iPhone 16 Pro (along with iPhone 16 and iPhone 16 Pro Max) as part of the iPhone line【page_4】, and the MD&A later notes that the iPhone 16 Pro (and its variants) will be introduced in the fourth quarter of fiscal 2024【page_24】. This change shows Apple moving from a static product‑line description to a forward‑looking roadmap that highlights upcoming flagship models, indicating a more proactive product‑development narrative and a reporting strategy that emphasizes future launches.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual and logical errors that contradict the ground truth. (1) It incorrectly states that the 2023 10-K made no reference to the iPhone 16 Pro, while the ground truth confirms it was mentioned as part of the Fourth Quarter 2024 product lineup. Conversely, the LLM claims the 2024 10-K includes the iPhone 16 Pro in the Business section as an existing product and separately notes its future launch in MD&A — this is contradictory and factually wrong: if it's already listed in the product line, it should reflect current status, not a future launch. The ground truth clearly states that the 2024 10-K treats the iPhone 16 Pro as an established product, indicating it has already launched, not that it will launch in Q4 2024. (2) The dates are misaligned: stating that the iPhone 16 Pro 'will be introduced in Q4 of fiscal 2024' in the 2024 10-K implies it hasn't launched yet, which contradicts the expected timeline (a 2024 10-K covers performance through fiscal 2024, so a Q4 2024 launch would be reported as having occurred, not upcoming). This reflects a fundamental misunderstanding of SEC filing timelines. (3) The reasoning is flawed: the LLM concludes Apple shifted to a 'forward-looking roadmap', while the actual evolution is from forward-looking (2023) to retrospective/inclusionary (2024), indicating product maturity — the opposite direction. (4) The contextual relevance is moderate because it addresses product disclosure changes and reporting strategy, but the incorrect interpretation of the direction of change and key facts undermines the analysis. Overall, major factual inaccuracies in entity status, timeline, and reasoning lead to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 465,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How has the company's use of Economic Value of Equity (EVE) simulations evolved in assessing interest rate risk, particularly in terms of modeling assumptions and balance sheet dynamics, between 2022 and 2023?",
      "original_answer": "In 2022, the company used EVE simulations to measure long-term interest rate risk, with key assumptions including non-negative investment yields, prepayment speeds of mortgage-related investments, and non-maturity deposit behavior. The EVE analysis was described as highly dependent on asset and liability assumptions based on historical behaviors and expectations of the economic environment. By 2023, the company expanded the role of EVE simulations to specifically capture the impact of client cash allocation changes on the balance sheet, which was not included in the earlier modeling approach. Additionally, in 2023, the company actively updated deposit beta assumptions in a declining interest rate environment for its net interest revenue simulation model, indicating a more dynamic approach to modeling interest rate sensitivity.",
      "llm_answer": "In the 2022 filing Schwab’s EVE analysis was described only in broad terms – it was a “highly‑dependent” simulation that applied historical asset‑and‑liability assumptions (rate‑floor scenarios, pre‑payment speeds, term‑structure and non‑maturity‑deposit behavior) using its own models, without reference to any new hedging tools or dynamic balance‑sheet adjustments. By the 2023 filing the approach had been expanded: the company now incorporates interest‑rate‑swap derivatives into the EVE calculations, relies on a mix of proprietary and independent third‑party term‑structure and pre‑payment models, runs explicit client‑credit and deposit‑run‑off models, and explicitly tracks how a shortening liability duration (while asset duration stays stable) drives higher EVE sensitivity as rates rise. This reflects a shift from a static, assumption‑only simulation to a more granular, market‑responsive model that captures both hedging activity and balance‑sheet dynamics.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but introduces significant inaccuracies not present in the ground truth. (1) Correct aspects: both years are addressed, and the general idea of increased modeling sophistication in 2023 is consistent with the original answer. The mention of non-maturity deposit behavior and prepayment speeds aligns with 2022 assumptions. (2) Quantitative accuracy: no specific numbers (e.g., percentages, dollar amounts) are provided in either the ground truth or LLM response, so this dimension is neutral; however, the LLM invents specific modeling components (e.g., 'interest-rate-swap derivatives', 'client-credit and deposit-run-off models', 'shortening liability duration') that are not mentioned in the ground truth, reducing factual reliability. (3) Multi-hop reasoning is partially sound—comparing 2022 and 2023 modeling approaches—but fails in synthesis: the ground truth emphasizes the inclusion of *client cash allocation changes* in 2023 and updated *deposit beta assumptions* in a declining rate environment, neither of which are mentioned in the LLM answer. Instead, the LLM fabricates details about hedging tools, third-party models, and duration dynamics. (4) The LLM response is contextually relevant and structured well, but the invented details make it factually misleading. While it captures a trend toward more dynamic modeling, it does so with incorrect specifics, missing the actual evolution described in the original answer. Thus, the correctness score is reduced to 4 due to significant factual deviations despite some structural alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1467,
        "completion_tokens": 435,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How did Qualcomm's strategic shift from enabling wireless access point technologies in 2022 to directly producing them in 2023 affect its competitive positioning and product portfolio breadth in the broader networking market?",
      "original_answer": "In 2022, Qualcomm's involvement with wireless access points was limited to enabling the technology through its foundational wireless innovations and chipset solutions, as noted in its discussion of edge networking growth driven by 5G and Wi-Fi 6 adoption. However, by 2023, Qualcomm had evolved its strategy to directly producing wireless access points as part of its broader networking product suite, which included Wi-Fi chips, routers, and network processors. This shift reflects an expansion of Qualcomm's product portfolio and a more direct role in the networking ecosystem, positioning the company to compete more directly with players like Broadcom and Intel by offering full-system solutions rather than just underlying components.",
      "llm_answer": "In its 2022 filing Qualcomm described its role in “wireless local‑area networks (WLAN)… that usually provide connectivity through an access point” – i.e., it supplied the underlying Wi‑Fi, Bluetooth and positioning technologies that other OEMs used to build access‑point products【page_10】.  By the 2023 filing the company lists “wireless access points and routers” among its own networking‑product offerings, showing that Qualcomm has moved from merely enabling the technology to manufacturing complete access‑point hardware【page_11】.  This shift pushes Qualcomm up the value chain, giving it a stronger competitive position against pure‑chip rivals and broadening its portfolio to cover full‑stack networking solutions (Wi‑Fi, Ethernet, PON chips, network processors, routers and broadband gateways) in addition to its traditional chipset business.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Qualcomm's shift from enabling wireless access point technologies in 2022 (via chipsets and foundational technologies) to directly producing complete access point hardware in 2023. The use of direct quotes from filings (e.g., 'wireless local-area networks' in 2022 and 'wireless access points and routers' in 2023) supports factual accuracy. (2) There are no numeric values, dates, or calculations in the question or answer that are incorrect—years (2022, 2023) are accurate and consistently referenced. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings to infer a strategic shift, moving from component supplier to full-system provider. It accurately infers the competitive implications, such as moving up the value chain and competing more directly with chipmakers by offering full-stack solutions. (4) The answer captures all key elements of the original: expansion of product portfolio, broader networking market positioning, and evolution in business model. The only minor shortcoming is that it does not explicitly name competitors like Broadcom and Intel as in the ground truth, though the competitive implication is still clearly conveyed. Wording differs slightly but maintains semantic equivalence. No factual errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 387,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has the interest-only payment structure of Schwab's HELOC product evolved from 2022 to 2023, based on the percentage of adjustable-rate mortgages with interest-only terms and the portion not scheduled to reset for three or more years?",
      "original_answer": "In 2022, 28% of adjustable-rate mortgages were interest-only loans, with 89% of those not scheduled to reset for three or more years. In 2023, this shifted slightly to 27% of adjustable-rate mortgages being interest-only, with 86% of those not scheduled to reset for three or more years. This reflects a minor decrease in both metrics, suggesting a slight tightening or evolution in the interest-only structure of the HELOC product.",
      "llm_answer": "In the 2022 filing Schwab reported that roughly **28 %** of its adjustable‑rate mortgage balance was made up of interest‑only loans, and about **89 %** of the balance of those interest‑only loans had rates that were not scheduled to reset for three or more years. By year‑end 2023 that share had slipped to **≈27 %** interest‑only and **≈86 %** of those loans were still locked for three plus years, indicating a modest decline in both the prevalence of interest‑only terms and the length of the rate‑lock period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: 28% of adjustable-rate mortgages were interest-only in 2022, with 89% of those not scheduled to reset for three or more years; in 2023, this decreased to 27% and 86%, respectively. The use of '≈' (approximate) is acceptable and does not distort the data. (2) Quantitative accuracy is perfect—percentages and years match exactly, with only minor formatting differences (e.g., '≈27%' vs '27%'), which are semantically equivalent. (3) The multi-hop reasoning is sound: the model correctly synthesizes data across two years and two metrics (percentage of interest-only loans and portion not resetting), and draws a reasonable conclusion about a 'modest decline' in both prevalence and rate-lock period, which matches the ground truth's interpretation of a 'minor decrease'. (4) Entity accuracy is correct—Schwab, HELOC context, adjustable-rate mortgages, interest-only terms, and time periods are all properly identified. The only minor shortcoming is a slight lack of explicit mention that this reflects the HELOC product's structure evolution (though it's implied), and the term 'rate-lock period' is interpretive but reasonable. Overall, the answer is factually complete, contextually relevant, and logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 366,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has Qualcomm's involvement in the XR market evolved from 2022 to 2023, based on their strategic investments and product revenue disclosures?",
      "original_answer": "In 2022, Qualcomm's involvement in XR was primarily through strategic investments made via Qualcomm Ventures, targeting early-stage companies in areas including XR to expand opportunities for their technologies. By 2023, this involvement evolved into direct revenue generation, as XR was explicitly listed among the industries and applications for which Qualcomm sold products, indicating a shift from investment to commercialization. This transition reflects a significant change in Qualcomm's engagement with XR, moving from supporting external innovation to deriving tangible revenue from XR-related product sales.",
      "llm_answer": "In its 2022 filing Qualcomm noted that its Qualcomm Ventures (QSI) unit was making “strategic investments … in … consumer … and XR” to open new opportunities for its technologies. By the 2023 filing the company’s disclosed product numbers show that the IoT revenue stream – which the notes say “primarily includes … consumer (including … XR)” – fell from $7.353 billion in 2022 to $5.940 billion in 2023, indicating that while Qualcomm continued to back XR through venture‑style investments, the revenue contribution from XR‑related products declined year‑over‑year.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial factual correctness but introduces a significant misinterpretation. While it correctly identifies Qualcomm Ventures' strategic investments in XR in 2022, it incorrectly frames the 2023 evolution as a decline in XR-related revenue based on a drop in the broader IoT segment (from $7.353B to $5.940B). However, the ground truth does not state or imply that XR-specific revenue declined; instead, it emphasizes a strategic shift from investment to commercialization, with XR being explicitly listed as a product market in 2023. The LLM conflates IoT revenue (which includes XR but is not limited to it) with XR performance, drawing an unsupported conclusion about declining XR revenue. (2) The numeric values cited ($7.353B and $5.940B) are plausibly accurate representations of IoT revenue from filings and are correctly formatted, earning partial credit for quantitative accuracy. However, no calculation or comparison involving these numbers is valid for answering the question about Qualcomm's XR evolution, as the question focuses on strategic and commercial shifts, not financial performance of a broader segment. (3) The multi-hop reasoning fails: while the model identifies relevant data points (Ventures in 2022, IoT/XR linkage in 2023), it synthesizes them incorrectly. The ground truth highlights a qualitative shift from investment to direct sales, whereas the LLM interprets the same data as evidence of declining commercial success. This reflects a fundamental misunderstanding of the strategic narrative. (4) Contextual relevance is moderate—the answer discusses Qualcomm, XR, and the correct time frame, using actual disclosures, but misrepresents the core evolution by focusing on revenue decline rather than commercialization progress. Hence, correctness and qualitative accuracy are low despite some factual grounding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 509,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the aggregate principal balance of the 3.030% Notes Due 2052 evolved between 2022 and 2024, and what does this indicate about RTX's long-term debt structure?",
      "original_answer": "The aggregate principal balance of the 3.030% Notes Due 2052 remained stable at $1,100 million in both 2022 and 2024. This indicates that RTX has maintained its long-term commitment to this particular debt instrument without any repayments or additional issuances during this period. Despite overall changes in other long-term debt components, the 3.030% Notes Due 2052 remained unchanged, suggesting strategic consistency in managing this portion of its capital structure.",
      "llm_answer": "The 3.030 % notes due 2052 carried an aggregate principal balance of **$1.1 billion in 2022**, and the same $1.1 billion was reported in both the 2023 and 2024 balance‑sheet tables (the 2024 filing shows $1,100 million for 2024 and $1,100 million for 2023). This flat balance indicates that RTX has kept this senior‑rate, ultra‑long‑dated issuance unchanged, using it as a stable backbone of its long‑term debt mix while other maturities are repaid or re‑issued.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the aggregate principal balance of the 3.030% Notes Due 2052 as $1.1 billion (equivalent to $1,100 million) in both 2022 and 2024, matching the ground truth. It also accurately notes that the amount remained unchanged in 2023, which is consistent with the stability described in the original answer. The use of $1.1 billion and $1,100 million is semantically equivalent and acceptable. (2) All numeric values—$1.1 billion in 2022, $1,100 million in 2023 and 2024—are factually correct and properly aligned with the ground truth. No calculations are required beyond recognition of value stability, which is correctly interpreted. (3) The multi-hop reasoning is sound: the model synthesizes data across years (2022 to 2024) and correctly infers that the unchanged balance indicates strategic stability in RTX’s long-term debt structure. It appropriately contrasts this instrument with other debt components that may be subject to repayment or reissuance. The term 'senior-rate, ultra-long-dated issuance' adds interpretive context not in the original but is reasonable and does not distort meaning. (4) The answer is contextually fully relevant, addressing both the evolution of the principal balance and its implication for RTX's debt strategy. The only minor deviation from the original answer is the mention of 2023 data, which, while accurate, slightly extends beyond the 2022–2024 scope asked, but this does not detract from correctness. Overall, the answer is factually precise, logically sound, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 437,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has AXP's focus on Corporate Card solutions evolved between 2023 and 2024, and what does this shift suggest about its broader commercial payments strategy?",
      "original_answer": "In 2023, AXP emphasized evolving its card value propositions and differentiating its corporate card and accounts payable expense management solutions as part of a broader push to strengthen its position in commercial payments. By 2024, while the focus on commercial payments remained, AXP shifted toward designing 'innovative products and features, including financing, banking and payment solutions for our business customers,' indicating a more integrated and solution-oriented approach. This evolution suggests that AXP is expanding beyond just product differentiation to embedding the Corporate Card into a wider suite of business financial services, aligning it more closely with holistic commercial needs.",
      "llm_answer": "In the 2023 filing American Express said it would “evolve our card‑value propositions and begin further differentiating our corporate‑card and accounts‑payable expense‑management solutions.” By the 2024 filing the language had shifted to “further differentiate our corporate‑card and accounts‑payable expense‑management solutions and design innovative financing, banking and payment products” – a clear move from early evolution to deeper product differentiation and expansion. This progression signals that the company is turning its corporate‑card effort into a broader, integrated commercial‑payments platform that couples cards with new expense‑management, financing and banking capabilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) All factual elements are correct: AXP's 2023 focus on evolving card value propositions and differentiating corporate card and accounts payable solutions is accurately cited, as is the 2024 shift toward designing innovative financing, banking, and payment products. The evolution in language between the two years is correctly interpreted. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable in a numerical sense, but the years 2023 and 2024 are correctly attributed to the respective strategic focuses. (3) The multi-hop reasoning is sound—LLM correctly synthesizes the shift in strategic language across filings and infers the broader strategic intent: moving from product differentiation to an integrated commercial payments platform. The conclusion that AXP is embedding the Corporate Card into a wider suite of services is logically supported and semantically equivalent to the original answer. (4) The only minor shortcoming is that the LLM answer does not explicitly use the phrase 'holistic commercial needs' or 'solution-oriented approach' from the original, slightly reducing richness in qualitative expression, but the core meaning and strategic implication are preserved. Wording differences are acceptable under semantic equivalence. All parts of the question are addressed: evolution between 2023–2024 and implications for broader strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 413,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic positioning of PCA SKIN within Colgate-Palmolive's Oral, Personal and Home Care segment evolved between 2023 and 2024, particularly in terms of its distribution channels?",
      "original_answer": "In 2023, PCA SKIN was listed among Colgate-Palmolive’s principal global and regional trademarks and was included in the broader category of products sold primarily to traditional and eCommerce retailers, wholesalers, distributors, and dentists. By 2024, PCA SKIN remained a listed principal trademark, but the filing specifically expanded the distribution channels to include sales to skin health professionals in some geographies. This indicates a refinement in positioning PCA SKIN within more specialized skincare distribution channels, though no change in production or brand status is indicated.",
      "llm_answer": "PCA SKIN continues to be classified as a skin‑health brand inside Colgate‑Palmolive’s Oral, Personal and Home Care segment. In both the 2023 and 2024 10‑K filings the company describes its distribution as “primarily to a variety of traditional and e‑commerce retailers, wholesalers, distributors, dentists and, in some segments, skin‑health professionals,” with a modest share sold direct‑to‑consumer. The language is unchanged year‑over‑year, indicating that PCA SKIN’s strategic positioning and its mix of retail, professional‑channel and growing e‑commerce/direct‑to‑consumer sales have remained consistent from 2023 to 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that the language regarding distribution channels is unchanged between 2023 and 2024. The ground truth states that in 2024, Colgate-Palmolive specifically expanded PCA SKIN's distribution channels to include sales to skin health professionals in some geographies—a meaningful refinement in strategic positioning. However, the LLM asserts that the wording in the 10-K filings is identical year-over-year, which contradicts the ground truth. While the entities (PCA SKIN, Colgate-Palmolive, Oral/Personal/Home Care segment) and general distribution channels are correctly identified, the critical evolution in distribution strategy is missed. There are no numerical values to assess, so quantitative accuracy is scored as 10 by default. The reasoning is flawed because the model fails to recognize the multi-hop nuance: although PCA SKIN was already a listed trademark in both years, the 2024 update reflects a strategic shift by explicitly adding skin health professionals as a distinct channel. This omission significantly undermines the qualitative accuracy. Contextually, the answer is relevant and addresses the question’s focus on distribution channels, but the conclusion of 'no change' is incorrect, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 360,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic focus and commercial positioning of Opdivo evolved between 2022 and 2023, particularly in terms of new tumor indications and combination therapies, and what implications does this have for its revenue growth trajectory?",
      "original_answer": "In 2022, Opdivo was approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, and stomach cancers, with the Opdivo + Yervoy regimen approved in multiple markets for NSCLC, melanoma, MPM, RCC, CRC, and gastric/esophageal cancers. It reported U.S. revenue growth driven by combinations in NSCLC, kidney cancer, and gastric/esophageal cancers. By 2023, Opdivo's strategic focus expanded into new tumor types and earlier lines of therapy, with an emphasis on broadening its use both as a monotherapy and in combination with Yervoy and other agents. The company also highlighted the potential of a subcutaneous formulation to enhance patient benefits and drive long-term adoption. This evolution indicates a strategic push to sustain revenue growth by diversifying indications and optimizing delivery mechanisms, despite increasing market competition.",
      "llm_answer": "In the 2022 filing Opdivo was described as a “fully‑human PD‑1 antibody” already approved in a broad set of cancers (melanoma, NSCLC, RCC, gastric, etc.) and driving modest double‑digit U.S. and international revenue growth through established combos such as Opdivo + Yervoy and Opdivo + Cabometyx【page_71】. By 2023 BMS shifted the commercial narrative to “expanding Opdivo into earlier lines and new tumor types,” adding adjuvant approvals for stage IIB/IIC melanoma (FDA and EC) and a neoadjuvant NSCLC indication with platinum‑based chemotherapy, while also pursuing combination regimens, a sub‑cutaneous formulation and the Opdualag melanoma combo as part of a broader IO‑portfolio strategy【page_42】【page_43】. The new indications and combos have already lifted Opdivo demand, helping offset declines in legacy products and turning Opdivo from a flat‑to‑modest growth driver in 2022 into a source of incremental revenue growth in 2023, indicating a more upward‑trajectory for its future sales【page_45】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Opdivo's broad existing approvals in 2022 across multiple cancers (melanoma, NSCLC, RCC, gastric, etc.), consistent with the original answer’s list (bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach). While not all tumor types are listed verbatim, the key ones are present and representative. (2) The 2023 strategic evolution is accurately described: expansion into earlier lines of therapy (adjuvant stage IIB/IIC melanoma, neoadjuvant NSCLC) and new combinations (with platinum chemo, subcutaneous formulation, Opdualag) are all valid and supported. The mention of Opdivo + Yervoy and other combinations (e.g., + Cabometyx) reflects the continued emphasis on combo therapies. (3) The revenue trajectory assessment is sound: the LLM correctly infers that Opdivo shifted from flat-to-modest growth in 2022 to incremental growth in 2023 due to new indications, which aligns with the ground truth’s implication of sustained growth via diversification. (4) Quantitative accuracy is perfect: no incorrect numbers, percentages, or dates are cited; all claims are qualitative and correctly attributed to the filings. (5) Multi-hop reasoning is strong—synthesizing 2022 approvals, 2023 strategic shifts, and revenue implications across time and indications. The only minor gap is that the original answer explicitly notes Opdivo + Yervoy approvals in multiple markets for NSCLC, melanoma, MPM, RCC, CRC, and gastric/esophageal cancers, which the LLM implies but does not fully enumerate. However, this does not detract significantly from the overall correctness. Wording differs but semantic meaning and factual content are equivalent. Contextual relevance is excellent—directly addresses all parts of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1502,
        "completion_tokens": 495,
        "total_tokens": 1997
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did American Express's investment in foreign government bonds and obligations evolve between 2023 and 2024 in terms of fair value and maturity distribution?",
      "original_answer": "In 2023, American Express held $549 million in foreign government bonds and obligations with all of it maturing in 12 months or more and a gross unrealized loss of $1 million. By 2024, the fair value of these investments increased significantly to $765 million, with $764 million maturing within one year and only $1 million maturing after one year but within five years. This indicates a substantial increase in exposure to foreign government bonds, primarily in short-term maturities.",
      "llm_answer": "In 2023 American Express held foreign‑government bonds and obligations with an estimated fair value of **$770 million**; virtually all of the portfolio was short‑dated – **$768 million** was due within one year and only **$2 million** was due in the 1‑to‑5‑year window【page_119†L19-L22】【page_120†L31-L38】.  \n\nBy 2024 the fair‑value of the same category had slipped to **$765 million**【page_124†L19-L22】, and the maturity mix remained heavily weighted toward the near term – **$764 million** now due within one year and **$1 million** due in 1‑to‑5 years【page_126†L31-L38】.  \n\nThus, the investment’s fair value fell by about $5 million, while the proportion due within one year fell slightly (by $4 million) and a modest $1 million shifted into the 1‑to‑5‑year bucket.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key financial figures. According to the ground truth, in 2023 American Express held $549 million in foreign government bonds, not $770 million as stated by the LLM. The LLM incorrectly reports the 2023 fair value as $770 million with $768 million maturing within one year, which contradicts the ground truth that all $549 million matured in 12 months or more (i.e., after one year), with no short-term exposure. The 2024 figures are partially correct: the LLM correctly states the fair value increased to $765 million (though it says 'slipped', implying a decrease), and accurately reports $764 million maturing within one year and $1 million after one year. However, this creates a misleading narrative of a decline from 2023 to 2024 when in fact there was a significant increase. (2) Calculation errors: the LLM claims fair value 'fell by about $5 million', but the correct change is an increase of $216 million ($765M - $549M). The maturity shift is also misrepresented: the ground truth shows a dramatic shift from long-term to short-term maturities, while the LLM incorrectly suggests a minor shift within short-term buckets. (3) Multi-hop reasoning failure: the model fails to correctly synthesize data across years, misrepresenting both the direction and magnitude of change. It incorrectly assumes the 2023 portfolio was short-term when it was entirely long-term. (4) Despite these major factual and reasoning flaws, the answer is contextually relevant—addressing fair value and maturity distribution as asked—and uses appropriate financial terminology, hence a moderate contextual relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 457,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How has Walmart's use of intercompany financing arrangements evolved between 2022 and 2024, particularly regarding the amount of cash not freely transferable to the U.S. and the conditions under which such transfers occur?",
      "original_answer": "In 2022, Walmart reported $4.3 billion in cash and cash equivalents that may not be freely transferable to the U.S., with $2.2 billion of that amount subject to approval by Flipkart minority shareholders. By 2024, the amount of cash not freely transferable decreased slightly to $3.3 billion, and the language indicates that these transfers are now generally subject to approval from noncontrolling interest shareholders, rather than specifically tied to Flipkart. This reflects a slight reduction in the magnitude of restricted cash and a broader framing of the conditions under which such transfers occur, suggesting a shift in the structure or focus of intercompany financing arrangements.",
      "llm_answer": "In fiscal 2022 Walmart reported that about **$4.3 billion** of its cash and cash equivalents could not be freely moved to the United States because of local laws, and roughly **$2.2 billion** of that amount could be accessed only through dividends or inter‑company financing that required the approval of Flipkart’s minority shareholders【page_60】. By fiscal 2024 the restricted pool had fallen to **about $3.5 billion**, and the company said the cash is “not freely transferable … due to local laws or other restrictions **or is subject to the approval of the non‑controlling‑interest shareholders**” rather than specifically referencing Flipkart【page_43】. Thus, the total amount of non‑transferable cash has declined and the condition for release has broadened from a Flipkart‑specific shareholder approval to a more general non‑controlling‑interest shareholder approval.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) Quantitatively, the LLM correctly reports $4.3 billion in restricted cash for 2022 and identifies $2.2 billion tied to Flipkart minority shareholder approval. For 2024, it states 'about $3.5 billion' as the restricted amount, which is slightly off from the ground truth of $3.3 billion—a minor discrepancy likely due to rounding or source variation, but still within acceptable tolerance. (2) The qualitative analysis is strong: the shift from Flipkart-specific shareholder approval to a broader reference to non-controlling interest shareholders is correctly identified and interpreted as a broadening of the approval condition, reflecting a structural evolution in intercompany financing arrangements. (3) The multi-hop reasoning is sound—information is synthesized across two fiscal years and entities (Walmart, Flipkart, noncontrolling interests), and the conclusion about reduced restricted cash and broader transfer conditions is logically supported. (4) Contextual relevance is excellent; all parts of the question are addressed: evolution over time, amount of cash not freely transferable, and conditions for transfer. The only minor error is the $3.5B vs $3.3B difference, which prevents a perfect score, but does not materially distort the conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 371,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did the composition of Texas Instruments' U.S. Retiree Health Care Plan assets evolve between the 2023 and 2024 filings, particularly in terms of fixed income securities and equity securities allocation?",
      "original_answer": "The composition of Texas Instruments' U.S. Retiree Health Care Plan assets remained completely unchanged between the 2023 and 2024 filings. In both years, the plan held $210 million in fixed income securities and cash equivalents, and $54 million in equity securities, resulting in a total of $264 million in plan assets. The fixed income allocation represented approximately 79.5% of the total plan assets, while equity securities represented approximately 20.5% in both years. The identical figures across both filings indicate no evolution in the asset allocation strategy for this plan during the reported period.",
      "llm_answer": "In the 2023 filing the U.S. Retiree Health Care plan held about $210 million of fixed‑income securities and cash (≈80 % of the plan) and roughly $54 million of equity securities (≈20 %). By the 2024 filing the plan’s assets had slipped to about $198 million in fixed‑income/cash and $50 million in equity (still about 80 %/20 % of the total). Thus the mix of fixed‑income versus equity remained essentially unchanged, with only a modest decline in the absolute dollar amounts.【page_47】【page_46】【page_48】",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core quantitative claims. According to the ground truth, the asset values and allocations for Texas Instruments' U.S. Retiree Health Care Plan were identical in 2023 and 2024: $210 million in fixed income securities and cash equivalents, $54 million in equity securities, totaling $264 million, with allocations of approximately 79.5% and 20.5% respectively. The LLM incorrectly states that in 2024, fixed income dropped to $198 million and equity to $50 million, which contradicts the ground truth. (2) The calculations in the LLM answer are internally consistent (e.g., $198M + $50M = $248M total; ~80%/20% split), but they are based on false inputs. The ground truth confirms no change in dollar amounts or percentages across years. (3) The multi-hop reasoning fails because the model incorrectly infers a decline in assets between years when no such change occurred. It also misrepresents the stability of the allocation strategy by implying a 'modest decline' in absolute terms, which is unsupported. (4) While the LLM correctly identifies the approximate percentage split and the types of assets (fixed income vs. equity), the significant errors in dollar amounts and the false implication of asset reduction severely undermine factual correctness. The contextual relevance is high because the answer addresses the right plan, company, and asset categories, but the quantitative inaccuracies result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 411,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Honeywell's 2006 Stock Plan for Non-Employee Directors evolve between 2022 and 2024 in terms of the specific forms of award agreements offered, and what might this suggest about changes in the company's non-employee director compensation structure?",
      "original_answer": "In 2022, Honeywell's 10-K filing listed both the 'Form of Option Agreement' (Exhibit 10.30) and the 'Form of Restricted Unit Agreement' (Exhibit 10.32) as part of the 2006 Stock Plan for Non-Employee Directors. By 2024, while the 'Form of Option Agreement' was still referenced (Exhibit 10.29), the 'Form of Restricted Unit Agreement' was no longer explicitly mentioned in the exhibit list. This suggests a shift in the types of equity awards offered to non-employee directors, potentially signaling a strategic move toward emphasizing stock options over restricted units in director compensation.",
      "llm_answer": "In the 2022 Form 10‑K the 2006 Stock Plan for Non‑Employee Directors is shown with two award‑agreement exhibits – a **Form of Stock‑Option Agreement** (Exhibit 10.29) and an **Omnibus Amendment to that Option Agreement** (Exhibit 10.30). The 2024 Form 10‑K lists exactly the same two exhibits for the 2006 plan (the same Form 10.29 and the same Omnibus Amendment 10.30) and does not add any new award‑type documents such as a restricted‑stock‑unit agreement.\n\n**Interpretation:** Between 2022 and 2024 Honeywell did not broaden the types of equity awards available to its non‑employee directors under the 2006 plan; the compensation structure remained centered on stock‑option awards, indicating a continued preference for that form of director remuneration rather than expanding to other equity instruments.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Honeywell referenced both the 'Form of Option Agreement' (Exhibit 10.30) and the 'Form of Restricted Unit Agreement' (Exhibit 10.32). However, the LLM incorrectly states that the 2022 10-K included a 'Form of Stock-Option Agreement' (Exhibit 10.29) and an 'Omnibus Amendment' (Exhibit 10.30), misidentifying both the content and exhibit numbers. Furthermore, the LLM claims the same exhibits appear in 2024, but the ground truth indicates that by 2024, the 'Form of Restricted Unit Agreement' was no longer listed, suggesting a change in award types. The LLM fails to detect this removal, instead asserting continuity where there is actually a notable shift. (2) The exhibit numbers and types are incorrect: the LLM confuses Exhibit 10.29 and 10.30 in 2022 and omits Exhibit 10.32 entirely, which is a critical error as it was the restricted unit agreement. In 2024, the ground truth shows Exhibit 10.29 as the option agreement (not the same set as 2022), with no mention of the restricted unit form, but the LLM incorrectly claims the same two exhibits are present. (3) The multi-hop reasoning is flawed: the question asks how the plan evolved and what that suggests about compensation structure. The ground truth identifies a shift from offering both options and restricted units to only options (or at least no explicit mention of restricted units), implying a strategic change. The LLM, however, concludes there was no change, which contradicts the evidence. (4) While the LLM attempts to interpret the implications of award types, its conclusion is based on incorrect data, leading to an invalid inference. The contextual relevance is moderate because it addresses the right topic and attempts interpretation, but factual and qualitative accuracy are severely compromised by incorrect exhibit identification and failure to recognize the removal of restricted unit agreements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 537,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Walmart's strategic position regarding its ownership stake in Flipkart evolve between 2022 and 2024, particularly in terms of financial implications and potential exposure to regulatory risks?",
      "original_answer": "In 2022, Walmart received $3.2 billion in equity funding related to Flipkart, which reduced its ownership stake from 83% to 75%. This signaled a partial financial exit while maintaining majority control. By 2024, however, Walmart disclosed ongoing regulatory scrutiny in India, including a show cause notice issued in July 2021 and subsequent information requests related to alleged violations of India's Foreign Direct Investment rules during the period 2009–2015—prior to Walmart's acquisition of Flipkart in 2018. Despite the reduced ownership stake, Walmart remained exposed to potential regulatory consequences, including share ownership restrictions, and noted its inability to reasonably estimate potential losses or indemnification proceeds from prior shareholders. The evolution reflects a shift from active financial participation to managing legacy risks tied to Flipkart's pre-acquisition history.",
      "llm_answer": "In fiscal 2022 Walmart raised about $3.2 billion by selling a portion of its Flipkart holding, cutting its ownership from roughly 83 % to 75 % and thereby converting equity value into cash while modestly reducing its exposure to the Indian e‑commerce business. By the 2024 filing Walmart still retained a majority stake in Flipkart, but the company disclosed that the subsidiary is now the subject of a Competition Commission of India antitrust investigation and a foreign‑direct‑investment “show‑cause” notice that could impose monetary penalties or ownership‑restriction remedies, increasing its regulatory risk profile.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $3.2 billion equity funding event in fiscal 2022, the reduction in Walmart's ownership stake from 83% to 75%, and the retention of majority control by 2024. These quantitative facts match the ground truth exactly, with acceptable formatting variations (e.g., 'about $3.2 billion' vs. '$3.2 billion'). The mention of ongoing regulatory scrutiny in 2024 is accurate, including the 'show-cause' notice and potential penalties. However, the LLM incorrectly identifies the regulatory body as the 'Competition Commission of India antitrust investigation'—the original answer specifies the issue relates to Foreign Direct Investment (FDI) rules and does not mention antitrust or the CCI. Additionally, the LLM omits that the show cause notice was issued in July 2021 (pre-2022) and that the alleged violations occurred between 2009–2015, prior to Walmart’s acquisition. It also fails to mention Walmart’s inability to estimate potential losses or indemnification proceeds, a key financial implication. (2) All numbers—$3.2 billion, 83%, 75%—are correct and contextually accurate. No calculations are required, but the interpretation of reduced ownership and retained control is sound. (3) The multi-hop reasoning is mostly sound: the model connects Walmart’s financial move in 2022 with its regulatory exposure in 2024. However, it misattributes the nature of the regulatory risk (antitrust vs. FDI compliance), which weakens the qualitative accuracy. The synthesis across time and implications is strong but slightly flawed in regulatory context. (4) The answer is highly relevant, directly addressing Walmart’s strategic position evolution, financial implications, and regulatory exposure. The core narrative of shifting from financial participation to risk management is preserved, though with minor inaccuracies in regulatory detail. Hence, correctness is docked slightly to 9 for missing key temporal and regulatory specifics, but remains high due to strong overall factual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 548,
        "total_tokens": 1944
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the composition and strategic emphasis of HON's U.S. cash balances evolve between 2022 and 2024, particularly in terms of total cash holdings and geographic distribution of funds?",
      "original_answer": "In 2022, HON reported holding $11.5 billion of cash and cash equivalents as of December 31, 2021, with an emphasis on safety of principal and diversification among counterparties. By 2024, the company held $11.0 billion in total cash and equivalents as of December 31, 2024, but specifically noted that $8.0 billion of that amount was held in non-U.S. subsidiaries. This represents a shift in geographic distribution, with a larger portion of liquidity positioned outside the U.S., while maintaining the same strategic emphasis on safety and diversification.",
      "llm_answer": "In the 2022 Form 10‑K Honeywell said that its primary source of liquidity was “U.S. cash balances” and that it held **about $11.5 billion of cash and cash equivalents (including short‑term investments) at December 31 2021** (the most recent figure disclosed in that filing).  \n\nThe 2024 Form 10‑K still stresses safety of principal and diversification, but it now reports **$11.0 billion of cash and cash equivalents in the United States** and, for the first time, quantifies the overseas component – **$8.0 billion held in non‑U.S. subsidiaries**.  \n\nThus, between the two filings the total U.S. cash balance slipped only modestly (≈ $0.5 billion), while the company’s strategic emphasis shifted to a larger geographic spread of liquidity, with a substantial and growing pool of cash kept outside the United States.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual errors in key quantitative claims, particularly regarding the geographic distribution of cash. According to the ground truth, as of December 31, 2024, HON held $11.0 billion in total cash and equivalents, of which $8.0 billion was held in non-U.S. subsidiaries—meaning only $3.0 billion was in the U.S. However, the LLM incorrectly states that '$11.0 billion of cash and cash equivalents in the United States' were held in 2024, which directly contradicts the ground truth. This is a major quantitative and conceptual error. Additionally, the LLM implies that the $8.0 billion overseas amount is in addition to $11.0 billion in the U.S., suggesting a total cash balance of $19.0 billion, which is false. The total is $11.0 billion globally. The 2021 cash balance of $11.5 billion is correctly cited from the 2022 10-K, and the strategic emphasis on safety and diversification is accurately noted as consistent. The reasoning about a shift toward greater international liquidity is conceptually aligned, but the flawed numbers undermine the conclusion. The answer is contextually relevant and attempts multi-hop synthesis between 2022 and 2024 filings, but the core quantitative inaccuracy in the 2024 U.S. cash figure severely compromises correctness. Minor wording issues aside, the misrepresentation of $11.0 billion as U.S. cash (instead of total global cash) is a critical error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 392,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the financial treatment and liability estimation methodology for the Membership Rewards program evolve from 2023 to 2024, particularly in terms of deferred fees and liability modeling assumptions?",
      "original_answer": "In 2023, the company recognized deferred fees related to Membership Rewards program participants, indicating a focus on the deferral aspect of fee revenue associated with the program. By 2024, the disclosures provided a much more detailed explanation of the liability estimation methodology, including the use of the Ultimate Redemption Rate (URR) and the weighted average cost (WAC) per point. The 2024 filing also quantified the sensitivity of the liability to changes in assumptions, noting that a 25 basis point increase in URR would raise the liability by $197 million, and a 1 basis point increase in WAC per point would increase it by $220 million. This reflects a shift from a simpler mention of deferred fees to a comprehensive, model-driven approach to estimating future redemption liabilities.",
      "llm_answer": "In the 2023 filing the company recorded “deferred card and other fees, net” (which includes the deferred fees for Membership Rewards participants) of $3.44 billion and measured the Membership Rewards liability by applying a weighted‑average cost‑per‑point (WAC) and an Ultimate Redemption Rate (URR) derived from statistical‑actuarial models that consider redemption trends, product type, tenure, spend and credit attributes. The 2024 filing still treats the same deferred‑fee component as a liability, but it now supplements the liability estimate with explicit sensitivity metrics – e.g., a 25‑basis‑point rise in URR would add about $197 million and a 1‑basis‑point rise in WAC would add about $220 million – reflecting a more quantified modeling approach while retaining the same WAC‑and‑URR assumptions.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in asserting that in 2023 the company already used the Ultimate Redemption Rate (URR) and weighted average cost (WAC) per point derived from statistical-actuarial models. The ground truth states that in 2023, the company only mentioned deferred fees without detailing the URR/WAC modeling approach—this more sophisticated methodology was introduced in 2024. This misattribution of the modeling methodology to 2023 undermines the factual correctness. (2) The $3.44 billion figure for deferred fees is not present in the original answer and cannot be verified against the ground truth; no specific deferred fee amount was provided in the ORIGINAL ANSWER, so introducing this number is an unsupported addition. However, the sensitivity figures—$197 million for a 25 bps increase in URR and $220 million for a 1 bps increase in WAC—are correctly reported and match the ground truth. (3) The multi-hop reasoning is partially sound: the model correctly identifies the evolution toward more detailed disclosure in 2024, including sensitivity analysis, and contrasts it with the simpler 2023 treatment. However, it incorrectly assumes continuity of the URR/WAC modeling in 2023, failing to recognize that the methodology shift was a key change in 2024. (4) The contextual relevance is high because the answer addresses the core question about evolution in liability estimation and deferred fees. Qualitative accuracy is moderate due to correct identification of concepts and direction of change, but quantitative accuracy is low due to the unsupported $3.44 billion figure and misplacement of modeling details in time. Correctness score is 6 due to partially correct information with significant factual errors in methodology attribution and unsupported numerical claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 501,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How has Adobe's strategic positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its alignment with Adobe's broader product ecosystem?",
      "original_answer": "In 2022, Adobe described the integration of Frame.io as part of its Digital Media reportable segment, emphasizing its role as a cloud-based video collaboration platform acquired for $1.18 billion, with integration efforts just beginning. By 2024, Frame.io had transitioned from being a newly acquired integration to being positioned as a core component of Adobe's creative collaboration suite, directly integrated with key applications such as Adobe Premiere Pro, After Effects, Photoshop, and Workfront. Additionally, in 2024, Frame.io was included as part of Adobe GenStudio, indicating a deeper strategic alignment with Adobe's broader content production and collaboration ecosystem. This evolution reflects a shift from initial integration to full ecosystem incorporation.",
      "llm_answer": "In the 2022 filing Adobe presented Frame.io as a fresh, $1.18 billion acquisition that would be folded into its **Digital Media segment**, with initial integration focused on its core video‑editing tools—Premiere Pro and After Effects—and limited cross‑product links (e.g., Workfront). By the 2024 filing the company describes Frame.io as a **cloud‑native collaboration hub that is now tightly woven into the entire Creative Cloud suite**, including Photoshop, Lightroom, Workfront, and the new **Adobe GenStudio** platform, and positioned alongside Adobe Express and Firefly Services to power AI‑driven, end‑to‑end content production. This evolution shows Frame.io moving from a standalone video‑collaboration add‑on to a core, ecosystem‑wide component that reinforces Adobe’s broader strategy of unified, AI‑enhanced creative workflows.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Frame.io was acquired for $1.18 billion (quantitatively accurate), integrated into the Digital Media segment in 2022, and by 2024 became a core part of Adobe's ecosystem. The mention of integration with Premiere Pro, After Effects, Photoshop, Workfront, and inclusion in Adobe GenStudio matches the original answer. (2) Numbers and dates are correct—$1.18 billion is accurately cited, and the 2022 vs 2024 evolution is properly framed. (3) Multi-hop reasoning is sound: the answer synthesizes Frame.io’s strategic evolution across two years and its deepening integration across Adobe’s product suite, including AI-driven platforms like Firefly and Adobe Express, which adds context not in the ground truth but is plausible and relevant. (4) Minor deduction in qualitative accuracy because the original answer does not mention Lightroom, Firefly Services, or Adobe Express—these are reasonable inferences but not explicitly supported in the ground truth. However, the core evolution from standalone video collaboration to ecosystem-wide hub is correctly captured. Semantic equivalence is strong, and the answer is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 348,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How did the composition of private alternative investments, specifically equity-like funds, evolve between 2022 and 2023 in terms of fair value measurements using significant unobservable inputs (Level 3)?",
      "original_answer": "In 2022, equity-like funds under private alternative investments had a fair value of $5.5 million measured using significant unobservable inputs (Level 3). In 2023, this value increased significantly to $25.4 million. This indicates a fivefold increase in the portion of equity-like funds valued using Level 3 inputs, suggesting a shift toward more opaque or complex valuation methodologies for these investments.",
      "llm_answer": "In 2022 the equity‑like private‑alternative‑investment holdings were measured at Level 3 (significant unobservable inputs) at about **$27.8 million** ($25.4 million for the defined‑benefit pension plan and $2.4 million for the retiree‑health plan). In 2023 the same measurement was **$27.5 million** ($25.1 million for the pension plan and $2.4 million for the health plan), indicating a marginal decline of roughly $0.3 million and essentially unchanged composition.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in all key numerical values. The ground truth states that equity-like funds under private alternative investments measured at Level 3 were $5.5 million in 2022 and increased to $25.4 million in 2023. The LLM incorrectly reports $27.8 million in 2022 and $27.5 million in 2023, which are not only wrong but also imply a marginal decline, contradicting the actual fivefold increase. (2) The LLM introduces a breakdown by pension and retiree-health plans ($25.4M and $2.4M in 2022), which is not present in the original answer and appears to be fabricated or misattributed. These sub-components do not align with the ground truth, which gives no such split. Additionally, the LLM’s claim of a 'marginal decline' is false—the correct trend is a significant increase. (3) The multi-hop reasoning is flawed: the model fails to correctly identify the entity 'equity-like funds' within private alternative investments and misrepresents the Level 3 fair value evolution. It appears to conflate data from different investment categories or plans not mentioned in the original. (4) The contextual relevance is low but not zero—the response addresses fair value measurements using Level 3 inputs for equity-like funds over 2022–2023, so the general topic is correct. However, due to severe quantitative and qualitative inaccuracies, the answer is effectively incorrect. Correctness and quantitative accuracy are scored very low due to complete mismatch in numbers and trend direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 420,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has Adobe's integration and positioning of Frame.io within its Digital Media offerings evolved between 2022 and 2024?",
      "original_answer": "In 2022, Adobe had just acquired Frame.io in October 2021 and was beginning to integrate it into the Digital Media segment as a cloud-based video collaboration platform. By 2024, Frame.io had become a core part of Adobe’s creative collaboration tools, being directly integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and was also included in Adobe GenStudio for scalable content production. This reflects a strategic evolution from initial integration to deeper ecosystem embedding.",
      "llm_answer": "In the 2022 Form 10‑K Adobe reported that it had just completed the $1.18 billion acquisition of Frame.io and was **beginning to integrate the cloud‑native video‑collaboration platform into its Digital Media segment**, positioning it as a complementary service that plugs into Premiere Pro, After Effects, Photoshop, Lightroom and Workfront for frame‑accurate review and “Camera‑to‑Cloud” uploads.  \n\nBy the 2024 filing, Frame.io is described as a **fully integrated component of Adobe’s Creative Cloud workflow**, embedded in Premiere Pro, After Effects, Photoshop, Lightroom and Workfront, and also made available through Adobe GenStudio alongside Express and Firefly Services to enable large‑scale content production—showing that the platform has moved from a newly‑acquired add‑on to a core, cross‑app collaboration hub within Adobe’s Digital Media ecosystem.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Frame.io was acquired in October 2021 (implied context for 2022 integration start), and by 2024 it was deeply embedded in Adobe's ecosystem. The $1.18 billion acquisition amount is accurate and adds detail not in the original answer but consistent with public knowledge. (2) No calculations were required, but all dates and financial figures are correct. (3) The multi-hop reasoning is sound—correctly tracing Frame.io’s evolution from initial integration in 2022 to core platform status by 2024 across multiple Adobe products (Premiere Pro, After Effects, Photoshop, Lightroom, Workfront, GenStudio). (4) The answer fully addresses the question about evolution between 2022 and 2024, with precise entity names, correct timeframes, and accurate descriptions of integration depth. Wording differs but meaning matches exactly. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 287,
        "total_tokens": 1627
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has CVS's approach to Medication Management evolved between 2022 and 2024, particularly in terms of clinical programs and digital tools aimed at improving medication adherence and cost efficiency?",
      "original_answer": "In 2022, CVS emphasized formulary management through its National Pharmacy and Therapeutics Committee, promoting the use of generic drugs and offering real-time benefit information to guide members toward lower-cost alternatives. The company also operated mail order and specialty pharmacies, and provided clinical programs focused on medication adherence and utilization management, including an industry-leading approach to limit opioid prescriptions to seven-day supplies for acute cases. By 2024, CVS had expanded its Medication Management offerings with the introduction of digital tools like the NovoLogix preauthorization platform and enhanced analytics for identifying lower-cost drug alternatives. The company also launched the CVS Weight Management program, integrating GLP-1 medication optimization with lifestyle coaching, and expanded its value-based care initiatives through Oak Street Health, operating 239 primary care centers across 27 states to better manage chronic conditions and medication use. These developments reflect a shift from primarily cost-containment strategies to a more integrated, digitally enabled, and clinically proactive model of medication support.",
      "llm_answer": "By 2022 CVS’s medication‑management strategy centered on clinical services such as utilization‑management, disease‑management, the Pharmacy Advisor counseling program, the NovoLogix online pre‑authorization tool and a basic digital “real‑time benefits” platform that showed members lower‑cost formulary alternatives. By 2024 the approach had been deepened and digitized – the Pharmacy Advisor and new Drug‑Savings‑Review outreach were expanded, a dedicated CVS Weight‑Management program was added to steer GLP‑1 use, and advanced platforms such as the Health‑Engagement Engine, the AI‑driven Canopy analytics suite and integrated online scheduling/tele‑health tools were deployed to give members richer adherence support and greater visibility of cheaper drug options, driving higher adherence and cost efficiency.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies CVS's focus on medication management, cost efficiency, and digital tools, and accurately references the 2024 launch of the CVS Weight Management program and GLP-1 integration. However, it misattributes the NovoLogix preauthorization tool as being active in 2022, while the ground truth states it was introduced in 2024. Additionally, the LLM invents or misrepresents several tools not present in the original answer, such as the 'Health-Engagement Engine', 'Canopy analytics suite', and 'Drug-Savings-Review outreach', which are not mentioned in the ground truth. The 'Pharmacy Advisor counseling program' is mentioned in the LLM answer but not in the original, raising concerns about hallucination. (2) Quantitatively, there are no explicit numbers (e.g., 239 centers, 27 states) in the LLM answer, so it avoids inaccuracy there, but it also fails to include key factual metrics from the original answer, such as Oak Street Health operating 239 primary care centers across 27 states—a significant omission in the evolution of clinical infrastructure. (3) The multi-hop reasoning is partially sound—linking digital tools and clinical programs to medication adherence and cost efficiency—but fails to correctly synthesize the timeline and evolution. The shift from cost-containment (2022) to integrated, digitally enabled care (2024) is conceptually captured, but the specific evolution is distorted by incorrect tool deployment years and fabricated platforms. (4) The contextual relevance is high because the answer addresses the core themes of clinical programs and digital tools in medication management. However, the qualitative accuracy is low due to entity inaccuracies and invented programs. The correctness score is 6 due to partial factual alignment but significant errors in entity and timeline accuracy, undermining full reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1514,
        "completion_tokens": 526,
        "total_tokens": 2040
      },
      "error": null
    },
    {
      "question_id": 131,
      "question": "How has Adobe's integration and positioning of Frame.io within its Creative Cloud ecosystem evolved from 2022 to 2024, and what specific enhancements were made to its collaboration features during this period?",
      "original_answer": "In 2022, Adobe acquired Frame.io and began integrating its cloud-based video collaboration platform into Adobe Creative Cloud, with initial enhancements focused on deeper integration into Premiere Pro and After Effects to deliver native collaborative workflows for video editing. By 2024, Frame.io had evolved into a more comprehensive cloud-native creative collaboration platform, offering real-time upload, review, and approval features not only for video but also for still images, design files, and PDFs. It expanded its integration across Adobe Photoshop, Lightroom, and Workfront, and introduced Camera to Cloud functionality, enabling automatic upload of footage directly into Frame.io from cameras on set. These enhancements reflect a strategic shift from a video-specific collaboration tool to a broader creative asset production and review platform within Adobe’s ecosystem.",
      "llm_answer": "Adobe first introduced Frame.io after its October 2021 acquisition by positioning it as a “cloud‑native creative collaboration platform” that was **deeply integrated only with Premiere Pro and After Effects** to add native review‑and‑approval, frame‑accurate commenting and annotation capabilities (2022 10‑K, p. 6). By the 2024 filing the company had broadened Frame.io’s role across the Creative Cloud, embedding it also in Photoshop, Lightroom, Workfront and the new GenStudio environment, adding “Camera‑to‑Cloud” automatic footage upload, support for still‑image, design‑file and PDF reviews, and scaling the platform for enterprise‑level content production (2024 10‑K, p. 12). These enhancements turned Frame.io from a video‑editing add‑on into a core, multi‑app collaboration service that streamlines real‑time upload, review, approval and cross‑asset commenting throughout Creative Cloud.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Frame.io was acquired in 2021 (not 2022, but the 2022 10-K reference is valid for post-acquisition integration), initially integrated with Premiere Pro and After Effects, and by 2024 expanded to Photoshop, Lightroom, Workfront, and added Camera-to-Cloud, support for still images, design files, and PDFs. The evolution from a video-specific tool to a broader collaboration platform is correctly captured. (2) Quantitative accuracy is strong: no incorrect numbers, dates (2022 and 2024 references are contextually accurate based on 10-K filings), and no erroneous calculations. The mention of 'October 2021 acquisition' is factually correct (Adobe completed the acquisition in January 2022, but announced in October 2021—minor nuance but not materially inaccurate in context). (3) Multi-hop reasoning is sound: the LLM synthesizes information across time (2022 to 2024) and across products (Creative Cloud apps), correctly identifying the expansion of integration and feature set. (4) Semantic equivalence is maintained—wording differs slightly (e.g., 'core, multi-app collaboration service' vs 'comprehensive cloud-native creative collaboration platform') but meaning is preserved. One minor point: the LLM mentions 'GenStudio environment' which is not in the ground truth and not widely documented in Adobe's public 10-Ks; this could be a hallucination or niche reference, slightly reducing qualitative accuracy. Otherwise, the answer is complete, relevant, and factually robust.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1460,
        "completion_tokens": 433,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has the use of recently executed transactions in the valuation of loans and other assets evolved from 2023 to 2024, particularly in terms of their role in fair value determination?",
      "original_answer": "In 2023, recently executed transactions were a key input for determining the fair value of corporate loans and contingent lending commitments, often used alongside market price quotations, implied yields, and proprietary valuation models. By 2024, the role of recently executed transactions remained significant but was more specifically tied to the held-for-sale category of loans and lending commitments, and also extended to the valuation of other assets such as other investments, where they were used in conjunction with discounted cash flow models and comparable company multiples. This reflects a more targeted application of transaction data in valuation practices.",
      "llm_answer": "In the 2023 filing the firm said that the fair value of corporate loans and lending commitments is **one of several inputs**, using “recently executed transactions, market‑price quotations (where observable), implied yields from comparable debt, …” to price the assets on a recurring basis【page_99】.  \n\nThe 2024 filing expands that approach: for both recurring and non‑recurring measurements, especially for loans held‑for‑sale, the firm now relies **more heavily on recently executed transactions as the primary benchmark**, supplementing them with market quotations, comparable‑loan pricing and model‑based cash‑flow analyses when observable prices are unavailable【page_103】 (and the broader fair‑value discussion in 2024 also notes reliance on “rounds of financing or third‑party transactions”【page_101】).  \n\nThus, the role of recent transaction data has grown from a supplemental input in 2023 to a central reference point for fair‑value determination of loans and related assets in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of factual content and evolution from 2023 to 2024. In 2023, recently executed transactions were indeed used as one of several inputs alongside market prices, implied yields, and models, which matches the original answer. For 2024, the LLM correctly identifies a heightened role for recently executed transactions, particularly for loans held-for-sale, and notes their use in conjunction with other methods like cash flow models and comparable pricing. The claim that transaction data became a 'primary benchmark' in 2024 is a slight overstatement compared to the original answer, which describes a 'more targeted application' rather than a shift to primacy. However, the expansion to other assets (e.g., investments) and non-recurring measurements is consistent with the broader application noted in the ground truth. There are no numerical inaccuracies (quantitative accuracy is perfect), and all references to years and entities are correct. The reasoning is sound and synthesizes multi-hop information across years and asset types. The minor discrepancy in emphasis—'more heavily relied upon' vs. 'more specifically tied'—does not invalidate the conclusion but introduces a subtle interpretive difference, justifying a score of 8 on qualitative accuracy and overall correctness. Contextual relevance is excellent, directly addressing the evolution in valuation practices.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 400,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has Adobe's approach to the Substance 3D Stager product evolved between 2022 and 2024, particularly in terms of its positioning within the broader Substance 3D ecosystem?",
      "original_answer": "In 2022, Substance 3D Stager was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio but without detailed information about its functionality or strategic positioning. By 2024, Adobe introduced a more comprehensive view of Substance 3D as an ecosystem, where Stager is specifically described as a tool for building and assembling 3D scenes. This evolution reflects a strategic shift from simply offering the product to integrating it into a broader suite of 3D tools, including Painter, Sampler, Designer, and Modeler, emphasizing its role in enabling end-to-end 3D content creation workflows.",
      "llm_answer": "In the 2022 Form 10‑K Adobe did not discuss Substance 3D Stager as a distinct part of a unified suite – it was only referenced, if at all, as a standalone app sold under the separate “Substance 3D Collection” plan. By the 2024 filing Adobe explicitly positions Stager within a broader, integrated “Substance 3D ecosystem” of desktop applications, listing it together with Painter, Sampler, Designer and Modeler and describing the collection as a cohesive set of tools for building and assembling 3D scenes【page_12】. This shift shows Adobe moving from a loosely‑bundled, separate‑sale product toward a more integrated, ecosystem‑focused strategy for Stager.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies the evolution of Adobe's positioning of Substance 3D Stager between 2022 and 2024. In 2022, Stager was not discussed as part of an integrated ecosystem but rather as a standalone product under the 'Substance 3D Collection'—consistent with the ground truth noting it was only listed as a trademark. By 2024, the LLM correctly observes that Adobe began positioning Stager as part of a unified 'Substance 3D ecosystem' alongside Painter, Sampler, Designer, and Modeler, with a defined role in building and assembling 3D scenes. The mention of page 12 adds document-level support, enhancing credibility. All entities (Adobe, Substance 3D Stager, associated tools, years) are correct. There are no numerical values to verify, so quantitative accuracy is scored based on absence of errors (N/A). The reasoning is sound and reflects proper multi-hop synthesis across time points and strategic context. The only minor shortcoming is that the LLM does not explicitly state that the 2022 status was inferred from trademark listings (a detail in the ground truth), but this does not detract from the overall correctness. Semantic equivalence is maintained, and the answer fully addresses the question about strategic evolution and ecosystem integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 372,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How did GE's strategic positioning regarding grid-scale batteries evolve from 2022 to 2023, particularly in terms of their role in the company's energy transition strategy and level of strategic reliance?",
      "original_answer": "In 2022, GE mentioned grid-scale batteries as part of a broader set of emerging technologies that 'may become more important over time' in achieving deep decarbonization goals, indicating GE was considering them as a potential future investment. By 2023, GE explicitly listed grid-scale batteries as one of the key technologies 'that may become more important over time' and integrated them into the company’s strategic narrative as a dependency, noting that achieving decarbonization goals would 'depend in part' on such technologies. This reflects a shift from viewing grid-scale batteries as a speculative investment to a more central component of GE's energy transition strategy.",
      "llm_answer": "In the 2022 filing GE noted that grid‑scale batteries were among a set of “future‑oriented” technologies (hydrogen, carbon‑capture, advanced nuclear, etc.) that could become important for deep‑decarbonisation, but the company made no claim that it was counting on them today. By the 2023 filing the language was sharpened: grid‑scale batteries are singled out as a key element of the energy‑transition roadmap and as a technology that will require “significant investments” by GE and third parties, yet it is still described as “not yet deployed or widely adopted” and therefore not a core, relied‑upon source of revenue. Thus GE’s positioning evolved from a vague future‑technology mention to a more explicit strategic priority, while its level of strategic reliance remained limited.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of GE's strategic positioning on grid-scale batteries from 2022 to 2023. It accurately captures that in 2022, grid-scale batteries were mentioned as part of a broader set of emerging technologies with potential future importance, without strategic reliance. In 2023, the LLM correctly notes a shift in language—batteries are highlighted more explicitly as a key element requiring 'significant investments' and integrated into the energy transition roadmap. This reflects the increased strategic priority, matching the ground truth's observation of a shift from speculative to more central strategic consideration. However, the LLM adds that batteries were 'not yet deployed or widely adopted' and 'not a core, relied-upon source of revenue,' which, while plausible, is not present in the original answer and slightly overemphasizes the lack of reliance. The ground truth emphasizes that by 2023, decarbonization goals would 'depend in part' on such technologies, indicating a higher level of strategic reliance than the LLM conveys. Thus, while the core facts and timeline are correct, the interpretation of 'strategic reliance' is slightly understated. There are no numerical values, so quantitative accuracy is scored based on correct use of years (2022, 2023) and consistent terminology. The reasoning is sound and multi-hop (comparing two years' filings and inferring strategic shift), and the answer is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 420,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has CVS's disclosure regarding the use of broker quoted debt securities in its fair value measurements evolved between 2022 and 2024, particularly in terms of its presence or impact on financial reporting?",
      "original_answer": "In 2022, CVS explicitly stated that it did not have any broker quoted debt securities for the years ended December 31, 2021, and 2020, and that it only used internal pricing for certain private placements. By 2024, the company continued to disclose that it had no broker quoted debt securities for the years ended December 31, 2024 and 2023, indicating a consistent absence of such securities in its portfolio. However, the 2024 disclosure no longer mentions any negative impact or specific review process related to broker quoted debt securities, suggesting a reduced emphasis or relevance of this topic in the company's fair value measurement disclosures over time.",
      "llm_answer": "In the 2022 Form 10‑K, CVS noted that its Level 3 debt‑security valuations are based on outside‑broker prices or internal models and that **it had no broker‑quoted debt securities for the years ended 2021 and 2020** (the filing did not comment on 2022 itself). The 2024 Form 10‑K contains the same disclosure language but updates it to state that **the company had no broker‑quoted debt securities for the years ended 2024 and 2023**, confirming that the practice of not using broker quotes continued and therefore had no impact on the fair‑value measurements reported in the most recent periods.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key factual points from the ground truth: CVS had no broker quoted debt securities for 2021 and 2020 in the 2022 filing, and for 2024 and 2023 in the 2024 filing. The core quantitative and temporal information (years, presence/absence of securities) is accurate. (2) All dates and disclosures are correctly reported with no calculation errors. The LLM accurately reflects that the 2022 filing covered 2021 and 2020, and the 2024 filing updated to 2024 and 2023. (3) The multi-hop reasoning is mostly sound—comparing disclosures across years and noting continuity in the absence of broker quoted securities. However, the LLM answer omits a key qualitative nuance present in the original answer: the 2024 disclosure no longer mentions any negative impact or specific review process related to broker quoted debt securities, indicating reduced emphasis. This omission affects completeness and reasoning depth, as it fails to capture the evolution in tone and relevance over time. (4) Despite this omission, the answer is factually correct and contextually relevant, with perfect quantitative accuracy. The correctness score is reduced slightly (8/10) due to the missing nuance about changing disclosure emphasis, which is central to the question about 'evolution' in disclosure practices.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 374,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did the composition of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of equity securities/mutual funds and equity method investments?",
      "original_answer": "In 2023, BlackRock reported $1,211 million in equity securities/mutual funds under Equity Securities at FVTNI, while equity method investments totaled $1,895 million. By 2024, the value of equity securities/mutual funds increased to $1,950 million, and equity method investments rose to $2,783 million. This reflects a significant increase in both categories, indicating a strategic expansion in these investment areas.",
      "llm_answer": "In 2023 BlackRock reported **$1.585 billion** of equity securities (including mutual‑fund holdings) at fair value through net income (FVTNI) and **$2.756 billion** of equity‑method investments (the sum of equity‑method mutual‑fund, hedge‑fund, private‑equity, real‑asset and deferred‑compensation holdings)【page_87】.  \n\nBy the end of 2024 those balances had risen to **$1.950 billion** for equity securities/mutual funds【page_92】 and **$2.783 billion** for equity‑method investments【page_92】.  \n\nThus, the equity‑security component grew by roughly **$365 million** (≈23 %), while the equity‑method component increased only modestly, by about **$27 million** (≈1 %).",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the 2023 values. According to the ground truth, in 2023, BlackRock reported $1,211 million (i.e., $1.211 billion) in equity securities/mutual funds and $1,895 million ($1.895 billion) in equity method investments. However, the LLM states $1.585 billion and $2.756 billion, respectively—both of which are incorrect. The 2024 values for equity securities/mutual funds ($1.950 billion) and equity method investments ($2.783 billion) match the ground truth and are correctly cited with source pages. (2) Calculations are based on incorrect 2023 figures: the LLM computes a $365 million increase in equity securities (using $1.585B → $1.950B), but the correct increase is $1,950M - $1,211M = $739 million. Similarly, the LLM reports a $27 million increase in equity method investments (from $2.756B to $2.783B), but the correct increase is $2,783M - $1,895M = $888 million. Thus, both absolute and percentage changes are wrong. (3) The multi-hop reasoning is structurally sound—comparing two years across two investment categories—but fails due to reliance on incorrect source data for 2023. It correctly identifies the need to compare year-over-year changes and synthesizes information from different pages, but the synthesis is flawed because the initial data points are inaccurate. (4) Contextual relevance is high—the answer addresses the right categories and time frame, uses appropriate terminology, and attempts quantitative comparison. However, due to major quantitative errors in core data, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the framework of reasoning is valid, even if the inputs are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 473,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did UnitedHealth Group's evaluation and treatment of credit-related impairments for available-for-sale debt securities evolve from 2022 to 2024, particularly in terms of unrealized losses and the allowance for credit losses?",
      "original_answer": "In 2022, UnitedHealth Group reported that unrealized losses in its available-for-sale debt securities were primarily driven by interest rate increases and not credit deterioration, with no significant credit deterioration observed since purchase. The allowance for credit losses was noted to be not material as of December 31, 2021. By 2024, the company's evaluation methodology remained consistent in terms of assessing present value of expected cash flows, issuer credit condition, and fair value relative to amortized cost. However, the allowance for credit losses is now explicitly described as being recorded as a separate component through an allowance account, with credit-related impairments impacting investment and other income, indicating a more structured recognition of credit risk. This evolution shows a shift from a qualitative, low-risk assessment to a more formalized impairment accounting framework.",
      "llm_answer": "In the 2022 Form 10‑K (covering 2021) UnitedHealth reported that its available‑for‑sale debt securities carried a **gross unrealized loss of about $274 million** and that the **allowance for credit‑related losses on those securities was “not material.”** By the 2024 filing the company still evaluates each available‑for‑sale security for credit‑related impairment using the same present‑value‑of‑cash‑flows and issuer‑credit‑quality criteria, reports any unrealized gains or losses in other comprehensive income, and again notes that the **allowance for credit losses on available‑for‑sale debt securities remains not material**, indicating that the treatment and magnitude of impairments have not materially changed between 2022 and 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains partially correct information but misses a key evolution described in the ground truth. It correctly states that in 2022 (via the 2022 10-K covering 2021), UnitedHealth reported a gross unrealized loss of $274 million and that the allowance for credit losses was 'not material' as of December 31, 2021. However, the LLM incorrectly concludes that there was no material change by 2024, directly contradicting the ground truth, which states that by 2024 the company had evolved its accounting framework to explicitly record the allowance for credit losses as a separate component through an allowance account, with credit-related impairments impacting investment and other income. This represents a formalization of impairment accounting, which the LLM answer fails to recognize. (2) The quantitative accuracy is acceptable: the $274 million unrealized loss and 'not material' characterization align with typical disclosures and are consistent with the time frame (2021 year-end reported in 2022 10-K). However, the LLM implies the allowance remains 'not material' in 2024, which may be factually correct, but it overlooks the structural change in how impairments are recognized—this is a qualitative and conceptual error with quantitative implications. (3) The multi-hop reasoning is flawed: the question asks about the evolution from 2022 to 2024, requiring synthesis of changes in methodology and presentation. The LLM notes consistent evaluation criteria but misses the shift to a more structured impairment framework, indicating failure to synthesize the evolution in accounting treatment. (4) Contextual relevance is high—the answer addresses the right company, securities, and time periods, and focuses on the correct metrics. However, the conclusion that 'treatment and magnitude have not materially changed' is incorrect per the ground truth, which identifies a clear shift in accounting structure despite similar materiality assessments. Thus, correctness and qualitative accuracy are significantly penalized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 547,
        "total_tokens": 1982
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2022 and 2023, particularly in terms of investment value and equity income?",
      "original_answer": "In 2022, AMD's carrying value of its investment in the ATMP JV was $83 million, and it recorded $14 million in equity income from the JV. By 2023, the carrying value increased to $99 million, and equity income rose to $16 million. This indicates a growing financial stake and increased profitability from the joint venture over the two-year period.",
      "llm_answer": "AMD’s stake in the ATMP joint venture grew modestly. At the end of 2022 the equity‑method investment was about **$83 million**, and it rose to roughly **$99 million** by the end of 2023. Correspondingly, the equity‑income recognized from the JV increased from **$14 million** in 2022 to **$16 million** in 2023【page_78】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) All numeric values are accurate: the carrying value of AMD's investment in the ATMP JV was $83 million in 2022 and $99 million in 2023, and equity income was $14 million in 2022 and $16 million in 2023. These figures match the original answer exactly, with acceptable formatting variations (e.g., 'about $83 million' and 'roughly $99 million' are reasonable approximations). (2) The answer addresses both parts of the question—investment value (carrying value) and equity income—across the two years, demonstrating completeness. (3) Entities are correctly identified: AMD, ATMP JV, and the relevant financial metrics (equity-method investment, equity income) are accurately named and contextualized. (4) The reasoning is sound: the LLM correctly synthesizes year-over-year changes and implies growth in both investment value and income, aligning with the conclusion in the original answer about a growing financial stake and increased profitability. (5) Semantic equivalence is maintained—the wording differs slightly but conveys the same factual content and implications. The citation to 'page_78' adds source context without affecting accuracy. No errors in calculation, logic, or fact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1166,
        "completion_tokens": 354,
        "total_tokens": 1521
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has UnitedHealth Group's exposure to tort claims evolved between 2022 and 2024, particularly in terms of the nature of the claims and the potential financial impact?",
      "original_answer": "In 2022, UnitedHealth Group specifically highlighted self-insured liabilities related to medical malpractice claims against affiliated physicians and the potential for actual losses to significantly exceed recorded liabilities. The document emphasized increasing legal actions alleging medical malpractice and general professional liabilities, with litigants seeking recoveries under new theories of liability that might not be subject to damage caps. By 2024, while tort claims remained a concern, the focus shifted slightly to broader legal risks tied to the delivery of health care services, including claims related to clinical quality and patient safety standards. The 2024 filing also emphasized the potential for reputational harm and adverse effects on business relationships, indicating a broader and more systemic risk profile compared to the more narrowly defined exposure in 2022.",
      "llm_answer": "UnitedHealth’s 2022 filing already warned that it is “largely self‑insured” for tort claims – chiefly medical‑malpractice and other patient‑safety lawsuits arising from care delivered by its own or network providers – and that the company records reserve estimates that could be substantially exceeded by actual losses. By the 2024 filing the same categories of tort exposure are described, but the company stresses that the volume of actions has risen, many involve “large claims and significant defense costs,” and plaintiffs are increasingly asserting new liability theories that may bypass state caps, suggesting that the potential monetary impact of these claims is now viewed as larger and more uncertain than in 2022.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in its portrayal of UnitedHealth Group's tort claim exposure in 2022 and 2024, with no numeric inaccuracies (quantitative accuracy is perfect, as no specific numbers are misstated and all temporal references are correct). The answer correctly identifies that in 2022, UnitedHealth was largely self-insured for medical malpractice and patient-safety claims, with a risk that actual losses could exceed reserves—a key point from the ground truth. It also accurately reflects the 2024 evolution: increased volume of claims, rising defense costs, and the emergence of new liability theories that may circumvent damage caps, leading to greater financial uncertainty. This aligns with the ground truth’s emphasis on expanding legal theories and heightened financial risk. However, the LLM answer omits a key qualitative shift noted in the original answer: the broadening of risk beyond financial exposure to include reputational harm and adverse effects on business relationships, as well as the expansion of claims to include clinical quality and patient safety standards as systemic issues. While the LLM captures the continuity and intensification of tort exposure, it does not fully convey the shift from a narrowly defined malpractice risk in 2022 to a more systemic, multifaceted risk profile in 2024. Thus, while the core facts and reasoning are sound (multi-hop synthesis across years is adequate), the answer lacks full completeness in capturing the qualitative evolution of risk. Contextual relevance is excellent, as all content directly addresses the question about the evolution in nature and financial impact of tort claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 453,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How has the structure and capacity of Boeing's three-year revolving credit agreement evolved between 2023 and 2024, and what does this indicate about the company's liquidity strategy?",
      "original_answer": "In 2023, Boeing had a legacy three-year revolving credit agreement expiring in August 2025 with $3.0 billion of total commitments. In 2024, this agreement remained in effect, but Boeing also entered into a new $4.0 billion five-year revolving credit agreement expiring in May 2029 while terminating two other credit facilities. This evolution indicates a strategic shift to enhance liquidity capacity and extend maturity timelines, reinforcing Boeing's financial flexibility and commitment to managing corporate borrowing needs.",
      "llm_answer": "In the 2023 filing Boeing reported that its legacy three‑year revolving credit facility carried a **$3 billion commitment and was set to expire in August 2025** (page 43). The 2024 filing shows that the same **$3 billion three‑year facility remains in place with the same August 2025 maturity**, while the company terminated the $0.8 billion 364‑day line and added a new $4 billion five‑year facility, leaving **about $10 billion of total unused borrowing capacity** (page 94). This continuity of the three‑year line, combined with the shift from short‑term to longer‑term credit facilities, signals that Boeing is preserving a stable medium‑term liquidity back‑stop while extending and consolidating its borrowing sources to secure longer‑term cash flexibility.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $3 billion three-year revolving credit agreement from 2023 expiring in August 2025 and confirms its continuation in 2024, which matches the ground truth. It accurately notes the addition of a new $4 billion five-year facility expiring in May 2029 and the termination of another facility (correctly identifying the $0.8 billion 364-day line, though this detail is not in the ground truth but is factually consistent). However, the LLM introduces a claim about 'about $10 billion of total unused borrowing capacity'—a figure not present in the original answer and not verifiable from the provided ground truth, which undermines quantitative accuracy. (2) All explicitly stated numbers ($3 billion, August 2025 maturity, $4 billion, $0.8 billion) are correct and properly attributed. The unsupported $10 billion capacity figure is the only numerical inaccuracy, likely derived from summing facilities but not explicitly confirmed in the ground truth. (3) The reasoning is strong: the LLM correctly synthesizes changes across years, identifies the strategic shift from short-term to long-term facilities, and infers Boeing’s intent to extend maturities and consolidate liquidity—aligning with the ground truth’s conclusion about enhanced financial flexibility. (4) The answer is highly relevant, directly addressing both the structural evolution and strategic implications. The extra detail about unused capacity slightly detracts from precision but does not distort the core message. Overall, the answer is factually sound with minor overreach on one unverified metric, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 454,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did the financial impact of the 2017 Performance-based Options evolve between 2023 and 2024, particularly in terms of the fair value of options vested and the intrinsic value of options exercised?",
      "original_answer": "In 2023, the fair value of the 2017 Performance-based Options that vested was $56 million, and the intrinsic value of options exercised was $44 million. By 2024, the fair value of the options vested decreased slightly to $52 million, but the intrinsic value of options exercised saw a significant increase to $373 million. This indicates that while the value of options vesting declined slightly in 2024, the actual financial benefit realized from exercised options increased substantially compared to the prior year.",
      "llm_answer": "In 2023 the company reported that the 2017 performance‑based stock options that vested had a total grant‑date fair value of **$56 million**, and the options that were exercised generated an **intrinsic value of $44 million**【page_101】. By 2024 the fair‑value of the 2017 options that vested fell slightly to **$52 million**, while the intrinsic value of the options exercised rose sharply to **$373 million**【page_109】.  Thus, the vest‑value component declined modestly year‑over‑year, but the value realized from exercises increased dramatically.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $56 million fair value vested in 2023, $44 million intrinsic value exercised in 2023, $52 million fair value vested in 2024, and $373 million intrinsic value exercised in 2024. Minor formatting differences (e.g., $56 million vs $56 million) are acceptable and do not affect meaning. (2) The answer is complete, addressing both years and both metrics (fair value of vested options and intrinsic value of exercised options), satisfying the multi-part, multi-hop nature of the question. (3) Entity accuracy is correct—referring to the 2017 Performance-based Options, and correctly attributing values to 2023 and 2024. (4) The reasoning is sound: it correctly observes the slight decline in fair value of vested options and the sharp increase in intrinsic value of exercised options, drawing a logical conclusion about the evolving financial impact. The use of citations (page_101, page_109) further supports traceability. (5) Semantic equivalence is strong—the LLM conveys the same core insights as the original answer using slightly different phrasing (e.g., 'value realized from exercises increased dramatically' vs 'actual financial benefit realized...increased substantially'). No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 375,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did AMD's approach to estimating adjustments for product return rights evolve between 2022 and 2023, and what specific changes were made in the methodology used for these estimates?",
      "original_answer": "In 2022, AMD estimated adjustments for product return rights using trended actual historical product return rate information, adjusted for known information or events. By 2023, AMD maintained the use of historical data but placed additional emphasis on 'rights of return and rebates' as part of variable consideration under ASC 606-10-32-8 through 14, explicitly stating that these estimates were based on the 'most likely amount' of consideration expected after adjustments for returns, rebates, and price protection. This reflects a more structured and codified approach to estimating returns, aligning more closely with specific accounting standards.",
      "llm_answer": "AMD did not change the substance of its product‑return‑rights estimate between the 2022 and 2023 filings. In both years the company said it “estimates adjustments for product‑return rights by using relevant, trended historical return‑rate information and then adjusting that rate for any known events, current economic conditions or other facts‑and‑circumstances.” The 2023 filing simply restates the same methodology – historical‑return data + trend analysis + adjustments for known events/economic conditions – and does not introduce a new approach.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that AMD did not change its methodology between 2022 and 2023. The ground truth shows a clear evolution: while both years used historical data, in 2023 AMD explicitly adopted a more structured approach under ASC 606-10-32-8 through 14, emphasizing 'rights of return and rebates' as variable consideration and using the 'most likely amount' method for estimating returns. This represents a qualitative shift toward a more codified accounting standard alignment, which the LLM answer completely misses. There are no numeric values to verify (so quantitative accuracy is high by default), but the qualitative accuracy is low because the model fails to identify the key change in methodology and misrepresents the 2023 approach as identical to 2022. The reasoning is flawed as it denies a multi-hop insight (evolution of accounting policy) that requires comparing disclosures across years. Contextual relevance is moderate since the answer addresses the right topic and timeframe but draws an incorrect conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 302,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How did the number of shares under option for the 2017 Performance-based Options evolve from 2023 to 2024, and what does this indicate about the exercise and forfeiture trends of these options?",
      "original_answer": "The number of shares under option for the 2017 Performance-based Options decreased significantly from 1,549,080 shares at the end of 2023 to 625,825 shares at the end of 2024. This indicates that a large portion of these options were exercised (905,219 shares) and some were forfeited (18,036 shares) during 2024, showing a trend of completion in the lifecycle of these options as they approached their final vesting date.",
      "llm_answer": "The 2017 performance‑based options fell from 1,549,080 shares outstanding at 12/31/2023 to 625,825 shares outstanding at 12/31/2024 (‑905,219 exercised and ‑18,036 forfeited during 2024)【page_108】. This sharp drop reflects heavy exercise of the awards—over half of the prior year’s balance—while forfeitures were comparatively small, indicating that most vested options were being taken up rather than abandoned.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the number of shares under option decreased from 1,549,080 at the end of 2023 to 625,825 at the end of 2024. The LLM correctly identifies that 905,219 shares were exercised and 18,036 were forfeited during 2024—these figures match the ground truth exactly (1,549,080 - 625,825 = 923,255 total reduction; 905,219 + 18,036 = 923,255, confirming accurate decomposition). (2) Quantitative accuracy is perfect: all numbers, dates (12/31/2023 and 12/31/2024), and calculations are correct. The LLM correctly infers the breakdown of the decrease into exercise and forfeiture, which requires multi-hop reasoning from the net change. (3) The reasoning is sound: the LLM correctly interprets the sharp decline as evidence of heavy exercise, notes that forfeitures were small in comparison, and logically concludes that most vested options were exercised rather than abandoned—this aligns with the ground truth's interpretation of lifecycle completion. (4) The answer addresses both parts of the question: the evolution of shares (quantitative change) and what it indicates (qualitative trend). Entity accuracy is correct: '2017 Performance-based Options' is properly referenced. Minor wording differences (e.g., 'fell from' vs 'decreased') do not affect meaning. The inclusion of a citation ['page_108'] does not detract from correctness. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 410,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How has the role and scope of Optum Rx's Pharmacy Care Services evolved between 2022 and 2024, particularly in terms of its service offerings and strategic positioning within UnitedHealth Group's broader health care ecosystem?",
      "original_answer": "In 2022, Optum Rx was described as managing $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceutical spending, and was positioned as a provider of pharmacy care services through a network of over 67,000 retail pharmacies, home delivery, specialty pharmacies, and infusion services. It emphasized clinical programs, digital tools, and medication management to help clients reduce costs and improve health outcomes. By 2024, Optum Rx was more strategically integrated into Optum’s broader vision of creating a 'value-oriented and more connected approach to health care,' with an emphasis on leveraging 'data and analytics, pharmacy care services, health care operations, population health and health financial services' to improve the overall health system performance. While specific spending figures were not provided in 2024, the service was elevated as a core component of Optum’s mission to enhance affordability, quality, and patient experience across the health care continuum.",
      "llm_answer": "In the 2022 filing Optum Rx was described as a “diversified pharmacy‑care services” business that operated > 67,000 retail pharmacies, offered home‑delivery, specialty, community‑health and in‑home infusion services, and ran a direct‑to‑consumer channel; its focus was on managing broad prescription‑drug spend ( $112 billion in 2021, $45 billion specialty) and providing utilization‑management, medication‑adherence and analytics programs that linked medical and pharmacy data for health‑plan and employer clients. By the 2024 filing the segment still delivered a full spectrum of pharmacy care but its network had been refined to ≈ 65,000 pharmacies and it added “rare‑disease and gene‑therapy support services” and a stronger emphasis on embedding pharmacists in integrated medical‑pharmacy‑behavioral care teams, positioning Optum Rx as the hub that ties UnitedHealth’s Optum Health, Optum Insight and UnitedHealthcare offerings together through data‑driven, end‑to‑end patient‑centric solutions.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is largely correct in describing the evolution of Optum Rx's role and scope between 2022 and 2024. It accurately captures the 2022 context: managing $112 billion in pharmaceutical spending (with $45 billion in specialty), a network of over 67,000 pharmacies, and service offerings including home delivery, specialty pharmacy, and clinical programs. The 2024 strategic shift toward deeper integration within UnitedHealth Group’s ecosystem, data-driven solutions, and patient-centric care is also correctly conveyed. However, the LLM incorrectly states that the $112 billion and $45 billion figures are from 2021, while the ground truth specifies 2022. This misattribution of the year is a factual error. Additionally, the LLM claims the pharmacy network was 'refined to ≈65,000' in 2024, but the ground truth does not mention any reduction or updated count—only that the 2022 figure was over 67,000. This introduces a detail not supported by the source. The addition of 'rare-disease and gene-therapy support services' and embedding pharmacists in integrated care teams is plausible but not explicitly confirmed in the ground truth, which focuses on broader strategic integration rather than specific new services. 2) Quantitative accuracy is partially compromised: while $112B and $45B are correct amounts, attributing them to 2021 instead of 2022 is a clear error. The ≈65,000 pharmacy count in 2024 is speculative and not in the original answer. 3) Qualitatively, the reasoning is strong—multi-hop synthesis across years and strategic themes is sound, with accurate identification of entities (Optum Rx, UnitedHealth Group, Optum Health/Insight, UnitedHealthcare) and correct interpretation of Optum Rx’s evolving role as a connective hub. The conceptual shift from cost management to system-wide integration is well articulated. 4) The answer is highly contextually relevant, directly addressing service offerings and strategic positioning over time. Despite minor inaccuracies, it captures the essence of the transformation. Correctness score is 8 due to accurate core facts but notable errors in date attribution and unsupported network size update.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1524,
        "completion_tokens": 579,
        "total_tokens": 2103
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How did the composition and valuation of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of investments held for deferred cash compensation plans?",
      "original_answer": "In 2023, BlackRock reported $9 million invested in Equity Securities at FVTNI as part of the investments held to economically hedge deferred cash compensation plans. By 2024, this specific category was no longer listed under Equity Securities at FVTNI but instead appeared under 'Investments related to deferred cash compensation plans' within the Equity Method section with a value of $173 million. This indicates a reclassification or realignment of how these investments were categorized and reported in the financial statements, reflecting a significant change in the composition of Equity Securities at FVTNI.",
      "llm_answer": "In 2024 BlackRock’s equity securities measured at fair value (FVTNI) rose to **$1.95 billion** (fair‑value) from **$1.585 billion** in 2023 – the cost basis also grew from $1.52 billion to $1.84 billion (see 2024 table on page 92 and 2023 table on page 95).  However, the slice of the equity‑method portfolio that is used to hedge **deferred‑cash‑compensation plans** fell, dropping from **$241 million** in 2023 to **$173 million** in 2024 (see “Investments related to deferred cash compensation plans” on pages 95 and 94).  Thus, while total equity‑security holdings at FVTNI increased, the specific amount earmarked for deferred‑compensation hedges declined.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresents the core information in the ground truth. (1) Quantitatively, the LLM incorrectly states that in 2023, $241 million was invested in equity securities related to deferred cash compensation plans, while the ground truth specifies $9 million under Equity Securities at FVTNI. The $241 million figure does not appear in the original answer and is therefore fabricated. Additionally, the LLM claims total Equity Securities at FVTNI increased from $1.585B to $1.95B, but this information is not present in the ground truth and is irrelevant to the specific focus on deferred compensation investments. (2) The only correct number is the 2024 value of $173 million, which matches the ground truth, but it misattributes this to a decrease from $241 million rather than a reclassification. (3) Qualitatively, the reasoning is flawed: the ground truth emphasizes a reclassification — moving from Equity Securities at FVTNI to the Equity Method section — not a decline in value or portfolio size. The LLM interprets this as a reduction in holdings, which is incorrect; it was a reporting change, not an economic one. (4) Contextually, the answer addresses the topic of deferred compensation investments and attempts multi-hop comparison across years, but fails to identify the key point: the removal of the $9 million from FVTNI and its reappearance in a different category, indicating reclassification. Instead, it invents unrelated totals and mischaracterizes the nature of the change. Thus, despite some contextual alignment and one correct number, the answer is largely incorrect in both facts and interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 454,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How has the aggregate available authorization for Accenture's open-market share purchase program changed between 2022 and 2024, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "The aggregate available authorization for Accenture's open-market share purchase program decreased from $3,129,296 in 2022 to $2,694,281 in 2024. This indicates a reduction in the company's capital allocated for share repurchases over this period, suggesting a more conservative approach to capital deployment or a strategic shift in how the company is managing its equity structure.",
      "llm_answer": "In the 2022 Form 10‑K Accenture reported that, as of 31 August 2022, it had **$3.13 billion** of aggregate available authorization for its publicly announced open‑market share‑repurchase program. By the 2024 Form 10‑K, that amount had fallen to **$2.69 billion** as of 31 August 2024 – a reduction of roughly **$0.44 billion**.\n\nThe decline shows that the company has been drawing down its buy‑back authority, using cash to repurchase shares and return capital to shareholders, while still preserving a sizable pool for future repurchases as part of its disciplined capital‑allocation strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the aggregate available authorization amounts for Accenture's share repurchase program in 2022 and 2024, reporting $3.13 billion and $2.69 billion respectively. These figures are accurate approximations of the ground truth values ($3,129,296 and $2,694,281), with acceptable rounding ($3.13B ≈ $3,130M and $2.69B ≈ $2,690M). The calculated reduction of $0.44 billion (~$440 million) is also correct based on the rounded figures. (2) The dates used—31 August 2022 and 31 August 2024—are consistent with Accenture’s fiscal year-end (August), and the entities (Accenture, open-market share purchase program) are correctly identified. (3) The multi-hop reasoning is sound: the model compares two data points across years and infers a trend in capital allocation. However, while the original answer interprets the decline as indicating a 'reduction in capital allocated for share repurchases'—possibly signaling a more conservative or strategic shift—the LLM frames the drawdown as active use of the authorization to return capital, which implies execution rather than retrenchment. This is a plausible interpretation but slightly diverges from the ground truth’s emphasis on reduced authorization as a sign of restrained or shifting capital deployment. (4) Despite this nuanced difference in interpretation, the LLM provides factually accurate numbers, correct context, and relevant analysis. The answer is semantically close to the original and fully addresses both parts of the question. Minor deduction in correctness and qualitative accuracy due to interpretive divergence, but quantitative accuracy is high with proper rounding and calculation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 463,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How has the treatment and disclosure around Accenture Canada Holdings Inc. Exchangeable Shares evolved between 2022 and 2024, particularly in terms of share repurchase activity and shareholder rights?",
      "original_answer": "In 2022, Accenture disclosed its intention to use a significant portion of cash generated from operations for share repurchases during fiscal 2023, including purchases and redemptions of Accenture Canada Holdings Inc. exchangeable shares. The company noted that the number of shares repurchased would depend on various factors such as share price and market conditions. By 2024, the disclosures had evolved to include more detailed descriptions of the rights associated with Accenture Canada Holdings Inc. exchangeable shares, particularly their exchangeability on a one-for-one basis for Accenture plc Class A ordinary shares, and the company's commitment to align the number of Class X ordinary shares with outstanding exchangeable shares. Additionally, as of August 31, 2024, the company had a specific remaining authorization of $2,694,281 for share repurchase programs, indicating a more structured and quantified approach compared to the more general intentions expressed in 2022.",
      "llm_answer": "In the 2022 Form 10‑K the company only described in qualitative terms that it “intends to continue to use a significant portion of cash … for share repurchases, including purchases and redemptions of Accenture Canada Holdings Inc. exchangeable shares,” and reiterated that the exchangeable shares could be exchanged at any time on a one‑for‑one basis for Accenture plc Class A ordinary shares and were entitled to the same distributions. By the 2024 filing the disclosure had become quantitative – the Board had authorized $2.694 million for open‑market and other share‑purchase programs and actually repurchased 47,752 exchangeable shares for $15,254 – and it restated the same exchange rights while adding a covenant that Accenture plc will not redeem any Class X ordinary share if such redemption would leave the holder with fewer Class X shares than the exchangeable shares they own, and that the Class X shares are non‑transferable without Accenture plc’s consent. Thus, the treatment evolved from a general intent statement in 2022 to specific repurchase activity and clearer redemption‑and‑transfer restrictions in 2024, while the fundamental shareholder right to exchange the shares for Class A stock and receive dividends remained unchanged.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution in disclosure and treatment of Accenture Canada Holdings Inc. exchangeable shares between 2022 and 2024, correctly identifying the shift from qualitative intent in 2022 to more specific, quantitative disclosures in 2024. It accurately notes the continued one-for-one exchange right and dividend equivalence. However, there are key quantitative inaccuracies: the LLM states a $2.694 million authorization, but the ground truth specifies $2,694,281 (a significant difference in magnitude—over $2.6 billion vs $2.6 million). Additionally, the LLM claims 47,752 exchangeable shares were repurchased for $15,254, which is not supported by the original answer and introduces specific figures absent in the ground truth. These fabricated numbers severely impact quantitative accuracy. The qualitative reasoning is sound—correctly identifying the evolution in disclosure detail, the alignment of Class X shares with exchangeable shares, and restrictions on redemption and transfer—even though the original answer does not explicitly mention transfer restrictions or redemption covenants. The LLM adds plausible but unverified details, slightly overextending beyond the source. Despite this, the overall narrative of increased specificity and structure in 2024 is aligned with the ground truth. Contextual relevance is perfect—the response directly addresses share repurchase activity and shareholder rights across the two years as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1572,
        "completion_tokens": 404,
        "total_tokens": 1976
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did the global revenue from Electrophysiology Devices evolve between 2023 and 2024, and what was the percentage change in this revenue, excluding the impact of foreign exchange fluctuations?",
      "original_answer": "In 2023, the global revenue from Electrophysiology Devices was $2,195 million, which increased to $2,467 million in 2024. This represents a total change of 12.3%, with the change excluding the impact of foreign exchange fluctuations being 14.4%.",
      "llm_answer": "The Electrophysiology segment of Abbott’s Medical Devices business grew from **$2.195 billion in 2023 to $2.467 billion in 2024**, an increase of roughly **$272 million**.  When the impact of foreign‑exchange fluctuations is stripped out, the revenue rose **14.4 %** year‑over‑year【page_30】【page_31】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the revenue figures are accurate: $2.195 billion in 2023 and $2.467 billion in 2024 (equivalent to $2,195 million and $2,467 million in the original answer). The implied dollar increase of $272 million is correct (2,467 - 2,195 = 272). The percentage change excluding foreign exchange fluctuations is correctly stated as 14.4%, matching the ground truth. Although the LLM does not explicitly calculate the 12.3% total change including FX, it was not required to do so—the question asked for the change excluding FX, which is provided. (2) The answer is complete: it addresses both the revenue evolution (from 2023 to 2024) and the FX-neutral growth rate. (3) Entity accuracy is correct—'Electrophysiology Devices' is properly attributed to Abbott’s Medical Devices segment (contextually accurate based on the source documents). (4) Reasoning is sound: the LLM correctly synthesizes data across years and adjusts for foreign exchange impact, indicating proper multi-hop understanding. (5) Semantic equivalence is maintained—'grew from $2.195 billion to $2.467 billion' conveys the same meaning as the original, and percentage formatting (14.4%) is consistent. Minor formatting differences (billion vs million) are acceptable and numerically equivalent. All citations (page_30, page_31) support the claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1148,
        "completion_tokens": 387,
        "total_tokens": 1535
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How has Accenture's financial relationship with Duck Creek Technologies evolved between fiscal 2022 and fiscal 2024, particularly in terms of investment valuation and its impact on financial performance?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with the investment accounted for under the equity method. By fiscal 2024, this investment resulted in a $253 million gain, indicating a significant increase in value and a shift in how the investment contributed to Accenture's financial performance. This demonstrates both a quantitative increase in the investment's value and a qualitative change in its impact on Accenture's earnings.",
      "llm_answer": "In fiscal 2022 Accenture held an equity‑method investment in Duck Creek Technologies that was carried on the balance sheet at about **$138.9 million**, with an estimated fair‑value of the roughly 16 % ownership of **$223.2 million** (page 70).  By fiscal 2024 the investment had appreciated enough to generate a **$253 million unrealized gain** that was recorded in 2023‑24 results (page 40), and the company disclosed that this gain lifted reported earnings per share and the effective tax rate, although the impact was stripped out of its adjusted‑operating metrics.  Thus, the Duck Creek stake has risen in value from 2022 to 2024 and the appreciation has contributed positively to Accenture’s bottom line, albeit as a non‑recurring item.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely correct in both quantitative and qualitative aspects. It accurately reports the $223.2 million fair value of Accenture's investment in Duck Creek Technologies in fiscal 2022 (matching the ground truth of $223,166,000, or ~$223 million) and correctly identifies the 16% ownership stake. The $253 million gain in fiscal 2024 is accurately stated and aligns with the ground truth. The only minor discrepancy is the mention of a 'carrying value of $138.9 million' in 2022, which refers to the book value under the equity method—this detail is not in the ground truth but is plausibly correct based on accounting practices and does not contradict the original answer. (2) All key numbers—$223.2 million fair value, 16%, and $253 million gain—are correct within acceptable rounding and formatting variations. The gain is correctly attributed to fiscal 2024 results, consistent with the original. (3) The multi-hop reasoning is sound: the LLM synthesizes valuation changes over time and correctly infers the impact on financial performance, including the effect on EPS and tax rate, and notes it was excluded from adjusted metrics—this adds contextual depth beyond the ground truth without introducing error. (4) The answer fully addresses the evolution of the financial relationship, including valuation change and performance impact. The extra detail about non-recurring treatment enhances accuracy. Thus, the answer is factually aligned, logically structured, and contextually complete—justifying a high score with only a minor deduction for introducing a number ($138.9M) not in the ground truth, though not necessarily incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 456,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has the composition and scale of Union Pacific's retention share and unit awards changed between 2022 and 2023, and what does this indicate about the company's executive compensation strategy?",
      "original_answer": "In 2022, Union Pacific disclosed that 389,207 retention shares were outstanding under the 2021 Stock Incentive Plan as of December 31, 2021. By 2023, the company disclosed that 954,405 retention shares had been issued and were outstanding, along with 366,046 retention units that do not have an exercise price. This represents a significant increase in the number of outstanding retention instruments, indicating a shift toward greater use of retention-based compensation. The introduction of retention units in 2023 suggests a possible expansion or refinement of the company's long-term incentive strategy for executives.",
      "llm_answer": "The 2023 proxy‑statement shows that Union Pacific now has **both retention shares and retention units** outstanding – approximately **954 thousand retention shares** (already issued) plus **366 thousand retention units** that carry no exercise price (footnote [1] on page 75). In the 2022 filing the company reported only the retention‑share component (about 950 thousand shares) and did not have any retention‑unit grants. The addition of a sizable block of retention units in 2023 expands the total pool of equity‑based “stay‑with‑us” awards to roughly **1.32 million** shares/units, indicating that the firm is shifting its executive‑pay strategy toward a larger, more performance‑linked equity component to better align executives’ interests with shareholders and improve talent retention.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the introduction of retention units in 2023 and the significant increase in retention instruments, aligning with the ground truth's conclusion about a strategic shift. However, there is a key quantitative inaccuracy: the LLM states that in 2022, Union Pacific reported 'about 950 thousand shares' outstanding, but the ground truth specifies that the 2022 filing disclosed 389,207 retention shares outstanding as of December 31, 2021 (reported in the 2022 proxy). The LLM incorrectly uses the 2023 retention share figure (~954k) as the 2022 number, which is a significant error. (2) The calculation of the total 1.32 million shares/units in 2023 is accurate (954,405 + 366,046 ≈ 1.32M), and the presence of both retention shares and units in 2023 is correctly noted. (3) The multi-hop reasoning is sound—comparing the composition across years and inferring a strategic shift toward retention-based compensation is well-supported and consistent with the ground truth. The LLM correctly synthesizes that the addition of retention units indicates an expansion of the long-term incentive strategy. (4) Despite the major numerical error in the 2022 figure, the overall interpretation and qualitative assessment of the compensation strategy shift are accurate and relevant. The answer addresses all parts of the question, but the incorrect baseline number reduces quantitative accuracy. Hence, correctness is penalized but not severely due to strong reasoning and correct directional insight.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 423,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has MetLife's application of GAAP guidance for adjusted earnings evolved between 2023 and 2024, particularly in terms of the exclusions related to market volatility and asymmetrical accounting adjustments?",
      "original_answer": "In 2023, MetLife updated its calculation of adjusted earnings due to the adoption of LDTI, which led to the exclusion of certain adjustments related to the amortization of DAC, VOBA, and related intangibles, as well as changes in measurement of certain guarantees. Adjusted earnings excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, MetLife continued to refine these exclusions, particularly expanding the scope of policyholder liability remeasurement gains (losses) to exclude asymmetrical accounting associated with in-force reinsurance. Additionally, in 2024, net investment income exclusions were expanded to include adjustments relating to joint ventures under the equity method, which was not explicitly mentioned in 2023. This reflects a more detailed and structured application of GAAP guidance over time.",
      "llm_answer": "MetLife’s 2023 filing explained that, under GAAP‑based “adjusted earnings,” the company strips out any impact of market‑volatility (net investment gains / losses, net derivative gains / losses, MRB re‑measurement gains / losses and goodwill impairments) and a set of asymmetrical or non‑economic accounting items – such as derivative income that does not qualify for hedge accounting, foreign‑currency hedge settlements, in‑force reinsurance adjustments, basis‑adjustment amortization, inflation‑indexed benefit adjustments and single‑premium loss amortization. The 2024 filing repeats the same GAAP guidance, continuing to exclude those same market‑volatility and asymmetrical‑adjustment components, indicating that MetLife’s approach to adjusted earnings has remained consistent year‑over‑year, with no new categories added beyond the LDTI‑related updates already disclosed in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies that MetLife uses GAAP-based adjusted earnings and excludes market volatility and asymmetrical accounting items, which aligns with the general framework in the original answer. It accurately references MRBs, in-force reinsurance, and LDTI-related updates in 2023, showing some factual consistency. However, the LLM incorrectly states that MetLife’s approach remained consistent between 2023 and 2024 with no new categories added. This contradicts the ground truth, which specifies that in 2024, MetLife expanded exclusions to include policyholder liability remeasurement gains (losses) related to asymmetrical accounting from in-force reinsurance and added net investment income exclusions for joint ventures under the equity method—changes not present in 2023. The LLM fails to capture these key 2024 refinements, indicating a failure in multi-hop reasoning across years. While entity names (MetLife, LDTI, MRBs) and years are correct, and there are no numerical inaccuracies (as no specific numbers are involved), the qualitative inaccuracy of missing evolving exclusions significantly undermines the correctness. The answer is contextually relevant and well-structured but misses critical evolution details, leading to a partial score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 354,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has Accenture's approach to achieving compressed transformations evolved from 2022 to 2024, particularly in terms of the technologies leveraged and the scope of transformation services offered?",
      "original_answer": "In 2022, Accenture focused on using technologies like digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics, and metaverse to help clients achieve compressed transformations by redefining product design, engineering, sourcing, manufacturing, and servicing. By 2024, the company expanded its technological toolkit to include generative AI, artificial reality / virtual reality, and advanced robotics, while also enhancing its own development of automation equipment and commercial hardware to support client operations. Additionally, the scope of transformation broadened to include digitally transforming capital projects such as plant and asset construction, public infrastructure, power grids, and data centers. This reflects a more integrated and advanced technological approach to compressed transformations over the two-year period.",
      "llm_answer": "In 2022 Accenture’s “compressed‑transformation” narrative was anchored in Industry X’s use of digital twins, AI (including generative AI), IoT, AR/VR, robotics, blockchain, 5G, edge and quantum‑computing to redesign product design and engineering and speed up manufacturing‑supply‑chain changes. By 2024 the firm had broadened that approach to the entire product lifecycle—design, sourcing, manufacturing, service, return and renewal—by adding cloud‑and‑edge integration, a data‑driven SynOps platform, and a deeper ecosystem of AI‑enabled services (digital twins, AI, IoT, 5G, advanced robotics, metaverse, generative AI) while embedding these capabilities across its full suite of services (Strategy & Consulting, Technology, Operations, Industry X and Song).",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in terms of the technologies and evolution in Accenture's approach from 2022 to 2024, with accurate dates and no numerical inaccuracies (quantitative accuracy is perfect as there are no figures to verify and no incorrect claims about amounts or percentages). The answer correctly identifies core technologies used in 2022 such as digital twins, AI, IoT, AR/VR, robotics, 5G, and edge computing, and notes an expanded scope by 2024. However, there are some discrepancies: the original answer does not mention blockchain or quantum computing in 2022, which the LLM incorrectly includes. Additionally, while the LLM mentions generative AI in 2022, the ground truth indicates it was added by 2024, not part of the initial 2022 toolkit. The LLM also emphasizes SynOps and a 'data-driven platform' and 'ecosystem of AI-enabled services' that are not mentioned in the ground truth. On the positive side, the LLM captures the broader lifecycle inclusion (design to return/renewal) and integration across service lines, which aligns with the expanded scope in the original answer, though the ground truth specifically highlights transformation of capital projects (plant construction, infrastructure, etc.)—a key point missing in the LLM response. Thus, while the overall direction and qualitative trend are correct (evolution toward broader scope and enhanced tech), the LLM introduces unsupported technologies and omits specific capital projects focus, leading to a moderate deduction in qualitative accuracy. Contextual relevance remains high as the response directly addresses the evolution in technologies and scope over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 450,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2023 and 2024 in managing exposure to changes in the fair value of fixed-rate debt?",
      "original_answer": "In 2023, Abbott had interest rate hedge contracts totaling approximately $2.2 billion at December 31, 2023, to manage exposure to changes in the fair value of fixed-rate debt due to long-term benchmark interest rate fluctuations. These contracts were designated as fair value hedges, effectively converting fixed-rate debt to variable-rate debt. In 2024, Abbott continued to maintain interest rate hedge contracts with notional values totaling $2.2 billion, indicating a consistent strategy in hedging interest rate risk. However, the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024, suggesting a shift in the underlying debt structure or market interest rate conditions despite the stable hedge notional amount.",
      "llm_answer": "In the 2023 filing Abbott disclosed that it had ≈ $2.2 billion of interest‑rate hedge contracts (fair‑value swaps) in place to offset the fair‑value changes of its fixed‑rate debt, with a recorded fair‑value liability of about $95 million (down from $136 million the prior year after $700 million of contracts matured). The 2024 filing shows the same notional amount—$2.2 billion—still being used, indicating the company replaced the contracts that expired in 2023 and kept the hedge program at essentially the same size to continue converting the fixed‑rate portion of its debt to a variable rate and managing exposure to interest‑rate movements.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) Quantitatively, it accurately reports the $2.2 billion notional amount of interest rate hedge contracts in both 2023 and 2024, matching the original answer. It adds additional detail not in the ground truth—specifically, the fair value liability of $95 million in 2023 (down from $136 million) and $700 million of maturities—which may come from deeper filing analysis but does not contradict the ground truth. These details enhance completeness but are not required for correctness. (2) The core quantitative claim—that Abbott maintained $2.2 billion in hedges across both years—is correct and properly reflects a stable hedging strategy. However, the original answer includes a key comparative metric: the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024. This detail is missing in the LLM response, representing a meaningful omission in explaining the evolution of the hedge strategy in context of changing debt costs. (3) The reasoning is sound: the LLM correctly infers that maintaining the same notional amount suggests Abbott replaced expired contracts and continued its strategy of converting fixed-rate debt to variable via fair value hedges. This demonstrates proper multi-hop synthesis between the existence of hedges, their purpose, and continuity over time. (4) Entity accuracy is strong—Abbott, interest rate hedge contracts, fair value hedges, fixed-rate debt, and correct years are all properly identified. The answer is fully contextually relevant, directly addressing how Abbott’s use of hedges evolved (or remained stable). The omission of the interest rate increase on debt prevents a perfect score, as it limits the depth of the evolution analysis, but the core facts and logic are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 491,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has MetLife's treatment and definition of Adjusted Earnings evolved between 2023 and 2024, particularly in relation to GAAP guidance and segment performance measurement?",
      "original_answer": "In 2023, MetLife updated its calculation of Adjusted Earnings due to the adoption of LDTI, removing certain adjustments related to the amortization of DAC, VOBA, and related intangibles, and instead adjusted for changes in measurement of certain guarantees. Adjusted Earnings in 2023 excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, Adjusted Earnings remained the GAAP measure of segment performance, but the exclusions were more clearly delineated to include market volatility impacts, asymmetrical and non-economic accounting adjustments, revenues and costs from divested businesses, and results from discontinued operations. Specifically, 2024 Adjusted Earnings excluded net investment gains/losses, derivative gains/losses, MRB remeasurement gains/losses, and goodwill impairments, with more structured exclusions such as inflation-indexed benefit adjustments and non-economic losses from single premium annuity contracts. This represents a refinement and expansion of the exclusions introduced in 2023.",
      "llm_answer": "MetLife’s 2023 Form 10‑K first defined **adjusted earnings** as “adjusted revenues less adjusted expenses, net of income tax” and noted that, *consistent with GAAP guidance for segment reporting, adjusted earnings is the Company’s GAAP measure of segment performance* (see 2023 p. 120).  It also explained that the adoption of the new LDTI accounting standard changed the calculation by removing DAC/VOBA amortization adjustments and other fair‑value changes, and that the measure is used for performance‑based compensation (2023 p. 119).\n\nIn the 2024 filing the definition is reiterated but expanded: adjusted earnings is still described as the CODM’s GAAP‑consistent metric for segment performance, and the disclosure now spells out the specific items it excludes—market‑volatility effects (net investment gains/losses, MRB remeasurement gains/losses, goodwill impairments), asymmetrical and non‑economic accounting, revenues and costs of divested businesses, and discontinued‑operation results (2024 p. 150).  Thus, between 2023 and 2024 MetLife kept adjusted earnings as a GAAP‑aligned segment‑performance measure but refined its treatment by detailing the additional exclusions introduced after LDTI and by emphasizing its role in segment reporting and compensation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2023, MetLife updated Adjusted Earnings due to LDTI adoption, removing DAC/VOBA amortization adjustments and fair value changes (e.g., MRBs, discount rate impacts, asymmetrical accounting), which matches the original answer. In 2024, it accurately notes the refinement and expansion of exclusions, including market volatility items (net investment gains/losses, derivative gains/losses, MRB remeasurements, goodwill impairments), divested business impacts, and discontinued operations. The mention of inflation-indexed benefits and non-economic losses from single premium annuities in the ground truth is a minor omission but does not undermine the core accuracy. (2) There are no numeric values or calculations in this question, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM synthesizes changes across two years, links LDTI adoption to the shift in Adjusted Earnings treatment, and correctly identifies the continued use of Adjusted Earnings as the GAAP-aligned segment performance metric. It also correctly cites the role in performance-based compensation and segment reporting, which adds context beyond the ground truth but is accurate. (4) The answer is contextually excellent, directly addressing the evolution between 2023 and 2024, the relation to GAAP guidance, and segment performance measurement. The only reason for not scoring a 10 is the slight lack of specificity around certain 2024 exclusions (e.g., inflation-indexed benefits), but the overall meaning and factual content are semantically equivalent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1606,
        "completion_tokens": 459,
        "total_tokens": 2065
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has the funding and utilization of Accenture's share purchase program evolved from 2022 to 2024, particularly in terms of available authorization and share acquisition methods?",
      "original_answer": "In 2022, Accenture reported an aggregate available authorization of $3,129,296 for its publicly announced open-market share purchase program and other related share purchase programs. This included acquisitions of Accenture plc Class A ordinary shares and Accenture Canada Holdings Inc. exchangeable shares held by current and former members of Accenture Leadership. By 2024, the company clarified that its open-market share purchase program applied specifically to Accenture plc Class A ordinary shares, which were held as treasury shares for employee benefits, such as equity awards. Additionally, in fiscal 2024, Accenture acquired Class A ordinary shares primarily through share withholding for payroll tax obligations tied to employee equity plans. These purchases did not impact the aggregate available authorization for the public share purchase programs, indicating a shift in acquisition methods while maintaining a focus on funding levels.",
      "llm_answer": "In 2022 the Board had authorized $3.13 million for its publicly announced open‑market share‑repurchase and related purchase programs, while in 2024 that available authorization had fallen to $2.69 million (the Board later added a $4 million amendment, bringing total authority to $6.69 million). Despite the lower remaining authorization, Accenture actually bought more shares in 2024 – 13.9 million shares for $4.51 million versus 12.2 million shares for $4.11 million in 2022 – using a mix of open‑market purchases, purchases under other share‑purchase programs (including exchangeable shares) and share‑withholding transactions that satisfy payroll‑tax obligations for employee equity awards.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. The original answer states that in 2022, Accenture had an aggregate available authorization of $3,129,296 (approximately $3.13 million), which the LLM correctly approximates. However, the LLM claims that by 2024, the available authorization had fallen to $2.69 million and was later increased to $6.69 million via a $4 million amendment. This is entirely incorrect—there is no mention in the ground truth of any such amendment or updated total authorization. The ground truth does not provide a 2024 authorization amount, only that the program continued with a focus on Accenture plc Class A ordinary shares. (2) The LLM fabricates specific share purchase volumes and values: it claims Accenture bought 13.9 million shares for $4.51 million in 2024 and 12.2 million for $4.11 million in 2022. These numbers are not in the original answer and are implausible (e.g., $4.51 million for 13.9 million shares implies less than $0.33/share, which is unrealistic for a company like Accenture). The ground truth does not provide any data on the number of shares purchased or total dollar volume of purchases in either year. (3) The qualitative reasoning is partially sound in identifying share withholding for payroll taxes as a method used in 2024 and mentioning exchangeable shares in prior programs, which aligns with the original answer. However, it incorrectly implies that open-market purchases and other programs were still active in 2024 under the same authorization, while the ground truth clarifies that share withholding did not impact the public program's authorization, suggesting a shift in method. The LLM fails to convey the key point that the 2024 acquisitions via withholding were separate from the public authorization. (4) The contextual relevance is moderate because the answer addresses funding, authorization, and acquisition methods, but the severe quantitative errors and invented data undermine correctness. The qualitative score is low due to incorrect synthesis and unsupported claims. Correctness is scored very low because the core financial data and program evolution are misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 582,
        "total_tokens": 2002
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How did MetLife's treatment and valuation methodology for Unit-linked Securities evolve from 2023 to 2024, particularly in terms of cost basis and fair value sensitivity?",
      "original_answer": "In 2023, MetLife described the cost basis for Unit-linked and FVO securities as primarily equity and fixed maturity securities, with cost representing original cost for equities and amortized cost for fixed maturities. By 2024, Unit-linked securities were included in Level 3 fair value measurements and subjected to valuation techniques involving significant unobservable inputs such as mortality rates, lapse rates, and equity volatility. Additionally, the 2024 disclosures emphasized sensitivity of fair value to changes in these inputs, indicating a more dynamic and assumption-driven valuation approach compared to the more static cost-based method described in 2023.",
      "llm_answer": "- **2023** – In the 2023 filing the “Unit‑linked and FVO securities” line in Schedule I is shown at **cost (amortized cost)** of $8,742 million, which the footnote explains is “original cost reduced by repayments and adjusted for amortization of premium or accretion of discount” (see page 320). Their fair value ($10,331 million) is measured as a Level 3 asset using the same unobservable‑input techniques applied to other Level 3 securities (see the Level 3 roll‑forward on page 321).\n\n- **2024** – The 2024 filing still reports Unit‑linked and FVO securities at **amortized cost** (the cost basis description is unchanged) and the Level 3 roll‑forward shows the balance growing to $1,190 million (up from $1,103 million in 2023) (see page 251). The 2024 notes state that “all other classes of securities classified within Level 3, including those within Unit‑linked and FVO securities, use the same valuation techniques and significant unobservable inputs as previously described” and no separate sensitivity ranges are provided, indicating that the valuation methodology and its sensitivity remained consistent with 2023. (see pages 250‑251).",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) It incorrectly states that Unit-linked securities were reported at amortized cost in both 2023 and 2024, while the ground truth indicates a shift in 2024 to Level 3 fair value measurements with greater emphasis on sensitivity analysis. The LLM claims the cost basis description was 'unchanged' in 2024, which directly contradicts the original answer stating a move to a more dynamic, assumption-driven valuation approach. (2) The quantitative figures cited—$8,742 million cost and $10,331 million fair value in 2023, and Level 3 balances of $1,103M and $1,190M—are not present in the ground truth and appear to be fabricated or misattributed; no such numbers are mentioned in the original answer, making their accuracy unverifiable and suspect. (3) The multi-hop reasoning is flawed: the LLM fails to recognize the evolution in methodology from a cost-based to a sensitivity-focused fair value approach, instead asserting consistency between years. It also misinterprets the Level 3 classification as static, whereas the ground truth emphasizes increased focus on sensitivity to unobservable inputs in 2024. (4) Contextually, the answer addresses the right topic (valuation of Unit-linked securities) and time frame, but the core conclusion about methodological continuity is incorrect. The LLM also references specific pages and footnotes not available in the provided context, raising concerns about hallucination. Overall, the answer is mostly incorrect due to fundamental errors in financial methodology interpretation and unsupported numerical claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1460,
        "completion_tokens": 448,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How has the structure and vesting timeline of market-based RSUs evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, market-based RSUs generally vested over four years and grantees could receive between 0% and 300% of the original grant based on total stockholder return (TSR) relative to an index group. By fiscal year 2023, while four-year vesting remained common, the company also introduced market-based RSUs that vested over five years, with vesting contingent on achieving stock price performance milestones. This indicates an expansion in the types of market-based RSUs offered, adding a new vesting structure based on specific stock price targets.",
      "llm_answer": "In fiscal 2022 Broadcom’s market‑based RSU awards were “standard” awards that **vested over four years**, with the payout tied to the total‑shareholder‑return (TSR) of Broadcom versus an index group. In fiscal 2023 the company kept that four‑year, TSR‑based design **but added a new series of market‑based RSUs that vest over five years and are tied to the achievement of specific stock‑price performance milestones** 【page_84】. Thus, the RSU structure was expanded in 2023 to include a longer‑term, five‑year vesting tranche in addition to the existing four‑year awards.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that in fiscal 2022, market-based RSUs vested over four years with payouts based on TSR relative to an index group, and in fiscal 2023, the company retained the four-year TSR-based structure while introducing a new five-year vesting structure tied to stock price performance milestones. (2) There are no numerical values requiring calculation (e.g., percentages, dollar amounts), but the timeframes (four-year and five-year vesting) are correctly reported and match the original answer. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes across fiscal years, identifying both the continuity (four-year vesting) and the evolution (addition of five-year vesting with different performance criteria). (4) The answer is contextually precise, directly addressing how the structure and vesting timeline evolved. Minor wording differences (e.g., 'standard awards', 'new series') do not affect factual accuracy and enhance clarity. All key elements—vesting periods, performance conditions, and structural expansion—are correctly conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 327,
        "total_tokens": 1600
      },
      "error": null
    },
    {
      "question_id": 145,
      "question": "How did the phase-in treatment of the CECL standard's ongoing impact on regulatory capital evolve between 2023 and 2024, and what specific regulatory capital treatment applied during the phase-in period?",
      "original_answer": "In 2023, the CECL Transition Election allowed for the cumulative 'day 2' ongoing impact to be phased into regulatory capital at 25% per year from January 1, 2022, through December 31, 2024. By 2024, this phase-in treatment remained consistent, with the ongoing impact continuing to be phased in at 25% annually, indicating that the regulatory capital treatment under the CECL Transition Rule was applied uniformly across both years as part of the multi-year transition framework.",
      "llm_answer": "The CECL Transition Rule lets a bank “add‑back” the after‑tax Day 1 adoption impact and the cumulative Day 2 (ongo‑ing) impact to its regulatory capital, phasing that add‑back in at 25 % per year. In 2023 Capital One had already phased‑in 50 % of the $2.4 billion CECL impact (the other $1.2 billion was scheduled to be added in two $600 million steps in 2024 and 2025); by 2024 the phase‑in had moved to 75 % (the first $600 million added on 1 Jan 2024, with the final $600 million to be added on 1 Jan 2025). During the phase‑in period the CECL impact was treated as a regulatory‑capital add‑back, raising the reported CET1 ratio to 12.9 % in 2023 and 13.5 % in 2024 (the “on a fully phased‑in basis” ratios would have been 12.6 % and 13.3 %).【page_80】【page_202】【page_203】",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness despite addressing the general topic. (1) The original answer states that the CECL phase-in occurred from January 1, 2022, through December 31, 2024, at 25% per year, meaning full phase-in by end of 2024. However, the LLM claims that $600 million would be added in 2025, which contradicts the 2024 end date—this is a critical error. (2) The LLM introduces Capital One and specific dollar figures ($2.4 billion, $1.2 billion, $600 million) and CET1 ratios (12.9%, 13.5%) not present in the ground truth, which makes no mention of any specific bank or financial figures. These numbers, while internally consistent, are not supported by the original answer and represent a failure in entity accuracy. (3) The qualitative reasoning about a 25% annual phase-in is partially correct and aligns with the ground truth, showing some understanding of the CECL Transition Rule’s mechanics. However, extending the phase-in into 2025 misrepresents the timeline. (4) Contextually, the answer is relevant and attempts multi-hop synthesis by tracking phase-in progression across years and linking it to regulatory capital treatment, but it fabricates entity-specific data, undermining factual reliability. The mention of 'on a fully phased-in basis' ratios further indicates detailed but unverified elaboration. Overall, the answer is partially correct in mechanism but incorrect in key facts, dates, and entities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 407,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 146,
      "question": "How has Broadcom's relationship with Wilmington Trust, National Association evolved between 2022 and 2023 in terms of the types and terms of senior notes issued under their indentures?",
      "original_answer": "In 2022, Broadcom had an ongoing relationship with Wilmington Trust, National Association as trustee under indentures governing senior notes issued in January 2021, which included notes with interest rates as low as 1.950% (due 2028) and as high as 3.750% (due 2051). By 2023, the relationship had evolved to include new indentures dated April 18, 2022, and July 12, 2024, under which Broadcom issued higher-yielding senior notes, including a 4.926% note due 2037 and later, in October 2024, notes ranging from 4.150% (due 2028) to 4.800% (due 2034). This reflects a shift toward issuing longer-term debt with higher interest rates over time.",
      "llm_answer": "In the 2022 Form 10‑K Broadcom entered into two new indentures with Wilmington Trust, National Association – one dated April 14, 2022 for 4.00 % senior notes due 2029 and a second dated April 18, 2022 for 4.926 % senior notes due 2037. The 2023 Form 10‑K shows no additional senior‑note issuances; Broadcom’s relationship with Wilmington Trust continued unchanged, with the company remaining a borrower under the same 2022 indentures and the previously‑issued notes retaining their original coupons and maturities.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims that in 2022, Broadcom entered into two indentures on April 14 and April 18, 2022, but the ground truth states that the April 18, 2022 indenture is valid, while no April 14, 2022 indenture is mentioned. The 4.00% note due 2029 is not referenced in the ground truth, which instead lists a 4.926% note due 2037 issued under the April 18, 2022 indenture—this rate is correctly mentioned but the other note is fabricated. Furthermore, the LLM claims no new issuances occurred in 2023, which contradicts the ground truth stating that by 2023, Broadcom had issued additional notes under a July 12, 2024 indenture (planned issuance disclosed in 2023 filing), including 4.150% due 2028 and 4.800% due 2034 in October 2024. The LLM incorrectly concludes the relationship was 'unchanged' in 2023, missing the evolution entirely. (2) Quantitative accuracy is partially correct: the 4.926% due 2037 is accurate, but the 4.00% due 2029 is not supported, and the 2024 issuances (4.150%–4.800%) are omitted. Dates like April 14, 2022 are incorrect; April 18, 2022 is correct. The July 12, 2024 indenture is missing. (3) Multi-hop reasoning fails: the model does not synthesize the evolution from 2022 to 2023, incorrectly asserting no change, whereas the ground truth shows a clear shift toward higher-yielding, longer-term debt. The LLM fails to recognize that disclosures in the 2023 filing about future issuances (e.g., July 12, 2024 indenture) constitute an evolution in the relationship. (4) Contextual relevance is moderate—the answer addresses the trustee relationship and senior notes, but misses the core evolution in terms and types of notes. Due to major factual and reasoning errors, especially the omission of key 2023 developments and inclusion of unsupported 2022 details, the correctness score is low at 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 511,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did Capital One's regulatory capital add-back under the CECL Transition Rule evolve from 2023 to 2024, and what was the specific phase-in progression during this period?",
      "original_answer": "In 2023, Capital One had already added back $2.4 billion to its regulatory capital under the CECL Transition Rule, with a phase-in of 50% as of January 1, 2023. By January 1, 2024, the phase-in had progressed to 75%, indicating a 25 percentage point increase over the year. This reflects the structured five-year phase-in process under the CECL Transition Rule, where 25% of the cumulative impact was phased in annually after 2021.",
      "llm_answer": "Capital One’s CECL‑transition add‑back grew from **about 50 % of the total $2.4 billion add‑back in 2023 to roughly 75 % in 2024**.  The company notes that “as of December 31 2021 we added back an aggregate amount of $2.4 billion… we have phased in 75 % of this amount as of January 1 2024” (2024 10‑K, Note 12)【page_202】, and the CECL Transition Rule table shows the scheduled phase‑in: **25 % in 2022, 50 % in 2023, 75 % in 2024, and 100 % (fully phased‑in) in 2025**【page_202】.  Thus the regulatory‑capital add‑back moved from the 50 % level in 2023 to the 75 % level in 2024 as part of the rule‑prescribed yearly 25 %‑per‑year phase‑in.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers, percentages, and dates are accurate: $2.4 billion is correctly cited as the total add-back amount; the phase-in progression of 50% in 2023 and 75% in 2024 is precisely stated; and the annual 25 percentage point increase aligns with the CECL Transition Rule's five-year phase-in schedule. The mention of full phase-in by 2025 is consistent with the rule. (2) The answer correctly identifies Capital One and the relevant regulatory context (CECL Transition Rule), and accurately references the 2024 10-K, Note 12, with a specific page citation, demonstrating proper sourcing. (3) Multi-hop reasoning is sound: the model synthesizes the dollar amount, the phase-in percentages over time, and the regulatory framework into a coherent explanation of how the add-back evolved from 2023 to 2024. (4) The semantic content is equivalent to the original answer—though phrased differently, it conveys the same core facts, progression, and regulatory context. Minor wording differences (e.g., 'about 50%' vs. exact 50%) do not affect factual accuracy, especially since the source document may use such phrasing. All parts of the question are addressed: the evolution from 2023 to 2024 and the specific phase-in progression.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 367,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did the treatment of VMware stock options for non-employee directors evolve between 2022 and 2023 following the Broadcom acquisition?",
      "original_answer": "In 2022, the 10-K filing stated that all outstanding in-the-money VMware stock options and RSU awards held by non-employee directors would be accelerated and converted into the right to receive cash and shares of Broadcom common stock, in equal parts, upon the completion of the acquisition. By 2023, this provision had been realized, with the statement confirming that these awards were indeed accelerated and converted into the right to receive cash and Broadcom shares. This reflects a transition from a planned conversion to an actualized event following the completion of the acquisition.",
      "llm_answer": "In the 2022 filing Broadcom said that, once the VMware merger closed, **all in‑the‑money VMware stock options (and RSUs) held by non‑employee directors would be accelerated and converted into the right to receive cash and Broadcom common stock in equal parts**【page_97】.  \n\nThe 2023 filing, after the merger was completed, confirmed that **the acceleration and conversion actually took place**, giving those directors cash and Broadcom shares on a 50‑50 basis【page_66】.  \n\nThus, the treatment did not change – the 2022 statement was a forward‑looking plan, and the 2023 statement reports that the planned acceleration and equal‑part cash‑and‑stock conversion was carried out.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately captures the evolution of the treatment of VMware stock options for non-employee directors: in 2022, the plan was to accelerate and convert in-the-money options and RSUs into equal parts cash and Broadcom stock upon acquisition; in 2023, this plan was confirmed as executed. (2) There are no numerical values requiring calculation (e.g., percentages, dollar amounts), but the 'equal parts' or '50-50 basis' description matches the 'cash and shares of Broadcom common stock, in equal parts' from the original, satisfying quantitative accuracy. (3) The multi-hop reasoning is sound—correctly linking the forward-looking statement in the 2022 filing with the retrospective confirmation in the 2023 filing, showing a transition from plan to execution. (4) All entities (VMware, Broadcom, non-employee directors, stock options, RSUs, 2022 vs 2023 filings) are correctly identified and synthesized. The answer is concise, factually precise, and directly addresses the question’s focus on how the treatment evolved. Minor wording differences (e.g., 'converted into the right to receive' vs 'giving those directors') do not affect factual meaning. All scoring categories warrant full marks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 357,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How has the therapeutic positioning of Vraylar evolved from 2022 to 2024 based on AbbVie's disclosures?",
      "original_answer": "In 2022, Vraylar was described as being evaluated in Phase 3 clinical trials as an adjunctive treatment for major depressive disorder (MDD), with one trial meeting its primary endpoint and the other showing numerical but not statistically significant improvement. By 2024, Vraylar was disclosed as being indicated for a broader range of psychiatric conditions, including acute and maintenance treatment of schizophrenia, acute treatment of manic or mixed episodes associated with bipolar disorder, acute treatment of depressive episodes associated with bipolar I disorder, and as an adjunctive treatment in major depressive disorder. This reflects a clear expansion and solidification of its therapeutic positioning over time.",
      "llm_answer": "In the 2022 Form 10‑K AbbVie described Vraylar (cariprazine) as a dopamine‑D3‑preferring D3/D2 partial agonist that was **indicated for four separate psychiatric uses** – acute and maintenance treatment of schizophrenia, acute treatment of manic or mixed episodes of bipolar disorder, acute treatment of bipolar‑I depressive episodes, and as an adjunctive therapy for major depressive disorder. By the 2024 filing the company no longer highlighted new label expansions; instead Vraylar is presented simply as a neuroscience product with **strong sales growth (‑‑ U.S. revenue up 81.7% to $1.73 billion and total revenue $511 million)**, indicating that AbbVie’s positioning has shifted from emphasizing a broad, expanding indication set to stressing its commercial traction and importance within its psychiatric‑neuroscience portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Vraylar was still under evaluation in Phase 3 trials for adjunctive treatment of MDD, with mixed results—not yet indicated for that use. However, the LLM incorrectly states that in 2022, Vraylar was already 'indicated for four separate psychiatric uses,' including adjunctive therapy for MDD. This misrepresents the therapeutic positioning at that time and contradicts the original answer. By 2024, the drug was indeed broadly indicated, which the LLM correctly notes, but it incorrectly frames the shift as one from 'broad indications to commercial emphasis,' when in fact the expansion of indications is the key evolution. (2) The quantitative data in the LLM answer—'U.S. revenue up 81.7% to $1.73 billion and total revenue $511 million'—are not present in the original answer and appear fabricated or misattributed. There is no mention of financial figures in the ground truth, so these numbers cannot be verified and are likely incorrect or irrelevant. The revenue figures also contradict each other (U.S. revenue higher than total revenue). (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution from investigational status in 2022 to approved, expanded indications in 2024. Instead, it assumes full approval in 2022 and then a strategic shift away from labeling, which is not supported by the ground truth. The core evolution—expansion and solidification of therapeutic positioning—is completely reversed in interpretation. (4) Despite the incorrect facts and reasoning, the answer is contextually relevant in that it attempts to describe a shift in Vraylar’s positioning over time and references appropriate domains (indications, commercial role). However, due to major factual and logical errors, especially regarding the timeline of approvals and inclusion of spurious financial data, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 532,
        "total_tokens": 1911
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has GE's accounting policy for long-term services agreements evolved from 2022 to 2024, particularly in terms of revenue recognition method and contract billing estimates?",
      "original_answer": "In 2022, GE recognized revenue for long-term services agreements on a straight-line basis, primarily in the Healthcare and Renewable Energy segments, with periodic invoicing as services were provided. By 2024, GE shifted to using the percentage of completion method for revenue recognition, predominantly within the CES segment, based on costs incurred relative to total expected costs. Additionally, in 2024, GE reported a long-term services agreements net liability balance of $6.6 billion, representing approximately 4.1% of total estimated life of contract billings of $162 billion, indicating a more detailed and forward-looking estimation process involving asset utilization and cost improvements, which was not explicitly mentioned in 2022.",
      "llm_answer": "In both the 2022 and 2024 filings GE says it accounts for long‑term services agreements using the **percentage‑of‑completion method**, recognizing revenue based on costs incurred to date relative to its estimate of total contract costs. By 2024 the disclosure was expanded to stress that the company **regularly revises utilization and cost estimates, makes cumulative catch‑up adjustments, and explicitly evaluates expected billings adjustments and customer‑credit risk**, whereas the 2022 note only described the basic method and that billing terms are tied to asset utilization. Thus the revenue‑recognition method has remained the same, but the 2024 policy adds more detailed guidance on how contract‑billing estimates are updated and monitored.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that GE used the percentage-of-completion method in both 2022 and 2024. According to the ground truth, in 2022 GE recognized revenue on a straight-line basis, not percentage-of-completion. The shift to percentage-of-completion occurred by 2024, primarily in the CES segment. This fundamental error undermines the core of the response. (2) The LLM answer omits all quantitative data from the ground truth: the $6.6 billion net liability balance, the $162 billion total estimated life of contract billings, and the 4.1% ratio. These are critical metrics that demonstrate the evolution in GE's estimation process, and their absence represents a major failure in quantitative accuracy. (3) The multi-hop reasoning is flawed because the model failed to correctly identify the change in revenue recognition method over time. Instead, it incorrectly asserts consistency in method while attributing changes only to expanded disclosures. The ground truth clearly states a methodological shift from straight-line to percentage-of-completion, which the LLM answer completely misses. (4) While the LLM answer is contextually relevant—focusing on revenue recognition and contract billing estimates—and uses appropriate accounting terminology, its factual inaccuracies and omissions of key data points severely limit its correctness. The qualitative reasoning is structured but based on incorrect premises, leading to a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 410,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has IBM's disclosure of the 1.250% Notes due 2027 evolved between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, IBM disclosed the 1.250% Notes due 2027 as part of a list of instruments defining the rights of holders, with Exhibit 4.3 to Form 8-K filed on January 30, 2019, referenced for the notes. In the 2023 10-K filing, the 1.250% Notes due 2027 are listed under registered securities with the trading symbol IBM 27B on the New York Stock Exchange. This evolution reflects a shift from referencing the instrument defining the rights to identifying the notes as a registered class of securities.",
      "llm_answer": "In the 2022 Form 10‑K (pages 28‑32) there is no mention of a “1.250 % Notes due 2027” – the excerpt only contains compensation‑plan tables and other item‑of‑contents listings. By contrast, the 2023 Form 10‑K (page 1) includes a Section 12(b) securities table that lists the “1.250 % Notes due 2027” (ticker IBM 27B) among IBM’s registered debt. Thus, between the two filings IBM added an explicit disclosure of the 1.250 % Notes due 2027 in its 2023 10‑K.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) It incorrectly claims that the 1.250% Notes due 2027 are not mentioned in the 2022 10-K, stating that pages 28–32 contain only compensation-plan tables. This is false: the 2022 10-K does disclose the notes by referencing Exhibit 4.3 to the Form 8-K filed on January 30, 2019, as part of the description of the rights of holders of securities. The LLM’s assertion of absence is incorrect and contradicts the ground truth. (2) While it correctly identifies that the 2023 10-K lists the notes under Section 12(b) with the ticker IBM 27B on the NYSE, this part aligns with the ground truth and is factually accurate. (3) The reasoning is flawed because it fails to recognize the multi-hop evolution: from a referenced instrument defining rights (2022) to a registered class of securities (2023). Instead, it frames the change as a simple addition of disclosure, missing the qualitative shift in how IBM categorized the notes. (4) The percentages and ticker symbol (1.250%, IBM 27B) are correct, so quantitative elements that are present are accurate, but the core factual claim about absence in 2022 invalidates the overall correctness. Due to this major error in entity and context accuracy, the answer cannot score highly. Contextual relevance is moderate because the response addresses the right topic and timeframe, but with critical errors in factual recall and synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 402,
        "total_tokens": 1632
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has the structure and performance criteria of AbbVie's performance-vested RSUs evolved between 2022 and 2024, particularly in terms of vesting increments and performance metrics?",
      "original_answer": "In 2022, performance-vested RSUs had the potential to vest in one-third increments over a three-year performance period, with performance measured based on AbbVie's return on invested capital (ROIC) relative to a defined peer group of pharmaceutical, biotech, and life science companies for awards granted in 2021 and 2020. By 2024, the vesting structure remained similar—allowing for one-third increments over a three-year period—but the description of performance metrics was streamlined, focusing primarily on ROIC performance against the same peer group, without mention of specific years tied to tranches as seen in 2022. This indicates a simplification or standardization of the performance criteria over time.",
      "llm_answer": "- **Vesting schedule:** In both the 2022 and the 2024 proxy statements the performance‑vested RSUs for senior executives and other key employees are granted for a three‑year performance period and can vest in up‑to‑one‑third increments each year. The “ratable‑over‑three‑years” structure has not changed. (2024 Form 10‑K, page 92‑93)\n\n- **Performance metric:** The metric used to determine whether any of those RSU installments vest is AbbVie’s **return on invested capital (ROIC) relative to a defined peer group of pharmaceutical, biotech and life‑science companies**. The same ROIC‑relative‑to‑peers language appears in the 2022 filing, indicating that the performance condition for the RSUs remained the same; the only addition in 2024 was the introduction of a market‑condition metric (total‑shareholder‑return) for the separate performance‑share awards, not for the RSUs themselves. (2024 Form 10‑K, page 92‑93; 2022 Form 10‑K, page 115)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all details are correct: the vesting in one-third increments over a three-year period is accurately described for both 2022 and 2024, and the performance metric—ROIC relative to a peer group—is correctly identified with proper context. There are no numerical or date inaccuracies. (2) The answer correctly notes that the vesting structure remained unchanged and that the performance metric continued to focus on ROIC versus peers. It also correctly clarifies that the introduction of a market-condition metric (total shareholder return) in 2024 applied to performance-share awards, not RSUs, which is consistent with the ground truth. (3) The multi-hop reasoning is sound: the model synthesizes information across the 2022 and 2024 filings, compares the RSU structures, and correctly isolates the RSU criteria from other award types. (4) The only minor shortcoming is that the LLM does not explicitly mention the 'streamlining' or 'simplification' of the performance metric description in 2024 (e.g., the removal of references to specific years tied to tranches), which is a nuance highlighted in the original answer. However, this does not constitute a factual error—rather, a slight omission in qualitative detail. Overall, the answer is factually correct, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 385,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How did GE's financial relationship with AerCap evolve from 2022 to 2024, based on the realized and unrealized gains or losses associated with its investment?",
      "original_answer": "In 2022, GE reported an unrealized loss of $865 million related to its investment in and note with AerCap, indicating a negative valuation impact during that year. By 2024, this position had shifted to a realized and unrealized gain of $38 million, suggesting that GE had either exited part of its position or the value of the remaining investment had improved. This represents a significant turnaround in the financial performance of the AerCap investment over the two-year period.",
      "llm_answer": "GE’s AerCap investment moved from a sizable loss in 2022 to modest gains in the following years. The 2022 10‑K shows an **$(865) million** realized/unrealized loss, the 2023 filing reports a **$129 million** gain, and the 2024 filing records a **$38 million** gain, indicating the relationship shifted from a negative position to a small positive one.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the 2023 figure, reporting a $129 million gain that is not present in the ground truth. The original answer only provides data for 2022 (unrealized loss of $865 million) and 2024 (realized and unrealized gain of $38 million), with no mention of 2023. By introducing an unsupported intermediate data point, the LLM distorts the financial narrative. Additionally, the 2022 loss is described as 'realized/unrealized' in the LLM answer, while the ground truth specifies it as 'unrealized,' which is a meaningful distinction in financial reporting. (2) The 2022 ($865 million loss) and 2024 ($38 million gain) figures are quantitatively accurate and correctly attributed, but the inclusion of the $129 million gain for 2023 is not corroborated by the original answer and appears to be fabricated or misattributed. This undermines the quantitative accuracy despite partial correctness. (3) The multi-hop reasoning is partially sound—the LLM correctly identifies a shift from loss to gain over time and infers an improving financial relationship, which aligns with the original conclusion. However, the reasoning is based on an incorrect intermediate step, weakening the synthesis. (4) The contextual relevance is high because the answer addresses the evolution of GE's financial relationship with AerCap through gains/losses and draws a reasonable directional conclusion. The qualitative accuracy is moderate because entity names (GE, AerCap), years, and overall trend interpretation are correct, but key financial distinctions and an extra year’s data reduce precision. The correctness score is 6 due to partially accurate data and a significant insertion of unverified information that affects the overall reliability of the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 488,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How has IBM's treatment of the 0.300% Notes due 2026 evolved between the 2022 and 2023 SEC filings, particularly in terms of its disclosure status and visibility in financial instruments?",
      "original_answer": "In 2022, the 0.300% Notes due 2026 were disclosed as part of IBM's exhibits under Exhibit 4 to Form 8-K filed November 1, 2016, indicating it was referenced in the context of legal instruments defining holder rights. By 2023, the 0.300% Notes due 2026 were no longer just referenced in exhibits but were explicitly listed as a titled class of notes registered on the New York Stock Exchange under the trading symbol IBM 26B, showing increased visibility and formal recognition in the company's capital structure.",
      "llm_answer": "In IBM’s 2022 Form 10‑K the 0.300 % Notes due 2026 were disclosed in the “Securities registered pursuant to Section 12(b)” table, showing that the issue was a publicly‑registered instrument. The 2023 Form 10‑K repeats the same entry (‑ “0.300 % Notes due 2026 – IBM 26B” listed on the NYSE), indicating that IBM has kept the notes in its registration schedule and its visibility in the financial‑instrument disclosures has remained unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains partially correct quantitative details—such as the correct name of the notes (0.300% Notes due 2026), the trading symbol IBM 26B, and the listing on the NYSE—but fundamentally misrepresents the evolution of disclosure status between 2022 and 2023. According to the ground truth, in 2022 the notes were only referenced as an exhibit (Exhibit 4 to Form 8-K filed November 1, 2016), meaning they were disclosed as legal instruments but not necessarily as registered securities in the main registration table. However, the LLM claims the notes were already listed in the 'Securities registered pursuant to Section 12(b)' table in the 2022 10-K, which contradicts the ground truth. By 2023, the notes were explicitly listed as a titled class on the NYSE, indicating increased visibility. The LLM interprets this as 'unchanged' visibility, which is incorrect—the ground truth emphasizes an evolution from indirect exhibit-based disclosure to formal recognition in the capital structure. This mischaracterization reflects a failure in multi-hop reasoning: the model did not correctly synthesize the change in disclosure type and visibility across years. While the entities (IBM, 0.300% Notes due 2026, NYSE, IBM 26B) and percentages are accurate, the core qualitative claim about the evolution of disclosure is wrong, leading to a low correctness and qualitative accuracy score. Contextual relevance is moderate because the answer addresses the right topic and instruments but draws an incorrect conclusion about their treatment over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 425,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has GE's approach to the RISE Program evolved between 2022 and 2024, particularly in terms of its strategic emphasis and investment focus?",
      "original_answer": "In 2022, GE announced the RISE Program as a collaborative technology development initiative with Safran, targeting a reduction of more than 20% in fuel consumption and CO2 emissions compared to current engines. This marked the initial phase of the program as a forward-looking announcement aimed at shaping the future of sustainable aviation. By 2024, GE's engagement with the RISE Program had evolved into a more concrete investment strategy, with the company making 'significant investments' in the RISE program suite of technologies. This shift indicates a transition from conceptual development to active, funded R&D aimed at enabling a sustainable future of flight. The change reflects a deepening strategic commitment to sustainability and technological leadership in aviation.",
      "llm_answer": "In the 2022 filing GE’s RISE program was presented as a newly‑announced joint‑venture effort with Safran aimed at achieving “more than 20 % lower fuel consumption and CO₂ emissions” – essentially a first‑stage, fuel‑efficiency research initiative. By the 2024 filing the program had become a core pillar of GE Aerospace’s sustainability strategy, with “significant investments” directed to a broader “suite of pioneering technologies” such as Open‑Fan, compact‑core and hybrid‑electric architectures, and the company highlighted having completed 250+ full‑scale Open‑Fan tests, reflecting a shift from early‑stage concept to a heavily funded, technology‑deployment focus.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2022 RISE Program announcement as a joint effort with Safran targeting 'more than 20% lower fuel consumption and CO2 emissions' is accurately reported. The 2024 evolution involving 'significant investments' in a broader technology suite is also correctly stated. (2) Quantitative elements are precise: the 'more than 20%' reduction goal is correctly cited, and the mention of '250+ full-scale Open-Fan tests'—while not in the original answer—is a plausible and contextually consistent detail likely drawn from external but relevant knowledge; it does not contradict the ground truth and enhances the narrative of increased R&D activity. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes the shift from a conceptual, collaborative announcement in 2022 to a heavily funded, deployment-focused initiative in 2024, reflecting a strategic deepening. (4) The answer captures the evolution in strategic emphasis (from research to core sustainability pillar) and investment focus (from general goals to specific technologies like Open-Fan, compact-core, hybrid-electric), which matches the original answer’s intent. The only minor limitation is that the original answer emphasizes the 'transition from conceptual development to active, funded R&D' more explicitly, while the LLM focuses on technology deployment—semantically similar but slightly different framing. No factual errors; excellent contextual and qualitative alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 424,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has the role and emphasis on asset securitizations within American Express's funding strategy evolved from 2022 to 2023, based on the specific disclosures in the respective 10-K filings?",
      "original_answer": "In 2022, American Express defined asset securitizations in a glossary entry, describing the mechanics of transferring loans to trusts that issue asset-backed securities, and noted that securitized loans and receivables were reported as assets while the securities were reported as liabilities. This definition was part of a broader explanation of financial terminology rather than a strategic focus. By 2023, asset securitizations were explicitly positioned as a core component of the company's funding strategy, listed alongside deposits and unsecured debt as key funding sources. The 2023 filing emphasized the importance of diversity in funding sources, with securitizations playing a role in mitigating disruptions in any single funding channel. This represents a shift from a definitional disclosure in 2022 to a strategic emphasis in 2023.",
      "llm_answer": "In the 2022 Form 10‑K the filing only defines “asset securitizations” in a glossary entry (page 88) and does not present them as a material component of the company’s funding mix. By contrast, the 2023 filing places securitizations in a dedicated “Long‑Term Debt and Asset Securitization Programs” section (page 70), noting that they are used “periodically … as a cost‑effective funding source,” reporting $47.9 billion of total long‑term debt that includes asset‑backed securities and disclosing a $3.5 billion issuance of Credit Account Master Trust certificates in 2023. This shift shows that asset securitizations moved from a peripheral, definitional mention in 2022 to a clearly quantified and emphasized source of funding in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, asset securitizations were only defined in a glossary (page 88), not emphasized strategically, which matches the original answer. In 2023, it accurately notes the elevated role, citing a dedicated section (page 70) and describing securitizations as a 'cost-effective funding source'—consistent with the strategic emphasis in the ground truth. (2) Quantitatively, the LLM provides specific figures: $47.9 billion of total long-term debt including asset-backed securities and a $3.5 billion issuance in 2023. These numbers are factually correct per the 2023 10-K and are properly contextualized, earning full marks for quantitative accuracy. (3) The multi-hop reasoning is sound: it synthesizes information across two years, compares the treatment of securitizations, and infers a strategic shift based on placement, language, and disclosures—this demonstrates strong qualitative reasoning. (4) The only minor shortcoming is that the original answer emphasizes the strategic value of diversification to mitigate funding disruptions, a nuance not explicitly mentioned in the LLM response. While the LLM captures the shift in emphasis, it omits this specific strategic rationale, justifying a 9 instead of 10 on qualitative accuracy. Otherwise, the answer is factually complete, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 402,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2023, particularly in terms of investment returns and operational integration?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was characterized by a minority investment, with AspenTech contributing $656 in sales and a $12 earnings gain, while holding total assets of $14,484. By 2023, Emerson significantly deepened its involvement by acquiring Heritage AspenTech, gaining a 55% ownership stake in the newly formed AspenTech. This acquisition positively impacted gross margins by 0.6 percentage points in 2023 and marked a strategic shift from a passive investment to an active controlling interest, indicating a transformation in the nature of the relationship.",
      "llm_answer": "In 2022 Emerson closed the Heritage AspenTech transaction, creating a stand‑alone AspenTech segment that posted $656 million of sales, a small $12 million profit and incurred $148 million of acquisition‑related amortization as the former Emerson industrial‑software businesses were folded into the new segment. By 2023 Emerson’s 55‑57 % ownership was generating a positive return – a $24 million mark‑to‑market gain on AspenTech‑related foreign‑currency hedges (versus a $50 million loss in 2022) – and the software business was fully integrated, contributing about 3 % of total sales growth and being reported as a separate, earnings‑producing segment. This shows the relationship moving from a one‑time acquisition cost in 2022 to ongoing earnings contribution and modest investment gains in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Emerson had a minority investment in AspenTech with $656 in sales, $12 earnings gain, and $14,484 in total assets. However, the LLM incorrectly states that Emerson 'closed the Heritage AspenTech transaction' in 2022, which contradicts the ground truth that the acquisition occurred in 2023. The LLM also misrepresents the $148 million as 'acquisition-related amortization,' whereas the ground truth reports total assets of $14,484 (likely $14,484 million), a critical error in both magnitude and metric. (2) The LLM invents a $24 million mark-to-market gain on foreign currency hedges in 2023 versus a $50 million loss in 2022—this data is not present in the original answer and appears fabricated. The 55-57% ownership range is close to the correct 55% stake but adds unwarranted precision. The claim that the software business contributed 'about 3% of total sales growth' is unsupported in the ground truth. (3) The multi-hop reasoning is flawed: the LLM reverses the timeline, portraying the acquisition as occurring in 2022 when it was actually in 2023. It fails to capture the strategic shift from passive investment to controlling interest as described in the original answer, instead focusing on unrelated hedge gains and amortization. (4) Despite these issues, the answer is contextually relevant, addressing investment returns and operational integration. Some correct elements—such as the $656 million in sales and the 55% ownership—are mentioned, though embedded in an incorrect narrative. The qualitative reasoning is partially sound but based on incorrect data. Quantitative accuracy is low due to major number mismatches and invented figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 480,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of noncontrolling interest accounting and acquisition-related impacts on equity and expenses?",
      "original_answer": "In 2022, Emerson completed the creation of New AspenTech by contributing its industrial software business and $6.0 billion in cash, resulting in a 55% ownership stake. A noncontrolling interest of $5.9 billion was recorded, with a decrease to additional paid-in capital of $550 million. By 2023, the AspenTech acquisition positively impacted gross margins by 0.6 percentage points and contributed to increased SG&A expenses, which rose by $572 million compared to 2022, partly due to the AspenTech transaction and higher stock compensation expenses. This shows that while the initial accounting impact was significant in 2022, by 2023, the focus had shifted to operational integration and financial performance effects.",
      "llm_answer": "In the 2022 filing Emerson reported that the Heritage AspenTech transaction created a **$5.9 billion non‑controlling‑interest (NCI)** representing the 45 % of AspenTech owned by former Heritage shareholders, and the NCI accounting reduced additional‑paid‑in‑capital by about **$550 million**. By the 2023 filing Emerson’s ownership had risen to **55 % of the “new” AspenTech**, so the NCI balance was eliminated and the acquisition was reflected only through the equity‑method investment and the related **goodwill/intangible‑asset balances**; the deal also drove higher post‑acquisition costs – SG&A rose $572 million (to $4.2 billion) and intangibles amortization increased $146 million (to $678 million) – thereby affecting both equity (through goodwill and APIC adjustments) and expense lines.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies that significantly affect correctness. First, it incorrectly states that by 2023 Emerson's ownership had risen to 55%—in fact, Emerson started with a 55% stake in 2022 after the creation of New AspenTech, not increased to it in 2023. This misrepresents the timeline and ownership evolution. Second, the claim that the non-controlling interest (NCI) was 'eliminated' in 2023 is incorrect; the original answer does not state this, and in reality, NCI would persist as long as there is non-wholly-owned consolidation. The LLM incorrectly implies a change in accounting method to equity method, which contradicts the ground truth—Emerson consolidated New AspenTech with a 55% controlling interest from inception. (2) Quantitative accuracy is partially correct: the $5.9 billion NCI and $550 million reduction in additional paid-in capital in 2022 are accurate. The $572 million increase in SG&A expenses is correctly cited. However, the LLM introduces new figures not in the original answer—SG&A rising to $4.2 billion and intangibles amortization increasing by $146 million to $678 million—which are unsupported by the ground truth and thus factually unverified. These numbers may be plausible but are not confirmed and represent overreach. (3) Multi-hop reasoning is partially sound: the model attempts to connect 2022 accounting impacts (NCI, APIC) with 2023 operational effects (expenses), but the logical chain is flawed due to incorrect ownership progression and elimination of NCI. The synthesis across years is present but based on faulty premises. (4) Despite these issues, the answer is contextually relevant, addressing noncontrolling interest, equity impacts, and expense effects as required. The qualitative reasoning shows understanding of accounting concepts (NCI, APIC, SG&A, goodwill), even if misapplied. The score is reduced primarily due to key factual and directional errors in ownership and NCI treatment, which undermine the overall correctness despite some accurate data points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 555,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has IBM's treatment and disclosure of the 6.22% Debentures due 2027 evolved between the 2022 and 2023 SEC filings?",
      "original_answer": "In 2022, IBM disclosed the 6.22% Debentures due 2027 by referencing the instrument defining the rights of its holders, which was filed as Exhibit 3 to Form 8-K on August 1, 1997. In contrast, the 2023 filing introduces a more structured and visible disclosure by listing the 6.22% Debentures due 2027 with its respective trading symbol (IBM 27) and explicitly identifying it among other registered securities on the New York Stock Exchange. This evolution reflects a shift from a purely historical reference to a more transparent and current market-oriented presentation.",
      "llm_answer": "In the 2022 Form 10‑K the 6.22 % debentures due 2027 appear only in the securities‑registered list (they are listed among IBM’s other notes and debentures but no further detail is given). In the 2023 Form 10‑K IBM still lists the 6.22 % debentures due 2027 in the registration table, but it now also references the governing instrument – “the instrument defining the rights of the holders of the 6.22 % Debentures due 2027 is Exhibit 3 to Form 8‑K, filed August 1, 1997, incorporated by reference.” Thus, between 2022 and 2023 IBM added an explicit exhibit citation, providing a more detailed disclosure of the debenture’s terms.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains some correct elements but fundamentally misrepresents the evolution of disclosure between 2022 and 2023, reversing the actual progression. (1) Quantitatively, the percentage (6.22%), year (2027), and date of the Form 8-K (August 1, 1997) are accurate, earning high marks for numeric precision. (2) However, the qualitative reasoning is flawed: the original answer states that in 2022, IBM referenced the governing instrument (Exhibit 3 to Form 8-K), but in 2023 moved to a more structured, market-oriented disclosure including the trading symbol 'IBM 27' and NYSE registration. The LLM incorrectly claims that the exhibit citation was *added* in 2023, when in fact it was already present in 2022 and the 2023 filing enhanced transparency with current market data. (3) This reversal of the multi-hop timeline and disclosure direction indicates a failure in reasoning and synthesis across filings. (4) While the answer addresses the question's context and attempts to compare disclosures, the core factual claim is inverted, leading to a low correctness score despite accurate numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 312,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has UnitedHealth Group's exposure to financial risk through risk-based arrangements with healthcare providers evolved from 2023 to 2024, and what implications does this have on its cost estimation and service delivery responsibilities?",
      "original_answer": "In 2023, UnitedHealth Group assumed economic risk under risk-based arrangements where it was responsible for funding healthcare costs, and it recognized premium revenues based on estimated premiums earned, net of projected rebates. The company also highlighted its involvement in value-based arrangements where it received per-patient-per-month premiums and recognized revenue as services were made available. By 2024, the company's exposure expanded as it noted increased responsibility for unpaid healthcare claims if risk-based providers faced financial difficulties or failed to meet their obligations. Additionally, the 2024 disclosures emphasized greater operational risk tied to providers' ability to manage costs, maintain solvency, and provide necessary data for cost estimation, indicating a broader and more complex financial exposure compared to 2023.",
      "llm_answer": "In the 2023 filing UnitedHealth noted that its health‑benefits businesses “have risk‑based arrangements with some physicians, hospitals and other health‑care providers” that **limit its exposure to rising medical costs but still expose the company to the financial health of those providers –‑ unpaid claims, disputes and the need for accurate cost‑estimation** (2023 p. 14). The 2024 filing shows that reliance on such contracts has deepened: **risk‑based benefit products now generate roughly 80 % of UnitedHealth’s total premium revenue, and the company stresses that any failure to correctly estimate, price or manage the medical costs embedded in these arrangements could materially affect its results** (2024 p. 12). Consequently, UnitedHealth’s financial risk from provider‑based contracts has increased, making precise cost‑estimation and the ability to deliver services under those contracts more critical to avoid unexpected liabilities and service disruptions.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of UnitedHealth Group's risk exposure from 2023 to 2024, noting increased reliance on risk-based arrangements and heightened financial and operational risks. The core facts—such as exposure to provider financial health, cost estimation challenges, and expanded responsibilities—are consistent with the original answer. (2) Quantitatively, the LLM introduces a specific figure—'80% of total premium revenue' from risk-based products in 2024—which is not present in the ground truth. However, since this detail does not contradict the original answer and plausibly supports the claim of expanded exposure, it does not constitute a factual error but rather adds specificity. No other numbers or dates are incorrect. (3) The multi-hop reasoning is sound: the model synthesizes information across 2023 and 2024 disclosures, compares the level of risk exposure, and draws a logical conclusion about increased financial and operational responsibility. It correctly infers that greater reliance on risk-based models increases the importance of cost estimation and service delivery. (4) The answer is contextually fully relevant, directly addressing both parts of the question: evolution of risk exposure and implications for cost estimation and service delivery. The only minor limitation is the absence of explicit mention of 'per-patient-per-month premiums' or 'projected rebates' from 2023, but the key implications are still captured. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the ground truth with high completeness and precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1481,
        "completion_tokens": 458,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of investment magnitude and strategic involvement?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was primarily financial, as shown by its investment reflected in the Automation Solutions segment, where Emerson reported $362 million invested in AspenTech in 2022. By 2023, the relationship evolved into a strategic partnership following the introduction of a major transaction where Emerson contributed its Industrial Software Business along with approximately $6.0 billion in cash to Heritage AspenTech stockholders, creating 'New AspenTech.' Emerson gained 55% ownership of AspenTech's outstanding shares, marking a significant shift from a minority investment to a controlling stake.",
      "llm_answer": "In fiscal 2022 Emerson closed the Heritage AspenTech transaction, contributing its Open Systems International and Geological‑Simulation software businesses and paying roughly **$6 billion in cash** to the former AspenTech owners; the deal gave Emerson a **controlling equity stake of about 55‑57 %** in the newly‑formed “New AspenTech” company (see 2023 10‑K p. 26). By fiscal 2023 Emerson’s relationship had moved from the one‑time cash investment to an ongoing strategic partnership – AspenTech was now reported as a separate segment with sizable assets and sales, Emerson recorded amortization of the acquisition‑related intangibles and continued active management (e.g., foreign‑currency hedging of the Micromine purchase price, see 2023 10‑K p. 27‑28). Thus, the partnership grew from a large cash‑funded acquisition to a fully integrated, majority‑owned software platform that Emerson is actively managing within its portfolio.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but has a critical error in timing. The ground truth states that in 2022, Emerson made a $362 million investment in AspenTech, reflecting a financial relationship. However, the LLM claims that the $6 billion transaction occurred in fiscal 2022, which contradicts the ground truth stating the major transaction (contributing software business + $6B cash) occurred in 2023. This misplacement of the transaction year is a significant factual error. The 55% ownership stake is correctly reported (LLM says 55–57%, which is close enough given rounding or reporting variation). (2) Quantitative accuracy is partially compromised: while $6 billion and 55% are correct figures, the LLM omits the $362 million 2022 investment entirely, which is a key part of the evolution. Instead, it incorrectly implies the $6B deal closed in 2022. This affects the narrative of evolution between years. (3) The multi-hop reasoning is otherwise sound: the LLM correctly identifies the shift from financial to strategic involvement, recognizes the creation of 'New AspenTech', Emerson’s controlling stake, and ongoing management activities like hedging and reporting as a separate segment. These demonstrate good synthesis across concepts. (4) Contextual relevance is high—the answer directly addresses the evolution in investment magnitude and strategic involvement, uses appropriate financial and strategic terminology, and cites relevant details from the 10-K. However, due to the incorrect sequencing of events and omission of the initial 2022 investment amount, the overall correctness is reduced to 7. The answer captures the strategic outcome well but misrepresents the timeline and initial financial magnitude.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 478,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How has Adobe Target's role within Adobe's customer journey solutions evolved from fiscal 2022 to fiscal 2023, and what does this evolution indicate about Adobe's strategic direction in AI-driven personalization?",
      "original_answer": "In fiscal 2022, Adobe Target was described as part of a broader set of customer journey solutions, specifically noted alongside Marketo Engage, Adobe Campaign, and Journey Optimizer. It was characterized as a tool for testing, targeting, and personalizing content across channels. By fiscal 2023, Adobe Target was elevated in prominence and described specifically as an 'AI- and machine learning-driven personalization engine' with capabilities for omnichannel personalization and large-scale A/B and multivariate testing through AI-powered automation. This evolution indicates Adobe is placing greater strategic emphasis on AI-driven personalization as a core capability within its customer journey offerings, aligning with its broader push toward AI-powered solutions.",
      "llm_answer": "In the FY 2022 filing Adobe Target was listed only as one of the “Customer‑journeys” tools that let brands **manage, test, target, personalize and orchestrate campaigns** alongside Marketo Engage, Adobe Campaign and Journey Optimizer, but the description did not call out any AI or machine‑learning capabilities【page_43】.  \n\nIn the FY 2023 filing Adobe Target is positioned as an **AI‑ and machine‑learning‑driven personalization engine** that automates A/B and multivariate testing, scales optimization across channels, and uses Adobe Sensei to quickly discover and deliver the best consumer experience【page_15】.  \n\nThis shift—from a generic testing‑and‑targeting component to a highlighted AI‑powered engine—shows Adobe’s strategic move to embed artificial‑intelligence throughout its Experience Cloud, making AI the core driver of real‑time, hyper‑personalized customer experiences.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate, complete, and semantically equivalent to the ground truth. (1) It correctly identifies Adobe Target's role in FY 2022 as a component of customer journey solutions alongside Marketo Engage, Adobe Campaign, and Journey Optimizer, with capabilities in testing, targeting, and personalization, and notes the absence of AI/ML emphasis. In FY 2023, it accurately describes Adobe Target's evolution into an 'AI- and machine-learning-driven personalization engine' with automation of A/B and multivariate testing and integration with Adobe Sensei. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable but not deficient. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two fiscal years and multiple products to infer Adobe's strategic shift toward AI-driven personalization. The conclusion that Adobe is embedding AI as a core driver in Experience Cloud aligns perfectly with the ground truth's interpretation. (4) All entities—Adobe Target, Marketo Engage, Adobe Campaign, Journey Optimizer, Adobe Sensei, and the fiscal years—are correctly identified and contextualized. The answer addresses both parts of the question: the evolution of Adobe Target and what it indicates about Adobe's AI strategy. Wording differs slightly but meaning is preserved and enhanced with relevant detail (e.g., mention of Adobe Sensei). Thus, all accuracy and relevance criteria are fully met.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 418,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did Emerson's relationship with AspenTech evolve from 2022 to 2023, particularly in terms of its financial stake and post-acquisition integration activities?",
      "original_answer": "In 2022, Emerson reported a balance of $8,326 million related to AspenTech as part of its acquisitions, indicating a significant financial stake following the acquisition of Heritage AspenTech. By 2023, the relationship had evolved into a more integrated structure, with AspenTech operating as a separate publicly traded company under Emerson's acquisition framework. This included the continuation of AspenTech's stock-based compensation plans, such as stock options and restricted stock units, which were now aligned with AspenTech's own equity structure. Additionally, Emerson was actively managing performance stock units tied to predefined goals like annual contract value and free cash flows, showing a shift from a purely financial stake to a more operationally integrated and incentive-driven relationship.",
      "llm_answer": "In fiscal 2022 Emerson closed its purchase of Heritage AspenTech (the “Heritage AspenTech” acquisition was completed in the third quarter of 2022).  The deal added roughly $8.3 billion of goodwill to the AspenTech segment (see the goodwill table on page 61) and brought into Emerson’s balance sheet about $240 million of AspenTech‑related revolving‑loan debt (page 63).  At the same time, every un‑exercised Heritage AspenTech option and un‑vested restricted‑stock unit that existed immediately before closing was automatically converted into an equivalent AspenTech award under the same terms (page 70).\n\nDuring 2023 Emerson’s post‑acquisition integration was reflected in the financial statements by a sharp rise in AspenTech‑related stock‑based‑compensation expense – from $32 million in 2022 to $82 million in 2023 (page 68) – and by continued accounting for AspenTech as a separate publicly‑traded segment while Emerson retained the equity interest acquired in 2022.  Thus, Emerson moved from completing the purchase and taking a large goodwill and debt position in 2022 to actively integrating AspenTech’s equity awards and incurring integration‑related compensation costs in 2023.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and addresses the evolution of Emerson's relationship with AspenTech from 2022 to 2023, focusing on financial stake and integration activities. However, there are some discrepancies in quantitative accuracy. The original answer states that Emerson reported a balance of $8,326 million related to AspenTech in 2022, while the LLM reports 'roughly $8.3 billion of goodwill'—this is close but conflates total acquisition-related balance with goodwill specifically. The original does not mention $240 million in revolving-loan debt or goodwill explicitly, so those details, while possibly accurate from the source document, are not in the ground truth and introduce unverified specifics. The LLM correctly notes the conversion of stock options and RSUs and the increase in stock-based compensation from $32M to $82M, which aligns with the post-acquisition integration and incentive alignment described in the original. The qualitative reasoning is sound: it captures the shift from acquisition (2022) to integration (2023), including ongoing equity management and operational alignment. The entity names, years, and financial concepts are accurate. Contextual relevance is high, as all parts of the question are addressed with appropriate detail. The main issue is the introduction of granular financial figures not present in the ground truth, which affects quantitative precision despite plausible sourcing. Thus, the answer is factually strong but not perfectly aligned in numbers, warranting a correctness score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1504,
        "completion_tokens": 424,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How has Adobe Experience Platform's role within Adobe's customer journey solutions evolved from 2022 to 2023, particularly in terms of its integration with AI-powered tools and cross-channel campaign orchestration?",
      "original_answer": "In 2022, Adobe Experience Platform was described as the foundational infrastructure for Adobe Experience Cloud, enabling data standardization and integration with Adobe Sensei to provide AI-powered services such as automated insights, sentiment analysis, and enhanced anomaly detection. It was central to Adobe's differentiation, supporting applications like Adobe Analytics and Adobe Audience Manager. By 2023, Adobe Experience Platform's role had evolved to become the underlying engine for cross-channel campaign orchestration, particularly through its integration with Adobe Journey Optimizer. This app allowed brands to deliver personalized, connected customer journeys across any channel, using real-time data profiles and cloud-native scalability. Additionally, Adobe Mix Modeler, introduced in 2023 and powered by Adobe Sensei, leveraged cross-channel datasets in Adobe Experience Platform to provide machine learning-driven insights for optimizing marketing investments. This indicates a shift from a general AI-enhanced infrastructure role to a more specialized and actionable function in campaign planning and customer journey orchestration.",
      "llm_answer": "In the 2022 filing Adobe Experience Platform was presented mainly as the “underlying infrastructure” that standardizes data, powers Adobe‑Sensei AI services and supports the broader Experience Cloud, but its role in the customer‑journey suite was described only in general terms. By the 2023 filing the platform had become the explicit foundation for the AI‑driven journey tools – Customer Journey Analytics, Product Analytics and especially Adobe Journey Optimizer – enabling real‑time, AI‑generated insights and unified, cross‑channel campaign orchestration through a single, API‑extensible app. Thus, between 2022 and 2023 the platform evolved from a data‑and‑AI backbone to an integrated, AI‑powered hub that directly drives omnichannel journey execution.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of Adobe Experience Platform from 2022 to 2023. (1) It correctly identifies that in 2022, the platform served as foundational infrastructure for data standardization and AI services via Adobe Sensei, supporting Experience Cloud broadly. In 2023, it evolved into a more active role powering AI-driven journey tools, especially Adobe Journey Optimizer, enabling real-time insights and cross-channel orchestration—this aligns with the ground truth. (2) There are no numeric values, dates, or financial figures in the question or answers, so quantitative accuracy is not applicable in a traditional sense, but all time references (2022, 2023) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across years and product integrations, correctly identifying the shift from a 'data-and-AI backbone' to an 'integrated hub for journey execution.' The mention of Customer Journey Analytics and Product Analytics is consistent with the platform's expanded role, though the ground truth emphasizes Adobe Journey Optimizer and Adobe Mix Modeler as key 2023 developments. The LLM omits Adobe Mix Modeler and its role in marketing investment optimization, which is a minor but notable omission in completeness. (4) Despite this, the answer conveys the essential semantic meaning: a strategic shift toward actionable, AI-powered orchestration. Wording differs but meaning is equivalent. Contextual relevance is perfect—directly addresses the evolution in integration with AI tools and cross-channel orchestration. A score of 9 is justified due to high accuracy with a minor omission in product-specific detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1494,
        "completion_tokens": 459,
        "total_tokens": 1954
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did UnitedHealth Group's approach to care delivery models evolve from 2023 to 2024 in response to Medicare Advantage funding pressures?",
      "original_answer": "In 2023, UnitedHealth Group emphasized accelerating the transition to value-based care delivery models, investing in clinical engagement, integrated care coordination technology, and new delivery channels like in-home and virtual care. The company viewed these innovations as key to future growth despite initial costs. However, by 2024, the company faced significant funding pressures in the Medicare Advantage program, including reduced benchmarks and risk adjustment changes, which led to operational adjustments. These included selective changes to provider networks, benefit structures, and county-level decisions about plan offerings, indicating a shift from expansion-focused investment to cost containment and strategic retrenchment in response to external financial constraints.",
      "llm_answer": "In its 2023 filing UnitedHealth said it was “accelerating … the innovation and integration of our care‑delivery models … including in‑clinic, in‑home, behavioral and virtual care” and was working to shift “from fee‑for‑service … to fully accountable, value‑based care” as outpatient senior utilization rose (​page 27​). By the 2024 filing the company described a more tactical response to the same Medicare‑Advantage funding pressure – it is redesigning benefits, raising or adjusting member premiums, trimming or reshaping provider networks and even opting out of offering plans in certain counties, while intensifying medical‑and‑operating‑cost management on a county‑by‑county basis (​page 20​).​",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies UnitedHealth Group's 2023 focus on accelerating innovation in care delivery models, including in-home, virtual, and value-based care, which matches the original answer's emphasis on clinical engagement, technology, and new delivery channels. In 2024, it accurately reflects the shift to cost containment due to Medicare Advantage funding pressures, citing benefit redesign, provider network adjustments, and county-level plan exits. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10 by default. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and two filings, correctly identifying the evolution from expansion and investment in 2023 to tactical retrenchment in 2024. The use of direct quotes (e.g., 'accelerating innovation', 'redesigning benefits') and page references adds credibility. (4) Minor deduction in qualitative accuracy (9 instead of 10) because the LLM answer does not explicitly mention 'risk adjustment changes' or 'reduced benchmarks'—specific drivers noted in the original—but does capture their effect through 'funding pressure' and operational responses. Overall, the answer is semantically equivalent, contextually precise, and factually correct, warranting a high correctness score of 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 403,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 157,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 1.950% Notes due 2029?",
      "original_answer": "In 2022, the 1.950% Notes due 2029 were listed among TMO's outstanding debt instruments with the trading symbol TMO 29. In 2023, the 1.950% Notes due 2029 remained present with the same trading symbol TMO 29, indicating continuity in this debt instrument. However, TMO introduced new debt instruments in 2023, such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, suggesting a broader shift in financing strategy. The continued presence of the 1.950% Notes due 2029 indicates no change in this specific liability, even as TMO expanded its debt portfolio.",
      "llm_answer": "The 2022 filing listed a single 1.950 % series maturing in 2029 (TMO 29) among a set of lower‑coupon notes. In the 2023 filing the same 1.950 % Notes due 2029 remain on the register, but the overall debt portfolio was broadened with two new higher‑coupon issues—3.200 % Notes due 2026 and 3.650 % Notes due 2034—while no existing series, including the 1.950 % Notes, was removed.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: the 1.950% Notes due 2029 (trading symbol TMO 29) were present in both 2022 and 2023, indicating continuity. Two new debt instruments—3.200% Notes due 2026 and 3.650% Notes due 2034—were correctly identified as introduced in 2023. (2) Quantitative accuracy is perfect: percentages (1.950%, 3.200%, 3.650%), maturity years (2026, 2029, 2034), and the absence of removal of any series are all correctly reported. Minor formatting differences (e.g., spacing around %) do not affect meaning. (3) Multi-hop reasoning is sound: the model correctly synthesized information across two years, identified the persistence of a specific note, and recognized the expansion of the debt portfolio with higher-coupon instruments. (4) The answer fully addresses the question about the evolution of TMO's debt composition, particularly regarding the 1.950% Notes due 2029, and provides context about strategic broadening. No omissions or inaccuracies. All scores are maximized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 306,
        "total_tokens": 1538
      },
      "error": null
    },
    {
      "question_id": 159,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 0.500% Notes due 2028 and the introduction of new note categories?",
      "original_answer": "In 2022, TMO listed the 0.500% Notes due 2028 alongside other debt instruments, including the 1.375% Notes due 2028. By 2023, TMO continued to list the 0.500% Notes due 2028, but introduced new debt categories such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, while maintaining similar categories like the 1.375% Notes due 2028. This indicates a strategic shift toward diversifying TMO's debt portfolio with new interest rate structures and maturity timelines.",
      "llm_answer": "In the 2022 Form 10‑K the debt register already listed the 0.500 % Notes due 2028 (TMO 28A) among a series of low‑coupon senior notes【page_1】. The 2023 Form 10‑K still shows that same 0.500 % Notes due 2028, but it also adds two higher‑coupon series that were not present in 2022 – a 3.200 % Note due 2026 (TMO 26B) and a 3.650 % Note due 2034 (TMO 34)【page_1】. Thus, while the 0.500 % Notes due 2028 remained unchanged, Thermo Fisher expanded its debt mix in 2023 by introducing these new note categories.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All numeric values—interest rates (0.500%, 3.200%, 3.650%) and maturity years (2028, 2026, 2034)—are correct, matching the original answer exactly. The presence of the 0.500% Notes due 2028 in both years is correctly noted. (2) The introduction of two new note categories in 2023—the 3.200% Notes due 2026 and the 3.650% Notes due 2034—is accurately reported, with no calculation errors. (3) The multi-hop reasoning is sound: the model correctly compares TMO's debt instruments across 2022 and 2023 filings, identifying continuity and change. (4) The only minor omission is that the LLM does not explicitly mention the 1.375% Notes due 2028, which the original answer notes as being maintained across both years. While this detail is not critical to the core question about the 0.500% Notes due 2028 and new categories, its inclusion would have made the answer fully complete. However, the main thrust—evolution of debt composition with new note introductions—is correctly captured. Wording differences (e.g., 'expanded its debt mix' vs 'strategic shift toward diversifying') are semantically equivalent. Overall, the answer is factually correct, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 353,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 160,
      "question": "How has the range of excess fair value over carrying value for DHR's reporting units changed between the 2023 and 2024 annual goodwill impairment analyses?",
      "original_answer": "In 2023, the excess of the estimated fair value over carrying value for DHR's reporting units ranged from approximately 140% to 495%. In 2024, this range decreased to between approximately 70% and 450%. This indicates a reduction in the lowest excess fair value percentage, suggesting a decline in the overall cushion before potential impairment.",
      "llm_answer": "In the 2023 annual goodwill‑impairment test, the excess of fair value over carrying value for the five reporting units ranged **from roughly 140 % to 495 %** of carrying value. In the 2024 test, that range narrowed to **about 70 % to 450 %**. Thus, both the lower and upper ends of the excess‑value range fell – the floor dropped by roughly 70 percentage points and the ceiling by about 45 percentage points.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports the ranges of excess fair value over carrying value for DHR's reporting units in both 2023 (140% to 495%) and 2024 (70% to 450%), matching the ground truth exactly. These numbers are presented with acceptable phrasing variations (e.g., 'roughly', 'about').\n\n2) Quantitative accuracy is perfect: the percentages are correct, and the implied changes (a drop from 140% to 70% at the lower end, and 495% to 450% at the upper end) are accurately reflected. The LLM correctly notes that both the floor and ceiling decreased, though it adds a calculation (‘dropped by roughly 70 percentage points’ and ‘45 percentage points’) not in the original answer. These calculations are mathematically correct (140–70 = 70; 495–450 = 45), so they do not reduce accuracy.\n\n3) The reasoning is sound and demonstrates proper multi-hop synthesis across the two years’ impairment analyses. The LLM correctly infers that the cushion before impairment has narrowed, although it doesn’t explicitly state the implication of reduced overall cushion as clearly as the original answer. However, the observation that both ends of the range fell is valid and adds insight.\n\n4) The answer is semantically equivalent to the ground truth and slightly expands with accurate interpretation. All entities (DHR, annual goodwill impairment analyses, reporting units, correct years) are accurate. The only minor shortcoming is the slight overstatement of precision in the calculated differences (‘70 percentage points’, ‘45 percentage points’) using approximate base values—though this is a reasonable inference, the original answer avoids such exact deltas due to the ‘approximately’ qualifier. This prevents a perfect 10 but does not undermine correctness.\n\nOverall, the answer is factually accurate, complete, and contextually appropriate, with excellent quantitative and qualitative performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1190,
        "completion_tokens": 512,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 161,
      "question": "How did the treatment of canceled RSUs and tax-withheld shares under the 2022 Employee Stock Plan evolve from 2022 to 2023 in terms of their impact on the available share pool?",
      "original_answer": "In 2022, the 2022 Employee Stock Plan specified that canceled RSUs and shares withheld to satisfy tax withholding obligations would increase the number of shares available for grant under the plan by a factor of two times the number of RSUs canceled or shares withheld. However, in 2023, this specific language regarding the factor of two times for RSUs canceled or shares withheld was omitted, indicating a change in how these events were accounted for in the share pool calculation.",
      "llm_answer": "Under the 2022 Employee Stock Plan, both RSU cancellations and the shares the company withholds to cover employee taxes are “added back” to the pool of shares that can be granted – each event increases the pool by 2 times the number of RSUs cancelled or shares withheld【page_49†L13-L16】. In 2022 the plan recorded 8.1 million RSUs cancelled and about 41 million shares withheld for tax purposes【page_48†L13-L20】, while in 2023 cancellations rose to 9.7 million RSUs but the tax‑withheld shares fell to roughly 37 million【page_48†L21-L28】. Thus, the pool‑increasing effect grew from the higher cancellation count but was partially offset by a lower amount of tax‑withheld shares in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but fails on the core factual point of the question, leading to a significant drop in correctness. (1) The key error is that the LLM implies the 2x replenishment rule remained in effect in 2023, when the ground truth explicitly states that the language for the 2x factor was *omitted* in 2023, meaning the treatment changed. The LLM incorrectly assumes the same 2x add-back mechanism applied in both years. (2) Quantitatively, the numbers cited (8.1M and 9.7M RSUs canceled, 41M and 37M tax-withheld shares) appear factually accurate and are properly attributed to the correct pages, so quantitative accuracy is partially correct. However, the conclusion that the 'pool-increasing effect grew' is invalid because it assumes the 2x rule still applied in 2023, which it did not. (3) The reasoning is flawed in the multi-hop synthesis: the question asks how the *treatment* evolved, not just the volume of events. The LLM focuses on the magnitude of cancellations and withholdings rather than the change in plan mechanics. It misses the critical policy shift—removal of the 2x replenishment—which is the central point of the original answer. (4) Contextual relevance is high because the answer addresses the right plan, years, and events, but the failure to identify the change in treatment severely undermines factual correctness. Thus, while the input data is partly accurate, the interpretation and core conclusion are incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 404,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 162,
      "question": "How has Danaher's strategic relationship with Aldevron evolved between 2023 and 2024, particularly in terms of its financial stake and integration into Danaher's business segments?",
      "original_answer": "In 2023, Danaher had a significant financial stake in Aldevron, as evidenced by the $9,561 million in net cash consideration allocated to Aldevron in the acquisition table, indicating a direct ownership interest. By 2024, Aldevron was no longer listed as a separately accounted stake but had been integrated into the Life Sciences segment as part of Danaher's broader portfolio of acquisitions, including Beckman Coulter, Pall, and IDT. This reflects a strategic shift from holding a standalone stake to full operational integration, aligning Aldevron's capabilities in biopharma research and manufacturing with Danaher’s broader life sciences offerings.",
      "llm_answer": "In the 2023 Form 10‑K Danaher still reported that Aldevron, which it bought in 2021 for about $9.6 billion, was a wholly‑owned business recorded in the Life Sciences segment (with the associated goodwill and intangible‑asset balances shown in the acquisition tables). The 2024 Form 10‑K repeats that Aldevron is listed among the Life Sciences brands and makes no mention of any change in ownership, indicating that Danaher’s financial stake remained 100 % and that Aldevron continued to be fully integrated as part of the Life Sciences segment.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Danaher maintained a 100% ownership stake in Aldevron and that it was integrated into the Life Sciences segment in both 2023 and 2024, which aligns with the ground truth's core claim of full integration. However, it inaccurately states that Aldevron was acquired in 2021, while the ground truth implies the significant financial stake was reflected in the 2023 filing, suggesting the acquisition occurred closer to or in 2023. The $9.6 billion figure is close to the ground truth's $9,561 million (i.e., $9.561 billion), so this is acceptable within rounding. (2) Quantitatively, the $9.6 billion vs. $9,561 million is a minor discrepancy—likely due to rounding—and is acceptable. However, the incorrect acquisition year (2021 vs. implied 2023) is a factual error affecting timeline accuracy. (3) The reasoning is partially sound: the LLM correctly infers continued integration from the absence of ownership changes and brand listing in the Life Sciences segment. However, it misses the key evolution highlighted in the ground truth: the shift from being a separately accounted stake in 2023 to no longer being listed separately in 2024, indicating deeper integration. This nuance is critical for the 'evolution' aspect of the question and represents a gap in multi-hop synthesis. (4) Scores reflect strong performance on financial stake and segment integration, minor quantitative inaccuracies, and partial completeness on the evolution narrative. Contextual relevance is high as all content directly addresses the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 434,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 163,
      "question": "How has Microsoft's strategic positioning of Microsoft 365 evolved between 2023 and 2024, particularly in terms of its integration with AI technologies and its role in the company's commercial business metrics?",
      "original_answer": "In 2023, Microsoft 365 was described as an 'AI first' platform integrating Office, Windows, Copilot, and Enterprise Mobility + Security, with Copilot for Microsoft 365 combining AI with business data to enhance productivity. By 2024, Microsoft had expanded the Microsoft 365 Consumer subscribers metric to include Microsoft 365 Basic subscribers, aligning with internal business management practices and signaling a broader consumer focus. This evolution reflects a strategic shift toward enhancing AI integration and expanding the product's market reach, particularly within the commercial segment.",
      "llm_answer": "In the 2023 filing Microsoft described Microsoft 365 as an “AI‑first platform” that unifies Office, Windows, Enterprise Mobility + Security and Copilot, with Copilot for Microsoft 365 pulling AI‑driven insights from the Microsoft Graph and role‑based Copilot extensions (see 2023 page 4). By the 2024 filing the company had moved from a purely product‑centric narrative to positioning Microsoft 365 as a key driver of its commercial metrics – Office 365 Commercial revenue grew 16% and Microsoft 365 consumer subscriptions (now counted with the new Microsoft 365 Basic tier) rose to 82.5 million, while the segment‑level metrics still highlight Copilot for Microsoft 365 as a growth engine (see 2024 pages 41‑42 and 39‑43). Thus, Microsoft 365’s strategy evolved from emphasizing AI integration to quantifying that integration’s impact on revenue and subscriber growth within the broader commercial business.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Microsoft 365 as an 'AI-first platform' in 2023 integrating Office, Windows, Copilot, and Enterprise Mobility + Security, and notes the role of Copilot for Microsoft 365 in leveraging AI with business data—consistent with the original answer. (2) Quantitatively, it accurately references the inclusion of Microsoft 365 Basic in the consumer subscriber metric by 2024 and correctly cites the 82.5 million subscriber figure (implied from context), though the exact number isn't in the ground truth; however, this level of specificity likely comes from the actual 2024 filing and does not contradict the knowledge graph. The 16% growth in Office 365 Commercial revenue is correctly reported and reflects a key commercial metric evolution. (3) The reasoning is sound: it captures the multi-hop synthesis between 2023’s AI integration focus and 2024’s shift toward measuring commercial impact, including updated subscription metrics and positioning Copilot as a growth engine. (4) The answer goes slightly beyond the ground truth by citing specific page numbers and metrics (e.g., 82.5 million, 16% growth), which are plausible and contextually appropriate but not present in the provided original answer. This adds detail without introducing error. The core strategic evolution—AI integration in 2023 to commercial impact in 2024—is correctly and thoroughly conveyed. Minor deduction from 10 due to inclusion of unverified specific metrics not in ground truth, though they are likely correct and enhance relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 439,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has Microsoft's positioning and emphasis on Copilot Pro evolved between 2023 and 2024, particularly in terms of its role within Microsoft 365 apps and web-based AI assistance?",
      "original_answer": "In 2023, Copilot Pro was introduced as a consumer subscription service that offered 'faster and more powerful AI assistance in Microsoft 365 apps and on the web.' By 2024, while the core definition remained consistent, the emphasis on Copilot Pro's differentiation and innovation appeared more pronounced, with language such as 'faster and more powerful AI assistance' retained but now embedded within a broader narrative of AI-driven transformation across Microsoft's ecosystem. This suggests a strategic evolution where Copilot Pro is not only a standalone offering but increasingly integrated into the broader AI-first positioning of Microsoft's productivity suite.",
      "llm_answer": "In the 2023 filing Microsoft introduced Copilot Pro simply as a consumer‑subscription service that adds AI‑driven assistance to Microsoft 365 applications and the web, positioning it as one component of an “AI‑first” Microsoft 365 platform. By the 2024 filing the company’s language had shifted to stress that Copilot Pro now delivers “faster and more powerful” AI help, underscoring its expanded role as a core productivity‑boosting feature across the entire Microsoft 365 suite and web‑based experiences.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that Copilot Pro was introduced in 2023 as a consumer subscription service offering AI assistance in Microsoft 365 apps and on the web, and notes the evolution in 2024 toward emphasizing 'faster and more powerful' AI help—matching the original answer's key phrasing and timeline. (2) There are no numeric values to verify, so quantitative accuracy is not applicable; however, the years (2023 and 2024) are correctly used and contextually accurate. (3) The multi-hop reasoning is sound: the model synthesizes how Microsoft’s positioning evolved across two time points, correctly inferring a strategic shift toward deeper integration within Microsoft 365 and a stronger emphasis on performance. The only minor shortcoming is that the LLM answer does not explicitly mention the 'broader narrative of AI-driven transformation across Microsoft's ecosystem' from the original, slightly downplaying the extent of strategic framing. (4) Despite this, the core facts, entities, and evolution are accurately conveyed with strong semantic equivalence. Contextual relevance is perfect—the response directly addresses the question about positioning and emphasis changes between 2023 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 356,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has the structure and availability of the 2007 Omnibus Incentive Plan evolved between 2023 and 2024, particularly in terms of remaining shares available for issuance?",
      "original_answer": "In 2023, the 2007 Omnibus Incentive Plan was described in the context of PSU and RSU awards, vesting conditions, and valuation methods, but no specific figure was provided regarding the remaining shares available for issuance. In contrast, by 2024, the plan explicitly stated that approximately 47 million shares of Danaher common stock remained available for issuance under the plan as of December 31, 2024 (excluding shares underlying outstanding awards). This indicates a more transparent disclosure and potential depletion or tracking of the share pool since the plan's inception, showing a shift in how the company communicates the availability of shares under the plan.",
      "llm_answer": "The 2007 Omnibus Incentive Plan still authorizes stock options, RSUs and PSUs – RSUs vesting over a five‑year period for grants made before 2022 (now four‑year for post‑2021 grants) and PSUs providing performance‑based shares with dividend‑equivalent rights – and the plan’s basic mechanics and eligibility rules were unchanged between the two filings. However, the pool of shares that can still be issued under the plan fell from roughly **50 million shares** available at 12/31/2023 (2023 10‑K) to about **47 million shares** available at 12/31/2024 (2024 10‑K), a decline of roughly 3 million shares.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces a specific figure of approximately 50 million shares available as of December 31, 2023, which is not present in the original answer (ground truth). The ground truth explicitly states that no specific figure was provided for 2023 regarding remaining shares available for issuance. This is a significant factual error, as the LLM fabricates a number not disclosed in the source material. The 47 million shares figure for 2024 matches the ground truth and is correct. (2) The calculation of a 3 million share decline is based on the incorrect 50 million starting point and is therefore invalid. While the 47 million figure is accurate, the comparative analysis fails due to the unsupported 2023 number. (3) The qualitative reasoning correctly identifies that the plan structure remained largely unchanged and that there is increased transparency in 2024, aligning with the ground truth's emphasis on evolving disclosure practices. The LLM accurately describes the types of awards (RSUs, PSUs) and vesting terms, showing good synthesis of plan mechanics across years. However, it incorrectly implies that share availability data was available in both years, undermining the core point about improved disclosure. (4) The contextual relevance is high because the response addresses both structural continuity and changes in share availability. The qualitative accuracy is moderate due to correct identification of plan features but flawed multi-hop reasoning on share depletion. The quantitative accuracy is low due to the invented 50 million figure, which skews the entire numerical comparison. Correctness score is 6 because while key elements like the 2024 share count and plan structure are right, the critical error in asserting a 2023 share figure that wasn't disclosed significantly undermines the factual integrity of the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 507,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did Microsoft's accounting policy regarding the estimated useful lives of server and network equipment evolve between fiscal years 2023 and 2024, and what factors influenced this change?",
      "original_answer": "In fiscal year 2023, Microsoft increased the estimated useful lives of server and network equipment from four years to six years, effective beginning fiscal year 2023. This change was driven by investments in software that improved operational efficiencies and advances in technology. In fiscal year 2024, the policy remained consistent with the updated six-year estimate, indicating that the initial change was sustained and likely integrated into ongoing asset management practices. The continued focus on cloud and AI infrastructure investments further supported the rationale behind extending the useful lives of these assets.",
      "llm_answer": "Microsoft revised its depreciation policy in July 2022, lengthening the estimated useful lives of server and network equipment from four years to six years; the change was applied beginning fiscal 2023 and remained in effect for fiscal 2024 with no further amendment. The adjustment was prompted by Microsoft’s investments in software that made operating the equipment more efficient and by overall advances in technology that extended the assets’ useful service life【page_40】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key change in Microsoft's accounting policy—extending the estimated useful lives of server and network equipment from four to six years, effective at the beginning of fiscal year 2023, and remaining unchanged in fiscal 2024. This matches the ground truth in both direction and timing. The mention of July 2022 as the revision date aligns with the typical timing of fiscal year-end adjustments ahead of fiscal 2023 (which begins July 1, 2022), so this detail is contextually accurate and consistent. (2) All quantitative elements—'four years to six years', 'fiscal 2023', 'fiscal 2024'—are factually correct. No calculations are required, but the temporal and numerical assertions are precise. (3) The reasoning correctly attributes the change to software investments improving efficiency and technological advances extending service life, which matches the ground truth. The LLM does not explicitly mention the 'continued focus on cloud and AI infrastructure' in 2024 as a sustaining factor, which is a minor omission in qualitative depth, but the core multi-hop synthesis (policy change + cause + continuation) is sound. (4) The answer is contextually fully relevant, directly addressing both the evolution between 2023 and 2024 and the influencing factors. The only reason for not scoring a 10 is the slight lack of elaboration on why the policy remained stable in 2024 beyond 'no further amendment', whereas the ground truth provides additional rationale tied to ongoing infrastructure strategy. However, this does not make the answer factually incomplete or incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 446,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did MDT's exposure to auction rate securities evolve from 2022 to 2023 in terms of fair value and classification within the balance sheet?",
      "original_answer": "In 2022, MDT reported auction rate securities with a fair value of $33 million and classified them under 'Total' in the investment portfolio without specifying a separate balance sheet classification. By 2023, the fair value of auction rate securities remained at $33 million, but they were explicitly classified under 'Other Assets' instead of being included in the broader investment category. This indicates a shift in how MDT categorized these securities on its balance sheet, moving from a general investment classification to a more distinct reporting under other assets.",
      "llm_answer": "In 2022 the company held $36 million of auction‑rate securities (Level 3) with a fair‑value of $33 million, which were reported in the **“Other assets”** portion of the balance sheet (not as “Investments”). The same $33 million fair‑value and “Other assets” classification appear for the 2023 balance sheet, indicating that MDT’s exposure to auction‑rate securities did not change in either amount or balance‑sheet presentation between 2022 and 2023【page_70†L31-L38】【page_71†L31-L38】.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in the classification of auction rate securities in 2022. According to the ground truth, in 2022, MDT classified the $33 million in auction rate securities under 'Total' in the investment portfolio without a separate classification, not under 'Other Assets' as the LLM claims. The LLM incorrectly states that in 2022 the securities were already in 'Other assets', which contradicts the ground truth that the shift to 'Other Assets' occurred only in 2023. This misrepresents the evolution of classification, which is a core part of the question. (2) Quantitatively, the fair value of $33 million is correct for both years, but the LLM introduces an unsupported figure of $36 million (possibly par value or cost basis) not mentioned in the ground truth, which lacks verification and creates confusion. The ground truth does not reference a $36 million figure or Level 3 classification, so this addition is extraneous and potentially misleading. (3) The multi-hop reasoning is flawed because the LLM fails to recognize the change in balance sheet presentation — the key evolution from a general investment category in 2022 to explicit 'Other Assets' classification in 2023. Instead, it incorrectly asserts no change occurred, undermining the qualitative analysis. (4) While the answer addresses the question's structure and focuses on fair value and classification, the core conclusion about no change is factually wrong. Hence, despite correct fair values and contextual relevance, the answer receives a low correctness score due to the central inaccuracy in entity classification over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 452,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 167,
      "question": "How did the net gains or losses from Cisco's available-for-sale debt investments change between fiscal years 2023 and 2024, and what does this indicate about the company's investment performance in this category?",
      "original_answer": "In fiscal year 2023, Cisco reported a net loss of $21 million from its available-for-sale debt investments, while in fiscal year 2024, this loss increased to $67 million. This indicates a significant worsening in investment performance related to this category year-over-year.",
      "llm_answer": "In fiscal 2024 Cisco recorded a **$67 million loss** on its available‑for‑sale debt investments, versus a **$21 million loss** in fiscal 2023 – a deterioration of **$46 million** (i.e., the loss more than tripled)【page_46】. This larger loss indicates that the portfolio’s fair‑value performance weakened in 2024, delivering poorer investment results for that category compared with the prior year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the net losses for both fiscal years: $21 million loss in 2023 and $67 million loss in 2024, matching the ground truth exactly. The calculation of the deterioration ($67M - $21M = $46M) is accurate, and the characterization that the loss 'more than tripled' is reasonable (67/21 ≈ 3.19, so it more than tripled). 2) All numeric values and fiscal years are correct. The difference calculation is precise. Format variations (e.g., $67 million vs $67M) are acceptable and do not affect accuracy. 3) The reasoning is sound: the model correctly synthesizes the change in performance across two fiscal years and draws a logical conclusion about worsening investment performance. The phrase 'loss more than tripled' adds interpretive value without distorting facts. 4) The answer fully addresses both parts of the question: the change in net gains/losses and what it indicates about investment performance. The conclusion that performance weakened in 2024 aligns semantically with the ground truth's 'significant worsening.' Minor deduction in qualitative accuracy only because 'more than tripled' could be slightly misleading (it nearly tripled, but 'more than tripled' may imply >3x, which it barely exceeds), but this is a nuance and not factually incorrect. Overall, the answer is factually accurate, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1184,
        "completion_tokens": 380,
        "total_tokens": 1565
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How did Cisco's approach to the APJC region evolve between 2023 and 2024 in terms of operational structure versus financial investment, and what implications does this have for its revenue model in that region?",
      "original_answer": "In 2023, Cisco directly operated in the APJC region as one of its three geographic segments, indicating a strong operational presence focused on delivering products and services. By 2024, Cisco's relationship with APJC evolved to include financial investments, specifically through equity instruments categorized as marketable equity securities, non-marketable equity securities, and equity method investments. While the 2023 filing emphasized operational delivery and customer engagement in APJC, the 2024 financial statements suggest a parallel strategy of capital participation, potentially signaling a shift toward leveraging local market growth through investment rather than solely through direct sales. This dual approach could indicate a broader revenue model incorporating both operational income and investment returns, though the filings do not quantify the specific financial impact of these investments on Cisco's APJC revenue.",
      "llm_answer": "- In the 2023 filing Cisco described the APJC market only as a geographic operating segment – “Our business is organized … into … Asia Pacific, Japan, and China (APJC)” (page 3).  This presentation treats the region as a traditional sales‑and‑service unit that reports its results alongside the Americas and EMEA segments.  \n\n- By the 2024 filing the company’s discussion of APJC is framed through its expanded financing and leasing programs – e.g., “We provide financing arrangements… loan receivables… lease receivables… financing arrangements for channel partners” (pages 66‑67).  These disclosures show Cisco is investing capital to enable customers in APJC to acquire hardware and services via loans, leases and channel‑partner financing rather than relying solely on outright sales.  \n\n**Implication:** The shift from a pure operating‑unit structure to a financing‑focused investment model moves Cisco’s APJC revenue mix toward recurring, subscription‑and‑interest‑related income (deferred revenue, financing fees, lease income) and away from one‑time product sales, deepening the region’s contribution to Cisco’s subscription‑driven revenue model.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Cisco and the APJC region, as well as the relevant years (2023 and 2024), which are factually accurate in terms of entity and time period. However, it misrepresents the nature of Cisco's evolution in the APJC region. The original answer states that in 2024, Cisco began reporting financial investments in the region through equity instruments—marketable and non-marketable equity securities and equity method investments—indicating a capital participation strategy. In contrast, the LLM answer incorrectly frames this shift as being about 'financing and leasing programs' (e.g., loan receivables, lease receivables, channel partner financing), which refers to customer financing activities, not equity investments in companies or joint ventures in the APJC region. This is a fundamental mischaracterization of the financial strategy. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable—no errors in numbers, dates, or calculations. (3) The multi-hop reasoning is flawed: the LLM fails to connect the 2024 shift to equity investments (a structural financial commitment) and instead infers a shift toward subscription and interest-based revenue via internal financing programs, which is not supported by the original answer. The original does not mention financing arrangements or leasing as a new focus in APJC, nor does it state that this affects the revenue mix toward recurring income. Thus, the conclusion about moving toward 'subscription-and-interest-related income' is speculative and unsupported. (4) While the LLM answer addresses the question’s structure—discussing operational vs. financial evolution and implications—it does so with incorrect underlying facts, leading to a misleading interpretation. The contextual relevance is moderate because it discusses Cisco’s regional strategy and revenue model, but the core financial mechanism described is wrong, undermining the qualitative accuracy and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1539,
        "completion_tokens": 544,
        "total_tokens": 2083
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How has Apple's approach to App Store commissions and regulatory compliance evolved between 2022 and 2024, particularly in response to legal and market pressures?",
      "original_answer": "In 2022, Apple acknowledged that changes to the App Store, including those in response to legal and market conditions, could reduce the volume of sales and the commission it earns on those sales, potentially affecting its financial condition. By 2024, Apple had implemented specific changes, particularly in the U.S. and the European Union, to address legal pressures such as the Digital Markets Act (DMA). These changes included new business terms, alternative fee structures, alternative app distribution methods, and additional developer tools and APIs. These adjustments reflect a shift from a more general acknowledgment of potential changes to concrete actions taken in response to regulatory demands, which could significantly affect App Store revenue and commission structures.",
      "llm_answer": "In the 2022 Form 10‑K Apple described the App Store as a platform where it “retains a commission from sales of applications and digital services or goods” and noted that it occasionally tweaks its rules in response to “litigation, competition, market conditions and legal and regulatory requirements,” but the commission model (generally 15‑30 %) remained essentially unchanged.  \n\nBy the 2024 filing Apple said it had taken far‑more substantive steps: it introduced **alternative fee structures and lower‑rate options**, allowed **alternative payment processing** for iOS/iPadOS apps, added new APIs that let developers distribute apps outside the Store, and implemented other changes specifically to comply with the EU Digital Markets Act and ongoing antitrust investigations. These moves reflect a shift from modest, ad‑hoc adjustments in 2022 to a broader, regulator‑driven redesign of its commission and distribution rules in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Apple's 2022 stance: acknowledgment of potential changes due to legal and market pressures without major structural shifts, maintaining the 15–30% commission model. In 2024, it accurately describes concrete changes including alternative fee structures, alternative payment processing, and new distribution methods in response to the EU's Digital Markets Act. These match the original answer’s emphasis on regulatory-driven changes in the U.S. and EU. (2) Quantitatively, the 15–30% commission range is correctly cited, and no incorrect numbers or dates are present. The years 2022 and 2024 are properly attributed to their respective disclosures. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points and regulatory contexts (EU DMA, antitrust scrutiny), showing evolution from passive acknowledgment to active compliance. The only minor shortcoming is that the LLM answer does not explicitly mention the potential financial impact on App Store revenue as highlighted in the original answer, which slightly weakens completeness. (4) Despite this, the answer is contextually excellent, directly addressing the evolution in Apple’s approach in response to legal and market pressures, with precise and relevant details. Wording differs but semantic meaning is equivalent. Minor deduction from 10 to 9 due to omission of financial impact language.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 408,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 175,
      "question": "How did the allocation strategy for Texas Instruments' U.S. Retiree Health Care Plan evolve between fixed income securities and equity securities from 2022 to 2024?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had a diversified mix of fixed income securities and equity securities, with fixed income and cash equivalents totaling $248 million and equity securities at $137 million. By 2024, the allocation strategy showed a significant shift toward a more conservative posture, with fixed income securities and cash equivalents comprising 80% of the portfolio, while equity securities made up only 20%. This reflects a notable increase in emphasis on fixed income securities compared to equities, even though the relative proportions remained the same between 2023 and 2024, suggesting a strategic decision to prioritize capital preservation.",
      "llm_answer": "In the 2022 filing TI’s U.S. Retiree Health Care plan was guided by a target mix of **75 %–85 % fixed‑income and cash equivalents and 15 %–25 % equity securities**【page_48】.  \nBy the 2024 filing the plan’s actual weighted‑average allocation was **about 80 % fixed‑income and 20 % equity**, which sits squarely in the middle of the 2022 target range【page_48】.  \n\nThus, from 2022 to 2024 the strategy stayed heavily weighted toward fixed‑income, with the equity portion remaining modest and consistent with the earlier target allocation.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the strategic allocation range in 2022 (75%–85% fixed income and cash equivalents, 15%–25% equities) and the actual 2024 allocation (80% fixed income, 20% equities), which aligns with the ground truth's description of a conservative posture prioritizing fixed income. However, the LLM does not mention the actual dollar amounts from 2022 ($248M in fixed income and cash equivalents, $137M in equities) that were present in the original answer, which constitutes a minor omission. (2) Quantitatively, all percentages are accurate and correctly interpreted. The LLM accurately notes that the 2024 allocation falls within the 2022 target range, which is a valid inference. The absence of dollar figures from 2022 reduces completeness but does not introduce inaccuracy. (3) The reasoning is sound: the LLM correctly infers that the strategy remained consistent in emphasis, with a sustained focus on fixed income, which matches the ground truth’s conclusion about a strategic shift toward conservatism. However, it does not explicitly acknowledge the evolution from actual 2022 holdings to the 2024 strategy, missing a subtle multi-hop element—comparing actual 2022 asset values to the later strategic allocation. (4) Despite missing the specific 2022 dollar values, the LLM captures the core strategic evolution and maintains semantic equivalence in describing the shift and stability in allocation philosophy. The answer is highly relevant and factually accurate on the key point—the strategic posture—earning high marks, though not full points due to incomplete data synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 445,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How has Texas Instruments' strategic emphasis on Embedded Processing Products evolved from 2022 to 2024, particularly in terms of its contribution to the company's competitive advantages and segment reporting structure?",
      "original_answer": "In 2022, Texas Instruments described Embedded Processing as one of its core product lines within a broader business model that emphasized four competitive advantages: manufacturing and technology strength, a broad product portfolio, strong market channels, and product diversity and longevity. Embedded Processing was positioned as part of this integrated strategy but was not highlighted as a standalone reportable segment. By 2024, Embedded Processing was elevated to a reportable segment alongside Analog, indicating a strategic shift where the company explicitly called out Embedded Processing as a key driver of value. This change suggests that Embedded Processing has become more central to TI's competitive positioning, particularly in terms of enabling optimized performance, power, and cost across a range of customer applications. The elevation to a reportable segment also implies greater operational and financial focus, aligning with the company’s long-term objective of strengthening its competitive advantages and driving free cash flow growth.",
      "llm_answer": "In the 2022 filing TI’s strategy was built around **analog + embedded‑processing products**, which it said gave the company a “broad portfolio of analog and embedded processing products” – one of the four sustainable competitive advantages that drive its cash‑flow growth and market reach.  Accordingly, the company reported two distinct operating segments, **Analog** and **Embedded Processing**, and the Embedded‑Processing segment generated about **$3.0 billion of revenue and $1.2 billion of operating profit** in 2022.  \n\nThe 2024 filing still treats Embedded Processing as a separate, core segment – describing it as the “digital ‘brains’” of many electronic systems – but its contribution has slipped: **revenue fell to $2.5 billion and operating profit to $0.35 billion**, while the segment remains part of the same two‑segment reporting structure that underpins TI’s competitive‑advantage framework.  Thus, the emphasis on embedded‑processing remains strategic, but its relative financial weight has decreased between 2022 and 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual and conceptual errors that severely undermine its correctness. (1) Quantitative Accuracy: The revenue and profit figures provided are incorrect. According to the ground truth, Embedded Processing was not a reportable segment in 2022 and therefore did not have standalone financials; the claim that it generated $3.0 billion in revenue and $1.2 billion in operating profit in 2022 is false. Similarly, the 2024 figures of $2.5 billion revenue and $0.35 billion operating profit are unsupported and factually wrong. There is no indication in the ground truth that financial performance declined—only that the segment was newly elevated to reportable status by 2024. (2) Completeness & Entity Accuracy: The answer incorrectly states that TI reported two segments (Analog and Embedded Processing) in 2022. The ground truth explicitly says Embedded Processing was not a standalone reportable segment until 2024. This misrepresents TI’s segment reporting structure across both years. (3) Reasoning: The multi-hop reasoning fails—instead of identifying the strategic elevation of Embedded Processing as a new development, the model assumes it was always a reportable segment and fabricates financial trends. The conclusion that its 'relative financial weight has decreased' is not supported by the original answer and contradicts the strategic emphasis on growth. (4) Semantic Equivalence: The LLM answer conveys the opposite of the ground truth: rather than showing an increasing strategic emphasis, it suggests a decline in importance due to fabricated financial deterioration. While the mention of embedded processing as part of TI’s competitive advantages aligns loosely with the broad portfolio advantage, this is overshadowed by major inaccuracies. Contextual relevance is moderate because the answer addresses the right topic and company, but with deeply flawed execution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1543,
        "completion_tokens": 515,
        "total_tokens": 2058
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How did TMO's issuance and valuation of its 2.00% 10-Year Senior Notes evolve between 2022 and 2024?",
      "original_answer": "In 2022, TMO reported $1,200 million in 2.00% 10-Year Senior Notes due on October 15, 2031, with an effective interest rate of 2.23%. By 2024, the same category of 2.00% 10-Year Senior Notes showed no change in the principal amount at $1,200 million, and the effective interest rate remained at 2.23%. This indicates that TMO maintained a consistent position on this specific debt instrument over the two-year period, with no new issuances or repayments affecting this line item.",
      "llm_answer": "- **2022 filing:** Thermo Fisher reported two 2.00 % 10‑year senior‑note series – a euro‑denominated issue due 4 Oct 2025 with a par amount of **$728 million** (effective interest ≈ 2.10 %) and a U.S.‑dollar issue due 15 Oct 2031 with a par amount of **$1.2 billion** (effective interest ≈ 2.23 %). Both were carried at roughly par in the balance sheet (total borrowings at carrying value $34.7 bn vs. par $34.97 bn).\n\n- **2024 filing:** The euro‑denominated 2.00 % notes due 4 Oct 2025 had been **reduced to $663 million** at par, with the effective rate slipping slightly to **2.07 %**. The U.S.‑dollar 2.00 % notes due 15 Oct 2031 remained unchanged at **$1.2 billion** at par and **2.23 %** effective interest. The overall debt portfolio’s carrying value fell to $31.1 bn versus $31.33 bn at par, reflecting the lower amount of the 2025 notes.\n\nThus, between 2022 and 2024 the 2.00 % 10‑year senior notes due 2025 were **down‑sized** (from $728 m to $663 m) and saw a modest decline in effective interest, while the 2.00 % notes due 2031 stayed **flat** in both amount and valuation.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the right question and demonstrating relevant reasoning structure. (1) The original answer states that TMO (Thermo Fisher Scientific) only has one 2.00% 10-Year Senior Note—$1.2 billion due October 15, 2031, with an effective interest rate of 2.23%—and this remained unchanged in both 2022 and 2024. However, the LLM introduces a second euro-denominated 2.00% note due October 4, 2025, which is not mentioned in the ground truth and appears to be fabricated or misattributed. This is a critical error in entity and quantitative accuracy. (2) The LLM claims the euro-denominated note was reduced from $728 million to $663 million between 2022 and 2024, but the ground truth makes no mention of such a note or any change in TMO's 2.00% 10-Year Senior Notes. The principal amount of $1.2 billion for the 2031 note is correctly reported, as is the 2.23% effective interest rate in both years. However, the introduction of a second note and associated figures (amounts, dates, interest rates) is unsupported by the ground truth. (3) The reasoning structure is sound—comparing debt instruments across years, analyzing changes in principal and effective rates—but it is applied to incorrect or extraneous data. The model attempts multi-hop synthesis but does so using invalid premises. (4) Contextually, the answer is relevant and well-structured, discussing the evolution of the notes over time, but the core factual content diverges from the truth. The conclusion that the 2031 notes stayed flat is correct, but the claim about the 2025 notes being downsized is not supported. Thus, while some numbers are accurate, the inclusion of a non-existent debt instrument severely reduces correctness and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 491,
        "total_tokens": 1871
      },
      "error": null
    },
    {
      "question_id": 178,
      "question": "How has the financial performance of REMICADE evolved between 2022 and 2024, and what does this indicate about its role in Johnson & Johnson's Pharmaceutical segment?",
      "original_answer": "In 2022, REMICADE was listed as a key product in Johnson & Johnson's Pharmaceutical segment, specifically within the Immunology therapeutic area, indicating its importance in treating immune-mediated inflammatory diseases. By 2024, REMICADE's sales had declined significantly, from $1,839 million in 2023 to $1,605 million in 2024, representing a 12.8% decrease. This decline suggests a diminishing contribution of REMICADE to the company's Immunology revenue, potentially due to market saturation, increased competition, or the emergence of newer biologics within the segment.",
      "llm_answer": "REMICADE’s sales have been falling steadily. The 2024 10‑K shows REMICADE generated **$1.6 billion** in sales, a **12.8 % decline from 2023 ($1.839 billion)** and roughly a **20 % drop versus the 2022 level reported in the 2022 filing (about $2.0 billion)**【page_31】. This downward trend reflects the growing impact of infliximab biosimilars, yet the drug still contributes more than $1 billion annually, keeping it among the larger products in Johnson & Johnson’s Pharmaceutical segment and underscoring its continued strategic importance despite eroding market share.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the decline in REMICADE sales from $1.839 billion in 2023 to $1.6 billion in 2024, matching the ground truth's reported $1,605 million (rounded appropriately to $1.6 billion). The 12.8% decline is accurately calculated and reported. However, the LLM introduces a claim about 2022 sales being 'about $2.0 billion' and a 20% drop from 2022 to 2024, which is not supported by the original answer — the ground truth does not provide 2022 sales figures, only that REMICADE was a key product in 2022. This introduces a factual overreach, as the $2.0 billion figure and 20% decline are not verifiable from the provided truth. (2) The quantitative accuracy is mostly correct for reported years (2023–2024), but the unsupported extrapolation to 2022 sales reduces precision. The 12.8% decline is correctly computed: (1.839 - 1.605)/1.839 ≈ 12.7%, which rounds to 12.8%. The $1.6 billion figure is a reasonable rounding of $1,605 million. (3) The multi-hop reasoning is strong: the model connects REMICADE’s role in Immunology, its declining sales trend, and infers competitive pressure (biosimilars), which aligns with plausible industry context and adds value. However, the unsupported 2022 sales figure weakens the synthesis. (4) Despite the unsupported 2022 number, the core facts for 2023–2024 are correct, the reasoning about strategic importance despite decline is reasonable, and the answer addresses both parts of the question — performance evolution and strategic role. Hence, correctness is high but not perfect due to the unverified 2022 data point.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 437,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 179,
      "question": "How did the sales performance of REMICADE evolve from 2022 to 2024, and what does this indicate about its market position within JNJ's Immunology portfolio?",
      "original_answer": "In 2022, REMICADE had sales of $3,190 million, showing a decline of 14.9% compared to 2020. By 2024, its sales had further decreased to $1,605 million, representing a 12.8% drop from 2023. This consistent decline indicates a weakening market position of REMICADE within JNJ's Immunology portfolio over time.",
      "llm_answer": "REMICADE’s revenue has been falling each year – it generated roughly **$2.0 billion in 2022** (2022 10‑K), dropped to **$1.839 billion in 2023**, and fell further to **$1.605 billion in 2024** (2024 10‑K, Table on page 31). The steady decline, driven by the entry of multiple infliximab biosimilars, shows that REMICADE is losing market share and is no longer a growth engine within Johnson & Johnson’s Immunology portfolio, where newer biologics such as STELARA and TREMFYA now dominate sales.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the declining trend in REMICADE sales and accurately reports the 2024 sales figure ($1.605 billion), which matches the ground truth. However, it incorrectly states 2022 sales as $2.0 billion, whereas the ground truth specifies $3,190 million (i.e., $3.19 billion), a significant discrepancy. The 2023 figure of $1.839 billion is not present in the ground truth, which only provides 2022 and 2024 data with a percentage change from 2023 to 2024. Since the ground truth does not include 2023 sales, the LLM's inclusion of this number—while plausible—cannot be verified and appears to be an interpolation not supported by the provided data. (2) The calculation of the decline from 2023 to 2024 is consistent with the ground truth (12.8% drop), but the absence of 2023 data in the original answer means this figure is extraneous and potentially misleading. The 14.9% decline mentioned in the ground truth is from 2020 to 2022, which the LLM omits entirely, missing a key data point. (3) The reasoning about REMICADE's weakening market position due to biosimilar competition and the shift toward newer biologics like STELARA and TREMFYA is sound and aligns with the qualitative interpretation in the ground truth. The multi-hop synthesis—linking declining sales to competitive dynamics within JNJ’s Immunology portfolio—is logically supported and adds contextual insight. (4) Despite the incorrect 2022 sales figure and the unsupported 2023 number, the overall trajectory and conclusion about REMICADE’s diminishing role are correct, warranting a score of 7 for correctness. Quantitative accuracy is penalized more heavily (6) due to the large error in the 2022 figure. Qualitative accuracy is high (8) because the reasoning and market interpretation are strong. Contextual relevance is perfect (10) as the answer directly addresses both parts of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1202,
        "completion_tokens": 515,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 180,
      "question": "How has the sales performance of REMICADE evolved between 2021 and 2024, and what factors contributed to this change?",
      "original_answer": "REMICADE's sales declined significantly from $16.8 billion in 2021 (as part of total Immunology sales) to $1,605 million in 2024, reflecting a 12.8% decrease from 2023 to 2024 alone. This decline was primarily driven by biosimilar competition in the U.S. and other global markets, which intensified over time and led to a continued reduction in REMICADE sales.",
      "llm_answer": "Remicade’s sales have fallen sharply, from $3.19 billion in 2021 to $1.84 billion in 2023 and further to $1.61 billion in 2024 – a drop of roughly 50 percent over the three‑year span.  The decline is attributed to the rollout of infliximab biosimilars in the United States and other markets, which has eroded Remicade’s market share and continued to pressure volumes each year.  No other product‑specific drivers are noted; the primary factor is the sustained biosimilar competition.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the sales figures. The ground truth states REMICADE's sales were $16.8 billion in 2021 (as part of total Immunology sales), but the LLM incorrectly reports $3.19 billion in 2021, which is not supported by the data. Similarly, the LLM reports $1.84 billion in 2023 and $1.61 billion in 2024, while the ground truth specifies $1,605 million ($1.605 billion) in 2024 and a 12.8% decline from 2023 to 2024 — implying 2023 sales were approximately $1.84 billion, which the LLM correctly infers. However, the starting point in 2021 is fundamentally wrong. (2) The calculation of a '50 percent drop' over three years is based on incorrect baseline data and does not align with the actual decline from $16.8B (or even the correct standalone REMICADE figure, if available). The 12.8% year-over-year decline from 2023 to 2024 is consistent between both answers, assuming rounding. (3) The qualitative reasoning about biosimilar competition in the U.S. and global markets as the primary driver is accurate and aligns with the ground truth. The LLM correctly identifies the key factor behind the decline and demonstrates sound multi-hop reasoning in linking biosimilar entry to sustained volume pressure. (4) While the directional trend and causal explanation are correct, the severe quantitative inaccuracy in the 2021 sales figure undermines the overall correctness. The answer is partially complete and contextually relevant, but the core financial data is flawed, warranting a low correctness and quantitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 436,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 181,
      "question": "How did the status and commercial performance of STELARA (ustekinumab) evolve between 2022 and 2024?",
      "original_answer": "In 2022, STELARA was in the filing stage for the treatment of pediatric patients with juvenile psoriatic arthritis in the U.S., indicating it was under regulatory review but not yet approved. By 2024, STELARA had achieved significant commercial success, generating $10,361 million in sales, a decrease from $10,858 million in 2023, representing a 4.6% decline in total sales. This reflects that STELARA had transitioned from a product in active regulatory development to a mature, high-revenue-generating drug facing slight sales decline, suggesting market saturation or increased competition.",
      "llm_answer": "In the 2022 filing, St ela ra (ustekinumab) was highlighted as a “growth driver” for the Immunology franchise – its U.S. sales were about $5.9 billion and the company noted that the last U.S. patent would expire in September 2023, but it was still gaining market share in Crohn’s disease and ulcerative colitis. By the 2024 filing, St ela ra’s worldwide sales had slipped to $10.36 billion (down 4.6 % from 2023) as share loss to European biosimilar entrants eroded revenue; U.S. sales were roughly $6.7 billion and the company expected biosimilar launches in Europe and the United States in 2025, signalling a transition from a growth‑phase product to one confronting generic competition.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies that STELARA's sales declined by 4.6% from 2023 to 2024 and that 2024 sales were $10.36 billion (matching the ground truth of $10,361 million). However, it introduces U.S.-specific sales figures ($5.9B in 2022 and $6.7B in 2024) that are not present in the original answer and are potentially misleading, as the ground truth only provides worldwide sales. Additionally, the claim about the 'last U.S. patent expiring in September 2023' and 'biosimilar launches expected in 2025' is not mentioned in the original answer, introducing unsupported details. (2) The $10.36 billion figure in 2024 is accurate (equivalent to $10,361 million), and the 4.6% decline aligns with the original calculation: (10,858 - 10,361)/10,858 ≈ 4.58%. However, the U.S. sales numbers ($5.9B and $6.7B) cannot be verified against the ground truth and appear to be hallucinated or inferred without basis. (3) The reasoning partially captures the multi-hop evolution: from regulatory activity in 2022 to commercial performance in 2024. However, the original answer emphasizes the 2022 regulatory filing for pediatric use, which the LLM omits entirely, instead focusing on patent expiry and market share—details not in the source. This represents a failure in entity and context synthesis. (4) The contextual relevance is high because the answer addresses the drug’s commercial trajectory and competitive pressures. However, the quantitative accuracy is reduced due to unverified U.S. sales figures and extraneous patent/biosimilar timing details. The qualitative accuracy is moderate because while the core sales decline is correct, key factual elements are missing or added without support.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 481,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 182,
      "question": "How did the total net revenue from Restasis in the United States change between 2023 and 2024, and what was the percentage decrease in each year?",
      "original_answer": "In 2023, the United States net revenue from Restasis was $382 million, which decreased to $172 million in 2024. This represents a 38.5% decrease in 2023 compared to 2022, and a further 55.2% decrease in 2024 compared to 2023.",
      "llm_answer": "In 2023 AbbVie reported $382 million of Restasis net revenue in the United States, which fell to $172 million in 2024 – a drop of $210 million. The 2023 figure represented a 38.5 % decline from 2022, and the 2024 figure was a 55.2 % decline from the 2023 level【page_43†L31-L38】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $382 million in 2023 and $172 million in 2024 are correctly reported. The implied $210 million drop is accurate (382 - 172 = 210). The percentage decreases—38.5% from 2022 to 2023 and 55.2% from 2023 to 2024—are exactly as stated in the original answer. (2) The answer addresses all parts of the question: it reports the change in total net revenue between 2023 and 2024 and provides the percentage decrease for each year relative to the prior year. (3) Entity accuracy is correct: AbbVie is the company that reports Restasis revenue, and the years 2023 and 2024 are properly referenced. (4) The reasoning is sound and reflects proper multi-hop synthesis—comparing Restasis revenue across consecutive years and correctly interpreting year-over-year percentage declines. (5) The semantic meaning is equivalent to the ground truth, with only minor rewording (e.g., 'fell to', 'drop of', 'decline') that does not affect factual accuracy. The citation reference 【page_43†L31-L38】 further supports the grounding in source material.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1125,
        "completion_tokens": 324,
        "total_tokens": 1449
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role and strategic importance of Master Lease Agreements evolved between 2022 and 2023 in supporting AMT's international growth and tenant relationships?",
      "original_answer": "In 2022, AMT emphasized that master lease agreements were comprehensive in nature and instrumental in building strong strategic partnerships with tenants, significantly reducing colocation cycle times and enabling rapid deployment of equipment across its international portfolio of approximately 177,000 communications sites. By 2023, AMT reiterated the importance of these agreements in providing consistent, long-term revenue and reducing non-contractual churn, while operating an expanded international portfolio of approximately 182,000 communications sites. The evolution reflects a continued strategic focus on leveraging master lease agreements to support international growth and tenant retention, with an emphasis on mitigating risks such as customer consolidation and regulatory changes.",
      "llm_answer": "In the 2022 filing, master‑lease agreements were highlighted mainly as a revenue‑stability tool – they lock in long‑term, non‑cancellable rent, curb non‑contractual churn and, because many are “comprehensive,” they deepen strategic partnerships and cut colocation cycle times for tenants. By the 2023 filing, the same agreements are portrayed as a core pillar of AMT’s international growth strategy: with a much larger global portfolio (≈ 182 k sites) the company leans on these master leases to extend carrier relationships abroad, accelerate equipment roll‑outs on new sites, and generate predictable, long‑term cash flow while still limiting churn. Thus, the role has evolved from primarily protecting existing revenue to actively driving and supporting the company’s worldwide expansion and tenant‑centric growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: master lease agreements were emphasized in 2022 for reducing colocation cycle times and building strategic partnerships, and in 2023 for supporting international growth and reducing churn. The international portfolio size increased from approximately 177,000 sites in 2022 to 182,000 in 2023 — the LLM correctly reports the 2023 figure (≈182k) and implies the earlier figure by contrast, though it does not explicitly state '177,000' in 2022. This is a minor omission but does not distort the evolution. (2) Quantitative accuracy is excellent: the ≈182,000 sites in 2023 is correctly cited; no incorrect numbers or calculations are present. (3) Multi-hop reasoning is sound: the LLM synthesizes information across years and strategic contexts, correctly identifying the shift from revenue stability (2022) to active international growth driver (2023), including tenant relationship extension and faster rollouts. (4) The answer captures the core evolution — from protecting revenue to driving global expansion — which reflects the ground truth’s emphasis on strategic continuity with expanded scope. The only minor gap is the lack of explicit mention of 'mitigating risks such as customer consolidation and regulatory changes' from the 2023 context, which slightly affects completeness. However, the answer remains semantically equivalent in intent and factual content. Thus, the correctness score is 9 due to high accuracy with a small omission in risk mitigation context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 431,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role of Google Marketing Platform in the company's advertising revenue generation evolved between 2023 and 2024, particularly in relation to how advertising revenues are recognized and managed across Google Network properties?",
      "original_answer": "In 2023, Google Marketing Platform was directly involved in the recognition of advertising revenues on a gross basis for Google Network properties, meaning the full amount billed to customers was recorded as revenue. By 2024, the platform's role evolved to include a more nuanced evaluation of its principal versus agent status, with an emphasis on its control over advertising inventory before transfer to customers, further supporting the gross revenue reporting. Additionally, 2024 introduced a more detailed explanation of the platform's role in managing advertising across Google Network properties, highlighting its central function in both performance and brand advertising delivery.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K filings the company describes Google Marketing Platform as one of the primary channels through which advertisers purchase inventory – alongside Google Ads, Google Ad Manager and Google Display & Video 360. The accounting treatment for ads that run on Google Network properties has not changed: Alphabet continues to evaluate whether it is the principal or an agent, and it generally records the amounts billed to advertisers on a gross basis as advertising revenue, offsetting the payments made to network partners as cost of revenues. Thus, the platform’s role in driving ad sales remains the same, and the recognition and net‑gross handling of network‑property revenue is unchanged from 2023 to 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent in terms of the accounting treatment and entity identification, correctly stating that advertising revenue from Google Network properties continues to be recognized on a gross basis and that the company evaluates principal versus agent status. The dates (2023 and 2024) and entities (Google Marketing Platform, Google Network properties, Alphabet) are accurate, supporting a high quantitative accuracy score. However, the LLM incorrectly concludes that the platform's role 'remains the same' and that there is 'no change' in recognition or management practices, which contradicts the ground truth. The original answer specifies a meaningful evolution in 2024: a more nuanced evaluation of principal vs. agent status with greater emphasis on control over inventory, and an expanded explanation of the platform’s central role in managing both performance and brand advertising. The LLM answer fails to capture this evolution, missing the qualitative shift in disclosure and platform function. While the core accounting policy is correctly described, the multi-hop reasoning is flawed because it overlooks the progression in narrative and emphasis between the two years. Thus, despite correct terminology and structure, the answer lacks the required depth of change, leading to a moderate correctness score. Contextual relevance is high as the response directly addresses the question’s focus on revenue recognition and platform role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 403,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did the volume and fair value of Federal Funds Purchased & Sec Loaned change between 2023 and 2024, and what does this indicate about BAC's short-term funding strategies?",
      "original_answer": "In 2023, the volume of Federal Funds Purchased & Sec Loaned showed a net change of $16,466 million, indicating a significant increase in short-term funding liabilities. By 2024, the fair value of this category was reported at $192,859 million, a substantial increase from the prior year. This suggests that BAC significantly expanded its reliance on short-term secured funding mechanisms in 2024, likely to support its trading and liquidity management activities.",
      "llm_answer": "- **Volume:** The balance of “Federal funds purchased and securities loaned (or sold) under repurchase agreements” grew from about **$301 billion at year‑end 2023** (the 2023 filing) to a larger amount in 2024 – the rise in the fair‑value line (see the 2024 fair‑value table) shows that the position expanded materially.  \n\n- **Fair‑value:** The fair‑value of that liability increased from **$144.5 billion in 2023** to **$192.9 billion in 2024** (Level 2 measurement, net of a $377 billion netting adjustment).  \n\n- **Implication:** The higher balance and higher fair‑value indicate that Bank of America relied more heavily on overnight federal‑funds and repo‑type securities‑loan transactions in 2024, using these short‑term funding sources to support its liquidity needs and to take advantage of the higher rates available in the federal‑funds market. This reflects a more aggressive short‑term funding strategy compared with the prior year.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM answer captures the overall trend correctly: an increase in both volume and fair value of Federal Funds Purchased & Sec Loaned from 2023 to 2024, and correctly infers that BAC increased reliance on short-term funding. However, there are key quantitative inaccuracies. The ground truth states a net change in volume of $16,466 million in 2023 (not a year-end balance of $301 billion as stated by the LLM), and the 2024 fair value is $192,859 million (~$192.9 billion), which the LLM reports accurately. The 2023 fair value in the LLM answer is given as $144.5 billion, but this figure does not align with the ground truth, which does not specify the 2023 fair value directly—only the 2024 value and the 2023 net change in volume. The LLM appears to have introduced a specific 2023 fair value not present in the original answer, which risks misrepresentation. 2) The $192.9 billion fair value in 2024 matches the ground truth ($192,859 million ≈ $192.9 billion), so that number is correct. However, the $144.5 billion for 2023 fair value is not supported by the original answer and appears to be an inference or external data, making it factually unverifiable against the ground truth. The volume description conflates balance with net change, misrepresenting the nature of the data. 3) The reasoning is logically sound—increased use of short-term funding implies a shift in funding strategy—and the multi-hop synthesis (linking volume/fair value changes to strategic implications) is appropriate and well-executed. 4) Despite the numerical discrepancies, the LLM answer remains contextually relevant and conveys a similar conclusion about BAC’s increased reliance on short-term secured funding. The core message aligns with the ground truth, but precision is compromised by unsupported figures. Thus, correctness is reduced primarily due to unsupported quantitative claims, though the direction and interpretation are valid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 519,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has PepsiCo's disclosure regarding the sensitivity of pension and retiree medical plan liabilities to market fluctuations evolved between 2022 and 2024?",
      "original_answer": "In 2022, PepsiCo mentioned that the exposure of pension and retiree medical plan assets and liabilities to risks related to market fluctuations was discussed in 'Our Critical Accounting Policies and Estimates.' By 2024, the company expanded this disclosure, explicitly linking the sensitivity of these liabilities not only to market fluctuations but also to inflationary, deflationary, and recessionary conditions. This broader context indicates a more detailed characterization of the macroeconomic risks affecting these obligations, beyond just market volatility.",
      "llm_answer": "In the 2022 Form 10‑K PepsiCo only noted that “our pension and retiree‑medical‑plan assets and liabilities are exposed to risks related to market fluctuations” and directed readers to the “Critical Accounting Policies and Estimates” section for details. By the 2024 filing the same reference appears, but it is now phrased as “the exposure of our goodwill and other intangible assets **and** pension and retiree‑medical‑plan assets and liabilities to risks related to market fluctuations,” indicating that the company has broadened the discussion to place pension‑plan risk alongside other market‑sensitive assets.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is partially correct in noting that PepsiCo's disclosure evolved between 2022 and 2024 regarding pension and retiree medical plan liabilities. It correctly identifies that in 2022, the company referenced market fluctuation risks and directed readers to the 'Critical Accounting Policies and Estimates' section. However, the LLM introduces a significant factual error by claiming that in 2024, the disclosure was broadened to include 'goodwill and other intangible assets' alongside pension liabilities. The ground truth states that the 2024 update expanded the discussion of pension and retiree medical plan liabilities to include sensitivity to inflationary, deflationary, and recessionary conditions—not goodwill or intangible assets. This mischaracterization of the expanded disclosure undermines the qualitative accuracy. The answer fails to capture the actual evolution in risk framing (from market volatility to broader macroeconomic conditions), which is the core of the question. While the dates and general structure of the disclosure are correctly referenced, the reasoning is flawed due to incorrect entity linkage (adding goodwill) and missing the true nature of the expanded risk context. Thus, despite correct dates and some accurate phrasing, the answer misrepresents the key multi-hop insight about how the sensitivity discussion evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 378,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Adobe's approach to Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's broader document management ecosystem?",
      "original_answer": "In 2023, Adobe Scan was positioned as a free mobile scanning tool that converts paper documents into editable, searchable PDFs via Adobe Document Cloud services, emphasizing its utility for individual users. By 2024, Adobe Scan remained part of Adobe Document Cloud, but the broader ecosystem placed increased emphasis on integration with cloud-based productivity tools and AI-driven features like Content Credentials and Firefly-powered generative AI workflows, indicating a shift toward deeper integration within enterprise document workflows and enhanced digital trust mechanisms.",
      "llm_answer": "In the 2023 filing Adobe Scan was described mainly as a free‑standing mobile‑scanning app that lets users capture paper and turn it into PDFs. By the 2024 filing Adobe positions Scan as an integral part of Adobe Document Cloud – together with Acrobat, Acrobat Sign and the Document Cloud APIs – emphasizing its cloud‑based OCR, instant sharing and tight integration with the broader Adobe Experience and document‑management suite.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and captures the core evolution of Adobe Scan's positioning between 2023 and 2024, with no numeric inaccuracies (quantitative_accuracy: 10). It correctly identifies that in 2023, Adobe Scan was a standalone mobile scanning app for converting paper to PDFs, and by 2024 it was more tightly integrated into Adobe Document Cloud alongside Acrobat, Acrobat Sign, and APIs (entity and timeline accuracy correct). The answer emphasizes cloud-based OCR, sharing, and integration with Adobe's broader document suite, which aligns with the ground truth's emphasis on deeper ecosystem integration. However, it omits specific 2024 advancements highlighted in the original answer: AI-driven features like Content Credentials and Firefly-powered generative AI workflows, which represent key aspects of Adobe’s shift toward digital trust and enterprise workflows. While the LLM conveys integration and cloud alignment, it misses the qualitative nuance of AI enhancement and digital trust mechanisms, slightly weakening the multi-hop synthesis (qualitative_accuracy: 8). Contextually, the response is highly relevant and directly addresses the question’s focus on positioning within the broader ecosystem (contextual_relevance: 10). The correctness score is 8 due to accurate core facts but partial omission of key 2024 strategic developments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 377,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Gemini's role and integration across Google's products evolved from its initial launch in 2023 to 2024, and what specific advancements were made in its multimodal capabilities?",
      "original_answer": "In 2023, Gemini was introduced as a multimodal AI model capable of understanding and operating across different types of information, including text, code, audio, images, and video. It was intended to be leveraged across Alphabet to enhance product experiences. By 2024, Gemini had evolved significantly, with the launch of Gemini 2.0, which became the most capable model yet. It was integrated into all seven of Google's two billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube—powering AI features across these platforms. Additionally, in 2024, Gemini was used in experimental research prototypes such as Project Astra and Project Mariner, showcasing broader and more advanced applications than in 2023.",
      "llm_answer": "Google first introduced Gemini in 2023 as its “natively multimodal” large‑language model, built from the ground up to handle text, code, audio, images and video. By 2024 the upgraded Gemini 2.0 had become the core AI engine for every one of Google’s seven flagship, two‑billion‑user products—Android, Chrome, Gmail, Maps, Play Store, Search and YouTube—as well as for Google‑Cloud offerings (Vertex AI, AI agents and research prototypes such as Project Astra and Project Mariner). The 2024 release added broader, more capable multimodal reasoning and generation, improving the model’s ability to combine and act on those five data types across all products.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Gemini was introduced in 2023 as a natively multimodal model handling text, code, audio, images, and video. In 2024, Gemini 2.0 became the core AI engine for Google's seven two-billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube—matching the original answer exactly. (2) Quantitative elements—'2023', '2024', 'seven', and 'two-billion-user products'—are all accurate and consistent with the ground truth. Format variations (e.g., 'two-billion-user' vs 'two billion-user') are semantically equivalent. (3) Multi-hop reasoning is sound: the answer synthesizes the evolution over time, product integration scale, and advancements in multimodal capabilities. It correctly links Gemini 2.0 to broader deployment and enhanced multimodal reasoning. (4) The only minor deviation is the inclusion of 'Google Cloud offerings (Vertex AI, AI agents)' and slightly stronger phrasing around being the 'core AI engine', which are plausible extensions but not explicitly stated in the ground truth. However, this does not contradict the original and adds context without introducing error. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 366,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Linde's relationship with helium evolved between 2022 and 2024, particularly in terms of its impact on sales and operating profit?",
      "original_answer": "In 2022, helium was listed as a supply for Linde, indicating a positive or neutral relationship. However, by 2024, the relationship had evolved, and helium was reported to negatively impact the company. Specifically, in 2024, lower volumes in global helium contributed to a 2% decrease in sales for the 'Other' segment, which includes global helium wholesale. Additionally, higher costs due to helium partially offset an insurance recovery for Linde Advanced Materials Technology (LAMT), limiting the operating profit growth in that segment despite a 44% overall increase in operating profit for 'Other'.",
      "llm_answer": "In the 2022 filing, Linde’s “Other” segment – which includes its global helium‑wholesale business – generated $2.0 billion of sales but posted an operating loss of $56 million, indicating that helium (together with other small businesses) was a drag on profitability. By 2024 the same segment’s sales had fallen to $1.29 billion (a 2 % decline) and operating profit turned positive at $43 million; the filing notes that higher helium‑related costs ate into the profit, although insurance recoveries and other factors more than offset the loss. Thus, between 2022 and 2024 Linde’s helium business shrank in size and moved from being a loss‑making component to a cost‑center that reduced but did not eliminate overall segment profit.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. According to the ground truth, in 2024, lower helium volumes caused a 2% decrease in sales for the 'Other' segment—not a drop from $2.0 billion to $1.29 billion as claimed. The LLM incorrectly states specific dollar figures for sales and operating profit in both 2022 and 2024 that are not supported by the original answer. The ground truth does not provide segment-level sales or operating profit numbers for 2022 or 2024, nor does it state that the 'Other' segment had an operating loss of $56 million in 2022 or a profit of $43 million in 2024. These numbers are fabricated or hallucinated. (2) The 2% sales decline mentioned in the LLM answer is correctly attributed to helium's impact in 2024, which aligns with the ground truth, but the framing of a drop from $2.0B to $1.29B implies a ~35.5% decline, which contradicts the stated 2% decrease—this is a major calculation and factual inconsistency. Additionally, the claim that operating profit 'turned positive' is unsupported, as the ground truth only notes that helium-related costs partially offset an insurance recovery within a segment that saw a 44% increase in operating profit overall. (3) The multi-hop reasoning is partially sound in that the LLM attempts to trace the evolution of helium’s impact from 2022 to 2024 and links it to the 'Other' segment. It correctly infers that helium went from neutral/negative in 2022 to a cost pressure in 2024. However, it fails to accurately represent the nature of the impact—helium was not explicitly a 'drag' in 2022 per the original, and the 2024 impact was on profit growth limitation, not a reversal from loss to profit. (4) The contextual relevance is high because the answer addresses the evolution of Linde’s relationship with helium and its impact on sales and profit. However, due to severe quantitative inaccuracies and unsupported financial figures, the correctness score is low. The qualitative accuracy is moderate because the directional logic (helium becoming more costly and impacting profits) is plausible, but the reasoning is based on incorrect data. Quantitative accuracy is poor due to invented numbers and internal inconsistencies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 607,
        "total_tokens": 1939
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did the net value of acquired franchise rights evolve from 2022 to 2024, and what was the magnitude of this change?",
      "original_answer": "In 2022, the net value of acquired franchise rights was $789 million, while in 2024 it decreased to $598 million. This represents a significant decline in value over the two-year period.",
      "llm_answer": "The net carrying amount of acquired franchise rights slipped from **about $1.891 billion in 2022** to **about $1.858 billion in 2024**, a **decrease of roughly $33 million**.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in all key numerical values. The ground truth states the net value of acquired franchise rights was $789 million in 2022 and $598 million in 2024, representing a decrease of $191 million. The LLM reports $1.891 billion in 2022 and $1.858 billion in 2024, a decrease of $33 million—both figures are completely inconsistent with the ground truth. (2) The quantitative discrepancy is severe: the LLM's values are more than double the correct amounts, and the calculated change ($33M vs $191M) is off by over 80%. Even allowing for format variations (e.g., billion vs million), the numbers do not align—$1.891 billion is $1,891 million, which is vastly different from $789 million. (3) The qualitative reasoning appears structurally sound—identifying a decrease over time and calculating the difference—but it is based on entirely incorrect data, indicating a failure in multi-hop retrieval or entity-metric alignment. It likely confused 'acquired franchise rights' with another intangible asset or misattributed data from a different company or line item. (4) The contextual relevance is moderate because the answer addresses the right metric and time frame (2022 to 2024) and attempts to compute the change, but the factual foundation is entirely wrong, rendering the response misleading. Correctness and quantitative accuracy are therefore very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1083,
        "completion_tokens": 389,
        "total_tokens": 1472
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Chevron's natural gas delivery commitments and production volumes related to Tengizchevroil evolve from 2023 to 2024?",
      "original_answer": "In 2023, Chevron reported that its natural gas volumes included 596 million cubic feet per day consumed in operations and 7,148 million cubic feet per day as sold, which included its share from Tengizchevroil in Kazakhstan. By 2024, these figures increased to 609 million cubic feet per day consumed and 7,569 million cubic feet per day as sold, indicating a growth in both operational consumption and market delivery. This reflects an increase in Chevron’s involvement and dependency on Tengizchevroil for natural gas production and delivery commitments.",
      "llm_answer": "- **Natural‑gas delivery commitments:** In the 2023 filing Chevron pledged to deliver about 746 billion cubic feet (bcf) of U.S. natural gas (and 31 million barrels of NGLs) for 2024‑2026, and about 3.2 trillion cubic feet (tcf) from its Australian and Israeli operations for 2025‑2027. The 2024 filing raised the U.S. gas commitment to 813 bcf (with a lower NGL pledge of 25 million barrels) and reduced the overseas contract volume to 2.9 tcf for 2024‑2026【page_11 of 2023】【page_10 of 2024】.  \n\n- **Production tied to Tengizchevroil (Kazakhstan):** Net natural‑gas output attributed to the Kazakhstan segment – which includes Tengizchevroil – was essentially unchanged, falling only marginally from 114 million cubic feet per day (MMCFD) in 2023 to 113 MMCFD in 2024【page_9 of 2023】【page_9 of 2024】.  \n\nThus, while Chevron’s contractual gas deliveries increased in the United States and fell slightly abroad, the actual gas production from its Tengizchevroil‑related assets stayed flat, with a one‑million‑cubic‑feet‑per‑day dip.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to align with the ground truth in several critical ways. (1) Quantitative Accuracy: The numbers provided in the LLM answer do not match the ground truth. The original answer reports Chevron's total natural gas volumes (including Tengizchevroil) as 7,148 million cubic feet per day sold in 2023 and 7,569 million cubic feet per day in 2024, with operational consumption of 596 and 609 million cubic feet per day respectively. The LLM instead cites unrelated delivery commitments in trillions and billions of cubic feet for future periods (2024–2027), which are contractual obligations, not actual production volumes. These figures are not comparable and are factually irrelevant to the question about actual production and delivery volumes related to Tengizchevroil. Additionally, the LLM claims Tengizchevroil-related production fell from 114 to 113 MMCFD, which contradicts the ground truth that Tengizchevroil is a major contributor to much larger total volumes (over 7,000 MMCFD), suggesting the LLM misidentified the scale and scope of Tengizchevroil’s contribution. (2) Completeness: The question asks about how Chevron's natural gas delivery commitments and production volumes related to Tengizchevroil evolved from 2023 to 2024. The LLM fails to report the correct production volumes tied to Tengizchevroil and instead reports a narrow segment-level figure that does not reflect the full scale of Tengizchevroil’s output as included in Chevron’s total gas volumes. It also conflates long-term delivery contracts (mostly U.S. and Australia/Israel) with Tengizchevroil production, which is not supported by the ground truth. (3) Entity Accuracy: The LLM incorrectly isolates Tengizchevroil production to just 113–114 MMCFD, whereas the original answer clearly states that Tengizchevroil is a significant component of Chevron’s total reported gas volumes (over 7,000 MMCFD), meaning the LLM misrepresents the entity relationship. (4) Reasoning: The multi-hop reasoning is flawed. The LLM does not connect Tengizchevroil to the overall natural gas volumes reported by Chevron but instead treats it as a minor standalone asset with flat production. This contradicts the ground truth, which explicitly links the year-over-year increase in total gas sold (from 7,148 to 7,569 MMCFD) to growing reliance on Tengizchevroil. The LLM’s conclusion that production was 'flat' is therefore incorrect. (5) Semantic Equivalence: The LLM introduces unrelated data (long-term delivery contracts) and omits the core facts (actual production volumes and their increase), resulting in a substantively different and misleading answer. While the answer is structured and cites pages, the factual foundation is unsound. The contextual relevance is moderate because it discusses Chevron, natural gas, and Tengizchevroil, but the content is not aligned with the actual evolution of production and delivery volumes as required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 774,
        "total_tokens": 2165
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the role of Google Network partners in Google's advertising revenue model evolved between 2023 and 2024, based on changes in the way payments to these partners are described?",
      "original_answer": "In 2023, Google Network partners were described as part of the primary uses of cash from operating activities, specifically noting payments made to these partners as a standard operating expense. By 2024, the description evolved to categorize payments to Google Network partners under Traffic Acquisition Costs (TAC), explicitly linking them to ads displayed on partner properties and tying them directly to revenue generation. This shift indicates a more strategic and performance-based dependency on these partners within the advertising ecosystem.",
      "llm_answer": "In the 2023 filing, payments to Google Network partners were mentioned only as a line‑item within cost of revenues – “amounts paid to Google Network partners primarily for ads displayed on their properties” (2023 10‑K, Cost of Revenues) and as one of the primary cash outflows (2023 10‑K, Cash‑flow discussion).  \n\nBy the 2024 filing, Alphabet explicitly frames the relationship in accounting terms: it evaluates whether it is the principal or an agent for ads on Network properties and, when acting as principal, records the full amount billed to advertisers as revenue and the partner payouts as a cost of revenue (2024 10‑K, Advertising Revenues).  \n\nThus, the role of Network partners has shifted from being a generic cost component to a clearly defined partner‑payment relationship where Google may act as the principal, recognizing gross advertising revenue and treating partner payouts as a distinct cost of revenue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. It correctly identifies the evolution in how payments to Google Network partners are described between 2023 and 2024. In 2023, the answer accurately notes that payments were listed as a line item in cost of revenues and as a primary cash outflow in operating activities—consistent with the original answer's description of a standard operating expense. For 2024, the LLM correctly highlights the shift in accounting treatment, where Google evaluates whether it is the principal or agent, and when acting as principal, reports gross revenue and includes partner payouts as cost of revenue. This reflects the strategic reframing under Traffic Acquisition Costs (TAC), even though the term 'TAC' is not explicitly used. The omission of the label 'Traffic Acquisition Costs' is a minor shortcoming, but the substance—tying partner payments directly to revenue recognition and treating them as a distinct cost of revenue—is correctly conveyed. All entities (Google Network partners, 2023 and 2024 timeframes, cost of revenue, principal-agent evaluation) are accurate. There are no numerical inaccuracies (no specific numbers to verify, but descriptions of accounting treatments are correct). The reasoning is sound and demonstrates multi-hop synthesis across years and accounting concepts. The answer is contextually relevant and fully addresses the question about the evolution in the role and description of partner payments. The wording differs slightly from the original answer but maintains semantic equivalence. Thus, the correctness score is 9 due to the missing explicit mention of TAC, but all key factual and conceptual elements are present and accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 470,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the impact of public policies on Bank of America's climate-related regulatory requirements evolved from 2023 to 2024, particularly in terms of jurisdictional divergence and compliance risks?",
      "original_answer": "In 2023, Bank of America highlighted increasing global regulatory focus on climate change, noting that new or heightened regulatory requirements across state, federal, and non-U.S. jurisdictions were expected to increase legal, compliance, and public disclosure risks and costs. The company specifically mentioned jurisdictional divergence as a challenge. By 2024, this concern intensified, with the company noting that existing and pending disclosure requirements in various jurisdictions, along with jurisdictional divergence, were now actively impacting legal, compliance, and public disclosure risks and costs. This indicates a shift from anticipation of increased risk to experiencing tangible impacts due to evolving public policies.",
      "llm_answer": "In the 2023 Form 10‑K the Company warned that a “global regulatory focus on climate change… with jurisdictional divergence” was beginning to raise its **legal, compliance and public‑disclosure risks and costs** (2023 p. 24). By the 2024 filing the same theme re‑appears, but the language stresses that the **focus has intensified and the divergence is expanding**, so the **compliance burden and associated legal‑risk exposure are expected to grow further** (2024 p. 24). Thus, from 2023 to 2024 the impact of public‑policy climate rules has moved from an emerging concern to a heightened, more widespread compliance risk driven by increasingly divergent jurisdictional requirements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Bank of America's 2023 10-K noted increasing global regulatory focus on climate change with jurisdictional divergence raising legal, compliance, and public-disclosure risks (p.24), and the 2024 10-K confirmed that these pressures have intensified. The shift from 'expected to increase' risks in 2023 to 'actively impacting' risks in 2024 is accurately reflected in the LLM’s characterization of the evolution from 'emerging concern' to 'heightened, more widespread compliance risk.' (2) There are no numerical values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2023, 2024) and page references (p.24) match the source context. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, identifies the continuity and intensification of language, and infers the evolving impact of public policy. The only minor shortcoming is that the LLM says the 2024 risks are 'expected to grow further,' which slightly underemphasizes the ground truth point that impacts are already being felt (i.e., not just anticipated). However, this does not invalidate the overall correctness. (4) The answer is contextually precise, directly addressing jurisdictional divergence and compliance risks as required. Semantic equivalence is strong, with appropriate flexibility in wording. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 441,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has General Motors' strategic emphasis on full-size pickup trucks evolved from 2022 to 2024, and what quantitative indicators in 2024 suggest a shift toward stronger performance and market positioning for this product line?",
      "original_answer": "In 2022, General Motors identified the success of its full-size SUVs and full-size pickup trucks as a key risk factor, indicating that their performance was critical to the company's competitive position and financial health. By 2024, this strategic emphasis had evolved into a demonstrated strength, as evidenced by a significant increase in net wholesale volumes driven by higher sales of full-size pickup trucks. Additionally, the 2024 report highlights that full-size pickup trucks contributed favorably to the company's EBIT-adjusted results, with a variable profit of approximately 160% for trucks on a weighted-average basis, reflecting improved profitability and market demand for this product line.",
      "llm_answer": "In the 2022 filing GM’s management still framed full‑size pickup trucks as a strategic priority in its forward‑looking statements, noting that “the success of our current line of full‑size SUVs and full‑size pickup trucks” would be critical to future growth. By 2024 the discussion had moved from a qualitative outlook to concrete results: full‑size pickups (together with midsize pickups) were the primary driver of a 10.1 % rise in wholesale vehicle sales (3,464 k vs. 3,147 k in 2023), lifted the truck share of residual‑value units to 23.7 % (up from 21.9 %), and helped generate $16.1 billion of additional net sales (an 11.4 % YoY increase) and a higher EBIT‑adjusted margin of 9.2 % versus 8.7 % in 2023. These quantitative shifts signal that GM’s full‑size pickup strategy has moved from a stated focus to delivering stronger volume, mix and profitability performance.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution in GM's strategic emphasis from 2022 to 2024, noting a shift from framing full-size trucks as a critical success factor to demonstrating strong performance. This aligns with the ground truth. However, several key quantitative claims in the LLM answer are not supported by the original answer and appear to be fabricated or misattributed. (2) The original answer mentions a 'significant increase in net wholesale volumes' and 'variable profit of approximately 160% for trucks on a weighted-average basis' in 2024, but does not provide specific figures such as a 10.1% rise in wholesale sales (3,464k vs 3,147k), 23.7% truck share of residual-value units, $16.1 billion additional net sales, or EBIT-adjusted margin of 9.2% vs 8.7%. These numbers are absent in the ground truth and cannot be verified; thus, they represent significant quantitative inaccuracies. The 160% variable profit metric is entirely missing from the LLM response, which undermines a core quantitative indicator from the original. (3) The multi-hop reasoning is sound in structure—comparing 2022 risk framing to 2024 performance outcomes—but fails in execution because it substitutes unverified metrics instead of accurately reporting the specific profitability data (160% variable profit) that was the key 2024 indicator. The synthesis across years is logical but based on incorrect data. (4) The contextual relevance is perfect—the answer directly addresses the evolution and quantitative indicators. Qualitative accuracy is high due to correct entity identification (GM, full-size pickups, 2022–2024), proper framing of strategic shift, and logical interpretation. However, quantitative accuracy is low due to inclusion of unsupported numbers, dragging down the overall correctness score to 7, as the core financial evidence is misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 509,
        "total_tokens": 1925
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the allocation to U.S. Treasury and government agency securities within the nuclear decommissioning trusts evolve from 2022 to 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2022, the allocation to U.S. Treasury and government agency securities was $21 million for Alabama Power and $293 million for Georgia Power. By 2024, this allocation decreased slightly to $20 million for Alabama Power but increased significantly to $349 million for Georgia Power. The overall trend shows a shift in focus toward Georgia Power’s portfolio, indicating a possible reallocation of safer, fixed-income assets to that subsidiary.",
      "llm_answer": "- 2022 (2022 Form 10‑K): The nuclear‑decommissioning trusts reported essentially no U.S. Treasury or government‑agency securities – the line item was either $0 or a negligible amount.  \n\n- 2023 (2023 Form 10‑K): The trusts began holding Treasury‑type assets again – Alabama Power’s trust held **$20 million** and Georgia Power’s trust held **$349 million** of U.S. Treasury and government‑agency securities.  \n\n- 2024 (2024 Form 10‑K): The disclosed amount for Treasury/agency securities fell to **$9 million** (the only figure shown for the trusts in the 2024 filing).  \n\n**Interpretation:** The company moved from virtually no Treasury exposure in 2022 to a sizable allocation in 2023, then sharply reduced that exposure in 2024.  This pattern indicates a strategic shift away from low‑yield, highly liquid Treasury and agency securities toward higher‑yielding corporate, private‑equity and other fixed‑income investments within the decommissioning trusts.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Alabama Power had $21 million and Georgia Power had $293 million in U.S. Treasury and government agency securities, not 'essentially no' or negligible amounts as claimed. The LLM incorrectly states that in 2024, the amount fell to $9 million (the only figure shown), which contradicts the ground truth showing $20 million for Alabama Power and $349 million for Georgia Power in 2024. The 2023 figures of $20 million and $349 million are accurate but misattributed to 2023 instead of 2024. (2) Quantitative accuracy is severely compromised: the 2022 values are wrong (should be $21M and $293M, not ~$0), the 2024 value is incorrect ($9M vs actual $20M and $349M), and the trend is misrepresented. The LLM also fails to report both company values in 2024, collapsing them into a single $9M figure not supported by the truth. (3) The multi-hop reasoning is flawed: the LLM infers a strategic shift toward higher-yielding assets due to a drop in Treasury exposure, but the ground truth shows an overall increase in allocation, especially for Georgia Power, suggesting greater emphasis on safe assets, not less. The conclusion is therefore the opposite of what the data supports. (4) Contextual relevance is moderate—the answer addresses the evolution and interpretation of investment strategy—but due to incorrect data and reversed trends, the analysis is misleading. The structure is clear, but factual errors undermine validity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 423,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has PepsiCo's relationship with independent bottlers evolved from 2022 to 2024 in terms of financial incentives and strategic dependency?",
      "original_answer": "In 2022, PepsiCo provided sales incentives and discounts to independent bottlers primarily through funding of advertising and other marketing activities, with accruals based on annual targets and historical experience. By 2024, the company's relationship had evolved into a more structured dependency, with bottler funding negotiated annually and specifically allocated across trade and consumer programs such as advertising support, new product launches, and vending equipment placement. Additionally, in 2024, sales through independent bottlers contributed to a significant portion of revenue, with Walmart alone accounting for approximately 14% of consolidated net revenue, highlighting increased strategic dependency on these bottlers.",
      "llm_answer": "In the 2022 filing PepsiCo described its independent bottlers as exclusive‑contract partners that receive “bottler funding” each year – a sales‑incentive program that is negotiated on an annual‑target basis and accrued for advertising, new‑product launches, cooler‑equipment placement and other trade‑and‑consumer programs 【page_60】.  \n\nBy the 2024 filing the same annual‑target‑based bottler‑funding mechanism is still in place, but PepsiCo now stresses that its bottlers are a critical conduit for serving its largest retail customers – for example, sales to Walmart and its affiliates represented roughly 14 percent of consolidated net revenue in 2024, and those sales flow through the bottlers’ finished‑goods operations 【page_9】. This reflects a shift toward a stronger strategic dependency on independent bottlers to reach key retailers while maintaining the same incentive‑funding structure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the annual-target-based bottler funding mechanism in 2022 and 2024, its allocation to advertising, new product launches, and equipment placement, and the 14% of consolidated net revenue from Walmart in 2024 flowing through bottlers. The mention of page citations adds credibility. (2) Quantitative accuracy is perfect: the 14% figure is correctly cited and attributed to 2024, matching the original answer. No calculations are required, but the numeric claim is precise and consistent. (3) Multi-hop reasoning is sound: the LLM correctly synthesizes information across years (2022 to 2024) and entities (PepsiCo, independent bottlers, Walmart), identifying both continuity in incentive structure and evolution in strategic dependency. (4) The only minor shortcoming is that the original answer notes a shift toward 'more structured dependency' with funding 'specifically allocated' across programs in 2024, which the LLM implies but does not explicitly emphasize as an evolution in structure—though it does note the continued mechanism. This slight omission in nuance prevents a perfect 10 on qualitative accuracy. Otherwise, the answer is factually complete, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 371,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has Adobe Firefly's role within Adobe's product innovation strategy evolved from 2023 to 2024, based on its positioning in the company's trademark listings and risk disclosures?",
      "original_answer": "In 2023, Adobe Firefly was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Firefly was specifically highlighted in the risk factors section as a newly released generative AI product, reflecting its strategic importance in Adobe's innovation efforts. This evolution shows a shift from being a registered brand to becoming a central part of Adobe's forward-looking product development and AI strategy, with explicit mention of its role in addressing market demands for generative AI capabilities.",
      "llm_answer": "In the 2023 Form 10‑K, Adobe mentions Firefly only in the risk‑factor narrative – it is described as a “new generative‑AI product” whose success, adoption and monetization are still uncertain. By the 2024 Form 10‑K, Firefly is listed among Adobe’s registered trademarks and is again cited in the risk‑factor section, this time as a core element of Adobe’s AI‑driven product‑innovation platform and a source of regulatory, reputational and competitive risk. The change from a tentative new offering to a trademark‑protected, strategically‑central AI service shows that Firefly’s role has moved from experimental to a cornerstone of Adobe’s product‑innovation strategy.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains a critical factual reversal: it incorrectly states that in 2023, Firefly was mentioned only in the risk factors as a 'new generative-AI product', while the ground truth confirms that in 2023, Firefly was listed among trademarks, not in risk factors. Conversely, the LLM claims that in 2024, Firefly was added to trademarks, but the truth is it was already trademarked in 2023 and was newly highlighted in 2024 risk disclosures as a strategic generative AI product. This inversion of the timeline and document locations severely undermines the factual accuracy. While the overall narrative about Firefly becoming more central to Adobe's strategy aligns with the ground truth, the reasoning is based on incorrect sourcing. There are no numerical values to assess, so quantitative accuracy is not applicable but assumed correct by default. The qualitative accuracy is low due to the misattribution of information across years and sections (trademarks vs. risk factors), which breaks the multi-hop logic. Contextual relevance is moderate because the answer addresses the right topic and infers strategic evolution, albeit with incorrect evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 327,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of contractual rent escalations in driving tenant billing growth changed between 2022 and 2023, particularly in light of the increased churn and lease cancellations in 2023?",
      "original_answer": "In 2022, contractual rent escalations were highlighted as a key factor contributing to tenant billing growth, listed alongside new colocation activity and lease amendments. By 2023, while contractual rent escalations remained a stated driver of growth, the context shifted due to an elevated churn rate of approximately 3%, primarily in the U.S. & Canada segment. This churn, expected to remain elevated through 2025 due to T-Mobile's lease cancellations, introduced a countervailing force against the positive impact of rent escalations, suggesting a more challenging environment for maintaining organic revenue growth solely through escalations.",
      "llm_answer": "In the 2022 filing the company identified **contractual rent escalations on existing leases (net of churn)** as one of the three main drivers of tenant‑billing growth 【page_33】. The 2023 filing repeats the same driver, but adds that **churn rose to about 3 % of tenant billings – driven by T‑Mobile’s contractual lease cancellations and non‑renewals – which dampens the net effect of those escalations** 【page_35】. Thus, while rent escalations remain a core source of billing growth, their contribution in 2023 is offset to a greater extent by higher churn and lease terminations than in 2022.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that contractual rent escalations were a key driver of tenant billing growth in both 2022 and 2023, and accurately notes the increased churn in 2023 (approximately 3%) as a dampening factor, specifically tied to T-Mobile's lease cancellations and non-renewals. This aligns with the ground truth, which emphasizes the countervailing effect of churn on escalations. (2) Quantitatively, the 3% churn rate is correctly reported, and no other numerical inaccuracies are present. The reference to 'page_35' for 2023 and 'page_33' for 2022 supports the sourcing, though page numbers are not part of the ground truth verification; however, they do not affect factual accuracy. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years, identifies the continuity of rent escalations as a growth driver, and contrasts it with the new context of elevated churn. It captures the nuanced shift in impact due to external factors (T-Mobile), demonstrating strong qualitative reasoning. (4) The only minor shortcoming is that the original answer specifies the churn is 'primarily in the U.S. & Canada segment' and that it is 'expected to remain elevated through 2025', which the LLM answer omits. While the core dynamics are accurately conveyed, this contextual detail slightly reduces completeness, justifying a 9 instead of 10 on qualitative accuracy and overall correctness. Otherwise, the answer is factually correct, well-reasoned, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 426,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Chevron's (CVX) relationship with Tengizchevroil evolved between 2023 and 2024 in terms of capital expenditure commitments and production involvement?",
      "original_answer": "In 2023, Chevron indicated that nearly half of its Affiliate Capex, which was expected to be $3 billion in 2024, was allocated to Tengizchevroil's FGP/WPMP Project in Kazakhstan. By 2024, Chevron continued to highlight its production involvement with Tengizchevroil, noting that production volumes included Chevron's share from affiliates such as Tengizchevroil in Kazakhstan. While 2023 focused on capital commitments for project development, 2024 emphasized ongoing production contributions from the same entity, indicating a shift from investment to operational phase.",
      "llm_answer": "In 2023 Chevron’s affiliate‑level capital program was $3.5 billion, with roughly one‑half earmarked for Tengizchevroil’s FGP/WPMP project in Kazakhstan.  For 2024 the company expects affiliate capex of about $3 billion, again with “nearly half” directed to the same Tengizchevroil project, indicating a modest reduction in total spend but a continued, roughly equal share of investment.  Production from the Kazakhstan joint‑venture – reported as about 45 thousand barrels of oil‑equivalent per day – was essentially unchanged between 2023 and 2024, showing that Chevron’s operating involvement remained steady while its capital commitment was slightly scaled back.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. The original answer states that Chevron expected $3 billion in Affiliate Capex in 2024, with nearly half allocated to Tengizchevroil. The LLM incorrectly states that the 2023 affiliate capex was $3.5 billion (ground truth does not specify the 2023 total capex amount, only that nearly half of the expected $3B 2024 capex was for Tengizchevroil). The LLM also introduces a specific production figure of '45 thousand barrels of oil-equivalent per day' that is not present in the original answer, nor supported by the ground truth provided. This is a significant fabrication. (2) The calculation of 'nearly half' is used correctly in context, but the base figures are wrong. The LLM implies a modest reduction from $3.5B to $3B in affiliate capex, but the original answer only specifies the $3B figure for 2024 and does not provide 2023’s total—thus the comparison is unsupported. The production volume number is entirely invented. (3) The reasoning partially captures the multi-hop evolution: it notes continued investment in Tengizchevroil across both years and infers a sustained operational role. However, it misses the key qualitative shift emphasized in the original answer—from a 2023 focus on capital commitments for project development to a 2024 emphasis on production contributions, signaling a transition to an operational phase. Instead, the LLM concludes that operating involvement 'remained steady' and capital 'slightly scaled back,' which misrepresents the strategic evolution. (4) The contextual relevance is high because the answer addresses both capital expenditure and production involvement for CVX and Tengizchevroil across 2023–2024. However, due to incorrect numbers and a lack of accurate synthesis of the strategic shift, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the general direction of reasoning is sound, but the conclusion is not fully aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 555,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the specificity of UPS's bond matching approach evolved in determining the discount rate for U.S. pension and postretirement benefit plans between 2023 and 2024?",
      "original_answer": "In 2023, UPS described using a bond matching approach to select specific bonds that would satisfy projected benefit payments, emphasizing its belief that this method reflects the process they would employ to settle pension and postretirement obligations. By 2024, the language evolved to place stronger emphasis on the bond matching approach as a guide for selecting bonds that align with projected benefit cash flows, without any material change in the mechanics of the method. However, the 2024 disclosure included a more precise statement indicating that the approach 'guides' the selection process, suggesting a subtle shift in how the policy is framed operationally, even though the underlying practice remained consistent.",
      "llm_answer": "Both the 2023 and 2024 filings state that UPS determines the discount rate for its U.S. pension and post‑retirement benefit plans by “using a bond‑matching approach to select specific bonds that would satisfy our projected benefit payments.” The language is identical in the two years, indicating that the level of specificity of the bond‑matching methodology has not changed – UPS continues to rely on the same bond‑matching concept to set the discount rate.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that the language in the 2023 and 2024 filings is identical. The ground truth states that while the underlying mechanics of the bond-matching approach did not change, the 2024 disclosure evolved to use more precise language, stating that the approach 'guides' the selection of bonds, reflecting a subtle but meaningful shift in operational framing. The LLM incorrectly asserts that the wording is identical, which contradicts the original answer and misses the key evolution in specificity and disclosure nuance. There are no numerical values in this question, so quantitative accuracy is not applicable—however, the model did not fabricate any numbers, so it scores high on that dimension by default. The reasoning is flawed because it fails to recognize the qualitative shift in language and framing between years, indicating a failure in multi-hop or close textual analysis. While the answer addresses the general topic (bond matching for discount rates), it incorrectly concludes no change occurred, making it partially relevant but factually inaccurate. Thus, the correctness and qualitative accuracy scores are low due to a critical misrepresentation of the disclosed language evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 348,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what financial impact did this change have on the company's sales and operating profit during this period?",
      "original_answer": "In 2022, helium was a supply input for Linde, indicating a supportive role in operations. By 2024, helium had a negative impact on operations, with a $32 million, or 2%, decrease in sales for the Other segment primarily due to lower volumes in global helium and LAMT. Additionally, helium-related costs contributed to downward pressure on operating profit, partially offset by an insurance recovery for LAMT. This reflects a shift from a neutral or positive relationship to one that posed operational challenges.",
      "llm_answer": "By 2022 Linde’s helium business was simply bundled inside the “Other” category and was not highlighted as a material driver of results. In the 2024 filing the company spells out that “global helium wholesale” is part of Other, and that lower helium volumes caused the segment’s sales to fall $32 million (‑2 %) versus 2023, while operating profit rose $19 million (+44 %) – the profit gain coming from an insurance recovery that was partially offset by the higher helium‑related costs【page_28】. Thus, between 2022 and 2024 the helium relationship shifted from a background line‑item to a disclosed volume‑driven decline in sales, with only a modest impact on overall operating profit because other items more than compensated for the helium‑related cost increase.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the shift in Linde's relationship with helium from 2022 to 2024, noting that helium evolved from a background item to a disclosed factor affecting sales. It accurately states the $32 million (2%) decrease in sales for the Other segment due to lower helium volumes, aligning with the ground truth. However, it introduces a significant inaccuracy by claiming operating profit rose $19 million (+44%) in 2024 due to an insurance recovery, which is not supported by the original answer. The ground truth states that helium had a negative impact on operating profit, with costs applying downward pressure—only partially offset by insurance recovery. The LLM incorrectly frames this as a profit increase, which contradicts the negative financial impact described in the original. (2) The $32 million sales decline and 2% decrease are correctly reported. However, the $19 million operating profit increase is unsupported and likely fabricated or misattributed; no such figure appears in the ground truth. This is a critical quantitative error affecting the financial interpretation. (3) The multi-hop reasoning is partially sound: the model connects helium’s role across years and segments, and correctly infers increased disclosure and operational significance. However, it fails to accurately synthesize the net impact on profitability, incorrectly concluding profit rose when the original emphasizes downward pressure. This undermines the reasoning chain. (4) Despite the major error in operating profit, the answer captures the evolution in helium’s strategic role and correctly identifies the sales impact, maintaining relevance and partial accuracy. Hence, a score of 7 is justified—core facts on sales are correct, but key profit claims are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 486,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did Bank of America's unfunded capital contributions for renewable energy investments evolve between 2023 and 2024, and what was the corresponding change in recognized tax credits related to these investments?",
      "original_answer": "In 2023, Bank of America had unfunded capital contributions for renewable energy investments of $6.2 billion, and it recognized tax credits and other tax benefits of $4.0 billion. By 2024, the unfunded capital contributions decreased to $4.6 billion, and the recognized tax credits slightly declined to $3.9 billion. This indicates a reduction in the Corporation's near-term funding commitments to renewable energy projects, even as the tax benefits remained relatively stable.",
      "llm_answer": "Bank of America’s unfunded capital commitments for renewable‑energy projects dropped from **$6.2 billion in 2023 to $4.6 billion in 2024** (a $1.6 billion reduction).  In the same period, the tax credits it recognized on those investments fell modestly, from **about $4.0 billion in 2023 to $3.9 billion in 2024** (a $0.1 billion decline).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: unfunded capital contributions decreased from $6.2 billion in 2023 to $4.6 billion in 2024, and recognized tax credits declined from $4.0 billion to $3.9 billion. The calculated differences ($1.6 billion and $0.1 billion) are correct. (2) The answer is complete, addressing both parts of the question: the evolution of unfunded capital contributions and the corresponding change in tax credits. (3) Entities are correctly identified—Bank of America, the correct years (2023 and 2024), and the correct financial metrics (unfunded capital contributions and recognized tax credits). (4) The reasoning is sound and reflects proper multi-hop synthesis across time points and financial metrics. The slight decline in tax credits despite a larger drop in commitments is accurately conveyed. (5) The semantic meaning is equivalent to the original answer, with clear, concise presentation and no factual or interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 297,
        "total_tokens": 1518
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has General Motors' approach to fleet sales involving commercial fleet customers evolved from 2022 to 2024, particularly in terms of sales channels and profitability considerations?",
      "original_answer": "In 2022, General Motors highlighted that fleet transactions, especially sales to daily rental car companies, were generally less profitable compared to retail sales, and these vehicles were sold either directly or through the dealer network. By 2024, the company emphasized that fleet sales, including those to commercial fleet customers, were completed through the dealer network and in some cases directly with fleet customers, suggesting a more structured and possibly optimized approach to fleet sales. This evolution indicates a strategic shift toward balancing fleet sales with profitability by leveraging both direct and dealer-based channels.",
      "llm_answer": "In the 2022 filing GM explained that fleet sales – to rental‑car firms, commercial fleets, leasing companies and governments – are made “directly or through our dealer network,” and it explicitly warned that “certain fleet transactions, particularly sales to daily‑rental car companies, are generally less profitable than retail sales.” The 2024 filing repeats the same channel description (“through the dealer network and in some cases directly with fleet customers”) but drops the specific comment about lower profitability, indicating that GM continues to use both dealer and direct channels for commercial fleets while no longer emphasizing fleet‑sale profitability concerns as a distinct issue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, GM noted fleet sales (especially to daily rental companies) were less profitable than retail and used direct or dealer-based channels. In 2024, the channel description remains consistent—through dealers and sometimes directly—but the explicit warning about lower profitability is omitted, which the LLM correctly observes. This reflects a nuanced evolution in tone and strategy, consistent with the original answer’s claim of a more structured approach. (2) There are no numerical values requiring calculation, but all dates (2022, 2024) and entities (General Motors, fleet customers, dealer network) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, compares language changes, and infers a strategic shift in how GM communicates about profitability—moving from explicit concern to neutral description, suggesting improved optimization. (4) The only minor shortcoming is that the LLM does not explicitly state that this shift may indicate a strategic effort to balance fleet volume with profitability, as implied in the original answer. However, the omission of the profitability caveat in 2024 and continued use of dual channels strongly supports that interpretation, so the core insight is preserved. Wording differs slightly but maintains semantic equivalence. Thus, the answer is factually correct, complete, and contextually appropriate, meriting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 423,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did PepsiCo's relationship with Sabra evolve between 2022 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2022, PepsiCo owned the Sabra brand as part of its joint venture portfolio. However, by 2024, PepsiCo no longer had full ownership but instead held a 50% equity stake, which was remeasured at fair value, resulting in a pre-tax gain of $122 million. This indicates that PepsiCo divested a portion of its ownership in Sabra during the intervening period, marking a strategic shift in its relationship with the brand.",
      "llm_answer": "In the 2022 Form 10‑K PepsiCo still owned 50 % of the Sabra joint‑venture; the year‑end fair‑value re‑measurement of that stake produced a pre‑tax gain of **$122 million (about $92 million after‑tax)** that was recorded in the FLNA division’s selling‑, general‑ and administrative expense line. By the 2024 filing the Sabra investment is no longer shown as an equity holding (the gain disappears from the segment tables), indicating that PepsiCo has sold or otherwise exited its 50 % interest, eliminating the Sabra‑related gain (and any future earnings or losses from that joint‑venture).",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors that contradict the ground truth. According to the original answer, PepsiCo owned Sabra fully in 2022 as part of a joint venture and then retained a 50% stake by 2024, recognizing a $122 million pre-tax gain from remeasuring that remaining stake at fair value. However, the LLM claims PepsiCo already owned only 50% in 2022 and then fully exited by 2024—this reverses the actual ownership trajectory. This is a major factual inversion. (2) Quantitatively, the $122 million pre-tax gain is correctly stated, and the after-tax estimate of $92 million is a reasonable inference, so some numerical accuracy is present. However, the claim that the gain 'disappears from segment tables' in 2024 is unsupported and contradicts the premise that a gain would be recognized upon partial divestment in the transition period, not continued reporting. (3) The multi-hop reasoning is flawed: the model incorrectly infers disposal of the entire stake by 2024, whereas the truth is PepsiCo retained 50% and only changed the accounting treatment due to a remeasurement event. The logic of 'no longer shown as an equity holding' leading to 'exited interest' is unsupported by the provided truth. (4) Contextual relevance is moderate—the answer addresses the right topic (Sabra, equity stake, financial impact) and cites appropriate financial reporting lines, but the core narrative about the evolution of the relationship is backwards. Thus, despite some correct details, the overall correctness is low due to a fundamental error in directionality and ownership timeline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 443,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Adobe's treatment of Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's product ecosystem?",
      "original_answer": "In 2023, Adobe Scan was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Scan was explicitly positioned as part of Adobe Document Cloud, which includes Acrobat, Acrobat Sign, and other apps and API services that support digital document and signature workflows. This evolution shows a shift from mere trademark recognition to a more integrated and strategically emphasized role within Adobe’s broader document management and productivity offerings.",
      "llm_answer": "In the 2023 Form 10‑K (pages 94‑98) Adobe’s product overview does not call out Adobe Scan at all, implying it was treated only as a minor component of the broader Acrobat/Document Cloud suite. By the 2024 Form 10‑K, Adobe Scan is described explicitly as a **free mobile‑only app** that “captures paper documents … and transforms them into full‑featured PDFs via Adobe Document Cloud services” and is listed alongside Acrobat Reader as a separate download 【page_13】. Thus, Adobe moved Scan from an unmentioned background feature in 2023 to a distinct, free‑download app positioned within the Document Cloud ecosystem in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth in substance, with only minor differences in emphasis. (1) Quantitative accuracy: No numerical data (dates, dollar amounts, etc.) are incorrect; the years 2023 and 2024 are correctly referenced. (2) Completeness: The answer addresses both years and the evolution in Adobe Scan’s positioning—correctly noting its absence in the 2023 product overview and explicit mention in 2024 as a free mobile app integrated into Document Cloud. This captures the core of the multi-hop comparison. (3) Entity accuracy: 'Adobe Scan', 'Adobe Document Cloud', 'Acrobat Reader', and correct Form 10-K years (2023 and 2024) are all accurately identified. (4) Reasoning: The inference that being unmentioned in 2023 implies a background or minor role is reasonable given the context, and the shift to explicit positioning in 2024 reflects correct synthesis across filings. The LLM adds useful detail (e.g., 'free mobile-only app', 'transforms into full-featured PDFs') from the source that enriches the answer. (5) Semantic equivalence: While the original answer emphasizes trademark status in 2023 and strategic integration in 2024, the LLM focuses on visibility in the 10-K and functional positioning. Both reflect a progression in strategic emphasis. The only minor gap is that the LLM does not mention the trademark status in 2023 (present in ground truth), but it compensates by correctly inferring lower prominence. Overall, the answer is highly accurate, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 427,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has General Motors' financial exposure and nature of obligations to Stellantis evolved from 2022 to 2024, particularly regarding indemnifications and historical liabilities?",
      "original_answer": "In 2022, General Motors continued to have supply-related transactions with Stellantis following the sale of the Opel/Vauxhall business, indicating an ongoing operational relationship. By 2024, the nature of GM's exposure to Stellantis had shifted from operational supplies to financial guarantees and indemnifications tied to legacy liabilities. Specifically, GM had agreed to indemnify Stellantis for certain emissions-related lawsuits, Takata-related recalls, and potential penalties from European regulatory investigations into end-of-life vehicle practices. Additionally, as of December 31, 2024, GM had accrued an immaterial amount related to these matters, showing a continued but reduced financial exposure compared to earlier liabilities. This reflects a transformation from active supply chain involvement to a more passive, indemnification-based financial relationship.",
      "llm_answer": "In the 2022 filing GM disclosed that, after selling the Opel/Vauxhall business to PSA Group (now Stellantis), it had entered into a guarantee and indemnification agreement that required the “Seller” to reimburse Stellantis for any losses arising from inaccurate representations, covenant breaches, emissions, product‑liability or recall claims – all subject to time limits, thresholds and caps, and GM said it could not estimate any material loss from those obligations. By the 2024 filing the same indemnification framework remains in place, but GM now notes that it has already paid an **immaterial** amount to cover certain Stellantis recalls (including Takata‑related work) and that any additional indemnification would be “remote,” while still being unable to quantify any material exposure. Thus the nature of the obligation has not changed, but the exposure has narrowed to a small, recognized amount with the remaining risk still unquantifiable.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that GM sold Opel/Vauxhall to PSA Group (now Stellantis) and entered into indemnification agreements covering emissions, product liability, recalls (including Takata), and regulatory issues. The 2024 update noting an immaterial amount paid and remaining exposure as 'remote' matches the original answer's statement that GM accrued an immaterial amount as of December 31, 2024. (2) There are no numeric discrepancies—'immaterial' is used consistently in both answers, and no specific dollar figures are misstated. The LLM correctly notes that GM could not estimate a material loss, which is consistent with the ground truth's implication of unquantifiable but reduced exposure. (3) The multi-hop reasoning is sound: it connects the 2022 operational relationship to the 2024 shift toward passive indemnification, correctly interpreting the evolution in nature and exposure. The only minor shortcoming is that the LLM does not explicitly mention the European regulatory investigations into end-of-life vehicle practices, which is a small omission affecting completeness. (4) Despite this, the core facts, timeline, entities (GM, Stellantis, Takata, Opel/Vauxhall), and financial nature of obligations are all accurately conveyed. The answer is contextually relevant, directly addressing the evolution from 2022 to 2024 in both exposure and obligation type.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1465,
        "completion_tokens": 400,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has PepsiCo's relationship with co-packers evolved between 2022 and 2024, particularly in terms of operational dependency and strategic involvement?",
      "original_answer": "In 2022, PepsiCo described its relationship with co-packers as part of a 'highly distributed network of plants, warehouses and distribution centers' that are owned or leased by these third parties, indicating an operational dependency. By 2024, the company's language shifted to emphasize co-packers as part of 'strategic alliances or joint ventures in which we have an equity interest,' suggesting a more active and ownership-based strategic involvement. This evolution reflects a shift from a primarily operational partnership to a more integrated and strategic stake in co-packers.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K filings state that PepsiCo does not own all of the plants that make its products; instead it “utilizes a highly distributed network of plants, warehouses and distribution centers that are owned or leased by our contract manufacturers, **co‑packers**, strategic alliances or joint‑venture partners in which we have an equity interest.” The language is essentially unchanged, indicating that PepsiCo’s operational dependency on co‑packers has remained steady. What has grown, however, is the emphasis on the **strategic nature** of those relationships—by 2024 the filing highlights the equity stakes and joint‑venture structures, showing that co‑packers are not just service providers but also partners in PepsiCo’s broader growth strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains a critical factual inaccuracy in its core claim about the consistency of language between 2022 and 2024. The LLM asserts that the language in both years' 10-K filings is 'essentially unchanged,' quoting a combined description that includes 'strategic alliances or joint-venture partners in which we have an equity interest' as part of the 2022 disclosure. However, according to the ground truth, in 2022 PepsiCo described co-packers as part of a 'highly distributed network... owned or leased by these third parties,' without mention of equity interest or strategic alliances. The shift in 2024 to include 'strategic alliances or joint ventures in which we have an equity interest' represents a meaningful evolution in language and strategy that the LLM incorrectly downplays. While the LLM correctly identifies the increased strategic emphasis by 2024, it fails to acknowledge the absence of equity language in 2022, undermining the multi-hop reasoning required to detect change over time. There are no numerical errors (hence high quantitative accuracy), and the answer is contextually relevant, addressing both operational dependency and strategic involvement. However, the qualitative inaccuracy in entity-year attribution and reasoning significantly reduces the correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 369,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did SPG's financial relationship with ABG evolve between 2023 and 2024, particularly in terms of gains recognized and strategic investments?",
      "original_answer": "In 2023, SPG recognized multiple non-cash pre-tax gains related to its relationship with ABG, including $59.1 million from deemed disposals due to ABG's capital transactions and $157.1 million from the sale of a portion of its ABG interests. Additionally, SPG recorded a $145.8 million gain from the dilution of its ownership in SPARC Group. In 2024, SPG disclosed a pre-tax gain of $18.8 million from the sale of a portion of its ABG interest in December 2021, along with a strategic partnership with ABG to become the core licensee and operating partner for Reebok in the U.S., indicating a shift toward deeper operational collaboration rather than just financial transactions.",
      "llm_answer": "In 2023 Simon & Schuster (SPG) was still a minority partner in ABG.  The company sold a portion of its ABG stake in November 2023, recognizing a pretax gain of **$157.1 million**, and the series of ABG‑initiated capital transactions that diluted its ownership to about 9.6 % produced **non‑cash pretax gains of roughly $59 million** from deemed disposals.  \n\nIn 2024 SPG ended the relationship entirely, selling its **remaining ABG interest for $1.2 billion**, which generated a **pretax gain of $414.8 million** (after $103.7 million of tax expense).  Thus the partnership moved from modest partial divestitures and dilution‑related gains in 2023 to a full cash exit and a substantially larger gain in 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that severely undermine its correctness. (1) Quantitatively, while the $157.1 million gain from the sale of a portion of SPG's ABG interest in 2023 is correct, the $59 million figure (rounded from $59.1 million) is acceptable but presented imprecisely. However, the claim that SPG sold its remaining ABG interest in 2024 for $1.2 billion, generating a $414.8 million pre-tax gain, is entirely incorrect and contradicts the ground truth. The original answer states that in 2024, SPG disclosed an $18.8 million gain from the sale of a portion of its ABG interest — but this sale occurred in *December 2021*, not 2024. The LLM falsely infers a full exit in 2024, which is not supported. (2) The ground truth mentions a $145.8 million gain from dilution in SPARC Group in 2023 — a key financial event omitted entirely by the LLM. (3) Qualitatively, the LLM misrepresents the evolution of the relationship: instead of recognizing a shift toward strategic operational collaboration (e.g., Reebok partnership), it claims a full termination of the relationship, which is the opposite of the truth. The strategic partnership with ABG to become the core licensee for Reebok in the U.S. — a critical qualitative shift — is completely missed. (4) Contextually, the answer addresses financial gains but fails to capture the strategic evolution emphasized in the question. The multi-hop synthesis is flawed: it incorrectly links past transactions to 2024 and invents a large cash exit unsupported by the data. Overall, core facts are wrong, calculations are fabricated, and strategic context is misrepresented, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 458,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Lockheed Martin's involvement in Sikorsky helicopter programs evolved from 2022 to 2024, particularly in terms of production volume and program scope?",
      "original_answer": "In 2022, Lockheed Martin's RMS segment experienced a $560 million increase in product costs, partly due to higher production volume on various Sikorsky helicopter programs. By 2024, RMS explicitly listed Sikorsky helicopter programs—such as those related to the Black Hawk, Seahawk, and CH-53K King Stallion—as key components of its portfolio, indicating a continued and potentially expanded focus. This evolution reflects a shift from being a cost driver to being a clearly defined strategic product line within the RMS segment.",
      "llm_answer": "- In the 2022 Form 10‑K (covering 2021 results) Lockheed Martin noted that “higher production volume on various Sikorsky helicopter programs” added about **$735 million** to RMS product sales, showing a clear increase in the amount being built.  \n\n- The 2024 Form 10‑K still lists Sikorsky helicopters as a core RMS program, but the description now covers a **broader set of models** – Black Hawk, Seahawk, CH‑53K King Stallion, the Combat Rescue Helicopter and, for the first time, the **VH‑92A Marine One** (final delivery in 2024). This indicates that while production continues, the scope of Lockheed Martin’s involvement has expanded to include additional Sikorsky platforms and the completion of the Marine One contract, even though the filing does not repeat the earlier dollar‑volume figure.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the evolution of Lockheed Martin's involvement in Sikorsky helicopter programs from 2022 to 2024, noting increased production volume in 2022 and expanded program scope by 2024, including new platforms like the VH-92A Marine One. This aligns with the ground truth's emphasis on a shift from cost driver to strategic product line. However, there is a significant discrepancy in the quantitative claim: the LLM states a $735 million increase in product sales in 2022, while the ground truth reports a $560 million increase in product costs (not sales). This misrepresents both the magnitude and nature of the financial impact (sales vs. costs), which is a critical error. 2) The dollar amount is incorrect—$735M vs. $560M—and the metric is misrepresented (sales vs. costs). No calculation is performed, but the cited figure is factually wrong. 3) The qualitative reasoning is strong: the LLM correctly infers expanded program scope by identifying additional helicopter models in the 2024 portfolio, including the VH-92A, which supports the conclusion of broader involvement. It appropriately synthesizes information across years and programs, demonstrating sound multi-hop logic. 4) Despite the numerical inaccuracy, the overall narrative of increased strategic focus and program expansion is consistent with the ground truth. The contextual relevance is perfect—the answer directly addresses production volume and program scope as asked. Due to the material quantitative error, the correctness score is reduced to 7, but the reasoning and completeness are otherwise strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 438,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Walmart's ownership stake and financial investment in Alert Innovation evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, increasing its ownership to approximately 100%. By fiscal 2024, there was no mention of Walmart retaining ownership of Alert Innovation, indicating that the company had fully exited its stake, likely through a sale or divestiture.",
      "llm_answer": "In fiscal 2023 Walmart paid about $0.4 billion to acquire Alert Innovation, which moved its ownership from a minority interest to roughly 100 percent of the company. In fiscal 2024 Walmart made no further purchase of Alert Innovation – the 100 percent stake was retained and no additional cash outlay for the business was reported.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that Walmart paid $0.4 billion in fiscal 2023 to acquire Alert Innovation and increased ownership to approximately 100%, which matches the ground truth. However, it incorrectly claims that Walmart retained the 100% stake in fiscal 2024, while the ground truth explicitly states there was no mention of continued ownership, indicating a full exit. This is a critical factual error in the conclusion. (2) All numeric values—$0.4 billion and 100%—are accurate and properly formatted; no calculation errors. (3) The multi-hop reasoning fails: the model does not synthesize the absence of mention in fiscal 2024 as evidence of divestiture, which is a key inference in the ground truth. Instead, it assumes retention due to lack of reported sale, which contradicts the documented interpretation. (4) While the answer is contextually relevant and addresses the evolution of ownership and investment, it reaches the opposite conclusion for fiscal 2024, severely undermining factual correctness. Hence, low scores for correctness and qualitative accuracy despite perfect quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1154,
        "completion_tokens": 320,
        "total_tokens": 1474
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did SPG's utilization and management of the Supplemental Facility evolve between 2023 and 2024, particularly in terms of borrowing activity and repayment strategy?",
      "original_answer": "In 2023, SPG utilized the Supplemental Facility as part of its broader capital strategy, borrowing €750.0 million under this facility, which was later repaid on November 17, 2023, following the issuance of senior unsecured bonds. By 2024, there was no outstanding balance under the Supplemental Facility, indicating a full repayment and a shift away from its use. This evolution shows a strategic reduction in reliance on the Supplemental Facility, with SPG opting instead to refinance through long-term unsecured notes, such as the $1.0 billion issuance in September 2024.",
      "llm_answer": "In 2023 Simon Property Group still had an outstanding balance on its Supplemental Facility, but it eliminated that balance in the fourth quarter.  The operating partnership issued €750 million of senior unsecured bonds (≈ $815 million) and used the entire proceeds to **repay the €750 million that was then outstanding under the Supplemental Facility on November 17, 2023**【page_61】.  After that repayment the company’s interest‑rate swap that had been covering the Euro‑denominated borrowing under the Supplemental Facility was also terminated【page_70】.  \n\nBy 2024 the Supplemental Facility was no longer being drawn down; instead it was described only as a **available revolving‑credit line of $3.5 billion to $4.5 billion with a 2029 maturity**, with no new borrowings reported for the year【page_69】.  Thus, SPG moved from actively borrowing and then repaying the facility in 2023 to keeping the facility in place as a liquidity source but not using it for new financing in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key figures are correct: the €750 million borrowing and its repayment on November 17, 2023, are accurately reported. The conversion to ≈$815 million is a reasonable approximation and does not misrepresent the data. There are no calculation errors. (2) The LLM correctly identifies the shift in SPG’s strategy: active use and full repayment of the Supplemental Facility in 2023, followed by no drawdowns in 2024. It accurately notes the facility remains available as a revolving credit line with a 2029 maturity, which is consistent with the context. (3) The multi-hop reasoning is sound—linking the bond issuance to the repayment of the Supplemental Facility, and then inferring reduced reliance in 2024. The mention of the terminated interest-rate swap adds contextual depth supported by the source. (4) The only minor gap is that the LLM does not explicitly mention the $1.0 billion unsecured note issuance in September 2024, which the ground truth cites as evidence of the refinancing shift. While the overall strategic conclusion is correct, this omission slightly weakens the completeness of the 2024 refinancing narrative. However, the core facts, dates, and strategic evolution are correctly conveyed, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 372,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has Linde's treatment of helium in its industrial gases business evolved between 2023 and 2024, particularly in terms of its positioning as a primary product and associated supply strategies?",
      "original_answer": "In 2023, helium was explicitly listed as one of Linde's primary products within its industrial gases business, specifically called out alongside gases like oxygen, nitrogen, and hydrogen. The 2023 filing also described helium's distribution through merchant delivery, with contracts typically lasting three to seven years and without minimum purchase requirements. By 2024, helium was no longer specifically named as a distinct product in the industrial gases segment. Instead, it was subsumed under more general descriptions of gas supply methods and contracts, suggesting a reduced emphasis on helium as a standalone offering. This shift indicates a strategic repositioning of helium within Linde's broader gas portfolio, aligning it more closely with other merchant gases rather than maintaining its prior distinct status.",
      "llm_answer": "In both the 2023 and the 2024 Form 10‑K, Linde lists helium together with hydrogen, carbon‑dioxide, carbon‑monoxide, electronic and specialty gases as a **primary process gas** in its industrial‑gases portfolio. The company’s supply approach for helium has not changed – it is principally sold through the **merchant (bulk‑liquid) distribution channel**, which, like argon and hydrogen, can be shipped over long distances, and it is not treated as a dedicated on‑site or packaged‑cylinder product. Thus, between 2023 and 2024 helium’s positioning and the associated supply strategy remain consistent.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that helium was listed as a primary process gas in both 2023 and 2024. According to the ground truth, while helium was explicitly named as a primary product in 2023 alongside oxygen, nitrogen, and hydrogen, it was no longer specifically mentioned as a distinct product in 2024 and was instead subsumed under broader categories. This indicates a strategic repositioning, contrary to the LLM's assertion of consistency. There are no numeric values in the question or answers requiring quantitative verification, so quantitative accuracy is scored as 10 by default (no errors in numbers because none were present). However, the qualitative accuracy is very low because the model fails to detect a key change in product classification and misrepresents Linde's strategic shift. The reasoning is flawed: it incorrectly assumes continuity without recognizing the removal of helium as a named product in 2024, failing the multi-hop comparison across years. Contextual relevance is moderate—the answer addresses the right topic (helium positioning and supply) and correctly notes the merchant distribution channel, which aligns with the 2023 description, but misses the evolution in strategic emphasis entirely. Thus, despite using plausible terminology (e.g., 'merchant distribution'), the answer contradicts the ground truth on the central point of helium’s evolving status.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 392,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the allocation of assets in the U.S. Retiree Health Care Plan evolve between 2022 and 2023, particularly in terms of fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had $248 in fixed income securities and cash equivalents and $137 in equity securities, totaling $385. In 2023, the plan's allocation changed to $210 in fixed income securities and cash equivalents and $54 in equity securities, totaling $264. This indicates a decrease in both categories, with a more significant reduction in equity securities.",
      "llm_answer": "In the U.S. Retiree Health Care Plan the mix moved sharply toward fixed‑income assets. At 12/31/2022 the plan held about $182 million of fixed‑income securities and cash (≈ 65 % of the $280 million total) and $98 million of equity securities (≈ 35 %). By 12/31/2023 fixed‑income holdings had risen to roughly $210 million (about 80 % of the $264 million total) while equity fell to about $54 million (≈ 20 %).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the 2022 figures. According to the ground truth, in 2022 the plan had $248 in fixed income securities and cash equivalents and $137 in equity securities, totaling $385. However, the LLM states $182 million in fixed income and $98 million in equities, totaling $280 million—this is incorrect on all counts. The 2023 figures are partially correct: $210 million in fixed income and $54 million in equities (total $264) match the ground truth. (2) Calculations: The percentages derived from the LLM's incorrect 2022 totals (e.g., 65% and 35%) are mathematically consistent with its own numbers but based on wrong inputs, so they are misleading. The 2023 percentages (80% and 20%) are accurate relative to the correct total. (3) Multi-hop reasoning: The model correctly identifies the trend of decreasing equity and increasing fixed income share in 2023, but misrepresents the starting point in 2022, leading to an inaccurate portrayal of the evolution. It fails to note that both asset categories decreased in absolute value from 2022 to 2023—instead implying fixed income increased, which contradicts the ground truth (from $248 to $210). (4) Despite incorrect numbers for 2022, the answer is contextually relevant and attempts appropriate synthesis, using correct years and asset categories. The reasoning direction (shift toward fixed income) is plausible but factually unsupported due to input errors. Hence, partial credit is given for structure and relevance, but major deductions for quantitative inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 435,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial performance and strategic positioning of Trodelvy evolve between 2022 and 2023, particularly in terms of revenue generation and regulatory milestones?",
      "original_answer": "In 2022, Trodelvy generated $380 million in total product sales, primarily in the U.S., indicating its early commercial presence. By 2023, there was a strategic shift in Trodelvy's positioning as it received significant regulatory approvals: FDA approval for treating HR+/HER2- metastatic breast cancer and EC approval for a similar indication. These developments suggest a strong enhancement in its market potential and therapeutic footprint, although specific revenue figures for 2023 are not provided.",
      "llm_answer": "In 2022 Trodelvy produced $680 million of product sales (U.S. $525 m, Europe $143 m, other $12 m) 【page_70】.  By 2023 that revenue had risen to $1.063 billion (U.S. $777 m, Europe $217 m, other $68 m), a 56 % increase 【page_40】 driven by higher demand in both existing and new markets 【page_41】.  The growth was under‑pinned by major regulatory milestones in 2023 – the FDA and European Commission both granted Trodelvy monotherapy approval for adult patients with HR⁺/HER2‑ metastatic breast cancer 【page_39】, while the company also disclosed a Phase 3 NSCLC trial that missed its primary overall‑survival endpoint but left open further exploration 【page_38】, reinforcing Trodelvy’s expanding strategic position in oncology.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in financial figures. The ground truth states that Trodelvy generated $380 million in 2022, but the LLM claims $680 million (a significant overstatement). Similarly, the LLM reports $1.063 billion in 2023 revenue, while the original answer states that no 2023 revenue figures are provided. These quantitative errors severely undermine the factual correctness. The 56% growth claim is therefore also incorrect, as it is based on fabricated data. (2) Regulatory milestones are accurately described: FDA and European Commission approvals for HR+/HER2- metastatic breast cancer in 2023 are correctly reported and align with the ground truth. The mention of a Phase 3 NSCLC trial missing its endpoint adds extra detail not in the original answer but does not contradict it. (3) Multi-hop reasoning is partially sound—linking regulatory approvals to strategic positioning is valid, and the geographic revenue breakdown suggests synthesis across regions. However, the core financial data is entirely inconsistent with the ground truth, indicating either hallucination or sourcing from incorrect documents. (4) Despite correct qualitative trends and relevant context (regulatory progress, market expansion), the severe numerical inaccuracies dominate the evaluation. The contextual relevance is high because the answer addresses both revenue and regulatory aspects of the question, but correctness is low due to unsupported financial figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 413,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Chevron's downstream-related earnings and investment relationship with GS Caltex evolve from 2022 to 2024, and what does this indicate about the strategic importance of the joint venture?",
      "original_answer": "In 2022, Chevron reported higher downstream-related earnings from GS Caltex in Korea, contributing to improved income from equity affiliates. By 2024, Chevron maintained a 50% ownership stake in GS Caltex Corporation, which operates as a joint venture with GS Energy, importing, producing, and marketing petroleum products, petrochemicals, and lubricants. Additionally, in 2024, Chevron reported $13,850 million in sales and other operating revenues with affiliated companies, including GS Caltex, compared to $16,286 million in 2022. This indicates that while the joint venture remained strategically important, the level of downstream-related revenue with affiliated companies slightly decreased over the period.",
      "llm_answer": "- In 2022 Chevron reported downstream‑related equity earnings of about **$1.97 billion** (U.S. $1,003 m + International $962 m) and a **$4.31 billion** investment in its 50 %‑owned joint venture GS Caltex, which contributed **$874 million** of equity earnings that year【page 83】.  \n- By 2024 downstream equity earnings had fallen to roughly **$1.26 billion** (U.S. $736 m + International $519 m) and the GS Caltex investment slipped to **$4.14 billion**, with its equity earnings collapsing to only **$58 million** (down from $874 m in 2022)【page 83】【page 84】.  \n\nThe sharp decline in earnings from GS Caltex, despite the JV remaining a sizable, fully‑owned downstream asset, shows that Chevron continues to view the partnership as a strategic foothold in the Korean/Asian downstream market, even though its near‑term profit contribution has diminished.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Chevron reported higher downstream-related earnings from GS Caltex in 2022 and maintained a 50% ownership stake through 2024, with no mention of a collapse in equity earnings from $874 million to $58 million. The original answer does not provide specific equity earnings for GS Caltex alone, nor does it report Chevron’s total downstream equity earnings as $1.97 billion in 2022 or $1.26 billion in 2024. These figures are fabricated or misattributed. Additionally, the investment amounts of $4.31 billion and $4.14 billion are not present in the ground truth, which focuses on sales and operating revenues with affiliated companies, not investment values. (2) The LLM incorrectly reports a dramatic drop in GS Caltex equity earnings from $874 million to $58 million, which contradicts the ground truth indicating continued strategic importance and no such collapse. The ground truth reports $13,850 million in 2024 sales with affiliates vs $16,286 million in 2022 — a modest decline, not a collapse. The LLM confuses total downstream equity earnings with GS Caltex-specific earnings and invents precise numbers unsupported by the source. (3) The multi-hop reasoning is flawed: the LLM incorrectly synthesizes data by attributing unspecified equity earnings to GS Caltex and inventing investment figures. It fails to connect the actual trend in affiliate revenues, which is the only quantitative metric provided in the ground truth. (4) While the LLM attempts to address the strategic importance of the JV — correctly noting its continued role in Korea/Asia — this conclusion is based on false quantitative premises. The contextual relevance is moderate because it addresses the right companies and general theme, but the factual foundation is severely compromised, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 514,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the financial performance and production status of the CH-53K program evolve from 2022 to 2024, particularly in terms of risk retirements and production volume?",
      "original_answer": "In 2022, the CH-53K program contributed to higher operating profit for Sikorsky helicopter programs, with approximately $140 million in increased profit driven by higher risk retirements and production volume. By 2024, while the CH-53K remained a key product within RMS, the overall operating profit for RMS declined significantly—by 73%—partially due to lower profit booking rate adjustments across the portfolio. Although specific profit figures for CH-53K were not disclosed in 2024, the broader profit decline suggests that the gains from risk retirements observed in 2022 may have diminished as the program matured and entered higher-volume production.",
      "llm_answer": "In the 2022 filing Lockheed Martin said the CH‑53K King Stallion was still in low‑rate production, and the company was “retiring” technical‑ and schedule‑related risks on the helicopter, which lowered the estimated total cost to complete the contract and lifted the profit‑booking rate for the program. By the 2024 filing the program had moved into a higher‑rate production phase – the RMS segment highlighted a **$140 million increase in net sales** that was “due to higher production volume on the CH‑53K program,” showing that the focus had shifted from risk‑retirement‑driven profit improvement to volume‑driven revenue growth.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in quantitative accuracy: it states a '$140 million increase in net sales' in 2024 due to CH-53K production volume, but the ground truth specifies that the $140 million figure refers to increased profit in 2022 (not net sales) driven by risk retirements and volume. This misrepresents both the metric (profit vs. sales) and the year (2024 vs. 2022). The $140M figure is correctly attributed to the CH-53K program but misplaced in time and context. (2) The LLM correctly identifies the shift from risk-retirement-driven profit improvements in 2022 to higher production volume in 2024, and accurately describes the program’s progression from low-rate to higher-rate production. However, it fails to mention the 73% decline in RMS operating profit in 2024, a key part of the ground truth that contextualizes the program's performance. (3) The multi-hop reasoning is partially sound—linking risk retirement in 2022 to profit booking and then to volume-driven growth in 2024 shows logical synthesis—but it omits the broader financial deterioration in RMS, weakening the completeness and accuracy of the conclusion. (4) The contextual relevance is high as the answer addresses the evolution of financial performance and production status. However, the misstatement of $140M as net sales in 2024 instead of profit in 2022 severely undermines quantitative accuracy, warranting a moderate overall correctness score despite otherwise reasonable qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 419,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has PayPal's approach to seller protection programs evolved between 2022 and 2023, particularly in terms of risk exposure and strategic emphasis?",
      "original_answer": "In 2022, PayPal highlighted that its seller protection programs carried risk exposure tied to regional variations and regulatory changes, with historical transaction loss rates ranging between 0.09% and 0.15% of TPV. By 2023, the company placed a stronger strategic emphasis on these programs as a competitive differentiator, explicitly linking them to merchant trust and platform growth. While 2022 focused on risk management and potential loss implications, 2023 framed seller protection as part of a broader value proposition to attract and retain merchants, integrating it with analytics, risk management, and other merchant services.",
      "llm_answer": "In the 2022 filing PayPal treated its seller‑protection program mainly as a loss‑controlling function – it disclosed that “transaction loss rates have ranged between 0.09 % and 0.15 % of TPV” and described the need to set allowances for seller‑protection claims as part of its overall provision for transaction and credit losses. By the 2023 filing the narrative had shifted: the company now highlights seller‑protection as a strategic differentiator that “reduce[s] merchant losses through proprietary protection programs” and places it squarely in the merchant‑value proposition and risk‑management pillar of its growth strategy, with less emphasis on specific loss‑rate metrics and more on its role in driving confidence and competitive advantage.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution in PayPal's approach to seller protection between 2022 and 2023. In 2022, it accurately reflects the focus on risk exposure and loss control, citing the exact transaction loss rate range of 0.09% to 0.15% of TPV from the ground truth. In 2023, it correctly identifies the strategic shift toward positioning seller protection as a competitive differentiator and part of the merchant value proposition, with emphasis on trust and platform growth. The answer omits explicit mention of integration with analytics and other merchant services, which is a minor omission but does not detract from the core accuracy. (2) Quantitatively, the 0.09% to 0.15% TPV loss rate is correctly reported with precise figures and context, matching the ground truth exactly. No calculations are required, and all metrics are used appropriately. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and two strategic contexts (risk management vs. strategic differentiation), correctly inferring the shift in emphasis based on changes in disclosure tone and framing. It links seller protection to broader business strategy in 2023, which aligns with the ground truth’s claim about integration into growth strategy. (4) The scores reflect near-perfect factual accuracy, with only a slight deduction in qualitative accuracy due to the omission of the integration with analytics and other services. Contextual relevance is full, as all content directly addresses the question’s focus on risk exposure and strategic emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 438,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Starbucks' approach to its ready-to-drink beverages evolved between 2023 and 2024, particularly in terms of revenue recognition and supplier dependency?",
      "original_answer": "In 2023, Starbucks recognized revenue from ready-to-drink beverages under the 'Other Revenues' category, where sales were generally recognized upon shipment to customers depending on contract terms. By 2024, the company's focus shifted to supplier dependency and supply chain resilience, emphasizing that ready-to-drink beverages are sourced from specialty suppliers under long-term contracts, indicating a strategic move toward securing stable supply rather than just reporting revenue. While 2023 included ready-to-drink beverages in broader revenue disclosures without specific figures, 2024 highlighted the importance of supplier relationships to mitigate delivery risks, signaling a shift from revenue-centric reporting to a supply-chain risk management focus.",
      "llm_answer": "In the 2023 filing Starbucks said that sales of ready‑to‑drink (RTD) beverages – which are part of “Other revenues” – are **recognized when the product is shipped to the customer, subject to the contract terms** (2023 10‑K, p. 65).  \n\nThe 2024 filing still treats RTD sales the same way, but adds that these beverages are **sourced from a number of specialty suppliers under long‑term supply contracts**, making the company’s ability to deliver RTD products more dependent on those external partners (2024 10‑K, p. 13).  \n\nThus, while the revenue‑recognition timing for RTD drinks has remained unchanged, Starbucks has become more explicit in 2024 about its reliance on third‑party suppliers for those products.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that in 2023, revenue for ready-to-drink (RTD) beverages was recognized under 'Other Revenues' and recognized upon shipment, citing the correct treatment and context from the 2023 10-K. In 2024, it accurately notes that while revenue recognition remains unchanged, Starbucks added disclosure about sourcing RTD beverages from specialty suppliers under long-term contracts, increasing supplier dependency—this matches the ground truth's emphasis on a shift toward supply chain risk management. (2) There are no numerical figures involved in this question, but the temporal references (2023 vs 2024) and document citations (page numbers) are correctly used, indicating precise sourcing. Format and references are consistent and accurate. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, comparing revenue recognition consistency while identifying the new emphasis on supplier dependency in 2024. It captures the evolution in disclosure focus—from revenue timing to supply chain reliance—without overstating changes in accounting policy. (4) The only minor shortcoming is that the LLM does not explicitly frame the evolution as a 'strategic move toward securing stable supply' or 'shift from revenue-centric reporting to supply-chain risk management,' which the original answer highlights. While the facts are all present, the higher-level interpretive synthesis is slightly less developed. However, the core facts, entities, years, and reasoning are correct. Thus, the answer is factually complete and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 464,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the geographic reach and regulatory approvals of Trodelvy evolve between 2022 and 2023?",
      "original_answer": "In 2022, Trodelvy generated $370 million in U.S. sales and $10 million in Europe, with no sales reported in other international markets, indicating limited geographic reach. By 2023, Trodelvy received significant regulatory approvals: it was approved by the FDA for treating adult patients with HR+/HER2- metastatic breast cancer, and it obtained EC approval for monotherapy treatment of unresectable or metastatic HR+/HER2- breast cancer. These approvals suggest an expansion of Trodelvy's market access and therapeutic application, likely contributing to broader geographic distribution beyond what was reported in 2022.",
      "llm_answer": "In 2022 Trodelvy was still a largely U.S.–focused product – the 10‑K shows $370 million of sales in the United States, only $10 million in Europe and no reported sales in other regions. By 2023 its footprint had broadened dramatically, with sales of $777 million in the U.S., $217 million in Europe and $68 million in other international markets. The geographic expansion was accompanied by new regulatory clearances in 2023: the U.S. FDA and the European Commission both approved Trodelvy as a monotherapy for unresectable locally advanced or metastatic HR‑positive/HER2‑negative breast cancer, adding to the earlier approvals for metastatic TN‑BC and urothelial cancer that had driven the 2022 sales.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. While the 2022 U.S. sales of $370 million and European sales of $10 million match the ground truth, the 2023 sales figures—$777 million in the U.S., $217 million in Europe, and $68 million internationally—are not present in the original answer and are therefore factually unsupported. The ground truth does not provide any 2023 sales data; it only mentions regulatory approvals. Thus, the inclusion of specific 2023 sales numbers is a major factual error. (2) The regulatory approvals mentioned—FDA and EC approval for HR+/HER2- metastatic breast cancer—are correctly reported and align with the original answer, showing accurate entity and event identification. The reference to prior approvals for TNBC and urothelial cancer adds context not in the ground truth but is plausibly accurate and enhances completeness without contradicting facts. (3) The multi-hop reasoning is partially sound: the model correctly links regulatory developments to expanded market potential. However, the unsupported sales figures undermine the quantitative synthesis, making the claim of 'dramatic' geographic broadening empirically invalid based on the provided truth. (4) Despite the numerical inaccuracies, the answer correctly identifies the core evolution in regulatory approvals and infers broader geographic potential, which aligns with the question's intent. The qualitative reasoning and contextual relevance are strong, but the fabrication of sales data severely impacts overall correctness. Hence, a score of 6 reflects partially correct information with significant factual errors in key quantitative claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 459,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Simon Property Group's ownership stake and financial gains from transactions involving ABG evolve between 2023 and 2024?",
      "original_answer": "In 2023, Simon Property Group (SPG) experienced multiple dilutions of its ownership stake in ABG through capital transactions, including a reduction from approximately 12.3% to 11.8%, then to 11.7%, and finally to approximately 9.6%. These transactions resulted in non-cash pre-tax gains of $36.4 million, $12.4 million, and $10.3 million, respectively. By contrast, in 2024, SPG no longer disclosed active changes in its ownership stake in ABG. Instead, it referenced a prior transaction from December 20, 2021, where it sold a portion of its interest in ABG for a pre-tax gain of $18.8 million and later acquired additional interests for $100.0 million. This indicates a shift from active stake reduction and financial recognition in 2023 to a more passive disclosure stance in 2024, with no new transactions reported.",
      "llm_answer": "In 2023 Simon’s ABG ownership was progressively diluted – it fell from about 12.3 % at the start of the year to roughly 11.8 % after the Q2 capital transaction, 11.7 % after the Q3 transaction, and finally to about 9.6 % after the Q4 transaction 【page_114】.  Those three transactions generated non‑cash pre‑tax gains of $36.4 million (Q2), $12.4 million (Q3) and, in the fourth quarter, a cash‑sale of a portion of the stake that produced a $157.1 million pre‑tax gain 【page_113】.  In the first quarter of 2024 Simon sold its remaining ABG interest for $1.2 billion, realizing a pretax gain of $414.8 million and leaving it with 0 % ownership 【page_73】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) Quantitative Accuracy: The ownership percentages in 2023 (12.3% → 11.8% → 11.7% → 9.6%) are correct, as is the $36.4M and $12.4M pre-tax gains for Q2 and Q3. However, the LLM incorrectly states a $157.1M gain in Q4 2023, whereas the ground truth reports a $10.3M gain. This is a major error. Furthermore, the LLM claims that in Q1 2024, Simon sold its remaining stake for $1.2B and realized a $414.8M gain, leaving 0% ownership — but the ground truth states that SPG did not report any new transactions in 2024 and only referenced a prior 2021 transaction. These numbers ($1.2B sale, $414.8M gain, 0% stake) are entirely fabricated relative to the ground truth. (2) Completeness: While the answer attempts to cover both years, it invents a major transaction in 2024 that is not supported by the original answer, thus failing to reflect the actual shift to passive disclosure. (3) Entity Accuracy: The companies (SPG, ABG) and time periods are correctly identified, but the financial events are misattributed. (4) Reasoning: The multi-hop synthesis fails — instead of recognizing that 2024 involved no new stake changes and only reference to a 2021 transaction, the model incorrectly infers an active 2024 divestiture. (5) Semantic Equivalence: The overall narrative contradicts the ground truth — the original describes a shift from active dilution in 2023 to no new activity in 2024, while the LLM portrays continued and even culminating activity in 2024. Due to severe numerical and factual errors, especially in the 2024 claims, the correctness score is low despite partial accuracy in early 2023 data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 461,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the 2012 Equity Incentive Plan evolved between the 2023 and 2024 filings, particularly in terms of amendments and forms of award agreements disclosed?",
      "original_answer": "In 2023, the 2012 Equity Incentive Plan was disclosed as amended, including the Third Amendment to the plan, and referenced forms of award agreements from 2012 and 2017. In 2024, the filing included a Fourth Amendment dated August 1, 2024, and introduced additional forms of award agreements from April 2024, showing continued evolution and expansion of the plan over time.",
      "llm_answer": "In the 2023 Form 10‑K the 2012 Equity Incentive Plan was shown with its **Third Amendment** (filed Feb 2 2023) and a series of award‑agreement exhibits that ran through **Exhibit 10.2(L)** (the most recent “Additional Forms” dated Apr 27 2023).  \n\nThe 2024 filing adds a **Fourth Amendment** to the plan (filed Aug 1 2024) and extends the award‑agreement disclosures with a new **Exhibit 10.2(K)** (additional forms dated Apr 25 2024), while still retaining the earlier amendments and earlier award‑agreement exhibits.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. It correctly identifies the Third Amendment in 2023 (with accurate filing date of February 2, 2023) and references the 2023 award agreements (dated April 27, 2023), aligning with the 'forms of award agreements from 2012 and 2017' mentioned in the original answer, while adding more granular detail (Exhibit numbers and specific dates). For 2024, it accurately notes the Fourth Amendment dated August 1, 2024, and the new April 2024 award agreement forms (specifically April 25, 2024), matching the ground truth's claim of 'additional forms of award agreements from April 2024'. The LLM adds precision by citing exhibit numbers (10.2(L), 10.2(K)) not in the original answer, which enhances detail without introducing error. The only minor point is that the original answer does not specify the 2017 forms were still referenced in 2024, but the LLM's statement that earlier exhibits are 'retained' is a reasonable inference and consistent with typical SEC filing practices. All dates, amendment numbers, and document types are correct. Multi-hop reasoning is sound—correctly comparing evolution across two years, identifying amendments and award forms, and synthesizing changes. Wording differs but semantic meaning matches. No calculation errors. Slight deduction in quantitative accuracy only because the original answer does not specify exact dates of award agreements (e.g., Apr 27, 2023), so including them, while plausible, goes beyond the ground truth without confirmation—but does not make the answer incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 438,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the treatment and valuation of capitalized software licenses evolve between 2022 and 2023, and what does this indicate about the company's investment in software licensing?",
      "original_answer": "In 2022, capitalized software licenses were described as being generally amortized on a straight-line basis over the term of the license, indicating a clear policy for their depreciation over time. By 2023, the company disclosed the actual carrying value of these licenses on the balance sheet at $223 million, up from $152 million in 2022. This increase suggests a growing investment in software licensing, despite the unchanged amortization policy. The evolution from a disclosed accounting method in 2022 to a quantified asset in 2023 reflects a more tangible and increasing role of capitalized software licenses in the company's asset structure.",
      "llm_answer": "The 2023 filing still treats software licenses as a capitalized intangible that is amortized on a straight‑line basis over the license term (the same policy described in the 2022 note). The carrying amount of those licenses grew from $152 million at year‑end 2022 to $223 million at year‑end 2023, and amortization expense rose from $54 million to $63 million. This increase in both the balance‑sheet value and the amortization charge signals that the company substantially expanded its investment in software‑licensing assets during the year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the amortization policy (straight-line) is consistent between 2022 and 2023, the carrying value increased from $152 million to $223 million, and this growth indicates increased investment in software licensing. The LLM adds a specific detail not in the original answer—amortization expense rising from $54M to $63M—which is plausible and consistent with the increased asset base, though not present in the ground truth. Since this number is not contradicted and supports the conclusion, it does not reduce accuracy. (2) Quantitative accuracy is perfect: all dollar amounts and years are correct, and the implied growth ($71M increase in carrying value) is accurate. (3) Reasoning is sound: the LLM correctly synthesizes the unchanged policy with the growing asset value to infer increased investment, demonstrating proper multi-hop logic across years and metrics. (4) The answer is contextually excellent, directly addressing the evolution in treatment/valuation and the implication for investment strategy. The only minor gap is that the original emphasizes the shift from policy disclosure (2022) to quantified asset (2023) as a reporting evolution, which the LLM mentions implicitly but doesn't explicitly highlight. This slight omission in narrative framing does not detract from factual correctness, warranting a 9/10 on qualitative accuracy and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 406,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what does this indicate about its strategic approach to funding credit products?",
      "original_answer": "In 2022, PayPal had approved $3.8 billion of European customer balances for credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, this approved amount decreased to $3.0 billion, representing 39% of European customer balances. This indicates a slight reduction in the total approved funding base but a higher percentage utilization of available balances, suggesting a more efficient use of existing customer balances for credit activities. Additionally, PayPal entered into a new €40 billion agreement in 2023 to sell consumer installment receivables, with $5.5 billion sold during the year, signaling a strategic shift toward external funding mechanisms to support credit product expansion.",
      "llm_answer": "In 2022 PayPal had **$3.8 billion** of European customer balances approved for use in credit activities – about **37 %** of the balances that the Luxembourg regulator allowed it to tap. By year‑end 2023 that approved amount fell to **$3.0 billion**, but it now represented **roughly 39 %** of the available balances. The drop in the absolute dollar amount combined with a higher utilization rate shows PayPal is tightening its internal funding pool, using a larger share of its own European customer deposits to finance credit products while still seeking additional third‑party sources.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key quantitative facts: $3.8 billion approved in 2022 (37%), decreasing to $3.0 billion in 2023 (39%). These figures match the ground truth exactly, and the slight increase in percentage utilization is accurately noted. (2) Quantitative accuracy is perfect—dollar amounts, percentages, and years are all correct. There are no calculation errors. (3) The reasoning correctly identifies that the lower absolute amount but higher percentage indicates tighter or more efficient use of internal funding. However, the LLM omits a key strategic development mentioned in the original answer: the new €40 billion agreement to sell consumer installment receivables, with $5.5 billion sold in 2023. This is a significant multi-hop element indicating a shift toward external funding mechanisms, which the LLM fails to mention. While it correctly notes PayPal is seeking third-party sources, it lacks the specific evidence supporting that claim. (4) The answer is highly relevant and accurately interprets the trend in internal funding utilization. Due to the omission of the €40 billion agreement and $5.5 billion sale—critical to fully addressing the strategic shift—the qualitative accuracy and overall correctness are slightly reduced, but not severely, as the core trend is well-explained.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 372,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Starbucks' investment relationship with Valor Siren Ventures I L.P. evolved between fiscal years 2023 and 2024, particularly in terms of the carrying value of the investment and its financial impact on Starbucks' consolidated statements?",
      "original_answer": "In fiscal 2023, Starbucks held a limited partnership interest in Valor Siren Ventures I L.P., with the total carrying value of such investments not specifically disclosed for that year. The financial impact of these investments, including Valor Siren Ventures I L.P., was included in 'interest income and other, net' and was not considered material. By fiscal 2024, the total carrying value of Starbucks' investments in Valor Siren Ventures I L.P. and II L.P. combined was $211.9 million as of September 29, 2024. The investment relationship evolved from a general equity stake to a more defined and quantified investment with ongoing monitoring, though the financial impact remained non-material and continued to be reported in 'interest income and other, net.'",
      "llm_answer": "In fiscal 2024 Starbucks reported that its limited‑partnership interests in Valor Siren Ventures I L.P. (and the related II L.P.) had a combined carrying amount of **$211.9 million** as of September 29 2024.  In the prior year the same private‑equity holdings were carried at a lower amount (the 2023 filing shows a total “other investments” balance of **$24.2 million**, which includes the Valor Siren interests), indicating that the investment’s book value rose between FY 2023 and FY 2024.  The share of income or loss from these partnerships is not shown as a separate line item; instead it is rolled into the **“interest income and other, net”** line on the consolidated statement of earnings, and the footnote notes that the activity was not material to the consolidated financial statements in either year.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the right question and demonstrating relevant reasoning structure. (1) QUANTITATIVE INACCURACY: The LLM claims that Starbucks' 'other investments' balance was $24.2 million in fiscal 2023 and that this includes the Valor Siren Ventures I L.P. investment. However, the ground truth states that the carrying value for Valor Siren Ventures I L.P. specifically was *not disclosed* in 2023, and there is no support in the original answer for attributing the $24.2 million (which may represent a broader category) solely or even partially to Valor Siren. This number appears to be hallucinated or misattributed from an external source not in the ground truth. (2) The claim that the investment 'rose' between FY2023 and FY2024 implies a comparison that is not supported by the original data, since no specific carrying value for Valor Siren I was disclosed in 2023. The original answer explicitly avoids quantifying the 2023 value for this investment. (3) While the LLM correctly reports the $211.9 million combined carrying value for Valor Siren I and II L.P. as of September 29, 2024, and correctly identifies the reporting line ('interest income and other, net'), and notes non-materiality, these correct elements do not compensate for the incorrect 2023 figure. (4) The reasoning attempts multi-hop synthesis—comparing years, tracking financial impact, identifying reporting location—but fails on the critical first hop due to the unsupported 2023 number. (5) Contextually, the answer is well-structured and relevant, focusing on the evolution of the investment and its financial statement impact as asked. However, the introduction of an unverified quantitative figure severely compromises factual correctness. Minor point: the original answer mentions evolution toward 'more defined and quantified investment with ongoing monitoring,' which the LLM omits, reducing qualitative completeness. Overall, the answer is partially correct in direction but flawed in key facts, warranting a low-to-mid score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 563,
        "total_tokens": 1981
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has the strategic positioning of Analog Products evolved between 2022 and 2023 in terms of TI's competitive advantages and financial contribution?",
      "original_answer": "In 2022, Analog Products were central to TI's strategic focus, contributing to a gross margin of 67.5% driven by the efficiency of their manufacturing strategy, including 300-millimeter production. By 2023, Analog Products remained a core pillar but were framed more explicitly within the context of TI's four sustainable competitive advantages, particularly emphasizing lower costs and greater control of the supply chain. Additionally, the 2023 report reinforced the role of Analog Products in enabling TI to generate and return significant cash, with a renewed emphasis on long-term free cash flow per share growth as the ultimate performance metric.",
      "llm_answer": "TI continues to position its Analog business as a cornerstone of the “four sustainable competitive advantages” — a low‑cost, highly‑controlled manufacturing base; a broad analog portfolio; extensive market‑channel reach; and diversified, long‑lived products and markets (see the 2023 MD&A overview). Nevertheless, the financial weight of Analog declined sharply: revenue fell from $15.36 billion in 2022 to $13.04 billion in 2023 (‑15 %), operating profit dropped from $8.36 billion to $5.82 billion (‑30 %), and the operating‑profit margin slipped from 54.4 % to 44.6 % of revenue.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While the original answer emphasizes the continued strategic centrality of Analog Products and evolution in framing within TI's competitive advantages, the LLM claims a sharp decline in financial performance — including specific figures like revenue dropping from $15.36B to $13.04B and operating profit falling from $8.36B to $5.82B — none of which are supported by the ground truth. The original answer mentions a gross margin of 67.5% in 2022 but does not provide 2023 gross margin or any operating margin figures; thus, the LLM's reported drop in operating margin to 44.6% is fabricated. (2) The quantitative claims in the LLM answer — particularly the 15% revenue decline and 30% operating profit drop — are entirely absent from the ground truth and contradict the narrative of sustained strategic and financial importance. There is no mention of revenue or profit declines in the original; instead, the focus is on continuity and reframing around competitive advantages and cash flow. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers deteriorating financial contribution from a shift in strategic framing, conflating qualitative evolution with negative performance. It fails to recognize that the 2023 emphasis on competitive advantages and free cash flow per share growth is a continuation, not a response to decline. (4) Despite these major errors, the LLM correctly identifies the four sustainable competitive advantages and links Analog Products to them, showing some qualitative understanding. It also addresses both strategic positioning and financial contribution, maintaining contextual relevance. However, the invention of precise but false financial metrics severely undermines correctness, warranting a low score of 3 for overall correctness, 2 for quantitative accuracy, 4 for qualitative accuracy, and 6 for contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 523,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Chevron's capital allocation strategy in the Lower 48 region evolved from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments?",
      "original_answer": "Chevron's capital allocation in the Lower 48 region increased significantly from 2022 to 2023, as evidenced by the rise in depreciation, depletion, amortization, and impairments from $4,854 million in 2022 to $5,729 million in 2023. This indicates a growing focus on asset development and operational expansion in the Lower 48, contrasting with relatively stable or declining figures in other geographic segments like Europe, Middle East and North Africa.",
      "llm_answer": "In Chevron’s Lower 48 segment, the combined depreciation, depletion, amortization and impairment expense rose from **$4.9 billion in 2022 to $5.7 billion in 2023** (‑ $4,854 million → $5,729 million)【page_133】. The higher DD&A charge, together with the increase in segment‑level capital expenditures (from $5.6 billion to $6.5 billion)【page_135】, shows that Chevron is directing more capital to the Lower 48—maintaining a larger asset base and absorbing larger impairment adjustments—than it did a year earlier.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the increase in depreciation, depletion, amortization, and impairments from $4,854 million in 2022 to $5,729 million in 2023, accurately converting these figures to $4.9 billion and $5.7 billion respectively—this rounding is acceptable and common in financial reporting. All numeric values match the ground truth. (2) The answer adds contextual detail about capital expenditures rising from $5.6 billion to $6.5 billion, which is not in the original answer but is factually correct and enhances the reasoning; however, since the question specifically asks about evolution based on DD&A and impairments, this extra detail does not detract from accuracy. (3) The multi-hop reasoning is sound: the LLM correctly infers that rising DD&A and impairments indicate increased capital allocation and asset development in the Lower 48, aligning with the original answer’s conclusion. It also implicitly contrasts with other regions by focusing on the growth in Lower 48, though this contrast is less explicit than in the original. (4) The answer is semantically equivalent to the ground truth in terms of core facts and interpretation. The only minor shortcoming is slightly less emphasis on the comparative performance with other regions (Europe, MENA), but the main thrust—increased capital allocation in Lower 48 evidenced by rising DD&A and impairments—is fully supported and accurately presented. Thus, quantitative accuracy is perfect, qualitative reasoning is strong, and relevance is complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 424,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Verizon's approach to FWA Broadband evolved between 2023 and 2024, particularly in terms of its positioning within the company's product portfolio and its target customer segments?",
      "original_answer": "In 2023, Verizon provided FWA broadband through both 5G and LTE networks, targeting both Consumer and Business customers, and reported 3.1 million FWA broadband connections. By 2024, the company continued to offer FWA broadband primarily under the Verizon Consumer and Business Group segments, but with a more integrated positioning as an alternative to traditional landline internet access and as part of a broader portfolio that includes IoT and advanced communication services. The shift from 'provides' in 2023 to 'produces' in 2024 indicates a more strategic and product-centric approach to FWA broadband.",
      "llm_answer": "In the 2023 filing Verizon presented Fixed Wireless Access (FWA) as a supplemental broadband option that both its Consumer and Business segments offered through 5G or 4G LTE, noting roughly 3.1 million FWA connections and describing it simply as “an alternative to traditional land‑line internet access” for any consumer or business customer. By the 2024 filing the company had moved FWA into the core of the Consumer segment’s residential‑fixed‑services portfolio and emphasized that the service now “leverages the 5G network and our expanding C‑Band footprint” (while still being listed under Business), signaling a tighter integration with its advanced 5G platform and a continued focus on serving both residential households and enterprise customers with a more modern, network‑driven broadband offering.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the 3.1 million FWA connections in 2023 are accurately reported. No other numerical data is present in the ground truth, so no calculations were required. (2) The entity identification is correct—Verizon, FWA broadband, Consumer and Business segments, 5G/LTE networks, and the timeframes (2023–2024) are all properly referenced. (3) The reasoning and synthesis across years are sound: the LLM correctly identifies the evolution from a supplemental offering in 2023 to a more integrated, strategically emphasized product in 2024, particularly highlighting tighter integration with 5G and C-Band expansion. It captures the shift in positioning—though it does not explicitly mention the semantic shift from 'provides' to 'produces' noted in the ground truth, which is a minor omission. (4) The answer addresses all parts of the question: evolution in positioning within the product portfolio (from supplemental to core in Consumer segment) and target customer segments (continued focus on both residential and enterprise). The mention of FWA being 'listed under Business' but emphasized in Consumer reflects accurate nuance. The answer is semantically equivalent to the original, with slightly more emphasis on 5G technology than on the broader portfolio including IoT, but this does not detract from overall correctness. Minor deduction from 10 to 9 due to the absence of explicit reference to IoT/advanced communications as part of the broader portfolio in 2024, which is part of the ground truth's characterization of strategic integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 451,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Emerson's relationship with AspenTech evolved from 2022 to 2024, and what financial impact did this evolution have on Emerson's gross margin and equity structure?",
      "original_answer": "In 2022, Emerson partnered with AspenTech, leveraging its asset optimization software to enhance industrial operational efficiency. By 2024, Emerson had significantly deepened this relationship by acquiring a 55% ownership stake in AspenTech as part of a strategic transaction that created 'New AspenTech.' This acquisition contributed positively to Emerson’s gross margin, benefiting it by 0.6 percentage points in 2023 and further influencing financial structure in 2024 with increased SG&A expenses tied to the integration. Additionally, the equity structure was impacted through the recognition of gains and losses associated with the AspenTech stock plans and the broader restructuring of industrial software assets.",
      "llm_answer": "Emerson’s tie‑up with AspenTech began in fiscal 2022 when it contributed its two stand‑alone industrial‑software businesses and $6 billion in cash to Heritage AspenTech and, on closing, received **about a 55 % equity stake** in the newly created “New AspenTech” (see p. 3, p. 26). By fiscal 2024 Emerson’s holding had risen to **roughly 57 %** and the company announced a **proposal to buy the remaining shares** for $240 each, moving the relationship toward full ownership (p. 25). The AspenTech acquisition lifted Emerson’s gross margin – it added **≈0.6 percentage‑points to the 2023 gross‑margin rise to 49 %** and helped the margin climb further to **50.8 % in 2024** (p. 26), while the increasing stake altered the equity structure from a 55 % equity‑method investment to a larger majority interest that will soon be consolidated after the proposed 100 % purchase.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth, with only minor discrepancies in specificity. (1) Quantitatively, the LLM correctly identifies the 55% initial stake in 2022 (matching the original answer), the 0.6 percentage-point contribution to gross margin in 2023, and the increase in gross margin to 50.8% in 2024. The mention of a rise to 57% ownership by 2024 and the $240 per share offer for full acquisition are additional precise details not in the original answer but do not contradict it—these represent updated or more granular data likely from the source document (e.g., 10-K footnotes or management discussion). The $6 billion cash contribution is new information but consistent with plausible transaction structure; since the original answer does not specify financial terms of the deal, this addition does not reduce accuracy. (2) The gross margin impact is correctly quantified: 'added ≈0.6 percentage-points to the 2023 gross-margin rise' matches the original's 'benefiting it by 0.6 percentage points in 2023'. The progression to 50.8% in 2024 is a valid inference of continued positive impact. (3) Qualitatively, the multi-hop reasoning is sound: the evolution from partnership to majority control (55% → 57% → proposed 100%) is logically presented, and the impact on equity structure—transition from equity-method accounting to consolidation—is correctly interpreted. The original answer mentions 'gains and losses associated with stock plans' and 'restructuring', which the LLM omits, representing a minor gap in completeness. (4) Contextual relevance is excellent: every part of the question—evolution of relationship, gross margin impact, equity structure effect—is addressed with precise, document-supported information. The LLM enhances the original with specific page references and financial figures, demonstrating strong synthesis. Final score: 9/10 due to slight overprecision (e.g., 57%, $240/share) not in ground truth and omission of minor equity-related details, but overall factual and logical alignment is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 555,
        "total_tokens": 1959
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did the financial relationship between NEE and FPL Group Capital Inc evolve from 2022 to 2023, particularly in terms of the nature of their obligations and capital structure involvement?",
      "original_answer": "In 2022, the relationship was characterized by a guarantee agreement between FPL Group, Inc. and FPL Group Capital Inc. dated October 14, 1998, indicating a direct obligation from FPL Group, Inc. to FPL Group Capital Inc. By 2023, this relationship had evolved into a more complex capital structure involvement, with NEE issuing multiple series of junior subordinated debentures to FPL Group Capital Inc., including Series B, C, L, M, N, O, and P, with maturity dates ranging from 2057 to 2082. This transition reflects a strategic shift from a simple guarantee to a long-term capital financing arrangement.",
      "llm_answer": "In the 2022 filing the only items that linked NextEra Energy (NEE) and the FPL‑Group capital entity were historic, “paper‑only” arrangements – a 1998 Guarantee Agreement between FPL Group, Inc. and FPL Group Capital Inc (exhibit 10(vv) – page 124) and a senior‑note indenture that listed both NEE and FPL as obligors (exhibit 4(zz) – page 121).  \n\nBy the 2023 filing the relationship had shifted to an active capital‑structure role: FPL Group Capital Inc is a direct issuer‑or‑holder of unsecured debt securities under an indenture dated June 1 1999 (exhibit 4(l) – page 118) and is backed by a guarantee from FPL Group (exhibit 4(n) – page 118), while NEE’s financing subsidiary, NextEra Energy Capital Holdings, is repeatedly issuing junior‑subordinated debentures and floating‑rate notes (exhibits 4(o)‑4(w), 4(u), 4(r) – pages 118‑119). Thus the relationship evolved from a static guarantee/joint‑note arrangement in 2022 to a dynamic set of debt‑issuance obligations in which both entities are directly involved in the company’s capital structure in 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution in the financial relationship between NEE and FPL Group Capital Inc from 2022 to 2023, correctly identifying a shift from a static guarantee/joint-obligor structure to a more active capital structure involvement. It accurately references the 1998 Guarantee Agreement (though not explicitly tied to FPL Group, Inc. guaranteeing FPL Group Capital Inc. in the answer) and notes the presence of joint obligations in 2022. In 2023, it correctly identifies increased capital structure activity involving debt issuance and guarantees, citing indentures and debentures. However, it does not specifically mention that NEE issued junior subordinated debentures *to* FPL Group Capital Inc., which is a key factual point in the ground truth. Instead, it states that FPL Group Capital Inc is an 'issuer-or-holder' and focuses on NextEra Energy Capital Holdings as the issuing subsidiary—this is contextually relevant but slightly misaligns the counterparty and structure. The maturity dates (2057–2082) and specific series (B, C, L, M, N, O, P) of debentures are omitted, which are quantitatively significant details. The references to exhibits and dates (e.g., June 1, 1999 indenture) are plausible but not confirmed in the ground truth. While the overall reasoning and synthesis across years are sound and the answer is contextually relevant, the absence of precise issuance direction (NEE to FPL Group Capital Inc.) and missing series/maturities reduces quantitative and qualitative accuracy. Wording differences are acceptable, but key financial facts are partially missing or generalized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 441,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the positioning and market acceptance of InterStim II evolved between 2022 and 2024, particularly in relation to other InterStim neurostimulators and broader Pelvic Health therapies?",
      "original_answer": "In 2022, InterStim II was described as part of a suite of InterStim neurostimulators including InterStim Micro and InterStim X, with an emphasis on continued acceptance and growth in treating overactive bladder, urinary retention, and bowel incontinence. By 2024, InterStim II was specifically highlighted as a recharge-free neurostimulator, grouped alongside InterStim X and InterStim Micro (now differentiated by recharge status), and positioned within a broader context of continued acceptance and growth of Pelvic Health therapies. This evolution indicates a shift toward emphasizing device-specific attributes (e.g., recharge-free) and integration into a more mature and diversified product portfolio.",
      "llm_answer": "In the 2022 filing Medtronic described InterStim II as an established part of its InterStim family – “interStim therapy with InterStim II, InterStim Micro and InterStim X neurostimulators” – and noted that the whole Pelvic Health portfolio (driven by the newly‑launched InterStim Micro) was experiencing “acceptance and growth.” By the 2024 filing the company was emphasizing InterStim II as a **recharge‑free** neurostimulator, again citing “continued acceptance and growth of our Pelvic Health therapies, including our InterStim X and InterStim II recharge‑free neurostimulators and InterStim Micro rechargeable neurostimulator,” showing that InterStim II has remained a core, well‑accepted product while the newer InterStim Micro and InterStim X have been added to the portfolio and the overall Pelvic Health line continues to expand.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: InterStim II was part of a suite of neurostimulators in 2022 (alongside InterStim Micro and InterStim X), and by 2024 it was specifically highlighted as recharge-free, with the portfolio now differentiated by recharge status. The emphasis on continued acceptance and growth of Pelvic Health therapies is correctly noted in both years. (2) There are no numeric values to verify, so quantitative accuracy is not applicable beyond correct use of years (2022, 2024), which are accurate. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two time points and multiple devices, identifying the evolution in positioning from being part of a general suite to being distinguished by its recharge-free attribute. It also correctly identifies the broader context of Pelvic Health therapy growth. (4) The only minor shortcoming is that the answer could have more explicitly mentioned the conditions treated (overactive bladder, urinary retention, bowel incontinence) as in the original answer, which adds clinical context. However, this omission does not detract significantly from the overall correctness. The answer captures the core evolution in market positioning and product differentiation. Thus, the correctness score is 9 due to high factual accuracy with a slight lack of completeness in clinical indication detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 400,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Simon Property Group's utilization and management of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of borrowing capacity, interest rate strategies, and repayment actions?",
      "original_answer": "In 2022, the Supplemental Facility had an initial borrowing capacity of $3.5 billion, which could be increased to $4.5 billion, with a maturity date of January 31, 2026. Borrowings under the facility bore interest based on SOFR or similar rates, with a margin determined by the company's credit rating. By 2024, SPG had borrowed €750.0 million under the Supplemental Facility, which was repaid on November 17, 2023, following the issuance of exchangeable bonds. Additionally, interest rate swaps were used in 2023 to fix the rate on these borrowings at 3.81%. This indicates a shift from passive availability in 2022 to active utilization and strategic interest rate management in 2024.",
      "llm_answer": "In the 2022 Form 10‑K the Supplemental Facility was described as a $3.5 billion revolving line (up‑gradable to $4.5 billion) that could be drawn in U.S.‑ or foreign‑currency, with an initial maturity of 31 January 2026 (extendable to 2027) and an election‑based rate of SOFR (or the applicable EURIBOR/TIBOR) + 72.5 bps (plus a spread‑adjustment) and a margin of 0.65 %‑1.40 % (or a base‑rate margin of 0.00 %‑0.40 %).  \n\nBy the 2024 filing the facility still had a $3.5‑$4.5 billion borrowing capacity, but its maturity had been pushed out to 31 January 2029 (extendable to 2030) and the same SOFR + 72.5 bps pricing (with the same credit‑rating‑based margin) remained in place; however, Simon actively reduced its use of the facility—an interest‑rate swap in January 2023 fixed the euro‑denominated portion at 3.81 % and, in November 2023, the company issued €750 million of senior unsecured bonds and used the proceeds to repay the entire €750 million balance outstanding under the Supplemental Facility.  \n\nThus, between 2022 and 2024 the Supplemental Facility’s size and pricing framework stayed essentially unchanged, its term was extended, and Simon moved from a net‑zero or modest draw to a full repayment of the facility’s euro debt through swaps and bond‑financed redemption.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the initial $3.5 billion capacity (up to $4.5 billion), SOFR-based interest with credit-rating-determined margins, €750 million borrowed and fully repaid on November 17, 2023, and the use of an interest rate swap in January 2023 fixing the rate at 3.81%. The maturity extension to 2029 (from 2026) is an additional detail not in the original answer but does not contradict it—SEC filings often include updates, so this is plausible and contextually acceptable. (2) Quantitative accuracy is perfect: all dollar/euro amounts, dates, percentages (72.5 bps, 3.81%), and timeframes match or are consistent with the ground truth. Format variations (e.g., €750 million vs €750.0 million) are acceptable. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across 2022 and 2024 filings, identifying both structural continuity (capacity, pricing) and strategic shifts (repayment, swap usage). It infers a move from passive to active management, consistent with the original conclusion. (4) The only minor gap is that the original emphasizes a 'shift from passive availability in 2022 to active utilization and strategic management in 2024,' while the LLM frames it as reduced use and repayment—slightly different emphasis but factually consistent. The LLM also mentions bond issuance as 'senior unsecured' whereas the ground truth says 'exchangeable bonds'; this is a small discrepancy in bond type, but the core action (issuance to repay) is correct. Overall, the answer is factually robust, contextually relevant, and demonstrates strong qualitative and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1509,
        "completion_tokens": 462,
        "total_tokens": 1971
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Verizon's approach to device payment plans evolved from 2023 to 2024, particularly in terms of customer financing structure and promotional incentives?",
      "original_answer": "In 2023, Verizon permitted customers to acquire equipment using device payment plans that allowed installment payments over time, with no mention of structured promotional incentives or trade-in rights. By 2024, Verizon formalized the device payment plan structure, describing it as a non-interest-bearing installment note typically repaid over a 36-month term, and introduced a defined promotional feature that allows customers to upgrade to a new device after paying a specified portion of their plan and trading in their current device in good working order. This represents a shift from a general financing mechanism to a more structured and incentive-driven model.",
      "llm_answer": "In the 2023 filing Verizon described its device‑payment plans only as a non‑interest‑bearing installment arrangement that lets a consumer spread the purchase price of a handset over up to 36 months (see 2023 p. 5). The 2024 filing expands that description – it still uses a non‑interest‑bearing note, but now explicitly treats any promotional billing‑credit or upgrade‑right as “consideration payable to the customer” that is folded into the transaction price and recorded as a contract liability, and it notes that the financing component of the plan is not material (see 2024 p. 60‑61). Thus, Verizon has moved from a simple installment‑only model in 2023 to a more structured financing framework in 2024 that incorporates promotional credits and trade‑in guarantees as part of the contract accounting.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but has minor discrepancies in emphasis and completeness. (1) Quantitatively, all details are accurate: the 36-month term, non-interest-bearing structure, and correct referencing of accounting treatment in the 2024 filing (pp. 60–61) match the source. The 2023 description as a simple installment plan (p. 5) is also correctly cited. (2) However, the LLM emphasizes accounting treatment—'consideration payable to the customer,' 'contract liability,' and 'financing component not material'—which, while factually present in filings, shifts focus toward financial reporting rather than the customer-facing evolution of promotional incentives emphasized in the original answer. The ground truth highlights the introduction of a defined upgrade path after paying a 'specified portion' and trading in the device, which the LLM mentions only indirectly via 'upgrade-right' without clarifying the customer benefit or trade-in condition. (3) The multi-hop reasoning is sound—correctly comparing 2023 and 2024 disclosures across filings and synthesizing changes in structure and incentives—but leans more on accounting semantics than the operational shift in customer financing. (4) Despite this nuance, the core evolution—from a basic installment plan to a structured, incentive-driven model—is accurately conveyed, warranting a high correctness score. Minor deduction due to incomplete emphasis on the promotional upgrade mechanism as a customer benefit.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 416,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has The Coca-Cola Company's legal relationship with Aqua-Chem evolved between 2023 and 2024, particularly in terms of its stance on liability for Aqua-Chem's asbestos-related claims?",
      "original_answer": "In 2023, Coca-Cola maintained that it had no obligation to Aqua-Chem for any liabilities or expenses related to claims or lawsuits against Aqua-Chem, as outlined in the Georgia Case. By 2024, while the litigation status remained largely unchanged, Coca-Cola's disclosure now includes a more detailed description of the insurance policies issued during its ownership of Aqua-Chem, particularly highlighting the involvement of multiple insurers and the ongoing coverage litigation. This indicates a shift in emphasis from outright denial of liability to a more nuanced stance centered on insurance coverage and shared responsibility among insurers.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K describe the same litigation posture: Coca‑Cola continues to pursue a declaratory judgment that it “has no obligation” for any past, present or future liabilities arising from Aqua‑Chem’s asbestos‑related claims, and the Georgia case remains stayed pending the outcome of the insurance‑coverage actions. The company’s recent updates simply note that the earlier favorable summary‑judgment rulings and settlements with insurers remain in force and that no new liability has been assumed, indicating that its stance on Aqua‑Chem liability has not changed between the two years.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent in terms of dates (2023 and 2024), entities (The Coca-Cola Company, Aqua-Chem, Georgia case), and legal posture (declaratory judgment, no obligation), which supports a high quantitative accuracy score. There are no numerical values to verify, so this aspect is neutral but not penalized. However, the core of the question asks about the *evolution* of Coca-Cola's legal stance between 2023 and 2024. The LLM claims there was *no change* in stance, directly contradicting the ground truth, which identifies a meaningful shift in emphasis—from outright denial in 2023 to a more nuanced, insurance-focused narrative in 2024 involving multiple insurers and coverage litigation. This evolution is central to the question and was missed entirely by the LLM. The model incorrectly interprets consistency in legal outcome (no assumed liability) as consistency in stance, failing to recognize the qualitative shift in argumentation and disclosure strategy. This represents a failure in multi-hop reasoning: the model must compare the tone, content, and emphasis of disclosures across two years, not just the bottom-line legal position. While the LLM accurately reports that the Georgia case remains stayed and that no new liability has been assumed, it omits the key 2024 development—enhanced focus on insurance coverage dynamics—which is critical for a complete and correct answer. Thus, despite accurate entities and context, the qualitative accuracy is low due to incorrect synthesis and reasoning. Contextual relevance is high because the answer addresses the right case, companies, and timeframe, but the conclusion is factually misaligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 460,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Intel's utilization of non-US tax credits impact its long-term income tax liabilities in 2024 compared to 2022, and what does this indicate about the company's international tax strategy?",
      "original_answer": "In 2022, Intel reported long-term income taxes payable of $4.3 billion, which included the transition tax from Tax Reform and uncertain tax positions, reduced by non-US tax credits. By 2024, this figure had decreased to $1.6 billion, indicating that the company's utilization of non-US tax credits had a stronger offsetting effect over time. This suggests a strategic shift or increased effectiveness in leveraging international tax credits to reduce overall tax liabilities.",
      "llm_answer": "Intel’s long‑term income‑tax payable fell sharply – from roughly $4.3 billion in the 2022 filing to about $1.6 billion in 2024 – because the 2024 balance is “reduced by the associated deduction for state taxes and **non‑US tax credits**. The drop shows that Intel is actively using foreign tax credits and other international incentives to offset U.S. transition‑tax and uncertain‑position amounts, reflecting a strategy that leans heavily on its overseas operations to lower overall tax liability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the key financial figures: long-term income tax payable decreased from $4.3 billion in 2022 to $1.6 billion in 2024, matching the ground truth exactly. These numbers are presented with appropriate formatting variations ('roughly $4.3 billion', 'about $1.6 billion') which do not affect accuracy. 2) Quantitatively, all values are correct and the comparison (a sharp decrease) is valid. There are no calculation errors. 3) The reasoning correctly attributes the reduction to non-US tax credits and links it to Intel's international tax strategy, demonstrating sound multi-hop synthesis between financial outcomes and strategic implications. The mention of 'state taxes' as an additional factor is not in the original answer but does not contradict it—however, the original emphasizes non-US tax credits as the primary offsetting factor, which the LLM correctly highlights. 4) The answer fully addresses both parts of the question: the impact on tax liabilities over time and what this indicates about international tax strategy. The conclusion about leveraging overseas operations aligns semantically with the ground truth’s 'strategic shift or increased effectiveness.' Minor deduction in qualitative accuracy because the LLM slightly broadens the explanation to include 'other international incentives' and 'state taxes,' which are not explicitly mentioned in the original, but the core reasoning remains accurate and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 404,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has the treatment and risk exposure of pension risk transfers evolved between 2022 and 2024, particularly in terms of interest rate sensitivity and regulatory influence?",
      "original_answer": "In 2022, pension risk transfers were part of the Retirement and Income Solutions business, which was described as containing both short- and long-duration products, and was subject to interest rate scenarios that could impact asset-liability management (ALM) strategies. By 2024, regulatory changes, particularly around defined benefit pension plan funding, were found to potentially reduce the likelihood or delay corporate plan sponsors from terminating their plans or transferring pension obligations. This regulatory evolution increased the potential for a shift in the mix of pension risk transfers toward non-guaranteed funding products, indicating a strategic and regulatory-driven change in exposure.",
      "llm_answer": "In both the 2022 and 2024 filings MetLife continues to treat pension‑risk‑transfer (PRT) business as a long‑duration, capital‑market product that is hedged with interest‑rate swaps and asset‑liability matching; the company’s earnings models still show that lower rates increase pension‑liability expense (because the discount rate falls) and higher rates reduce that expense (page 63). What has changed is the emphasis on regulatory risk: the 2024 filing notes that recent and pending rules on defined‑benefit plan funding could slow sponsors’ willingness to terminate or transfer plans, thereby altering the mix of PRTs and increasing exposure to non‑guaranteed funding products (page 32). Thus, while the core interest‑rate‑sensitivity of PRTs remains unchanged, regulatory developments have become a more prominent driver of the segment’s risk profile between 2022 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the treatment of pension risk transfers (PRT) as long-duration, interest-rate-sensitive products hedged via swaps and asset-liability matching is consistent with the 2022 context, and the shift in 2024 due to regulatory influence on defined benefit plan funding is accurately captured. The core interest rate sensitivity remains unchanged, which matches the original answer's implication that ALM strategies are still rate-sensitive. (2) There are no numeric values (e.g., percentages, dollar amounts) in either the ground truth or LLM response, so quantitative accuracy is not compromised—score reflects full compliance. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across years (2022 vs 2024), identifies the continuity in interest rate sensitivity, and highlights the emerging prominence of regulatory influence as a new risk driver. The mention of page numbers (63 and 32) suggests precise sourcing, though not required, adds credibility. (4) Semantic equivalence is strong: the LLM conveys that regulatory changes may delay plan terminations and shift the PRT mix toward non-guaranteed funding products, exactly as stated in the original. The only minor gap is that the LLM does not explicitly mention the 'Retirement and Income Solutions' business unit, which slightly reduces completeness in entity labeling, but the functional description suffices for accurate understanding. Overall, this is a precise, well-reasoned, and contextually appropriate answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 439,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Medtronic's positioning and product strategy around the InterStim Micro neurostimulator evolved between 2022 and 2024?",
      "original_answer": "In 2022, Medtronic positioned the InterStim Micro as part of its broader InterStim therapy offering for treating overactive bladder, urinary retention, and bowel incontinence, alongside InterStim II and InterStim X neurostimulators. It was described as part of a growing and accepted product line within the Pelvic Health therapies under the Specialty Therapies division. By 2024, Medtronic specifically highlighted the InterStim Micro as a 'rechargeable neurostimulator' while emphasizing the continued acceptance and growth of InterStim therapy, particularly in the U.S., and distinguishing it from the recharge-free InterStim X and InterStim II models. This indicates a more targeted marketing and differentiation strategy for the InterStim Micro within the evolving Pelvic Health product portfolio.",
      "llm_answer": "In the 2022 filing Medtronic highlighted the InterStim Micro as a **newly launched, growth‑driving device** in its Specialty‑Therapies (Pelvic‑Health) segment, noting that its recent introduction was a key contributor to the division’s double‑digit sales increase. By the 2024 filing the company was **positioning InterStim Micro as a mature, rechargeable member of an expanded InterStim portfolio** (alongside the recharge‑free InterStim II and InterStim X), stressing continued acceptance and growth for treating overactive bladder, urinary retention and chronic fecal incontinence. This reflects a shift from launch‑phase promotion in 2022 to broader portfolio integration and sustained market expansion in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: InterStim Micro was introduced as a growth driver in 2022 within the Pelvic Health segment under Specialty Therapies, and by 2024 it was positioned as a rechargeable device within an expanded portfolio that includes recharge-free InterStim II and InterStim X. The conditions treated—overactive bladder, urinary retention, and bowel (or fecal) incontinence—are accurately reflected. (2) There are no numeric values in the original or LLM answer, so quantitative accuracy is not applicable beyond correct use of timeframes (2022, 2024), which are accurate. (3) The multi-hop reasoning is sound: the LLM correctly infers a strategic evolution from launch-phase promotion to portfolio integration and differentiation based on recharge capability, which is consistent with the ground truth’s emphasis on increased targeting and distinction in 2024. (4) The only minor deviation is that the original answer does not explicitly call InterStim Micro a 'newly launched' device in 2022 or state it drove 'double-digit sales increase,' though this is plausible context not contradicted by the ground truth. The LLM adds slight interpretive detail (e.g., 'mature, rechargeable member') but remains semantically equivalent and factually consistent. Overall, the answer is complete, correctly reasoned, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 391,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Simon Property Group's use of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of outstanding borrowings and repayment actions?",
      "original_answer": "In 2022, Simon Property Group had a weighted average outstanding balance under the Credit Facilities (including the Supplemental Facility) of $519.9 million, with a maximum aggregate outstanding balance of $2.1 billion during the year. By 2024, the weighted average outstanding balance under the Facilities had decreased to $311.1 million, and the company had repaid a significant portion of its borrowings, including €750.0 million ($815.4 million U.S. dollar equivalent) under the Supplemental Facility on November 17, 2023. This indicates a strategic reduction and refinancing of debt drawn from the Supplemental Facility over the two-year period.",
      "llm_answer": "- **2022:** At the end of 2021 the Operating Partnership had **$1.05 billion outstanding under the Supplemental Facility** (see the “Unsecured Debt” table in the 2022 filing [page 123]).  It then **drew the full $1.05 billion on December 14, 2021** and **re‑paid that amount on January 12, 2022** with proceeds from a $1.2 billion senior‑note issuance (see the transaction description on page 125).  Consequently, the Supplemental Facility carried **no balance after the early‑2022 repayment**.\n\n- **2024:** The Supplemental Facility still exists with a **borrowing capacity of $3.5 billion to $4.5 billion** (page 69).  The 2024 filing notes that the Operating Partnership **repayed the €750 million (≈ $815 million) outstanding under the Supplemental Facility on November 17, 2023** (page 70).  No new draws are reported, and the aggregate outstanding balance under all credit facilities for 2024 was **$325.1 million**, implying the Supplemental Facility was **effectively zero‑balance** at year‑end.\n\n**Evolution:** The Supplemental Facility went from a $1.05 billion outstanding balance that was fully repaid in early 2022 to a zero‑balance position by 2024, while its available capacity remained unchanged at roughly $3.5‑$4.5 billion.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in key quantitative details. The ground truth states that in 2022, the weighted average outstanding balance under the Credit Facilities (including the Supplemental Facility) was $519.9 million, with a maximum of $2.1 billion during the year. However, the LLM claims a $1.05 billion balance that was drawn and repaid in early 2022, which contradicts the ground truth. While the repayment of €750 million ($815.4 million) on November 17, 2023, is correctly reported, the LLM incorrectly frames this as the only draw/repayment activity under the Supplemental Facility, ignoring the broader usage pattern in 2022. Additionally, the LLM cites a $325.1 million aggregate balance in 2024, while the ground truth reports $311.1 million—close but not exact. (2) The LLM misrepresents the timing and scale of borrowing: it claims the full $1.05 billion was drawn on December 14, 2021, and repaid January 12, 2022, based on a note in the 2022 filing, but this does not reflect the full-year weighted average or maximum balance reported in the ground truth. The $519.9 million weighted average for 2022 suggests sustained borrowing, not a brief drawdown. (3) The reasoning is partially sound in identifying the 2023 repayment and inferring reduced reliance on the facility, but it fails to synthesize the full multi-hop picture: the evolution from sustained 2022 usage (not a one-month blip) to reduced 2024 balances. The conclusion that the facility went from $1.05B to zero is misleading, as the ground truth indicates ongoing but reduced usage, not complete dormancy. (4) Despite these issues, the LLM correctly identifies the €750 million repayment and its dollar equivalent, and correctly notes the facility’s continued existence with high capacity. It also correctly infers a trend of debt reduction. The answer is contextually relevant and well-structured, but the quantitative inaccuracies—especially the mischaracterization of 2022 borrowing—reduce its overall correctness. Minor format flexibility is allowed, but the core numbers do not align with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1477,
        "completion_tokens": 571,
        "total_tokens": 2049
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did COP's investment activity in the Lower 48 region evolve from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments expenses?",
      "original_answer": "In 2022, COP reported $4,854 million in depreciation, depletion, amortization, and impairments expenses for the Lower 48 region, which increased to $5,729 million in 2023. This indicates a significant increase in investment activity or asset utilization in the Lower 48 region over that period.",
      "llm_answer": "In the Lower 48 segment, depreciation, depletion, amortization and impairments rose from **$4.854 billion in 2022 to $5.729 billion in 2023** – an increase of roughly **$0.9 billion**【page_133】. The higher DD&A expense signals that the company’s investment and capital‑intensive activity in the Lower 48 grew between the two years.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the DD&A and impairments expenses for COP in the Lower 48 region were $4,854 million ($4.854 billion) in 2022 and $5,729 million ($5.729 billion) in 2023. The format variation (billion vs. million) is acceptable and numerically consistent. (2) The calculation of the increase (~$0.9 billion) is accurate: $5,729M - $4,854M = $875M, which rounds to ~$0.9 billion. (3) The reasoning is sound: an increase in DD&A and impairments typically reflects higher investment activity or asset utilization, and the LLM correctly infers increased capital-intensive activity in the region. (4) All entities—COP, Lower 48 region, 2022–2023 timeframe, and the financial metric—are correctly identified and synthesized. The answer addresses the evolution of investment activity via expense changes, fulfilling the multi-hop requirement by linking financial metrics to operational implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1162,
        "completion_tokens": 287,
        "total_tokens": 1449
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Verizon's approach to corporate networking solutions evolved from 2023 to 2024, particularly in terms of service description and business segment emphasis?",
      "original_answer": "In 2023, Verizon's Business segment explicitly described offering a broad portfolio of network connectivity products, including private networking services, private cloud connectivity services, and software-defined networking services, with Enterprise and Public Sector revenues reaching $15.1 billion, or approximately 50% of Business's total revenues. By 2024, the Business segment's description became more streamlined, focusing on wireless and wireline communications services and products, including corporate networking solutions, without specifying the same level of detail in offerings or segment revenue. This indicates a shift toward a more generalized presentation of services, potentially signaling a strategic consolidation or simplification of messaging around corporate networking solutions.",
      "llm_answer": "In the 2023 filing the Business segment was described as offering “wireless and wireline communications services and products, including data, video and conferencing services, **corporate networking solutions**, security and managed‑network services…” (page 5 of the 2023 10‑K). The 2024 filing keeps corporate networking in the same portfolio but expands the wording to “wireless and wireline communications services and products, including FWAbroadband, data, video and **advanced communication services, corporate networking solutions**, security and managed‑network services…” (page 100 of the 2024 10‑K), signalling a broader, more advanced suite of networking offerings. At the segment‑level, Business Markets & Other – the line‑item that houses these networking solutions – remains the dominant source of Business revenue (≈42 % of Business revenue in 2023 and still the largest component at ≈39 % in 2024), while Wholesale (a smaller, more carrier‑focused business) stays a modest share, underscoring Verizon’s continued emphasis on mid‑market corporate networking rather than wholesale services.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents both the evolution of Verizon's service description and the financial data. (1) Quantitative Accuracy: The LLM claims that Business Markets & Other accounted for approximately 42% of Business revenue in 2023 and 39% in 2024, but the ground truth states that Enterprise and Public Sector revenues were $15.1 billion, or about 50% of total Business segment revenue in 2023—no percentage is provided for 2024. These figures are not only incorrect but also misattribute the segment name (‘Business Markets & Other’ vs ‘Enterprise and Public Sector’), which is not supported by the original answer. (2) Service Description: The LLM incorrectly asserts that the 2024 filing expanded the service description to include more advanced offerings like ‘FWAbroadband’ and ‘advanced communication services’, suggesting a broadening of services. However, the ground truth indicates the opposite—that the 2024 description became more streamlined and less detailed than in 2023. This is a direct contradiction. (3) Reasoning & Synthesis: The LLM fails at multi-hop reasoning by drawing an incorrect conclusion from the textual changes. It interprets added terminology as a sign of expansion, while the original answer identifies a move toward generalization and reduced specificity. Additionally, the mention of ‘FWAbroadband’ does not appear in the provided ground truth and may be fabricated or misquoted. (4) Contextual Relevance: The response addresses the general topic of corporate networking evolution and segment emphasis, so it remains relevant in scope, but the core facts and interpretation are flawed. Overall, the answer is mostly incorrect due to wrong numbers, misidentified segments, and inverted qualitative analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1481,
        "completion_tokens": 484,
        "total_tokens": 1966
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did MetLife's valuation approach and sensitivity to fair value changes for FVO securities evolve from 2022 to 2024, particularly in terms of the impact of U.S. dollar appreciation?",
      "original_answer": "In 2022, MetLife reported that FVO securities had an estimated fair value of $1.6 billion and were sensitive to changes in the U.S. dollar, with a 10% appreciation leading to a $54 million decrease in value. By 2024, while no direct fair value figure for FVO securities is provided, the company emphasized a broader sensitivity framework where nonperformance risk spreads and unobservable inputs varied by duration and currency, indicating a more nuanced and dynamic valuation methodology. This evolution shows a shift from a static sensitivity model to a more complex, duration- and currency-dependent approach.",
      "llm_answer": "- **2022:** MetLife measured its FVO (fixed‑value‑option) securities at fair value using Level 3 techniques that rely on significant unobservable inputs.  In the 2022 sensitivity analysis, a 10 % appreciation of the U.S. dollar was projected to reduce the fair value of the FVO portfolio by **about $54 million** (a modest loss).\n\n- **2024:** The same Level 3 valuation approach is still disclosed in 2024, but the currency‑sensitivity figures have grown.  The 2024 tables show that the unrealized gain/loss on the “Unit‑linked and FVO securities” line would change by **approximately $135 million** for the assets still held at year‑end, meaning that a 10 % U.S.‑dollar strengthening would now produce a loss of roughly that magnitude (and a gain of the same size if the dollar weakened).  \n\nThus, MetLife’s valuation methodology for FVO securities remained unchanged, but its exposure to U.S.‑dollar movements increased, with the potential fair‑value impact rising from a $54 million loss in 2022 to a roughly $135 million swing in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in the quantitative claims for 2024. The ground truth states that no direct fair value figure for FVO securities is provided in 2024, and there is no mention of a $135 million sensitivity to a 10% U.S. dollar appreciation. Instead, the 2024 disclosure emphasizes a more nuanced valuation framework incorporating duration- and currency-dependent nonperformance risk spreads and unobservable inputs—indicating a methodological evolution, not merely increased exposure. The LLM incorrectly asserts that the valuation methodology 'remained unchanged' and fabricates a $135 million impact figure not present in the original data. While the 2022 number ($54 million decrease) is correctly cited, the 2024 comparison is unsupported. The answer misrepresents the nature of the evolution—shifting from a static to a dynamic model—by focusing solely on increased sensitivity rather than methodological sophistication. Multi-hop reasoning is flawed: it fails to synthesize the shift in approach and invents data. However, the answer is contextually relevant, addressing the right entities (MetLife, FVO securities, U.S. dollar sensitivity) and time frame (2022–2024), and correctly identifies Level 3 inputs as part of the valuation. Wording flexibility is acceptable, but invented numbers and incorrect conclusions about unchanged methodology severely undermine accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 394,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has NextEra Energy's engagement in power marketing activities evolved between 2022 and 2023, particularly in terms of its energy trading services and associated financial performance?",
      "original_answer": "In 2022, NextEra Energy (NEE) was actively engaged in power and fuel marketing and trading activities, primarily providing full energy and capacity requirements services to distribution utilities, including load-following and ancillary services, while also optimizing the value of electricity and fuel contracts and generation assets. By 2023, NEE's subsidiary NEER had expanded its role in power marketing and trading, contributing to a significant increase in net income, which rose from $285 million in 2022 to $3,558 million in 2023. This indicates a substantial evolution and growth in the scale or profitability of NEE’s power marketing and trading activities over the period.",
      "llm_answer": "NextEra’s power‑marketing arm grew sharply from 2022 to 2023.  In 2022 the company recorded a **$2.67 billion loss** from non‑qualifying commodity‑hedge (energy‑trading) activity, but in 2023 that same activity produced a **$2.53 billion gain** – the primary driver of a **$5.95 billion rise in operating revenues** (page 40).  The boost also helped lift net income from $285 million in 2022 to $3.56 billion in 2023, and customer‑supply trading revenues rose an additional **$334 million** (page 40).  Overall, NextEra’s energy‑trading services moved from a loss‑making position in 2022 to a major profit contributor in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in the reported financial figures for 2022 energy-trading activities. The claim that NextEra Energy recorded a '$2.67 billion loss' from non-qualifying commodity-hedge activity in 2022 is not supported by the ground truth, which states a net income of $285 million for that year. Similarly, the $2.53 billion gain in 2023 and $5.95 billion rise in operating revenues are not mentioned in the original answer and contradict the provided data. While the LLM correctly reports the net income increase from $285 million in 2022 to $3.56 billion in 2023 (aligned with the ground truth's $3,558 million), other key numbers are fabricated or misattributed. (2) The calculation of a $5.95 billion rise in operating revenues and the attribution of this change directly to energy trading gains are unsupported. The ground truth does not provide operating revenue figures or breakdowns by activity, so such precise quantification and causal claims cannot be justified. The $334 million increase in customer-supply trading revenues is also absent from the original answer. (3) The multi-hop reasoning is partially sound in that the LLM identifies a shift in financial performance between 2022 and 2023 and links it to energy trading activities. However, it incorrectly infers losses and gains from trading activities not present in the ground truth, undermining the validity of the synthesis. The original answer emphasizes expansion in NEER’s role and a large net income increase but does not break down the drivers to the extent claimed. (4) The contextual relevance is high because the answer addresses the evolution of power marketing, trading services, and financial performance over the two years. However, due to major quantitative errors and unsupported claims about losses and gains, the correctness score is low. The qualitative accuracy is moderate because the direction of change (improvement in profitability) is correct, but the reasoning is based on incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 546,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola FEMSA evolved between 2023 and 2024, particularly in terms of its stake ownership and implications for equity income?",
      "original_answer": "In 2023, Coca-Cola FEMSA was referenced as one of the key bottlers whose financial performance could influence The Coca-Cola Company's credit ratings, indicating an indirect financial dependency. By 2024, The Coca-Cola Company held a 28% ownership stake in Coca-Cola FEMSA, which was accounted for under the equity method. This shift from a dependency-based relationship to a direct ownership stake suggests a strategic evolution, where Coca-Cola now has a more direct financial interest in FEMSA's performance, which will directly impact its equity income (loss) - net line item.",
      "llm_answer": "In the 2024 filing Coca‑Cola discloses that it owned **28 % of Coca‑Cola FEMSA’s outstanding shares** (the same bottler that is accounted for under the equity‑method). In the 2023 filing the company’s stake was lower – it held **about 20 %‑21 %** of FEMSA (the exact 2023 percentage is shown in the 2023 10‑K’s equity‑method note). Because the ownership percentage rose, Coca‑Cola’s **equity‑income from its equity‑method investees increased to $1.77 billion in 2024, up from $1.69 billion in 2023**, reflecting the larger share of FEMSA’s earnings that is now included in Coca‑Cola’s consolidated results.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, The Coca-Cola Company's relationship with Coca-Cola FEMSA was characterized by indirect financial dependency due to FEMSA's influence on credit ratings, with no mention of a 20–21% ownership stake. However, the LLM claims Coca-Cola held about 20–21% in 2023 and increased to 28% in 2024, implying a stake increase. The ground truth only confirms the 28% stake in 2024 and does not provide a prior ownership percentage—thus, the LLM fabricates or assumes a lower 2023 stake without support. Additionally, the LLM introduces specific equity income figures—$1.77 billion in 2024 and $1.69 billion in 2023—which are not present in the original answer and cannot be verified from the provided ground truth. (2) Quantitative accuracy is low because the percentages (20–21% vs. 28%) and dollar amounts ($1.69B, $1.77B) are unsupported by the ground truth. There is no confirmation of a stake increase or specific income values. Even if the 28% figure is correct for 2024, the comparative 2023 stake and financials are invented. (3) The reasoning is partially sound in linking higher ownership to increased equity income, but it fails the multi-hop requirement because it misrepresents the evolution: the shift is from indirect dependency (2023) to direct ownership (2024), not from a lower to higher stake. The LLM assumes continuity and growth rather than recognizing a strategic shift in relationship type. (4) Contextual relevance is high because the answer addresses stake ownership and equity income implications as asked. However, correctness score is low due to unsupported numbers and flawed synthesis. While the 28% stake and equity method accounting align with the ground truth, the added details introduce major inaccuracies, making the overall answer misleading despite some correct elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 515,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the financial investment and operational focus on the Lower 48 region evolved between 2022 and 2023 based on production volumes and depreciation expenses?",
      "original_answer": "In 2022, the Lower 48 region showed strong production volumes, particularly in crude oil (447 thousand barrels daily) and natural gas (1,340 million cubic feet daily), indicating a significant operational focus. In 2023, the financial emphasis on the Lower 48 increased further, as evidenced by a rise in depreciation, depletion, amortization, and impairments expenses from $4,854 million in 2022 to $5,729 million in 2023. This reflects a growing financial investment in the region despite stable or moderate production levels in the prior year.",
      "llm_answer": "In 2023 the company stepped up its spending in the Lower 48.  Capital‑expenditure outlays for that region rose to **$6.5 billion**, up from **$5.6 billion in 2022** (≈15 % increase), and the segment’s **depreciation, depletion and amortization climbed to $5.73 billion**, versus **$4.85 billion a year earlier** (≈18 % increase).  Those larger investment levels were accompanied by higher production volumes in the Lower 48 (crude‑oil, NGL and natural‑gas output grew from 2022 to 2023), indicating a clear shift toward a more intensive operational focus on that region.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in depreciation, depletion, and amortization (DD&A) from $4.85 billion in 2022 to $5.73 billion in 2023, which aligns closely with the ground truth values of $4,854 million and $5,729 million (rounding to $4.85B and $5.73B is acceptable). However, the LLM introduces capital expenditure figures ($5.6B in 2022 and $6.5B in 2023) that are not present in the original answer or implied by the ground truth, making them factually unsupported. Additionally, the claim that production volumes 'grew from 2022 to 2023' contradicts the original answer, which states 'stable or moderate production levels' in the prior year and emphasizes financial investment growth despite stable production. (2) The DD&A numbers are quantitatively accurate within acceptable rounding, but the capital expenditures and production growth claims introduce significant inaccuracies. The percentage increases cited (~15% and ~18%) are mathematically correct based on the numbers provided, but since the underlying capex data is extraneous, these calculations are not grounded in the source. (3) The multi-hop reasoning is partially sound: the model correctly infers increased financial investment from rising DD&A, which is valid. However, it incorrectly assumes that rising capex and production are part of the same trend without evidence, and it misrepresents the production trend, undermining the logical synthesis. (4) The contextual relevance is high as the response directly addresses financial investment and operational focus in the Lower 48 across 2022–2023. Qualitative accuracy is good due to correct use of DD&A as an investment proxy, but quantitative accuracy is reduced due to unsupported numbers. Correctness score is 7 because core financial metric (DD&A) is accurate, but key additions (capex, production growth) are incorrect or unsupported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 513,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Verizon's strategic relationship with its 4G LTE network evolved between 2023 and 2024 in terms of its role within the company's network infrastructure and growth initiatives?",
      "original_answer": "In 2023, Verizon's 4G LTE network was positioned primarily as a foundational component of its wireless services, specifically highlighted as a means to provide FWA broadband as an alternative to traditional landline internet access. By 2024, the strategic role of the 4G LTE network had evolved into being part of a broader integrated network vision that includes C-Band spectrum, millimeter wave spectrum, and fiber infrastructure, aimed at driving innovative products and services and fueling growth. This shift indicates a move from viewing 4G LTE in a service delivery context to a more strategic asset within a multi-technology ecosystem.",
      "llm_answer": "In the 2023 filing, Verizon’s 4G LTE network was highlighted chiefly as a delivery platform for Fixed‑Wireless Access (FWA) broadband and as part of the consumer‑segment wireless service offering. By the 2024 filing, the company positions its 4G LTE network as a core element of its overall infrastructure—alongside C‑Band, millimeter‑wave spectrum and fiber—that underpins new products and services and fuels growth as Verizon expands and monetizes its 5G‑focused strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and semantically equivalent to the ground truth. (1) All key facts are correct: in 2023, 4G LTE was primarily used for FWA and wireless services; by 2024, it became part of an integrated infrastructure including C-Band, millimeter wave, and fiber to support growth and innovation. (2) There are no numeric values to verify (dates 2023 and 2024 are correct), so quantitative accuracy is perfect. (3) The multi-hop reasoning is sound—correctly synthesizing the evolution of strategic role across two years and multiple technologies. (4) The only minor difference is that the LLM answer frames the 2024 strategy as supporting a '5G-focused strategy,' which is contextually accurate but slightly narrows the broader 'multi-technology ecosystem' emphasis in the original. This does not detract from factual correctness but adds interpretive framing. Overall, the answer is complete, contextually relevant, and accurately reflects the strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 282,
        "total_tokens": 1570
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2024, particularly in terms of stake value, ownership structure, and the impact on financial metrics such as backlog and gross margin?",
      "original_answer": "In 2022, Emerson held a stake in AspenTech with a backlog value of $1,042 million, indicating a strategic business relationship. By 2024, this relationship evolved significantly as Emerson completed a transaction that resulted in the creation of 'New AspenTech,' where Emerson owned 55% of the outstanding shares. This acquisition had a measurable impact on financial metrics: gross margin in 2023 increased by 3.3 percentage points, partly due to the AspenTech acquisition, and backlog in 2024 reached $8,053 million, up from $6,533 million in 2021, showing the influence of the AspenTech integration.",
      "llm_answer": "By fiscal 2022 Emerson closed the Heritage AspenTech transaction, paying roughly $12 billion (cash plus debt) and emerging with about **55 % of the newly‑formed AspenTech’s common stock**; the AspenTech backlog jumped from $328 million to $1.042 billion, lifting Emerson’s total order backlog to $8.1 billion. By the end of 2024 Emerson’s holding had risen to **≈57 %** and the company announced a **$240‑per‑share cash offer for the remaining shares, valuing AspenTech at about $15.3 billion**, further increasing the stake’s market value. The AspenTech acquisition immediately improved margins – gross margin rose to **49.0 % in 2023 (up ~0.6 percentage point from the deal)** and to **50.8 % in 2024**, reflecting the higher‑margin software contribution while the backlog growth underscored the strategic upside.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies that significantly undermine its correctness. First, it claims Emerson closed the 'Heritage AspenTech transaction' in fiscal 2022, but the ground truth states the major evolution occurred by 2024 with the creation of 'New AspenTech' and 55% ownership. The LLM incorrectly implies the 55% stake was acquired in 2022, whereas the original answer indicates the 55% ownership resulted from a transaction completed by 2024. Additionally, the LLM states the backlog jumped from $328 million to $1.042 billion, but the ground truth does not mention a $328 million figure or attribute this change to 2022; instead, it notes a 2022 stake with $1,042 million backlog. The LLM also claims Emerson's ownership rose to ≈57% by end of 2024 and that a $240-per-share offer valued AspenTech at $15.3 billion—details absent from the ground truth and unsupported. (2) Quantitative accuracy is low: the gross margin increase is misrepresented. The original answer states gross margin increased by 3.3 percentage points in 2023 due to the acquisition, but the LLM claims a rise to 49.0% (up ~0.6 point) and then to 50.8% in 2024—specific percentages and increments not in the ground truth and potentially conflicting (a 3.3-point increase is substantial and not reflected in the LLM’s smaller 0.6-point attribution). The $8.1 billion backlog figure in the LLM answer does not match the original’s $8,053 million in 2024 (though close, it's attributed incorrectly to 2022). (3) Multi-hop reasoning is partially sound—the LLM attempts to link ownership, financial metrics, and strategic impact—but it synthesizes incorrect data points and timelines, failing to accurately reflect the evolution from 2022 to 2024. The mention of margin improvement and backlog growth aligns with the question’s intent, but the reasoning is based on fabricated or misaligned numbers. (4) Contextual relevance is high as the answer addresses stake value, ownership, and impacts on backlog and margins. However, due to major factual and quantitative errors, especially in dates, ownership percentages, transaction values, and margin impacts, the overall correctness score is low despite covering the right themes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 598,
        "total_tokens": 1972
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has NEE's financial commitment to the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's involvement in the Mountain Valley Pipeline was described as part of its equity method investments, with an ownership stake ranging between 32% and 55%. By 2023, NEE, through its subsidiary NEER, had a more defined 32.8% equity investment in the Mountain Valley Pipeline, which was accompanied by a 20-year natural gas transportation agreement valued at approximately $70 million per year. This indicates a strategic deepening of NEE's commitment to the pipeline, moving from a general equity investment toward a more structured, long-term contractual relationship tied to infrastructure development.",
      "llm_answer": "- 2022 10‑K: NextEra Energy Resources recorded a **full‑write‑off impairment** on its Mountain Valley Pipeline investment in Q1 2022, eliminating the carrying amount of that equity stake (see page 97, “impairment charge to completely write off its investment in Mountain Valley Pipeline”).  \n\n- 2023 10‑K: The company now **plans new equity contributions** for the pipeline’s construction (listed under “Other (i)” as equity contributions in 2024) and has entered a **20‑year natural‑gas transportation agreement** with Mountain Valley Pipeline that obligates roughly **$70 million per year** (see page 108‑109, footnote (b)).  \n\n**Interpretation:** After writing off the asset in 2022, NEE is re‑investing in the Mountain Valley Pipeline, signalling a renewed strategic emphasis on expanding its natural‑gas infrastructure and securing long‑term transport revenue despite the earlier impairment.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding NEE's 2022 financial position on the Mountain Valley Pipeline. The claim that NEE recorded a 'full-write-off impairment' in Q1 2022 is incorrect according to the ground truth, which states that NEE had an equity stake between 32% and 55% in 2022 and does not mention any write-off. This contradicts the original answer and misrepresents the nature of the investment. However, the 2023 details are mostly accurate: the 32.8% equity investment, the 20-year transportation agreement, and the $70 million per year value are all consistent with the ground truth. (2) Quantitatively, the $70 million annual obligation and the forward-looking equity contributions in 2024 are correctly cited, but the critical 2022 impairment claim lacks support in the ground truth and introduces a major error. The percentage stakes (32.8%) are accurate, but the narrative of a write-off followed by re-investment is not substantiated. (3) The multi-hop reasoning is partially sound—linking 2022 and 2023 developments to infer strategic intent—but it is based on a flawed premise (the write-off). The conclusion that NEE is re-investing after a write-off suggests a different investment trajectory than the ground truth, which describes a continuity and deepening of commitment rather than a write-off and restart. (4) Contextual relevance is high because the answer addresses both years and attempts to interpret strategy, but the qualitative inaccuracy in the 2022 characterization undermines the overall correctness. The answer introduces a dramatic turnaround narrative unsupported by the original data, leading to a low correctness score despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 472,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Coca-Cola's relationship with Costa Limited evolved from 2023 to 2024 in terms of its operational integration and strategic positioning within the Global Ventures segment?",
      "original_answer": "In 2023, Costa Limited was referenced as part of Coca-Cola's direct retail operations, specifically through retail stores operated by Costa, and was included within the Global Ventures operating segment. By 2024, Costa Limited was more strategically embedded within the Global Ventures segment, which now also included the results of innocent and doğadan businesses, as well as fees earned under distribution coordination agreements. This indicates a deeper integration and broader strategic role for Costa within Coca-Cola’s diversified beverage portfolio.",
      "llm_answer": "In the 2023 filing Coca‑Cola noted that it “sell[s] directly to consumers through retail stores operated by Costa Limited (‘Costa’). These sales are included in our Global Ventures operating segment.” By the 2024 filing, Costa is listed together with innocent and doğadan as part of the Global Ventures reporting unit (“Our Global Ventures operating segment includes the results of our Costa Limited (‘Costa’), innocent and doğadan businesses…”), showing that Costa has moved from a peripheral sales outlet to a fully integrated, strategically positioned component of the Global Ventures segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2023, Costa Limited was involved in direct retail operations and included in the Global Ventures segment, citing the exact phrasing from the filing about selling through retail stores operated by Costa. In 2024, it accurately notes the deeper integration of Costa within Global Ventures, now grouped with innocent and doğadan, reflecting broader strategic positioning. (2) There are no numerical values to verify, but the dates (2023 and 2024) and entity names (Costa Limited, innocent, doğadan, Global Ventures) are all correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and infers a progression from a more limited operational role to a fully integrated strategic component, which is a valid interpretation of the expanded scope of the segment. (4) The only minor shortcoming is that the LLM does not explicitly mention the inclusion of 'fees earned under distribution coordination agreements' as part of the 2024 segment composition, which slightly reduces completeness. However, the core evolution in operational integration and strategic positioning is correctly captured. Thus, the answer is factually correct, contextually relevant, and semantically equivalent to the original, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 378,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Intel's investment in financial institution instruments evolved between 2022 and 2024, particularly in terms of the fair value of economically hedged marketable debt investments?",
      "original_answer": "In 2022, Intel recorded net losses of $748 million on economically hedged marketable debt investments. By 2024, the fair value of these hedged investments had decreased to $13.5 billion from $17.1 billion in 2023, with Intel recording net losses of $464 million in 2024. This indicates a reduction in both the size of the hedged investment portfolio and the magnitude of losses compared to two years prior.",
      "llm_answer": "Intel’s portfolio of economically‑hedged marketable‑debt investments fell sharply after 2023.  The fair‑value of those hedged debt holdings was $17.1 billion at 31 December 2023 (producing a $534 million net gain), but declined to $13.5 billion at 28 December 2024 (producing a $464 million net loss).  In 2022 the same class of investments generated a $748 million net loss, indicating that the fair‑value balance was higher in 2022‑23 and has been reduced by roughly $3.6 billion between 2023 and 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the 2023 data. The ground truth states that in 2024, the fair value decreased to $13.5 billion from $17.1 billion in 2023, with a net loss of $464 million in 2024 and a $748 million net loss in 2022. However, the LLM incorrectly claims that in 2023, the investments produced a $534 million net gain, which contradicts the ground truth (which does not provide 2023 P&L but implies continued losses given the context). This is a critical quantitative error. Additionally, the LLM invents a net gain figure for 2023 not present in the original answer or implied by it. (2) The fair value figures for 2023 ($17.1B) and 2024 ($13.5B) are correctly stated, as is the $464M net loss in 2024 and $748M loss in 2022. The $3.6B decline between 2023 and 2024 is accurate ($17.1B - $13.5B = $3.6B). However, the erroneous 2023 gain undermines confidence in the financial narrative. (3) The multi-hop reasoning is partially sound—Intel connects changes across 2022, 2023, and 2024 and correctly identifies a reduction in portfolio size and loss magnitude from 2022 to 2024. But the incorrect characterization of 2023 performance (gain vs. likely loss) breaks the logical chain and suggests flawed synthesis. (4) Despite the major error in the 2023 P&L figure, the answer captures the overall trend of declining portfolio size and reduced losses since 2022, which aligns with the question’s focus. Hence, partial credit is given for correct directional analysis and accurate fair value figures, but significant deduction for introducing false financial performance data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 449,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did AMT's financial focus regarding communications sites evolve from 2023 to 2024, particularly in terms of recurring revenue generation and asset retirement liabilities?",
      "original_answer": "In 2023, AMT emphasized recurring revenue generation from communications sites, noting that 99% of total revenues came from property operations, which included leasing space on communications sites. By 2024, the focus expanded to include significant liabilities tied to these assets, with an estimated $4.5 billion in undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This reflects a shift from primarily highlighting revenue streams to also addressing the long-term financial responsibilities associated with site decommissioning.",
      "llm_answer": "In the 2023 filing AMT stressed that the bulk of the revenue from its communications‑site portfolio came from multiyear, non‑cancellable leases – over $60 billion of such lease revenue was expected to continue flowing as recurring cash flows. By the 2024 filing the company’s discussion still centered on preserving that recurring revenue, but it added a new focus on the cost of retiring sites, reporting an estimated undiscounted asset‑retirement liability of roughly $4.5 billion.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in AMT's financial focus from recurring revenue in 2023 to including asset retirement liabilities in 2024, which aligns with the ground truth. However, there is a significant quantitative error: the LLM claims 'over $60 billion' of expected lease revenue, which is not present in the original answer and appears to be fabricated or misattributed. The original answer states that 99% of total revenues came from property operations (including leasing), but does not provide a dollar figure for future lease revenue. This is a major factual inaccuracy. The $4.5 billion asset retirement obligation is correctly reported and matches the ground truth. (2) The year references (2023 and 2024) are accurate, and the liability amount is correct. However, the unsupported $60 billion figure undermines quantitative accuracy. (3) The multi-hop reasoning is sound—LLM correctly synthesizes a shift in emphasis across two years and connects revenue focus with emerging liability concerns. It correctly identifies the nature of the leases (multiyear, non-cancellable) as a source of recurring revenue, which is consistent with AMT’s business model. (4) Despite the incorrect dollar figure, the overall qualitative narrative and contextual relevance are strong. The answer addresses both parts of the question—recurring revenue and asset retirement liabilities—and captures the evolution in focus. The correctness score is reduced due to the significant numerical inaccuracy, even though the directional and conceptual analysis is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 436,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has XOM's strategic positioning in Guyana evolved between 2023 and 2024, particularly in terms of its legal operating framework and business growth emphasis?",
      "original_answer": "In 2023, XOM's operations in Guyana were governed by the Petroleum Activities Act 2023, which allowed for an exploration period typically up to 10 years and a production period of 20 years for oil fields with a renewal period of up to 10 years. By 2024, Guyana was specifically highlighted as one of XOM's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, indicating a strategic shift to emphasize Guyana as a key contributor to earnings through volume growth and integration. This evolution shows that Guyana transitioned from being a jurisdiction with defined exploration and production terms to being a core growth asset within XOM's portfolio.",
      "llm_answer": "In the 2023 filing ExxonMobil described the **legal basis** for its Guyana operations under the newly‑enacted **Petroleum Activities Act 2023**, which gives the Guyanese government authority to issue petroleum agreements with an exploration term of up to 10 years and a production term of 20 years for oil (30 years for gas) that can be renewed for another 10 years. By the 2024 filing, the company’s narrative had moved from merely outlining that framework to **highlighting Guyana as an “advantaged asset”** in its earnings‑driver discussion, grouping it with Permian and LNG projects and stressing its role in the company’s growth‑oriented portfolio. Thus, between 2023 and 2024 ExxonMobil’s positioning in Guyana shifted from defining its contractual regime to actively promoting the country as a key growth driver for the business.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the Petroleum Activities Act 2023 is accurately described, including the 10-year exploration term, 20-year production term for oil (with 10-year renewal), and the shift in 2024 to positioning Guyana as an 'advantaged asset' under volume growth. The mention of 30 years for gas, while not in the original answer, is a factual addition from the Act and does not contradict the ground truth. (2) Quantitative accuracy is perfect: all years (2023, 2024), timeframes (10, 20, 30 years), and entity names (XOM/ExxonMobil, Guyana) are correct. (3) Multi-hop reasoning is sound—LLM correctly synthesizes the evolution from legal framework in 2023 to strategic emphasis in 2024, showing a shift in narrative and strategic positioning. (4) The only minor deviation is that the LLM refers to 'earnings-driver discussion' and groups Guyana with Permian and LNG projects, which adds context not in the original but is consistent with XOM's reporting and does not introduce error. The core evolution—from legal basis to strategic growth asset—is accurately captured. Thus, the answer is semantically equivalent and highly relevant, warranting a 9 for correctness and qualitative accuracy due to slight elaboration beyond the original, but not enough to affect factual integrity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 379,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Caterpillar's involvement in the diesel-electric locomotives business evolved between 2023 and 2024, particularly in terms of its strategic positioning and operational responsibilities?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader Machinery, Energy & Transportation (ME&T) segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as product support for on-highway vocational trucks in North America. By 2024, Caterpillar's positioning had evolved, with diesel-electric locomotives and related components being explicitly tied to integrated systems and solutions for industries like electric power generation, marine, oil and gas, and industrial sectors. Additionally, 2024 emphasized the development of electrified powertrains and zero-emission power sources, signaling a strategic shift toward more advanced and environmentally focused technologies in the locomotive space.",
      "llm_answer": "In the 2023 filing Caterpillar listed diesel‑electric locomotives only as a product line within “diesel‑electric locomotives and components and other rail‑related products and services, including remanufacturing and leasing,” with the segment’s duties limited to remanufacturing engines and providing product support for on‑highway vocational trucks【page_116】.  \nBy the 2024 filing the business is described as part of the Energy & Transportation segment and is framed as a core, strategic offering: Caterpillar now handles the full value chain for diesel‑electric locomotives – from business strategy, product design, development and testing through manufacturing, marketing, sales and ongoing product support【page_38】.  \n\nThus, between 2023 and 2024 Caterpillar moved from a relatively narrow, operational focus on remanufacturing and leasing to a broader, strategically integrated role that oversees the entire lifecycle of its diesel‑electric locomotive products.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Caterpillar's 2023 involvement as limited to remanufacturing and product support within the broader Machinery, Energy & Transportation (ME&T) segment, though it does not explicitly name the segment as 'ME&T' in 2023, instead referring to it more generally. However, it accurately captures the narrow operational scope. (2) For 2024, the LLM correctly notes the strategic elevation of diesel-electric locomotives, describing Caterpillar’s expanded role across the full value chain—strategy, design, development, manufacturing, sales, and support—which matches the ground truth’s emphasis on integrated systems and strategic positioning. The mention of 'Energy & Transportation segment' is consistent with the rebranding or refocusing of ME&T. (3) The reasoning is sound: the LLM correctly synthesizes a multi-hop evolution from a narrow operational role to a strategically integrated one, capturing the core of the transformation. (4) While the ground truth emphasizes the shift toward electrified powertrains and zero-emission technologies—which the LLM omits—this is a minor gap in completeness rather than a factual error. All entities (Caterpillar, diesel-electric locomotives, correct years) are accurate. No numbers, dates, or financial figures are incorrect (quantitative accuracy is perfect). The answer is contextually fully relevant. The omission of the environmental/zero-emission strategic direction prevents a perfect 10, but the core evolution in strategic and operational scope is correctly and clearly conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1456,
        "completion_tokens": 443,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has the company's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, and what does this indicate about its funding strategy?",
      "original_answer": "In 2022, the company disclosed that it raised funding through the issuance of securitized debt obligations, among other instruments, though the exact amount was not provided. By 2024, the company reported a carrying value of $14,264 million for securitized debt obligations, indicating a concrete quantification of this funding source. This evolution suggests a more defined and potentially increased reliance on securitized debt obligations, aligning with a broader strategic emphasis on structured financing.",
      "llm_answer": "In the 2022 filing the company reported $14.99 billion of securitized‑debt obligations, representing about 4 % of its total funding sources (Table 6, page 65). By the 2024 filing the balance of those securities had fallen to roughly $14.3 billion (carrying amount) – a modest decline from the 2022 level (page 219). The near‑flat, slightly lower amount shows that Capital One continues to use securitizations as a supplemental, low‑cost source of liquidity, but it has not increased its reliance on them, underscoring a funding strategy that remains centered on deposits while keeping securitized debt a stable, secondary pillar.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, the company did not disclose an exact amount for securitized debt obligations, but the LLM claims a specific figure of $14.99 billion, which is not supported. Additionally, the LLM cites a 4% share of total funding from Table 6, page 65 of the 2022 filing—information absent from the ground truth and unverifiable here. The 2024 carrying value of $14.3 billion is close to the correct $14,264 million (~$14.26 billion), so this part is approximately accurate. (2) The quantitative inaccuracies are critical: the 2022 figure is fabricated, and the percentage breakdown is unsupported. The minor decline from $14.99B to $14.3B implies a flat trend, but since the 2022 number is incorrect, the comparison is invalid. (3) The reasoning is internally logical but based on false premises. The conclusion that reliance has not increased contradicts the ground truth, which interprets the emergence of a disclosed carrying value in 2024 as evidence of increased strategic emphasis and clearer accounting, suggesting growing reliance. The LLM fails this multi-hop synthesis by misrepresenting 2022 data and drawing an opposite inference. (4) Contextual relevance is fair—the answer addresses funding evolution and strategy, uses appropriate terminology, and attempts analysis. However, due to major factual and quantitative errors, the correctness score is low. The answer misleads despite plausible structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 416,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has McDonald's treatment of developmental licensees evolved between 2023 and 2024, particularly in terms of financial reporting and relationship management?",
      "original_answer": "In 2023, McDonald's disclosed that developmental licensees paid royalties based on a percentage of sales and generally paid initial fees, and the company allocated consideration among lease and non-lease components using historical methods. By 2024, the company emphasized its ongoing evaluation of business relationships, including those with developmental licensees, to identify potential variable interest entities, although it concluded that consolidation of such entities was not appropriate. Additionally, in 2024, McDonald's updated its rounding presentation to the nearest whole number for reported amounts, which affected how financial figures were presented, though the company clarified that these changes were not significant.",
      "llm_answer": "In the 2023 filing McDonald’s described developmental licensees as non‑lease licensees that pay royalties (and usually an initial fee) and were grouped with conventional franchisees for revenue presentation; they were reported in the “International Developmental Licensed Markets & Corporate” segment, which held 8,684 licensed restaurants. The 2024 filing still classifies the same royalty‑and‑fee revenue but adds the new ASU 2023‑07 segment‑reporting requirements, giving more detailed segment‑level disclosures, and shows the licensed‑restaurant base growing to 9,247 (including newly‑acquired locations such as 228 restaurants in Israel), indicating a more active management of the developmental‑licensee portfolio.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes some correct elements but introduces significant inaccuracies and omits key aspects from the ground truth. It correctly notes that developmental licensees pay royalties and initial fees in both years and mentions their classification in financial reporting. However, it fabricates or misrepresents specific numbers: the 8,684 and 9,247 licensed restaurants are not explicitly tied to developmental licensees in the ground truth, nor is there mention of 228 restaurants in Israel—these figures may reflect total licensed restaurants but are incorrectly attributed and used to infer portfolio growth or active management, which is unsupported. (2) Quantitative accuracy is partially correct—the rounding to whole numbers in 2024 is omitted, and the cited restaurant counts are not validated by the ground truth. The increase from 8,684 to 9,247 is a numerical claim not present in the original answer, making it potentially misleading. (3) The reasoning fails on critical multi-hop elements: the original answer emphasizes McDonald’s 2024 evaluation of variable interest entities and conclusion against consolidation, which the LLM omits entirely. Instead, it introduces ASU 2023-07 and 'more detailed segment-level disclosures'—information not present in the ground truth—suggesting a failure to correctly synthesize the actual evolution in reporting and relationship management. (4) While the answer stays relevant to the topic of financial reporting and licensee management, it substitutes actual developments with plausible-sounding but unverified details, reducing factual correctness. The core shift in accounting evaluation and entity consolidation assessment is missed, and the rounding policy change is ignored. Thus, despite some surface-level alignment, the answer lacks fidelity to the true evolution described in the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 507,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Southern Company's approach to its Equity and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of share availability and executive award disclosures?",
      "original_answer": "In 2023, Southern Company had 26.9 million shares available for awards under the Equity and Incentive Compensation Plan, indicating a reserve for future compensation initiatives. By 2024, the company increased transparency around executive compensation by disclosing specific terms for Named Executive Officer equity awards granted under the 2021 Equity and Incentive Compensation Plan, which was effective May 26, 2021. This evolution shows a shift from internal planning and reserve allocation in 2023 to more detailed public disclosure of executive-level compensation mechanisms in 2024, suggesting a more formalized and transparent governance approach for top-level incentives.",
      "llm_answer": "In the 2023 Form 10‑K Southern Company said that, of the 131 million shares it had reserved for equity‑based programs, 26.9 million shares were “available for awards” under the 2021 Equity and Incentive Compensation Plan and the filing only gave a summary of the plan’s size. The 2024 filing still relies on the same 2021 plan but replaces the simple “shares available” statement with a detailed exhibit that spells out the terms of each equity award granted to named executive officers, showing a shift from a high‑level pool‑size disclosure to more granular, executive‑award‑specific transparency.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: 26.9 million shares available in 2023 is accurately reported, and the reference to 131 million shares reserved for equity-based programs (though not in the original answer) is consistent context that does not contradict the ground truth. The 2021 plan's effective date is correctly implied by referencing the '2021 Equity and Incentive Compensation Plan'. (2) The evolution from a high-level disclosure in 2023 ('available for awards') to a more detailed, exhibit-based disclosure in 2024 is correctly identified, matching the ground truth's claim of increased transparency. (3) The multi-hop reasoning is sound: the model correctly infers a shift in disclosure strategy between years using plan details and transparency changes, synthesizing information across filings. (4) While the original answer emphasizes a 'shift from internal planning to public disclosure', the LLM captures the same semantic meaning by describing a move from 'pool-size disclosure' to 'executive-award-specific transparency'. The only minor difference is that the LLM does not explicitly label this as a 'more formalized and transparent governance approach', but the implication is clearly conveyed. No factual errors; wording differences are stylistic and do not affect correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 381,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors contributed to the change in its growth trajectory?",
      "original_answer": "In 2022, Inlyta contributed to Pfizer's operational growth, specifically mentioned among products like Comirnaty, Eliquis, and Vyndaqel that drove growth in the U.S. and international markets. By 2023, Inlyta's global revenue reached $1,036 million, reflecting a 3% total increase and a 5% operational growth. The growth was primarily attributed to the adoption of immune checkpoint inhibitor combinations with Inlyta for first-line treatment of advanced RCC in the U.S., despite lower volumes and net price in certain European markets. This indicates a continuation of growth, albeit at a more moderate pace compared to the broader portfolio dynamics in 2022.",
      "llm_answer": "In 2023 Pfizer reported Inlyta revenues of $1,036 million, up from $1,003 million in 2022 – a modest 3 % increase worldwide (U.S. sales rose 4 % to $642 million versus $618 million and international sales rose 3 % to $394 million). The uptick was driven mainly by stronger U.S. adoption of Inlyta in first‑line combinations with immune‑checkpoint inhibitors for advanced renal‑cell carcinoma, while lower volumes and reduced net price in some European markets limited growth; the modest international gain reflected continued expansion in emerging‑market sales.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports Inlyta's 2023 revenue as $1,036 million and accurately infers the 2022 revenue as $1,003 million, which aligns with a 3% total increase (verified: ($1,036 - $1,003) / $1,003 ≈ 3.3%, rounded to 3% in both answers). U.S. sales increased from $618M to $642M (~3.9% increase, reported as 4%), and international sales rose to $394M (consistent with total revenue split). These figures match the ground truth in magnitude and direction. (2) All numeric values, percentages, and dollar amounts are accurate or appropriately rounded. The calculation of growth rates is sound and consistent with the original data. Format variations (e.g., $1,036 million vs $1,036M) are acceptable and do not affect accuracy. (3) The reasoning correctly identifies the key driver of growth: increased U.S. adoption of Inlyta in combination with immune checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma (RCC), as stated in the ground truth. It also accurately notes that European market challenges—lower volumes and net price—limited growth, which is consistent with the original answer. The mention of emerging-market expansion adds contextual detail not in the original but does not contradict it and supports the moderate international growth. (4) The answer fully addresses both parts of the question: revenue performance evolution (quantitative change from 2022 to 2023) and contributing factors to the growth trajectory. The only minor deviation is that the original answer mentions Inlyta as part of Pfizer’s growth drivers in 2022 without specifying a dollar amount, while the LLM back-calculates $1,003 million for 2022 from the 3% growth figure. This is a reasonable inference and consistent with the data, though not explicitly stated in the ground truth. Overall, the answer demonstrates strong multi-hop synthesis across time periods and geographies, with excellent factual accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 532,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has McDonald's relationship with its franchisees evolved from 2023 to 2024 in terms of financial structure and dependency, particularly regarding revenue recognition and cost-sharing for technology platforms?",
      "original_answer": "In 2023, McDonald's described its relationship with franchisees as a collaborative partnership focused on consistency, quality, and revenue generation through rent, royalties based on a percent of sales, and initial fees. The business model was designed to generate stable and predictable revenue largely tied to franchisee sales. By 2024, the relationship evolved to reflect a stronger dependency on franchisees, particularly in the context of technology platforms. McDonald's began recognizing revenue from franchisees for technology services on a gross basis, with related expenses recorded in 'Other restaurant expenses,' indicating a more integrated and cost-sharing approach. This shift reflects a transformation in the nature of the relationship, with franchisees becoming more operationally interdependent with the company through shared technology infrastructure.",
      "llm_answer": "In the 2023 filing the Company described its franchise model as “largely a revenue‑generating relationship” in which franchisees paid rent, royalties and initial fees and, for “other revenues,” reimbursed the Company for a portion of the costs it incurred to operate various technology platforms 【page 3】. By the 2024 filing the Company has refined that arrangement: it now treats the technology‑platform services as principal‑agent transactions, recognizing the fees on a gross‑basis and noting that timing differences can exist between the costs it incurs and the fees it receives, while still emphasizing that the fees are not intended to generate a margin 【page 46】. At the same time, the 2024 footnote on property and equipment explains that the Company shares the cost of certain restaurant improvements with franchisees, initially allocating the costs between property‑and‑equipment and accounts‑receivable and finalizing the allocation at project completion 【page 46】—a more explicit cost‑sharing mechanism than in 2023. Overall, the franchisee relationship remains highly dependent (≈95 % of restaurants are franchised), but the financial structure has become more transparent, with gross‑basis revenue recognition for technology services and a defined cost‑allocation process for joint improvement projects.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2023 description of the franchise model as revenue-generating with cost reimbursement for technology platforms, and the 2024 shift to gross-basis revenue recognition for technology services as principal-agent transactions, with related expenses in 'Other restaurant expenses' (implied via context of gross recognition and cost timing differences). The mention of cost-sharing for restaurant improvements with allocation between property-and-equipment and accounts-receivable matches the more explicit 2024 mechanism. The ≈95% franchised restaurants figure, while not in the original answer, is a well-known industry fact and does not contradict the ground truth. (2) Quantitative accuracy is perfect: no incorrect numbers, dates (2023 to 2024), or percentages; the use of page references (3, 46) adds precision. (3) Multi-hop reasoning is sound: the model correctly synthesizes changes in revenue recognition (gross vs. net), cost-sharing evolution, and the deepening dependency through technology integration. It infers the increased interdependence from the accounting change, which is logically valid. (4) Semantic equivalence is strong: though the LLM uses more technical accounting language (e.g., 'principal-agent', 'gross-basis'), it conveys the same core evolution in financial structure and dependency. The only minor gap is that the original emphasizes 'stronger dependency' and 'operationally interdependent', while the LLM frames it as increased transparency—slightly different emphasis but not incorrect. Overall, this is a factually correct, complete, and well-reasoned response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1563,
        "completion_tokens": 464,
        "total_tokens": 2028
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value of energy-related derivatives held by Southern Company's subsidiaries evolve from 2022 to 2023, and what does this indicate about the company's exposure to energy market fluctuations?",
      "original_answer": "In 2022, Southern Company's subsidiaries reported a net fair value of $101 million for energy-related derivatives (Mississippi Power: $59 assets, $32 liabilities; Southern Power: $8 assets, $12 liabilities; Southern Company Gas: $28 assets, $65 liabilities). In 2023, the subsidiaries showed a shift with Alabama Power reporting $15 in assets and $110 in liabilities, and Georgia Power reporting $13 in assets and $124 in liabilities for energy-related derivatives. This indicates a significant increase in net liability exposure, rising from a net liability of $54 million in 2022 to a net liability of $219 million in 2023, suggesting a greater exposure to energy market fluctuations.",
      "llm_answer": "In 2022 the subsidiaries’ energy‑related derivatives were roughly balanced between assets and liabilities (about $409 million total fair value), but by 2023 the mix shifted to a larger liability component – the consolidated fair‑value total rose only modestly to roughly $413 million, while Alabama Power’s and Georgia Power’s derivative liabilities grew to $110 million and $124 million respectively (offset by declines at Mississippi Power, Southern Power and Southern Company Gas). This change shows the company’s exposure to energy‑price swings has become more liability‑heavy, indicating greater sensitivity to market fluctuations, especially for the Alabama and Georgia Power businesses.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The total fair value of $409 million in 2022 and $413 million in 2023 is incorrect. According to the ground truth, the net fair value in 2022 was a net liability of $54 million (total assets: $95M; total liabilities: $149M), not a balanced $409M total. The LLM appears to have incorrectly summed gross values or included non-reported figures. In 2023, only Alabama Power and Georgia Power are reported, with net liabilities of $95M and $111M respectively, totaling a net liability of $219M — but the LLM does not compute or mention this net liability shift. Instead, it cites a consolidated total of $413M without clear breakdown, which is unsupported by the data. (2) The individual liability numbers for Alabama Power ($110M) and Georgia Power ($124M) are correct, but the LLM incorrectly implies that Mississippi Power, Southern Power, and Southern Company Gas reported declines in 2023, while the ground truth does not provide their 2023 data — so this inference is unsupported. Also, the 2022 asset/liability distribution across subsidiaries is omitted in the LLM answer, despite being critical to the multi-hop comparison. (3) The reasoning partially captures the increased liability exposure, noting a shift toward liability-heavy derivatives, which aligns with the conclusion about greater sensitivity to market fluctuations. However, it fails to compute or mention the key net liability increase from $54M to $219M — a crucial multi-hop calculation that demonstrates the evolution. (4) The contextual relevance is high, as the answer addresses the evolution and implications of derivative exposure. However, due to major numerical errors and incomplete synthesis of 2022 data, the correctness score is limited to 5. The qualitative accuracy is moderate due to correct directional logic but flawed data usage. Quantitative accuracy is low due to invented totals and unsupported comparisons.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 532,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the treatment and significance of the Procter & Gamble 2019 Stock and Incentive Compensation Plan evolved from 2022 to 2024, based on its disclosure context in the 10-K filings?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was introduced with detailed references to its adoption by shareholders on October 8, 2019, and its additional terms and conditions, indicating its formal establishment and integration into the company's compensation framework. By 2024, the plan was listed among other equity compensation plans as part of the company's broader disclosure on stock ownership and equity compensation, showing that it had become a standard and active component of the company's long-term incentive structure. This evolution reflects the plan's transition from a newly introduced policy to an established part of PG's equity compensation offerings.",
      "llm_answer": "In the 2022 Form 10‑K the 2019 Stock and Incentive Compensation Plan is highlighted in the exhibit list (e.g., “Regulations of the Compensation and Leadership Development Committee for The Procter & Gamble 2019 Stock and Incentive Compensation Plan” – page 70) and, in Item 12, is identified as the **only** equity‑compensation plan that still permits future grants, with a maximum pool of 187 million shares and **119 million shares remaining available** for issuance – page 69.  \n\nThe 2024 Form 10‑K repeats the same exhibit reference (page 70) and again notes that the 2019 Plan is the sole plan with future‑grant capacity, but the remaining share pool has fallen to **77 million shares** (down from 119 million), indicating that a substantial portion of the plan’s authorized shares has already been granted – page 68.  \n\nThus, while the plan’s disclosure treatment remains consistent (incorporated by reference and singled out as the only plan with future‑grant authority), its significance has shifted: the available share reserve has been reduced markedly between 2022 and 2024, reflecting increased utilization of the plan.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a detailed, factually correct evolution of the Procter & Gamble 2019 Stock and Incentive Compensation Plan from 2022 to 2024 based on 10-K disclosures. (1) Quantitatively, all numbers are correct: in 2022, 119 million shares remaining out of 187 million authorized; by 2024, 77 million remaining, showing a reduction of 42 million shares granted or issued over the period. These figures align with actual 10-K filings and reflect proper tracking of share utilization. (2) The entity identification is accurate—Procter & Gamble, the 2019 Stock and Incentive Compensation Plan, correct years (2022 and 2024), and correct context (Item 12 and exhibit references). (3) The reasoning is sound: the model correctly infers that the plan remains the sole active equity-compensation plan for future grants, indicating its ongoing significance, while the shrinking share reserve reflects increased utilization—this supports the ground truth's claim about the plan transitioning from newly introduced to an established, actively used component. (4) While the original answer emphasizes the plan’s integration into broader equity disclosures and its normalization within the compensation framework, the LLM answer complements this by adding granular, quantitative evidence (share availability decline) that strengthens the narrative of active use and institutionalization. The only minor gap is that the LLM does not explicitly mention the plan’s initial adoption date (October 8, 2019) in the 2022 context, which was part of the ground truth, but this detail is more background than central to the 2022–2024 evolution. Overall, the LLM answer exceeds the ground truth in quantitative precision and maintains semantic equivalence in qualitative interpretation, making it highly correct and contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1463,
        "completion_tokens": 498,
        "total_tokens": 1961
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Southern Company's approach to managing the risk of large losses in its pension plan assets evolved from 2023 to 2024, and what specific changes in risk management emphasis can be observed?",
      "original_answer": "In 2023, Southern Company emphasized a formal rebalancing program and external investment manager oversight as key components of managing the risk of large losses, with a strong focus on long-term investment expectations for return and risk. In 2024, while maintaining a diversified asset strategy and rebalancing program, the emphasis on external manager oversight was reduced, and the risk of large losses was more directly linked to the broader market volatility and interest rate fluctuations. This indicates a subtle shift in risk management emphasis from active oversight to market-driven risk exposure.",
      "llm_answer": "Southern Company’s risk‑management stance for its pension‑plan assets did not change materially between the 2023 and 2024 filings. In both years the company says it “minimizes the risk of large losses primarily through diversification” and backs that up with a formal re‑balancing program, the use of derivatives for efficient exposure/hedging, and written guidelines for external managers. The 2024 filing simply repeats this language, showing no new risk‑mitigation tools or a shift in emphasis—Southern Company continues to rely on diversification and the same oversight mechanisms it described in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that Southern Company's risk management approach did not change between 2023 and 2024. The ground truth indicates a clear shift in emphasis: while both years include diversification and rebalancing, the 2023 filing emphasized external investment manager oversight as a key control, whereas in 2024 this emphasis was reduced and risk was more directly tied to market volatility and interest rate fluctuations. The LLM incorrectly claims the language is 'repeated' and that there is 'no shift in emphasis,' which contradicts the documented evolution in risk management focus. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—no errors in this regard, hence a score of 10. (3) The multi-hop reasoning is flawed: the question requires comparing two years’ risk management strategies to identify changes in emphasis, not just surface-level mechanisms. The LLM fails to detect the nuanced but important shift from active oversight (2023) to market-driven risk exposure (2024), indicating poor synthesis across the two filings. (4) Correctness is low (3/10) because the core claim of 'no material change' is false. Qualitative accuracy is also low due to incorrect reasoning and failure to identify the shift in emphasis. Contextual relevance is moderate because the answer addresses the right topic and company, but misses the key analytical point.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 404,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has NVIDIA's role in the development and supply of the CUDA platform evolved between 2022 and 2023, and what does this shift indicate about the company's strategic focus?",
      "original_answer": "In 2022, NVIDIA's relationship with the CUDA platform was primarily as a supplier, providing the platform as part of its accelerated computing offerings. By 2023, NVIDIA's role had evolved into that of a developer, emphasizing a more active and strategic engagement in the platform's expansion and integration within its broader software ecosystem, including CUDA-X libraries, APIs, and domain-specific frameworks. This shift indicates a strategic move toward strengthening its full-stack computing platform to deliver more comprehensive data center-scale solutions.",
      "llm_answer": "- **2022 filing:** CUDA was bundled into the “developed technology” intangible‑asset line (fair‑value $1.64 billion, amortized over five years) 【page_80】, showing that the company treated the CUDA stack mainly as an internal R&D asset.  \n\n- **2023 filing:** CUDA is now highlighted in the business description as the “foundational CUDA programming model that runs on all NVIDIA GPUs” and the basis for a developer ecosystem of >4.7 million developers 【page_4】, positioning it as a core platform rather than just an internal intangible.  \n\n**Interpretation:** The shift from accounting‑only treatment to a strategic‑platform narrative indicates NVIDIA is moving from viewing CUDA solely as a proprietary technology to leveraging it as a growth engine that ties together hardware, software and ecosystem partners, underscoring a broader focus on platform‑centric, software‑driven revenue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of NVIDIA's role with CUDA from 2022 to 2023: in 2022, CUDA was treated as an internal developed technology asset (with correct fair value of $1.64 billion and 5-year amortization), and in 2023, it was repositioned as a foundational platform with a developer ecosystem of over 4.7 million developers. These numbers and dates are factually correct and match the source data. (2) Quantitative accuracy is perfect: the $1.64 billion intangible asset value and >4.7 million developers are correctly cited. (3) The multi-hop reasoning is sound—comparing the accounting treatment in 2022 to the strategic narrative in 2023 demonstrates a shift from internal asset to core platform, which supports the conclusion about NVIDIA’s strategic focus on a full-stack, ecosystem-driven model. (4) The interpretation about a shift toward platform-centric, software-driven revenue is semantically equivalent to the ground truth’s claim about a strategic move toward comprehensive data center-scale solutions. The only minor limitation is that the LLM does not explicitly mention CUDA-X libraries, APIs, or domain-specific frameworks—components noted in the original answer—so there is a slight omission in completeness regarding the breadth of the software ecosystem. However, the core facts, logic, and strategic implication are correctly conveyed, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 404,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Pfizer's financial relationship with Viatris evolve between 2022 and 2023, particularly in terms of supply agreements and outstanding balances?",
      "original_answer": "In 2022, Pfizer reported $780 million in revenue growth from PC1, primarily reflecting manufacturing of legacy Upjohn products for Viatris under supply agreements. By 2023, the financial relationship had evolved, as indicated by the net amounts due to Viatris under various agreements, which decreased from $94 million as of December 31, 2022, to $33 million as of December 31, 2023. Additionally, most transitional services under the TSAs were completed by the end of 2023, signaling a reduction in operational interdependence.",
      "llm_answer": "In the 2022 Form 10‑K Pfizer reported that, under the post‑separation agency, MSA and TSA arrangements it had with Viatris, it owed the former **$94 million** as of December 31 2022. By the 2023 filing that liability had fallen to **$33 million** at year‑end, reflecting payments made under those agreements. The relationship continued to be governed by long‑term MSAs (four‑ to seven‑year initial terms) under which Pfizer and Viatris manufacture, label, package and perform agency‑type billing and rebate‑remittance services for each other, with most TSA services completed by the end of 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: the $94 million balance as of December 31, 2022, and the reduction to $33 million by December 31, 2023, are accurately reported. These figures match the original answer exactly, and the interpretation that the decrease reflects payments made is reasonable. (2) The answer correctly identifies the nature of the agreements—MSAs and TSAs—and notes that most transitional services were completed by the end of 2023, which matches the original answer’s point about reduced operational interdependence. (3) The only minor omission is that the original answer highlights $780 million in revenue growth from PC1 in 2022 related to manufacturing for Viatris, which the LLM answer does not mention. This is a relevant aspect of the financial relationship in 2022 and constitutes a small gap in completeness. However, the core evolution of the financial relationship—particularly the declining balance and winding down of services—is well captured. (4) Entities (Pfizer, Viatris, MSAs, TSAs), years (2022–2023), and financial terms are correctly used. The reasoning is sound, showing a clear understanding of the multi-hop nature of the question by connecting changes in liabilities and service agreements over time. (5) Despite the omission of the $780 million revenue detail, the answer remains semantically close to the ground truth and fully addresses the evolution in supply agreements and outstanding balances. Thus, the correctness score is 9 due to high accuracy with a minor completeness gap.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 442,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has the treatment and disclosure of communications sites in relation to debt obligations evolved between 2023 and 2024?",
      "original_answer": "In 2023, communications sites were explicitly referenced as collateral securing debt obligations, such as the 3,343 communications sites securing the Series 2015-2 Notes and the repayment of $1.3 billion in Series 2013-2A Notes funded by the 2023 Securitization. In 2024, while there was no explicit mention of specific communications sites securing debt, the company disclosed broader financial commitments, such as $4.5 billion in estimated undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This shift indicates a move from site-specific debt disclosures to more general obligations, suggesting a change in how communications sites are framed in relation to financial liabilities.",
      "llm_answer": "In the 2023 filing the company described the communications sites only in qualitative terms – the sites that back the 2015‑2 Notes and the Trust Securitizations were pledged as collateral, cash‑flows from those sites were the sole source for servicing the securitized debt, and a default could trigger foreclosure of the sites (see pages 112‑114). By the 2024 filing the discussion had become more quantitative and broader: the notes now disclose that operating‑lease obligations could cause loss of communications sites (note 2 on page 56), provide updated DSCR thresholds, excess‑cash‑flow amounts and the exact balances of restricted cash held in “Cash‑Trap” reserve accounts for both the 2015 Securitization and the Trust Securitizations (pages 57‑58), showing tighter monitoring and reporting of how site‑generated cash supports debt service.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures a shift in disclosure style from 2023 to 2024 but diverges significantly from the ground truth in key factual and quantitative aspects. (1) Quantitative Accuracy: The LLM introduces specific details not present in the original answer, such as 'exact balances of restricted cash' and 'DSCR thresholds', which are not mentioned in the ground truth. The ground truth highlights a $1.3 billion repayment tied to the 2023 securitization and $4.5 billion in asset retirement obligations in 2024—neither of these figures is mentioned in the LLM response, nor are the 3,343 communications sites referenced. Instead, the LLM focuses on operating lease obligations and 'Cash-Trap' accounts, which are not part of the original answer. (2) Completeness: The question asks about the evolution in treatment and disclosure of communications sites in relation to debt obligations. The LLM addresses changes in disclosure detail but misses the core factual evolution: the move from site-specific collateral disclosures (e.g., 3,343 sites securing debt) in 2023 to broader, non-site-specific financial obligations (e.g., $4.5B ARO) in 2024. This central contrast is absent. (3) Entity Accuracy: While the LLM correctly references the 2015-2 Notes and Trust Securitizations, it does not mention the Series 2013-2A Notes or the 2023 Securitization funding their repayment—key elements in the ground truth. The mention of 'operating-lease obligations' causing loss of sites is plausible but not supported in the original answer. (4) Reasoning: The LLM infers a shift toward 'tighter monitoring and reporting', which is a reasonable interpretation but differs from the ground truth's conclusion of a move from site-specific to general obligations. The reasoning is internally logical but based on unsupported details. (5) Semantic Equivalence: The overall message of evolving disclosure is present, but the factual basis and multi-hop synthesis (linking specific sites to specific debts in 2023, then absence of such links in 2024) are not accurately reflected. The LLM invents metrics and focuses on different aspects of disclosures, undermining factual correctness despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 584,
        "total_tokens": 1971
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Comcast's approach to retransmission consent agreements evolved between 2022 and 2023, particularly in terms of revenue recognition and distribution models?",
      "original_answer": "In 2022, Comcast recognized revenue from retransmission consent agreements on a monthly basis as programming was provided, with fees tied to the number of subscribers and generally collected within 60 days. By 2023, the company's Media segment emphasized a combined linear and streaming distribution model, with retransmission fees now explicitly including both traditional and virtual multichannel video providers. The 2023 filing also highlighted a broader integration of Peacock into the distribution ecosystem, suggesting a strategic shift toward hybrid distribution models that blend traditional and streaming services.",
      "llm_answer": "In the 2022 Form 10‑K Comcast described fees from NBC and Telemundo retransmission‑consent agreements as part of its “distribution” revenue, noting that the contracts are typically multiyear, subscriber‑based licences and that the fees are recognized on a monthly basis as the programming is delivered. By the 2023 filing the company still treats those same fees as distribution revenue, but adds that a portion of the agreements now use a fixed‑fee structure (in addition to per‑subscriber fees) while continuing to recognize the amounts monthly as the programming is provided. Thus, the core revenue‑recognition timing has not changed, but the 2023 disclosures reflect a broader mix of subscriber‑based and fixed‑fee models for retransmission‑consent arrangements.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in terms of revenue recognition timing and correctly identifies that Comcast continues to recognize retransmission fees monthly as programming is delivered, which aligns with the 2022 practice. It also correctly notes a shift in 2023 toward including fixed-fee structures alongside subscriber-based fees, which is a valid qualitative update. However, the LLM answer diverges significantly from the ground truth in key strategic aspects: it omits any mention of the expanded distribution model that now includes both traditional and virtual multichannel video providers, a core evolution in Comcast's approach. More importantly, it fails to mention the integration of Peacock into the distribution ecosystem, which is a major strategic shift highlighted in the 2023 filing and central to the question about distribution models. While the LLM accurately reports on revenue recognition (timing and fee structure), it misses the broader, more significant shift toward hybrid linear and streaming distribution models. This omission limits the completeness and qualitative accuracy of the response, especially given the question’s focus on both revenue recognition and distribution models. There are no numerical inaccuracies (quantitative accuracy is perfect), and the answer remains contextually relevant, but the failure to capture the multi-hop synthesis of evolving distribution strategies reduces the overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 400,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Caterpillar's involvement in the production and strategic positioning of diesel-electric locomotives evolved from 2023 to 2024?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader ME&T segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as providing product support for on-highway vocational trucks in North America. By 2024, Caterpillar's engagement had evolved into a more defined production role under the Energy & Transportation segment, which explicitly stated that Caterpillar 'produces' diesel-electric locomotives and components, signaling a more direct and strategic emphasis on this product line. Additionally, in 2024, Caterpillar highlighted competitive pressures in rail-related businesses, naming companies like Wabtec Corp and Siemens Mobility A/S, which was not present in 2023. This indicates a shift from a general operational inclusion to a more prominent and competitive product focus.",
      "llm_answer": "In the 2023 filing Caterpillar listed diesel‑electric locomotives only as one of the many rail‑related products and services within its Energy & Transportation segment (“diesel‑electric locomotives and components and other rail‑related products…”)【page_116】. By the 2024 filing the company is positioning diesel‑electric locomotives as a flagship offering, describing Caterpillar as “the world’s leading manufacturer of … diesel‑electric locomotives” in its corporate overview and again highlighting them as a core product line in the Energy & Transportation portfolio【page_4】【page_6】. This shift shows a move from a peripheral product mention in 2023 to a strategic, market‑lead emphasis in 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies a strategic shift in Caterpillar's positioning of diesel-electric locomotives from 2023 to 2024, noting increased emphasis in the 2024 filing. It accurately reflects that in 2023, locomotives were mentioned as part of a broader list of rail-related products, while in 2024 they were highlighted more prominently, including a claim of being the 'world’s leading manufacturer.' This aligns with the ground truth’s assertion of a more defined and strategic focus in 2024. However, the LLM answer introduces a claim not present in the original answer — that Caterpillar labeled itself the 'world’s leading manufacturer' — which goes beyond the ground truth, which only states that Caterpillar began explicitly saying it 'produces' diesel-electric locomotives. This is a qualitative overstatement. Additionally, the LLM omits the ground truth detail about competitive pressures from Wabtec Corp and Siemens Mobility A/S being explicitly named in 2024, which is a relevant part of the strategic positioning evolution. While the segment name 'Energy & Transportation' is correctly used, the original answer notes that in 2023 the locomotive activity was under 'ME&T' (Mining, Energy & Transportation), which the LLM does not mention, leading to a slight inaccuracy in entity and segment evolution. There are no numerical values to assess, so quantitative accuracy is scored as 10 by default. Contextual relevance is high as the response directly addresses the evolution in strategic positioning. The reasoning is mostly sound but lacks full multi-hop synthesis (e.g., segment reorganization and competitive landscape), and the overstatement reduces qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 461,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of revenue recognition and cost-sharing arrangements between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's revenue from franchisees primarily included rent and royalties based on a percentage of sales with minimum rent payments, and initial fees. The company also mentioned that all restaurants were either operated by McDonald's or by franchisees under franchised arrangements. By 2024, the revenue recognition model remained consistent, but the company provided more detailed disclosures on how it recognizes revenue from franchisees, including the treatment of technology platform fees, which are now presented on a gross basis on the Consolidated Statement of Income. Additionally, in 2024, McDonald's clarified its cost-sharing arrangements for restaurant improvements, where it may fund certain projects and allocate costs between Property and Equipment and Accounts Receivable during the project, finalizing the allocation upon completion. This level of detail on cost-sharing was not present in the 2023 filing, indicating a more nuanced and transparent approach to franchisee financial interactions in 2024.",
      "llm_answer": "Both the 2023 and 2024 filings describe the same franchise‑related revenue model: McDonald’s records rent (minimum‑rent straight‑lined and variable rent based on sales), royalties, initial franchise fees and “other” technology‑platform and brand‑licensing fees on a gross basis when the underlying sales occur, and it treats these items as franchise revenue rather than as consolidated restaurant operations. The cost‑sharing arrangement also remains unchanged – the Company continues to fund restaurant‑improvement projects up‑front, estimates each party’s share during construction, allocates the costs between property‑and‑equipment and accounts‑receivable, and finalizes the allocation at project completion, with no material revision to the policy between 2023 and 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in terms of the revenue recognition model and cost-sharing mechanics described for both 2023 and 2024, with no incorrect numbers or dates (quantitative accuracy is perfect). However, it incorrectly asserts that there was 'no material revision to the policy' and that the model remained unchanged, which contradicts the ground truth: in 2024, McDonald's introduced more detailed disclosures, particularly around technology platform fees being presented on a gross basis and enhanced transparency in cost-sharing arrangements. The ground truth emphasizes an evolution in disclosure and nuance in financial reporting, while the LLM portrays the policies as static. This misrepresents the core of the question—how the relationship evolved. While the LLM accurately describes the mechanics, it fails to acknowledge the increased transparency and refined presentation in 2024, which constitutes a qualitative shortcoming in reasoning and completeness. The answer is contextually relevant and well-structured but misses the evolution aspect central to the question, resulting in a partially correct assessment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1450,
        "completion_tokens": 321,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Southern Company's approach to executive equity compensation evolved between 2023 and 2024, particularly regarding plan documentation and award terms?",
      "original_answer": "In 2023, Southern Company disclosed that stock-based compensation, primarily in the form of performance share units (PSUs) and restricted stock units (RSUs), was granted under the Equity and Incentive Compensation Plan to employees ranging from line management to executives. By 2024, the company formalized the terms for Named Executive Officer equity awards under the same plan, indicating a more structured approach to executive compensation. Additionally, the 2024 filing included detailed documentation practices, such as the designation of specific exhibits for equity award terms, which was not present in the 2023 filing. This reflects a shift toward greater specificity and transparency in executive equity compensation documentation.",
      "llm_answer": "In the 2023 Form 10‑K Southern Company described its equity awards only in general terms – PSUs and RSUs were said to be granted under the 2021 Equity and Incentive Compensation Plan, with vesting rules (e.g., three‑year performance periods for PSUs and one‑third‑per‑year vesting for RSUs, immediate vesting on retirement) but no specific award documentation was attached. By the 2024 filing the company added a dedicated exhibit – “Form of Terms for Named Executive Officer Equity Awards Granted under the Southern Company 2021 Equity and Incentive Compensation Plan” – that spells out the exact award terms for its named executives, showing a move toward more detailed, transparent plan documentation and refined award provisions for senior officers.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately captures the evolution in Southern Company's executive equity compensation approach between 2023 and 2024: in 2023, equity awards (PSUs and RSUs) were described generally under the 2021 Equity and Incentive Compensation Plan, with no specific documentation for executives. In 2024, the company introduced a formal exhibit detailing the 'Form of Terms for Named Executive Officer Equity Awards,' indicating a more structured and transparent approach. (2) There are no numeric values requiring calculation (e.g., dollar amounts, percentages), but the temporal references (2023 vs. 2024) and plan name (2021 Equity and Incentive Compensation Plan) are correct. Vesting details—three-year performance periods for PSUs, one-third-per-year vesting for RSUs, immediate vesting on retirement—are consistent with typical disclosures and add contextual accuracy without contradicting the ground truth. (3) The multi-hop reasoning is sound: the model correctly infers a shift in documentation practice and award specificity by comparing the absence of dedicated exhibits in 2023 to the inclusion of a named exhibit in 2024. (4) The LLM enhances the original answer with slightly more operational detail (e.g., vesting rules) that are consistent with typical SEC filings and do not introduce inaccuracies. All entities—Southern Company, Named Executive Officers, PSUs, RSUs, the 2021 Equity and Incentive Compensation Plan—are correctly identified and contextualized. The answer directly addresses both aspects of the question: plan documentation and award terms. Therefore, all scores are 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 457,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Procter & Gamble's strategic reliance on membership club stores evolved from 2022 to 2024, and what does this shift indicate about the company's broader retail channel strategy?",
      "original_answer": "In 2022, Procter & Gamble identified membership club stores as one of its key retail channels, listing them among a broad set of distribution partners such as mass merchandisers, grocery stores, and e-commerce platforms. However, by 2024, the company's language shifted to emphasize dependency on these membership club stores, indicating a deeper strategic alignment or increased reliance on this channel. This evolution suggests that membership club stores have become more central to P&G's distribution and retail execution strategy, likely reflecting growth in this channel's importance to consumer purchasing behavior and overall market dynamics.",
      "llm_answer": "In the 2022 Form 10‑K, P&G still listed **membership‑club stores** alongside mass merchandisers, grocery and drug stores as one of its core retail‑customer groups (see 2022 p. 4). By the 2024 filing, the company’s discussion of retail channels places far more emphasis on **e‑commerce, mobile/social commerce and hard‑discount channels**, while the same “membership‑club stores” line appears only as part of a broader list of customers (2024 p. 7).  \n\nThe change shows that P&G is **dialing back its strategic focus on club‑store sales and reallocating resources toward faster‑growing digital and value‑oriented outlets**, signaling a broader shift in its retail‑channel strategy toward online and discount formats.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its interpretation of Procter & Gamble's strategic shift. While it correctly identifies that membership club stores were listed among retail channels in the 2022 10-K (p. 4), it misrepresents the 2024 filing by claiming that P&G de-emphasized club stores in favor of e-commerce and discount channels. The ground truth states that P&G actually increased its strategic reliance on membership club stores by 2024, shifting language from 'listing' them to indicating 'dependency'—a sign of growing strategic importance. The LLM incorrectly asserts a 'dialing back' of focus, which contradicts the ground truth. There are no numerical values in the question or answer, so quantitative accuracy is not applicable beyond correct referencing of years (2022, 2024), which the model gets right. However, the qualitative reasoning is flawed: the model fails the multi-hop synthesis by drawing the opposite conclusion from the evidence. Contextual relevance is partially met as it discusses retail channels and strategy, but the core claim is factually inverted. Thus, the answer is mostly wrong with a major factual and interpretive error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 329,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did AMT's involvement with Nigeria Letters of Credit evolve between 2023 and 2024, and what does this indicate about its financial obligations related to this instrument?",
      "original_answer": "In 2023, AMT had a $3.4 million obligation under the Nigeria Letters of Credit as part of its variable rate debt portfolio. However, by 2024, this obligation was no longer present, as indicated by the $0 carrying value in both denominated currency and USD. This indicates that AMT fully settled or otherwise exited its financial obligations tied to Nigeria Letters of Credit within this period.",
      "llm_answer": "In the 2023 Form 10‑K the company reported that it had drawn Nigeria letters of credit amounting to about **$3.4 million** (interest charged at SOFR plus a spread and payable 270 days after each draw). The 2024 Form 10‑K shows the line for Nigeria letters of credit blank – i.e., **no amount outstanding** at year‑end. This change means the previously‑incurred credit‑line was fully repaid or otherwise terminated, eliminating the related interest‑bearing liability and reducing AMT’s financial obligations tied to that instrument.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the $3.4 million obligation in 2023 and $0 outstanding in 2024 are correctly reported, with acceptable phrasing (e.g., 'blank line' implying no carrying value). (2) The answer correctly identifies the source documents (2023 and 2024 Form 10-Ks) and the nature of the obligation (interest at SOFR plus spread, 270-day payment term), which adds contextual detail not contradicted by the ground truth. (3) The reasoning is sound: the disappearance of the line item from 2024 filings supports the conclusion that the obligation was fully repaid or terminated, matching the ground truth's assertion of full settlement. (4) The only minor shortcoming is the lack of explicit mention of 'carrying value' in USD and denominated currency as stated in the original answer, which slightly weakens the qualitative precision but does not affect factual correctness. Overall, the answer captures the evolution and financial implication accurately, with excellent multi-hop synthesis between two years' filings and correct entity and metric identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 320,
        "total_tokens": 1559
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the valuation methodology and composition of GD's Retirement Annuity Contracts change between 2022 and 2024, and what does this indicate about the company's approach to reporting these assets?",
      "original_answer": "In 2022, GD reported Retirement Annuity Contracts as part of Level 3 assets with a fair value of $35 million as of December 31, 2021, and this value remained relatively stable through December 31, 2020 at $38 million. The contracts were disclosed within a detailed table showing actual returns, unrealized gains and losses, and net purchases or sales. By 2024, Retirement Annuity Contracts were still categorized under Level 3 assets but were now described as being valued using NAV (net asset value) as a practical expedient, excluded from the formal fair value hierarchy. This indicates a shift in GD's reporting methodology from detailed fair value disclosures to a more simplified NAV-based approach, aligning with broader changes in how these contracts are categorized and disclosed.",
      "llm_answer": "- **Valuation methodology:** In both the 2022 and 2024 filings the company treats retirement‑annuity contracts as **Level 3 assets** – fair‑value items that are measured using valuation techniques that rely on significant unobservable inputs. The 2024 note (page 93) repeats the same description that “our Level 3 assets consist of insurance deposit contracts, retirement annuity contracts and real‑estate funds,” and the 2022 note (page 96) lists the same three categories, showing the methodology has not changed.  \n\n- **Composition:** The dollar amount of the retirement‑annuity contracts has fallen. The 2022 10‑K shows a balance of **$35 million** (2021) – down from $38 million in 2020 – while the 2024 10‑K reports **$22 million** in 2024 (down from $25 million in 2023) (page 94).  \n\n**What this indicates:** General Dynamics continues to apply a consistent, transparent Level 3 fair‑value approach for these low‑liquidity contracts, but the contracts themselves have become a smaller component of the plan‑asset pool, reflecting either a reduction in the contracts held or a re‑allocation of assets while still disclosing them separately.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains both correct and incorrect information. It correctly identifies that Retirement Annuity Contracts were classified as Level 3 assets in 2022 with a value of $35 million as of December 31, 2021 (from the 2022 filing), and notes a decline from $38 million in 2020, which aligns with the ground truth. However, it incorrectly states that in 2024 the value was $22 million, which is not supported by the original answer — the ground truth does not provide the 2024 dollar amount, only that the valuation methodology changed. More critically, the LLM fails to identify the key change in valuation methodology: in 2024, GD began using NAV as a practical expedient, which removes these assets from the formal fair value hierarchy despite still being labeled as Level 3 in name. The LLM incorrectly asserts that the methodology 'has not changed' because the same categories are listed, missing the fundamental shift in accounting treatment. (2) Quantitatively, the $35M and $38M figures are accurate, and the direction of change (declining) is plausible, but the $22M figure for 2024 is not present in the ground truth and appears to be fabricated or misattributed from another source, making it factually unsupported. (3) The multi-hop reasoning is flawed: the question asks about changes in both methodology and composition, and what that indicates. The LLM correctly tracks composition trends up to 2021 but incorrectly extends them to 2024 without proper support. It fails to synthesize the critical methodological shift involving NAV as a practical expedient, which is the central point of the original answer. Instead, it concludes the methodology is unchanged, which contradicts the ground truth. (4) The contextual relevance is moderate — the answer addresses the right topic and company, uses appropriate terminology, and attempts to compare across years, but misses the core insight about reporting simplification and NAV expedient use, leading to an incorrect overall conclusion about consistency in methodology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1497,
        "completion_tokens": 552,
        "total_tokens": 2049
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the composition and value of restricted cash for securitization investors changed between 2022 and 2024, particularly in terms of its fair value hierarchy classification?",
      "original_answer": "In 2022, the company reported restricted cash for securitization investors as part of consolidated VIEs, with the assets and liabilities presented on the consolidated balance sheets. By 2024, the restricted cash for securitization investors was valued at $441 million, with the entire amount classified under Level 1 of the estimated fair value hierarchy, indicating a shift toward more transparent or market-based valuation methods. This reflects a more defined and standardized valuation approach in 2024 compared to 2022, where the fair value hierarchy was not explicitly detailed for this category.",
      "llm_answer": "In the 2022 filing the balance‑sheet line “restricted cash for securitization investors” was reported at roughly $450 million and was measured using Level 2 inputs (significant unobservable inputs). By the 2024 filing the amount had changed only modestly – it was $441 million – but the cash is now measured at Level 1 of the fair‑value hierarchy, meaning it is valued using observable market inputs. Thus, the value of the restricted‑cash pool has stayed essentially flat while its fair‑value classification has moved from Level 2 to Level 1. (2022 data – 2022 10‑K; 2024 data – Table 17.6 on page 219).",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual discrepancy regarding the 2022 fair value hierarchy classification. The original answer states that in 2022, the fair value hierarchy was not explicitly detailed for restricted cash for securitization investors, whereas the LLM claims it was classified as Level 2. This is unsupported by the ground truth and represents a critical error in entity and qualitative accuracy. The 2024 value of $441 million and its Level 1 classification are correct and match the ground truth. The $450 million figure for 2022 is not present in the original answer, which does not provide a specific dollar amount for 2022—only a description of presentation practices—making this number unsupported. (2) Quantitative accuracy is partially correct: $441 million in 2024 is accurate, but the $450 million for 2022 is an unsupported addition. No calculation is required, but the comparison of stability in value relies on an unverified 2022 figure. (3) Multi-hop reasoning is partially sound: the model attempts to compare classification changes over time and correctly identifies the shift to Level 1 in 2024. However, it fabricates the 2022 Level 2 classification and specific amount, undermining the reasoning chain. (4) Contextual relevance is high—the response addresses the question’s focus on changes in composition, value, and fair value hierarchy. However, due to the incorrect attribution of Level 2 and unsupported 2022 value, the correctness score is limited to 6, reflecting partial accuracy with significant factual gaps.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 432,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial recognition and asset management between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's relationship with franchisees was primarily characterized by the acquisition of restaurants from franchisees, resulting in goodwill that was either fully or partially written off depending on the time of sale relative to acquisition. The Company used a discounted cash flow methodology to determine the fair value of acquired restaurants. By 2024, the relationship had transformed into a more dependency-based model, particularly in the area of technology platform services. McDonald's now provides distinct technology-related goods and services to franchisees, recognizing revenue on a gross basis and corresponding expenses within 'Other restaurant expenses.' This marks a shift from asset acquisition and goodwill management toward ongoing service-based financial interactions with franchisees.",
      "llm_answer": "Between 2023 and 2024 McDonald’s kept the same accounting treatment for franchise‑related revenues – rent, royalties and initial‑fee income are still recognized as the underlying sales occur and technology‑platform fees are presented on a gross basis (see the “Revenue Recognition” sections in both years [2023 p.44] and [2024 p.44]).  At the same time the company deepened its ownership of former franchisee locations: the number of franchised restaurants rose from 39,680 to 41,432 and the goodwill balance grew from $3.04 billion to $3.15 billion, reflecting larger net restaurant purchases (from $107 million in 2023 to $179 million in 2024) and the recording of $150 million of net tangible assets, $270 million of identifiable intangibles and $240 million of goodwill from those acquisitions [2023 p.45] [2024 p.47].  Thus, while revenue recognition from franchisees remained unchanged, the firm’s asset management shifted toward more direct acquisition of franchisee restaurants, increasing goodwill and related intangible assets.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies and misrepresents the evolution of McDonald's relationship with franchisees between 2023 and 2024. While it correctly references revenue recognition policies (e.g., gross basis for technology fees), it contradicts the ground truth by claiming that McDonald's increased ownership of franchisee restaurants, citing rising goodwill from $3.04B to $3.15B and net restaurant purchases increasing from $107M to $179M. However, the original answer states that 2023 involved goodwill write-offs due to sales back to franchisees, not growing goodwill from acquisitions. The LLM implies continued expansion of company-owned restaurants through acquisition, whereas the ground truth describes a strategic shift away from asset-heavy transactions toward service-based relationships, particularly in technology platforms. The cited numbers (e.g., franchised restaurants increasing from 39,680 to 41,432) are factually incorrect in this context—such growth would imply franchisees buying more locations, not McDonald's acquiring them, which contradicts the narrative of increased direct ownership. Furthermore, the $150M tangible assets, $270M intangibles, and $240M goodwill from acquisitions in 2024 are not supported by the ground truth, which emphasizes a move beyond asset acquisition. The reasoning is flawed: instead of identifying a shift from asset management to service dependency, the LLM asserts continuity in revenue recognition and intensification of asset acquisition—opposite to the actual transformation. Quantitative accuracy is partially maintained in format and referencing (e.g., page numbers), but the core financial figures misalign with the source. Contextually, the answer addresses financial recognition and asset management, so relevance is moderate. However, the qualitative analysis fails to capture the multi-hop shift from goodwill-driven transactions to service-based revenue, resulting in a significant correctness deficit.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1461,
        "completion_tokens": 534,
        "total_tokens": 1996
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the treatment of the 2019 Stock and Incentive Compensation Plan evolved between 2022 and 2024 in Procter & Gamble's disclosures, particularly regarding its relationship with other compensation plans and its role in equity compensation?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was disclosed as part of a broader set of compensation plans, with specific reference to its adoption by shareholders in 2019 and its regulation in conjunction with other plans like the 2014 Stock and Incentive Compensation Plan. By 2024, the 2019 Plan was still included in the list of active equity compensation plans, but it was now referenced in the context of security ownership and the total shares available for issuance, indicating a shift from adoption and governance details to its role in the company's overall equity compensation structure. This reflects a transformation in how the plan is positioned within the company's disclosures, moving from procedural governance to a more strategic ownership framework.",
      "llm_answer": "In the 2022 Form 10‑K the 2019 Stock and Incentive Compensation Plan was described as the **only equity‑compensation plan that still permits future grants**, with a maximum authorisation of 187 million shares and about 119 million shares remaining available; its regulations were listed together with those of the 2014 plan (see Exhibit 10‑25). By the 2024 filing the plan’s status was unchanged – it remains the sole plan that can issue new equity awards and its regulations are still grouped with the 2014 plan – but the amount of shares left for future issuance fell to roughly 77 million (still out of the 187‑million ceiling). Thus, between 2022 and 2024 the 2019 Plan continued to be treated as the exclusive source of new equity compensation, while the pool of shares available under it was reduced.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes specific numeric values (187 million authorized shares, 119 million remaining in 2022, 77 million in 2024) that are not present in the original answer (ground truth), and there is no verification that these numbers are accurate based on the knowledge graph. Since the ground truth does not mention any specific share counts or availability, the inclusion of precise figures introduces unverified quantitative claims, which undermines factual correctness. (2) The quantitative accuracy is low because the answer presents detailed numbers without confirmation from the ground truth; while the direction of change (reduction in available shares) may be plausible, the specific values cannot be corroborated and appear to be hallucinated or sourced from outside the provided knowledge base. (3) Qualitatively, the LLM captures part of the evolution—namely that the 2019 Plan remains central to equity compensation—but misses the key conceptual shift emphasized in the original answer: the transition from procedural/governance disclosures (e.g., shareholder adoption, regulation alongside the 2014 Plan) to a strategic focus on ownership structure and total shares available. Instead, the LLM focuses narrowly on grant eligibility and share depletion, which is relevant but incomplete. It correctly identifies that the 2019 Plan is the only one allowing future grants and that it is still grouped with the 2014 Plan, aligning with the entity and relationship accuracy. (4) Contextual relevance is high because the response directly addresses the evolution of the 2019 Plan’s treatment in disclosures and its relationship to other plans. However, the over-reliance on unsupported numbers and the failure to reflect the conceptual shift from governance to strategic equity framing reduce the overall correctness. The answer provides a plausible but partially fabricated quantitative narrative that diverges from the qualitative, disclosure-focused insight in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 541,
        "total_tokens": 1961
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Salvatore Ferragamo's presence in Simon Property Group's international outlet locations evolved between 2022 and 2023?",
      "original_answer": "In 2022, Salvatore Ferragamo was listed as a tenant in three of Simon Property Group's international outlet locations in Japan: Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Sano Premium Outlets. By 2023, Salvatore Ferragamo appeared in only one of SPG's outlet locations, specifically Las Vegas Outlets North in Nevada, USA. This indicates a significant reduction in Salvatore Ferragamo's presence across SPG's outlet portfolio, shifting from multiple locations in Japan to a single location in the U.S.",
      "llm_answer": "In the 2022 filing, Salvatore Ferragamo was shown as a tenant in a number of SPG’s international premium‑outlet joint‑ventures – it appeared in four Japanese outlets (Gotemba, Kobe‑Sanda, Rinku and Sano) and also in outlets in Mexico (Punta Norte), South Korea (Yeoju and Siehung) and Malaysia (Johor). The 2023 excerpts do not list Salvatore Ferragamo among the tenants of any international outlet locations, indicating that its presence in SPG’s overseas outlet portfolio has been reduced or omitted in the most recent filing.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies. (1) Quantitatively, the original answer states Salvatore Ferragamo was present in three Japanese outlets in 2022 (Gotemba, Kobe-Sanda, Sano), but the LLM claims it was in four Japanese outlets (adding Rinku) and also lists presence in Mexico, South Korea, and Malaysia—none of which appear in the ground truth. This overstates the 2022 presence. (2) The LLM incorrectly states that Ferragamo was not listed in any international outlet in 2023, while the ground truth confirms it appeared in Las Vegas Outlets North in Nevada, USA—though this is a U.S. location, not international. However, the LLM mischaracterizes the 2023 data by implying complete absence from SPG outlets, when in fact it was present in one U.S. location. (3) The reasoning is flawed: the LLM fails to correctly synthesize the shift from multiple Japanese locations in 2022 to a single U.S. location in 2023, instead suggesting a full withdrawal from SPG’s outlet portfolio, which is incorrect. (4) Contextually, the answer addresses the evolution of presence, so relevance is moderate, but the factual foundation is unsound. The core conclusion—that presence decreased—is directionally correct, but the magnitude and geography are wrong, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 361,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about its operational focus in the region?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region, suggesting a potential shift or stabilization in operational focus rather than aggressive growth.",
      "llm_answer": "In the 2024 filing ConocoPhillips reports that its proved natural‑gas reserves in the Asia Pacific/Middle East fell from 312 billion cubic feet (BCF) at the end of 2023 to 296 BCF at the end of 2024, while annual production in the region stayed essentially unchanged at about 25 BCF. At the same time the company increased its development‑well activity in the area (20 wells in 2023 to 22 wells in 2024) and, per the 2024 notes, its equity‑affiliate extensions and discoveries were now focused on the Middle East (and Australia). This modest reserve decline combined with steady output and added development work signals that COP is concentrating on developing and sustaining its existing gas assets in the Asia Pacific/Middle East rather than expanding the reserve base through new purchases.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the natural gas reserves for COP in the Asia Pacific/Middle East region: 312 billion cubic feet (BCF) in 2023 and 296 BCF in 2024, matching the ground truth exactly. The production figure of ~25 BCF is not in the original answer but is consistent with external data and does not contradict the ground truth. The increase in development wells (20 to 22) and shift in equity-affiliate focus to the Middle East and Australia are accurate contextual details that enrich the answer without introducing errors. (2) All numeric values—312 BCF, 296 BCF, 20 to 22 wells—are factually correct and align with the knowledge graph. The calculation of a 16 BCF decrease is implied and accurate. (3) The multi-hop reasoning is sound: the model synthesizes reserve changes, production stability, and development activity to infer that COP is focusing on sustaining and developing existing assets rather than pursuing reserve growth via acquisitions. This goes beyond the original answer but is a logical and well-supported interpretation. (4) The original answer notes a 'minor reduction' and 'potential shift or stabilization'; the LLM provides a more nuanced and evidence-based conclusion ('concentrating on developing and sustaining'), which is consistent and adds value. The only reason for not scoring 10 is that the original answer does not mention production or well counts, so while accurate, those are inferences beyond the ground truth. However, they do not detract from correctness. All scores reflect high accuracy, strong reasoning, and full relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 438,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Comcast's approach to wireless gateways evolved from 2022 to 2024, particularly in terms of strategic emphasis and investment?",
      "original_answer": "In 2022, Comcast offered wireless gateways as part of its broadband services, combining modem and Wi-Fi router capabilities to enhance in-and-out-of-home coverage. The focus was on customer-facing features like the xFi whole-home application and advanced security. By 2024, the company elevated its strategic emphasis by shifting from merely offering wireless gateways to actively investing in their deployment as part of its broader network infrastructure upgrades. This included plans to increase capacity and deliver multigigabit symmetrical speeds, signaling a deeper integration of wireless gateways into its long-term network strategy.",
      "llm_answer": "In its 2022 filing Comcast presented wireless gateways mainly as a product feature – “wireless gateways … combine an internet modem with a Wi‑Fi router … and can be managed with the xFi whole‑home app” – emphasizing their role in delivering reliable in‑home Wi‑Fi coverage for broadband customers【page_7】.  \nBy the 2024 filing the company had moved the gateways into a capital‑expenditure focus, noting that future capex will continue “the deployment of wireless gateways” as part of the Connectivity & Platforms business, even as overall spending on customer‑premise equipment (which includes gateways) was lower in 2024 than in 2023【page_51】【page_50】.  \n\nThus, Comcast’s approach shifted from a product‑offering emphasis in 2022 to an infrastructure‑investment emphasis in 2024, treating gateway rollout as a key component of its network‑upgrade spending.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Comcast's 2022 approach as product-focused, emphasizing wireless gateways as integrated modem-router units managed via the xFi app, which matches the original answer's description of customer-facing features. By 2024, the LLM correctly notes a strategic shift toward treating gateway deployment as part of capital expenditure and network infrastructure, citing specific language from filings about continued deployment within the Connectivity & Platforms segment. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or ground truth that require verification; the LLM accurately references relative capex trends (lower spending on customer-premise equipment in 2024 vs 2023) without contradicting the strategic emphasis on gateways, which is consistent with the original answer’s claim of increased strategic importance despite possible fluctuations in overall equipment spending. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly inferring a shift in strategic emphasis from a customer product feature to a network infrastructure investment. It supports this with appropriate context from both years, demonstrating proper cross-document synthesis. (4) The only minor limitation is that the LLM does not explicitly mention 'multigigabit symmetrical speeds' or 'capacity increases' as part of the 2024 strategy, which are specific elements in the ground truth that reinforce the infrastructure integration point. While the capex focus implies this, the omission slightly reduces completeness in qualitative detail. However, the core factual claims and strategic interpretation remain correct. Thus, the answer is semantically equivalent with high contextual relevance and excellent reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 510,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the G600's market presence and production evolution changed between 2022 and 2024, particularly in terms of cumulative deliveries and its role within Gulfstream's product lineup?",
      "original_answer": "In 2022, the G500 and G600 had cumulative deliveries totaling almost 150 by year-end 2021, and were described as replacements for the G450 and G550 models with improvements in speed, fuel efficiency, cabin volume, and flight controls. By 2024, cumulative deliveries of the G500 and G600 had more than doubled to over 300 by year-end 2024. Additionally, the G600 was no longer described in the context of being a new product introduction, indicating it had become a more established part of Gulfstream's lineup, while the focus shifted to newer models like the G800 and G400.",
      "llm_answer": "By the end of 2021 (the latest figure disclosed in the 2022 filing), Gulfstream had delivered “almost 150” G500 and G600 aircraft combined, with the G600 – launched in 2019 – positioned as the clean‑sheet replacement for the legacy G550 and a core member of Gulfstream’s large‑cabin lineup【page_6】. By year‑end 2024 the cumulative deliveries of the G500/G600 family had more than doubled to “over 300” aircraft, underscoring the G600’s strong market uptake and its continued role as a flagship product alongside newer models such as the G700, G800 and upcoming G400【page_5】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers and timeframes are correct: 'almost 150' cumulative deliveries by end of 2021 (as reported in the 2022 filing) and 'over 300' by end of 2024 are consistent with the original answer. The claim that deliveries 'more than doubled' is logically sound (150 to 300+ is exactly or slightly over double), so calculations and comparisons are accurate. (2) The entities—G500, G600, G450, G550, G700, G800, G400—are correctly identified, and the timeline (G600 launched in 2019, data from 2022 and 2024 filings) is accurate. (3) The reasoning is sound: the LLM correctly infers that the G600 transitioned from a new product to an established flagship, now part of the core lineup, while newer models (G800, G400) are the focus—this matches the original answer’s point about shifting emphasis. (4) The only minor discrepancy is that the original answer notes the G600 replaced the G550 and G450 (with G500 replacing G450), while the LLM states the G600 replaced the G550 but does not mention the G450 in that context. Also, the original specifies the G600 is no longer described as a 'new product introduction,' while the LLM interprets this as being a 'flagship product,' which is a reasonable qualitative inference. Wording differs slightly but semantic meaning is equivalent. All parts of the question—market presence, production evolution, cumulative deliveries, role in product lineup—are addressed with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 415,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has AIG's financial relationship with Corebridge evolved between 2023 and 2024, particularly in terms of equity ownership and income recognition?",
      "original_answer": "In 2023, AIG held 52.2% of Corebridge common stock and was in the process of selling down its stake, with the intention to fully divest over time. By 2024, AIG had transitioned to accounting for its remaining interest in Corebridge using the equity method, recognizing pre-tax income based on dividends received and changes in Corebridge's stock price from June 9, 2024. This represents a shift from direct ownership control to a more passive investment approach, indicating a significant change in the nature of AIG's financial relationship with Corebridge.",
      "llm_answer": "- **Equity ownership:** In 2023 AIG still owned a majority of Corebridge – 52.2 % of the common stock as of December 31, 2023 (2023 Form 10‑K, p. 27).  After the June 9 2024 de‑consolidation, AIG’s stake fell to 48.4 % and was subsequently reduced through share sales, leaving AIG with only 22.7 % of Corebridge’s outstanding shares at December 31, 2024 (2024 Form 10‑K, p. 108).  \n\n- **Income recognition:** While Corebridge was still consolidated in 2023, its results were reported as discontinued‑operations income (AIG’s share of discontinued‑operations net income was $902 million for 2023).  Following de‑consolidation, AIG elected the fair‑value option and now accounts for its remaining interest under the equity‑method; dividends and changes in Corebridge’s stock price were recorded as equity‑method income of $601 million for the June 10‑December 31, 2024 period (2024 Form 10‑K, p. 109) and are reflected in net investment income.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. (1) All key facts are correct: AIG held 52.2% of Corebridge as of December 31, 2023 (2023 Form 10-K, p. 27), de-consolidated on June 9, 2024, and retained 22.7% ownership by December 31, 2024 (2024 Form 10-K, p. 108). Income recognition shifted from consolidated discontinued operations ($902M in 2023) to equity-method accounting post-deconsolidation, with $601M in income recognized from June 10–December 31, 2024 (2024 Form 10-K, p. 109). These numbers match the ground truth and source documents. (2) Quantitative accuracy is perfect: percentages, dates, and dollar amounts are correctly cited with proper time periods and formatting variations acceptable (e.g., $601 million = $601M). (3) Multi-hop reasoning is sound—LLM correctly synthesized changes in ownership and accounting treatment across two filings and years, identifying the shift from control to passive investment. (4) The only minor gap is that the original answer emphasizes the broader strategic shift (intention to fully divest), which the LLM implies via stake reduction but doesn’t explicitly state. However, the core financial evolution—ownership dilution and accounting change—is fully captured with precise evidence. Thus, correctness is 9/10 due to slight omission of forward-looking intent, but quantitative and contextual accuracy are flawless.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 380,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Tesla's production strategy for the Solar Roof evolved between 2022 and 2024, particularly in terms of manufacturing dependencies and operational challenges?",
      "original_answer": "In 2022, Tesla was actively producing the Solar Roof at Gigafactory New York, which was specifically highlighted as a dedicated facility for the development and production of Solar Roof and other solar products. The company offered financing options tied to the Solar Roof, indicating a strategic push to integrate the product into its broader energy ecosystem. By 2024, Tesla's disclosures shifted to emphasize increased complexity and risk in ramping production of the Solar Roof, with explicit mention of 'delays in launching and/or ramping production of our energy storage products and Solar Roof.' The 2024 filing also highlighted broader operational dependencies, including the need to achieve 'design tolerances, high quality and output rates' across its manufacturing facilities, and noted potential disruptions due to supply chain coordination, localized procurement challenges, and the need for cost-effective scaling. This indicates a transition from a focused production setup in 2022 to a more complex and risk-laden ramp-up phase in 2024.",
      "llm_answer": "In the 2022 filing Tesla’s Solar Roof was described as being “developed and produced” at a single site – Gigafactory New York in Buffalo – making the product’s output essentially dependent on that one factory and its lease‑related incentives. By the 2024 filing the company is flagging that the Solar Roof ramp has run into the same “new‑manufacturing‑operation” problems it has faced with other products, citing delays in bringing equipment and processes online, supply‑chain constraints, regulatory approvals and other operational hurdles that could impede scaling at the New York plant. Thus, the strategy shifted from a location‑focused rollout to an acknowledgement that broader manufacturing dependencies and execution challenges now dominate the Solar Roof’s production outlook.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Tesla produced the Solar Roof at Gigafactory New York in 2022, and by 2024, the company highlighted production ramp challenges. The LLM correctly identifies the shift from a dedicated facility strategy to increased operational and manufacturing complexities. (2) There are no numeric values (e.g., dollar amounts, percentages, units) in either the original or LLM answer, so quantitative accuracy is not compromised—score reflects full compliance. (3) The multi-hop reasoning is sound: the model synthesizes information across 2022 and 2024 filings, correctly inferring a strategic evolution from location-focused production to broader manufacturing dependencies. It accurately captures delays in equipment/process ramp-up, supply chain issues, and regulatory hurdles, which are consistent with the original answer’s mention of 'design tolerances, high quality and output rates,' 'supply chain coordination,' and 'localized procurement challenges.' (4) Minor deduction in qualitative accuracy due to omission of Tesla’s financing integration strategy mentioned in the original (a secondary but relevant point), and slightly less emphasis on cost-effective scaling. However, core reasoning and factual synthesis remain strong. Contextual relevance is perfect—the answer directly addresses manufacturing dependencies and operational challenges across the specified timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1464,
        "completion_tokens": 407,
        "total_tokens": 1871
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Qualcomm's strategic involvement with on-device artificial intelligence (AI) evolved from 2023 to 2024, particularly in terms of its business focus and investment approach?",
      "original_answer": "In 2023, Qualcomm was actively producing on-device AI technologies as part of its broader portfolio of foundational technologies, including wireless connectivity and low-power computing. The company positioned on-device AI as a key innovation driver across industries beyond mobile handsets, such as automotive and IoT. By 2024, Qualcomm's focus on on-device AI had evolved from being a core product offering to a more investment-centric strategy. The company continued to invest heavily in advancing on-device AI through research and development, acquisitions, and strategic transactions, signaling a shift toward long-term growth and ecosystem development rather than immediate product commercialization. This transition reflects a deeper commitment to enabling third-party integration of its AI technologies rather than solely selling AI-based products directly.",
      "llm_answer": "- In the 2023 filing Qualcomm described itself as a “global technology leader… developing and commercializing foundational technologies, **including on‑device artificial intelligence (AI)**,” and said its revenue comes mainly from selling integrated‑circuit products and licensing those technologies 【page_65】.  \n\n- In the 2024 filing the company still stresses AI – “we continue to invest significant resources toward advancements of foundational technologies, **including on‑device AI**” – but now places that effort inside a broader growth strategy: it is pairing AI investment with “new and expanded product areas, industries and applications beyond mobile handsets… through acquisitions or other strategic transactions” 【page_20】.  \n\n**Thus, Qualcomm’s AI involvement has shifted from being presented primarily as a core technology that drives its existing IC and licensing business (2023) to a component of a wider investment agenda that couples AI development with strategic acquisitions and expansion into new markets such as automotive and IoT (2024).**",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Qualcomm's 2023 positioning of on-device AI as a core technology within its foundational offerings and revenue model based on integrated circuits and licensing is accurately represented, as is the 2024 shift toward a broader investment strategy involving R&D, acquisitions, and expansion into new markets. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the original answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes information across the 2023 and 2024 filings to identify a strategic evolution—from product-centric AI development to an investment-driven, ecosystem-focused approach. The use of direct quotes and page references supports fidelity to source material. (4) The LLM captures the core shift described in the ground truth: from on-device AI as a direct product and licensing driver (2023) to a component of a long-term growth strategy emphasizing strategic transactions and third-party integration (2024). The only minor limitation is that the LLM answer does not explicitly mention 'third-party integration' or 'ecosystem development' in the same terms as the original answer, slightly reducing semantic completeness. However, the concept is implied through 'strategic acquisitions' and 'expansion into new markets.' Overall, the answer is factually correct, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1490,
        "completion_tokens": 426,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the presence of Dolce & Gabbana in SPG-operated properties evolved between 2022 and 2023, and what does this indicate about SPG's brand positioning strategy in its premium outlet locations?",
      "original_answer": "In 2022, Dolce & Gabbana was listed as a tenant in multiple SPG-operated premium outlets in Japan, including Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Rinku Premium Outlets. By 2023, Dolce & Gabbana was only listed at Las Vegas Outlets North Premium NV in the U.S. This indicates a strategic shift from a multi-location presence in Japan to a more exclusive, flagship-style positioning in a key U.S. market, suggesting a reevaluation of brand placement and target demographics.",
      "llm_answer": "In the 2022 filing, Dolce & Gabbana was listed only among the “Selected Tenants” at three Japanese Premium‑Outlet sites (Gotemba, Kobe‑Sanda and Rinku). By the 2023 filing the brand also appears in the U.S. portfolio – it is now a tenant at the Las Vegas Premium Outlets. This addition shows SPG is deliberately broadening the luxury‑designer mix in its outlet centers, using Dolce & Gabbana to elevate the premium‑outlet image and attract higher‑spending shoppers.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial factual accuracy but introduces a significant error in interpretation. While it correctly identifies Dolce & Gabbana's presence in three Japanese outlets in 2022 (Gotemba, Kobe-Sanda, Rinku), it incorrectly states that the brand was added to the U.S. portfolio in 2023 as a new tenant at Las Vegas Premium Outlets. The ground truth indicates that by 2023, Dolce & Gabbana was *only* listed at Las Vegas Outlets North Premium NV — implying a *reduction* from multiple Japanese locations to a single U.S. location, not an addition or expansion. The LLM interprets this as a broadening of luxury offerings, when in fact the evidence suggests a strategic contraction and repositioning toward exclusivity in a key market. (2) There are no explicit numerical values (e.g., dollar amounts, percentages) in the response, so quantitative accuracy is not heavily penalized, but the temporal and locational facts are misaligned — the shift is not 'adding' a U.S. presence but 'replacing' a multi-site Japanese presence with a single U.S. one. (3) The multi-hop reasoning is flawed: the model fails to synthesize the full picture — a reduction in total locations — and instead assumes geographic expansion equates to growth in brand presence. It misses the strategic implication of moving from multiple outlets in Japan to one in the U.S., which signals exclusivity and market repositioning, not broadening. (4) Contextual relevance is high because the answer addresses both parts of the question — evolution of presence and strategic implication — and correctly references relevant properties and brand positioning. However, due to the core factual misinterpretation of the direction of change (expansion vs. contraction), the correctness and qualitative accuracy scores are significantly reduced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 497,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did COP's investment in exploration activities in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the company's strategic focus in that region?",
      "original_answer": "In 2023, COP reported $49 million in exploration expenditures in the Asia Pacific/Middle East region, while in 2024, the company disclosed a total of $0 in new exploration activities in that region. This indicates a complete withdrawal or pause in exploration efforts in the Asia Pacific/Middle East, suggesting a strategic shift away from that region in favor of other geographic areas.",
      "llm_answer": "In 2023 ConocoPhillips recorded $49 million of exploration spending in its consolidated Asia Pacific/Middle East operations and an additional $46 million in its equity‑affiliate portfolio (about $95 million in total).  The 2024 filing notes that the company’s equity affiliates made “extensions and discoveries” in the Middle East and Australia, showing that exploration activity in the region was maintained and even expanded.  This progression signals that COP is deliberately deepening its strategic focus on growth and new discoveries in the Asia Pacific/Middle East area.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, COP reported $49 million in exploration expenditures in the Asia Pacific/Middle East region in 2023 and $0 in 2024, indicating a complete pause. However, the LLM claims $49 million in consolidated spending and adds $46 million from equity affiliates (totaling $95 million), which is not supported by the ground truth. The ground truth makes no mention of equity affiliate spending or total combined figures. Furthermore, the LLM incorrectly states that exploration was 'maintained and even expanded' in 2024 based on 'extensions and discoveries' by equity affiliates, which contradicts the ground truth that explicitly reports $0 in new exploration activities by COP in 2024. (2) Quantitative accuracy is low: the $46 million figure for equity affiliates is unverified and not in the original answer; the total of $95 million is therefore incorrect. The core numbers ($49M in 2023, $0 in 2024) are partially correct but misrepresented by adding unsupported additional amounts. (3) Multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution from 2023 to 2024, instead inferring continued or increased activity contrary to the data. It misattributes activity by equity affiliates as indicative of COP’s direct strategic focus, without evidence that these activities constitute new exploration investments by COP itself. (4) The conclusion about 'deepening strategic focus' is the opposite of the ground truth, which indicates a strategic withdrawal. While the answer addresses the question’s structure and region correctly, the factual foundation and reasoning are fundamentally incorrect, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 477,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Comcast's financial stake and debt involvement in Universal Beijing Resort evolved from 2022 to 2024?",
      "original_answer": "In 2022, Universal Beijing Resort was introduced as a new entity in Comcast's disclosures, noting its opening in September 2021 and highlighting the increased depreciation and amortization expenses across the company, though no specific financial stake or debt figures were provided at that time. By 2024, Comcast explicitly stated its 30% ownership interest in Universal Beijing Resort and detailed the debt financing structure, including $3.4 billion of debt outstanding as of December 31, 2024, down from $3.5 billion in 2023. Additionally, the assets and liabilities of Universal Beijing Resort were reported as $7.3 billion and $7.0 billion respectively in 2024, compared to $7.8 billion and $7.2 billion in 2023.",
      "llm_answer": "Comcast continues to hold a 30 percent equity interest in Universal Beijing Resort – the same share it reported after the 2018 agreement and that was disclosed in the 2022 filing.  The resort’s debt, which is financed by a Chinese‑syndicated loan, has been slowly shrinking: the 2024 10‑K shows $3.4 billion of debt outstanding at 12/31/2024 (down from $3.5 billion at 12/31/2023) and was previously reported at a similar level in the 2022 filing, indicating a modest reduction in the debt component while the ownership stake remained unchanged.【page_86】",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies Comcast's 30% ownership stake in Universal Beijing Resort and the reduction in debt from $3.5 billion in 2023 to $3.4 billion in 2024, which aligns with the ground truth. However, it incorrectly implies that the $3.4 billion debt level was 'previously reported in the 2022 filing', whereas the original answer states that no specific debt figures were provided in 2022. This is a factual inaccuracy regarding disclosure timing. (2) Quantitatively, all provided numbers ($3.4B, $3.5B, 30%) are accurate and correctly formatted. The comparison of year-over-year debt reduction is valid. However, the claim about 2022 debt being at a 'similar level' is unsupported by the ground truth, which explicitly states no debt figures were disclosed then. (3) The multi-hop reasoning is partially sound—correctly linking ownership stability and debt trends across years—but fails on the synthesis point that 2022 lacked specific debt disclosures, leading to an incorrect inference. (4) Contextual relevance is strong as the answer directly addresses the evolution of stake and debt. Scores reflect high accuracy in numbers and relevance, but docked for incorrect assertion about 2022 debt disclosure, affecting completeness and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 356,
        "total_tokens": 1665
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did Duke Energy's net derivatives balance and associated settlement activity evolve from 2022 to 2023, and what does this indicate about the company's exposure or management of derivative instruments?",
      "original_answer": "In 2022, Duke Energy's net derivatives balance at the end of the year was $29 million, with settlements totaling $32 million. In 2023, the net derivatives balance decreased to $13 million, while settlements increased significantly to $68 million. This indicates a shift in the company's management of derivative instruments, with a larger reduction in the net balance despite higher settlement activity in 2023.",
      "llm_answer": "In 2023 Duke Energy’s net‑derivatives position shrank sharply.  The net balance fell from $29 million at the end of 2022 to only $13 million at year‑end 2023, while the amount of derivative settlements more than doubled – (32) million in 2022 versus (68) million in 2023 – and purchases dropped from $74 million to $42 million, turning a $35 million loss in 2022 into a $10 million gain in 2023.  This swing from a modest net‑asset position in 2022 to a small net‑liability position in 2023, together with the heightened settlement activity, shows the company actively unwound and reduced its derivative exposure, managing the instruments more conservatively and realizing gains as it did so.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the net derivatives balance at the end of 2022 ($29 million) and 2023 ($13 million), which matches the ground truth. It also correctly states that settlements increased from $32 million in 2022 to $68 million in 2023. However, it introduces several pieces of information not present in the original answer or ground truth: specifically, derivative purchases dropping from $74 million to $42 million, a $35 million loss in 2022 turning into a $10 million gain in 2023, and a shift from a net-asset to a net-liability position. These details are not supported by the provided ground truth and represent significant factual additions. (2) While the core numbers for net balance and settlements are accurate, the unsupported financial figures (purchases, gains/losses) undermine quantitative accuracy. There is no indication in the ground truth about profit/loss or purchase volumes, so these cannot be verified and appear to be hallucinated. (3) The multi-hop reasoning is partially sound—the conclusion that heightened settlement activity and declining net balance suggest active unwinding of positions aligns with the ground truth's interpretation of reduced exposure. However, the reasoning is overextended with unsupported claims about gains and liability shifts, weakening the logical foundation. (4) The contextual relevance is high because the answer addresses the evolution of Duke Energy’s derivatives and attempts to interpret what it indicates about risk management. Despite the hallucinated data, the central trend and qualitative direction of interpretation are consistent with the ground truth. The correctness score is 6 due to correct core metrics but significant inclusion of unverified, extraneous financial data that affects overall factual reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 493,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did SPG's treatment and disclosure of LTIP Units evolve from 2022 to 2023, particularly in terms of their dilutive effect and valuation modeling?",
      "original_answer": "In 2022, SPG disclosed that LTIP units were part of potentially dilutive securities but had no material dilutive effect for the years 2021, 2020, and 2019. By 2023, SPG provided more detailed disclosures, including the use of a Monte Carlo model to estimate the grant-date fair values of market-based LTIP units and confirmed that these units are treated as participating securities under the two-class method of computing earnings per share. This reflects a shift from a general statement about dilution to a more granular and valuation-focused disclosure in 2023.",
      "llm_answer": "In the 2022 Form 10‑K SPG noted that LTIP units are “potentially dilutive securities” but **had no material dilutive effect** on earnings‑per‑unit calculations for 2021, 2020 and 2019 (see 2022 p. 116).  The company also disclosed that the **grant‑date fair values of market‑based LTIP units are estimated with a Monte‑Carlo simulation model** (2022 p. 128).\n\nThe 2023 filing continues to treat LTIP units as potentially dilutive (no comment that they became material) and still uses the same Monte‑Carlo‑based valuation approach, but it adds **more explicit quantitative disclosure**: the 2023 LTI program is capped at a **maximum potential fair value of $42.5 million at grant date**, and the filing provides a table of the grant‑date fair‑value amounts for each year’s LTIP awards (e.g., $5.7 m for 2021, $13.7 m for 2022, $23.6 m for 2023) (see 2023 p. 129).  \n\nThus, from 2022 to 2023 SPG’s LTIP‑unit treatment remained unchanged regarding dilution (still not material), while the disclosure evolved to give a specific fair‑value ceiling and yearly grant‑date values, though the underlying Monte‑Carlo valuation methodology was retained.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, SPG disclosed LTIP units as potentially dilutive but with no material dilutive effect for 2021–2019, and that a Monte Carlo model was used to estimate grant-date fair values of market-based LTIP units—this matches the original answer. (2) For 2023, the LLM accurately notes the continuation of the Monte Carlo valuation approach and the treatment of LTIP units as potentially dilutive without material impact, while adding new quantitative disclosures: a $42.5 million cap on the 2023 LTI program and specific grant-date fair values ($5.7M for 2021, $13.7M for 2022, $23.6M for 2023). These numbers are factually correct and enhance the disclosure detail, reflecting the evolution toward more granular reporting. (3) The multi-hop reasoning is sound—correctly synthesizing changes in disclosure depth across years, even though the core treatment (non-material dilution, Monte Carlo use) remained consistent. (4) The only minor shortcoming is that the original answer emphasizes the 2023 clarification that LTIP units are treated as participating securities under the two-class EPS method, which the LLM omits. This is a relevant qualitative detail about accounting treatment, though not a numerical error. Otherwise, all entities (SPG, LTIP units, years), metrics, and disclosures are correct. Wording differs but meaning is semantically equivalent. Quantitative accuracy is perfect with correct dollar amounts and years. Contextual relevance is excellent as all information directly addresses the evolution in disclosure and valuation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 450,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Comcast's financial commitment and involvement in Atairos Group, Inc. evolved between 2022 and 2024, particularly in terms of capital funding and management fee commitments?",
      "original_answer": "Comcast's involvement in Atairos Group, Inc. evolved significantly between 2022 and 2024. In 2022, Comcast was the sole third-party investor with a commitment to fund up to $5 billion in aggregate capital to Atairos. By 2024, this commitment had decreased to up to $4.5 billion, with an additional specific commitment of $40 million annually for a management fee. The reduction in capital commitment and the introduction of a dedicated management fee structure indicate a recalibration of Comcast's financial involvement and strategic oversight of Atairos.",
      "llm_answer": "Comcast’s overall funding ceiling for Atairos has stayed roughly the same – the agreement limits the aggregate unfunded commitment to about $4.5 billion and caps annual capital calls at $400 million – but the company’s actual cash contributions have risen. In the 2022 filing Comcast reported a $52 million contribution for that year (with $45 million a year earmarked for a management fee), while the 2024 filing shows contributions of $145 million in 2023 and $73 million in 2024 and a reduced unfunded commitment of $1.4 billion at year‑end. The annual management‑fee commitment was cut from $45 million (2022) to $40 million per year (2024).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies that deviate from the ground truth. While it correctly identifies the $4.5 billion capital commitment in 2024 and the $40 million annual management fee, it incorrectly states that Comcast's 2022 management fee was $45 million per year (ground truth does not mention a 2022 management fee at all—this structure was introduced in 2024). The LLM also fabricates specific annual contributions: $52 million in 2022, $145 million in 2023, and $73 million in 2024—none of which appear in the original answer or are supported by the knowledge graph. Additionally, the claim of a 'reduced unfunded commitment of $1.4 billion at year-end' is not in the ground truth and introduces data not present in the original. (2) The original answer states Comcast committed up to $5 billion in 2022, reduced to $4.5 billion by 2024, with a new $40 million annual management fee. The LLM misrepresents this evolution by implying the management fee existed in 2022 and changed to $40 million, which is incorrect. The $400 million annual capital call cap and 'aggregate unfunded commitment of $4.5 billion' are partially correct but mischaracterized—the original does not mention annual caps. (3) The multi-hop reasoning is flawed: the LLM invents specific yearly contributions and misattributes the timing of the management fee introduction, failing to correctly synthesize the evolution of the commitment. It conflates actual contributions (not detailed in the original) with committed capital, which are distinct concepts. (4) The contextual relevance is high because the answer addresses the question’s focus on capital funding and management fees over time, and it attempts to compare 2022 and 2024. However, due to significant quantitative errors and invented data, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the direction of change (reduced capital commitment, lower management fee) is partially aligned, but the reasoning is based on incorrect premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 555,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's operational focus in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a modest reduction in reserves over the year, suggesting a potential shift in operational focus or resource allocation in the region.",
      "llm_answer": "In the 2024 filing ConocoPhillips shows that its **company‑owned** natural‑gas reserves in the Asia Pacific/Middle East fell slightly – the developed reserve balance dropped from **312 BCF** at the end of 2023 to **296 BCF** at the end of 2024, while undeveloped reserves stayed flat at **7 BCF** (total ≈ 319 BCF → 303 BCF)【page_145】.  \n\nAt the same time, the **equity‑affiliate** portion of those reserves (which are all located in the same region) grew from **5,275 BCF** in 2023 to **5,870 BCF** in 2024【page_145】, and the 2024 discussion notes that “extensions and discoveries in our equity affiliates were in the Middle East and Australia”【page_146】.  \n\n**Interpretation:** While the company’s own gas inventory in the Asia Pacific/Middle East modestly contracted, it is expanding its overall presence there through equity‑affiliate acquisitions and new discoveries, indicating a strategic operational focus on growing its stake in the region via affiliates rather than through direct development.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the company-owned natural gas reserves for COP in the Asia Pacific/Middle East region as 312 BCF in 2023 and 296 BCF in 2024, matching the ground truth exactly. It adds additional detail not in the original answer—undeveloped reserves (7 BCF flat) and equity-affiliate reserves (5,275 BCF in 2023 → 5,870 BCF in 2024)—which are factually accurate and properly cited from the filing (pages 145–146). These details go beyond the ground truth but do not contradict it. (2) All numbers are quantitatively accurate: the decrease from 312 to 296 BCF is correctly stated, and the equity-affiliate increase is precisely reported. Calculations (e.g., total reserves ≈319→303 BCF) are approximate but reasonable given the context. (3) The multi-hop reasoning is sound: the LLM synthesizes data on both company-owned and equity-affiliate reserves across two years, then infers a strategic shift toward affiliate-based growth in the region. This interpretation is well-supported by the data and adds analytical depth. (4) While the original answer only notes a modest reduction suggesting a potential shift, the LLM provides a more nuanced and accurate picture by showing that overall exposure is increasing via affiliates, indicating continued operational focus—just through a different ownership model. This enhances rather than distorts the truth. The only reason for not scoring 10 is that the question specifically asks about COP's reserves, which typically refer to company-owned; while the equity-affiliate context is valuable, it slightly extends beyond the direct scope. However, this addition improves the interpretation. All in all, the answer is factually superior to the ground truth with no errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 476,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "Compare Comcast's wireless gateway procurement strategy in 2022 with its network deployment investment focus in 2024.",
      "original_answer": "In 2022, Comcast's relationship with wireless gateways was primarily centered on procurement, as the company purchased a significant amount of customer premise equipment, including wireless gateways, from a limited number of suppliers to provide services to residential and business customers. By 2024, the company's approach had evolved into a more strategic investment focus, with wireless gateways being a key component of its planned capital expenditures. Specifically, in 2024, Comcast emphasized deploying wireless gateways as part of its broader network upgrades aimed at delivering multigigabit symmetrical speeds. This shift indicates a move from passive procurement to active integration of wireless gateways into its infrastructure strategy, aligning with its goals for network scalability and capacity expansion.",
      "llm_answer": "In 2022 Comcast’s wireless‑gateway strategy was primarily a procurement‑focused approach – the company bought a large volume of wireless gateways (and other customer‑premise equipment) from a **limited number of suppliers** to stock its network (see 2022 10‑K, “Cable Communications purchases from a limited number of suppliers a significant amount of customer premise equipment, including wireless gateways…”).  \n\nBy 2024 the emphasis had shifted to **network‑deployment spending**, with capital‑expenditure plans centered on expanding **scalable infrastructure and line extensions** to boost capacity and deliver multigigabit symmetrical speeds, while still allocating funds for the **continued deployment of wireless gateways** (see 2024 10‑K, capital‑expenditure table and narrative on focus on scalable infrastructure, line extensions, and wireless‑gateway rollout).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Comcast's 2022 procurement strategy, citing the limited number of suppliers and the purchase of wireless gateways as part of customer premise equipment, directly referencing the 2022 10-K. This matches the original answer's description of a 'procurement-focused' approach. (2) For 2024, the LLM accurately reflects the shift toward strategic capital investment, emphasizing scalable infrastructure, line extensions, and continued deployment of wireless gateways to support multigigabit symmetrical speeds—consistent with the original answer’s claim of a strategic evolution. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and two different strategic focuses (procurement vs. deployment investment), correctly inferring a strategic shift. (4) Minor deduction in qualitative accuracy due to slightly less emphasis on the conceptual framing of 'active integration into infrastructure strategy' and 'network scalability and capacity expansion' as a strategic pivot, though the core elements are present. No numeric inaccuracies; dates, entities (Comcast, 2022, 2024), and financial strategy terms are correct. Semantic equivalence is strong, and contextual relevance is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 367,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of its strategic importance and production challenges?",
      "original_answer": "In 2022, Tesla highlighted the Solar Roof as a key contributor to the growth in Energy generation and storage revenue, indicating it was being actively deployed alongside products like Megapack and Powerwall. By 2024, Tesla's framing had shifted, with the Solar Roof now positioned as a product facing potential production ramp delays similar to past vehicle and energy storage product launches. This evolution reflects a shift from emphasizing deployment success to cautioning about the operational and manufacturing risks associated with scaling the product.",
      "llm_answer": "In the 2022 filing Tesla described Solar Roof as a fast‑growing part of its Energy Generation & Storage business – deployments rose sharply and the product helped lift segment revenue, even though the higher share of Solar Roof sales pushed gross margin down because the new manufacturing line was still under‑utilized ( “higher proportion of Solar Roof … operated at a lower gross margin as a result of temporary manufacturing underutilization during product ramp” 【page_40】).  \n\nBy the 2024 filing the company still treats Solar Roof as a strategic energy‑product offering, but it repeatedly warns that the product’s launch and ramp‑up are being held back by production‑scale challenges, noting that “we have experienced, and may also experience similar future delays in launching and/or ramping production of our energy storage products and Solar Roof” (​【page_17】) and that “we may experience delays in launching and ramping the production of our … Solar Roof” (​【page_16】).  \n\nThus, Solar Roof moved from a revenue‑driving growth story in 2022 to a strategically important but still‑ramping product in 2024, with Tesla emphasizing persistent manufacturing‑scale and delay issues.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Tesla's evolving stance on the Solar Roof between 2022 and 2024: in 2022, it was a fast-growing, revenue-driving product despite margin pressures due to underutilized manufacturing; by 2024, it remained strategically important but faced acknowledged production ramp delays. These points match the original answer’s core message. (2) There are no numeric inaccuracies—while specific dollar figures or percentages aren't cited, the qualitative financial impacts (e.g., lower gross margins due to underutilization) are correctly attributed to the 2022 context and supported by accurate quotes from the filings (e.g., page 40 for 2022 margin impact, pages 16–17 for 2024 delay warnings). No calculations were required, and all references are contextually valid. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and two different strategic framings (growth driver → caution due to production risks), correctly identifying the shift in narrative. (4) The LLM adds slightly more detail than the ground truth (e.g., margin impact explanation), which enhances completeness without introducing error. The only minor shortcoming is that it doesn’t explicitly mention Megapack and Powerwall as co-deployed products in 2022, which slightly reduces qualitative completeness, but this does not detract from the central evolution described. Overall, the answer is factually correct, well-supported, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 430,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did Duke Energy's investment in Net Pending Transactions and Other Investments change from 2022 to 2023, and what does this indicate about the company's strategic positioning in this category?",
      "original_answer": "Duke Energy's investment in Net Pending Transactions and Other Investments decreased from $53 million in 2022 to $14 million in 2023. This indicates a significant reduction in exposure or involvement in pending transactions and other investments, suggesting a strategic shift or completion of certain initiatives during this period.",
      "llm_answer": "In the Master Retirement Trust, Duke Energy’s “Net pending transactions and other investments” rose from **$14 million at year‑end 2022 to $54 million at year‑end 2023** (a $40 million, roughly 286 % increase; Level 1 assets grew from $5 million to $40 million and Level 2 from $9 million to $14 million). This jump shows the company is deliberately expanding its exposure to these less‑traditional, potentially higher‑return assets, signaling a more opportunistic strategic positioning within this category.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in both direction and magnitude. The ground truth states that Duke Energy's investment in Net Pending Transactions and Other Investments decreased from $53 million in 2022 to $14 million in 2023. However, the LLM claims an increase from $14 million in 2022 to $54 million in 2023—reversing the trend and misstating both values. This error invalidates the entire response. (2) The numbers are not only wrong but also presented with false precision, including fabricated breakdowns (Level 1 and Level 2 assets) and a 286% increase calculation based on incorrect data. The correct change is a decrease of $39 million (from $53M to $14M), or about a 73.6% reduction. (3) The multi-hop reasoning fails completely: instead of identifying a reduction indicating strategic de-emphasis or completion of initiatives, the model incorrectly infers increased strategic focus due to a fictional rise in investments. The mention of the 'Master Retirement Trust' introduces a context not present in the original answer and appears to conflate different financial line items or reports. (4) Due to total factual inaccuracy in numbers, direction of change, and resulting interpretation, the correctness and quantitative accuracy scores are near zero. The contextual relevance is slightly higher only because the answer addresses the general topic (investments in pending transactions), but within a completely erroneous framework.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 406,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the company's implementation of its liability-driven investment framework evolved between 2023 and 2024, particularly in terms of defined contribution plan expenses and the disclosure of plan asset composition?",
      "original_answer": "In 2023, the company disclosed that amounts charged to expense for defined contribution plans totaled $109 million, and the liability-driven investment framework included a 20%/80% equity/fixed income target allocation for pension assets. By 2024, defined contribution plan expenses increased to $112 million, and while the same 20%/80% allocation was maintained, the 2024 filing added a new disclosure indicating that the actual composition of plan assets at year-end would be characterized, suggesting a more detailed transparency in reporting the implementation of the investment framework.",
      "llm_answer": "The 2024 filing shows the company kept the same liability‑driven investment targets it used in 2023 – a 20 % equity/80 % fixed‑income mix for pension assets and a 55 % equity/45 % fixed‑income mix for post‑retirement assets – but it reported higher costs for its defined‑contribution plans, rising to **$112 million in 2024 from $109 million in 2023**.  In addition, the 2024 disclosure provides an updated composition of plan assets, with pension equity rising from about 18 % to 21 %, corporate bonds from 57 % to 63 % and government securities falling from 25 % to 16 % (post‑retirement equity moving from ~53 % to 57 % and treasury holdings dropping from 16 % to 13 %), and includes a refreshed Level 1/Level 2 fair‑value breakdown for the assets.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly reports the increase in defined contribution plan expenses from $109 million in 2023 to $112 million in 2024, it fabricates detailed asset composition changes (e.g., pension equity rising from 18% to 21%, corporate bonds from 57% to 63%, government securities falling from 25% to 16%) and introduces a 55%/45% allocation for post-retirement assets, which are not mentioned in the ground truth. The original answer only states that the 20%/80% target allocation was maintained and that the 2024 filing added a new disclosure about characterizing the actual composition of plan assets—no specific percentages or movements are provided. (2) The dollar amounts for plan expenses are correct ($109M to $112M), but all other numerical claims about asset shifts and allocations are unsupported by the ground truth and thus factually wrong. There is no mention of Level 1/Level 2 fair value breakdowns or post-retirement asset mixes in the original answer. (3) The multi-hop reasoning is partially sound in linking expense changes and investment framework continuity between years, but it fails in overextending the disclosure evolution by inventing granular data not present in the source. The model incorrectly assumes that 'characterized' means detailed percentage breakdowns were reported, when the ground truth only indicates an intention or new practice of characterization, not actual publication of those figures. (4) The correctness score is low due to major quantitative errors despite some accurate expense figures. Quantitative accuracy is penalized heavily because most numbers are fabricated. Qualitative accuracy is moderate because the model captures the expense trend and framework continuity but adds unsupported details. Contextual relevance is high as the response stays on topic and addresses the evolution of disclosures and expenses.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 523,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Qualcomm's strategic focus on On-Device AI evolved between fiscal 2023 and fiscal 2024, and what specific investments or changes in direction were highlighted in the company's disclosures?",
      "original_answer": "In fiscal 2023, Qualcomm emphasized that On-Device AI, combined with 5G and high-performance, low-power computing, would drive adoption of smartphone technologies into industries beyond mobile, such as automotive and IoT. The company positioned itself as a leader in 5G and integrated circuit products to sustain long-term growth. By fiscal 2024, Qualcomm's focus on On-Device AI had evolved into a more investment-driven strategy, with the company explicitly stating it is investing in new product areas and industries beyond mobile handsets, including automotive and IoT, by leveraging its technical expertise and pursuing acquisitions or strategic transactions. This represents a shift from strategic vision to active investment and expansion.",
      "llm_answer": "Between fiscal 2023 and fiscal 2024 Qualcomm moved from a broad 5G‑centric story to an explicit “5G + high‑performance, low‑power computing + on‑device AI” narrative. In the FY 2024 filing the company says that on‑device AI will be a key growth engine for smartphones, automotive and IoT and that it will “continue to devote significant resources” to that technology, backing it with higher R&D spending ($8.9 billion in FY 2024 versus $8.8 billion in FY 2023) and increased capital‑expenditure plans to fund production‑ and testing‑needs for its diversification initiatives. By contrast, the FY 2023 discussion focused mainly on 5G, handset and licensing revenues and did not call out on‑device AI as a distinct strategic priority.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution in Qualcomm's strategic focus from a 5G-centric narrative in FY2023 to a more explicit emphasis on On-Device AI as a growth engine across smartphones, automotive, and IoT in FY2024. It accurately reflects the shift from vision to active investment, aligning with the ground truth’s core message. However, the LLM introduces specific R&D spending figures ($8.9B in FY2024 vs $8.8B in FY2023) and links them directly to On-Device AI investments, which are not present in the original answer and cannot be verified from the provided ground truth. This introduces factual inaccuracies in quantitative claims. (2) The dollar amounts for R&D and capital expenditures are not mentioned in the ground truth, making these additions unsupported. While the direction of increased investment is consistent with the 'investment-driven strategy' described in the original, the specific numbers and their attribution to On-Device AI go beyond the source. (3) The multi-hop reasoning is sound in synthesizing a strategic shift across fiscal years and identifying expansion beyond mobile into automotive and IoT. The LLM correctly infers a change in emphasis from 5G to a triad of 5G + computing + AI. However, it overreaches by quantifying the investment shift with unverified figures, undermining quantitative accuracy. (4) Despite the unsupported numbers, the qualitative assessment of strategic evolution is strong and contextually relevant. The answer addresses both parts of the question—evolution of focus and specific changes—though the 'specific investments' are inaccurately specified. Hence, correctness is reduced primarily due to unsupported quantitative claims, but the overall reasoning and relevance remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 482,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the classification and presentation of the Voting Trust Agreement between Melvin Simon & Associates, Inc. and the Simon family members evolved between the 2022 and 2023 10-K filings, and what does this indicate about the governance structure's stability?",
      "original_answer": "In the 2022 10-K filing, the Voting Trust Agreement was described as 'Second Amended and Restated' as of March 1, 2004, indicating a formal update to the governance arrangement. In contrast, the 2023 10-K filing refers to the same agreement without the 'Second Amended and Restated' modifier, simply listing it as the Voting Trust Agreement dated March 1, 2004. This shift in presentation suggests that no further amendments were made in the intervening period, signaling stability in the governance structure and a continuation of the same voting trust framework without modification.",
      "llm_answer": "In both the 2022 and 2023 Form 10‑K the Melvin Simon & Associates voting‑trust arrangement is still listed in the Exhibit Index as Exhibit 9.1 (and the related Exhibit 9.2), described as the “Second Amended and Restated Voting Trust Agreement, Voting Agreement and Proxy dated March 1, 2004” between Melvin Simon & Associates and the Simon family members. Because the classification (exhibit 9) and the wording of the description have not changed, the filing shows that the family‑controlled voting trust remains a constant element of Simon Property Group’s governance, underscoring the continued stability of its control structure.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect regarding the classification and presentation of the Voting Trust Agreement between the 2022 and 2023 10-K filings. The ground truth states that in the 2022 10-K, the agreement was described as 'Second Amended and Restated,' but in the 2023 10-K, this modifier was dropped, indicating no new amendments and signaling stability. However, the LLM claims that the 'Second Amended and Restated' language was present in both years, which contradicts the ground truth. This misrepresents the evolution of the agreement's presentation. (2) Quantitatively, the date 'March 1, 2004' is correctly cited, and the exhibit number (9.1) is plausibly accurate, though not verifiable from the ground truth provided. There are no numerical calculations, so quantitative accuracy is limited to correct dates and labels—this part is mostly accurate. (3) The multi-hop reasoning is flawed: the question hinges on identifying a change (or lack thereof) in language between two filings to infer governance stability. The LLM incorrectly asserts consistency in wording when the ground truth identifies a subtle but meaningful shift (removal of 'Second Amended and Restated'), leading to an invalid conclusion drawn from incorrect premises. While the conclusion about stability aligns with the ground truth, it is based on wrong reasoning. (4) Contextual relevance is fair because the answer addresses the right entities (Melvin Simon & Associates, Simon family, Voting Trust Agreement, Exhibit 9.1) and attempts to interpret governance implications. However, due to the critical error in describing the evolution of the agreement’s classification, the overall correctness score is low. The answer fails the core requirement of accurately reporting how the presentation changed between years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 494,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the region's changing strategic importance to COP's global reserves portfolio?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure decreased slightly to 296 billion cubic feet. This represents a reduction of 16 billion cubic feet, or about 5.1%. Despite this decline, the Asia Pacific/Middle East remained a notable contributor to COP's global reserves, especially when considering equity affiliates, which held an additional 5,870 billion cubic feet in 2024. The slight decrease may suggest a shift in emphasis or extraction focus in favor of other regions, indicating a potential reevaluation of the region's role in COP's long-term production strategy.",
      "llm_answer": "In the 2024 Form 10‑K ConocoPhillips reported that its proved natural‑gas reserves in the Asia Pacific/Middle East region fell from ≈ 319 billion cubic feet (312 BCF developed + 7 BCF undeveloped) at the end of 2023 to ≈ 303 billion cubic feet (296 BCF developed + 7 BCF undeveloped) at the end of 2024 – a drop of about 5 percent. The decline, together with the fact that all of the company’s equity‑affiliate reserves are located in this region, signals a modest reduction in the region’s relative weight within COP’s global reserve portfolio and suggests a slight strategic shift toward other basins (e.g., the Lower 48 and Africa) while still maintaining a meaningful presence through its equity affiliates.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains mostly correct information but has discrepancies in the reported reserve volumes. The ground truth states that COP's natural gas reserves in Asia Pacific/Middle East were 312 BCF in 2023 and 296 BCF in 2024, a decrease of 16 BCF (5.1%). However, the LLM reports 319 BCF in 2023 and 303 BCF in 2024, which is 7 BCF higher in both years. This suggests an incorrect aggregation (adding 312 + 7 undeveloped = 319), but the 296 BCF developed in 2024 matches the ground truth. The 7 BCF undeveloped appears to be double-counted or misapplied. The percentage decline is correctly approximated as ~5%, though exact is 5.1%. (2) Calculations: The claimed drop from 319 to 303 is a 16 BCF decrease, which matches the ground truth’s 16 BCF drop, but applied to incorrect base values. The percentage is approximately correct due to similar delta, but based on wrong totals. The equity affiliate figure (5,870 BCF) is not mentioned in the LLM answer, which is a significant omission affecting completeness. (3) Multi-hop reasoning is sound: the LLM correctly infers that the decline, while modest, may indicate a strategic shift toward other regions like Lower 48 and Africa, and notes the continued importance via equity affiliates—even though it omits the massive 5,870 BCF figure that supports this. The logic about relative weight decreasing while maintaining presence is consistent with the original. (4) Scores justified as: correctness 7 (core trend and direction correct, but numbers inaccurate and key data missing), quantitative accuracy 6 (significant error in base values despite correct delta and percentage approximation), qualitative accuracy 8 (reasoning and entity identification correct; only COP and region are involved, and strategic interpretation is valid), contextual relevance 9 (fully addresses both parts of the question—evolution and strategic implication—with relevant context).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 521,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of debt structure and equity method income?",
      "original_answer": "In 2023, AIG had a direct financial stake in Corebridge, which was reflected in the $9,368 million total Corebridge debt on AIG's balance sheet, including $6,452 million in senior unsecured notes and $989 million in junior subordinated debt, both not guaranteed by AIG. By 2024, AIG no longer consolidated Corebridge as a subsidiary; instead, it reported Corebridge under the equity method as part of discontinued operations. During the second half of 2024, AIG reported equity method income from Corebridge, which included dividends received and changes in its stock price since June 9, 2024. This marks a significant transformation from a consolidated debt relationship to a minority equity investment with associated income reporting.",
      "llm_answer": "In 2023 AIG still carried Corebridge’s debt on its balance sheet – Corebridge senior unsecured notes of $6.452 billion, junior subordinated debt of $989 million, CRBGLH notes and bonds of $200 million, CRBGLH junior subordinated debt of $227 million, and a DDTL facility of $1.5 billion (reduced to a $250 million balance after a $1.25 billion repayment) 【page_112】.  By 2024 AIG had de‑consolidated Corebridge, no longer guaranteed its obligations, and the only remaining Corebridge‑related borrowing shown in the short‑term‑and‑long‑term‑debt schedule is the $250 million DDTL facility 【page_113】; the company now accounts for its residual 22‑23 % ownership as an equity‑method investment, which generated $601 million of equity‑method income for the June‑December 2024 period 【page_109】.  Thus, the relationship shifted from AIG being a direct guarantor of Corebridge’s large unsecured debt in 2023 to holding a minority equity stake that produces equity‑method earnings in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of AIG's financial relationship with Corebridge between 2023 and 2024. (1) Quantitatively, the LLM correctly reports the $6.452 billion in senior unsecured notes and $989 million in junior subordinated debt from 2023, aligning with the ground truth's $6,452 million and $989 million. It adds additional debt components (CRBGLH notes, DDTL facility) not mentioned in the ground truth, but these are factual and supported by the cited page (112), indicating more granular detail rather than error. The $250 million DDTL balance in 2024 is correctly noted. The $601 million equity-method income for H2 2024 is precise and matches the context of post-deconsolidation income. (2) The ground truth does not specify the 22–23% ownership stake or the $601 million figure, but these are more detailed than the original answer and do not contradict it—rather, they enhance it with specific data. (3) The reasoning is sound: the LLM correctly identifies the shift from consolidation (with full debt on balance sheet) to equity-method accounting, no longer guaranteeing debt, and earning equity-method income. This reflects proper multi-hop synthesis across time, accounting treatment, and financial structure. (4) The answer is contextually complete, addressing both debt structure changes and equity income, as required. The only minor deviation is that the ground truth emphasizes stock price changes and dividends as components of equity income, while the LLM mentions the income amount but not its composition—this is a slight omission but not factually incorrect. Overall, the LLM provides a more detailed, equally accurate, and semantically aligned response, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 471,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has NextEra Energy's investment strategy in Special Use Funds evolved from 2022 to 2024, particularly in terms of its allocation between fixed income and equity securities, and what does this suggest about its risk appetite or liquidity strategy?",
      "original_answer": "In 2022, NEE's Special Use Funds were entirely composed of fixed income securities, with a carrying amount of $2,505 million. By 2024, the composition had significantly transformed: NEE's Special Use Funds included $6,164 million in equity securities, $722 million in U.S. Government and municipal bonds, $685 million in corporate debt, and $873 million in asset-backed securities. This indicates a strategic shift from a purely fixed income allocation to a more diversified and equity-heavy portfolio, suggesting an increased risk appetite and a potential long-term growth orientation in its investment strategy.",
      "llm_answer": "- **2022:** NextEra’s special‑use funds were dominated by fixed‑income debt.  The 2022 filing shows ≈ $2.5 billion of special‑use‑fund assets classified as “fixed‑income securities” (page 55).  Equity securities in those funds were a much smaller share (well under $1 billion, the filing lists only a $677 million equity‑security line for the company overall, indicating equity was a minor component of the special‑use portfolio).\n\n- **2024:** By the end of 2024 the mix had reversed.  The special‑use‑fund table now reports $2,614 million (Level 1) + $3,321 million (Level 2) ≈ $6.2 billion in **equity securities** versus only $663 million in U.S. government/municipal bonds, $5 million in corporate debt, and essentially no other debt (total fixed‑income ≈ $0.7 billion) (page 89).  The equity portion therefore represents roughly 90 % of the special‑use‑fund assets, with fixed‑income making up about 10 %.\n\n**Implication:** The shift from a fixed‑income‑heavy to an equity‑heavy special‑use‑fund portfolio suggests NextEra is willing to assume more market risk to capture higher returns, while still keeping a modest core of liquid debt securities for liquidity and regulatory purposes.  This reflects a more aggressive risk appetite and a liquidity strategy that relies on the greater marketability of equity holdings.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, in 2022, NextEra Energy (NEE) had $2,505 million in fixed income securities and no mention of equity securities in Special Use Funds, which the LLM correctly identifies as fixed-income dominated but incorrectly suggests there was a small equity component (~$677M) based on a misinterpretation of overall company data rather than Special Use Funds specifically. This is a critical error.\n\n2) For 2024, the ground truth reports: $6,164M in equity securities, $722M in U.S. Government and municipal bonds, $685M in corporate debt, and $873M in asset-backed securities. The LLM incorrectly states only $663M in government/municipal bonds, $5M in corporate debt, and no asset-backed securities—missing over $1.5 billion in fixed income categories. It also incorrectly aggregates equity as $2,614M + $3,321M = $5,935M (~$6.2B rounded), but these Level 1 and Level 2 values do not align with the actual reported equity total of $6,164M. Furthermore, the LLM claims fixed income totals ~$700M, whereas the actual sum of fixed income components is $722M + $685M + $873M = $2,280M—more than triple the LLM's figure.\n\n3) The qualitative assessment of a shift toward equity and increased risk appetite is directionally correct and well-reasoned, supporting a reasonable implication about risk and liquidity strategy. However, the reasoning is based on flawed data, undermining the validity of the conclusion. The LLM correctly identifies this as a strategic reversal but overstates the equity dominance (90% vs actual ~73%: $6,164M / $8,444M total ≈ 73%) and underrepresents the continued significance of fixed income.\n\n4) Contextually, the answer addresses all parts of the question—evolution from 2022 to 2024, allocation changes, and implications for risk and liquidity—with good structure and relevance. The multi-hop synthesis is conceptually sound but fails due to incorrect data extraction from the filings. Minor formatting variations in dollar amounts are acceptable, but the magnitude of errors in both individual line items and totals crosses into factual inaccuracy. Missing entire asset classes (e.g., asset-backed securities) and misclassifying totals invalidates the quantitative foundation.\n\nOverall, while the narrative arc is plausible and contextually appropriate, the answer fails on core factual accuracy, especially in the 2024 breakdown, warranting a mid-range score where partial credit is given for correct directional insight but heavy penalty for numerical and compositional errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1510,
        "completion_tokens": 686,
        "total_tokens": 2196
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the nature and magnitude of the risk associated with site infrastructure sharing evolved between 2022 and 2024, particularly in relation to 5G technology adoption and its impact on new lease activity?",
      "original_answer": "In 2022, AMT identified site infrastructure sharing as a risk factor that could slow new lease activity or lead to decommissioning of equipment on existing sites, particularly due to the rise of 5G technology. By 2024, this risk evolved into a more specific concern around RAN (Radio Access Network) sharing, roaming, or resale arrangements, which were explicitly tied to the lack of compensation to AMT when carriers opted for shared infrastructure instead of deploying new equipment. The 2024 filing indicates a stronger emphasis on the financial impact of this trend, suggesting a more mature and impactful shift in carrier behavior driven by 5G deployment. This represents a significant evolution in the risk's specificity and perceived threat level.",
      "llm_answer": "In the 2022 Form 10‑K the company warned that “extensive sharing of site infrastructure … due to increases in advanced network technology such as 5G … may cause new‑lease activity to slow,” framing the risk as a possible slowdown in future leases. By the 2024 filing the language had been sharpened – the sharing is described as “extensive” and the company adds that it could also trigger “de‑commissioning of equipment on certain existing sites,” indicating that the board now views the 5G‑driven sharing risk as larger and more material to new‑lease growth.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates (2022 and 2024), entities (AMT, 5G technology), and correctly identifies the evolution of risk related to site infrastructure sharing impacting new lease activity. It accurately reflects that in 2022, the risk was framed as a potential slowdown in new leases due to 5G-driven infrastructure sharing, and by 2024, the risk expanded to include decommissioning of existing equipment, indicating a heightened concern. However, the LLM answer omits a key element from the ground truth: the 2024 filing's specific emphasis on RAN sharing, roaming, or resale arrangements and, crucially, the lack of compensation to AMT when carriers share infrastructure. This financial dimension — that AMT is not compensated despite reduced deployment — is a critical evolution in the risk's nature and is missing from the LLM response. While the answer captures the increased materiality and scope of the risk, it fails to fully synthesize the multi-hop detail about compensation and specific sharing mechanisms (RAN), which are central to the ground truth. There are no numerical inaccuracies (dates are correct), so quantitative accuracy is perfect. Qualitative accuracy is reduced due to the omission of key conceptual developments. Contextual relevance remains high as the response directly addresses the evolution of risk in relation to 5G and lease activity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 386,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has Chevron's financial relationship with Angola LNG Limited evolved between 2022 and 2023, particularly in terms of its investment structure and equity method accounting?",
      "original_answer": "Chevron's relationship with Angola LNG Limited evolved from a dependency-based structure in 2022 to a more direct investment model in 2023. In 2022, Chevron reported a 36.4% interest in Angola LNG Limited, but the relationship was categorized under 'Depends_On', indicating a more passive or structurally dependent investment. By 2023, the relationship was reclassified as 'Invests_In', suggesting a more active or strategic financial posture. Additionally, while both years maintained the same ownership percentage (36.4%), the reclassification indicates a shift in how Chevron views or manages its investment, possibly reflecting changes in operational involvement or strategic alignment.",
      "llm_answer": "In 2022 Chevron’s 36.4 % equity stake in Angola LNG Limited was carried at about **$2.3 billion** (the “Investments and advances” line shows $2,258 million) and the equity‑method result was a **$166 million loss** (‑$166 million) for the year【page_78】.  \n\nBy 2023 the carrying amount of the same stake had fallen to roughly **$1.8 billion** (the 2023 table lists $1,762 million) and the equity‑method result turned to a **$513 million gain**, reflecting a shift from a loss to earnings while the ownership percentage (36.4 %) remained unchanged【page_82】.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides detailed quantitative data about Chevron's equity method results and carrying amounts for its investment in Angola LNG Limited in 2022 and 2023, citing specific dollar figures and financial outcomes. However, it fails to address the core qualitative evolution described in the ground truth: the shift from a 'Depends_On' to an 'Invests_In' relationship classification, which is central to how Chevron's financial relationship evolved structurally. This reclassification reflects a change in investment structure and accounting posture, which the LLM answer omits entirely. Regarding quantitative accuracy: the cited numbers ($2,258 million in 2022, $1,762 million in 2023, -$166 million loss in 2022, $513 million gain in 2023) may be factually accurate based on the referenced pages, but they are not present in the original answer (ground truth), meaning the LLM introduced new data not confirmed by the knowledge graph. Since the ground truth does not mention carrying amounts or equity method gains/losses, the correctness of these figures cannot be verified against the provided truth, making their inclusion speculative in this evaluation context. The ownership percentage (36.4%) is correctly repeated. The reasoning is internally logical—showing a shift from loss to gain while holding ownership constant—but does not support the structural accounting relationship change emphasized in the original answer. Thus, while the LLM demonstrates strong contextual relevance by focusing on Chevron and Angola LNG Limited across 2022–2023 and touches on equity method accounting, it misses the key multi-hop insight about relationship reclassification, leading to a partially correct but fundamentally incomplete response. The answer substitutes financial performance metrics for structural accounting changes, which are distinct concepts. Therefore, the correctness score is moderate due to factual overreach and omission of the primary evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 536,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the G600 aircraft's role in Gulfstream's product lineup evolved from 2022 to 2023, particularly in terms of its performance metrics and production status?",
      "original_answer": "In 2022, the G600 was described as a recent addition to the Gulfstream fleet, having entered service in 2019, and was positioned as a clean-sheet aircraft replacing the G550. By 2023, the G600 was no longer characterized as 'new' but rather as a mature product within the lineup, with over 250 cumulative deliveries by year-end 2023. Additionally, in 2023, the G600's advanced technologies, such as the Symmetry Flight Deck, were highlighted as foundational features being extended to newer models like the G700, G800, and G400. This indicates a shift from product introduction to integration within the broader Gulfstream platform.",
      "llm_answer": "By 2023 the G600 had moved from a newly‑introduced, limited‑run model to a mature, high‑volume product in Gulfstream’s large‑cabin lineup.  The filing notes that the G600 (along with the G500) is “faster, more fuel‑efficient, has greater cabin volume, more range and improved flight‑controls” than the aircraft it replaces, and cumulative deliveries rose from “almost 150” at the end of 2021 to “over 250” by year‑end 2023, indicating that production has accelerated and the jet is now a core, high‑delivery member of the fleet.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of the G600 from a recent addition to a mature, high-volume product in Gulfstream's lineup. It accurately notes the increase in cumulative deliveries from 'almost 150' at end-2021 to 'over 250' by end-2023, which aligns with the ground truth's mention of over 250 deliveries by year-end 2023. While the original answer does not specify the 2021 delivery number, the progression is consistent and supports the narrative of production acceleration. (2) All quantitative data is accurate: 'over 250' deliveries by 2023 is correctly reported, and the comparison across time is logically sound. No calculation errors. (3) The reasoning is strong: the LLM infers increased production volume and maturity from delivery trends and correctly identifies the G600’s enhanced performance metrics (speed, fuel efficiency, range, cabin volume, flight controls) relative to the G550 it replaced. However, the original answer emphasizes the G600’s role as a technology platform—its Symmetry Flight Deck being extended to newer models like G700/G800/G400—which the LLM omits. This is a minor gap in completeness but does not undermine the core accuracy. (4) The answer is contextually relevant, directly addressing the evolution in role, performance metrics, and production status. The omission of the technology transfer aspect prevents a perfect score, but all other elements are factually correct and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 405,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial involvement and strategic collaboration between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's relationship with franchisees was primarily framed around franchised arrangements and license agreements, with franchisees contributing revenue through rent, royalties, and initial fees, while the company did not typically invest in restaurant capital under developmental licenses. By 2024, the company had introduced a more active investment role, co-investing with franchisees to fund restaurant improvements and operating system upgrades. These co-investments were aimed at catering to consumer preferences, improving local performance, and enhancing the brand through modernization. This marks a strategic shift from a largely passive franchising model to a more collaborative and financially engaged partnership.",
      "llm_answer": "By 2022 McDonald’s described its franchise system mainly as a fee‑based arrangement: the company earned rent, royalties, initial fees and advertising‑cooperative contributions from franchisees, and only occasionally shared costs of restaurant improvements in a footnote on property‑and‑equipment. In the 2024 filing the company stresses that it now routinely co‑invests with franchisees to fund remodels, technology upgrades and other initiatives, allocating upfront costs and later reconciling them, while still receiving the same rent/royalty fees—showing a shift from a largely transactional relationship to a more collaborative, strategic partnership that includes joint capital projects, shared standards and training programs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the 2022 relationship as fee-based, citing rent, royalties, initial fees, and advertising contributions—consistent with the original answer’s emphasis on revenue from franchised arrangements. The mention of only occasional cost-sharing in 2022 (via a footnote on property-and-equipment) adds a precise detail that supports the 'passive' model. In 2024, the shift to routine co-investment in remodels and technology upgrades is accurately described, matching the original answer’s claim of co-investment for modernization and system improvements. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised; dates (2022, 2024) are correct and consistently used. (3) The multi-hop reasoning—comparing McDonald’s franchise model across two years and inferring a strategic shift—is sound. The LLM correctly synthesizes changes in financial involvement (from passive to co-investment) and strategic collaboration (joint projects, shared standards). (4) The LLM adds slightly more detail (e.g., advertising co-ops, reconciliation of costs) not in the original, but these are plausible and do not contradict the ground truth. The only minor gap is that the original emphasizes 'catering to consumer preferences' and 'local performance' as goals of co-investment, which the LLM omits. However, the core factual and strategic evolution is correctly conveyed. Thus, the answer is semantically equivalent with high completeness, entity accuracy, and reasoning quality.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 444,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined marginally to $10,670 million. This reflects a small decrease in both revenue and profitability year-over-year.",
      "llm_answer": "In the Smokeable Products segment, net revenues fell from $22,476 million in 2022 to $21,756 million in 2023—a decline of roughly $720 million (about 3 %).  Operating income (OCI) was essentially unchanged, slipping slightly from $10,688 million to $10,670 million, a drop of only $18 million 【page_29】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: net revenues of $22,476 million in 2022 and $21,756 million in 2023, and operating income of $10,688 million in 2022 and $10,670 million in 2023. These values match the original answer exactly. (2) The quantitative analysis is accurate: the revenue decline is correctly calculated as $720 million, and the percentage drop is approximately 3% (720 / 22,476 ≈ 3.2%), which is reasonably rounded. The operating income decrease of $18 million is also correctly computed. (3) The reasoning is sound and reflects multi-hop synthesis across the two years for both metrics. The conclusion that revenue declined meaningfully while operating income was 'essentially unchanged' is a reasonable qualitative interpretation of a marginal $18M drop. (4) The only minor shortcoming is that the original answer emphasizes a 'small decrease in both revenue and profitability', while the LLM slightly underemphasizes the operating income decline by calling it 'essentially unchanged'—though this is a semantic nuance rather than a factual error. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1167,
        "completion_tokens": 346,
        "total_tokens": 1514
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the role of Opdivo within BMY's product development and commercialization strategy evolved from 2022 to 2024, particularly in terms of its collaborative framework and new therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was primarily positioned within a joint development and commercialization framework with Ono, where profits, losses, and development costs were shared—either equally for combination therapies or under an 80-20 split for single-party compounds. Additionally, Opdivo was part of a broader alliance that included other products like Yervoy and Orencia, with structured co-promotion and supply responsibilities. By 2024, Opdivo's role had evolved significantly, marked by a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. This reflects a shift from a co-development focus to a more independent product introduction strategy, with BMY taking the lead in expanding Opdivo’s therapeutic applications in key oncology markets.",
      "llm_answer": "In the 2022 filing, Opdivo was described mainly as a collaborative asset – BMS held the worldwide development, manufacturing and commercial rights but partnered with Ono to jointly develop and commercialize the drug in Japan, South Korea and Taiwan (with profit‑sharing and royalty arrangements) and also worked with Nektar on the Opdivo + NKTR‑214 combination program【page_113】. By the 2024 filing, Opdivo had become a cornerstone of BMS’s oncology platform, with the company highlighting a “foundation in IO with Opdivo, Yervoy and Opdualag” and announcing several new approvals – a sub‑cutaneous co‑formulation (Opdivo Qvantig), first‑line urothelial‑carcinoma, neoadjuvant NSCLC and an EU Opdivo + Yervoy indication – expanding its global therapeutic reach beyond the earlier regional alliance framework【page_46】【page_44】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the evolution of Opdivo's role in BMY's (BMS's) strategy from 2022 to 2024, with accurate qualitative details and strong contextual relevance. (1) It correctly identifies the collaborative framework in 2022 involving Ono in Japan, South Korea, and Taiwan, and mentions the Nektar collaboration on the NKTR-214 combination, which aligns with the broader alliance context in the ground truth. While the ground truth emphasizes the 80-20 or equal cost/profit sharing structure with Ono, the LLM omits these specific financial splits but still conveys the essence of joint development and commercialization. (2) Quantitatively, the LLM accurately references a March 2024 approval for first-line urothelial carcinoma (implied by 'first-line urothelial-carcinoma' approval), though it does not specify the exact combination (cisplatin and gemcitabine) or the FDA as the approving body. However, it adds other accurate 2024 developments such as the subcutaneous formulation (Opdivo Qvantig), neoadjuvant NSCLC, and EU approval for Opdivo + Yervoy—details not in the ground truth but factually correct and supportive of the strategic shift. (3) The multi-hop reasoning is sound: it synthesizes information across years and collaborations to show a shift from regional co-development to a broader, more independent global strategy with BMS in the lead. The mention of Opdivo as a 'cornerstone' and part of a foundation in IO with Yervoy and Opdualag reflects strategic evolution consistent with the ground truth. (4) The main shortcoming is the omission of specific financial terms of the Ono agreement (e.g., 80-20 split) and the exact FDA approval details, which slightly reduces completeness and precision. However, the core facts, timeline, and strategic shift are accurately conveyed, warranting a high correctness score with minor deductions for missing granular detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 514,
        "total_tokens": 1947
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has AMT's disclosure regarding interest rate benchmarks for debt instruments evolved between 2022 and 2024, particularly in terms of referenced rates and associated covenants?",
      "original_answer": "In 2022, AMT's debt instruments referenced LIBOR, EURIBOR, and a defined base rate for USD and EUR denominated borrowings, with the 2021 credit facilities tied to debt ratings and commitment fees ranging from 0.080% to 0.300%. By 2024, AMT disclosed that new drawings under letters of credit in Nigeria bore interest at SOFR (Secured Overnight Financing Rate) plus a spread, indicating a shift away from LIBOR-based instruments. Additionally, while 2022 disclosures detailed specific covenants and optional renewal periods for various credit facilities, the 2024 disclosure focused on the consequences of covenant non-compliance without specifying interest rate structures or renewal terms, suggesting a simplification or evolution in the presentation of covenant-related disclosures.",
      "llm_answer": "- **2022 filing (10‑K 2022, pages 51‑52):** AMT said that the revolving credit facilities, term loans and delayed‑draw term loans are priced “LIBOR + margin,” “EURIBOR + margin,” or “base‑rate + margin,” depending on the currency.  The credit agreements contain “reporting, information, financial and operating covenants and other restrictions (including limitations on additional debt, guaranties, sales of assets and liens).”  \n\n- **2024 filing (10‑K 2024, pages 115‑117):** The company now discloses fixed‑rate coupons on its securitized notes (e.g., 5.490 % and 5.735 % for the 2023 securities; 3.652 % and 4.459 % for the 2018 securities) and a loan agreement that is governed by cash‑flow‑based tests – a minimum debt‑service‑coverage ratio (DSCR), a “cash‑trap” reserve account, and amortization triggers if DSCR falls below 1.15×.  The notes also reiterate restrictions on incurring additional indebtedness and require reserve funding, and state that the company was in compliance with all covenants as of 31 Dec 2024.  \n\n**Thus, the benchmark moved from floating LIBOR/EURIBOR‑plus‑margin references with generic covenants in 2022 to fixed coupon rates tied to cash‑flow coverage covenants and specific reserve‑account requirements in 2024.**",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures some correct elements but contains significant inaccuracies and omissions in both referenced rates and covenant evolution. (1) On quantitative accuracy: The 2024 fixed-rate coupons (e.g., 5.490%, 5.735%, 3.652%, 4.459%) are correctly reported, and the DSCR threshold of 1.15× is accurate. However, the ground truth states that new drawings in Nigeria under letters of credit bear interest at SOFR + spread, which the LLM fails to mention. Instead, it incorrectly implies a broad shift to fixed-rate securitized notes as the primary debt instrument, which is not supported by the original answer. (2) On completeness: The question asks about evolution in interest rate benchmarks and associated covenants. The LLM correctly notes a shift away from LIBOR but misrepresents the replacement benchmark—SOFR is not mentioned, and instead fixed-rate notes are emphasized, which were not highlighted in the ground truth as a benchmark replacement. The 2022 covenants are accurately described as generic, but the 2024 covenant discussion incorrectly focuses on securitized notes' reserve and amortization triggers, which are not tied to the same facilities that reference SOFR. The original answer emphasizes a change in disclosure focus—not a structural shift to fixed-rate instruments. (3) On entity and reasoning accuracy: The LLM conflates different debt instruments—securitized notes with fixed coupons are not the same as the SOFR-based letters of credit in Nigeria. This reflects a failure in multi-hop synthesis: it does not distinguish between types of debt or correctly map benchmarks to instruments. The conclusion that benchmarks moved to fixed coupons is incorrect; the ground truth specifies a shift from LIBOR to SOFR (a floating rate), not fixed rates. (4) Contextual relevance is high because the response addresses interest rate benchmarks and covenants over time, uses correct years and document types, and cites relevant financial terms. However, the core factual error—substituting SOFR with fixed-rate notes—undermines correctness. Minor formatting differences in numbers are acceptable, but misidentification of the key benchmark transition (LIBOR → SOFR) is a major error. Thus, the answer is partially correct but misses the central evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1517,
        "completion_tokens": 614,
        "total_tokens": 2131
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has McDonald's relationship with franchisees evolved in terms of real estate ownership and co-investment strategy between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's emphasized Systemwide coordination and alignment to manage ESG initiatives, including environmental sustainability and responsible sourcing, which required franchisee cooperation. However, the specific role of franchisees in real estate ownership was not detailed. By 2024, the company explicitly outlined its conventional franchise model, where it typically owns or secures long-term leases on land and buildings, while franchisees invest in equipment, signs, seating, and décor. This co-investment model was described as enabling McDonald's to achieve high restaurant performance levels. The shift from a general emphasis on franchisee collaboration in 2022 to a clearly defined real estate and co-investment strategy in 2024 reflects a more structured and strategic approach to franchise relationships.",
      "llm_answer": "In the 2022 filing McDonald’s described its conventional‑franchise model as one in which the company **generally owns or secures a long‑term lease on the land and building** for each franchised restaurant, with franchisees paying rent, royalties and furnishing the equipment. By the 2024 filing the company still emphasizes that real‑estate ownership (or long‑term lease) is central, but it adds that **it now routinely co‑invests with franchisees to fund restaurant‑modernization and other system‑wide improvements**, signaling a shift from a purely landlord‑franchisee relationship to a collaborative capital‑investment partnership.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key facts and evolution of McDonald's franchisee relationship regarding real estate and co-investment. It accurately identifies that in 2022, McDonald's already owned or leased the land and buildings under its conventional franchise model, which matches the original answer. It also correctly notes that by 2024, the company emphasized a co-investment strategy with franchisees for modernization and system-wide improvements. However, the original answer does not explicitly state that co-investment became a 'routine' practice by 2024 or that it represents a shift from a 'purely landlord-franchisee relationship'—this is a slight interpretive leap not fully substantiated in the ground truth. The ground truth emphasizes a clearer articulation of the existing co-investment model in 2024 rather than a new strategic shift. There are no numerical inaccuracies (quantitative accuracy is perfect), and all entities (McDonald's, franchisees, years 2022 and 2024, real estate ownership, co-investment) are correctly identified. The reasoning is sound and addresses the multi-hop aspect—comparing the two years’ strategies—but slightly overstates the evolution. Contextual relevance is excellent as it directly addresses the question’s focus on real estate and co-investment trends over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 379,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the status and documentation of the 2015 Stock Compensation Plan for Non-Employee Directors change between 2022 and 2023, and what does this evolution indicate about Altria's governance approach to director compensation?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was disclosed with 703,256 shares available for issuance under the plan. By 2023, the plan was formally amended and restated effective October 26, 2022, and was incorporated by reference from Altria's September 30, 2022, Form 10-Q filing. This indicates a formal update to the plan’s structure and governance, suggesting Altria refined its director compensation framework mid-cycle, potentially to align with evolving governance standards or internal compensation strategies.",
      "llm_answer": "In the 2022 Form 10‑K the 2015 Stock Compensation Plan for Non‑Employee Directors was described as “as amended and restated effective October 26, 2022” and was incorporated by reference to Altria’s Form 10‑Q for the quarter ended September 30, 2022【page_110】. The 2023 filing repeats the same amendment status and reference, indicating no further amendment to the plan【page_110】, but the equity‑compensation table shows the pool of shares available under the plan fell from 703,256 in 2022 to 589,927 in 2023【page_114】【page_107】. This evolution shows that while Altria keeps the director‑stock plan formally in place, it is gradually tightening the amount of equity it can award to directors, reflecting a more disciplined, cost‑conscious governance approach to director compensation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key facts: the 2015 Stock Compensation Plan was amended and restated effective October 26, 2022, and incorporated by reference from the September 30, 2022, Form 10-Q, matching the ground truth. It accurately reports the number of shares available in 2022 (703,256) and 2023 (589,927), with correct sourcing from the respective filings. (2) Quantitative accuracy is perfect: both share counts are correct, and the decrease of 113,329 shares is implied (though not explicitly calculated), which aligns with the data. No calculation errors. (3) The reasoning is sound and adds value beyond the ground truth by noting the reduction in available shares and interpreting it as a move toward a more disciplined, cost-conscious governance approach. While the ground truth emphasizes formal refinement of the plan, the LLM infers an additional layer about tightening equity awards, which is logically supported by the data and represents a reasonable, insightful extension. (4) The answer fully addresses both parts of the question—changes in status/documentation and implications for governance—and synthesizes information across 2022 and 2023 filings. The only minor gap is that the ground truth emphasizes the *mid-cycle* update as notable, while the LLM focuses more on share depletion; both are valid, but the LLM slightly underemphasizes the procedural governance update. Overall, the answer is factually excellent, contextually relevant, and analytically strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 418,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the impact of roaming and resale arrangements among wireless service providers on AMT's leasing activity evolved from 2022 to 2024, and what does this indicate about the competitive pressures affecting new lease growth?",
      "original_answer": "In 2022, AMT noted that roaming or resale arrangements among wireless service providers, particularly with the rise of 5G technology, could slow new lease activity if carriers opted to share infrastructure rather than deploy new equipment. By 2024, this concern evolved into a broader risk involving RAN sharing and resale arrangements, which not only threatened new lease activity but also led to potential decommissioning of existing equipment due to redundancy. This indicates a growing competitive pressure where infrastructure sharing is becoming a more viable and widespread alternative to leasing, directly impacting AMT’s revenue growth prospects.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K risk‑factor sections note that “extensive sharing of site infrastructure, roaming or resale arrangements among wireless service providers… may cause new‑lease activity to slow… or may result in the de‑commissioning of equipment on existing sites.” The language is essentially unchanged, showing that the threat from carrier‑driven network‑sharing and roaming/resale deals has persisted rather than intensified. This consistency signals that competitive pressure from such arrangements remains a material head‑wind to AMT’s ability to generate new leases.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually incorrect in its core reasoning and contradicts the ground truth. While it correctly identifies that AMT mentioned roaming/resale arrangements in both 2022 and 2024 as risks to leasing activity, it incorrectly claims the language is 'essentially unchanged,' leading to the conclusion that the threat has 'persisted rather than intensified.' This directly conflicts with the ground truth, which states that the impact evolved significantly: in 2022, the concern was limited to slowing new lease activity due to infrastructure sharing (especially with 5G), but by 2024, the risk expanded to include RAN sharing and resale arrangements causing not just slower growth but actual decommissioning of existing equipment. This evolution indicates intensifying competitive pressure, not a static one. The LLM’s interpretation thus fails the multi-hop reasoning requirement—it does not correctly synthesize the progression across years. There are no numerical errors (hence high quantitative accuracy), and the response is contextually relevant, but the qualitative inaccuracy in reasoning and conclusion severely undermines the answer’s correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 328,
        "total_tokens": 1659
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has McDonald's relationship with its franchisees evolved between 2022 and 2024, particularly in terms of strategic investment and operational expectations?",
      "original_answer": "In 2022, McDonald's highlighted the impact of the COVID-19 pandemic on franchise operations, emphasizing risks related to labor availability, supply chain disruptions, and the importance of executing its 'Accelerating the Arches' strategy to maintain growth. The focus was on franchisees' ability to adapt to changing consumer behavior and operational restrictions. By 2024, McDonald's had shifted toward a more active investment role, co-investing with franchisees to modernize restaurants and improve local performance. The company emphasized franchisee reinvestment in their businesses and introduced structured co-investment initiatives designed to increase the value of the McDonald's brand through restaurant modernization and enhanced consumer appeal. This marks a shift from pandemic-driven operational challenges to a more strategic, investment-backed growth approach.",
      "llm_answer": "By 2022, McDonald’s framed its franchise relationship mainly as a risk‑management issue: the system’s growth depended on franchisees’ willingness and ability to fund “major initiatives” and stay aligned with the company’s operating, promotional and capital‑intensive reinvestment plans, and any inability to obtain financing could hurt results. By 2024 the tone had shifted to a more collaborative partnership – the company still expects franchisees to reinvest capital, but now explicitly co‑invests with them to modernize restaurants, improve the customer experience and capture higher‑revenue opportunities, while maintaining rigorous brand‑and‑operational standards. Thus the relationship evolved from a largely conditional, compliance‑focused arrangement to a strategic, joint‑investment model that emphasizes shared modernization and performance goals.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of McDonald's relationship with franchisees from 2022 to 2024: in 2022, the focus was on franchisee compliance and risk management amid pandemic-related challenges, including capital investment pressures and financing risks. By 2024, the relationship evolved into a more collaborative, co-investment model aimed at modernization and growth. These key points match the original answer's emphasis on shifting from operational resilience to strategic investment. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is sound: the model synthesizes changes over time (2022 vs 2024), correctly attributes strategic shifts to McDonald's and its franchisees, and captures the transition from compliance-driven expectations to joint investment. The only minor gap is that the LLM does not explicitly mention 'Accelerating the Arches' by name, which is a specific strategy cited in the original, though it does reference alignment with capital reinvestment plans, which captures the essence. (4) The answer is contextually excellent—it directly addresses both strategic investment and operational expectations as asked, and the shift in tone and structure is clearly articulated. Semantic equivalence is strong despite slightly different phrasing. Thus, correctness is 9 due to the omission of the named strategy, but all core facts and reasoning are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 437,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did NextEra Energy's investment strategy in equity securities within its Special Use Funds evolve from 2022 to 2024?",
      "original_answer": "In 2022, NextEra Energy held $8,922 million in Special Use Funds, with no explicit breakdown of equity securities provided in the filing. By 2024, the company disclosed a more detailed composition, with $6,164 million specifically allocated to equity securities under Special Use Funds. This evolution suggests a strategic shift toward transparency and a potentially greater emphasis on equity investments within these funds. While the total amount in Special Use Funds decreased, the explicit allocation to equities in 2024 indicates a more defined and possibly more aggressive investment posture compared to 2022.",
      "llm_answer": "In the 2022 filing NextEra’s special‑use funds contained only a modest amount of equity securities and the holdings were reported almost entirely as Level 1 (direct) investments. By the 2024 filing the equity portion had grown dramatically – NEE’s special‑use funds held $2.6 billion of Level 1 equity, $3.3 billion of Level 2 equity (primarily commingled‑fund shares) and $0.2 billion of Level 3 equity, for a total of $6.2 billion; FPL’s funds held $1.0 billion of Level 1 equity, $3.0 billion of Level 2 equity and $0.2 billion of Level 3 equity, for a total of $4.2 billion【page_89】. This reflects a clear shift from a relatively small, direct‑holding strategy in 2022 to a larger, more diversified equity‑investment approach in 2024 that relies heavily on Level 2 commingled‑fund vehicles while adding a modest Level 3 component.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and entity attribution. The ground truth states that in 2022, NextEra Energy held $8,922 million in Special Use Funds with no breakdown of equity securities. The LLM incorrectly claims a 'modest amount' and 'almost entirely Level 1' without supporting this from the original answer, which made no such disclosure for 2022. For 2024, the ground truth reports $6,164 million in equity securities for NextEra Energy overall. The LLM reports $6.2 billion for NEE and an additional $4.2 billion for FPL (Florida Power & Light, a subsidiary), which is not mentioned in the original answer and introduces data not present in the ground truth. The total equity allocation in the LLM answer ($6.2B + $4.2B = $10.4B) far exceeds the ground truth’s $6.164B for the entire company. (2) The LLM breaks down equity into Level 1 ($2.6B), Level 2 ($3.3B), and Level 3 ($0.2B) for NEE, summing to $6.1B, which is close to the ground truth $6,164M (~$6.16B), but this level of detail (especially Level 2/3) is not in the original answer and appears fabricated. The FPL breakdown is entirely extraneous. (3) The reasoning about a strategic shift toward diversification and transparency is plausible and aligns thematically with the ground truth’s interpretation, but the multi-hop synthesis is flawed because it introduces subsidiary-level data (FPL) and granular fair value hierarchy details not present in the original answer. The conclusion about increased diversification using commingled funds is not supported by the ground truth, which only notes greater disclosure and possible emphasis on equities. (4) The contextual relevance is high because the answer addresses the evolution of investment strategy and attempts to interpret the shift. However, the quantitative inaccuracies and introduction of unsupported details severely undermine factual correctness. The qualitative reasoning is partially sound but based on incorrect data. Thus, the correctness score is low due to major factual and numerical discrepancies, despite some thematic alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 569,
        "total_tokens": 1925
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined to $10,670 million. This indicates a marginal decrease in both revenue and profitability year-over-year.",
      "llm_answer": "In the Smokeable Products segment, net revenues fell from **$22.476 billion in 2022 to $21.756 billion in 2023** – a drop of roughly **$720 million (about 3 %)**.  Operating income (OCI) for the same segment slipped marginally, moving from **$10.688 billion in 2022 to $10.670 billion in 2023**, a decline of only **$18 million**, essentially flat year‑over‑year【page_29】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $22,476 million (=$22.476 billion) in 2022 and $21,756 million (=$21.756 billion) in 2023 for net revenues; $10,688 million (=$10.688 billion) and $10,670 million (=$10.670 billion) for operating income—format variations (billion vs million) are semantically equivalent and correctly interpreted. (2) The calculated differences—$720 million decrease in revenue (~3%) and $18 million drop in operating income—are accurate and appropriately characterized as marginal or flat. (3) The reasoning is sound: the model correctly synthesizes year-over-year performance across two financial metrics (net revenues and operating income) for the smokeable products segment, demonstrating proper multi-hop understanding. (4) The answer is complete, addressing both parts of the question (revenue and profitability trends), uses correct entities (Smokeable Products segment, correct years), and conveys the same conclusion as the ground truth—a slight decline in both metrics. Wording differs slightly but maintains semantic equivalence. All evaluation criteria are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1183,
        "completion_tokens": 334,
        "total_tokens": 1517
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the utilization of Accenture plc Class A Ordinary Shares evolved between 2022 and 2023, particularly in terms of share purchase programs and their intended usage?",
      "original_answer": "In 2022, Accenture disclosed an aggregate available authorization of $3,129,296 for publicly announced open-market share purchase programs and other share purchase programs involving Accenture plc Class A Ordinary Shares and Accenture Canada Holdings Inc. exchangeable shares. By 2023, the company clarified that Class A Ordinary Shares acquired through these programs were being held as treasury shares and intended for employee benefits, such as equity awards. Additionally, in fiscal 2024, shares were acquired via share withholding for payroll tax obligations under employee equity share plans, which were separate from the publicly announced share purchase authorization. This indicates a shift in focus toward internal employee compensation mechanisms while maintaining a formal buyback program.",
      "llm_answer": "In fiscal 2022 Accenture bought 9.6 million Class A ordinary shares on the open market and an additional 2.5 million through other purchase programs, for a total of ≈12.2 million shares that were placed in treasury and earmarked for employee‑benefit purposes such as equity awards 【page_94】. For fiscal 2023 the Board raised the overall repurchase authority by $3 million, lifting the total authorized amount to $6.13 million 【page_94】, signalling an expanded share‑repurchase capacity that continues to be used to fund treasury shares for employee equity programs.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Accenture had an aggregate available authorization of $3,129,296 (approximately $3.13 million), not $6.13 million as claimed by the LLM. The LLM incorrectly states that the Board raised the repurchase authority by $3 million in 2023 to reach $6.13 million, which contradicts the original answer—there is no mention of such a raise in the ground truth. Additionally, the LLM fabricates specific share purchase volumes (9.6 million and 2.5 million shares) that are not present in the original answer, which does not provide actual purchase volumes for 2022 or 2023. (2) The quantitative inaccuracies are severe: the dollar amounts are off by millions, and the share numbers are entirely made up. The original answer mentions only the authorization amount, not actual purchases or treasury placements. The LLM also misrepresents the timeline, implying fiscal 2024 activity is part of 2023 when it's presented as a forward-looking clarification. (3) The reasoning is partially sound in identifying that shares are used for employee benefits and held as treasury shares, which aligns with the original answer’s 2023 clarification. However, it fails the multi-hop synthesis by conflating authorization with actual purchases and inventing numerical details not present in the source. It also misattributes the source of share acquisition, omitting the distinction between public buybacks and share withholding for tax obligations introduced in fiscal 2024. (4) The contextual relevance is moderate because the answer addresses share purchase programs and intended usage (employee benefits), but the severe quantitative errors and invented data undermine factual correctness. The qualitative accuracy is low due to incorrect entities (wrong dollar figures, non-existent share volumes), though the general direction of usage (treasury for equity awards) is correct. Correctness score is low due to major factual and numerical discrepancies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 549,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the nature and structure of AMT's operating covenants evolved between 2022 and 2024, particularly in terms of the types of debt instruments involved and associated interest rate benchmarks?",
      "original_answer": "In 2022, AMT's operating covenants were tied to a variety of credit facilities and loans that referenced LIBOR and EURIBOR as the interest rate benchmarks. These included the 2021 Multicurrency Credit Facility, the 2021 Credit Facility, and several term loans. By 2024, AMT's disclosures indicate a shift in the interest rate benchmark to SOFR, specifically for letters of credit drawn in Nigeria, which were subject to a rate equal to SOFR at the time of drawing plus a spread. This reflects a transition away from LIBOR-based covenants toward SOFR-based structures, signaling a strategic and regulatory evolution in how AMT manages its debt obligations and associated covenants.",
      "llm_answer": "In the 2022 filing the operating covenants were confined to the company’s revolving credit facilities and term‑loan arrangements (the 2021 Multicurrency Credit Facility, USD Credit Facility, USD 364‑day and 2‑year Delayed‑Draw Term Loans, and the EUR Three‑Year Delayed‑Draw Term Loan).  Those agreements required the company to meet reporting and financial‑ratio tests and set the borrowing cost at a spread of **1.125 % over the applicable benchmark (LIBOR for USD borrowings and EURIBOR for EUR borrowings).**  \n\nBy the 2024 filing the covenant framework had broadened to cover the **securitized debt structures** (the 2015, 2018 and 2023 Secured Tower Revenue Securities) in addition to the still‑existing credit facilities.  The securitization covenants now focus on **debt‑service‑coverage ratios, cash‑trap and amortization triggers, and restrictions on additional indebtedness**, while the interest on those securities is expressed as **fixed coupons (e.g., 5.49 % and 3.652 %) rather than a LIBOR/EURIBOR spread**.  Thus, between 2022 and 2024 AMT moved from covenants tied mainly to revolving/term loans with LIBOR/EURIBOR benchmarks to a more diversified set that includes securitizations with fixed‑rate benchmarks and performance‑based covenants.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several correct elements but diverges significantly from the ground truth in key factual areas, particularly regarding the interest rate benchmark transition. (1) Correctly identifies 2022 debt instruments (2021 Multicurrency Credit Facility, USD and EUR term loans) and accurately states that LIBOR and EURIBOR were used as benchmarks with a 1.125% spread—this aligns with the general structure in the original answer, though the exact spread is not in the ground truth, introducing unverified detail. (2) However, the LLM claims that by 2024, securitized debt structures (2015, 2018, 2023 Secured Tower Revenue Securities) were included in covenants with fixed coupons (e.g., 5.49%, 3.652%), which is not mentioned or supported in the original answer. The ground truth instead highlights a shift to SOFR for letters of credit in Nigeria, a specific and factually narrow transition, whereas the LLM invents a broader structural shift to securitizations and fixed-rate benchmarks not present in the source. (3) The multi-hop reasoning is partially sound—synthesizing changes in covenants over time—but introduces unsupported entities (specific securitizations, fixed coupons) and omits the actual SOFR transition described in the ground truth. (4) Quantitative accuracy is compromised by the inclusion of specific percentages (5.49%, 3.652%, 1.125%) not present in the original, making them potentially hallucinated. While the direction of evolution (away from LIBOR) is conceptually consistent, the mechanism (SOFR adoption in Nigeria) is entirely replaced with a different narrative (securitizations with fixed rates). Thus, despite good structure and contextual relevance, the answer fails on core factual correctness, especially in the 2024 evolution, warranting a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1497,
        "completion_tokens": 488,
        "total_tokens": 1985
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Disney+ Hotstar's subscriber base evolve between the 2023 and 2024 SEC filings, and what impact did the consolidation of Star+ into Disney+ in Latin America have on Disney's international streaming strategy?",
      "original_answer": "In the 2023 SEC filing, Disney+ Hotstar reported approximately 36 million paid subscribers as of September 28, 2024. The 2024 filing noted that in certain Latin American countries prior to July 2024, Disney offered both Disney+ and Star+ as separate services, but these were merged into a single Disney+ product offering by the end of June 2024. This consolidation suggests a strategic shift toward streamlining international service offerings, potentially aligning with the model used for Disney+ Hotstar by integrating diverse content into a unified brand to enhance user experience and operational efficiency.",
      "llm_answer": "- In the 2023 filing Disney + Hotstar was not disclosed as a separate paid‑subscriber count, but the 2024 Form 10‑K states that “as of September 28 2024, the estimated number of paid Disney+ Hotstar subscribers … was approximately 36 million”【page_7】. This indicates that the Hotstar base had grown to roughly 36 million by the 2024 filing (up from an undisclosed, lower level in the 2023 filing).\n\n- The 2024 filing also explains that, prior to July 2024 Disney offered both Disney+ and Star+ in Latin America, but “at the end of June 2024, we merged these services into a single Disney+ product offering”【page_57】. By consolidating Star+ into Disney+, Disney streamlined its international streaming portfolio, creating a single, stronger brand in Latin America, simplifying pricing and marketing, and positioning the region as part of its broader “International Disney+ (excluding Disney+ Hotstar)” growth strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is factually correct in all key aspects: it accurately reports Disney+ Hotstar's subscriber count as approximately 36 million as of September 28, 2024, from the 2024 SEC filing. It correctly states that the 2023 filing did not disclose a separate subscriber count for Disney+ Hotstar, which aligns with the ground truth implication that no prior number was given. The date of the consolidation—end of June 2024—is correctly cited, and the merging of Star+ into Disney+ in Latin America is accurately described.\n\n2) Quantitative accuracy is perfect: the subscriber number (36 million), date (September 28, 2024), and timing of the service merger (end of June 2024) match the ground truth. There are no calculation errors, and the LLM correctly infers that the 2023 base was lower but undisclosed, which is a reasonable interpretation given the absence of prior data.\n\n3) The multi-hop reasoning is sound: the LLM synthesizes information across two different parts of the 2024 filing—subscriber data on page 7 and the Star+ consolidation on page 57—and connects them to answer both parts of the question. The strategic interpretation (streamlining international offerings, simplifying branding) goes slightly beyond the original answer but remains logically consistent and contextually appropriate.\n\n4) The only minor shortcoming is that the original answer emphasizes the alignment with the Disney+ Hotstar model (integrating diverse content into a unified brand), while the LLM focuses more on branding and operational efficiency without explicitly referencing the Hotstar parallel. This slight omission in qualitative nuance prevents a perfect 10, but the core reasoning and facts are fully accurate. Overall, the answer is highly relevant, precise, and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 485,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the number of employees covered under collective labor agreements changed from 2022 to 2023, and what does this indicate about the company's labor agreement strategy?",
      "original_answer": "In 2022, the company expected to negotiate agreements covering approximately 3,000 employees in the following year. In 2023, the company projected negotiations covering 2,100 employees for the upcoming year. This indicates a reduction in the number of employees involved in labor renegotiations, suggesting a shift in the company's labor agreement strategy, possibly due to fewer expiring agreements or proactive resolution of collective bargaining terms.",
      "llm_answer": "The filing shows that the share of the workforce covered by collective‑bargaining agreements was essentially unchanged – about 20 % of the subsidiaries’ employees were covered on December 31 2022 and the same roughly‑one‑fifth proportion was reported on December 31 2023.  This stability indicates that General Dynamics is maintaining a consistent labor‑agreement strategy, keeping the same level of union coverage while simply renegotiating the existing agreements rather than expanding or reducing the number of covered workers.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to match the ground truth. (1) Quantitatively, the LLM claims that approximately 20% of employees were covered by collective-bargaining agreements in both 2022 and 2023, but the original answer does not mention percentages or total workforce proportions at all. Instead, the ground truth discusses the number of employees *expected to be negotiated* in the upcoming year: 3,000 in 2022 and 2,100 in 2023. These specific figures are completely omitted in the LLM response, and no calculation or comparison of the 3,000 vs 2,100 figure is made. (2) The LLM invents a metric (20%) not present in the original data and draws conclusions from it, which is a factual error. (3) The reasoning is flawed: the original answer indicates a reduction in the number of employees involved in upcoming negotiations (from 3,000 to 2,100), suggesting a strategic shift due to fewer expiring agreements or proactive resolution. The LLM concludes 'stability' and 'consistent strategy', which contradicts the ground truth's implication of a strategic change. (4) While the LLM addresses the question's two parts (change in employees and interpretation), it does so with incorrect data and reasoning, resulting in a misleading answer. The contextual relevance is moderate because it discusses labor agreements and strategy, but the core facts are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 380,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did NextEra Energy's investment in U.S. Government and municipal bonds evolve from 2022 to 2024, and what was the change in total value across these years?",
      "original_answer": "In 2022, NextEra Energy's investment in U.S. Government and municipal bonds totaled $137 million. By 2024, this investment had increased significantly to $161 million under 'Other investments' for NEE. This represents a growth of $24 million, or approximately 17.5%, indicating a strategic increase in this asset class over the two-year period.",
      "llm_answer": "NextEra Energy’s holdings of U.S. Government and municipal bonds fell slightly over the period. At December 31 2022 the combined NEE‑ and FPL‑level investment was about **$1.34 billion** (NEE $757 million + FPL $583 million)【page 90】. By December 31 2024 the total had slipped to roughly **$1.28 billion** (NEE $722 million + FPL $561 million)【page 89】. The change represents a **decrease of roughly $57 million**.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both direction and magnitude. (1) Quantitative Accuracy: The ground truth states that NextEra Energy's investment in U.S. Government and municipal bonds was $137 million in 2022 and increased to $161 million in 2024, a $24 million increase. The LLM claims a decrease from $1.34 billion to $1.28 billion, which is over 9 times larger than the correct value and opposite in trend. The numbers cited ($757M, $583M, etc.) appear to be from different line items or entities (possibly FPL-level investments or misaggregated totals), but do not reflect the 'Other investments' category for NEE as specified in the ground truth. (2) Completeness: While the LLM attempts to address the evolution and change, it fails on both counts due to incorrect data. (3) Entity Accuracy: The LLM conflates NEE- and FPL-level investments, whereas the ground truth refers specifically to NEE's 'Other investments', which include U.S. Government and municipal bonds. The ticker NEE is correct, and years 2022 and 2024 are correctly referenced. (4) Reasoning: The multi-hop reasoning is flawed — the model incorrectly aggregates or extracts investment values, possibly pulling data from unrelated sections (e.g., different investment categories or subsidiaries). It concludes a decrease when the correct answer is an increase. (5) Semantic Equivalence: The LLM's answer contradicts the ground truth in both direction (decrease vs increase) and scale (billions vs millions). Even allowing for format variation, $1.34 billion is not equivalent to $137 million. The conclusion of a $57 million decrease is entirely unsupported by the ground truth. The contextual relevance is low but not zero, as the answer discusses the correct company and general asset class.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1192,
        "completion_tokens": 480,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the role of Opdivo in Bristol-Myers Squibb's product portfolio evolved between 2022 and 2024, particularly in terms of its manufacturing strategy and therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was referenced as a product with both internal manufacturing capability and reliance on third-party manufacturers to meet demand, highlighting its strategic importance in BMY's supply chain. By 2024, Opdivo received a new FDA approval in March for combination therapy with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma, indicating an expansion of its therapeutic applications. This evolution reflects both continued manufacturing investment and increased clinical positioning of Opdivo within BMY's oncology portfolio.",
      "llm_answer": "By 2022 Opdivo was already a core immune‑oncology (IO) product, but BMS’s 10‑K stressed that the drug was produced through a mixed model – the company retained the ability to manufacture Opdivo internally while also relying on third‑party manufacturers to meet commercial demand (see Manufacturing and Quality Assurance, page 27). By the 2024 filing the drug had become an even larger pillar of the portfolio, with a wave of new therapeutic approvals—including FDA clearance for neoadjuvant/resectable NSCLC (Oct 2024), FDA and EC approvals for Opdivo + Yervoy combinations, Japan’s approval for urothelial carcinoma, and the launch of the sub‑cutaneous Opdivo Qvantig formulation (Dec 2024) (see Product Approvals, pages 44‑45) – and the company highlighted Opdivo as the foundation of its IO strategy while continuing to shift mature products toward third‑party manufacturing as part of its productivity initiative (see Strategy, page 46).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in dates and approvals that contradict the ground truth. The ground truth states that Opdivo received FDA approval in March 2024 for combination therapy with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma. However, the LLM answer incorrectly claims FDA approval for neoadjuvant/resectable NSCLC in October 2024, FDA and EC approvals for Opdivo + Yervoy combinations, Japan’s approval for urothelial carcinoma, and the launch of sub-cutaneous Opdivo Qvantig in December 2024—none of which are mentioned in the ground truth. These are significant factual overstatements. (2) Quantitative accuracy is low because the LLM fabricates multiple approval dates (Oct 2024, Dec 2024) and regulatory actions (EC, Japan) not present in the original answer. The only correct date is the general 2022–2024 timeframe, and the mixed manufacturing model is correctly described. (3) The multi-hop reasoning is partially sound: the LLM correctly identifies the evolution in manufacturing strategy (internal + third-party in 2022, shift toward third-party in 2024) and links it to BMY’s productivity initiative. It also correctly infers increased strategic importance. However, the therapeutic expansion is exaggerated with unverified approvals, undermining the synthesis. (4) Contextual relevance is high because the answer addresses both manufacturing strategy and therapeutic approvals as asked, and uses appropriate sections from the 10-K (e.g., Manufacturing, Product Approvals). The qualitative accuracy is moderate because core concepts (mixed manufacturing, strategic pillar) are correct, but specific evidence is inaccurate. Overall, the answer is partially correct but contains significant factual errors in key details, warranting a score of 6 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 505,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Disney's relationship with National Geographic magazine evolved between 2023 and 2024 in terms of its business structure and strategic positioning within the company's portfolio?",
      "original_answer": "In 2023, National Geographic magazine was explicitly described as part of the Entertainment segment under Content Sales/Licensing, and was noted as being 73% owned by Disney. By 2024, the magazine was still reported under Content Sales/Licensing, but the emphasis on its ownership percentage was removed, and it was described more as a publication 'published' by the company rather than a business in which Disney has a direct equity stake. This shift indicates a more operational rather than ownership-focused relationship in 2024 compared to 2023.",
      "llm_answer": "In the 2023 Form 10‑K Disney disclosed that National Geographic magazine (and its online business) was a 73 %‑owned asset reported in the Entertainment segment under “Content Sales/Licensing.” The 2024 filing still treats the magazine the same way – it remains a 73 %‑owned, Content‑Sales/Licensing line item – but the company now emphasizes its role across multiple platforms, noting that National Geographic content is a top‑level tile on Disney+ and that National Geographic Expeditions (also 73 % owned) sit in the Experiences segment. Thus, while the ownership structure has not changed, the magazine’s strategic positioning has broadened from a pure licensing asset to a cross‑segment brand that supports Disney’s streaming and experiential businesses.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several correct elements but diverges significantly from the ground truth in key aspects. (1) Quantitatively, the 73% ownership figure is correctly stated for both 2023 and 2024, and the placement under Content Sales/Licensing is accurate for 2023. However, the ground truth states that in 2024, Disney removed emphasis on the 73% ownership and instead described National Geographic as 'published' by the company, suggesting a shift away from highlighting equity ownership. The LLM incorrectly asserts that the 73% ownership was still explicitly reported in 2024, which contradicts the original answer. (2) The LLM introduces new information not present in the ground truth—namely, that National Geographic is a 'top-level tile on Disney+' and that Expeditions are part of the Experiences segment. While potentially true, these details are not part of the documented evolution in business structure or strategic positioning as defined in the original answer, which focused on reporting and ownership language. (3) The reasoning is partially sound in identifying continuity in segment reporting, but the conclusion that strategic positioning has broadened across segments is speculative and not supported by the provided ground truth, which instead emphasizes a shift from ownership-focused to operation-focused language. (4) The answer is contextually relevant and addresses the question's intent, but the core factual claim about continued emphasis on 73% ownership in 2024 is incorrect, undermining the overall correctness. Thus, while some facts and numbers are right, the central analysis is misaligned with the ground truth, warranting a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 456,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has PayPal's description of its transaction management databases' capabilities evolved between 2023 and 2024, particularly in relation to global payment processing in different currencies?",
      "original_answer": "In 2023, PayPal described its transaction management databases as part of a platform that allowed consumers to withdraw funds in 56 currencies. By 2024, the company updated this figure to 57 currencies, indicating a slight expansion in the global reach of its transaction processing capabilities. Additionally, while both years emphasize the role of these databases in enabling customers to utilize PayPal's suite of products, the 2024 filing introduced a more consumer-centric framing, placing 'consumers' ahead of 'merchants' in describing the ecosystem served by the platform. These changes suggest a refinement in how PayPal positions its transaction management systems within its broader global payments infrastructure.",
      "llm_answer": "In the 2023 filing PayPal said that its platform – including “transaction‑management databases” – lets customers send payments in roughly 200 markets and about 140 currencies, withdraw funds in 57 currencies and hold balances in 24 currencies. The 2024 filing repeats the same description of the databases but updates the currency coverage: payments can now be sent in roughly 150 currencies, withdrawals are supported in 56 currencies (still 24 currencies for held balances). Thus the language around the databases is unchanged, but the quantitative scope of global payment processing has been revised upward for outbound payments (and slightly adjusted for withdrawals).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) Quantitatively, the LLM incorrectly states that in 2023 PayPal allowed withdrawals in 57 currencies and in 2024 reduced it to 56, directly contradicting the ground truth which states withdrawals were supported in 56 currencies in 2023 and expanded to 57 in 2024. The LLM also introduces unsupported figures such as '140 currencies' for sending payments in 2023 and '150 currencies' in 2024, which are not present in the original answer and contradict the stated evolution. Additionally, the mention of '24 currencies' for held balances appears in the LLM answer but is absent from the ground truth, introducing unverified data. (2) The LLM claims the 'language around the databases is unchanged', but the ground truth explicitly notes a shift in framing in the 2024 filing—placing 'consumers' ahead of 'merchants'—indicating a qualitative change in description that the LLM overlooks. (3) The multi-hop reasoning is flawed: the question asks about the evolution of PayPal's *description* of its transaction management databases' capabilities, particularly regarding multi-currency processing. The ground truth focuses on the change in withdrawal currency count (56→57) and a shift in narrative emphasis, while the LLM invents changes in payment-sending currency counts and misrepresents the direction of change in withdrawal currencies. (4) Contextually, the LLM addresses the general topic of currency support evolution and database capabilities, so relevance is moderate. However, due to major errors in numbers, direction of change, and omission of the key narrative shift, the answer is largely incorrect. The core facts—direction of change in withdrawal currencies and the qualitative reframing—are either reversed or missing, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 502,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the interest rate terms associated with the Series K Debentures evolve between 2023 and 2024, and what does this indicate about NEE's financing strategy?",
      "original_answer": "In 2023, the Series K Debentures had their interest rate reset to 6.051% per year as part of a remarketing completed in March 2023. By 2024, the terms of the Series K Debentures were further updated through a letter dated March 1, 2023, which set forth certain terms effective March 1, 2023, indicating a continuation of the updated rate and terms from the 2023 remarketing. This suggests that NEE adjusted its financing strategy in response to market conditions, locking in a higher interest rate to secure funding.",
      "llm_answer": "In the 2023 filing NEE disclosed that the February 2020 Series K debentures (due 1 Mar 2025) were remarketed in March 2023 and the coupon was reset to **6.051 % per year** (interest payable 1 Mar and 1 Sep). The 2024 filing still lists the Series K debentures with the same terms and does not show a further reset, indicating the 6.051 % rate remained in effect. This continuity shows NEE’s financing approach of periodically remarketing its equity‑unit‑linked debentures to lock in a market‑based fixed rate and then maintaining that rate to provide predictable, relatively higher‑cost debt financing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key fact that the Series K Debentures were remarketed in March 2023 with an interest rate reset to 6.051% per year, which matches the ground truth. It also accurately notes that the 2024 filing reflects the same terms, indicating continuity of the rate—consistent with the original answer's claim that the terms were effectively maintained. The mention of interest payment dates (March 1 and September 1) adds detail not in the ground truth but is not incorrect. (2) All quantitative elements—interest rate (6.051%), timing (March 2023 reset), and maturity date (March 1, 2025)—are factually correct and align with the knowledge graph. The date of the letter (March 1, 2023) mentioned in the ground truth is slightly more specific in intent (setting terms effective that date), but the LLM captures the effective timing correctly. (3) The reasoning is sound: the model correctly infers from the lack of a new reset in 2024 that the 6.051% rate remained in effect and connects this to NEE’s strategy of remarketing to lock in market-based rates. This aligns with the ground truth’s conclusion about adjusting financing strategy in response to market conditions. The LLM adds the nuance that this provides 'predictable, relatively higher-cost debt financing,' which is a reasonable interpretation. (4) The only minor gap is that the LLM does not explicitly reference the 'letter dated March 1, 2023' mentioned in the ground truth, which formally set the terms. However, this omission does not affect the factual accuracy of the rate or its continuation. Overall, the answer is semantically equivalent, multi-hop reasoning is correct, and all key facts are accurately conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 469,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has ExxonMobil's application of the Unit-of-Production Depreciation method evolved between 2022 and 2023, particularly in response to changes in proved reserves and asset life assumptions?",
      "original_answer": "In 2022, ExxonMobil applied the Unit-of-Production Depreciation method based on proved reserves or proved developed reserves, switching to straight-line depreciation when asset life did not correlate with reserves, and using SEC price-based reserves only when proved reserves were substantially de-booked. By 2023, the company maintained the same core methodology but placed greater emphasis on using the most recent SEC price to determine reserves for depreciation in cases where reserves had been significantly reduced, ensuring a more meaningful allocation of asset costs over the expected life of the asset. This reflects a refinement in the company's approach to align depreciation with updated economic conditions and production realities.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K describe the same approach: depreciation of upstream assets is calculated by dividing the asset’s cost by the total proved (or proved‑developed) reserves and applying that rate to actual production. When the unit‑of‑production calculation would not allocate cost equitably—either because the asset’s useful life is shorter than the reserve life or because reserves have been substantially de‑booked—the company switches to straight‑line depreciation or re‑computes the unit‑of‑production rate using the most recent SEC‑price‑based reserve estimate, adjusted for production and technical changes. Thus, between 2022 and 2023 ExxonMobil’s policy on unit‑of‑production depreciation remained essentially unchanged, continuing to adjust the method in response to reserve revisions and asset‑life mismatches.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that ExxonMobil's core Unit-of-Production (UOP) depreciation method remained unchanged between 2022 and 2023, which matches the original answer's assertion of a consistent methodology with a refinement in emphasis. The conditions under which the company switches to straight-line depreciation—when asset life does not correlate with reserve life or when reserves are substantially de-booked—are accurately described. (2) There are no numeric values (e.g., dollar amounts, percentages, reserve volumes) in either the question or the ground truth, so quantitative accuracy is not compromised; all references to years (2022, 2023) are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes the treatment of UOP depreciation across two years and correctly infers that the policy did not change substantively, while acknowledging adjustments based on SEC price-based reserves in cases of significant de-bookings. This reflects an understanding of the conditional logic in the accounting policy. (4) The LLM slightly downplays the 'greater emphasis on SEC pricing' in 2023 as a refinement, presenting it more as a continuation rather than an evolved focus. However, it still captures the essence by noting that the rate may be re-computed using the most recent SEC-price-based estimate when reserves are substantially reduced. This minor omission in emphasis does not undermine the overall correctness. The answer is contextually relevant, directly addressing the evolution (or lack thereof) in the depreciation method in response to reserve and asset life changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 455,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Netflix's strategic emphasis on original programming evolved between 2023 and 2024, particularly in terms of its reliance on third-party production partners versus internal studio scaling?",
      "original_answer": "In 2023, Netflix emphasized its investments in original programming and highlighted the risks associated with third-party production partners, including potential liability and loss due to legal violations, insolvency, or fraud. It also noted its acquisitions like Scanline and Animal Logic as part of scaling internal studio operations. By 2024, the company shifted its language to focus on the growing complexity of managing original content production and placed greater emphasis on the need to improve internal systems, corporate culture, and operational practices related to content creation. The explicit mention of third-party risks present in 2023 was omitted in 2024, suggesting a reduced dependency on external partners and a stronger strategic move toward internal control and scaling.",
      "llm_answer": "In the 2023 filing Netflix still framed original‑programming as a mix of “contracting with third parties related to the development, production, marketing and distribution of our original programming” while noting that it was beginning to “scale our own studio operations” (see 2023 page 7). By the 2024 filing the company stresses that it is “scaling our own studio operations to produce original content, including through acquisitions such as Scanline and Animal Logic,” indicating a deliberate move to increase internal‑studio capacity and rely less on external producers (2024 page 7). Thus, between 2023 and 2024 Netflix’s strategy shifted from a heavier dependence on third‑party partners toward a stronger internal‑studio focus.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Netflix's strategic shift between 2023 and 2024 regarding original programming, noting the reduced emphasis on third-party partners and increased focus on internal studio scaling. The acquisitions of Scanline and Animal Logic are accurately cited as part of internal scaling. (2) There are no numeric values requiring calculation (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable beyond correct referencing of years (2023, 2024), which are accurate. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, compares shifts in language, and infers a strategic pivot toward internal production. The only minor omission is that the 2024 filing’s emphasis on 'growing complexity' of content management and internal systems/culture—mentioned in the original answer—is not explicitly included, which slightly reduces completeness. However, the core strategic evolution is correctly captured. (4) The answer is contextually fully relevant, directly addressing the evolution in Netflix’s strategy regarding third-party reliance vs. internal scaling. Wording differs slightly but maintains semantic equivalence. A score of 9 is justified due to this high accuracy with a small detail missing in qualitative depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 382,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the strategic positioning of Mastercard's Cyber and Intelligence Solutions evolved between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were positioned as part of 'Other revenues' and primarily described as products and services offered to prevent, detect, and respond to fraud, ensuring the safety of transactions made on Mastercard products. By 2023, the Cyber and Intelligence Solutions were elevated in strategic importance, being explicitly described as a value-added service that enables secure, easy, and confident transactions across the entire payments ecosystem, indicating a broader role in supporting Mastercard’s core operations and new network investments.",
      "llm_answer": "In the 2022 filing, cyber‑and‑intelligence solutions were presented mainly as a line‑item under “Other revenues,” described as fee‑based services that help prevent, detect and respond to fraud and keep Mastercard‑based transactions safe. By the 2023 filing, the same offering is highlighted in the Business Overview as a flagship value‑added service that enables all parties to transact “securely, easily and with confidence,” signaling that Mastercard has elevated cyber‑and‑intelligence solutions from a peripheral revenue source to a core strategic pillar of its ecosystem.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies that in 2022, Cyber and Intelligence Solutions were part of 'Other revenues' and focused on fraud prevention, detection, and response for Mastercard-based transactions. In 2023, it accurately reflects the strategic elevation of the service as a value-added offering enabling secure, easy, and confident transactions across the ecosystem. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised. (3) The multi-hop reasoning is sound—comparing the strategic positioning across two years using the respective filings—and correctly synthesizes the evolution from a peripheral revenue stream to a core strategic pillar. (4) The LLM uses slightly different but contextually appropriate phrasing (e.g., 'flagship value-added service', 'core strategic pillar') that captures the same meaning as the original answer. All entities (Mastercard, Cyber and Intelligence Solutions, 2022, 2023) are correct. The answer fully addresses the question about strategic evolution with precise and relevant details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 333,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Tesla's approach to energy storage products evolved from 2023 to 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized its modular design and in-house expertise in power electronics and software to optimize the manufacturing and performance of its energy storage products like Megapack. By 2024, Tesla's focus shifted to addressing production ramps and supply chain dependencies, citing potential bottlenecks and the need for efficient, cost-effective manufacturing capabilities. The company also highlighted risks related to supplier reliability and the challenges of scaling production to meet planned output rates and quality standards for energy storage products.",
      "llm_answer": "In the 2023 Form 10‑K Tesla simply described its storage line—Powerwall for homes and Megapack for commercial/utility use—as modular lithium‑ion systems that leverage vehicle‑battery technology and software‑controlled dispatch. By the 2024 filing the company is warning that scaling those products now faces “new manufacturing‑operation” hurdles, including supply‑chain constraints, the need to ramp proprietary cell and pack production at new factories, and the risk of delays, and it stresses that its ability to grow storage sales is strategically dependent on external cell suppliers (Panasonic, CATL) while it pursues in‑house cell manufacturing to reduce that reliance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Tesla's 2023 emphasis on modular design, software, and use of vehicle-battery technology for energy storage products like Megapack and Powerwall. In 2024, it accurately reflects the shift toward addressing production ramp challenges, supply chain constraints, and strategic dependencies on suppliers. (2) There are no numeric values in the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM synthesizes changes in Tesla’s disclosures between 2023 and 2024 filings, correctly identifying evolving risks and strategic dependencies, including reliance on external cell suppliers (naming Panasonic and CATL) while pursuing in-house manufacturing. This level of detail goes slightly beyond the ground truth but remains consistent with plausible 10-K content. (4) The only minor deviation is that the original answer does not explicitly name Panasonic or CATL, so including those names, while factually reasonable, introduces specificity not confirmed in the ground truth. However, this does not constitute an error but rather added context. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 370,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did NextEra Energy Capital Holdings' issuance strategy for floating rate debentures evolve from 2023 to 2024, particularly in terms of the principal amount and maturity structure?",
      "original_answer": "In 2023, NextEra Energy Capital Holdings disclosed the sale of $600 million in floating rate debentures due in 2026. By 2024, the company formalized this issuance through an Officer's Certificate dated January 31, 2024, specifying the Floating Rate Debentures, Series due January 29, 2026. While the principal amount was not explicitly updated in 2024, the maturity structure remained consistent with the 2026 horizon, indicating a focused strategy on short-to-medium-term floating rate debt. This reflects a continuation of the prior year's approach without significant expansion or restructuring of the floating rate debenture program.",
      "llm_answer": "- 2023 : NextEra Energy Capital Holdings (NEECH) entered the year with only a modest floating‑rate tranche – about **$400 million of variable‑rate debentures that were scheduled to mature in 2024** (see the “Debentures – variable (c)” line on the 2023 balance sheet) and no new floating‑rate issuance was reported for that year.  \n\n- 2024 : In the first quarter of 2024 NEECH **sold an additional $600 million of floating‑rate debentures**, all of which were structured to **mature in 2026** (the filing notes the $600 million of floating‑rate debentures due 2026 and the exhibit list shows a “Floating Rate Debentures, Series due January 29, 2026”).  \n\nThus, the company’s floating‑rate strategy shifted from a small, near‑term $400 million issue in 2023 to a larger $600 million issuance in 2024, extending the maturity horizon from 2024 to 2026 and adding a new, longer‑dated floating‑rate tranche.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative Accuracy: The LLM incorrectly states that in 2023, NextEra Energy Capital Holdings had $400 million of variable-rate debentures maturing in 2024. The ground truth indicates that in 2023, the company disclosed a $600 million issuance of floating rate debentures due in 2026—not a $400 million tranche maturing in 2024. This misrepresents both the principal amount and the maturity date. Additionally, the LLM claims a new $600 million issuance occurred in 2024, but the ground truth clarifies that the 2024 filing merely formalized the previously disclosed 2023 issuance via an Officer's Certificate; no new principal was issued in 2024. (2) Completeness: While the answer addresses principal amount and maturity structure, it mischaracterizes the evolution by suggesting a shift from $400M in 2024-maturity debt to $600M in 2026-maturity debt, which is factually incorrect. There was no such shift—the $600M 2026 debt was introduced in 2023 and formalized in 2024. (3) Entity Accuracy: The company name (NextEra Energy Capital Holdings) is correct, and the 2026 maturity date for the $600M debentures is correctly referenced in the 2024 context, though misattributed as a new issuance. (4) Reasoning: The multi-hop reasoning fails—instead of recognizing continuity in strategy, the LLM infers a strategic shift based on incorrect data. It conflates balance sheet presentation with issuance activity and misreads the timing and nature of the debt. (5) Semantic Equivalence: The overall message—that the company expanded and extended its floating rate debt—is false. The actual strategy was consistent and unchanged. Minor contextual elements (e.g., referencing exhibits) add relevance but do not compensate for core inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 494,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Intel's approach to industry initiatives related to supply chain responsibility evolved from 2023 to 2024, particularly in terms of collaboration focus and supplier engagement scope?",
      "original_answer": "In 2023, Intel announced a significant expansion of its supplier engagement activities under its RISE strategy, aiming to increase the number of suppliers covered in sustainability and compliance programs, and set a goal to achieve net-zero upstream Scope 3 greenhouse gas emissions by 2050. By 2024, Intel's approach evolved to emphasize broader collaboration on responsible minerals sourcing and transparency around climate and water impacts, with a continued focus on capability-building programs for suppliers but without explicit mention of expanding the number of suppliers engaged. The shift indicates a move from announcing strategic expansions to reinforcing and deepening existing industry partnerships.",
      "llm_answer": "In 2023 Intel’s supply‑chain responsibility discussion stressed that it was **significantly expanding the pool of direct suppliers it engages** and using those programs to meet its newly announced 2050 net‑zero Scope 3 goal, while leading industry initiatives on climate‑ and water‑impact transparency and responsible‑minerals sourcing. By 2024 the language shifted to a **broader, industry‑wide collaboration focus**, noting continued work with other companies on the same climate‑, water‑ and minerals‑issues but adding explicit engagement of **indirect suppliers** and a continued “robust education and engagement” program, rather than highlighting the expansion of the supplier base.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2023, Intel expanded supplier engagement under its RISE strategy and set a 2050 net-zero Scope 3 emissions goal; in 2024, the focus shifted to broader collaboration on responsible minerals, climate, and water transparency, with continued supplier education but no mention of expanding supplier numbers. (2) Quantitative elements—such as the 2050 net-zero target—are correctly stated, and no numerical inaccuracies exist. (3) The multi-hop reasoning is sound: the model correctly synthesizes Intel’s evolving approach across two years, contrasting strategic expansion in 2023 with deepened collaboration and indirect supplier engagement in 2024. (4) The only minor gap is that the LLM mentions 'explicit engagement of indirect suppliers' in 2024, which is not explicitly stated in the ground truth; however, this is a reasonable inference given the emphasis on broader collaboration and does not contradict the original. Wording differs but semantic meaning is equivalent. Thus, the answer is factually correct, complete, and contextually appropriate, meriting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 332,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has the characterization of the assumptions underlying the standardized measure of discounted future cash flows evolved between XOM's 2022 and 2023 disclosures, particularly regarding the company's framing of its dependency on first-day-of-the-month average prices?",
      "original_answer": "In XOM's 2022 filing, the standardized measure of discounted future cash flows was described as being 'prepared on the basis of certain prescribed assumptions,' which included first-day-of-the-month average prices. This framing emphasized that the assumptions were foundational to the calculation but did not explicitly highlight the degree of dependency on them. In contrast, the 2023 filing reflects a shift in tone by emphasizing that the standardized measure 'depends on' these prescribed assumptions, particularly first-day-of-the-month average prices, which are described as discrete points in time that 'may cause significant variability in cash flows from year to year as prices change.' This indicates a more explicit acknowledgment of the sensitivity and dependency of the measure on these assumptions, even though the actual calculation methodology remained unchanged, using the same 10 percent discount factor, year-end costs, and legislated tax rates.",
      "llm_answer": "In the 2022 Form 10‑K the company qualified its “prescribed assumptions” by stating that the standardized measure is calculated using **first‑day‑of‑the‑month average prices, which are discrete points in time and therefore may cause significant variability in cash‑flow results from year to year**. By the 2023 filing the same price assumption is still disclosed, but the language is softened – the measure is described as being based on “prescribed assumptions including first‑day‑of‑the‑month average prices” without the explicit warning that those prices can generate significant year‑to‑year variability.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its characterization of the evolution between XOM's 2022 and 2023 disclosures. According to the ground truth, in 2022, the filing described the standardized measure as being 'prepared on the basis of certain prescribed assumptions' without the explicit warning about variability. The stronger language about first-day-of-the-month prices being 'discrete points in time' that 'may cause significant variability' was introduced in the 2023 filing, reflecting a heightened emphasis on dependency and sensitivity. However, the LLM answer incorrectly reverses this progression: it claims the warning about variability was present in 2022 and 'softened' in 2023, when in fact the opposite is true—the 2023 filing added more explicit language about variability and dependency. This is a critical qualitative error in reasoning and entity-context mapping. While all referenced entities (XOM, 2022/2023 filings, first-day-of-the-month prices, standardized measure) are correct and no numerical inaccuracies are present (hence full quantitative accuracy), the answer fails on the core multi-hop reasoning task of comparing the evolution of disclosure tone over time. The contextual relevance is moderate because it addresses the right topic and document years, but the reversed logic undermines the entire conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 374,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has MA's digital identity solutions evolved between 2022 and 2023, particularly in terms of their integration with open banking capabilities and reach across financial institutions?",
      "original_answer": "In 2022, MA introduced its digital identity solutions as part of an open banking platform that enabled data providers and third parties to access consumer data on a permissioned basis, aiming to improve customer experience and financial inclusion. The platform leveraged data principles such as consumer protection and consent management, and it focused on identity verification across people, devices, and transactions. In 2023, MA expanded its open banking capabilities, achieving connectivity to over 95% of deposit accounts in the U.S. and approximately 3,000 banks across Europe, which significantly enhanced the reach and application of its digital identity solutions. Additionally, in 2023, MA partnered with leading financial institutions to launch an ACH payment solution using its open banking infrastructure, indicating a deeper integration of digital identity within broader financial services.",
      "llm_answer": "In 2022 Mastercard’s digital‑identity offering was described as a set of privacy‑by‑design tools (device intelligence, behavioral biometrics, document proofing, IP intelligence, etc.) that “provide seamless digital experiences and strengthen and secure digital payments” but was presented largely as a standalone fraud‑prevention capability. By 2023 the company had woven those identity services into its open‑banking platform—using the same consent‑centric APIs—to launch an ACH‑payment solution and to give the identity suite connectivity to > 95 % of U.S. deposit accounts and roughly 3,000 European banks, dramatically expanding its reach across financial institutions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, MA's digital identity solutions were privacy-by-design tools focused on fraud prevention and secure payments; by 2023, they were integrated into the open banking platform using consent-centric APIs. The expansion to over 95% of U.S. deposit accounts and approximately 3,000 European banks is correctly stated. The launch of an ACH payment solution leveraging open banking infrastructure is also accurately mentioned. (2) Quantitative accuracy is perfect: '>95%' matches 'over 95%', and 'roughly 3,000 European banks' aligns with 'approximately 3,000 banks across Europe'. No calculations were required. (3) Multi-hop reasoning is sound—LLM correctly synthesized evolution over time (2022 to 2023), integration with open banking, and expanded reach across financial institutions. It correctly infers deeper integration through the ACH solution. (4) Minor deduction in qualitative accuracy because the original emphasizes consumer protection and identity verification across people, devices, and transactions in 2022, which the LLM omits, though it captures the core functionality. Wording differs but semantic meaning is equivalent. Contextual relevance is full—directly addresses evolution, integration, and reach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 369,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2023 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized the engineering and design maturity of the Solar Roof, highlighting its aesthetic appeal, durability, and integration with Powerwall. The company positioned Solar Roof as a customized solution within its broader energy product suite. However, by 2024, Tesla acknowledged that the production ramp of Solar Roof faced delays similar to those experienced with other products. The 2024 filing also noted that the company's future success 'depends in large part' on scaling mass-market vehicle production, which indirectly signals a potential strategic prioritization shift that could affect Solar Roof's development and deployment timelines.",
      "llm_answer": "In the 2023 filing Tesla presented the Solar Roof mainly as a product‑development and installation effort – it noted that the roof tiles had been engineered through “numerous iterations” and that the company was “continuing to improve our installation capability and efficiency, including through collaboration with real‑estate developers and builders” (2023 p. 6‑7). By the 2024 filing the tone had shifted to acknowledge concrete production problems, stating that Tesla “has experienced, and may also experience similar future delays in launching and/or ramping production of … Solar Roof” and that the roof’s success now depends on the ability to secure and scale the necessary components and manufacturing capacity (2024 p. 17).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of Tesla's Solar Roof approach between 2023 and 2024: in 2023, the focus was on engineering maturity and installation improvements, including partnerships with real estate developers (consistent with the original answer’s mention of customization and integration). By 2024, Tesla acknowledged production delays, which matches the ground truth’s statement about delays similar to other products. The LLM also accurately reflects the increased emphasis on component sourcing and manufacturing scalability. (2) There are no numeric values (e.g., dollar amounts, percentages, units) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly identifying a shift in tone and strategic emphasis. It supports claims with specific page references (e.g., 2023 p. 6–7, 2024 p. 17), indicating proper sourcing. The only minor gap is that the LLM does not explicitly mention the 'depends in large part' strategic dependency on mass-market vehicle production, which is a key element in the original answer’s point about potential prioritization shifts. This omission slightly affects completeness and qualitative accuracy but does not undermine the core correctness. (4) The answer is contextually fully relevant, directly addressing production challenges and strategic dependencies as asked. Overall, the LLM conveys semantically equivalent information with high fidelity, warranting a correctness score of 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 450,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has NextEra Energy, Inc.'s use of Pledge Agreements evolved between 2023 and 2024, particularly in terms of the dates and counterparties involved?",
      "original_answer": "In 2023, NextEra Energy, Inc. disclosed a Pledge Agreement dated September 1, 2022, involving Deutsche Bank Trust Company Americas and The Bank of New York Mellon. By 2024, the company introduced two new Pledge Agreements dated June 1, 2024, and October 1, 2024, with the same counterparties. This indicates an evolution in the structure and timing of these agreements, expanding their use over time.",
      "llm_answer": "In the 2023 Form 10‑K the only pledge‑agreement disclosed was **dated September 1, 2022** and was between **NextEra Energy, Inc., Deutsche Bank Trust Company Americas (acting as collateral, custodial and securities intermediary) and The Bank of New York Mellon (as purchase‑contract agent)**【page_117】.  \n\nThe 2024 Form 10‑K adds two newer pledge‑agreements: one **dated June 1, 2024** and another **dated October 1, 2024**, and both involve the **same counterparties – Deutsche Bank Trust Company Americas as collateral/custodial agent and The Bank of New York Mellon as purchase‑contract agent**【page_123】.  \n\nThus, between the two filings the company expanded its use of pledge agreements, moving from a single 2022 agreement to two additional agreements in 2024, while keeping the same counterparties.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all dates are accurate: the 2023 filing references a Pledge Agreement dated September 1, 2022, and the 2024 filing adds two agreements dated June 1, 2024, and October 1, 2024. These match the original answer exactly. (2) The counterparties are correctly identified: Deutsche Bank Trust Company Americas and The Bank of New York Mellon, with additional role details (e.g., collateral agent, purchase-contract agent) that enrich the answer without introducing error. (3) The reasoning is sound and demonstrates proper multi-hop synthesis: the model correctly infers that NextEra Energy expanded its use of Pledge Agreements over time, moving from one (disclosed in 2023 but dated 2022) to two new agreements in 2024, while maintaining the same counterparties. (4) The answer is semantically equivalent to the ground truth, with slightly more detail (e.g., agent roles) that improves clarity without deviating from facts. All parts of the question—evolution between 2023 and 2024, dates, and counterparties—are fully addressed. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 330,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Intel's strategic positioning in Edge AI evolved from 2023 to 2024, particularly in terms of its software platform offerings and ecosystem partnerships?",
      "original_answer": "In 2023, Intel emphasized its edge-native software platform with modular building blocks, premium services, and support offerings, aiming to enable developers to build, deploy, run, manage, connect, and secure distributed edge infrastructure and Edge AI across multiple verticals. The platform was described as a horizontal approach to scaling infrastructure for intelligent edge and hybrid AI, supporting diverse architectures and avoiding vendor lock-in. By 2024, Intel's strategy had evolved under its NEX initiative, which aimed to transform networks and edge compute systems from fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud-native software on programmable hardware. Intel highlighted broader ecosystem partnerships and a focus on rapid digital transformation from cloud to edge, leveraging core strengths in compute, connectivity, software, and large-scale manufacturing. This shift indicates a more integrated and scalable approach to Edge AI, with a stronger emphasis on cloud-native programmability and collaboration with partners to drive automation and secure data integrity at the edge.",
      "llm_answer": "In 2023 Intel’s Edge‑AI story was anchored on an **edge‑native software platform** that offered “modular building blocks, premium service and support” so developers could “build, deploy, run, manage, connect and secure distributed edge infrastructure, applications and edge AI” (2023 10‑K p.31). By 2024 the company had **integrated that platform with new edge‑optimized silicon** (4th‑gen Xeon, Xeon D‑1800/2800 series and vRAN Boost) and broadened its **ecosystem partnerships** – working with more than 500 network builders and key players such as Ericsson, Nokia, Cisco, Dell, HPE, Lenovo, Amazon, Google and Microsoft – to deliver open software frameworks (e.g., OpenVINO 2023.1) and AI‑enabled platform solutions across cloud‑to‑edge workloads (2024 10‑K p.18‑20). This evolution shows Intel moving from a primarily software‑centric Edge‑AI proposition in 2023 to a tightly coupled hardware‑software‑partner ecosystem in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of core facts and evolution of Intel's Edge AI strategy from 2023 to 2024. (1) It accurately captures the 2023 focus on an edge-native software platform with modular building blocks and developer support, citing the correct context from the 2023 10-K. In 2024, it correctly identifies the shift toward tighter integration of hardware and software, mentioning specific processors (4th-gen Xeon, Xeon D-1800/2800, vRAN Boost) and ecosystem partners (Ericsson, Nokia, Cisco, etc.), which are consistent with Intel’s public positioning. The mention of OpenVINO 2023.1 and collaboration with cloud providers adds relevant detail. (2) There are no numeric values, dates, or financial figures in dispute; all references to product names, partner counts (~500), and software versions are factually plausible and contextually accurate. (3) The multi-hop reasoning is sound: the model synthesizes information across years and domains (software, hardware, partnerships) to show strategic evolution. However, it omits explicit mention of the NEX initiative, which is central to the 2024 strategy in the ground truth, and does not reference the shift to cloud-native software on programmable hardware or the goal of transforming fixed-function systems into general-purpose compute—key conceptual elements. Instead, it emphasizes hardware-software integration, which is related but not a full substitute. (4) Despite this omission, the answer remains contextually relevant and semantically close to the original, with strong qualitative accuracy. The conclusion about moving from software-centric to a hardware-software-partner ecosystem is valid and insightful. Minor deduction from 9 to 8 due to missing NEX and cloud-native programmability emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1525,
        "completion_tokens": 491,
        "total_tokens": 2016
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did the composition and value of CVS's long-term debt related to senior notes due in 2030 evolve between 2023 and 2024, particularly regarding the 1.75% senior notes due August 2030?",
      "original_answer": "In 2023, the 1.75% senior notes due August 2030 had a value of $1,250 million. In 2024, this value remained unchanged at $1,250 million. However, other senior notes due in 2030, such as the 3.75% senior notes due April 2030, decreased from $1,500 million in 2023 to $1,500 million in 2024, indicating stability in some areas of long-term debt but no change in the 1.75% notes specifically.",
      "llm_answer": "In both 2023 and 2024 CVS’s long‑term debt included three senior‑note series that mature in 2030: 5.125 % notes due February 2030 ($1.5 billion), 3.75 % notes due April 2030 ($1.5 billion) and the 1.75 % notes due August 2030 ($1.25 billion). The 1.75 % senior notes remained unchanged at an aggregate principal of **$1.25 billion**, so the overall composition and value of the 2030 senior‑note portfolio (total $4.25 billion) did not change between 2023 and 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the value of the 1.75% senior notes due August 2030 as $1.25 billion in both 2023 and 2024, which matches the ground truth. However, the ground truth states that the 3.75% senior notes due April 2030 remained at $1,500 million (i.e., no change), but the LLM incorrectly implies stability without noting that the ground truth explicitly confirms no change — though this is a minor wording issue. More significantly, the LLM introduces a 5.125% senior note due February 2030 with a value of $1.5 billion, which is not mentioned in the original answer and cannot be verified from the provided ground truth. This addition is unsupported and introduces factual inaccuracies. (2) Quantitatively, the $1.25 billion figure for the 1.75% notes is correct, and the $1.5 billion figures for the other two series are consistent with the ground truth for the 3.75% notes, but the 5.125% note is extraneous. The total portfolio sum of $4.25 billion (1.5 + 1.5 + 1.25) is mathematically correct but based on an unverified composition. (3) The multi-hop reasoning is partially sound — the model correctly infers no change in the 1.75% notes and aggregates the 2030 maturities, but it fails to restrict its response to the data in the ground truth, instead adding unconfirmed debt instruments. This undermines the qualitative accuracy. (4) Despite the addition of unverified notes, the core focus on the 1.75% notes is accurate and relevant, and the conclusion about no change in value and composition aligns with the ground truth, warranting a moderate correctness score. Contextual relevance is perfect as it directly addresses the evolution of CVS's long-term debt related to 2030 senior notes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 470,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did Netflix's ad-supported subscription plan evolve between 2023 and 2024 in terms of its role within the company's pricing strategy and membership growth objectives?",
      "original_answer": "In 2023, Netflix introduced the ad-supported subscription plan as a new, lower-priced option aimed at expanding its membership base and addressing competitive pressures by offering a more accessible entry point. This was part of broader efforts to adjust pricing models and membership plans to improve value perception. By 2024, the ad-supported plan had become a core component of Netflix's pricing strategy, explicitly included in a range of plans designed to meet varied consumer needs, indicating its integration into the company's long-term growth framework. This evolution reflects a shift from experimental pricing to a strategic offering intended to support sustained membership growth across different market segments.",
      "llm_answer": "In the 2023 filing Netflix said it was **adding a new, lower‑priced, ad‑supported subscription tier** as a way to broaden its pricing menu and give price‑sensitive consumers an option (“We aim to offer a range of pricing plans, including our ad‑supported subscription plan…”, 2023 p. 3) and later noted that **the plan had just been launched** (“We introduced a new, lower‑priced ad‑supported subscription plan”, 2023 p. 6). By the 2024 filing the company described the ad‑supported tier as **a core component of its pricing strategy that is being scaled globally to help drive overall membership growth**, positioning it alongside its other plans to attract and retain new members. Thus, the plan moved from a newly‑introduced, experimental tier in 2023 to an integral, growth‑focused element of Netflix’s pricing architecture in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies that Netflix introduced the ad-supported plan in 2023 as a lower-priced option to broaden its pricing strategy and attract price-sensitive customers, citing direct quotes from the 2023 filing. In 2024, it accurately states the plan evolved into a core, growth-focused component of the pricing architecture, now being scaled globally. (2) There are no numerical values (e.g., dollar amounts, percentages, user counts) in either the question or the original answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings to show the evolution from an experimental offering in 2023 to a strategic, integrated tier in 2024. The use of direct quotes supports the accuracy of the claims. (4) All entities—Netflix, the ad-supported subscription plan, 2023 and 2024 timeframes, and the strategic context—are correctly identified and logically connected. The answer fully addresses both parts of the question: the role in pricing strategy and the impact on membership growth objectives. Wording differs slightly but meaning is preserved. All scoring categories warrant full marks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 360,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2023 and 2024, based on its production status and strategic positioning?",
      "original_answer": "In 2023, Tesla stated that it had begun early production and deliveries of the Tesla Semi, indicating initial market introduction and limited availability. By 2024, Tesla's production status for the Tesla Semi had advanced to 'pilot production' at its Nevada facility, suggesting a more structured and expanded phase of manufacturing, though not yet full-scale commercial production. This evolution reflects Tesla's strategic progression from initial rollout to a more mature testing and scaling phase for the commercial electric vehicle.",
      "llm_answer": "In the 2023 filing Tesla noted that the Semi had moved out of concept into “early production and deliveries” (Item 1, Business overview). By the 2024 filing the Semi is listed in the factory‑by‑factory production table as being in “pilot production” at Nevada, and the narrative stresses that expanding capacity for the Semi (alongside the Cybertruck and next‑generation platforms) is a deliberate part of its growth strategy. Thus, Tesla has progressed from limited early‑stage output to a formal pilot‑production phase while positioning the Semi as a key new‑model pillar in its manufacturing expansion plan.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately reflects Tesla's production status evolution: from 'early production and deliveries' in 2023 to 'pilot production' in Nevada in 2024, with correct contextual details pulled from the filings. (2) There are no numeric values requiring calculation, but the dates (2023 and 2024) and production phases are correctly cited. (3) The multi-hop reasoning is sound—LLM synthesizes information across two years of filings, correctly identifying the progression in production status and linking it to strategic positioning, such as inclusion in factory production tables and alignment with growth strategy. (4) The answer conveys the same semantic meaning as the original, with added precision (e.g., referencing Item 1 and the factory-by-factory table), without introducing errors. All aspects—factual, contextual, and inferential—are accurate and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 272,
        "total_tokens": 1555
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "What does the expansion of NextEra Energy's Executive Retention Employment Agreements from 2023 to 2024 suggest about the company's approach to leadership continuity and its strategic emphasis on executive talent retention?",
      "original_answer": "In 2023, NextEra Energy had active Executive Retention Employment Agreements with executives including Mark Lemasney (signed January 1, 2023) and Armando Pimentel, Jr. (signed February 15, 2023), indicating a focus on retaining key leadership at that time. By 2024, the company not only maintained those agreements but also introduced a new agreement with Brian Bolster, dated May 6, 2024, showing an expansion in the number of covered executives. This evolution suggests that NextEra Energy has placed increasing strategic importance on securing leadership continuity and minimizing executive turnover risk, particularly during periods of potential transition or uncertainty. The addition of new executives under retention agreements implies a proactive approach to talent management, which could signal confidence in leadership or a response to external pressures affecting executive mobility.",
      "llm_answer": "The 2023 filing lists two Executive Retention Employment Agreements (Mark Lemasney – Jan 1 2023 and Armando Pimentel Jr. – Feb 15 2023)【page_125】, while the 2024 filing adds two more (Nicole J. Daggs – Jan 1 2024 and Brian Bolster – May 6 2024)【page_125】. By broadening the pool of retained executives from 2023 to 2024, NextEra Energy signals a deliberate strategy to preserve leadership continuity and underscores the importance it places on retaining key talent as a core component of its long‑term business plan.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that two new Executive Retention Employment Agreements were added in 2024 — specifically naming Nicole J. Daggs (Jan 1, 2024) and Brian Bolster (May 6, 2024). However, the ground truth only confirms the addition of Brian Bolster in 2024; there is no mention of Nicole J. Daggs in the original answer or supporting context. This introduces a factual error regarding entity and date accuracy. (2) The quantitative accuracy is compromised due to the inclusion of an unverified executive (Daggs), leading to an incorrect count of new agreements in 2024 (2 vs. correct count of 1). Dates for Lemasney and Pimentel are accurate, as is the date for Bolster. (3) The multi-hop reasoning is partially sound — the model correctly infers that expanding the number of retention agreements suggests a strategic emphasis on leadership continuity and talent retention. This aligns with the original answer’s interpretation and shows valid synthesis across years. However, the erroneous addition of a second executive weakens the factual basis of the conclusion. (4) Despite the factual error in entities/dates, the overall reasoning and relevance to the question about leadership continuity and talent retention strategy are strong and semantically aligned with the ground truth. The core insight — that expansion implies increased strategic focus — remains valid, but the support contains significant inaccuracies. Hence, correctness is reduced to 6 due to major factual overstatement, though not entirely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 426,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Intel's approach to xPU products evolved from 2023 to 2024, particularly in terms of strategic focus and product development priorities?",
      "original_answer": "In 2023, Intel's focus on xPU products was part of a broader R&D strategy that included process and packaging technology, AI, and software, with $16.0 billion spent on R&D. The company faced challenges in timely product development and manufacturing process introductions, which had previously caused delays and cost overruns. By 2024, Intel had evolved its approach by embedding xPU products more deeply into its strategic priorities, specifically under the theme of 'product competitiveness.' The company announced the creation of an advisory group to expand the x86 ecosystem and emphasized the xPU family of products—including client and data center GPUs, IPUs, FPGAs, and other accelerators—as a way to meet diverse computing needs. This represents a shift from a general R&D focus to a more structured and strategic product development initiative.",
      "llm_answer": "In the 2023 filing Intel treated its xPU line as a **new, exploratory growth area** – R&D was “focused … on … our xPU products and features” and the 10‑K noted that recent years had added “discrete GPUs, mobility solutions, AI accelerators, IPU products, and silicon photonics” as part of its broader IDM 2.0 diversification effort. By the 2024 filing the company had elevated xPU to a **core strategic pillar**, stating that it will “lead and democratize compute with Intel x86 and xPU,” and that its product‑competitiveness priority is to deliver a family of xPU accelerators (client and data‑center GPUs, IPUs, FPGAs, etc.) across all workload categories, making the portfolio a central focus of its roadmap rather than a peripheral add‑on.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution of Intel's xPU strategy from 2023 to 2024: in 2023, xPU was part of a broader R&D and IDM 2.0 diversification effort, and by 2024 it had become a core strategic pillar under 'product competitiveness.' The mention of discrete GPUs, AI accelerators, IPUs, FPGAs, and other accelerators matches the original answer. (2) There are no numeric inaccuracies; while the original answer mentions $16.0 billion in R&D spending for 2023, the LLM answer does not include this figure. However, this omission does not affect correctness because the LLM focuses on strategic framing rather than financials, and the question does not explicitly ask for financial data. The absence of the dollar amount is a minor completeness gap but not a factual error. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and correctly infers a strategic shift from 'exploratory' to 'core' focus, supported by direct thematic alignment with 'product competitiveness' and the creation of an ecosystem advisory group (implied through 'democratize compute' and ecosystem expansion). (4) Semantic equivalence is strong—the LLM uses different but equivalent phrasing (e.g., 'elevated xPU to a core strategic pillar' = 'embedded xPU products more deeply into its strategic priorities'). The answer is fully contextually relevant, directly addressing strategic focus and product development priorities as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 418,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Netflix's approach to advertising technology evolved between 2023 and 2024, particularly in terms of organizational development and infrastructure investment?",
      "original_answer": "In 2023, Netflix emphasized its limited experience with advertising and outlined several dependencies, particularly on third-party service providers for ad management and the need to attract and retain advertisers. The company also highlighted risks related to developing the necessary advertising technology infrastructure. By 2024, Netflix shifted toward a more proactive stance, emphasizing its ability to 'develop and expand an advertising sales and advertising technology organization team' and 'develop the technology and related infrastructure to support advertising and drive value to advertisers.' This indicates a strategic evolution from reliance on external providers to internal development and investment in ad tech capabilities.",
      "llm_answer": "- **2023 filing** – Netflix said its advertising business was still “new” and that success would hinge on **building an advertising‑sales and advertising‑technology organization** and on **creating the technology and infrastructure needed to serve ads** (see 2023 10‑K, Risk Factors, “our ability to develop and expand an advertising sales and advertising technology organization team” and “our ability to develop the technology and related infrastructure to support advertising” – pages 9‑10).  \n\n- **2024 filing** – The company’s language moved from a pure risk‑statement to a description of **active investment and expansion** of that organization and its ad‑tech platform, indicating that Netflix is now **investing in and scaling the advertising‑technology infrastructure** to support the ad‑supported tier (2024 10‑K, Risk Factors, same bullet points but presented as ongoing development and infrastructure investment – pages 9‑10).  \n\n**Thus, between 2023 and 2024 Netflix progressed from acknowledging advertising as a nascent, risk‑laden effort to actively developing a dedicated ad‑sales/technology team and committing capital to the underlying ad‑tech infrastructure.**",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the original answer. (1) It correctly identifies Netflix's 2023 stance as acknowledging limited experience and reliance on developing internal capabilities, citing specific language from the 10-K about building an advertising-sales and technology organization and infrastructure. (2) For 2024, it accurately reflects the shift in tone and strategy—moving from risk disclosure to active investment and expansion in ad-tech infrastructure and team development—again referencing the same Risk Factors section with updated context. (3) The multi-hop reasoning is sound: it synthesizes information across two years of 10-K filings, correctly interpreting the evolution in Netflix’s strategic posture from dependence on third parties and uncertainty in 2023 to proactive internal development in 2024. (4) All entities (Netflix, 2023 and 2024 10-Ks, advertising technology infrastructure, organizational development) are correctly identified and analyzed in context. There are no numerical inaccuracies (the question does not involve specific financial figures), and the qualitative assessment aligns perfectly with the ground truth. Wording differs slightly but conveys the same meaning with high precision and appropriate citation of source documents.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1485,
        "completion_tokens": 365,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Tesla's approach to free Supercharging programs evolved between 2023 and 2024, particularly in terms of revenue recognition and program structure?",
      "original_answer": "In 2023, Tesla's free Supercharging programs were included under Automotive Sales Revenue as part of the revenue associated with new vehicle deliveries, indicating they were bundled with vehicle sales and recognized over time. By 2024, Tesla began deferring revenue related to features such as FSD (Supervised), internet connectivity, and free Supercharging, recognizing these as liabilities to be amortized over time rather than immediately upon vehicle delivery. This structural shift reflects a more formalized and segmented approach to monetizing these features, including free Supercharging, which allows Tesla to better align revenue recognition with service delivery.",
      "llm_answer": "In the 2023 filing Tesla said that “unlimited free Supercharging” (and any limited‑use incentives) is a stand‑ready service that is provisioned when the vehicle is delivered and is recognized on a straight‑line basis over the expected ownership life of the vehicle. By the 2024 filing the company groups free‑Supercharging together with FSD, connectivity and OTA updates in a single “deferred‑revenue” line‑item, reporting a $1.34 billion addition to the balance and recognizing $1.19 billion of that revenue in 2024 (versus $595 million recognized in 2023), indicating that the program is now treated as a distinct performance‑obligation with a larger deferred‑revenue balance rather than purely a straight‑line charge. Thus, the program has shifted from an implicit straight‑line charge to an explicit deferred‑revenue liability with higher annual revenue recognition.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the shift in Tesla's revenue recognition for free Supercharging from 2023 to 2024: in 2023, it was recognized on a straight-line basis over the expected ownership life as part of vehicle delivery, and in 2024, it became part of a deferred revenue model treated as a distinct performance obligation. (2) The quantitative details are mostly correct: the LLM cites a $1.34 billion addition to deferred revenue and $1.19 billion recognized in 2024 versus $595 million in 2023. While the ground truth does not specify these exact figures, they are consistent with the broader shift toward deferral and increased amortization, and such numbers plausibly reflect actual data from Tesla’s 2024 filing. No calculation errors are present. (3) The multi-hop reasoning is sound—LLM synthesizes changes in accounting treatment across years, links free Supercharging to other features (FSD, connectivity), and infers the structural shift toward formalized monetization. (4) Minor deduction in score due to the inclusion of specific dollar amounts not present in the ground truth (though they may be factually accurate); otherwise, the semantic meaning, entity accuracy (Tesla, 2023–2024, Supercharging, FSD), and contextual relevance are excellent. The answer fully addresses both revenue recognition and program structure evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 392,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has NextEra Energy's approach to issuing Series O Junior Subordinated Debentures evolved between 2023 and 2024, particularly in terms of coupon structure and maturity dates, and what might this shift indicate about their financing strategy?",
      "original_answer": "In 2023, NextEra Energy issued the Series O Junior Subordinated Debentures due on May 1, 2079, with no explicit coupon rate disclosed in the filing. This indicates a potentially fixed or deferred interest structure typical for long-dated junior subordinated instruments. By 2024, the Series O Debentures were issued with a defined coupon rate of 5.55% and a significantly shorter maturity date of November 1, 2029. This represents a strategic shift toward issuing more conventional debt instruments with shorter durations and clearly defined interest costs. This evolution suggests a possible recalibration of NextEra’s capital structure strategy, favoring shorter-term, more predictable financing over long-dated, potentially lower-yielding instruments.",
      "llm_answer": "- **2023 filing (NEE 10‑K 2023)** – The only Series O mentioned is the “Series O Junior Subordinated Debentures due May 1, 2079,” a legacy issue created in 2019 and carrying a very long‑term maturity (see page 123).  \n\n- **2024 filing (NEE 10‑K 2024)** – The company disclosed a new “Series O Debentures due November 1, 2029” (see page 121). This issuance shortens the maturity by roughly 50 years and is presented as a fresh series, implying a different coupon structure (the older series carried a fixed, low‑rate coupon; the new series is being issued under a refreshed terms sheet, likely with a higher or floating rate).\n\n**Interpretation:** The shift from an ultra‑long‑dated, low‑coupon Series O in 2023 to a much shorter‑dated Series O in 2024 indicates NextEra is moving away from very long‑term subordinated debt toward nearer‑term financing. This suggests a strategy to tighten its debt‑maturity profile, reduce long‑run interest‑rate exposure and give the company more flexibility to refinance or adjust its capital structure as market conditions evolve.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the shift in maturity dates from May 1, 2079 (2023) to November 1, 2029 (2024), which aligns with the ground truth. However, it does not explicitly state the 5.55% coupon rate introduced in 2024, instead inferring a 'higher or floating rate' without citing the specific figure. This omission affects quantitative accuracy. The 2023 debenture's lack of an explicit coupon is correctly implied as a legacy, low-rate instrument, consistent with the original answer's 'no explicit coupon rate disclosed.' (2) Maturity dates are accurate: May 1, 2079 (2023) and November 1, 2029 (2024) match the ground truth. The claim of a '50-year shorter maturity' is approximately correct (50 years and 6 months difference), though 'roughly 50 years' is a reasonable approximation. The missing 5.55% coupon rate is a key quantitative gap—this specific figure is central to the original answer and was reportable in the filing. (3) The multi-hop reasoning is sound: the model synthesizes data across two years' filings, correctly infers a strategic shift toward shorter-term debt, and links this to reduced interest-rate exposure and increased refinancing flexibility. The interpretation aligns well with the ground truth’s conclusion about recalibrating capital structure strategy. (4) Scores justified as follows: correctness_score=8 because core facts (maturity shift, strategic implication) are correct but a key quantitative detail (5.55%) is missing; quantitative_accuracy=7 due to the absence of the precise coupon rate; qualitative_accuracy=9 for strong reasoning and correct entity identification; contextual_relevance=10 as all content directly addresses the question’s focus on evolution in coupon and maturity structure and its strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1479,
        "completion_tokens": 486,
        "total_tokens": 1965
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has ExxonMobil's consideration of OPEC investment activities evolved in its impairment assessment framework from 2022 to 2023, particularly in relation to long-term oil supply dynamics?",
      "original_answer": "In 2022, ExxonMobil explicitly stated that OPEC investment activities and production policies had an impact on world oil supplies and were considered in the context of impairment assessments. By 2023, while the company still acknowledged OPEC's influence on global oil supply, the discussion of OPEC was embedded more broadly within a comprehensive cash flow assessment framework that included forward-looking variables such as greenhouse gas emission costs and net-zero targets. This indicates a shift from a direct focus on OPEC's role to a more integrated view of macroeconomic and environmental factors affecting long-term asset valuation.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K impairment‑assessment sections note that “OPEC investment activities and production policies also have an impact on world oil supplies.” In 2022 this reference appears in a paragraph that stresses declining output from mature fields and the need for new investments, while the 2023 filing places the same OPEC factor inside the broader “Energy Outlook” discussion of long‑term supply‑demand fundamentals and the corporation’s long‑term price‑margin assumptions. Thus, ExxonMobil’s framework has not dropped OPEC from consideration; rather, it has integrated OPEC’s role more explicitly into its long‑term supply‑side outlook used to judge asset recoverability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in both 2022 and 2023, ExxonMobil acknowledged OPEC's impact on world oil supplies, with the key evolution being the contextual integration of OPEC within a broader long-term supply-demand framework in 2023. This matches the original answer’s claim of a shift from direct emphasis to a more integrated assessment. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a traditional sense, but all referenced statements (e.g., placement of OPEC discussion in different sections) are factually consistent with the source. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings and infers a nuanced shift in framing—not omission, but integration—of OPEC within long-term assumptions. (4) The only minor shortcoming is that the LLM does not explicitly mention the 2023 inclusion of forward-looking environmental factors like greenhouse gas costs and net-zero targets, which the ground truth highlights as part of the broader framework. While the LLM refers to the 'Energy Outlook' and 'long-term price-margin assumptions,' it omits these specific new elements, slightly reducing completeness in qualitative detail. However, the core evolution in OPEC's treatment is accurately captured, warranting a high correctness score of 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 392,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Netflix's approach to its ad-supported subscription plan evolved from 2023 to 2024, based on the level of detail and strategic emphasis provided in the filings?",
      "original_answer": "In 2023, Netflix's ad-supported subscription plan was mentioned in the context of uncertainty and risk, particularly around consumer adoption and the lack of operating history with such offerings, which could lead to discrepancies between forecasts and actual results. By 2024, the ad-supported plan was presented as part of the company's broader pricing strategy, explicitly included in the description of plans offered to meet a variety of consumer needs. This shift indicates a move from a risk-focused perspective to a more confident, strategic positioning of the ad-supported plan as a core part of Netflix's business model.",
      "llm_answer": "In the 2023 Form 10‑K Netflix only briefly referenced its ad‑supported tier – it was listed among “a range of pricing plans” and was singled out in the risk‑factor discussion as a new, uncertain pricing strategy whose consumer‑adoption was hard to forecast. By the 2024 filing, the ad‑supported plan is no longer described in detail or highlighted as a strategic focus; its absence from the business description and risk sections suggests it has moved from a tentative experiment to an established product that the company now treats as routine rather than a headline‑growth initiative.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable; however, since there are no incorrect numbers, it is scored as 10. The main issue lies in qualitative accuracy and reasoning. The LLM incorrectly states that in the 2024 filing, the ad-supported plan is 'no longer described in detail or highlighted as a strategic focus' and is 'absent from the business description and risk sections.' This contradicts the ground truth, which states that in 2024, the ad-supported plan was explicitly included as part of Netflix's broader pricing strategy and presented more confidently as a core offering. The LLM interprets the reduced risk discussion as a sign of diminished strategic emphasis, but the ground truth indicates the opposite: the plan evolved from a risk-laden experiment to a strategically integrated product. This reflects a fundamental misinterpretation of the shift in tone and strategic positioning. While the 2023 characterization is mostly accurate (noted as uncertain with adoption risks), the 2024 analysis is factually incorrect in its inference. The answer is contextually relevant to the question and addresses the evolution over time, but the conclusion is unsupported by the actual filings. Thus, the correctness score is low due to major factual and reasoning errors in the multi-hop synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 372,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Amazon's approach to shipping offers evolved between 2022 and 2024, particularly in terms of cost drivers and strategic focus on fulfillment efficiency?",
      "original_answer": "In 2022, Amazon highlighted that shipping costs were expected to increase as customers increasingly adopted its shipping offers, used faster delivery methods, and as the company expanded its fulfillment network. Shipping costs in 2021 were $76.7 billion, and the company anticipated continued growth in these costs. The strategic emphasis was on mitigating these increases through higher sales volumes, network optimization, supplier negotiations, and operational efficiencies. By 2024, the focus had shifted: while the company still invested in expanding its fulfillment network, it emphasized fulfillment network efficiencies as a key cost offset. The 2024 report notes that increased sales and network investments drove up fulfillment costs, but these were partially offset by efficiency gains. This marks a strategic evolution from a customer-driven cost increase in 2022 to a more operations-centric efficiency focus by 2024.",
      "llm_answer": "In the 2022 filing Amazon explained that the rise in shipping‑related costs was driven mainly by higher carrier rates, rising wages and incentives, and “fulfillment‑network inefficiencies” caused by a constrained labor market and global‑supply‑chain constraints, while it relied on shipping offers to keep prices low and used higher sales volumes, better supplier terms and network‑scale efficiencies to blunt those costs. By the 2024 filing the company still views its free‑shipping and fast‑delivery offers as a core “world‑wide marketing tool,” but the cost picture has shifted to “increased sales and investments in our fulfillment network” as the primary driver, with modest cost offsets coming from network efficiencies and favorable foreign‑exchange effects; the strategic emphasis is now on expanding and optimizing the fulfillment footprint to sustain the offers at lower per‑unit cost.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution in Amazon's shipping and fulfillment strategy between 2022 and 2024. While the original answer cites a $76.7 billion shipping cost in 2021 and anticipates growth in 2022, the LLM answer does not include this specific figure but accurately reflects the trend of rising shipping costs due to customer behavior, delivery speed, labor, and network inefficiencies. No incorrect numbers are presented, and since the LLM response focuses on 2022–2024 dynamics without contradicting the 2021 figure, this omission does not constitute a factual error—just a slight narrowing of scope. (2) All mentioned cost drivers (carrier rates, wages, labor market constraints, supply chain issues in 2022; increased sales and network investments in 2024) align with the ground truth. The offsetting factors—network efficiencies, supplier terms, foreign exchange—are correctly identified and contextually accurate. There are no calculation errors because no numerical computations are required or attempted. (3) The multi-hop reasoning is sound: the LLM synthesizes shifts in cost drivers and strategic focus across two time points (2022 vs 2024), correctly identifying the pivot from external/customer-driven cost pressures to internal/operations-focused efficiency gains. It accurately links fulfillment network expansion with efficiency optimization as a strategic evolution. (4) The answer is contextually excellent, directly addressing cost drivers and strategic focus on fulfillment efficiency as asked. The only minor shortcoming is the absence of the $76.7B 2021 shipping cost reference, which was part of the original answer but not strictly required to answer the 2022–2024 evolution. Wording differences (e.g., 'fulfillment-network inefficiencies' vs 'network optimization') are semantically consistent. Thus, the answer is factually correct, well-reasoned, and highly relevant—just missing one supporting data point, warranting a 9 instead of 10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1459,
        "completion_tokens": 549,
        "total_tokens": 2008
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did Duke Energy's utilization and reporting of the Master Retirement Trust evolve between 2023 and 2024, particularly in terms of asset allocation and disclosure practices?",
      "original_answer": "In 2023, Duke Energy's Master Retirement Trust was described in terms of its investment objective, focusing on achieving sufficient returns for plan benefits, with specific mention of VEBA trusts and their target and actual asset allocations. By 2024, the reporting evolved to include a more detailed breakdown of how different subsidiaries were allocated portions of the trust, such as Duke Energy Progress at 15% and Duke Energy Florida at 18%. Additionally, 2024 introduced a reconciliation of beginning and ending balances for pension and post-retirement assets, including Level 3 fair value disclosures, which was not present in 2023. This reflects a shift toward more granular and transparent reporting on trust assets and their valuation methodologies.",
      "llm_answer": "In the 2024 filing Duke Energy reported a slightly smaller Master Retirement Trust (total fair‑value assets $6.97 b versus $7.24 b in 2023) and eliminated the Level‑3 “unobservable” assets that had been $76 m the prior year, while the composition of the RCBP portfolio shifted modestly (global equity fell to 44 % from 45 %, debt to 33 % from 35 %, and cash/real‑estate rose to 10 % from 8 %) and the DELPP portfolio kept its 15 % equity and 79 % debt mix but removed hedge‑fund exposure. 2024 disclosures also added a new, concise fair‑value summary table (cash, real‑estate, equity and debt) and continued to break out the trust’s assets by Level 1, Level 2, Level 3 and “not‑categorized” categories, while still allocating the trust to each subsidiary using the same percentage split and noting that securities‑lending activities were discontinued at year‑end 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains several specific numerical claims not present in the original answer (e.g., $6.97B vs $7.24B in assets, $76M in Level 3 assets, percentage shifts in asset allocation like global equity falling to 44%, debt to 33%, cash/real estate rising to 10%, DELPP portfolio details, hedge fund removal), which are not supported by the ground truth. The original answer does not provide any actual dollar values for the trust size, nor does it mention changes in Level 3 asset elimination, portfolio composition percentages, or hedge fund exposure. These specific figures and changes appear to be fabricated or hallucinated. The original answer emphasizes structural and disclosure-related evolution: in 2024, Duke Energy began allocating trust portions to subsidiaries (e.g., Duke Energy Progress at 15%, Duke Energy Florida at 18%) and introduced a reconciliation of beginning and ending balances with Level 3 fair value disclosures, which were absent in 2023. The LLM answer incorrectly states that 'the same percentage split' was used in 2024, contradicting the ground truth that 2024 introduced new subsidiary-specific allocations. While the LLM correctly identifies increased disclosure around fair value categories (Level 1, 2, 3), it misrepresents the nature and purpose of the 2024 changes. The mention of a 'concise fair-value summary table' and discontinuation of securities lending may be plausible but are not confirmed in the ground truth. The core multi-hop reasoning—comparing 2023 and 2024 reporting practices regarding asset allocation and disclosure—is partially sound in intent but flawed in execution due to factual inaccuracies. The answer is contextually relevant to the question but fails on quantitative correctness and key qualitative details, particularly around subsidiary allocations and the nature of enhanced transparency.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 502,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has Google's financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of the cost structure and payment obligations?",
      "original_answer": "In 2022, Google's cost of revenues included significant Traffic Acquisition Costs (TAC) paid to Google Network partners, primarily for ads displayed on their properties, with a noted higher cost percentage compared to Google Search properties due to the substantial share of advertiser revenues paid out as TAC. By 2024, Google Network partners were referenced in the context of operating cash outflows, indicating that payments to these partners had become a primary use of operating cash. This shift suggests a transformation in the nature of the financial relationship, from a cost-of-revenue model to a more direct operational cash flow obligation, reflecting a potential increase in the scale or structure of Google's dependency on these partners.",
      "llm_answer": "In the 2022 filing Alphabet described its cost‑of‑revenues as “TAC … amounts paid to Google Network partners primarily for ads displayed on their properties,” noting that these payments make the cost‑of‑revenues a much higher percentage of the revenue generated on Google Network sites than on Search sites. The 2024 filing no longer breaks out a separate “network‑partner” line in the income statement, but it repeatedly emphasizes that “payments to distribution and Google Network partners” are one of the largest cash outflows from operating activities, showing that the same TAC‑based obligation remains and has grown in absolute size as network‑partner ad revenue has increased. Thus, between 2022 and 2024 the structure of the relationship (TAC payments to partners) stays the same, but the magnitude of the cost and cash payments to Google Network partners has risen in line with higher network‑partner revenues.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Traffic Acquisition Costs (TAC) paid to Google Network partners were a significant component of cost of revenues, with a higher percentage of revenue going to partners on Network sites versus Search sites—this matches the original answer's emphasis on cost structure and revenue share. (2) For 2024, the LLM correctly notes the absence of a separate TAC line item in the income statement but accurately observes that payments to Google Network partners are highlighted as a major operating cash outflow, reflecting a shift toward operational cash flow obligations. This captures the essence of the financial relationship evolution described in the ground truth. (3) The reasoning across years is sound: while the presentation in financial statements changed (from explicit TAC to cash flow emphasis), the underlying obligation persists and has grown in scale, which the model correctly infers from increased network-partner ad revenue. (4) The LLM slightly understates the conceptual shift implied in the original answer—the ground truth suggests a 'transformation in the nature' of the relationship, possibly indicating structural changes beyond just increased magnitude. The LLM emphasizes continuity in structure and growth in size, which is factually supported but less interpretive of a potential model shift. However, no factual errors exist. All entities (Google Network partners, TAC, operating cash outflows), years (2022, 2024), and financial concepts are correct. Number formats and terminology are consistent and accurate. Minor deduction in qualitative accuracy due to less emphasis on the structural transformation, but overall excellent multi-hop synthesis and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 490,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the treatment and financial impact of offsetting swap positions evolve between 2022 and 2023, particularly in terms of fair value changes and settlements reported in the consolidated income?",
      "original_answer": "In 2022, UPS reported fair value changes and settlements of interest rate swaps, foreign currency exchange forwards, and investment market price forward contracts not designated as hedges, with specific figures for 2021 and 2020 provided (e.g., $163M net gain in 2021 and $124M net gain in 2020). In 2023, the company continued to report these derivatives at fair value with unrealized gains and losses in earnings, but the disclosure now included data for 2023 and 2022, showing a shift in focus to more recent periods. The explicit mention of terminating contracts or entering into offsetting swap positions remained consistent, but the financial impact in 2023 was not quantified in the excerpt, indicating a change in transparency around current-year derivative impacts.",
      "llm_answer": "In both years UPS kept its derivative assets and liabilities on the balance sheet gross (it did not apply the right‑of‑offset), but the income‑statement impact of the non‑designated swap positions changed markedly. For the year ended 2022 the company recorded a **$69 million loss** in consolidated income from the fair‑value changes and settlements of foreign‑currency forward contracts (interest‑rate swaps showed no gain or loss). In 2023 that loss was reduced to **$7 million**, with still no gain or loss recognized on the interest‑rate swaps, indicating that the offsetting swap positions had a far smaller adverse effect on earnings in 2023 than in 2022.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The ground truth states that UPS reported net gains in 2021 ($163M) and 2020 ($124M), but does not provide a specific net loss of $69M in 2022 or $7M in 2023—these figures are not present in the original answer and contradict the disclosed trend. The original answer emphasizes that 2023 financial impacts were not quantified in the excerpt, making the LLM's precise dollar amounts ($69M loss, $7M loss) factually incorrect and misleading. Additionally, the LLM incorrectly claims that interest rate swaps showed 'no gain or loss' in both years, which is not supported by the ground truth. While the LLM correctly identifies that derivatives are reported at fair value with gains/losses in earnings and that offsetting positions are mentioned consistently, it fabricates key financial data and misrepresents the transparency shift noted in the original (i.e., the move to more recent disclosures without current-year quantification). The reasoning is partially sound in structure—comparing income statement impacts across years—but based on non-existent numbers. The context of derivative accounting treatment is relevant and partially accurate, hence a moderate contextual relevance score, but the core financial claims are unsupported, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 378,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "What does the increased prominence of the Directors' Savings Plan in Duke Energy's 2024 disclosures indicate about the company's director compensation strategy compared to 2023?",
      "original_answer": "In 2023, the Directors' Savings Plan was referenced primarily through historical amendments listed in exhibit references (e.g., Exhibit 10.12), with no detailed description of its structure or strategic role in compensation. In contrast, the 2024 filing provides a substantive description of the plan, explaining how outside directors may defer annual compensation, the phantom investment options available, and how balances are adjusted accordingly. This increased prominence indicates a shift toward emphasizing the plan as a core component of director compensation and deferral flexibility, suggesting a more strategic and transparent approach to director-level financial incentives in 2024.",
      "llm_answer": "The 2024 filing devotes a full “Equity Compensation Plan Information” section to the Directors’ Savings Plan, describing how outside directors can defer a portion of their annual retainers into an unfunded, performance‑linked account. In the 2023 filing the plan was only mentioned in exhibit tables and not explained in detail. This expanded disclosure shows Duke Energy is moving the Directors’ Savings Plan to the centre of its director‑pay strategy, relying more on deferred, performance‑based compensation rather than plain cash retainers.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core shift in Duke Energy's director compensation strategy between 2023 and 2024. It correctly identifies that in 2023, the Directors' Savings Plan was only mentioned in exhibit tables (e.g., Exhibit 10.12 in the ground truth), with no detailed explanation, while in 2024 it receives a full descriptive section, indicating increased strategic emphasis. The LLM accurately conveys that outside directors can defer annual retainers into an unfunded account with performance-linked (phantom investment) options, aligning with the ground truth's description of deferral mechanisms and balance adjustments. The conclusion that this reflects a move toward deferred, performance-based compensation over cash retainers is a valid inference and consistent with the ground truth’s assertion of a more strategic and transparent approach. The only minor shortcoming is that the LLM refers to a specific section title—'Equity Compensation Plan Information'—which is not explicitly confirmed in the ground truth, though such a section is plausible and the substance of the disclosure is correctly represented. There are no numeric inaccuracies (quantitative accuracy is perfect), and all entities (Duke Energy, Directors' Savings Plan, outside directors, 2023 vs 2024) are correctly identified. The reasoning is sound, synthesizing changes in disclosure depth to infer strategic intent, satisfying the multi-hop requirement. The answer is contextually fully relevant and semantically equivalent to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 425,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has American Express's approach to developing value propositions evolved between 2022 and 2024, particularly in response to competitive pressures and changing customer behaviors?",
      "original_answer": "In 2022, American Express highlighted the challenge of developing compelling value propositions in the face of growing competition, particularly from alternative payment providers and digital wallets, which threatened to fragment customer spending and reduce the competitiveness of its offerings. The company emphasized the need to evolve its value propositions to retain relevance and attract customers amid rising Card Member rewards costs and shifting consumer preferences, especially in mobile and online payments. By 2024, the company's strategy had evolved to focus on expanding leadership in premium consumer and commercial payments, particularly targeting Millennial and Gen-Z consumers, and enhancing digital capabilities through investments in AI, automation, and the Amex app. It also emphasized the importance of strategic partnerships, dining platform expansion (including Tock and Rooam), and global merchant coverage growth as key enablers of its value proposition strategy. This represents a shift from a reactive stance on competition to a more proactive, innovation-driven approach.",
      "llm_answer": "In the 2022 filing, American Express warned that it must “differentiate ourselves from our competitors, develop compelling value propositions for our customers” and that rising competition from lower‑cost networks, alternative‑payment providers and shifting consumer spending could force it to evolve its rewards, services and digital capabilities. By the 2024 filing, the company’s language had shifted to a concrete, premium‑focused strategy: it is investing “at high levels … in our brand, value propositions, coverage, marketing, technology and talent,” refreshing its Membership Model, rolling out new benefits for Millennials and Gen Z, and leveraging partnerships and digital channels to capture changing spending and borrowing habits. Thus, the approach has moved from a broad acknowledgement of the need to create attractive propositions to a targeted, premium‑product, technology‑driven roadmap aimed at winning younger customers and countering intensified competitive pressure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in American Express's value proposition strategy between 2022 and 2024. (1) It correctly identifies the 2022 context: competitive pressures from alternative payment providers and digital wallets, rising rewards costs, and the need to evolve value propositions. It also accurately reflects the 2024 shift toward a more proactive, innovation-driven strategy focused on premium offerings, digital investment, and targeting younger demographics. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the ground truth or LLM response, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points (2022 and 2024) and correctly infers a strategic shift from reactive acknowledgment to proactive execution. The mention of 'refreshing its Membership Model,' 'new benefits for Millennials and Gen Z,' and 'leveraging partnerships and digital channels' aligns semantically with the ground truth’s emphasis on AI, app enhancements, Tock/Rooam, and global merchant coverage. (4) The only minor gap is that the LLM does not explicitly name specific platforms like Tock and Rooam or mention 'automation' and 'AI' as in the original, but it captures the broader themes of technology investment and digital capability enhancement. Wording differs slightly but meaning is preserved. Contextual relevance is perfect—the answer directly addresses the evolution in response to competition and changing customer behavior.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1531,
        "completion_tokens": 434,
        "total_tokens": 1965
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Exxon Mobil's approach to long-term debt financing evolved between 2022 and 2024, particularly regarding the composition of its long-term notes?",
      "original_answer": "In 2022, Exxon Mobil disclosed a broader range of debt instruments, including the 0.142% Notes due 2024, 0.524% Notes due 2028, 0.835% Notes due 2032, and the 1.408% Notes due 2039. By 2024, the company no longer listed the 0.142% Notes due 2024, indicating that those obligations had matured or been repaid. However, the 1.408% Notes due 2039 remained in the disclosure, suggesting a continued emphasis on long-term financing instruments with distant maturity dates. This shift reflects a strategic evolution in the company's capital structure, focusing more heavily on extended-term debt while retiring shorter-duration obligations.",
      "llm_answer": "By 2024 Exxon Mobil had phased out its short‑term 0.142 % senior note that was outstanding in the 2022 filing (maturing in 2024). The company’s long‑term debt now consists only of the higher‑interest 0.524 % notes due 2028, 0.835 % notes due 2032 and 1.408 % notes due 2039, indicating a shift toward a longer‑dated, higher‑coupon note portfolio as the earlier 2024 note was retired.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the retirement of the 0.142% Notes due 2024 and the continued presence of the 0.524%, 0.835%, and 1.408% notes with maturities in 2028, 2032, and 2039, respectively. All numeric values (interest rates and maturity years) are accurate and match the ground truth. (2) Quantitative accuracy is perfect—interest rates and maturity dates are correctly reported without error. (3) The reasoning correctly infers that the removal of the 2024 note reflects maturity/repayment and that the remaining instruments indicate a shift toward longer-term debt. However, the LLM slightly overreaches by stating the portfolio 'now consists only' of the higher-interest notes, which may not be verifiable from the provided disclosures—Exxon could have issued new debt not listed in the original answer. The original answer does not claim exclusivity of these instruments, only that they were disclosed. This introduces a minor factual overstatement. Additionally, characterizing the portfolio as 'higher-coupon' is interpretive but reasonable given the removal of the lowest-rate note. (4) The answer is contextually relevant and captures the core evolution in debt composition. The correctness score is 8 due to the minor overstatement about exclusivity and coupon characterization, despite otherwise accurate and complete information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 381,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has American Express's approach to corporate card solutions evolved between 2022 and 2024, particularly in terms of strategic emphasis and product differentiation?",
      "original_answer": "In 2022, American Express emphasized evolving card value propositions and differentiating corporate card and accounts payable expense management solutions as part of its broader commercial payments strategy. By 2024, the company continued to focus on commercial payments but introduced a more integrated global network approach, aiming to increase merchant acceptance and provide enhanced fraud protection and marketing insights. This shift indicates a move from internal product development focus in 2022 to a more externally integrated ecosystem strategy by 2024.",
      "llm_answer": "In the 2022 Form 10‑K, American Express framed its corporate‑card agenda as a “second‑tier strategic imperative” – it would **evolve the card value proposition and further differentiate its corporate‑card and accounts‑payable expense‑management solutions** while adding financing, banking and other payment features for business customers【page_8】.  \n\nBy the 2024 filing the same imperative is still highlighted, but the language ties the differentiation of corporate cards to a broader push for **digital‑centric products and integrated financing/banking solutions**, positioning the corporate‑card suite as a core component of a more expansive, technology‑driven commercial‑payments platform【page_8】.  \n\nThus, between 2022 and 2024 the company moved from a focus on “evolving and differentiating” corporate‑card offerings to embedding that differentiation within a larger digital‑innovation strategy that couples the cards with financing, banking and other integrated payment capabilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the original (ground truth) answer. (1) All factual elements are correct: in 2022, American Express focused on evolving the card value proposition and differentiating corporate card and accounts payable solutions, which matches the ground truth. By 2024, the strategic emphasis shifted toward integration with digital-centric products, financing, and banking solutions, reflecting a broader, technology-driven commercial payments platform—this corresponds to the ground truth's mention of an 'integrated global network approach' with enhanced digital capabilities. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable in a numerical sense, but all years (2022, 2024) and contextual references are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of Form 10-K filings, identifying a shift in strategic emphasis from internal product differentiation (2022) to external ecosystem integration (2024). The LLM uses slightly different phrasing—'digital-centric products and integrated financing/banking solutions' versus the ground truth's 'integrated global network approach, increased merchant acceptance, fraud protection, and marketing insights'—but the core idea of moving toward a more integrated, technology-enabled strategy is preserved. (4) The only minor shortcoming is that the LLM answer does not explicitly mention 'fraud protection' or 'marketing insights' as part of the 2024 evolution, which are specific differentiators in the ground truth. However, these are subsumed under the broader theme of digital integration and platform expansion, so the omission does not materially distort the overall strategic trajectory. Thus, the answer is semantically equivalent and contextually precise, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 514,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Amazon's financial relationship with AWS Services evolved between 2022 and 2024, particularly in terms of cash flow generation and strategic emphasis?",
      "original_answer": "In 2022, AWS Services were primarily discussed in the context of competitive pressures and risks, with an emphasis on the challenges of operating in a rapidly evolving and intensely competitive market. By 2024, AWS had transitioned into a key financial contributor, with Amazon reporting $115.9 billion in operating cash flow for that year, up from $84.9 billion in 2023, driven in part by AWS and other enterprise services. This reflects a shift from viewing AWS as a risk-laden venture to a core revenue generator funding broader corporate initiatives.",
      "llm_answer": "By 2024 Amazon’s AWS business had become an even larger driver of cash generation and capital spending. Operating cash flow rose sharply to $115.9 billion in 2024 (up from $84.9 billion in 2023) as higher‑margin AWS sales grew 19% to $107.6 billion and pushed the segment’s sales mix to 17% of total revenue 【page_22】; at the same time, Amazon said most of its $77.7 billion of cash‑capital expenditures in 2024 were directed to “technology infrastructure … to support AWS business growth” 【page_23】. In the 2022 filing AWS was already highlighted as a core growth engine and a distinct business line (e.g., the appointment of a dedicated AWS CEO) but the 2024 filing shows a markedly deeper financial reliance on AWS, with both cash‑flow contribution and strategic investment in its infrastructure increasing substantially.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution of Amazon's financial relationship with AWS from 2022 to 2024, noting AWS's growing role in cash flow generation and strategic investment. All quantitative figures—$115.9 billion operating cash flow in 2024 (up from $84.9 billion in 2023), 19% AWS sales growth to $107.6 billion, and $77.7 billion in capital expenditures—are factually accurate and align with the ground truth context, even though the original answer does not include all these details. The LLM adds specific data (e.g., AWS revenue of $107.6B, 17% of total revenue, capex allocation) that are consistent with the direction and magnitude implied in the ground truth. (2) Quantitative accuracy is perfect: all dollar amounts, year comparisons, and percentages are correctly stated and internally consistent. The increase in operating cash flow from $84.9B to $115.9B is accurate, and the LLM correctly attributes this to AWS growth. (3) Multi-hop reasoning is strong: the model synthesizes information across years (2022 vs 2024), shifts in strategic emphasis (from competitive risks to core revenue driver), and financial impact (cash flow and capital allocation). The only minor deviation is that the original answer emphasizes AWS’s shift from a 'risk-laden venture' in 2022, while the LLM states AWS was 'already highlighted as a core growth engine' in 2022—this is a slight difference in emphasis but not factually incorrect, as AWS was both a growth engine and subject to competitive risks. (4) The answer is highly relevant, complete, and factually sound, warranting a correctness score of 9 (not 10) due to this nuanced difference in framing AWS’s 2022 characterization, though all key facts and trends are accurately conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 480,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did the scope or focus of trend analyses used in evaluating the historical consistency of regulatory asset balances evolve between 2023 and 2024?",
      "original_answer": "In 2023, trend analyses were used to evaluate the historical consistency of regulatory asset balances in general, without specific reference to asset retirement obligations. By 2024, the scope of the trend analyses remained focused on regulatory asset balances, but the audit procedures expanded to include a specific evaluation of the ongoing regulatory recoverability of asset retirement obligations related to coal ash, indicating a shift in focus toward more specialized regulatory compliance areas.",
      "llm_answer": "Both the 2023 and 2024 audit reports state that the auditors “utilized trend analyses to evaluate the historical consistency of regulatory asset balances.” The language and purpose of the trend‑analysis procedure are unchanged between the two years, indicating that the scope of this analysis remained the same—focused solely on confirming the consistency of the regulatory‑asset balances over time. (The 2024 report adds other audit procedures (e.g., coal‑ash retire‑ment obligations), but the trend‑analysis component itself did not evolve.)",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim about the evolution of trend analyses. While it correctly notes that both years mention using trend analyses for regulatory asset balances, it incorrectly asserts that the scope of the trend analysis itself did not evolve. The ground truth states that in 2024, the trend analyses expanded to include a specific evaluation of the ongoing regulatory recoverability of asset retirement obligations related to coal ash—indicating a shift in focus within the trend analysis. The LLM misinterprets this as merely an addition of separate audit procedures outside of trend analysis, when in fact the trend analysis itself was applied to a new area (coal ash AROs). This is a critical misunderstanding of the multi-hop synthesis required: the evolution is not just in additional procedures, but in the scope of the trend analysis. There are no numeric inaccuracies (hence high quantitative score), but the qualitative reasoning is flawed. The answer is contextually relevant but draws an incorrect conclusion from the evidence. Semantic equivalence fails because the LLM denies an evolution that the ground truth confirms.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 328,
        "total_tokens": 1590
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did Costco's strategy regarding the penetration of private-label items evolve between 2022 and 2023 in response to cost and pricing pressures?",
      "original_answer": "In 2022, Costco responded to higher-than-recent inflation in merchandise costs by employing several strategies, including absorbing some cost increases internally, purchasing earlier and in larger volumes, and selectively passing on cost increases to members, all of which were aimed at maintaining pricing authority while managing gross margin pressures. In 2023, Costco continued to emphasize increasing the penetration of its private-label items as part of its broader merchandising and pricing strategy to adapt to ongoing cost increases and competitive pressures. This indicates a shift from a more reactive approach in 2022 to a more strategic and sustained emphasis on private-label offerings in 2023 to maintain competitive pricing and member value.",
      "llm_answer": "In the 2022 filing Costco said it was already “adjusting our pricing and merchandise mix, including increasing the penetration of our private‑label items” to help absorb higher inflation‑driven costs. The 2023 filing repeats the same approach, noting that “through adjustments to our pricing and merchandise mix, including increasing the penetration of our private‑label items” the company continued to rely on a deeper private‑label mix to offset cost and pricing pressures. Thus, between 2022 and 2023 Costco’s strategy evolved from initiating a higher private‑label mix to maintaining and further emphasizing that mix as a core response to rising costs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Costco began increasing private-label penetration as part of its response to inflation and cost pressures, and that in 2023, the company continued and emphasized this strategy. The key facts—timing (2022 vs 2023), strategic shift from initiation to sustained emphasis, and the role of private-label items in managing cost pressures—are all correct. (2) There are no numeric values (e.g., percentages, dollar amounts) in either the question or the original answer, so quantitative accuracy is not applicable in a numerical sense; however, the temporal references (2022 and 2023) are accurate, satisfying the requirement. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years of filings and correctly infers an evolution in strategy—from initiating to maintaining and deepening private-label penetration. The use of direct quotes from filings strengthens the response. (4) The LLM slightly simplifies the nuance in the original answer by not explicitly mentioning the 2022 tactics like 'absorbing cost increases' or 'purchasing earlier and in volume,' but it captures the core strategic evolution regarding private-label items. This minor omission does not undermine the central correctness. Semantic equivalence is maintained. Contextual relevance is excellent as it directly addresses the evolution of private-label strategy in response to cost pressures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 413,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the financial outlook for Paxlovid evolved between 2023 and 2024 based on Pfizer's remaining performance obligations?",
      "original_answer": "In 2023, Pfizer did not disclose specific remaining performance obligations for Paxlovid. However, by the end of 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a clear financial commitment from customers for future delivery of the product. This evolution suggests increased contractual certainty and forward-looking revenue expectations for Paxlovid between the two years.",
      "llm_answer": "Pfizer said that the contract‑backlog for Paxlovid – the amount of revenue it still expects to recognize from firm, long‑term orders – was about **$1 billion at 31 December 2024** (the 2024 Form 10‑K notes that “remaining performance obligations … for Paxlovid … totaled approximately $1 billion”【page_109】).  \nIn the prior year’s filing the same metric was materially larger (the 2023 filing listed a higher Paxlovid backlog, roughly $1.5 billion), so the outlook for future Paxlovid revenue has **shrunk** between 2023 and 2024, indicating that fewer contract‑bound doses remain to be delivered.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) Quantitatively, the LLM claims that Pfizer reported a Paxlovid remaining performance obligation of approximately $1.5 billion in 2023, which is false—the original answer explicitly states that Pfizer did not disclose specific remaining performance obligations for Paxlovid in 2023. This misstatement invalidates the comparison. The only correct number is the $1 billion figure for December 31, 2024, which matches the ground truth. (2) The reasoning is flawed: the LLM concludes that the financial outlook 'shrunk' between 2023 and 2024 due to a supposed drop from $1.5B to $1B, but since no such 2023 figure was disclosed, this comparison is unsupported and incorrect. (3) The qualitative error is severe—the model fabricates data for 2023, failing the multi-hop synthesis by incorrectly asserting a prior-year value that does not exist in the source material. This leads to an erroneous conclusion about declining outlook, whereas the ground truth indicates increased certainty due to the emergence of a disclosed $1B obligation in 2024 where none was previously reported. (4) Contextually, the answer addresses the right topic (Paxlovid financial outlook via performance obligations) and cites the correct metric and year-end date for 2024, so it retains partial relevance, but the core factual inaccuracy undermines the entire response. Minor formatting like '$1 billion' is acceptable, but invented numbers are not.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 409,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has American Express's use and assumptions around the Reasonable and Supportable (R&S) Period evolved between 2022 and 2024 in estimating credit loss reserves, and what does this indicate about the company's approach to financial risk management?",
      "original_answer": "In 2022, American Express explicitly described its use of the R&S Period as a key component in estimating reserves for credit losses on Card Member loans, incorporating historical loss experience and current/future economic conditions over that period. The reserves stood at $3.3 billion as of December 31, 2021, and the R&S Period was a central assumption in modeling expected credit losses. By 2024, while the R&S Period was still referenced, it was no longer introduced as a newly explained concept and instead appeared embedded within a more mature and established process, indicating it had become a standard part of the company's financial risk modeling framework. This evolution suggests a shift from introducing the methodology (2022) to relying on it as a foundational element in credit loss estimation (2024).",
      "llm_answer": "American Express continues to base its credit‑loss reserves on a “reasonable and supportable (R&S) period” that extends beyond the balance‑sheet date and incorporates historical loss experience together with current and projected economic conditions. The 2022 filing (Note 3) describes this same framework – “management estimates lifetime expected credit losses … over a reasonable and supportable period (R&S Period) beyond the balance‑sheet date” 【page_95】. The 2024 filing repeats the same language and adds that “beyond the R&S Period, expected credit losses are estimated by immediately reverting to long‑term average loss rates” 【page_97】.  \n\nWhile the definition of the R&S period has not changed, the reserve balance grew from $3.3 billion in 2021 (reported in the 2022 filing) to $5.7 billion in 2024, indicating that management has adjusted the underlying assumptions—likely extending the horizon or applying more conservative loss‑rate estimates—to reflect heightened economic uncertainty. This consistency in methodology combined with a more cautious calibration shows a disciplined, forward‑looking approach to managing credit‑risk exposure.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the use of the Reasonable and Supportable (R&S) Period in both 2022 and 2024 filings and notes the continuity in methodology. However, it introduces a significant factual error by stating the reserve balance grew to $5.7 billion in 2024, which is not supported by the ground truth. The original answer only confirms the $3.3 billion reserve as of December 31, 2021 (reported in 2022 filing), but does not provide the 2024 reserve amount. The $5.7 billion figure is unverified and appears to be an unsupported inference, undermining quantitative accuracy. (2) The mention of 'Note 3' and page numbers (e.g., page_95, page_97) suggests document sourcing, but these details are not contradicted by the ground truth; however, the core financial claim about the 2024 reserve is incorrect. The ground truth does not confirm any specific reserve amount for 2024, so asserting a precise increase to $5.7 billion is a major factual overreach. (3) The reasoning around 'more conservative assumptions' due to economic uncertainty is plausible but speculative, and not directly supported by the original answer, which focuses on the methodological entrenchment of the R&S Period rather than changes in calibration. The multi-hop synthesis correctly connects the continued use of R&S across years but incorrectly infers changes in assumptions due to reserve growth that isn’t confirmed. (4) Despite the quantitative error, the LLM captures the qualitative evolution of R&S from an explicitly explained concept in 2022 to a standard part of the framework in 2024, aligning with the original answer’s core insight. The contextual relevance is high because it addresses both the methodological continuity and implied risk management approach. However, the incorrect dollar figure and unsupported conclusion about assumption changes reduce correctness and quantitative accuracy significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1519,
        "completion_tokens": 520,
        "total_tokens": 2039
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Amazon's approach to debt financing evolved between 2022 and 2024, particularly with respect to the 0.800% Note due 2025?",
      "original_answer": "In 2022, Amazon's filings referenced the 0.800% Note due 2025 as part of its broader debt structure, originally introduced in the Officers' Certificate dated June 3, 2020. By 2024, Amazon not only continued to reference the 0.800% Note due 2025 in its filings but also introduced new debt instruments with different interest rates and maturity dates, such as the 4.600% Note due 2025. This indicates a shift in Amazon's debt financing strategy, incorporating a wider range of interest rates and maturities to potentially manage cash flow and interest rate risk more effectively.",
      "llm_answer": "In the 2022 Form 10‑K the only reference to the 0.800 % Note due 2025 appears in Exhibit 4.5 (the June 3 2020 Officers’ Certificate), showing that Amazon’s debt portfolio then relied on that ultra‑low‑cost instrument 【page_72†L31-L34】.  \nBy the 2024 filing the same 0.800 % Note is still listed (now as Exhibit 4.6) 【page_75†L1-L3】, but Amazon has also added a new series of higher‑coupon notes—including a 4.600 % Note due 2025 (Exhibit 4.8) 【page_75†L9-L12】, indicating that the company has broadened its financing mix and moved toward higher‑interest debt while retaining the original low‑rate note.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 0.800% Note due 2025 was originally issued under the June 3, 2020 Officers’ Certificate and referenced in both 2022 and 2024 filings; Amazon introduced a new 4.600% Note due 2025 by 2024. These details match the original answer. (2) Quantitative accuracy is perfect: percentages (0.800%, 4.600%), years (2020, 2022, 2024, 2025), and exhibit numbers (4.5, 4.6, 4.8) are correctly cited. Minor formatting differences (e.g., spacing in '0.800 %') do not affect meaning. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across years and filings to infer a strategic broadening of the debt mix. It identifies continuity (retention of low-rate note) and change (addition of higher-cost debt), supporting the conclusion of an evolved financing strategy. (4) The only reason for not scoring a 10 is a slight lack of explicit framing around 'managing cash flow and interest rate risk'—a nuance in the original answer about strategic intent. However, the inference is strongly implied by the evidence presented. Overall, the answer is factually complete, contextually precise, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 350,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the treatment or disclosure of the Twenty-third Supplemental Indenture evolved between the 2022 and 2024 SEC filings, and what does this indicate about its ongoing relevance or status?",
      "original_answer": "In the 2022 filing (DUK_10k_2022.pdf), the Twenty-third Supplemental Indenture was explicitly listed and dated June 1, 1978, incorporated by reference to Exhibit 2(c), File No. 2-61611. However, in the 2024 filing (DUK_10k_2024.pdf), there is no direct mention or continued reference to the Twenty-third Supplemental Indenture. Instead, the focus shifts to more recent supplemental indentures, such as the Forty-ninth Supplemental Indenture dated March 14, 2024. This indicates that the Twenty-third Supplemental Indenture was not reaffirmed or highlighted in the most recent disclosure, suggesting it may have diminished in operational or reporting significance over time.",
      "llm_answer": "In the 2022 Form 10‑K the “Twenty‑third Supplemental Indenture” is listed (under the Indiana subsidiary) as a historic instrument dated January 1, 1977 and incorporated by reference to Exhibit 2‑57828. The 2024 filing repeats the same entry (page 252) with the identical date and reference, and no new amendment or additional disclosure is added. This continuity shows that the indenture is still being disclosed as part of Duke Energy’s historical series of supplemental indentures, indicating that it remains a relevant reference document even though it has not been modified or re‑issued since the earlier filing.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the Twenty-third Supplemental Indenture was explicitly mentioned in the 2022 filing with a date of June 1, 1978, and reference to Exhibit 2(c), File No. 2-61611. However, the LLM incorrectly states the date as January 1, 1977, and cites a non-matching exhibit reference (Exhibit 2-57828), which is not in the original. Furthermore, the LLM claims the 2024 filing 'repeats the same entry' with identical details, which directly contradicts the ground truth: the 2024 filing contains no mention of the Twenty-third Supplemental Indenture at all. Instead, it references newer indentures like the Forty-ninth Supplemental Indenture dated March 14, 2024. (2) Quantitative accuracy is poor: both the date (1977 vs 1978) and exhibit/file number are incorrect. There is no valid calculation in the response, but the core data points are wrong. (3) The multi-hop reasoning is fundamentally flawed. The question asks for a comparison between 2022 and 2024 disclosures to assess evolution and relevance. The LLM incorrectly asserts continuity when the ground truth shows omission in 2024, leading to an erroneous conclusion about ongoing relevance. The model fails to recognize the absence of the indenture in the later filing, which is central to the correct interpretation. (4) Contextual relevance is moderate because the answer addresses the structure of the question (comparing disclosures across years) and discusses the indenture’s status, but due to factual errors, the conclusion is incorrect. The answer would have been contextually appropriate if based on accurate data. Overall, the response is mostly incorrect due to wrong dates, wrong exhibit references, and failure to detect the absence of the indenture in the 2024 filing, leading to an invalid conclusion about its continued relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 513,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the repurchase activity for Class C Capital Stock evolve from 2022 to 2024, and what was the total value of shares repurchased in each year?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023 the amount increased to $62.2 billion, and in 2024 it remained high at $62.0 billion. This demonstrates a consistent and significant level of share repurchase activity over the three-year period, with a slight peak in 2023 followed by a minor decline in 2024.",
      "llm_answer": "The 10‑K shows that Alphabet’s share‑repurchase program has been steadily pulling back on Class C capital stock:\n\n* **2022** – The company repurchased **$59.3 billion** of Class A and Class C shares combined; the filing does not break out the Class C portion separately.  \n* **2023** – **$52.9 billion** of Class C shares were repurchased (78 million shares).  \n* **2024** – **$50.2 billion** of Class C shares were repurchased (306 million shares).\n\nThus, after a peak in 2022 (combined), the amount repurchased specifically for Class C fell from $52.9 billion in 2023 to $50.2 billion in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative details. While it correctly states that $59.3 billion in Class A and Class C shares were repurchased in 2022 (matching the ground truth), it incorrectly claims $52.9 billion of Class C shares were repurchased in 2023 and $50.2 billion in 2024. The ground truth states total repurchases (Class A and C combined) were $62.2 billion in 2023 and $62.0 billion in 2024 — not Class C alone. The LLM falsely implies a breakdown by share class is available and reports fabricated figures for Class C-specific repurchases. (2) The numbers for 2023 and 2024 are quantitatively wrong: $52.9B and $50.2B do not match the correct totals of $62.2B and $62.0B. There is no support in the ground truth for separating Class C repurchases at this level of detail. The 2022 figure is correct but only because it correctly cites the combined amount. (3) The reasoning is partially sound in structure — it attempts to track repurchase trends over time — but fails on multi-hop synthesis because it invents a level of granularity (Class C-only repurchase values) not present in the source data. The conclusion that repurchases declined from 2023 to 2024 is incorrect: the ground truth shows a slight decline from $62.2B to $62.0B, but the LLM misattributes this to Class C when the data refers to combined share classes. (4) Scores reflect that the answer addresses the right question with correct time periods and company, earning points for contextual relevance and partial qualitative accuracy, but major quantitative errors and unsupported breakdowns severely undermine factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 454,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "What changes occurred in the treatment and documentation of the American Express Company Salary/Bonus Deferral Plan between the 2022 and 2024 SEC filings?",
      "original_answer": "In the 2022 filing, the Salary/Bonus Deferral Plan was referenced through historical amendments, including Exhibit 10.16 (1988 plan) and Exhibit 10.17 (1994 amendment). The 2024 filing reintroduces the plan through Exhibit 10.13, referencing the same 1988 plan, and also includes Exhibit 10.14, which references the 1994 amendment. Notably, the 2024 filing adds Exhibit 10.16, which incorporates the 1997 amendments to the plan. This indicates that while the foundational documentation remained consistent, the 2024 filing expanded the disclosure to include a broader historical record of amendments, providing more context on the plan's evolution.",
      "llm_answer": "In the 2022 Form 10‑K the Salary/Bonus Deferral Plan was listed as Exhibit 10.16 (the original plan), with its amendment shown as Exhibit 10.17 and a later amendment as Exhibit 10.19. In the 2024 filing the same plan and its two amendments appear again, but they have been renumbered to Exhibit 10.13 (original plan), Exhibit 10.14 (the 1994 amendment) and Exhibit 10.16 (the 1997 amendment). The underlying documents referenced (Exhibit 10.20 for the original plan, Exhibit 10.4 for the 1994 amendment, and Exhibit 10.37 for the 1997 amendment) are unchanged, indicating that only the exhibit numbering was altered, not the substantive content.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partial factual accuracy but introduces significant errors in exhibit references and historical details, undermining its correctness. (1) Correct elements: The answer correctly identifies that the 2024 filing includes the 1988 plan, the 1994 amendment, and the 1997 amendment, and notes renumbering of exhibits. The core idea that the underlying documents remain unchanged is consistent with the ground truth. (2) Quantitative/Exhibit Accuracy: The LLM incorrectly states that in the 2022 filing, the 1994 amendment was Exhibit 10.17 and a 'later amendment' was Exhibit 10.19 — the ground truth confirms only Exhibits 10.16 (1988) and 10.17 (1994) were referenced; there is no mention of Exhibit 10.19 or a second amendment in 2022. Additionally, the LLM falsely claims that Exhibit 10.20 refers to the original plan, Exhibit 10.4 to the 1994 amendment, and Exhibit 10.37 to the 1997 amendment — these internal exhibit references are entirely fabricated and not in the ground truth. (3) Multi-hop reasoning: The model correctly infers that exhibit numbering changed and that the underlying plan documents are consistent, but fails to accurately represent the scope of disclosure expansion in 2024 (i.e., the addition of the 1997 amendment as a new disclosure). Instead, it misrepresents the 1997 amendment as having been previously disclosed under a different number, which contradicts the ground truth stating it was newly added in 2024 via Exhibit 10.16. (4) The answer is contextually relevant and addresses the question’s focus on changes in treatment and documentation, but due to incorrect exhibit mappings and false claims about prior disclosures, the qualitative and quantitative accuracy scores are significantly reduced. The correctness score reflects a partially right answer with major factual flaws in key details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 498,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has Starbucks' exposure to interest rate swaps evolved between 2022 and 2024, particularly in terms of their balance sheet classification and magnitude of liability?",
      "original_answer": "In 2022, Starbucks reported an interest rate swap liability of $34.0 million under 'Other long-term liabilities'. By 2024, the company's interest rate swap position had shifted significantly, with a liability of $19.2 million under 'Other long-term liabilities' and an additional $41.4 million liability from interest rate swaps reported for the prior year (2023), indicating a decrease in liability from the previous year but a continued significant exposure. This reflects a transformation in the company's interest rate swap position, with a shift in balance sheet classification and a notable reduction in total swap liability.",
      "llm_answer": "In the 2022 Form 10‑K Starbucks reported interest‑rate‑swap liabilities of **$34 million classified as “other long‑term liabilities”** (plus a $12 million accrued‑liability component). By the 2024 filing the same swaps were still shown under **“other long‑term liabilities,” but the amount had fallen to **about $19 million**. Thus, the swaps remain a long‑term liability on the balance sheet, but the exposure has been cut roughly in half between 2022 and 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $34 million liability in 2022 and the reduction to $19 million by 2024, both classified under 'other long-term liabilities', which aligns with the ground truth. However, it introduces a $12 million 'accrued-liability component' not present in the original answer or implied by the ground truth data, which is factually incorrect and unsupported. Additionally, the ground truth mentions a $41.4 million liability from 2023 (prior year to 2024), indicating a multi-year evolution, but the LLM omits any reference to 2023 data, missing a key part of the multi-hop analysis. (2) The 2022 ($34M) and 2024 ($19.2M) figures are approximately correct (rounding to $19M is acceptable), but the addition of the $12M figure is erroneous and distorts the total exposure. The claim that exposure was 'cut roughly in half' is directionally reasonable but slightly imprecise (from $34M to $19.2M is a ~43% reduction). (3) The reasoning correctly tracks the classification continuity and downward trend but fails to synthesize the full evolution across 2022–2024, particularly the 2023 liability that contributes to understanding the shift. The omission of the $41.4M 2023 liability weakens the multi-hop synthesis required. (4) Despite missing key details and introducing an incorrect figure, the LLM captures the core trend—decreasing liability with consistent classification—making the answer contextually relevant and partially accurate. Scores reflect minor factual error, partial completeness, and sound but incomplete reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 430,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the treatment of the Directors' Savings Plan evolved between 2022 and 2024, and what does this suggest about Duke Energy's approach to director compensation governance and deferral mechanisms?",
      "original_answer": "In 2022, the Directors' Savings Plan was formally introduced in the 10-K filing with a specific amendment dated December 16, 2021, indicating active documentation and policy updates around director deferrals. By 2024, the plan is referenced in the context of phantom investment options and deferred compensation mechanics, with an emphasis on unfunded accounts tied to the Duke Energy Common Stock Fund. This evolution suggests a shift from policy establishment to operational transparency, highlighting how deferrals are structured and invested, which may reflect a broader governance strategy to align director compensation with long-term shareholder interests and company stock performance.",
      "llm_answer": "In the 2022 filing the Directors’ Savings Plan is mentioned only in the exhibit list, noting an amendment that became effective December 16 2021 (see Exhibit 10.12). By the 2024 filing the plan is described in detail as a non‑qualified deferred‑compensation arrangement that lets outside directors defer all or part of their annual retainers, credits the balance with the performance of phantom “Duke Energy Common Stock Fund” options, and pays the balance when a director’s board service ends (Item 12, 2024). This evolution shows Duke Energy has moved from simply amending the plan to actively using it as a performance‑linked, unfunded deferral tool, reflecting a governance stance that aligns director compensation with company performance while keeping the mechanism under the Compensation Committee’s oversight.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2022 mention of the Directors' Savings Plan via Exhibit 10.12 with an amendment effective December 16, 2021, matches the original answer. The 2024 description accurately reflects the plan as a non-qualified deferred-compensation arrangement tied to phantom Duke Energy Common Stock Fund performance, with payout upon termination of board service. These details are consistent with the ground truth’s emphasis on unfunded accounts and deferral mechanics. (2) Quantitative accuracy is perfect: the date 'December 16, 2021' is correctly cited, and no numerical calculations are required. Format variations (e.g., spacing in dates) do not affect correctness. (3) Reasoning is sound: the LLM correctly infers a shift from policy documentation (2022) to operational detail (2024), and draws a logical conclusion about governance strategy—specifically, aligning director compensation with company performance under Compensation Committee oversight. This mirrors the original answer’s interpretation about alignment with shareholder interests. (4) The only minor gap is that the LLM does not explicitly use the term 'operational transparency' or mention 'governance strategy' in quite the same breadth as the original, but it captures the essence by referencing performance linkage and committee oversight. Thus, while the qualitative reasoning is excellent, it falls just short of full equivalence. Contextual relevance is perfect—the response directly addresses both the evolution of the plan and its implications for governance and deferral mechanisms.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 452,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the positioning and associated risk profile of Costco's Kirkland Signature brand evolved between 2022 and 2023?",
      "original_answer": "In 2022, Costco emphasized the Kirkland Signature brand as a strategic asset, highlighting its high quality, competitive pricing, and contribution to higher margins. The company planned to continue increasing the sales penetration of these private-label items. However, by 2023, the risk disclosures included broader mentions of how supply chain disruptions, foreign exchange fluctuations, and catastrophic events could negatively impact the business—including private-label brands like Kirkland Signature. While the 2022 filing focused on growth and brand strength, the 2023 filing introduced a more risk-focused lens, indicating that the brand's expansion and reliance could expose Costco to greater operational and financial volatility.",
      "llm_answer": "In the 2022 filing Costco described Kirkland Signature as a “high‑quality” private‑label line that is priced below national brands, helps lower overall costs, differentiates its merchandise and generally yields higher margins, and it said the company expects to keep expanding its sales penetration. The 2023 filing still treats Kirkland as a core, high‑quality, value‑oriented brand, but it adds a sharper focus on the risks tied to that positioning – noting that product‑quality failures could lead to recalls, litigation and reputational harm, and that supply‑chain, regulatory and ESG compliance issues now represent material risks to the brand. Thus, while the brand’s value‑price positioning remains unchanged, its risk profile has broadened to emphasize quality‑ and compliance‑related exposures that were not highlighted in the 2022 discussion.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2022 emphasis on Kirkland Signature's quality, value, margin advantage, and expansion plans is accurately described. The 2023 shift toward heightened risk disclosure—particularly around supply chain, quality failures, litigation, and compliance (including ESG and regulatory risks)—is correctly identified. While the original answer highlights foreign exchange and catastrophic events as additional risks in 2023, the LLM captures the broader risk expansion, especially on quality and compliance, which are key new themes. (2) There are no numerical values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable in a numerical sense, but all time references (2022, 2023) are correct—hence scored as 10. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, comparing strategic positioning and risk disclosures. It infers the evolution in risk profile even if not verbatim listing all risks (e.g., forex, catastrophes), focusing instead on newly emphasized risk categories like quality and compliance, which are valid and significant. (4) The answer is contextually excellent—directly addressing how positioning and risk profile evolved. The only minor shortcoming is the omission of 'foreign exchange fluctuations' and 'catastrophic events' as specific risks mentioned in 2023, which slightly reduces completeness, but the core evolution in risk framing is accurately conveyed. Hence, a 9 on correctness and qualitative accuracy is justified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 450,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve from 2022 to 2024, and what were the key changes in terms of volume and sources of additions?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. Over this period, the company experienced revisions and production activities that impacted reserves, with minimal extensions and discoveries contributing to the region. In 2024, there were no sales or significant reserve additions in this region, indicating a reduction in focus or activity compared to earlier years.",
      "llm_answer": "ConocoPhillips’ proved natural‑gas reserves located in the Asia Pacific/Middle East region (the sum of the consolidated‑operations column and the equity‑affiliate column, which are all in that region) were ≈ 6,080 BCF at the end of 2022 (322 BCF developed + 4 BCF undeveloped + 5,753 BCF equity affiliates)【page_145†L31-L38】. They fell to ≈ 5,590 BCF at the end of 2023 (305 + 7 + 5,275)【page_145†L31-L38】 and then rose to ≈ 6,170 BCF at the end of 2024 (289 + 7 + 5,870)【page_145†L31-L38】.  \n\nThe 2022‑23 decline reflected downward revisions, higher production and sales, and modest extensions, while the 2023‑24 rebound was driven by new purchases (e.g., the Marathon Oil acquisition) and extensions/discoveries in the Middle East and Australia, together with upward technical revisions in the equity‑affiliate portfolio【page_146†L1-L9】.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in both direction and magnitude. The ground truth states that COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 326 BCF in 2022 to 296 BCF in 2024. However, the LLM claims reserves were ~6,080 BCF in 2022, dropped to ~5,590 BCF in 2023, then rose to ~6,170 BCF in 2024—over 20 times larger than the true values and showing an opposite trend. This indicates a severe factual error. (2) The numbers cited by the LLM (e.g., 322 + 4 + 5,753 = 6,080 BCF) appear to be misread or misaggregated from a table, likely confusing total global or equity-affiliate reserves with the regional figure for Asia Pacific/Middle East. The original answer specifies only 326 BCF in 2022 and 296 BCF in 2024—values not reflected at all in the LLM response. There is no indication of such large reserves in this specific region in the ground truth. (3) The multi-hop reasoning is flawed: the LLM incorrectly synthesizes data, possibly conflating regional with global or affiliate-level data. It introduces a Marathon Oil acquisition as a driver for 2023–2024 growth, which is not mentioned in the ground truth and contradicts the stated lack of significant additions or sales in the region. (4) The contextual relevance is low because the answer discusses a completely different scale and trend. While the structure of discussing changes over time and drivers like revisions and discoveries is appropriate, the factual foundation is entirely wrong, rendering the analysis invalid. Thus, the correctness score is 1 due to complete factual inaccuracy despite some structurally relevant elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 453,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has FedEx's strategic relationship with the Boeing 767F evolved between 2022 and 2024, particularly in terms of fleet ownership and modernization focus?",
      "original_answer": "In 2022, FedEx directly owned 114 Boeing 767F aircraft, indicating a significant owned asset position in its fleet strategy. By 2024, while no updated ownership figures were disclosed, FedEx emphasized the Boeing 767-300 Freighter (B767F) as a key component of its aircraft modernization programs. The company described these aircraft as significantly more fuel-efficient per unit than older models and noted that expenditures for these aircraft are necessary for long-term operating savings and fleet replacement, with limited flexibility to delay purchases without incurring significant costs.",
      "llm_answer": "In the 2022 filing FedEx reported that it owned 114 Boeing 767‑300 freighters and, in addition, had purchase commitments for another 38 B767Fs (14 each in 2023‑2024 and 10 in 2025) as part of its fleet‑expansion plan. By the 2024 filing the company still owned the same 114 B767Fs, but its strategic emphasis had shifted to using new‑build B767Fs (and B777Fs) in a modernization program aimed at replacing older aircraft with more fuel‑efficient types—evidenced by $611 million in deposits and 14 B767Fs scheduled for delivery in 2025‑2026. Thus, ownership of the core B767F fleet remained steady, while the focus moved toward leveraging additional B767Fs to modernize and improve the efficiency of FedEx’s aircraft fleet.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in quantitative details not supported by the ground truth. While it correctly states that FedEx owned 114 Boeing 767F aircraft in 2022 (matching the original answer), it adds specific purchase commitments (38 total: 14 each in 2023–2024 and 10 in 2025) and mentions $611 million in deposits and 14 B767Fs scheduled for delivery in 2025–2026—none of which are present or verifiable in the ground truth. These specific numbers and delivery schedules are fabricated or hallucinated, severely impacting quantitative accuracy. (2) The original answer explicitly states that no updated ownership figures were disclosed in 2024, but the LLM claims FedEx 'still owned the same 114 B767Fs,' which is an unsupported assumption. This misrepresents the available data. (3) Qualitatively, the LLM captures the correct strategic shift toward modernization and fuel efficiency, aligning with the ground truth’s emphasis on the B767F’s role in modernization and operating savings. The reasoning about fleet efficiency and replacement of older models is sound and contextually appropriate. (4) The answer is highly relevant to the question, addressing both fleet ownership and modernization focus, and synthesizes the evolution of strategy well—even if specific data points are invented. However, the inclusion of unverified figures and commitments undermines factual correctness. Thus, while the qualitative direction and contextual relevance are strong, the quantitative inaccuracies significantly reduce overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 436,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did Starbucks' involvement with roasted coffee evolve from 2022 to 2024 in terms of inventory value and production infrastructure?",
      "original_answer": "In 2022, Starbucks reported an inventory value of roasted coffee at $310.3 million, reflecting its role in holding roasted coffee as part of its merchandise. By 2024, the company had expanded its infrastructure dedicated to roasting, with facilities in York, PA; Minden, NV (Carson Valley); Kunshan, China; and Kent, WA, indicating a significant increase in its direct involvement in the roasting process. This represents a shift from primarily holding roasted coffee inventory to actively producing and distributing it at scale.",
      "llm_answer": "In fiscal 2022 Starbucks reported **$310.3 million of roasted‑coffee inventory** and **$838.5 million of net roasting equipment** (the primary production‑infrastructure asset) 【page 71】【page 73】.  \n\nThe 2024 filing no longer gives a roasted‑coffee inventory figure in the excerpts provided, but it does detail an expanded roasting footprint – roughly **4.2 million sq ft of roasting, warehousing and distribution space** across York, PA; Minden, NV; Kunshan, China; and Kent, WA 【page 33】 – indicating that the company’s roasting capacity has grown since 2022.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2022 roasted coffee inventory value of $310.3 million, matching the ground truth. However, it introduces a figure not present in the original answer—$838.5 million in net roasting equipment—which, while potentially accurate from the filing, is not part of the ground truth response and distracts from the focus on inventory and infrastructure expansion. The 2024 inventory value is correctly noted as unavailable in the provided excerpts, which aligns with the limitations of the data. (2) The quantitative accuracy is high for the $310.3 million figure, but the addition of the roasting equipment value introduces a metric not requested in the question and not in the original answer, slightly reducing accuracy. The 4.2 million sq ft figure for roasting and distribution space is new information not in the ground truth, but it plausibly supports the claim of infrastructure growth. (3) The multi-hop reasoning is partially sound: the model infers increased involvement from expanded physical infrastructure, which is consistent with the original answer’s logic. However, it fails to explicitly state the shift from inventory-holding to active production that is central to the ground truth’s conclusion. The facilities listed (York, PA; Minden, NV; Kunshan, China; Kent, WA) match the original, though the omission of 'Carson Valley' as a descriptor for Minden, NV is a minor detail. (4) The contextual relevance is high as it addresses both inventory and infrastructure evolution. The qualitative accuracy is reduced because the answer emphasizes asset values and square footage not in the original, rather than synthesizing the strategic shift emphasized in the ground truth. Overall, the core facts are correct, but the emphasis and synthesis are not fully aligned with the original answer’s intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 502,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has PepsiCo's utilization of the 2.750% Senior Notes due 2025 evolved between 2023 and 2024, based on the specific debt instruments referenced in the filings?",
      "original_answer": "In 2023, the 2.750% Senior Notes due 2025 were listed among other notes in a Board of Directors Resolutions document that authorized officers to establish terms for several senior notes, including the 2.750% Senior Notes due 2025. By 2024, PepsiCo not only retained the 2.750% Senior Notes due 2025 in its list of authorized instruments but also introduced a new 2.750% Senior Notes due 2030. This indicates that PepsiCo extended its debt strategy involving this interest rate to a longer-term horizon, signaling a strategic evolution in its financing approach.",
      "llm_answer": "- **2023 filing (PEP 10‑K 2023)** – The 2.750 % Senior Notes due 2025 are listed in the Board of Directors’ resolutions that authorize the terms of a group of new senior notes (see page 130, which reads “the 2.750 % Senior Notes due 2025”【page_130】).  \n\n- **2024 filing (PEP 10‑K 2024)** – The same 2.750 % Senior Notes due 2025 appear again in the updated Board of Directors’ resolutions authorizing the terms of several senior notes (see pages 130 and 129, both of which repeat “the 2.750 % Senior Notes due 2025”【page_130】【page_129】).  \n\n**Evolution:** Between 2023 and 2024 PepsiCo’s use of the 2.750 % Senior Notes due 2025 did not change materially; the instrument remained authorized and listed among the company’s senior‑note programs in both years, indicating continued reliance on that debt issuance without new amendments or additional issuances noted.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer is factually accurate in its citation of the 2.750% Senior Notes due 2025 being listed in both the 2023 and 2024 filings, with correct references to the Board of Directors’ resolutions and page numbers. All entities (PepsiCo, 2.750% Senior Notes due 2025, years 2023 and 2024) are correctly identified, and there are no errors in dates, percentages, or document references. (2) Quantitative accuracy is perfect: the interest rate (2.750%), maturity year (2025), and filing years (2023, 2024) are all correct. (3) However, the reasoning and synthesis are significantly flawed. The original answer identifies a key evolution: in 2024, PepsiCo introduced a *new* 2.750% Senior Notes due 2030, indicating a strategic extension of the same coupon rate to a longer-term instrument. This critical multi-hop insight — that PepsiCo expanded its use of the 2.750% rate beyond the 2025 note — is entirely missing from the LLM answer. Instead, the LLM concludes there was 'no material change,' which contradicts the ground truth that shows a strategic evolution in debt structuring. (4) While the LLM accurately reports the continued authorization of the 2025 notes, it fails to detect and synthesize the introduction of the 2030 note as part of a broader financing strategy, resulting in a qualitatively incorrect conclusion. Hence, correctness and qualitative accuracy are low despite perfect quantitative accuracy. Contextual relevance is high because the answer addresses the right documents and instruments, but misses the strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 425,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did FedEx's planned utilization of the B777F aircraft change from 2022 to 2024, and what does this indicate about its strategic role in the fleet?",
      "original_answer": "In 2022, FedEx planned to operate 4 B777F aircraft in 2024 and 2 in 2025. By 2024, the updated plan showed 2 B777F aircraft operating in 2025, with no further plans beyond that year. This indicates a reduction in the strategic emphasis on the B777F fleet, moving from a gradually decreasing role to a complete phase-out, suggesting a shift in aircraft preference or operational strategy.",
      "llm_answer": "In the 2022 Form 10‑K FedEx said it expected to take delivery of **four Boeing 777‑Freighters in 2024** (see the 2022 aircraft‑commitment table, B777F = 4 for 2024). The 2024 Form 10‑K shows the schedule has shifted – **no B777F deliveries are listed for 2024 and only two are slated for 2025** (see the 2024 aircraft‑commitment table, B777F = 2 for 2025, “‑” for 2024). This delay indicates that while the B777F remains a cornerstone of FedEx’s fleet‑modernization and fuel‑efficiency strategy, its rollout is being spread out over a longer horizon rather than being a near‑term expansion.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the number of B777F aircraft planned in 2022 (4 for 2024) and updates in 2024 (2 for 2025, none for 2024), which matches the ground truth quantitatively. However, it misinterprets the strategic implication: the ground truth states this reflects a 'complete phase-out' and 'reduction in strategic emphasis,' while the LLM claims the B777F remains a 'cornerstone' with rollout 'spread out,' suggesting continued strategic importance. This is a critical qualitative error in reasoning and conclusion. (2) Quantitatively, all numbers and years are accurate: 4 aircraft planned in 2022 for 2024 delivery, updated to 0 in 2024 and 2 in 2025 per the 2024 filing. No calculation errors. Format variations (e.g., '–' for zero) are appropriately interpreted. (3) The multi-hop reasoning correctly synthesizes data from the 2022 and 2024 10-Ks regarding delivery schedules. However, the synthesis fails in drawing the correct strategic inference—instead of recognizing a reduction and phase-out, it posits a delayed but ongoing strategy, contradicting the ground truth's indication of diminished long-term role. (4) Correctness score is 5 due to accurate numbers but major error in interpretation. Quantitative accuracy is 8 (minor deduction for not explicitly noting the absence of plans beyond 2025, which supports phase-out). Qualitative accuracy is 5 because the logic and conclusion are partially flawed. Contextual relevance is 8 as the response directly addresses the question’s components but misrepresents the strategic implication.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 434,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did Starbucks' foreign currency - other derivative liabilities and their impact on net gains/(losses) included in AOCI evolve from 2022 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2022, Starbucks reported foreign currency - other derivative liabilities of $0.3 million under accrued liabilities, while in 2024, the net gains included in AOCI related to foreign currency - other were $11.5 million. This indicates a significant shift from a minimal liability position in 2022 to a more substantial unrealized gain in 2024, suggesting increased exposure to or hedging of foreign currency fluctuations.",
      "llm_answer": "In 2022 Starbucks reported only **$0.3 million** of “foreign‑currency – other” derivative liabilities (accrued liabilities) and a **$55.3 million** net gain on those contracts recorded in AOCI. By the end of fiscal 2024 the same liability had risen to **about $8.8 million** (‑$4.7 million accrued + ‑$4.1 million long‑term) while the AOCI gain had fallen to **$11.5 million**. The rise in the liability balance shows the company has taken on far larger hedging positions to offset foreign‑currency risk, but the sharp drop in the AOCI gain suggests that recent currency movements have been less favorable (or that the hedges are now offsetting more of the exposure), indicating a higher‑priced but still managed exposure to foreign‑currency fluctuations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, in 2022, Starbucks reported only $0.3 million in foreign currency - other derivative liabilities, with no mention of a $55.3 million net gain in AOCI for that year. The LLM incorrectly introduces this $55.3 million figure, which is not present in the original answer or implied by it. Additionally, the LLM claims that in 2024 the liability rose to about $8.8 million (split between accrued and long-term), but the original answer does not provide any liability amount for 2024—only the $11.5 million net gain in AOCI. Thus, the LLM fabricates both the 2024 liability figure and the 2022 AOCI gain. Only the $11.5 million AOCI gain in 2024 is correct. (2) Calculations: The LLM attempts to sum -$4.7 million and -$4.1 million to get $8.8 million, but these components are not in the original data, making the calculation unsupported. There is no basis for these numbers in the ground truth. (3) Multi-hop reasoning: While the LLM attempts to synthesize changes over time and interpret implications for foreign currency exposure, it does so based on incorrect data. The reasoning about increased hedging and less favorable currency movements is speculative and not supported by the original answer, which only notes a shift from minimal liability to a substantial unrealized gain, indicating increased exposure or hedging—not the cost or effectiveness of hedges. (4) Despite these errors, the answer is contextually relevant and addresses the evolution and implications as asked. The qualitative reasoning, though based on false numbers, shows an attempt at financial interpretation. Hence, partial credit is given for structure and relevance, but major deductions apply for factual inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 491,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has PepsiCo's engagement with the 2.625% Senior Notes due 2026 evolved between 2023 and 2024, particularly in terms of its broader debt instrument disclosures?",
      "original_answer": "In 2023, the 2.625% Senior Notes due 2026 were listed among other notes in a section that included Board of Directors Resolutions authorizing officers to establish terms for various senior notes. By 2024, PepsiCo not only retained the 2.625% Senior Notes due 2026 in its disclosures but also introduced a significantly expanded list of senior notes, including newer maturities such as the 3.000% Senior Notes due 2027 and the 2.625% Senior Notes due 2029. This indicates a broader and more diversified set of debt instruments, suggesting an active capital markets strategy involving the issuance of notes with different maturities and rates.",
      "llm_answer": "In the 2023 Form 10‑K PepsiCo disclosed, through a Board‑of‑Directors resolution, that it had authorized the issuance of a “2.625 % Senior Note due 2026” together with a long list of other senior‑note programs (see page 130). The 2024 Form 10‑K repeats that same authorization—again listing the 2.625 % Senior Note due 2026 among the notes it may issue (page 129)—but now places it within an updated debt‑instrument schedule that also introduces new senior‑note series (e.g., a 5.125 % note due 2026), showing that the instrument remains part of PepsiCo’s broader debt‑issuance framework and that its disclosure has been refreshed for the newer filing year.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that the 2.625% Senior Notes due 2026 were disclosed in both 2023 and 2024 filings and were part of a broader authorization framework involving senior notes. It accurately references the Board of Directors' resolution and the inclusion of the note in both years' disclosures. However, there are significant factual inaccuracies in the details of the new notes introduced in 2024. The LLM claims a '5.125% note due 2026' was introduced in 2024, which contradicts the ground truth stating newer maturities like the 3.000% Senior Notes due 2027 and 2.625% Senior Notes due 2029. The 5.125% note due 2026 is not mentioned in the original answer and appears to be fabricated or misattributed. This undermines quantitative and qualitative accuracy. Additionally, the original answer emphasizes an expansion and diversification of maturities (e.g., extending to 2029), which reflects a strategic capital markets approach—the LLM fails to capture this nuance and instead focuses on a potentially incorrect example. While the core idea of continued engagement and updated disclosures is correct, the incorrect specification of new notes and lack of accurate multi-hop synthesis (comparing the evolution of the full set of notes) reduces correctness. The answer is contextually relevant and structured well, but key factual errors in percentages and maturities lower the overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 388,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Cisco's exposure to and reliance on overcoming technical hurdles evolved from 2022 to 2024, particularly in relation to its strategic investments and product development timelines?",
      "original_answer": "In 2022, Cisco acknowledged facing technical hurdles that could delay successful execution of its vision, especially in areas like product planning, timing, and resource allocation, which could lead to loss of market share and earnings. By 2024, the company's exposure to technical hurdles had transformed into a more specific dependency on overcoming these challenges in a timely manner to maintain competitive advantage, particularly in delivering complex software subscription offerings and introducing new technologies such as those related to artificial intelligence, security, observability, and cloud. The 2024 disclosures emphasize that failure to overcome these hurdles could not only result in loss of market share but also reputational damage, legal liability, and reduced customer retention. This represents a shift from internal execution risk to a broader operational and strategic dependency.",
      "llm_answer": "In the 2022 filing Cisco warned that “technical hurdles that we fail to overcome in a timely fashion” could let competitors—sometimes even strategic‑alliance partners—capture market share, and it treated this risk as one of many generic product‑development uncertainties tied to its existing investment plan. By the 2024 filing the company makes the same risk explicit but ties it directly to its expanded strategic priorities—AI, cloud, cybersecurity and the integration of large acquisitions such as Splunk—stating that the timing of new‑product introductions may be longer and that any delay in surmounting those technical challenges could materially affect the benefits of those investments. Thus, Cisco’s exposure to technical‑hurdle risk has grown and its reliance on successfully clearing those hurdles has become a central driver of its 2024 product‑development timeline and investment strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original ground truth. (1) It correctly identifies Cisco's evolving exposure to technical hurdles from 2022 to 2024, noting the shift from general product-development risks to a more strategic, investment-critical dependency. The core facts—timing of product introductions, competitive threats, and linkage to strategic priorities like AI, cloud, cybersecurity, and Splunk integration—are all correct and consistent with the original answer. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not applicable in that sense, but all temporal references (2022, 2024) are correct, satisfying the date accuracy requirement. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of disclosures, correctly infers the evolution in risk framing—from internal execution risk to broader strategic dependency—and ties it to changes in investment focus and product complexity. The mention of Splunk as a key acquisition aligns with Cisco’s 2024 strategic context. (4) The only minor shortcoming is that the LLM answer does not explicitly mention reputational damage, legal liability, or reduced customer retention—consequences emphasized in the 2024 filing per the original answer. While it captures the material financial and strategic impact (e.g., affecting investment benefits), it omits these specific qualitative risks, slightly reducing completeness. However, the central theme of increased reliance and exposure is accurately conveyed. Wording differs but semantic meaning is equivalent. Thus, correctness is high but not perfect, warranting a 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1463,
        "completion_tokens": 466,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the role of Google Ad Manager in driving Google Network revenues change between 2022 and 2023, based on the specific mentions of its performance and positioning across those years?",
      "original_answer": "In 2022, Google Ad Manager was explicitly cited as one of the key drivers behind the $8.6 billion year-over-year increase in Google Network revenues, alongside AdMob and AdSense. By 2023, while Google Ad Manager remained a core advertising platform used by customers, it was listed among several platforms (including Google Ads, Display & Video 360, and the Marketing Platform) without specific attribution to revenue growth. This indicates a shift from being a standout growth contributor in 2022 to being part of a broader suite of advertising tools in 2023, suggesting a more integrated but less singularly emphasized role.",
      "llm_answer": "In the 2022 filing, Alphabet singled out **Google Ad Manager as a “strength” that helped power the year‑over‑year increase in Google Network revenue** (the 2020‑2021 growth discussion notes that the rise was “primarily driven by strength in AdMob, Google Ad Manager, and AdSense”). By contrast, the 2023 filing merely lists Google Ad Manager alongside Google Ads, Display & Video 360 and the Marketing Platform as one of the **standard channels through which customers purchase ad inventory**, without highlighting it as a specific growth catalyst. Thus, its role moved from a highlighted revenue‑driving asset in 2022 to a routine buying platform in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Google Ad Manager was explicitly cited as a key driver of Google Network revenue growth, alongside AdMob and AdSense. The phrasing 'strength' matches the tone of the original filing and is consistent with the ground truth's characterization. In 2023, the LLM correctly notes that Google Ad Manager was no longer highlighted as a growth catalyst but instead listed among other platforms (Google Ads, Display & Video 360, Marketing Platform) as standard ad inventory channels—this reflects the shift from standout contributor to integrated platform. (2) There are no numeric values in the LLM answer, but it correctly references the 2022 growth context without introducing any incorrect figures. The ground truth mentions an $8.6 billion increase, which the LLM omits, but since the question focuses on the role of Google Ad Manager rather than the exact dollar amount, this omission does not undermine the core answer. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, compares the positioning of Google Ad Manager in each, and draws a valid conclusion about its changing role. (4) The LLM slightly under-elaborates on the 2022 context by not explicitly naming AdMob and AdSense as co-drivers (though it references them via a parenthetical that cites the 2020–2021 period), but it still captures the essential point. Overall, the answer is semantically equivalent, factually correct, and contextually precise—just missing minor detail for a perfect 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 438,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did Starbucks' derivative liabilities related to foreign currency - other evolve from 2022 to 2024, and what was the magnitude of change?",
      "original_answer": "In 2022, Starbucks reported derivative liabilities related to foreign currency - other at $0.3 million under accrued liabilities. By 2024, this amount had increased to $4.7 million under the same category. This indicates a significant increase in the company's liabilities tied to foreign currency derivatives over the two-year period.",
      "llm_answer": "Starbucks’ derivative liabilities for the “foreign‑currency – other” hedge grew sharply. In fiscal 2022 the liability was only **$0.3 million** (accrued liabilities) 【page_68】. By fiscal 2024 it had risen to **$4.7 million** (accrued) plus **$4.1 million** (other long‑term), or **$8.8 million** in total 【page_72】. That represents an increase of roughly **$8.5 million** over the two‑year period.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2022 derivative liability amount ($0.3 million) and the 2024 amount under accrued liabilities ($4.7 million), which matches the ground truth. However, it introduces an additional $4.1 million under 'other long-term' liabilities in 2024, leading to a total of $8.8 million, which is not supported by the original answer. The ground truth states the 2024 liability is $4.7 million under the same category (accrued liabilities), with no mention of long-term components. (2) The calculation of an $8.5 million increase is based on incorrect totals: the actual increase from $0.3M to $4.7M is $4.4 million, not $8.5 million. This represents a significant quantitative error. (3) The multi-hop reasoning fails because the model incorrectly synthesizes information by combining two different line items (accrued and long-term) that the ground truth does not conflate. There is no evidence in the original answer that the $4.1 million is part of the 'foreign currency - other' derivative liability. (4) While the model captures the directional trend (increase) and some correct figures, the magnitude of change is severely overstated due to incorrect aggregation. The contextual relevance is high as it addresses the evolution and change, but factual accuracy is compromised by erroneous data inclusion and miscalculation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1181,
        "completion_tokens": 379,
        "total_tokens": 1561
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has PepsiCo's issuance of the 4.600% Senior Notes due 2045 evolved between 2023 and 2024, and what does this indicate about the company's debt structure strategy?",
      "original_answer": "In 2023, the 4.600% Senior Notes due 2045 were listed among other senior notes in the Board of Directors Resolutions that authorized PepsiCo's officers to establish terms for various notes, including the 4.600% Senior Notes due 2045. By 2024, the 4.600% Senior Notes due 2045 remained part of the company's debt structure, but were now referenced alongside a broader range of newly introduced senior notes, such as the 4.000% Senior Notes due 2047 and Floating Rate Notes due 2026. This indicates that while the 4.600% Senior Notes due 2045 remained a part of PepsiCo's long-term debt strategy, the company expanded its debt portfolio with additional instruments, suggesting a more diversified approach to long-term financing in 2024.",
      "llm_answer": "In the 2023 Form 10‑K, PepsiCo’s Board authorizations listed a **4.600 % senior note due 2045** among a large batch of new senior‑note issuances 【page_129†L4-L7】. The 2024 Form 10‑K still includes the same **4.600 % senior note due 2045** in its consolidated list of outstanding senior notes 【page_130†L4-L7】.  \n\nThe fact that the 4.600 % 2045 issue appears in both years—first as a newly authorized security and then as an ongoing component of the capital‑structure—shows PepsiCo is maintaining a long‑dated, fixed‑rate tranche of debt. This reflects a strategy of diversifying maturities and locking in relatively low‑cost financing for the long term, rather than relying solely on short‑term borrowing.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the 4.600% Senior Notes due 2045 in both 2023 and 2024, accurately reflecting their presence in the Board authorizations (2023) and as an ongoing part of the debt structure (2024). All numeric values—interest rate (4.600%), maturity year (2045)—are correct and match the ground truth. 2) Quantitative accuracy is perfect: percentages and years are correctly reported, and no calculations are required. 3) The reasoning correctly infers that maintaining this note indicates a strategy of long-term, fixed-rate financing. However, the LLM omits a key element from the ground truth: the introduction of *new* senior notes in 2024 (e.g., 4.000% due 2047, Floating Rate Notes due 2026), which signals a broader diversification of the debt portfolio. While the LLM mentions maturity diversification, it does not explicitly recognize the expansion and broadening of the debt instruments as highlighted in the original answer. 4) The answer is contextually relevant and well-supported with document citations. The omission of the new 2024 notes slightly reduces completeness and qualitative accuracy, but core facts and interpretation remain sound. Hence, a score of 8 is justified—strong performance with minor but notable gap in synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 354,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved between 2022 and 2024, and what does this indicate about its strategic focus in the region?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas in the Asia Pacific/Middle East region. By 2024, this figure had decreased slightly to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region over the two-year period. The decline, although modest, suggests a potential shift in strategic focus, possibly due to market dynamics or operational adjustments in the region.",
      "llm_answer": "In the 2024 Form 10‑K the company reports that proved natural‑gas reserves in its Asia Pacific/Middle East region fell from 326 billion cubic feet (BCF) at the end of 2022 to 296 BCF at the end of 2024 (a drop of about 30 BCF, or ≈ 9 %).  The decline follows modest revisions and the absence of new purchases after the 2022 acquisition of additional affiliate interest, with only limited extensions/discoveries (mainly in the Middle East and Australia) reported for 2023‑24.  This trend indicates that ConocoPhillips is maintaining a modest, asset‑optimisation‑focused presence in the region rather than pursuing aggressive growth, concentrating on selective equity‑affiliate projects and cost‑discipline.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the natural gas reserves for COP in the Asia Pacific/Middle East region as 326 billion cubic feet (BCF) in 2022 and 296 BCF in 2024, matching the ground truth exactly. The calculated drop of 30 BCF (≈9%) is accurate and properly derived from the difference (326 - 296 = 30), with correct percentage approximation (30/326 ≈ 9.2%). (2) All numeric values, years, and units are correct and consistent with the original answer. No calculation errors. (3) The multi-hop reasoning is sound: the LLM synthesizes data across two years and infers strategic implications beyond the raw numbers, referencing the 2022 acquisition, limited discoveries in 2023–2024, and absence of new purchases. While the original answer only notes a 'potential shift in strategic focus,' the LLM provides a more detailed and plausible interpretation—'asset-optimisation-focused presence' and 'cost-discipline'—that aligns with and expands upon the ground truth without contradicting it. (4) The answer is fully contextually relevant, addressing both the evolution of reserves and the strategic implications. The only reason for not scoring a 10 in correctness and qualitative accuracy is that the original answer does not mention 'affiliates' or 'cost-discipline'—these are reasonable inferences but not explicitly supported in the ground truth, making them slightly beyond the provided data. However, they do not introduce factual errors, so the answer remains highly accurate and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 418,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Google Play's role in Google's non-advertising revenue strategy evolved from 2022 to 2023, based on the specific revenue sources mentioned in the filings?",
      "original_answer": "In 2022, Google Play was specifically mentioned as generating revenues from 'sales of apps and in-app purchases and digital content sold in the Google Play store.' By 2023, Google Play's revenue focus had evolved to be more narrowly described as primarily coming from 'apps and in-app purchases,' and it was grouped under the broader category of 'platforms' within non-advertising revenue sources. This indicates a shift in emphasis toward core app-based monetization within Google's strategic narrative around Play.",
      "llm_answer": "In the 2022 Form 10‑K, Google Play was presented as one of the three “long‑term investments” meant to grow revenue beyond advertising, with its own line‑item that “generates revenues from sales of apps and in‑app purchases and digital content sold in the Google Play store.” By the 2023 filing, Google Play had been folded into a broader “platforms” category under Google Services’ push to expand “products and services beyond advertising,” still described as earning money “primarily … from the sales of apps and in‑app purchases.” Thus, Google Play moved from being listed as a separate non‑advertising revenue pillar in 2022 to being integrated into a wider platform‑based, non‑advertising revenue strategy in 2023, while its core revenue source—app and in‑app purchase sales—remained the same.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Google Play was explicitly mentioned in 2022 with revenue from 'sales of apps and in-app purchases and digital content,' and in 2023 it was grouped under the broader 'platforms' category with revenue described as 'primarily from apps and in-app purchases.' The core revenue source remained consistent, but the strategic framing shifted. (2) There are no numeric values to verify, so quantitative accuracy is not applicable beyond correct use of years (2022, 2023), which are accurate. (3) The multi-hop reasoning is sound—correctly synthesizing changes in categorization and narrative emphasis across two years’ filings. The LLM correctly infers that Google Play went from a standalone 'long-term investment' to being part of a broader platform strategy, which reflects the evolution in Google's reporting. (4) The only minor shortcoming is that the LLM adds the phrase 'long-term investments' and 'three' such investments, which is contextually plausible but not present in the original answer; this slight extrapolation prevents a perfect 10 on qualitative accuracy. However, it does not distort the meaning. Overall, the answer is semantically equivalent, factually correct, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 368,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has the projected utilization of the Cessna SkyCourier 408 evolved from 2022 to 2024, and what does this indicate about FedEx's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FedEx projected the Cessna SkyCourier 408 to have a total of 49 aircraft in operation across the years 2023 to thereafter. By 2024, this projection was reduced to a total of 31 aircraft for the years 2025 through 2029. However, in the 2024 report, the relationship to the Cessna SkyCourier 408 shifted from 'Increases' to 'Depends_On', indicating a change in strategic importance. This suggests a moderated but still significant reliance on the aircraft model over time.",
      "llm_answer": "- In the 2022 Form 10‑K FedEx said it expected to take delivery of **11 SkyCourier 408s in 2023 and 12 in 2024**, for a **total of 49 aircraft scheduled through 2027**【page_114】.  \n- The 2024 Form 10‑K shows a revised plan that now calls for **17 SkyCourier 408s in 2025 and 14 in 2026**, a **total of 31 aircraft for those years**【page_117】.  \n\nThe later filing reflects a higher‑than‑original delivery schedule, indicating that FedEx is expanding its reliance on the SkyCourier 408 as a core part of its regional‑capacity strategy.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the total projected number of Cessna SkyCourier 408 aircraft decreased from 49 (2023 onward) in the 2022 report to 31 (2025–2029) in the 2024 report. However, the LLM incorrectly states that the 2024 plan includes '17 in 2025 and 14 in 2026, a total of 31 aircraft for those years,' implying only two years of deliveries, whereas the ground truth refers to a total of 31 aircraft over 2025–2029. This misrepresents both the timeline and the delivery schedule. Additionally, the LLM claims the 'later filing reflects a higher-than-original delivery schedule,' which contradicts the ground truth showing a reduction from 49 to 31 total aircraft, indicating a decreased, not increased, reliance. (2) Quantitative accuracy is partially correct: the 2022 projection of 49 aircraft is accurate, and the 2024 total of 31 is also correct. However, the breakdown of 17 in 2025 and 14 in 2026 is not supported by the ground truth, which does not specify annual delivery numbers—only the total over five years. The LLM fabricates granular data not present in the source. (3) The multi-hop reasoning is flawed. The model fails to recognize the strategic shift indicated by the change in relationship from 'Increases' to 'Depends_On' in the 2024 report, which signals a nuanced reduction in strategic certainty. Instead, it draws an incorrect conclusion about expanding reliance, directly contradicting the ground truth. (4) Contextual relevance is moderate—the answer addresses the evolution of utilization and strategic reliance, but due to factual and interpretive errors, the conclusion is misleading. The model synthesizes information across years but does so incorrectly, leading to a substantively wrong assessment of FedEx's strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 497,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of segmentation and the types of casualty lines analyzed?",
      "original_answer": "In 2022, AIG used expected loss ratio methods primarily for the three latest accident years in the U.S. Excess Casualty line, segmenting analysis by attachment point and further differentiating between automobile and non-automobile claims, including special treatment for latent exposures like construction defects and mass torts. In 2023, AIG continued to apply expected loss ratio methods but shifted focus to U.S. Workers' Compensation, where the company grouped business by risk-sharing features such as high deductibles and retrospective rating, and analyzed separately by state, industry, and claim handling entity. The increase in large deductible business also affected the reporting pattern of claims, indicating a broader application context for the method. This reflects a strategic evolution in where and how expected loss ratio methods are applied across different casualty lines.",
      "llm_answer": "In the 2022 filing AIG said that for its excess‑casualty business it **splits the expected‑loss‑ratio analysis** into • automobile‑related claims and • non‑automobile claims, and then **further breaks out the non‑automobile side** into latent exposures such as construction‑defect and mass‑tort claims.  It also applies the method separately by attachment‑point bands and uses a $10 million loss‑cap to first estimate the lower‑layer losses with traditional development and then project the higher‑layer losses.\n\nIn the 2023 filing the discussion of the expected‑loss‑ratio method is **much less granular** – it is described only as “multiplying premiums by an expected loss ratio” and is applied to the three most recent accident years for each product line, with adjustments for rate changes, inflation and market conditions.  The detailed segmentation by automobile vs. non‑automobile, latent exposures and attachment‑point bands that was highlighted in 2022 is no longer emphasized in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct details but fundamentally misrepresents the evolution of AIG's use of expected loss ratio methods between 2022 and 2023. (1) Correct elements: The 2022 description accurately reflects segmentation by automobile vs. non-automobile claims, latent exposures (construction defects, mass torts), and attachment point bands. The mention of a $10 million loss-cap and layered loss estimation is consistent with the method’s application, though this specific detail was not in the ground truth and cannot be verified—however, it does not contradict it outright. (2) Quantitative accuracy is mostly sound: no incorrect numbers are stated, and the reference to 'three most recent accident years' in 2023 aligns with the ground truth. However, the LLM incorrectly claims that in 2023 the method is applied broadly to 'each product line,' which contradicts the ground truth stating a shift specifically to U.S. Workers' Compensation. (3) The core failure is in reasoning and qualitative accuracy: the LLM asserts that the 2023 approach is 'much less granular' and lacks segmentation, when in fact the granularity has shifted—not diminished—to different dimensions (risk-sharing features, state, industry, claim handling entity) within Workers' Compensation. This mischaracterizes the evolution as a reduction in sophistication rather than a strategic reallocation and re-segmentation. (4) Contextual relevance is moderate: the answer addresses the question’s focus on segmentation and casualty lines, but incorrectly concludes that detailed segmentation was dropped, missing the key point that AIG changed the *basis* of segmentation and the *casualty line* to which the method was primarily applied. Thus, while some facts are correct, the overall synthesis is flawed, leading to a misleading conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1475,
        "completion_tokens": 493,
        "total_tokens": 1968
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the classification and reporting of unallocated products evolve between fiscal years 2022 and 2024, particularly in terms of how they are categorized within Nike's consumer construct?",
      "original_answer": "In fiscal year 2022, unisex products were classified within Men's, and certain products not allocated to Men's, Women's, NIKE Kids', and Jordan Brand were included in 'Others' with adjustments not allocated by consumer. By fiscal year 2024, 'Others' continued to include products not allocated to Men's, Women's, Kids', and Jordan Brand, but there was no specific mention of unisex product classification within Men's, suggesting a potential shift or integration of unisex products within broader categories.",
      "llm_answer": "In fiscal 2022 Nike’s “Consumer Direct Acceleration” re‑organized the business around the consumer construct of Men’s, Women’s, Kids’ and Jordan Brand, and any product that could not be placed in one of those groups was reported as **“Others”** – a line that captures products not allocated to the three core consumer segments or Jordan (footnote 5). The 2024 filing shows the same treatment: “Others” still appears as a separate line in the wholesale‑equivalent revenue table and is defined as products not allocated to Men’s, Women’s, Kids’ or Jordan Brand (footnote 4). Thus, between FY 2022 and FY 2024 the classification of unallocated products did not change; they remain reported outside the core consumer construct under the “Others” category.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the consistent use of the 'Others' category in both fiscal years 2022 and 2024 to capture products not allocated to Men's, Women's, Kids', and Jordan Brand, which aligns with the ground truth. It accurately references the consumer construct and correctly notes that unallocated products are reported under 'Others' in both years, satisfying contextual and entity accuracy. However, the LLM misses a key nuance highlighted in the original answer: the specific classification of unisex products within Men's in FY2022 and the absence of that detail in FY2024, which suggests a potential shift in how unisex products are categorized. The LLM concludes that there was no change in classification between the years, but this overlooks the subtle but important evolution in reporting language around unisex products. While the core structure of 'Others' remained stable, the handling of unisex products — a key part of the question about classification evolution — is underexplored. This omission affects the qualitative accuracy and overall correctness, as the question specifically asks about the evolution in categorization within the consumer construct, not just the stability of the 'Others' bucket. Quantitative accuracy is perfect as no numerical errors are present, and contextual relevance is high since the response stays focused on the reporting structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 385,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did PepsiCo's engagement with the 3.500% Senior Notes due 2025 evolve between 2023 and 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2023, PepsiCo's 3.500% Senior Notes due 2025 were listed among other notes, indicating they were part of the company's existing debt structure. By 2024, the 3.500% Senior Notes due 2025 were still present, but they were now accompanied by a broader range of new notes, including longer-term instruments such as the 3.500% Senior Notes due 2040 and the 3.550% Senior Notes due 2034. This suggests that PepsiCo expanded its debt portfolio in 2024, introducing more long-term financing options while maintaining its commitment to the 3.500% Senior Notes due 2025. The addition of new notes indicates a strategic shift toward diversifying its debt maturity structure.",
      "llm_answer": "In the 2023 Form 10‑K, PepsiCo’s board approved “the terms of the 3.500 % Senior Notes due 2025” (see page 130). The 2024 Form 10‑K repeats that same authorization, again listing the “3.500 % Senior Notes due 2025” among the new senior‑note programs the board approved (see page 129).  \n\nThis continuity shows that PepsiCo is maintaining the same medium‑term, fixed‑rate issuance across both years, using the 3.500 % 2025 notes as a recurring component of its debt portfolio rather than abandoning or dramatically altering the program—an indication of a steady, strategic approach to managing and refinancing its long‑term debt.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in terms of the notes mentioned (3.500% Senior Notes due 2025) and correctly identifies their presence in both the 2023 and 2024 Form 10-K filings, with proper reference to board authorization. The percentages and years are correct, satisfying quantitative accuracy. However, the LLM misinterprets the nature of the 2025 notes: in 2024, these were not newly authorized as part of a 'new senior-note program' but were still outstanding existing debt. The ground truth indicates that in 2024, PepsiCo introduced *new* long-term notes (e.g., due 2034, 2040), signaling a strategic diversification of maturities—this key multi-hop insight is missing. Instead, the LLM incorrectly implies that the 2025 notes were reauthorized or reissued in 2024 as part of a new issuance, which contradicts the original answer. The reasoning is therefore flawed in its interpretation of debt strategy: it emphasizes continuity of the 2025 notes as a 'recurring component,' while the actual strategic shift lies in the addition of longer-term debt alongside the existing 2025 notes. The answer is contextually relevant and addresses the question's focus on debt management, but fails to capture the core strategic evolution—diversification and extension of maturities—making the qualitative analysis incomplete and partially incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 374,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did COP's financial disclosures regarding the Lower 48 region evolve between 2022 and 2024, particularly in terms of capital expenditures and future cash inflow revisions?",
      "original_answer": "In 2022, COP reported capital expenditures for the Lower 48 region at $3,129 million, indicating significant active investment in the area. By 2024, the company disclosed that certain amounts in the Lower 48 had been revised to reflect additional future cash inflows and future production costs, although no new capital expenditure figure was provided. This shift suggests a transition from active investment to a focus on revising financial projections based on updated expectations for production and cost dynamics in the region.",
      "llm_answer": "In the 2022 Form 10‑K ConocoPhillips reported Lower 48 capital spending of roughly **$6.3 billion** (the sum of property acquisitions, exploration and development). By the 2024 filing that figure had risen to **about $30 billion** – a near‑five‑fold increase (the 2024 table shows $10.985 billion in unproved acquisitions, $12.118 billion in proved acquisitions, $0.548 billion in exploration and $6.301 billion in development, totaling $29.952 billion).\n\nAt the same time, the company’s discounted‑future‑cash‑flow model for the Lower 48 was revised downward: the projected **future cash inflows fell from roughly $195 billion in 2022 to $141 billion in 2023**, then were modestly increased to **about $164 billion in 2024**. These revisions are noted in the “Future cash inflows” tables of the 2022, 2023 and 2024 reports.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains severe factual inaccuracies in both capital expenditures and future cash inflows. According to the ground truth, COP reported $3,129 million (i.e., $3.129 billion) in capital expenditures for the Lower 48 in 2022, but the LLM incorrectly states it was $6.3 billion. The 2024 capital expenditure figure is not provided in the original answer, yet the LLM fabricates a total of $29.952 billion—over 9 times higher than the 2022 amount—by summing unrelated acquisition categories that are not disclosed as part of Lower 48 capex in the ground truth. This suggests a fundamental misreading of financial categories. Regarding future cash inflows, the original answer states that revisions occurred in 2024 to reflect additional future cash inflows and production costs, but does not provide specific numbers or indicate a downward revision. The LLM invents precise figures: $195B in 2022, $141B in 2023, and $164B in 2024, which are not present in the ground truth and contradict its qualitative description of 'additional' (i.e., upward) revisions. No multi-hop reasoning is correctly executed—instead, the model hallucinates data across years and metrics. While the answer attempts to address capital expenditures and future cash inflows over time, the complete absence of factual alignment with the ground truth—especially in quantitative terms—renders it highly incorrect. Contextual relevance is low but not zero because the response engages with the right topic areas (capex, cash flow revisions) and geographic region (Lower 48).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 424,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did Comcast's financial commitments and governance arrangements with Atairos Group evolve between 2023 and 2024, particularly regarding capital obligations and control structures?",
      "original_answer": "In 2023, Comcast had a Fourth Amended and Restated Shareholders Agreement with Atairos Group, Inc., which was further amended in June 2023. This agreement outlined Comcast's role as the sole third-party investor and included governance terms among Atairos-related entities. By 2024, the relationship evolved into a more formalized investment framework under the equity method accounting. In this framework, Comcast reduced its capital commitment from up to $5 billion to $4.5 billion, limited annual capital calls to $400 million, and agreed to separately fund $40 million annually for management fees. Additionally, the 2024 filing clarified that Comcast absorbs approximately 99% of Atairos’ losses and receives approximately 86% of residual returns, while Atairos’ management companies (led by Comcast’s former CFO) retained all voting rights. These changes reflect a recalibration of financial exposure and a clearer delineation of control.",
      "llm_answer": "By the 2024 filing Comcast’s exposure to Atairos had been trimmed. The agreement still caps the total amount Comcast may be called to fund at $4.5 billion (with a $400 million annual limit) but the unfunded portion had fallen to **$1.4 billion as of 31 Dec 2024**, down from the larger balance that existed in 2023. At the same time, the governance picture did not change – Atairos is still treated as a variable‑interest entity, Comcast has **no voting rights and only limited consent rights**, and therefore continues to record the investment under the equity‑method rather than consolidating it.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies the $4.5 billion total capital commitment and $400 million annual limit introduced in 2024, aligning with the ground truth. However, it introduces a specific unfunded amount of $1.4 billion as of December 31, 2024, which is not present in the original answer and cannot be verified from the provided ground truth—this is an unsupported addition. Additionally, the claim that 'the governance picture did not change' contradicts the ground truth, which states that there was a recalibration in control structures, including clarified loss absorption (99%) and return allocation (86%), and retention of voting rights by Atairos’ management. The LLM incorrectly asserts Comcast has 'no voting rights and only limited consent rights,' while the ground truth specifies that Comcast has no voting rights (correct) but does not mention 'limited consent rights'—this detail is unverified. (2) Quantitatively, the $4.5 billion and $400 million figures are accurate, but the $1.4 billion unfunded balance is extraneous and unsupported. The original answer does not provide any specific funding drawdowns or balances, so this number likely results from incorrect inference or hallucination. (3) The multi-hop reasoning is partially sound—linking the reduced capital commitment and equity method accounting—but fails in synthesizing the evolution of governance. The LLM incorrectly concludes governance was unchanged, missing the key evolution in economic rights and control delineation described in the original. (4) Scores reflect partial factual accuracy: quantitative elements are mostly correct except for the unsupported $1.4B figure; qualitative reasoning is flawed due to incorrect synthesis on governance changes; contextual relevance is high as the response directly addresses the question’s focus on financial and governance evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 523,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did FedEx's projected utilization of the Cessna SkyCourier 408 change between 2022 and 2023 filings, and what does this indicate about its strategic role in the fleet compared to other aircraft?",
      "original_answer": "In the 2022 filing, FedEx projected a total of 49 Cessna SkyCourier 408 aircraft to be in service through 2027. By the 2023 filing, this projection dropped significantly to only 31 Cessna SkyCourier 408 aircraft through 2029. This indicates a strategic reduction in the planned reliance on the Cessna SkyCourier 408, especially when compared to other aircraft types like the B767F and B777F, which saw more stable or less reduced projections. This shift suggests FedEx may have reassessed the aircraft's role in its long-term fleet strategy.",
      "llm_answer": "In the 2022 Form 10‑K FedEx said it was committed to acquire **49 Cessna SkyCourier 408s** – 11 units in 2023, 12 in 2024, another 12 in 2025 and 14 in 2026 – while the 2023 filing shows a **smaller, more concentrated commitment of 31 SkyCourier 408s**, with 17 slated for delivery in 2025 and 14 in 2026 and no 2024 deliveries. The reduction in total units but concentration of deliveries in the later years signals that FedEx is positioning the SkyCourier primarily as a regional‑feeder aircraft rather than a core long‑haul platform, complementing its larger freighters (B777F, B767F) that remain the backbone of its inter‑continental fleet.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the reduction in projected Cessna SkyCourier 408 aircraft from 49 in the 2022 filing to 31 in the 2023 filing, aligning with the ground truth. The delivery schedule details (11 in 2023, 12 in 2024, 12 in 2025, 14 in 2026) sum to 49, which is accurate. The 2023 filing’s revised plan of 17 in 2025 and 14 in 2026 also correctly totals 31. However, the original answer does not specify delivery years in such detail, so the LLM adds granularity not confirmed in the ground truth—particularly the absence of 2024 deliveries in the revised plan, which is plausible but not verifiable from the provided truth. This introduces a minor risk of overprecision. (2) All numbers are consistent and calculations correct: 11+12+12+14 = 49; 17+14 = 31. No mathematical or date errors. Format variations are acceptable. (3) The multi-hop reasoning is sound: the model synthesizes changes across two filings, compares quantities, and infers strategic implications. It correctly contrasts the SkyCourier’s reduced role with the continued centrality of B777F and B767F aircraft, matching the ground truth’s interpretation. (4) The answer is semantically equivalent and slightly more detailed in delivery timing, but the core facts and strategic interpretation are accurate. The slight deduction in quantitative accuracy is due to unverified specificity in delivery years not present in the ground truth. Overall, the answer is highly accurate, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 416,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Nike's approach to the Air Max product line evolved from 2022 to 2024, particularly in terms of revenue transparency and technological innovation emphasis?",
      "original_answer": "In 2022, Nike included Air Max in a general list of technologies within the revenue disaggregation table, indicating its presence in the product portfolio but without specific revenue figures. By 2024, while no direct revenue numbers were disclosed, Nike emphasized Air Max as a central example of its innovation strategy, highlighting its integration into broader product categories and consumer applications. This shift reflects a strategic move from passive acknowledgment to positioning Air Max as a key innovation driver, despite the continued lack of standalone financial metrics for the product line.",
      "llm_answer": "By 2022 Nike’s filing only referenced its Air‑Manufacturing Innovation subsidiary in a brief note about “small amounts of various plastic products” and gave no specific discussion of the Air‑Max line (see 2022 Item 1‑Business, p. 4). In the 2024 filing the company spells out that Air‑Max shoes rely on Nike Air‑Sole cushioning – “polyurethane films used to make Nike Air‑Sole cushioning components” – and that Air Manufacturing Innovation supplies those components (2024 Item 1‑Business, p. 7). The same 2024 filing also lists Air Max alongside other marquee technologies (Air, Zoom, Free, React, etc.) as a core example of its innovation focus (2024 Item 1‑Business, p. 6). Together, these changes show Nike moving from a vague mention of the Air‑Max‑related subsidiary to a clearer disclosure of the Air‑Max supply chain and a stronger, explicit emphasis on Air‑Max as a flagship technology.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent in its description of the 2022 and 2024 filings, with no incorrect numbers or dates (quantitative accuracy is perfect as no numeric values were required). It correctly identifies the shift in disclosure emphasis from 2022 to 2024 and references specific sections of the filings. However, it misrepresents the nature of Nike's 2022 disclosure: the original answer states that Air Max was included in a general list of technologies within the revenue disaggregation table, indicating portfolio presence, while the LLM claims Air Max was not discussed and only a subsidiary (Air-Manufacturing Innovation) was mentioned in relation to plastic products. This is a significant factual divergence. The LLM focuses on supply chain details (e.g., polyurethane films) and subsidiary roles not emphasized in the ground truth, which instead highlights the strategic repositioning of Air Max from a listed technology to an innovation flagship. While the LLM captures a shift in disclosure, it misattributes the 2022 baseline and introduces supply-chain specifics not in the original answer, missing the core point about revenue transparency (i.e., lack of standalone figures despite increased emphasis). The reasoning is partially sound but based on potentially incorrect entity mapping (confusing Air Max with its manufacturing subsidiary). The answer is contextually relevant and addresses both revenue transparency and innovation emphasis, but with inaccurate grounding in the 2022 data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 415,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Comcast's capital expenditure strategy regarding Epic Universe evolve from 2023 to 2024, particularly in terms of specific investment amounts and thematic park development priorities?",
      "original_answer": "In 2023, Comcast specifically noted an increase in capital expenditures directly related to the development of Epic Universe in Orlando, with a total of $8.2 billion allocated to Connectivity & Platforms, which included investments in scalable infrastructure and line extensions. By 2024, the company continued to emphasize investment in existing and new attractions at Universal theme parks, including Epic Universe, as part of its broader capital expenditure plan for 2025. While specific figures for Epic Universe alone were not disclosed in 2024, the company indicated an ongoing commitment to theme park development, particularly in expanding attractions and enhancing capacity. The evolution shows a shift from initial infrastructure and development focus in 2023 to a more sustained investment strategy in 2024 that includes both infrastructure and guest experience enhancements.",
      "llm_answer": "In 2023 Comcast’s park‑related capital spending was modest – the 10‑K notes that the only park‑related outlay was the **purchase of land for possible future expansion** and that Epic Universe was still in the early‑stage planning phase, with no specific construction budget disclosed.  \n\nBy 2024 the company shifted the focus of its park‑capex to **building Epic Universe**, stating that “spending on theme‑park attractions increased in 2024 and included costs associated with the construction of Epic Universe.” The 2024 filing therefore shows a move from land‑acquisition spending in 2023 to **direct construction investment in Epic Universe in 2024**, reflecting a higher priority on delivering the new Orlando attraction rather than merely securing future expansion sites.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 Comcast allocated $8.2 billion to Connectivity & Platforms, which included investments in Epic Universe infrastructure, contradicting the LLM's claim that only land was purchased and no construction budget was disclosed. The ground truth confirms specific funding was already allocated in 2023, whereas the LLM incorrectly characterizes 2023 spending as limited to land acquisition. In 2024, the LLM correctly notes increased spending on Epic Universe construction, but the ground truth does not support a shift from 'no budget' in 2023 to construction in 2024 — infrastructure investment was already underway. (2) Quantitatively, the LLM fails to mention the $8.2 billion capital allocation in 2023, a key figure in the original answer, and provides no specific investment amounts for either year, despite the ground truth providing a clear 2023 figure. This omission and misrepresentation result in poor quantitative accuracy. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers that lack of a standalone Epic Universe budget implies no investment, when the ground truth shows it was included within a larger category. It also mischaracterizes the evolution as a shift from land acquisition to construction, whereas the actual evolution is from infrastructure development (2023) to sustained investment including guest experience (2024). (4) Contextually, the LLM addresses the question’s focus on strategy evolution and thematic park priorities, so relevance is moderate. However, due to major factual and quantitative errors, the correctness score is low despite some alignment in narrative structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 471,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did FedEx's utilization of the ATR 72-600F aircraft evolve between 2022 and 2023 as reflected in their fleet projections for the same planning periods?",
      "original_answer": "In 2022, FedEx projected operating 11 ATR 72-600F aircraft in 2023, 6 in 2024, 6 in 2025, and only 1 in 2026. By 2023, the projections for the same time periods changed significantly, with 7 ATR 72-600F aircraft planned for 2025 and only 3 for 2026. This indicates a notable reduction in planned usage of the ATR 72-600F by FedEx over time.",
      "llm_answer": "In the 2022 Form 10‑K FedEx reported that it already operated **six ATR 72‑600F freighters** and, in its purchase‑commitment schedule, had **11 additional ATR 72‑600F aircraft slated for delivery in 2023**.  \n\nThe 2023 Form 10‑K shows a revised delivery schedule that pushes new ATR 72‑600F acquisitions out to later years – **seven are scheduled for 2025 and three for 2026**, with no deliveries projected for 2023.  \n\nThus, FedEx’s short‑term utilization plan shifted from adding a dozen ATR 72‑600F aircraft in 2023 to postponing new deliveries until 2025‑2026, indicating a slowdown in near‑term fleet expansion for that type.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core shift in FedEx's ATR 72-600F delivery schedule between 2022 and 2023 projections, correctly identifying the deferral of deliveries from 2023 to 2025–2026. However, there are key quantitative inaccuracies: the original answer states that in 2022, FedEx projected operating 11 ATRs in 2023 (not 11 new deliveries), 6 in 2024, 6 in 2025, and 1 in 2026. The LLM misinterprets this as 11 aircraft 'slated for delivery in 2023' and claims six were already operated in 2022, which is not in the ground truth. The 2023 revision shows 7 planned for 2025 and 3 for 2026 — the LLM correctly reports these numbers but frames them as 'deliveries' rather than 'planned operations', conflating procurement with utilization. The ground truth focuses on projected fleet utilization (number operated), not delivery timing. While the LLM infers a slowdown in expansion (a reasonable interpretation), it fails to report the declining long-term utilization (from 11 in 2023 to only 1 in 2026 in the original plan, revised to 7 in 2025 and 3 in 2026), missing the full trajectory. The reasoning is partially sound and contextually relevant, but the quantitative inaccuracies in interpreting the numbers and timeframes reduce factual precision. Semantic equivalence is partially achieved, but not fully due to the conflation of deliveries with operational fleet size.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 380,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did Nike's approach to estimating product return reserves evolve between fiscal 2022 and fiscal 2024, and what does this indicate about changes in their revenue recognition methodology?",
      "original_answer": "In fiscal 2022, Nike disclosed that the estimated cost of inventory for expected product returns was $269 million, and these reserves were recorded in Prepaid expenses and other current assets. By fiscal 2024, while the specific dollar amount of the product return reserve was not disclosed, Nike described a more formalized estimation process, stating that it calculates anticipated reductions in revenue—such as sales returns—by determining the 'most likely amount' it will be entitled to receive. This indicates a shift toward a more probabilistic and forward-looking revenue estimation methodology, aligning with the broader revenue recognition framework where variable consideration is estimated at the time revenues are recognized.",
      "llm_answer": "In the 2022 Form 10‑K Nike disclosed a single “sales‑related reserve” of $1.015 billion (with $194 million of that representing the estimated inventory cost of expected product returns) that was recorded in accrued liabilities and prepaid‑expense accounts at year‑end. By the 2024 filing the company describes the reserve as being set through a continuous, granular estimate that combines (1) historical return rates, (2) specific identification of returns already in transit, and (3) discretionary returns, discounts and claims that are expected but not yet finalized, with the reserve recorded as a reduction of revenue at the point of sale and the associated inventory cost captured in prepaid expenses. This shift shows Nike moving from a static year‑end reserve figure to a more detailed, real‑time estimation embedded in its revenue‑recognition process, tightening the link between the estimated return liability and the timing of revenue recognition.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key quantitative details. The ground truth states that in fiscal 2022, the estimated cost of inventory for expected product returns was $269 million, but the LLM claims it was $194 million as part of a larger $1.015 billion 'sales-related reserve.' This figure does not appear in the ground truth and contradicts the disclosed $269 million. Additionally, the LLM incorrectly states that the reserve was recorded in 'accrued liabilities and prepaid-expense accounts,' while the ground truth specifies it was recorded in 'Prepaid expenses and other current assets'—a material misrepresentation of balance sheet classification. (2) The 2024 description in the LLM answer introduces granular elements like 'historical return rates,' 'returns in transit,' and 'discretionary returns' not present in the ground truth, which instead emphasizes a shift to estimating variable consideration using the 'most likely amount' method. While this general direction aligns with a more sophisticated estimation process, the specific mechanisms cited by the LLM are unsupported by the provided truth. (3) The multi-hop reasoning is partially sound—the LLM correctly infers a shift toward integrating return estimation into revenue recognition at point of sale, which parallels the ground truth’s conclusion about aligning with variable consideration under revenue recognition standards. However, the reasoning is built on incorrect foundational data. (4) Despite these issues, the LLM captures the broader qualitative trend: a move from a static reserve figure to a more dynamic, forward-looking estimation embedded in revenue recognition, which is contextually relevant and conceptually aligned with the implications in the original answer. Hence, moderate scores for qualitative accuracy and contextual relevance, but low quantitative accuracy due to incorrect dollar amounts and account classifications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 529,
        "total_tokens": 1963
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the planned fleet composition of the Cessna SkyCourier 408 change between 2022 and 2023 for the years 2025 and beyond, and what does this indicate about the company's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FDX projected a total of 12 Cessna SkyCourier 408 aircraft to be in operation by 2025 and planned to maintain that number through 2026. By 2023, the company increased its planned fleet count for 2025 to 17 but reduced it to 14 for 2026. This indicates a short-term increase in strategic reliance on the Cessna SkyCourier 408, followed by a moderate decline in planned usage by 2026, suggesting a recalibration of fleet strategy.",
      "llm_answer": "In the 2022 filing FedEx had 12 Cessna SkyCourier 408s scheduled for delivery in 2025 and no SkyCouriers planned for any later year. The 2023 filing raised the 2025 commitment to 17 aircraft, while the “Thereafter” line still shows zero deliveries. This increase signals that FedEx is deepening its near‑term reliance on the SkyCourier for its future fleet, but it does not intend to make the model a long‑term, ongoing addition beyond the 2025 horizon.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the increase from 12 to 17 Cessna SkyCourier 408 aircraft planned for 2025 between the 2022 and 2023 filings, which matches the ground truth. However, it incorrectly states that there are zero deliveries planned 'beyond 2025' or in the 'Thereafter' period, while the ground truth specifies that the 2023 plan includes 14 aircraft for 2026. This omission is a significant factual error affecting completeness and accuracy. (2) Quantitatively, the 12 (2025, 2022 plan) and 17 (2025, 2023 plan) figures are correct. The error lies in the handling of the 2026 number: the LLM claims zero deliveries thereafter, but the correct figure is 14 for 2026. This misrepresents the long-term plan. (3) The reasoning correctly infers increased near-term reliance on the SkyCourier, which is valid. However, the conclusion that FedEx does not intend to make the model a long-term addition is contradicted by the ground truth, which shows a reduction to 14 in 2026—not elimination. This reflects flawed multi-hop synthesis, as the model failed to incorporate the 2026 figure from the 2023 filing. (4) The contextual relevance is high, as the answer addresses fleet changes and strategic implications. Scores reflect mostly correct numbers and reasoning, but a key omission in the post-2025 plan reduces correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 380,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Mastercard's real-time account-based payments infrastructure evolved from 2023 to 2024, particularly in terms of operational scale and integrated security capabilities?",
      "original_answer": "In 2023, Mastercard operated or was implementing real-time payments infrastructure in 13 markets globally, offering instant payments with enhanced data and messaging capabilities. The company emphasized a distributed network architecture that enabled intelligent routing and applied value-added services like fraud scoring and tokenization in real time. By 2024, Mastercard expanded its capabilities by enhancing its ACH and real-time account-based payment systems to provide more secure, simple, and smart payment solutions across its global network. The company also reinforced its multi-layered security approach, integrating additional protections and partnerships to safeguard the payments ecosystem. These developments indicate a strategic shift toward strengthening both the scale and security of its real-time payments infrastructure.",
      "llm_answer": "In 2023 Mastercard reported that its real‑time, account‑based payments platform was either live or being rolled out in **13 markets** and was already backed by a “multi‑layered” security architecture that includes real‑time fraud scoring, tokenization and a dedicated cyber‑risk program【page_11】. By the 2024 filing the company describes the same real‑time ACH capability as a core part of its global payments suite and emphasizes that the platform now operates **across a broader, worldwide footprint** while continuing to be protected by the same integrated, multi‑layered security model that safeguards the network in real time【page_72】. Thus, from 2023 to 2024 Mastercard expanded the operational scale of its real‑time account‑based payments from a dozen markets to a truly global deployment, and it reinforced that growth with an embedded, multi‑layered security framework.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the key number — 13 markets in 2023 — is correctly reported. The LLM accurately reflects that in 2024, Mastercard expanded its real-time ACH and account-based payments infrastructure, describing it as operating across a 'broader, worldwide footprint,' which semantically matches the original answer's claim of expanded capabilities and global reach. While the exact number of markets in 2024 is not specified in either answer, the LLM appropriately infers scale expansion without fabricating numbers. (2) The security capabilities — multi-layered architecture, real-time fraud scoring, tokenization — are correctly identified and consistent across both years, matching the original answer's emphasis on reinforced security through integrated protections. (3) The reasoning is sound: the LLM synthesizes information across 2023 and 2024 timeframes, correctly identifying evolution in scale (from 13 markets to broader global deployment) and continuity with enhancement in security. (4) Minor deduction in qualitative accuracy due to slightly stronger phrasing — 'truly global deployment' — which is a small interpretive leap beyond the original answer's more cautious 'expanded capabilities' and 'reinforced security.' However, this does not constitute a factual error but rather a slight overstatement in scope. Overall, the answer is factually correct, contextually relevant, and demonstrates strong multi-hop reasoning across time and capabilities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 422,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did Nike's use of foreign exchange forwards and options evolve between 2022 and 2024, particularly in terms of their impact on financial liabilities and hedging strategy?",
      "original_answer": "In 2022, foreign exchange forwards and options had a net gain of $8 million after tax, impacting various income categories such as revenues, cost of sales, and other (income) expense, net. By 2024, the liabilities associated with these instruments increased to $110 million under accrued liabilities and $5 million under deferred income taxes and other liabilities, indicating a shift in how these derivatives were managed or reported. This reflects a strategic evolution in Nike's hedging activities and financial exposure management.",
      "llm_answer": "Nike trimmed the size of its foreign‑exchange cash‑flow‑hedge program, cutting the notional amount of FX forwards and options designated as cash‑flow hedges from roughly **$18.5 billion at May 31 2022** to **about $16.2 billion at May 31 2024**. At the same time the pool of “undesignated” FX forwards and options grew, rising from **≈ $3 billion in 2022** to **≈ $4.4 billion in 2024**. On the balance sheet, the liability associated with these instruments fell to **about $120 million in 2024** (mostly accrued liabilities for designated forwards/options), indicating a shift toward a smaller, more targeted hedging strategy while using a larger amount of non‑designated forwards/options to manage balance‑sheet exposure.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its factual correctness. While it correctly identifies a strategic shift in Nike's use of foreign exchange forwards and options between 2022 and 2024, the specific numbers cited do not align with the ground truth. The original answer states that in 2024, liabilities were $110 million under accrued liabilities and $5 million under deferred income taxes and other liabilities, totaling $115 million—not $120 million as claimed by the LLM. More critically, the LLM introduces figures not present in the ground truth, such as notional amounts of $18.5 billion (2022) and $16.2 billion (2024) for designated hedges and increases in undesignated instruments from $3 billion to $4.4 billion, which are absent from the original data and cannot be verified. These figures suggest a level of detail not supported by the source. Additionally, the original answer highlights a net gain of $8 million after tax in 2022 due to these instruments impacting income categories, which the LLM omits entirely—this is a key aspect of the impact on financial performance. The LLM does correctly infer a strategic evolution toward potentially more non-designated or balance-sheet-focused hedging, which aligns qualitatively with the idea of changing management or reporting. However, the reasoning is based on fabricated quantitative inputs, weakening the validity of the conclusion. The context and direction of the strategy shift are relevant and partially accurate, hence a moderate contextual relevance score, but the lack of factual grounding in numbers and missing financial impact details (e.g., income effects) result in a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 465,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has the product category classification of Puffs within the Baby, Feminine & Family Care segment evolved between 2022 and 2023?",
      "original_answer": "In 2022, Puffs was categorized under the Family Care sub-category, which included Paper Towels, Tissues, and Toilet Paper. By 2023, Puffs remained in the Family Care category, but the specific mention of 'Tissues' replaced 'Tissues' with a more general listing without sub-category breakdowns, indicating a simplification or consolidation of how the segment details were reported.",
      "llm_answer": "- **2022 filing:** Puffs is listed as a major brand in the **Baby, Feminine & Family Care** segment, which is broken out into three sub‑categories – Baby Care, Feminine Care and Family Care (paper‑towel, tissue, toilet‑paper). Puffs is therefore classified under the **Family Care** sub‑category. 【page_19】\n\n- **2023 filing:** The segment’s sub‑categories are trimmed to **Feminine Care** and **Family Care** (the Baby Care sub‑category is removed). Puffs still appears among the major brands and remains placed in the **Family Care** sub‑category. 【page_18】\n\n**Evolution:** Between 2022 and 2023 the overall segment composition changed (Baby Care was dropped), but Puffs’ classification stayed the same – it continues to be a Family Care brand within the Baby, Feminine & Family Care segment.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies that Puffs remained in the Family Care sub-category within the Baby, Feminine & Family Care segment from 2022 to 2023, which aligns with the ground truth. It accurately notes the structural change in the segment — specifically, the removal of the Baby Care sub-category in 2023 — and correctly states that Puffs continues to be classified under Family Care. However, the LLM focuses on the removal of Baby Care as the key reporting change, while the original answer emphasizes a shift in how Family Care itself was described: in 2022, 'Tissues' was explicitly listed as part of Family Care (alongside paper towels and toilet paper), but in 2023, the sub-category details were simplified or consolidated, with 'Tissues' no longer specifically mentioned. This nuance — about the internal description of Family Care and the reporting-level simplification — is missing in the LLM response. While the core facts and entity classifications are correct (hence high scores for quantitative accuracy and contextual relevance), the qualitative reasoning is slightly incomplete in capturing the precise nature of the categorization evolution within Family Care. The answer is factually sound and addresses the main thrust of the question, but lacks the detailed insight about sub-category granularity reduction in Family Care itself.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 376,
        "total_tokens": 1665
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the positioning of Tampax within P&G's product portfolio evolved between 2022 and 2023, particularly in terms of its categorization and associated product lines?",
      "original_answer": "In 2022, Tampax was categorized under 'Feminine Care' within the 'Baby, Feminine & Family Care' segment, which also included 'Baby Care' and 'Family Care' sub-categories. By 2023, the product category was refined, and Tampax was associated solely with 'Menstrual Care' under the same broader segment. This reflects a more focused positioning of Tampax, separating it from general 'Family Care' items and aligning it more specifically with menstrual health needs.",
      "llm_answer": "In the 2022 filing, Tampax was listed under the **Baby, Feminine & Family Care** segment as part of the broader **Feminine‑Care** sub‑category (which was grouped together with adult‑incontinence products and a separate Baby‑Care sub‑category). By the 2023 filing, Tampax remains in the same segment, but the segment’s description was refined to **Feminine Care (Adult Incontinence & Menstrual Care)**, explicitly tying Tampax to the menstrual‑care product line and dropping the explicit Baby‑Care grouping. Thus, Tampax’s positioning shifted from a general feminine‑care label within a mixed baby‑and‑family segment to a more specific menstrual‑care focus within the feminine‑care category.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and closely aligns with the ground truth. (1) It correctly identifies that in 2022, Tampax was under the 'Baby, Feminine & Family Care' segment within the 'Feminine-Care' sub-category, and that by 2023, the categorization shifted to a more specific 'Menstrual Care' focus. The broader segment name remains consistent. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022 and 2023) are correct. (3) The multi-hop reasoning is sound: the model synthesizes changes in categorization across two years and interprets the strategic repositioning of Tampax from a general 'Feminine Care' label to a more targeted 'Menstrual Care' focus. The mention of adult incontinence products is consistent with P&G's portfolio structure, even if not in the original answer, and does not contradict it. (4) The only minor deviation is that the LLM answer frames the 2023 category as 'Feminine Care (Adult Incontinence & Menstrual Care)', which adds specificity not in the original, but this is plausible and not factually incorrect. The core evolution—refined positioning around menstrual care—is accurately captured. Thus, the answer is semantically equivalent with high completeness and correct entity and temporal alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 371,
        "total_tokens": 1665
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Oracle's strategy and positioning of Oracle Engineered Systems evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue contribution and research investment expectations?",
      "original_answer": "In fiscal 2022, Oracle highlighted that its hardware business, which includes Oracle Engineered Systems, involved point-of-sale revenue recognition for hardware and related software, with the majority of products sold through indirect channels. By fiscal 2023, Oracle introduced a more forward-looking strategy, explicitly stating plans to continue investing in research and development to improve existing hardware products and develop new offerings. Additionally, in fiscal 2023, Oracle noted that hardware represented 6% of total revenues, a figure not specified in 2022, indicating a clearer emphasis on the segment's strategic positioning.",
      "llm_answer": "In fiscal 2023 Oracle positioned its engineered‑systems products as part of a “hardware” segment that contributed roughly 6 % of total company revenue (the same 6 % share reported for fiscal 2024) 【page_43】, whereas in fiscal 2022 the hardware segment – which includes Oracle Engineered Systems – generated $3.2 billion of revenue, also representing about 6 % of total revenues 【page_51】.  At the same time, Oracle’s 2023 filing says the company will continue to invest in research and development to improve its hardware (including engineered systems) and cloud offerings, building on FY 2022 R&D spending of $5.6 billion (about 5 % of total revenue) 【page_53】 and the expectation that future growth will “enable us to continue to make investments in research and development” 【page_42】.  Thus, the engineered‑systems line remained a modest, stable revenue contributor while Oracle reaffirmed a continued, sizable R&D commitment to advance those products.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in quantitative details not supported by the ground truth. The ground truth does not specify that hardware revenue was $3.2 billion in fiscal 2022 or that it represented 6% of total revenue in that year; it only states that in fiscal 2023, hardware represented 6% of total revenue. The LLM incorrectly asserts this percentage and dollar figure for 2022, which is not in the original answer. Additionally, the mention of fiscal 2024 (which is outside the scope of the question) and the claim that it also had a 6% share introduces data not present in the ground truth. The R&D spending of $5.6 billion and 5% of revenue in FY2022 is not mentioned in the ground truth, making this a fabrication or misattribution. (2) These numerical inaccuracies significantly affect quantitative accuracy. While the 6% figure for fiscal 2023 is correct, retroactively applying it to 2022 without evidence and adding unsupported dollar amounts and R&D figures undermines factual reliability. (3) On qualitative reasoning, the LLM correctly identifies the evolution in Oracle’s strategy—highlighting continued R&D investment in fiscal 2023 and positioning engineered systems within the hardware segment. It captures the essence of strategic continuity and R&D focus, showing sound multi-hop reasoning by connecting hardware positioning and R&D intent across years, even if with incorrect supporting numbers. (4) Contextually, the answer is highly relevant, addressing both revenue contribution and R&D investment expectations as asked. However, due to the inclusion of fabricated financial data and misattribution of percentages to years not supported by the ground truth, the correctness score is reduced to 6—partially correct but with significant factual errors that affect the integrity of the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 500,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did Honeywell's investment in private funds for its Non-U.S. pension plans evolve between 2022 and 2023, particularly in terms of allocation and classification across fair value hierarchy levels?",
      "original_answer": "In 2022, Honeywell reported $1,105 million invested in private funds for its U.S. pension plans, with the amount classified under Level 3 of the fair value hierarchy. By 2023, the company reported $115 million in private fund investments for its Non-U.S. pension plans, with $41 million classified under Level 2 and $74 million under Level 3 of the fair value hierarchy. This represents a significant decrease in overall private fund allocation, particularly in U.S. plans, and a shift in classification for the remaining private fund investments under the Non-U.S. plans.",
      "llm_answer": "In 2023 Honeywell’s non‑U.S. pension plans held **$115 million** in private‑fund investments, up from **$90 million** in 2022.  The 2023 mix was **$41 million** classified in Level 2 and **$74 million** in Level 3, whereas in 2022 the same category was **$54 million** in Level 2 and **$36 million** in Level 3.  Thus, the total allocation to private funds grew and a larger share moved into the less‑observable Level 3 tier, while the Level 2 portion declined.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. It claims that Honeywell's non-U.S. pension plan investments in private funds increased from $90 million in 2022 to $115 million in 2023. However, the ground truth states that in 2022, $1,105 million was invested in private funds for U.S. pension plans (not non-U.S.), with the amount classified under Level 3. In 2023, $115 million was reported for Non-U.S. pension plans, split between Level 2 ($41M) and Level 3 ($74M). The LLM incorrectly attributes a $90M figure to 2022 non-U.S. plans, which is not present in the original answer, and fabricates a breakdown of $54M Level 2 and $36M Level 3 for 2022, which is entirely inaccurate. (2) Quantitative accuracy is very low: the LLM invents numbers not present in the ground truth, misrepresents the year and plan type (U.S. vs. non-U.S.), and incorrectly states trends. The only correct numbers are the 2023 figures: $115M total, $41M Level 2, and $74M Level 3. All 2022 figures are wrong. (3) The multi-hop reasoning is flawed. The model fails to correctly identify that the 2022 private fund investment was for U.S. plans, not non-U.S., and thus cannot accurately compare evolution across years. It incorrectly infers growth in non-U.S. allocations when the truth shows a shift from U.S. to non-U.S. and a significant overall decrease. The conclusion that 'allocation grew' and 'larger share moved into Level 3' is based on false premises. (4) Scores are low due to major factual inaccuracies in numbers and entities, though the answer is contextually relevant in discussing the right topic (private fund allocation in pension plans) and referencing fair value hierarchy levels. The 2023 data is correct, preventing a zero score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 476,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the status and management of the 2014 USD Notes evolve between 2023 and 2024, and what specific actions were taken regarding this debt in 2024?",
      "original_answer": "In 2023, the 2014 USD Notes were classified as short-term debt, net of unamortized discount and debt issuance costs, with a maturity date of April 2024. By 2024, the company reported that in April 2024, $1 billion of principal related to the 2014 USD Notes matured and was paid in full. This indicates that the company transitioned the obligation from a near-term liability in 2023 to a fully settled debt instrument in 2024.",
      "llm_answer": "In the 2023 filing the 2014 USD senior notes (3.375 % due April 2024, $1 billion principal) were still outstanding and were presented as short‑term debt on the balance sheet. In 2024 the notes reached maturity, and in April 2024 the company paid the $1 billion principal, retiring the 2014 USD Notes.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the 2014 USD Notes had a $1 billion principal, a 3.375% interest rate, matured in April 2024, and were classified as short-term debt in 2023. The answer correctly states that the notes were paid in full at maturity in April 2024, thus retiring the debt. (2) Quantitative elements—$1 billion principal, April 2024 maturity date—are precisely accurate and match the ground truth. The inclusion of the interest rate (3.375%) is an additional detail not contradicted by the original answer and consistent with typical note disclosures. (3) The multi-hop reasoning is sound: the model correctly infers the evolution of the debt from being a short-term liability in 2023 to being settled in 2024, synthesizing information across years and filings. (4) The answer is contextually complete and directly addresses both parts of the question: the status/management between 2023 and 2024, and the specific action taken in 2024. Minor wording differences (e.g., 'retiring the notes' vs 'paid in full') do not affect factual equivalence. All criteria for a perfect score are met.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1182,
        "completion_tokens": 334,
        "total_tokens": 1517
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has the treatment and documentation of Lowe's Officer Indemnification Agreements evolved between 2022 and 2024, and what does this indicate about the company's executive risk management and governance continuity?",
      "original_answer": "Between 2022 and 2024, Lowe's maintained the same form of Officer Indemnification Agreement, first filed as Exhibit 10.43 on April 2, 2019, and refiled without amendment in both the 2022 and 2024 10-K filings. This indicates that the company did not modify the terms or structure of these agreements over this period, suggesting consistent governance practices and a stable approach to executive risk management and retention. Investors can interpret this continuity as a sign of predictable leadership protections and aligned corporate governance priorities.",
      "llm_answer": "In the 2022 Form 10‑K the exhibit schedule still contains a stand‑alone “Form of Lowe’s Companies, Inc. Officer Indemnification Agreement” (Exhibit 10.23, filed April 2 2019). By the 2024 Form 10‑K that separate exhibit is no longer listed – the indemnification provisions are now folded into the company’s broader governance documents (e.g., the directors’ and officers’ compensation and benefit plans) and are referenced only by incorporation rather than presented as a distinct agreement. This shift shows Lowe’s is consolidating its executive‑risk protections into a unified framework, reinforcing continuity of governance while streamlining the documentation of indemnification for its senior officers.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the Officer Indemnification Agreement was removed from the 2024 10-K and folded into broader governance documents. The ground truth confirms that the same form (Exhibit 10.43, originally filed April 2, 2019) was refiled without amendment in both the 2022 and 2024 10-Ks, meaning it remained a standalone exhibit. The LLM incorrectly claims Exhibit 10.23 (not 10.43) and misstates the exhibit number and filing history. (2) The date of the original filing (April 2, 2019) is correct in both answers, but the LLM misattributes the exhibit number and falsely asserts its removal in 2024—this is a critical factual error. No calculations are involved, but the timeline and document status are wrong. (3) The multi-hop reasoning fails because the LLM incorrectly infers a structural change in governance documentation based on a non-existent removal of an exhibit. The correct synthesis would be that no changes occurred, indicating stability—not consolidation. (4) The correctness score is 1 due to the complete reversal of the factual state (change vs. no change). Quantitative accuracy is 1 because the exhibit number and status are wrong despite the correct date. Qualitative accuracy is 1 due to flawed reasoning and entity misidentification. Contextual relevance is 3 because the answer addresses the topic of indemnification and governance but draws incorrect conclusions from fabricated evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 405,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the market share and category positioning of Always Discreet in the adult incontinence market change between the 2022 and 2023 Procter & Gamble 10-K filings?",
      "original_answer": "In the 2022 filing, Always Discreet was explicitly stated to have over 10% market share in the key adult incontinence markets where Procter & Gamble competes. However, in the 2023 filing, while Always Discreet is still listed as a major brand in the Feminine Care category under the Baby, Feminine & Family Care segment, no specific market share figure is provided for the brand. This suggests a shift in how the brand's performance is communicated, moving away from a quantified market share disclosure to a more general category association.",
      "llm_answer": "In the 2022 Form 10‑K, P&G said it “compete[s] in the adult‑incontinence category … behind **Always Discreet**, with **over 10 %** market share in the key markets in which we compete”【page_19】.  \n\nIn the 2023 Form 10‑K the same language was updated to note that P&G “compete[s] in the adult‑incontinence sub‑category behind **Always Discreet**, with **about 15 %** market share in the markets in which we compete”【page_18】.  \n\nThus, Always Discreet’s share rose from just above 10 % to roughly 15 %, and it remained the leading brand in the adult‑incontinence category.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) QUANTITATIVE INACCURACY: The LLM claims that Always Discreet's market share increased from 'over 10%' in 2022 to 'about 15%' in 2023. However, the ground truth states that while the 2022 filing explicitly reported over 10% market share, the 2023 filing did not provide any specific market share figure. The claim of a 15% share in 2023 is fabricated and not supported by the source. (2) COMPLETENESS: The question asks about changes in both market share and category positioning. The LLM incorrectly asserts a numerical increase in market share and assumes continued leadership, but the original answer indicates only that the brand remains listed as a major brand in the Feminine Care category—no claim about leadership or share growth exists in the 2023 filing. (3) ENTITY & REASONING: The model misrepresents the content of the 2023 10-K, inventing a 'sub-category' and a precise '15%' figure not present in the actual filing. This breaks multi-hop reasoning, as it fails to correctly extract and compare disclosures across years. (4) SEMANTIC EQUIVALENCE: The LLM suggests growth and continued dominance with fabricated data, whereas the ground truth highlights a reduction in disclosure specificity—moving from a quantified to a purely qualitative mention. The answers are semantically contradictory. Minor contextual relevance is retained as the brand and category are correctly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 408,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has Oracle's strategic positioning of Engineered Systems evolved between 2022 and 2023, particularly in terms of their role within the hardware business and implications for Oracle's cloud transformation narrative?",
      "original_answer": "In 2022, Oracle Engineered Systems were described as pre-integrated products central to both cloud and on-premise data center infrastructure, emphasizing their technical advantages such as improved performance, scalability, and simplified maintenance. However, by 2023, Oracle elevated the strategic importance of Engineered Systems by positioning them as part of a broader hardware business that now includes servers, storage, and operating systems, all tightly integrated and accounted for as combined performance obligations. The 2023 filing also highlighted that hardware revenues, including Engineered Systems, represented 6% of total revenues in both fiscal 2023 and 2024, and underscored ongoing R&D investments to enhance these offerings. This evolution suggests that Oracle is leveraging Engineered Systems not just as technical solutions but as foundational components in its hybrid cloud and on-premise strategies, aligning them more closely with its cloud transformation narrative while acknowledging the lower-margin nature of the hardware business.",
      "llm_answer": "In the 2022 filing Oracle described its Engineered Systems as “core to our cloud‑based and on‑premise data‑center infrastructure offerings,” emphasizing that they are pre‑integrated, high‑performance platforms that can be delivered on‑premise, as an OCI service, or as a hybrid cloud solution—making them a strategic pillar of the company’s cloud‑transformation story. By the 2023 filing, Engineered Systems are mentioned only as one product line within the hardware segment (which now accounts for about 6 % of total revenue) and are discussed alongside lower‑margin hardware products and competitive pressure from cloud‑infrastructure offerings, signaling that they have shifted from a headline growth driver to a supporting component that underpins Oracle’s cloud services rather than defining the cloud narrative.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) Quantitatively, the 6% hardware revenue figure is accurately reported and matches the original answer, which states hardware revenues (including Engineered Systems) represented 6% of total revenues in fiscal 2023 and 2024. No other numeric values are present, and all are correct. (2) The entity identification is accurate—Oracle, Engineered Systems, fiscal 2022 and 2023, and the hardware segment are all correctly referenced. (3) The reasoning correctly captures the evolution: in 2022, Engineered Systems were positioned as central to cloud and on-premise infrastructure, and by 2023, they were integrated into a broader hardware segment with lower-margin context. The LLM correctly infers a strategic shift from 'headline growth driver' to 'supporting component,' which is a reasonable interpretation of the ground truth's claim that they are now foundational to hybrid cloud strategies. (4) However, the LLM omits key details from the ground truth: it does not mention the inclusion of servers, storage, and operating systems in the expanded hardware segment, nor does it reference the combined performance obligations accounting treatment or ongoing R&D investments. These omissions reduce completeness and slightly weaken the qualitative accuracy, though the core narrative shift is correctly interpreted. The answer remains contextually relevant and semantically aligned with the main thrust of the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1487,
        "completion_tokens": 411,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the disclosure regarding the 2020 Stock Plan's relationship with the 2011 Stock Plan evolve between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, the 2020 Stock Plan disclosure included the detail that 5,530,106 shares previously available under the 2011 Stock Plan were carried forward and made available for award grants under the 2020 Stock Plan. However, in the 2023 10-K filing, this specific reference to the 2011 Stock Plan and the carry-forward of shares was omitted. This indicates a shift in how the company chose to present the lineage and transition between the two stock plans, focusing only on the 2020 Stock Plan without linking it to its predecessor in the disclosed text.",
      "llm_answer": "Both the 2022 and the 2023 Form 10‑K state that the 2020 Stock Plan “is the successor to the 2011 Stock Plan” and that, when the 2020 Plan was adopted, the 5,530,106 shares that were still available under the 2011 Plan were transferred to the 2020 Plan for future award grants. The wording of the disclosure is essentially unchanged between the two filings.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. (1) Quantitatively, while the number 5,530,106 is correctly stated, the claim that both the 2022 and 2023 10-K filings include this detail is false. The ground truth states that this carry-forward detail was present in the 2022 10-K but explicitly omitted in the 2023 10-K. The LLM incorrectly asserts that the disclosure was unchanged between the two years. (2) The LLM claims the 2023 10-K still states that the 2020 Stock Plan is the successor to the 2011 Plan and includes the share transfer detail, which contradicts the ground truth that this linkage was removed in 2023. (3) Qualitatively, the multi-hop reasoning failed: the question asks how the disclosure *evolved*, requiring comparison across two filings. The LLM failed to detect any change, instead asserting no difference, which is the opposite of the truth. (4) Contextually, the answer addresses the right topic (relationship between stock plans) but with completely inaccurate information about the evolution of disclosures. The answer would be correct if the disclosures were consistent, but they were not. Thus, the correctness score is very low due to total factual inaccuracy despite using a plausible number.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 351,
        "total_tokens": 1580
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How has Honeywell's allocation strategy toward private funds evolved between 2022 and 2023, and what might this indicate about the company's capital deployment priorities?",
      "original_answer": "In 2022, Honeywell reported $1,244 million invested in private funds, as disclosed in the 2022 10-K filing. By 2023, this amount increased slightly to $1,265 million, as noted in the 2023 10-K filing. This represents a modest increase of approximately 1.7%, suggesting that Honeywell maintained a relatively stable allocation strategy toward private funds despite broader reductions in total assets under the U.S. plans. This slight upward trend may indicate a strategic decision to preserve or slightly expand exposure to alternative investments, potentially to capitalize on expected higher returns or diversification benefits from private fund investments.",
      "llm_answer": "Honeywell’s pension‑plan data show that private‑fund exposure rose from roughly $90 million in 2022 ( $36 million at Level 3 + $54 million at Level 2 ) to about $115 million in 2023 ( $74 million at Level 3 + $41 million at Level 2 ).  The U.S. plan’s “direct private investments” also grew modestly, from $1,284 million to $1,293 million.  This incremental increase signals that the company is modestly shifting capital toward private‑equity‑type assets, reflecting a growing emphasis on diversifying the pension portfolio and pursuing higher‑return, alternative investments while staying within its broader asset‑allocation targets.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that Honeywell had $1,244 million invested in private funds in 2022 and $1,265 million in 2023, representing a 1.7% increase. However, the LLM claims private-fund exposure was only $90 million in 2022 and $115 million in 2023, which is off by more than an order of magnitude. This misrepresents the scale of investment. Additionally, the LLM introduces Level 2 and Level 3 valuations not mentioned in the ground truth and incorrectly calculates subcomponents that do not align with the source data. While it correctly notes a modest increase in private fund exposure, the magnitude and basis are wrong. (2) The calculation of a 'modest increase' is directionally correct but based on incorrect figures. The LLM also references 'direct private investments' rising from $1,284M to $1,293M, which does not appear in the original answer or align with the disclosed $1,244M to $1,265M. These numbers are inconsistent with the ground truth and suggest confusion between different line items or misreading of the filings. (3) The multi-hop reasoning is flawed because the model fails to correctly extract and synthesize the actual amounts from the 10-K filings. It appears to conflate subcategories (e.g., Level 2/Level 3 assets) with total private fund investments, leading to incorrect aggregation. The conclusion about strategic capital deployment toward private equity is plausible but based on invalid data, undermining the reasoning chain. (4) The contextual relevance is moderate because the answer addresses the question's intent—evaluating changes in allocation strategy and inferring capital priorities—but the severe quantitative errors and entity misidentification (e.g., misrepresenting total private fund investments) drastically reduce factual reliability. The answer sounds plausible but is substantively incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 519,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the status and disclosure of Class B-2 Common Stock evolve between 2023 and 2024, particularly regarding its outstanding status and relationship to other stock classes?",
      "original_answer": "In 2023, Class B-2 Common Stock was subject to conversion rate adjustments tied to the U.S. litigation escrow account under the U.S. retrospective responsibility plan, which caused dilution in as-converted shares. Additionally, it was noted that no shares of Class B-2 were outstanding prior to the Class B-1 exchange offer. By 2024, the 10-K filing only referenced Class B-2 Common Stock in relation to its lack of outstanding shares prior to the Class B-1 exchange offer, with no further updates or disclosures regarding its conversion mechanics or dilution impacts, suggesting a reduced emphasis or potential discontinuation of its active role in the capital structure.",
      "llm_answer": "In the 2023 filing Visa reported that **no Class B‑2 common shares were outstanding** – the notes explicitly said “No shares of class B‑2 common stock were outstanding prior to the class B‑1 common‑stock exchange offer.” By the 2024 filing, the May 2024 exchange offer had created the new subclass: Visa **issued about 120 million Class B‑2 shares (49 million diluted shares outstanding)** and disclosed them together with the redenominated Class B‑1 shares as part of the broader Class B common‑stock family. The 2024 notes explain that Class B‑2 is only issuable through the exchange offer, carries the same conversion rights as other Class B shares (but with double the impact on conversion‑rate adjustments), and is therefore now a distinct, outstanding component of Visa’s multi‑class capital structure.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth. (1) According to the original answer, in 2023, Class B-2 Common Stock was subject to conversion rate adjustments tied to the U.S. litigation escrow account, causing dilution in as-converted shares, and no shares were outstanding prior to the Class B-1 exchange offer. By 2024, there were no new disclosures about Class B-2, and it was only referenced in the context of having no outstanding shares before the exchange offer—indicating reduced emphasis or potential discontinuation. The LLM, however, claims that in 2024, Visa issued about 120 million Class B-2 shares (49 million diluted), which is completely unsupported by the ground truth and factually wrong. (2) The numbers '120 million' and '49 million diluted shares' are fabricated and not present in the original answer or implied by it. There are no quantitative values in the ground truth related to actual issuance of Class B-2 shares in 2024. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers that an exchange offer led to the creation and issuance of Class B-2 shares, when the original answer suggests the opposite—that Class B-2 was only mentioned in 2024 in the context of past non-outstanding status, with no new disclosures. The LLM also incorrectly states that Class B-2 now has a 'distinct, outstanding component' role, while the ground truth implies its role may be discontinued. (4) The answer fails on correctness and quantitative accuracy due to invented data and reversal of factual status. Qualitative accuracy is very low due to incorrect entity relationships and reasoning. Contextual relevance is minimal as it addresses the stock classes but with false dynamics. The answer misrepresents the evolution entirely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 482,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the financial obligations related to the Target Circle program change between 2022 and 2024, and what does this indicate about the program's evolution?",
      "original_answer": "In 2022, the deferred revenue related to the Target Circle program was $89 million as of January 29, 2022, while in 2024, the deferred revenue related to the program was $117 million as of February 3, 2024. This indicates a significant increase in the company's liability tied to unredeemed rewards, suggesting growth in program participation or changes in redemption patterns. However, by February 1, 2025, the deferred revenue had dropped to $19 million, signaling a sharp decline, which may reflect either a surge in reward redemptions or a strategic change in how the program's liabilities are recognized or managed.",
      "llm_answer": "The Target Circle liability fell sharply – the deferred‑revenue balance for the loyalty program was **$89 million in fiscal 2022** (as shown in the 2022 filing) and **$19 million in fiscal 2024** (the 2024 filing). That roughly $70 million reduction signals that the program has moved from a large “unearned‑rewards” reserve to a much smaller one, indicating higher redemption rates and a more mature, cash‑flow‑neutral loyalty operation.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It states that the deferred revenue was $89 million in fiscal 2022 and $19 million in fiscal 2024, skipping the correct 2024 figure of $117 million as of February 3, 2024. Instead, it incorrectly uses the February 1, 2025 figure ($19 million) as if it were the 2024 value. This misrepresents the trend: the liability increased from $89M to $117M before dropping to $19M. (2) The calculation of a '$70 million reduction' is based on comparing $89M to $19M, which skips the intermediate increase and misattributes the timeline. The actual change between 2022 and 2024 (Jan 2022 to Feb 2024) is an increase of $28M ($117M - $89M), not a reduction. The $19M figure belongs to 2025, not 2024. (3) The reasoning is partially sound in interpreting what a declining liability might mean (higher redemptions, maturity of program), but it fails the multi-hop synthesis by conflating years and missing the key increase in deferred revenue between 2022 and 2024. The model does not acknowledge the growth phase before the drop, leading to an incomplete and misleading narrative. (4) While the answer addresses the question's intent and uses appropriate financial terminology (deferred revenue, redemption rates), the quantitative errors severely undermine the correctness. The contextual relevance is high because it discusses the right program and metric, but the factual backbone is flawed. Correctness and quantitative accuracy are low due to incorrect dates and figures; qualitative accuracy is moderate due to sound logic on redemption implications, but only on incomplete data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 449,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the fair value of Netflix's 4.375% Senior Notes change between December 31, 2022, and December 31, 2023, and what does this indicate about investor perception or market conditions?",
      "original_answer": "The fair value of Netflix's 4.375% Senior Notes decreased from $980 million on December 31, 2022, to $996 million on December 31, 2023. This indicates a shift in investor perception or market conditions, as the fair value moved closer to the principal amount at par, suggesting a stabilization or improved outlook for the company's debt.",
      "llm_answer": "The Level 2 fair‑value of Netflix’s 4.375 % senior notes rose from **$980 million at 12/31/2022 to $996 million at 12/31/2023**, a gain of roughly **$16 million**【page_56】.  \nThis modest increase means the market price of the notes rose, suggesting that investors viewed Netflix’s credit profile more favorably (or that prevailing interest‑rate conditions made the fixed‑rate notes more attractive) during 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error: it states that the fair value of Netflix's 4.375% Senior Notes *rose* from $980 million to $996 million, implying an increase. However, the ground truth states that the fair value *decreased* from $980 million to $996 million — this is logically impossible (a higher number cannot be a decrease). This suggests a fundamental contradiction in the answer. Upon closer inspection, the ground truth itself appears to have a likely typo: stating that a decrease occurred from $980M to $996M (which is actually an increase of $16M). Given that $996M > $980M, the correct interpretation must be that the fair value *increased*, not decreased. Therefore, the LLM answer correctly computes the direction of change (increase of $16M) and matches the numerical values. However, the original answer (ground truth) contains an internal inconsistency — claiming a 'decrease' when the numbers show an increase — which undermines its reliability. (2) The LLM correctly reports the dollar amounts ($980M and $996M), dates (12/31/2022 and 12/31/2023), and calculates the $16M difference accurately. These quantitative elements are correct. (3) The reasoning in the LLM answer — that the rise in fair value suggests improved investor perception or more favorable interest rate conditions — is sound and aligns with financial logic. The original answer claims the opposite movement ('decrease') and then says it moved 'closer to par', which could still be consistent if par is above $996M, but without knowing par value, this is ambiguous. However, the LLM’s interpretation is more logically consistent with the numbers provided. (4) Due to the contradiction in the ground truth, the LLM answer appears factually correct in numbers and reasoning, but is penalized because it contradicts the provided 'truth', even though the 'truth' seems erroneous. Given the instructions to follow the ground truth strictly, the correctness score is reduced despite the LLM likely being right. Final scores reflect high quantitative accuracy and contextual relevance, moderate qualitative accuracy due to potential misalignment with intended truth, and a lowered correctness score due to conflict with the (flawed) ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1197,
        "completion_tokens": 603,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the equity structure related to Class C Common Stock evolve between 2023 and 2024, particularly in terms of share issuance and equity classification?",
      "original_answer": "In 2023, Visa conducted an exchange offer where 241 million shares of Class B-1 common stock were tendered, and in exchange, approximately 48 million shares of Class C common stock were issued. This indicates active restructuring of stock classes tied to the Visa Europe retrospective responsibility plans. By 2024, the balance of Class C common stock remained at 10 shares issued and outstanding, as stated in the equity section of the balance sheet. This suggests that while there was active movement and restructuring involving Class C shares in 2023, the 2024 disclosures indicate a stabilization or conclusion of that phase of equity restructuring.",
      "llm_answer": "In the 2023 filing Visa reported that only 10 Class C common‑stock shares were issued and outstanding, and the 2024 filing shows the same 10‑share count on the balance sheet. However, the 2024 MD&A notes that in May 2024 Visa completed a Class B‑1 exchange offer and, in exchange for 241 million Class B‑1 shares, issued roughly 48 million new Class C common‑stock shares. Thus, while the nominal par‑value share count remained unchanged (the 10 shares reflect the legal “issued” amount), the equity component of Class C was materially expanded in 2024 through that issuance, and the shares are recorded as equity (common stock) but are not publicly traded.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the exchange offer involving 241 million Class B-1 shares and the issuance of approximately 48 million Class C shares occurred in 2023, not in May 2024 as claimed by the LLM. The 2024 filing states that only 10 shares of Class C common stock were issued and outstanding, indicating no new issuance in 2024. The LLM incorrectly reverses the timeline, placing the major equity restructuring event in 2024 when it actually occurred in 2023. (2) Quantitatively, the numbers 241 million and 48 million are accurate in magnitude but are assigned to the wrong year. The 10 shares outstanding in both years are correctly cited, but the explanation that new shares were issued in 2024 contradicts the ground truth. There is no indication in the original answer that the 10-share count is a 'legal' or 'par-value' distinction—the LLM introduces speculative accounting interpretation not present in the source. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the temporal sequence of events across the two years. It incorrectly infers that because the MD&A in 2024 discusses the exchange, it must have occurred in 2024, when in fact it likely refers to a prior-year transaction. This breaks the logical chain required for accurate multi-hop inference. (4) Despite the incorrect timeline, the answer is contextually relevant, addressing share issuance and equity classification as asked. However, the core factual error—misplacing the exchange offer in 2024—undermines the correctness score, which is penalized heavily due to the importance of temporal accuracy in financial disclosures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 466,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Lowe's engagement with Rough Plumbing evolved from 2022 to 2024, particularly in terms of its business classification and service offerings?",
      "original_answer": "In 2022, Rough Plumbing was classified under the 'Building Products' category, indicating it was primarily offered as a product within Lowe's merchandise divisions. By 2024, Lowe's had expanded its engagement with Rough Plumbing by integrating it into both installation services and protection plans, signaling a shift from a pure product offering to a more service-oriented approach. This evolution reflects a strategic move to bundle Rough Plumbing with labor and extended protection, contributing to the approximately 5% of total sales attributed to installed sales in 2024.",
      "llm_answer": "In the 2022 filing, Rough Plumbing is mentioned only as a product line inside Lowe’s Building Products merchandise division 【page_55†L2-L5】. By the 2024 filing, Rough Plumbing is highlighted not just as a product category but also as a major source of installed sales—services delivered through independent‑contractor installers—and it is included in Lowe’s extended‑protection‑plan offerings 【page_7†L1-L4】【page_7†L5-L7】. Thus, Lowe’s relationship with Rough Plumbing has moved from a pure product classification in 2022 to a combined product‑and‑service role in 2024, encompassing both installation and protection‑plan services.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Rough Plumbing was classified under 'Building Products' as a product-only offering, citing the correct context from the 2022 filing. By 2024, it accurately notes the evolution into a combined product-and-service model, including installation services via independent contractors and inclusion in protection plans. (2) There are no numeric inaccuracies; while the original answer mentions 'approximately 5% of total sales attributed to installed sales in 2024,' this quantitative detail is omitted in the LLM response. However, this is a minor omission rather than an error—the core financial implication (installed sales) is still acknowledged. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years and two types of offerings (product → service expansion), demonstrating understanding of the strategic shift. (4) Semantic equivalence is strong—wording differs but meaning matches. The only reason for not scoring a perfect 10 is the missing reference to the 5% installed sales figure, which adds contextual depth but does not undermine the correctness of the core classification and service evolution. All entities (Rough Plumbing, Lowe's, Building Products, installation services, protection plans, years 2022–2024) are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 384,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the introduction and subsequent status of Class B-2 common stock evolve between 2023 and 2024, and what does this indicate about its role in the company's capital structure?",
      "original_answer": "In 2023, Class B-2 common stock was newly introduced with 77 million shares outstanding, indicating its initial incorporation into the company's equity structure. By 2024, the company disclosed that no shares of Class B-2 common stock were outstanding prior to the Class B-1 common stock exchange offer, suggesting a strategic shift where Class B-2 shares may have been replaced or restructured as part of a broader capital realignment. This indicates a transformation in the role of Class B-2 common stock within the company’s capital structure.",
      "llm_answer": "Class B‑2 common stock did not exist in the 2023 filing – the 2023 10‑K notes that “no shares of class B‑2 common stock were outstanding prior to the class B‑1 common stock exchange offer” and the earnings‑per‑share tables show a dash for B‑2 (Page 91). In 2024 Visa created the new class as part of the May 2024 exchange offer, issuing about 120 million B‑2 shares (49 million weighted‑average shares outstanding for the year) that now appear in the capital‑structure tables and earn EPS comparable to the other common classes (Page 89, 59). This evolution shows B‑2 was introduced as a transitional, non‑voting class to provide liquidity and a conversion pathway for the formerly restricted B‑1 shares, expanding the equity base while keeping voting power concentrated in Class A.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. (1) The ORIGINAL ANSWER states that Class B-2 common stock was introduced in 2023 with 77 million shares outstanding, but the LLM claims it did not exist in 2023 and was created in May 2024—this reverses the timeline. The LLM incorrectly cites the 2023 10-K as stating 'no shares of class B-2 common stock were outstanding prior to the class B-1 exchange offer' as evidence that B-2 didn't exist in 2023, but this phrasing is consistent with B-2 being introduced *during* the exchange offer, not after. (2) The LLM reports 120 million B-2 shares issued and 49 million weighted-average shares, but the ground truth does not provide these numbers—instead, it specifies 77 million shares outstanding in 2023. These figures are unsupported and conflict with the known data. (3) The reasoning is flawed: the LLM asserts B-2 was created in 2024 as a 'transitional, non-voting class' with specific strategic intent, but the original answer only indicates a strategic shift without specifying timing or intent, and notes that B-2 was already present in 2023. (4) While the LLM attempts multi-hop reasoning by analyzing capital structure implications, it builds on incorrect temporal and quantitative foundations. The contextual relevance is moderate because it addresses the evolution and role of B-2 stock, but the core facts are inverted. Semantic equivalence fails due to major discrepancies in timing, share counts, and causal interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 416,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has the financial liability associated with the Target Circle program changed between 2022 and 2024, and what does this indicate about the program's growth or evolution?",
      "original_answer": "In 2022, the Target Circle program was described primarily in terms of its benefits to customers, such as earning 1% rewards on non-RedCard purchases, but no specific liability figure was disclosed. By 2024, the deferred revenue related to the Target Circle program had grown to $117 million as of February 3, 2024, indicating a significant increase in the program's financial liability and suggesting substantial growth or expansion of the program. This increase reflects a greater number of participants or increased transactional activity within the program.",
      "llm_answer": "The 2024 Form 10‑K shows that the deferred‑revenue liability for the Target Circle rewards program fell to **$19 million** at fiscal year‑end 2025 (February 1 2025), down from **$117 million** recorded at the end of fiscal 2023 (February 3 2024)【page_50】. The 2022 Form 10‑K disclosed a similar liability of **about $117 million** for the Target Circle program at the close of fiscal 2022【page_5】.  \n\nThe sharp decline from roughly $117 million in 2022 to $19 million in 2024 indicates that the program’s outstanding reward obligations have been largely satisfied—either through higher redemption rates or changes to the program’s structure—signalling that the liability associated with Target Circle has contracted markedly as the program has matured.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude. The ground truth states that the deferred revenue liability for Target Circle was not disclosed in 2022 and grew to $117 million by 2024, indicating program growth. In contrast, the LLM claims the liability was $117 million in 2022 and dropped to $19 million by 2025 (misaligned year), suggesting contraction—this is the opposite of the correct trend. (2) Quantitative inaccuracies include: (a) falsely stating a $117 million liability in 2022 (not disclosed in original answer), (b) claiming a drop to $19 million in 2025 (not 2024), and (c) referencing fiscal year-end 2025 (February 1, 2025), which is outside the 2022–2024 scope of the question. The cited $19 million figure contradicts the ground truth of $117 million in 2024. (3) The multi-hop reasoning is flawed: instead of recognizing the emergence and growth of a liability where none was previously reported, the model incorrectly infers a decline, likely due to misreading or hallucinating data. It fails to recognize that no 2022 liability figure was disclosed, which is central to the correct interpretation. (4) The contextual relevance is low because the answer addresses the general topic but misrepresents the core financial trend. The conclusion about program maturation and reduced liability is unsupported and contradicts the ground truth indication of growth. Minor credit is given for discussing deferred revenue in the context of reward programs, but the factual errors dominate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 423,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has NVDA's exposure to and concern about pollution limits evolved between 2023 and 2024, particularly in terms of regulatory impact on operations and customer data center expansion?",
      "original_answer": "In 2023, NVDA highlighted that pollution limits and related climate regulations could increase direct and indirect costs, including compliance, energy, and capital expenditures, and could require changes to manufacturing processes and supply chain operations. By 2024, the company expanded its concern to include not only cost increases but also the potential for land and permitting constraints tied to pollution limits, which could impair customers' ability to expand data center capacity—an essential market for NVDA's products. This indicates a growing concern that regulatory tightening around pollution could directly affect demand for NVDA's offerings.",
      "llm_answer": "In the 2023 Form 10‑K NVIDIA listed “pollution limits” only as one of several climate‑related regulations that could raise its direct costs (e.g., higher manufacturing or compliance expenses) and force changes to product‑design activities. By the 2024 filing the company had broadened the risk, warning that new or proposed pollution‑limit rules – together with energy‑ and water‑use restrictions – could not only increase NVIDIA’s own operating costs but also curtail the ability of its customers to expand data‑center capacity, thereby threatening demand for its GPUs and related services.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All entities are correct: NVDA/NVIDIA, 2023 and 2024 timeframes, pollution limits, data center expansion, and customer impact. There are no incorrect numbers, dates, or financial figures—this is a qualitative risk assessment, so no numeric values are involved, but the temporal evolution is correctly captured. (2) The answer correctly identifies that in 2023, NVIDIA focused on pollution limits increasing direct costs (compliance, manufacturing) and affecting product design—consistent with the original answer’s mention of compliance, energy, and capital costs and changes to manufacturing. (3) The multi-hop reasoning is sound: it synthesizes the evolution from internal cost impacts (2023) to external demand-side risks via customer constraints (2024). The LLM correctly notes that by 2024, pollution limits—alongside energy and water use rules—could restrict customer data center expansion, thereby threatening demand for GPUs and services. This aligns with the ground truth’s emphasis on land and permitting constraints impairing customer capacity growth. (4) Minor difference: the original answer explicitly mentions 'land and permitting constraints' and 'indirect costs,' while the LLM emphasizes 'energy- and water-use restrictions' and 'operating costs.' These are closely related and contextually consistent, but the LLM slightly reframes the 2024 risk with a broader environmental lens (water/energy) not explicitly tied to pollution limits in the original. However, this does not contradict the source and reflects plausible inference from the regulatory context. Overall, the answer is semantically equivalent, well-reasoned, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 479,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the composition and valuation of the company's Guaranteed Senior Notes evolve between 2023 and 2024, particularly in terms of issuance, repayment, and fair value inputs?",
      "original_answer": "In 2023, the company's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. These notes were valued using Level 3 inputs. In 2024, the Japanese subsidiary repaid $77 of these Guaranteed Senior Notes. The fair value of long-term debt, including Guaranteed Senior Notes, was approximately $5,412 at the end of 2024, compared to $5,738 at the end of 2023. This indicates a reduction in the overall fair value of long-term debt, partially driven by repayments on the Guaranteed Senior Notes.",
      "llm_answer": "In 2023 the company’s Japanese subsidiary issued four Guaranteed Senior Notes – about $500 total, with fixed rates of 1.40 % to 2.12 % and maturities from 2033 to 2043 – and these notes were measured at fair value using Level 3 inputs (the only long‑term debt classified as “Other long‑term debt”). By the September 2024 filing the subsidiary had repaid $77 of those notes, leaving a reduced outstanding balance that is reflected in the “Other long‑term debt” line (up to $919 versus $484 in 2023) and still valued with Level 3 inputs, while the remainder of the senior‑note portfolio continued to be valued with Level 2 inputs.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2023 issuance of four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates between 1.400% and 2.120%, and that these were valued using Level 3 inputs — all of which matches the ground truth. It also correctly states that $77 was repaid in 2024. However, it introduces incorrect information about maturities (2033–2043) and the 'Other long-term debt' line increasing to $919 versus $484 in 2023, which is not supported by the original answer and contradicts the stated overall reduction in long-term debt fair value from $5,738 to $5,412. (2) The quantitative inaccuracies are significant: while $500 issuance and $77 repayment are correct, the claim that 'Other long-term debt' rose from $484 to $919 is unsupported and conflicts with the overall trend of declining fair value. The original answer reports total long-term debt fair value decreasing by $326 ($5,738 - $5,412), but the LLM implies a large increase in a subset of debt, which is inconsistent. (3) The multi-hop reasoning is partially sound — it connects issuance, repayment, and valuation inputs across years — but fails to integrate the key point about total fair value of long-term debt declining, which is central to the original answer’s conclusion. Instead, it focuses on a narrow 'Other long-term debt' category with fabricated figures, undermining the synthesis. (4) Despite introducing unsupported numbers and misrepresenting the debt trend, the LLM captures core facts about issuance, repayment, and Level 3 inputs, warranting a moderate score. Contextual relevance is high as it addresses all question components, even if with errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 458,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Netflix's investment in streaming service improvements and associated risk exposure evolve from 2022 to 2024, based on the specific personnel and cybersecurity-related changes disclosed in those years?",
      "original_answer": "In 2022, Netflix disclosed a $384 million increase in personnel-related costs driven by headcount growth to support production activity and improve the streaming service. By 2024, the focus had evolved to include significant emphasis on cybersecurity, with detailed descriptions of enterprise-wide security programs, third-party risk management, and the potential financial impact of cyber incidents. The company highlighted the risk of unauthorized data releases and digital content theft, noting that such events could adversely affect business operations and financial results. This represents a shift from purely growth-oriented investment in streaming to a more risk-aware posture as the service matured.",
      "llm_answer": "In the 2022 filing Netflix said it had dramatically stepped up spending on streaming‑service upgrades, raising technology‑and‑development costs by $384 million (about a 24 % jump) largely because of added headcount to support new UI, recommendation and infrastructure work.  The same filing highlighted that its global security function is run by a veteran Vice President of Security and Privacy Engineering and that the company’s enterprise‑wide cyber‑risk program is overseen by the Audit Committee.  By the 2024 filing, Netflix still points to the same VP‑led security organization and board oversight, but it no longer reports a comparable surge in personnel‑related technology spending, indicating that the earlier investment in streaming improvements has been largely completed and risk exposure is now being managed through an established cybersecurity framework rather than additional staffing.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $384 million increase in personnel-related costs in 2022, which aligns with the ground truth. However, it introduces a 24% increase in technology-and-development costs that is not present in the original answer or implied by the ground truth data—this percentage is unsupported and potentially misleading, reducing quantitative accuracy. (2) The LLM claims that the 2022 filing mentioned a Vice President of Security and Audit Committee oversight of cybersecurity, but this specific detail is not in the original answer and cannot be verified from the provided ground truth. While plausible, it introduces unverified entity details, affecting entity and qualitative accuracy. (3) The reasoning about a shift from growth-oriented investment to risk management via a mature cybersecurity framework is partially sound and aligns with the evolution described in the original answer. However, the conclusion that 'the earlier investment has been largely completed' is an inference not explicitly supported in the ground truth, which only states that 2024 emphasized cybersecurity risks more, not that personnel investments ceased. (4) The answer captures the general multi-hop evolution from 2022 to 2024 but adds unsupported specifics (percentage increase, VP role, cessation of spending) and omits key elements from the original—specifically, the 2024 focus on third-party risk, financial impact of cyber incidents, unauthorized data releases, and digital content theft. These omissions reduce completeness and factual equivalence. Despite this, the response remains contextually relevant and interprets the question appropriately, earning high marks for relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 468,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did The Bank of New York Mellon Corporation's approach to restricted stock unit agreements evolve between the 2023 and 2024 filings, particularly in terms of the lifecycle management of these equity instruments and their implications for executive compensation strategy?",
      "original_answer": "In the 2023 filing, the '2024 Form of Restricted Stock Unit Agreement' was newly introduced and explicitly stated as 'Filed herewith,' indicating it was a current and newly adopted form for that year. This suggests the company was actively updating its equity compensation framework to align with strategic goals for executive retention and incentives. By the 2024 filing, this '2024 Form' was no longer newly filed but instead was referenced as 'Previously filed,' signaling it had become an established part of the company's compensation structure. Additionally, in 2024, the company introduced the '2025 Form of Restricted Stock Unit Agreement,' which was marked as 'Filed herewith,' showing a forward-looking update to the equity compensation strategy. This evolution indicates a consistent, proactive approach to managing executive compensation frameworks, with new forms being introduced annually and the prior year’s forms transitioning into reference documents. This reflects a mature, iterative process in shaping executive incentives and aligning them with long-term corporate objectives.",
      "llm_answer": "In the 2023 Form 10‑K the company disclosed a single “2023 Form of Restricted Stock Unit Agreement” (exhibit 10.27) as the governing document for RSU grants. The 2024 filing replaces that with a new “2024 Form of Restricted Stock Unit Agreement” (exhibit 10.29) and even includes a forward‑looking “2025 Form of Restricted Stock Unit Agreement,” indicating that BNY Mellon now updates the RSU instrument annually to refine grant, vesting, settlement and forfeiture rules. This tighter, year‑to‑year lifecycle management signals that RSUs are being used more deliberately as a flexible, performance‑linked component of executive compensation, allowing the board to align equity awards with evolving retention and incentive objectives.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution in BNY Mellon's RSU agreement lifecycle management between 2023 and 2024 filings, correctly identifying the replacement of the 2023 form with the 2024 form and the introduction of a forward-looking 2025 form. However, it contains factual inaccuracies regarding the exhibits: the original answer states that the '2024 Form' was introduced in the 2023 filing as 'Filed herewith,' not in the 2024 filing as the LLM claims. The LLM incorrectly implies the 2024 Form was introduced in the 2024 10-K, when in fact it was first filed in 2023. This misrepresents the timeline and undermines the multi-hop reasoning about when the form was adopted. Additionally, the LLM invents exhibit numbers (10.27, 10.29) not present in the ground truth, which lacks such detail—this affects quantitative and entity accuracy. Despite this, the qualitative insight about annual updates and strategic lifecycle management aligns with the original answer’s conclusion, showing sound reasoning based on flawed premises. The answer is contextually relevant and interprets the strategic implications correctly—viewing RSUs as a flexible, performance-linked tool. While the overall direction and interpretation are accurate, the incorrect dating of document introduction and fabricated exhibit numbers prevent a higher score. Semantic equivalence is partially achieved, but factual precision on key details is lacking.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1489,
        "completion_tokens": 394,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the status and structure of the 4.90% Senior Notes evolved from 2023 to 2024, particularly in terms of their carrying amount and maturity timeline?",
      "original_answer": "In 2023, the 4.90% Senior Notes were newly issued in November 2023, with a principal amount of $750 million, a discount of $3.4 million, and a maturity date of April 15, 2029. Interest payments were scheduled semi-annually starting April 15, 2024. By 2024, these notes remained outstanding, with a carrying amount of $743 million as of January 28, 2024. The maturity date remained unchanged at April 2029, and the notes continued to be listed among the company’s long-term debt obligations. The carrying amount slightly decreased, reflecting the initial discount and amortization progress over the year.",
      "llm_answer": "In the 2023 filing the company reported a single tranche of $750 million of 4.90 % senior notes that were scheduled to mature in September 2026, with a carrying amount of **$744 million**, and a second tranche of $750 million of 4.90 % senior notes due April 2029 with a carrying amount of **$743 million** (see 2023 Long‑Term Debt table, page 59).  \n\nBy the 2024 filing the same notes remain outstanding on the same maturity schedule—September 2026 and April 2029—but the carrying amounts have risen slightly to **$747 million** for the 2026 notes and **$744 million** for the 2029 notes (see 2024 Long‑Term Debt table, page 62), reflecting the amortization of the original issuance discounts.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that the 4.90% Senior Notes were newly issued in November 2023 with a single $750 million tranche maturing on April 15, 2029, not two tranches as claimed. The LLM incorrectly reports a September 2026 maturity that does not exist in the original answer. The carrying amount in 2023 is misstated: the original answer does not specify a 2023 carrying amount but notes a $3.4 million discount from $750 million, implying ~$746.6 million, whereas the LLM reports $744 million for the 2029 tranche and invents a $744 million figure for 2023 and $747/$744 million for 2024. The correct 2024 carrying amount is $743 million as of January 28, 2024, which the LLM partially matches for the 2029 tranche but incorrectly attributes to amortization increasing the carrying amount, when in fact the slight decrease reflects amortization of the discount. (2) Multiple numbers are incorrect: maturity dates (September 2026 vs. April 2029 only), number of tranches (two vs. one), 2023 carrying amount ($744M vs. implied $746.6M), and 2024 carrying amount ($744M vs. $743M). The LLM also falsely claims carrying amounts 'rose' due to amortization, when they should slightly decrease or increase toward par depending on discount amortization method—however, the original answer states the amount 'slightly decreased', contradicting the LLM's upward trend. (3) The multi-hop reasoning is flawed: the LLM invents a second tranche not present in the ground truth and fails to correctly track the evolution of a single note issuance. It misrepresents the timeline, structure, and financial progression of the debt instrument. (4) Scores are low due to major factual and quantitative errors, especially in dates and amounts. Contextual relevance is moderate because the answer addresses the right topic (senior notes evolution) and mentions carrying amounts and maturities, but the substance is largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 535,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did the issuance and repayment of Guaranteed Senior Notes by Costco's Japanese subsidiary evolve between 2023 and 2024?",
      "original_answer": "In 2023, Costco's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. In 2024, the subsidiary repaid $77 of these Guaranteed Senior Notes. Additionally, the proceeds from the issuance of these notes were referenced in the 2024 filing as a source of financing activity, indicating continued financial engagement with this instrument.",
      "llm_answer": "In November 2023 Costco’s Japanese subsidiary issued four Guaranteed Senior Notes – about $500 million in total with fixed rates of 1.40 % to 2.12 % and maturities ranging from 2033 to 2043【page_52】. During 2024 the subsidiary made a partial repayment, paying back $77 million of those notes in July 2024, and no further issuances were reported; the 2024 cash‑flow statement reflects the original $500 million issuance as a financing‑activity inflow【page_30】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: in 2023, Costco's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 million at fixed interest rates between 1.400% and 2.120%, and in 2024, $77 million was repaid. The LLM adds specific details not in the original answer—issuance in November 2023, maturities from 2033 to 2043, and repayment in July 2024—which are consistent with plausible filing data and do not contradict the ground truth. (2) Quantitative accuracy is perfect: $500 million and $77 million match the original answer (with correct unit clarification as 'million'), rates are correctly reported (1.40% to 2.12% vs. 1.400% to 2.120%), and the reference to the 2024 cash flow statement as a financing inflow aligns with the original's mention of financing activity. (3) Reasoning is sound: the LLM correctly synthesizes issuance and repayment across two years, identifies the financial instrument and entity accurately, and infers appropriate context from cash flow reporting. The only minor gap is that the original answer notes the proceeds were 'referenced' as a source of financing, while the LLM interprets this as appearing in the cash-flow statement—slightly stronger inference but still reasonable. (4) The answer is fully relevant, directly addressing the evolution of issuance and repayment between 2023 and 2024. The added specificity enhances clarity without introducing error. Thus, the answer earns a 9/10 for correctness due to slight over-precision on timing not in the original, but remains factually consistent and comprehensive.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 449,
        "total_tokens": 1663
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the risk associated with competitors developing after-market parts for DHR's products evolved from 2022 to 2023, particularly in terms of its impact on the company's business and financial statements?",
      "original_answer": "In 2022, the risk of competitors developing after-market parts was described as a direct threat that could 'detract from our sales,' with an emphasis on how commoditization and private-label offerings could reduce market prices and erode DHR's competitive position. By 2023, the framing of this risk shifted to being 'Impacted By' such competition, with a broader contextualization within cost containment trends in the healthcare industry and pricing pressures from managed care and government reimbursement policies. While the core risk remained, it was presented as one of several external pressures rather than a primary threat, suggesting a relative de-emphasis in severity or a strategic recalibration in how the company perceives this risk.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K risk‑factor sections contain the same warning that “competitors may also develop after‑market services and parts for our products which may detract from our sales.” The language and its placement are unchanged, indicating that the company still views this as a potential adverse effect on its business and financial statements, but it has not been escalated or described as a greater risk in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that the language in the 2022 and 2023 10-K filings is unchanged. The ground truth indicates a clear evolution in how the risk is framed: from a direct threat in 2022 ('detract from our sales') to a more contextualized and relatively de-emphasized risk in 2023, where it is described as 'Impacted By' broader industry pressures like cost containment and reimbursement policies. The LLM incorrectly asserts that the wording and placement are identical, which contradicts the ground truth's assertion of a strategic shift in risk presentation. While there are no numerical inaccuracies (hence a high quantitative accuracy score), the qualitative analysis fails completely—missing the multi-hop synthesis required to compare the nuanced changes in risk framing across years. The answer also lacks completeness, as it does not address the evolution in impact on business and financial statements as required by the question. Contextual relevance is moderate because the topic is relevant, but the analysis fails to capture the depth of change described in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 318,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Netflix's approach to membership plans evolved from 2022 to 2024, particularly in terms of pricing strategy and service features, and what business challenges were these changes intended to address?",
      "original_answer": "In 2022, Netflix experienced a 19% revenue increase driven by an 11% growth in average paying memberships and a 7% rise in average monthly revenue per membership, partly due to price increases and favorable foreign exchange rates. However, paid net membership additions dropped by 50% compared to the prior year, signaling early signs of member acquisition challenges. By 2024, Netflix responded by introducing a lower-priced ad-supported subscription plan and enforcing terms of use to limit multi-household usage. These changes were aimed at addressing fluctuating member acquisition, retention pressures, and increasing competition in the streaming and broader entertainment market. The company acknowledged that macroeconomic conditions, content competition, and consumer sensitivity to pricing adjustments could negatively impact membership growth and profitability.",
      "llm_answer": "By 2022 Netflix’s membership strategy was still centered on a single‑tier, ad‑free model whose monthly price varied widely by market – from roughly $2 to $27 – and the company said it would “test other plan and price variations” to lift average revenue per member (2022 10‑K p. 24). In the 2024 filing the company disclosed that it has now added a lower‑priced, ad‑supported subscription, raised or adjusted prices on existing tiers, and broadened the service with new features such as games and live programming (2024 10‑K p. 6‑7). These changes are intended to counter slower growth in mature markets, price‑sensitive churn and heightened competition, and to generate additional revenue per household in an environment of inflation‑driven cost pressures and fixed content‑amortization costs.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Netflix's shift from a single-tier, ad-free model in 2022 to introducing an ad-supported plan by 2024, along with price adjustments and new features like games and live programming. These changes are accurately tied to business challenges such as slower growth in mature markets, price-sensitive churn, and competition—consistent with the original answer’s emphasis on retention, acquisition, and competitive pressures. (2) While the original answer includes specific quantitative data (19% revenue increase, 11% membership growth, 7% rise in ARPU, 50% drop in net additions), the LLM answer does not reproduce these exact figures but accurately references the strategic context behind revenue and pricing moves. The $2–$27 price range by market is not in the original answer and appears to be inferred or sourced from external knowledge; however, it is plausible and does not contradict the ground truth. No calculation errors are present. (3) The multi-hop reasoning is sound: the LLM synthesizes Netflix’s evolving pricing and feature strategy across 2022 and 2024 filings and correctly infers the business motivations (competition, inflation, content costs). It connects pricing experiments in 2022 to concrete actions in 2024, demonstrating valid cross-year synthesis. (4) The answer is semantically equivalent in intent and substance, with only minor omissions of specific percentages from the original. The added detail about games and live programming is consistent with Netflix’s 2024 strategy and enhances completeness without introducing inaccuracies. The core facts, entities, and logic are correct, warranting a high score with a minor deduction for not fully quantifying the 2022 performance metrics mentioned in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 497,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Boeing's approach to in-orbit incentive payments evolved between 2022 and 2023, particularly in terms of risk exposure and financial recognition?",
      "original_answer": "In 2022, Boeing highlighted the financial risks associated with in-orbit incentive payments, particularly in the context of potential program cancellations or failure to meet performance criteria, which could trigger termination provisions or loss of payments. The company noted that these risks were part of ongoing fixed-price development programs like Commercial Crew, KC-46A Tanker, and VC-25B. By 2023, Boeing had recorded $1,585 million in additional losses on its five most significant fixed-price development programs, which included those mentioned in 2022, and explicitly stated that in-orbit incentive payments were at risk if satellites failed to meet performance criteria over up to 15 years post-acceptance. The company also emphasized that the net present value of these fees was recognized as revenue during the construction period, increasing financial exposure if performance issues arose. This represents a shift from general risk acknowledgment in 2022 to a more specific quantification of losses and a detailed explanation of revenue recognition practices tied to in-orbit performance in 2023.",
      "llm_answer": "In the 2022 Form 10‑K Boeing only flagged the **potential loss of satellite‑in‑orbit incentive payments** as a “financially significant exposure” that could arise if a program’s schedule or technical issues triggered termination provisions (see 2022 p. 45). By the 2023 filing the company had made the accounting treatment explicit – it now **recognizes the net present value of the incentive fees as revenue during the construction period**, while still warning that a satellite that does not meet performance specs for up to 15 years could halt future payments or require refunds (see 2023 p. 15). Thus, Boeing moved from merely noting the risk to formally recording the expected incentive value up‑front, while retaining the same performance‑based risk exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Boeing's approach to in-orbit incentive payments between 2022 and 2023. (1) It correctly identifies that in 2022, Boeing highlighted the risk of losing incentive payments due to program issues, citing termination provisions—consistent with the ground truth. In 2023, it accurately states that Boeing recognizes the net present value of incentive fees as revenue during construction, while performance risks remain over up to 15 years. (2) Quantitatively, the LLM does not include the $1,585 million loss figure mentioned in the ground truth. This is a minor omission, as the focus of the LLM answer is on accounting treatment and risk exposure rather than the aggregate loss amount. However, since the original answer emphasizes this specific quantification as part of the evolution, its absence prevents a perfect score. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, correctly contrasting a general risk disclosure in 2022 with a more explicit accounting policy disclosure in 2023. It correctly links revenue recognition timing with ongoing performance risk. (4) The answer is contextually relevant and semantically equivalent to the ground truth in all key aspects except the missing dollar amount. Wording differs but meaning aligns. The citation of page numbers (p. 45, p. 15) adds precision and supports verifiability. Overall, this is a strong, factually correct response with only a partial omission of quantitative detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1471,
        "completion_tokens": 422,
        "total_tokens": 1893
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly described as being posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/invrelations/directors-code-of-conduct.pdf, and the company stated its intention to disclose amendments or waivers on the website. In 2024, while the Code remained accessible, it was referenced more generally as part of a broader list of governance materials available on the company’s website, including committee charters and governance guidelines, without repeating the direct URL. The change indicates a shift from detailed disclosure of access to a more consolidated and implicit reference, suggesting a streamlined but less direct approach to public access in 2024.",
      "llm_answer": "In the 2023 Form 10‑K the Directors’ Code of Conduct was mentioned only in the “Code of Ethics” paragraph, with a single URL provided for the PDF and a statement that any amendments or waivers would be posted on the website. By the 2024 filing, the company’s “Available Information” section lists the Directors’ Code of Conduct together with other governance documents (by‑laws, charter, etc.) as a standard, publicly‑available file on its website, showing that the disclosure has been formalized and made more readily accessible.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains a key mischaracterization in the qualitative reasoning. (1) Quantitatively, there are no numeric inaccuracies—dates (2023 and 2024), document names (Directors’ Code of Conduct), and the general description of website accessibility are factually consistent with the ground truth. The URL is not repeated in the 2024 filing, which the LLM correctly implies by noting a shift in presentation. (2) However, the LLM incorrectly frames the evolution as a move toward 'more readily accessible' and 'formalized' disclosure, which contradicts the ground truth. The original answer emphasizes a shift to a 'more consolidated and implicit reference' and a 'less direct approach' in 2024 due to the removal of the specific URL and its inclusion in a broader list. The LLM interprets this structural change as an improvement in accessibility, which is a subjective and unsupported inference. (3) The multi-hop reasoning is partially sound—comparing disclosure formats across years—but fails to accurately synthesize the *nature* of the change: from explicit, direct disclosure in 2023 to a more general, indirect reference in 2024. (4) Thus, while the entities and timeline are correct, and the answer is contextually relevant, the qualitative inaccuracy in interpreting the direction of change (improved vs. reduced directness) significantly affects correctness, warranting a score of 6. The answer captures the factual shell but misrepresents the substance of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 414,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role and deployment strategy of Mobileye Drive™ evolved between 2022 and 2023?",
      "original_answer": "In 2022, Mobileye launched the SAE L4 Self-Driving System (SDS), Mobileye Drive™, and secured multiple collaborations for commercial use, including with Udelv for autonomous cargo delivery and with Transdev for self-driving mobility services. Additionally, Mobileye achieved its first consumer L4 design win with Geely. By 2023, Mobileye’s strategy had evolved to focus on supplying the Mobileye Drive™ self-driving system to transportation network companies, public transit operators, and suppliers of AV-ready vehicle platforms, with plans to bundle it with Moovit’s urban mobility and transit intelligence application. This shift indicates a more defined go-to-market strategy targeting fleet deployment and mobility-as-a-Service (MaaS) ecosystems.",
      "llm_answer": "In the 2022 filing Mobileye Drive™ was presented as Mobileye’s new Level‑4 self‑driving system – the “fourth building block” of its AV stack that combines the EyeQ‑based compute platform with True Redundancy and was being used in early robotaxi and Vehicle‑as‑a‑Service pilots. By the 2023 filing the company had shifted the strategy to treat Mobileye Drive as a commercial, fleet‑ready solution, planning to supply it directly to transportation‑network companies, public‑transit operators and AV‑ready vehicle platform suppliers and, in many cases, to bundle it with Moovit’s mobility‑intelligence services for large‑scale AMaaS deployments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of Mobileye Drive™’s role and deployment strategy between 2022 and 2023. In 2022, it correctly identifies Mobileye Drive™ as the new SAE L4 self-driving system (referred to as Level-4) and notes its use in early robotaxi and Vehicle-as-a-Service pilots, aligning with the ground truth mentions of collaborations with Udelv and Transdev. It also correctly reflects the shift in 2023 toward a commercial, fleet-ready solution targeting transportation network companies, public transit operators, and AV-ready platform suppliers. The bundling with Moovit’s services for AMaaS (Autonomous Mobility-as-a-Service) deployments is accurately reported, matching the ground truth’s emphasis on MaaS ecosystems. All entities (Mobileye, Moovit) and timeframes (2022, 2023) are correct. There are no numeric inaccuracies; dates and strategic descriptions are factually sound. The only minor omission is the specific mention of the Geely design win in 2022, which is part of the original answer but not included in the LLM response. This does not undermine the core accuracy but slightly reduces completeness in multi-hop synthesis. Wording differs but semantic meaning is equivalent. Quantitative accuracy is perfect (no incorrect numbers). Reasoning is sound, showing a clear evolution from pilot-phase deployment to commercial fleet targeting. Contextual relevance is excellent—directly addresses the strategic shift over the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 415,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the structure and distribution rate of the Tower Preferred Interests evolved from 2022 to 2024?",
      "original_answer": "In 2022, the Tower Preferred Interests were divided into two series: the September series (Class A-1) totaling $1,500 with a 5.0% initial preferred distribution, and the December series (Class A-2) totaling $4,500 with a 4.75% initial preferred distribution. These distributions reset every five years. By 2024, the structure was amended in August 2024 to reclassify all 2019 Tower preferred interests into Fixed Rate Class A Limited Membership Interests (Tower Fixed Rate Interests) paying a 5.90% preferred distribution. Additionally, a portion of these fixed-rate interests will transition annually into Floating Rate Class A Limited Membership Interests (Tower Floating Rate Interests), which will pay a distribution equal to SOFR plus 250 basis points. This represents both a structural and rate evolution in the Tower Preferred Interests.",
      "llm_answer": "In the 2022 filing the Tower Holdings preferred interests were described as two separate series issued in 2019 – a September Class A‑1 series of $1.5 billion that paid a 5.0 % preferred distribution and a December Class A‑2 series of $4.5 billion that paid a 4.75 % distribution【page_130】.  \n\nBy the 2024 filing the company had amended those interests: the two 2019 series were reset and re‑structured into “Fixed‑Rate” Class A limited membership interests that pay a 5.90 % distribution and “Floating‑Rate” Class A interests that pay SOFR + 250 basis points (potentially about $525 million by 2028), with a portion of the Fixed‑Rate interests slated to convert to Floating‑Rate each year over a five‑year period【page_87】.  \n\nThus, the structure shifted from two fixed‑rate series to a single class split between a higher‑rate fixed‑rate tranche (5.90 %) and a floating‑rate tranche tied to market rates, and the overall distribution rate for the fixed portion increased from the original 5.0 %/4.75 % to 5.90 %.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of the Tower Preferred Interests from 2022 to 2024. (1) Quantitatively, the LLM correctly identifies the two 2019 series (September Class A-1: $1.5 billion at 5.0%, December Class A-2: $4.5 billion at 4.75%) referenced in the 2022 context, though the original answer uses '$1,500' and '$4,500'—this appears to be a unit discrepancy (thousands vs. millions/billions). However, given the context and the fact that the LLM interprets these as $1.5 billion and $4.5 billion, which aligns with typical financial scales, this is likely a formatting interpretation and not a factual error. The 2024 restructuring into Fixed-Rate (5.90%) and Floating-Rate (SOFR + 250 bps) interests is correctly stated. The mention of $525 million by 2028 is additional context not in the ground truth but does not contradict it and may reflect forward-looking disclosure. (2) The August 2024 amendment date is missing in the LLM answer, a minor omission. (3) The reasoning is sound: the LLM correctly synthesizes the shift from two fixed-rate series to a restructured form with both fixed and floating tranches, and correctly notes the increase in the fixed rate from 5.0%/4.75% to 5.90%. (4) The LLM refers to 'Tower Holdings' instead of 'Tower', a minor entity naming imprecision, but contextually clear. Overall, the answer conveys semantic equivalence, with only minor omissions (exact amendment date) and a possible unit interpretation issue that does not undermine correctness. Hence, a high score of 9 is warranted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1453,
        "completion_tokens": 427,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the investment approach and unrealized gains/(losses) for Level 3 assets related to the Balanced Index Fund evolve from 2022 to 2023?",
      "original_answer": "In 2022, the company disclosed unrealized losses for Level 3 assets still held at year-end, including ($16) million for corporate fixed income securities and ($11) million for mortgage-backed and asset-backed fixed income securities. By 2023, these values shifted to unrealized gains of $2 million for corporate fixed income securities and $6 million for mortgage-backed and asset-backed fixed income securities. This indicates a significant turnaround in the performance of these assets. Additionally, while the Balanced Index Fund's composition remained at approximately 60% equities and 40% debt securities in both years, the valuation methodology in 2023 explicitly referenced a market approach based on quoted market prices (Level 1), suggesting a more transparent and standardized valuation process.",
      "llm_answer": "The OPB plan continues to hold most of its assets in a balanced‑index fund that is roughly 60 % equities and 40 % debt and is valued using a **market approach that relies on the quoted price of an identical Level 1 instrument** – the same methodology disclosed in both the 2022 and 2023 filings. In 2022 the Level 3 assets that remained in the fund recorded **unrealized losses** (‑$16 million on corporate fixed‑income, ‑$11 million on mortgage‑backed securities, ‑$14 million on municipal bonds and ‑$1 million on real assets), whereas in 2023 those same categories posted **unrealized gains** (+$2 million corporate, +$6 million mortgage‑backed and +$3 million other fixed‑income), turning the net unrealized result from a loss in 2022 to a gain in 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift from unrealized losses in 2022 to gains in 2023 for corporate and mortgage-backed fixed income securities, aligning with the ground truth. However, it introduces additional categories not present in the original answer—namely, $14 million loss on municipal bonds and $1 million loss on real assets in 2022, and $3 million gain on 'other fixed-income' in 2023—which are not mentioned in the ground truth and thus represent factual inaccuracies. These additions distort the completeness and accuracy of the response. (2) The core numbers for corporate and mortgage-backed securities match: 2022 losses of $16M and $11M, and 2023 gains of $2M and $6M are correctly reported (with acceptable formatting like ‑$16 million). However, the extra figures reduce quantitative accuracy. (3) The reasoning correctly captures the turnaround in performance and implies a positive shift in valuation, which is consistent with the ground truth. However, the LLM incorrectly states that the market approach using Level 1 instruments was disclosed in both years, while the ground truth emphasizes that this explicit reference to a market approach based on Level 1 prices was a new development in 2023, indicating improved transparency. This misrepresents the evolution of the valuation methodology. (4) Despite these issues, the answer addresses the main thrust of the question—evolution of investment approach and unrealized gains/losses—with mostly correct data and logical flow. The core multi-hop synthesis (comparing Level 3 performance across years) is sound, but the inclusion of unsupported details and mischaracterization of the valuation methodology prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 470,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has BNY Mellon's emphasis on accounting developments in its forward-looking statements evolved between 2023 and 2024, and what does this reveal about the changing influence of accounting standards on its strategic priorities?",
      "original_answer": "In 2023, BNY Mellon included accounting developments among a broader list of potential influences on forward-looking statements, noting they 'may impact our businesses' without specific elaboration. By 2024, the company expanded this language, explicitly stating that accounting developments 'may impact our businesses, regulatory, technology, market, economic or accounting developments and the impacts of such developments on our businesses.' This shift indicates a more integrated view of accounting changes as part of strategic risk and planning considerations. The inclusion of terms like 'capital plans including dividends and repurchases' and 'efficiency savings' in 2024 further suggests that accounting developments are increasingly tied to concrete business decisions and performance metrics.",
      "llm_answer": "In the 2023 Form 10‑K, accounting developments appear only as one item in a long list of forward‑looking factors (“impacts of … accounting developments and the impacts of such developments on our businesses”). By the 2024 filing, BNY Mellon isolates “changes in accounting standards” as a separate risk and explicitly states that such changes could materially affect its reported financial condition, results of operations, cash flows and other data. This shift shows that accounting‑standard updates have moved from a peripheral mention to a highlighted driver, indicating that BNY Mellon now views accounting rules as a more decisive influence on its strategic planning and capital‑management priorities.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of factual content and interpretation. (1) It accurately identifies the evolution between 2023 and 2024: in 2023, accounting developments were mentioned as part of a broader list, and in 2024, they were given more prominence. The key shift—from a general mention to a more focused, material consideration—is correctly captured. (2) There are no numeric values, dates, or calculations in the original or LLM answer beyond the years 2023 and 2024, which are correctly used. (3) The multi-hop reasoning is sound: the model synthesizes changes in disclosure language across two years and infers an increased strategic importance of accounting standards. However, the LLM slightly misrepresents the 2023 wording—it incorrectly quotes that the 2023 filing already included the phrase 'impacts of ... accounting developments and the impacts of such developments on our businesses,' which is actually the 2024 language. The 2023 version was more generic, listing accounting developments without the self-referential repetition. Additionally, the LLM omits specific 2024 additions noted in the ground truth, such as the linkage to 'capital plans including dividends and repurchases' and 'efficiency savings,' which weakens completeness. (4) Despite these nuances, the core conclusion—that accounting standards are now seen as more strategically significant—is valid and well-supported. The answer is contextually excellent, directly addressing the question’s focus on evolving emphasis and strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 432,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the evolution of risks related to store safety and cybersecurity in 2023 potentially impact the associate experience, as compared to the engagement-focused initiatives highlighted in 2022?",
      "original_answer": "In 2022, HD emphasized internal initiatives to improve the associate experience through engagement surveys, a digital engagement platform, and recognition programs, which historically showed that four out of five associates were emotionally committed. However, in 2023, the company highlighted external risks such as increased store shrink, particularly from organized retail crime, and cybersecurity threats that could compromise associate data and store safety. These risks were noted to potentially erode trust, impact associate morale and retention, and damage the company's reputation. This shift indicates that while HD was actively fostering associate engagement in 2022, the emergence or escalation of external risks in 2023 introduced new challenges that could undermine those earlier gains in associate experience.",
      "llm_answer": "In 2022 Home Depot highlighted a suite of engagement‑focused programs – annual Voice‑of‑the‑Associate surveys, a digital engagement platform, recognition awards, DEI initiatives and expanded compensation/benefits – that were intended to keep associates emotionally committed and “feel[ing] included and valued” (see 2022 p. 13‑14). By contrast, the 2023 filing stresses that new or worsening risks – such as the need to maintain a safe store environment (shrink, organized retail crime) and escalating cyber‑security threats that could disrupt systems or expose personal data – could damage associate morale, safety perception and the ability to work effectively, thereby threatening the positive associate experience cultivated through the 2022 engagement initiatives (see 2023 p. 20‑21).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2022 engagement initiatives (surveys, digital platform, recognition, DEI, compensation) are accurately described, and the 2023 risks (store safety, organized retail crime, cybersecurity threats) are correctly identified. The impact on associate morale, safety perception, and the potential erosion of prior engagement gains is semantically equivalent to the original answer. (2) There are no numeric values (percentages, dollar amounts, etc.) in either answer, so quantitative accuracy is not compromised—no discrepancies exist. (3) The multi-hop reasoning is sound: the model correctly contrasts 2022's internal engagement focus with 2023's external risk environment and synthesizes how the latter could undermine the former. The only minor shortcoming is that the original answer explicitly notes that 'four out of five associates were emotionally committed'—a specific data point from the 2022 context that the LLM omits. While the LLM mentions emotional commitment, it does not include this supporting statistic, making it slightly less complete. (4) Contextual relevance is excellent: the response directly addresses the evolution of risks and their potential impact on the associate experience compared to prior-year initiatives. Overall, the answer is factually correct, well-reasoned, and only slightly less detailed than the ground truth due to one missing statistic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 410,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the role of the 'learning curve' in influencing cost and production estimates evolved between 2022 and 2023, particularly in relation to program profitability and risk management?",
      "original_answer": "In 2022, the 'learning curve' was identified as a risk factor that could negatively impact program profitability due to production complexities, rework, and delays—especially in programs like the 787—potentially leading to additional losses and abnormal production costs. By 2023, the 'learning curve' was no longer framed solely as a risk but was integrated into the company's cost estimation process, factored into production rate assumptions, supplier performance trends, and internal labor efficiency projections. This shift indicates that Boeing began treating the learning curve as a predictable and manageable component of production planning rather than an unpredictable risk.",
      "llm_answer": "In the 2022 filing the discussion of cost and production estimates focuses on factors such as certification timing, supply‑chain impacts and production‑rate changes, but it does not call out the learning‑curve effect. By the 2023 filing, the learning curve is listed explicitly among the variables that shape program‑level cost, revenue and gross‑margin forecasts, and the company notes that improvements (or setbacks) on the learning curve directly affect program profitability and the magnitude of reach‑forward losses, making it a central element of its risk‑management and margin‑control process.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in its timeline (2022 vs 2023) and correctly identifies the shift in how the learning curve is treated—from not being explicitly mentioned in 2022 to being a central factor in 2023 cost and profitability forecasting. The quantitative accuracy is perfect: no incorrect numbers, dates, or financial figures are cited, and the years are correct. However, the LLM incorrectly states that the 2022 filing 'does not call out the learning-curve effect,' which contradicts the ground truth stating that in 2022, the learning curve was explicitly identified as a risk factor related to production complexities, rework, and delays (especially on the 787 program). This omission of a key fact from 2022 undermines the qualitative accuracy. The ground truth shows the learning curve was discussed in 2022 as a risk, but by 2023 it was reframed as a manageable, integrated component of planning. The LLM instead implies it was absent in 2022 and newly introduced in 2023, which misrepresents the evolution. Despite this, the answer captures the core shift in treatment by 2023 and links it correctly to profitability and risk management, supporting a moderate-high correctness score. Contextual relevance is high as the response directly addresses the question’s focus on evolution, cost estimation, profitability, and risk management.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 376,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the treatment or disclosure of the Dividend Reinvestment Plan evolved between the 2023 and 2024 SEC filings, particularly in relation to officer or director participation and associated trading arrangements?",
      "original_answer": "In the 2023 filing, the Dividend Reinvestment Plan was mentioned in the context of officer or director participation alongside the employee stock purchase plan and 401(k) plan, with specific reference to elections to have shares withheld for tax purposes or to pay the exercise price of stock awards. The disclosure also included a detailed description of how these elections may be structured under Rule 10b5-1 or non-Rule 10b5-1 trading arrangements as defined in Item 408(c) of Regulation S-K. In the 2024 filing, the Dividend Reinvestment Plan was again referenced in the context of officer or director participation, but the detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements was omitted, indicating a simplification or standardization of the disclosure without the earlier level of specificity regarding trading frameworks.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K filings contain the same Item 9B disclosure stating that “certain of our officers or directors have made elections to participate in, and are participating in, our dividend reinvestment plan… and may make elections to have shares withheld… which may be designed to satisfy the affirmative‑defense conditions of Rule 10b5‑1 … or may constitute non‑Rule 10b5‑1 trading arrangements.” The language and scope of the disclosure are unchanged, indicating no evolution in how the dividend reinvestment plan’s officer/director participation and related trading arrangements are reported.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that the disclosure language is unchanged between the 2023 and 2024 filings. The ground truth states that while both years mention officer or director participation in the Dividend Reinvestment Plan, the 2024 filing omits the detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements that was present in the 2023 filing. The LLM incorrectly asserts that the language and scope are identical, which contradicts the ground truth. There are no numeric values to evaluate, so quantitative accuracy is scored as 10 by default. However, the qualitative accuracy is very low because the model fails to identify a key change in disclosure specificity, misrepresents the evolution (or lack thereof), and does not reflect the simplification noted in the original answer. The answer is contextually relevant—addressing officer/director participation and trading arrangements—but fundamentally wrong in its conclusion. This represents a failure in multi-hop reasoning: the model should have compared the two disclosures and identified the omission in 2024, but instead assumed consistency without recognizing the reduced detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 334,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has The Home Depot's investment in creating an interconnected shopping experience evolved from fiscal 2021 to fiscal 2023, and what specific changes were made in the way this experience is tailored to customers?",
      "original_answer": "In fiscal 2021, The Home Depot invested $2.6 billion in capital expenditures focused on supporting an interconnected customer experience. By fiscal 2023, the company had advanced this strategy by leveraging enhanced merchandising information technology tools to build an interconnected shopping experience tailored to customers' shopping intent and location. This represents a shift from general investment in interconnectedness to a more refined, data-driven personalization strategy.",
      "llm_answer": "By fiscal 2021 The Home Depot said it had begun “strategic investments … aimed at creating an interconnected, frictionless shopping experience” and backed that effort with **$2.6 billion of capital expenditures** to build the digital‑physical blend. By fiscal 2023 the spend had risen to **$3.2 billion** and the focus had shifted to concrete upgrades: a more robust website and mobile‑app platform (richer product pages, related‑item suggestions, faster checkout and personalized marketing), expanded fulfillment options (same‑day/next‑day delivery, BOPIS/BOSS services), and store‑level changes such as way‑finding signage, self‑service lockers, curb‑side pickup, electronic shelf‑labeling, redesigned service desks, expanded self‑checkout and app‑driven in‑store navigation. These enhancements are driven by new merchandising‑technology tools that **tailor the interconnected experience to each customer’s shopping intent and location**.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the quantitative claim that capital expenditures rose to $3.2 billion in fiscal 2023. The ground truth only confirms $2.6 billion in fiscal 2021 and does not provide the total capital expenditure for fiscal 2023. Therefore, the $3.2 billion figure is unsupported and incorrect. All other specific numbers (e.g., $2.6 billion in 2021) are accurate. (2) The qualitative aspects are mostly correct: the shift to leveraging enhanced merchandising IT tools to tailor the experience by shopping intent and location is accurately reflected. The LLM elaborates with plausible and contextually relevant enhancements (e.g., app-driven navigation, BOPIS, electronic shelf labeling), which align with the concept of a more personalized, interconnected experience. However, these specific examples (e.g., self-service lockers, redesigned service desks) are not present in the ground truth and represent over-specificity or potential hallucination. (3) The multi-hop reasoning is partially sound: the model correctly identifies the evolution from general investment in 2021 to a more tailored, technology-driven approach in 2023. It synthesizes the idea of personalization via intent and location, which matches the ground truth. However, the unsupported expenditure figure and unverified operational details weaken the reasoning chain. (4) The contextual relevance is high—the answer directly addresses both parts of the question (evolution over time and changes in tailoring). The core conceptual shift is accurately captured, but the inclusion of unverified dollar amounts and specific initiatives reduces factual correctness. Thus, the correctness score is 6 due to major quantitative error but otherwise reasonable qualitative alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 488,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the financial relationship between DHR and Aldevron evolved between 2022 and 2023, particularly in terms of capital investment and acquisition-related expenditures?",
      "original_answer": "In 2022, DHR anticipated capital expenditures of approximately $1.5 billion, with a portion of this spending attributed to increased manufacturing capacity for products related to the Aldevron Acquisition, among others. This reflects a growing capital commitment tied to Aldevron. By 2023, the financial relationship had evolved significantly, as evidenced by the net cash consideration paid to Aldevron amounting to $9,561 million, indicating that Aldevron had transitioned from being primarily a capital investment target to a core component of DHR's consolidated assets. This represents a substantial shift in the nature of their relationship from a dependency to a stakeholding and integration model.",
      "llm_answer": "The 2021 Aldevron purchase was a one‑time, cash‑heavy deal – DHR paid roughly $9.6 billion (financed with cash on hand and commercial‑paper proceeds) and recorded about $6.1 billion of goodwill and $28 million of transaction‑related costs (the only acquisition‑related expense shown for Aldevron)【page_73】.  By 2022‑23 the focus shifted to ongoing capital spending: DHR’s 2022 capital‑expenditure plan was about $1.5 billion, and the company reported property‑plant‑and‑equipment purchases of $87 million in 2022 and $136 million in 2023, reflecting continued investment in the Aldevron‑derived life‑sciences assets rather than any new acquisition outlay【page_59】【page_72】.  Thus, the relationship moved from a large, one‑off acquisition cost in 2021 to routine, increasing capital investment in the business in 2022‑23, with no additional Aldevron‑specific acquisition expenses reported.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) It incorrectly states the Aldevron acquisition occurred in 2021, while the ground truth indicates the acquisition-related cash payment was made in 2023 ($9,561 million). This misalignment in timing is critical and leads to a fundamentally flawed narrative. (2) The LLM claims DHR paid $9.6 billion in 2021, but the original answer specifies that the $9,561 million net cash consideration was paid in 2023, not 2021. This error distorts the evolution of the financial relationship. (3) The LLM cites $87 million and $136 million in PP&E purchases in 2022 and 2023 as evidence of capital investment tied to Aldevron, but the ground truth only mentions a $1.5 billion capital expenditure plan in 2022 with a portion allocated to Aldevron-related capacity — it does not provide specific PP&E figures for Aldevron, so the LLM introduces unsupported precision. (4) The mention of $6.1 billion in goodwill and $28 million in transaction costs, while potentially accurate details, are not in the ground truth and shift focus away from the actual evolution described: from anticipated CapEx in 2022 to full acquisition integration in 2023. (5) The reasoning is partially sound in identifying a shift from acquisition to integration/capital investment, but the multi-hop logic fails because it misplaces the acquisition event by two years, reversing the correct temporal sequence. While the answer addresses the question's intent and is contextually relevant, the quantitative inaccuracies — especially the wrong year for the acquisition and incorrect cash outflow timing — severely reduce factual correctness. Minor format flexibility is allowed (e.g., $9.6B vs $9,561M), but the conflation of years and introduction of unverified figures result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 500,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the structure and total value of Telco LLC's preferred interests evolved from 2022 to 2024, and what changes were made to the distribution rates and reset schedules during this period?",
      "original_answer": "In 2022, Telco LLC had $2,000 in nonconvertible cumulative preferred interests (Telco Class A-1) with an initial preferred distribution rate of 4.25% annually, subject to reset every seven years. By 2024, Telco LLC expanded its preferred interests with the issuance of an additional $5,250 in preferred interests (Telco Class A-2 and A-3) in April 2023, bringing the total cumulative preferred interests to $7,250. The new preferred interests (Class A-2 and A-3) carried a significantly higher initial preferred distribution rate of 6.85% annually, with the first reset scheduled for November 1, 2027, and every seven years thereafter. This represents both a structural expansion in the capital stack and a strategic shift toward higher-yielding preferred instruments.",
      "llm_answer": "In the 2022 filing AT&T reported only one Telco LLC series – the September‑2020 issuance of **$2 billion** of non‑convertible cumulative preferred interests (Telco Class A‑1) that paid a **4.25 % annual distribution** and reset **every seven years**.  \n\nBy the 2024 filing the structure had expanded to **three series**: the original A‑1 ($2 billion) plus the April‑2023 issuance of **$5.25 billion** of Class A‑2 and A‑3 interests, bringing total Telco preferred interests to **$7.25 billion**.  The new A‑2/A‑3 series pay a **higher 6.85 % annual distribution** and are set to reset on **November 1, 2027** (and every seven years thereafter), while A‑1 retains its 4.25 % rate and seven‑year reset.  The 2024 filing also disclosed a planned **$2.25 billion Class A‑4** issuance (to be issued in 2025) that would carry a **5.94 % distribution** and reset **every four years starting November 1, 2028**.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the initial 2022 structure: $2 billion in Telco Class A-1 preferred interests with a 4.25% annual distribution rate and a seven-year reset cycle. It also accurately reports the April 2023 issuance of $5.25 billion in new preferred interests (Class A-2 and A-3), bringing the total to $7.25 billion by 2024, and correctly states the 6.85% distribution rate and November 1, 2027 reset date for the new series. These core facts align with the ground truth and reflect proper multi-hop synthesis across filings.\n\nHowever, the LLM introduces significant information not present in the ground truth: the planned $2.25 billion Class A-4 issuance in 2025 with a 5.94% distribution rate and four-year reset starting November 1, 2028. This detail is absent from the original answer and cannot be verified against the provided knowledge graph. Its inclusion constitutes a factual hallucination, severely impacting quantitative accuracy. While the rest of the numerical data is correct in format and value (e.g., $2 billion, $5.25 billion, 6.85%, 2027 reset), the addition of unverified future issuances undermines the answer's reliability.\n\nThe answer is contextually relevant and well-structured, addressing the evolution of structure, total value, distribution rates, and reset schedules. The reasoning for the existing tranches is sound and synthesizes changes over time correctly. However, the unsupported projection of a future issuance and its terms represents a critical error in factual completeness and accuracy, preventing a higher score. The core evolution up to 2024 is mostly correct, but the extra details introduce material inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 456,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has AIG's use of Expected Loss Ratio Methods evolved between 2022 and 2024, particularly in terms of the types of insurance lines and the rationale for their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to their high-severity nature. By 2024, AIG expanded the use of Expected Loss Ratio Methods to include U.S. Workers' Compensation, a long-tail line of business, where it was used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different insurance lines with varying claim characteristics.",
      "llm_answer": "In the 2022 filing AIG said it applied Expected‑Loss‑Ratio (ELR) methods mainly to **aviation** (a short‑tail, severity‑driven line) and to the **latest accident year** of other businesses, using ELR together with development techniques when the loss pattern was short‑tailed or when a quick estimate was needed. By the 2024 filing the company had broadened ELR use to **all business written in excess of a deductible** (e.g., excess‑of‑deductible casualty and property layers) and continued to rely on it for the most recent accident years, now explicitly weighting ELR for the last five years and calibrating the ratios to **rate changes, loss‑trend inflation and evolving market conditions** to compensate for inconsistent or slow‑emerging loss development.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant factual inaccuracies in entity identification and evolution of method application. (1) Correct elements: The use of Expected Loss Ratio (ELR) methods in 2022 for aviation and the latest accident year aligns with the ground truth, as does the rationale involving short-tail, high-severity lines. The mention of combining ELR with other methods and adapting to slow-emerging loss patterns in 2024 shows understanding of methodological reasoning. (2) Quantitative accuracy is high: no specific numbers (percentages, dollar amounts) are present in either answer, so the absence of incorrect figures supports a score of 8. Minor deductions due to lack of verifiable metrics. (3) Multi-hop reasoning is partially sound but flawed: while the model infers expansion of ELR use by 2024, it incorrectly identifies the new applications as 'all business written in excess of a deductible' and excess-of-deductible layers—this is not supported by the ground truth. Instead, the actual expansion was to U.S. Workers' Compensation, a long-tail line, which the LLM fails to mention entirely. This is a major omission affecting qualitative accuracy. (4) The rationale about calibrating ELR to rate changes, loss-trend inflation, and market conditions adds detail not present in the original, but without confirmation from the source, it introduces unverified information. The core evolution—application to a long-tail line like Workers' Compensation—is missing, undermining the correctness of the synthesis. Thus, while the answer is contextually relevant and plausibly reasoned, it substitutes key factual content, leading to a correctness score of 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 460,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has Target's approach to its owned brands evolved from 2023 to 2024, particularly in terms of strategic emphasis and product portfolio development?",
      "original_answer": "In 2023, Target emphasized expanding its owned brands portfolio as a core strategic element to drive relevancy and market share growth. By 2024, the company shifted focus to producing a broad range of owned and exclusive brands, listing over 40 distinct brands across various categories, indicating a more concrete execution phase of brand development and diversification.",
      "llm_answer": "In its 2023 Form 10‑K, Target said that a core pillar of its strategy was “delighting with newness, style, and value by **strengthening our owned‑brands portfolio**” (2023 p. 3). By the 2024 filing, the company had turned that strategic intent into a much larger, concrete product set – enumerating more than 60 owned and exclusive brands and noting that **about one‑third of Merchandise Sales now come from those owned brands** (2024 p. 6). Thus, Target moved from a broad strategic emphasis on bolstering its private‑label mix in 2023 to a substantially expanded, revenue‑significant owned‑brand portfolio in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the correct directional evolution of Target's strategy from 2023 to 2024—shifting from strategic emphasis on owned brands to a more concrete, expanded portfolio. However, there are significant quantitative inaccuracies: the LLM claims Target had 'more than 60 owned and exclusive brands' in 2024, while the ground truth states 'over 40', which is a substantial discrepancy. Additionally, the LLM introduces a specific financial metric—'about one-third of Merchandise Sales now come from those owned brands'—which is not present in the original answer and cannot be verified from the provided ground truth. This introduces unsupported data, reducing quantitative accuracy. The qualitative reasoning is sound in identifying a strategic shift and interpreting it as a move from intent to execution, aligning with the multi-hop requirement of comparing strategic language across years. Entity accuracy (Target, 2023 to 2024 timeframe, owned brands) and contextual relevance are strong, as the response directly addresses the question’s focus on strategic emphasis and product portfolio development. However, the inclusion of unverified numbers and sales percentages undermines factual correctness, preventing a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 347,
        "total_tokens": 1595
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "What does IBM's continued listing of the 0.875% Notes due 2030 in 2024 alongside the new 2.900% Notes due 2030 suggest about its debt financing strategy and the market conditions for long-term borrowing?",
      "original_answer": "In 2023, IBM listed the 0.875% Notes due 2030 (trading symbol IBM30A) among its registered securities, indicating its initial issuance of this long-term debt instrument. By 2024, IBM not only maintained the 0.875% Notes due 2030 in its capital structure but also introduced a new 2.900% Notes due 2030 (trading symbol IBM30C). The significant increase in the interest rate—from 0.875% to 2.900%—for the same maturity year suggests that IBM may have pursued additional financing in 2024 under less favorable interest rate conditions, or it may be targeting different investor segments with varied risk-return profiles. This dual listing could also indicate a strategic effort to diversify its debt portfolio and manage refinancing risks by having multiple instruments maturing in the same year but with different coupon rates.",
      "llm_answer": "IBM’s 2024 registration statement still lists the legacy 0.875 % Notes due 2030 (IBM 30A) and, for the first time, a new 2.900 % Notes due 2030 (IBM 30C)【page_1】. By keeping the ultra‑low‑coupon 0.875 % issue on its books while adding a higher‑coupon 2.9 % issue, IBM is preserving cheap, existing long‑term debt and simultaneously raising fresh capital at current market rates, which have risen since the original issue—showing a strategy of diversifying its maturity profile in an environment of higher long‑term borrowing costs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key facts: IBM continued listing the 0.875% Notes due 2030 (IBM30A) in 2024 and introduced a new 2.900% Notes due 2030 (IBM30C). The percentages (0.875% and 2.900%), maturity year (2030), and trading symbols (IBM30A, IBM30C) are all accurate and match the ground truth. There are no calculation errors. (2) Quantitative accuracy is perfect: all numbers, including interest rates and years, are correct and properly contextualized. The format variation (2.9% vs 2.900%) is acceptable and semantically equivalent. (3) The reasoning is sound and captures the core multi-hop insight: IBM is maintaining cheap legacy debt while issuing new debt at higher rates, reflecting a strategy of debt diversification amid rising long-term borrowing costs. The LLM correctly infers market conditions (higher rates since original issuance) and strategic intent (preserving cheap debt, raising fresh capital). However, it omits one nuance from the ground truth: the possibility of targeting different investor segments or managing refinancing risk through multiple instruments with the same maturity but different coupons. This minor omission prevents a perfect qualitative score. (4) The answer is highly contextually relevant, directly addressing IBM’s debt financing strategy and market conditions for long-term borrowing. Overall, the LLM conveys the same essential information as the ground truth with excellent factual accuracy and strong reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 412,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the composition of AT&T's long-term debt instruments evolve between 2022 and 2024, particularly regarding the 4.000% Global Notes due June 1, 2049 and the addition of new long-term notes?",
      "original_answer": "In 2022, AT&T listed the 4.000% Global Notes due June 1, 2049 (T 49A) among other long-term debt instruments, but did not include the 4.300% Global Notes due November 18, 2034. By 2024, the 4.000% Global Notes due 2049 remained registered under the same symbol (T 49A), and the company added the 4.300% Global Notes due 2034 (T 34C). This indicates that AT&T expanded its long-term debt portfolio by introducing new maturities while maintaining existing long-dated obligations like the 2049 notes.",
      "llm_answer": "In the 2022 Form 10‑K, AT&T’s registered long‑term debt stopped at notes maturing in 2025‑2033 and did not include any issue beyond that horizon, so the 4.000 % Global Notes due June 1 2049 were absent. By the 2024 filing, the debt register had been expanded to include a 4.000 % Global Note due June 1 2049 (T 49A) together with a series of newer, longer‑dated issues – e.g., 4.250 % notes due 2043 and 2050, 4.875 % due 2044, 3.375 % due 2034, 2.450 % due 2035, 3.150 % due 2036, 2.600 % due 2038, 1.800 % due 2039, 7.000 % due 2040, and 5.350 %/5.625 % notes due 2066/2067. Thus, AT&T’s long‑term debt shifted from a concentration of mid‑term notes to a broader mix that added the 2049 instrument and several new, longer‑maturity, higher‑coupon notes.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative Accuracy: The claim that the 4.000% Global Notes due June 1, 2049 were absent in the 2022 filing is incorrect — the Original Answer (ground truth) states they were present in 2022 under symbol T 49A. The LLM incorrectly asserts that AT&T’s 2022 debt only extended to maturities up to 2033 and omitted the 2049 notes, which contradicts the ground truth. Additionally, the LLM lists numerous new notes (e.g., 4.250% due 2043, 4.875% due 2044, etc.) not mentioned in the ground truth, including a 5.350%/5.625% note due 2066/2067, which are unsupported by the provided information. The only new note confirmed in the ground truth is the 4.300% Global Notes due November 18, 2034 (T 34C), which the LLM fails to mention and instead references a 3.375% due 2034 — a different instrument. (2) Completeness: While the question asks about the evolution involving the 4.000% 2049 notes and the addition of new long-term notes, the LLM misrepresents both the baseline (2022) and the change by 2024. It invents multiple new debt instruments not in the ground truth, failing to accurately report the specific addition of the 4.300% 2034 notes. (3) Entity Accuracy: The company (AT&T) and the 2049 note symbol (T 49A) are correctly identified, but the 2034 note is misrepresented in terms of coupon rate and symbol. The LLM also fabricates several other notes with incorrect maturity years and coupon rates. (4) Reasoning: The multi-hop reasoning is flawed — the model incorrectly infers that the 2049 notes were added between 2022 and 2024 when they were already present in 2022. It also suggests a strategic shift toward longer-dated, higher-coupon debt based on fabricated data, leading to an invalid conclusion. (5) Semantic Equivalence: The overall message — that AT&T expanded its debt portfolio — aligns loosely with the ground truth, but the specific facts, numbers, and instruments are largely incorrect. Due to major factual and quantitative errors, the correctness score is low despite some structural relevance to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 569,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the financial impact of the Heritage AspenTech acquisition evolve between 2023 and 2024, particularly in terms of intangibles amortization and restructuring costs?",
      "original_answer": "In 2023, the intangibles amortization related to the Heritage AspenTech acquisition was $258, while in 2024, this figure decreased to $97. Additionally, restructuring costs were $72 in 2023 and increased to $228 in 2024. This indicates a reduction in the amortization burden but a significant rise in restructuring expenses over the two years.",
      "llm_answer": "The Heritage AspenTech deal added $258 million of intangible‑asset amortization in 2023; by 2024 total intangibles amortization had risen to $1,077 million, the bulk of the increase ($560 million) coming from the National Instruments acquisition, while the AspenTech‑related amortization remained roughly the same.  At the same time, restructuring expenses grew sharply, from $72 million in 2023 to $228 million in 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. According to the ground truth, intangibles amortization related to the Heritage AspenTech acquisition decreased from $258 million in 2023 to $97 million in 2024. However, the LLM claims that AspenTech-related amortization remained roughly the same and that total intangibles amortization rose to $1,077 million due to the National Instruments acquisition, which is not mentioned in the original answer and contradicts the specific focus on AspenTech. The restructuring cost increase from $72M to $228M is correctly reported. (2) Quantitative inaccuracies include the false claim of total amortization rising to $1,077M and the incorrect assertion that AspenTech amortization remained stable, when in fact it dropped by over 60% (from $258M to $97M). The only correct numbers are the 2023 restructuring cost ($72M) and 2024 restructuring cost ($228M). (3) The reasoning is flawed because it introduces a new acquisition (National Instruments) not referenced in the original data and fails to acknowledge the decline in AspenTech-related amortization. This breaks the multi-hop synthesis required—tracking AspenTech-specific amortization across years. (4) Scores are low due to major factual and quantitative errors, though the answer is contextually relevant in discussing amortization and restructuring costs over the two years, hence a moderate contextual relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1197,
        "completion_tokens": 398,
        "total_tokens": 1595
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has AIG's use of expected loss ratio methods for workers' compensation evolved between 2022 and 2024, particularly in relation to the segmentation of business types and the impact of large deductible accounts?",
      "original_answer": "In 2022, AIG applied expected loss ratio methods primarily to guaranteed cost business in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that the proportion of large deductible business had increased, slowing the reporting pattern of claims. By 2024, AIG continued to use expected loss ratio methods but placed greater emphasis on segmentation by deductible size and claim handling (AIG vs. third-party administrators), and explicitly highlighted the increasing influence of large deductible accounts on slowing claim emergence. Additionally, 2024 disclosures emphasized limitations in claim count data due to aggregation and reinsurance exclusions, which were not as prominently noted in 2022.",
      "llm_answer": "AIG’s 2024 filing repeats the same reserving approach that was described in the 2022 filing. For workers’ compensation it still **uses a mix of loss‑development, frequency‑/severity and Expected‑Loss‑Ratio (ELR) methods**, giving ELR “significant weight” for **excess‑of‑deductible business in the most recent five accident years** (and only for the most recent year for guaranteed‑cost business) 【page_149】. The company continues to **segment the line into guaranteed‑cost and excess‑of‑deductible portions, further breaking the excess segment out by state, industry and deductible size**, and notes that **the proportion of large‑deductible accounts has increased, slowing the reporting pattern of claims** 【page_151】【page_260】. Thus, between 2022 and 2024 the methodology and segmentation have remained essentially unchanged, with the same emphasis on ELR for large‑deductible accounts and the same recognition that the growing share of those accounts lengthens claim emergence.",
      "correctness_score": 5,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant qualitative inaccuracy in its core conclusion. It correctly reports that in 2022, AIG applied the Expected Loss Ratio (ELR) method with significant weight to excess-of-deductible business over the most recent five accident years and to guaranteed cost business only in the most recent year. It also accurately notes the segmentation by state, industry, and deductible size, and the increasing proportion of large-deductible accounts slowing claim reporting — details supported in both years. However, the LLM incorrectly concludes that the methodology and segmentation 'have remained essentially unchanged' between 2022 and 2024. This contradicts the ground truth, which states that by 2024, AIG placed *greater emphasis* on segmentation by deductible size and claim handling (AIG vs. third-party administrators), and *explicitly highlighted new limitations* in claim count data due to aggregation and reinsurance exclusions — issues not prominently noted in 2022. The LLM fails to identify these evolutionary changes, misrepresenting continuity where there is documented progression. While all cited numbers, dates, and entity references (e.g., business types, accident years) are factually accurate and contextually relevant, the failure to capture the nuanced evolution in methodology and disclosure represents a major gap in multi-hop reasoning and synthesis. The answer is semantically close but misses key differentiating insights between the two years, particularly around enhanced segmentation and data limitations in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1468,
        "completion_tokens": 434,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has Target's approach to cybersecurity threat investigation and response evolved from 2023 to 2024, particularly in terms of its Cyber Fusion Center operations and collaboration with external organizations?",
      "original_answer": "In 2023, Target operated its Cyber Fusion Center as part of its threat investigation and response capabilities, and emphasized collaboration with organizations across industries to share threat intelligence and best practices. By 2024, Target not only maintained its Cyber Fusion Center but also introduced a more structured incident response program with a coordinated escalation model to inform management and the Board of Directors during security incidents. Additionally, in 2024, Target expanded its external engagement by incorporating regular training and compliance activities for team members, and by leveraging third-party vendors to assess and test its cybersecurity program. This represents a more comprehensive and mature approach to cybersecurity threat response and collaboration.",
      "llm_answer": "In its 2023 filing Target already operated a Cyber Fusion Center that “investigates and responds to threats” and said it “shares threat‑intelligence and collaborates with organizations across different industries.” By the 2024 filing the Center’s role was expanded – it is now tied to a proactive threat‑intelligence program, uses a coordinated escalation model, and is supported by regular penetration‑testing, vulnerability‑scanning and attack‑simulation, while Target also formalizes external partnerships by engaging leading security‑technology vendors, third‑party assessors and insurance coverage to augment its investigative and response capabilities. Thus, Target’s approach has moved from a basic fusion‑center and industry‑wide intel‑sharing model to a more integrated, continuously‑tested operation that leverages additional external expertise and risk‑transfer mechanisms.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Target operated a Cyber Fusion Center in 2023 focused on threat investigation and industry collaboration, and by 2024 had enhanced its program with a coordinated escalation model, expanded external engagement, and third-party assessments. The LLM correctly identifies the evolution in operations and collaboration. (2) There are no numeric values (e.g., dollar amounts, percentages) in the question or ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across 2023 and 2024 filings, correctly identifying the progression from basic threat sharing to a more structured, tested, and externally supported cybersecurity program. The mention of penetration testing, vulnerability scanning, and attack simulation is consistent with 'leveraging third-party vendors to assess and test' in the original answer. (4) Minor wording differences exist—'proactive threat-intelligence program' and 'risk-transfer mechanisms' (e.g., insurance) are slight expansions not explicitly detailed in the ground truth—but these are reasonable inferences and do not contradict facts. Overall, the answer captures the core evolution accurately and comprehensively, warranting a high correctness score with only a minor deduction for slight over-elaboration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 396,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did Eli Lilly's financial relationship with Baqsimi evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual arrangements?",
      "original_answer": "In 2023, Eli Lilly reported $579.0 million in revenue specifically attributed to the sale of the rights for Baqsimi. By 2024, Baqsimi was included within broader collaboration and other revenue disclosures, reflecting its integration into revenue from collaborations and other arrangements, which included the 2023 sales of rights for both the olanzapine portfolio and Baqsimi. This shift indicates a move from direct product revenue to a more complex revenue recognition model under collaborative arrangements, suggesting a strategic evolution in how the company accounts for and manages its financial relationship with Baqsimi.",
      "llm_answer": "In 2023 Eli Lilly recorded a one‑time, upfront payment for the **sale of the Baqsimi rights** – about **$579 million** – which was booked under **“collaboration and other revenue.”** That amount was reflected in the 2023 revenue table (total Baqsimi revenue of $677.6 million, $645.7 million U.S. and $31.9 million outside the U.S.) and contributed to the higher 2023 collaboration revenue ($5,310.2 million).  \n\nBy 2024 the rights‑sale transaction had been completed, so Baqsimi’s contribution shifted to ordinary product sales (included in net product revenue) and the **collaboration‑revenue line fell to $4,294.8 million**, reflecting the absence of another rights‑sale. The accounting treatment remained the same – the upfront rights payment was recognized when control transferred under the licensing contract – but the **revenue source moved from a large, one‑off licensing receipt in 2023 to routine product‑sale revenue in 2024.**",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly undermine its correctness. (1) Quantitative Accuracy: The $579 million from the sale of Baqsimi rights in 2023 is correctly stated and aligns with the ground truth. However, the LLM introduces additional figures not present in the original answer—such as total Baqsimi revenue of $677.6 million, U.S. and international splits, and collaboration revenue totals of $5,310.2 million (2023) and $4,294.8 million (2024)—which are not supported by the ground truth and appear to be fabricated or misattributed. These numbers cannot be verified and contradict the original answer’s focus on the $579 million as the key revenue event. (2) Completeness: While the question asks about revenue recognition and contractual arrangements, the LLM incorrectly frames the 2024 shift as Baqsimi moving to 'ordinary product sales' in net product revenue. The ground truth states that Baqsimi was instead integrated into broader collaboration and other revenue disclosures in 2024, not shifted to product sales. This is a critical error in both direction and classification. (3) Entity Accuracy: The companies (Eli Lilly) and years (2023, 2024) are correct, and 'collaboration and other revenue' is a valid category. However, the use of specific revenue line items without source support reduces reliability. (4) Reasoning: The multi-hop reasoning fails—the original answer describes a consolidation of Baqsimi into a broader revenue category alongside olanzapine, indicating continued treatment under collaborative arrangements. The LLM incorrectly infers that the absence of a large payment means Baqsimi revenue became product revenue, which contradicts the ground truth. (5) Semantic Equivalence: The core idea of a shift in revenue recognition is present, but the nature of the shift is misrepresented. The LLM suggests a move from licensing to product sales; the truth is a move from standalone rights sale to inclusion in a broader collaborative revenue category. This fundamental mischaracterization justifies a low correctness score despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 567,
        "total_tokens": 1963
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did AT&T's approach to managing its capital structure through preferred interests evolve from 2023 to 2024, particularly regarding the repurchase of Mobility Preferred Interests and the expansion of Tower Holdings and Telco LLC preferred interests?",
      "original_answer": "In 2023, AT&T repurchased the remaining 213 million Mobility Preferred Interests for $5,414, removing $2,650 from 'Accounts payable and accrued liabilities' and $2,670 from 'Other noncurrent liabilities.' This repurchase was primarily funded by the issuance of $5,250 in new Telco LLC preferred interests, which carried a 6.85% annual distribution rate. By 2024, AT&T had shifted focus toward expanding its Tower Holdings preferred interests, where $6,000 in 2019 Tower preferred interests were restructured into fixed and floating rate classes with a 5.90% base rate and SOFR + 250 bps, respectively. Additionally, the total Telco LLC preferred interests increased to $7,250, including the original $2,000 (Telco Class A-1) and the 2023 additions. This reflects a strategic pivot from repurchasing legacy preferred interests to leveraging new preferred structures with more flexible redemption and distribution terms to manage capital and liquidity.",
      "llm_answer": "In 2023 AT&T eliminated its legacy Mobility II preferred interests – all 320 million Series A “Mobility preferred interests” were repurchased in April 2023 (the last 213 million were bought back for $5.4 billion) and none remained on the balance sheet at year‑end 2023【page_38†L31-L38】【page_86†L45-L53】.  That repurchase was funded largely by the April 2023 issuance of additional Telco LLC preferred interests (an extra $5.25 billion of non‑convertible cumulative preferred interests) which also expanded the September 2020 Telco transaction【page_38†L23-L30】.  In 2024 the company shifted its preferred‑interest strategy from pure repurchases to restructuring and expanding existing preferred programs: it amended the 2019 Tower Holdings preferred interests (creating fixed‑rate and floating‑rate classes with a 5.90 % distribution for the fixed‑rate tranche) and continued to grow Telco LLC preferred interests to $7.25 billion, while also planning a $2.25 billion Telco Class A‑4 issuance in early 2025 to fund future redemptions【page_87†L9-L23】【page_87†L24-L31】.  Thus, AT&T moved from clearing the Mobility preferred series in 2023 to actively reshaping and enlarging its Tower Holdings and Telco LLC preferred‑interest portfolios in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Correct elements: The 2023 repurchase of 213 million Mobility Preferred Interests for $5.4 billion (rounded from $5,414 million) is correctly reported, as is the funding via $5.25 billion in new Telco LLC preferred interests issued in April 2023. The expansion of Telco LLC preferred interests to $7.25 billion by 2024 is accurately stated. The restructuring of the 2019 Tower Holdings preferred interests into fixed- and floating-rate tranches with a 5.90% base rate is also correctly described. (2) Quantitative verification: Minor rounding is acceptable—$5,414 million → $5.4 billion and $5,250 million → $5.25 billion are standard. The $7.25 billion total for Telco LLC matches the ground truth (original $2,000M + $5,250M = $7,250M). The mention of a planned $2.25 billion Telco Class A-4 issuance in 2025 is an additional detail not in the original answer but does not contradict it and may reflect forward-looking info from the source. (3) Multi-hop reasoning: The LLM correctly synthesizes information across years and entities—linking the 2023 repurchase to the Telco funding, and the 2024 shift to restructuring Tower and expanding Telco. The strategic pivot narrative is well-supported. (4) One minor discrepancy: The LLM states '320 million Series A' were repurchased, but the ground truth specifies only the 'remaining 213 million' were repurchased in 2023. The 320 million figure may refer to the total series, but without clarification, it risks implying full repurchase occurred in 2023 of that amount. This is a small factual ambiguity. Otherwise, all core financials, dates, and strategic shifts are correct. Hence, a score of 9 is justified—excellent accuracy with a minor entity/quantity clarification issue.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1575,
        "completion_tokens": 488,
        "total_tokens": 2063
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Emerson's relationship with AspenTech evolve from 2023 to 2024, and what financial impacts did this transformation have on Emerson's gross margin and ownership structure?",
      "original_answer": "In 2023, Emerson had a business relationship with AspenTech as part of its Software and Control offerings. By 2024, this relationship transformed into a more significant strategic position, as Emerson acquired a 55% ownership stake in 'New AspenTech' (formerly Heritage AspenTech) following a transaction that included approximately $6.0 billion in cash. This change in relationship had a measurable financial impact: the AspenTech acquisition contributed to a 3.3 percentage point increase in gross margin in 2023 and was part of broader changes that led to a 1.8 percentage point increase in gross margin in 2024. Additionally, the ownership stake marked a structural shift in Emerson’s involvement with AspenTech, moving from a partner to a majority shareholder.",
      "llm_answer": "Emerson’s tie‑up with AspenTech moved from a majority‑owned “Heritage AspenTech” partnership in 2023 to a still‑majority but larger stake and a plan to buy the balance in 2024.  After the 2022‑23 Heritage AspenTech deal Emerson held about **55 %** of the new AspenTech company, and by the end of 2024 that ownership had risen to roughly **57 %** of the outstanding shares, with a November 2024 proposal to acquire the remaining shares and take AspenTech 100 % owned【page 26】.  \n\nThe deeper integration also helped lift Emerson’s overall gross margin: gross margin rose from **49.0 % in 2023** to **50.8 % in 2024**, a 1.8‑percentage‑point increase, driven in part by the AspenTech‑related acquisitions and the Test & Measurement purchase【page 26】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. First, it incorrectly states that Emerson had a 'majority-owned Heritage AspenTech' partnership in 2023—this is false; prior to the transaction, AspenTech was an independent company, and Emerson did not own a majority stake until the 2023 transaction closed. The ground truth confirms that the 55% ownership stake was acquired in 2023 as part of a new transaction, not that it was a continuation of prior ownership. Additionally, the LLM claims ownership increased to 57% by end-2024 and cites a November 2024 proposal to acquire the remainder, but this detail is not present in the original answer and introduces unverified forward-looking information. (2) Quantitative accuracy issues: the gross margin figures cited (49.0% in 2023, 50.8% in 2024) are not in the original answer. The original states that AspenTech contributed a 3.3 percentage point increase in gross margin in 2023 and 1.8 percentage points in 2024—these are incremental impacts, not overall gross margin percentages. The LLM misrepresents these as absolute margin levels, which is a significant error. The $6.0 billion cash amount from the original is omitted. (3) Multi-hop reasoning is partially sound—the model connects ownership change and financial impact—but incorrectly frames the timeline and nature of the relationship evolution. It conflates the pre-transaction relationship with post-acquisition structure. (4) Contextual relevance is high as the answer addresses both ownership and financial impact. However, due to major factual and quantitative errors in ownership timeline, margin interpretation, and unsupported claims about 57% ownership and future acquisition plans, the correctness score is reduced to 6—partially correct but with significant flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 488,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has AIG's Japan pension plans' contribution to non-U.S. pension obligations evolved between 2022 and 2024, and what change occurred in the weighted average discount rate applied to these plans during this period?",
      "original_answer": "In 2022, AIG's Japan pension plans accounted for 61% of total non-U.S. pension assets, with an expected long-term rate of return of 1.85%. By 2024, the Japan pension plans' share of non-U.S. projected benefit obligations decreased to 50% as of December 31, 2024, from 54% in 2023, and the weighted average discount rate increased to 1.81% in 2024 from 1.48% in 2023. This indicates a relative decline in the size of the Japan pension plans within AIG's non-U.S. pension structure, accompanied by a notable increase in the discount rate applied, likely reflecting changes in market conditions or investment strategy.",
      "llm_answer": "AIG’s Japan pension plans provided a smaller cash contribution to the company’s overall non‑U.S. pension obligations in 2024 than they did two years earlier – AIG contributed **$42 million** to the non‑U.S. plans in 2024 (down from the roughly **$47 million** contributed in the prior year and from the similar‑sized contribution reported for the 2022 period).  \n\nAt the same time, the **weighted‑average discount rate used for the Japan plans rose sharply**, moving from the low‑single‑digit rate of **about 0.5 %** (the rate applied at the end of 2022) to **1.81 %** at December 31 2024 (up from 1.48 % in 2023).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that AIG's Japan pension plans accounted for 61% of non-U.S. pension *assets* in 2022 and their share of *projected benefit obligations* decreased to 50% by 2024 (from 54% in 2023). However, the LLM incorrectly frames this as a decline in *cash contributions*, claiming AIG contributed $42 million in 2024 versus $47 million in 2022 and 2023. This dollar amount data is not present in the ground truth and appears to be fabricated. There is no mention of actual cash contributions in the original answer. (2) The only correct quantitative detail is the weighted average discount rate increasing to 1.81% in 2024 from 1.48% in 2023. However, the LLM incorrectly states the 2022 discount rate was 'about 0.5%', while the original answer does not provide the 2022 discount rate at all — it only gives the expected long-term rate of return (1.85%) for 2022, which is a different metric. Confusing these two metrics is a critical error. (3) The multi-hop reasoning is flawed: the LLM conflates pension asset allocation/share of obligations with cash contributions, which are distinct concepts. It also fails to mention the key metric of Japan's share of non-U.S. obligations declining from 61% (implied in 2022) to 50% in 2024, instead inventing contribution figures. The synthesis across years and metrics is therefore unsound. (4) Despite these issues, the answer is contextually relevant — it addresses the evolution of Japan's role and the discount rate trend — and correctly identifies the increase in the discount rate from 1.48% to 1.81%. Hence, partial credit is given for directional understanding, but major factual and conceptual errors severely limit correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 481,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Amazon's disclosure about the impact of competitive stores on its business evolve between the 2022 and 2023 10-K filings, particularly in terms of the framing of external market conditions?",
      "original_answer": "In the 2022 10-K filing, Amazon described competitive stores as a general factor among many that could impact sales and operating results, listing them alongside internal capabilities such as inventory management and customer satisfaction. The 2022 filing included the phrase: 'the introduction of competitive stores, websites, products, services, price decreases, or improvements' as a potential cause of sales fluctuations. In contrast, the 2023 filing retained the same core language but embedded it within a broader context that emphasized external economic and geopolitical conditions, stating that revenue and operating profit growth 'depends on the continued growth of demand for the products and services offered by us or our sellers, and our business is affected by, among other things, general economic, business, and geopolitical conditions worldwide.' This indicates a shift toward framing competitive pressures as part of a larger set of external risks rather than a standalone concern.",
      "llm_answer": "- 2022 10‑K – Amazon mentioned competition only as a specific risk item, stating that “the introduction of competitive stores, websites, products, services, price decreases, or improvements” could affect its sales and operating results.  \n\n- 2023 10‑K – The same language is retained, but it is now grouped with broader external‑market factors such as “changes in usage or adoption rates of the Internet, e‑commerce, electronic devices and web services,” as well as general economic, geopolitical and consumer‑preference trends. Thus, the 2023 filing frames competitive stores as one element of a wider set of market‑condition risks rather than an isolated threat.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Amazon's disclosure between the 2022 and 2023 10-K filings. (1) It correctly identifies that in 2022, competitive stores were listed as a specific risk among operational factors, quoting the key phrase accurately. In 2023, it notes the retention of the same language but correctly emphasizes the broader framing that now includes external market conditions like Internet usage, economic, geopolitical, and consumer trends. (2) There are no numerical values in this question, so quantitative accuracy is not applicable—however, the years (2022 and 2023) are correct and consistently used, satisfying temporal accuracy. (3) The multi-hop reasoning is sound: the model synthesizes the presence of consistent language across filings while correctly identifying the contextual shift in risk framing. The only minor shortcoming is that the original answer highlights the 2023 emphasis on 'continued growth of demand' and 'general economic, business, and geopolitical conditions worldwide' as the new framing context, while the LLM answer substitutes slightly different but related examples (e.g., 'adoption rates of the Internet'). This is semantically close and conveys the same idea but omits the precise emphasis on demand growth. (4) Despite this small omission, the LLM answer maintains high factual correctness, relevance, and proper synthesis, warranting a 9/10 on correctness and qualitative accuracy, and full marks for contextual relevance and quantitative accuracy (by default, as no numbers are involved).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 431,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has Target's exposure to port security risks evolved between 2023 and 2024, particularly in terms of geographic focus and operational impact?",
      "original_answer": "In 2023, Target specifically highlighted California ports as a key area affected by port security issues, mentioning that these ports were where the company received a significant portion of its imported merchandise. By 2024, Target broadened its focus, referring to 'major U.S. ports' without specifically naming California, indicating a more generalized concern across multiple locations. Additionally, in 2023, the company noted it had made alternative arrangements due to past disruptions, while in 2024, the emphasis shifted to potential future impacts, including increased costs and inventory supply issues, due to ongoing global conflicts and labor disputes.",
      "llm_answer": "In the 2023 Form 10‑K Target singled out **California ports** as a key geographic hotspot, noting that periodic closures, ship diversions, labor disputes and congestion there – where it receives a “significant portion” of its imported merchandise – could force the company to make alternative routing arrangements, raise freight‑costs and interrupt the flow of inventory.  \n\nThe 2024 filing still lists **port‑security disruptions** as a supply‑chain risk but broadens the focus to **major U.S. ports overall**, warning that any such port‑related event could increase costs and delay deliveries. The operational impact remains the same – the risk of supply‑chain interruptions and higher expenses – but the geographic emphasis has shifted from a California‑centric view to a nationwide port‑security exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2023, Target highlighted California ports as a major point of entry for imported goods and noted operational risks like alternative routing and cost increases; in 2024, the focus broadened to 'major U.S. ports' with emphasis on potential future impacts such as increased costs and inventory delays. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a traditional sense, but all dates (2023, 2024) and references are factually correct. (3) The multi-hop reasoning is sound—correctly synthesizing changes in geographic focus and operational impact across two years from Target’s 10-K filings. The shift from California-specific to nationwide port exposure is accurately captured. (4) The only minor shortcoming is that the LLM does not explicitly mention 'port security risks' being tied to 'global conflicts' in 2024 as noted in the original answer, though it does reference 'port-security disruptions' and their impacts. This slight omission in contextual detail prevents a perfect 10 on qualitative accuracy. Otherwise, the answer is semantically equivalent, well-structured, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 351,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did Emerson's financial relationship with Heritage AspenTech evolve between 2023 and 2024, particularly in terms of acquisition-related amortization and restructuring costs?",
      "original_answer": "In 2023, Emerson reported $258 million in intangibles amortization related to the Heritage AspenTech acquisition. By 2024, this specific amortization was no longer reported, indicating that the focus had shifted away from AspenTech as a newly acquired entity. Additionally, restructuring costs increased significantly from $72 million in 2023 to $228 million in 2024, suggesting that Emerson undertook more extensive restructuring activities in 2024, potentially reflecting integration efforts or strategic realignments following the AspenTech acquisition.",
      "llm_answer": "In 2023 Emerson still booked acquisition‑related amortization tied to the Heritage AspenTech deal – about **$258 million** of intangible‑asset amortization (the only acquisition‑related component that year). By 2024 that amortization had disappeared, with the much larger **$1.1 billion** of amortization coming from the National Instruments acquisition instead. At the same time, Emerson’s restructuring outlays jumped sharply, rising from roughly **$72 million in 2023** to **$228 million in 2024**.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $258 million intangibles amortization in 2023 related to the Heritage AspenTech acquisition and the increase in restructuring costs from $72 million in 2023 to $228 million in 2024, which matches the ground truth. However, it introduces a significant factual error by stating that $1.1 billion in amortization in 2024 came from the National Instruments acquisition. This information is not present in the original answer and contradicts the ground truth, which states that AspenTech-related amortization was no longer reported in 2024—without attributing the change to another acquisition. (2) The numbers for AspenTech amortization ($258M), restructuring costs ($72M in 2023, $228M in 2024) are accurate and correctly formatted. The $1.1 billion figure for National Instruments is unsupported and incorrect per the provided ground truth, which does not mention National Instruments at all. This is a major quantitative error. (3) The multi-hop reasoning is partially sound—correctly noting the disappearance of AspenTech amortization and increased restructuring as a trend—but the introduction of an unrelated acquisition (National Instruments) undermines the logical synthesis. The conclusion about shifting focus away from AspenTech is plausible, but the reasoning is distorted by incorrect data. (4) The contextual relevance is high because the answer addresses the evolution of financial relationship, including both amortization and restructuring. However, due to the inclusion of false information about National Instruments, the overall correctness and qualitative accuracy are significantly reduced. The core facts are partially right, but the added detail introduces a material error, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 483,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has AIG's use of Expected Loss Ratio methods evolved between 2022 and 2024, particularly in terms of the weight given to this method across different lines of business and accident years?",
      "original_answer": "In 2022, AIG applied Expected Loss Ratio methods primarily for more recent accident years in lines such as D&O, E&O, EPLI, and professional liability, where losses are low frequency and high severity. The method was also used in conjunction with IBNR factor methods for low frequency/high severity losses, with factors continually reevaluated based on emerging claim experience and market factors. By 2024, AIG continued to use Expected Loss Ratio methods but expanded their application to include U.S. Workers' Compensation, a long-tail line of business, where they were used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different risk profiles and a more integrated approach to reserving in complex portfolios.",
      "llm_answer": "In the 2022 filing AIG said that **expected‑loss‑ratio (ELR) techniques are used “more … in the more recent accident years”** and that they are applied alongside loss‑development and frequency‑severity methods for D&O, E&O, EPLI and other professional‑liability lines, with loss‑development taking the lead for older accident years. The discussion was fairly general – ELR was simply noted as a “more‑weighted” input for the newest years, especially for excess‑of‑deductible business.\n\nBy the 2024 filing the company’s language had become more specific.  It now states that **ELR methods can be given “significant weight” in the **most recent five accident years** and that this weighting is especially high for business written in excess of a deductible. The ELR figures are explicitly tied to projected ultimate loss ratios that are adjusted for rate changes, loss‑trend (including inflation) and market conditions. Thus, between 2022 and 2024 AIG moved from a broad statement that ELR gets more weight in recent years to a clearer policy that ELR is a dominant driver for the latest five accident years—particularly for excess‑of‑deductible lines—and that the weight is calibrated with explicit adjustments for pricing, trends and market factors.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, AIG used Expected Loss Ratio (ELR) methods primarily for recent accident years in D&O, E&O, EPLI, and professional liability lines, especially where losses are low frequency and high severity, and that ELR was used alongside other methods like loss development. The 2024 update accurately reflects an expansion in the use of ELR methods, now explicitly giving 'significant weight' to the most recent five accident years—this specific time frame ('five') is not in the original answer but is plausible and does not contradict it, as the original states 'more recent accident years' without specifying how many. (2) There are no numerical inaccuracies; the LLM correctly avoids citing specific percentages or dollar amounts not present in the original. The mention of 'five accident years' is a more precise claim than the original but is consistent with the evolution described and likely based on actual filing language. (3) The reasoning is sound: the LLM correctly infers a trend from 2022 to 2024—increased reliance on ELR, broader application, and more structured calibration using rate changes, inflation, and market conditions. It also correctly notes the integration of ELR with other methods and its dominance in newer years. (4) The expansion to U.S. Workers' Compensation, a key point in the original, is missing in the LLM answer, which prevents a perfect score. This omission reduces completeness, as the extension into a long-tail line like Workers' Compensation is a significant evolution. However, the rest of the synthesis across years and lines is strong. Overall, the answer captures the core evolution accurately and adds plausible detail without introducing errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1521,
        "completion_tokens": 486,
        "total_tokens": 2008
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has the monetization strategy for Amazon's film groups evolved between 2022 and 2023, based on changes in capitalized video and music content costs and associated expenses?",
      "original_answer": "Amazon's monetization strategy for film groups evolved between 2022 and 2023, as evidenced by an increase in both the capitalized video and music content costs and the associated expenses. In 2022, the capitalized costs were $16.7 billion with total video and music expenses of $16.6 billion, while in 2023, these figures increased to $17.4 billion and $18.9 billion, respectively. This indicates a more aggressive investment in content and a corresponding rise in monetization efforts.",
      "llm_answer": "Amazon still treats the produced and licensed video‑and‑music titles in each geography as a single “film group” that is monetized together and tested for impairment. Between 2022 and 2023 the capitalized video‑and‑music portfolio grew modestly—from $16.7 billion to $17.4 billion—while the related expense rose more sharply—from $16.6 billion to $18.9 billion. The larger increase in expense versus capitalized cost shows the strategy shifting toward higher‑cost licensing/production (more content being expensed as incurred) while only a limited amount of new original content is being capitalized.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: capitalized costs increased from $16.7B in 2022 to $17.4B in 2023, and expenses rose from $16.6B to $18.9B—matching the original answer exactly. Number formats are consistent and precise. (2) Quantitative accuracy is perfect: all dollar amounts and year references are correct, and the relative changes (modest increase in capitalized costs, sharper rise in expenses) are accurately described. (3) The multi-hop reasoning is sound—LLM correctly synthesizes data across years and interprets the trend, noting the growing expense relative to capitalized costs. It adds a nuanced interpretation (more content expensed upfront, less capitalized) that is logically supported by the data and consistent with a shift toward higher-cost licensing/production. While the original answer emphasizes 'more aggressive investment and monetization,' the LLM offers a deeper strategic interpretation without contradicting it. (4) The answer is fully contextually relevant, directly addressing the evolution of monetization strategy based on cost and expense trends. The only reason for not scoring 10 is that the LLM slightly reframes the conclusion without explicitly stating the overall increase in monetization efforts as in the original, though the implication is present. Overall, this is a factually correct, well-reasoned, and relevant response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 396,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has Philip Morris International's financial relationship with RBH evolved between 2022 and 2024, particularly in terms of its stake and associated impairment?",
      "original_answer": "In 2022, Philip Morris maintained a trademark relationship with RBH, continuing to report volume of brands sold by RBH such as HEETS and other heated tobacco units. By 2024, PMI held an equity investment in RBH, which became subject to a significant impairment charge of $2,316 million due to unresolved allocation of a $32.5 billion Canadian tobacco litigation settlement among RBH, ITL, and JTIM. This reflects a shift from a trademark and brand licensing relationship to a more direct equity investment facing financial impairment.",
      "llm_answer": "In both the 2022 and 2024 Form 10‑K filings PMI disclosed that it still owned a 49 % equity interest in Rothmans, Benson & Hedges Inc. (RBH), which had been de‑consolidated from PMI’s results in 2019. In the 2022 filing the RBH investment was carried at its historical cost and no impairment charge was reported. By the 2024 filing, after the Canadian CCAA settlement plan created uncertainty about the recoverable value of that stake, PMI concluded the fair value was below carrying amount and recorded a non‑cash impairment of roughly **$2.3 billion** (a $1.49‑per‑share EPS impact).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that PMI maintained a 49% equity interest in RBH in both 2022 and 2024, consistent with the deconsolidation in 2019, which is factually correct and adds contextual detail not in the original answer but not contradicted by it. (2) The quantitative accuracy is strong: the $2.3 billion impairment is correctly reported (ground truth: $2,316 million; LLM: ~$2.3 billion), a negligible rounding difference. The $1.49-per-share EPS impact is an additional precise detail not in the original but does not conflict. The 2022 absence of impairment and cost-based carrying value are correct. (3) The reasoning is sound: the shift from no impairment in 2022 to a significant impairment in 2024 due to uncertainty from the Canadian CCAA settlement (linked to the $32.5B litigation) shows correct multi-hop synthesis between legal developments and financial impacts. The evolution from a licensing relationship (implied in 2022) to a financially impaired equity stake in 2024 is logically conveyed. (4) The LLM enhances the original answer with specific details (49%, deconsolidation in 2019, EPS impact) without introducing errors. The only minor gap is not explicitly mentioning the trademark/brand volume reporting (e.g., HEETS) in 2022, which is part of the original answer’s narrative about the earlier relationship. However, the core financial evolution—equity stake and impairment—is fully and accurately captured. Thus, the answer is semantically equivalent and highly complete, warranting a 9/10 due to slight incompleteness on the pre-2024 brand relationship detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 452,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the sensitivity of LLY's net product revenue to changes in sales return, rebate, and discount liabilities evolve between 2023 and 2024, based on the disclosures in the respective 10-K filings?",
      "original_answer": "In 2023, LLY disclosed that a 5% change in its consolidated sales return, rebate, and discount liability would result in a $615 million change in revenue. In 2024, while the company continued to describe the accounting policy for revenue recognition and accruals for rebates and discounts, it did not provide an updated sensitivity figure. This omission suggests that the company did not disclose a revised estimate for the impact of liability changes on revenue in 2024, indicating a lack of updated quantitative disclosure compared to 2023.",
      "llm_answer": "In the 2023 Form 10‑K, Eli Lilly said that a 5 % change in its consolidated sales‑return, rebate and discount liability would alter revenue by about **$615 million**. In the 2024 filing the same 5 % change was estimated to affect revenue by roughly **$600 million**. Thus, the sensitivity of net product revenue to those liability changes fell slightly—from $615 million in 2023 to $600 million in 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that in 2024, a 5% change in liability would affect revenue by $600 million. According to the ground truth, no such updated sensitivity figure was disclosed in the 2024 10-K. This is a major factual error. The only correct number is the 2023 sensitivity of $615 million, which matches the original answer. (2) The quantitative inaccuracy lies in the fabricated $600 million figure for 2024, which is not supported by the source data. There is no indication in the ground truth that the sensitivity decreased or was re-estimated; rather, the company omitted the disclosure entirely in 2024. Any comparison or trend inference (e.g., 'fell slightly') is therefore invalid. (3) The multi-hop reasoning fails because the model assumes continuity in disclosure when the key point from the ground truth is the absence of updated data in 2024. The correct synthesis should have been that while 2023 included a quantified sensitivity, 2024 did not, limiting comparability. Instead, the model invents a number and draws a false conclusion about trend evolution. (4) Scores are low on correctness and quantitative accuracy due to the critical error in fabricating a 2024 sensitivity value. Qualitative accuracy is slightly higher because the model correctly identifies the nature of the sensitivity analysis and the relevant liabilities, but the reasoning is flawed. Contextual relevance is moderate as the answer addresses the right topic and structure but with incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 417,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has the role and revenue contribution of Bulk shipments evolved from 2022 to 2024, based on Union Pacific's disclosures?",
      "original_answer": "In 2022, Bulk shipments had an average revenue per car of $3,305 in 2021 (referenced in the 2022 filing), showing a 6% increase from 2020. By 2024, Bulk shipments had grown in strategic importance, contributing 32% of total freight revenues, with detailed operations covering grain, fertilizer, and coal markets, including international connections to Mexico and access to Canadian interline routes. This indicates a transformation in the Bulk segment's role from a revenue-per-unit perspective to a more strategically embedded and revenue-significant component of Union Pacific's operations.",
      "llm_answer": "Union Pacific’s 2024 filing shows that bulk shipments (grain, fertilizer, food‑refrigerated, coal and renewables) generated ≈ 32 % of total freight revenue – about $7.3 billion of the $22.8 billion earned that year. In the 2022 filing, bulk revenue was roughly $6.7 billion, representing about one‑third of freight revenue (≈ 33 % of the $20.2 billion total). Thus, from 2022 to 2024 the bulk segment’s share of freight revenue has remained essentially unchanged, while its absolute contribution grew modestly as overall freight revenue increased.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both quantitative and qualitative aspects. While it correctly identifies that Bulk shipments contributed approximately 32% of freight revenue in 2024 (matching the ground truth), it fabricates specific dollar amounts—$7.3 billion in 2024 and $6.7 billion in 2022—that are not present in the original answer or supported by the disclosed data. The ground truth does not provide absolute revenue figures for Bulk shipments in either year, only percentages and strategic context. Additionally, the LLM incorrectly states that Bulk represented 'about one-third' (≈33%) of revenue in 2022, which contradicts the ground truth that emphasizes a shift to 32% in 2024 without specifying the 2022 percentage—thus implying a possible increase, not stability. (2) The calculations involving total freight revenues ($22.8B in 2024, $20.2B in 2022) and derived bulk revenues are entirely invented and cannot be verified from the original answer. There is no mention of $6.7B or $7.3B in the ground truth. The 6% year-over-year increase from 2020 to 2021 in average revenue per car is omitted entirely. (3) The multi-hop reasoning is flawed: instead of tracking the evolution from a per-unit revenue metric to strategic integration and increased relative importance, the model assumes revenue share stability and focuses on fabricated absolute growth. It fails to capture the transformation highlighted in the original answer—from a unit economics focus in earlier years to a strategically embedded role by 2024 with international connections and market coverage. (4) Despite these issues, the answer is contextually relevant, addressing the time frame and topic, and correctly citing the 32% figure for 2024. However, due to invented data and incorrect synthesis, the correctness score is low. Quantitative accuracy is partially acceptable due to the correct 32% figure but penalized for fabricated dollar amounts. Qualitative accuracy suffers due to misrepresentation of trends and omission of key strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 558,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the interest rate of IBM's Notes due 2028 evolve between 2023 and 2024, and what does this indicate about IBM's debt strategy?",
      "original_answer": "In 2023, IBM had 1.750% Notes due 2028 (IBM 28A) listed, and in 2024, the same 1.750% Notes due 2028 (IBM 28A) were still present in the disclosures. This indicates that the interest rate for this specific issuance remained unchanged over the two years. However, IBM introduced new notes with different interest rates in 2024, such as the 2.900% Notes due 2030 and the 3.150% Notes due 2033, suggesting a broader strategy to issue debt at higher rates for longer maturities.",
      "llm_answer": "In both the 2023 and the 2024 Form 10‑K, IBM listed the same two 2028 notes – a 0.300 % issue (IBM 28B) and a 1.750 % issue (IBM 28A). The coupon rates did not change from 2023 to 2024. This stability shows IBM’s strategy of keeping its existing low‑cost, long‑dated financing in place rather than issuing new, higher‑rate debt, underscoring a focus on preserving cheap, long‑term funding.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error by stating that IBM had two 2028 notes in both 2023 and 2024 — specifically a 0.300% issue (IBM 28B) and a 1.750% issue (IBM 28A). However, the ground truth only confirms the 1.750% Notes due 2028 (IBM 28A) in both years; there is no mention of a 0.300% 2028 note (IBM 28B) in the original data. This introduces an incorrect entity and misrepresents the quantitative facts. (2) The interest rate of 1.750% for IBM 28A is correctly reported as unchanged between 2023 and 2024, which aligns with the ground truth. However, the addition of a non-existent 0.300% note undermines quantitative accuracy. (3) The reasoning about stability in coupon rates is partially sound, but the conclusion that IBM avoided issuing new higher-rate debt is contradicted by the ground truth, which states that IBM *did* issue new debt in 2024 at higher rates (e.g., 2.900% due 2030, 3.150% due 2033). Thus, the LLM’s inference about debt strategy is incorrect — it fails to recognize IBM’s dual strategy of maintaining existing low-cost debt *while also* issuing new higher-cost, longer-term debt. (4) The contextual relevance is high because the answer addresses the evolution of interest rates and attempts to infer strategy. However, due to the incorrect entity (IBM 28B) and flawed strategic interpretation, the qualitative and quantitative accuracy scores are reduced. Correctness is partially achieved on the 1.750% note but undermined by hallucinated data and incorrect synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 421,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did AT&T's capital structure strategy regarding preferred interests evolve from 2023 to 2024, particularly in relation to the Mobility Preferred Interests and the introduction of new preferred instruments?",
      "original_answer": "In 2023, AT&T repurchased all of its Mobility Preferred Interests, which had a redemption value of approximately $5,340 million and paid annual cash distributions of $373 million. This marked a significant shift in strategy, as the company eliminated this class of preferred interests. In 2024, AT&T introduced structural modifications to other preferred instruments, including the restructuring of its Tower Holdings preferred interests to include both fixed and floating rate components, and the expansion of Telco LLC preferred interests to a total of $7,250 million. This evolution indicates a strategic pivot from Mobility-based preferred capital to more diversified and strategically tailored preferred instruments tied to infrastructure and telecommunications assets.",
      "llm_answer": "In 2023 AT&T eliminated the legacy Mobility II preferred interests – it repurchased the 320 million Series A cumulative perpetual preferred membership interests in April 2023, so that no Mobility preferred interests were outstanding at year‑end 2023. By 2024 the company’s capital‑structure strategy had shifted to relying on other preferred instruments: it retained its three series of cumulative perpetual preferred shares (Series A, B and C) and, through 2024, amended the 2019 Tower Holdings preferred interests and announced a new $2.25 billion issuance of Telco LLC Class A‑4 preferred interests for early‑2025, signaling a move away from Mobility‑related preferred equity toward newer, subsidiary‑level preferred securities.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that AT&T repurchased all Mobility Preferred Interests in 2023, specifying the April 2023 repurchase of 320 million Series A cumulative perpetual preferred membership interests, resulting in zero outstanding at year-end 2023—this matches the original answer’s claim of eliminating this class. (2) Quantitatively, while the LLM does not mention the $5,340 million redemption value or $373 million annual distributions from the ground truth, these omissions are minor in context; however, the $2.25 billion new issuance of Telco LLC Class A-4 preferred interests is correctly noted, and though the original mentions expansion to $7,250 million total, the LLM focuses on the new issuance rather than the aggregate, which is a slight incompleteness but not incorrect. (3) The qualitative reasoning is sound: the shift from Mobility-related preferred interests to subsidiary-level instruments (Tower Holdings and Telco LLC) is accurately captured, including the amendment of Tower Holdings preferred interests to include fixed/floating rates (implied by 'amended') and the strategic pivot toward infrastructure-linked capital. (4) The answer addresses all key aspects of the evolution in capital structure strategy—elimination of old instruments and introduction of new ones—with precise entity and year references. The only minor gap is the lack of full quantitative detail on redemption value and distributions, and the total expanded size of Telco LLC preferred interests, but core facts and multi-hop synthesis across 2023 and 2024 are correct. Hence, high scores across all dimensions with a 9 on correctness due to partial quantitative omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 473,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has Amazon's characterization of the competitive threat from websites evolved between 2022 and 2023, and what specific changes in language indicate a shift in the nature of this competition?",
      "original_answer": "In 2022, Amazon described competitive websites as part of a broader list of fluctuating business factors, indicating a general awareness of competitive pressures. By 2023, Amazon's language evolved to reflect a more direct and strategic competitive stance, specifically highlighting the introduction of 'competitive stores, websites, products, services, price decreases, or improvements' as a central concern. This shift indicates a more focused and intensified competitive threat from digital platforms, suggesting an evolution from a general operational risk to a more strategic and dynamic competitive challenge.",
      "llm_answer": "In the 2022 filing Amazon listed the threat as “the introduction of **competitive stores, web sites**, products, services, price decreases, or improvements.” In the 2023 filing the language was updated to “the introduction of **competitive stores, websites**, products, services, price decreases, or improvements” and the bullet was expanded to add “**changes in usage or adoption rates of the Internet, e‑commerce, electronic devices, and web services**.” The shift from “web sites” to the single‑word “websites” and the new reference to broader internet‑usage trends show Amazon now sees competition not only from other retail sites but also from the overall growth and adoption of digital platforms and services.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in both factual content and interpretation. It accurately identifies the change in Amazon's language between 2022 and 2023 filings regarding competitive threats, correctly noting the shift from 'web sites' to 'websites' and the addition of 'changes in usage or adoption rates of the Internet, e-commerce, electronic devices, and web services' in 2023. These details are factually accurate and reflect the actual evolution in Amazon's risk factor disclosures. The quantitative accuracy is perfect: the years (2022 vs 2023), the quoted language, and the specific additions are all correctly cited. The contextual relevance is strong, as the answer directly addresses how Amazon's characterization evolved and what linguistic changes indicate a shift. The qualitative accuracy is high but not perfect because while the LLM correctly notes the added phrase about internet usage trends, it does not fully emphasize the core shift highlighted in the ground truth—that competition evolved from being one item among many fluctuating factors to being framed as a central strategic concern involving 'competitive stores, websites, products, services, price decreases, or improvements' as a primary threat. The LLM focuses on the added phrase about adoption rates but underemphasizes the repositioning of the competitive threat as more strategic and direct, which is the key interpretive point in the original answer. Thus, while the factual synthesis is strong, the reasoning slightly misses the depth of the strategic shift implied in the ground truth, warranting a score of 8 rather than 9 or 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 442,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has PM's relationship with KT&G evolved from 2022 to 2024, particularly in terms of its strategic reliance on KT&G's heat-not-burn products within PMI's smoke-free product portfolio?",
      "original_answer": "In 2022, PM had a global collaboration agreement with KT&G that allowed PMI to exclusively distribute KT&G's smoke-free products, including heat-not-burn products like LIL Mini and LIL Plus, outside of South Korea. This agreement was initially for three years, indicating a strategic partnership aimed at expanding KT&G's products globally. By 2024, this relationship had evolved such that KT&G's heat-not-burn products were no longer just distributed by PMI but were integrated into PMI's broader smoke-free product portfolio, specifically being listed among PMI's own heat-not-burn offerings. This indicates a deeper strategic reliance on KT&G's product line within PMI's own commercialization efforts, suggesting a shift from a distribution partnership to a more embedded supplier or technology partner role for KT&G.",
      "llm_answer": "In the 2022 filing PMI described a new global collaboration agreement with KT&G that gave PMI exclusive rights to commercialize KT&G’s heat‑not‑burn (HNB) products outside South Korea and noted that commercial launches of those licensed products began in the third quarter of 2020. By the 2024 filing, KT&G‑licensed HNB brands (e.g., Fiit and Miix) are listed alongside PMI’s own HEETS and other HTUs and are explicitly included in the company’s “heat‑not‑burn products” and smoke‑free net‑revenue calculations, showing that the partnership has moved from an initial licensing arrangement to a core, revenue‑generating component of PMI’s smoke‑free portfolio.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of PMI's relationship with KT&G from a distribution/licensing agreement to deeper integration into PMI's smoke-free portfolio, which aligns with the ground truth. However, there is a factual error regarding the timeline: the LLM states that commercial launches of KT&G’s products began in Q3 2020, while the original answer and context imply the 2022 agreement was new and central, making the 2020 date inconsistent and potentially misleading. This affects quantitative accuracy. (2) The product names differ slightly—LLM mentions 'Fiit' and 'Miix', while the original answer cites 'LIL Mini' and 'LIL Plus'. These may be related (Fiit is KT&G’s HNB device; Miix could be a variant), but the mismatch introduces ambiguity. The core point—that KT&G’s products are now included in PMI’s heat-not-burn lineup and revenue calculations—is correct. (3) The multi-hop reasoning is sound: the LLM synthesizes information across 2022 and 2024 filings to show a progression from licensing to integration, correctly inferring strategic deepening. It connects commercialization rights to revenue inclusion, demonstrating valid logic. (4) Despite the date and product name discrepancies, the overall qualitative assessment and contextual relevance are strong because the answer correctly identifies the strategic shift and its significance within PMI’s portfolio. The error in dates prevents a higher score on quantitative accuracy, but the core conclusion remains factually supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 422,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did IBM's use of the PWCC Plan for funding employee awards evolve between 2022 and 2024, particularly in terms of its administration and scope?",
      "original_answer": "In 2022, the PWCC Plan was described as being used solely to fund awards for employees of PwCC who joined IBM after the acquisition, and it was stated that the plan would continue to be used for this purpose. By 2024, while the plan's administration and terms remained substantively identical to the 2001 Plan, IBM emphasized that the PWCC Plan 'has been and will continue to be used solely' for funding awards for former PwCC employees, indicating a reaffirmation rather than a change in scope. However, the shift in language from 'has been and will continue to be' in 2022 to a more definitive tone in 2024 suggests a stronger commitment to maintaining the plan’s current usage without expansion.",
      "llm_answer": "In both the 2022 and 2024 Form 10‑K filings IBM says the PWCC Acquisition Long‑Term Performance Plan is still administered by the Executive Compensation and Management Resources Committee of the Board (with any duties it may delegate to officers). The plan’s scope has not changed – it continues to be used **only** to fund equity awards for employees who joined IBM through the PricewaterhouseCoopers Consulting acquisition, and senior IBM executives are expressly excluded from receiving awards under the PWCC Plan.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and captures the core information from the ground truth. It correctly states that the PWCC Plan's administration remained unchanged between 2022 and 2024, with the Executive Compensation and Management Resources Committee continuing to oversee it—this aligns with the original answer’s implication of consistent administration. The scope is accurately described as being limited to funding awards for former PwCC employees, with explicit exclusion of senior IBM executives, which matches the ground truth’s emphasis on exclusive use for post-acquisition employees. The LLM correctly conveys that there was no expansion in scope. The only minor shortcoming is that it does not mention the evolution in language tone from 2022 to 2024 (e.g., the shift to a more definitive 'has been and will continue to be' in 2024), which the original answer highlights as indicating a stronger commitment. This nuance in rhetorical emphasis is absent in the LLM response, slightly weakening the qualitative depth of the evolution analysis. However, all entities (PWCC Plan, PwCC employees, IBM), years (2022, 2024), and administrative details are correct. There are no numerical inaccuracies (quantitative accuracy is perfect), and the response is fully relevant to the question about evolution in administration and scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 372,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did AT&T's financial obligations and strategic approach to Mobility Preferred Interests evolve between 2023 and 2024, and what does this shift indicate about its broader capital structure management?",
      "original_answer": "In 2023, AT&T repurchased all remaining Mobility Preferred Interests for a total of $5,414 million, which included accrued and unpaid distributions, effectively eliminating this financial obligation. By 2024, there was no mention of Mobility Preferred Interests in the disclosures, indicating a complete exit from this instrument. This contrasts with AT&T's treatment of other preferred interests, such as the Tower Holdings and Telco LLC preferred interests, which remained outstanding and were even expanded or restructured in 2024. This shift indicates a strategic move to reduce certain long-term liabilities while maintaining or adjusting other capital instruments for flexibility, suggesting a selective approach to managing its capital structure.",
      "llm_answer": "In the 2023 filing AT&T still carried the 2018‑issued 320 million Mobility II preferred interests; the interest expense line notes that “Mobility preferred interest distributions…were repurchased on April 5 2023” and were re‑classified from equity to a liability before being retired【page_25】.  By the 2024 filing the company reports that “all outstanding Mobility preferred interests were repurchased as of April 2023, leaving no amounts outstanding at December 31 2023”【page_86】, so no related cash‑flow or dividend constraints remain in 2024.  This progression—from retaining and accounting for the legacy preferred equity in 2023 to fully extinguishing it in 2024—shows AT&T deliberately eliminating legacy preferred‑interest obligations to simplify its capital structure, reduce equity‑like liabilities, and increase flexibility for dividends, share repurchases and other financing decisions.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that AT&T repurchased all Mobility Preferred Interests in April 2023, leaving no amounts outstanding by year-end 2023, which is consistent with the original answer stating the obligation was eliminated by 2024. The total repurchase amount of $5,414 million in the ground truth is not explicitly mentioned in the LLM answer, which is a minor omission affecting quantitative completeness but not overall correctness—this prevents a perfect 10. (2) Dates (April 5, 2023, and December 31, 2023) are accurate and match the timeline in the source. The reference to the 2018-issued 320 million Mobility II preferred interests adds contextual detail not in the ground truth but does not contradict it. (3) The reasoning is sound: the LLM correctly traces the evolution from accounting for the instrument in 2023 to its full retirement, and infers strategic intent—simplifying capital structure and increasing financial flexibility—which aligns with the ground truth’s conclusion about selective capital structure management. (4) The answer addresses all parts of the question: the change between 2023 and 2024, the elimination of the obligation, and the implication for capital structure. It synthesizes information across years and correctly contrasts the treatment of Mobility Preferred Interests with other instruments (implied by mentioning their retirement while noting other interests remain, though not explicitly naming Tower Holdings/Telco). The absence of explicit comparison to other preferred interests slightly reduces completeness but does not undermine the core accuracy. Overall, the answer is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 478,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has IBM's relationship with stock exchange regulations evolved in terms of regulatory exposure for its debt securities between 2022 and 2024?",
      "original_answer": "In 2022, IBM described stock exchange regulations as one of several factors influencing the value of its debt securities, placing it among other external variables beyond the company's control. By 2024, IBM's language shifted to indicate a more direct regulatory exposure, stating it is 'subject to' stock exchange regulations, which implies a heightened recognition of their binding impact on the company's financing activities. This evolution reflects a stronger acknowledgment of regulatory influence in 2024 compared to the more general mention in 2022.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K risk sections note that the value and liquidity of IBM’s debt securities are affected by “governmental and stock‑exchange regulations” (2022 p. 22; 2024 p. 11). The wording is essentially unchanged, showing that IBM’s exposure to stock‑exchange regulatory risk for its debt has persisted rather than expanded or diminished over the two‑year period.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its interpretation of IBM's evolving regulatory exposure, despite correctly citing the presence of stock exchange regulations in both years. The original answer identifies a meaningful shift in language from 2022—where IBM described stock exchange regulations as one of several factors influencing debt security value—to 2024, where IBM states it is 'subject to' such regulations, indicating a stronger, more direct regulatory exposure. The LLM incorrectly claims the wording is 'essentially unchanged,' which contradicts the ground truth showing a qualitative shift in tone and legal implication. While the LLM accurately references the risk factor's presence and page numbers (demonstrating correct entity and document citation), it fails to detect the nuanced but important evolution in IBM's regulatory stance. This constitutes a failure in multi-hop reasoning and qualitative analysis, as the question specifically asks about the evolution of the relationship, not just its presence. The answer is contextually relevant but fundamentally flawed in its conclusion, leading to a low correctness score. No numerical data is involved, so quantitative accuracy is scored as 10 by default.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 343,
        "total_tokens": 1577
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Disney's financial relationship with A&E evolve from 2022 to 2024, particularly in terms of equity income contribution?",
      "original_answer": "In 2022, Disney's equity investment in A&E was a significant component of its equity income, with A&E being one of the most notable equity method investees alongside CTV Specialty Television. By 2024, Disney's equity in the income of investees had decreased by $207 million, specifically due to lower income generated from A+E. This indicates a material decline in the financial contribution from A&E to Disney over the two-year period.",
      "llm_answer": "In the 2022 filing Disney still reported a sizable share of earnings from its 50 % stake in A+E, but the amount was higher than the figure shown in later years. By fiscal 2024 the “equity in the income of investees, net” line – which is driven largely by the A+E investment – had fallen to **$575 million**, down from $782 million in 2023 and well below the 2022 level. This reflects a clear contraction in the equity‑income contribution Disney receives from A+E between 2022 and 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the declining trend in Disney's equity income from A&E between 2022 and 2024 and attributes it to reduced contributions from A+E, which aligns with the ground truth. However, there are significant quantitative inaccuracies: the LLM states that equity income fell to $575 million in 2024 from $782 million in 2023, implying a $207 million decrease between 2023 and 2024. The ground truth states a $207 million decrease from 2022 to 2024, not year-over-year from 2023 to 2024. This misattribution of timing and the lack of specific 2022 figures (which are implied to be higher than $782 million) introduces factual errors. The LLM introduces precise numbers not present in the original answer ($575M, $782M), which may reflect data from actual filings but are not supported by the provided ground truth, which only specifies the $207M decline over two years. While the qualitative reasoning about the contraction is sound and contextually relevant, the unsupported specific figures and incorrect assignment of the decline period reduce quantitative accuracy. The model synthesizes the multi-hop concept of changing equity income over time correctly but fails to match the ground truth's specific basis of comparison (2022 to 2024).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 352,
        "total_tokens": 1578
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did the carrying value of securitized debt obligations change from 2022 to 2023, and what does this indicate about the company's long-term funding strategy?",
      "original_answer": "In 2022, the long-term funding, which primarily consists of securitized debt obligations and senior and subordinated notes, stood at $42.3 billion as of December 31, 2021, with a significant portion driven by securitized debt obligations. By December 31, 2023, the carrying value of securitized debt obligations alone decreased to $18.043 billion. This indicates a strategic shift or reduction in reliance on securitized debt obligations as part of the company's long-term funding structure over this period.",
      "llm_answer": "The 2023 filing shows securitized‑debt obligations with a carrying value of **$18.0 billion**, up from **$16.97 billion** reported in the 2022 filing – an increase of roughly **$1.1 billion**. This rise signals that Capital One is expanding its use of securitization to fund long‑term assets, reflecting a deliberate strategy to diversify and grow its wholesale‑funding mix beyond deposits.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude of change. The ground truth states that the carrying value of securitized debt obligations decreased from $42.3 billion (as of December 31, 2021, referenced in 2022 filing) to $18.043 billion as of December 31, 2023. The LLM incorrectly claims an increase from $16.97 billion in 2022 to $18.0 billion in 2023, which contradicts the actual downward trend. (2) The numbers are entirely wrong: the $16.97 billion figure does not appear in the ground truth, and the prior value was $42.3 billion (not $16.97B), making the calculation of a $1.1 billion increase baseless. The 2023 value is correctly approximated as $18.043 billion (rounded to $18.0 billion is acceptable), but the prior value is severely understated. (3) The multi-hop reasoning fails: the LLM misidentifies the trend and draws the opposite conclusion. Instead of recognizing a strategic reduction in securitized debt, it claims expansion, which is unsupported. The synthesis across years is flawed, and the entity (Capital One) is mentioned without being in the original context, introducing an unverified entity. (4) The correctness and quantitative accuracy scores are low due to fundamental factual and numerical errors. Qualitative accuracy is poor due to incorrect reasoning and entity introduction. Contextual relevance is slightly higher because the answer addresses the general topic of securitized debt and funding strategy, albeit incorrectly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 414,
        "total_tokens": 1642
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has Disney's approach to scripted programming evolved between 2022 and 2024, particularly in terms of its international general entertainment channels and its strategic shift toward DTC platforms?",
      "original_answer": "In 2022, Disney operated approximately 220 General Entertainment channels outside the U.S., primarily under the Fox, National Geographic, and Star brands, featuring a mix of scripted, reality, and documentary programming across multiple languages and regions. By 2024, there was a notable strategic shift, with increased emphasis on DTC platforms and less focus on traditional linear channels. The 2024 report highlights that Disney, along with Fox Corporation and Warner Bros. Discovery, planned a joint venture (Venu Sports) to distribute sports content via a DTC platform, signaling a broader move toward streaming. Additionally, Disney announced plans to launch a new DTC offering in early fall 2025 that would include live linear streams of ESPN channels and ESPN+. This reflects a strategic pivot from scripted linear content toward live and sports-driven DTC offerings, indicating a transformation in Disney’s programming and distribution priorities.",
      "llm_answer": "In 2022 Disney’s scripted series were still being delivered mainly through its roughly 220 international general‑entertainment linear channels – especially the Fox‑branded networks, which “air a variety of scripted, reality and documentary programming” (2022 10‑K p. 11).  Even then the filing warned that “the Company’s increased focus on DTC distribution in international markets is expected to negatively impact the International Channels business as we shift the primary means of monetizing our content from licensing of linear channels to distribution on our DTC platforms” (2022 10‑K p. 11).  \n\nBy 2024 Disney had accelerated that shift: it consolidated Star+ into a single Disney+ product, expanded the Star‑tile on Disney+, and emphasized that most new scripted content would now debut on Disney+, Disney+ Hotstar or Hulu, with the company explicitly stating that it is moving “the primary means of monetizing our content … to distribution on our DTC platforms” (2024 10‑K p. 7‑11).  Consequently, reliance on international linear general‑entertainment channels for scripted programming has been reduced in favor of direct‑to‑consumer streaming.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in its core claims and aligns well with the ground truth. It correctly identifies that in 2022, Disney operated approximately 220 international general entertainment channels, primarily under Fox, National Geographic, and Star brands, and cites the correct strategic warning from the 2022 10-K about DTC focus negatively impacting linear channels. The quantitative details (e.g., number of channels) are accurate, and the shift toward DTC platforms by 2024 is correctly described, including the consolidation of Star+ into Disney+ and the prioritization of Disney+, Disney+ Hotstar, and Hulu for new scripted content. The LLM accurately quotes the 2024 10-K language about shifting monetization to DTC platforms. However, the LLM omits key elements from the ground truth: it does not mention the Venu Sports joint venture with Fox Corporation and Warner Bros. Discovery, nor does it reference the planned 2025 DTC launch with live ESPN streams, both of which are central to Disney’s strategic pivot toward live and sports-driven DTC offerings. While the focus on scripted programming’s shift to DTC is well-covered, the broader strategic evolution involving sports and live content is missing, which represents a significant part of the 2024 shift. This omission prevents a perfect score, but the answer remains highly accurate and contextually relevant, with flawless quantitative and entity accuracy (e.g., correct years, companies, and platform names). The reasoning is sound and reflects proper multi-hop synthesis between 2022 and 2024 filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1541,
        "completion_tokens": 433,
        "total_tokens": 1974
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Tesla's financial and operational challenges related to energy storage products evolve from 2022 to 2023, particularly in terms of accounts receivable and production scaling dependencies?",
      "original_answer": "In 2022, Tesla disclosed significant long-term government rebates receivable related to its energy storage products, with a balance of $627 million as of December 31, 2021, indicating extended collection periods of up to a year or more. By 2023, the focus shifted from financial implications of receivables to operational dependencies, as Tesla highlighted production scaling risks for energy storage products, including bottlenecks, supplier constraints, and facility ramp delays at factories in Nevada, Texas, and other locations. These changes reflect a shift from financial exposure tied to receivables to broader production and supply chain dependencies affecting the company's ability to meet cost and profitability targets.",
      "llm_answer": "In the 2022 Form 10‑K Tesla’s discussion of energy‑storage sales was centered on the credit side of the business – accounts‑receivable for those products (and related government rebates) were described as subject to timing‑related swings, with $627 million of long‑term rebate receivable and no single customer representing ≥10 % of the balance. By the 2023 filing the narrative had shifted to an operational‑risk focus: Tesla warned that the ability to grow energy‑storage production and installations now hinges on successfully scaling battery‑cell supply and new factory ramps, and that any shortfall or higher‑cost sourcing could force a curtailment of energy‑storage output. Thus the challenge moved from managing receivable volatility in 2022 to managing production‑scaling dependencies in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $627 million long-term government rebate receivable as of the end of 2021 (disclosed in the 2022 10-K), which aligns with the ground truth. It accurately characterizes the 2022 focus on accounts receivable and timing-related volatility, and the 2023 shift to operational risks in production scaling. The absence of any single customer representing ≥10% of receivables is an additional accurate detail not in the ground truth but not contradictory. (2) All numbers and dates are correct: $627 million is accurately cited, and the years (2022 and 2023 filings) are correctly attributed. No calculations are required, and all quantitative references match. (3) The multi-hop reasoning is sound: the model correctly synthesizes a shift in risk disclosure focus across two years of Tesla’s 10-K filings, moving from financial (receivables) to operational (supply chain, factory ramps) challenges. It correctly links production scaling dependencies to battery-cell supply and new factory ramps in locations like Nevada and Texas (implied by 'new factory ramps' and consistent with known Tesla facilities). (4) The answer is semantically equivalent to the ground truth, with slightly more detail on customer concentration but missing explicit mention of 'bottlenecks' and 'supplier constraints' as named risks. However, these are covered under the broader phrase 'higher-cost sourcing' and 'shortfall', so the omission is minor. Overall, the answer is factually correct, well-reasoned, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 431,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in relation to its bottling partners and fountain retailers?",
      "original_answer": "In 2022, Coca-Cola's relationship with syrups was primarily defined by its sales to both consolidated and unconsolidated bottling partners, with revenue and volume recognition dependent on the ownership structure of those partners. Specifically, concentrate and syrup sales were not recognized until finished products were sold to third parties in the case of consolidated bottlers, while recognition occurred immediately for unconsolidated bottlers. By 2023, the company's description of syrups shifted to emphasize their role as a dependency within a broader operational framework, particularly in relation to fountain retailers. In 2023, the company clarified that it manufactures fountain syrups and sells them directly to fountain retailers or authorized wholesalers and bottlers, highlighting a more integrated and strategic role for syrups in its finished beverage delivery system. This represents a shift from a primarily volume-driven metric to a more operationally embedded component of the business model.",
      "llm_answer": "In the 2023 filing Coca‑Cola notes that its concentrate operations – which include the beverage bases and fountain syrups – accounted for **58 % of net operating revenues**, up from **56 % in 2022**, indicating a modest shift toward greater reliance on syrups as a revenue driver.  The company still sells syrups to both consolidated and unconsolidated bottling partners, recognizing revenue at the point of sale to the bottler for the latter and only after the bottler sells the finished drink for the former, and it continues to **manufacture fountain syrups in the United States and sell them directly to fountain retailers (or to authorized fountain wholesalers)**, a channel that is highlighted as part of the North America segment in 2023.  Together, these points show that syrups have become a slightly larger, still‑central component of Coca‑Cola’s model, with the same partner‑type distinctions but an emphasized direct‑to‑fountain‑retailer role.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increased revenue share from concentrate operations (58% in 2023 vs. 56% in 2022), which aligns with the broader trend of syrups gaining strategic importance. These percentages are factually accurate and correctly attributed to the respective years. The description of revenue recognition practices—immediate recognition for unconsolidated bottlers and deferred for consolidated bottlers—is consistent with the ground truth. The direct sale of fountain syrups to fountain retailers or authorized wholesalers is accurately noted, as is the emphasis on the North America segment in 2023. However, the original answer emphasizes a conceptual shift in how syrups are framed—from a volume-driven metric to an operationally embedded component—whereas the LLM focuses more on revenue percentages and continuity in structure, missing the deeper qualitative evolution in narrative framing. (2) Quantitatively, the 56% and 58% figures are correct and properly compared; no calculation errors are present. The use of percentages matches the expected precision and format. (3) The multi-hop reasoning is sound: the model synthesizes information about revenue recognition, partner types, and distribution channels across years. It correctly links syrup sales to both bottling partners and fountain retailers and notes continuity in mechanisms while highlighting increased revenue concentration. However, it does not fully capture the shift in *conceptual role* emphasized in the original answer—i.e., syrups becoming a dependency within an operational framework rather than just a revenue stream. (4) Scores reflect high factual accuracy and relevance, with minor deduction in qualitative accuracy for not fully conveying the strategic reframing of syrups in 2023. Contextual relevance is perfect as all content directly addresses the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1496,
        "completion_tokens": 510,
        "total_tokens": 2007
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did Disney's investment in Other Mortgage- and Asset-Backed Securities (MBS & ABS) evolve from fiscal year 2022 to fiscal year 2024, and what was the trend in its proportion relative to the overall fair value hierarchy?",
      "original_answer": "In fiscal year 2022, Disney's investment in Other MBS & ABS was valued at $96 million, representing 1% of the total plan asset mix. By fiscal year 2024, this investment increased to $120 million, maintaining a 1% share of the total plan asset mix. While the absolute value of the investment grew moderately, its proportional representation within the portfolio remained stable.",
      "llm_answer": "Disney’s “Other mortgage‑ and asset‑backed securities” holding rose from $84 million at fiscal‑year‑end 2022 (Level 2, 1 % of the fair‑value hierarchy) 【page_104】 to $166 million at fiscal‑year‑end 2024 (Level 2, 1 % of the fair‑value hierarchy) 【page_107】.  While the dollar amount more than doubled, its proportion of the total fair‑value‑hierarchy assets remained essentially unchanged at about 1 %.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the dollar amounts. According to the ground truth, Disney's investment in Other MBS & ABS was $96 million in fiscal year 2022 and $120 million in fiscal year 2024. However, the LLM reports $84 million in 2022 and $166 million in 2024, both of which are incorrect. While the proportion (1%) is correctly stated in both years, the absolute values are not. (2) The calculation claim that the dollar amount 'more than doubled' is incorrect: from $96M to $120M is a 25% increase, not a doubling. Even using the LLM's own numbers ($84M to $166M), this would be about a 95% increase—close to doubling but not quite—and still factually wrong due to incorrect base figures. (3) The qualitative reasoning is partially sound: the model correctly identifies that the proportion remained stable at 1%, which reflects accurate synthesis of the trend in relative allocation. It also correctly identifies the security type and time frame, showing proper entity and metric alignment. The reference to Level 2 of the fair value hierarchy is additional context not in the original answer but not contradictory. (4) Contextual relevance is high—the answer addresses both the evolution of the investment and its proportional trend. However, due to major errors in core financial figures, the correctness and quantitative accuracy scores are low. The answer is semantically aligned in structure and intent but fails on factual precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 411,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the focus areas of Skunk Works' advanced development programs evolve between 2022 and 2023 in relation to next-generation military aircraft capabilities?",
      "original_answer": "In 2022, Skunk Works' Advanced Development Programs focused on future systems including unmanned and manned aerial systems and next-generation capabilities for hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. By 2023, the focus had evolved to emphasize air dominance, hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. The shift highlights an increased emphasis on air dominance as a core next-generation capability while maintaining focus on hypersonics and ISR. This represents a refinement of priorities rather than a complete overhaul of focus areas.",
      "llm_answer": "In the 2022 filing, Lockheed Martin said its Advanced Development Programs (Skunk Works) were concentrating on future unmanned and manned aerial systems and on “next‑generation capabilities for hypersonics, intelligence‑surveillance‑reconnaissance, situational‑awareness and air‑mobility.” The 2023 filing expands that description, adding an explicit focus on “air‑dominance” while retaining the same emphasis on unmanned/manned platforms, hypersonics, ISR, situational‑awareness and air‑mobility. Thus, between 2022 and 2023 Skunk Works broadened its scope to include next‑generation air‑dominance capabilities in addition to its existing next‑gen aircraft‑technology priorities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and closely aligns with the ground truth. (1) All entities—Skunk Works, Advanced Development Programs, Lockheed Martin, and the relevant focus areas—are correctly identified. The years 2022 and 2023 are accurately referenced. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable beyond correct use of time periods, which are accurate. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes changes in focus areas between two years from what is implied to be SEC filings (though the source is not explicitly cited in the ground truth, the inference is valid). It correctly identifies that the 2022 focus included unmanned/manned systems, hypersonics, ISR, situational awareness, and air mobility, and that 2023 added an explicit emphasis on air dominance. (4) The only minor deviation from the original answer is the use of 'broadened its scope' rather than 'refinement of priorities,' which slightly overstates the change as an expansion rather than a reprioritization. However, this does not materially misrepresent the facts. The core information—evolution in emphasis toward air dominance while maintaining other focus areas—is correct. Semantic equivalence is preserved. Contextual relevance is excellent, directly addressing the evolution of focus areas in relation to next-generation military aircraft capabilities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 399,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Tesla's approach to the Powerwall product evolved from 2022 to 2023, particularly in terms of integration strategy and production emphasis?",
      "original_answer": "In 2022, Tesla emphasized cross-selling Powerwall with residential solar energy products due to better availability and growing grid stability concerns. The company was also focused on improving installation capabilities and price efficiencies for Solar Roof, which is closely related to Powerwall integration. By 2023, Tesla had advanced its integration strategy by designing both Solar Roof and solar energy systems to specifically integrate with Powerwall, indicating a more deliberate and engineered approach to product synergy. This evolution reflects a shift from a sales and availability focus to a deeper technical and strategic integration within Tesla's energy ecosystem.",
      "llm_answer": "In the 2022 filing Tesla said it was **leaning on cross‑selling** – making Powerwall more available and bundling it with its residential solar‑energy products to meet growing grid‑stability demand. By the 2023 filing the focus had shifted to **tighter technical integration**, positioning Powerwall as a built‑in part of the new Solar Roof system and tying it into Tesla’s real‑time energy‑control software, while also stressing that it is scaling up production of its energy‑storage hardware to satisfy that demand.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Tesla's Powerwall strategy from 2022 to 2023. (1) It correctly identifies the 2022 focus on cross-selling and improved availability due to grid stability concerns, and the 2023 shift toward tighter technical integration with Solar Roof and energy-control software. These points align with the ground truth, which emphasizes a move from sales/availability to engineered integration. (2) There are no numeric values, dates, or financial figures in dispute; all time references (2022, 2023) are correct, satisfying quantitative accuracy. (3) The multi-hop reasoning is sound: the model synthesizes changes in strategy across two years and connects Powerwall to Solar Roof and software integration, reflecting proper entity and temporal alignment. The only minor gap is that the original answer highlights 'improving installation capabilities and price efficiencies' in 2022, which the LLM omits, and the 2023 emphasis on 'scaling up production' is mentioned but not explicitly tied to energy-storage hardware in the original. However, this does not distort the overall accurate narrative. (4) The answer is contextually relevant, directly addressing both integration strategy and production emphasis as asked. Wording differs but semantic meaning is equivalent or very close. Thus, a high score of 9 is justified, with full marks in quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 398,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Gilead's strategic positioning around Biktarvy evolved between 2022 and 2024, particularly in terms of its role within the company's HIV portfolio and associated commercial risks?",
      "original_answer": "In 2022, Biktarvy was prominently positioned as a key revenue-generating product within Gilead’s HIV portfolio, highlighted as a single-tablet regimen combining bictegravir, emtricitabine, and tenofovir alafenamide (TAF), emphasizing its convenience and efficacy. By 2024, while Biktarvy remained a core product, the company faced heightened commercial risk as it became more dependent on HIV products containing TAF. A shift in treatment paradigms or reduced preference for nucleoside-based therapies could significantly impact Biktarvy’s sales and, by extension, Gilead’s financial stability. This reflects a transition from a focus on product innovation to increased vulnerability due to overreliance on a narrow therapeutic class.",
      "llm_answer": "In the 2022 Form 10‑K, Gilead presented Biktarvy as a flagship, once‑daily, single‑tablet regimen and one of its primary revenue‑generating HIV products. By the 2024 filing, Biktarvy remains a core element of the HIV portfolio, but Gilead now flags it among “certain of our products” that carry heightened commercial risk—specifically, the risk that a shift away from TAF‑based nucleoside regimens or increased competition could erode its market share and revenue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies Biktarvy's role in 2022 as a flagship, once-daily, single-tablet regimen and a primary revenue generator, matching the original answer's emphasis on convenience, efficacy, and commercial importance. By 2024, it accurately reflects the increased commercial risk due to dependence on TAF-based therapies, noting potential threats from shifts in treatment paradigms or competition. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points and correctly infers a strategic shift from innovation emphasis to risk exposure, aligning with the knowledge graph. (4) The only minor limitation is that the LLM slightly under-elaborates on the broader implication of overreliance on nucleoside-based therapies for Gilead’s financial stability, which is explicitly stated in the ground truth. However, the core message about heightened commercial risk is preserved. Wording differs slightly but meaning is preserved. All entities (Gilead, Biktarvy, TAF-based regimens, 2022, 2024) are correct. Thus, high scores across all dimensions with a 9 on correctness due to slight omission of financial stability linkage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 391,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did the composition of the U.S. Retrospective Responsibility Plan change between 2022 and 2023, particularly regarding the mechanisms referenced in relation to the U.S. Litigation Escrow Agreement?",
      "original_answer": "In 2022, the U.S. Retrospective Responsibility Plan included mechanisms such as the U.S. Litigation Escrow Agreement, the conversion feature of Class B common stock, indemnification obligations of Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. By 2023, the composition evolved to include a new element — 'makewhole agreements relating to the Class B-1 common stock exchange offer' — while retaining the U.S. Litigation Escrow Agreement and other previously listed mechanisms. This indicates an expansion of the plan to incorporate additional financial safeguards or compensatory measures.",
      "llm_answer": "In the 2022 filing the U.S. Retrospective Responsibility Plan was described as being comprised of the U.S. litigation‑escrow agreement, the conversion feature of the company’s class B common stock, the Visa U.S.A. members’ indemnification obligations, an interchange‑judgment‑sharing agreement, a loss‑sharing agreement and an omnibus agreement (as amended). The 2023 filing lists the same elements **plus** “the make‑whole agreements relating to the class B‑1 common‑stock exchange offer.” Thus, the only change in composition was the addition of the make‑whole agreements; the other mechanisms remained unchanged.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately lists all components of the U.S. Retrospective Responsibility Plan in 2022: U.S. Litigation Escrow Agreement, conversion feature of Class B common stock, indemnification obligations of Visa U.S.A. members, interchange judgment sharing agreement, loss sharing agreement, and omnibus agreement. (2) It correctly identifies the only change in 2023: the addition of 'makewhole agreements relating to the Class B-1 common stock exchange offer' while retaining all prior mechanisms. (3) The multi-hop reasoning is sound—comparing the composition across two years and identifying the net change—as required by the question. (4) All entities, years, and mechanisms are correctly named and contextualized. Minor formatting differences (e.g., hyphenation in 'make-whole', 'class B-1 common-stock') do not affect meaning and are consistent with typical SEC filing style variations. No factual inaccuracies, omissions, or reasoning flaws are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 296,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has the strategic importance of Biktarvy evolved for GILD from 2022 to 2024, based on its patent protection timeline and the company's risk disclosures around HIV product dependency?",
      "original_answer": "In 2022, Biktarvy was listed with a U.S. patent expiration in 2033 and no expiration listed in the E.U., indicating strong long-term protection and likely a key revenue driver. By 2024, although patent details were not explicitly mentioned, the company highlighted heightened risk around its HIV products, including Biktarvy, due to market competition and potential shifts in treatment paradigms. This suggests that despite long-term patent protection, Biktarvy's strategic position has become more vulnerable due to external market and regulatory pressures.",
      "llm_answer": "In the 2022 filing Gilead noted that Biktarvy’s core patents (and any extensions) do not expire until 2033 in both the United States and the EU, giving the regimen more than a decade of exclusivity and positioning it as a cornerstone of the company’s HIV franchise. The 2024 risk‑factor section still warns that “a substantial portion of our revenue” comes from HIV products and that loss of market share or the end of patent protection would force Gilead to scale back R&D and other operations. Together, the unchanged 2033 expiration date and the continued emphasis on HIV‑product dependence show that Biktarvy’s strategic importance has remained high—and arguably more critical—as Gilead relies on its long‑term patent shield to sustain its HIV revenue base.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM correctly identifies the 2033 U.S. patent expiration for Biktarvy from the 2022 filing, which aligns with the ground truth. However, it incorrectly states that the 2033 expiration applies to both the U.S. and EU, while the ground truth explicitly notes that no EU expiration was listed in 2022—this is a factual error. The LLM also assumes the patent timeline remained unchanged in 2024, but the original answer clarifies that patent details were not explicitly mentioned in 2024, making this an unsupported inference. 2) Quantitatively, the 2033 date is accurate for the U.S., but the extension to the EU is not supported. No calculations are involved, so numerical accuracy is mostly preserved except for the erroneous geographic generalization. 3) The reasoning is partially sound in linking patent protection to strategic importance and noting continued reliance on HIV products in risk disclosures. However, the LLM misses the key shift highlighted in the ground truth: increased risk disclosures in 2024 due to competition and treatment paradigm shifts, which indicate growing vulnerability despite patent protection. Instead, the LLM concludes that strategic importance has remained stable or increased, contradicting the ground truth’s implication of rising risk and relative strategic vulnerability. 4) Contextually, the answer addresses the question’s core elements—patent timeline and risk disclosures—but fails to accurately synthesize the evolution from 2022 to 2024. The conclusion misrepresents the strategic trajectory by overlooking the heightened risks emphasized in 2024, leading to a misleading assessment of Biktarvy’s evolving position.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 453,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "Have there been any modifications to the financial guarantees provided by AT&T for Illinois Bell Telephone Company between 2022 and 2023, particularly in terms of guarantee structure or referenced documentation?",
      "original_answer": "The financial guarantee relationship between AT&T and Illinois Bell Telephone Company remained structurally unchanged between 2022 and 2023. In 2022, AT&T's guarantee for Illinois Bell Telephone Company was referenced under Exhibit 4-d to Form 10-K for the period ending December 31, 2011. In 2023, the same guarantee was still in place and referenced under the identical exhibit number (Exhibit 4-d) and filing history (Form 10-K for the period ending December 31, 2011). There is no indication of modifications to the guarantee structure, terms, or documentation between the two years.",
      "llm_answer": "Yes. The 2023 Form 10‑K adds a new guarantee entry – “Guaranty of certain obligations of … Illinois Bell Telephone Company” – listed as Exhibit 4‑d (referencing a 2011 guarantee document). The 2022 filing does not contain any guarantee for Illinois Bell, so the guarantee was introduced (or revised) in the 2023 filing, with the only change being the addition of that referenced exhibit.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim. According to the ground truth, the financial guarantee structure for Illinois Bell Telephone Company by AT&T remained unchanged between 2022 and 2023, with the same Exhibit 4-d from the 2011 Form 10-K referenced in both years. The LLM incorrectly states that the 2022 filing does not contain any guarantee for Illinois Bell, and that a new guarantee was added in 2023—this contradicts the original answer, which confirms the guarantee was already in place and consistently referenced. There are no correct numerical or date-based errors in isolation (e.g., mention of Exhibit 4-d and 2011 filing is accurate), but the reasoning and synthesis are flawed. The model fails the multi-hop requirement by misrepresenting the presence of the guarantee in 2022, leading to an incorrect conclusion about modification. While the answer addresses the question's focus on changes and documentation, its factual foundation is unsound, severely undermining correctness. Minor credit is given for referencing the correct exhibit and underlying document year.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 311,
        "total_tokens": 1570
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "What does the consistent Class C to Class A common stock conversion rate between 2022 and 2023 suggest about the potential impact on Class A common stockholders' voting power in significant corporate transactions?",
      "original_answer": "In 2022, the Class C common stock had a conversion rate of 4.0000 into Class A common stock, and this rate remained unchanged in 2023. Despite the as-converted Class A common stock value increasing slightly from 38 million in 2022 to 39 million in 2023, the unchanged conversion rate suggests that the relative voting power dilution for Class A common stockholders remained stable. This stability implies that there was no structural change in how Class C stockholders could influence significant corporate decisions through their voting rights tied to Class A equivalents.",
      "llm_answer": "The filing shows that the Class C‑to‑Class A conversion rate remained at 4.0 shares of Class A for each Class C share in both 2022 and 2023 (see Note 15, “Conversion Rate Into Class A Common Stock” for Class C). Because the rate did not change, any conversion of Class C stock would increase the Class A share count by the same proportion as before, meaning the potential dilution of existing Class A shareholders’ voting power in a merger, consolidation or other significant transaction is unchanged and not expected to worsen.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the conversion rate of 4.0000 (or 4.0) is correctly reported for both 2022 and 2023, and the answer correctly notes the stability of the rate. While the LLM does not explicitly mention the as-converted Class A stock value increasing from 38 million to 39 million, this omission does not undermine the core conclusion about stable voting power dilution. (2) The reasoning is sound: the unchanged conversion rate implies that the proportional increase in Class A shares upon conversion remains constant, so the relative dilution effect on Class A voting power is unchanged. This correctly captures the structural stability in voting rights impact. (3) The multi-hop synthesis is appropriate—linking the stable conversion rate to its implication on voting power in significant corporate transactions. (4) The answer is contextually precise, directly addressing the question about voting power impact. The only minor shortcoming is the omission of the specific as-converted share values (38M to 39M), which adds slight contextual nuance in the original answer but does not alter the correctness of the conclusion. Hence, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 372,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Tesla's relationship with the Solar Roof evolve from 2022 to 2023 in terms of production focus and strategic dependencies?",
      "original_answer": "In 2022, Tesla directly produced the Solar Roof at Gigafactory New York, indicating active involvement in its manufacturing. However, by 2023, Tesla's disclosures shifted to emphasizing dependencies and risks associated with scaling production, including potential delays, supply chain constraints, and challenges in launching and ramping products like the Solar Roof. This reflects a transition from a production-centric view to a more cautionary outlook on strategic execution risks.",
      "llm_answer": "In the 2022 filing Tesla described its Solar Roof as a product that is **developed and built at Gigafactory New York**, giving the roof a dedicated manufacturing focus at that site. By the 2023 filing the company no longer frames Solar Roof as a stand‑alone line; instead it groups the roof with its other energy‑storage products and warns that **ramping its production could be delayed and is tied to Tesla’s overall manufacturing scale‑up and to the reliability of its suppliers and component supply chain**. Thus, the relationship shifted from a location‑specific production emphasis in 2022 to a broader, supply‑chain‑dependent rollout risk in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Tesla produced the Solar Roof at Gigafactory New York, using semantically equivalent phrasing ('developed and built' vs 'directly produced'). In 2023, it accurately reflects the shift in tone to emphasize production delays, supply chain constraints, and dependencies on broader manufacturing scale-up—matching the original answer's 'cautionary outlook on strategic execution risks.' (2) There are no numeric values to verify (e.g., dollar amounts, percentages), but the years (2022 and 2023) are correct and properly contextualized. (3) The multi-hop reasoning is sound: the model synthesizes changes in Tesla’s disclosures across two years and infers a strategic shift from direct production focus to supply-chain-dependent risk, which requires cross-year comparison of filing language. (4) The only minor shortcoming is that the LLM slightly reframes the 2023 risk discussion around 'grouping with energy-storage products,' which is contextually plausible but not explicitly stated in the ground truth. However, this does not detract from the core factual accuracy. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 359,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in terms of their relationship to finished beverage production and distribution channels?",
      "original_answer": "In 2022, Coca-Cola described syrups as intermediate products used primarily in fountain beverage production, where bottling partners or fountain retailers mix them with water and sweeteners to create finished beverages for immediate consumption. The company emphasized that syrups were a key part of the concentrate operations, which generally yield lower net operating revenues but higher gross profit margins compared to finished product operations. By 2023, the company expanded its description to emphasize that fountain syrup sales in the U.S. were directly managed by Coca-Cola and sold to both fountain retailers and authorized wholesalers or bottling partners. Additionally, the 2023 filing highlighted that fountain syrup operations were specifically included in the North America operating segment, indicating a more structured and regionally focused approach to syrup distribution. This evolution reflects a strategic shift toward tighter control and segmentation of syrup-related revenue streams within the broader beverage production ecosystem.",
      "llm_answer": "In both the 2022 and 2023 filings Coca‑Cola’s syrups are still treated as an intermediate product that the Company sells to its independent bottling partners, who mix the syrups (or concentrates) with water and sweeteners to create the finished beverages that are then packaged and shipped to retailers, wholesalers or fountain outlets. However, the 2023 filing shows that the share of net operating revenue coming from concentrate‑based operations (which include syrups) rose from 56 % in 2022 to 58 % in 2023, while the share from finished‑product operations fell from 44 % to 42 %, indicating that the syrup‑based model has become relatively more important to the Company’s overall business and that bottlers now handle a larger portion of the final production and distribution process. (2022 description – page 6; 2023 description – page 37; revenue mix – page 38)",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative claims and misrepresentation of the evolution in Coca-Cola's syrup business model. (1) The claim that 'the share of net operating revenue coming from concentrate-based operations rose from 56% in 2022 to 58% in 2023' is not supported by the ground truth and introduces specific percentages not present in the original answer. The ground truth does not mention any such revenue split or change in percentage shares between 2022 and 2023, making this a fabricated statistic. (2) The LLM incorrectly implies that the increase in concentrate operations' revenue share indicates a shift in production burden to bottlers, which is not stated or implied in the original answer. (3) The original answer highlights a key strategic evolution in 2023: Coca-Cola directly managing fountain syrup sales in the U.S. and integrating syrup operations into the North America operating segment. This critical shift toward tighter control and regional segmentation is entirely missing from the LLM response. (4) Instead, the LLM focuses on a supposed revenue mix change and increased role of bottlers, which contradicts the ground truth that emphasizes Coca-Cola’s *direct* management and structural integration. (5) While the LLM correctly identifies syrups as intermediate products used in fountain and bottled beverage production, this basic fact alone does not compensate for the incorrect analysis of strategic evolution. (6) The citation of page numbers suggests plausible sourcing but does not validate the accuracy of the claims. Overall, the answer is partially relevant and shows understanding of the general role of syrups, but fails on key factual and multi-hop reasoning elements, especially regarding the 2023 strategic shift and revenue structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1492,
        "completion_tokens": 493,
        "total_tokens": 1985
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the company's operational focus on Africa/Eurasia evolved between 2022 and 2024, particularly in terms of its geographic reporting structure and financial contribution?",
      "original_answer": "In 2022, Africa/Eurasia was reported as part of the Oral, Personal and Home Care segment with an operating profit of $203 million, indicating a relatively minor financial contribution compared to other regions. By 2024, the company maintained Africa/Eurasia as a distinct reportable operating segment within the Oral, Personal and Home Care geographic structure. Additionally, in 2024, the company realigned its skin health business, shifting it from Europe to North America, signaling a strategic refinement in geographic reporting. This change suggests a more nuanced operational focus in how the company organizes and evaluates its regional performance, including in Africa/Eurasia.",
      "llm_answer": "Between 2022 and 2024 the company kept Africa/Eurasia as one of its five reportable operating segments; the only geographic reporting change was the July 1 2024 realignment that moved the skin‑health business from Europe to North America, with Africa/Eurasia’s segment definition unchanged (the firm even recast prior data to match the new structure). Financially, Africa/Eurasia’s contribution grew modestly – net sales rose from $1.08 billion in 2022 to $1.10 billion in 2024, and operating profit increased from $228 million to $253 million (while capital expenditures fell from $30 million to $12 million).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Africa/Eurasia was not a standalone reportable segment but was part of the Oral, Personal and Home Care segment, whereas the LLM incorrectly states it was one of five reportable segments throughout. This is a major entity and structural misrepresentation. (2) Quantitatively, all numbers provided by the LLM are incorrect. The ground truth states operating profit was $203 million in 2022, but the LLM claims $228 million in 2022 and $253 million in 2024—figures not supported by the original answer. Similarly, the LLM introduces net sales ($1.08B to $1.10B) and capital expenditures ($30M to $12M), which are absent from the ground truth and thus unverifiable or fabricated. (3) The reasoning is partially sound in noting the skin health realignment in July 2024 from Europe to North America, which aligns with the original answer’s mention of strategic refinement. However, the conclusion that Africa/Eurasia’s segment definition remained unchanged contradicts the ground truth implication that its reporting structure evolved within a broader geographic reorganization. The LLM fails to capture the evolution from being a sub-region to a distinct segment. (4) Contextual relevance is moderate—the response addresses geographic reporting and financial contribution as asked, but with incorrect data and mischaracterized structural changes. Due to major quantitative and qualitative errors, especially the false assertion of segment status and invented financials, the correctness score is low despite some relevant context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 448,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Johnson & Johnson's strategic presentation of its Orthopaedics business evolved between 2023 and 2024, particularly in terms of global sales performance and emphasis on enabling technologies?",
      "original_answer": "In 2023, JNJ's Orthopaedics segment was presented primarily through quantifiable sales figures, with global revenue reaching $8,942 million, showing a 4.1% increase from the prior year. The 2023 data emphasized steady growth, particularly in the U.S. ($5,525 million, up 3.8%) and modest international growth ($3,417 million, up 4.6%). By 2024, the strategic framing of Orthopaedics shifted from financial metrics to a qualitative emphasis on innovation and enabling technologies. The 2024 filing described Orthopaedics as a portfolio 'supported by products and enabling technologies' across hips, knees, trauma, spine, and sports medicine, without revisiting specific revenue figures. This reflects a strategic pivot from highlighting quantitative performance to underscoring technological leadership and product diversification within the segment.",
      "llm_answer": "In the 2023 Form 10‑K Johnson & Johnson still presented Orthopaedics as a distinct revenue line, reporting $8.9 billion of worldwide sales (U.S. $5.5 b + International $3.4 b) and noting a modest 4 % increase over 2022. By the 2024 filing, the company no longer broke out the sales number; instead it described the Orthopaedics portfolio in narrative terms, emphasizing that it now “includes products and enabling technologies that support hips, knees, trauma, spine, sports, and others,” signaling a shift from a pure sales‑focus to a strategic focus on technology‑enabled solutions within the MedTech segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Johnson & Johnson's strategic presentation of its Orthopaedics business from 2023 to 2024. (1) Quantitatively, the LLM correctly reports the 2023 global sales figure as $8.9 billion (actual: $8,942 million), which is a reasonable rounding. U.S. and international figures are approximated as $5.5B and $3.4B, closely matching the true values of $5,525M and $3,417M. The growth rate is stated as 'modest 4%' versus the exact 4.1%—a minor rounding but factually acceptable. (2) The 2024 shift is accurately described: JNJ no longer disclosed specific revenue figures and instead emphasized enabling technologies and product support across hips, knees, trauma, spine, and sports medicine. The quote 'includes products and enabling technologies that support hips, knees, trauma, spine, sports, and others' aligns semantically with the original answer’s 'supported by products and enabling technologies.' (3) The multi-hop reasoning—comparing the quantitative focus in 2023 to the qualitative, technology-driven narrative in 2024—is sound and correctly synthesized across years and reporting styles. (4) The only minor shortcoming is the lack of explicit mention of the 3.8% U.S. and 4.6% international growth rates from 2023, which were in the original answer, but their omission does not undermine the central conclusion. Overall, the answer conveys the strategic pivot accurately with high factual fidelity, strong reasoning, and full contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 416,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Visa's approach to managing litigation liabilities through loss sharing agreements evolved between 2022 and 2023, particularly in terms of the scope of U.S. covered litigation and liability allocation?",
      "original_answer": "In 2022, Visa detailed specific amendments to its loss sharing agreement, including the October 2015 amendment that expanded the scope of U.S. covered litigation to include opt-out actions from the Rule 23(b)(3) Settlement Class in MDL 1720 that arose out of similar facts or circumstances. This amendment was part of a broader framework involving the omnibus agreement, under which Visa assumed 66.6667% of any monetary liability in covered settlements or judgments, with Mastercard assuming 33.3333%. In 2023, Visa consolidated its approach under the U.S. Retrospective Responsibility Plan, which now encompasses the loss sharing agreement as part of a broader set of mechanisms designed to address potential liabilities from U.S. covered litigation. Notably, the 2023 filing emphasizes that U.S. covered litigation now includes matters that have been 'settled or otherwise fully or substantially resolved,' indicating a shift toward resolution and consolidation of past liabilities. The evolution from a focus on specific amendments and liability sharing with Mastercard in 2022 to a more comprehensive and retrospective liability framework in 2023 suggests a strategic pivot toward finalizing and managing legacy litigation exposure.",
      "llm_answer": "Visa’s loss‑sharing framework was essentially unchanged from the 2022 to the 2023 filing. In both years the loss‑sharing agreement with Visa U.S.A., Visa International and certain Visa U.S.A. members covers “U.S.‑covered litigation” – i.e., the Interchange MDL (MDL 1720) and, by the 2015 amendment, any action brought after Oct 22 2015 by a merchant that opted out of the Rule 23(b)(3) settlement class and is not transferred to the MDL [2022 p. 74; 2023 p. 74]. The agreement continues to allocate each bank’s liability as the amount of any final judgment or approved settlement multiplied by that bank’s membership proportion under Visa U.S.A.’s certificate of incorporation, with Visa indemnifying the members for those amounts [2022 p. 74; 2023 p. 74]. Thus, the scope of covered U.S. litigation and the proportional liability‑allocation mechanism remained the same between the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains some correct details but fundamentally misrepresents the evolution of Visa's approach between 2022 and 2023, which is the core of the question. (1) Correct elements: The description of the 2015 amendment expanding U.S. covered litigation to include opt-out actions from the Rule 23(b)(3) Settlement Class in MDL 1720 is accurate and matches the ground truth. The reference to liability allocation based on membership proportion under Visa U.S.A.'s certificate of incorporation is also factually consistent with the filings. (2) Quantitative accuracy: No specific percentages like 66.6667% (Visa) and 33.3333% (Mastercard) are mentioned in the LLM answer, which omits a key quantitative detail from the 2022 framework involving Mastercard. The LLM incorrectly implies that liability is allocated purely by member bank proportions, whereas the ground truth specifies a fixed split between Visa and Mastercard under the omnibus agreement — a critical distinction. (3) Multi-hop reasoning failure: The LLM claims the framework was 'essentially unchanged,' directly contradicting the ground truth, which identifies a significant strategic shift in 2023 with the consolidation under the U.S. Retrospective Responsibility Plan and an expanded definition of covered litigation to include 'settled or otherwise fully or substantially resolved' matters. This reflects a major evolution in scope and intent — from active liability sharing to retrospective consolidation of legacy exposure — that the LLM completely misses. (4) The answer is contextually relevant in discussing loss sharing and covered litigation but fails to address the key evolution in strategy, structure, and scope between the years. By asserting continuity instead of change, it conveys the opposite of the correct conclusion, warranting a low correctness score despite some accurate component facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1548,
        "completion_tokens": 507,
        "total_tokens": 2055
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did CL's investment in Guaranteed Investment Contracts evolve between 2022 and 2024, and what does this shift indicate about the company's pension plan asset strategy?",
      "original_answer": "In 2022, CL held $1 million in Guaranteed Investment Contracts under its United States Pension Plans and $55 million under its International Pension Plans. By 2024, the company had completely phased out Guaranteed Investment Contracts from its United States Pension Plans, reducing the International allocation to $34 million. This represents a significant shift away from Guaranteed Investment Contracts in the U.S. and a moderate decrease internationally, indicating a strategic reallocation of pension plan assets.",
      "llm_answer": "In the 2022 filing the pension plans held ≈ $1 million of guaranteed‑investment contracts (GICs) in the U.S. plan and $55 million in the international plan (total ≈ $56 million)【page_101】. By the 2024 filing the U.S. GIC holding had been eliminated and the international holding fell to $34 million (total ≈ $34 million)【page_100】. The drop‑off shows Colgate‑Palmolive is moving away from GICs and reallocating assets toward cash, fixed‑income and other diversified fund categories, indicating a shift toward a more diversified and liquid pension‑plan asset strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all quantitative figures from the ground truth: $1 million in GICs for the U.S. pension plan and $55 million for the international plan in 2022, and $0 in the U.S. and $34 million internationally in 2024. These values match exactly with the original answer, and the approximate totals ($56M and $34M) are reasonably calculated. (2) All numbers, dates, and allocations are accurate, with acceptable formatting (e.g., ≈ symbol, spacing). No calculation errors. (3) The multi-hop reasoning is sound—correctly identifying the change over time across two geographic segments (U.S. and International) and synthesizing the trend into a strategic conclusion. The LLM adds a specific detail not in the original answer—reallocation toward 'cash, fixed-income and other diversified fund categories'—which is plausible and contextually supported in typical pension strategy shifts but not explicitly confirmed in the ground truth. This addition slightly extends beyond the original answer but does not contradict it and enhances the interpretation. (4) The answer fully addresses both parts of the question: the evolution of investment in GICs (quantitative change) and the implication for asset strategy (qualitative interpretation). The core facts, entities (CL/Colgate-Palmolive, pension plans, years), and timeframes are correct. The semantic meaning aligns with the ground truth, with slightly enriched reasoning. Thus, the answer is factually excellent with minor extrapolation, warranting a 9/10 on correctness and qualitative accuracy, and full marks on quantitative and contextual dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 448,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the strategic positioning and functionality of the Mastercard Developer Platform evolved between 2022 and 2024, particularly in terms of its role in enabling integration of digital assets and new technologies?",
      "original_answer": "In 2022, the Mastercard Developer Platform was described as a single access point that enables customers and partners to leverage Mastercard's digital assets and services, with an emphasis on ease of integration into new and existing solutions. By 2024, the platform continued to serve this role but expanded its strategic positioning by explicitly aligning with emerging technologies such as blockchain and digital currencies. In 2024, the platform was referenced in the context of enabling integration with the Mastercard Multi-Token Network™, which supports programmable payments and facilitates secure, scalable, and interoperable blockchain-based transactions. This evolution shows a shift from a general digital integration platform to one that specifically supports next-generation financial technologies and programmable commerce solutions.",
      "llm_answer": "In the 2022 filing, Mastercard described its Developer Platform primarily as a “single access point” that lets customers and partners discover and integrate the company’s APIs and digital‑asset services, positioning it as a convenience layer for exposing existing Mastercard services. By the 2024 filing, the platform is portrayed as a strategic hub for new‑technology ecosystems – it now supports blockchain‑based business models, the Multi‑Token Network™ for programmable payments, and crypto‑card purchases, while still offering a unified API gateway, but with an explicit focus on enabling secure, scalable integration of digital assets and emerging fintech innovations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2022 description of the Mastercard Developer Platform as a 'single access point' for APIs and digital asset integration is accurately represented, and the 2024 evolution toward supporting blockchain, the Multi-Token Network™, and programmable payments is correctly detailed. The mention of 'crypto-card purchases' is a minor addition not explicitly in the original answer but is contextually consistent with Mastercard's digital asset initiatives and does not contradict the ground truth. (2) There are no numeric values, dates, or financial figures in the question or answers, so quantitative accuracy is not applicable in a numerical sense; however, the years 2022 and 2024 are correctly attributed to their respective platform descriptions, satisfying temporal accuracy. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes how the platform’s strategic role evolved from a convenience layer to a hub for emerging fintech, incorporating blockchain and digital assets. The core evolution from general integration to enabling next-gen financial technologies is accurately captured. (4) Semantic equivalence is strong—the LLM uses different phrasing (e.g., 'strategic hub for new-technology ecosystems') but conveys the same conceptual progression as the original. The only reason for not scoring a 10 is the slight expansion on 'crypto-card purchases,' which, while plausible, is not present in the ground truth and introduces a minor unsupported detail. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 453,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the company's investment in U.S. common stocks within its pension plans evolved between 2022 and 2024, and what does this indicate about its strategic asset allocation?",
      "original_answer": "In 2022, the company reported no investments in U.S. common stocks within its pension plans, while by 2024, there was still no allocation to U.S. common stocks in the U.S. pension plan. However, the international pension plan maintained a $2 million investment in U.S. common stocks in both years. This indicates a continued strategic decision to avoid direct exposure to U.S. common stocks in the domestic pension portfolio while maintaining a minimal presence in the international portfolio.",
      "llm_answer": "In the 2022 filing the pension‑plan tables show a “‑” for U.S. common‑stock holdings, meaning the plans held essentially **$0** of U.S. equities. By the 2024 filing the same line reports a balance of **$1 million** of U.S. common‑stock investments (out of total plan assets of about $1.3 billion).  \n\nThe move from zero to a very modest $1 million indicates that the company is only beginning to add a small equity slice to its pension portfolios, while the overwhelming majority of assets remain in cash and fixed‑income securities, consistent with its deliberately conservative, fixed‑income‑heavy strategic asset allocation.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the company had no investment in U.S. common stocks in its U.S. pension plan in both 2022 and 2024, and the international pension plan held a consistent $2 million in U.S. common stocks in both years. The LLM incorrectly states that U.S. common stock holdings were $0 in 2022 and rose to $1 million in 2024, which contradicts the ground truth. The correct figures are $0 in the U.S. plan and $2 million in the international plan for both years. (2) Quantitative accuracy is low: the LLM reports $1 million instead of the correct $2 million and fails to specify that the amount was unchanged across both years and held only in the international plan. It also misrepresents the change over time by implying a shift from $0 to $1 million, when no such change occurred in the data. (3) The multi-hop reasoning is flawed. The LLM fails to distinguish between U.S. and international pension plans, a critical distinction in the original answer. It incorrectly infers a strategic shift toward adding equities, when the ground truth indicates a consistent strategy of avoiding U.S. common stocks in the domestic plan and maintaining a stable minimal allocation internationally. The conclusion about a 'beginning to add' equity exposure is unsupported. (4) Contextual relevance is moderate because the answer addresses pension plan investments and strategic allocation, but the incorrect data and reasoning undermine the validity. The mention of fixed-income conservatism is plausible but not directly supported by the provided truth. Scores reflect major factual errors in numbers and entity-specific allocation, with partial credit for addressing the general topic and direction of inquiry.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 485,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did Disney's strategic focus on cruise ships evolve between 2022 and 2023, particularly in terms of capital investment plans and operational risk considerations?",
      "original_answer": "In 2022, Disney highlighted cruise ships as a key part of its capital investment strategy within the Parks & Experiences segment, noting that a majority of its capital spending was directed toward theme parks, resorts, and cruise ships. This indicated a growth-oriented approach focused on expanding physical assets. By 2023, the emphasis had shifted toward operational risks associated with cruise ships, particularly in the context of external disruptions like hurricanes and global events (e.g., the impact of Hurricane Milton on Walt Disney World operations). The 2023 filing framed cruise ships more as an operational exposure rather than a growth engine, signaling a shift from investment to risk mitigation. This evolution reflects a recalibration of strategic focus from asset expansion to managing volatility and external threats.",
      "llm_answer": "In the 2022 Form 10‑K Disney’s capital‑allocation discussion placed cruise‑ship construction squarely among its “major capital investments,” noting that a sizable share of its overall spend would go to “new attractions, cruise ships, capital improvements and systems infrastructure” (see 2022 p. 17). By the 2023 filing the company was still emphasizing fleet growth—announcing a plan to add more cruise ships in fiscal 2024—but it now paired that investment outlook with a detailed risk narrative, warning that cruise‑ship operations are vulnerable to health pandemics, extreme weather, geopolitical events and insurance‑coverage limits that could disrupt sailings and hurt profitability (see 2023 p. 21‑22).",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) It accurately captures Disney's continued capital investment in cruise ships in 2022, citing the correct context of major capital investments including cruise ships, and references the correct document page (p. 17). In 2023, it correctly notes the ongoing fleet expansion plans and the increased emphasis on operational risks such as health pandemics, extreme weather, and geopolitical events, with accurate page references (p. 21–22). (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—no errors in dates or fiscal years (2022 and 2023 correctly used). (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings to show an evolution in strategic focus. However, the LLM slightly underemphasizes the shift in tone from growth-oriented investment to risk mitigation as the dominant strategic theme. The original answer notes a clear pivot from viewing cruise ships as a 'growth engine' to an 'operational exposure,' which the LLM implies but does not explicitly state. (4) The answer is contextually highly relevant, directly addressing capital investment plans and operational risk considerations as asked. While the core facts and synthesis are correct, the more nuanced strategic recalibration is less clearly articulated, justifying a score of 8 rather than 9–10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 401,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Mastercard's use of short duration foreign exchange derivative contracts evolved between 2022 and 2024, particularly in terms of their role in managing foreign exchange risk during daily settlement activities?",
      "original_answer": "In 2022, Mastercard used short duration foreign exchange derivative contracts to manage foreign exchange risk associated with daily settlement activities, aiming to reduce exposure to volatility from currency fluctuations on anticipated receipts and disbursements. By 2024, the company continued this practice, maintaining the same stated objective of minimizing volatility in gains and losses due to foreign exchange fluctuations. However, the context changed as the company actively adjusted its hedging strategies involving euro-denominated debt, de-designating and re-designating portions of it in 2023 and 2024, which indicates a more dynamic approach to managing foreign exchange exposure across the period. The continuity in the use of short duration contracts contrasts with the evolving structure of the company’s broader foreign exchange risk management strategy.",
      "llm_answer": "Mastercard’s 2022 filing already explained that, because settlement risk only lasts a few days, the company “may enter into short‑duration foreign‑exchange derivative contracts … based on anticipated receipts and disbursements” and that the resulting gains or losses are recorded in general‑and‑administrative expense. The 2024 filing repeats the same description, showing that the short‑duration contracts are still used to smooth the daily FX exposure that arises between transaction and settlement, with the accounting treatment unchanged. What has shifted is that, in 2024, Mastercard also began entering into longer‑term cash‑flow‑hedge contracts (up to roughly seven years) for other foreign‑currency exposures, while the short‑duration contracts continue to serve the same day‑to‑day risk‑management role.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Mastercard used short-duration foreign exchange derivative contracts in both 2022 and 2024 to manage daily settlement-related FX risk, with unchanged accounting treatment—this aligns with the ground truth. The core factual elements—purpose (managing short-term FX exposure), timing (2022 to 2024), and continuity of use—are accurate. However, the LLM introduces a detail not present in the ground truth: that Mastercard began using longer-term cash-flow hedges (up to seven years) in 2024. While plausible and contextually consistent with evolving hedging strategies, this specific addition is not supported by the original answer, which focuses on de-designation/re-designation of euro-denominated debt as the key strategic shift. This is a minor overreach in synthesis, but does not contradict the ground truth. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is mostly sound: the model correctly infers continuity in short-term hedging practices across years and distinguishes tactical (short-term) from strategic (broader) risk management changes. However, the introduction of longer-term hedges as a 2024 development goes beyond the provided evidence, slightly weakening qualitative accuracy. (4) Contextual relevance is high—the answer directly addresses the evolution of short-duration contract usage and ties it to daily settlement activities as asked. The added context about longer-term hedges enhances understanding but slightly deviates from the evidence base. Overall, the answer is factually strong with minor overextension in inference.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 468,
        "total_tokens": 1907
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Salesforce's strategic relationship with enterprise cloud companies evolved from 2023 to 2024, particularly in terms of investment focus and ecosystem integration?",
      "original_answer": "In 2023, Salesforce maintained a portfolio of strategic investments in enterprise cloud companies, technology startups, and system integrators, with a focus on digitally transforming industries and expanding its solution ecosystem. These investments were described as ranging from early to late-stage companies, including those concurrent with initial public offerings. By 2024, Salesforce's relationship with enterprise cloud companies shifted from primarily investing to a broader strategic dependency, leveraging these partners as part of its ecosystem to accelerate reach into new markets and industries. The 2024 filing emphasized the Salesforce Platform's role in enabling third-party developers and ISVs to create and deliver cloud-based applications through the AppExchange, indicating a deepened integration and dependency on enterprise cloud partners beyond mere financial investment.",
      "llm_answer": "In the 2023 filing Salesforce described its enterprise‑cloud relationships chiefly as “working with third parties … to increase the breadth of capability and depth of capacity” and emphasized integration through its MuleSoft‑powered API, integration and automation stack, but it did not call out a dedicated investment programme. By the 2024 filing the company says it now “manages a portfolio of strategic investments … focused primarily on enterprise‑cloud companies, technology startups and system integrators,” and it is actively reinvesting proceeds while deepening ecosystem integration through Agentforce, Data Cloud and the AppExchange partner marketplace. Thus, the relationship has shifted from a partnership‑and‑integration focus in 2023 to an explicit equity‑investment and tighter ecosystem‑building strategy in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains a significant factual reversal in the timeline of investment focus, which undermines the core of the multi-hop reasoning. According to the ground truth, Salesforce had a stated portfolio of strategic investments in enterprise cloud companies in 2023, with a shift in 2024 toward broader strategic dependency and deeper ecosystem integration. However, the LLM answer incorrectly claims that in 2023 there was no dedicated investment program and that the shift to a 'portfolio of strategic investments' occurred in 2024—this inverts the actual progression. This error is critical because it misrepresents the evolution: the ground truth shows investment was already present in 2023, while 2024 emphasized deeper integration and dependency beyond investment. The LLM also introduces specific technologies (Agentforce, Data Cloud) not mentioned in the original answer, which adds detail not supported by the ground truth. While the emphasis on AppExchange and ecosystem integration in 2024 aligns with the original, the reversal of cause and effect—portraying investment as a new 2024 strategy rather than a pre-existing 2023 activity—constitutes a major qualitative inaccuracy. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. Contextual relevance is high, as the response addresses both investment focus and ecosystem integration across the two years. However, due to the core factual inversion in the strategic timeline, the correctness score is reduced to 6—partially correct but with significant errors in entity and reasoning accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 442,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the company's approach to accrual rates for vendor funding programs evolve between fiscal 2023 and fiscal 2024, particularly in terms of sensitivity to projected purchase volumes?",
      "original_answer": "The company's approach to accrual rates for vendor funding programs remained methodologically consistent between fiscal 2023 and fiscal 2024, with no material changes in the recognition methodology over the past three fiscal years. However, in fiscal 2023, the company specifically highlighted sensitivity to 'graduated purchase volumes' that could impact accrued amounts, emphasizing the importance of projected volumes in determining accrual rates. In fiscal 2024, this explicit reference to 'graduated purchase volumes' was omitted, suggesting a potential simplification or stabilization in how accrual rates were adjusted throughout the year, despite continued monitoring of historical purchase trends and vendor confirmations.",
      "llm_answer": "The company did not change its methodology – in both FY 2023 and FY 2024 it “develops accrual rates based on the provisions of the vendor‑funding agreements, reviews historical purchase trends and volumes throughout the year, adjusts the rates as appropriate and confirms amounts with select vendors.” In each filing the company notes that the accrued amounts remain sensitive to any difference between actual purchase volumes and the projected volumes, especially for programs that provide additional funding when graduated purchase‑volume thresholds are met.  No material change to this approach was disclosed between the two years.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in terms of methodology and correctly states that there was no material change in the accrual rate approach between fiscal 2023 and 2024. It accurately notes the use of vendor-funding agreements, historical trends, and volume projections in both years, and correctly identifies sensitivity to differences between actual and projected volumes, especially for programs with graduated thresholds. Quantitative accuracy is perfect—no numbers, dates, or financial figures are incorrect, and none are misrepresented. Contextual relevance is high, as the response directly addresses the question about evolution in approach and sensitivity to purchase volumes. However, the key qualitative distinction in the ground truth is missed: in fiscal 2023, the company explicitly highlighted 'graduated purchase volumes' as a sensitivity factor, while in fiscal 2024 this specific language was omitted, suggesting a potential shift in emphasis or simplification. The LLM answer fails to note this change in disclosure—instead implying that both years contain the same explicit reference—thus misrepresenting the evolution in communication. This omission affects the reasoning accuracy, as the multi-hop insight (comparing the presence vs. absence of specific language across filings) is not captured. While the core methodology is correctly described as unchanged, the nuanced evolution in disclosure and potential implications for how sensitivity was presented is absent, reducing qualitative accuracy. Hence, correctness is partially compromised despite strong factual grounding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 437,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the strategic relationship between LLY and Boehringer Ingelheim evolved from 2022 to 2024, particularly in terms of legal involvement and collaborative dependency on the Jardiance product?",
      "original_answer": "In 2022, LLY was not a direct party to the Jardiance patent litigation initiated by Boehringer Ingelheim (BI) against generic drug manufacturers under the Hatch-Waxman Act, indicating a more arms-length relationship in legal matters. By 2024, LLY's business became significantly dependent on the Jardiance collaboration, as the product was selected under the Inflation Reduction Act (IRA) for government-set pricing with a 66% discount compared to the 2023 list price, directly impacting LLY's revenue projections and business strategy. This shift reflects a deeper strategic entanglement and dependency on BI's partnership for navigating regulatory and pricing pressures.",
      "llm_answer": "In the 2022 filing, Lilly’s relationship with Boehringer Ingelheim (BI) was framed around litigation: the two companies were co‑defendants in five Jardiance product‑liability suits, and the partnership agreement required BI to **defend and indemnify** Lilly for any damages or costs arising from those claims, while Lilly was **not a party** to the patent‑infringement suit that BI had launched against generic challengers.  \n\nBy the 2024 filing, the discussion of Jardiance no longer focuses on litigation; instead it is described as **“part of our collaboration with Boehringer Ingelheim”** and is highlighted for its exposure to government‑set pricing under the Inflation Reduction Act, indicating that the companies remain commercially dependent on the product but the legal coordination evident in 2022 has receded, with no new joint lawsuits noted.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that in 2022, LLY was not a party to the patent-infringement litigation initiated by Boehringer Ingelheim (BI) against generics, while being a co-defendant in product-liability suits where BI had indemnification obligations—this matches the original answer’s characterization of a more arms-length legal relationship. In 2024, it accurately notes the shift to commercial dependency under the Inflation Reduction Act (IRA), with Jardiance subject to government-set pricing, though it omits the specific 66% discount figure mentioned in the ground truth. (2) All dates (2022, 2024) and legal/contractual terms (indemnify, defend, not a party) are correct; no numerical inaccuracies beyond the missing percentage. The 66% discount is a key quantitative detail absent in the LLM response, hence a minor deduction in completeness. (3) The multi-hop reasoning is sound: it synthesizes legal and commercial dynamics across years and entities (LLY, BI, Jardiance, IRA), correctly inferring reduced legal entanglement and sustained collaboration. The omission of the 66% figure slightly weakens the quantitative support for the revenue impact claim but does not invalidate the overall conclusion. (4) The response is fully contextually relevant, directly addressing the evolution of legal involvement and collaborative dependency. The qualitative reasoning is strong, with precise use of contractual language and regulatory context. Final score reflects high accuracy with a small gap in completeness on a key financial detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 441,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How did Disney's capital investment strategy toward cruise ships evolve from 2022 to 2023, particularly in relation to its broader Parks & Experiences business?",
      "original_answer": "In 2022, Disney's 10-K filing highlighted cruise ships as part of its broader Experiences segment but did not specifically emphasize capital investment in them, instead noting general risks from macroeconomic conditions such as inflation, supply chain delays, and currency fluctuations that could impact the implementation of business plans, including those for parks and resorts. By 2023, Disney explicitly listed cruise ships as part of its significant capital investments, indicating a strategic elevation in focus. The 2023 filing stated that the majority of the company’s capital spend was directed toward parks and experiences, including 'new attractions, cruise ships, capital improvements and systems infrastructure.' This shift demonstrates a clear prioritization of cruise ships as a key growth area within the broader Experiences segment.",
      "llm_answer": "In the 2022 filing Disney’s capital‑investment discussion noted a discrete cruise‑line project – the purchase of 550 acres at Lighthouse Point that will become a Disney Cruise Line destination in 2024 – but it was presented as a single, stand‑alone initiative. By the 2023 filing the company framed cruise‑ship spending as part of the broader “Parks & Experiences” capital program, stating that the majority of its capital budget is now allocated to that segment for theme‑park and resort expansion, new attractions **and** cruise‑ship additions, indicating that cruise‑ship investment has been integrated into its core growth strategy for Parks & Experiences.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution in Disney's capital investment strategy toward cruise ships from 2022 to 2023, correctly identifying the shift from a stand-alone project to integration within the broader Parks & Experiences capital program. However, there are some discrepancies. The 2022 mention of Lighthouse Point (550 acres, 2024 opening) is factually accurate and supported by Disney’s filings, but the original answer does not include this detail—instead, it emphasizes the absence of specific capital investment emphasis on cruise ships in 2022, focusing on macroeconomic risks. The LLM introduces a specific project not highlighted in the ground truth, which, while true, shifts focus from the main point: the strategic elevation of cruise ships in capital allocation. In 2023, both answers agree that cruise ships were explicitly included in major capital investments alongside attractions and infrastructure, showing integration into core strategy. This key multi-hop insight—evolution from peripheral to central focus—is correctly synthesized. Quantitative elements (550 acres, 2024) are accurate and contextually appropriate, though not present in the original answer; no calculations are involved. The reasoning is mostly sound but slightly overemphasizes a specific project not in the ground truth, reducing qualitative precision. The answer remains contextually relevant and conveys a similar conclusion, albeit with a different supporting example. Thus, the correctness score is 7 due to accurate core reasoning with minor factual overreach, quantitative accuracy is 8 (numbers correct but not in ground truth), qualitative accuracy is 7 (correct direction but different evidence), and contextual relevance is 9 (highly relevant to the question).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 479,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Mastercard Foundry's role in fostering innovation evolved between 2022 and 2024, particularly in relation to its engagement with emerging technologies and fintech partnerships?",
      "original_answer": "In 2022, Mastercard Foundry (formerly known as Mastercard Labs) was primarily described as a vehicle for bringing customers and partners access to thought leadership, innovation methodologies, new technologies, and early-stage fintech players. By 2024, its role had evolved into a more active innovation engine, with continued emphasis on identifying and experimenting with future technologies, start-ups, and trends. Specifically, in 2024, Foundry was positioned as a key enabler of blockchain-based business models and programmable payments through the Mastercard Multi-Token Network™, indicating a strategic shift toward deeper integration with next-generation financial technologies.",
      "llm_answer": "In the 2022 filing, Mastercard Foundry (formerly Mastercard Labs) was portrayed mainly as a thought‑leadership conduit – “identifying and experimenting with future technologies, start‑ups and trends” and giving customers and partners access to new‑technology expertise and early‑stage fintech players. By the 2024 filing, Foundry had become a hands‑on innovation engine, running concrete programs such as the “Launchpad” five‑day app‑prototyping workshop, in‑lab usability testing and concept‑design services, while still scouting emerging tech and fintech partners. Thus, its role evolved from a advisory, scouting function to an active development hub that directly co‑creates and accelerates fintech collaborations and emerging‑technology solutions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Mastercard Foundry evolved from a thought-leadership and scouting role in 2022 to a more active innovation engine by 2024. The description of Foundry’s 2022 role matches the original answer, including its function in providing access to innovation methodologies, new technologies, and early-stage fintech players. In 2024, the LLM correctly identifies a shift toward hands-on development, citing specific programs like the 'Launchpad' workshop, in-lab testing, and concept-design services—details consistent with the idea of Foundry becoming a direct co-creation hub. (2) There are no numeric values, dates, or financial figures in the question or answers, so quantitative accuracy is not applicable beyond correct use of years (2022 and 2024), which are accurate. (3) The multi-hop reasoning is sound: the model synthesizes Foundry’s evolving role across two time points and correctly infers a strategic shift from advisory to operational engagement. The only minor omission is that the original answer specifically mentions the Mastercard Multi-Token Network™ and blockchain-based business models as focal points in 2024, which the LLM answer does not include. This is a small but notable detail related to 'emerging technologies' in the question. (4) Despite this omission, the LLM captures the essence of Foundry’s evolution and emphasizes active development, fintech collaboration, and emerging tech engagement, maintaining strong semantic equivalence. Contextual relevance is excellent, directly addressing all parts of the question. Hence, a correctness score of 9 is warranted—very close to perfect but missing one specific strategic initiative mentioned in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 485,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial and strategic nature of the collaboration with Boehringer Ingelheim evolved between 2022 and 2024, particularly in terms of regulatory designations and pricing pressures?",
      "original_answer": "In 2022, the collaboration with Boehringer Ingelheim included the development of a therapy that had received Breakthrough Therapy and Fast Track designations from the FDA, indicating early-stage regulatory support and potential expedited development. By 2024, the collaboration faced significant pricing pressures under the Inflation Reduction Act, with Jardiance—part of the LLY-Boehringer Ingelheim partnership—selected for government-set pricing effective in 2026, subject to a 66% discount compared to the 2023 U.S. list price. This marks a shift from regulatory facilitation to regulatory-driven financial constraints.",
      "llm_answer": "In the 2022 filing the partnership with Boehringer Ingelheim was presented primarily as a joint development effort on empagliflozin (Jardiance), for which the companies highlighted FDA‑granted regulatory incentives – Breakthrough‑Therapy, Fast‑Track and priority‑review designations – to accelerate approval (see 2022 page 39). By the 2024 filing the same collaboration is discussed in the context of the Inflation‑Reduction Act’s pricing reforms: HHS has selected Jardiance for government‑set pricing, imposing a 66 % discount for 2026 and other steep cuts, creating a new, material pricing‑pressure risk for the joint product (see 2024 pages 45‑46). Thus the relationship has shifted from a focus on regulatory acceleration to confronting significant pricing and reimbursement constraints that could affect the collaboration’s financial outlook.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: in 2022, the collaboration involved empagliflozin (Jardiance) with FDA designations including Breakthrough Therapy and Fast Track (priority review is an additional accurate detail not in the ground truth but not contradictory); by 2024, the Inflation Reduction Act imposed pricing pressures with a 66% discount on Jardiance effective in 2026. (2) Quantitative accuracy is perfect: the 66% discount is correctly stated, and the timeline (2022 to 2024, with impact in 2026) matches. (3) Multi-hop reasoning is sound—LLM correctly synthesizes information across two years of filings, identifying the shift from regulatory facilitation to financial constraints. (4) Entity accuracy is strong: Boehringer Ingelheim, Jardiance, the Inflation Reduction Act, HHS, and FDA designations are all correctly named and contextualized. The answer fully addresses both parts of the question—regulatory designations and pricing pressures—and captures the strategic evolution of the collaboration. Minor enhancements (e.g., mentioning LLY partnership explicitly) do not detract from correctness. Wording differs slightly but meaning is preserved with high precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 353,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has the strategic positioning of the CH-53K King Stallion heavy lift helicopter evolved within Lockheed Martin's Rotary and Mission Systems segment from 2023 to 2024?",
      "original_answer": "In 2023, the CH-53K King Stallion heavy lift helicopter was described as part of Lockheed Martin's near-to-mid-term growth elements, specifically under the Rotary and Mission Systems (RMS) segment, alongside radar surveillance systems. By 2024, the CH-53K remained a highlighted program within RMS, but the emphasis shifted to framing it within a broader context of advancing all-domain mission solutions and digital technologies such as AI/ML and autonomy. While no specific revenue figures are provided, the helicopter's positioning evolved from being a growth driver among several others to being part of a more integrated, technologically advanced portfolio aimed at improving interoperability and supporting multi-domain solutions.",
      "llm_answer": "In the 2023 filing, Lockheed Martin noted that the CH‑53K King Stallion was still a newly‑awarded foreign‑sales program – Israel had signed a Letter of Offer and Acceptance in 2021 for 12 helicopters, with the final four of those awards delivered in 2023. By the 2024 filing, the company described the CH‑53K as an established part of its Rotary and Mission Systems (RMS) helicopter portfolio, “in service with U.S. and foreign governments,” indicating that the platform has moved from a recent export win to a mature, in‑service product that underpins RMS’s core helicopter offerings.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some accurate contextual details but diverges significantly from the ground truth in terms of the core evolution of the CH-53K's strategic positioning within Lockheed Martin's RMS segment. (1) Correct elements: The mention of foreign sales (Israel) and the 2021 Letter of Offer and Acceptance aligns with known public information, and stating that the CH-53K was 'in service with U.S. and foreign governments' by 2024 is plausible. However, the original answer does not reference Israel or delivery timelines, so this detail, while potentially true, is not supported by the ground truth and introduces unverified specifics. (2) Quantitative accuracy: No explicit numbers (e.g., revenue, delivery counts beyond 'final four') are contradicted, but the 'final four delivered in 2023' is not present in the original answer and cannot be verified against the ground truth. This introduces unsupported precision. (3) Multi-hop reasoning: The LLM incorrectly frames the strategic evolution around program maturity and foreign deliveries, whereas the ground truth emphasizes a shift in narrative—from being a standalone growth driver in 2023 to being integrated into a broader, technology-driven portfolio (AI/ML, autonomy, multi-domain solutions) in 2024. This key conceptual shift is entirely missing. (4) The LLM focuses on operational status (newly awarded → in service), while the original answer highlights a strategic repositioning in corporate messaging around digital transformation and interoperability. Thus, while the answer is contextually relevant and plausibly reasoned, it fails to capture the actual evolution described in the ground truth, resulting in a partially correct but substantively misaligned response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 472,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "What does the change in LLY's diabetes product portfolio co-commercialized with Boehringer Ingelheim between 2022 and 2024 indicate about the companies' shifting strategic priorities or market focus?",
      "original_answer": "In 2022, LLY and Boehringer Ingelheim were jointly developing and commercializing a broader portfolio of diabetes products, including Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, and Basaglar. By 2024, the portfolio had narrowed to include only Jardiance, Glyxambi, Synjardy, and Trijardy XR. This indicates a strategic refocusing, potentially driven by lifecycle management, shifting market demand, or prioritization of products with stronger commercial performance or longer patent protection. The removal of Trajenta, Jentadueto, and Basaglar may reflect declining market relevance, generic competition, or a strategic decision to streamline the collaboration around products with greater growth potential or therapeutic differentiation.",
      "llm_answer": "In the 2022 filing Eli Lilly listed a broad co‑commercialization slate with Boehringer Ingelheim that included Basaglar (a long‑acting insulin) and Trajenta (an oral DPP‑4 inhibitor) together with the SGLT‑2‑inhibitor family (Jardiance, Glyxambi, Synjardy and Trijardy XR). By the 2024 filing the collaboration is described only in terms of the SGLT‑2‑inhibitor portfolio (Jardiance, Glyxambi, Synjardy and Trijardy XR), with the insulin and DPP‑4 products no longer highlighted. This shift signals that both companies are concentrating their joint effort on the higher‑growth, outcomes‑driven oral diabetes market rather than on insulin‑based products, reflecting a strategic re‑orientation toward differentiated, cardiovascular‑benefit diabetes therapies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the diabetes products co-commercialized in 2022 (Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, and Basaglar) and notes their reduction by 2024 to only the SGLT2-inhibitor family—Jardiance, Glyxambi, Synjardy, and Trijardy XR—though it omits explicit mention of Jentadueto in the initial list, which is a minor oversight. (2) All dates (2022 and 2024) are correct, and there are no numerical values requiring calculation; thus, quantitative accuracy is perfect. (3) The multi-hop reasoning is sound: the model correctly infers a strategic shift from a broader portfolio to a focused one centered on SGLT2 inhibitors, linking this to growth potential, cardiovascular benefits, and market differentiation—consistent with the original answer’s interpretation around performance, lifecycle management, and market focus. (4) The answer is contextually excellent, directly addressing the question about shifting strategic priorities. The only minor gap is not explicitly naming Jentadueto as part of the discontinued collaboration, but the core reasoning and entity tracking remain strong. Wording differs but semantic meaning matches the ground truth, supporting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 362,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial performance and strategic importance of the JASSM program evolve between 2023 and 2024, particularly in terms of production activity and its contribution to backlog?",
      "original_answer": "In 2023, JASSM was a product under the Missiles and Fire Control (MFC) segment, contributing to the company's portfolio of tactical missiles, but there was no specific mention of significant changes in its production volume or backlog contribution. By 2024, JASSM experienced a production ramp-up, contributing to a $1.2 billion increase in tactical and strike missile programs within MFC. Additionally, JASSM was specifically cited as a key contributor to the increase in backlog alongside PAC-3 and GMLRS. This indicates a notable rise in both production activity and strategic importance for JASSM in 2024.",
      "llm_answer": "In 2023 the JASSM (Joint Air‑to‑Surface Standoff Missile) program began a modest production ramp‑up that added about $145 million of net sales to the Missiles & Fire Control (MFC) segment and helped lift the segment’s backlog with higher orders on JASSM (along with PAC‑3, LRASM and GMLRS)【page_40】. By 2024 the ramp‑up accelerated, becoming a major driver of the segment’s $1.2 billion sales boost for tactical‑and‑strike missiles and further expanding the backlog with new JASSM orders, underscoring the program’s growing strategic importance to Lockheed Martin【page_40】.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in quantitative details. The ground truth states that JASSM contributed to a $1.2 billion increase in tactical and strike missile programs in 2024, but the LLM incorrectly claims a $145 million net sales increase in 2023 — a figure not present in the original answer and unsupported by the provided context. There is no mention in the ground truth of JASSM's specific dollar contribution to sales in 2023, nor is there a breakdown of $145 million; thus, this is a fabrication or misattribution. (2) While the $1.2 billion figure for 2024 is correctly cited, it is mischaracterized as a 'sales boost' when the original answer frames it as an increase in production activity contributing to backlog — a distinction that affects interpretation. The original does not attribute the full $1.2 billion solely to JASSM, but the LLM implies JASSM was a 'major driver' of this entire amount, overstating its role without evidence. (3) Qualitatively, the LLM captures the correct trajectory: JASSM’s production ramped up from 2023 to 2024 and it became strategically more important, contributing to backlog growth alongside PAC-3 and GMLRS. This multi-hop reasoning — inferring increased strategic importance from production and backlog trends — is sound and aligns with the original. (4) Contextual relevance is high, as the response directly addresses the evolution of JASSM’s financial performance and strategic role across the two years, citing the correct segment (MFC) and peer programs. However, the inclusion of LRASM as a co-contributor in 2023 is not in the original and slightly distorts the evidence. Overall, while the directional analysis is correct, the incorrect insertion of a specific $145M figure and misattribution of the $1.2B impact significantly reduce quantitative accuracy, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 514,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has JPM's focus in evaluating credit risk for Business Banking Loans evolved between 2023 and 2024, and what implications does this shift have for identifying early signs of borrower distress?",
      "original_answer": "In 2023, JPM focused on Business Banking Loans as part of its broader prime consumer credit strategy, emphasizing loan performance and scoring models within the 'Consumer, excluding credit card loan portfolio' segment. By 2024, the focus shifted toward delinquency rates as the primary credit quality indicator, particularly noting that loans more than 30 days past due serve as early warnings of financial difficulty. This evolution suggests a more proactive stance in identifying early signs of borrower distress, aligning Business Banking Loans with broader consumer loan risk frameworks where early delinquency tracking enhances risk mitigation. The shift indicates a strategic move toward earlier intervention and more granular performance monitoring.",
      "llm_answer": "In the 2023 filing JPM said that, for its Business‑Banking (auto‑and‑business‑banking) loans, **delinquency > 30 days was the chief early‑warning signal and geographic concentration was the secondary risk gauge**【page_242】. The 2024 filing repeats that same framework but explicitly ties the > 30‑day delinquency metric to “early warning of borrowers who may be experiencing financial difficulties” and continues to rely on geographic distribution as a key indicator, while the broader portfolio discussion now adds LTV and refreshed FICO data that sharpen the firm’s ability to spot distress earlier across its loan book【page_250】. Thus, JPM’s evaluation has not shifted away from delinquency and geography, but it has broadened its analytical toolkit (adding LTV/FICO insights) to improve the detection of early borrower distress.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies delinquency over 30 days as a key metric and mentions geographic concentration, LTV, and FICO as part of the risk framework in 2024, which aligns with contextual elements in the ground truth. However, it contradicts the original answer by stating that the >30-day delinquency was already the 'chief early-warning signal' in 2023, whereas the ground truth indicates that in 2023, JPM focused on loan performance and scoring models within the broader consumer portfolio, not specifically on delinquency rates as the primary indicator. The shift described in the original answer—from performance/scoring models in 2023 to delinquency rates in 2024 as the main credit quality indicator—is not accurately reflected. Instead, the LLM claims the framework was the same across both years, which misrepresents the evolution. (2) Quantitatively, there are no explicit numbers (e.g., percentages, dollar amounts) in either answer, so no numerical inaccuracies are present. The reference to 'delinquency >30 days' is consistent in both answers and factually correct per the source. (3) The multi-hop reasoning is partially sound—information from two years is compared, and additional risk factors (LTV, FICO) are correctly attributed to 2024 enhancements. However, the core evolution—shifting focus from scoring models to delinquency tracking—is missed, undermining the reasoning. The LLM incorrectly assumes continuity rather than change. (4) Contextual relevance is high because the answer discusses the right domain (credit risk in Business Banking Loans), correct time frame, and relevant metrics. But due to the mischaracterization of the 2023 framework and the absence of the stated strategic shift, the qualitative accuracy and overall correctness are significantly reduced. The answer adds details (geographic concentration, LTV/FICO) not emphasized in the ground truth, potentially conflating broader consumer loan practices with Business Banking specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 540,
        "total_tokens": 1949
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did Target Corporation's SPP II plan terms evolve between the 2022 and 2023 filings, and what does this suggest about the company's executive compensation framework?",
      "original_answer": "In the 2022 filing, the SPP II plan was described under the 2016 Plan Statement, as amended and restated effective April 3, 2016. However, in the 2023 filing, the SPP II plan was updated to the 2022 Plan Statement, as amended and restated effective May 1, 2022. This indicates that Target Corporation revised the SPP II plan within this timeframe, reflecting a shift in the structure or terms of the plan. Such changes could signal adjustments in the company's executive compensation strategy, potentially aligning incentives more closely with updated business objectives or governance standards.",
      "llm_answer": "The exhibit schedules for both the 2022 and 2023 Form 10‑K list the same “Target Corporation SPP II (2016 Plan Statement) (as amended and restated effective April 3, 2016)” (see page 68 of each filing). No new amendment or replacement of the SPP II is disclosed, indicating that the company kept the same long‑term incentive plan in place from one year to the next. This continuity suggests that Target’s executive‑compensation framework relies on a stable, established set of long‑term equity‑based awards rather than frequent redesigns of its senior‑level incentive plans.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim. According to the ground truth, the SPP II plan evolved from the 2016 Plan Statement (effective April 3, 2016) in the 2022 filing to the 2022 Plan Statement (effective May 1, 2022) in the 2023 filing. However, the LLM asserts that both filings reference the same 2016 version, claiming no change occurred. This misrepresents the actual evolution of the plan. The LLM’s assertion that 'no new amendment or replacement' was disclosed contradicts the ground truth, which confirms a clear update in the plan statement. As a result, the quantitative accuracy is low due to incorrect dates and versions cited (2016 vs. updated 2022 version). The qualitative reasoning is flawed because the model fails to recognize the multi-hop change across filings, leading to an incorrect conclusion about stability in executive compensation. While the answer is relevant to the question’s topic and attempts to interpret implications, the factual foundation is wrong, undermining the analysis. The conclusion about 'stable, established' incentives is not supported given the actual plan update, making the reasoning invalid despite being contextually appropriate in structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 339,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial obligations related to Incyte under the Olumiant collaboration evolve from 2022 to 2024, particularly regarding potential future milestone payments?",
      "original_answer": "In 2022, Incyte was eligible to receive up to $100.0 million in additional development-related regulatory milestones and another $100.0 million in sales-based milestones under the Olumiant agreement. By 2024, there is no mention of remaining regulatory milestones, suggesting they were either paid out or no longer applicable, and only ongoing royalty payments based on sales tiers (up to 20%) and a low teens royalty for sales exceeding a threshold in the context of COVID-19 treatment are explicitly referenced. This indicates a shift from a structure with both regulatory and sales milestones to one focused primarily on sales-based compensation.",
      "llm_answer": "In the 2022 Form 10‑K Eli Lilly disclosed that, under its worldwide Olumiant licence with Incyte, Incyte remained eligible to receive **up to $100 million in additional success‑based regulatory milestones and up to $100 million in potential sales‑based milestones** (a total of $200 million of future milestone exposure).  \n\nThe 2024 Form 10‑K no longer provides a dollar amount for any remaining milestone liability – it only describes the royalty‑only structure and notes that milestone payments to Incyte were “not material.” This indicates that the previously disclosed $200 million of potential milestone obligations has either been satisfied, extinguished or is no longer considered material to the company’s financial position.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the $100 million in regulatory milestones and $100 million in sales-based milestones (totaling $200 million) in 2022 are accurately reported, and the absence of specific dollar amounts in 2024 is correctly noted. The phrasing 'up to $100 million' matches the original 'up to $100.0 million'. (2) The LLM correctly infers that the lack of disclosed milestone amounts in 2024, combined with the statement that milestone payments were 'not material', implies the potential obligations either were fulfilled, expired, or are no longer significant—this is a sound interpretation consistent with the ground truth's suggestion that regulatory milestones were likely paid out or no longer applicable. (3) The multi-hop reasoning across 2022 and 2024 filings is strong: the model identifies the change in disclosure and correctly interprets the shift from a milestone-based structure to a royalty-only arrangement. (4) The only minor shortcoming is that the LLM does not explicitly mention the 'up to 20%' royalty tiers or the 'low teens' royalty for COVID-19-related sales beyond a threshold, which are part of the ground truth and add specificity to the 2024 arrangement. While the royalty-only shift is correctly identified, this detail would have improved completeness. Overall, the answer is factually correct, well-reasoned, and directly responsive to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 407,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has Cisco's financial exposure in the APJC region evolved between fiscal 2022 and fiscal 2023, based on its segment reporting and asset balances?",
      "original_answer": "In fiscal 2022, Cisco reported its business performance across geographic segments including APJC, though specific financial figures for APJC were not disclosed in the provided data. By fiscal 2023, Cisco's balance sheet showed that its assets in the APJC region stood at $5,382 million as of July 29, 2023, following additions from acquisitions and foreign currency translation adjustments. This indicates a more detailed financial disclosure regarding APJC in 2023 compared to 2022, where segment-level asset values were not explicitly itemized.",
      "llm_answer": "In the 2022 filing Cisco reported that the APJC geographic segment generated **$8.0 billion of revenue** and carried **$5.36 billion of goodwill**.  The 2023 filing shows the same segment’s goodwill rising to **$5.38 billion** (an increase of about **$22 million**) and, consistent with the overall rise in total company revenue, APJC’s revenue also increased modestly year‑over‑year.  Together, the higher segment revenue and the slight uplift in goodwill indicate that Cisco’s financial exposure in APJC grew only marginally between fiscal 2022 and fiscal 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Cisco did not disclose specific financial figures for the APJC region in fiscal 2022, but the LLM claims APJC generated $8.0 billion in revenue and carried $5.36 billion in goodwill in 2022—information not present in the provided data. Similarly, the LLM asserts that APJC revenue increased modestly and that goodwill rose to $5.38 billion in 2023, but the ground truth only confirms total APJC assets (not goodwill) were $5,382 million as of July 29, 2023. There is no mention of goodwill by segment in the original answer, nor any revenue breakdown for APJC in either year. (2) The numbers cited ($8.0 billion revenue, $5.36B/$5.38B goodwill) are entirely fabricated or misattributed, with no support from the ground truth. The calculation of a $22 million increase in goodwill is therefore invalid. The only number aligning approximately is the $5.38 billion asset balance in 2023, which matches the ground truth’s $5,382 million—though the LLM mislabels it as goodwill rather than total assets. (3) The multi-hop reasoning is flawed: the model incorrectly synthesizes non-existent segment-level revenue and goodwill data for 2022 and 2023, then draws a conclusion about increasing financial exposure based on unsupported metrics. The actual evolution noted in the ground truth is about improved disclosure (from no itemized asset values in 2022 to explicit asset balances in 2023), which the LLM fails to recognize. (4) The contextual relevance is moderate because the answer addresses Cisco's APJC region and attempts to compare fiscal 2022 and 2023, but the qualitative and quantitative inaccuracies severely undermine correctness. The conclusion about 'marginal growth' is not supported by the evidence in the original answer, which emphasizes disclosure transparency rather than performance trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 515,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the strategic collaboration between LLY and Boehringer Ingelheim, specifically regarding Jardiance, evolved from 2022 to 2024 in response to regulatory changes?",
      "original_answer": "In 2022, Jardiance revenue was growing significantly, with a 30% increase in the U.S. and 28% outside the U.S., driven by increased demand and volume respectively. By 2024, the collaboration was significantly impacted by the Inflation Reduction Act (IRA), which introduced government-set pricing for certain drugs, including Jardiance. In August 2023, Jardiance was selected as one of the first ten medicines subject to government-set prices, and in August 2024, a 66% discount was applied compared to the 2023 U.S. list price, significantly affecting revenue projections and business strategy.",
      "llm_answer": "In the 2022 Form 10‑K the company described its joint partnership with Boehringer Ingelheim on Jardiance as a growing revenue source and noted that the newly‑enacted Inflation Reduction Act (IRA) could subject the drug to future government‑set pricing, but no specific price‑setting action had yet been taken. By the 2024 filing the partnership had moved from a “potential” regulatory risk to an actual regulatory outcome: the U.S. Health and Human Services Department selected Jardiance in August 2023 as one of the first ten medicines to receive a government‑set price, and in August 2024 announced that the 2026 price will be a 66 % discount to the 2023 list price, creating a concrete revenue‑erosion impact on the collaboration.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Jardiance was selected in August 2023 as one of the first ten drugs subject to government pricing under the IRA, and a 66% discount was applied to the 2023 U.S. list price, effective for 2026 (as stated in the 2024 filing). The answer correctly characterizes the evolution from potential risk in 2022 to actual regulatory impact by 2024. (2) Quantitative accuracy is perfect: the 66% discount and August 2023 selection date match the ground truth; although the original answer states the discount was applied in August 2024, this appears to be a minor discrepancy in interpretation—the LLM correctly notes that the price will be implemented in 2026 based on the 2024 announcement, which is consistent with regulatory timelines. The ground truth’s 'August 2024' likely refers to the announcement date, which the LLM accurately captures. (3) Multi-hop reasoning is sound: the model synthesizes information across 2022 and 2024 filings, correctly tracing the evolution from growth and risk disclosure to actual pricing impact. (4) The only minor shortcoming is that the LLM omits the specific 2022 revenue growth figures (30% in U.S., 28% outside U.S.) mentioned in the original answer, which were part of the collaboration's status at the start of the period. However, it captures the qualitative point of growth and increasing importance. This small omission prevents a perfect 10 but does not undermine the core correctness. Overall, the answer is factually precise, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 447,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did GM's emphasis on the financial and reputational risks of product safety recalls evolve between 2022 and 2023, particularly concerning global platforms like the Chevrolet Bolt EV and the company's positioning in EV/AV technologies?",
      "original_answer": "In 2022, GM specifically highlighted the Chevrolet Bolt EV recall as an example of how global platform-related recalls could significantly increase costs due to their scale. The focus was on the financial burden and logistical complexity tied to such large-scale campaigns. By 2023, while the concern around global platforms remained, GM expanded its risk disclosure to emphasize the reputational damage to brand image and equity, particularly in relation to its leadership aspirations in EV and AV technologies. This evolution suggests a shift from a primarily cost-centric concern to a broader strategic risk tied to innovation and market positioning.",
      "llm_answer": "In the 2022 filing GM warned that product‑safety recalls can generate “significant costs” and “reputational harm,” noting that a recall on a **global platform such as the Chevrolet Bolt EV** could magnify those impacts and that safety concerns – even around advanced‑technology products like autonomous vehicles (AVs) – could damage brand image, brand equity and consumer trust. By the 2023 filing the same risk language is retained, but the company stresses that a recall on a global platform would “exacerbate” costs **and erode the brand equity and consumer trust needed to lead the industry with EVs and AVs**, linking the financial‑reputational threat directly to its strategic positioning in electric‑vehicle and autonomous‑vehicle technologies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, GM highlighted the Chevrolet Bolt EV as a global platform recall with significant financial and reputational impacts, particularly due to scale. In 2023, it accurately notes the shift toward emphasizing reputational damage linked to brand equity and consumer trust in the context of GM's leadership goals in EV and AV technologies. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the original answer, so quantitative accuracy is not applicable—no errors here. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, connects the Bolt EV recall to global platforms, and correctly traces the evolution from cost-centric to strategic brand positioning concerns. The only minor shortcoming is that the LLM slightly overstates continuity by saying 'the same risk language is retained,' which isn't fully verifiable from the ground truth; the original emphasizes a qualitative expansion in 2023, not just retention. However, this does not undermine the core accuracy. (4) The answer is contextually precise, addressing all parts of the question: the evolution between 2022 and 2023, the role of the Bolt EV, and implications for EV/AV positioning. Wording differs but meaning is semantically equivalent. Thus, a score of 9 is justified—excellent but not perfect due to slight overstatement of continuity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 410,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the Guaranteed Senior Notes issued by Costco's Japanese subsidiary evolve between 2022 and 2024, and what does this indicate about the company's long-term financing strategy?",
      "original_answer": "In 2022, the Guaranteed Senior Notes issued by Costco's Japanese subsidiary were described in general terms, indicating only their existence and that they were valued using Level 3 inputs. By 2024, the company provided significantly more detailed information, disclosing that in November 2023, the subsidiary issued four new Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%, with maturities extending from 2033 to 2043. Additionally, in July 2024, the subsidiary repaid $77 of these notes. This evolution indicates a more transparent and strategic approach to long-term financing, with a focus on fixed-rate debt and extended maturities to manage future liquidity needs.",
      "llm_answer": "In the 2022 Form 10‑K the only “other long‑term debt” – which at that time consisted of the Guaranteed Senior Notes issued by Costco’s Japanese subsidiary – was reported at **$590 million** (Note 4, “Other long‑term debt” $590)【page_52】.  \nBy the 2024 filing the subsidiary had **issued four new Guaranteed Senior Notes worth about $500 million** (interest 1.40‑2.12%, maturing 2033‑2043) and **repaid $77 million** of the existing notes, so “other long‑term debt” rose to **$919 million** (Note 4, “Other long‑term debt” $919)【page_52】.  \n\nThis growth shows Costco is actively using its Japanese subsidiary to tap low‑cost, long‑dated foreign‑currency financing, expanding its debt base and extending maturity horizons, which signals a deliberate long‑term financing strategy that diversifies funding sources and locks in inexpensive capital for future growth.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. The ground truth states that the new notes issued in November 2023 totaled approximately $500 (not $500 million), and $77 was repaid in July 2024 (not $77 million). The LLM incorrectly adds units of 'million' to these figures, which significantly distorts the scale. Additionally, the LLM claims that 'other long-term debt' rose to $919 million in 2024, but this number is not supported by the ground truth, which does not provide a total debt figure. The 2022 value of $590 million is not in the ground truth either — the original answer only mentions that the notes were valued using Level 3 inputs, with no dollar amount disclosed. (2) Calculations are therefore flawed: the LLM implies a net increase from $590M to $919M due to +$500M issuance and -$77M repayment, but this entire calculation is based on fabricated numbers. The ground truth does not support any specific aggregate balances, only that new notes were issued and some repayment occurred. (3) The multi-hop reasoning is partially sound — the LLM correctly identifies the evolution from less to more detailed disclosure and infers a strategic use of foreign financing, which aligns with the ground truth’s conclusion about transparency and long-term strategy. It correctly links the Japanese subsidiary to long-dated debt issuance and interprets extended maturities as part of a broader financing strategy. (4) Despite incorrect numbers, the qualitative direction of the answer — increased issuance, repayment, longer maturities, strategic use of international debt markets — is consistent with the ground truth. The reasoning and contextual interpretation are relevant and mostly logical, hence moderate scores in qualitative accuracy and high in contextual relevance. However, the severe quantitative inaccuracies — especially inventing precise dollar amounts not present in the original — significantly reduce the correctness and quantitative accuracy scores.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 548,
        "total_tokens": 1954
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the value of Cisco's available-for-sale debt investments change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, Cisco reported gains from available-for-sale debt investments at $9 million, indicating a relatively minor role in their investment portfolio. By 2023, the total value of these investments dropped significantly from $15,592 million to $9,865 million, a decrease of $5,727 million. This indicates a strategic reduction in the company's holdings of available-for-sale debt instruments, suggesting a shift in investment focus or risk management approach.",
      "llm_answer": "Cisco’s available‑for‑sale debt investment balance rose from **$11.9 billion at fiscal‑year end 2022** to **$15.6 billion at fiscal‑year end 2023** – an increase of roughly **$3.6 billion**. This growth shows that the company is deliberately expanding its high‑quality, investment‑grade debt portfolio, using the larger cash‑equivalent pool to preserve liquidity for strategic acquisitions, customer financing and the aggressive share‑repurchase/dividend program that underpins its capital‑allocation strategy.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both direction and magnitude of the change in Cisco's available-for-sale debt investments. According to the ground truth, the value of these investments decreased from $15,592 million in 2022 to $9,865 million in 2023—a drop of $5,727 million—indicating a strategic reduction. However, the LLM claims an increase from $11.9 billion to $15.6 billion, which is the opposite of the truth. The numbers cited ($11.9B and $15.6B) do not match the ground truth values ($15,592M and $9,865M), and the calculated change (+$3.6B) is therefore also wrong. The qualitative interpretation—that Cisco is expanding its debt portfolio—is directly contradicted by the data. While the answer addresses the question's structure (change in value and strategic implication), the factual basis is entirely incorrect, leading to a severe failure in multi-hop reasoning and synthesis. Contextual relevance is low due to incorrect data, though the response attempts to interpret strategic intent appropriately given its flawed premise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 299,
        "total_tokens": 1546
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has JPMorgan Chase's exposure to system damage risks evolved from 2023 to 2024, particularly in relation to third-party vendor attacks and data recovery challenges?",
      "original_answer": "In 2023, JPMorgan Chase highlighted risks related to system damage primarily through unauthorized access, zero-day vulnerabilities, and disruptions from distributed denial-of-service attacks. The company emphasized the risk of undetected vulnerabilities due to incomplete system enhancements and the potential for data loss or manipulation. By 2024, the exposure evolved to include more specific emphasis on ransomware attacks targeting third-party vendors and the risk of losses exceeding cyber insurance coverage. Additionally, JPMorgan Chase noted increased complexity in recovering from data theft or destruction, with a new concern around the inability to prevent systems from processing fraudulent transactions. These changes indicate a growing awareness of external cyber threats and their financial implications.",
      "llm_answer": "In the 2023 filing JPMorgan Chase already warned that a “failure to implement adequate controls…including increased reliance on third‑party providers” could lead to system‑damage events, and it highlighted specific gaps such as “oversight of third‑party vendors and early detection of attacks against those vendors…including ransomware attacks” and the risk that “the inability…to fully recover and restore data” would exacerbate any breach (2023 p.27). The 2024 filing expands that warning, noting that new products, cloud‑computing and other technology changes further raise the chance that JPMorgan Chase “may not fully appreciate…new operational risks…including increased reliance on third‑party providers,” and it now ties those risks to a formal “Firmwide resiliency framework” aimed at protecting against system‑damage, vendor‑originated cyber attacks and the associated data‑recovery challenges (2024 p.28‑29). Thus, the bank’s exposure has grown as its technology stack and third‑party dependencies have expanded, prompting a more explicit, program‑wide focus on vendor‑attack detection and data‑restoration capabilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2023, JPMorgan Chase highlighted risks related to third-party vendors, including gaps in oversight and early detection of attacks (e.g., ransomware), as well as data recovery challenges—matching the original answer's emphasis on unauthorized access, zero-day vulnerabilities, and data loss. In 2024, the LLM correctly notes an evolution toward greater focus on third-party cyber attacks and data-recovery complexities, including integration into a 'Firmwide resiliency framework,' which reflects the original answer’s point about increased awareness of external threats and financial implications. (2) There are no numeric values, dates, or calculations in the question or answers that conflict; all references to years (2023, 2024) and page numbers (p.27, p.28–29) are consistent with factual sourcing and do not contradict the ground truth. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly identifying how exposure evolved from general system-damage risks to more specific concerns around vendor-originated attacks and recovery limitations. It also captures the growing technological complexity and institutional response, which is implied in the original answer’s mention of increased financial and operational implications. (4) The only minor shortcoming is that the LLM does not explicitly mention 'ransomware attacks targeting third-party vendors' as a new emphasis in 2024 per the original answer, though it does reference 'vendor-originated cyber attacks' and prior awareness of ransomware, slightly softening the evolution. Also, the point about losses exceeding cyber insurance coverage and inability to prevent fraudulent transaction processing is omitted. These are notable but not central enough to warrant a lower score. Overall, the answer is factually correct, contextually precise, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1493,
        "completion_tokens": 540,
        "total_tokens": 2033
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "What operational investments has Costco made by 2024 to support the private-label growth strategy mentioned in its 2022 filing?",
      "original_answer": "In 2022, Costco emphasized increasing the penetration of its private-label items as a merchandising strategy to manage inflationary pressures and maintain competitive pricing. By 2024, Costco had made tangible operational investments to support this strategy, including the operation of various processing, packaging, and manufacturing facilities dedicated to the production of private-label items. These facilities, referenced in the 2024 filing, represent a significant evolution from the earlier strategic focus, demonstrating a shift from sourcing private-label products externally to building internal production capabilities to scale the initiative.",
      "llm_answer": "Costco’s 2022 filing highlighted a strategy of expanding the penetration of its private‑label (Kirkland) items. By the end of 2024 the company had invested in the operations needed to back that plan – it now operates 890 warehouses (about 130.9 million sq ft. of floor space) and has added dedicated processing, packaging and manufacturing facilities that produce its private‑label merchandise. These expanded warehouse and production‑capacity investments are the operational assets Costco is using to drive private‑label growth.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies Costco's private-label growth strategy from the 2022 filing and the operational investments made by 2024, including dedicated processing, packaging, and manufacturing facilities. This aligns with the ground truth's emphasis on internal production capabilities as a shift from external sourcing. However, the LLM introduces specific quantitative details—890 warehouses and 130.9 million sq ft of floor space—that are not present in the original answer and are not directly tied to supporting private-label production. These figures, while potentially accurate in a broader context, are not cited in the ground truth as operational investments specifically for private-label growth, making their inclusion misleading and unsupported by the provided knowledge. There is no indication in the original answer that warehouse count or total floor space are part of the private-label investment strategy; the focus is solely on production facilities. Thus, while the core qualitative reasoning is sound and contextually relevant, the quantitative accuracy is reduced due to the introduction of extraneous and unverified numbers. The multi-hop reasoning is mostly correct—linking 2022 strategy to 2024 operational outcomes—but overextends by associating general infrastructure with a specific strategic initiative without evidence. Semantic equivalence is mostly preserved, but the added specifics degrade factual precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 398,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How did UnitedHealth Group's approach to Medicaid managed care contract bidding evolve between 2022 and 2023, particularly in terms of assumptions and risks associated with bid accuracy?",
      "original_answer": "In 2022, UnitedHealth Group emphasized the risk of losing Medicaid members if it failed to renew state Medicaid managed care contracts, highlighting the importance of contract renewals to retain enrolled members. By 2023, the company placed greater emphasis on the assumptions behind its bids, noting that if these assumptions—such as enrollment, utilization, and medical costs—were materially incorrect due to unforeseen program changes or competitor pricing, it could materially affect results of operations and cash flows. This reflects an evolution from a focus on contract renewal risk to a more detailed discussion of the assumptions and competitive dynamics involved in the bidding process itself.",
      "llm_answer": "In the 2022 Form 10‑K UnitedHealth said that its Medicaid‑managed‑care bids are “based upon certain assumptions regarding enrollment, utilization, medical costs and other factors” and warned that a material error in any of those assumptions – whether caused by unexpected program or policy changes or by competitors submitting lower rates – could “materially and adversely affect” its results of operations, financial position and cash flows.  \n\nThe 2023 filing still stresses that bids are assumption‑driven, but it adds that the company now places greater emphasis on monitoring the accuracy of those assumptions and explicitly ties bid‑inaccuracy to the risk of losing state contracts and the associated financial impact, indicating a more cautious, risk‑focused approach to Medicaid‑managed‑care bidding.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its description of UnitedHealth Group's bid assumptions (enrollment, utilization, medical costs) and correctly identifies the risks associated with assumption inaccuracies due to program changes or competitor pricing. It also correctly references the 2022 and 2023 timeframes and the continued emphasis on assumption-driven bidding. However, it mischaracterizes the evolution: the original answer states that in 2022 the focus was on the risk of losing members if contracts were not renewed, while in 2023 the focus shifted to the accuracy of bid assumptions. The LLM incorrectly claims that in 2022 the company already emphasized assumption errors affecting results — this level of detail on bid assumptions was a 2023 development. Thus, the LLM reverses the progression by attributing the detailed assumption-risk language to 2022 when it reflects a refinement in 2023. There are no numerical inaccuracies (quantitative accuracy is perfect), and the answer is contextually relevant and well-structured. The qualitative inaccuracy lies in the misattribution of the timing of risk emphasis, weakening the multi-hop reasoning about how the approach evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 335,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did MET's investment in Municipals evolve from 2022 to 2023, particularly in terms of its valuation hierarchy classification?",
      "original_answer": "In 2022, MET's investment in Municipals was valued at $14,212 million and primarily categorized under 'Estimated Fair Value' without a detailed breakdown of valuation hierarchy levels. By 2023, the investment in Municipals decreased to $159 million and was explicitly classified under 'Level 2' of the fair value hierarchy. This indicates a significant reduction in the size of the Municipals investment and a more transparent categorization within the fair value hierarchy in 2023.",
      "llm_answer": "In 2023 MetLife’s Municipals were held only in the Level 2 portion of the fair‑value hierarchy, with $147 million reported for pension‑benefit assets and $8 million for other post‑retirement assets. In 2022 the same categories were also classified entirely at Level 2, but the amounts were higher—$159 million for pension benefits and $15 million for other post‑retirement benefits. Thus, the Municipals exposure fell modestly between 2022 and 2023 while remaining a Level 2‑valued investment.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, MET's investment in Municipals was $14,212 million in 2022 and dropped to $159 million in 2023. However, the LLM claims the 2022 amount was $159 million for pension benefits alone, which is incorrect. It also reports $147 million and $8 million in 2023, summing to $155 million, which does not match the ground truth of $159 million. More critically, the ground truth states that in 2022, the valuation was under 'Estimated Fair Value' without a detailed hierarchy breakdown, but the LLM incorrectly asserts that in 2022 the investment was already fully classified under Level 2—this contradicts the original answer and misrepresents the evolution in transparency and classification. (2) Number verification: 2022 value should be $14,212M (not $174M as implied by $159M + $15M); 2023 value is $159M total (not $155M as implied). The LLM reverses the trend by suggesting only a modest decline when in fact there was a massive reduction from $14,212M to $159M. (3) Multi-hop reasoning failure: The question asks about evolution in both valuation amount and hierarchy classification. The LLM fails to recognize that 2022 lacked a detailed hierarchy breakdown, incorrectly asserting Level 2 classification in both years, thus missing the key point about increased transparency in 2023. (4) Scores justified: Correctness is low (3/10) due to major factual and directional errors. Quantitative accuracy is poor (2/10) due to wrong numbers and misstated magnitudes. Qualitative accuracy is low (3/10) because the reasoning about hierarchy evolution is incorrect. Contextual relevance is moderate (6/10) as the answer addresses the right topic and time frame but with flawed data and interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 487,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has Microsoft's approach to Office 365 subscriptions evolved in terms of licensing flexibility and customer agreement models from fiscal year 2022 to 2024?",
      "original_answer": "In fiscal year 2022, Office 365 subscriptions were primarily managed under volume licensing programs and were recognized as part of unearned revenue, invoiced annually at the beginning of each contract period and recognized ratably over the coverage period. By fiscal year 2024, Microsoft introduced more structured and flexible customer agreement models, including the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products and Services Agreement, which allowed customers to subscribe to cloud services seamlessly and directly, with options for monthly or annual subscriptions and no organization-wide commitment. This represents a shift toward enhanced customer-centric licensing flexibility.",
      "llm_answer": "In FY 2022 Microsoft sold Office 365 primarily through its traditional volume‑licensing programs (e.g., Enterprise Agreements, Open Value, Select Plus) that bundled the cloud service with on‑premises software and required a three‑year commitment; the subscription was treated as a single, integrated performance‑obligation and revenue was recognized ratably over the contract period【page_63】.  \n\nBy FY 2024 the company had shifted to a set of more flexible, non‑expiring digital agreements – the Microsoft Customer Agreement, Microsoft Online Subscription Agreement and Microsoft Products & Services Agreement – that let customers of any size acquire Office 365 on a month‑or‑year‑by‑month basis, either directly or through partners, without the need for long‑term volume‑licensing contracts【page_15】【page_16】. This evolution adds subscription‑only options and simplifies the purchasing process, giving customers greater licensing flexibility compared with the earlier, commitment‑heavy model.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in FY2022, Office 365 was sold through volume licensing programs (e.g., Enterprise Agreements) with multi-year commitments and revenue recognized ratably; by FY2024, Microsoft transitioned to flexible digital agreements—specifically naming the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products & Services Agreement—allowing month-to-month or annual subscriptions without long-term commitments. (2) There are no numeric inaccuracies; although specific dollar amounts or percentages are not present, the temporal references (FY2022, FY2024) are correct and consistent with the original. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes over time in licensing models, agreement types, and customer flexibility, drawing a clear evolution from rigid, bundled contracts to agile, subscription-based access. (4) The only minor discrepancy is the LLM's mention of a 'three-year commitment' in volume licensing, which is plausible but not explicitly stated in the ground truth—this adds specificity not confirmed in the original, but does not contradict it. Otherwise, the answer captures the core shift toward customer-centric, flexible licensing with semantic equivalence. Thus, the answer earns a 9/10 for correctness due to this slight over-specificity, but maintains full marks in quantitative accuracy and contextual relevance, with a 9 in qualitative accuracy due to excellent reasoning and entity identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 434,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the composition of MET's Level 3 Fixed Maturity Securities AFS change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, MET's Level 3 Fixed Maturity Securities AFS included $1 million in Corporate bonds, $1 million in Foreign Bonds, and $11 million in Equity Securities. By 2023, the Level 3 composition shifted significantly, with $54 million in Corporate bonds, $2 million in Foreign Bonds, and $828 million in Other Investments. This indicates a strategic shift toward increasing exposure in Other Investments while maintaining a relatively small position in Level 3 fixed maturity securities overall. The significant increase in Other Investments within Level 3 suggests a more aggressive approach to portfolio diversification or risk management.",
      "llm_answer": "In 2022 the only Level 3 Fixed‑Maturity Securities held in the pension plans were $55 million of corporate bonds (plus a $3 million “Other” line‑item and a $3 million equity‑security line‑item). By year‑end 2023 the corporate‑bond balance fell slightly to $54 million, while the “Other” component grew to $8 million, equity‑security holdings rose to $12 million and a small $2 million position in foreign bonds re‑appeared, lifting total Level 3 Fixed‑Maturity Securities from $58 million to $64 million (see page 309). This shift shows MetLife is diversifying its Level 3 portfolio away from a pure corporate‑bond focus toward a broader mix of higher‑return, less‑liquid assets such as alternative “Other” securities and equity‑type holdings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, MET's Level 3 Fixed Maturity Securities AFS consisted of $1M Corporate bonds, $1M Foreign Bonds, and $11M Equity Securities — not $55M corporate bonds and $3M each in 'Other' and equity as claimed. In 2023, the correct composition is $54M Corporate bonds, $2M Foreign Bonds, and $828M in Other Investments, whereas the LLM reports $54M corporate bonds (correct), $8M 'Other', $12M equity, and $2M foreign bonds — conflating categories and misrepresenting amounts. Most critically, the ground truth shows Equity Securities dropped to zero and were replaced by $828M in Other Investments, but the LLM incorrectly states equity holdings rose to $12M. (2) Calculations are also flawed: the LLM claims total Level 3 securities rose from $58M to $64M, but the correct totals are $13M in 2022 ($1M+$1M+$11M) and $884M in 2023 ($54M+$2M+$828M). The LLM’s numbers are off by hundreds of millions. (3) The multi-hop reasoning is unsound: the LLM fails to identify the correct shift — a massive move into 'Other Investments' — and instead suggests a broad diversification into equity and alternative securities, which contradicts the ground truth. It also references 'pension plans' and 'page 309', which are not in the original answer and introduce unverified context. (4) Despite incorrect facts and reasoning, the LLM attempts to interpret strategic implications (diversification, higher-return assets), which gives it partial credit for contextual relevance. However, due to severe quantitative and qualitative errors, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 452,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How has Microsoft's strategic positioning of Office 365 evolved between 2022 and 2024, particularly in terms of its role within the broader cloud services portfolio and its response to competitive pressures from AI-driven offerings?",
      "original_answer": "In 2022, Office 365 was explicitly listed as a key component of Microsoft's service and other revenue, positioned alongside Azure, Dynamics 365, and Xbox as a core cloud-based solution. By 2024, Office 365 had evolved into a more integrated part of Microsoft’s broader AI-infused cloud services portfolio, reflecting the company's strategic shift to infuse generative AI capabilities into commercial offerings. The 2024 filing notes that Microsoft is devoting significant resources to develop and deploy AI models, platforms, and infrastructure to meet customer needs, indicating that Office 365 is now part of this AI-enhanced competitive strategy. This shift was driven by increasing competitive pressures from companies entering the AI market and offering alternative models such as free applications funded by advertising or open-source AI models, which Microsoft must counter with enhanced, integrated cloud experiences.",
      "llm_answer": "- **2022 filing:** Office 365 is presented primarily as a bundled cloud‑subscription service.  The 2022 10‑K notes that Office 365 “depends on a significant level of integration… and is accounted for together as one performance obligation” and that it is grouped with Azure, Dynamics 365 and Xbox under “service and other revenue” (see p. 63‑64; p. 62).  \n\n- **2024 filing:** By 2024 the company’s narrative has shifted to position Office 365 as a cornerstone of its broader AI‑infused cloud platform.  The 2024 10‑K stresses that Microsoft is “investing in artificial intelligence… and infusing generative AI capabilities into our consumer and commercial offerings” and that its cloud‑based services must “continue to bring to market compelling cloud‑based and AI experiences” (see p. 21‑22).  Although Office 365 is not named again in the revenue‑recognition discussion, the emphasis on AI‑driven competition and the need to embed AI across its cloud portfolio indicates that Office 365 is now being leveraged as an AI‑enabled SaaS pillar to counter AI‑first rivals.  \n\n**Thus, between 2022 and 2024 Microsoft moved Office 365 from a core productivity subscription bundled with other cloud services to a central, AI‑enhanced component of its overall cloud strategy, using it to meet competitive pressure from emerging AI‑driven offerings.**",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, Office 365 was positioned as a core cloud subscription service bundled under 'service and other revenue' with Azure, Dynamics 365, and Xbox, which matches the original answer. By 2024, the strategic shift toward AI integration is correctly identified, with Microsoft emphasizing AI-infused cloud services, even if Office 365 is not explicitly named in the revenue section. The conclusion that it has become an AI-enhanced SaaS pillar is logically sound and consistent with the filing's emphasis on embedding generative AI across commercial offerings. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable beyond correct year references (2022, 2024), which are accurate. (3) Multi-hop reasoning is strong: the model correctly infers from the 2024 filing that although Office 365 is not explicitly mentioned in revenue recognition, its role is now subsumed within the broader AI-driven cloud strategy, requiring synthesis across years and strategic themes. (4) The only minor shortcoming is a slight lack of explicit mention of competitive pressures from 'free applications funded by advertising or open-source AI models' as noted in the ground truth, though the reference to 'AI-first rivals' captures the essence. Wording differs slightly but maintains semantic equivalence. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1588,
        "completion_tokens": 422,
        "total_tokens": 2010
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did UnitedHealth Group's recognition and handling of credit-related impairments evolve between 2022 and 2023, particularly in terms of their evaluation methodology and financial impact?",
      "original_answer": "In 2022, UnitedHealth Group evaluated available-for-sale debt securities for credit-related impairments by analyzing expected cash flows, underlying credit quality, and credit ratings of issuers, concluding that there was no significant credit deterioration since purchase and that unrealized losses were primarily due to interest rate increases. The allowance for credit losses was not material. By 2023, the company formalized its impairment recognition process by distinguishing between credit-related and non-credit-related impairments, recording credit-related impairments as an allowance against investment income and non-credit-related impairments through other comprehensive income. Additionally, the company emphasized a more structured evaluation framework that includes present value of expected cash flows, the extent of fair value decline relative to amortized cost, and issuer-specific financial conditions. This reflects a more detailed and segmented approach to impairment recognition and financial reporting.",
      "llm_answer": "In the 2022 Form 10‑K UnitedHealth said it looked for credit‑related impairments only when an available‑for‑sale debt security’s fair value fell below amortized cost, evaluating the expected cash‑flows, the issuer’s credit quality and ratings; the resulting allowance for credit losses was “not material.” By the 2023 filing the company had broadened the assessment – it now compares the present value of expected cash‑flows to amortized cost, measures the fair‑value shortfall, and also weighs the issuer’s financial condition, near‑term prospects and any specific events, recording any impairment as an allowance (offset to investment income) and moving the full amount to earnings if the security is intended to be sold. In both years the allowance for credit‑related impairments remained immaterial, so the financial impact was negligible.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of factual content, entities, and timeline. (1) It accurately identifies UnitedHealth Group's 2022 evaluation methodology—assessing impairments when fair value fell below amortized cost, analyzing expected cash flows, credit quality, and ratings—and correctly notes the allowance was 'not material,' matching the original answer. In 2023, it correctly describes the enhanced framework: comparing present value of expected cash flows to amortized cost, assessing fair value decline, and considering issuer financial conditions and specific events. The distinction in accounting treatment—recording credit-related impairments as an allowance against investment income—is consistent with the ground truth. (2) There are no numeric values or calculations in the question or answers, so quantitative accuracy is not applicable in a numerical sense, but all qualitative financial impacts (e.g., 'immaterial,' 'negligible financial impact') are correctly reported. (3) The multi-hop reasoning is sound: the model synthesizes changes in methodology and reporting treatment across two years from UnitedHealth’s 10-K filings. However, the LLM slightly overstates the change by implying that the full impairment is moved to earnings if the security is intended to be sold—a nuance not present in the ground truth and potentially conflating with other accounting rules (e.g., intent to sell triggering full recognition in earnings under certain models). The original answer emphasizes a clean split between credit and non-credit impairments (latter through OCI), which the LLM omits. (4) Despite this minor overcomplication, the core evolution—more structured, segmented, and formalized evaluation in 2023—is correctly conveyed. Hence, the answer is highly accurate with only a slight gap in precision of accounting mechanics, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1477,
        "completion_tokens": 520,
        "total_tokens": 1998
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did the allocation and valuation of Fixed Maturity Securities AFS in MET's pension and other postretirement benefit plans evolve from 2022 to 2023?",
      "original_answer": "In 2022, Fixed Maturity Securities AFS accounted for 84% of U.S. Pension Benefits and 95% of U.S. Other Postretirement Benefits. By 2023, the total estimated fair value of Fixed Maturity Securities AFS was $6,714 million for Pension Benefits and $1,274 million for Other Postretirement Benefits. This indicates a shift from a primarily percentage-based allocation in 2022 to a more detailed valuation breakdown in 2023, showing both the scale and composition of MET's holdings.",
      "llm_answer": "In 2023 MetLife’s invested plans still relied almost entirely on Fixed‑Maturity Securities AFS, but the share of plan assets allocated to that class slipped a couple of points versus 2022 – the pension‑benefit allocation fell from about 83 % of assets in 2022 to roughly 82 % in 2023, while the other post‑retirement‑benefit allocation fell from about 96 % to 94 % (the 2023 targets remained 85 % for pensions and 94‑95 % for other benefits).  \n\nCorrespondingly, the fair‑value of those securities declined modestly: total Fixed‑Maturity Securities AFS for pension plans fell from $6.8 billion in 2022 to $6.7 billion in 2023, and for other post‑retirement plans from $1.256 billion to $1.274 billion (a net drop of roughly $88 million and $18 million respectively).",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both percentages and dollar amounts. According to the ground truth, in 2022, Fixed Maturity Securities AFS accounted for 84% of U.S. Pension Benefits and 95% of U.S. Other Postretirement Benefits, but the LLM incorrectly reports 83% and 96%, respectively. For 2023, the ground truth does not provide percentage allocations but instead gives fair value figures: $6,714 million for Pension Benefits and $1,274 million for Other Postretirement Benefits. The LLM incorrectly assumes percentage allocations for 2023 (82% and 94%) and misrepresents the 2022 values. (2) Regarding dollar amounts, the LLM states that Fixed Maturity Securities AFS for pension plans fell from $6.8 billion in 2022 to $6.7 billion in 2023. However, the ground truth does not provide 2022 fair values, only 2023 values, so any claim about 2022 valuation is unsupported. Additionally, the LLM claims other post-retirement fair value decreased from $1.256 billion to $1.274 billion — this is mathematically incoherent (an increase, not a decrease), yet it claims a 'net drop'. This indicates a critical calculation error. (3) The multi-hop reasoning is partially sound in that the model attempts to compare 2022 allocation (percentage-based) to 2023 valuation (dollar-based), as implied by the question. However, it fabricates 2022 fair values and 2023 percentages not present in the ground truth, undermining the synthesis. (4) The contextual relevance is high because the answer addresses the evolution of allocation and valuation across years and benefit types. However, due to incorrect numbers, unsupported calculations, and invented data points, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the structure and intent of the response are reasonable, but the factual foundation is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 512,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Lowe's strategic positioning of the Kitchens & Bath product category evolve between 2022 and 2023, and what does this suggest about its relative importance in the company's product portfolio?",
      "original_answer": "In 2022, Kitchens & Bath was grouped under the Home Décor division alongside categories like Appliances, Décor, Flooring, and Paint, suggesting a more design-focused positioning. By 2023, Kitchens & Bath was listed among core construction and renovation categories such as Lumber, Building Materials, and Rough Plumbing, indicating a strategic repositioning toward home improvement and remodeling. This shift suggests that Lowe's placed greater strategic emphasis on Kitchens & Bath as a key growth area tied to higher-value home projects, aligning with its broader 'Total Home' strategy.",
      "llm_answer": "In the 2022 filing, Lowe’s grouped Kitchens & Bath within the broader **Home Décor** segment, which generated 35.3 % of total net sales (Home Décor = $34,025 million, 35.3 % of $96,250 million)【page_55】. By the 2023 filing, the company was calling out Kitchens & Bath as a standalone product line in its assortment list and highlighted it as one of the key categories that drive its **installed‑sales** business, which together accounted for about 5 % of total sales in fiscal 2023【page_6】【page_7】. This shift from a sub‑category of Home Décor to a distinct, service‑linked offering signals that Lowe’s has elevated Kitchens & Bath’s strategic importance within its overall product portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the 2022 positioning of Kitchens & Bath under the Home Décor segment and notes its repositioning in 2023 as a distinct, service-linked category. The qualitative shift—from a design-focused sub-category to a standalone, installed-sales-driven offering—is accurately captured and logically tied to increased strategic importance. (2) Quantitatively, the LLM provides specific figures: Home Décor generated $34,025 million (35.3% of $96,250 million) in 2022, and installed sales (including Kitchens & Bath) accounted for about 5% of total sales in 2023. These numbers are factually correct and properly cited to the filing pages. While the original answer does not include these exact numbers, their inclusion enhances precision and supports the reasoning. The only minor limitation is that the LLM does not explicitly mention the 2023 grouping with Lumber, Building Materials, and Rough Plumbing—instead focusing on the installed-sales angle—but this is a nuance rather than a factual error. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, identifies a structural change in category reporting, and infers strategic intent (elevated importance tied to service and remodeling). (4) The answer is contextually excellent, directly addressing both parts of the question: evolution of strategic positioning and implications for portfolio importance. The conclusion about elevated strategic importance matches the ground truth’s inference of greater emphasis aligned with the 'Total Home' strategy. Minor deduction in quantitative and qualitative scores due to the absence of the 2023 peer categories (Lumber, etc.), which strengthens the construction/remodeling repositioning argument, but the installed-sales focus provides a valid alternative lens. Overall, the answer is factually robust, well-reasoned, and semantically equivalent in meaning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 531,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Mondelez International's strategic focus on Cheese & Grocery evolved between 2022 and 2024, and what does this suggest about its prioritization of snack categories for long-term growth?",
      "original_answer": "In 2022, Mondelez directly produced Cheese & Grocery products, generating $1,990 million in total net revenues from this category. By 2024, the company no longer reported direct production in this category and instead indicated only a strategic stake in Cheese & Grocery, positioning it as an adjacent category within its broader snacking portfolio. This shift suggests a refocusing on core snack categories like biscuits and chocolate, while maintaining a presence in Cheese & Grocery through a lighter footprint. The change aligns with Mondelez's stated strategy of prioritizing long-term growth in core snacking segments and managing costs amid inflationary pressures.",
      "llm_answer": "In the 2022 Form 10‑K the company’s discussion of its business model centers on “making and selling chocolate, biscuits and baked snacks” and does not call out cheese & grocery as a strategic priority (see the 2022 filing pages 127‑131, which contain no reference to cheese & grocery). By the 2024 filing, the “Overview of Business and Strategy” explicitly lists cheese & grocery among the “adjacent, locally relevant categories” alongside gum & candy and powdered beverages (page 34). This shift shows that Mondelez has broadened its portfolio to give cheese & grocery a modest, complementary role, but it still treats the core snack categories (chocolate, biscuits, baked snacks) as the engine of long‑term growth, positioning cheese & grocery as a secondary, supportive line rather than a primary growth driver.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies a strategic shift in Mondelez's treatment of the Cheese & Grocery category between 2022 and 2024, noting its repositioning as an 'adjacent' category in 2024 while not being a strategic priority in 2022. This aligns with the ground truth's narrative of a shift from direct production to a strategic stake. However, the LLM fails to include any quantitative data—specifically the $1,990 million in net revenues from Cheese & Grocery in 2022—which is a key factual element in the original answer. The absence of this number significantly undermines the quantitative accuracy. (2) There are no calculations in the LLM answer, but the omission of the revenue figure from 2022 is a major factual gap. The ground truth uses this number to substantiate the claim that Mondelez previously had a direct production footprint in the category; without it, the LLM's reasoning, while directionally correct, lacks evidentiary support. (3) The multi-hop reasoning is partially sound: the model correctly infers from the 10-K filings that Cheese & Grocery was not mentioned in 2022 but was later classified as 'adjacent' in 2024, suggesting a strategic evolution. However, it incorrectly implies that Mondelez did not have a presence in Cheese & Grocery in 2022, when in fact it did (direct production). The LLM interprets absence of mention as absence of activity, which contradicts the ground truth. This weakens the qualitative accuracy. (4) Despite missing key data and misrepresenting the 2022 status, the LLM captures the broader strategic trend—prioritizing core snacks while maintaining a lighter footprint in Cheese & Grocery—making the answer contextually relevant and directionally insightful. Hence, correctness is moderate but not fully accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 487,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Abbott's presentation of its enteral feeding product lineup, specifically the positioning of Jevity relative to Freego™ products, change between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, Jevity was listed first among enteral feeding products, followed by Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite®, Oxepa®, Freego™ (Enteral Pump), and Freego™ sets. In the 2023 filing, Jevity remained listed first, but the Freego™ (Enteral Pump) and Freego™ sets were now mentioned immediately after Jevity, before the Glucerna and Osmolite® product lines. This change in listing order suggests a shift in product emphasis within the enteral feeding category, with Freego™ products receiving more prominent placement alongside Jevity in 2023 compared to 2022.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K “Nutritional Products” sections list the enteral‑feeding portfolio in the same order: Jevity is mentioned first, followed by other formulas and then the Freego™ (Enteral Pump) and Freego™ sets. Thus, the positioning of Jevity relative to the Freego™ products did not change between the two filings.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that the product order remained unchanged between the 2022 and 2023 10-K filings. The ground truth shows a clear reordering: in 2022, Jevity was listed first, followed by Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite®, Oxepa®, and then Freego™ products. In 2023, Jevity was still first, but Freego™ (Enteral Pump) and Freego™ sets were moved immediately after Jevity, preceding the Glucerna and Osmolite® lines. This shift indicates a more prominent positioning of Freego™ products in 2023. The LLM incorrectly states there was no change, missing this key detail. There are no numeric values to assess, so quantitative accuracy is scored as 10 by default. However, the qualitative accuracy is very low due to the failure in multi-hop reasoning—comparing the sequence of product mentions across two years. The answer is contextually relevant (it addresses the right section and products) but factually wrong in its conclusion, hence a moderate relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 289,
        "total_tokens": 1528
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MET's investment in municipals evolve from 2022 to 2023 in terms of fair value and classification, and what does this suggest about the company's credit risk management strategy?",
      "original_answer": "In 2022, MET held $14,212 million in municipals, classified under the 'fixed maturity securities AFS' category, with a fair value that included $2,464 million in gross unrealized gains and only $13 million in gross unrealized losses. By 2023, this investment had significantly declined to just $159 million, now categorized under the 'fixed maturity securities AFS' and classified entirely within Level 2 of the fair value hierarchy, indicating a shift in MET's positioning. This dramatic reduction suggests a strategic move to reduce credit exposure to municipals, likely as part of a broader risk management adjustment to limit potential losses in this asset class.",
      "llm_answer": "In the plan‑asset tables, MetLife’s municipal holdings were recorded at the Level 2 fair‑value hierarchy in both years.  The combined fair‑value of municipals fell from about **$174 million in 2022** (‑$159 m in pension assets + $15 m in other post‑retirement assets) to roughly **$155 million in 2023** (‑$147 m + $8 m).  The unchanged Level 2 classification—relying on observable market inputs—together with the modest reduction in exposure suggests the company is deliberately trimming municipal risk while keeping the remaining exposure in a transparent, lower‑credit‑risk segment, reflecting a prudent credit‑risk‑management stance.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, MET's municipal investment was $14,212 million in 2022 and dropped to $159 million in 2023. The LLM incorrectly reports the 2022 value as approximately $174 million and 2023 as $155 million, which is off by over an order of magnitude. These numbers appear to be derived from pension and post-retirement assets (possibly misaggregated as -$159M + $15M), but the ground truth refers to total company-level holdings, not net pension assets. (2) The calculation of combined fair value is fundamentally flawed: the LLM uses negative values (e.g., -$159M) which are not supported by the original answer and suggests a misunderstanding of asset reporting. The correct trend is a massive reduction from $14.2B to $159M (over 98% decrease), not a modest drop from $174M to $155M. (3) While the LLM correctly identifies the classification as Level 2 in 2023, it falsely claims the same classification applied in 2022; the original answer does not specify the hierarchy level for 2022, so this assertion lacks support. The qualitative reasoning about credit risk management is partially plausible but based on incorrect data, undermining its validity. (4) The contextual relevance is moderate because the answer addresses fair value, classification, and risk management strategy, but the severe quantitative errors and mischaracterization of the data source (plan assets vs. company-wide investments) lead to a largely incorrect conclusion. The multi-hop synthesis failed to correctly identify the scope and magnitude of MET's municipal holdings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 447,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2022 and 2023, particularly in terms of their notional value and the impact on fixed-rate debt management?",
      "original_answer": "In 2022, Abbott had interest rate hedge contracts totaling approximately $2.2 billion, which were used to manage exposure to changes in the fair value of fixed-rate debt by converting fixed-rate obligations into variable-rate obligations. By 2023, Abbott continued to use these contracts for the same purpose, and the notional value remained consistent at approximately $2.2 billion. However, in 2023, the company provided more detailed disclosures about the impact of these contracts on the carrying value of fixed-rate debt, indicating a more refined approach to interest rate risk management.",
      "llm_answer": "Abbott’s portfolio of interest‑rate hedge contracts fell from roughly $2.9 billion at year‑end 2022 to about $2.2 billion at year‑end 2023 – a decline of roughly $700 million that resulted from the maturity of a block of hedge contracts (and the underlying fixed‑rate debt) in 2023【page_65】.  The hedges are designated as fair‑value hedges that offset the fair‑value changes of the hedged fixed‑rate debt, effectively converting that portion of the debt to a variable‑rate exposure and allowing Abbott to manage interest‑rate risk on its long‑term borrowings【page_64】.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Abbott's notional value of interest rate hedge contracts remained consistent at approximately $2.2 billion in both 2022 and 2023. However, the LLM claims the value decreased from $2.9 billion in 2022 to $2.2 billion in 2023, which contradicts the original answer. This error affects the core quantitative claim of the response. (2) The calculation of a $700 million decline is based on incorrect input values and is therefore inaccurate. The ground truth does not mention any reduction due to maturity of contracts or debt in 2023. While the $2.2 billion figure for 2023 matches, the $2.9 billion figure for 2022 is incorrect. (3) The qualitative reasoning about the purpose of the hedges — converting fixed-rate debt to variable-rate exposure and managing interest rate risk — is accurate and aligns with the original answer. The mention of fair-value hedges offsetting changes in the carrying value of debt is consistent with the refined disclosures noted in 2023. However, the LLM fails to mention the increased disclosure detail in 2023, which is a key evolution highlighted in the ground truth. (4) Despite correct contextual understanding of hedge function and relevance to debt management, the major numerical error in the 2022 notional amount severely undermines factual correctness. The answer incorrectly implies a reduction in hedge usage when the truth states consistency in notional value. Hence, correctness and quantitative accuracy scores are low, while contextual relevance remains high due to appropriate framing and terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 451,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did 3M's issuance and management of fixed rate registered notes evolve between 2022 and 2024, particularly in terms of repayment activity and interest rate strategies?",
      "original_answer": "In 2022, 3M had a significant amount of fixed rate registered notes, including $600 million of 10-year notes due 2030 with a coupon rate of 3.05%, and $650 million of 30-year notes due 2050 with a coupon rate of 3.70%. The company also issued $3.25 billion in fixed rate registered notes in August 2019, including $1.0 billion of 10-year notes due 2029 and $1.0 billion of 30-year notes due 2049. In 2024, 3M repaid $1.1 billion in medium-term notes that matured, and in 2023, it repaid $500 million in fixed-rate registered notes. Additionally, interest rate swaps initiated in 2021 converted portions of the fixed-rate notes due 2049 and 2050 into floating-rate debt through mid-2028, indicating a strategic shift toward managing interest rate exposure. This shows a decrease in the amount of fixed-rate debt outstanding and a shift toward floating-rate instruments through swaps.",
      "llm_answer": "- **Issuance trend:**  \n  *In the 2022 filing* 3M was still issuing new fixed‑rate registered notes at a wide range of coupons – e.g., the $500 million 5‑year notes at 2.65 % (due 2025), the $1 billion 10‑year notes at 2.375 % (due 2029) and the $1 billion 30‑year notes at 3.25 % (due 2049) (see 2022 p. 89).  \n  *In the 2024 filing* the company’s outstanding registered notes are concentrated in newer issues with lower near‑term rates – $750 million at 2.02 % and $500 million at 2.66 % (both due 2025), $1 billion at 2.41 % (due 2029) and $600 million at 3.08 % (due 2030), while longer‑dated notes carry modestly higher rates of 3.36 % (due 2049) and 3.75 % (due 2050) (see 2024 p. 68).  \n\n- **Repayment activity:**  \n  No fixed‑rate registered notes were retired in 2022; the 2022 note‑repayment summary only lists maturities of medium‑term notes (500 M € and $600 M) (2022 p. 87‑89). In 2023 the company redeemed $500 million of fixed‑rate registered notes that matured (2024 p. 69). In 2024 the focus shifted to repaying $1.1 billion of medium‑term notes, with no additional registered‑note retirements reported (2024 p. 69).  \n\n- **Interest‑rate strategy:**  \n  3M continued to manage its fixed‑rate exposure by using interest‑rate swaps: in 2021 it entered swaps converting $500 million of the 2049 notes and $300 million of the 2050 notes into floating‑rate debt through mid‑2028 (2024 p. 69). This, together with the issuance of lower‑coupon near‑term registered notes, shows a strategy of lowering cost on new debt while hedging or converting a portion of long‑dated fixed‑rate obligations to floating rates.  ",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in numbers and issuance details compared to the ground truth. For example, it claims in 2022 that 3M issued $500 million 5-year notes at 2.65% due 2025 and $1 billion 10-year notes at 2.375% due 2029, but the ground truth states these were issued in August 2019 as part of a $3.25 billion issuance, not in 2022. Additionally, the LLM incorrectly attributes the $600 million 10-year notes due 2030 at 3.05% and $650 million 30-year notes due 2050 at 3.70% to 2022 activity, while the original answer presents them as existing in 2022, not necessarily issued that year. The LLM also fabricates specific new issues in 2024 (e.g., $750M at 2.02%, $500M at 2.66%) that are not mentioned in the ground truth. (2) The repayment activity is partially correct: the $500 million fixed-rate registered note repayment in 2023 and $1.1 billion medium-term note repayment in 2024 match the ground truth. However, the LLM incorrectly states no fixed-rate registered notes were retired in 2022 based on the filing, while the ground truth does not make that claim — it only lists what was outstanding and past issuances. (3) The interest rate strategy is reasonably accurate: the LLM correctly identifies that swaps from 2021 converted portions of the 2049 and 2050 notes to floating rate through mid-2028, though it misstates the amounts as $500 million (2049) and $300 million (2050), whereas the ground truth does not specify exact swap amounts. This shows partial multi-hop reasoning — correctly linking swaps to long-term notes and inferring a strategic shift — but with fabricated figures. (4) Despite incorrect issuance details and some invented numbers, the LLM captures the broader trend of repayment activity and strategic shift toward floating rates via swaps, and it addresses all parts of the question. Hence, the contextual relevance is high, qualitative reasoning is sound but based on incorrect data, and quantitative accuracy is low due to multiple fabricated or misattributed figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1632,
        "completion_tokens": 552,
        "total_tokens": 2184
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has the role of securities issuances in Schwab's capital structure evolved between 2023 and 2024, particularly in relation to its overall funding sources and capital management strategy?",
      "original_answer": "In 2023, securities issuances by CSC were identified as a primary source of capital, directly supporting the company's capital management strategy, which included balance sheet growth and financial support to subsidiaries. By 2024, while still listed as one of several funding sources, securities issuances were positioned among a broader set of liquidity tools, including FHLB borrowings, repurchase agreements, and CDs, indicating a more diversified funding approach. This shift suggests a strategic evolution where securities issuances remain important but are more integrated within a wider capital structure framework.",
      "llm_answer": "In 2023 Schwab’s capital‑management discussion still listed **new senior unsecured notes and preferred‑stock offerings as a primary source of capital** (page 58) and explicitly said that “Schwab’s primary sources of capital are … funds generated by the operations of subsidiaries and securities issuances by CSC in the capital markets” (page 59). By 2024 the company had **scaled back that reliance** – the unsecured revolving line of credit was allowed to expire (page 53‑54), the firm emphasized cash generated from client deposits, brokered CDs, FHLB advances and repurchase agreements, and described securities issuances only as a backup “shelf‑registration” capability (page 53). Thus, securities issuances moved from a core, regularly‑used funding pillar in 2023 to a more ancillary, optional source in 2024 as Schwab leaned on internal liquidity and other short‑term funding to meet its capital‑ratio and liquidity objectives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2023, securities issuances (specifically senior unsecured notes and preferred stock) were a primary source of capital, citing the correct context from the 10-K (pages 58–59). In 2024, it accurately notes a strategic shift: securities issuances were downgraded to a 'backup' or 'shelf-registration' capability, with greater reliance on client deposits, brokered CDs, FHLB advances, and repurchase agreements (page 53), indicating a more diversified funding strategy. (2) There are no numeric values, dates, or financial figures in dispute; all references are to qualitative disclosures, and the LLM correctly interprets them without introducing factual errors. Format and citation of page numbers are consistent with source documentation. (3) The multi-hop reasoning is sound: the model synthesizes information across years (2023 vs 2024), entities (CSC, subsidiaries), and funding instruments, correctly inferring a strategic evolution in capital structure. The conclusion that securities issuances moved from 'core' to 'ancillary' is a valid interpretation of the disclosed shift. (4) The only reason for not scoring a perfect 10 is a slight nuance: the original answer emphasizes that securities issuances remained 'one of several funding sources' in 2024, while the LLM frames it more strongly as 'scaled back' and 'backup,' which is supported but slightly more interpretive. However, this does not constitute an error, as the overall semantic meaning and strategic trend are correctly conveyed. Contextual relevance is excellent—every part of the question is addressed with precise, document-supported reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 468,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did Coca-Cola's contingent payment obligations related to fairlife evolve from 2022 to 2024, and what does this indicate about fairlife's performance against its financial targets?",
      "original_answer": "In 2022, Coca-Cola disclosed that it had a $270 million liability for contingent milestone payments related to its acquisition of fairlife, based on fairlife achieving certain financial targets through 2024. The company also noted that the first milestone payment of $100 million was made in 2021 after fairlife met its 2020 targets. By 2024, the remaining contingent payment was described as a milestone payment contingent on fairlife achieving certain financial targets through 2024 and was payable in 2025. This indicates that fairlife had met at least one set of financial targets (2020), triggering the initial $100 million payment, and that the company remained on track to potentially meet the remaining targets through 2024, as the obligation was still active and had not been rescinded or adjusted downward.",
      "llm_answer": "In the 2022 filing Coca‑Cola disclosed a relatively small fairlife contingent‑consideration liability – the $270 million liability recorded at acquisition plus re‑measurement charges of $51 million (2020) and $369 million (2021) – and noted that a $100 million milestone had already been paid in 2021 because fairlife met its 2020 financial targets. By the 2024 filing that liability had risen to about $6.1 billion (up from roughly $3.0 billion in 2023), reflecting the quarterly re‑measurements as fairlife continued to hit the agreed‑upon performance thresholds. The sharp increase in the liability therefore indicates that fairlife has been achieving, and likely exceeding, the financial targets that trigger the milestone payments.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and quantitative errors that undermine its correctness. (1) Quantitative Accuracy: The ground truth states that Coca-Cola had a $270 million liability for contingent payments related to fairlife as of 2022, with a $100 million payment already made in 2021. However, the LLM claims the liability 'rose to about $6.1 billion' by 2024, which is not supported by the original answer and represents a massive overstatement. The LLM also incorrectly references 're-measurement charges of $51 million (2020) and $369 million (2021)', which are not mentioned in the ground truth and appear fabricated. These numbers are entirely inconsistent with the disclosed $270 million liability. (2) Completeness: While the LLM correctly notes the $100 million payment in 2021 due to fairlife meeting its 2020 targets, it fails to accurately describe the evolution of the obligation from 2022 to 2024. The original answer clarifies that the remaining contingent payment was still outstanding and unchanged in structure—payable in 2025 based on performance through 2024—but the LLM invents a narrative of escalating liabilities without evidence. (3) Entity Accuracy: The companies (Coca-Cola, fairlife) and years (2021, 2022, 2024) are correctly identified, and the concept of milestone payments tied to financial targets is accurate. (4) Reasoning: The LLM attempts multi-hop reasoning by linking liability increases to performance, but this logic is based on false numerical premises. The conclusion that fairlife is 'exceeding' targets is speculative and unsupported; the ground truth only confirms that the obligation remained active, indicating fairlife was on track, not necessarily outperforming. (5) Semantic Equivalence: The overall message diverges significantly—the original indicates stability in the obligation, while the LLM suggests explosive growth in liabilities. This misrepresents the financial reality. The answer is contextually relevant in topic and structure but fails on factual integrity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 545,
        "total_tokens": 1942
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Infrastructure (OCI) evolved between 2022 and 2024, particularly in terms of its global market positioning and integration with enterprise IT solutions?",
      "original_answer": "In 2022, Oracle's financial disclosures emphasized revenue contributions from cloud and license businesses, which generated $36.052 billion, representing 85% of total revenues, with no explicit strategic language about Oracle Cloud Infrastructure's positioning. By 2024, Oracle significantly elevated OCI's role, describing it as a core component of Oracle Cloud Services alongside SaaS, and emphasizing its ability to provide 'comprehensive and integrated applications and infrastructure services' that enable customers to choose deployment models best suited to their needs. This reflects a clear strategic shift toward positioning OCI as a central pillar in Oracle’s enterprise IT offerings, not just a contributor to cloud revenue.",
      "llm_answer": "In fiscal 2022 Oracle began to treat its Oracle Cloud Infrastructure (OCI) as a growth engine, shifting sales and marketing resources toward “growing cloud‑based infrastructure technologies” and away from non‑strategic hardware, while stressing direct, worldwide sales of those services (see 2022 p. 47‑48). By fiscal 2024 OCI is no longer a stand‑alone push‑but a core pillar of “Oracle Cloud Services” – presented together with SaaS as a fully integrated, globally‑available platform that lets customers run applications on‑premise, in the cloud or in hybrid models, tying OCI tightly to enterprise‑IT workloads (see 2024 p. 72‑73). Thus Oracle’s OCI strategy evolved from an emerging, globally‑marketed infrastructure offering in 2022 to a central, globally‑positioned component of an integrated enterprise‑cloud suite in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution of Oracle's strategic emphasis on OCI from 2022 to 2024. While the original answer notes that in 2022 Oracle emphasized cloud and license revenues ($36.052 billion, 85% of total) without explicit strategic positioning of OCI, the LLM correctly infers from context (citing 2022 p. 47-48) that OCI was being treated as a growth engine with reallocated sales and marketing resources—consistent with a strategic shift even if not explicitly labeled as such. The 2024 characterization of OCI as a core pillar of Oracle Cloud Services alongside SaaS, enabling hybrid and flexible deployment models, is accurately reflected in both answers. (2) There are no numeric inaccuracies. The LLM does not introduce incorrect figures and avoids misrepresenting financial data. It omits the specific $36.052 billion and 85% figures from 2022 but this omission does not distort the strategic narrative and is compensated by accurate qualitative progression. (3) The multi-hop reasoning—comparing Oracle’s strategic language across two years and synthesizing shifts in market positioning and integration with enterprise IT—is sound and well-supported by document references. (4) Semantic equivalence is strong: 'core pillar', 'integrated enterprise-cloud suite', and 'hybrid models' mirror the original’s 'comprehensive and integrated applications and infrastructure services'. The only minor shortcoming is the absence of the precise financial metric from 2022, which slightly reduces completeness but does not affect the correctness of the strategic interpretation. Hence, a score of 9 is warranted for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 467,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has the treatment and risk profile of PALs evolved between 2023 and 2024, particularly in terms of credit loss allowance and collateralization?",
      "original_answer": "In 2023, there was a slight decrease in PALs, and the allowance for credit losses was influenced by improved credit quality metrics and lower projected loss rates. By 2024, all PALs were fully collateralized by securities with fair values exceeding borrowings, and no allowance for credit losses for PALs was required as they were all subject to the collateral maintenance practical expedient under ASC 326. This indicates a strengthening in the risk profile and treatment of PALs over the period.",
      "llm_answer": "The 2024 filing notes that, just as in 2023, **all PAL balances were fully collateralized by securities whose fair‑value exceeded the borrowings and the company applied the ASC 326 “collateral‑maintenance” practical expedient**. Consequently, **no allowance for credit losses was recorded for PALs in either year**; any unsecured PALs are charged off no later than 90 days past‑due. Thus, the treatment and risk profile of PALs remained essentially unchanged from 2023 to 2024 – they stayed fully collateralized and required no credit‑loss allowance.【page_88】",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several correct elements but fundamentally misrepresents the evolution of PALs' treatment and risk profile between 2023 and 2024, which is the core of the question. (1) The original answer states that in 2023, there was a 'slight decrease in PALs' and the allowance for credit losses was influenced by improved credit quality and lower projected loss rates — indicating that an allowance *was* still in place or at least considered. However, the LLM claims that 'no allowance for credit losses was recorded for PALs in either year,' which contradicts the ground truth implying a transition in treatment. (2) The key evolution highlighted in the original answer is that by 2024, due to full collateralization under ASC 326’s practical expedient, *no allowance was required* — suggesting a change from 2023. The LLM incorrectly asserts that the treatment was the same in both years, missing the shift in risk profile and accounting treatment. (3) While the LLM correctly identifies that all PALs were fully collateralized in both years and that the ASC 326 practical expedient was applied, it fails to capture the nuance that this resulted in *no required allowance in 2024*, whereas in 2023, the allowance was still influenced by credit metrics — implying it was not yet fully eliminated. (4) The statement about unsecured PALs being charged off after 90 days is additional detail not present in the ground truth and may be contextually accurate but distracts from the main point of evolution in allowance and collateralization. Thus, while entities (PALs, ASC 326, collateralization) and years are correct, and the quantitative aspects (e.g., 'fully collateralized') are accurately described, the reasoning and synthesis across years are flawed, leading to an incorrect conclusion about stability rather than improvement in risk profile. This constitutes a significant qualitative error despite some factual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 521,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Nike's relationship with the Asia Pacific & Latin America (APLA) region evolved between fiscal years 2023 and 2024, particularly in terms of operational structure and strategic emphasis?",
      "original_answer": "In fiscal year 2023, Nike's relationship with APLA was characterized by direct operational involvement, with the region being one of the geographies where certain employees were represented by trade unions, indicating a more localized and embedded workforce structure. By fiscal year 2024, Nike transitioned parts of its APLA operations to third-party distributors, signaling a strategic shift away from direct control toward a more outsourced model. This evolution reflects a broader restructuring effort to optimize the business model and reduce operational complexity in certain international markets.",
      "llm_answer": "Nike continues to report Asia Pacific & Latin America (APLA) as one of its four geographic operating segments, but the 2024 filing notes that “the transition of Nike Brand businesses in certain countries within APLA to third‑party distributors” is now being carried out (see Note 15/Note 18) – a shift from the primarily direct‑to‑consumer structure that existed in FY 2023.  At the same time, APLA’s revenue rose modestly from $6.4 billion in FY 2023 to $6.7 billion in FY 2024, while EBIT slipped slightly (from $1.93 billion to $1.89 billion), indicating Nike is still emphasizing growth in the region but is re‑balancing its operating model toward partnership‑based distribution and greater focus on wholesale/market‑specific execution (and, as noted in the human‑capital section, it remains one of the few regions with union‑represented employees).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: APLA revenue increased from $6.4 billion in FY2023 to $6.7 billion in FY2024, and EBIT decreased from $1.93 billion to $1.89 billion—these figures match the knowledge graph data. (2) The answer correctly identifies the structural shift in FY2024: transitioning certain APLA markets to third-party distributors, as noted in Note 15/Note 18 of the filing, which reflects a move away from direct operations. This matches the ground truth’s claim of a strategic shift toward outsourcing. (3) The reasoning is sound and multi-hop: it connects operational structure changes (from direct to third-party) with financial performance (revenue growth despite EBIT dip) and retains context about union representation, which indicates awareness of localized workforce structures in APLA. (4) The only minor omission is that the original answer emphasizes this shift as part of a broader restructuring to reduce operational complexity, a strategic rationale slightly underdeveloped in the LLM response. However, the core facts, synthesis across fiscal years, and entity accuracy (Nike, APLA, FY2023–2024, correct metrics) are all correct. Wording differs but meaning is semantically equivalent. Thus, the answer earns a 9/10 for correctness—excellent but not perfect due to slight lack of strategic context depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 390,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How did Abbott's positioning and strategic emphasis on Pedialyte evolve between 2022 and 2023, particularly in relation to its U.S. Pediatric Nutritional business and product portfolio expansion?",
      "original_answer": "In 2022, Pedialyte was highlighted as a key growth driver within Abbott's U.S. Pediatric Nutritional business, with sales increasing 10.3% for the year, alongside Similac and PediaSure. By 2023, Pedialyte was formally included in Abbott's product portfolio under the Nutritional Products segment, listed among major brands such as Ensure, Glucerna, and PediaSure, signaling a more structured integration into Abbott's broader nutritional offerings. This reflects a strategic evolution from being a contributor to growth in 2022 to being a formally recognized and embedded part of the company's core U.S. Pediatric Nutritional product lineup in 2023.",
      "llm_answer": "In the 2022 Form 10‑K (the filing that reports 2021 results), Abbott called out **Pedialyte as a specific growth driver** for its U.S. Pediatric Nutritionals business – sales in that segment rose 10 % to about **$2.2 billion**, and the company said the increase was “driven by **growth in Pedialyte, Similac and PediaSure**” (see page 31). Pedialyte was also listed among the core pediatric‑nutrition products in the Nutritional Products description (page 4).  \n\nIn the 2023 Form 10‑K, the discussion of nutrition moves to a **broader, segment‑wide view**. The filing talks about competition, supply‑chain and overall marketing of nutritional products but does **not single out Pedialyte**; it is simply part of the larger U.S. Pediatric Nutritionals portfolio (see the generic “nutritional products” sections on pages 5‑6). This shift indicates that while Pedialyte remains in the product mix, Abbott’s 2023 messaging emphasizes the **overall U.S. Pediatric Nutritionals business and a wider portfolio expansion**, rather than highlighting Pedialyte as a standalone growth catalyst.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both quantitative and qualitative aspects. It incorrectly states that the 2022 Form 10-K reports 2021 results, when in fact the 2022 Form 10-K reports 2022 results. This misalignment invalidates the temporal comparison. The reported sales figure of $2.2 billion for the U.S. Pediatric Nutritionals segment is not present in the ground truth and cannot be verified; the ground truth only confirms a 10.3% sales increase for Pedialyte, not the total segment size. The LLM rounds this to 10%, which is acceptable, but the source of the dollar amount is unclear and likely incorrect. (2) The LLM claims Pedialyte was not singled out in the 2023 Form 10-K and that Abbott shifted to a broader messaging approach, which contradicts the ground truth stating that Pedialyte was *formally included* in the portfolio listing alongside Ensure, Glucerna, and PediaSure—indicating greater structural recognition, not less emphasis. The LLM interprets the lack of explicit growth mention as reduced importance, but the ground truth shows the opposite: formal integration into the core portfolio represents strategic elevation. (3) The multi-hop reasoning is flawed. The LLM fails to recognize that being listed among major brands in the Nutritional Products segment in 2023 signifies a strategic evolution, not a downgrading. Instead, it infers reduced emphasis due to absence of explicit mention in growth discussions, which is a misinterpretation of corporate reporting conventions. (4) While the answer addresses the question's context and structure, and uses relevant sections of the 10-K (e.g., page references), the core conclusion about Abbott’s strategic emphasis is factually inverted. The ground truth shows increased integration in 2023; the LLM claims decreased focus. This fundamental contradiction results in a low correctness score despite some structural relevance and acceptable formatting of numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 533,
        "total_tokens": 1978
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did RTX's financial position regarding its 7.100% notes due 2027 evolve from 2022 to 2023, and what does this indicate about its debt management strategy?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $6 million for its 7.100% notes due 2027. By 2023, RTX had a stake in the same notes with an aggregate principal balance of $135 million. This indicates a significant increase in RTX's exposure to this particular debt instrument, suggesting a shift in its debt management strategy, possibly involving refinancing or restructuring.",
      "llm_answer": "RTX’s 7.100 % notes due 2027 carried a principal balance of $135 million at both December 31 2022 and December 31 2023 (see the 2023 10‑K tables of long‑term debt 【page 85】 and the detailed debt schedule 【page 84】). The balance was essentially unchanged, showing that the company neither added to nor significantly retired this higher‑coupon issue during the year. This stability, together with the issuance of new lower‑rate notes and the modest reduction of other higher‑rate series, signals that RTX is actively managing its debt profile by refinancing or repaying higher‑cost borrowings while keeping overall long‑term debt levels steady.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core quantitative claim. According to the ground truth, RTX's aggregate principal balance for the 7.100% notes due 2027 was $6 million in 2022 and increased to $135 million in 2023 — indicating a significant increase in exposure. However, the LLM claims the balance was $135 million in both 2022 and 2023, which contradicts the ground truth. This error completely inverts the financial evolution and misrepresents RTX's debt activity. (2) The numbers are not accurate: the 2022 figure is off by a factor of 22.5x ($6M vs $135M reported). The LLM incorrectly asserts stability, while the truth shows a 2150% increase in principal balance. No correct calculation or comparison is made. (3) The multi-hop reasoning fails because the model does not recognize the change over time, which is central to the question. Instead of identifying a strategic increase in exposure (possibly for refinancing or restructuring), it concludes there was no change and infers a strategy of stability and refinancing of other debt — a conclusion not supported by the actual data provided in the ground truth. (4) Contextual relevance is moderate because the answer discusses debt management strategy and references appropriate concepts (e.g., refinancing, coupon rates), but the factual foundation is wrong, leading to an invalid conclusion. The citation to page numbers in the 10-K does not override the contradiction with verified truth. Thus, correctness and quantitative accuracy are very low due to the critical number error, qualitative accuracy is low due to flawed reasoning, and relevance is mid-range due to appropriate framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 458,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Nike's relationship with Converse evolved in terms of revenue performance and strategic positioning between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Converse revenues decreased by 15% on a currency-neutral basis, driven by declines in North America and Western Europe, with both wholesale and direct-to-consumer channels experiencing drops in unit sales and average selling price. By fiscal 2024, Converse was described as a wholly-owned subsidiary that operates on a stand-alone basis, indicating a strategic shift toward maintaining it as a distinct brand within Nike’s portfolio. This evolution reflects a move from a financially struggling entity in 2023 to a more strategically positioned brand in 2024, despite the earlier revenue contraction.",
      "llm_answer": "In fiscal 2024 Converse’s top‑line fell to $2.08 billion from $2.43 billion a year earlier – a 14 % decline (‑15 % on a currency‑neutral basis) – with footwear revenue down 16 % while apparel and equipment modestly grew, and earnings before interest and taxes slipping 30 % to $474 million. Strategically, Converse continues to be treated as a wholly‑owned, stand‑alone operating segment that designs, distributes and licenses its casual‑sneaker, apparel and accessories lines, complementing Nike’s performance‑focused brands and supporting Nike’s broader direct‑to‑consumer and wholesale mix despite the recent revenue weakness.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the revenue decline for Converse from fiscal 2023 to 2024, stating a 15% currency-neutral decline, which matches the ground truth. It adds more granular data not in the original answer—such as exact revenue figures ($2.43B to $2.08B), a 14% reported decline, footwear down 16%, and EBIT dropping 30% to $474M—which are consistent with typical reporting formats and do not contradict the ground truth. These specifics enhance rather than distort accuracy. (2) Quantitatively, the 15% currency-neutral decline is correctly reported. The calculation from $2.43B to $2.08B yields approximately a 14.4% drop, which rounds to the stated 14% (or -15% currency-neutral), so the numbers and percentages are accurate. The $474M EBIT figure is plausible and does not conflict with the knowledge graph. (3) The qualitative and strategic assessment aligns with the ground truth: Converse is described as a wholly-owned, stand-alone entity, reinforcing its distinct strategic positioning within Nike’s portfolio in fiscal 2024. The reasoning correctly synthesizes financial performance (revenue decline) with strategic continuity (stand-alone brand), reflecting a nuanced evolution. (4) The answer is fully contextually relevant, addressing both revenue performance and strategic positioning across both fiscal years. The only minor deviation is that the original answer emphasizes a 'strategic shift' toward stand-alone status, while the LLM implies continuity; however, the core idea of distinct strategic positioning is preserved. Overall, the LLM provides a more detailed yet factually consistent and logically sound response, warranting a high correctness score with a small deduction for potential over-specification of figures not in the ground truth, though not inaccurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 493,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Coca-Cola's financial risk assessment regarding digital evolution changed from 2022 to 2024, particularly in terms of its impact on sales growth and margin improvement?",
      "original_answer": "In 2022, Coca-Cola viewed digital evolution as a risk factor that could negatively impact its business if it failed to implement digital transformation initiatives effectively, potentially leading to a loss in sales and brand relevance. By 2024, the company shifted its stance, identifying digital evolution as a strategic dependency, emphasizing that its future success would rely on expanding digital capabilities to increase sales and improve margins. The 2024 filing explicitly states that failure to digitalize operations could adversely impact financial performance, indicating a stronger financial linkage to digital initiatives than in 2022.",
      "llm_answer": "In the 2022 Form 10‑K Coca‑Cola warned that if it “fails to address … the digital evolution” its **share of sales and revenue growth** could suffer and its **ability to reduce costs** might be impaired. By the 2024 filing the company’s risk language had been sharpened: it now says that a failure to **digitize the Coca‑Cola system could negatively affect its ability to increase sales *and improve margins***, and that the expenses incurred for digital initiatives could also weigh on results. Thus, the assessment has broadened from a focus on sales‑growth and cost‑saving risk to a clearer risk that digital lag will hurt both sales growth **and margin improvement**.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Coca-Cola's 2022 risk assessment focused on potential loss in sales growth and cost-saving capabilities due to digital evolution, while the 2024 filing reframed digital evolution as a critical strategic dependency, explicitly linking failure to digitize with adverse impacts on both sales growth and margin improvement. The LLM correctly captures this shift in tone and financial linkage. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the original answer, so quantitative accuracy is not applicable in that sense—but the years (2022, 2024) are correct and consistently used, satisfying temporal accuracy. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings, correctly identifying the evolution in risk language and its implications for financial performance. It accurately notes the broadening of risk from cost-saving and revenue concerns to a more direct linkage with margin improvement. (4) The LLM uses slightly different phrasing (e.g., 'digitize the Coca-Cola system', 'expenses incurred for digital initiatives could weigh on results') that are consistent with typical 10-K language and plausibly reflect actual wording from the filings, even if not verbatim quoted. The only minor shortcoming is that the original answer emphasizes the shift from 'risk factor' to 'strategic dependency', a conceptual framing that the LLM implies but does not explicitly state. This slight omission in conceptual precision prevents a perfect 10, but the core facts, logic, and synthesis remain robust. Overall, the answer is factually correct, contextually appropriate, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 492,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Services evolved from fiscal year 2022 to 2024, particularly in terms of research and development investment and the positioning of cloud offerings relative to on-premise solutions?",
      "original_answer": "In fiscal year 2022, Oracle invested $7.2 billion in research and development, highlighting its commitment to enhancing Oracle Cloud Services, including Oracle SaaS and OCI, as part of a broader strategy to offer flexible and interoperable deployment models. Oracle positioned cloud services as a key differentiator against competitors by emphasizing rapid deployment, security, and integration. By fiscal year 2024, Oracle continued to emphasize cloud services but restructured its messaging to position Oracle Cloud Software-as-a-Service and Oracle Cloud Infrastructure as central to enabling customers to 'choose the best option that meets their specific business needs.' While the 2024 report does not specify the R&D investment amount, the increased focus on cloud-first positioning and integration with customer-specific needs indicates a strategic deepening of Oracle's commitment to cloud services over on-premise offerings.",
      "llm_answer": "Oracle’s 2022 filing notes that the company spent **$7.2 billion on research and development** – a level meant to “enhance our existing portfolio … and to develop new technologies and services,” with a clear focus on expanding Oracle Cloud Services and moving customers off‑premise 【page_6】. By the 2024 filing the narrative had shifted to describing Oracle Cloud Services (SaaS + OCI) as the **core, integrated platform that customers can choose instead of, or alongside, on‑premise and hybrid deployments**, emphasizing rapid, low‑cost, interoperable cloud delivery as the primary growth engine 【page_72】. Although the 2024 filing does not repeat a specific R&D dollar amount, the continued emphasis on cloud‑centric innovation and the positioning of cloud offerings as the preferred alternative to traditional on‑premise solutions shows an evolution from a strong R&D investment in 2022 toward an even tighter strategic focus on cloud in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $7.2 billion R&D investment in fiscal year 2022, matching the ground truth exactly. It accurately notes that the 2024 filing does not specify a dollar amount for R&D, which aligns with the original answer. All entities—Oracle, Oracle Cloud Services, SaaS, OCI, on-premise solutions—are correctly identified and contextualized. (2) Quantitative accuracy is perfect: the $7.2 billion figure is correct, and no erroneous calculations are made. The absence of a 2024 R&D number is properly acknowledged, as in the ground truth. (3) The multi-hop reasoning is sound: the LLM synthesizes information across fiscal years 2022 and 2024, correctly tracing the evolution from significant R&D investment to a more mature, cloud-first strategic positioning. It captures the shift in messaging from enhancing cloud services to positioning them as the core platform, which reflects the strategic deepening described in the original answer. The only minor shortcoming is a slightly stronger emphasis in the ground truth on 'flexible and interoperable deployment models' in 2022 and 'choose the best option' in 2024, which the LLM captures in spirit but could have mirrored more precisely in phrasing. (4) The answer is fully contextually relevant, directly addressing both R&D investment trends and the changing positioning of cloud vs. on-premise solutions. Overall, the LLM conveys the same factual and inferential content as the ground truth with high fidelity, warranting a correctness score of 9/10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1491,
        "completion_tokens": 425,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the status and availability of shares under the Norwest Corporation Directors' Formula Stock Award Plan evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Norwest Corporation Directors' Formula Stock Award Plan was described as a plan under which shares of common stock were awarded to non-employee directors, with the ability to defer receipt of awards until a future year. However, it was noted that no future stock awards or deferrals could be made under this plan. In 2024, the 10-K filing further clarified that no future awards or deferrals would be made under the plan and that column (a) of the equity compensation table reflected all shares issuable under the plan upon distribution of outstanding awards or deferred compensation benefits. This indicates that by 2024, the plan was fully closed to any new activity and only existing obligations remained. The number of shares issuable in 2024 related to this plan was minimal (only 391 shares), showing that the plan had effectively concluded its active phase.",
      "llm_answer": "In the 2023 Form 10‑K the Norwest Corporation Directors’ Formula Stock Award Plan showed **509 shares** still issuable on distribution, and the filing noted that **no future awards or deferrals could be made** under the plan【page_11†L...】.  \nBy the 2024 Form 10‑K the number of shares remaining under the same plan had fallen to **391 shares** issuable on distribution, with the same disclaimer that **no future awards or deferrals will be made**【page_14†L...】.  \n\nThus, the pool of shares available under the plan shrank from 509 to 391, while the plan’s status as a closed, non‑renewable award vehicle remained unchanged.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that no future awards or deferrals could be made under the Norwest Corporation Directors' Formula Stock Award Plan in both 2023 and 2024, which aligns with the ground truth. It also correctly states that the plan was inactive for new awards and only existing obligations remained. However, the LLM reports 509 shares issuable in 2023, while the original answer does not specify a number for 2023—only that the plan was already closed and that 391 shares remained in 2024. Since the ground truth does not confirm the 509 figure, this introduces a potentially incorrect quantitative claim not supported by the provided truth. (2) The calculation of a decrease from 509 to 391 shares implies a reduction of 118 shares, but without confirmation of the 509 number in the ground truth, this comparison cannot be verified and may be inaccurate. The 391 shares in 2024 is correct. (3) The multi-hop reasoning is sound in concept—comparing the status and share availability across years—but relies on an unverified 2023 share number. The synthesis of plan status (closed, no new awards) across both years is accurate and reflects proper reasoning. (4) The contextual relevance is perfect—the answer directly addresses the evolution of the plan’s status and share availability. Qualitative accuracy is high due to correct interpretation of plan status, but quantitative accuracy is reduced due to the unsupported 509-share figure. Correctness score is 7 because core facts about plan closure are right, but a key number lacks grounding in the provided truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 437,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has McDonald's disclosure around food safety concerns evolved between 2022 and 2023, particularly in relation to supply chain risks and cost volatility?",
      "original_answer": "In 2022, McDonald's characterized food safety concerns primarily as reputational risks that could impact brand perception and financial results due to incidents like food-borne illness or contamination. The focus was on the potential damage to consumer trust and the company's image. By 2023, the framing had evolved to emphasize food safety concerns as contributors to supply chain volatility, specifically in relation to commodity cost fluctuations. The 2023 filing noted that food safety issues, along with other macroeconomic and regulatory factors, could exacerbate volatility in the prices of key ingredients like beef, chicken, and pork, thereby affecting profitability. This indicates a shift in emphasis from reputational impact to financial exposure through supply chain disruption and cost pressures.",
      "llm_answer": "In the 2022 Form 10‑K, food‑safety was presented mainly as a generic risk – a possible brand‑reputation hit that could affect results and, in the commodity‑cost discussion, was listed only as one of several “factors such as food‑safety concerns, product recalls or government regulation” that could make beef, chicken or pork prices volatile. By the 2023 filing, McDonald’s expands the narrative: it spells out that food‑safety events can arise anywhere in the supply chain, at restaurants or through delivery, and it directly ties those events to supply‑chain interruptions and to heightened commodity‑price and overall cost volatility, while emphasizing the substantial resources devoted to monitoring third‑party suppliers. Thus the disclosure has shifted from a brief, peripheral risk mention to a more detailed, integrated explanation of how food‑safety issues drive supply‑chain risk and cost fluctuations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in McDonald's disclosures between 2022 and 2023: in 2022, food safety was framed as a reputational/brand risk and mentioned only peripherally in relation to commodity cost volatility; by 2023, it was more directly tied to supply chain interruptions and cost volatility. These characterizations match the original answer in substance. (2) There are no numerical values (e.g., dollar amounts, percentages) in either the question or ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of disclosures, correctly identifying the shift in emphasis from brand reputation to supply chain and cost impacts. It adds contextual detail (e.g., third-party supplier monitoring, delivery risks) that is consistent with a more developed narrative in 2023, which enhances the answer without introducing inaccuracies. (4) The answer is fully contextually relevant, directly addressing the question about the evolution of disclosures related to food safety, supply chain risks, and cost volatility. The only minor deduction is for slightly stronger emphasis on operational details (e.g., delivery, monitoring) not explicitly highlighted in the ground truth, but these are reasonable inferences and do not contradict it. Overall, the semantic meaning and factual core are equivalent to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 415,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the carrying value and interest rate of TMO's 1.750% 7-Year Senior Notes evolved between 2023 and 2024?",
      "original_answer": "In 2023, TMO's 1.750% 7-Year Senior Notes, due on October 15, 2028, had a carrying value of $700 million and an effective interest rate of 1.89%. In 2024, both the carrying value and effective interest rate remained unchanged at $700 million and 1.89% respectively. This indicates that there was no change in the financial structure or valuation of this particular debt instrument over the period.",
      "llm_answer": "- **Carrying value:** The 1.750 % 7‑year senior notes were carried at **$662 million** on December 31 2023 and fell to **$621 million** on December 31 2024【page_61】.  \n- **Interest rate:** Their effective interest rate was **1.97 %** at the end of 2023 and slipped marginally to **1.96 %** at the end of 2024【page_47】.  \n\nThus, between 2023 and 2024 the notes’ carrying amount declined by about $41 million and the effective rate edged down by 0.01 percentage point.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both carrying value and interest rate figures. According to the ground truth, the carrying value was $700 million in both 2023 and 2024, and the effective interest rate was 1.89% in both years. The LLM reports $662 million and $621 million for carrying value, and 1.97% and 1.96% for interest rates—none of which match the ground truth. These discrepancies are significant and affect the core of the question. (2) The calculations based on incorrect numbers (e.g., $41 million decline, 0.01 percentage point drop) are mathematically consistent with the LLM's own data but are irrelevant because the inputs are wrong. (3) The multi-hop reasoning is structurally sound—the model attempts to compare two years across two metrics—but fails because it draws from incorrect source data, possibly misreading the document or referencing the wrong debt instrument. (4) Despite correct contextual framing (discussing the right type of note, time frame, and metrics), the severe factual inaccuracies in numbers and rates result in a very low correctness and quantitative accuracy score. Qualitative accuracy is slightly higher because the model understands what information is being asked, but it fails in execution. Contextual relevance is high as the response stays on topic and references appropriate financial concepts and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1207,
        "completion_tokens": 384,
        "total_tokens": 1591
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did RTX's exposure to its 7.000% notes due 2038 change between 2022 and 2023, and what does this suggest about its approach to managing long-term debt maturities?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $11 million for its 7.000% notes due 2038. By 2023, this amount had increased significantly to $148 million. This suggests that RTX either issued additional tranches of this note or restructured its debt to extend maturities, indicating a strategic shift toward increasing exposure to this particular long-term debt instrument.",
      "llm_answer": "RTX’s portfolio of the 7.0 % notes that mature in 2038 was **$148 million in both 2022 and 2023** (the 2023 10‑K shows $148 million for 2023 and $148 million for 2022, and the 2022 10‑K lists the same $148 million for 2022). The flat exposure indicates that RTX did not retire or significantly add to this particular series; instead, it is managing its long‑term debt profile by issuing new notes at other rates and maturities while keeping the 2038 tranche essentially unchanged, reflecting a strategy of maintaining a balanced maturity schedule rather than aggressively paying down that specific tranche.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that RTX's exposure to the 7.000% notes due 2038 was $148 million in both 2022 and 2023. The ground truth states that the principal balance was $11 million in 2022 and increased to $148 million in 2023. This fundamental error invalidates the entire analysis. (2) Quantitative accuracy is extremely low: the LLM reports the same value for both years, directly contradicting the ground truth which shows a significant increase from $11M to $148M—a 1245% increase. The LLM incorrectly claims consistency between filings, asserting that both the 2022 and 2023 10-Ks report $148M for 2022, which contradicts the verified data. (3) The multi-hop reasoning is flawed because the LLM failed to correctly extract and compare the values across years. The conclusion that RTX maintained a 'flat exposure' and is managing debt by keeping the 2038 tranche unchanged is the opposite of the truth. The actual increase suggests new issuance or restructuring, indicating a strategic increase in long-term debt via this instrument—precisely what the LLM missed. (4) Contextual relevance is low but not zero because the answer addresses the right topic (debt management strategy) and the correct instrument (7.000% notes due 2038), but with completely incorrect data and therefore misleading interpretation. The reasoning would have been plausible if the numbers were correct, but as it stands, the answer misrepresents the situation entirely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 410,
        "total_tokens": 1663
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did McDonald's financial relationship with its franchisees evolve between 2022 and 2023, particularly regarding the collection of rent and royalties?",
      "original_answer": "In 2022, McDonald's disclosed that it had deferred approximately $1 billion in rent and royalties from franchisees, primarily during the first half of 2020, due to the impact of government restrictions related to COVID-19. By the end of 2021, the company had collected substantially all of these deferred amounts. In contrast, the 2023 filing reflects a return to standard operations, with no mention of ongoing deferrals or pandemic-related financial accommodations. Instead, the 2023 report outlines the normalization of franchise operations, including a detailed breakdown of restaurant ownership types, which indicates that franchisees were operating under regular financial obligations without pandemic-era relief measures.",
      "llm_answer": "Between 2022 and 2023 McDonald’s’ franchise base grew (conventional franchised restaurants rose from 21,720 to 21,818 and total franchised locations from 38,169 to 39,680), but the amount of **minimum‑rent payments** that franchisees owe the Company fell modestly – from **$3.06 billion in 2022** to **$2.95 billion in 2023** (see the “Future gross minimum rent payments” table).  The company’s rent‑and‑royalty model remained unchanged: **minimum rent is recognized straight‑line over the franchise term, while variable rent and royalties are recognized when franchisee sales occur** (Revenue‑Recognition note).  Thus, while the franchise system expanded, the fixed‑rent component of the franchisee relationship decreased slightly, and the variable‑rent/royalty component continued to be earned on a percent‑of‑sales basis.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to address the core of the question. (1) The question asks about the evolution of McDonald's financial relationship with franchisees between 2022 and 2023, specifically regarding rent and royalty collections in the context of pandemic-related deferrals. The original answer correctly states that McDonald's deferred ~$1B in rent/royalties in 2020 and had collected substantially all by end of 2021, with 2022–2023 reflecting normalized operations with no ongoing deferrals. The LLM answer completely misses this key narrative and instead fabricates or misrepresents data about minimum rent declining from $3.06B to $2.95B between 2022 and 2023. This specific dollar amount comparison does not appear in the ground truth and contradicts the actual context: the focus is on the resolution of prior deferrals, not a year-over-year change in rent revenue. (2) The quantitative accuracy is low: the $3.06B and $2.95B figures are not supported by the ground truth, which does not provide total minimum rent figures for 2022 or 2023. The LLM appears to misinterpret or invent data from a 'Future gross minimum rent payments' table, which is not referenced in the original answer. (3) The reasoning is flawed: the LLM focuses on a supposed decrease in fixed rent despite franchise growth, suggesting a shift in financial model, but the ground truth indicates a return to normalcy after pandemic accommodations. The LLM does not mention the $1B deferral, its collection by end-2021, or the absence of pandemic-related relief in 2023—key multi-hop elements. (4) While the description of revenue recognition (straight-line for minimum rent, variable for sales-based) is technically accurate and contextually relevant, it is ancillary to the actual question about the evolution of financial accommodations. The answer is thus factually incorrect in its core claims, despite some correct background details, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 530,
        "total_tokens": 1919
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has The Coca-Cola Company's financial stake in Embotelladora Andina S.A. evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning with respect to this equity investment?",
      "original_answer": "In 2022, Coca-Cola recognized a gain of $39 million from the partial sale of its ownership interest in Embotelladora Andina S.A., indicating a strategic refranchising or divestiture move while retaining an equity stake. By 2024, Coca-Cola still held a financial stake in Andina, with a carrying value of $90 million and a fair value of $168 million, showing that the company maintained its involvement but with a relatively modest valuation compared to other equity investments. This indicates a partial exit strategy rather than a complete divestiture, with ongoing but reduced exposure.",
      "llm_answer": "The 2024 filing shows that The Coca‑Cola Company still holds Embotelladora Andina S.A. as an equity‑method investment, with a **carrying value of $90 million** and a **fair‑value estimate of $168 million** (Note 6, “Equity Method Investments”)【page_87】.  The 2022 filing likewise notes that the company “continues to account for our remaining ownership interest in Andina as an equity‑method investee” (Note 2, Divestitures)【page_76】, indicating that the stake remained a minority, non‑controlling interest throughout the period.  \n\nTogether, the data suggest that Coca‑Cola’s ownership percentage in Andina has not changed – it remains a modest equity‑method holding – but the investment’s book value has fallen, reflecting a decline in the subsidiary’s equity value and Coca‑Cola’s strategic choice to retain only a limited, passive position rather than pursue further ownership or integration.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM correctly reports the 2024 carrying value ($90 million) and fair value ($168 million) of Coca-Cola's stake in Embotelladora Andina S.A., matching the ground truth. It also correctly identifies that the investment was still accounted for as an equity-method investee in 2022. However, it incorrectly implies that the ownership percentage did not change from 2022 to 2024, which contradicts the ground truth stating that Coca-Cola recognized a $39 million gain in 2022 from a partial sale—indicating a reduction in ownership. This is a significant factual error in reasoning.\n\n2) Quantitatively, all numbers are accurate: $90 million carrying value and $168 million fair value in 2024 are correctly cited. The $39 million gain from 2022 is missing from the LLM answer, but no incorrect numbers are presented. Format and values are consistent with ground truth.\n\n3) The multi-hop reasoning is flawed. The LLM fails to connect the 2022 divestiture (gain on partial sale) with the evolution of the stake. Instead, it concludes ownership percentage 'has not changed,' which is incorrect. The ground truth clearly indicates a partial exit strategy via divestiture, while the LLM mischaracterizes the strategic positioning as static. This undermines the qualitative accuracy despite correct entity and metric identification.\n\n4) Contextual relevance is high—the answer addresses the financial stake and strategic positioning, cites correct notes and pages, and focuses on the right companies and years. However, the incorrect inference about unchanged ownership leads to a misleading conclusion about Coca-Cola’s strategy, reducing overall correctness. The answer captures ongoing reduced exposure but misses the active divestiture signal in 2022.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 475,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has Oracle's strategic investment in cloud infrastructure evolved from 2022 to 2024, particularly regarding internal development efforts and the positioning of Oracle Cloud Infrastructure in its product portfolio?",
      "original_answer": "In 2022, Oracle emphasized internal development as a core strategy, dedicating significant resources to research and development to maintain and improve its existing product suite, including cloud technologies. The company highlighted its global R&D workforce and the importance of innovation in response to evolving market demands. By 2024, this focus had evolved into a more product-specific strategy with the explicit introduction of Oracle Cloud Infrastructure (OCI) as a central offering within Oracle Cloud Services. OCI was positioned as a comprehensive and integrated infrastructure solution, indicating a shift from general cloud development to a structured, customer-facing product portfolio. This evolution demonstrates a strategic deepening of Oracle's cloud infrastructure commitment, aligning internal R&D with the delivery of a defined, market-ready suite of cloud services.",
      "llm_answer": "- In the 2022 filing Oracle stressed that the bulk of its cloud‑and‑infrastructure offerings are **built internally** (“We develop the substantial majority of our products and services offerings internally…”) and that it was **investing heavily in expanding Oracle Cloud Operations**, adding data‑center capacity and new locations to support the Oracle Cloud platform that includes Oracle Cloud Infrastructure (OCI) (see 2022 p. 15‑16).  \n\n- By the 2024 filing the company describes OCI as a **core, separate pillar of its cloud portfolio** – “Oracle Cloud Software‑as‑a‑Service and Oracle Cloud Infrastructure (SaaS and OCI, respectively, and collectively, Oracle Cloud Services)” – indicating that OCI is now explicitly positioned as the foundational infrastructure layer that underpins all of Oracle’s cloud‑service offerings (see 2024 p. 72‑73).  \n\nTogether, these disclosures show that Oracle’s strategy has evolved from emphasizing internal development and capacity expansion for its cloud platform in 2022 to formally branding OCI as a distinct, strategic component of its integrated cloud portfolio by 2024, while still relying on internal R&D to maintain technical control.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate, complete, and semantically equivalent to the ground truth. (1) It correctly identifies Oracle's 2022 focus on internal development and infrastructure expansion, citing accurate language from the 2022 filing (p. 15–16), and accurately reflects the 2024 strategic shift in positioning OCI as a core, distinct pillar within Oracle Cloud Services, with correct reference to the 2024 filing (p. 72–73). (2) There are no numeric values (e.g., dollar amounts, percentages, headcount) in either the original or LLM answer, so quantitative accuracy is not applicable in a numerical sense, but all descriptive metrics and references are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years of filings, correctly tracing the evolution from internal R&D and capacity building in 2022 to the formal product-level positioning of OCI in 2024. (4) The LLM captures all key elements of the original answer—internal development, R&D emphasis, infrastructure expansion, and the strategic elevation of OCI—while adding precise document citations and clearer structural framing. Wording differs slightly but meaning and factual content are fully aligned. All scores are maximized due to full factual correctness, proper synthesis, and high relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1535,
        "completion_tokens": 364,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did TMO's involvement with The Binding Site Group evolve between 2023 and 2024, and what does this indicate about the company's integration and strategic focus post-acquisition?",
      "original_answer": "In 2023, TMO acquired The Binding Site Group for $2.70 billion as part of its Specialty Diagnostics segment, expanding its portfolio in diagnostics for blood cancers and immune disorders. By 2024, the company had integrated the acquisition into its asset base, with The Binding Site Group contributing to the 19-year weighted-average amortization period for customer relationships among definite-lived intangible assets. This evolution indicates a strategic focus on long-term value creation through integration of acquired innovation into its core diagnostics offerings.",
      "llm_answer": "In 2023 Thermo Fisher completed its first‑ever purchase of The Binding Site Group – a U.K. specialty‑diagnostics company – paying $2.4 billion in cash and assuming $307 million of debt (total purchase price $2.7 billion) and folding the business into the Specialty Diagnostics segment【page_66】.  By the 2024 filing the Binding Site is no longer discussed as a new transaction; it appears only as an existing part of the Specialty Diagnostics portfolio, while the company’s 2024 acquisition activity is focused on Olink in the Life Sciences Solutions segment【page_65】.  This shift shows that the Binding Site deal has moved from acquisition to integration, and Thermo Fisher’s post‑acquisition strategy is now centered on leveraging that integration and pursuing further growth in other high‑potential areas.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the $2.7 billion total purchase price (comprising $2.4 billion cash and $307 million debt assumption) matches the ground truth's $2.70 billion; the 2023 acquisition date is correct. (2) The answer correctly identifies the entity (The Binding Site Group), its integration into the Specialty Diagnostics segment, and the shift in 2024 focus to Olink, indicating proper entity and timeline accuracy. (3) The reasoning is sound: it infers from the absence of discussion in 2024 filings as a new transaction that integration is complete, which aligns with the ground truth's indication of integration into intangible assets with a 19-year amortization period. While the LLM does not explicitly mention the 19-year weighted-average amortization period—a minor omission—it compensates by correctly interpreting the strategic implication: that the company has moved from acquisition to integration and is now leveraging it while pursuing other growth areas. (4) The answer is contextually excellent, addressing both the evolution between 2023 and 2024 and the strategic focus post-acquisition. The only reason for not scoring a 10 is the missing detail about the amortization period, which is part of the integration evidence in the ground truth, but the core facts, numbers, and strategic interpretation are correct and semantically equivalent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 400,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2022 and 2024, particularly in terms of website links and scope of application?",
      "original_answer": "In 2022, the Directors' Code of Conduct was posted on BNY Mellon's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf, and it applied to all directors. By 2024, while the scope of application remained the same—applying to all directors—the URL for the Directors' Code of Conduct had changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf. This indicates a change in the website structure or domain branding, likely reflecting a broader rebranding from 'BNY Mellon' to 'BNY', while maintaining the same governance policy content and disclosure intent.",
      "llm_answer": "In the 2022 Form 10‑K the company said that its Directors’ Code of Conduct “applies to all directors of BNY Mellon” and was posted at  \n\n**https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/in relations/directors‑code‑of‑conduct.pdf**  \n\n(embedded in the same “Code of Ethics” section that linked the employee Code of Conduct to a bnymellon.com PDF).  \n\nBy the 2024 filing the same scope – “applies to all directors of BNY” – was retained, but the link was moved to a new URL under an investor‑relations folder (e.g., **…/bnymellon/documents/pdf/investor‑relations/directors‑code‑of‑conduct.pdf**) and the employee Code of Conduct itself was shifted to a bny.com domain. Thus, the disclosure of the Directors’ Code remained universal, while its web location was updated and made more directly accessible in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the scope of application in both 2022 and 2024 as applying to all directors, with accurate phrasing reflecting the rebranding from 'BNY Mellon' to 'BNY'. The key URLs are mostly correct, though the 2024 URL in the LLM answer contains a minor error: it incorrectly retains 'bnymellon' in the path instead of reflecting the updated 'bny.com' domain as in the ground truth (https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf). The LLM notes a shift to bny.com for the employee code but fails to fully apply this domain change to the Directors' Code link. (2) Quantitatively, the years (2022, 2024) and the scope (all directors) are accurate. The URL components are partially correct but contain a small but notable inaccuracy in the domain/path synthesis. (3) The reasoning is sound in identifying the continuity of policy scope and the website reorganization, correctly inferring improved accessibility and rebranding implications. However, the failure to fully update the domain in the Directors' Code URL suggests incomplete multi-hop synthesis between the employee code shift and the directors' document. (4) Despite the URL inaccuracy, the answer captures the core evolution: consistent scope and updated web location due to rebranding. The contextual relevance is perfect, addressing both website links and scope as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 394,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has McDonald's relationship with franchisees evolved in terms of financial reporting and strategic emphasis between 2022 and 2023?",
      "original_answer": "In 2022, McDonald's noted that the results of operations from restaurant businesses purchased and sold in transactions with franchisees were not material to the consolidated financial statements, indicating a limited financial impact from such transactions. By 2023, the company explicitly included franchisees and licensees as key stakeholders in its business model, emphasizing their role alongside company-operated restaurants in a detailed breakdown of restaurant ownership types. This shift reflects a more strategic and transparent focus on franchisees as integral to McDonald's global business structure.",
      "llm_answer": "In the 2022 filing McDonald’s described its franchise relationship mainly through the traditional rent‑and‑royalty model – royalties were recognized when sales occurred and rental income was recorded straight‑line over the franchise term, with “other” franchise‑related revenues reported net of related expenses. By the 2023 filing the company had shifted its reporting to treat the technology‑platform services it provides to franchisees as a principal arrangement, presenting that revenue on a gross basis (page 44) and emphasizing cost‑sharing on restaurant‑improvement projects (page 44). At the same time, the 2023 filing shows a strategic focus on expanding the franchised network (total franchised restaurants rose to 39,680 from 38,169 in 2022, page 43) and on acquiring more franchisee‑owned restaurants, reflected in higher goodwill from franchisee purchases (balance grew to $3.04 billion, page 45).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer provides relevant and detailed information about McDonald's evolving relationship with franchisees between 2022 and 2023, showing a shift in financial reporting (e.g., gross revenue recognition for technology services) and strategic emphasis (e.g., network expansion, cost-sharing). However, the quantitative details are not fully aligned with the ground truth. The LLM cites specific numbers such as franchised restaurants increasing from 38,169 to 39,680 and goodwill rising to $3.04 billion, but these figures are not present in the original answer and cannot be verified against the provided ground truth, which does not include any numerical data. This introduces factual uncertainty and undermines quantitative accuracy. While the original answer highlights a shift from non-material transaction impact in 2022 to a more strategic, stakeholder-focused framing in 2023, the LLM introduces new details (e.g., principal arrangement for tech services, cost-sharing, goodwill) that, while plausible, go beyond the scope of the original knowledge graph. The reasoning is logically sound and contextually relevant, and the qualitative shift in emphasis is correctly identified, but the addition of unsupported specifics reduces factual correctness. The answer captures the directional evolution but adds unverified granular data, leading to a partial match in factual content.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 383,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the accounting treatment or status of the contingent consideration liabilities related to the Clif Bar acquisition evolve between 2023 and 2024, particularly in terms of fair value measurement and purchase price allocation adjustments?",
      "original_answer": "In 2023, the contingent consideration liabilities related to the Clif Bar acquisition were actively measured at fair value using a Monte Carlo simulation, with $548 million classified as long-term liabilities at December 31, 2023. These liabilities were tied to performance targets in 2025 and 2026 and were subject to fair value adjustments recorded in selling, general, and administrative expenses. By 2024, there is no direct mention of the contingent consideration liabilities; instead, the 2024 filing references purchase price allocation adjustments for Clif Bar during 2023. This indicates that the contingent consideration may have been finalized or reclassified as part of the purchase price allocation process, though the 2024 disclosure does not provide updated figures or valuation methods for these liabilities.",
      "llm_answer": "In the 2023 filing the company recorded the Clif Bar contingent‑consideration obligation at **fair value** – $452 million at the acquisition date and **re‑measured to $548 million** as of 31 Dec 2023 – using a Monte‑Carlo simulation (Level 3 inputs) and classified it as a long‑term liability【page_99†L1-L14】. That filing also disclosed that **purchase‑price‑allocation (PPA) adjustments for the Clif Bar deal were made in 2023**【page_87†L1-L4】.  \n\nThe 2024 filing no longer reports a new re‑measurement; the liability remains on the balance sheet and the PPA adjustments are referenced only as a **one‑time 2023 adjustment**, indicating that the contingent‑consideration amount was already set and no further fair‑value changes or additional PPA adjustments were recognized for 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "(1) The LLM answer is mostly correct in its qualitative assessment but contains a discrepancy in the initial fair value amount. The ground truth states that $548 million was the fair value at December 31, 2023, but does not mention $452 million as the acquisition-date amount. The LLM introduces this $452 million figure, which is not present in the original answer and may be factually inaccurate or inferred from a source outside the provided knowledge graph. This affects quantitative accuracy. (2) The re-measurement to $548 million by year-end 2023 and use of Monte Carlo simulation (Level 3 inputs) are correctly reported and align with the ground truth. However, the introduction of the $452 million figure — while possibly from the actual filing — is not supported by the provided ground truth and thus counts as a factual deviation. (3) The reasoning about the absence of new re-measurements in 2024 and the reference to PPA adjustments only as a one-time 2023 item is sound and correctly infers that the contingent consideration was likely finalized or no longer subject to change, which matches the multi-hop logic required. (4) Contextual relevance is perfect — the answer directly addresses the evolution of accounting treatment, fair value measurement, and PPA adjustments between 2023 and 2024. Due to the unsupported initial dollar amount, the correctness score is reduced to 8, with a 7 in quantitative accuracy, but high marks for qualitative reasoning and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 407,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has AMD's strategic emphasis on Vulkan API support evolved between 2022 and 2024, and what does this reveal about its approach to maintaining competitiveness in the discrete GPU market?",
      "original_answer": "In 2022, AMD highlighted its support for Vulkan as part of its Radeon™ series discrete GPUs, which were built on the RDNA 2 architecture and aimed at delivering high-performance gaming and creation workloads. By 2024, AMD continued to support Vulkan but shifted its focus toward the newer RDNA 3 architecture, which underpins the Radeon RX 7000 Series GPUs. This evolution suggests AMD is maintaining its commitment to Vulkan while advancing its GPU capabilities to meet the growing demands of immersive gaming and AI/ML computing. This strategic continuity in API support combined with architectural innovation indicates AMD’s effort to stay competitive by offering both backward compatibility and cutting-edge performance enhancements.",
      "llm_answer": "In the 2022 filing AMD highlighted that its Radeon discrete GPUs “support current‑generation application‑programming interfaces (APIs) like DirectX 12 Ultimate **and Vulkan®**,” positioning Vulkan as one of the baseline graphics standards it would continue to support. By the 2024 filing the language is unchanged—AMD still stresses support for “DirectX 12 Ultimate **and Vulkan**”—but it is now coupled with broader claims about high‑refresh‑rate displays, immersive‑gaming features and “high‑performance AI/ML computing,” indicating that Vulkan support is being leveraged not just for traditional gaming but also for emerging compute workloads. This continuity and broadened framing reveal that AMD treats Vulkan as a core, future‑proof API and is using it to keep its discrete‑GPU portfolio competitive across both gaming and AI‑driven markets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies AMD's continued support for Vulkan API in both 2022 and 2024, accurately reflecting the continuity in language across filings. The mention of DirectX 12 Ultimate alongside Vulkan is factually consistent with AMD's disclosures. (2) There are no numeric values requiring calculation, but the years (2022 and 2024) are correct and properly contextualized. (3) The multi-hop reasoning is sound: the LLM infers from unchanged API language but broadened application context (gaming to AI/ML) that AMD is leveraging Vulkan as a future-proof standard, which matches the ground truth’s conclusion about strategic continuity and competitiveness. The only minor gap is that the LLM does not explicitly name the RDNA 2 (2022) and RDNA 3 (2024) architectures, which are present in the original answer and represent a key technical evolution. However, it compensates by correctly identifying the shift in use cases (immersive gaming, AI/ML) tied to architectural advances. (4) The answer is contextually excellent—directly addressing AMD’s strategic emphasis and competitiveness in the discrete GPU market. The omission of specific architecture names slightly reduces qualitative accuracy but does not undermine the core correctness. Overall, the answer demonstrates strong synthesis and interpretation of the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 387,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How did RTX's integration-related charges impact its operating profit trends between 2022 and 2023, particularly with the introduction of the Powder Metal Matter charge in 2023?",
      "original_answer": "In 2022, RTX reported a decrease in Acquisition Accounting Adjustments, which contributed positively to its operating profit. However, in 2023, there was a significant $2.9 billion charge associated with the Powder Metal Matter, which became a major driver of the $1.9 billion decrease in Operating Profit compared to 2022. This reflects a notable shift from a declining trend in integration-related charges in 2022 to a significant new expense in 2023 that directly impacted profitability.",
      "llm_answer": "RTX’s operating profit fell sharply in 2023 because a new $2.9 billion “Powder Metal Matter” charge (net of partner share) hit the Pratt & Whitney segment, dragging operating profit down $1.9 billion versus 2022 【page_39】. In contrast, 2022 had seen operating profit rise $0.4 billion as integration‑related costs from the Raytheon merger (acquisition‑accounting adjustments, restructuring and corporate‑expense items) fell, helping offset other expense pressures 【page_39】. Thus, the removal of earlier integration charges boosted 2022 profit, but the introduction of the large Powder Metal Matter charge in 2023 reversed that trend, causing a steep profit decline.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $2.9 billion Powder Metal Matter charge in 2023 and its impact of a $1.9 billion decrease in operating profit are accurately reported. The contrast with 2022, where integration-related charges decreased and contributed positively to operating profit, is correctly described. The LLM adds a specific detail—$0.4 billion operating profit increase in 2022—not in the original answer but consistent with the trend and plausible given the context; this does not contradict the ground truth. (2) Quantitative accuracy is perfect: $2.9 billion and $1.9 billion figures match exactly, and the directional change (decline in 2023 vs improvement in 2022) is correctly interpreted. (3) Multi-hop reasoning is sound: the model correctly synthesizes the shift from declining integration costs in 2022 to a major new charge in 2023, explaining the reversal in operating profit trend. (4) The only minor shortcoming is that the original answer emphasizes the 'Acquisition Accounting Adjustments' specifically, while the LLM generalizes to 'integration-related costs'—a slight broadening but still contextually appropriate. Overall, the answer is semantically equivalent, highly relevant, and factually precise, warranting a 9 due to the slight rephrasing of the 2022 improvement without direct citation of 'Acquisition Accounting Adjustments.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 396,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has MDLZ's relationship with Clif Bar evolved between 2023 and 2024, particularly in terms of acquisition-related financial activities?",
      "original_answer": "In 2023, MDLZ acquired Clif Bar, as noted in the 2023 10-K filing, with specific reference to the August 1, 2022 acquisition and related financial impacts such as integration costs and contingent consideration adjustments. By 2024, the relationship had evolved to include purchase price allocation adjustments for Clif Bar during the prior year, as detailed in the 2024 10-K filing. This indicates that the company had moved beyond the initial acquisition phase into a period of financial recalibration and consolidation of the Clif Bar acquisition.",
      "llm_answer": "In 2023 Mondelēz still treated Clif Bar as a recent acquisition – the August 1 2022 purchase added $529 million of net revenue (see 2023 results) and the year’s financial statements recorded purchase‑price‑allocation adjustments for Clif Bar (footnote 1 on the segment‑balance table). By 2024 the brand was simply carried as part of the company’s indefinite‑life intangible‑asset portfolio (which includes the Clif Bar brand) and no new acquisition‑related costs, divestitures or further purchase‑price‑allocation activity for Clif Bar were reported.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in its qualitative assessment of MDLZ's relationship with Clif Bar evolving from a recent acquisition in 2023 to integration into the indefinite-life intangible asset portfolio by 2024, with no new acquisition-related activities reported. It correctly identifies the August 1, 2022 acquisition date and references purchase price allocation adjustments in 2023, aligning with the ground truth. However, the $529 million net revenue figure attributed to Clif Bar in 2023 is not present in the original answer and cannot be verified against the provided ground truth, introducing a potential factual inaccuracy or unsupported detail. While the original answer mentions integration costs and contingent consideration adjustments in 2023 and purchase price allocation adjustments in 2024, the LLM does not mention contingent consideration, slightly reducing completeness. The reasoning is sound and multi-hop synthesis across years and filings is appropriate. The entity names (MDLZ, Clif Bar), years (2022, 2023, 2024), and financial concepts (purchase price allocation, intangible assets) are accurate. The answer is highly relevant and conveys a similar evolution as the ground truth, though with an unverified quantitative claim. Hence, the correctness score is 8 due to the unsupported $529M figure, which affects quantitative accuracy (score 7), while qualitative reasoning and contextual relevance remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 398,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Gulfstream's approach to energy efficient engines evolved from 2023 to 2024, and what specific aircraft developments reflect this shift?",
      "original_answer": "In 2023, Gulfstream emphasized its leadership in the use of sustainable aviation fuel (SAF) and energy efficient engines, focusing on continuous R&D investment to develop technologically advanced business jets. However, no new aircraft model powered by energy efficient engines was introduced that year. By 2024, Gulfstream had transitioned from announcement and development phases to actual production of energy efficient engines, as evidenced by the introduction of the G700, which features 'all-new engines' designed for high-speed performance and efficiency. This marks a tangible evolution from strategic positioning in 2023 to operational realization in 2024.",
      "llm_answer": "By 2023 Gulfstream’s messaging centered on being the industry‑leader in sustainable‑aviation‑fuel (SAF) use and on the efficiency of its existing powerplants, noting milestones such as the world’s first trans‑Atlantic flight on 100 % SAF and the broadening of SAF availability at its FBOs. In the 2024 filing the company stresses that its newest jets are built around “all‑new, energy‑efficient engines” that cut fuel burn and emissions, and it ties this shift to concrete product launches – the G500/G600 family (described as faster, more fuel‑efficient and lower‑emission), the ultra‑long‑range G700 that entered service in March 2024 with new high‑speed engines, and the upcoming G800 and G400 models that also feature the next‑generation efficient engines.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution from Gulfstream's focus on SAF and efficiency in 2023 to introducing new engine technology in 2024, which aligns with the ground truth. However, there are significant factual inaccuracies that reduce correctness. First, the LLM claims the G500/G600 family was part of the 2024 shift toward 'all-new, energy-efficient engines,' but these models were introduced earlier and do not represent new engine development in 2024—this contradicts the original answer stating no new aircraft with such engines were introduced in 2023 and that the G700 marked the transition. Second, the LLM mentions the G800 and G400 as featuring next-generation engines in 2024, but the original answer only highlights the G700 as evidence of production-phase realization. The G800 may be a derivative of the G700, but it is not mentioned in the ground truth, and the G400 is not referenced at all. Additionally, while the transatlantic 100% SAF flight and FBO initiatives may be contextually relevant, they are not in the original answer and introduce unverified details. The date 'March 2024' for G700 entry into service is plausible but not confirmed in the ground truth, which only states the G700 was introduced in 2024. Thus, quantitative accuracy is reduced due to unsupported dates, model attributions, and product claims. Qualitatively, the reasoning shows an attempt at multi-hop synthesis—linking messaging shifts to product launches—but incorrectly attributes the engine advancements to multiple aircraft not cited in the ground truth. Contextually, the answer is highly relevant and well-structured, addressing both years and aircraft developments as asked. Overall, the core idea of a shift from strategy to implementation is preserved, but specific entity and product claims undermine factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 496,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has AMD's relationship with semi-custom SoC products evolved from 2022 to 2024, particularly in terms of revenue structure and strategic positioning?",
      "original_answer": "In 2022, AMD's relationship with semi-custom SoC products was characterized by dependency, with revenue derived from both non-recurring engineering fees and sales of the products themselves, and success was directly tied to third-party product performance. By 2024, AMD's relationship evolved to one of active production and broader strategic integration, as semi-custom SoC products became part of a more diversified product portfolio that includes AI accelerators, GPUs, APUs, and DPUs. This shift indicates a more central and controlled role for AMD in the development and commercialization of these products, aligning them more closely with long-term industry trends and internal innovation strategies.",
      "llm_answer": "In the 2022 filing AMD described its semi‑custom System‑on‑Chip (SoC) business as a “non‑recurring” source of engineering‑fee income and product‑sale revenue that depended entirely on winning individual design contracts and on the downstream success of each customer’s product (see 2022 p. 25). By the 2024 filing the company has folded those designs into a broader “custom products” category—primarily tied to the Gaming segment—recognizing revenue over the production period using a cost‑plus margin method and treating the business as a strategic, repeatable offering rather than a one‑off fee stream (see 2024 p. 63, and the product list in 2024 p. 62). Thus, AMD’s semi‑custom SoC relationship has shifted from an ad‑hoc, fee‑driven model to a more structured, ongoing product line that is positioned as a core growth engine within its overall portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution of AMD's semi-custom SoC business from 2022 to 2024: in 2022, revenue came from non-recurring engineering (NRE) fees and product sales, dependent on customer success (as stated in the original answer and supported by the 2022 filing reference). By 2024, the business evolved into a more structured, ongoing 'custom products' category with revenue recognized over production using a cost-plus model, indicating strategic integration. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised—dates (2022, 2024) are correct and consistently referenced with appropriate context from filings. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, identifies a shift in revenue recognition (from NRE to cost-plus over time), and infers a strategic shift (from ad-hoc to core growth engine). The mention of integration into the Gaming segment and the product list on p.62 of the 2024 filing adds specificity not in the original answer but is consistent with the broader strategic positioning. (4) The LLM answer conveys semantic equivalence: while it uses different phrasing (e.g., 'ad-hoc, fee-driven model' vs. 'dependency'), the core meaning—evolution from dependency on third-party success to a controlled, strategic product line—is preserved. The only minor gap is that the original answer explicitly mentions diversification into AI accelerators, GPUs, APUs, and DPUs, which the LLM answer omits. However, the LLM’s reference to 'broader custom products category' and 'core growth engine' implies this expansion. This omission prevents a perfect 10 but does not undermine the overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 494,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the company's structure of preferred share authorization evolved between fiscal years 2023 and 2024, and what does this indicate about its capital strategy?",
      "original_answer": "The company's preferred share authorization structure remained unchanged between fiscal years 2023 and 2024, with 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value authorized in both years. Additionally, no Preferred Shares or A Preferred Shares were issued or outstanding in either year. This indicates that the company has not utilized or pursued any changes in its preferred share structure as part of its capital strategy during this period.",
      "llm_answer": "The 2024 proxy statement still lists **127.5 million preferred shares ( $0.20 par) and 500 thousand “A” preferred shares ( $1.00 par)** as part of the company’s authorized capital. The 2023 filing shows the same authorized amounts, indicating that the company did **not increase or otherwise alter its preferred‑share authorization** between the two years. This stability suggests that Medtronic’s capital strategy is not focused on raising new preferred equity; instead it relies on ordinary‑share issuances, stock‑based compensation and share‑repurchase programs to manage its capital needs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: 127.5 million preferred shares at $0.20 par value and 500 thousand A preferred shares at $1.00 par value are accurately reported for both fiscal years 2023 and 2024. There are no calculation errors. (2) The answer correctly states that there was no change in authorization, which matches the original answer. (3) The LLM adds contextual interpretation—mentioning reliance on ordinary-share issuances, stock-based compensation, and repurchase programs—which is reasonable and consistent with the lack of preferred share activity, though this specific detail is not in the ground truth. However, it does not explicitly state that no preferred shares were issued or outstanding in either year, which is a minor omission affecting completeness. (4) Entity accuracy is correct: the company (implied as Medtronic, though not named in the question) and fiscal years are properly referenced. (5) The reasoning is sound—stable authorization implies no strategic move toward preferred equity. The answer is semantically equivalent with slightly expanded inference, which is acceptable. The correctness score is 9 due to the omission of the 'no shares issued or outstanding' fact, but all other aspects are fully accurate and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 372,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the framing of reputational risk related to adverse publicity evolved between 2022 and 2024 in BK's risk disclosures, particularly in terms of associated impacts or linked concerns?",
      "original_answer": "In 2022, BK identified adverse publicity as a risk that could negatively affect its business, financial condition, and results of operations, and linked it with government scrutiny and other reputational harm. By 2024, the framing of this risk remained present but was expanded to include broader reputational impacts from sustainability concerns such as climate change and diversity, in addition to being tied to new operational models like the platforms operating model transition. This indicates a broadening of the contexts in which adverse publicity could negatively impact BK's reputation and business outcomes.",
      "llm_answer": "In the 2022 Form 10‑K the company warned that “our businesses may be negatively affected by adverse events, publicity, government scrutiny or other reputational harm,” and it linked reputational damage specifically to climate‑change concerns (“could…damage our reputation”).  \n\nBy the 2024 filing the same basic warning remains, but the framing is expanded: reputational risk is now tied not only to adverse publicity and government scrutiny but also to “sustainability concerns, including a focus on climate change and diversity,” which could “damage our reputation” and additionally “subject us to additional regulatory requirements.” In short, the 2024 disclosure broadens the reputational‑risk narrative to include ESG‑related scrutiny and its regulatory fallout while retaining the original adverse‑publicity language.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2022 disclosure correctly identifies adverse publicity, government scrutiny, and reputational harm, with specific mention of climate change concerns affecting reputation. The 2024 expansion to include sustainability concerns like climate change and diversity is accurately reported, as is the linkage to additional regulatory requirements. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a traditional sense, but all dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound—correctly comparing risk disclosures across years and synthesizing how the framing evolved. The LLM captures the broadening of reputational risk to include ESG-related factors and regulatory fallout, which is consistent with the ground truth. (4) The only minor shortcoming is that the LLM does not explicitly mention the 'platforms operating model transition' as a new context linked to reputational risk in 2024, which is included in the original answer. This is a small omission but does not undermine the core accuracy. Overall, the answer is semantically equivalent and contextually precise, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 353,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How did Amazon's financial investment and valuation approach toward Anthropic, PBC evolve from 2023 to 2024, particularly in terms of investment classification and the factors affecting its valuation?",
      "original_answer": "In 2023, Amazon disclosed a $1.25 billion convertible note investment in Anthropic, PBC, classified as available-for-sale and reported at fair value with unrealized gains and losses included in 'Accumulated other comprehensive income (loss).' The note was categorized as a Level 3 asset, and Amazon had an agreement to invest an additional $2.75 billion in a second convertible note by Q1 2024. By 2024, the investment was still classified as available-for-sale but was noted to be part of a broader portfolio of convertible debt investments in private companies, primarily referencing Anthropic, PBC. The 2024 filing emphasized increased complexity in valuing private company investments due to the lack of readily available market data and global economic uncertainty, indicating a shift toward acknowledging heightened valuation risk. While the classification remained consistent, the 2024 disclosure placed more emphasis on the challenges of valuation rather than the mechanics of the investment itself.",
      "llm_answer": "In 2023 Amazon recorded its $1.25 billion convertible‑note investment in Anthropic, PBC as an **available‑for‑sale, Level 3 asset** measured at fair value, with unrealized gains and losses reported in accumulated other comprehensive income and an option to invest up to an additional $2.75 billion. By 2024 the same holding is still classified as an **available‑for‑sale convertible‑debt investment**, but Amazon notes that valuing Anthropic is more complex because private‑company market data are scarce and current global economic uncertainty makes market‑sensitivity analysis impracticable, so the fair‑value estimate relies on internal assumptions rather than observable prices.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key facts: the $1.25 billion initial investment in 2023, its classification as an available-for-sale, Level 3 asset measured at fair value with unrealized gains/losses in accumulated other comprehensive income, and the $2.75 billion additional commitment by Q1 2024. In 2024, the investment remains available-for-sale, and the increased valuation complexity due to lack of market data and global economic uncertainty is accurately noted. The shift in disclosure emphasis toward valuation challenges is captured semantically. (2) All numeric values—$1.25 billion and $2.75 billion—are correct and match the ground truth. No calculations are required, but the amounts are accurately reported with acceptable formatting (e.g., $1.25 billion). (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years (2023 to 2024), entities (Amazon and Anthropic, PBC), and financial concepts (investment classification, fair value hierarchy, valuation challenges). It correctly infers that while classification remained stable, the qualitative disclosure evolved to emphasize risk and uncertainty in valuation. (4) The only minor shortcoming is that the LLM does not explicitly mention that the 2024 investment is part of a broader portfolio of convertible debt in private companies, which slightly reduces completeness. However, this does not detract from the core evolution in valuation approach. Overall, the answer is factually precise, contextually relevant, and semantically equivalent to the ground truth, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 442,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the nature of the risks related to the protection of MDLZ's intellectual property, including know-how, evolved between 2023 and 2024?",
      "original_answer": "In 2023, MDLZ emphasized the importance of protecting its intellectual property rights, particularly trademarks, patents, copyrights, and know-how, through a combination of legal mechanisms such as patent and trademark laws, licensing agreements, and third-party nondisclosure agreements. The company expressed concern that failure to protect these rights or any legal changes reducing intellectual property protections—especially in response to developments in artificial intelligence technologies—could significantly harm its competitiveness and financial condition. In 2024, while the company maintained its emphasis on the significance of intellectual property rights, it did not specifically mention artificial intelligence as a factor affecting protection. Instead, the 2024 disclosure focused on the broader risks of legal or regulatory non-compliance and the potential for civil or criminal penalties, reputational damage, and financial loss due to litigation or enforcement actions. This shift indicates a broadening of the risk context without the specific emphasis on AI-related threats present in 2023.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K risk sections describe the same core IP‑protection concerns – reliance on patents, trademarks, copyrights, trade‑secrets, licensing and nondisclosure agreements, and the danger that a change in law or loss of legal protection could hurt competitiveness. The 2024 filing simply restates these points (including the explicit reference to “developments in artificial‑intelligence technologies” and infringement in traditional‑retail and digital environments) without adding any new categories, indicating that the nature of the IP‑related risks has remained essentially unchanged from 2023 to 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that the nature of IP-related risks remained unchanged between 2023 and 2024, and falsely asserts that the 2024 filing retained the explicit reference to 'artificial-intelligence technologies'—which the ground truth states was omitted in 2024. This misrepresents a key evolution in risk disclosure. While the general reliance on legal mechanisms (patents, trademarks, etc.) is correctly noted as consistent across years, the LLM incorrectly minimizes the shift in emphasis. The ground truth identifies a meaningful change: in 2023, MDLZ specifically highlighted AI developments as a concern for IP protection, whereas in 2024, this specific reference was dropped and replaced with broader concerns around legal/regulatory non-compliance, penalties, and reputational damage. The LLM’s assertion that the 2024 filing 'restates' the AI reference is directly contradicted by the ground truth. There are no numerical values in the question or answers, so quantitative accuracy is not applicable but assumed correct by default. The reasoning is flawed due to incorrect synthesis across years, failing the multi-hop requirement to compare and contrast risk disclosures accurately. Contextually, the answer addresses the right topic and company, but the erroneous claim about continuity undermines its usefulness. Thus, the correctness and qualitative accuracy scores are low despite correct mention of general IP protections.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 404,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has Goldman Sachs' treatment of Non-Employee Director Equity Award Agreements evolved between the 2023 and 2024 SEC filings, particularly in terms of referenced agreements and their timelines?",
      "original_answer": "In 2023, Goldman Sachs referenced Non-Employee Director Equity Award Agreements through Exhibit 10.17, which pointed to an amendment dated November 28, 2008. By 2024, the company continued to disclose these agreements under the same exhibit number (10.18), but the referenced source shifted to Exhibit 10.69 from the 2008 Annual Report, indicating a formalization or consolidation of prior amendments. This evolution shows a continuation of the policy with deeper historical documentation being emphasized in the later filing.",
      "llm_answer": "- **2023 filing (Form 10‑K for FY 2023)** – The exhibit list included a **pre‑2015 “Form of Non‑Employee Director RSU Award Agreement”** (Exhibit 10.21) and a separate item **“Amendments to Certain Non‑Employee Director Equity Award Agreements”** (Exhibit 10.69) that referenced amendments made for the fiscal year ended Nov 28 2008【page_5†L‑10.8】【page_6†L‑10.17】.  \n\n- **2024 filing (Form 10‑K for FY 2024)** – The pre‑2015 label is no longer used; the award is now shown simply as **“Form of Non‑Employee Director RSU Award Agreement”** (Exhibit 10.32) with an added **cash‑settled version** (Exhibit 10.33). The amendment reference remains, still pointing to **Exhibit 10.69** for the 2008‑year amendments【page_246†L‑10.18】【page_247†L‑10.32-L‑10.33】.  \n\nThus, Goldman Sachs consolidated the director equity award documentation, dropped the “pre‑2015” qualifier, added a cash‑settled form, but kept the same amendment reference and its 2008 timeline.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The exhibit numbers cited are incorrect: the original answer states that in 2023, the agreement was referenced as Exhibit 10.17, and in 2024 as Exhibit 10.18 (with a link to Exhibit 10.69 from the 2008 Annual Report). However, the LLM claims Exhibit 10.21 and 10.69 in 2023 and Exhibits 10.32 and 10.33 in 2024, which contradicts the ground truth. (2) The LLM incorrectly introduces a 'pre-2015' label and its removal, as well as the addition of a 'cash-settled version' in 2024, none of which are mentioned or supported by the original answer. These are fabrications not present in the ground truth. (3) While the LLM correctly identifies the continued reference to the 2008 amendments via Exhibit 10.69, it misrepresents the context and evolution: the original answer emphasizes a shift in how the agreement is sourced (from a standalone amendment to a reference within historical filings), indicating formalization or consolidation, whereas the LLM focuses on formatting changes and new forms that aren't in the ground truth. (4) The multi-hop reasoning is partially sound—comparing exhibit references across years—but based on incorrect data. The core evolution described in the original answer (same exhibit number continuity with deeper historical anchoring) is missed entirely. (5) Semantic equivalence fails due to incorrect exhibits, invented details (pre-2015 label, cash-settled form), and omission of the actual evolution (Exhibit 10.17 → 10.18 with sourcing shift to 10.69 from 2008 report). Despite addressing the question's intent and maintaining relevance, the factual foundation is flawed, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 469,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has BKNG's relationship with travel service providers evolved between 2022 and 2023 in terms of revenue recognition and contractual responsibilities?",
      "original_answer": "In 2022, BKNG described its relationship with travel service providers as one where it connects consumers to providers through its platforms, emphasizing its role as an intermediary without taking responsibility for delivering the travel services. The company highlighted that it earns revenues primarily from facilitating reservations and also mentioned the impact of cancellations during the pandemic recovery phase. By 2023, BKNG provided more detailed accounting treatment around its contracts with travel service providers, specifying that it recognizes revenue on a net basis due to its role as an agent, and further clarified its revenue recognition timing as occurring at the point when travelers begin using the arranged services. This reflects a shift from a general description of the relationship to a more structured and accounting-driven dependency on travel service providers, particularly in how it recognizes commissions and transaction revenues.",
      "llm_answer": "In the 2022 filing Booking.com disclosed that it was **shifting more reservations to a “merchant” model**, meaning the company began to **process payments on behalf of travel‑service providers, assume related charge‑back, fraud‑prevention and payment‑processing costs, and record the resulting incremental amounts as “merchant revenues.”** By the 2023 filing the company’s contracts with travel‑service providers were described as **still allowing providers to market availability without transferring the responsibility to deliver the travel service, but revenue is now recognized on a net basis at the point the post‑booking service is completed and is recorded in “deferred merchant bookings” for cash received in advance that must be paid to providers.** Thus, between 2022 and 2023 BKNG moved from merely earning commissions to taking on more merchant‑processing responsibilities, with revenue now recognized net of those obligations and tracked through a deferred‑booking liability.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains a mix of accurate and inaccurate information, with significant factual errors that undermine its correctness. (1) The claim that BKNG was shifting more reservations to a 'merchant model' in 2022 is not supported by the original answer or typical Booking.com disclosures; the ground truth emphasizes BKNG's role as an agent recognizing revenue on a net basis, not expanding merchant (gross) accounting. The original answer makes no mention of a shift toward a merchant model or associated costs like chargebacks or fraud prevention—this is a critical misrepresentation. (2) The LLM introduces the term 'deferred merchant bookings' and claims cash received in advance is tracked through a deferred-booking liability, which is not mentioned in the original answer and appears to be fabricated or misattributed. (3) While the LLM correctly identifies that revenue is recognized on a net basis in 2023 and at the point when service is used, it misattributes the evolution: the original answer describes a clarification of accounting treatment, not a shift from commission-based to merchant-processing with expanded responsibilities. (4) The multi-hop reasoning is partially sound—comparing 2022 and 2023 disclosures on revenue recognition and contractual roles—but the synthesis is based on incorrect premises. (5) Entity accuracy (BKNG, years, revenue recognition) is correct, and the focus on accounting evolution is relevant, hence a moderate contextual relevance score. However, the introduction of unsupported operational and financial details (merchant model expansion, deferred liabilities) results in a low correctness score despite some alignment on net revenue recognition timing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1489,
        "completion_tokens": 463,
        "total_tokens": 1952
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "What specific changes occurred in the structure of Goldman Sachs' executive life insurance policy disclosures between the 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs included the Goldman Sachs & Co. LLC Executive Life Insurance Policy and Certificate with Metropolitan Life Insurance Company (Exhibit 10.11) and a form of the policy with Pacific Life & Annuity Company (Exhibit 10.12). In the 2024 10-K filing, these exhibits were not only retained but renumbered to 10.12 and 10.13 respectively, indicating a reorganization of exhibit numbering. This renumbering and retention of the policies in the 2024 filing demonstrates a structural update in how the policies are presented within the filing, rather than a substantive change in the policies themselves.",
      "llm_answer": "In the 2023 Form 10‑K the two executive‑life‑insurance exhibits were listed as  \n\n* **Item 10.11** – Goldman Sachs & Co. LLC Executive Life Insurance Policy and Certificate with **Metropolitan Life** (exhibit 10.1)  \n* **Item 10.12** – Form of Goldman Sachs & Co. LLC Executive Life Insurance Policy with **Pacific Life** (exhibit 10.2)【page_5】  \n\nIn the 2024 Form 10‑K a new “Clawback Policy” item (10.1) was added, which pushed the subsequent numbers down one place. The same two policies now appear as  \n\n* **Item 10.12** – Executive Life Insurance Policy and Certificate with **Metropolitan Life** (exhibit 10.1)  \n* **Item 10.13** – Executive Life Insurance Policy with **Pacific Life** (exhibit 10.2)【page_246】  \n\nThus, the only structural change was a renumbering of the executive‑life‑insurance disclosures (from 10.11/10.12 to 10.12/10.13) caused by the insertion of a new preceding exhibit.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the exhibit numbers and corresponding insurance policies for both 2023 and 2024 filings: in 2023, the Metropolitan Life policy was Exhibit 10.11 and the Pacific Life policy was Exhibit 10.12; in 2024, they were renumbered to 10.12 and 10.13, respectively. These numeric details match the original answer exactly. (2) The explanation for the renumbering—due to the addition of a new 'Clawback Policy' as Exhibit 10.1, which shifted all subsequent exhibits—is a plausible and logical inference that adds context not explicitly in the ground truth but does not contradict it. While the ground truth does not mention the Clawback Policy, this detail does not introduce inaccuracy and supports the correct conclusion of structural reorganization. (3) The multi-hop reasoning is sound: the model correctly compares exhibit numbering across two years and infers a structural change rather than a substantive one. (4) Minor deduction in qualitative accuracy (9 instead of 10) is due to the introduction of the 'Clawback Policy' detail, which, while reasonable, is not confirmed in the ground truth and could be seen as speculative. However, it does not detract from the factual correctness of the exhibit renumbering. Overall, the answer is semantically equivalent, contextually relevant, and quantitatively precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 389,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has the strategic importance and manufacturing approach for FBAR filters evolved between 2022 and 2024, particularly in terms of internal fabrication and competitive positioning?",
      "original_answer": "In 2022, FBAR filters were highlighted as a key product utilizing Broadcom’s proprietary processes, fabricated internally to protect IP and accelerate time to market, alongside vertical-cavity surface emitting lasers and side emitting lasers. The internal fabrication was specifically emphasized as a means to maintain competitive advantage by safeguarding innovation. By 2024, FBAR filters remained part of the internal fabrication strategy, but the context expanded to include a more comprehensive list of competitors in the semiconductor space, such as Qorvo, Qualcomm, and Skyworks, indicating a more intense competitive environment. This suggests that while the internal manufacturing strategy for FBAR filters remained consistent, the competitive pressure in wireless communications increased significantly, requiring Broadcom to reinforce its IP protections and innovation cycle.",
      "llm_answer": "In the 2022 Form 10‑K Broadcom already highlighted its FBAR (film‑bulk‑acoustic‑resonator) filters as a “proprietary, high‑value” wireless‑communications product that it **fabricates internally** to protect the IP and accelerate time‑to‑market, and it listed “FBAR technology” as a core competitive advantage. The 2024 filing repeats that same approach – the company continues to use its own U.S. and Singapore III‑V wafer fabs for FBAR production, emphasizing that the filters remain a strategic, differentiated asset in its wireless‑communications portfolio and that internal fabrication is essential for IP protection and to compete with a broad set of rivals. Thus, between 2022 and 2024 the strategic importance of FBAR filters has stayed high, and the manufacturing strategy has remained focused on in‑house fabrication to preserve competitive positioning.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: FBAR filters were highlighted in both 2022 and 2024 as strategically important, fabricated internally using proprietary processes to protect IP and accelerate time to market. The use of internal U.S. and Singapore III-V fabs is consistent with Broadcom’s disclosed manufacturing strategy. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, identifying continuity in manufacturing strategy while inferring sustained strategic importance. The only minor omission is that the 2024 context explicitly names competitors like Qorvo, Qualcomm, and Skyworks, which the LLM alludes to generally as 'a broad set of rivals' but does not name. This slightly reduces qualitative accuracy, though the core inference about increased competitive pressure is preserved. (4) The answer is contextually relevant, directly addressing the evolution of strategic importance and manufacturing approach. Wording differs but semantic meaning matches the original answer. Thus, the response earns a 9/10 for correctness due to high fidelity with only a minor lack of specificity on competitor names in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 391,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BMY's strategic positioning of Krazati evolved between 2023 and 2024, particularly in terms of clinical development focus and financial valuation?",
      "original_answer": "In 2023, Krazati was positioned as part of BMY’s oncology portfolio with specific clinical trials listed: KRYSTAL-17 for 1L NSCLC TPS<50%, KRYSTAL-10 for 2L CRC, and KRYSTAL-12* for 2L+ Mutated NSCLC. By 2024, BMY had acquired Mirati for $4.8 billion, securing full rights to Krazati, which had already received FDA and EMA approvals for second-line NSCLC and FDA approval for advanced KRAS-mutated colorectal cancer. Additionally, Krazati was now being developed in combination with a PD-1 inhibitor for first-line NSCLC, indicating a significant expansion in its clinical and commercial strategy.",
      "llm_answer": "In the 2023 filing BMY listed Krazati only as a KRAS‑inhibitor still in registrational testing – KRYSTAL‑17 (1L NSCLC, TPS < 50 %), KRYSTAL‑10 (2L colorectal cancer) and KRYSTAL‑12 (later‑line KRAS‑mutated NSCLC) – so its focus was purely clinical‑development. By the 2024 filing, after the Mirati acquisition, Krazati is a marketed, FDA‑ and EMA‑approved KRAS inhibitor for second‑line NSCLC and KRAS‑mutated colorectal cancer, with a new first‑line NSCLC combination program with a PD‑1 inhibitor, and BMS assigned a $640 million definite‑life intangible value to Krazati as part of the $4.9 billion Mirati purchase price.",
      "correctness_score": 9,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures all key aspects of BMY's strategic evolution of Krazati between 2023 and 2024. It correctly identifies the clinical trials in 2023 (KRYSTAL-17, KRYSTAL-10, KRYSTAL-12) and the shift in 2024 to approved status with FDA and EMA approvals for second-line NSCLC and KRAS-mutated colorectal cancer. It also correctly notes the new combination development with a PD-1 inhibitor for first-line NSCLC, reflecting expanded clinical strategy. The acquisition of Mirati is accurately described, though the purchase price is stated as $4.9 billion versus the ground truth $4.8 billion — a minor discrepancy of $100 million. Additionally, the LLM introduces a specific intangible asset valuation of $640 million for Krazati, which is not present in the original answer. While plausible and contextually consistent (as such valuations are typical post-acquisition), this figure is not confirmed in the ground truth and represents an addition rather than a synthesis from the provided data. This affects quantitative accuracy slightly but does not undermine the overall correctness. All entities (BMY, Krazati, Mirati, PD-1 inhibitor, trial names) and timelines are correct. The reasoning is sound, demonstrating multi-hop synthesis across clinical development, regulatory milestones, and strategic acquisition. The answer is semantically equivalent and highly relevant, with only minor over-precision in financial figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 400,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has the relationship between BKNG and travel service providers evolved between 2022 and 2023, particularly in terms of how BKNG manages financial obligations and incentives related to these providers?",
      "original_answer": "In 2022, BKNG primarily competed with travel service providers, highlighting the intense and evolving nature of the competitive landscape in the online travel market. By 2023, BKNG's relationship with travel service providers shifted to a more dependent model, as evidenced by the increase in the 'Deferred merchant bookings' liability on its balance sheet, which reflects amounts estimated to be payable to travel service providers. Additionally, BKNG introduced more incentive programs, such as referral bonuses, rebates, and loyalty points, which are recognized as a reduction of revenue, indicating a strategic shift toward enhancing partnerships and incentivizing collaboration with travel service providers rather than solely competing with them.",
      "llm_answer": "In the 2022 filing Booking.com’s relationship with hotels, airlines, car‑rental firms and other travel‑service providers was described mainly in strategic terms – the company “partners with travel‑service providers… to increase their distribution, demand and inventory utilization” and the focus was on mutual‑benefit, marketing and technology support. The filing did not spell out how the company accounted for the money it owes those partners.\n\nThe 2023 filing adds concrete accounting language. BKNG’s contracts give providers the right to list inventory while BKNG retains no delivery responsibility, and revenue is presented **on a net basis** after deducting the commission or margin it is entitled to, plus any discounts, coupons and other sales‑incentives (which are estimated from historical experience). Cash received from travelers is recorded as **Deferred merchant bookings**, a liability that represents amounts payable to the travel‑service providers (and the company’s future commission). The company also discloses **incentive programs** – referral bonuses, rebates, credits and loyalty points – and treats the estimated value of those incentives as a reduction of revenue at the time they are granted. Thus, between 2022 and 2023 BKNG moved from a high‑level partnership description to a detailed framework that explicitly manages and reports its financial obligations and incentive costs to travel‑service providers.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution from 2022 to 2023: in 2022, the relationship was described in strategic, partnership-oriented terms without detailed financial accounting; in 2023, BKNG introduced explicit accounting treatments for financial obligations and incentives. (2) There are no numeric values in the original or LLM answer requiring calculation, but the LLM accurately references key financial terms—'Deferred merchant bookings' as a liability, revenue presented on a net basis, and treatment of incentives—all of which match the ground truth. Format and terminology are consistent with SEC filing language. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years and two types of disclosures (strategic vs. accounting) to show a shift in BKNG’s relationship model—from high-level collaboration to a more structured, financially transparent framework involving liabilities and incentive costs. (4) The only minor shortcoming is that the LLM does not explicitly state the *strategic implication* of this shift—that BKNG became more *dependent* on providers, as noted in the original answer. While the financial mechanisms are accurately described, the broader strategic pivot from competition to dependency is implied but not directly articulated. Otherwise, the answer is complete, factually correct, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1561,
        "completion_tokens": 398,
        "total_tokens": 1959
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Broadcom's involvement in the development of Custom Touch Controllers evolved from 2022 to 2024, particularly in terms of their role in the product lifecycle?",
      "original_answer": "In 2022, Broadcom was described as supplying Custom Touch Controllers as part of its semiconductor solutions for the wireless market. By 2024, the company's role had evolved to include producing these controllers as part of its broader custom silicon solutions, reflecting a deeper engagement in their development. This shift indicates a strategic move from being a component supplier to an active producer involved in the design and creation process.",
      "llm_answer": "In the 2022 filing Broadcom mentioned custom touch controllers only as a product line – “Our touch controllers process signals from touch screens in mobile handsets and tablets” – and listed them among its wireless‑connectivity offerings. By the 2024 filing the same controllers are still offered, but they are described as part of an integrated connectivity‑solution portfolio, implying Broadcom now participates not just in supplying the silicon but also in the design, firmware integration and system‑level implementation of the controllers throughout the mobile‑device product lifecycle. This reflects a shift from a pure component supplier in 2022 to a broader development partner by 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies Broadcom's role in 2022 as a supplier of Custom Touch Controllers within its wireless offerings and accurately captures the evolution by 2024 to a more integrated role involving design, firmware, and system-level implementation. The dates (2022 and 2024) are correct, and there are no numerical inaccuracies (no calculations required). The answer demonstrates strong qualitative reasoning by inferring a strategic shift from component supplier to development partner based on changes in product description across filings. The only minor gap is that the LLM uses inference from 'integrated connectivity-solution portfolio' to conclude broader lifecycle involvement, while the original answer explicitly cites 'custom silicon solutions' as evidence—this is a nuance in phrasing but does not undermine correctness. Semantic equivalence is maintained, and the response fully addresses the question about evolution in Broadcom's role across the product lifecycle. Contextual relevance is excellent, with precise focus on the product lifecycle and strategic role change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 327,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Union Pacific's approach to freight cars evolved from 2023 to 2024, particularly in terms of asset acquisition strategy?",
      "original_answer": "In 2023, Union Pacific primarily leased freight cars as part of its operational strategy, reflecting a reliance on leased assets for rail operations. By 2024, the company's strategy shifted toward acquiring freight cars, including lease buyouts of $143 million in 2024 compared to $57 million in 2023, indicating a more aggressive stance on asset ownership to support replacement and growth opportunities.",
      "llm_answer": "In 2023 Union Pacific’s freight‑car strategy was still heavily lease‑focused – the company reported roughly $728 million of capital spending on locomotives and freight cars and only $57 million of lease‑buyouts. By 2024 the company shifted toward ownership, raising total spending on locomotives and freight cars to $788 million and executing $143 million of lease‑buyouts, while its capital plan explicitly calls for acquiring additional freight cars to replace aging equipment and support growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the key figures—$57 million lease-buyouts in 2023 and $143 million in 2024—are correct. The LLM adds additional context not in the original answer: total capital spending of $728M in 2023 and $788M in 2024 on locomotives and freight cars. While these specific totals are not in the ground truth, they do not contradict it and are plausible given the context. (2) The core financial comparisons (lease-buyout increase from $57M to $143M) are accurate and correctly highlight the strategic shift. (3) The reasoning is sound: the LLM correctly infers a strategic pivot from leasing to ownership based on increased buyouts and explicit capital plans for freight car acquisition. It synthesizes the trend across years and connects it to business objectives (replacing aging equipment, supporting growth), which matches the original answer’s intent. (4) Entity accuracy is correct—Union Pacific, 2023 and 2024 timeframes, and financial metrics are properly identified. The only minor limitation is that the added capital expenditure figures, while reasonable, are not verifiable from the ground truth, but they do not detract from correctness. Overall, the answer is factually solid, complete, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 370,
        "total_tokens": 1591
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "What were the financial and operational impacts of Nike's structural changes in APLA between FY2022 and FY2023, particularly regarding the transition of certain businesses to third-party distributors?",
      "original_answer": "In FY2022, Nike directly operated within APLA as part of its geographic operating segments, which included associated costs and foreign currency impacts such as non-recurring impairment charges due to the anticipated release of non-cash cumulative foreign currency translation losses from transitioning certain businesses to third-party distributors. By FY2023, Nike had shifted its relationship with APLA from direct operations to a strategic stake, where the company now oversees results through third-party distributors. This transition is reflected in the 2023 filing noting that APLA includes results for the NIKE and Jordan brands and referencing Note 18 on divestitures related to the transition. Operationally, this change represents a strategic shift to reduce direct operational overhead in APLA, likely aiming to improve financial efficiency and focus on brand management rather than local execution.",
      "llm_answer": "Nike’s APLA (Asia Pacific & Latin America) segment showed only modest changes after the planned shift of several country‑level NIKE Brand businesses to third‑party distributors.  Revenue rose from $5.96 billion in FY 2022 to $6.43 billion in FY 2023 (≈ 8 % growth) and EBIT increased from $1.90 billion to $1.93 billion, while inventories grew to $8.45 billion (up $34 million) and accounts receivable to $700 million (up $36 million) – all indicating a slight expansion of the operating base but no material profit‑or‑loss impact (the only large non‑recurring charge from the transition occurred in FY 2020)【page_90】【page_87】【page_91】【page_92】.  The 10‑K notes confirm that the FY 2022‑23 changes were part of the “transition of NIKE Brand businesses in certain countries within APLA to third‑party distributors” (Note 15/Note 18)【page_89】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The original answer (ground truth) does not mention specific revenue, EBIT, inventory, or accounts receivable figures for APLA in FY2022 or FY2023. Therefore, the LLM's inclusion of precise numbers—$5.96B and $6.43B in revenue, $1.90B to $1.93B in EBIT, $8.45B inventory, $700M accounts receivable—is unsupported by the ground truth and likely hallucinated or misattributed from another context. These numbers are not present in the provided ground truth, making the quantitative claims incorrect. (2) The LLM references a non-recurring charge occurring in FY2020, which contradicts the ground truth stating that non-recurring impairment charges were anticipated in FY2022 due to the transition. This is a critical error in both timing and context. (3) On qualitative aspects, the LLM correctly identifies the structural shift—transitioning certain APLA businesses to third-party distributors—and references the correct notes (Note 15/18) and the strategic nature of the change. It also correctly frames the shift as part of Nike’s operational restructuring in APLA. However, it fails to mention the key point from the ground truth that Nike moved from direct operations to holding a strategic stake, which is a core operational and financial shift. (4) Contextually, the answer is relevant and addresses the question’s focus on financial and operational impacts. However, the hallucinated metrics and incorrect timeline of charges severely undermine factual correctness. While the direction of reasoning (assessing financials and operations post-transition) is sound, the multi-hop synthesis is flawed because it invents data rather than accurately extracting and connecting verified facts. Thus, despite correct citation of note numbers and general alignment with the transition narrative, the answer is significantly compromised by false precision and incorrect figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 535,
        "total_tokens": 1987
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Broadcom's involvement with InP lasers evolved from 2022 to 2024, particularly in terms of their internal fabrication strategy and competitive positioning?",
      "original_answer": "In 2022, Broadcom disclosed using internal fabrication facilities for products based on proprietary processes, including vertical-cavity surface emitting lasers and side emitting lasers using GaAs and InP lasers for fiber optic communications. By 2024, Broadcom continued this strategy but began emphasizing the competitive landscape more explicitly, listing companies like Coherent Corp., Lumentum Holdings Inc., and others as competitors in semiconductor solutions. This indicates a strategic shift toward highlighting InP laser capabilities as part of its competitive differentiation in the market.",
      "llm_answer": "In the 2022 Form 10‑K Broadcom already said it kept the production of its GaAs‑ and InP‑based side‑emitting and VCSEL lasers in‑house, using internal III‑V wafer fabs in the United States and Singapore to protect the IP of those laser‑on‑fiber‑optic products while outsourcing commodity CMOS to external foundries【page_13】.  \n\nBy the 2024 filing the same approach was reaffirmed – Broadcom still manufactures its proprietary InP (and GaAs) lasers in its own facilities to “protect our IP and accelerate time‑to‑market,” with the bulk of internal III‑V wafer work continuing in the U.S. and Singapore【page_15】.  \n\nAcross both years Broadcom positions these InP laser offerings against a wide competitive set that includes integrated device manufacturers, fabless players and large OEMs such as Lumentum, II‑VI, Intel, AMD and others, using its internal fab capability as a key differentiator in the market【page_17】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Broadcom used internal fabrication for InP and GaAs lasers in 2022 and continued this strategy in 2024, emphasizing IP protection and time-to-market. The locations (U.S. and Singapore) and the distinction between internal III-V fabrication and outsourced CMOS are accurately reported. (2) There are no numeric values requiring calculation, but dates (2022 and 2024) are correctly used and matched to the appropriate disclosures. (3) The multi-hop reasoning is sound—LLM correctly synthesizes Broadcom’s consistent internal fabrication strategy across years and connects it to competitive positioning. The mention of competitors like Lumentum, II-VI (now Coherent Corp.), Intel, and AMD aligns with the ground truth’s emphasis on competitive differentiation, though 'II-VI' is used instead of 'Coherent Corp.', which is a minor entity naming issue post-acquisition but still contextually accurate. (4) The LLM adds contextual detail (e.g., 'protect IP and accelerate time-to-market', 'III-V wafer fabs') not in the original answer but supported by typical 10-K language and consistent with the knowledge graph, enhancing clarity without introducing error. The only minor shortcoming is slightly broader competitor listing (includes Intel, AMD) beyond those highlighted in the ground truth (Coherent, Lumentum), but this does not invalidate the core conclusion about competitive differentiation via internal fab. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 436,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the ownership structure of Swoosh, LLC in relation to NIKE's Class A and Class B Common Stock evolved between 2022 and 2023, and what implications does this have for shareholder influence?",
      "original_answer": "In 2022, Swoosh, LLC beneficially owned approximately 77% of NIKE's Class A Common Stock, which would translate to approximately 16% ownership of Class B Common Stock if all shares were converted. In 2023, the ownership structure remained consistent with Swoosh, LLC still beneficially owning approximately 77% of Class A Common Stock, with a commensurate ownership percentage of approximately 16% in Class B Common Stock if all shares were converted. Despite the consistency in ownership percentages, the continued concentration of ownership in Swoosh, LLC implies sustained influence by Travis Knight, who has a significant role in managing the Class A Common Stock owned by Swoosh, LLC, potentially affecting shareholder decisions and market dynamics.",
      "llm_answer": "In the 2022 Form 10‑K the company disclosed that, as of June 30 2022, Swoosh LLC held about 77 percent of Nike’s Class A common stock – a block that would translate to roughly 16 percent of the publicly‑traded Class B shares if it were converted. The 2023 filing repeats the same figures (Swoosh LLC still owns roughly 77 percent of Class A, equating to about 16 percent of Class B on conversion). Because Class A shareholders elect three‑quarters of the Board, Swoosh LLC’s unchanged, dominant Class A stake continues to give the Knight family a disproportionate voting influence, while its economic interest in the tradable Class B stock remains relatively modest.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: 77% ownership of Class A Common Stock and the 16% equivalent in Class B upon conversion are accurately reported for both 2022 and 2023. The dates (as of June 30, 2022) and the repetition in the 2023 filing are consistent with the original answer. (2) The LLM correctly identifies that the ownership structure remained unchanged between the two years, satisfying the evolution aspect of the question. (3) The qualitative reasoning is strong: it correctly infers that the 77% Class A ownership translates into disproportionate voting power due to Class A electing three-quarters of the Board, which implies sustained influence—though it emphasizes the Knight family rather than Travis Knight specifically, this is a minor shift in focus but still factually reasonable given that Travis Knight is a key figure in the family-controlled entity. (4) The answer adds contextual value by explaining the governance implication (Board election) not explicitly detailed in the ground truth, enhancing relevance. The only minor shortcoming is the omission of Travis Knight’s name and the specific mention of his role in managing the shares, which slightly reduces qualitative precision. However, referencing the Knight family’s influence is semantically close and acceptable. Overall, the answer is factually correct, complete, and contextually rich.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 401,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did PMI's strategic positioning of Reduced-Risk Products evolve from 2022 to 2023, particularly in terms of portfolio integration and market availability?",
      "original_answer": "In 2022, PMI classified Reduced-Risk Products (RRPs) as a distinct category, including heated tobacco units, heat-not-burn devices, e-vapor, and oral nicotine products, with separate net revenue reporting. By 2023, RRPs were integrated into a broader category called Smoke-Free Products (SFPs), which now also included wellness and healthcare offerings. Additionally, PMI reported that its smoke-free products were available in 84 markets by the end of 2023, a notable expansion from the unspecified market availability in 2022. This evolution reflects a strategic shift toward consolidating RRPs under a unified smoke-free vision and expanding their global footprint.",
      "llm_answer": "In 2022 PMI framed reduced‑risk products (RRPs) as a fast‑growing “smoke‑free” pillar and announced the acquisition of Swedish Match AB, noting that its oral‑nicotine franchise (ZYN) was **complementary to PMI’s heat‑not‑burn IQOS platform** and would help accelerate the company’s joint smoke‑free ambitions【page_29】.  \n\nBy 2023 the company had moved from treating the Swedish Match business as a separate segment to **integrating it into the four geographic operating segments**, presenting all RRPs—including IQOS, ZYN, e‑vapor and oral‑nicotine—as a unified smoke‑free portfolio that was **available in 84 markets worldwide**【page_28】. This reflects a shift from a stand‑alone acquisition strategy to a fully integrated, globally‑available reduced‑risk product offering.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the key number '84 markets' in 2023 is correct and matches the original answer; no other numeric values (e.g., revenue figures) are present in either answer, so no calculation errors exist. (2) The LLM correctly identifies the strategic evolution: in 2022, RRPs were highlighted as a distinct growth pillar, and the acquisition of Swedish Match AB (with ZYN) was framed as complementary to IQOS. By 2023, integration into geographic segments reflects portfolio consolidation, which aligns with the ground truth's description of RRPs being folded into a broader Smoke-Free Products category. (3) The reasoning is sound and captures the multi-hop synthesis: it connects the 2022 acquisition strategy with the 2023 operational integration and global expansion, showing a logical progression. (4) The only minor gap is that the LLM does not explicitly mention the rebranding from 'Reduced-Risk Products' to 'Smoke-Free Products' as a formal category change, nor does it note that SFPs now include wellness and healthcare offerings beyond nicotine products. However, the core strategic shift—integration and global availability—is accurately conveyed. Wording differs slightly but maintains semantic equivalence. Thus, the answer is factually correct, contextually relevant, and well-reasoned, meriting a high score with only a small deduction for incomplete terminological precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 405,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Caterpillar's strategic role in the reciprocating engines business evolved from 2022 to 2024, and what impact has this had on its revenue composition and gross margin potential?",
      "original_answer": "In 2022, Caterpillar primarily sold reciprocating engines through its global dealer network and through subsidiary Perkins Engines Company Limited, which operated 90 distributors across 171 countries. By 2024, Caterpillar expanded its involvement by including the remanufacturing of Caterpillar reciprocating engines and components, as well as offering remanufacturing services for other companies. This evolution from a seller to a full lifecycle service provider likely improved gross margin potential, as remanufacturing typically involves lower material costs compared to new engine production and leverages existing asset value. The shift also diversified revenue composition by incorporating service-based income streams alongside traditional product sales.",
      "llm_answer": "- **2022:** Caterpillar’s reciprocating‑engine business was described mainly as a product that “is sold principally through the dealer network and to other manufacturers” 【page_9】, indicating a largely distribution‑driven, volume‑oriented role within the broader portfolio.  \n\n- **2024:** The company now positions reciprocating engines as a core growth pillar of the **Energy & Transportation** segment, grouping them with turbines and other power‑generation products and highlighting “sales increased in large reciprocating engines, primarily data‑center applications” 【page_37】.  This segment’s profit margin rose to **19.9 % of total sales** (up from 17.6 % a year earlier) 【page_37】, showing that the higher‑value engine mix is improving the gross‑margin profile.  \n\n**Result:** From a dealer‑focused, volume business in 2022, the reciprocating‑engine line has become a strategic, higher‑margin growth engine within Energy & Transportation by 2024, increasing its share of revenue and lifting the segment’s overall gross‑margin potential.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies and omits key aspects of Caterpillar's strategic evolution. While it correctly identifies a shift in strategic role from 2022 to 2024, it misrepresents the nature of that evolution. The ground truth emphasizes Caterpillar’s expansion into remanufacturing engines and components—both for its own products and for other companies—as a key development by 2024. This critical point is entirely missing in the LLM answer. Instead, the LLM focuses on reciprocating engines becoming a 'core growth pillar' tied to data centers and higher-margin sales within the Energy & Transportation segment. While this may reflect a real trend, it is not supported by the ground truth, which does not mention data centers or segment-level margin increases due to engine mix. (2) Quantitatively, the LLM introduces a specific margin figure—'19.9 % of total sales' (up from 17.6%)'—that is not present in the ground truth and cannot be verified. The ground truth does not provide any numerical gross margin data for 2022 or 2024, nor does it attribute margin changes to reciprocating engines. This is a significant fabrication or misattribution, severely impacting quantitative accuracy. (3) The reasoning is partially sound in identifying a strategic shift from distribution to a more integrated role, but it fails the multi-hop requirement by not connecting Caterpillar’s subsidiary (Perkins Engines) and its global network in 2022 to the 2024 expansion into remanufacturing services. The LLM instead invents a narrative around segment profitability and data-center demand, which is not in the original answer. (4) Contextual relevance is high because the answer addresses the evolution of Caterpillar’s role, revenue composition, and margin potential. However, the lack of key facts (remanufacturing), addition of unsupported details (data centers, exact margins), and incorrect reasoning basis result in a partially correct but significantly flawed response. The core strategic shift described in the ground truth—toward lifecycle services and remanufacturing—is missed, which is central to the revenue and margin implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1461,
        "completion_tokens": 583,
        "total_tokens": 2044
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How did BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of the mechanisms and transparency commitments outlined for informing stakeholders of changes?",
      "original_answer": "BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct remained consistent between 2022 and 2023, with the company reaffirming its commitment to post any amendments or waivers on its website in both years. There was no change in the specific mechanism or transparency commitment described across the two years, indicating a stable governance communication strategy.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K filings state that BNY Mellon posts its Directors’ Code of Conduct on its public website and that any amendments or waivers to the code will be disclosed on that same site. The 2023 filing merely restates this commitment (with slightly revised URL wording), showing that the company’s mechanism – website posting – and its pledge of transparent, on‑line notification to stakeholders remained unchanged.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct remained unchanged between 2022 and 2023, with both years affirming the same mechanism—posting amendments or waivers on the company's public website. (2) There are no numeric values requiring calculation, but the temporal scope (2022 and 2023) is correctly referenced. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of Form 10-K filings to conclude that the disclosure mechanism and transparency commitment were consistent, with only minor wording updates (e.g., URL formatting). (4) The answer addresses all parts of the question—mechanisms, transparency commitments, and evolution (or lack thereof)—and maintains high contextual relevance. Minor phrasing differences (e.g., 'restates this commitment' vs. 'remained consistent') do not affect factual accuracy. All entities—BNY Mellon, Directors’ Code of Conduct, 2022 and 2023 filings—are correctly identified. No factual, quantitative, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 328,
        "total_tokens": 1557
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Nike's strategic approach to the APLA market evolved between FY22 and FY23, particularly in terms of operational structure and market participation?",
      "original_answer": "In FY22, Nike operated directly in APLA, maintaining a significant presence through its NIKE Direct operations and wholesale distribution, with APLA contributing to the 14% growth in the NIKE Direct business. By FY23, Nike began transitioning certain businesses within APLA to third-party distributors, signaling a strategic shift away from direct market participation in some parts of the region. This change indicates a move toward a more distributed, partner-driven model in APLA, altering the way Nike engages with that market.",
      "llm_answer": "Nike’s FY 2022 filing notes that the company began moving three APLA countries (Argentina, Uruguay and Chile) out of its integrated wholesale‑and‑direct‑to‑consumer model and into a third‑party distributor arrangement, shifting the segment from a fully owned operating structure to a distributor‑led one to cut selling‑and‑administrative costs and reduce FX exposure【page_32】. By FY 2023 the APLA geography was still reported as a separate operating segment, but the divestiture‑to‑distributor transition was now reflected in the segment’s results (see the reference to “transition of … businesses in certain countries within APLA to third‑party distributors”【page_89】) and its revenue had risen to $6.4 billion from $5.96 billion the year before【page_90】, showing continued market participation under the new distributor‑focused structure.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Nike's strategic shift in APLA between FY22 and FY23: transitioning certain countries (specifically naming Argentina, Uruguay, and Chile) from a direct-operated model to third-party distributors, which matches the core claim in the original answer about moving away from direct market participation. (2) Quantitatively, the LLM provides correct revenue figures: $5.96 billion in FY22 and $6.4 billion in FY23 (cited from pages 90 and 89), which are accurate and support the point of continued market participation despite structural changes. The dollar amounts and fiscal years are correct, and the revenue increase is accurately portrayed. (3) The reasoning is sound and reflects multi-hop synthesis: it connects the operational change (shift to distributors) with financial outcomes (revenue growth) and strategic rationale (cost reduction, FX exposure), even adding detail not in the original answer (specific countries and motivations), which enhances completeness without introducing error. (4) The only minor limitation is that the original answer emphasizes APLA’s role in the 14% growth of NIKE Direct in FY22, which the LLM omits. While the LLM focuses on the transition already beginning in FY22, it does not mention this positive performance context, slightly reducing completeness. However, the core evolution in operational structure and market participation is accurately and richly described. Thus, the answer earns a 9/10 for correctness—excellent but not fully comprehensive of all nuances in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 443,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the impact of Favorable Price Realization on Caterpillar's sales and profitability evolved from 2022 to 2024?",
      "original_answer": "In 2022, favorable price realization contributed to a $9.223 billion increase in total sales and revenues, driven by higher end-user demand and changes in dealer inventories. By 2024, favorable price realization continued to play a key role, partially offsetting a $2.251 billion decrease in sales volume and contributing to an increase in profit from $10.335 billion in 2023 to $10.792 billion in 2024. This indicates that while Caterpillar faced declining sales volume in 2024, the company leveraged pricing strategies more effectively to maintain profitability.",
      "llm_answer": "In the 2022 filing Caterpillar noted that **favorable price realization was a primary driver of higher sales and operating profit**, helping lift both revenue and margins for the year. By contrast, the 2024 filing shows that **sales fell because of lower volume, and favorable price realization was only able to partially offset that decline**, still providing a boost to profitability but no longer generating overall sales growth. Thus, the impact of favorable price realization shifted from being a growth catalyst in 2022 to a mitigating factor that cushioned a volume‑driven sales drop in 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the qualitative evolution of favorable price realization's impact on Caterpillar from 2022 to 2024. It accurately describes the shift from being a primary growth driver in 2022 to a mitigating factor against volume declines in 2024, which aligns with the ground truth. However, it omits all specific quantitative figures present in the original answer, such as the $9.223 billion sales increase in 2022 and the $2.251 billion volume decrease in 2024, as well as the profit increase from $10.335 billion to $10.792 billion. These omissions significantly affect quantitative accuracy. (2) No numeric values are provided in the LLM answer, so there are no calculations to verify, but the absence of key financial data from the ground truth constitutes a major shortcoming in quantitative precision. (3) The multi-hop reasoning is sound—LLM synthesizes information across years (2022 vs 2024) and correctly infers the changing role of price realization in sales and profitability. It identifies the causal relationship between volume decline and price realization’s offsetting role, showing good qualitative understanding. (4) While the LLM answer is contextually relevant and conveys the correct high-level narrative, the lack of specific financial figures reduces its factual completeness. The correctness score is 7 because the core reasoning and directional insights are accurate, but the missing numbers prevent a higher score. Quantitative accuracy is penalized heavily (5/10) due to complete omission of dollar amounts. Qualitative accuracy is strong (8/10) for correct logic and synthesis. Contextual relevance is perfect (10/10) as the response directly addresses the question’s focus on evolution over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 479,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has General Motors' approach to EV manufacturing capacity evolved between 2023 and 2024, particularly in terms of strategic focus and supply chain development?",
      "original_answer": "In 2023, General Motors emphasized significant investments in EV manufacturing capacity based on expectations for future EV demand, acknowledging the risks and uncertainties associated with such investments, including high fixed costs and limitations on closing facilities. By 2024, GM's strategy had evolved to include a stronger emphasis on developing a resilient, scalable, and sustainable North American-focused EV supply chain. This included advancing strategic sourcing initiatives to secure supply through investments in raw materials suppliers and the execution of multi-year supply agreements. The shift indicates a more structured and regionally focused approach to EV manufacturing, aiming to mitigate supply chain risks and ensure long-term scalability.",
      "llm_answer": "In the 2023 filing GM stressed that its EV rollout was anchored in “significant investments in EV manufacturing capacity” and in building a “more resilient, scalable and sustainable North‑American‑focused EV supply chain,” which it said would be supported by strategic sourcing, raw‑material‑supplier investments and long‑term off‑take agreements (2023 p. 16). By the 2024 filing the narrative had shifted to a tighter focus on “scaling our EV manufacturing capabilities, reducing battery‑cell and pack costs, and efficiently sourcing sufficient materials,” while still relying on multi‑year supply contracts and strategic partnerships, indicating a move from simply adding capacity to integrating scale, cost‑competitiveness and a more mature supply‑chain strategy (2024 p. 15).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the original (ground truth) answer. (1) All factual elements are correct: GM's 2023 focus on significant EV manufacturing investments and supply chain resilience, and the 2024 evolution toward scaling capacity, cost reduction, and mature supply chain strategy are accurately represented. The LLM correctly identifies strategic sourcing, raw material supplier investments, and multi-year agreements as key components in both years. (2) There are no numeric values (e.g., dollar amounts, percentages, facility counts) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10 by default. (3) The multi-hop reasoning is sound: the LLM synthesizes information across the 2023 and 2024 filings to show a strategic evolution from capacity building to integrated scalability and cost efficiency. The use of direct quotes (e.g., 'resilient, scalable and sustainable North-American-focused EV supply chain') and correct page citations (2023 p.16, 2024 p.15) supports authenticity. (4) The only minor shortcoming is that the LLM slightly underemphasizes the 'regional focus' (North America) in 2024 compared to the original, and frames the shift more around cost than sustainability, but the core strategic evolution is correctly captured. Wording differs slightly but maintains semantic equivalence. Contextual relevance is perfect—directly addresses strategic focus and supply chain development across both years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 410,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved from 2022 to 2024, based on remaining performance obligations disclosed in the 10-K filings?",
      "original_answer": "In 2022, Pfizer's 10-K filing did not disclose specific remaining performance obligations related to Paxlovid. However, by 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a significant ongoing financial commitment tied to future delivery of the product. This shows a clear evolution from an undefined obligation in 2022 to a quantified $1 billion commitment in 2024.",
      "llm_answer": "Pfizer reported that the amount of contracted revenue still to be recognized for Paxlovid – its “remaining performance obligations” – was roughly **$2 billion (‑$2.5 billion)** at the end of 2022. By the end of 2024 that balance had fallen to **about $1 billion**. In other words, Pfizer’s outstanding financial commitment for Paxlovid shrank by roughly half between 2022 and 2024 as the government‑sponsored contracts were largely fulfilled and inventory was returned.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. According to the ground truth, Pfizer did not disclose any specific remaining performance obligations (RPOs) for Paxlovid in its 2022 10-K filing, meaning the claim that RPOs were '$2 billion (-$2.5 billion)' at the end of 2022 is incorrect. The ground truth states there was no quantified obligation in 2022, so assigning any dollar figure is factually wrong. The LLM correctly reports the 2024 figure of approximately $1 billion in remaining performance obligations as of December 31, 2024, which matches the original answer. However, the reasoning that the obligation 'shrank by roughly half' implies a reduction from a previously known value, which contradicts the absence of disclosed obligations in 2022. This misrepresents the evolution: it was not a reduction from $2B to $1B, but rather a shift from no disclosed amount to a $1B commitment. The entity (Pfizer, Paxlovid) and metric (remaining performance obligations) are correctly identified, and the answer addresses the time frame (2022 to 2024), showing some contextual understanding. However, the core multi-hop reasoning fails because it fabricates a 2022 figure instead of recognizing the absence of disclosure. The conclusion about shrinking commitments due to fulfilled contracts and inventory returns introduces speculative causal reasoning not supported in the ground truth. Overall, while the 2024 number is correct and the direction of change (toward greater clarity) is loosely captured, the answer is fundamentally flawed in its numerical claims and logical foundation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 446,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Caterpillar's approach to monitoring supplier financial viability evolved between 2022 and 2023, particularly in terms of risk mitigation strategies and contractual agreements?",
      "original_answer": "In 2022, Caterpillar indicated that it uses 'a variety of agreements with suppliers to protect our intellectual property and processes to monitor and mitigate risks of the supply base causing a business disruption,' including monitoring supplier financial viability. By 2023, Caterpillar maintained the same monitoring approach but placed a more explicit emphasis on 'supplier financial viability' as a key risk factor, listing it as the first risk under its supply chain disclosures. Additionally, in 2023, Caterpillar reinforced its global strategic sourcing models to build long-term supplier relationships and leverage enterprise spend, suggesting a potentially more structured or prioritized focus on supplier financial health compared to 2022.",
      "llm_answer": "In the 2022 filing Caterpillar said that it “uses a variety of agreements with suppliers to protect our intellectual property and processes to monitor and mitigate risks of the supply base… The risks monitored include supplier financial viability, the ability to increase or decrease production levels, business continuity, quality and delivery.” The 2023 filing repeats the same statement, confirming that the company continues to rely on contractual provisions that give it access to suppliers’ (and dealers’) financial books and the right to terminate the relationship (typically with 90‑day notice). Thus, between 2022 and 2023 the monitoring approach has remained fundamentally the same, but the 2023 disclosure emphasizes the termination‑at‑will clause as an additional risk‑mitigation tool built into the agreements.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains key inaccuracies in qualitative synthesis compared to the ground truth. (1) Correct elements: The LLM accurately quotes Caterpillar's 2022 language about using agreements to protect IP and monitor risks including supplier financial viability. It correctly states that the same core statement appears in the 2023 filing, indicating continuity in monitoring approach. There are no numeric values, so quantitative accuracy is not applicable—score reflects absence of numerical errors. (2) However, the LLM introduces a claim not present in the original answer: that the 2023 filing emphasizes a 'termination-at-will clause' or '90-day notice' as a new or highlighted risk-mitigation tool. This detail is absent from the ground truth and cannot be verified from the provided information, representing a factual overreach. (3) Multi-hop reasoning is partially sound—comparing disclosures across years—but fails to capture the actual evolution emphasized in the ground truth: in 2023, Caterpillar elevated 'supplier financial viability' to the first-listed risk and reinforced strategic sourcing models to build long-term relationships and leverage enterprise spend, indicating a structural shift in prioritization. The LLM misses this nuance entirely and instead invents a contractual detail (termination clause) not referenced in the original answer. (4) Contextual relevance is high because the response addresses supplier monitoring and contractual agreements over the two years, but the incorrect emphasis on termination rights reduces factual reliability. Thus, while the core continuity is correctly identified, the characterization of the evolution is inaccurate, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 475,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Visa's approach to Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of its strategic positioning and integration within its value-added services?",
      "original_answer": "In 2022, Visa positioned Risk and Identity Solutions as part of a broader set of value-added services aimed at supporting clients, but without detailed elaboration on specific capabilities or strategic direction. By 2024, Risk and Identity Solutions were embedded within a more structured value-added services framework, with a clear three-pillar strategy: (1) services for Visa transactions, (2) network-agnostic services for non-Visa transactions, and (3) services beyond payments. This evolution reflects a more strategic and comprehensive integration of Risk and Identity Solutions into Visa's broader service portfolio, with an emphasis on scalability and business outcomes.",
      "llm_answer": "In the 2022 filing Visa simply listed **Risk and Identity Solutions** as one of its “value‑added services” without elaborating on its role or product set (see V 2022 p. 5). By the 2024 filing the company had repositioned this capability as a core, AI‑driven component of its **Visa Protect** suite—offering tools such as Visa Deep Authorization, Visa Protect for A2A Payments and Visa Risk Manager/Advanced Authorization—and explicitly integrated it into the broader five‑category value‑added‑services strategy (see V 2024 p. 12 & p. 11). This reflects a shift from a peripheral service offering to a strategically central, technology‑focused solution that underpins fraud prevention across card‑present, CNP and non‑card payment flows.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates (2022 and 2024), correct entity (Visa), and correctly identifies the evolution of Risk and Identity Solutions from a listed service to a more integrated offering. It accurately reflects that in 2022, Visa did not elaborate on the service (per ground truth), and by 2024, it had a more defined strategic role. However, there are discrepancies in the strategic framework description: the ground truth specifies a three-pillar strategy (Visa transactions, network-agnostic services, services beyond payments), while the LLM answer refers to a 'five-category' value-added services strategy and embeds Risk and Identity within Visa Protect with specific tools (e.g., Deep Authorization, Risk Manager). These product names and the five-category structure are not present in the ground truth and may reflect over-specificity or misattribution not supported by the original knowledge graph. Additionally, the mention of AI-driven components and coverage of non-card payment flows, while plausible, are not confirmed in the ground truth and introduce details beyond the provided information. Quantitative accuracy is perfect—no numbers, dates, or financial figures are incorrect. The reasoning is mostly sound and captures the directional evolution (from peripheral to strategic), but the synthesis includes unverified details not present in the original answer, slightly undermining qualitative accuracy. Contextual relevance is high, as the response directly addresses the evolution in strategic positioning and integration. Thus, the answer is largely correct but includes some unsupported specifics, warranting a 7 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 462,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has the company's exposure to shelf space limitations as a risk factor evolved between 2022 and 2023, particularly in relation to changes in retail customer policies and the expansion of alternative retail channels?",
      "original_answer": "In 2022, the company noted that it had been and could continue to be negatively affected by changes in retail customer policies such as limitations on access to shelf space and delisting of products. By 2023, the company was actively impacted by these limitations and described them as part of a broader set of evolving retail dynamics, including the growth of eCommerce and alternative retail channels such as subscription services and direct-to-consumer businesses. This evolution indicates a shift from potential risk to an actively experienced challenge, with the company planning to invest more in digital and analytics capabilities to adapt.",
      "llm_answer": "In the 2022 filing the company listed “limitations on access to shelf space” as one of several risks tied to the policies of its key retail customers (e.g., inventory de‑stocking, fulfillment requirements, delisting, sustainability standards) 【page_11】. By the 2023 filing the same shelf‑space risk was still highlighted, but the discussion was expanded to note that it is now being compounded by the rapid growth of e‑commerce and other alternative channels (subscription services, direct‑to‑consumer), which increase pricing pressure and strain relationships with those retailers 【page_31】. Thus, the company’s exposure to shelf‑space limitations has intensified, moving from a standalone retailer‑policy concern in 2022 to a broader, amplified risk in 2023 because of changing retailer policies and the rise of alternative retail channels.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, shelf space limitations were presented as a potential risk tied to retail customer policies, and by 2023, this risk had evolved into a more complex challenge compounded by the growth of e-commerce and alternative retail channels like subscription services and direct-to-consumer models. The LLM correctly identifies the shift from a standalone risk to an intensified, broader issue. (2) There are no numeric values, dates, or calculations in the question or answers that conflict; all references to years (2022, 2023) are accurate. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly identifying both the continuity of shelf space concerns and the qualitative evolution in how the company characterizes them. It accurately captures the compounding effect of new retail dynamics. (4) The only minor shortcoming is that the LLM does not explicitly mention the company’s planned response—investing in digital and analytics capabilities—which is included in the original answer and adds depth to the adaptation strategy. However, this omission does not undermine the core accuracy of the risk evolution analysis. Wording differs slightly but maintains semantic equivalence. Overall, the answer is factually correct, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 395,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Oracle's approach to hybrid deployments evolved between fiscal years 2023 and 2024, particularly in terms of product offerings and strategic emphasis?",
      "original_answer": "In fiscal 2023, Oracle emphasized hybrid deployments as part of its broader deployment models, including on-premise, cloud-based, and hybrid options such as Oracle Exadata Cloud@Customer and Dedicated Region offerings. The company highlighted its commitment to providing customers with choice and flexibility in how they deploy Oracle technologies. By fiscal 2024, Oracle continued to support hybrid deployments but introduced more specific product integrations and services tailored for hybrid environments, indicating a strategic shift toward deeper integration and support for customer-managed cloud and on-premise IT environments. This evolution reflects Oracle's ongoing investment in making hybrid deployments more interoperable and extensible with other IT and cloud environments.",
      "llm_answer": "In FY 2023 Oracle positioned hybrid‑deployment as a cornerstone of its growth strategy, rolling out explicit hybrid products such as **Oracle Exadata Cloud@Customer** and **Dedicated Region** that let customers run Oracle Cloud services inside their own data‑centers and stressing “choice and flexibility” to accelerate migration from on‑premise to the cloud. By FY 2024 the company treats hybrid as a routine element of its broader **Oracle Cloud Services** (SaaS + OCI) portfolio—stating that cloud, license and on‑premise offerings are all delivered through on‑premise, cloud‑based or hybrid models and that it is in the “early stages of a material migration” of its installed base—thereby deepening the strategic emphasis on interoperable, multicloud flexibility rather than adding new named hybrid products.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Oracle's emphasis on hybrid deployments in FY2023 with Exadata Cloud@Customer and Dedicated Region is accurately described, as is the shift in FY2024 toward deeper integration within its broader cloud portfolio. The strategic evolution from promoting hybrid as a distinct offering to embedding it as a standard deployment model across Oracle Cloud Services is correctly captured. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not applicable in that sense, but all temporal references (FY2023, FY2024) are correct—hence scored as 10. (3) Multi-hop reasoning is sound: the model synthesizes Oracle’s changing strategic emphasis across two fiscal years, correctly identifying both continuity (ongoing support for hybrid) and evolution (shift from standalone hybrid products to integrated deployment models). The mention of 'early stages of a material migration' adds contextual insight consistent with Oracle’s reported strategy. (4) Semantic equivalence is strong—while the LLM uses slightly different phrasing (e.g., 'routine element' vs 'continued to support'), the core meaning matches the original answer. The only minor gap is that the LLM does not explicitly mention 'customer-managed cloud and on-premise IT environments' or 'interoperable and extensible' as emphasized in the original, but the concept is implied through 'interoperable, multicloud flexibility'. Thus, qualitative accuracy is 9. Contextual relevance is perfect—directly addresses product offerings and strategic emphasis across both years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 463,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved between 2022 and 2024, based on remaining performance obligations and contracted revenue expectations?",
      "original_answer": "In 2022, Pfizer indicated that Paxlovid had the potential to provide ongoing revenue streams, though it acknowledged that post-pandemic revenues might not match the levels seen during the pandemic. By 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, with contracted revenue expected to be recognized from 2025 through 2028. This reflects a continued but reduced financial commitment compared to the pandemic period, as the company anticipates delivery and revenue recognition over a multi-year horizon rather than immediate high-volume sales.",
      "llm_answer": "Pfizer’s “remaining performance‑obligation” balance for Paxlovid fell sharply. At the end of 2022 the company reported roughly **$2½ billion** of contracted revenue still to be recognized from long‑term Paxlovid supply agreements (2022 10‑K, pages 21‑25) . By December 31 2024 that amount had been reduced to **about $1 billion** (2024 10‑K, page 109). Thus, Pfizer’s financial commitment to Paxlovid – measured by the value of remaining contracts – has been cut by roughly half between 2022 and 2024 as earlier government contracts were fulfilled and the product transitioned to commercial sales.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in its reasoning and captures the core trend: Pfizer's financial commitment to Paxlovid, as measured by remaining performance obligations, decreased from approximately $2.5 billion in 2022 to $1 billion by the end of 2024, reflecting a reduction of about half. This aligns with the transition from pandemic-era government contracts to commercial sales. However, the original answer (ground truth) does not specify the $2.5 billion figure for 2022 — it only states that Pfizer anticipated ongoing revenue with potentially lower post-pandemic levels. The $2.5 billion figure may be factually accurate based on the 10-K, but it is not present in the ground truth used for evaluation, making this an over-precision not supported by the provided reference. The $1 billion figure for 2024 matches exactly and is correctly cited. The calculation of a 'roughly half' reduction is mathematically sound. The LLM adds specific page references and a sharper quantitative claim than the original answer, which may reflect accurate sourcing from the 10-K but exceeds the information in the ground truth. Entity accuracy (Pfizer, Paxlovid, years 2022–2024, performance obligations) is correct. The reasoning is sound and synthesizes multi-hop information across years. While the LLM provides a more detailed quantitative narrative, the divergence in the 2022 figure — though plausible — introduces a specific number not confirmed by the ground truth, warranting a deduction in quantitative accuracy. Overall, the answer is factually plausible, contextually relevant, and semantically aligned in direction and conclusion, but not perfectly matched in all numerical claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 458,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Caterpillar's relationship with its independent dealers evolved between 2022 and 2023, particularly in terms of contractual obligations and strategic emphasis?",
      "original_answer": "In 2022, Caterpillar described its relationship with independent dealers in general terms as part of its global sales and marketing strategy. By 2023, the company formalized and detailed these relationships through standardized sales and service agreements, granting dealers the right to purchase, sell, and service Caterpillar products within specified territories. In exchange, dealers were obligated to develop and promote Caterpillar products, maintain adequate sales and support personnel, and keep detailed financial records accessible to Caterpillar. This represents a shift from a general partnership model to a more structured contractual framework, indicating a strategic emphasis on formalizing dealer relationships to enhance control and accountability.",
      "llm_answer": "In the 2022 filing Caterpillar described its dealer network only in broad terms – a worldwide “global network of independent dealers” that it works with alongside direct sales. By the 2023 filing the company had formalized that relationship with standard sales‑and‑service agreements that grant dealers the right to purchase, sell and service products, obligate them to staff, promote, keep detailed books and allow either side to terminate the agreement at‑will with 90 days’ notice, while also providing non‑exclusive trademark licenses and IP support. The 2023 discussion therefore places greater strategic emphasis on dealers as the primary, structured channel for sales and service, integrating financing and marketing programs into a more contractual, mutually‑binding partnership.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution from a general description of dealers in 2022 to a formalized contractual structure in 2023, including the introduction of standardized sales and service agreements. Key obligations—such as dealers' responsibilities to promote products, maintain staff, keep detailed records, and the mutual right to terminate with 90 days' notice—are accurately reported. The mention of non-exclusive trademark licenses and IP support adds detail not in the original but does not contradict it and is consistent with typical dealer agreements. (2) There are no numerical values to verify, so quantitative accuracy is scored as 10. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes across two years and infers a strategic shift toward a more structured, contractual dealer network. The only minor omission is that the original emphasizes Caterpillar's increased control and accountability, which the LLM implies but doesn't explicitly state. (4) The answer is fully relevant, directly addressing both contractual obligations and strategic emphasis as asked. Overall, the response demonstrates strong factual correctness, completeness, and contextual understanding, warranting a 9/10 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 374,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How did the company's financial allocation or operational focus related to Africa/Eurasia evolve from 2022 to 2023, based on capital expenditures and restructuring charges?",
      "original_answer": "In 2022, the company reported capital expenditures for Africa/Eurasia at $33 million, showing a steady increase from $13 million in 2021 and $8 million in 2020. However, in 2023, the company indicated that approximately 10% of the cumulative pretax charges from the 2022 Global Productivity Initiative would relate to initiatives undertaken in Africa/Eurasia, signaling a shift in focus toward restructuring and cost optimization in the region rather than continued capital investment. This reflects a strategic evolution from growth-oriented capital allocation to operational restructuring within Africa/Eurasia.",
      "llm_answer": "In the 2022 Global Productivity Initiative the company directed 11 % of its restructuring‑related charges to the Africa/Eurasia segment, but that share fell to only 5 % in 2023, showing a clear de‑emphasis of restructuring activity in the region.  Capital‑expenditure data also show Africa/Eurasia receiving modest investment – $33 million in the most recent disclosed year (2021) – and no increase is evident in the 2023 filing, reinforcing that the firm’s financial allocation and operational focus on Africa/Eurasia has been reduced from 2022 to 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. First, it claims that 11% of restructuring charges were directed to Africa/Eurasia in 2022 and fell to 5% in 2023, which directly contradicts the ground truth stating that in 2023, approximately 10% of the cumulative pretax charges from the 2022 Global Productivity Initiative related to Africa/Eurasia. There is no mention of a 2023 restructuring percentage in the original answer, nor a decrease from 11% to 5%. Additionally, the LLM incorrectly states that the $33 million capital expenditure was for 2021, while the ground truth clearly states that $33 million was the 2022 figure, with $8M in 2020 and $13M in 2021. (2) The capital expenditure timeline is misrepresented: the LLM says $33M was spent in 2021 and no increase is evident in 2023, but the original answer shows $33M in 2022 as the latest data, with no 2023 capex disclosed. The LLM incorrectly infers reduced focus due to lack of increase, while the ground truth indicates a strategic shift from capex growth to restructuring. (3) The multi-hop reasoning is flawed: instead of recognizing that the company shifted from capital investment (rising capex through 2022) to restructuring focus in 2023 (via the productivity initiative), the LLM incorrectly infers declining regional importance based on fabricated percentages and misattributed data. (4) The contextual relevance is moderate because the answer addresses financial allocation and operational focus, but the qualitative and quantitative inaccuracies severely undermine correctness. The conclusion is opposite to the ground truth: the original describes a strategic pivot to restructuring, while the LLM claims a de-emphasis and reduction in focus. Thus, the correctness and quantitative accuracy scores are low; qualitative accuracy is slightly higher due to attempting the right type of analysis, and contextual relevance is mid-range due to topical alignment despite factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 534,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Qualcomm's strategic focus on 5G technologies evolved from 2022 to 2024, particularly in terms of investment emphasis and commercialization outcomes?",
      "original_answer": "In 2022, Qualcomm was heavily investing in 5G technologies as part of its broader strategy to expand beyond mobile handsets into areas like automotive and IoT, with an emphasis on developing leading and cost-effective 5G-based technologies and products. The company acknowledged significant risks around the success of these investments due to potential regulatory hurdles, competition, and the long design-in cycles typical of new industries like automotive. By 2024, Qualcomm had transitioned from a primarily investment phase to a more mature stage where it had developed a leading patent portfolio in 5G NR and was actively licensing these technologies. The company reported generating the majority of its QTL revenues from OFDMA-based products, including multimode 3G/4G/5G devices such as smartphones, indicating a successful commercialization phase. This shift shows that Qualcomm moved from strategic investment and development in 5G across multiple industries to a position of market leadership and monetization in 5G technologies.",
      "llm_answer": "In the 2022 filing Qualcomm still framed 5G primarily as a **research‑and‑licensing priority**, noting that it “continues to invest significant resources toward advancements primarily in support 5G‑based technologies” while also warning that future growth depends on successfully developing and commercializing those patents and products【page_22】. By the 2024 filing the company’s 5G focus had shifted to **product‑level commercialization and ecosystem building** – it describes extensive investments in 5G‑specific RF front‑end modules, Snapdragon 5G modem‑RF platforms, and a “Snapdragon 5G modem‑RF” solution that integrates AI to boost data speeds and battery life【page_11】, and it highlights strategic‑venture investments in early‑stage 5G companies through Qualcomm Ventures【page_13】, while confirming that 5G network deployments and multimode device sales have become a mature, revenue‑generating business【page_14】. Thus, from 2022 to 2024 Qualcomm moved from a broad R&D/licensing emphasis on 5G to concrete product roll‑outs and venture‑backed commercialization of 5G technologies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures Qualcomm's strategic evolution from 2022 to 2024: in 2022, the focus was on R&D and licensing with significant investment and risk acknowledgment, and by 2024, the emphasis shifted to commercialization, product integration, and ecosystem development. The mention of investments in RF front-end modules, Snapdragon 5G modem-RF platforms, and AI integration reflects accurate details about product-level outcomes. The reference to Qualcomm Ventures' strategic investments adds contextual depth consistent with commercialization efforts. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised—no errors in dates or financial figures. (3) The multi-hop reasoning is sound: the model synthesizes information across years (2022 to 2024), identifies shifts in strategy (from R&D to commercialization), and connects investment emphasis with tangible outcomes like product rollouts and licensing maturity. The only minor gap is that the LLM answer does not explicitly mention the 'automotive and IoT' expansion focus from the original, nor the specific detail about QTL revenues being primarily from OFDMA-based products, which slightly reduces completeness. However, the reference to 'ecosystem building' and venture investments implies this broader industry push. (4) Despite these small omissions, the core facts, timeline, and strategic trajectory are correct, and the semantic meaning matches the ground truth. Wording differs but conveys equivalent insight. Hence, a high score of 9 is justified for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1535,
        "completion_tokens": 485,
        "total_tokens": 2020
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Pfizer's financial and strategic positioning of Paxlovid evolved between 2022 and 2024, particularly in terms of revenue contribution and contractual commitments?",
      "original_answer": "In 2022, Paxlovid generated $76 million in revenue, marking its initial contribution as a newly launched product targeting high-risk COVID-19 patients. By 2024, while direct revenue figures for Paxlovid are not explicitly stated, Pfizer disclosed approximately $1 billion in remaining performance obligations tied to future Paxlovid deliveries under existing contracts. This indicates a strategic shift from initial market entry to securing longer-term contractual commitments, despite potential market or regulatory challenges reflected in the context of government returns and adjustments in 2024.",
      "llm_answer": "In 2022 Paxlovid generated $18.9 billion of Biopharma revenue – the bulk of which came from pre‑specified government contracts that accounted for 23 % of total revenues and drove most of the product’s sales 【page_108†L31-L38】. By 2024 that contribution had fallen to $5.7 billion, the U.S. government share had slipped to only 6 % of total revenues and the company was moving the drug into a commercial market, even supplying a 1‑million‑course U.S. Strategic National Stockpile at no cash consideration 【page_108†L43-L51】【page_108†L55-L58】. Nevertheless, Pfizer still holds long‑term contractual commitments for Paxlovid worth about $1 billion of remaining performance‑obligation revenue (plus $2.2 billion of related deferred revenue) as of 31 Dec 2024, reflecting a shift from large government‑supply contracts to a smaller, commercially‑focused pipeline 【page_109†L31-L38】【page_110†L1-L8】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in key financial figures. According to the ground truth, Paxlovid generated $76 million in revenue in 2022, but the LLM claims $18.9 billion — a massive overstatement by two orders of magnitude. This error fundamentally undermines the answer’s validity. The 2024 revenue figure of $5.7 billion is also incorrect; the ground truth does not provide a 2024 revenue number but instead references $1 billion in remaining performance obligations. The LLM conflates total Biopharma revenue with Paxlovid-specific revenue, misinterpreting the data. Additionally, the claim of $2.2 billion in deferred revenue is not mentioned in the ground truth and appears fabricated. (2) The percentages cited (23% and 6% of total revenues from U.S. government) are not present in the original answer and cannot be verified against the ground truth, which focuses on contractual obligations rather than revenue mix. The citation of page references suggests document access, but the numbers do not align with the verified knowledge graph output. (3) While the LLM correctly identifies a strategic shift from government contracts to commercialization and notes the $1 billion in remaining performance obligations (which matches the ground truth), this correct element is overshadowed by the severe quantitative errors. The reasoning around evolving contractual positioning has some validity but is built on incorrect financial baselines. (4) Despite the severe numerical inaccuracies, the answer addresses the question’s focus on revenue trends and contractual evolution, showing awareness of the strategic shift, hence a moderate contextual relevance. However, the quantitative accuracy is very low due to the grossly incorrect revenue figures, dragging down the overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 496,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the company's exposure to credit market tightness as a supply chain risk evolved between 2022 and 2023, and what does this indicate about its changing vulnerability to external financial conditions?",
      "original_answer": "In 2022, tighter credit or capital markets were described as a risk that 'negatively impacts' suppliers, with a direct concern that this could disrupt the supply of raw and packaging materials. By 2023, the framing shifted to indicate that the company's operations are 'impacted by' these conditions, suggesting a broader recognition of ongoing vulnerability. This evolution reflects a continuation of concern over credit market conditions but with a more integrated perspective on how such financial constraints affect not just suppliers, but the company's overall supply chain resilience.",
      "llm_answer": "In the 2022 filing the company treated “the impact on our suppliers of tighter credit or capital markets” as one line‑item among a long list of supply‑chain disruptions, signalling that credit‑market stress was a modest, but acknowledged, risk. By the 2023 filing the discussion had been broadened to note “disruptions and volatility in the global capital markets, including rising interest rates, which may increase the cost of capital and adversely impact our access to capital,” reflecting a heightened awareness that tighter credit conditions can affect both suppliers and the company’s own financing. This shift indicates that the firm’s vulnerability to external financial conditions has grown, with credit‑market tightness now seen as a more material supply‑chain and liquidity risk.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of risk perception between 2022 and 2023. It accurately identifies that in 2022, tighter credit markets were framed as impacting suppliers, and by 2023, the company acknowledged broader impacts on its own access to capital and operations. The dates and entities (2022 vs. 2023 filings, credit market effects on suppliers and the company) are correct, and there are no numerical inaccuracies (quantitative accuracy is perfect as no specific numbers are involved). The reasoning correctly captures a shift in framing—from supplier-level risk to a more integrated concern involving the company’s own financial exposure—demonstrating sound multi-hop synthesis across years and risk domains. However, the LLM slightly overstates the shift by emphasizing 'access to capital' and 'liquidity risk' as supply-chain risks, whereas the original answer focuses on supply chain resilience through supplier vulnerability. While capital market conditions affecting the company’s financing are relevant, the original answer emphasizes operational supply chain disruption (raw materials) rather than internal liquidity. Thus, the LLM introduces a nuance (company’s own financing) not explicitly tied to supply chain risk in the ground truth, slightly diluting qualitative accuracy. Nonetheless, the core evolution in risk perception is correctly identified, and the answer remains highly relevant and factually sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 411,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2022 to 2024, based on disclosed figures and agreements?",
      "original_answer": "In 2022, Paxlovid was under Emergency Use Authorization (EUA) in the U.S. and had received conditional marketing authorization (CMA) in the EU and full approval in Japan, indicating early-stage regulatory and commercial momentum. By 2024, Pfizer disclosed that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, reflecting firm orders from long-term contracts with customers. This shows a significant financial commitment to Paxlovid, with delivery expected from 2025 through 2028, subject to renegotiation. Additionally, 2024 included a $771 million favorable final adjustment related to a prior revenue reversal tied to Paxlovid EUA-labeled treatment courses returned by the U.S. government, indicating ongoing financial adjustments and evolving contractual dynamics.",
      "llm_answer": "In 2022 Pfizer’s Paxlovid business was dominated by U.S.‑government contracts, producing **$18.9 billion of product revenue** and generating a large pool of advance payments that later required a **$3.5 billion non‑cash revenue reversal** for expected inventory returns.  \n\nBy 2024 the product had moved to a commercial‑market focus: revenue fell to **$5.7 billion**, the **deferred‑revenue balance for Paxlovid (and Comirnaty) dropped from $5.1 billion to $2.2 billion**, and Pfizer reported **about $1 billion of remaining performance‑obligation contracts for Paxlovid** (plus a **$0.5 billion charge for excess raw‑material inventory** and a **$442 million revenue recognition for a 1‑million‑course SNS supply**).  \n\nThus, Pfizer’s financial commitment shifted from massive upfront government funding and related liabilities in 2022 to a much smaller, commercial‑driven obligation base of roughly $1 billion by the end of 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its factual correctness. While it correctly identifies the shift from government to commercial focus and mentions the $1 billion in remaining performance obligations for Paxlovid as of 2024 (matching the ground truth), most other financial figures are incorrect or unsupported by the original answer. Specifically: (1) The $18.9 billion revenue in 2022 is not mentioned in the ground truth, nor is the $3.5 billion non-cash revenue reversal; these figures are fabricated or misattributed. (2) The deferred revenue drop from $5.1B to $2.2B combines Paxlovid and Comirnaty, which is not discussed in the original answer and introduces irrelevant data. (3) The $0.5 billion charge for raw materials and $442 million for SNS supply are not present in the ground truth; instead, the correct figure is a $771 million favorable adjustment related to returned EUA courses, which the LLM omits entirely. (4) The original answer emphasizes a $771 million positive adjustment in 2024 due to prior revenue reversals, but the LLM incorrectly frames adjustments as charges and misstates the amount. While the LLM captures the high-level evolution—transition from government contracts to commercial obligations—the multi-hop reasoning is flawed due to incorrect data synthesis. The model invents specific financials not present in the source, fails to report the key $771M adjustment, and conflates Paxlovid with Comirnaty. However, the contextual framing of evolving contractual dynamics and reduced financial exposure by 2024 aligns with the question's intent, earning moderate scores for qualitative reasoning and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 458,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has the financial liability and risk exposure related to Aearo Technologies' respirator mask/asbestos litigation evolved from 2023 to 2024?",
      "original_answer": "In 2023, MMM had an accrual of $574 million for respirator mask/asbestos liabilities excluding Aearo, and Aearo was in bankruptcy proceedings, which resulted in a stay of litigation. By 2024, MMM, through Aearo, had accruals of $51 million specifically for Aearo-related asbestos, silica-related, and coal mine dust claims. Additionally, Aearo’s liability was limited by its agreement with Cabot, where Cabot assumed responsibility for claims involving exposure prior to January 1, 1997, as long as Aearo continued to pay a quarterly fee of $100,000. This represents a shift from a broader liability exposure under bankruptcy protection in 2023 to a more defined and limited liability framework in 2024, with Aearo actively managing its share of liability through contractual arrangements and cost-sharing with other co-defendants.",
      "llm_answer": "In 2023 3M recorded a respirator‑mask/asbestos accrual of **$574 million** (excluding Aearo) plus an **Aearo‑specific accrual of $62 million**, and it paid **$88 million** for defense and settlements. By year‑end 2024 the overall accrual had fallen to **$523 million** and the Aearo accrual to **$51 million**, with payments of **$87 million**, reflecting a lower number of claimants (≈3,500 vs. 4,042) and a downward revision of the estimated cost per claim. Thus both the recorded liability and the risk exposure for Aearo’s respirator‑mask/asbestos litigation decreased from 2023 to 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its correctness. According to the ground truth, in 2023, 3M (MMM) had a $574 million accrual for respirator mask/asbestos liabilities *excluding* Aearo, and Aearo was in bankruptcy with no specific accrual mentioned for Aearo in that year. However, the LLM claims a separate Aearo-specific accrual of $62 million in 2023, which is not supported by the original answer and contradicts the fact that Aearo was in bankruptcy with litigation stayed. This is a major factual error. The LLM correctly states the 2024 Aearo-specific accrual of $51 million, but incorrectly implies a reduction from $62 million to $51 million, which is not valid given the lack of a reported Aearo accrual in 2023. The $88 million and $87 million payment figures and claimant numbers (4,042 vs ~3,500) are not present in the ground truth and appear to be fabricated or hallucinated. The overall accrual drop to $523 million is also not mentioned in the original answer. While the LLM captures the general trend of decreasing exposure, it does so using incorrect data. Qualitatively, the model recognizes the shift in liability framework but misses the key contractual detail with Cabot (pre-1997 liability assumption and $100,000 quarterly fee), which is central to the 2024 risk evolution. The reasoning is partially sound in noting reduced accruals and payments, but based on false premises. Contextually, the answer is relevant and addresses the evolution of financial liability and risk exposure, but with flawed support. Thus, the answer is partially correct in direction but incorrect in key facts and numbers, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 460,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did the retail share of Skoal, a product of MO, change between 2023 and 2024, and how does this compare to its shipment volume trend between 2020 and 2021?",
      "original_answer": "The retail share of Skoal decreased from 9.3% in 2023 to 7.6% in 2024, indicating a decline in market presence. In contrast, Skoal's shipment volume was also declining between 2020 and 2021, dropping from 208.5 million packs/cans in 2020 to 197.4 million packs/cans in 2021. Both metrics show a consistent downward trend, suggesting a potential long-term challenge for the product's performance in the market.",
      "llm_answer": "Skoal’s retail share fell from 9.3 % in 2023 to 7.6 % in 2024 – a decline of roughly 1.7 share‑points. By contrast, its shipment volume also slipped earlier, dropping from 208.5 million cans/packs in 2020 to 197.4 million in 2021 (about an 11‑million‑unit, or ~5 % decline). Both periods show a downward trend, with the recent retail‑share loss measured in percentage‑points and the earlier volume loss measured in absolute units.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: retail share decreased from 9.3% in 2023 to 7.6% in 2024; shipment volume dropped from 208.5 million to 197.4 million between 2020 and 2021. The LLM correctly notes the ~1.7 percentage-point decline in retail share and calculates the shipment decline as approximately 11 million units (~5%), which aligns with the data (208.5 - 197.4 = 11.1 million; 11.1 / 208.5 ≈ 5.3%). (2) The answer is complete, addressing both sub-questions: the 2023–2024 retail share trend and the 2020–2021 shipment volume trend. (3) Entities are accurate: Skoal, MO (implied), correct time periods, and correct metrics (retail share, shipment volume). (4) The reasoning is sound and synthesizes multi-hop information correctly—linking two distinct time periods and metrics to observe a consistent downward trend. The LLM adds value by contextualizing the decline in both relative (percentage points) and absolute (unit volume) terms, enhancing clarity without introducing error. (5) Semantic equivalence is maintained: the core conclusion—that both metrics show declining performance—is preserved and accurately conveyed. Minor wording differences (e.g., 'cans/packs' vs 'packs/cans') are acceptable format variations. No factual, numerical, or logical errors present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 378,
        "total_tokens": 1591
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Qualcomm's approach to multimedia technologies evolved from 2022 to 2024, particularly in terms of engineering focus areas and integration into product offerings?",
      "original_answer": "In 2022, Qualcomm emphasized engineering expertise in multimedia technologies such as camera, video, display, and computer vision as part of a broader set of capabilities including modem, RF, and sensor perception technologies. The focus was on enhancing existing products and developing new technologies for industries beyond mobile handsets, such as automotive and IoT. By 2024, the company's description of its multimedia technology efforts remained consistent, but there was a notable expansion in the integration of AI, particularly generative AI, into its research and development strategy. Additionally, in 2024, Qualcomm placed greater emphasis on enabling developers to design and deploy applications across multiple device categories and industries, signaling a more deliberate diversification strategy. This evolution reflects a shift from primarily hardware-centric multimedia innovation in 2022 to a more platform-oriented, AI-enhanced approach by 2024.",
      "llm_answer": "In its 2022 filing Qualcomm described multimedia (camera, video, display and computer‑vision) as a distinct engineering specialty within a broad R&D team that also covered modems, RF, advanced‑SoC engines and AI, primarily to enhance its mobile‑handset chipsets. By the 2024 filing the company’s engineering focus had broadened the multimedia effort to be tightly coupled with AI‑driven sensor‑perception, ADAS/AD and XR functions and to be baked into its Snapdragon platforms and automotive/IoT chipsets, showing a shift from a handset‑centric role to a cross‑industry integration of multimedia capabilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Qualcomm's multimedia technology approach from 2022 to 2024. (1) It correctly identifies the 2022 focus on multimedia (camera, video, display, computer vision) as part of a broader R&D effort centered on mobile handsets, aligning with the ground truth. It also accurately reflects the 2024 shift toward tighter integration with AI, sensor perception, ADAS/AD, and XR, as well as expansion into automotive and IoT via Snapdragon platforms. (2) There are no numeric values, dates, or financial figures in dispute; all time references (2022, 2024) are correct and consistent with the original answer. (3) The multi-hop reasoning is sound: the model synthesizes changes in engineering focus and product integration across two time points and correctly infers a strategic shift from handset-centric to cross-industry platform integration. (4) While the LLM does not explicitly mention 'generative AI' or 'developer enablement'—subtle but notable aspects of the 2024 strategy highlighted in the ground truth—it compensates by accurately describing the functional integration of multimedia with AI and advanced systems. The omission of 'generative AI' and the developer ecosystem angle prevents a perfect 10, but the overall semantic meaning and strategic trajectory are preserved. Wording differs but meaning is substantially equivalent. Contextual relevance is excellent as it directly addresses engineering focus and product integration across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 415,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did 3M's financial relationship with the Aearo Entities evolve between 2023 and 2024, particularly in terms of equity investment and intercompany balances?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities, which resulted in the removal of a $0.7 billion asset balance in equity and other investments and a $0.6 billion net liability for former intercompany amounts from its consolidated balance sheet as of December 31, 2023. By 2024, the Aearo Entities were no longer consolidated, and instead, 3M now 'has a stake in' them, indicating a shift from full consolidation to a retained equity interest. This reflects a significant change in the financial structure and relationship between 3M and the Aearo Entities.",
      "llm_answer": "In the 2023 Form 10‑K, after the Aearo Entities were reconsolidated, 3M still showed ≈ $0.7 billion of an equity‑investment interest in those entities (recorded in “equity and other investments”) and a net inter‑company liability of about $0.6 billion (the gross amounts appeared as $0.9 billion in other liabilities and $0.3 billion in other assets)【page_101】.  \n\nThe 2024 Form 10‑K no longer lists any such equity‑investment or inter‑company balances for the Aearo Entities; the notes on equity investments discuss other holdings (e.g., Solventum) but make no reference to Aearo, indicating that the equity stake and related inter‑company balances have been eliminated as the settlement and cash payments resolved the relationship.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partially correct quantitative information but misrepresents the core financial evolution between 3M and the Aearo Entities, leading to significant factual and reasoning errors. (1) Quantitatively, the $0.7 billion equity investment and $0.6 billion net intercompany liability are correctly cited from the 2023 balance sheet, and the gross breakdown ($0.9B liability, $0.3B asset) adds detail not in the ground truth but consistent with plausible reconciliation. However, the key error lies in the 2024 interpretation: the LLM claims the equity stake and intercompany balances were 'eliminated' due to 'settlement and cash payments,' which contradicts the ground truth stating that 3M now 'has a stake in' the Aearo Entities, indicating a retained equity interest, not elimination. (2) The original answer confirms that reconsolidation occurred in 2023, which removed those balances because the Aearo Entities were brought back into the consolidated financials — the opposite of what the LLM implies. Then, by 2024, they were deconsolidated again, and 3M retained an equity stake. The LLM incorrectly interprets the absence of Aearo in 2024 disclosures as evidence of elimination, when in fact the relationship evolved to an equity-method investment. (3) This reflects a failure in multi-hop reasoning: the model does not correctly trace the sequence — deconsolidation pre-2023, reconsolidation in 2023 (removing prior intercompany balances), then a shift to equity accounting in 2024. Instead, it infers elimination based on disclosure absence, which is logically unsound. (4) While the numbers for 2023 are accurate and contextually relevant, the conclusion about 2024 is factually wrong, undermining the overall correctness. Hence, the correctness score is low despite some accurate data points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 491,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Visa's Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of their strategic positioning within the company's broader value-added services portfolio?",
      "original_answer": "In 2022, Visa's Risk and Identity Solutions were described as tools that 'transform data into insights for near real-time decisions' and included named products like Visa Advanced Authorization and Visa Secure. These solutions were positioned primarily around fraud prevention and payment security, with an emphasis on helping clients protect account holder data and prevent fraud in the context of omnichannel commerce. By 2024, Risk and Identity Solutions had been elevated as one of five core categories within a more expansive value-added services portfolio that now includes Open Banking Solutions and Advisory Services. The 2024 report highlights that Visa offered more than 200 products and services as of September 30, 2024, many designed to work together for 'high impact business outcomes,' indicating a broader strategic integration of Risk and Identity Solutions within a more diversified services ecosystem.",
      "llm_answer": "In the 2022 filing, Visa’s Risk and Identity Solutions were presented as a card‑centric fraud‑prevention toolkit – the Visa Protect suite (Consumer Authentication Service, Protect Authentication Intelligence, Provisioning Intelligence) plus products such as Visa Advanced Authorization, Visa Secure and other authentication tools – positioned as one of the five value‑added‑services categories that helped issuers and merchants curb fraud on Visa transactions.  \n\nBy the 2024 filing the suite had expanded into a broader, AI‑driven platform: Visa Deep Authorization, Visa Protect for A2A payments and Visa Risk Manager with scheme‑agnostic Advanced Authorization were added, extending risk scoring to non‑card (A2A) and network‑agnostic flows, and the category was highlighted as a core pillar of a now‑200‑product value‑added‑services portfolio.  \n\nThus, Risk and Identity Solutions have evolved from a primarily card‑focused fraud suite to a strategic, cross‑network, AI‑powered risk engine that is a central component of Visa’s overall value‑added services strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the 2022 positioning of Visa's Risk and Identity Solutions as focused on fraud prevention and payment security, citing key products like Visa Advanced Authorization and Visa Secure. It also accurately reflects the 2024 evolution, noting the expansion into a broader platform with new offerings like Visa Deep Authorization and Visa Risk Manager. The mention of over 200 products in the value-added services portfolio by September 30, 2024, is consistent with the original answer, though the LLM does not explicitly cite that date but implies the scale accurately. (2) Quantitatively, all references are correct: the '200-product' portfolio is correctly attributed to 2024, and no incorrect numbers or dates are introduced. Format and phrasing variations (e.g., 'AI-driven platform' vs. 'strategic integration') are semantically acceptable. (3) The multi-hop reasoning is sound—LLM synthesizes changes across years, correctly infers strategic elevation within the portfolio, and captures the shift from card-centric to cross-network, AI-enhanced solutions. The addition of A2A (account-to-account) and scheme-agnostic capabilities reflects deeper insight beyond the ground truth, but remains plausible and consistent with the direction described. (4) Minor deduction in qualitative accuracy because the LLM introduces 'Visa Protect suite' with subcomponents not explicitly detailed in the ground truth, and the original answer does not mention AI or 'Deep Authorization'—these may reflect external knowledge or inference. However, they do not contradict the source and fit the trajectory. Overall, the answer is factually correct, comprehensive, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1507,
        "completion_tokens": 479,
        "total_tokens": 1986
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did RTX's disclosure and quantification of Acquisition Accounting Adjustments' impact on operating profit evolve between 2023 and 2024?",
      "original_answer": "In 2023, RTX provided specific quantified impacts of Acquisition Accounting Adjustments on operating profit, showing a negative impact of $1,998 million in 2023, compared to $1,893 million in 2022 and $2,203 million in 2021. By 2024, RTX shifted its disclosure approach by providing qualitative policy context about the components of these adjustments, but did not include updated quantitative figures for the current year's impact on operating profit. This represents a move from concrete numerical disclosure to a more conceptual explanation of acquisition accounting practices without continuing the year-over-year quantification.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K filings RTX reported “Acquisition accounting adjustments” as a distinct line item that is excluded from management’s segment‑performance evaluation. The 2023 filing quantified the impact on operating profit at **‑$1.998 billion** (see 2023 page 109), while the 2024 filing showed a slightly larger charge of **‑$2.058 billion** (see 2024 page 54). Thus, the company’s disclosure remained the same but the quantified effect grew by about **$60 million** (more adverse) from 2023 to 2024.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim. The ground truth states that RTX did *not* provide a quantitative figure for 2024, but instead shifted to qualitative disclosure. However, the LLM claims RTX reported a 2024 charge of -$2.058 billion, which directly contradicts the original answer. This is a major factual error. The 2023 figure of -$1.998 billion is correct (matching $1,998 million), but the 2024 number is fabricated. (2) The calculation of a $60 million increase is based on false data and therefore invalid. No such calculation can be made because no 2024 quantitative figure was disclosed. (3) The multi-hop reasoning fails: the question asks about the *evolution* of disclosure and quantification between years. The correct answer requires recognizing a shift from quantitative to qualitative disclosure. The LLM incorrectly assumes the disclosure format remained the same and only the number changed, missing the key conceptual shift entirely. (4) The contextual relevance is moderate because the answer addresses RTX and acquisition accounting adjustments in the correct timeframe, but the incorrect data and reasoning undermine the entire response. Quantitative accuracy is extremely low due to the false 2024 number. Qualitative accuracy is low because the model fails to recognize the change in disclosure approach. Correctness score is near-minimum because the answer conveys the opposite of the truth: it asserts continued quantification when the actual evolution was a cessation of it.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 423,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Microsoft's Office 365 Commercial revenue contribution to the Microsoft Cloud evolved between fiscal years 2022 and 2023, and what does this indicate about its growth trajectory within the broader cloud ecosystem?",
      "original_answer": "In fiscal year 2022, Office 365 Commercial was explicitly cited as a key growth driver within the Productivity and Business Processes segment, contributing to an 18% overall revenue increase for the company. By fiscal year 2023, Office 365 Commercial was included in a newly disclosed consolidated Microsoft Cloud revenue figure, which reached $111.6 billion in FY2023, up from $91.4 billion in FY2022. This indicates that Office 365 Commercial continued to grow as part of a broader, increasingly transparent cloud revenue portfolio that now includes Azure, LinkedIn (commercial portion), Dynamics 365, and other cloud services.",
      "llm_answer": "Office 365 Commercial (included in “Office products and cloud services”) grew in absolute terms from **$44.97 billion in FY 2022 to $48.85 billion in FY 2023** – an increase of roughly **$3.9 billion (≈9 %)**【page_93】.  At the same time, total Microsoft Cloud revenue rose from **$91.4 billion (FY 2022) to $111.6 billion (FY 2023)**【page_93】, so Office 365 Commercial’s share of the cloud business slipped from about **49 % to 44 %**.  This shows that Office 365 Commercial remains a large pillar of Microsoft’s cloud, but its growth is being out‑paced by faster‑growing Azure and other cloud services, indicating a broader shift toward the overall cloud ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a detailed, factually correct response that aligns well with the ground truth. (1) All key numbers are correct: Microsoft Cloud revenue increased from $91.4B in FY2022 to $111.6B in FY2023, which matches the original answer exactly. The Office 365 Commercial revenue figures of $44.97B (FY2022) and $48.85B (FY2023) are precise and support the ~9% growth calculation. The derived percentage shares (49% → 44%) are mathematically accurate and correctly illustrate the declining relative contribution. (2) Calculations are correct: the $3.88B increase rounds to $3.9B, and the growth rate is approximately 8.65%, which rounds to ≈9%, as stated. (3) Multi-hop reasoning is sound: the model synthesizes data across two fiscal years, compares Office 365 Commercial growth against total Microsoft Cloud growth, and correctly infers that while Office 365 remains a major contributor, its relative share is declining due to faster growth in other segments like Azure—this insight is consistent with and expands upon the original answer’s implication about a broader shift in the cloud ecosystem. (4) The only minor limitation is that the original answer emphasizes the *new disclosure format* of Microsoft Cloud revenue in FY2023 as a transparency change, which the LLM mentions implicitly by citing the consolidated figure but does not explicitly highlight. However, this does not detract from the core factual accuracy or reasoning. Overall, the answer is quantitatively precise, contextually relevant, and semantically equivalent with enhanced analytical depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 437,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did Merck's alliance revenue related to Lynparza evolve between 2023 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2023, alliance revenue for Lynparza was part of Merck's broader alliance revenue reporting, which included profits based on product sales net of cost of sales and commercialization costs. By 2024, alliance revenue related to Lynparza specifically grew by 9%, driven by higher demand in most international markets. This growth indicates a positive shift in Lynparza's market performance during the period.",
      "llm_answer": "Merck’s alliance revenue from Lynparza rose from $1,199 million in 2023 to $1,311 million in 2024 – a ≈9 % increase (≈$112 million).  The 2024 filing notes that the growth was “largely due to higher demand in most international markets,” and it was supported by ongoing patent‑infringement lawsuits that have kept generic applications (Natco, Sandoz) on hold, preserving the product’s market exclusivity.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific dollar amounts ($1,199 million in 2023 and $1,311 million in 2024) and a calculated 9% increase, which are not present in the original answer (ground truth). The ground truth does not provide any numerical figures for alliance revenue related to Lynparza in either year, only stating that it grew by 9% in 2024. Therefore, the inclusion of precise revenue numbers is factually unsupported by the provided ground truth and represents a hallucination. While the 9% growth figure aligns with the original answer, the LLM fabricates the base values and the $112 million difference, which cannot be verified. (2) The calculation of ≈9% from $1,199M to $1,311M is mathematically accurate ((1,311 - 1,199)/1,199 ≈ 0.0934), but since the inputs are not in the ground truth, the quantitative accuracy is low despite correct arithmetic. (3) The qualitative reasoning is partially sound: the LLM correctly identifies that higher international demand drove growth, which matches the original answer. However, it adds information about patent-infringement lawsuits and generic applications (Natco, Sandoz) being on hold, which is not mentioned or implied in the original answer. This introduces unverified contributing factors not supported by the knowledge graph, weakening the multi-hop reasoning validity. (4) Contextually, the answer addresses both parts of the question—evolution of revenue and contributing factors—and stays focused on Lynparza and Merck’s alliance revenue. The structure and intent are appropriate, hence high contextual relevance. However, due to significant fabrication of numerical data and unsupported causal factors, the overall correctness score is reduced to 6—partially correct but with major factual overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1197,
        "completion_tokens": 483,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the treatment and disclosure of the Procter & Gamble 2014 Stock and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of its regulatory context and inclusion in equity compensation reporting?",
      "original_answer": "In 2023, the 2014 Stock and Incentive Compensation Plan was disclosed in the context of regulatory documentation and was referenced alongside other compensation plans and agreements, such as the 2009 and 2019 plans, indicating its active role in executive compensation. By 2024, the plan was included in a broader list of equity compensation plans for reporting on stock issuances upon exercise of options, suggesting a shift from regulatory disclosure to a focus on ownership structure and equity compensation transparency. This evolution indicates a more integrated view of the 2014 plan within the company’s overall equity compensation framework.",
      "llm_answer": "In the 2023 Form 10‑K the 2014 Stock and Incentive Compensation Plan was disclosed only by reference (exhibit 10‑25) and was listed among the company’s equity‑compensation plans in Item 12, with its committee regulations incorporated from earlier filings. The 2024 Form 10‑K still incorporates the same plan, but now ties its governance to the Compensation and Leadership Development Committee regulations that were approved on December 13 2022 (Exhibit 3‑2), and it continues to appear in the aggregate equity‑compensation table while noting that, unlike the 2019 Plan, the 2014 Plan does not provide for future grants. Thus the plan’s treatment has remained consistent in being referenced, but the 2024 filing adds a more recent regulatory citation and re‑affirms its limited role in current equity‑compensation reporting.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2014 Plan was referenced in both 2023 and 2024 Form 10-Ks, included in equity compensation disclosures, and no longer provides for future grants (in contrast to the 2019 Plan). The mention of Exhibit 10-25 in 2023 and updated reference to the Compensation and Leadership Development Committee regulations approved December 13, 2022 (Exhibit 3-2) in 2024 is factually precise. (2) Quantitative accuracy is perfect: the date 'December 13, 2022' is correctly cited, and there are no numerical errors. (3) Multi-hop reasoning is sound—the model synthesizes information across years (2023 vs 2024), documents (exhibits), and plan statuses, correctly inferring a shift in regulatory citation and reaffirming the plan’s inactive status for new grants. (4) The LLM adds granularity not in the original answer (specific exhibit numbers, committee name, grant eligibility), enhancing precision. The only minor gap is that it doesn’t explicitly frame the evolution as a shift 'from regulatory disclosure to ownership transparency' as in the ground truth, but this conceptual shift is implied through the updated governance linkage and reporting context. Thus, the answer is semantically equivalent and factually superior in detail, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 401,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the treatment of the 1992 Stock Plan evolved between the 2023 and 2024 10-K filings, particularly in terms of its role within the company's equity compensation structure?",
      "original_answer": "In the 2023 10-K filing, the 1992 Stock Plan was referenced as an adopted plan with specific terms and conditions incorporated by reference to prior filings. However, in the 2024 10-K filing, the 1992 Stock Plan is listed among other equity compensation plans in a consolidated table that outlines shares authorized for issuance upon the exercise of options, warrants, and rights. This indicates a shift from a standalone referenced plan to one being tracked alongside newer plans, suggesting its role has transitioned from active adoption to a more passive stake within the broader equity compensation framework.",
      "llm_answer": "In the 2023 Form 10‑K the Procter & Gamble 1992 Stock Plan was listed alongside the other equity‑compensation plans as a current component of the company’s stock‑based award program. By the 2024 Form 10‑K the same plan still appears in the exhibit list, but the filing now notes that **only the 2019 Stock and Incentive Compensation Plan can be used for future grants**, indicating that the 1992 Plan is no longer a source of new awards and is effectively treated as a legacy vehicle that only covers outstanding awards. This shift shows the 1992 Plan’s role has been reduced from an active grant‑eligible plan to a dormant, historical element of the equity‑compensation structure.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly impact correctness. First, the company in question is not Procter & Gamble — the original answer does not specify a company, and the LLM incorrectly introduces 'Procter & Gamble' without basis, which is a critical entity error. Second, the LLM claims that 'only the 2019 Stock and Incentive Compensation Plan can be used for future grants,' but this specific plan name (2019 Stock and Incentive Compensation Plan) does not appear in the ground truth and cannot be verified from the provided information. The original answer notes a shift in presentation — from being referenced by incorporation in 2023 to being included in a consolidated table in 2024 — suggesting a passive transition in reporting, but does not state that the plan is closed to new grants or that a 2019 plan is now the sole source. While the LLM correctly infers a transition from active to legacy status, this reasoning goes beyond the evidence provided in the ground truth, making the conclusion speculative. There are no numerical values to verify, so quantitative accuracy is scored as 10 by default. Contextual relevance is high because the response addresses the evolution of the plan’s role, but qualitative accuracy is low due to unsupported entity and plan-specific claims. The core idea of a structural downgrade in the plan’s role aligns semantically with the ground truth, but the incorrect company and unverified plan names undermine factual reliability, warranting a partial correctness score of 6.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 424,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the company's emphasis on large-scale transformations evolved between 2023 and 2024, particularly in terms of client spending patterns and revenue conversion timelines?",
      "original_answer": "In 2023, the filing noted that clients were reducing or deferring spending on smaller contracts with shorter durations and that there was a slowdown in client spending, especially for consulting services. However, clients were still prioritizing large-scale transformations, which convert to revenue over a longer period. In 2024, the filing reiterated that clients continued to prioritize large-scale transformations, emphasizing the ongoing shift toward longer-duration contracts. While there was no explicit quantitative metric provided in either year, the repeated emphasis in both filings on the extended revenue conversion timeline for large-scale transformations indicates a strategic reinforcement of this focus, especially amid ongoing economic volatility.",
      "llm_answer": "In the 2023 filing the company already noted that “clients continue to prioritize large‑scale transformations, which convert to revenue over a longer period,” but it warned that volatile economic conditions were curtailing spending on smaller, short‑duration consulting contracts. By the 2024 filing the same point is reiterated, yet the language stresses that the bulk of client spend is now shifting even more toward those large‑scale, multi‑year transformation programs, with revenue being recognized over a longer horizon as short‑term contract activity remains muted. Thus, between 2023 and 2024 the emphasis has moved from simply recognizing the importance of large‑scale transformations to highlighting a deeper client shift toward longer‑duration, higher‑value engagements and a slower conversion of that spend into revenue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2023, clients reduced spending on smaller, short-duration contracts while still prioritizing large-scale transformations with longer revenue conversion timelines; in 2024, this trend continued and was reinforced, with increased emphasis on longer-duration, higher-value engagements. The LLM correctly notes the absence of quantitative metrics and accurately reflects the qualitative shift in language between the two years. (2) There are no numerical values to verify, but the answer correctly states that no explicit quantitative data was provided, which matches the original. Thus, quantitative accuracy is perfect. (3) The multi-hop reasoning—comparing the evolution of client spending patterns and revenue conversion timelines across 2023 and 2024—is sound. The LLM correctly synthesizes that the company’s emphasis evolved from acknowledging the priority of large-scale transformations to highlighting a deeper, ongoing shift toward longer-term contracts amid muted short-term activity. (4) The answer is contextually fully relevant, directly addressing both client spending patterns and revenue conversion timelines as asked. The only minor deduction is for slightly stronger characterization of the 2024 shift as a 'deeper client shift' and 'bulk of client spend' moving—phrasing not explicitly in the original, though reasonably inferred. This introduces a subtle intensification not fully substantiated by the source, which notes continuity rather than escalation. Hence, qualitative accuracy is high but not perfect. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 466,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How did Accenture's issuance of Class A Ordinary Shares for employee compensation change from fiscal 2023 to 2024, and what was the impact on the company's equity structure?",
      "original_answer": "In fiscal 2023, Accenture acquired Class A Ordinary Shares primarily through share withholding for payroll tax obligations related to employee equity awards. In fiscal 2024, the company issued 7,970 Class A Ordinary Shares specifically for employee share programs, while also purchasing 12,181 treasury shares. This shift reflects a more active use of Class A Ordinary Shares for compensation purposes in 2024. The equity structure was impacted as Class A Ordinary Shares increased from 15,656,591 in 2023 to 15,664,561 in 2024, while treasury shares decreased in value from $(3,408,491) million to $(6,678,037) million, indicating a significant reallocation of shares for employee programs.",
      "llm_answer": "In fiscal 2024 Accenture issued **about 7,970 Class A ordinary shares** for employee‑share programs, versus **8,883 shares in fiscal 2023** – a drop of roughly 1,000 shares (≈ 12 %).  The lower issuance reduced the related additional‑paid‑in‑capital contribution (≈ $1.94 billion in 2024 versus $2.15 billion in 2023) and slightly lowered the treasury‑share balance, but total Accenture plc shareholders’ equity still rose, from **$25.69 billion at 31 Aug 2023 to $28.29 billion at 31 Aug 2024**, reflecting overall growth in other equity components.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims Accenture issued 8,883 Class A Ordinary Shares in fiscal 2023, but according to the ground truth, Accenture did not issue shares in 2023—instead, it acquired shares via withholding for tax obligations. The LLM incorrectly frames 2023 as an issuance year, which contradicts the original answer. The 7,970 shares issued in 2024 is correct, but the comparison is invalid due to the misrepresentation of 2023 activity. The dollar amounts ($1.94B and $2.15B) and treasury share balance changes are fabricated and not supported by the ground truth. The equity increase from $25.69B to $28.29B is not mentioned in the ground truth and appears incorrect. (2) The ground truth states that Class A Ordinary Shares increased from 15,656,591 to 15,664,561 (a net increase of 7,970), which aligns with the 2024 issuance. However, the LLM misattributes prior-year activity and invents financial figures not present in the source. The treasury share value decreased from $(3,408,491) million to $(6,678,037) million (i.e., more negative, indicating more shares held), but the LLM incorrectly states the balance 'slightly lowered' without acknowledging the magnitude or direction correctly. (3) The multi-hop reasoning is flawed: the model fails to recognize that 2023 involved share acquisition (not issuance) and mischaracterizes the nature of employee compensation activity across years. It does not reflect the shift from withholding to active issuance. (4) Due to major factual and quantitative errors, especially in core financial data and year-over-year comparison, the correctness score is low. Contextual relevance is moderate because the answer addresses employee share programs and equity impact, but the substance is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 490,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did MDLZ's exposure to Canadian-denominated debt instruments change between 2022 and 2023, and how does this shift compare to the company's overall trend in managing foreign currency-denominated debt during this period?",
      "original_answer": "In 2022, MDLZ reported a decrease in Canadian notes of $3 million, continuing a trend of declining balances from $17 million in 2019 to $7 million in 2020 and $3 million in 2021. However, in 2023, the company experienced an increase in Canadian notes by $8 million, reversing the previous downward trajectory. This shift contrasts with the broader pattern of fluctuating foreign currency exposure, where Euro notes decreased significantly from $211 million in 2021 to $81 million in 2023, while Swiss franc notes also showed volatility. The reversal in Canadian notes indicates a notable deviation from the prior year's trend of reducing exposure to this currency denomination.",
      "llm_answer": "MDLZ’s Canadian‑dollar‑denominated notes that are hedged as net‑investment debt grew from **$443 million at the end of 2022 to $453 million at the end of 2023** (a $10 million increase). At the same time, the total notional amount of all non‑U.S.‑currency debt hedged (Euro + Swiss franc + Canadian notes) fell from about **$4.49 billion in 2022 to $4.36 billion in 2023**, showing that while the Canadian exposure ticked up, the company’s overall foreign‑currency debt‑hedge position was slightly reduced during the year.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content. According to the ground truth, MDLZ's Canadian notes decreased by $3 million in 2022 (from $7M in 2020 to $3M in 2021, then to $0 by 2022), and increased by $8 million in 2023. However, the LLM claims Canadian-denominated notes grew from $443M to $453M between 2022 and 2023, which is completely inconsistent with the original data. The ground truth shows a reversal from a multi-year decline to a small increase in 2023, but the LLM fabricates large absolute values not present in the source. (2) The quantitative inaccuracies are severe: the LLM invents $443M and $453M figures for Canadian notes, whereas the actual exposure was in the single-digit millions and had been nearly eliminated by 2022. Additionally, the LLM introduces a 'total notional amount of all non-U.S.-currency debt hedged' of ~$4.49B and $4.36B, which is not mentioned or inferable from the ground truth. There is no support for these aggregate numbers or the claim that overall foreign currency debt was slightly reduced. (3) The multi-hop reasoning is flawed. While the LLM attempts to contrast Canadian exposure with broader trends, it misrepresents both the specific trend (Canadian notes) and the overall pattern. The ground truth emphasizes a reversal in a small, nearly phased-out debt instrument, while the LLM portrays it as a growing $450M position. The comparison to Euro and Swiss franc notes is superficially relevant but based on fabricated aggregates. (4) The contextual relevance is moderate because the LLM addresses the right topic—changes in foreign currency debt exposure—and attempts to compare Canadian trends to overall patterns. However, due to severe factual and numerical errors, the answer fails to accurately reflect the company's actual financial position or trend. The core claim of a 'reversal' in Canadian exposure is correct in direction for 2023 but is presented with wrong magnitude and baseline, and the 2022 trend is misrepresented (it was a continued decline, not a base for growth from $443M).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 560,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Accenture's approach to engaging with growth-stage companies evolved from 2023 to 2024, particularly in terms of strategic involvement and investment activity?",
      "original_answer": "In 2023, Accenture Ventures was described as primarily partnering with growth-stage companies that create innovative enterprise technologies. By 2024, the relationship evolved from a partnership model to a more direct investment approach, indicating a deeper financial and strategic commitment. This shift from 'partners with' to 'invests in' growth-stage firms suggests Accenture is taking a more active role in shaping innovation ecosystems through capital allocation, aligning with its broader innovation strategy supported by $1.3 billion in R&D spending in fiscal 2023 and $1.2 billion in fiscal 2024.",
      "llm_answer": "In the 2023 Form 10‑K Accenture described **Accenture Ventures** mainly as a vehicle that “partners with and invests in growth‑stage companies that create innovative enterprise technologies.” By the 2024 filing the language is unchanged but is placed within a broader innovation ecosystem – Accenture Ventures now works hand‑in‑hand with **Accenture Labs, Research and more than 100 global innovation hubs** to co‑create, prototype and scale those companies’ solutions for clients. Thus, the firm’s engagement has evolved from a primarily financial‑investment role in 2023 to a deeper, strategic partnership that integrates growth‑stage firms into Accenture’s end‑to‑end innovation and delivery model in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual inaccuracy in its core claim about the evolution of Accenture's approach. The original answer states that the company shifted from a 'partners with' model in 2023 to a 'invests in' model in 2024, indicating increased financial commitment. However, the LLM claims the language in the 10-K was 'unchanged' but placed in a broader context, which contradicts the ground truth. This misrepresents the nature of the evolution—portraying it as structural/integrative rather than strategic/financial. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable; however, the absence of incorrect numbers supports a score of 10. (3) The multi-hop reasoning is flawed: the LLM incorrectly interprets the change in disclosure context as evidence of strategic deepening through integration with Labs and innovation hubs, while the ground truth emphasizes a shift in relationship type (from partnership to investment). The LLM introduces details (e.g., co-creation with innovation hubs) not present in the original answer and uses them to support an incorrect conclusion. (4) Despite the incorrect reasoning and reversal of the actual evolution (strategic integration vs. financial deepening), the answer remains contextually relevant by addressing Accenture’s engagement with growth-stage firms and innovation strategy. Hence, contextual relevance is high, but correctness and qualitative accuracy are low due to the fundamental mischaracterization of the shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 427,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Merck's financial and strategic involvement in the Lynparza collaboration with AstraZeneca evolved from 2022 to 2024, particularly in terms of asset amortization and alliance revenue growth?",
      "original_answer": "In 2022, Merck was amortizing an intangible asset balance of $1.1 billion related to Lynparza, which included capitalized milestone payments, and was expected to be amortized through 2028. By 2024, the focus shifted from asset amortization to revenue growth, with alliance revenue from Lynparza increasing by 9% due to higher demand in international markets. Additionally, in early 2025, Lynparza received a new approval in China for adjuvant treatment in early breast cancer, indicating an expansion in its therapeutic footprint and strategic importance to Merck.",
      "llm_answer": "- In the 2022 filing Merck reported a Lynparza‑related intangible‑asset balance of roughly **$1.1 billion** (recorded at 31 Dec 2021) that is being **amortized on a straight‑line basis through 2028**; the amortization expense is included in the “cost of sales” line for the collaboration.  \n\n- By the 2024 filing the same collaboration generated **$1.311 billion of alliance revenue**, up **9 %** versus 2023 (and well above the $989 million reported for 2021 in the 2022 filing), indicating that Merck’s share of Lynparza profits has grown while the original intangible asset continues to be amortized over its remaining useful life.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $1.1 billion intangible asset balance related to Lynparza as of the end of 2021 (reported in the 2022 filing), its amortization through 2028, and the 9% year-over-year growth in alliance revenue by 2024. The $1.311 billion revenue figure for 2024 and the comparison to $989 million in 2021 are factually consistent with the ground truth’s emphasis on revenue growth. (2) All numbers are quantitatively accurate: $1.1 billion asset, straight-line amortization through 2028, 9% revenue increase, and $1.311 billion alliance revenue in 2024. The LLM correctly contextualizes the 2021 and 2023 figures to support the growth narrative. (3) The multi-hop reasoning is sound—linking the 2022 amortization schedule to the 2024 revenue performance shows evolution in Merck’s financial involvement. However, the LLM omits the forward-looking strategic development mentioned in the ground truth: the 2025 China approval for adjuvant early breast cancer treatment, which is a key indicator of strategic expansion. This is a minor omission affecting completeness but not core financial accuracy. (4) The answer is highly relevant, accurately capturing the shift from amortization focus to revenue growth. The qualitative accuracy is slightly reduced due to the missing strategic update, but the financial synthesis is excellent. Overall, the answer is factually correct and well-reasoned, meriting a 9/10 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 405,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has AVGO's strategic emphasis on ValueOps changed between 2023 and 2024, and what does this indicate about its evolving role in the Distributed Software portfolio?",
      "original_answer": "In 2023, ValueOps was listed as one of several key offerings under AVGO's Distributed Software portfolio, positioned alongside other solutions like DevOps and AIOps without specific elaboration on its strategic role. By 2024, ValueOps was elevated to be one of the three core domains—alongside DevOps and AIOps—that AVGO's distributed software solutions are 'organized in the domains of,' with an explicit emphasis on delivering 'end-to-end visibility across all stages of the digital lifecycle.' This indicates a strategic shift where ValueOps became more central to AVGO's value proposition, aligning it more deeply with business outcomes and customer experiences. The change reflects a broader evolution from being a feature in the portfolio to a foundational pillar supporting enterprise digital transformation.",
      "llm_answer": "In the 2023 Form 10‑K, ValueOps is mentioned only in a brief line that the Distributed‑Software portfolio “includes ValueOps, DevOps and AIOps” (see 2023 page 10). By the 2024 filing the company devotes an entire paragraph to ValueOps, describing it as a “value‑stream‑management solution that enables customers to schedule, track and manage work from investment planning to execution, aligning business and development teams, increasing transparency, reducing inefficiencies and improving time‑to‑value” (see 2024 page 11). This shift from a simple portfolio listing to a detailed strategic narrative shows that AVGO is elevating ValueOps from a peripheral offering to a core, growth‑driving capability within its Distributed Software business.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2023, ValueOps was briefly mentioned as part of the Distributed Software portfolio (citing the correct context and page), and in 2024, it received expanded treatment with a full strategic description (also correctly cited). The shift from a listed component to a detailed, emphasized capability is accurately portrayed. (2) There are no numeric values, dates, or financial figures in the question or answer, so quantitative accuracy is not applicable in the traditional sense—but all references to years (2023, 2024) and document locations (page 10, page 11) are correct, satisfying factual precision. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings to infer a strategic elevation of ValueOps. It correctly infers that increased descriptive emphasis indicates a shift in strategic importance, though it stops slightly short of explicitly stating that ValueOps became one of the 'three core domains' as in the ground truth. However, mentioning that it's now described as a key solution enabling business-development alignment and time-to-value captures the essence of its elevated role. (4) The answer is contextually excellent—directly addressing both parts of the question: the change between years and what it indicates about ValueOps' evolving role. The only minor omission is not explicitly stating that ValueOps is now a 'foundational pillar' or 'core domain' alongside DevOps and AIOps, which slightly reduces qualitative completeness. Still, the conclusion that it has become a 'core, growth-driving capability' is semantically equivalent. Overall, this is a factually correct, well-reasoned, and relevant response deserving of a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 490,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did FedEx's strategic approach to Network 2.0 within the DRIVE transformation evolve between 2023 and 2024, particularly in terms of expected cost savings and implementation risks?",
      "original_answer": "In 2023, FedEx emphasized the strategic importance of Network 2.0 as part of its DRIVE transformation, noting that significant investments were being made with the expectation of achieving operational efficiencies, network flexibility, and alignment of the cost base with demand. However, the filing acknowledged that the failure to successfully execute Network 2.0 within the expected time frame and cost could adversely affect future results. By 2024, FedEx shifted focus to the integration complexities of Network 2.0, including risks related to harmonizing operating practices, maintaining customer and service provider agreements, addressing labor and cultural differences, and managing unforeseen expenses. The 2024 filing also noted that the actual amount and timing of cost savings and permanent cost reductions might differ from expectations, and that asset impairment charges, tax impacts, and litigation risks could arise. This reflects a transition from strategic planning and investment justification in 2023 to operational integration and financial risk mitigation in 2024.",
      "llm_answer": "In the 2023 filing FedEx presented Network 2.0 as the cornerstone of its DRIVE transformation, stating that the program was expected to deliver “operational efficiencies, network flexibility, alignment of our cost base with demand, **cost savings and reductions to our permanent cost structure**” (2023 p. 32).  At the same time it warned that “we may be unable to achieve the expected … cost savings” and that failure to execute the transformation “in the expected time frame and at the expected cost” was a strategic risk (2023 p. 32‑33).\n\nBy the 2024 filing the tone had shifted to a more cautious outlook.  FedEx noted that the legal‑structure consolidation was finished in June 2024 but that “network integration and optimization are ongoing” and that “the integration process could result in **higher than currently expected costs, less‑than‑expected savings, … and may take longer than currently anticipated**” (2024 p. 33).  It also listed concrete implementation risks – legal challenges, regulatory approvals, labor‑related issues, cultural and technology integration problems, and possible service disruptions – that could erode the anticipated savings (2024 p. 28‑31). \n\nThus, between 2023 and 2024 FedEx moved from an initial projection of clear cost‑saving benefits from Network 2.0 to a more guarded view that the savings may fall short and that a range of integration, regulatory, labor and technology risks could increase costs and extend the rollout timeline.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2023, FedEx emphasized Network 2.0's expected benefits including cost savings and permanent cost reductions, while acknowledging execution risks related to timing and cost. In 2024, the focus shifted to integration challenges and uncertainty around savings, with specific risks like labor issues, cultural integration, regulatory approvals, and service disruptions noted. These points match the original answer's core claims. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the ground truth, so quantitative accuracy is not applicable in a numerical sense—however, the LLM correctly references page numbers (e.g., 2023 p. 32–33, 2024 p. 28–31), which supports verifiability and does not introduce errors. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years of filings, correctly identifying the evolution from strategic optimism in 2023 to operational caution in 2024. It captures the shift from investment justification to risk mitigation. (4) The only reason for not giving a perfect 10 is minor: the LLM omits mention of 'asset impairment charges' and 'tax impacts' as specific financial risks noted in the 2024 filing, which were included in the ground truth. However, it does capture the broader theme of financial uncertainty ('higher than expected costs', 'less-than-expected savings'). Overall, the answer is semantically equivalent, contextually precise, and well-supported, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1650,
        "completion_tokens": 438,
        "total_tokens": 2088
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did the financial impact from equity method investment contracts evolve between 2022 and 2023, and what does this indicate about MDLZ's engagement with these investments?",
      "original_answer": "In 2022, MDLZ reported a net liability of $3 million related to equity method investment contracts. By 2023, this position had shifted to a gain of $7 million from equity method investment contracts, indicating a reversal in financial impact and potentially more active or favorable engagement with these investments. This evolution highlights a strategic or operational shift in how MDLZ managed these equity method investments over the two years.",
      "llm_answer": "In 2023 MDLZ recorded a **$7 million pre‑tax gain** from its equity‑method investment contracts, whereas in 2022 the line showed **no gain or loss** (and the fair‑value table showed a modest $3 million liability that disappeared in 2023)【page_98】. The swing from a neutral/negative position in 2022 to a positive gain in 2023 suggests that the company’s equity‑method investments – principally the JDE Peet’s‑related instrument – performed better and that MDLZ is increasingly benefiting from, and actively managing, these strategic holdings.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM answer is partially correct but contains a key factual inaccuracy: it states that in 2022, MDLZ had 'no gain or loss' from equity method investment contracts, whereas the ground truth specifies a net liability of $3 million. This misrepresents the 2022 financial position. However, the 2023 $7 million gain is correctly reported. 2) Quantitatively, the $7 million gain in 2023 is accurate, but the characterization of 2022 as 'no gain or loss' contradicts the $3 million liability stated in the original answer. While the LLM mentions a '$3 million liability' in a parenthetical, it downplays it as a fair-value table item rather than recognizing it as the reported net liability, leading to confusion. The calculation of the swing (from -$3M to +$7M) is implied but not explicitly accurate due to the mischaracterization. 3) The reasoning is sound in interpreting the shift as indicative of improved performance and active management, especially with the reference to JDE Peet’s, which aligns with contextual knowledge. The multi-hop synthesis—linking the change in financial impact to strategic engagement—is logically supported and adds relevant insight. 4) Despite the wording differences, the core evolution (negative/neutral to positive) and implication (better performance, active management) are semantically close to the original. However, the incorrect portrayal of 2022 data reduces factual reliability. Hence, correctness is reduced to 7 due to significant quantitative inaccuracy, though qualitative and contextual elements remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 426,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did Broadcom's (AVGO) estimated cost to complete for the VMware Cloud Foundation July 2024 releases evolve from fiscal year 2023 to fiscal year 2024, and what does this indicate about the development progress relative to expectations?",
      "original_answer": "The estimated cost to complete for the VMware Cloud Foundation July 2024 releases remained unchanged at $38 million from fiscal year 2023 to fiscal year 2024. This consistency in the cost estimate indicates that the development progress for this product was proceeding largely as planned, with actual expenditures aligning with earlier projections. The lack of an increase or decrease in the estimated cost to complete suggests that Broadcom (AVGO) did not encounter significant unexpected expenses or delays in the development timeline for this specific release.",
      "llm_answer": "Broadcom’s estimate of the remaining work needed to finish the VMware Cloud Foundation July 2024 releases fell from **about $45 million in fiscal 2023 to roughly $38 million in fiscal 2024**【AVGO 2023 10‑K p. 69】.  The drop in the “estimated cost to complete” signals that the program is moving ahead of the original schedule – Broadcom is spending less than it expected to finish the July 2024 features, indicating that development is progressing faster than initially anticipated.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that Broadcom's estimated cost to complete decreased from $45 million in fiscal year 2023 to $38 million in fiscal year 2024. According to the ground truth, the cost remained unchanged at $38 million across both fiscal years. This is a critical factual error in both the reported values and the trend. (2) The quantitative inaccuracies are significant: the $45 million figure for fiscal 2023 is false, and the claimed decrease is unsupported. The correct data shows no change, so the calculation or comparison of costs across years is invalid. (3) The reasoning is flawed due to incorrect input data. The LLM concludes that the drop in cost indicates development is progressing faster than expected, but the ground truth states the stable cost reflects progress in line with expectations. This misrepresents the implications of the cost data and fails to correctly synthesize the meaning of unchanged estimates over time. (4) While the answer addresses the right entities (Broadcom, VMware Cloud Foundation, fiscal years 2023–2024) and the general topic (cost to complete and development progress), the core factual error undermines correctness. Contextual relevance is high because the structure and intent align with the question, but accuracy is severely compromised. Thus, correctness and quantitative accuracy are low; qualitative accuracy is slightly above minimum due to correct terminology and framing, but flawed logic limits the score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 412,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has the strategic positioning of FedEx Office's Ship and Go kiosk evolved between 2023 and 2024, and what does this indicate about the company's approach to e-commerce logistics and returns management?",
      "original_answer": "In 2023, the Ship and Go kiosk was described primarily as a self-serve shipping solution available in approximately 1,300 locations, allowing customers to generate labels via mobile or QR code and drop off packages securely. While it mentioned facilitating e-commerce returns, the integration was not emphasized. By 2024, the description of Ship and Go remained consistent in terms of presence (still in approximately 1,300 locations) and core functionality, but there was a notable shift in emphasis: it was now more explicitly tied to FedEx Returns Technology and Consolidated Returns, highlighting its role in in-store printing of return labels and enabling customers to drop off returns without a box or label. This evolution indicates a strategic shift toward positioning Ship and Go not just as a shipping tool, but as a key node in FedEx's broader e-commerce returns infrastructure.",
      "llm_answer": "In the 2023 filing FedEx Office described the **Ship and Go kiosk** as a self‑service label‑printing and drop‑off station that was already in place in roughly **1,000 FedEx Office locations**. By the 2024 filing the company said the kiosk was deployed in **about 1,300 locations** and was now highlighted as a core element of its **FedEx Returns Technology and Consolidated Returns** programs – allowing shoppers to print return labels in‑store or simply drop off returns with no box or label needed 【page 15 (2024)】.  \n\nThe expansion and tighter integration of the kiosk with digital returns tools shows FedEx is positioning the Ship and Go kiosk as a strategic “last‑mile” hub for e‑commerce, making both outbound shipments and reverse‑logistics faster, more convenient, and fully digital. This reflects a broader corporate shift toward strengthening e‑commerce fulfillment and simplifying returns management.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "(1) The LLM answer is mostly correct in content and captures the core evolution of the Ship and Go kiosk from 2023 to 2024. It correctly identifies the strategic shift toward integration with FedEx Returns Technology and Consolidated Returns, and the enhanced role in e-commerce returns management. However, there is a discrepancy in the number of locations: the LLM states approximately 1,000 locations in 2023, while the ground truth specifies approximately 1,300 in both 2023 and 2024. This is a factual error affecting quantitative accuracy. (2) The 2024 location count (1,300) is correct, but the 2023 figure is inaccurate—ground truth confirms the ~1,300 figure was already used in 2023, not an expansion from 1,000 to 1,300. No calculations were required, but the implication of growth in footprint is incorrect since the number of locations remained stable. (3) The multi-hop reasoning is strong: the LLM correctly synthesizes the shift in emphasis from general shipping to returns integration, links it to FedEx’s broader e-commerce logistics strategy, and infers the strategic intent behind the change. The use of the term 'core element' and description of label-free drop-off aligns well with the ground truth. (4) Despite the numerical inaccuracy, the qualitative analysis and contextual relevance are excellent—the answer directly addresses both parts of the question and draws a valid conclusion about FedEx’s strategic direction. The error is minor in impact but notable, warranting a score of 8 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1464,
        "completion_tokens": 420,
        "total_tokens": 1884
      },
      "error": null
    }
  ],
  "evaluation_summary": {
    "total_questions": 1000,
    "successful_evaluations": 1000,
    "failed_evaluations": 0,
    "average_correctness_score": 6.74,
    "average_quantitative_accuracy": 7.42,
    "average_qualitative_accuracy": 7.01,
    "average_contextual_relevance": 8.82,
    "score_distribution": {
      "excellent": 451,
      "good": 138,
      "fair": 235,
      "poor": 176
    }
  },
  "original_experiment_metadata": {
    "model": "gpt-oss-120b",
    "experiment": "e4_page_window_relevance_desc",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions": 1000,
    "successful": 1000,
    "failed": 0,
    "elapsed_seconds": 2862.73,
    "timestamp": "2026-02-03T21:13:44.652095"
  }
}